FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Fryer, SL
Woods, SW
Kiehl, KA
Calhoun, VD
Pearlson, GD
Roach, BJ
Ford, JM
McGlashan, TH
Mathalon, DH
AF Fryer, Susanna L.
Woods, Scott W.
Kiehl, Kent A.
Calhoun, Vince D.
Pearlson, Godfrey D.
Roach, Brian J.
Ford, Judith M.
McGlashan, Thomas H.
Mathalon, Daniel H.
TI Youth at Clinical High-Risk for Psychosis Fail to Suppress Default Mode
Regions During Task Performance
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE psychosis prodrome; ultra high-risk; schizophrenia; default mode
network; working memory
C1 [Fryer, Susanna L.; Ford, Judith M.; Mathalon, Daniel H.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Fryer, Susanna L.; Roach, Brian J.; Ford, Judith M.; Mathalon, Daniel H.] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA USA.
[Woods, Scott W.; Calhoun, Vince D.; Pearlson, Godfrey D.; Ford, Judith M.; McGlashan, Thomas H.; Mathalon, Daniel H.] Yale Univ, New Haven, CT USA.
[Kiehl, Kent A.; Calhoun, Vince D.] Univ New Mexico, Albuquerque, NM 87131 USA.
[Kiehl, Kent A.; Calhoun, Vince D.] Mind Res Network, Albuquerque, NM USA.
[Pearlson, Godfrey D.] Olin Neuropsychiat Res Ctr, Inst Living, New Haven, CT USA.
NR 0
TC 0
Z9 0
U1 2
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 941
BP 301S
EP 301S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671801249
ER
PT J
AU Storage, S
Mandelkern, M
Phuong, J
Kozman, M
Brody, A
AF Storage, Steven
Mandelkern, Mark
Phuong, Jonathan
Kozman, Maggie
Brody, Arthur
TI Relationship Between Harm Avoidance and Nicotinic Acetylcholine Receptor
Density
SO BIOLOGICAL PSYCHIATRY
LA English
DT Meeting Abstract
CT 68th Annual Scientific Meeting of the Society-of-Biological-Psychiatry
CY MAY 16-18, 2013
CL San Francisco, CA
SP Soc Biol Psychiat
DE Tobacco Dependence; Harm Avoidance; Positron Emission Tomography;
Nicotinic Acetylcholine Receptor; Temperament and Character Inventory
C1 [Storage, Steven] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA.
[Mandelkern, Mark] VA Greater Los Angeles Healthcare Syst, Nucl Med, Los Angeles, CA USA.
[Phuong, Jonathan; Kozman, Maggie] VA Greater Los Angeles Healthcare Syst, Res, Los Angeles, CA USA.
[Brody, Arthur] Univ Calif Los Angeles, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
SU S
MA 964
BP 308S
EP 308S
PG 1
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 140RE
UT WOS:000318671801272
ER
PT J
AU Bao, Y
Giovannucci, EL
Kraft, P
Qian, ZR
Wu, C
Ogino, S
Gaziano, JM
Stampfer, MJ
Ma, J
Buring, JE
Sesso, HD
Lee, IM
Rifai, N
Pollak, MN
Jiao, L
Lessin, L
Cochrane, BB
Manson, JE
Fuchs, CS
Wolpin, BM
AF Bao, Ying
Giovannucci, Edward L.
Kraft, Peter
Qian, Zhi Rong
Wu, Chen
Ogino, Shuji
Gaziano, J. Michael
Stampfer, Meir J.
Ma, Jing
Buring, Julie E.
Sesso, Howard D.
Lee, I-Min
Rifai, Nader
Pollak, Michael N.
Jiao, Li
Lessin, Lawrence
Cochrane, Barbara B.
Manson, JoAnn E.
Fuchs, Charles S.
Wolpin, Brian M.
TI Inflammatory Plasma Markers and Pancreatic Cancer Risk: A Prospective
Study of Five U.S. Cohorts
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID C-REACTIVE PROTEIN; NECROSIS-FACTOR-ALPHA; CARDIOVASCULAR-DISEASE;
WOMENS HEALTH; INSULIN-RESISTANCE; DIABETES-MELLITUS; PHYSICAL-ACTIVITY;
SERUM-LEVELS; OBESITY; MEN
AB Chronic inflammation may play a role in the development of pancreatic cancer. However, few prospective studies have examined the association between plasma inflammatory markers and pancreatic cancer risk. Therefore, we investigated the association of prediagnostic circulating C-reactive protein (CRP), interleukin-6 (IL-6), and TNF-alpha receptor II (TNF-alpha R2) with subsequent pancreatic cancer risk in a prospective, nested case-control study of 470 cases and 1,094 controls from Health Professionals Follow-up Study, Nurses' Health Study, Physicians' Health Study, Women's Health Initiative, and Women's Health Study. The median follow-up time of cases was 7.2 years (range 1-26 years). No association was observed between plasma CRP, IL-6, and TNF-alpha R2 and the risk of pancreatic cancer. Comparing extreme quintiles, the multivariate ORs were 1.10 [95% confidence interval (CI), 0.74-1.63; P-trend = 0.81] for CRP, 1.19 (95% CI, 0.81-1.76; P-trend = 0.08) for IL-6, and 0.88 (95% CI, 0.58-1.33; P-trend = 0.57) for TNF-alpha R2. In conclusion, prediagnostic levels of circulating CRP, IL-6, and TNF-alpha R2 were not associated with the risk of pancreatic cancer, suggesting that systemic inflammation as measured by circulating inflammatory factors is unlikely to play a major role in the development of pancreatic cancer. (C) 2013 AACR.
C1 [Bao, Ying; Giovannucci, Edward L.; Stampfer, Meir J.; Ma, Jing; Manson, JoAnn E.; Fuchs, Charles S.; Wolpin, Brian M.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.
[Gaziano, J. Michael; Buring, Julie E.; Sesso, Howard D.; Lee, I-Min; Manson, JoAnn E.] Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA.
[Ogino, Shuji] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Buring, Julie E.] Dept Ambulatory Care & Prevent, Boston, MA USA.
[Kraft, Peter; Buring, Julie E.; Sesso, Howard D.; Lee, I-Min] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Giovannucci, Edward L.; Kraft, Peter; Wu, Chen; Ogino, Shuji; Stampfer, Meir J.; Ma, Jing; Buring, Julie E.; Sesso, Howard D.; Lee, I-Min; Manson, JoAnn E.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Giovannucci, Edward L.; Stampfer, Meir J.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Manson, JoAnn E.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Rifai, Nader] Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA.
[Qian, Zhi Rong; Ogino, Shuji; Fuchs, Charles S.; Wolpin, Brian M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Pollak, Michael N.] McGill Univ, Fac Med, Dept Oncol, Canc Prevent Res Unit, Montreal, PQ, Canada.
[Jiao, Li] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
[Cochrane, Barbara B.] Univ Washington, Sch Nursing, Seattle, WA 98195 USA.
W Virginia Univ, Dept Community Med, Morgantown, WV 26506 USA.
[Gaziano, J. Michael] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr MA, Washington, DC USA.
[Lessin, Lawrence] Medstar Res Inst, Washington, DC USA.
RP Bao, Y (reprint author), Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA.
EM ying.bao@channing.harvard.edu
OI Qian, Zhi rong/0000-0003-1633-4120
FU National Cancer Institute, NIH [P01 CA87969, P01 CA55075, P50 CA127003,
R01 CA124908]; NCI [K07 CA140790]; American Society of Clinical
Oncology; Howard Hughes Medical Institute; Lustgarten Foundation; NIH
(Bethesda, MD) [CA 97193, CA 34944, CA 40360, HL 26490, HL 34595];
National Heart, Lung, and Blood Institute, National Institutes of
Health, U.S. Department of Health and Human Services [N01WH22110, 24152,
32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122,
42107-26, 42129-32, 44221]; NIH [CA047988, HL043851, HL080467]
FX The NHS and HPFS are supported by the National Cancer Institute, NIH
(Grant no. P01 CA87969, P01 CA55075, P50 CA127003, R01 CA124908). B.
Wolpin is supported by NCI K07 CA140790, an American Society of Clinical
Oncology Career Development Award, a Howard Hughes Medical Institute
Early Career Physician-Scientist Award, and the Lustgarten Foundation.;
The PHS I is supported by grant nos. CA 97193, CA 34944, CA 40360, HL
26490, and HL 34595 from the NIH (Bethesda, MD).; The WHI program is
funded by the National Heart, Lung, and Blood Institute, National
Institutes of Health, U.S. Department of Health and Human Services
through contracts N01WH22110, 24152, 32100-2, 32105-6, 32108-9,
32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32, and 44221.; The
WHS is supported by grants CA047988, HL043851, and HL080467 from the
NIH.
NR 46
TC 11
Z9 11
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD MAY
PY 2013
VL 22
IS 5
BP 855
EP 861
DI 10.1158/1055-9965.EPI-12-1458
PG 7
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA 143UR
UT WOS:000318894200013
PM 23462920
ER
PT J
AU Houssami, N
Abraham, LA
Kerlikowske, K
Buist, DSM
Irwig, L
Lee, J
Miglioretti, DL
AF Houssami, Nehmat
Abraham, Linn A.
Kerlikowske, Karla
Buist, Diana S. M.
Irwig, Les
Lee, Janie
Miglioretti, Diana L.
TI Risk Factors for Second Screen-Detected or Interval Breast Cancers in
Women with a Personal History of Breast Cancer Participating in
Mammography Screening
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID PREDICTION MODEL; FOLLOW-UP; SURVEILLANCE; SURVIVORS; DENSITY;
CONSERVATION; VALIDATION; GUIDELINES; ACCURACY; OBESITY
AB Background: Women with a personal history of breast cancer (PHBC) have increased risk of an interval cancer. We aimed to identify risk factors for second (ipsilateral or contralateral) screen-detected or interval breast cancer within 1 year of screening in PHBC women.
Methods: Screening mammograms from women with history of early-stage breast cancer at Breast Cancer Surveillance Consortium-affiliated facilities (1996-2008) were examined. Associations between woman-level, screen-level, and first cancer variables and the probability of a second breast cancer were modeled using multinomial logistic regression for three outcomes [screen-detected invasive breast cancer, interval invasive breast cancer, or ductal carcinoma in situ (DCIS)] relative to no second breast cancer.
Results: There were 697 second breast cancers, of these 240 were interval cancers, among 67,819 screens in 20,941 women. In separate models for women with DCIS or invasive first cancer, first breast cancer surgery predicted all three second breast cancer outcomes (P < 0.001), and high ORs for second breast cancers (between 1.95 and 4.82) were estimated for breast conservation without radiation (relative to mastectomy). In women with invasive first breast cancer, additional variables predicted risk (P<0.05) for at least one of the three outcomes: first-degree family history, dense breasts, longer time between mammograms, young age at first breast cancer, first breast cancer stage, and adjuvant systemic therapy for first breast cancer; and risk of interval invasive breast cancer was highest in women < 40 years at first breast cancer (OR, 3.41; 1.34-8.70), those with extremely dense breasts (OR, 2.55; 1.4-4.67), and those treated with breast conservation without radiation (OR, 2.67; 1.53-4.65).
Conclusion: Although the risk of a second breast cancer is modest, our models identify risk factors for interval second breast cancer in PHBC women.
Impact: Our findings may guide discussion and evaluations of tailored breast screening in PHBC women, and incorporating this information into clinical decision-making warrants further research. (C) 2013 AACR.
C1 [Houssami, Nehmat; Irwig, Les] Univ Sydney, Screening & Test Evaluat Program, Sch Publ Hlth, Sydney Med Sch, Sydney, NSW 2006, Australia.
[Abraham, Linn A.; Buist, Diana S. M.; Miglioretti, Diana L.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA.
[Kerlikowske, Karla] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Kerlikowske, Karla] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Kerlikowske, Karla] Univ Calif San Francisco, Gen Internal Med Sect, Dept Vet Affairs, San Francisco, CA 94143 USA.
[Lee, Janie] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Lee, Janie] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Lee, Janie] Massachusetts Gen Hosp, Dept Radiol, Inst Technol Assessment, Boston, MA 02114 USA.
[Miglioretti, Diana L.] Univ Calif Davis, Div Biostat, Dept Publ Hlth Sci, Davis, CA USA.
RP Houssami, N (reprint author), Univ Sydney, Screening & Test Evaluat Program, Sch Publ Hlth A27, Sydney Med Sch, Sydney, NSW 2006, Australia.
EM nehmath@med.usyd.edu.au
FU National Breast Cancer Foundation (NBCF); National Health and Medical
Research Council (NHMRC) [633003]; National Cancer Institute
[U01CA63740, U01CA86076, U01CA86082, U01CA63736, U01CA70013, U01CA69976,
U01CA63731, U01CA70040, HHSN261201100031C]
FX N. Houssami receives research support through a National Breast Cancer
Foundation (NBCF) Practitioner Fellowship. L. Irwig and N. Houssami are
partly supported via National Health and Medical Research Council
(NHMRC) program grant 633003 to the Screening & Test Evaluation Program.
This work was supported by the National Cancer Institute-funded Breast
Cancer Surveillance Consortium (U01CA63740, U01CA86076, U01CA86082,
U01CA63736, U01CA70013, U01CA69976, U01CA63731, U01CA70040,
HHSN261201100031C).
NR 30
TC 12
Z9 13
U1 0
U2 13
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD MAY
PY 2013
VL 22
IS 5
BP 946
EP 961
DI 10.1158/1055-9965.EPI-12-1208-T
PG 16
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA 143UR
UT WOS:000318894200023
PM 23513042
ER
PT J
AU Lo, WK
Chan, WW
AF Lo, Wai-Kit
Chan, Walter W.
TI Proton Pump Inhibitor Use and the Risk of Small Intestinal Bacterial
Overgrowth: A Meta-analysis
SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Review
DE Hypochlorhydria; Drug; Small Bowel Flora; Reflux; Side Effect
ID IRRITABLE-BOWEL-SYNDROME; GASTRIC-ACID-SECRETION; ELDERLY PATIENTS;
OMEPRAZOLE; PREDICTORS; THERAPY; DISEASE; HYPOCHLORHYDRIA; SUPPRESSION;
SIBO
AB BACKGROUND & AIMS: Use of proton pump inhibitors (PPIs) could predispose individuals to small intestinal bacterial overgrowth (SIBO) by altering the intraluminal environment and bacterial flora. There is controversy regarding the risk of SIBO among PPI users because of conflicting results from prior studies. A systematic review and meta-analysis were performed to evaluate the association between PPI use and SIBO, using objective clinical outcome measures.
METHODS: Clinical studies comparing SIBO risk among adult users of PPIs vs nonusers were identified in MEDLINE/PubMed, EMBASE, the Cochrane Central Register of Controlled Trials, and the National Institutes of Health Clinical Trials databases through July 2012. Two reviewers independently extracted data on study characteristics and outcomes. The primary metameter was the odds ratio (OR) of SIBO among PPI users vs nonusers. Subgroup analyses were performed to examine the influence of study characteristics, such as SIBO diagnostic modality, on study outcome.
RESULTS: Eleven studies (n = 3134) met inclusion criteria. The pooled OR of SIBO in PPI users vs nonusers was 2.282 (95% confidence interval [CI], 1.238 - 4.205). No significant single large study or temporal effect was seen. Subgroup analysis revealed an association between SIBO and PPI use in studies that used duodenal or jejunal aspirate cultures to diagnose SIBO (OR, 7.587; 95% CI, 1.805-31.894), but no relationship was found between SIBO and PPI use in studies that used the glucose hydrogen breath test (OR, 1.93; 95% CI, 0.69-5.42). Funnel plot analysis identified 4 outlying studies, indicating the possible presence of publication bias.
CONCLUSIONS: PPI use statistically was associated with SIBO risk, but only when the diagnosis was made by a highly accurate test (duodenal or jejunal aspirate culture). Differences in study results could arise from the use of different tests to diagnose SIBO.
C1 [Lo, Wai-Kit; Chan, Walter W.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Gastroenterol Hepatol & Endoscopy, Boston, MA 02115 USA.
Boston VA Healthcare Syst, Dept Gastroenterol, Boston, MA USA.
RP Chan, WW (reprint author), Brigham & Womens Hosp, Div Gastroenterol, 75 Francis St, Boston, MA 02115 USA.
EM wwchan@partners.org
OI Lo, Wai-Kit/0000-0002-1526-352X
NR 43
TC 46
Z9 50
U1 2
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1542-3565
J9 CLIN GASTROENTEROL H
JI Clin. Gastroenterol. Hepatol.
PD MAY
PY 2013
VL 11
IS 5
BP 483
EP 490
DI 10.1016/j.cgh.2012.12.011
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 140UX
UT WOS:000318682600011
PM 23270866
ER
PT J
AU Sonnenberg, A
Lee, BY
AF Sonnenberg, Amnon
Lee, Brent Y.
TI Birth-Cohort Analysis of Colorectal Cancer Incidence in the United
States
SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Letter
ID MORTALITY; TRENDS; ULCER
C1 [Sonnenberg, Amnon; Lee, Brent Y.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA.
RP Sonnenberg, A (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA.
NR 4
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1542-3565
J9 CLIN GASTROENTEROL H
JI Clin. Gastroenterol. Hepatol.
PD MAY
PY 2013
VL 11
IS 5
BP 582
EP 583
DI 10.1016/j.cgh.2013.01.022
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 140UX
UT WOS:000318682600030
PM 23376795
ER
PT J
AU Adamia, S
Pilarski, PM
Belch, AR
Pilarski, LM
AF Adamia, Sophia
Pilarski, Patrick M.
Belch, Andrew R.
Pilarski, Linda M.
TI Aberrant Splicing, Hyaluronan Synthases and Intracellular Hyaluronan as
Drivers of Oncogenesis and Potential Drug Targets
SO CURRENT CANCER DRUG TARGETS
LA English
DT Article
DE Alternative splicing; drug targets; hyaluronan; hyaluronan synthases;
oncogenesis
ID CHRONIC LYMPHOCYTIC-LEUKEMIA; GENOME-WIDE ASSOCIATION; COLON-CARCINOMA
CELLS; LARGE B-CELL; MARROW ENDOTHELIAL-CELLS; ACUTE MYELOID-LEUKEMIA;
MULTIPLE-MYELOMA; BREAST-CANCER; SOMATIC HYPERMUTATION; PROSTATE-CANCER
AB Current evidence suggests a significant role of aberrant splicing in the development and maintenance of malignancy. This multistep, tightly regulated epigenetic process leads to the production of abnormal proteins with abnormal functions contributing to underlying mechanisms of malignant transformation. Splicing patterns in malignant cells can be altered not only by the mutations detected on the aberrantly spliced gene, but also by the mutations detected on the genes encoding splicing factors. For example, aberrant pre-mRNA splicing, leading to intracellular or extracellular HA synthesis by HASs, contributes to the initiation and progression of various types of cancer. The influence of intracellular HA appears to be particularly significant and is promoted by aberrant splicing. In this review we report a model describing oncogenic potential of aberrant splicing, with a focus on HAS1 and intracellular HA. We also suggest that the influence of splicing mutations on malignant disease is likely multifactorial. For the triple axis of HA, HAS1 and RHAMM, mutations in HAS1 provide an indicator that these aberrations contribute to the events that lead to malignancy through increased risk and predisposition. Here, we also summarize the impact of splicing abnormalities on cancer and the possible oncogenic impact of aberrantly spliced HAS1. In conclusion, we emphasize that specific gene splice variants and the splicing process itself offer potential targets for novel drug treatment strategies.
C1 [Adamia, Sophia] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Pilarski, Patrick M.] Univ Alberta, Dept Comp Sci, Edmonton, AB, Canada.
[Belch, Andrew R.; Pilarski, Linda M.] Univ Alberta, Dept Oncol, Edmonton, AB, Canada.
[Belch, Andrew R.; Pilarski, Linda M.] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada.
RP Adamia, S (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02115 USA.
EM Sophia_Adamia@dfci.harvard.edu
RI Xia, Bo/P-9380-2016
FU Alberta Cancer Foundation; Myeloma Alberta; Alberta Innovates Centre for
Machine Learning; Alberta Innovates - Technology Futures; ASH scholar
award; LLS (Leukemia & Lymphoma Society)
FX SA is supported by an ASH scholar award for Clinical/Translational
Research Fellows, and LLS (Leukemia & Lymphoma Society) Translational
Research Program grant. PMP is funded by the Alberta Innovates Centre
for Machine Learning, and from Alberta Innovates - Technology Futures.
LMP and ARB are funded by the Alberta Cancer Foundation and Myeloma
Alberta.
NR 151
TC 12
Z9 12
U1 0
U2 7
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
EMIRATES
SN 1568-0096
J9 CURR CANCER DRUG TAR
JI Curr. Cancer Drug Targets
PD MAY
PY 2013
VL 13
IS 4
BP 347
EP 361
PG 15
WC Oncology
SC Oncology
GA 144XV
UT WOS:000318976500001
PM 23517594
ER
PT J
AU Calkins, AW
Berman, NC
Wilhelm, S
AF Calkins, Amanda W.
Berman, Noah C.
Wilhelm, Sabine
TI Recent Advances in Research on Cognition and Emotion in OCD: A Review
SO CURRENT PSYCHIATRY REPORTS
LA English
DT Review
DE Obsessive-compulsive Disorder; OCD; Cognition; Emotion; Cognitive
Processes; Cognitive Model; Anxiety; Disgust sensitivity; Psychiatry
ID OBSESSIVE-COMPULSIVE DISORDER; ANXIETY SENSITIVITY INDEX-3;
UCS-EXPECTANCY BIAS; SYMPTOM DIMENSIONS; RESPONSIBILITY BELIEFS;
NONCLINICAL SAMPLE; DISGUST; UNCERTAINTY; INTOLERANCE; CONTAMINATION
AB The cognitive model of OCD suggests that misinterpreting intrusive thoughts as unacceptable leads to increased anxiety and attempts to suppress or ignore the thoughts through avoidance or compulsive rituals. An insidious negative feedback loop develops as one's attention focuses on these thoughts and in turn the unwanted thoughts do not respond to efforts to avoid or suppress. This article is a current review of the research on cognitive processes in obsessive-compulsive disorder (OCD). We review research that has (1) empirically validated the theoretical underpinnings of the cognitive model, (2) altered maladaptive cognitive processes through state-of-the-art experimental procedures, (3) refined our understanding of the relationship between obsessive beliefs and OC symptoms and (4) examined how underlying traits (e.g., anxiety and disgust sensitivity) relate to the development and maintenance of OCD. We discuss the clinical implications of this research.
C1 [Calkins, Amanda W.; Berman, Noah C.; Wilhelm, Sabine] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Calkins, AW (reprint author), Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA.
EM acalkins@partners.org
OI Baker, Amanda/0000-0002-0103-5411
FU National Institutes of Health, National Institute of Mental Health;
International OCD Foundation; Tourette Syndrome Association; Charlie
Waller Institute; University of Reading; Internationale Tagung in Prien
am Chiemsee; North Shore University Hospital; Long Island Jewish Medical
Center; Massachusetts General Hospital Psychiatry Academy; Guilford
Press; Oxford University Press; New Harbinger Publications; Association
for Behavioral and Cognitive Therapies; National Institutes of Health
FX S. Wilhelm has received grants and research support from the National
Institutes of Health, National Institute of Mental Health and
International OCD Foundation; has received payment for lectures
including service on speakers bureaus from the Tourette Syndrome
Association, Charlie Waller Institute, University of Reading,
International OCD Foundation, Internationale Tagung in Prien am
Chiemsee, North Shore University Hospital and Long Island Jewish Medical
Center, and Massachusetts General Hospital Psychiatry Academy; has
received payment for manuscript preparation from Guilford Press; has
received royalties from Oxford University Press, New Harbinger
Publications and Guilford Press; has received payment for serving on
editorial boards from the Association for Behavioral and Cognitive
Therapies; and has received payment for grant reviews from National
Institutes of Health.
NR 56
TC 9
Z9 9
U1 4
U2 68
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523-3812
J9 CURR PSYCHIAT REP
JI Curr. Psychiatry Rep.
PD MAY
PY 2013
VL 15
IS 5
AR 357
DI 10.1007/s11920-013-0357-4
PG 7
WC Psychiatry
SC Psychiatry
GA 141YD
UT WOS:000318761600004
PM 23529510
ER
PT J
AU Friedlander, AH
Chang, TI
Aghazadehsanai, N
Berenji, GR
Harada, ND
Garrett, NR
AF Friedlander, A. H.
Chang, T. I.
Aghazadehsanai, N.
Berenji, G. R.
Harada, N. D.
Garrett, N. R.
TI Panoramic images of white and black post-menopausal females evidencing
carotid calcifications are at high risk of comorbid osteopenia of the
femoral neck
SO DENTOMAXILLOFACIAL RADIOLOGY
LA English
DT Article
DE atherosclerosis; panoramic images; osteopenia; fractures
ID BONE-MINERAL DENSITY; SERVICES TASK-FORCE; ARTERY CALCIFICATIONS; HIP
FRACTURE; OLDER WOMEN; OSTEOPOROSIS; RADIOGRAPHY; POPULATION; MORTALITY;
ATHEROMA
AB Objectives: Femoral neck fractures in older females resulting from decreased bone mineral density (BMD; osteopenia) are associated with increased morbidity and mortality. Bone mineralization inhibition is probably controlled by proteins which also foster vascular calcification. Therefore, we evaluated the relationship between calcified carotid artery plaque (CCAP) on panoramic images and BMD on dual energy X-ray absorptiometry (DXA) bone scans.
Methods: Images and hospital records identified by dentists defined two study groups (20 white females and 24 black females) having CCAP and an incidentally obtained bone scan. Ethnically matched (age +/- 7 years, body mass index +/- 3 units) control groups with panoramic images devoid of CCAP and accompanying DXA scan were likewise constituted. A physician determined the BMD on the DXA.
Results: Females with CCAP had significantly (p = 0.03) poorer BMD at the femoral neck than those without CCAP. Although mean femoral neck BMD was significantly lower (p = 0.009) for white than for black females, there was no significant interaction between race and CCAP (p = 0.80).
Conclusion: We observed a significant inverse association between the CCAP on panoramic images and femoral neck BMD in post-menopausal white females.
C1 [Friedlander, A. H.; Chang, T. I.; Berenji, G. R.] Vet Affairs Greater Los Angeles Healthcare Syst, Grad Med Educ, Los Angeles, CA USA.
[Friedlander, A. H.] Ronald Reagan UCLA Med Ctr, Hosp Dent Serv, Los Angeles, CA USA.
[Friedlander, A. H.; Chang, T. I.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA.
[Aghazadehsanai, N.] Vet Affairs Greater Los Angeles Healthcare Syst, Oral & Maxillofacial Surg Sect, Dent Serv, Los Angeles, CA USA.
[Berenji, G. R.; Harada, N. D.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Harada, N. D.] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA.
[Garrett, N. R.] Univ Calif Los Angeles, Sch Dent, Div Adv Prosthodont Biomat & Hosp Dent, Los Angeles, CA 90024 USA.
RP Friedlander, AH (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM arthur.friedlander@med.va.gov
FU Research Facilities Improvement Program from the National Center for
Research Resources, National Institutes of Health [C06 RR-14529-01]
FX Elements of this investigation were conducted in a facility constructed
with support from Research Facilities Improvement Program Grant Number
C06 RR-14529-01 from the National Center for Research Resources,
National Institutes of Health.
NR 31
TC 5
Z9 6
U1 0
U2 5
PU BRITISH INST RADIOLOGY
PI LONDON
PA 36 PORTLAND PLACE, LONDON W1N 4AT, ENGLAND
SN 0250-832X
J9 DENTOMAXILLOFAC RAD
JI Dentomaxillofac. Radiol.
PD MAY
PY 2013
VL 42
IS 5
AR 20120195
DI 10.1259/dmfr.20120195
PG 6
WC Dentistry, Oral Surgery & Medicine; Radiology, Nuclear Medicine &
Medical Imaging
SC Dentistry, Oral Surgery & Medicine; Radiology, Nuclear Medicine &
Medical Imaging
GA 146NY
UT WOS:000319099000001
PM 23571481
ER
PT J
AU Soria, JC
Baselga, J
Hanna, N
Laurie, SA
Bahleda, R
Felip, E
Calvo, E
Armand, JP
Shepherd, FA
Harbison, CT
Berman, D
Park, JS
Zhang, S
Vakkalagadda, B
Kurland, JF
Pathak, AK
Herbst, RS
AF Soria, Jean-Charles
Baselga, Jose
Hanna, Nasser
Laurie, Scott A.
Bahleda, Rastislav
Felip, Enriqueta
Calvo, Emiliano
Armand, Jean-Pierre
Shepherd, Frances A.
Harbison, Christopher T.
Berman, David
Park, Jong-Soon
Zhang, Steven
Vakkalagadda, Blisse
Kurland, John F.
Pathak, Ashutosh K.
Herbst, Roy S.
TI Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3
oral tyrosine kinase inhibitor, in patients with advanced or metastatic
solid tumours
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE Phase I-II; Pan-HER/VEGFR inhibitor; Solid tumours
ID CELL LUNG-CANCER; GROWTH-FACTOR-RECEPTOR; ADVANCED BREAST-CANCER;
NUDE-MOUSE MODEL; MONOCLONAL-ANTIBODY; COLORECTAL-CANCER; PLUS
IRINOTECAN; DOUBLE-BLIND; ANGIOGENESIS; CARCINOMA
AB Purpose: BMS-690514 is a potent, reversible oral inhibitor of epidermal growth factor receptor (EGFR/HER-1), HER-2 and -4, and vascular endothelial growth factor receptors (VEGFRs)-1 to -3 offering targeted inhibition of tumour growth and vascularisation in a single agent. This phase I-IIa study was designed to identify the maximum tolerated dose (MTD) and assess safety, antitumour activity, pharmacokinetics and pharmacodynamics of BMS-690514.
Patients and methods: In phase I, patients with advanced solid tumours received escalating doses of once-daily BMS-690514. In phase IIa, erlotinib-naive (cohort A) or erlotinib-resistant (cohort B) patients with advanced non-small-cell lung cancer (NSCLC) received BMS-690514 once-daily at the MTD.
Results: In phase I (n = 28), the MTD was determined to be 200 mg daily. BMS-690514 was rapidly absorbed and highly metabolised after repeated oral administration with minimum drug accumulation. In phase IIa (n = 62), the most frequent treatment-related adverse events were diarrhoea and acneiform rash. Adverse events that led to >1 discontinuation were diarrhoea (n = 4; 4%) and rash (n = 2; 2%). Disease control (>= 4 months) and objective response rates, respectively, were 43.3% and 3.3% (cohort A) and 22.6% and 3.2% (cohort B). Six of 21 (29%) NSCLC patients with wild-type EGFR achieved disease control versus seven of 10 (70%) patients with EGFR mutations (including T790M). At MTD, BMS-690514 modulated pharmacodynamic biomarkers associated with inhibition of VEGFR-and EGFR-signalling pathways.
Conclusion: This phase I-IIa study suggests that BMS-690514 has manageable safety profile and antitumour activity in patients with NSCLC at 200 mg/d, including those with EGFR mutations conferring resistance to erlotinib. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Soria, Jean-Charles; Bahleda, Rastislav] South Paris Univ, Inst Gustave Roussy, SITEP, Villejuif, France.
[Baselga, Jose; Felip, Enriqueta] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Hanna, Nasser] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA.
[Laurie, Scott A.] Ottawa Hosp, Ctr Canc, Ottawa, ON, Canada.
[Calvo, Emiliano] START Madrid, Ctr Integral Oncol Clara Campal, Madrid, Spain.
[Armand, Jean-Pierre] Inst Claudius Regaud, Toulouse, France.
[Shepherd, Frances A.] Univ Toronto, Div Med Oncol, Toronto, ON, Canada.
[Harbison, Christopher T.; Berman, David; Park, Jong-Soon; Zhang, Steven; Vakkalagadda, Blisse; Kurland, John F.; Pathak, Ashutosh K.] Bristol Myers Squibb Co, Princeton, NJ USA.
[Herbst, Roy S.] Smilow Canc Hosp, Yale Comprehens Canc Ctr, New Haven, CT USA.
RP Soria, JC (reprint author), Inst Gustave Roussy, Villejuif, France.
EM soria@igr.fr
FU Bristol-Myers Squibb [CA187-002]; AstraZeneca; Eli Lilly
FX Supported by research funding from Bristol-Myers Squibb (Study No.
CA187-002).; J.-C. Soria has received honoraria from Bristol-Myers
Squibb. J. Baselga has no conflicts of interest to disclose. N. Hanna
has received research funding from AstraZeneca and Eli Lilly. S. A.
Laurie has no conflicts of interest to disclose. R. Bahleda has no
conflicts of interest to disclose. E. Felip has no conflicts of interest
to disclose. E. Calvo has no conflicts of interest to disclose. J.-P.
Armand has no conflicts of interest to disclose. F. A. Shepherd has a
consultant or advisory relationship with and has received honoraria from
Daiichi Sankyo, Inc., Roche, and Bristol-Myers Squibb. C. T. Harbison
has an employment position at and stock or ownership interests in
Bristol-Myers Squibb. D. Berman has an employment position at and stock
or ownership interests in Bristol-Myers Squibb. J.-S. Park has an
employment position at Bristol-Myers Squibb. S. Zhang has an employment
position at and stock or ownership interests in Bristol-Myers Squibb. B.
Vakkalagadda has an employment position at and stock or ownership
interests in Bristol-Myers Squibb. J. F. Kurland has an employment
position at Bristol-Myers Squibb. A. K. Pathak has an employment
position at and stock or ownership interests in Bristol-Myers Squibb. R.
S. Herbst has no conflicts of interest to disclose.
NR 42
TC 9
Z9 9
U1 0
U2 12
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
J9 EUR J CANCER
JI Eur. J. Cancer
PD MAY
PY 2013
VL 49
IS 8
BP 1815
EP 1824
DI 10.1016/j.ejca.2013.02.012
PG 10
WC Oncology
SC Oncology
GA 139UN
UT WOS:000318610500003
PM 23490650
ER
PT J
AU Gukovsky, I
Li, N
Todoric, J
Gukovskaya, A
Karin, M
AF Gukovsky, Ilya
Li, Ning
Todoric, Jelena
Gukovskaya, Anna
Karin, Michael
TI Inflammation, Autophagy, and Obesity: Common Features in the
Pathogenesis of Pancreatitis and Pancreatic Cancer
SO GASTROENTEROLOGY
LA English
DT Review
DE Pancreatic Acinar Cell; Cytokines; Neutrophil; Pancreatic Ductal
Adenocarcinoma; K-Ras
ID NF-KAPPA-B; CERULEIN-INDUCED PANCREATITIS; TUMOR-NECROSIS-FACTOR;
PROTEIN-KINASE-C; ACINAR-CELLS; INSULIN-RESISTANCE; DEFICIENT MICE;
TRYPSINOGEN ACTIVATION; DUCTAL ADENOCARCINOMA; SIGNALING PATHWAYS
AB Inflammation and autophagy are cellular defense mechanisms. When these processes are deregulated (deficient or overactivated) they produce pathologic effects, such as oxidative stress, metabolic impairments, and cell death. Unresolved inflammation and disrupted regulation of autophagy are common features of pancreatitis and pancreatic cancer. Furthermore, obesity, a risk factor for pancreatitis and pancreatic cancer, promotes inflammation and inhibits or deregulates autophagy, creating an environment that facilitates the induction and progression of pancreatic diseases. However, little is known about how inflammation, autophagy, and obesity interact to promote exocrine pancreatic disorders. We review the roles of inflammation and autophagy, and their deregulation by obesity, in pancreatic diseases. We discuss the connections among disordered pathways and important areas for future research.
C1 [Gukovsky, Ilya; Gukovskaya, Anna] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Gukovsky, Ilya; Gukovskaya, Anna] Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90073 USA.
[Li, Ning; Todoric, Jelena; Karin, Michael] Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA.
[Li, Ning; Todoric, Jelena; Karin, Michael] Univ Calif San Diego, Sch Med, Dept Pathol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA.
[Todoric, Jelena] Med Univ Vienna, Dept Lab Med, Vienna, Austria.
RP Gukovskaya, A (reprint author), Univ Calif Los Angeles, Dept Vet Affairs, Los Angeles, CA 90073 USA.
EM agukovsk@ucla.edu
FU Department of Veterans Affairs; National Institutes of Health [DK59936];
Pancreatic Cancer Research Lustgarten Foundation grant [RFP-B-007];
Erwin Schrodinger Fellowship of the Austrian Science Fund [J 3233];
[P01 CA163200]; [AA19730]; [AI043477]; [CA163798]; [P50 AA011999];
[R03CA167120]
FX Our research was supported by the Department of Veterans Affairs and
National Institutes of Health grants DK59936, and, in part, P01 CA163200
(A.G.), AA19730 (I.G.), AI043477 (M.K.), CA163798 (M.K.), P50 AA011999
(A.G, I.G, Pilot Project to M.K.), and R03CA167120 (N.L.), by a
Pancreatic Cancer Research Lustgarten Foundation grant RFP-B-007 (M.K.),
and the Erwin Schrodinger Fellowship J 3233 of the Austrian Science Fund
(J.T.).
NR 201
TC 73
Z9 77
U1 5
U2 51
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD MAY
PY 2013
VL 144
IS 6
BP 1199
EP +
DI 10.1053/j.gastro.2013.02.007
PG 15
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 144AE
UT WOS:000318910600006
PM 23622129
ER
PT J
AU Farrell, JJ
Fernandez-del Castillo, C
AF Farrell, James J.
Fernandez-del Castillo, Carlos
TI Pancreatic Cystic Neoplasms: Management and Unanswered Questions
SO GASTROENTEROLOGY
LA English
DT Review
DE IPMN; Cyst Fluid; Surveillance, EUS
ID PAPILLARY-MUCINOUS NEOPLASMS; TERM-FOLLOW-UP; INTERNATIONAL CONSENSUS
GUIDELINES; SOLID-PSEUDOPAPILLARY TUMORS; OVARIAN-TYPE STROMA;
SEROUS-CYSTADENOMA; DUCTAL ADENOCARCINOMAS; ENDOSCOPIC ULTRASOUND;
ENDOCRINE NEOPLASMS; NATURAL-HISTORY
AB Approximately 10% of persons 70 years old or older are now diagnosed with pancreatic cysts, but it is not clear which ones require additional analysis, interventions, or follow-up. Primary care doctors rely on gastroenterologists for direction because no one wants to miss a diagnosis of pancreatic cancer, but meanwhile there is pressure to limit use of diagnostic tests and limit costs. We review the different cystic neoplasms of the pancreas and diagnostic strategies based on clinical features and imaging data. We discuss surgical and nonsurgical management of the most common cystic neoplasms, based on the recently revised Sendai guidelines. Intraductal papillary mucinous neoplasm (particularly the branch duct variant) is the lesion most frequently identified incidentally. We report what is known about its pathology, its risk of developing into pancreatic ductal adenocarcinoma, the pros and cons of current guidelines for management, and the potential role of endoscopic ultrasound in determining cancer risk. We also review surgical treatment and strategies for surveillance of pancreatic cysts.
C1 [Farrell, James J.] Yale Univ, Sch Med, Yale Pancreas Ctr, New Haven, CT 06510 USA.
[Farrell, James J.] Yale Univ, Sch Med, New Haven, CT 06510 USA.
[Fernandez-del Castillo, Carlos] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pancreas & Biliary Surg Program, Boston, MA USA.
RP Farrell, JJ (reprint author), Yale Univ, Sch Med, Sect Digest Dis, LMP 1080,15 York St, New Haven, CT 06510 USA.
EM j.farrell@yale.edu
NR 100
TC 61
Z9 64
U1 0
U2 18
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD MAY
PY 2013
VL 144
IS 6
BP 1303
EP 1315
DI 10.1053/j.gastro.2013.01.073
PG 13
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 144AE
UT WOS:000318910600017
PM 23622140
ER
PT J
AU Dobscha, SK
Corson, K
Helmer, DA
Bair, MJ
Denneson, LM
Brandt, C
Beane, A
Ganzini, L
AF Dobscha, Steven K.
Corson, Kathryn
Helmer, Drew A.
Bair, Matthew J.
Denneson, Lauren M.
Brandt, Cynthia
Beane, Anna
Ganzini, Linda
TI Brief assessment for suicidal ideation in OEF/OIF veterans with positive
depression screens
SO GENERAL HOSPITAL PSYCHIATRY
LA English
DT Article
DE Depression; Screening; Suicide; Veterans
ID PRIMARY-CARE; RISK; PHYSICIAN; SEVERITY; VALIDITY; RACE; IRAQ
AB Objectives: We describe processes, rates, and patient and system correlates of brief structured assessments (BSAs) for suicidal ideation among Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) veterans with positive depression screens.
Methods: Electronic Veterans Affairs (VA) medical record and Department of Defense data were used to identify individual-level and BSA-process variables for 1662 OEF/OIF veterans at three VA Medical Centers.
Results: Overall, 1349/1662 (81%) veterans received BSAs for suicidal ideation within 1 month of depression screening; 94% of BSAs were conducted within 1 day. Stratified analyses revealed significant intersite differences in veteran demographics, instruments used, clinical setting and staff performing assessments, and correlates of assessment completion. At two sites, men were more likely to be assessed than women [odds ratio (OR)=2.15 (95% confidence interval {CI}=1.06-4.38) and 3.14 (CI=1.27-7.76)]. In a combined model adjusted for intrasite correlation, assessment was less likely during months 8-12 and 13-18 of the study period [OR=0.39 (CI=0.28-0.54) and OR=0.48 (95% CI=0.35-0.68), respectively] and more likely to occur among veterans receiving depression or posttraumatic stress disorder diagnoses on the day of depression screening [OR=1.83 (CI=1.36-2.46) and OR=1.50 (CI=1.13-1.98), respectively].
Conclusions: Most veterans with positive depression screens receive timely BSAs for suicidal ideation. Processes used for brief assessment for suicidal ideation vary substantially across VA settings. Published by Elsevier Inc.
C1 [Dobscha, Steven K.; Corson, Kathryn; Denneson, Lauren M.; Beane, Anna; Ganzini, Linda] Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Phys & Mental D, Portland, OR USA.
[Dobscha, Steven K.; Corson, Kathryn; Denneson, Lauren M.; Ganzini, Linda] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA.
[Helmer, Drew A.] VA New Jersey Hlth Care Syst, War Related Illness & Injury Study Ctr, E Orange, NJ USA.
[Helmer, Drew A.] Baylor Coll Med, Houston, TX 77030 USA.
[Bair, Matthew J.] Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN USA.
[Brandt, Cynthia] West Haven Vet Affairs Med Ctr, West Haven, CT USA.
RP Dobscha, SK (reprint author), Portland VA Med Ctr, POB 1034 P3MHADM, Portland, OR 97207 USA.
EM steven.dobscha@va.gov
FU Department of Veterans Affairs, Veterans Health Administration; Health
Services Research and Development Service Project [DHI-08-096]
FX We gratefully acknowledge Jonathon Duckart, M. P. S.; Kathryn Dickinson,
M. P. H.; Ashley McComb, B. S.; Jose Perez, B. S.; and Megan
Crutchfield, M. P. H., for assistance with collecting and organizing
data and reviewing medical records. This material is based upon work
supported by the Department of Veterans Affairs, Veterans Health
Administration, and Health Services Research and Development Service
Project DHI-08-096. The views expressed in this article are those of the
authors and do not necessarily reflect the position or policy of the
Department of Veterans Affairs or the United States government.
NR 33
TC 5
Z9 5
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0163-8343
EI 1873-7714
J9 GEN HOSP PSYCHIAT
JI Gen. Hosp. Psych.
PD MAY-JUN
PY 2013
VL 35
IS 3
BP 272
EP 278
DI 10.1016/j.genhosppsych.2012.12.001
PG 7
WC Psychiatry
SC Psychiatry
GA 145DZ
UT WOS:000318995800010
PM 23351524
ER
PT J
AU Hall, TO
Wan, JY
Mata, IF
Kerr, KF
Snapinn, KW
Samii, A
Roberts, JW
Agarwal, P
Zabetian, CP
Edwards, KL
AF Hall, Taryn O.
Wan, Jia Y.
Mata, Ignacio F.
Kerr, Kathleen F.
Snapinn, Katherine W.
Samii, Ali
Roberts, John W.
Agarwal, Pinky
Zabetian, Cyrus P.
Edwards, Karen L.
TI Risk prediction for complex diseases: application to Parkinson disease
SO GENETICS IN MEDICINE
LA English
DT Article
DE genetics; Parkinson disease; risk prediction
ID GENOME-WIDE ASSOCIATION; VPS35 MUTATIONS; CANCER RISK; IDENTIFICATION;
POLYMORPHISMS; SPECIFICITY; SENSITIVITY; LIMITATIONS; POPULATION;
VARIANTS
AB Purpose: The aim of this study was to evaluate the risk of Parkinson disease using clinical and demographic data alone and when combined with information from genes associated with Parkinson disease.
Methods: A total of 1,967 participants in the dbGAP NeuroGenetics Research Consortium data set were included. Single-nucleotide polymorphisms associated with Parkinson disease at a genome-wide significance level in previous genome-wide association studies were included in risk prediction. Risk allele scores were calculated as the weighted count of the minor alleles. Five models were constructed. Discriminatory capability was evaluated using the area under the curve.
Results: Both family history and genetic risk scores increased risk for Parkinson disease. Although the fullest model, which included both family history and genetic risk information, resulted in the highest area under the curve, there were no significant differences between models using family history alone and those using genetic information alone.
Conclusion: Adding genome-wide association study-derived genotypes, family history information, or both to standard demographic risk factors for Parkinson disease resulted in an improvement in discriminatory capacity. In the full model, the contributions of genotype data and family history information to discriminatory capacity were similar, and both were statistically significant. This suggests that there is limited overlap between genetic risk factors identified through genome-wide association study and unmeasured susceptibility variants captured by family history. Our results are similar to those of studies of other complex diseases and indicate that genetic risk prediction for Parkinson disease requires identification of additional genetic risk factors and/or better methods for risk prediction in order to achieve a degree of risk prediction that is clinically useful.
C1 [Hall, Taryn O.; Edwards, Karen L.] Univ Washington, Inst Publ Hlth Genet, Seattle, WA 98195 USA.
[Wan, Jia Y.; Snapinn, Katherine W.; Edwards, Karen L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Mata, Ignacio F.; Samii, Ali; Zabetian, Cyrus P.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
[Mata, Ignacio F.; Samii, Ali; Zabetian, Cyrus P.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
[Kerr, Kathleen F.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Roberts, John W.] Virginia Mason Med Ctr, Seattle, WA 98101 USA.
[Agarwal, Pinky] Evergreen Hosp Med Ctr, Booth Gardner Parkinsons Care Ctr, Kirkland, WA USA.
RP Edwards, KL (reprint author), Univ Washington, Inst Publ Hlth Genet, Seattle, WA 98195 USA.
EM keddy@uw.edu
RI Kerr, Kathleen/A-2893-2013;
OI Fernandez Mata, Ignacio/0000-0003-1198-0633; Zabetian,
Cyrus/0000-0002-7739-4306
FU Department of Veterans Affairs [1I01BX000531]; National Institutes of
Health [P50 NS062684, R01 NS065070, R01 NS036960]
FX This work was supported by funding from the Department of Veterans
Affairs (1I01BX000531) and the National Institutes of Health (P50
NS062684, R01 NS065070, R01 NS036960).
NR 34
TC 7
Z9 7
U1 1
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1098-3600
J9 GENET MED
JI Genet. Med.
PD MAY
PY 2013
VL 15
IS 5
BP 361
EP 367
DI 10.1038/gim.2012.109
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA 143SN
UT WOS:000318888600007
PM 23222663
ER
PT J
AU Golnabi, AH
Meaney, PM
Paulsen, KD
AF Golnabi, Amir H.
Meaney, Paul M.
Paulsen, Keith D.
TI Tomographic Microwave Imaging With Incorporated Prior Spatial
Information
SO IEEE TRANSACTIONS ON MICROWAVE THEORY AND TECHNIQUES
LA English
DT Article
DE A priori spatial information; image reconstruction; microwave imaging;
multimodality imaging; regularization; soft prior; tissue dielectric
properties
ID BREAST-CANCER; RECONSTRUCTION; TISSUES; SYSTEM; DIAGNOSIS; WOMEN
AB We have implemented a soft prior regularization technique for microwave tomographic imaging that exploits spatial prior information from alternative imaging modalities. We have previously demonstrated in both simulation and phantom experiments that this approach is capable of improved property recovery compared with our conventional Tikhonov regularized method. An important concern with this type of integration is that the spatial information could be implemented in such a way as to overly influence or even bias the final results. For this reason, we have performed a rigorous quantitative analysis of this approach using both simulation and phantom experiments to investigate the sensitivity to inaccurate or even false spatial information. The majority of cases tested here involved simple targets to easily assess problems when the prior shapes are incorrect with respect to size and location or even when there is an extra target that does not exist in the actual imaging situation. In addition, we have also performed a simulated experiment utilizing anthropomorphic breast structural information to explore the capabilities in more challenging situations. The results are encouraging and demonstrate that the soft prior regularization can be a powerful tool, especially where the goal is specificity instead of sensitivity.
C1 [Golnabi, Amir H.; Meaney, Paul M.; Paulsen, Keith D.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA.
RP Golnabi, AH (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM Golnabi.Amir@MGH.Harvard.edu; Paul.M.Meaney@Dart-mouth.edu;
Keith.D.Paulsen@Dartmouth.edu
FU National Institutes of Health (NIH); National Cancer Institute (NCI)
[R33-CA102938-04]
FX Manuscript received October 15, 2012; revised January 28, 2013; accepted
January 30, 2013. Date of publication March 07, 2013; date of current
version May 02, 2013. This work was supported in part by the National
Institutes of Health (NIH) and the National Cancer Institute (NCI) under
Grant R33-CA102938-04.
NR 28
TC 17
Z9 17
U1 0
U2 13
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 0018-9480
J9 IEEE T MICROW THEORY
JI IEEE Trans. Microw. Theory Tech.
PD MAY
PY 2013
VL 61
IS 5
SI SI
BP 2129
EP 2136
DI 10.1109/TMTT.2013.2247413
PN 2
PG 8
WC Engineering, Electrical & Electronic
SC Engineering
GA 141BT
UT WOS:000318701100017
ER
PT J
AU Osguthorpe, JD
AF Osguthorpe, John David
TI Pathophysiology of and potential new therapies for allergic rhinitis
SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY
LA English
DT Review
DE T-helper lymphocyte; IgE; eosinophil; mast cell; humanized monoclonal
antibody; cytokine; chemokine
ID HYGIENE HYPOTHESIS; NASAL POLYPOSIS; IMMUNOTHERAPY; INFLAMMATION;
DISEASE; ASTHMA; IGE; RHINOSINUSITIS; MECHANISMS; DISORDERS
AB Background Advancement in laboratory techniques in the past decade, coupled with clinical studies, has afforded a better understanding of the genetic and molecular mechanisms underlying allergy. Methods The literature on the pathophysiology of allergic rhinitis, systemic and local, was reviewed, with emphasis on the last 3 years. Results The basis in allergic rhinitis for the T-lymphocyte helper 2 cell and associated cytokine bias, and the ameliorating effects of T-regulatory lymphocytes and their cytokines, is summarized. New or currently under development pharmacotherapeutic agents are briefly presented. Conclusion Much of the molecular basis for the manifestations of allergy can now be explained, and may afford strategies to interrupt the development of disease or ameliorate such already present.
C1 [Osguthorpe, John David] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA.
RP Osguthorpe, JD (reprint author), Ralph Johnson VA Med Ctr, Surg Serv 112, 109 Bee St, Charleston, SC 29401 USA.
EM osguthjd@musc.edu
NR 57
TC 7
Z9 8
U1 2
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2042-6976
J9 INT FORUM ALLERGY RH
JI Int. Forum Allergy Rhinol.
PD MAY
PY 2013
VL 3
IS 5
BP 384
EP 392
DI 10.1002/alr.21120
PG 9
WC Otorhinolaryngology
SC Otorhinolaryngology
GA 146ET
UT WOS:000319073200008
PM 23193028
ER
PT J
AU Cardarella, S
Johnson, BE
AF Cardarella, Stephanie
Johnson, Bruce E.
TI Meta-Analysis of EGFR Kinase Inhibitors: Not Always Greater Than the Sum
of Its Parts
SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Editorial Material
ID CELL LUNG-CANCER; PHASE-III TRIAL; 1ST-LINE TREATMENT;
CARBOPLATIN-PACLITAXEL; OPEN-LABEL; GEFITINIB; CHEMOTHERAPY;
ADENOCARCINOMA; MUTATIONS; ERLOTINIB
C1 [Cardarella, Stephanie; Johnson, Bruce E.] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02215 USA.
[Cardarella, Stephanie; Johnson, Bruce E.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Cardarella, Stephanie; Johnson, Bruce E.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
RP Johnson, BE (reprint author), Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, 450 Brookline Ave,Dana 1234, Boston, MA 02215 USA.
EM bejohnson@partners.org
NR 19
TC 2
Z9 2
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
J9 JNCI-J NATL CANCER I
JI JNCI-. Natl. Cancer Inst.
PD MAY
PY 2013
VL 105
IS 9
BP 589
EP 590
DI 10.1093/jnci/djt085
PG 2
WC Oncology
SC Oncology
GA 140UK
UT WOS:000318681200003
PM 23594425
ER
PT J
AU Brooks, GA
Li, L
Sharma, DB
Weeks, JC
Hassett, MJ
Yabroff, KR
Schrag, D
AF Brooks, Gabriel A.
Li, Ling
Sharma, Dhruv B.
Weeks, Jane C.
Hassett, Michael J.
Yabroff, K. Robin
Schrag, Deborah
TI Regional Variation in Spending and Survival for Older Adults With
Advanced Cancer
SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID OF-LIFE TREATMENT; CELL LUNG-CANCER; PALLIATIVE CARE; COMORBIDITY INDEX;
COSTS; END; INTENSITY; OUTCOMES; SATISFACTION; PREFERENCES
AB Background Medicare spending varies substantially across the United States. We evaluated the association between mean regional spending and survival in advanced cancer.
Methods We identified 116 523 subjects with advanced cancer from 2002 to 2007, using Surveillance, Epidemiology and End Results (SEER)-Medicare linked data. Subjects were aged 65 years and older with non-small cell lung, colon, breast, prostate, or pancreas cancer. Of these subjects, 61 083 had incident advanced-stage cancer (incident cohort) and 98 935 had death from cancer (decedent cohort); 37% of subjects were included in both cohorts. Subjects were linked to one of 80 hospital referral regions within SEER areas. We estimated mean regional spending in both cohorts. We assessed the primary outcome, survival, in the incident cohort; the exposure measure was the quintile of regional spending in the decedent cohort. Survival in quintiles 2 through 5 was compared with that in quintile 1 (lowest spending quintile) using Cox regression models.
Results From quintile 1 to 5, mean regional spending increased by 32% and 41% in the incident and decedent cohorts (incident cohort: $28 854 to $37 971; decedent cohort: $27 446 to $38 630). The association between spending and survival varied by cancer site and quintile; hazard ratios ranged from 0.92 (95% confidence interval [CI] = 0.82 to 1.04, pancreas cancer quintile 5) to 1.24 (95% CI = 1.11 to 1.39, breast cancer quintile 3). In most cases, differences in survival between quintile 1 and quintiles 2 through 5 were not statistically significant.
Conclusion There is substantial regional variation in Medicare spending for advanced cancer, yet no consistent association between mean regional spending and survival.
C1 [Brooks, Gabriel A.; Li, Ling; Sharma, Dhruv B.; Weeks, Jane C.; Hassett, Michael J.; Schrag, Deborah] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Yabroff, K. Robin] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA.
RP Brooks, GA (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM gabrooks@partners.org
OI Brooks, Gabriel/0000-0003-3984-9995; Yabroff, K.
Robin/0000-0003-0644-5572
FU National Cancer Institute of the National Institutes of Health
[5R01CA131847, T32CA009172]
FX This work was supported by grants from the National Cancer Institute of
the National Institutes of Health (5R01CA131847 to DS, and T32CA009172,
an institutional training grant supporting GAB). Contents of this
publication are solely the responsibility of the authors and do not
necessarily represent the official views of the National Cancer
Institute or the National Institutes of Health.
NR 39
TC 33
Z9 33
U1 5
U2 13
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
EI 1460-2105
J9 JNCI-J NATL CANCER I
JI JNCI-J. Natl. Cancer Inst.
PD MAY
PY 2013
VL 105
IS 9
BP 634
EP 642
DI 10.1093/jnci/djt025
PG 9
WC Oncology
SC Oncology
GA 140UK
UT WOS:000318681200010
PM 23482657
ER
PT J
AU Badr, CE
Van Hoppe, S
Dumbuya, H
Tjon-Kon-Fat, LA
Tannous, BA
AF Badr, Christian E.
Van Hoppe, Stephanie
Dumbuya, Hawasatu
Tjon-Kon-Fat, Lee-Ann
Tannous, Bakhos A.
TI Targeting Cancer Cells With the Natural Compound Obtusaquinone
SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID OXIDATIVE STRESS; TUMOR-SUPPRESSOR; STEM-CELLS; P53; GLIOBLASTOMA; ROS;
CARCINOMA; SURVIVAL
AB Background Tumor cells present high levels of oxidative stress. Cancer therapeutics exploiting such biochemical changes by increasing reactive oxygen species (ROS) production or decreasing intracellular ROS scavengers could provide a powerful treatment strategy.
Methods To test the effect of our compound, obtusaquinone (OBT), we used several cell viability assays on seven different glioblastoma (GBM) cell lines and primary cells and on 12 different cell lines representing various cancer types in culture as well as on subcutaneous (n = 7 mice per group) and two intracranial GBM (n = 6-8 mice per group) and breast cancer (n = 6 mice per group) tumor models in vivo. Immunoblotting, immunostaining, flow cytometry, and biochemical assays were used to investigate the OBT mechanism of action. Histopathological analysis (n = 2 mice per group) and blood chemistry (n = 2 mice per group) were used to test for any compound-related toxicity. Statistical tests were two-sided.
Results OBT induced rapid increase in intracellular ROS levels, downregulation of cellular glutathione levels and increase in its oxidized form, and activation of cellular stress pathways and DNA damage, subsequently leading to apoptosis. Oxidative stress is believed to be the main mechanism through which this compounds targets cancer cells. OBT was well tolerated in mice, slowed tumor growth, and statistically prolonged survival in GBM tumor models. The ratio of median survival in U251 intracranial model in OBT vs control was 1.367 (95% confidence interval [CI] of ratio = 1.031 to 1.367, P=.008). Tumor growth inhibition was also observed in a mouse breast cancer model (average tumor volume per mouse, OBT vs control: 36.3 vs 200.4 mm(3), difference = 164.1 mm(3), 95% CI = 72.6 to 255.6 mm(3), P =.005).
Conclusions Given its properties and efficacy in cancer killing, our results suggest that OBT is a promising cancer therapeutic.
C1 [Badr, Christian E.; Van Hoppe, Stephanie; Dumbuya, Hawasatu; Tjon-Kon-Fat, Lee-Ann; Tannous, Bakhos A.] Massachusetts Gen Hosp, Dept Neurol, Expt Therapeut & Mol Imaging Lab, Neurosci Ctr, Boston, MA 02114 USA.
[Badr, Christian E.; Tannous, Bakhos A.] Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA.
RP Tannous, BA (reprint author), Massachusetts Gen Hosp, Ctr Neurosci, Bldg 149,13th St, Charlestown, MA 02129 USA.
EM badr.christian@mgh.harvard.edu; btannous@hms.harvard.edu
FU National Institutes of Health/National Institute of Neurological
Disorders and Stroke [1R21NS061051, P30NS045776, 1R01NS064983]; American
Brain Tumor Association
FX This work was supported by grants from National Institutes of
Health/National Institute of Neurological Disorders and Stroke
(1R21NS061051, P30NS045776, and 1R01NS064983 [to BAT]) and the American
Brain Tumor Association (to CEB).
NR 25
TC 9
Z9 9
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
J9 JNCI-J NATL CANCER I
JI JNCI-. Natl. Cancer Inst.
PD MAY
PY 2013
VL 105
IS 9
BP 643
EP 653
DI 10.1093/jnci/djt037
PG 11
WC Oncology
SC Oncology
GA 140UK
UT WOS:000318681200011
PM 23479453
ER
PT J
AU Hanna, SC
Krishnan, B
Bailey, ST
Moschos, SJ
Kuan, PF
Shimamura, T
Osborne, LD
Siegel, MB
Duncan, LM
O'Brien, ET
Superfine, R
Miller, CR
Simon, MC
Wong, KK
Kim, WY
AF Hanna, Sara C.
Krishnan, Bhavani
Bailey, Sean T.
Moschos, Stergios J.
Kuan, Pei-Fen
Shimamura, Takeshi
Osborne, Lukas D.
Siegel, Marni B.
Duncan, Lyn M.
O'Brien, E. Tim, III
Superfine, Richard
Miller, C. Ryan
Simon, M. Celeste
Wong, Kwok-Kin
Kim, William Y.
TI HIF1 alpha and HIF2 alpha independently activate SRC to promote melanoma
metastases
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; GROWTH-FACTOR EXPRESSION; TUMOR
PROGRESSION; IN-VIVO; CANCER; HIF-2-ALPHA; HIF-1-ALPHA; TARGET; CELLS;
MITF
AB Malignant melanoma is characterized by a propensity for early lymphatic and hematogenous spread. The hypoxia-inducible factor (HIP) family of transcription factors is upregulated in melanoma by key oncogenic drivers. HIFs promote the activation of genes involved in cancer initiation, progression, and metastases. Hypoxia has been shown to enhance the invasiveness and metastatic potential of tumor cells by regulating the genes involved in the breakdown of the ECM as well as genes that control motility and adhesion of tumor cells. Using a Pten-deficient, Brarmutant genetically engineered mouse model of melanoma, we demonstrated that inactivation of HIF1 alpha or HIF2 alpha abrogates metastasis without affecting primary tumor formation. HIF1 alpha and HIF2 alpha drive melanoma invasion and invadopodia formation through PDGFR alpha and focal adhesion kinase-mediated (FAK-mediated) activation of SRC and by coordinating ECM degradation via MT1-MMP and MMP2 expression. These results establish the importance of HIFs in melanoma progression and demonstrate that HIF1 alpha and HIF2 alpha activate independent transcriptional programs that promote metastasis by coordinately regulating cell invasion and ECM remodeling.
C1 [Hanna, Sara C.; Krishnan, Bhavani; Bailey, Sean T.; Moschos, Stergios J.; Kuan, Pei-Fen; Siegel, Marni B.; Miller, C. Ryan; Kim, William Y.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
[Kuan, Pei-Fen] Univ N Carolina, Dept Biostat, Chapel Hill, NC 27599 USA.
[Shimamura, Takeshi] Loyola Univ Chicago, Dept Mol Pharmacol & Therapeut, Oncol Inst, Maywood, IL USA.
[Osborne, Lukas D.; O'Brien, E. Tim, III; Superfine, Richard] Univ N Carolina, Dept Phys & Astron, Chapel Hill, NC 27599 USA.
[Duncan, Lyn M.] Massachusetts Gen Hosp, Pathol Serv, Boston, MA 02114 USA.
[Duncan, Lyn M.] Massachusetts Gen Hosp, Dermatopathol Unit, Boston, MA 02114 USA.
[Miller, C. Ryan] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA.
[Simon, M. Celeste] Univ Penn, Howard Hughes Med Inst, Dept Cell & Dev Biol, Abramson Family Canc Res Inst,Dept Canc Biol, Philadelphia, PA 19104 USA.
[Wong, Kwok-Kin] Harvard Univ, Sch Med, Dept Med, Dept Med Oncol, Boston, MA USA.
[Wong, Kwok-Kin] Dana Farber Harvard Canc Ctr, Lowe Ctr Thorac Oncol, Boston, MA USA.
[Wong, Kwok-Kin] Dana Farber Harvard Canc Ctr, Ludwig Ctr, Boston, MA USA.
RP Kim, WY (reprint author), Univ N Carolina, Lineberger Comprehens Canc Ctr, CB 7295, Chapel Hill, NC 27599 USA.
EM wykim@med.unc.edu
RI Miller, Ryan/B-9365-2008;
OI Miller, Ryan/0000-0002-0096-8762; wong, kwok kin/0000-0001-6323-235X
FU CGIBD Imaging and Histology Core [NIH P30-DK-034987]; National Cancer
Institute [3P30CA016086]; National Institute of Environmental Health
Sciences [3P30ES010126]; Department of Defense [W81XWH-09-2-0042,
PC094631, W81XWH-08-1-0064]; UNC University Cancer Research Fund (UCRF);
Specialized Program of Research Excellence [IP50CA93683-03]; Melanoma
Research Foundation, NIH [R01 CA142794, R33 CA155618, U54 CA151652]; NCI
[CA 122794, 166480, 163896, 140594, 141576, 120964, 154303]; University
Cancer Research Fund (UCRF)
FX We would like to acknowledge the members of the Kim and Sharpless labs
as well as Nicole Neel and Kim Monahan for useful discussions and
advice. We thank Carolyn Suitt of the University of North Carolina CGIBD
Histology Core Facility, which is supported by the CGIBD Imaging and
Histology Core (NIH P30-DK-034987). The authors thank the UNC TPL, which
is supported, in part, by grants from the National Cancer Institute
(3P30CA016086), the National Institute of Environmental Health Sciences
(3P30ES010126), the Department of Defense (W81XWH-09-2-0042), and the
UNC University Cancer Research Fund (UCRF). We would also like to thank
the UNC Microscopy Services Laboratory Director, Robert Bagnell and the
UNC Mouse Phase 1 Unit (MP1U). The SkinSPORE melanocytic tumor
progression array was developed with the support of the Specialized
Program of Research Excellence (IP50CA93683-03). This work was supported
by the Melanoma Research Foundation (to W.Y. Kim), NIH R01 CA142794 (to
W.Y. Kim), R33 CA155618 (to R. Superfine), U54 CA151652 (to W.Y. Kim and
R. Superfine), NCI CA 122794, 166480, 163896, 140594, 141576, 120964,
and 154303 (to K. K. Wong), the University Cancer Research Fund (UCRF),
and Department of Defense grants PC094631 and W81XWH-08-1-0064 (to W.Y.
Kim). W.Y. Kim is a Damon Runyon Merck Clinical Investigator.
NR 41
TC 51
Z9 53
U1 0
U2 14
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD MAY
PY 2013
VL 123
IS 5
BP 2078
EP 2093
DI 10.1172/JCI66715
PG 16
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 145OA
UT WOS:000319025100029
PM 23563312
ER
PT J
AU Thurman, JM
Kulik, L
Orth, H
Wong, M
Renner, B
Sargsyan, SA
Mitchell, LM
Hourcade, DE
Hannan, JP
Kovacs, JM
Coughlin, B
Woodell, AS
Pickering, MC
Rohrer, B
Holers, VM
AF Thurman, Joshua M.
Kulik, Liudmila
Orth, Heather
Wong, Maria
Renner, Brandon
Sargsyan, Siranush A.
Mitchell, Lynne M.
Hourcade, Dennis E.
Hannan, Jonathan P.
Kovacs, James M.
Coughlin, Beth
Woodell, Alex S.
Pickering, Matthew C.
Rohrer, Baerbel
Holers, V. Michael
TI Detection of complement activation using monoclonal antibodies against
C3d
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID SITE-DIRECTED MUTAGENESIS; RECEPTOR-TYPE 2; FACTOR-H; MACULAR
DEGENERATION; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; CHOROIDAL
NEOVASCULARIZATION; ACQUIRED-IMMUNITY; PROTEIN BETA-1H; MICE DEFICIENT;
FLUID-PHASE
AB During complement activation the C3 protein is cleaved, and C3 activation fragments are covalently fixed to tissues. Tissue-bound C3 fragments are a durable biomarker of tissue inflammation, and these fragments have been exploited as addressable binding ligands for targeted therapeutics and diagnostic agents. We have generated cross-reactive murine monoclonal antibodies against human and mouse C3d, the final C3 degradation fragment generated during complement activation. We developed 3 monoclonal antibodies (3d8b, 3d9a, and 3d29) that preferentially bind to the iC3b, C3dg, and C3d fragments in solution, but do not bind to intact C3 or C3b. The same 3 clones also bind to tissue-bound C3 activation fragments when injected systemically. Using mouse models of renal and ocular disease, we confirmed that, following systemic injection, the antibodies accumulated at sites of C3 fragment deposition within the glomerulus, the renal tubulointerstitium, and the posterior pole of the eye. To detect antibodies bound within the eye, we used optical imaging and observed accumulation of the antibodies within retinal lesions in a model of choroidal neovascularization (CNV). Our results demonstrate that imaging methods that use these antibodies may provide a sensitive means of detecting and monitoring complement activation-associated tissue inflammation.
C1 [Thurman, Joshua M.; Kulik, Liudmila; Orth, Heather; Wong, Maria; Renner, Brandon; Sargsyan, Siranush A.; Hannan, Jonathan P.; Kovacs, James M.; Holers, V. Michael] Univ Colorado, Sch Med, Dept Med, Aurora, CO USA.
[Mitchell, Lynne M.; Hourcade, Dennis E.] Washington Univ, Sch Med, Dept Med, Div Rheumatol, St Louis, MO 63110 USA.
[Coughlin, Beth; Rohrer, Baerbel] Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA.
[Woodell, Alex S.; Rohrer, Baerbel] Ralph H Johnson VA Med Ctr, Res Serv 151, Charleston, SC USA.
[Pickering, Matthew C.] Univ London Imperial Coll Sci Technol & Med, Ctr Complement & Inflammat Res, London SW7 2AZ, England.
[Rohrer, Baerbel] Med Univ S Carolina, Dept Neurosci, Div Res, Charleston, SC 29425 USA.
RP Thurman, JM (reprint author), Univ Colorado Denver, Sch Med, Div Nephrol & Hypertens, B-115,POB 6511, Aurora, CO 80045 USA.
EM Joshua.Thurman@ucdenver.edu
OI Pickering, Matthew/0000-0002-1153-0192; Hannan,
Jonathan/0000-0003-3318-2341
FU Alexion Pharmaceuticals, Inc.; Beckman Initiative for Macular Research;
KIDNEEDS Foundation; NIH [R01 AR51749, R01 DK076690, R01 AI051436]
FX Joshua M. Thurman and V. Michael Holers are paid consultants for Alexion
Pharmaceuticals, Inc. A patent application has been filed for the
monoclonal antibodies described in this manuscript.; We thank Shaun
Bevers at the University of Colorado Biophysics Core for technical
assistance. This work was supported in part by the Beckman Initiative
for Macular Research (to V.M. Holers), the KIDNEEDS Foundation (to J.M.
Thurman), NIH grants R01 AR51749 (to V.M. Holers), R01 DK076690 (to J.M.
Thurman), and R01 AI051436 (to D.E. Hourcade), and a sponsored research
agreement with Alexion Pharmaceuticals, Inc.
NR 48
TC 16
Z9 16
U1 2
U2 7
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD MAY
PY 2013
VL 123
IS 5
BP 2218
EP 2230
DI 10.1172/JCI65861
PG 13
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 145OA
UT WOS:000319025100040
PM 23619360
ER
PT J
AU Li, N
Wu, XF
Holzer, RG
Lee, JH
Todoric, J
Park, EJ
Ogata, H
Gukovskaya, AS
Gukovsky, I
Pizzo, DP
VandenBerg, S
Tarin, D
Atay, C
Arkan, MC
Deerinck, TJ
Moscat, J
Diaz-Meco, M
Dawson, D
Erkan, M
Kleeff, J
Karin, M
AF Li, Ning
Wu, Xuefeng
Holzer, Ryan G.
Lee, Jun-Hee
Todoric, Jelena
Park, Eek-Joong
Ogata, Hisanobu
Gukovskaya, Anna S.
Gukovsky, Ilya
Pizzo, Donald P.
VandenBerg, Scott
Tarin, David
Atay, Cigdem
Arkan, Melek C.
Deerinck, Thomas J.
Moscat, Jorge
Diaz-Meco, Maria
Dawson, David
Erkan, Mert
Kleeff, Joerg
Karin, Michael
TI Loss of acinar cell IKK alpha triggers spontaneous pancreatitis in mice
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID ENDOPLASMIC-RETICULUM STRESS; NF-KAPPA-B; UNFOLDED PROTEIN RESPONSE;
TRYPSINOGEN ACTIVATION; OXIDATIVE STRESS; AUTOPHAGY; P62; CANCER;
INFLAMMATION; MOUSE
AB Chronic pancreatitis is an inflammatory disease that causes progressive destruction of pancreatic acinar cells and, ultimately, loss of pancreatic function. We investigated the role of I kappa B kinase alpha (IKK alpha) in pancreatic homeostasis. Pancreas-specific ablation of IKK alpha (Ikk alpha(Delta pan)) caused spontaneous and progressive acinar cell vacuolization and death, interstitial fibrosis, inflammation, and circulatory release of pancreatic enzymes, clinical signs resembling those of human chronic pancreatitis. Loss of pancreatic IKK alpha causes defective autophagic protein degradation, leading to accumulation of p62-mediated protein aggregates and enhanced oxidative and ER stress in acinar cells, but none of these effects is related to NF-kappa B. Pancreas-specific p62 ablation prevented ER and oxidative stresses and attenuated pancreatitis in Ikk alpha(Delta pan) mice, suggesting that cellular stress induced by p62 aggregates promotes development of pancreatitis. Importantly, downregulation of IKK alpha and accumulation of p62 aggregates were also observed in chronic human pancreatitis. Our studies demonstrate that IKK alpha, which may control autophagic protein degradation through its interaction with ATG16L2, plays a critical role in maintaining pancreatic acinar cell homeostasis, whose dysregulation promotes pancreatitis through p62 aggregate accumulation.
C1 [Li, Ning; Wu, Xuefeng; Holzer, Ryan G.; Lee, Jun-Hee; Todoric, Jelena; Park, Eek-Joong; Ogata, Hisanobu; Karin, Michael] Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA.
[Li, Ning; Wu, Xuefeng; Holzer, Ryan G.; Lee, Jun-Hee; Todoric, Jelena; Park, Eek-Joong; Ogata, Hisanobu; Karin, Michael] Univ Calif San Diego, Sch Med, Dept Pathol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA.
[Todoric, Jelena] Med Univ Vienna, Dept Lab Med, Vienna, Austria.
[Gukovskaya, Anna S.; Gukovsky, Ilya] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Gukovskaya, Anna S.; Gukovsky, Ilya] Univ Calif Los Angeles, Los Angeles, CA USA.
[Pizzo, Donald P.; VandenBerg, Scott; Tarin, David] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA.
[Atay, Cigdem; Arkan, Melek C.] Tech Univ Munich, Klinikum Rechts Isar, Dept Med 2, D-80290 Munich, Germany.
[Deerinck, Thomas J.] Univ Calif San Diego, Natl Ctr Microscopy & Imaging Res, La Jolla, CA 92093 USA.
[Moscat, Jorge; Diaz-Meco, Maria] Sanford Burnham Med Res Inst, La Jolla, CA USA.
[Dawson, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.
[Erkan, Mert; Kleeff, Joerg] Tech Univ Munich, Klinikum Rechts Isar, Dept Gen Surg, D-80290 Munich, Germany.
RP Karin, M (reprint author), Univ Calif San Diego, 9500 Gilman Dr,Mail Code 0723,Leichtag Bldg,Room, La Jolla, CA 92093 USA.
EM karinoffice@ucsd.edu
RI Kleeff, Jorg/B-2124-2009; Dawson, David/I-5917-2014
OI Kleeff, Jorg/0000-0003-3432-6669;
FU NIH [P50 AA011999, AI043477, CA163798, CA167120]; Pancreatic Cancer
Research Lustgarten Foundation grant [RFP-B-007]; Susan G. Komen for the
Cure [KG111506]; Austrian Science Fund's Erwin Schroedinger Fellowship
[J 3233]
FX This work was supported by NIH grants P50 AA011999 (Pilot Project to M.
Karin), AI043477 (to M. Karin), CA163798 (to M. Karin), and CA167120 (to
N. Li) and by Pancreatic Cancer Research Lustgarten Foundation grant
RFP-B-007 (to M. Karin). X. Wu was supported by a postdoctoral
fellowship from Susan G. Komen for the Cure (KG111506). J. Todoric was
supported by the Austrian Science Fund's Erwin Schroedinger Fellowship
(Project# J 3233). We thank S.L. Gonias, D. Brenner, M. Erkan, J.
Kleeff, and F.R. Greten for help in procuring human pancreatitis samples
and for helpful advice; J. Xiao for technical assistance; and M.G.
Farquhar and M. Niwa for helpful discussions regarding lysosomes and ER
stress, respectively. We also thank Santa Cruz Biotechnology Inc. and
Cell Signaling for antibody samples.
NR 62
TC 33
Z9 35
U1 0
U2 6
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD MAY
PY 2013
VL 123
IS 5
BP 2231
EP 2243
DI 10.1172/JCI64498
PG 13
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 145OA
UT WOS:000319025100041
PM 23563314
ER
PT J
AU Schlegel, J
Sambade, MJ
Sather, S
Moschos, SJ
Tan, AC
Winges, A
DeRyckere, D
Carson, CC
Trenthath, DG
Tentler, JJ
Eckhardt, SG
Kuan, PF
Hamilton, RL
Duncan, LM
Miller, CR
Nikolaishvili-Feinberg, N
Midkiff, BR
Liu, J
Zhang, WH
Yang, C
Wang, XD
Frye, SV
Earp, HS
Shields, JM
Graham, DK
AF Schlegel, Jennifer
Sambade, Maria J.
Sather, Susan
Moschos, Stergios J.
Tan, Aik-Choon
Winges, Amanda
DeRyckere, Deborah
Carson, Craig C.
Trenthath, Dimitri G.
Tentler, John J.
Eckhardt, S. Gail
Kuan, Pei-Fen
Hamilton, Ronald L.
Duncan, Lyn M.
Miller, C. Ryan
Nikolaishvili-Feinberg, Nana
Midkiff, Bentley R.
Liu, Jing
Zhang, Weihe
Yang, Chao
Wang, Xiaodong
Frye, Stephen V.
Earp, H. Shelton
Shields, Janie M.
Graham, Douglas K.
TI MERTK receptor tyrosine kinase is a therapeutic target in melanoma
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; RAF INHIBITOR RESISTANCE; TUMOR
PROGRESSION; APOPTOTIC CELLS; UP-REGULATION; EXPRESSION; CANCER; AXL;
CLEARANCE; MUTATIONS
AB Metastatic melanoma is one of the most aggressive forms of cutaneous cancers. Although recent therapeutic advances have prolonged patient survival, the prognosis remains dismal. C-MER proto-oncogene tyrosine kinase (MERTK) is a receptor tyrosine kinase with oncogenic properties that is often overexpressed or activated in various malignancies. Using both protein immunohistochemistry and microarray analyses, We demonstrate that MERTK expression correlates with disease progression. MERTK expression was highest in metastatic melanomas, followed by primary melanomas, while the lowest expression was observed in nevi. Additionally, over half of melanoma cell lines overexpressed MERTK compared with normal human melanocytes; however, overexpression did not correlate with mutations in BRAF or RAS. Stimulation of melanoma cells with the MERTK ligand. GAS6 resulted in the activation of several downstream signaling pathways including MAPK/ERK, PI3K/AKT, and JAK/STAT. MERTK inhibition via shRNA reduced MERTK-mediated downstream signaling, reduced colony formation by up to 59%, and diminished tumor volume by 60% in a human melanoma murine xenograft model. Treatment of melanoma cells with UNC1062, a novel MERTK-selective small-molecule tyrosine kinase inhibitor, reduced activation of MERTK-mediated downstream signaling, induced apoptosis in culture, reduced colony formation in soft agar, and inhibited invasion of melanoma cells. This work establishes MERTK as a therapeutic target in melanoma and provides a rationale for the continued development of MERTK-targeted therapies.
C1 [Schlegel, Jennifer; Sather, Susan; Winges, Amanda; DeRyckere, Deborah; Graham, Douglas K.] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA.
[Sambade, Maria J.; Moschos, Stergios J.; Kuan, Pei-Fen; Miller, C. Ryan; Nikolaishvili-Feinberg, Nana; Frye, Stephen V.; Earp, H. Shelton; Shields, Janie M.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
[Moschos, Stergios J.] Univ N Carolina, Dept Med, Chapel Hill, NC USA.
[Tan, Aik-Choon; Tentler, John J.; Eckhardt, S. Gail] Univ Colorado, Sch Med, Div Med Oncol, Aurora, CO USA.
[Carson, Craig C.; Shields, Janie M.] Univ N Carolina, Dept Dermatol, Chapel Hill, NC 27514 USA.
[Trenthath, Dimitri G.; Miller, C. Ryan] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC USA.
[Kuan, Pei-Fen] Univ N Carolina, Dept Biostat, Chapel Hill, NC USA.
[Hamilton, Ronald L.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA.
[Duncan, Lyn M.] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Miller, C. Ryan; Midkiff, Bentley R.] Univ N Carolina, Translat Pathol Core Lab, Chapel Hill, NC USA.
[Liu, Jing; Zhang, Weihe; Wang, Xiaodong; Frye, Stephen V.] Univ N Carolina, Eshelman Sch Pharm, Div Chem Biol & Med Chem, Chapel Hill, NC USA.
[Liu, Jing; Zhang, Weihe; Wang, Xiaodong; Frye, Stephen V.] Univ N Carolina, Sch Med, Ctr Integrat Chem Biol & Drug Discovery, Chapel Hill, NC USA.
[Yang, Chao] Anichem Inc, North Brunswick, NJ USA.
[Shields, Janie M.] Univ N Carolina, Sch Med, Dept Radiat Oncol, Chapel Hill, NC 27599 USA.
RP Graham, DK (reprint author), Dept Pediat, P18-4401,Mail Stop 8302,12800 East 19th Ave, Aurora, CO 80045 USA.
EM doug.graham@ucdenver.edu
RI liu, jing/G-3957-2011; Zhang, Weihe/A-3156-2011; Tan, Aik
Choon/A-3135-2011; Miller, Ryan/B-9365-2008;
OI Zhang, Weihe/0000-0001-5867-6407; Miller, Ryan/0000-0002-0096-8762; Tan,
Aik Choon/0000-0003-2955-8369
FU National Cancer Institute [HHSN261200800001E, 3P30CA016086]; American
Cancer Society [RGS082910121B]; National Institutes of Health
[RO1CA137078, CA115888, ES014635]; American Brain Tumor Basic Research
Fellowship; UNC University Cancer Research Fund (UCRF)
FX This work was supported in part by grants from the National Cancer
Institute (contract no. HHSN261200800001E), American Cancer Society
(RGS082910121B, to D.K. Graham), National Institutes of Health
(RO1CA137078, to D.K. Graham; CA115888 and ES014635, to J. Shields), and
the American Brain Tumor Basic Research Fellowship in honor of Mark
Linder (to M.J. Sambade). The UNC Translational Pathology Laboratory is
supported in part by grants from the National Cancer Institute
(3P30CA016086) and the UNC University Cancer Research Fund (UCRF). The
authors wish to thank Randall Wong of the University of Colorado DERC
Molecular Biology Core (NTH P30 DK57516) for cell line authentication;
Christine Childs of the University of Colorado Cancer Center Flow
Cytometry Shared Resource for technical assistance; and Charlene Santos
of the UNC-CH LCCC Animal Studies Facility for conducting animal
experiments using human melanoma xenografts.
NR 39
TC 45
Z9 46
U1 1
U2 20
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD MAY
PY 2013
VL 123
IS 5
BP 2257
EP 2267
DI 10.1172/JCI67816
PG 11
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 145OA
UT WOS:000319025100043
PM 23585477
ER
PT J
AU Ramirez, AS
Freres, D
Martinez, LS
Lewis, N
Bourgoin, A
Kelly, BJ
Lee, CJ
Nagler, R
Schwartz, JS
Hornik, RC
AF Ramirez, A. Susana
Freres, Derek
Martinez, Lourdes S.
Lewis, Nehama
Bourgoin, Angel
Kelly, Bridget J.
Lee, Chul-Joo
Nagler, Rebekah
Schwartz, J. Sanford
Hornik, Robert C.
TI Information Seeking From Media and Family/Friends Increases the
Likelihood of Engaging in Healthy Lifestyle Behaviors
SO JOURNAL OF HEALTH COMMUNICATION
LA English
DT Article
ID CANCER NEWS COVERAGE; PLANNED BEHAVIOR; PHYSICAL-ACTIVITY;
UNITED-STATES; PREVENTION; INTENTION; SERVICE; RISK; VARIABLES
AB The amount of cancer-related information available to the general population continues to grow; yet, its effects are unclear. This study extends previous cross-sectional research establishing that cancer information seeking across a variety of sources is extensive and positively associated with engaging in health-related behaviors. The authors studied how active information seeking about cancer prevention influenced three healthy lifestyle behaviors using a 2-round nationally representative sample of adults ages 4070 years (n=1,795), using propensity scoring to control for potential confounders including baseline behavior. The adjusted odds of dieting at follow-up were 1.51 (95% CI: 1.05, 2.19) times higher for those who reported baseline seeking from media and interpersonal sources relative to nonseekers. Baseline seekers ate 0.59 (95% CI: 0.28, 0.91) more fruits and vegetable servings per day and exercised 0.36 (95% CI: 0.12, 0.60) more days per week at 1-year follow-up compared with nonseekers. The effects of seeking from media and friends/family on eating fruits and vegetables and exercising were independent of seeking from physicians. The authors offer several explanations for why information seeking predicts healthy lifestyle behaviors: information obtained motivates these behaviors; information sought teaches specific techniques; and the act of information seeking may reinforce a psychological commitment to dieting, eating fruits and vegetables, and exercising.
C1 [Ramirez, A. Susana] NCI, Canc Prevent Fellowship Program, Bethesda, MD 20892 USA.
[Freres, Derek; Bourgoin, Angel; Hornik, Robert C.] Univ Penn, Annenberg Sch Commun, Ctr Excellence Canc Commun Res, Philadelphia, PA 19104 USA.
[Martinez, Lourdes S.] Michigan State Univ, E Lansing, MI 48824 USA.
[Lewis, Nehama] Florida Int Univ, Miami, FL 33199 USA.
[Kelly, Bridget J.] RTI Int, Washington, DC USA.
[Lee, Chul-Joo] Ohio State Univ, Sch Commun, Columbus, OH 43210 USA.
[Nagler, Rebekah] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Schwartz, J. Sanford] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
[Schwartz, J. Sanford] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA.
RP Ramirez, AS (reprint author), NCI, Canc Prevent Fellowship Program, 6130 Execut Blvd,Room 4051A, Bethesda, MD 20892 USA.
EM a.susana.ramirez@gmail.com
OI Hornik, Robert/0000-0002-2148-8805
FU NCI NIH HHS [P20 CA095856, P50 CA095856, P50-CA095856-05]
NR 42
TC 18
Z9 19
U1 3
U2 27
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 CHESTNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1081-0730
EI 1087-0415
J9 J HEALTH COMMUN
JI J. Health Commun.
PD MAY 1
PY 2013
VL 18
IS 5
BP 527
EP 542
DI 10.1080/10810730.2012.743632
PG 16
WC Communication; Information Science & Library Science
SC Communication; Information Science & Library Science
GA 136HO
UT WOS:000318353200004
PM 23472825
ER
PT J
AU Chuang, PY
Menon, MC
He, JC
AF Chuang, Peter Y.
Menon, Madhav C.
He, John C.
TI Molecular targets for treatment of kidney fibrosis
SO JOURNAL OF MOLECULAR MEDICINE-JMM
LA English
DT Review
DE Kidney; Fibrosis; HIPK2; Signaling pathways; Treatment
ID GROWTH-FACTOR-BETA; NF-KAPPA-B; RENAL INTERSTITIAL FIBROSIS; PROXIMAL
TUBULAR CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; SUBTOTALLY
NEPHRECTOMIZED RATS; INDUCED COLLAGEN EXPRESSION;
GLOMERULAR-FILTRATION-RATE; MATRIX GENE-EXPRESSION; TGF-BETA
AB Renal fibrosis is the culmination of processes driven by signaling pathways involving transforming growth factor-beta family of cytokines, connective-tissue growth factor, nuclear factor kappa B, Wnt/beta-catenin, Notch, and other growth factors. Many studies in experimental animal models have directly targeted these pathways and demonstrated efficacy in mitigating renal fibrosis. However, only a small fraction of these approaches have been attempted in human and even fewer have been successfully translated to clinical use for patient with kidney diseases. Drugs with proven efficacy for treatment of kidney diseases and tissue fibrosis exert some of their effects by interfering with components of these pathways. This review considers key molecular mediators of renal fibrosis and their potential as targets for treatment of renal fibrosis.
C1 [Chuang, Peter Y.; Menon, Madhav C.; He, John C.] Mt Sinai Sch Med, Div Nephrol, New York, NY 10029 USA.
[He, John C.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
RP Chuang, PY (reprint author), Mt Sinai Sch Med, Div Nephrol, 1 Gustave L Levy Pl,Box 1243, New York, NY 10029 USA.
EM peter.chuang@mssm.edu
FU NIH [1R01DK078897, 1R01DK088541-01A1, 5K08DK082760]; Veterans Affairs
Merit Review Award [1I01BX000345]
FX Due to space limitations, the authors could not individually acknowledge
work of many investigators in the field of renal fibrosis. We have cited
articles that review multiple publications on a topic and we encourage
the readers to use them as sources for further study. JCH is supported
by NIH 1R01DK078897 and 1R01DK088541-01A1 and a Veterans Affairs Merit
Review Award 1I01BX000345; PYC is supported by NIH 5K08DK082760.
NR 136
TC 29
Z9 33
U1 4
U2 31
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0946-2716
EI 1432-1440
J9 J MOL MED
JI J. Mol. Med.
PD MAY
PY 2013
VL 91
IS 5
BP 549
EP 559
DI 10.1007/s00109-012-0983-z
PG 11
WC Genetics & Heredity; Medicine, Research & Experimental
SC Genetics & Heredity; Research & Experimental Medicine
GA 140XT
UT WOS:000318690500003
PM 23179685
ER
PT J
AU Ratti, E
Bettica, P
Alexander, R
Archer, G
Carpenter, D
Evoniuk, G
Gomeni, R
Lawson, E
Lopez, M
Millns, H
Rabiner, EA
Trist, D
Trower, M
Zamuner, S
Krishnan, R
Fava, M
AF Ratti, Emiliangelo
Bettica, Paolo
Alexander, Robert
Archer, Graeme
Carpenter, David
Evoniuk, Gary
Gomeni, Roberto
Lawson, Erica
Lopez, Monica
Millns, Helen
Rabiner, Eugenii A.
Trist, David
Trower, Michael
Zamuner, Stefano
Krishnan, Ranga
Fava, Maurizio
TI Full central neurokinin-1 receptor blockade is required for efficacy in
depression: evidence from orvepitant clinical studies
SO JOURNAL OF PSYCHOPHARMACOLOGY
LA English
DT Article
DE Depression; receptor occupancy; neurokinin; substance P; clinical trials
ID SUBSTANCE-P RECEPTORS; DOUBLE-BLIND; FUNCTIONING QUESTIONNAIRE; SEXUAL
DYSFUNCTION; MAJOR DEPRESSION; DRUG DEVELOPMENT; RATING-SCALE; MICE
LACKING; ANTAGONIST; NK1
AB Full, persistent blockade of central neurokinin-1 (NK1) receptors may be a potential antidepressant mechanism. The selective NK1 antagonist orvepitant (GW823296) was used to test this hypothesis. A preliminary positron emission tomography study in eight male volunteers drove dose selection for two randomized six week studies in patients with major depressive disorder (MDD). Displacement of central [C-11]GR205171 binding indicated that oral orvepitant doses of 30-60 mg/day provided >99% receptor occupancy for >= 24 h. Studies 733 and 833 randomized patients with MDD and 17-item Hamilton Depression Rating Scale (HAM-D)>= 22 to double-blind treatment with orvepitant 30 mg/day, orvepitant 60 mg/day or placebo (1: 1: 1). Primary outcome measure was change from baseline in 17-item HAM-D total score at Week 6 analyzed using mixed models repeated measures. Study 733 (n=328) demonstrated efficacy on the primary endpoint (estimated drug-placebo differences of 30 mg: -2.41, 95% confidence interval (CI) (-4.50 to -0.31) p=0.0245; 60 mg: -2.86, 95% CI (-4.97 to -0.75) p=0.0082). Study 833 (n=345) did not show significance (estimated drug-placebo differences of 30 mg: -1.67, 95% CI (-3.73 to 0.39) p=0.1122; 60 mg: -0.76, 95% CI (-2.85 to 1.32) p=0.4713). The results support the hypothesis that full, long lasting blockade of central NK1 receptors may be an efficacious mechanism for the treatment of MDD.
C1 [Ratti, Emiliangelo; Bettica, Paolo; Alexander, Robert; Trist, David; Trower, Michael; Zamuner, Stefano] GlaxoSmithKline, Neurosci Ctr Excellence Drug Discovery, Verona, Italy.
[Archer, Graeme; Millns, Helen] GlaxoSmithKline, Neurosci Discovery Biometr, Harlow, Essex, England.
[Carpenter, David; Evoniuk, Gary; Lawson, Erica; Lopez, Monica] GlaxoSmithKline, Res & Dev, Res Triangle Pk, NC 27709 USA.
[Gomeni, Roberto] GlaxoSmithKline, Pharmacometr, Upper Merion, PA USA.
[Rabiner, Eugenii A.] GlaxoSmithKline, Clin Imaging Ctr, London, England.
[Krishnan, Ranga] Duke Natl Univ Singapore, Singapore, Singapore.
[Fava, Maurizio] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
RP Evoniuk, G (reprint author), GlaxoSmithKline, Res & Dev, 17-1229,5 Moore Dr, Res Triangle Pk, NC 27709 USA.
EM gee19685@gsk.com
RI Rabiner, Eugenii/G-6263-2012
OI Rabiner, Eugenii/0000-0003-3612-6687
FU GlaxoSmithKline; Cenerx; Orexigen; Cypress Bioscience; Sonexa; Atentiv;
Alta; Roche; Abbot Laboratories; Alkermes, Inc.; Aspect Medical Systems;
AstraZeneca; BioResearch; BrainCells Inc.; Bristol-Myers Squibb; CeNeRx
BioPharma; Cephalon; Clinical Trials Solutions, LLC; Clintara, LLC;
Covance; Covidien; Eli Lilly and Company; EnVivo Pharmaceuticals, Inc.;
Euthymics Bioscience, Inc.; Forest Pharmaceuticals, Inc.; Ganeden
Biotech, Inc.; Icon Clinical Research; i3 Innovus/Ingenix; Johnson &
Johnson Pharmaceutical Research Development; Lichtwer Pharma GmbH; Lorex
Pharmaceuticals; National Alliance for Research on Schizophrenia &
Depression (NARSAD); National Center for Complementary and Alternative
Medicine (NCCAM); National Institute of Drug Abuse (NIDA); National
Institute of Mental Health (NIMH); Novartis AG; Organon Pharmaceuticals;
PamLab, LLC.; Pfizer Inc.; Pharmavite(R) LLC; Photothera; Roche
Pharmaceuticals; RCT Logic, LLC; Sanofi-Aventis US LLC; Shire; Solvay
Pharmaceuticals, Inc.; Synthelabo; Wyeth-Ayerst
FX R Krishnan and M Fava acted as paid consultants to GlaxoSmithKline in
the design and conduct of these clinical trials.; R Krishnan has also
acted as a paid consultant to, and/or holds stock directly or indirectly
in Cenerx, Orexigen, Cypress Bioscience, Sonexa, Atentiv, Alta and
Roche.; M Fava has the following lifetime disclosures: Research support:
Abbot Laboratories; Alkermes, Inc.; Aspect Medical Systems; AstraZeneca;
BioResearch; BrainCells Inc.; Bristol-Myers Squibb; CeNeRx BioPharma;
Cephalon; Clinical Trials Solutions, LLC; Clintara, LLC; Covance;
Covidien; Eli Lilly and Company; EnVivo Pharmaceuticals, Inc.; Euthymics
Bioscience, Inc.; Forest Pharmaceuticals, Inc.; Ganeden Biotech, Inc.;
GlaxoSmithKline; Icon Clinical Research; i3 Innovus/Ingenix; Johnson &
Johnson Pharmaceutical Research & Development; Lichtwer Pharma GmbH;
Lorex Pharmaceuticals; National Alliance for Research on Schizophrenia &
Depression (NARSAD); National Center for Complementary and Alternative
Medicine (NCCAM); National Institute of Drug Abuse (NIDA); National
Institute of Mental Health (NIMH); Novartis AG; Organon Pharmaceuticals;
PamLab, LLC.; Pfizer Inc.; Pharmavite (R) LLC; Photothera; Roche
Pharmaceuticals; RCT Logic, LLC; Sanofi-Aventis US LLC; Shire; Solvay
Pharmaceuticals, Inc.; Synthelabo; Wyeth-Ayerst. Laboratories:
Advisory/Consulting: Abbott Laboratories; Affectis Pharmaceuticals AG;
Alkermes, Inc.; Amarin Pharma Inc.; Aspect Medical Systems; AstraZeneca;
Auspex Pharmaceuticals; Bayer AG; Best Practice Project Management,
Inc.; BioMarin Pharmaceuticals, Inc.; Biovail Corporation; BrainCells
Inc; Bristol-Myers Squibb; CeNeRx BioPharma; Cephalon, Inc.; Clinical
Trials Solutions, LLC; CNS Response, Inc.; Compellis Pharmaceuticals;
Cypress Pharmaceutical, Inc.; DiagnoSearch Life Sciences (P) Ltd.;
Dinippon Sumitomo Pharma Co. Inc.; Dov Pharmaceuticals, Inc.; Edgemont
Pharmaceuticals, Inc.; Eisai Inc.; Eli Lilly and Company; EnVivo
Pharmaceuticals, Inc.; ePharmaSolutions; EPIX Pharmaceuticals, Inc.;
Euthymics Bioscience, Inc.; Fabre-Kramer Pharmaceuticals, Inc.; Forest
Pharmaceuticals, Inc.; GenOmind, LLC; GlaxoSmithKline; Grunenthal GmbH;
i3 Innovus/Ingenis; Janssen Pharmaceutica; Jazz Pharmaceuticals, Inc.;
Johnson & Johnson Pharmaceutical Research & Development, LLC; Knoll
Pharmaceuticals Corp.; Labopharm Inc.; Lorex Pharmaceuticals; Lundbeck
Inc.; MedAvante, Inc.; Merck & Co., Inc.; MSI Methylation Sciences,
Inc.; Naurex, Inc.; Neuronetics, Inc.; NextWave Pharmaceuticals;
Novartis AG; Nutrition 21; Orexigen Therapeutics, Inc.; Organon
Pharmaceuticals; Otsuka Pharmaceuticals; PamLab, LLC.; Pfizer Inc.;
PharmaStar; Pharmavite (R) LLC.; PharmoRx Therapeutics; Precision Human
Biolaboratory; Prexa Pharmaceuticals, Inc.; Puretech Ventures;
PsychoGenics; Psylin Neurosciences, Inc.; Rexahn Pharmaceuticals, Inc.;
Ridge Diagnostics, Inc.; Roche; RCT Logic, LLC; Sanofi-Aventis US LLC.;
Sepracor Inc.; Servier Laboratories; Schering-Plough Corporation; Solvay
Pharmaceuticals, Inc.; Somaxon Pharmaceuticals, Inc.; Somerset
Pharmaceuticals, Inc.; Sunovion Pharmaceuticals; Supernus
Pharmaceuticals, Inc.; Synthelabo; Takeda Pharmaceutical Company
Limited; Tal Medical, Inc.; Tetragenex Pharmaceuticals, Inc.; TransForm
Pharmaceuticals, Inc.; Transcept Pharmaceuticals, Inc.; Vanda
Pharmaceuticals, Inc.
NR 42
TC 18
Z9 18
U1 0
U2 5
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0269-8811
J9 J PSYCHOPHARMACOL
JI J. Psychopharmacol.
PD MAY
PY 2013
VL 27
IS 5
BP 424
EP 434
DI 10.1177/0269881113480990
PG 11
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 145IZ
UT WOS:000319010100003
PM 23539641
ER
PT J
AU Ellis, C
Grubaugh, AL
Egede, LE
AF Ellis, Charles
Grubaugh, Anouk L.
Egede, Leonard E.
TI Factors Associated with SF-12 Physical and Mental Health Quality of Life
Scores in Adults with Stroke
SO JOURNAL OF STROKE & CEREBROVASCULAR DISEASES
LA English
DT Article
DE Disability; stroke; quality of life
ID EAST MELBOURNE STROKE; SURVIVORS; DETERMINANTS; DEPRESSION; RECOVERY;
VALIDITY; IMPACT; RELIABILITY; POSTSTROKE
AB Background: Studies of poststroke quality of life (QOL) have not consistently identified which factors are most likely to independently influence the physical and mental aspects of QOL. In this study, we sought to identify which sociodemographic, comorbid disease conditions, and disability factors independently influenced the physical and mental aspects of poststroke QOL. Methods: We completed a cross-sectional study of 666 US adults with a history of stroke from the 2007 Medical Expenditure Panel Survey (MEPS). We used sequentially built multiple linear regression models to identify sociodemographic, comorbidity, and stroke-related disability factors that independently affected short form-12 (SF-12) physical component summary (PCS) and mental component summary (MCS) scores. STATA software (version 10; StataCorp LP, College Station, TX) was used to perform the analysis to account for the complex survey design of the MEPS. Results: In fully adjusted models using a nationally representative sample of US adults, being non-Hispanic black (beta = 3.58), 45 to 64 years of age (beta = -3.48), 65 years of age or older (beta = -2.90), married (beta = -3.50), middle (beta = 2.78) and high income (beta = 3.73), or having hypertension (beta = -2.25), cardiovascular disease (beta = -2.05), arthritis (beta = -4.49), depression (beta = -2.98), physical limitations (beta = -7.60), social limitations (beta = -4.12), and a need for assistance with instrumental activities of daily living (beta = -4.49) were independently correlated with PCS scores. Being 45 to 64 years of age (beta = 3.96), depressed (beta = -15.92), or having social limitations (beta = -3.62) were independently correlated with MCS scores. Conclusions: Sociodemographic, comorbidity, and stroke-related disability factors have differential effect on physical and mental aspects of QOL in poststroke patients.
C1 [Ellis, Charles; Grubaugh, Anouk L.; Egede, Leonard E.] Med Univ S Carolina, Vet Affairs Ctr Dis Prevent & Hlth Intervent Dive, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA.
[Ellis, Charles] Med Univ S Carolina, Ctr Hlth Dispar Res, Dept Hlth Sci & Res, Charleston, SC 29425 USA.
[Grubaugh, Anouk L.] Med Univ S Carolina, Ctr Hlth Dispar Res, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Dept Med, Charleston, SC 29425 USA.
RP Ellis, C (reprint author), Med Univ S Carolina, Coll Hlth Profess, 77 President St,MSC 700, Charleston, SC 29425 USA.
EM ellisc@musc.edu
FU South Carolina HSRD [REA 08-261]; Veterans Health Administration Health
Services Research and Development program [07-012-3, 07-015-2]
FX Supported by the use of facilities at the Charleston, South Carolina
HSR&D-funded Center for Disease Prevention and Health Interventions for
Diverse Populations (REA 08-261). Dr Ellis is supported by a career
development award (CDA # 07-012-3) from the Veterans Health
Administration Health Services Research and Development program. Dr
Grubaugh is supported by a career development award (CDA2 # 07-015-2)
from the Veterans Health Administration Health Services Research and
Development program.
NR 36
TC 11
Z9 13
U1 1
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1052-3057
J9 J STROKE CEREBROVASC
JI J. Stroke Cerebrovasc. Dis.
PD MAY
PY 2013
VL 22
IS 4
BP 309
EP 317
DI 10.1016/j.jstrokecerebrovasdis.2011.09.007
PG 9
WC Neurosciences; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 144BX
UT WOS:000318915500005
PM 22005038
ER
PT J
AU Willey, JZ
Khatri, P
Khoury, JC
Merino, JG
Ford, AL
Rost, NS
Gonzales, NR
Ali, LK
Meyer, BC
Broderick, JP
AF Willey, Joshua Z.
Khatri, Pooja
Khoury, Jane C.
Merino, Jose G.
Ford, Andria L.
Rost, Natalia S.
Gonzales, Nicole R.
Ali, Latisha K.
Meyer, Brett C.
Broderick, Joseph P.
TI Variability in the Use of Intravenous Thrombolysis for Mild Stroke:
Experience Across the SPOTRIAS Network
SO JOURNAL OF STROKE & CEREBROVASCULAR DISEASES
LA English
DT Article
DE Mild stroke; stenosis
ID TISSUE-PLASMINOGEN ACTIVATOR; ACUTE ISCHEMIC-STROKE;
NEUROLOGICAL-DISORDERS; SCIENTIFIC STATEMENT; NATIONAL-INSTITUTE; EARLY
MANAGEMENT; ASSOCIATION; ELIGIBILITY; GUIDELINES; SYMPTOMS
AB Background: Current guidelines do not define the lower severity threshold for thrombolysis. In this study, we describe the variability of treatment of mild stroke patients across a network of academic stroke centers. Methods: Stroke centers within the Specialized Program of Translational Research in Acute Stroke (SPOTRIAS) prospectively collect data on patients treated with intravenous recombinant tissue plasminogen activator (IV rt-PA), including demographics, pretreatment National Institutes of Health Stroke Scale (NIHSS) scores, and in-hospital mortality. We examined the variability in proportion of total tissue plasminogen activator-treated patients in the NIHSS categories (0-3, 4-5, or >= 6) and associated outcomes. Results: A total of 2514 patients with reported NIHSS scores were treated with IV rt-PA between January 1, 2005 and December 31, 2009. The proportion of patients with mild stroke (NIHSS scores of 0-3) who were treated with IV rt-PA varied substantially across the centers (2.7-18.0%; P < .001). There were 5 deaths in the 256 treated with an NIHSS score of 0-3 (2.0%). The proportion of treated patients across the network with an NIHSS score of 0 to 3 increased from 4.8% in 2005 to 10.7% in 2009 (P = .001). Conclusions: There is substantial variability in the proportion of treated patients who have mild stroke across the SPOTRIAS centers, reflecting a paucity of data on how to best treat patients with mild stroke. Randomized trial data for this group of patients are needed to clarify the use of rt-PA in patients with the mildest strokes.
C1 [Willey, Joshua Z.] Columbia Univ, Dept Neurol, New York, NY USA.
[Khatri, Pooja; Broderick, Joseph P.] Univ Cincinnati, Cincinnati, OH 45221 USA.
[Ford, Andria L.] Washington Univ, St Louis, MO USA.
[Gonzales, Nicole R.] Univ Texas Houston, Houston, TX USA.
[Ali, Latisha K.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Meyer, Brett C.] Univ Calif San Diego, San Diego, CA 92103 USA.
[Khoury, Jane C.] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH USA.
[Merino, Jose G.] NINDS, Sect Stroke Diagnost & Therapeut, Div Intramural Res, Bethesda, MD 20892 USA.
[Rost, Natalia S.] Massachusetts Gen Hosp, Dept Neurol, Stroke Div, Boston, MA 02114 USA.
RP Willey, JZ (reprint author), Dept Neurol, 710 West 168th St,Box 30, New York, NY 10032 USA.
EM jzw2@columbia.edu
RI Khoury, Jane/O-2068-2015;
OI Merino, Jose/0000-0002-6676-0008
FU Intramural Division of the National Institute of Neurological Disorders
and Stroke/National Institutes of Health; National Institutes of
Neurological Diseases and Stroke [NINDS P50 NS049060]; NINDS
[1K23NS073104-01A1]
FX Supported in part by the Intramural Division of the National Institute
of Neurological Disorders and Stroke/National Institutes of Health.
SPOTRIAS is funded by the National Institutes of Neurological Diseases
and Stroke (NINDS P50 NS049060). JZW was funded by NINDS
1K23NS073104-01A1.
NR 19
TC 8
Z9 8
U1 1
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1052-3057
J9 J STROKE CEREBROVASC
JI J. Stroke Cerebrovasc. Dis.
PD MAY
PY 2013
VL 22
IS 4
BP 318
EP 322
DI 10.1016/j.jstrokecerebrovasdis.2011.09.005
PG 5
WC Neurosciences; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 144BX
UT WOS:000318915500006
PM 22177935
ER
PT J
AU Nadkarni, NK
Studenski, SA
Perera, S
Rosano, C
Aizenstein, HJ
Brach, JS
Van Swearingen, JM
AF Nadkarni, Neelesh K.
Studenski, Stephanie A.
Perera, Subashan
Rosano, Caterina
Aizenstein, Howard J.
Brach, Jennifer S.
Van Swearingen, Jessie M.
TI White Matter Hyperintensities, Exercise, and Improvement in Gait Speed:
Does Type of Gait Rehabilitation Matter?
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE gait; rehabilitation; white matter hyperintensities; subcortical
vascular disease; tracts
ID RANDOMIZED CONTROLLED-TRIAL; OLDER-ADULTS; CARDIOVASCULAR HEALTH;
COGNITIVE FUNCTION; ELDERLY-PEOPLE; BRAIN; ABNORMALITIES; LESIONS; MRI;
DEMENTIA
AB Objectives To examine whether white matter hyperintensities (WMHs) on brain magnetic resonance imaging (MRI) in tracts in older adults with mobility impairment are linked to outcomes of gait rehabilitation interventions. Design Twelve-week randomized controlled single-blind trial. Setting University-based mobility research laboratory. Participants Ambulatory adults aged 65 and older with mobility impairment. Intervention A conventional gait intervention focusing on walking, endurance, balance, and strength (WEBS, n=21) and a task-oriented intervention focused on timing and coordination of gait (TC, n=23). Measurements Self-paced gait speed was measured over an instrumented walkway before and after the intervention, and WMH and brain volumes were quantified on preintervention brain MRI using an automated segmentation process. A white matter tract atlas was overlaid on the segmented images to measure tract WMH volumes, and WMH volumes were normalized to total brain volume. Aggregate WMH volumes in all white matter tracts and individual WMH volumes in specific longitudinal tracts (superior longitudinal fasciculus, inferior longitudinal fasciculus, and fronto-occipital fasciculus) and the cingulum were measured. Results Gait speed gains in the TC group were of the same magnitude, independent of WMH volume measures in all except the cingulum, but in the WEBS group, gain in gait speed was smaller with greater overall tract WMH volumes (P<.001) and with greater WMH volume in the three longitudinal tracts (P<.001 to .02). Conclusion Gains in gait speed with two types of gait rehabilitation are associated with individual differences in WMHs. Task-oriented therapy that targets timing and coordination of gait may particularly benefit older adults with WMHs in brain tracts that influence gait and cognition.
C1 [Nadkarni, Neelesh K.; Studenski, Stephanie A.; Perera, Subashan] Univ Pittsburgh, Dept Med, Div Geriatr Med & Gerontol, Pittsburgh, PA 15213 USA.
[Studenski, Stephanie A.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA.
[Rosano, Caterina] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15213 USA.
[Aizenstein, Howard J.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15213 USA.
[Brach, Jennifer S.; Van Swearingen, Jessie M.] Univ Pittsburgh, Dept Phys Therapy, Pittsburgh, PA 15213 USA.
RP Nadkarni, NK (reprint author), Univ Pittsburgh, Dept Med, Div Geriatr Med & Gerontol, Suite 500,3471 5th Ave,Kaufman Med Bldg, Pittsburgh, PA 15213 USA.
EM nkn3@pitt.edu
RI Perera, Subashan/D-7603-2014;
OI Rosano, Caterina/0000-0002-0909-1506; Rosano,
Caterina/0000-0002-4271-6010
FU Pittsburgh Claude D. Pepper Older American's Independence Center [P30
AG024827]; Ortho Biotech; Lilly; Merck
FX This study was supported by Pittsburgh Claude D. Pepper Older American's
Independence Center Grant P30 AG024827. We appreciate the assistance of
Rebecca L. MacCloud for providing the figure inserts for the brain
tracts.; None of the authors have any financial, personal, or potential
conflict of interest with the material presented in this article.
Subhashan Perera and Stephanie A. Studenski have received past research
grants and funding from Ortho Biotech, Lilly, and Merck.
NR 58
TC 11
Z9 11
U1 1
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2013
VL 61
IS 5
BP 686
EP 693
DI 10.1111/jgs.12211
PG 8
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 145GB
UT WOS:000319002100002
PM 23590257
ER
PT J
AU Reeves, ST
Finley, AC
Skubas, NJ
Swaminathan, M
Whitley, WS
Glas, KE
Hahn, RT
Shanewise, JS
Adams, MS
Shernan, SK
AF Reeves, Scott T.
Finley, Alan C.
Skubas, Nikolaos J.
Swaminathan, Madhav
Whitley, William S.
Glas, Kathryn E.
Hahn, Rebecca T.
Shanewise, Jack S.
Adams, Mark S.
Shernan, Stanton K.
CA Amer Soc Echocardiography
Amer Soc Echocardiography
Soc Cardiovasc Anesthesiologists
TI Basic Perioperative Transesophageal Echocardiography Examination: A
Consensus Statement of the American Society of Echocardiography and the
Society of Cardiovascular Anesthesiologists
SO JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY
LA English
DT Article
DE Transesophageal echocardiography; Basic certification
ID BLUNT CHEST TRAUMA; TRANS-ESOPHAGEAL ECHOCARDIOGRAPHY; TWO-DIMENSIONAL
ECHOCARDIOGRAPHY; CARDIAC SURGICAL-PATIENTS; CAPILLARY WEDGE PRESSURE;
PARADOXICAL AIR-EMBOLISM; ACUTE PULMONARY-EMBOLISM; CRITICALLY ILL
PATIENTS; INTENSIVE-CARE-UNIT; TASK-FORCE
C1 [Reeves, Scott T.; Finley, Alan C.] Med Univ S Carolina, Charleston, SC USA.
[Skubas, Nikolaos J.] Weill Cornell Med Coll, New York, NY USA.
[Swaminathan, Madhav] Duke Univ, Durham, NC USA.
[Shernan, Stanton K.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
[Whitley, William S.; Glas, Kathryn E.] Emory Univ, Atlanta, GA 30322 USA.
[Hahn, Rebecca T.; Shanewise, Jack S.] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA.
[Adams, Mark S.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Reeves, ST (reprint author), Amer Soc Echocardiog, 2100 Gateway Ctr Blvd,Suite 310, Morrisville, NC 27560 USA.
NR 80
TC 32
Z9 33
U1 1
U2 75
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0894-7317
J9 J AM SOC ECHOCARDIOG
JI J. Am. Soc. Echocardiogr.
PD MAY
PY 2013
VL 26
IS 5
BP 443
EP 456
DI 10.1016/j.echo.2013.02.015
PG 14
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 143YV
UT WOS:000318906400001
PM 23622926
ER
PT J
AU Psaila, B
Bussel, JB
Frelinger, AL
Michelson, AD
AF Psaila, B.
Bussel, J. B.
Frelinger, A. L.
Michelson, A. D.
TI Differences in platelet function in patients with acute myeloid leukemia
and myelodysplasia compared to equally thrombocytopenic patients with
immune thrombocytopenia: a reply to a rebuttal
SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS
LA English
DT Letter
C1 [Psaila, B.] Univ London Imperial Coll Sci Technol & Med, Dept Haematol, London, England.
[Bussel, J. B.] Weill Cornell Med Coll, Div Pediat Hematol Oncol, Platelet Disorders Ctr, New York, NY 10065 USA.
[Frelinger, A. L.; Michelson, A. D.] Harvard Univ, Sch Med, Dana Farber Canc Inst,Boston Childrens Hosp, Div Hematol Oncol,Ctr Platelet Res Studies, Boston, MA 02115 USA.
RP Bussel, JB (reprint author), Weill Cornell Med Coll, Div Pediat Hematol Oncol, Platelet Disorders Ctr, 525 East 68th St,Payson Pavil 695, New York, NY 10065 USA.
EM jbussel@cornell.med.edu
OI Psaila, Beth/0000-0001-8198-9663
NR 3
TC 0
Z9 0
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1538-7933
J9 J THROMB HAEMOST
JI J. Thromb. Haemost.
PD MAY
PY 2013
VL 11
IS 5
BP 1002
EP 1003
DI 10.1111/jth.12191
PG 2
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA 145JQ
UT WOS:000319011900026
PM 23496753
ER
PT J
AU Percac-Lima, S
Benner, CS
Lui, R
Aldrich, LS
Oo, SA
Regan, N
Chabner, BA
AF Percac-Lima, Sanja
Benner, Carly S.
Lui, Raymond
Aldrich, Leslie S.
Oo, Sarah A.
Regan, Nessa
Chabner, Bruce A.
TI The Impact of a Culturally Tailored Patient Navigator Program on
Cervical Cancer Prevention in Latina Women
SO JOURNAL OF WOMENS HEALTH
LA English
DT Article
ID INCOME MINORITY WOMEN; ABNORMAL PAP-SMEARS; IMPROVING FOLLOW-UP;
URBAN-POPULATION; INTERVENTION; ADHERENCE; COLPOSCOPY; BARRIERS; RISK;
SCIENCE
AB Background: Cervical cancer disproportionately affects Latina women in the United States. This study evaluated the impact of patient navigation on cervical cancer prevention in Latinas.
Methods: Between January 2004 and April 2011, 533 Latina women with an abnormal Pap smear requiring colposcopy received patient navigation from their healthcare center in Chelsea, Massachusetts, to the Massachusetts General Hospital (MGH). The comparison group comprised 253 non-navigated Latinas from other primary care practices at MGH referred to the same MGH colposcopy clinic. Primary outcomes were the percentage of missed colposcopy appointments, time to colposcopy, and changes in the severity of cervical pathology at colposcopy over two time periods, 2004-2007 and 2008-2011.
Results: The mean age in both groups was 35 years (range 22-86). Navigated women had fewer missed colposcopy appointments over time, with the average falling from 19.8% to 15.7% (p = 0.024), compared with an insignificant increase in the no-show rates from 18.6% to 20.6% (p = 0.454) in the comparison group. The difference in the no-show rate trend over time between the groups was significant (p < 0.001). The time to colposcopy did not change in either group, though trends over time demonstrated a shorter follow-up for navigated women (p = 0.010). The grade of cervical abnormality among navigated women decreased from a numerical score of 2.03 to 1.83 (p = 0.035) over the two time intervals, while the severity of pathological score in the non-navigated group did not change significantly from 1.83 to 1.92 (p = 0.573) in the same interval. Comparison of trends in pathological score over time showed a decrease in the severity of cervical abnormality for navigated participants compared to the non-navigated group (p < 0.001).
Conclusion: Patient navigation can prevent cervical cancer in Latina women by increasing colposcopy clinic attendance, shortening time to colposcopy, and decreasing severity of cervical abnormalities over time.
C1 [Percac-Lima, Sanja; Oo, Sarah A.] MGH Chelsea HealthCare Ctr, Chelsea, MA 02150 USA.
[Percac-Lima, Sanja; Benner, Carly S.; Lui, Raymond; Chabner, Bruce A.] Harvard Univ, Sch Med, Boston, MA USA.
[Lui, Raymond] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA.
[Percac-Lima, Sanja; Aldrich, Leslie S.; Oo, Sarah A.; Regan, Nessa] Massachusetts Gen Hosp, Ctr Community Hlth Improvement, Boston, MA 02114 USA.
[Chabner, Bruce A.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
RP Percac-Lima, S (reprint author), MGH Chelsea HealthCare Ctr, 151 Everett Ave, Chelsea, MA 02150 USA.
EM spercaclima@partners.org
FU Proctor and Gamble; Agency for Healthcare Research and Quality [1R18
HS019161-01]
FX The authors would like to thank Diana Maldonado the cervical patient
navigator and her supervisor Denise Sidorowicz, NP, for their work on
the program. The authors are grateful to Steven Atlas, MD, MPH, for
support and review of the manuscript. The study was funded by a grant
from Proctor and Gamble to the MGH Chelsea Cervical Outreach Program.
Dr. Percac-Lima was supported in part by a grant from the Agency for
Healthcare Research and Quality (1R18 HS019161-01). It was presented at
the New England Meeting of the Society of General Medicine in Portland,
Maine on March 23, 2012 and at the Annual Meeting of the Society of
General Medicine in Orlando, Florida on May 9, 2012.
NR 38
TC 13
Z9 13
U1 0
U2 4
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-9996
J9 J WOMENS HEALTH
JI J. Womens Health
PD MAY
PY 2013
VL 22
IS 5
BP 426
EP 431
DI 10.1089/jwh.2012.3900
PG 6
WC Public, Environmental & Occupational Health; Medicine, General &
Internal; Obstetrics & Gynecology; Women's Studies
SC Public, Environmental & Occupational Health; General & Internal
Medicine; Obstetrics & Gynecology; Women's Studies
GA 142FC
UT WOS:000318781000007
PM 23621746
ER
PT J
AU Miller, TM
Pestronk, A
David, W
Rothstein, J
Simpson, E
Appel, SH
Andres, PL
Mahoney, K
Allred, P
Alexander, K
Ostrow, LW
Schoenfeld, D
Macklin, EA
Norris, DA
Manousakis, G
Crisp, M
Smith, R
Bennett, CF
Bishop, KM
Cudkowicz, ME
AF Miller, Timothy M.
Pestronk, Alan
David, William
Rothstein, Jeffrey
Simpson, Ericka
Appel, Stanley H.
Andres, Patricia L.
Mahoney, Katy
Allred, Peggy
Alexander, Katie
Ostrow, Lyle W.
Schoenfeld, David
Macklin, Eric A.
Norris, Daniel A.
Manousakis, Georgios
Crisp, Matthew
Smith, Richard
Bennett, C. Frank
Bishop, Kathie M.
Cudkowicz, Merit E.
TI An antisense oligonucleotide against SOD1 delivered intrathecally for
patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1,
randomised, first-in-man study
SO LANCET NEUROLOGY
LA English
DT Article
ID SUPEROXIDE-DISMUTASE; WILD-TYPE; DISEASE; THERAPY; ALS
AB Background Mutations in SOD1 cause 13% of familial amyotrophic lateral sclerosis. In the SOD1 Gly93Ala rat model of amyotrophic lateral sclerosis, the antisense oligonucleotide ISIS 333611 delivered to CSF decreased SOD1 mRNA and protein concentrations in spinal cord tissue and prolonged survival. We aimed to assess the safety, tolerability, and pharmacokinetics of ISIS 333611 after intrathecal administration in patients with SOD1-related familial amyotrophic lateral sclerosis.
Methods In this randomised, placebo-controlled, phase 1 trial, we delivered ISIS 333611 by intrathecal infusion using an external pump over 11.5 h at increasing doses (0.15 mg, 0.50 mg, 1.50 mg, 3.00 mg) to four cohorts of eight patients with SOD1-positive amyotrophic lateral sclerosis (six patients assigned to ISIS 333611, two to placebo in each cohort). We did the randomisation with a web-based system, assigning patients in blocks of four. Patients and investigators were masked to treatment assignment. Participants were allowed to re-enrol in subsequent cohorts. Our primary objective was to assess the safety and tolerability of ISIS 333611. Assessments were done during infusion and over 28 days after infusion. This study was registered with Clinicaltrials.gov, number NCT01041222.
Findings Seven of eight (88%) patients in the placebo group versus 20 of 24 (83%) in the ISIS 333611 group had adverse events. The most common events were post-lumbar puncture syndrome (3/8 [38%] vs 8/24 [33%]), back pain (4/8 [50%] vs 4/24 [17%]), and nausea (0/8 [0%] vs 3/24 [13%]). We recorded no dose-limiting toxic effects or any safety or tolerability concerns related to ISIS 333611. No serious adverse events occurred in patients given ISIS 333611. Re-enrolment and re-treatment were also well tolerated.
Interpretation This trial is the first clinical study of intrathecal delivery of an antisense oligonucleotide. ISIS 333611 was well tolerated when administered as an intrathecal infusion. Antisense oligonucleotides delivered to the CNS might be a feasible treatment for neurological disorders.
C1 [Miller, Timothy M.; Pestronk, Alan; Manousakis, Georgios; Crisp, Matthew] Washington Univ, Sch Med, St Louis, MO 63110 USA.
[David, William; Andres, Patricia L.; Mahoney, Katy; Allred, Peggy; Schoenfeld, David; Macklin, Eric A.; Cudkowicz, Merit E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA.
[Rothstein, Jeffrey; Ostrow, Lyle W.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Simpson, Ericka; Appel, Stanley H.] Methodist Neurol Inst, Houston, TX USA.
[Smith, Richard] Ctr Neurol Study, La Jolla, CA USA.
[Alexander, Katie; Norris, Daniel A.; Bennett, C. Frank; Bishop, Kathie M.] ISIS Pharmaceut, Carlsbad, CA 92008 USA.
RP Miller, TM (reprint author), Washington Univ, 115 Biotech Bldg,Box 8111,660 S Euclid, St Louis, MO 63110 USA.
EM millert@neuro.wustl.edu
OI Macklin, Eric/0000-0003-1618-3502
FU NIH; Muscular Dystrophy Association; Neuromuscular Research Fund;
Insmed; Knopp; Cytokinetics; Biogen Idec; ISIS; Genzyme;
GlaxoSmithKline; Ultragenyx; Sanofi; ALSA; MDA; Biogen; Psyadon
Pharmaceuticals; Isis Pharmaceuticals; Tau consortium; Mallinckrodt
Foundation; Cure PSP; Washington University Hope Center; ALS; Johns
Hopkins Packard Center; Washington University ICTS; The ALS Association;
National Institute of Neurological Disorders and Stroke (NIH)
[K08NS074194, R01NS078398]; Washington University Institute of Clinical
and Translational Sciences [UL1 TR000448]; National Center for Advancing
Translational Sciences (NIH); Grifols; Gamunex
FX Funding The ALS Association, Muscular Dystrophy Association, Isis
Pharmaceuticals.; KA, DN, KMB, and CFB are employees of Isis
Pharmaceuticals. Isis Pharmaceuticals provided support for this trial
and provides antisense oligonucleotides to TMM for animal studies. RS,
CFB, the Center for Neurologic Study, and Isis Pharmaceuticals have
filed a patent for use of the ISIS 333611. ES is a paid speaker for
Grifols for Gamunex and served on an advisory board for CSL Behring. AP
receives revenue related to antibody patent licenses and speaker
honoraria from Athena; owns stock in Johnson & Johnson; directs the
Washington University Neuromuscular Clinical Laboratory, which does
antibody testing; and receives research support from the NIH, Muscular
Dystrophy Association, Neuromuscular Research Fund, Insmed, Knopp,
Cytokinetics, Biogen Idec, ISIS, Genzyme, GlaxoSmithKline, Ultragenyx,
and Sanofi. RS is a consultant for Isis Pharmaceuticals. JR receives
grant support from NIH, ALSA, MDA, Cytokinetics, Biogen, and Psyadon
Pharmaceuticals. EAM serves on the data and safety monitoring boards for
Lantheus Medical Imaging and Shire Human Genetic Therapies. PLA is named
as an inventor for patent 7493 812. MEC receives grant support from Isis
Pharmaceuticals, Biogen, and Knopp and is a consultant for Teva,
Cytokinetics, and Biogen. TMM has received grant support from Isis
Pharmaceuticals, NIH, ALSA, MDA, Tau consortium, Mallinckrodt
Foundation, Cure PSP, Washington University Hope Center, Project 5 for
ALS, Johns Hopkins Packard Center, and Washington University ICTS. DS
does extensive consulting for pharmaceutical companies including Aptly
Solutions, Agenix, Asubio Pharmaceuticals, Alexion Pharmaceuticals,
Cytokinetics, Edison Pharmaceuticals, GlaxoSmith Kline, Merck,
NeuroNova, and Pfizer. The other authors declare that they have no
conflicts of interest. We thank the patients who participated in this
study, and their families and carergivers. This trial was funded by the
Muscular Dystrophy Association, The ALS Association, and Isis
Pharmaceuticals. TMM was supported by National Institute of Neurological
Disorders and Stroke (NIH) grants K08NS074194 and R01NS078398. Clinical
studies at Washington University were supported by the Washington
University Institute of Clinical and Translational Sciences grant UL1
TR000448, National Center for Advancing Translational Sciences (NIH). We
appreciate the hard work and dedication of many people who contributed
to this study: Massachusetts General Hospital Coordinating Center (Kate
Jackson, Alex Sherman, Marianne Kearney, Hong Yu, Lauren Schnupp, Bryan
Sweet, Jason Walker, Igor Katsovskiy, Ervin Sinani), Massachusetts
General Hospital clinical site (Swati Aggarwal, Melanie Majkut, Jennifer
Berndt, Darlene Sawicki), Johns Hopkins University School of Medicine
(Richard Kimball, Lora Clawson, Kristen Riley), Methodist Neurological
Institute (Sharon Halton, Luis Lay), Washington University in St Louis
(Julaine Florence, Catherine Siener, Brian Sommerville, Robert Swarm,
Leo Wang, Charlie Wulf), Isis Pharmaceuticals (Viola Kam, Jesse Kwoh,
Katherine Kwoh, John Madson, Gina McMullin, Dan Schultz). We also thank
Robert Brown, Benjamin Brooks, and Don Cleveland for input about
clinical study design, the data safety and monitoring board (Walter
Bradley, Karl Kieburtz, Carl Leventhal, Michael McDermott, Stephen
Reingold), and the many investigators of the Northeast ALS Trials
Consortium who referred patients to the study and for Patients Like Me
for referrals to Johns Hopkins University.
NR 22
TC 144
Z9 145
U1 8
U2 22
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1474-4422
J9 LANCET NEUROL
JI Lancet Neurol.
PD MAY
PY 2013
VL 12
IS 5
BP 435
EP 442
DI 10.1016/S1474-4422(13)70061-9
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA 142ZS
UT WOS:000318836700014
PM 23541756
ER
PT J
AU Tala, I
Chen, R
Hu, T
Fitzpatrick, ER
Williams, DA
Whitehead, IP
AF Tala, I.
Chen, R.
Hu, T.
Fitzpatrick, E. R.
Williams, D. A.
Whitehead, I. P.
TI Contributions of the RhoGEF activity of p210 BCR/ABL to disease
progression
SO LEUKEMIA
LA English
DT Article
DE chronic myelogenous leukemia; p210 BCR/ABL; RhoGEF domain; Rho GTPase
ID CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; BCR-ABL;
MYELOPROLIFERATIVE DISEASE; KINASE-ACTIVITY; TRANSFORMATION; ONCOGENE;
DOMAIN; ACTIVATION; CELLS
AB We have previously identified a tyrosine kinase-independent, guanine nucleotide exchange factor (GEF) activity, which is contained within the region of p210 no expansion BCR/ABL that distinguishes it from p190 BCR/ABL. In the current study, we have compared the transforming activity of p190 BCR/ABL, p210 BCR/ABL and a mutant that lacks GEF activity (p210 BCR/ABL(S509A)). In cell-based, ex vivo, and murine bone marrow transplantation (BMT) assays the transforming activity of p210 BCR/ABL(S509A) mimics p190 BCR/ABL, and is distinct from p210 BCR/ABL. Thus, in the BMT assay, the p190 BCR/ABL- and p210 BCR/ABL(S509A)-transplanted mice exhibit a more rapid onset of disease than mice transplanted with p210 BCR/ABL. The reduced disease latency is associated with erythroid hyperplasia in the absence of anemia, and expansion of the megakaryocyte-erythrocyte progenitor (MEP), common myeloid progenitor (CMP) and granulocyte-macrophage progenitor (GMP) populations, producing a phenotype that is similar to acute myeloid leukemia (AML-M6). The disease phenotype is readily transplantable into secondary recipients. This is consistent with ex vivo clonogenicity assays, where p210 BCR/ABL preferentially supports the growth of colony forming unit (CFU)-granulocyte-macrophage (GM), whereas p190 BCR/ABL and the mutant preferentially support the growth of burst forming unit-erythroid (BFU-E). These results suggest that the GEF activity that distinguishes p210 BCR/ABL from p190 BCR/ABL actively regulates disease progression.
C1 [Tala, I.; Chen, R.; Hu, T.; Fitzpatrick, E. R.; Whitehead, I. P.] Univ Med & Dent New Jersey, New Jersey Med Sch, Univ Hosp Canc Ctr, Newark, NJ 07103 USA.
[Williams, D. A.] Childrens Hosp Boston, Hematol Oncol Div, Boston, MA USA.
[Williams, D. A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Whitehead, IP (reprint author), Univ Med & Dent New Jersey, Canc Ctr H Level, 205 South Orange Ave, Newark, NJ 07101 USA.
EM whiteip@umdnj.edu
RI Hu, Tinghui/F-3213-2015
FU Public Health Service [CA097066, DK62757]; NIH [CA097066, DK62757]
FX This work was supported by Public Health Service grants CA097066 (IPW)
and DK62757 (DAW). NIH grants CA097066 (IPW) and DK62757 (DAW).
NR 38
TC 3
Z9 4
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
J9 LEUKEMIA
JI Leukemia
PD MAY
PY 2013
VL 27
IS 5
BP 1080
EP 1089
DI 10.1038/leu.2012.351
PG 10
WC Oncology; Hematology
SC Oncology; Hematology
GA 141AS
UT WOS:000318698300011
PM 23207522
ER
PT J
AU Goldman, S
Smith, L
Anderson, JR
Perkins, S
Harrison, L
Geyer, MB
Gross, TG
Weinstein, H
Bergeron, S
Shiramizu, B
Sanger, W
Barth, M
Zhi, J
Cairo, MS
AF Goldman, S.
Smith, L.
Anderson, J. R.
Perkins, S.
Harrison, L.
Geyer, M. B.
Gross, T. G.
Weinstein, H.
Bergeron, S.
Shiramizu, B.
Sanger, W.
Barth, M.
Zhi, J.
Cairo, M. S.
TI Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV
B-cell non-Hodgkin lymphoma: a Children's Oncology Group report
SO LEUKEMIA
LA English
DT Letter
ID ACUTE-LYMPHOBLASTIC-LEUKEMIA; CHOP CHEMOTHERAPY; ADOLESCENTS; RISK;
TRIAL
C1 [Goldman, S.] Med City Childrens Hosp, Dept Pediat Hematol Oncol, Dallas, TX USA.
[Smith, L.; Anderson, J. R.] Univ Nebraska, Coll Publ Hlth, Dept Biostat, Omaha, NE 68182 USA.
[Perkins, S.] Univ Utah, Dept Pathol, Salt Lake City, UT USA.
[Harrison, L.; Cairo, M. S.] New York Med Coll, Dept Pediat, Valhalla, NY 10595 USA.
[Geyer, M. B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA USA.
[Gross, T. G.] Ohio State Univ, Dept Pediat Hematol Oncol Blood & Marrow Transpla, Columbus, OH 43210 USA.
[Weinstein, H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat Hematol Oncol, Boston, MA USA.
[Bergeron, S.] CHOC Childrens Hosp, Dept Pediat Hematol Oncol, Orange, CA USA.
[Shiramizu, B.] Univ Hawaii, Dept Pediat Hematol Oncol, Honolulu, HI 96822 USA.
[Sanger, W.] Univ Nebraska, Med Ctr, Dept Cytogenet, Omaha, NE USA.
[Barth, M.] Roswell Pk Canc Inst, Dept Pediat, Buffalo, NY 14263 USA.
[Zhi, J.] Hoffmann La Roche Inc, Nutley, NJ 07110 USA.
[Cairo, M. S.] New York Med Coll, Dept Med, Valhalla, NY 10595 USA.
[Cairo, M. S.] New York Med Coll, Dept Pathol, Valhalla, NY 10595 USA.
[Cairo, M. S.] Dept Microbiol, Valhalla, NY USA.
[Cairo, M. S.] New York Med Coll, Valhalla, NY 10595 USA.
[Cairo, M. S.] New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA.
RP Goldman, S (reprint author), Med City Childrens Hosp, Dept Pediat Hematol Oncol, Dallas, TX USA.
EM Mitchell_cairo@nymc.edu
OI Geyer, Mark/0000-0001-5248-9117
FU NCI NIH HHS [CA98413-09, CA98543-09, U10 CA098413, U10 CA098543]; NIMHD
NIH HHS [U54 MD007584]
NR 13
TC 32
Z9 35
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
J9 LEUKEMIA
JI Leukemia
PD MAY
PY 2013
VL 27
IS 5
BP 1174
EP 1177
DI 10.1038/leu.2012.255
PG 5
WC Oncology; Hematology
SC Oncology; Hematology
GA 141AS
UT WOS:000318698300022
PM 22940833
ER
PT J
AU Arora, M
Pidala, J
Cutler, CS
Chai, X
Kurland, B
Jacobsohn, DA
Pavletic, SZ
Palmer, J
Vogelsang, G
Jagasia, M
Schultz, K
Lee, SJ
AF Arora, M.
Pidala, J.
Cutler, C. S.
Chai, X.
Kurland, B.
Jacobsohn, D. A.
Pavletic, S. Z.
Palmer, J.
Vogelsang, G.
Jagasia, M.
Schultz, K.
Lee, S. J.
TI Impact of prior acute GVHD on chronic GVHD outcomes: a chronic graft
versus host disease consortium study
SO LEUKEMIA
LA English
DT Letter
ID CONSENSUS DEVELOPMENT PROJECT; WORKING GROUP-REPORT;
MARROW-TRANSPLANTATION; CLINICAL-TRIALS; CRITERIA; SEVERITY; COHORT
C1 [Arora, M.] Univ Minnesota, Div Hematol Oncol & Transplant, Minneapolis, MN 55455 USA.
[Pidala, J.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
[Cutler, C. S.] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA.
[Chai, X.; Kurland, B.; Lee, S. J.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Chai, X.; Kurland, B.; Lee, S. J.] Univ Washington, Seattle, WA 98195 USA.
[Jacobsohn, D. A.] Childrens Natl Med Ctr, Washington, DC 20010 USA.
[Pavletic, S. Z.] NCI, Expt Transplantat & Immunol Branch, Ctr Canc Res, Bethesda, MD 20892 USA.
[Palmer, J.] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Vogelsang, G.] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
[Jagasia, M.] Vanderbilt Univ, Nashville, TN USA.
[Schultz, K.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
RP Arora, M (reprint author), Univ Minnesota, Div Hematol Oncol & Transplant, Minneapolis, MN 55455 USA.
EM arora005@umn.edu
OI Kurland, Brenda/0000-0002-5669-0595
FU NCI NIH HHS [R01 CA118953, CA 118953, U54 CA163438]
NR 15
TC 5
Z9 5
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
J9 LEUKEMIA
JI Leukemia
PD MAY
PY 2013
VL 27
IS 5
BP 1196
EP 1201
DI 10.1038/leu.2012.292
PG 7
WC Oncology; Hematology
SC Oncology; Hematology
GA 141AS
UT WOS:000318698300030
PM 23047477
ER
PT J
AU Auma, MA
Siedner, MJ
Nyehangane, D
Nalusaji, A
Nakaye, M
Mwanga-Amumpaire, J
Muhindo, R
Wilson, LA
Il, YB
Moore, CC
AF Auma, Mary A.
Siedner, Mark J.
Nyehangane, Dan
Nalusaji, Aisha
Nakaye, Martha
Mwanga-Amumpaire, Juliet
Muhindo, Rose
Wilson, L. Anthony
Il, Yap Boum
Moore, Christopher C.
TI Malaria is an uncommon cause of adult sepsis in south-western Uganda
SO MALARIA JOURNAL
LA English
DT Article
DE Sepsis; Uganda; Africa; Malaria; Adult
ID HOSPITALIZED FEBRILE PATIENTS; NORTHERN TANZANIA; MORTALITY;
TUBERCULOSIS; POPULATION; ADMISSIONS; MANAGEMENT; DIAGNOSIS; PARASITES;
CHILDREN
AB Background: Malaria is often considered a cause of adult sepsis in malaria endemic areas. However, diagnostic limitations can make distinction between malaria and other infections challenging. Therefore, the objective of this study was to determine the relative contribution of malaria to adult sepsis in south-western Uganda.
Methods: Adult patients with sepsis were enrolled at the Mbarara Regional Referral Hospital between February and May 2012. Sepsis was defined as infection plus >= 2 of the following: axillary temperature >37.5 degrees C or <35.5 degrees C, heart rate >90 or respiratory rate >20. Severe sepsis was defined as sepsis plus organ dysfunction (blood lactate >4 mmol/L, confusion, or a systolic blood pressure <90 mmHg). Sociodemographic, clinical and laboratory data, including malaria PCR and rapid diagnostic tests, as well as acid fast bacteria sputum smears and blood cultures were collected. Patients were followed until in-patient death or discharge. The primary outcome of interest was the cause of sepsis. Multivariable logistic regression was performed to assess predictors of mortality.
Results: Enrollment included 216 participants who were 51% female with a median age of 32 years (IQR 27-43 years). Of these, 122 (56%) subjects were HIV-seropositive of whom 75 (66%) had a CD4+ T cell count <100 cells/mu L. The prevalence of malaria was 4% (six with Plasmodium falciparum, two with Plasmodium vivax). Bacteraemia was identified in 41 (19%) patients. In-hospital mortality was 19% (n = 42). In multivariable regression analysis, Glasgow Coma Score <9 (IRR 4.81, 95% CI 1.80-12.8) and severe sepsis (IRR, 2.07, 95% CI 1.03-4.14), but no specific diagnoses were statistically associated with in-hospital mortality.
Conclusion: Malaria was an uncommon cause of adult sepsis in a regional referral hospital in south-western Uganda. In this setting, a thorough evaluation for alternate causes of disease in patients presenting with sepsis is recommended.
C1 [Auma, Mary A.; Mwanga-Amumpaire, Juliet; Muhindo, Rose; Wilson, L. Anthony; Il, Yap Boum] Mbarara Univ Sci & Technol, Fac Med, Mbarara, Uganda.
[Siedner, Mark J.] Harvard Univ, Sch Med, Div Infect Dis, Massachusetts Gen Hosp, Boston, MA USA.
[Nyehangane, Dan; Nalusaji, Aisha; Mwanga-Amumpaire, Juliet; Il, Yap Boum] Epictr Mbarara Res Base, Mbarara, Uganda.
[Nakaye, Martha] Mbarara Univ Sci & Technol, Dept Microbiol, Mbarara, Uganda.
[Moore, Christopher C.] Univ Virginia, Dept Med, Div Infect Dis & Int Hlth, Charlottesville, VA 22903 USA.
RP Moore, CC (reprint author), Univ Virginia, Dept Med, Div Infect Dis & Int Hlth, Charlottesville, VA 22903 USA.
EM ccm5u@virginia.edu
FU Pfizer Initiative in International Health; Center for Global Health at
the University of Virginia; Lacor Hospital administration, Gulu, Uganda;
Harvard Institute for Global Health; Fogarty International Clinical
Research Scholars and Fellows Program at Vanderbilt University [R24
TW007988]; National Institutes of Health [T32 AI007433]
FX Funding for the study was provided to MAA and CCM by the Pfizer
Initiative in International Health and the Center for Global Health at
the University of Virginia. This initiative was conceived to fund global
infectious disease research and exchange programmes between
post-doctoral fellows and students from the University of Virginia and
several international partners to conduct research on global health
issues. The major purpose of this programme is to foster and enhance
bidirectional research training. An independent board at the University
of Virginia determines the research proposals that are funded. Pfizer,
Inc provided funds to promote the initiative but has no role in the
planning or execution of research protocols, including the study
described in this article. MAA also received salary, tuition, and
research support from the Lacor Hospital administration, Gulu, Uganda.
MS received salary and research support from the Harvard Institute for
Global Health, the Fogarty International Clinical Research Scholars and
Fellows Program at Vanderbilt University (R24 TW007988), and the
National Institutes of Health (T32 AI007433).
NR 28
TC 5
Z9 5
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD MAY 1
PY 2013
VL 12
AR 146
DI 10.1186/1475-2875-12-146
PG 9
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 144YN
UT WOS:000318979000001
PM 23634654
ER
PT J
AU Shampo, MA
Kyle, RA
Steensma, DP
AF Shampo, Marc A.
Kyle, Robert A.
Steensma, David P.
TI Ian Wilmut-Pioneer of Cloning
SO MAYO CLINIC PROCEEDINGS
LA English
DT Editorial Material
C1 [Shampo, Marc A.; Kyle, Robert A.] Mayo Clin, Rochester, MN 55905 USA.
[Steensma, David P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Shampo, MA (reprint author), Mayo Clin, Rochester, MN 55905 USA.
OI Steensma, David/0000-0001-5130-9284
NR 0
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0025-6196
J9 MAYO CLIN PROC
JI Mayo Clin. Proc.
PD MAY
PY 2013
VL 88
IS 5
BP E41
EP E41
DI 10.1016/j.mayocp.2012.01.028
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 145BY
UT WOS:000318989700001
PM 23639503
ER
PT J
AU Papisov, MI
Belov, VV
Gannon, KS
AF Papisov, Mikhail I.
Belov, Vasily V.
Gannon, Kimberley S.
TI Physiology of the Intrathecal Bolus: The Leptomeningeal Route for
Macromolecule and Particle Delivery to CNS
SO MOLECULAR PHARMACEUTICS
LA English
DT Review
DE CNS; intrathecal; leptomeningeal; cerebrospinal fluid; CSF; drug
delivery; biopharmaceuticals; proteins; bacteriophage; drug carriers;
imaging
ID ENZYME REPLACEMENT THERAPY; VIRCHOW-ROBIN SPACES; CONVECTION-ENHANCED
DELIVERY; CENTRAL-NERVOUS-SYSTEM; GROWTH FACTOR-II/MANNOSE-6-PHOSPHATE
RECEPTOR; AMYOTROPHIC-LATERAL-SCLEROSIS; LYSOSOMAL STORAGE DISEASES;
CEREBROSPINAL-FLUID FLOW; TRAUMATIC BRAIN-INJURY; DORSAL-ROOT GANGLIA
AB Presently, there are no effective treatments for several diseases involving the CNS, which is protected by the bloo-brain, blood-CSF, and blood-arachnoid barriers. Traversing any of these barriers is difficult, especially for macromolecular drugs and particulates. However, there is significant experimental evidence that large molecules can be delivered to the CNS through the cerebrospinal fluid (CSF). The flux of the interstitial fluid in the CNS parenchyma, as well as the macro flux of CSF in the leptomeningeal space, are believed to be generally opposite to the desirable direction of CNS-targeted drug delivery. On the other hand, the available data suggest that the layer of pia mater lining the CNS surface is not continuous, and the continuity of the leptomeningeal space (LMS) with the perivascular spaces penetrating into the parenchyma provides an unexplored avenue for drug transport deep into the brain via CSF. The published data generally do not support the view that macromolecule transport from the LMS to CNS is hindered by the interstitial and CSF fluxes. The data strongly suggest that leptomeningeal transport depends on the location and volume of the administered bolus and consists of four processes: (i) pulsation-assisted convectional transport of the solutes with CSF, (ii) active "pumping" of CSF into the periarterial spaces, (iii) solute transport from the latter to and within the parenchyma, and (iv) neuronal uptake and axonal transport. The final outcome will depend on the drug molecule behavior in each of these processes, which have not been studied systematically. The data available to date suggest that many macromolecules and nanoparticles can be delivered to CNS in biologically significant amounts (>1% of the administered dose); mechanistic investigation of macromolecule and particle behavior in CSF may result in a significantly more efficient leptomeningeal drug delivery than previously thought.
C1 [Papisov, Mikhail I.; Belov, Vasily V.] Shriners Hosp Children, Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Papisov, Mikhail I.; Belov, Vasily V.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Gannon, Kimberley S.] NeuroPhage Pharmaceut Inc, Cambridge, MA 02142 USA.
RP Papisov, MI (reprint author), Shriners Hosp Children, Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM papisov@helix.mgh.harvard.edu
OI Papisov, Mikhail/0000-0003-4716-2122
FU NIH [R21 CA152384]; DoD [BC100684]
FX Authors thank Drs. P. Calias, R. Penn, M. Heartlein, T. McCauley, A.J.
Fischman, and R. Fisher for valuable discussions, and E. Papisov for
assistance with editing the manuscript. Previously unpublished data were
from studies supported by NIH Grant R21 CA152384 and DoD Grant BC100684.
NR 144
TC 15
Z9 15
U1 0
U2 16
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD MAY
PY 2013
VL 10
IS 5
BP 1522
EP 1532
DI 10.1021/mp300474m
PG 11
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 140QI
UT WOS:000318669600006
PM 23316936
ER
PT J
AU Valencia, PM
Pridgen, EM
Perea, B
Gadde, S
Sweeney, C
Kantoff, PW
Bander, NH
Lippard, SJ
Langer, R
Karnik, R
Farokhzad, OC
AF Valencia, Pedro M.
Pridgen, Eric M.
Perea, Brian
Gadde, Suresh
Sweeney, Christopher
Kantoff, Philip W.
Bander, Neil H.
Lippard, Stephen J.
Langer, Robert
Karnik, Rohit
Farokhzad, Omid C.
TI Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug
targeted polymeric nanoparticles
SO NANOMEDICINE
LA English
DT Article
DE cisplatin; combination chemotherapy; irinotecan; nanoparticle; PSMA
ID PLGA-PEG NANOPARTICLES; PROSTATE-CANCER; MEMBRANE ANTIGEN; IN-VIVO;
COMBINATIONS; THERAPY; DELIVERY; PLATFORM; PERSPECTIVES; CHEMOTHERAPY
AB Aim: Two unexplored aspects for irinotecan and cisplatin (I&C)combination chemotherapy are: actively targeting both drugs to a specific diseased cell type, and delivering both drugs on the same vehicle to ensure their synchronized entry into the cell at a well-defined ratio. In this work, the authors report the use of targeted polymeric nanoparticles (NPs) to coencapsulate and deliver I&C to cancer cells expressing the prostate-specific membrane antigen. Materials & methods: Targeted NPs were prepared in a single step by mixing four different precursors inside microfluidic devices. Results: I&C were encapsulated in 55-nm NPs and showed an eightfold increase in internalization by prostate-specific membrane antigen-expressing LNCaP cells compared with nontargeted NPs. NPs coencapsulating both drugs exhibited strong synergism in LNCaP cells with a combination index of 0.2. Conclusion: The strategy of coencapsulating both I&C in a single NP targeted to a specific cell type could potentially be used to treat different types of cancer.
C1 [Valencia, Pedro M.; Pridgen, Eric M.; Langer, Robert] MIT, Dept Chem Engn, Cambridge, MA 02139 USA.
[Perea, Brian] Arizona State Univ, Sch Engn Matter Transport & Energy, Tempe, AZ 85287 USA.
[Gadde, Suresh; Farokhzad, Omid C.] Harvard Univ, Sch Med, Lab Nanomed & Biomat, Brigham & Womens Hosp, Boston, MA 02115 USA.
[Gadde, Suresh; Farokhzad, Omid C.] Harvard Univ, Sch Med, Dept Anesthesiol, Brigham & Womens Hosp, Boston, MA 02115 USA.
[Sweeney, Christopher; Kantoff, Philip W.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02215 USA.
[Bander, Neil H.] Cornell Univ, Weill Med Coll, New York, NY 10065 USA.
[Lippard, Stephen J.; Langer, Robert] MIT, Dept Chem, Cambridge, MA 02139 USA.
[Lippard, Stephen J.; Farokhzad, Omid C.] MIT, MIT Harvard Ctr Canc Nanotechnol Excellence, Cambridge, MA 02139 USA.
[Karnik, Rohit] MIT, Dept Mech Engn, Cambridge, MA 02139 USA.
RP Farokhzad, OC (reprint author), Harvard Univ, Sch Med, Lab Nanomed & Biomat, Brigham & Womens Hosp, Boston, MA 02115 USA.
EM ofarokhzad@zeus.bwh.harvard.edu
RI Gadde, Suresh/B-9483-2012;
OI Gadde, Suresh/0000-0001-9102-3029; Perea, Brian/0000-0002-6805-2304
FU Koch-Prostate Cancer Foundation Award in Nanotherapeutics; NCI Center of
Cancer Nanotechnology Excellence at MIT-Harvard [U54-CA151884]; NSF
graduate research fellowship; NDSEG graduate research fellowship
FX OC Farokhzad and R Langer have financial interests in BIND Biosciences
and Selecta Biosciences. OC Farohkzad, R Langer and SJ Lippard have
financial interests in Blend Therapeutics. This research was supported
by the Koch-Prostate Cancer Foundation Award in Nanotherapeutics (R
Langer and OC Farokhzad) and by the NCI Center of Cancer Nanotechnology
Excellence at MIT-Harvard (U54-CA151884). PM Valencia is supported by
NSF graduate research fellowship. EM Pridgen is supported by a NDSEG
graduate research fellowship. The authors have no other relevant
affiliations or financial involvement with any organization or entity
with a financial interest in or financial conflict with the subject
matter or materials discussed in the manuscript apart from those
disclosed.
NR 35
TC 25
Z9 25
U1 7
U2 87
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 1743-5889
EI 1748-6963
J9 NANOMEDICINE-UK
JI Nanomedicine
PD MAY
PY 2013
VL 8
IS 5
BP 687
EP 698
DI 10.2217/NNM.12.134
PG 12
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
Topics
GA 143FL
UT WOS:000318852100008
PM 23075285
ER
PT J
AU Sperandio, FF
Sharma, SK
Wang, M
Jeon, S
Huang, YY
Dai, TH
Nayka, S
de Sousa, SCOM
Chiang, LY
Hamblin, MR
AF Sperandio, Felipe F.
Sharma, Sulbha K.
Wang, Min
Jeon, Seaho
Huang, Ying-Ying
Dai, Tianhong
Nayka, Suhasini
de Sousa, Suzana C. O. M.
Chiang, Long Y.
Hamblin, Michael R.
TI Photoinduced electron-transfer mechanisms for radical-enhanced
photodynamic therapy mediated by water-soluble decacationic C-70 and
C84O2 Fullerene Derivatives
SO NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Photodynamic therapy; Decacationic [70] fullerene derivatives;
Decacationic [84] fullerene-dioxide derivatives; Electron transfer;
Ascorbic acid
ID ENERGY-TRANSFER; SINGLET-OXYGEN; CANCER-CELLS; CHARGE-SEPARATION;
PLASMA-MEMBRANE; IONIC LIQUIDS; ASCORBIC-ACID; C-60; TRANSPORT;
KERATINOCYTES
AB Fullerenes are promising candidates for photodynamic therapy (PDT). Thus, C-70 and novel C84O2 fullerenes were functionalized with and without an additional deca-tertiary ethyleneamino-chain as an electron source, giving rise to two distinct pairs of photosensitizers, the monoadducts LC-17, LC-19 and the bisadducts LC18 and LC-20 to perform PDT in HeLa cells with UVA, blue, green, white and red light. Shorter wavelengths gave more phototoxicity with LC-20 while LC-19 was better at longer wavelengths; the ratio between killing obtained with LC-19 and LC-20 showed an almost perfect linear correlation (R = 0.975) with wavelength. The incorporation of a deca-tertiary amine chain in the C84O2 fullerene gave more PDT killing when excited with shorter wavelengths or in the presence of low ascorbate concentration through higher generation of hydroxyl radicals. Photoactivated C84O2 fullerenes induced apoptosis of HeLa cancer cells, together with mitochondrial and lysosomal damage demonstrated by acridine orange and rhodamine 123 fluorescent probes. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Sperandio, Felipe F.; de Sousa, Suzana C. O. M.] Univ Sao Paulo, Sch Dent, Dept Oral Pathol, BR-05508000 Sao Paulo, Brazil.
[Sperandio, Felipe F.; Sharma, Sulbha K.; Huang, Ying-Ying; Dai, Tianhong; Nayka, Suhasini; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Sperandio, Felipe F.; Huang, Ying-Ying; Dai, Tianhong; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Sperandio, Felipe F.] Minist Educ Brazil, CAPES Fdn, BR-70040020 Brasilia, DF, Brazil.
[Wang, Min; Jeon, Seaho; Chiang, Long Y.] Univ Massachusetts, Dept Chem, Inst Nanosci & Engn Technol, Lowell, MA 01854 USA.
[Chiang, Long Y.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada.
[Hamblin, Michael R.] Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, 40 Blossom St, Boston, MA 02114 USA.
EM hamblin@helix.mgh.harvard.edu
RI Sousa, Suzana/H-6154-2012;
OI Hamblin, Michael/0000-0001-6431-4605
FU NIH [R01CA137108, RO1AI050875]; CAPES Foundation, Ministry of Education
of Brazil [0310-11-5]; Airlift Research Foundation Extremity Trauma
Research Grant [109421]; Basic Research Grant from the Orthopaedic
Trauma Association [2012-16]
FX This work was supported by NIH grant R01CA137108 to LYC. FFS was
supported by CAPES Foundation, Ministry of Education of Brazil, grant
number 0310-11-5. TD was supported by an Airlift Research Foundation
Extremity Trauma Research Grant (grant 109421) and a Basic Research
Grant from the Orthopaedic Trauma Association (grant 2012-16). MRH was
supported by NIH grant RO1AI050875.
NR 51
TC 15
Z9 15
U1 1
U2 62
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549-9634
J9 NANOMED-NANOTECHNOL
JI Nanomed.-Nanotechnol. Biol. Med.
PD MAY
PY 2013
VL 9
IS 4
BP 570
EP 579
DI 10.1016/j.nano.2012.09.005
PG 10
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA 145AS
UT WOS:000318985600015
PM 23117043
ER
PT J
AU Lieber, DS
Calvo, SE
Shanahan, K
Slate, NG
Liu, ST
Hershman, SG
Gold, NB
Chapman, BA
Thorburn, DR
Berry, GT
Schmahmann, JD
Borowsky, ML
Mueller, DM
Sims, KB
Mootha, VK
AF Lieber, Daniel S.
Calvo, Sarah E.
Shanahan, Kristy
Slate, Nancy G.
Liu, Shangtao
Hershman, Steven G.
Gold, Nina B.
Chapman, Brad A.
Thorburn, David R.
Berry, Gerard T.
Schmahmann, Jeremy D.
Borowsky, Mark L.
Mueller, David M.
Sims, Katherine B.
Mootha, Vamsi K.
TI Targeted exome sequencing of suspected mitochondrial disorders
SO NEUROLOGY
LA English
DT Article
ID COMPLEX I DEFICIENCY; RESPIRATORY-CHAIN DISORDERS; WOLFRAM-SYNDROME; ATP
SYNTHASE; MUTATIONS; DISEASE; PATIENT; GENE; DNA; HETEROZYGOSITY
AB Objective: To evaluate the utility of targeted exome sequencing for the molecular diagnosis of mitochondrial disorders, which exhibit marked phenotypic and genetic heterogeneity.
Methods: We considered a diverse set of 102 patients with suspected mitochondrial disorders based on clinical, biochemical, and/or molecular findings, and whose disease ranged from mild to severe, with varying age at onset. We sequenced the mitochondrial genome (mtDNA) and the exons of 1,598 nuclear-encoded genes implicated in mitochondrial biology, mitochondrial disease, or monogenic disorders with phenotypic overlap. We prioritized variants likely to underlie disease and established molecular diagnoses in accordance with current clinical genetic guidelines.
Results: Targeted exome sequencing yielded molecular diagnoses in established disease loci in 22% of cases, including 17 of 18 (94%) with prior molecular diagnoses and 5 of 84 (6%) without. The 5 new diagnoses implicated 2 genes associated with canonical mitochondrial disorders (NDUFV1, POLG2), and 3 genes known to underlie other neurologic disorders (DPYD, KARS, WFS1), underscoring the phenotypic and biochemical overlap with other inborn errors. We prioritized variants in an additional 26 patients, including recessive, X-linked, and mtDNA variants that were enriched 2-fold over background and await further support of pathogenicity. In one case, we modeled patient mutations in yeast to provide evidence that recessive mutations in ATP5A1 can underlie combined respiratory chain deficiency.
Conclusion: The results demonstrate that targeted exome sequencing is an effective alternative to the sequential testing of mtDNA and individual nuclear genes as part of the investigation of mitochondrial disease. Our study underscores the ongoing challenge of variant interpretation in the clinical setting. Neurology (R) 2013;80:1762-1770
C1 [Lieber, Daniel S.; Calvo, Sarah E.; Slate, Nancy G.; Liu, Shangtao; Hershman, Steven G.; Gold, Nina B.; Chapman, Brad A.; Borowsky, Mark L.; Mootha, Vamsi K.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Lieber, Daniel S.; Calvo, Sarah E.; Slate, Nancy G.; Liu, Shangtao; Hershman, Steven G.; Gold, Nina B.; Sims, Katherine B.; Mootha, Vamsi K.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Lieber, Daniel S.; Calvo, Sarah E.; Hershman, Steven G.; Mootha, Vamsi K.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA USA.
[Lieber, Daniel S.; Calvo, Sarah E.; Hershman, Steven G.; Mootha, Vamsi K.] Broad Inst Harvard & MIT, Cambridge, MA USA.
[Shanahan, Kristy; Mueller, David M.] Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Dept Biochem & Mol Biol, Chicago, IL USA.
[Thorburn, David R.] Univ Melbourne, Murdoch Childrens Res Inst, Royal Childrens Hosp, Melbourne, Vic 3010, Australia.
[Thorburn, David R.] Univ Melbourne, Dept Paediat, Melbourne, Vic 3010, Australia.
[Berry, Gerard T.] Harvard Univ, Sch Med, Manton Ctr Orphan Dis Res, Childrens Hosp Boston, Boston, MA USA.
[Schmahmann, Jeremy D.; Sims, Katherine B.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Schmahmann, Jeremy D.; Sims, Katherine B.] Harvard Univ, Sch Med, Boston, MA USA.
[Mootha, Vamsi K.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
RP Mootha, VK (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
EM vamsi@hms.harvard.edu
RI Thorburn, David/G-6266-2013;
OI Hershman, Steven/0000-0001-9167-7380; Berry, Gerard/0000-0001-5299-3313;
thorburn, david/0000-0002-7725-9470
FU NSF; NIH [R01GM66223]; American Recovery and Reinvestment Act (ARRA)
funds from the National Human Genome Research Institute, NIH
[RC2HG005556]
FX This work was supported by an NSF Graduate Research Fellowship Program
grant (D. S. L.), a grant from NIH R01GM66223 (D. M. M.), and American
Recovery and Reinvestment Act (ARRA) funds through grant number
RC2HG005556 (V. K. M.) from the National Human Genome Research
Institute, NIH.
NR 39
TC 45
Z9 50
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD MAY
PY 2013
VL 80
IS 19
BP 1762
EP 1770
DI 10.1212/WNL.0b013e3182918c40
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA 141BL
UT WOS:000318700300034
PM 23596069
ER
PT J
AU Lin, BK
Edelman, E
McInerney, JD
O'Leary, J
Edelson, V
Hughes, KS
Drohan, B
Kyler, P
Lloyd-Puryear, M
Scott, J
Dolan, SM
AF Lin, Bruce K.
Edelman, Emily
McInerney, Joseph D.
O'Leary, James
Edelson, Vaughn
Hughes, Kevin S.
Drohan, Brian
Kyler, Penny
Lloyd-Puryear, Michele
Scott, Joan
Dolan, Siobhan M.
TI Personalizing prenatal care using family health history: identifying a
panel of conditions for a novel electronic genetic screening tool
SO PERSONALIZED MEDICINE
LA English
DT Article
DE clinical decision support; family health history; genetic screening;
personalized risk assessment; prenatal care
ID CYSTIC-FIBROSIS; RISK-ASSESSMENT; SURGEON-GENERALS; CLINICAL-USE;
PREVENTION; GUIDELINES; INFORMATION; COLLECTION; PROVIDERS; STATEMENT
AB In the age of genomic medicine, family health history (FHH) remains an important tool for personalized risk assessment as it can inform approaches to disease prevention and management. In primary care, including in prenatal settings, providers recognize that FHH enables them to assess the risk for birth defects and complex conditions that not only affect the fetus health, but also the mother's. However, many providers lack the time to gather FHH or the knowledge to confidently interpret the data. Electronic tools providing clinical decision support using FHH data can aid the busy provider with data collection and interpretation. We describe the scope of conditions included in a patient-entered FHH tool that provides clinical decision support and point-of-care education to assist with patient management. This report details how we selected the conditions for which it is appropriate to use FHH as a means to promote personalized medicine in primary prenatal care.
C1 [Lin, Bruce K.; Dolan, Siobhan M.] March Dimes Fdn, White Plains, NY 10605 USA.
[Edelman, Emily; McInerney, Joseph D.; Scott, Joan] Natl Coalit Hlth Profess Educ Genet, Lutherville Timonium, MD 21093 USA.
[O'Leary, James; Edelson, Vaughn] Genet Alliance, Washington, DC 20008 USA.
[Hughes, Kevin S.; Drohan, Brian] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Kyler, Penny] Hlth Resources Serv Adm, Rockville, MD 20857 USA.
RP Lin, BK (reprint author), March Dimes Fdn, 1275 Mamaroneck Ave, White Plains, NY 10605 USA.
EM blin@marchofdimes.com
OI Hughes, Kevin/0000-0003-4084-6484
FU Health Resources and Services Administration (HRSA), Maternal and Child
Health Bureau, Genetic Services Branch [U33MC12786]
FX This project is supported by grant U33MC12786 from Health Resources and
Services Administration (HRSA), Maternal and Child Health Bureau,
Genetic Services Branch. KS Hughes is the inventor of Hughes Risk Apps.
The authors are affiliated with institutions, with the exception of
HRSA, that may receive royalties from the licensing of the prenatal
module discussed in the manuscript. The authors have no other relevant
affiliations or financial involvement with any organization or entity
with a financial interest in or financial conflict with the subject
matter or materials discussed in the manuscript apart from those
disclosed.
NR 68
TC 3
Z9 3
U1 0
U2 8
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 1741-0541
J9 PERS MED
JI Pers. Med.
PD MAY
PY 2013
VL 10
IS 3
BP 307
EP 318
DI 10.2217/PME.13.18
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 141LW
UT WOS:000318727700014
ER
PT J
AU Milfred-LaForest, SK
Chow, SL
DiDomenico, RJ
Dracup, K
Ensor, CR
Gattis-Stough, W
Heywood, JT
Lindenfeld, J
Page, RL
Patterson, JH
Vardeny, O
Massie, BM
AF Milfred-LaForest, Sherry K.
Chow, Sheryl L.
DiDomenico, Robert J.
Dracup, Kathleen
Ensor, Christopher R.
Gattis-Stough, Wendy
Heywood, J. Thomas
Lindenfeld, JoAnn
Page, Robert L., II
Patterson, J. Herbert
Vardeny, Orly
Massie, Barry M.
TI Clinical Pharmacy Services in Heart Failure: An Opinion Paper from the
Heart Failure Society of America and American College of Clinical
Pharmacy Cardiology Practice and Research Network
SO PHARMACOTHERAPY
LA English
DT Article
DE heart failure; clinical pharmacist; multidisciplinary team; heart
transplant
ID UNITED-STATES HOSPITALS; ADVERSE DRUG-REACTIONS; INPATIENT MEDICATION
RECONCILIATION; VENTRICULAR ASSIST DEVICE; PRESCRIBER ORDER ENTRY;
INTENSIVE-CARE-UNIT; TRANSPLANT RECIPIENT; PHARMACEUTICAL CARE;
MANAGEMENT PROGRAM; CARDIOVASCULAR-DISEASE
AB Heart failure (HF) care takes place in multiple settings, with a variety of providers, and generally involves patients who have multiple comorbidities. This situation is a "perfect storm" of factors that predispose patients to medication errors. The goals of this paper are to outline potential roles for clinical pharmacists in a multidisciplinary HF team, to document outcomes associated with interventions by clinical pharmacists, to recommend minimum training for clinical pharmacists engaged in HF care, and to suggest financial strategies to support clinical pharmacy services within a multidisciplinary team. As patients transition from inpatient to outpatient settings and between multiple caregivers, pharmacists can positively affect medication reconciliation and education, assure consistency in management that results in improvements in patient satisfaction and medication adherence, and reduce medication errors. For mechanical circulatory support and heart transplant teams, the Centers for Medicare and Medicaid Services considers the participation of a transplant pharmacology expert (e. g., clinical pharmacist) to be a requirement for accreditation, given the highly specialized and complex drug regimens used. Although reports of outcomes from pharmacist interventions have been mixed owing to differences in study design, benefits such as increased use of evidence-based therapies, decreases in HF hospitalizations and emergency department visits, and decreases in all-cause read-missions have been demonstrated. Clinical pharmacists participating in HF or heart transplant teams should have completed specialized postdoctoral training in the form of residencies and/or fellowships in cardiovascular and/or transplant pharmacotherapy, and board certification is recommended. Financial mechanisms to support pharmacist participation in the HF teams are variable. Positive outcomes associated with clinical pharmacist activities support the value of making this resource available to HF teams.
C1 [Milfred-LaForest, Sherry K.] Louis Stokes Cleveland VA Med Ctr, Dept Pharm, Cleveland, OH USA.
[Chow, Sheryl L.] Western Univ Hlth Sci, Coll Pharm, Pomona, CA 91766 USA.
[DiDomenico, Robert J.] Univ Illinois, Coll Pharm, Chicago, IL USA.
[Dracup, Kathleen] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA.
[Ensor, Christopher R.] Univ Pittsburgh, Coll Pharm, Pittsburgh, PA USA.
[Gattis-Stough, Wendy] Campbell Univ, Coll Pharm & Hlth Sci, Dept Clin Res, Buies Creek, NC 27506 USA.
[Heywood, J. Thomas] Scripps Clin, Dept Med, La Jolla, CA 92037 USA.
[Lindenfeld, JoAnn] Univ Colorado Denver, Heart Transplantat Program, Dept Med, Div Cardiol, Aurora, CO USA.
[Page, Robert L., II] Univ Colorado Denver, Sch Pharm, Dept Med, Div Cardiol, Aurora, CO USA.
[Page, Robert L., II] Univ Colorado Denver, Sch Med, Dept Med, Div Cardiol, Aurora, CO USA.
[Patterson, J. Herbert] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC USA.
[Vardeny, Orly] Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA.
[Vardeny, Orly] Univ Wisconsin, Sch Med, Madison, WI USA.
[Massie, Barry M.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
[Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Chow, SL (reprint author), Western Univ Hlth Sci, Coll Pharm, 309 E 2nd St, Pomona, CA 91766 USA.
EM schow@westernu.edu; barry.massie@va.gov
OI DiDomenico, Robert/0000-0002-9374-8012
FU Medtronic; Gambro; St. Jude; Zensun; Otsuka; Novartis; Amgen
FX Robert J. DiDomenico is a consultant for F. Hoffman LaRoche. J. Thomas
Heywood has received speaking honoraria from Actelion, Medtronic, St
Jude, and Thoratec; is a consultant for Actelion, Medtronic, and
Thoratec; and has received research grants from Medtronic and Gambro and
fellowship support from St. Jude. JoAnn Lindenfeld is a consultant for
St Jude, Boston Scientific, and Abbott and has received a research grant
from Zensun. J. Herbert Patterson has received speaking honoraria from
Otsuka, is a consultant for Otsuka and Novartis, and has received
research grants from Otsuka, Novartis, and Amgen. All of the other
authors report no potential conflict of interest.
NR 135
TC 11
Z9 11
U1 1
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0277-0008
J9 PHARMACOTHERAPY
JI Pharmacotherapy
PD MAY
PY 2013
VL 33
IS 5
BP 529
EP 548
DI 10.1002/phar.1295
PG 20
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 137MB
UT WOS:000318438900115
PM 23649813
ER
PT J
AU Pan, JD
Bredella, MA
AF Pan, Judong
Bredella, Miriam A.
TI Imaging of Soft Tissue Abnormalities About the Hip
SO RADIOLOGIC CLINICS OF NORTH AMERICA
LA English
DT Article
DE Hip; Joint capsule; Tendons; Plica; Capsule; Myotendinous strain;
Ischiofemoral impingement
ID QUADRATUS FEMORIS MUSCLE; PIGMENTED VILLONODULAR SYNOVITIS; INSERTION
AVULSION SYNDROME; TROCHANTERIC-PAIN-SYNDROME; SNAPPING ILIOPSOAS
TENDON; CAPSULAR LIGAMENTS; CLINICAL FINDINGS; ABDUCTOR TENDONS; MR
ARTHROGRAPHY; DIAGNOSIS
AB Soft tissue abnormalities about the hip represent a common clinical problem. Although the signs and symptoms of some of these abnormalities are clinically evident, other entities are frequently overlooked. This article provides an overview and discusses the role of major imaging modalities, especially MR imaging, the primary modality for evaluation of many soft-tissue abnormalities. An introduction to fundamental imaging anatomy and functional roles of soft tissue structures about the hip is provided, recognizing their importance in making the correct diagnosis. lntra-articular and extra-articular soft tissue abnormalities reviewed systematically according to their mechanism of injury and anatomic or functional compartments.
C1 [Bredella, Miriam A.] Massachusetts Gen Hosp, Dept Radiol, Div Musculoskeletal Imaging & Intervent, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Bredella, MA (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Musculoskeletal Imaging & Intervent, 55 Fruit St,YAW-6E, Boston, MA 02114 USA.
EM mbredella@partners.org
NR 62
TC 1
Z9 1
U1 0
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0033-8389
J9 RADIOL CLIN N AM
JI Radiol. Clin. N. Am.
PD MAY
PY 2013
VL 51
IS 3
BP 353
EP +
DI 10.1016/j.rcl.2012.10.003
PG 18
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 146IR
UT WOS:000319085300003
PM 23622089
ER
PT J
AU Kapur, VK
Wilsdon, AG
Au, D
Avdalovic, M
Enright, P
Fan, VS
Hansel, NN
Heckbert, SR
Jiang, R
Krishnan, JA
Mukamal, K
Yende, S
Barr, RG
AF Kapur, Vishesh K.
Wilsdon, Anthony G.
Au, David
Avdalovic, Mark
Enright, Paul
Fan, Vincent S.
Hansel, Nadia N.
Heckbert, Susan R.
Jiang, Rui
Krishnan, Jerry A.
Mukamal, Kenneth
Yende, Sachin
Barr, R. Graham
TI Obesity Is Associated With a Lower Resting Oxygen Saturation in the
Ambulatory Elderly: Results From the Cardiovascular Health Study
SO RESPIRATORY CARE
LA English
DT Article
DE pulse oximetry; oxygen; obesity; body mass index; waist circumference;
hypoxemia; pulmonary function test
ID OLDER-ADULTS
AB BACKGROUND: The contribution of obesity to hypoxemia has not been reported in a community-based study. Our hypothesis was that increasing obesity would be independently associated with lower S-pO2 in an ambulatory elderly population. METHODS: The Cardiovascular Health Study ascertained resting S-pO2 in 2,252 subjects over age 64. We used multiple linear regression to estimate the association of body mass index (BMI) with S-pO2 and to adjust for potentially confounding factors. Covariates including age, sex, race, smoking, airway obstruction (based on spirometry), self reported diagnosis of emphysema, asthma, heart failure, and left ventricular function (by echocardiography) were evaluated. RESULTS: Among 2,252 subjects the mean and median S-pO2 were 97.6% and 98.0% respectively; 5% of subjects had S-pO2 values below 95%. BMI was negatively correlated with S-pO2 (Spearman R = -0.27, P < .001). The mean difference in S-pO2 between the lowest and highest BMI categories (< 25 kg/m(2) and >= 35 kg/m(2)) was 1.33% (95% CI 0.89-1.78%). In multivariable linear regression analysis, S-pO2 was significantly inversely associated with BMI (1.4% per 10 units of BMI, 95% CI 1.2-1.6, for whites/others, and 0.87% per 10 units of BMI, 95% CI 0.47-1.27, for African Americans). CONCLUSIONS: We found a narrow distribution of S-pO2 values in a community-based sample of ambulatory elderly. Obesity was a strong independent contributor to a low S-pO2 with effects comparable to or greater than other factors clinically associated with lower S-pO2.
C1 [Kapur, Vishesh K.; Au, David; Fan, Vincent S.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98104 USA.
[Wilsdon, Anthony G.] Univ Washington, Dept Biostat, Collaborat Hlth Studies Coordinating Ctr, Seattle, WA 98104 USA.
[Au, David; Fan, Vincent S.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Serv, Seattle, WA USA.
[Avdalovic, Mark] Univ Calif Davis, Sch Med, Div Pulm & Crit Care Med, Davis, CA 95616 USA.
[Enright, Paul] Univ Arizona, Coll Med, Resp Sci Ctr, Tucson, AZ USA.
[Hansel, Nadia N.] Johns Hopkins Univ, Div Pulm & Crit Care Med, Baltimore, MD USA.
[Heckbert, Susan R.] Univ Washington, Dept Epidemiol, Seattle, WA 98104 USA.
[Jiang, Rui; Barr, R. Graham] Columbia Univ, Med Ctr, Dept Epidemiol, Dept Med, New York, NY USA.
[Krishnan, Jerry A.] Univ Illinois Hosp & Hlth Sci Syst, Div Pulm Crit Care Sleep & Allergy, Chicago, IL USA.
[Mukamal, Kenneth] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA.
[Yende, Sachin] Univ Pittsburgh, Dept Crit Care Med, Clin Res Invest & Syst Modeling Acute Illness Ctr, Pittsburgh, PA USA.
RP Kapur, VK (reprint author), Univ Washington, Div Pulm & Crit Care Med, Box 359803,325 9th Ave, Seattle, WA 98104 USA.
RI Kapur, Vishesh/K-1054-2014
OI Kapur, Vishesh/0000-0002-5417-1097
FU National Institutes of Health [N01-HC-85239, N01-HC-85079, N01-HC-85080,
N01-HC-85081, N01-HC-85082, N01-HC-85083, N01-HC-85084, N01-HC-85085,
N01-HC-85086, N01-HC-35129, N01 HC-15103, N01-HC-55222, N01-HC-75150,
N01-HC-45133]; National Heart, Lung, and Blood Institute [HL080295];
National Institute of Neurological Disorders and Stroke; National
Institute on Aging [AG-023629, AG-15928, AG-20098, AG-027058]
FX This research was partly supported by National Institutes of Health
grants N01-HC-85239, N01-HC-85079 through N01-HC-85086, N01-HC-35129,
N01 HC-15103, N01-HC-55222, N01-HC-75150, N01-HC-45133, National Heart,
Lung, and Blood Institute grant HL080295, the National Institute of
Neurological Disorders and Stroke, and National Institute on Aging
grants AG-023629, AG-15928, AG-20098, and AG-027058. The Cardiovascular
Health Study principal investigators and institutions are listed at
http://www.chs-nhlbi.org/pi.htm.
NR 14
TC 3
Z9 3
U1 0
U2 3
PU DAEDALUS ENTERPRISES INC
PI IRVING
PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA
SN 0020-1324
J9 RESP CARE
JI Respir. Care
PD MAY
PY 2013
VL 58
IS 5
BP 831
EP 837
DI 10.4187/respcare.02008
PG 7
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 141UA
UT WOS:000318750800014
PM 23107018
ER
PT J
AU Myers, TR
Bollig, SM
Hess, DR
AF Myers, Timothy R.
Bollig, Suzanne M.
Hess, Dean R.
TI Respiratory Care Year in Review 2012: Asthma and Sleep-Disordered
Breathing
SO RESPIRATORY CARE
LA English
DT Review
DE asthma; lung function; pharmacology; diabetes; sleep-disordered
breathing; patient education
ID EMERGENCY-DEPARTMENT VISIT; EXHALED NITRIC-OXIDE; INHALED
CORTICOSTEROIDS; FOLLOW-UP; CONTROLLER MEDICATIONS; FENO MEASUREMENTS;
CONTROLLED-TRIAL; CHILDREN; APNEA; MANAGEMENT
AB Asthma has long been recognized as a common respiratory disease, and the recognition of sleep-disordered breathing is becoming more prevalent. Patients with these disorders are commonly seen by clinicians caring for patients with respiratory disease. There is also much academic interest in asthma and sleep-disordered breathing. The purpose of this paper is to review the recent literature related to asthma and sleep-disordered breathing in a manner that is most likely to have interest to the readers of RESPIRATORY CARE.
C1 [Myers, Timothy R.] Amer Assoc Resp Care, Irving, TX USA.
[Bollig, Suzanne M.] Hays Med Ctr, Sleep & Neurodiagnost Inst, Hays, KS USA.
[Hess, Dean R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Resp Care Serv, Boston, MA USA.
RP Hess, DR (reprint author), Massachusetts Gen Hosp, Resp Care Serv, Ellison 401,55 Fruit St, Boston, MA 02114 USA.
EM dhess@partners.org
NR 51
TC 1
Z9 1
U1 0
U2 2
PU DAEDALUS ENTERPRISES INC
PI IRVING
PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA
SN 0020-1324
J9 RESP CARE
JI Respir. Care
PD MAY
PY 2013
VL 58
IS 5
BP 874
EP 883
DI 10.4187/respcare.02481
PG 10
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 141UA
UT WOS:000318750800020
PM 23625896
ER
PT J
AU Schytz, HW
Jensen, BE
Jennum, P
Selb, J
Boas, DA
Ashina, M
AF Schytz, Henrik Winther
Jensen, Benedicte Ersted
Jennum, Poul
Selb, Juliette
Boas, David A.
Ashina, Messoud
TI Low-frequency oscillations and vasoreactivity of cortical vessels in
obstructive sleep apnea during wakefulness: A near infrared spectroscopy
study
SO SLEEP MEDICINE
LA English
DT Article
DE Obstructive sleep apnea; Continuous positive airway pressure; Cortical
vessels; Cerebral autoregulation; Near infrared spectroscopy;
Breath-holding tests; Autonomic nervous system; Stroke
ID POSITIVE AIRWAY PRESSURE; CEREBRAL HEMODYNAMICS; CEREBROVASCULAR
REACTIVITY; INTERMITTENT HYPOXIA; ADULTS; RISK; HYPERTENSION;
MECHANISMS; HYPOPNEA; STROKE
AB Objectives: Effective nasal continuous positive airway pressure (CPAP) therapy reduces the cardiovascular outcomes associated with obstructive sleep apnea (OSA), but the mechanism behind this effect is unclear. We investigated if OSA patients during wakefulness showed signs of increased sympathetic activity and decreased vasoreactivity in cerebral cortical vessels as measured with near-infrared spectroscopy (NIRS), and if this may be reversed by CPAP treatment.
Subjects and methods: 23 OSA patients (mean age, 55 y) naive to CPAP were included in a prospective interventional study. The OSA patients received CPAP therapy for at least two months. Cortical low-frequency oscillation (LFO) amplitudes and vasoreactivity during a breath hold test were measured with NIRS and were compared between baseline and after CPAP treatment. Baseline values also were compared to 13 healthy controls (mean age, 52 y).
Results: We found a decrease in LFO amplitudes after CPAP therapy (P = 0.022) in OSA patients. We found no differences in LFO amplitudes between OSA patients and healthy controls (P = 0.934). There were no differences in peak vascular response following breath hold tests in OSA patients before and after CPAP therapy (P = 0.158) or compared to healthy controls (P = 0.740).
Conclusion: Our NIRS study revealed a decrease in LFO amplitude following two months of CPAP treatment in OSA patients, which may reflect a decrease in sympathetic activity affecting cortical vessels. (c) 2013 Elsevier B.V. All rights reserved.
C1 [Schytz, Henrik Winther; Jensen, Benedicte Ersted; Ashina, Messoud] Glostrup Univ Hosp, Danish Headache Ctr, Glostrup, Denmark.
[Schytz, Henrik Winther; Jensen, Benedicte Ersted; Ashina, Messoud] Glostrup Univ Hosp, Dept Neurol, Glostrup, Denmark.
[Schytz, Henrik Winther; Jensen, Benedicte Ersted; Jennum, Poul] Glostrup Univ Hosp, Danish Ctr Sleep Med, Glostrup, Denmark.
[Selb, Juliette; Boas, David A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Opt Div,Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
RP Ashina, M (reprint author), Glostrup Cty Hosp, Danish Headache Ctr, Nordre Ringvej 57, DK-2600 Glostrup, Copenhagen, Denmark.
EM ashina@dadlnet.dk
OI Schytz, Henrik Winther/0000-0002-6262-2986
FU Lundbeck Foundation via the Lundbeck Foundation Center for Neurovascular
Signaling (LUCENS); Gangsted Foundation; Frimodt-Heineke Foundation;
Toyota Foundation; Augustinus Foundation
FX The authors wish to thank lab technicians, Winnie Gronning Nielsen and
Lene Elkjaer, for their excellent and dedicated assistance. The study
was supported by the Lundbeck Foundation via the Lundbeck Foundation
Center for Neurovascular Signaling (LUCENS), the Gangsted Foundation,
the Frimodt-Heineke Foundation, the Toyota Foundation and the Augustinus
Foundation.
NR 38
TC 5
Z9 5
U1 0
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1389-9457
J9 SLEEP MED
JI Sleep Med.
PD MAY
PY 2013
VL 14
IS 5
BP 416
EP 421
DI 10.1016/j.sleep.2012.12.009
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 139VC
UT WOS:000318612100006
PM 23517585
ER
PT J
AU Pena, JR
Saidman, S
Major, E
Hague, TJ
Berces, A
AF Pena, Jeremy R.
Saidman, Susan
Major, Endre
Hague, Tim J.
Berces, Attila
TI HLA TYPING IN THE CLINICAL LABORATORY USING NEXT GENERATION SEQUENCING
SO TISSUE ANTIGENS
LA English
DT Meeting Abstract
CT 27th Annual EFI European Immunogenetics and Histocompatibility
Conference
CY MAY 11-14, 2013
CL Maastricht, NETHERLANDS
SP EFI
C1 [Pena, Jeremy R.; Saidman, Susan] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Major, Endre; Hague, Tim J.; Berces, Attila] Omixon, Budapest, Hungary.
EM attila.berces@omixon.com
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-2815
J9 TISSUE ANTIGENS
JI Tissue Antigens
PD MAY
PY 2013
VL 81
IS 5
BP 350
EP 350
PG 1
WC Cell Biology; Immunology; Pathology
SC Cell Biology; Immunology; Pathology
GA 138QN
UT WOS:000318523600210
ER
PT J
AU Gao, C
Kong, NR
Li, AL
Tatetu, H
Ueno, S
Yang, YY
He, J
Yang, JC
Ma, YP
Kao, GS
Tenen, DG
Chai, L
AF Gao, Chong
Kong, Nikki R.
Li, Ailing
Tatetu, Hiro
Ueno, Shikiko
Yang, Youyang
He, Jie
Yang, Jianchang
Ma, Yupo
Kao, Grace S.
Tenen, Daniel G.
Chai, Li
TI SALL4 is a key transcription regulator in normal human hematopoiesis
SO TRANSFUSION
LA English
DT Article
ID EARLY EMBRYONIC-DEVELOPMENT; ENHANCED SELF-RENEWAL; CD34+ MARROW-CELLS;
STEM-CELLS; OKIHIRO-SYNDROME; DROSOPHILA EMBRYO; LEUKEMIC-CELLS;
HOMEOTIC GENE; MUTATIONS; BMI-1
AB BACKGROUND: Stem cell factor SALL4 is a zinc finger transcription factor. It plays vital roles in the maintenance of embryonic stem cell properties, functions as an oncogene in leukemia, and has been recently proposed to use for cord blood expansion. The mechanism(s) by which SALL4 functions in normal human hematopoiesis, including identification of its target genes, still need to be explored. STUDY DESIGN AND METHODS: Chromatin immunoprecipitation followed by microarray hybridization (ChIP-chip) was used for mapping SALL4 global gene targets in normal primary CD34+ cells. The results were then correlated with SALL4 functional studies in the CD34+ cells. RESULTS: More than 1000 potential SALL4 downstream target genes have been identified, and validation of binding by ChIP-quantitative polymerase chain reaction was performed for 5% of potential targets. These include genes that are involving in hematopoietic differentiation and self-renewal, such as HOXA9, RUNX1, CD34, and PTEN. Down regulation of SALL4 expression using small-hairpin RNA in these cells led to decreased in vitro myeloid colonyforming abilities and impaired in vivo engraftment. Furthermore, HOXA9 was identified to be a major SALL4 target in normal human hematopoiesis and the loss of either SALL4 or HOXA9 expression in CD34+ cells shared a similar phenotype. CONCLUSION: Taken together, SALL4 is a key regulator in normal human hematopoiesis and the mechanism of its function is at least in part through the HOXA9. Future study will determine whether modulating the SALL4/HOXA9 pathway can be used in cellular therapy such as cord blood expansion and/or myeloid engraftment.
C1 [Chai, Li] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol,Joint Program Transfus Med, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Joint Program Transfus Med,Dept Med Oncol, Boston, MA 02115 USA.
Nevada Canc Inst, Div Lab Med, Las Vegas, NV USA.
Natl Univ Singapore, Ctr Translat Med, Canc Sci Inst Singapore, Singapore 117548, Singapore.
Harvard Stem Cell Inst, Ctr Life Sci, Boston, MA USA.
RP Chai, L (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol,Joint Program Transfus Med, 77 Ave Louis Pasteur,NRB652, Boston, MA 02115 USA.
EM lchai@partners.org
OI Tenen, Daniel/0000-0002-6423-3888
FU [RO1HL092437]; [PO1HL095489]; [DK080665]
FX This work was supported in part through RO1HL092437 and PO1HL095489 (to
LC) and DK080665 (to DGT).
NR 32
TC 13
Z9 13
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
J9 TRANSFUSION
JI Transfusion
PD MAY
PY 2013
VL 53
IS 5
BP 1037
EP 1049
DI 10.1111/j.1537-2995.2012.03888.x
PG 13
WC Hematology
SC Hematology
GA 140MC
UT WOS:000318657200016
PM 22934838
ER
PT J
AU Channick, RN
Delcroix, M
Galie, N
Ghofrani, HA
Hunsche, E
Jansa, P
Le Brun, FO
Mehta, S
Mittelholzer, C
Perchenet, L
Pulido, T
Sastry, B
Sitbon, O
Souza, R
Torbicki, A
Rubin, LJ
Simonneau, G
AF Channick, R. N.
Delcroix, M.
Galie, N.
Ghofrani, H. A.
Hunsche, E.
Jansa, P.
Le Brun, F. O.
Mehta, S.
Mittelholzer, C.
Perchenet, L.
Pulido, T.
Sastry, B.
Sitbon, O.
Souza, R.
Torbicki, A.
Rubin, L. J.
Simonneau, G.
TI REDUCTION OF PULMONARY ARTERIAL HYPERTENSION (PAH)-RELATED
HOSPITALIZATIONS WITH MACITENTAN IN THE RANDOMIZED CONTROLLED TRIAL
SERAPHIN
SO VALUE IN HEALTH
LA English
DT Meeting Abstract
C1 [Channick, R. N.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Delcroix, M.] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium.
[Galie, N.] Univ Bologna, Bologna, Italy.
[Ghofrani, H. A.] Univ Hosp Giessen, Giessen, Germany.
[Hunsche, E.; Le Brun, F. O.; Mittelholzer, C.; Perchenet, L.] Actel Pharmaceut Ltd, Allschwil, Switzerland.
[Jansa, P.] Charles Univ Prague, Prague, Czech Republic.
[Mehta, S.] Western Univ, Victoria Hosp, London Hlth Sci Ctr, London, ON, Canada.
[Pulido, T.] Natl Heart Inst, Mexico City, DF, Mexico.
[Sastry, B.] CARE Hosp, Hyderabad, Andhra Pradesh, India.
[Sitbon, O.; Simonneau, G.] Univ Paris 11, Hop Univ Bicetre, Le Kremlin Bicetre, France.
[Souza, R.] Univ Sao Paulo, Sch Med, Heart Inst, Sao Paulo, Brazil.
[Torbicki, A.] ECZ Otwock, Ctr Postgrad Med Educ, Otwock, Poland.
[Rubin, L. J.] Univ Calif San Diego, La Jolla, CA 92093 USA.
RI Souza, Rogerio/I-3584-2013
NR 0
TC 1
Z9 1
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
J9 VALUE HEALTH
JI Value Health
PD MAY
PY 2013
VL 16
IS 3
BP A231
EP A231
PG 1
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA 144CE
UT WOS:000318916402151
ER
PT J
AU Fonda, JR
McGlinchey, RE
Milberg, WP
Rudolph, JL
Hunt, PR
Reynolds, MW
Yonan, C
AF Fonda, J. R.
McGlinchey, R. E.
Milberg, W. P.
Rudolph, J. L.
Hunt, P. R.
Reynolds, M. W.
Yonan, C.
TI STUDY OF PSEUDOBULBAR AFFECT SYMPTOMS IN VETERANS WITH MILD TRAUMATIC
BRAIN INJURY
SO VALUE IN HEALTH
LA English
DT Meeting Abstract
C1 [Fonda, J. R.; McGlinchey, R. E.; Milberg, W. P.; Rudolph, J. L.] VA Boston Healthcare Syst, Boston, MA USA.
[Hunt, P. R.; Reynolds, M. W.] United BioSource Corp Inc, Lexington, MA USA.
[Yonan, C.] Avanir Pharmaceut Inc, Grass Valley, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
J9 VALUE HEALTH
JI Value Health
PD MAY
PY 2013
VL 16
IS 3
BP A103
EP A103
PG 1
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA 144CE
UT WOS:000318916401032
ER
PT J
AU Frei, CR
Juday, TR
Jones, X
Labreche, MJ
Koeller, JM
Hebden, T
Seekins, DW
Oramasionwu, CU
Bollinger, M
Copeland, LA
Teshome, B
Mortensen, EM
AF Frei, C. R.
Juday, T. R.
Jones, X.
Labreche, M. J.
Koeller, J. M.
Hebden, T.
Seekins, D. W.
Oramasionwu, C. U.
Bollinger, M.
Copeland, L. A.
Teshome, B.
Mortensen, E. M.
TI COMPARATIVE VALUE OF FOUR MEASURES OF RETENTION IN EXPERT CARE IN
PREDICTING CLINICAL OUTCOMES AND HEALTH CARE UTILIZATION IN HIV PATIENTS
SO VALUE IN HEALTH
LA English
DT Meeting Abstract
C1 [Frei, C. R.; Koeller, J. M.; Teshome, B.] Univ Texas Austin, San Antonio, TX USA.
[Frei, C. R.; Koeller, J. M.; Teshome, B.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Juday, T. R.; Hebden, T.; Seekins, D. W.] Bristol Myers Squibb Co, Plainsboro, NJ USA.
[Jones, X.; Bollinger, M.] South Texas Vet Hlth Care Syst, Audie L Murphy Div, VERDICT Res Program, San Antonio, TX USA.
[Labreche, M. J.] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA.
[Oramasionwu, C. U.] Univ N Carolina, Chapel Hill, NC USA.
[Copeland, L. A.] Scott & White Healthcare, Ctr Appl Hlth Res, Cent Texas Vet Hlth Care Syst, Temple, TX USA.
[Mortensen, E. M.] VA North Texas Hlth Care Syst, Dallas, TX 75390 USA.
[Mortensen, E. M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
J9 VALUE HEALTH
JI Value Health
PD MAY
PY 2013
VL 16
IS 3
BP A184
EP A185
PG 2
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA 144CE
UT WOS:000318916401455
ER
PT J
AU Sansgiry, S
Naik, AD
Brown, AC
Latini, DM
AF Sansgiry, S.
Naik, A. D.
Brown, A. C.
Latini, D. M.
TI QUALITY OF LIFE AMONG DIABETES PATIENTS
SO VALUE IN HEALTH
LA English
DT Meeting Abstract
C1 [Sansgiry, S.; Naik, A. D.] Baylor Coll Med, Michael E DeBakey VA Med Ctr, VA HSR&D Ctr Excellence, Houston, TX 77030 USA.
[Brown, A. C.] Michael E DeBakey VA Med Ctr, VA HSR&D Ctr Excellence, Houston, TX USA.
[Latini, D. M.] San Francisco VA Med Ctr, Baylor Coll Med, Scott Dept Urol, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
J9 VALUE HEALTH
JI Value Health
PD MAY
PY 2013
VL 16
IS 3
BP A196
EP A196
PG 1
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA 144CE
UT WOS:000318916401515
ER
PT J
AU Tang, Y
Gellad, WF
Men, A
Donohue, JM
AF Tang, Y.
Gellad, W. F.
Men, A.
Donohue, J. M.
TI REGIONAL VARIATION IN USE OF GENERIC DRUGS AND MEDICARE PRESCRIPTION
DRUG COST SHARING
SO VALUE IN HEALTH
LA English
DT Meeting Abstract
C1 [Tang, Y.; Gellad, W. F.; Men, A.; Donohue, J. M.] Univ Pittsburgh, Pittsburgh, PA USA.
[Gellad, W. F.] RAND, VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
J9 VALUE HEALTH
JI Value Health
PD MAY
PY 2013
VL 16
IS 3
BP A248
EP A248
PG 1
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA 144CE
UT WOS:000318916402243
ER
PT J
AU Potenza, MN
Brody, AL
AF Potenza, Marc N.
Brody, Arthur L.
TI Commentary on Boileau etal. (2013): Distinguishing D2/D3 dopaminergic
contributions to addictions
SO ADDICTION
LA English
DT Editorial Material
DE [11C]-(+)-PHNO; [11C]-raclopride; addiction; D2; D3 dopamine; gambling;
striatum
ID POSITRON-EMISSION-TOMOGRAPHY; RECEPTOR; PET; IMPULSIVITY; RELEASE; PRE
C1 [Potenza, Marc N.] Yale Univ, Sch Med, Dept Psychiat, Connecticut Mental Hlth Ctr, New Haven, CT 06519 USA.
[Potenza, Marc N.] Yale Univ, Sch Med, Dept Child Study, Connecticut Mental Hlth Ctr, New Haven, CT 06519 USA.
[Potenza, Marc N.] Yale Univ, Sch Med, Dept Neurobiol, Connecticut Mental Hlth Ctr, New Haven, CT 06519 USA.
[Brody, Arthur L.] Univ Calif Los Angeles, Sch Med, Dept Psychiat, Los Angeles, CA 90095 USA.
[Brody, Arthur L.] VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA 90095 USA.
RP Potenza, MN (reprint author), Yale Univ, Sch Med, Dept Psychiat, Connecticut Mental Hlth Ctr, New Haven, CT 06519 USA.
EM abrody@ucla.edu
FU CSRD VA [I01 CX000412]; NIDA NIH HHS [P20 DA027844, R01 DA020872, R01
DA20872]
NR 19
TC 4
Z9 4
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0965-2140
J9 ADDICTION
JI Addiction
PD MAY
PY 2013
VL 108
IS 5
BP 964
EP 965
DI 10.1111/add.12119
PG 2
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA 127IK
UT WOS:000317691600023
PM 23587083
ER
PT J
AU Yan, TJ
Escarce, JJ
Liang, LJ
Longstreth, WT
Merkin, SS
Ovbiagele, B
Vassar, SD
Seeman, T
Sarkisian, C
Brown, AF
AF Yan, Tingjian
Escarce, Jose J.
Liang, Li-Jung
Longstreth, W. T., Jr.
Merkin, Sharon Stein
Ovbiagele, Bruce
Vassar, Stefanie D.
Seeman, Teresa
Sarkisian, Catherine
Brown, Arleen F.
TI Exploring psychosocial pathways between neighbourhood characteristics
and stroke in older adults: the cardiovascular health study
SO AGE AND AGEING
LA English
DT Article
DE neighbourhood; psychosocial factors; stroke; older adults
ID SOCIAL-ISOLATION; ISCHEMIC-STROKE; SOCIOECONOMIC-STATUS; DEPRESSIVE
SYMPTOMS; DISEASE; RISK; POPULATION; OUTCOMES; SUPPORT
AB Objectives: to investigate whether psychosocial pathways mediate the association between neighbourhood socioeconomic disadvantage and stroke.
Methods: prospective cohort study with a follow-up of 11.5 years.
Setting: the Cardiovascular Health Study, a longitudinal population-based cohort study of older adults >= 65 years.
Measurements: the primary outcome was adjudicated incident ischaemic stroke. Neighbourhood socioeconomic status (NSES) was measured using a composite of six census-tract variables. Psychosocial factors were assessed with standard measures for depression, social support and social networks.
Results: of the 3,834 white participants with no prior stroke, 548 had an incident ischaemic stroke over the 11.5-year follow-up. Among whites, the incident stroke hazard ratio (HR) associated with living in the lowest relative to highest NSES quartile was 1.32 (95% CI = 1.01-1.73), in models adjusted for individual SES. Additional adjustment for psychosocial factors had a minimal effect on hazard of incident stroke (HR = 1.31, CI = 1.00-1.71). Associations between NSES and stroke incidence were not found among African-Americans (n = 785) in either partially or fully adjusted models.
Conclusions: psychosocial factors played a minimal role in mediating the effect of NSES on stroke incidence among white older adults.
C1 [Yan, Tingjian] Cedars Sinai Med Ctr, Dept Resource & Outcomes Management, Los Angeles, CA 90048 USA.
[Escarce, Jose J.; Liang, Li-Jung; Brown, Arleen F.] Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA.
[Longstreth, W. T., Jr.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
[Longstreth, W. T., Jr.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Merkin, Sharon Stein; Seeman, Teresa; Sarkisian, Catherine] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, Los Angeles, CA 90095 USA.
[Ovbiagele, Bruce] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA.
[Vassar, Stefanie D.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA.
[Sarkisian, Catherine] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA.
RP Brown, AF (reprint author), Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA.
EM abrown@mednet.ucla.edu
FU American Heart Association Pharmaceutical Roundtable -Spina Outcomes
Research Center [0875135N, 0875133N, N01-HC-85239, N01-HC-85079,
N01-HC-85086, N01-HC-35129, N01HC-15103, N01 HC-55222, N01-HC-75150,
N01-HC-45133]; National Heart, Lung, and Blood Institute [U01 HL080295];
NIH/National Center for Advancing Clinical and Translational Science
(NCATS)/UCLA Clinical and Translational Science Institute [UL1TR000124]
FX This work was supported by the American Heart Association Pharmaceutical
Roundtable -Spina Outcomes Research Center #0875135N and #0875133N as
well as by contract numbers N01-HC-85239, N01-HC-85079 through
N01-HC-85086, N01-HC-35129, N01HC-15103, N01 HC-55222, N01-HC-75150,
N01-HC-45133, grant number U01 HL080295 from the National Heart, Lung,
and Blood Institute, with additional contribution from the National
Institute of Neurological Disorders and Stroke. A full list of principal
CHS investigators and institutions can be found at
http://www.chs-nhlbi.org/pi.htm. A.F.B. was also supported by the
NIH/National Center for Advancing Clinical and Translational Science
(NCATS)/UCLA Clinical and Translational Science Institute, grant #
UL1TR000124.
NR 25
TC 3
Z9 3
U1 0
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0002-0729
EI 1468-2834
J9 AGE AGEING
JI Age Ageing
PD MAY
PY 2013
VL 42
IS 3
BP 391
EP 397
DI 10.1093/ageing/afs179
PG 7
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 139AE
UT WOS:000318552800021
PM 23264005
ER
PT J
AU Tamez, H
Andress, D
Solomon, SD
Thadhani, R
AF Tamez, Hector
Andress, Dennis
Solomon, Scott D.
Thadhani, Ravi
TI Reply to "The role of fibroblast growth factor-23 in left atrial volume"
SO AMERICAN HEART JOURNAL
LA English
DT Letter
ID CHRONIC KIDNEY-DISEASE; LEFT-VENTRICULAR HYPERTROPHY; FGF23; MORTALITY;
THERAPY; TRIAL
C1 [Tamez, Hector; Thadhani, Ravi] Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02114 USA.
[Andress, Dennis] Abbott Labs, Abbott Pk, IL 60064 USA.
[Solomon, Scott D.] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA.
RP Tamez, H (reprint author), Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02114 USA.
EM thadhani.r@mgh.harvard.edu
RI Solomon, Scott/I-5789-2013
FU NIDDK NIH HHS [K24 DK094872]
NR 8
TC 1
Z9 1
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
J9 AM HEART J
JI Am. Heart J.
PD MAY
PY 2013
VL 165
IS 5
BP E23
EP E23
DI 10.1016/j.ahj.2013.02.023
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 141KL
UT WOS:000318724000002
PM 23622924
ER
PT J
AU Sonnenberg, A
Boardman, CR
AF Sonnenberg, Amnon
Boardman, Charles R.
TI When Cure Becomes Worse Than the Disease
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Letter
ID IRRITABLE-BOWEL-SYNDROME; SURGERY
C1 [Sonnenberg, Amnon; Boardman, Charles R.] Portland VA Med Ctr, Portland, OR 97239 USA.
[Sonnenberg, Amnon; Boardman, Charles R.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-GI ,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM sonnenbe@ohsu.edu
NR 4
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD MAY
PY 2013
VL 108
IS 5
BP 854
EP 855
DI 10.1038/ajg.2013.18
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 141FE
UT WOS:000318710200029
PM 23644967
ER
PT J
AU Kabbani, D
Weir, SK
Berg, G
Chien, GC
Strymish, J
Gupta, K
AF Kabbani, Dima
Weir, Susan K.
Berg, Gretchen
Chien, Gina C.
Strymish, Judith
Gupta, Kalpana
TI Cohorting based on nasal methicillin-resistant Staphylococcus aureus
status: An opportunity to share more than a room
SO AMERICAN JOURNAL OF INFECTION CONTROL
LA English
DT Article
DE Staphylococcus aureus; Colonization; Extra-nasal; Roommates
ID ACTIVE SURVEILLANCE CULTURES; APIC TASK-FORCE; LEGISLATIVE MANDATES;
POSITION STATEMENT; JOINT SHEA; INFECTIONS; CARRIAGE; COLONIZATION;
ENTEROCOCCI; STRAINS
AB Background: Hospital roommates are cohorted with similarly colonized patients to decrease methicillin-resistant Staphylococcus aureus (MRSA) transmission risk. However, little is known about differences in S aureus nasal and extranasal carriage between hospital roommates who are in MRSA or non-MRSA designated rooms.
Methods: Patients sharing hospital rooms were cultured for S aureus in the nose, throat, and other body sites. Differences in S aureus methicillin and mupirocin susceptibility and USA300 type were evaluated.
Results: Eighty-two patients comprising 48 roommate pairs were studied. Among 6 roommate pairs in MRSA rooms, 3 (50%) had differences in carriage based on having methicillin-susceptible S aureus at an extranasal body site. In non-MRSA rooms, 19 (45%) roommate pairs had differences in S aureus carriage. Extranasal colonization was significantly associated with discordance between roommates, P < .001. Antibiotic exposure, ward type, and the duration of room sharing were not associated with discordance.
Conclusion: Patients have almost a 50% chance of having differences in S aureus colonization compared with their hospital roommate, even in MRSA-designated rooms. Cohorting by MRSA status at the time of admission may not be as effective a control strategy as horizontal measures that do not rely on known colonization with S aureus or other pathogens. Copyright (c) 2013 by the Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.
C1 [Kabbani, Dima; Weir, Susan K.; Berg, Gretchen; Gupta, Kalpana] VA Boston HCS, Dept Med, Boston, MA USA.
[Kabbani, Dima; Weir, Susan K.; Strymish, Judith; Gupta, Kalpana] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA.
[Chien, Gina C.] Boston Univ, Sch Publ Hlth, Boston, MA USA.
[Strymish, Judith] Harvard Univ, Sch Med, Boston, MA USA.
[Gupta, Kalpana] Natl Ctr Occupat Hlth & Infect Control COHIC, Off Publ Hlth, Dept Vet Affairs, Gainesville, FL USA.
RP Gupta, K (reprint author), VA Boston HCS, 1400 VFW Pkwy, W Roxbury, MA 02132 USA.
EM Kalpana.gupta@va.gov
NR 16
TC 3
Z9 3
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-6553
J9 AM J INFECT CONTROL
JI Am. J. Infect. Control
PD MAY
PY 2013
VL 41
IS 5
BP 401
EP 404
DI 10.1016/j.ajic.2012.10.015
PG 4
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 139UU
UT WOS:000318611200005
PM 23499508
ER
PT J
AU Evans, ME
Kralovic, SM
Simbartl, LA
Obrosky, DS
Hammond, MC
Goldstein, B
Evans, CT
Roselle, GA
Jain, R
AF Evans, Martin E.
Kralovic, Stephen M.
Simbartl, Loretta A.
Obrosky, D. Scott
Hammond, Margaret C.
Goldstein, Barry
Evans, Charlesnika T.
Roselle, Gary A.
Jain, Rajiv
TI Prevention of methicillin-resistant Staphylococcus aureus infections in
spinal cord injury units
SO AMERICAN JOURNAL OF INFECTION CONTROL
LA English
DT Article
DE MRSA
ID ACUTE REHABILITATION UNIT; COLONIZATION; VETERANS; EPIDEMIOLOGY;
ORGANISMS
AB Background: Methicillin-resistant Staphylococcus aureus (MRSA) health care-associated infections (HAIs) are a concern in the 22 acute care Veterans Affairs (VA) spinal cord injury units where patients with unique rehabilitation and medical needs and a high risk of infection are treated.
Methods: A bundle was implemented in VA spinal cord injury units consisting of nasal surveillance for MRSA on admission/in-hospital transfer/discharge, contact precautions for patients colonized or infected with MRSA, an emphasis on hand hygiene, and an institutional culture change where infection control became everyone's responsibility.
Results: From October 2007, through June 2011, there were 51,627 admissions/transfers/discharges and 816,254 patient-days of care in VA spinal cord injury units. The percentage of patients screened increased to >95.0%. The mean admission MRSA prevalence was 38.6% +/- 19.1%. Monthly HAI rates declined 81% from 1.217 per 1,000 patient-days to 0.237 per 1,000 patient-days (P < .001). Bloodstream infections declined by 100% (P = .002), skin and soft-tissue infections by 60% (P = .007), and urinary tract infections by 33% (P = .07).
Conclusion: Universal surveillance, contact precautions, hand hygiene, and an institutional culture change was associated with significant declines in MRSA HAIs in a setting with a high prevalence of MRSA colonization and a high risk for infection.
C1 [Evans, Martin E.] Vet Hlth Adm, Dept Vet Affairs, MRSA MDRO Program Off, Washington, DC USA.
[Evans, Martin E.; Kralovic, Stephen M.; Simbartl, Loretta A.; Roselle, Gary A.] Vet Hlth Adm, Dept Vet Affairs, Natl Infect Dis Serv, Washington, DC USA.
[Evans, Martin E.; Kralovic, Stephen M.; Simbartl, Loretta A.; Roselle, Gary A.; Jain, Rajiv] Vet Hlth Adm, Dept Vet Affairs, VA Cent Off, Washington, DC USA.
[Evans, Martin E.] Lexington VA Med Ctr, Lexington, KY USA.
[Evans, Martin E.] Univ Kentucky, Coll Med, Lexington, KY USA.
[Kralovic, Stephen M.; Simbartl, Loretta A.; Roselle, Gary A.] Cincinnati VA Med Ctr, Cincinnati, OH USA.
[Kralovic, Stephen M.; Roselle, Gary A.] Univ Cincinnati, Coll Med, Cincinnati, OH USA.
[Obrosky, D. Scott] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Hammond, Margaret C.; Goldstein, Barry] Vet Hlth Adm, Dept Vet Affairs, VA Cent Off, Spinal Cord Injury Disorders Serv, Washington, DC USA.
[Hammond, Margaret C.; Goldstein, Barry] Vet Hlth Adm, Dept Vet Affairs, VA Cent Off, Spinal Cord Injury Disorders Serv, Seattle, WA USA.
[Evans, Charlesnika T.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, VA Spinal Cord Injury Qual Enhancement Res Initia, Hines, IL 60141 USA.
[Evans, Charlesnika T.] Northwestern Univ, Inst Healthcare Studies, Feinberg Sch Med, Chicago, IL 60611 USA.
RP Evans, ME (reprint author), VHA MDRO Program, 11I-CDD,1101 Vet Dr, Lexington, KY 40502 USA.
EM Martin.Evans@va.gov
FU Department of Veterans Affairs, Office of Research and Development,
Health Services Research and Development Service, Quality Enhancement
Research Initiative [RRP 09-163]
FX The authors thank Meredith Ambrose, MHA, and Kathleen J. Risa, MSN,
CRNP, CIC, for coordinating rollout of the Initiative and collecting
data along with providing MRSA education to all involved with the
Veterans Health Administration MRSA Prevention Initiative; Marta L.
Render, MD, and Ron W. Freyberg, MS, for managing the inpatient
evaluation center; and the clinical staff of the Veterans Affairs spinal
cord injury units, MRSA prevention coordinators, infection
preventionists, infectious diseases specialists, and clinical laboratory
personnel at each facility for their hard work and dedication toward
improving the health care of America's veterans. This study was
supported in part by the Department of Veterans Affairs, Office of
Research and Development, Health Services Research and Development
Service, Quality Enhancement Research Initiative (RRP 09-163).
NR 14
TC 9
Z9 9
U1 0
U2 6
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-6553
J9 AM J INFECT CONTROL
JI Am. J. Infect. Control
PD MAY
PY 2013
VL 41
IS 5
BP 422
EP 426
DI 10.1016/j.ajic.2012.06.006
PG 5
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 139UU
UT WOS:000318611200009
PM 23149087
ER
PT J
AU Pennock, S
Kim, D
Mukai, S
Kuhnle, M
Chun, DW
Matsubara, J
Cui, J
Ma, P
Maberley, D
Samad, A
Van Geest, RJ
Oberstein, SL
Schlingemann, RO
Kazlauskas, A
AF Pennock, Steven
Kim, David
Mukai, Shizuo
Kuhnle, Matthew
Chun, Dal W.
Matsubara, Joanne
Cui, Jing
Ma, Patrick
Maberley, David
Samad, Arif
Van Geest, Robert J.
Oberstein, Sarit L.
Schlingemann, Reinier O.
Kazlauskas, Andrius
TI Ranibizumab Is a Potential Prophylaxis for Proliferative
Vitreoretinopathy, a Nonangiogenic Blinding Disease
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL-DETACHMENT; MACULAR DEGENERATION;
DIABETIC-RETINOPATHY; INTRAVITREAL BEVACIZUMAB; EPIRETINAL MEMBRANES;
SIGNAL-TRANSDUCTION; EXPERIMENTAL-MODEL; FACTOR RECEPTOR; VITREOUS-HUMOR
AB Proliferative vitreoretinopathy (PVR) exemplifies a disease that is difficult to predict, Lacks effective treatment options, and substantially reduces the quality of life of an individual. Surgery to correct a rhegmatogenous retinal detachment fails primarily because of PVR. Likely mediators of PVR are growth factors in vitreous, which stimulate cells within and behind the retina as an inevitable consequence of a breached retina. Three classes of growth factors [vascular endothelial growth factor A (VEGF-A), platelet-derived growth factors (PDGFs), and non-PDGFs (growth factors outside of the PDGF family)] are relevant to PVR pathogenesis because they act on PDGF receptor alpha, which is required for experimental PVR and is associated with this disease in humans. We discovered that ranibizumab (a clinically approved agent that neutralizes VEGF-A) reduced the bioactivity of vitreous from patients and experimental animals with PVR, and protected rabbits from developing disease. The apparent mechanism of ranibizumab action involved derepressing PDGFs, which, at the concentrations present in PVR vitreous, inhibited non-PDGF-mediated activation of PDGF receptor alpha. These predinical findings suggest that available approaches to neutralize VEGF-A are prophylactic for PVR, and that anti-VEGF-based therapies may be effective for managing more than angiogenesis- and edema-driven pathological conditions.
C1 [Pennock, Steven; Kim, David; Mukai, Shizuo; Kazlauskas, Andrius] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Schepens Eye Res Inst, Boston, MA 02114 USA.
[Pennock, Steven; Kim, David; Mukai, Shizuo; Kazlauskas, Andrius] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA.
[Kuhnle, Matthew; Chun, Dal W.] Walter Reed Army Med Ctr, Dept Surg, Ophthalmol Serv, Washington, DC 20307 USA.
[Matsubara, Joanne; Cui, Jing; Ma, Patrick; Maberley, David] Univ British Columbia, Dept Ophthalmol & Visual Sci, Vancouver, BC V5Z 1M9, Canada.
[Samad, Arif] Dalhousie Univ, Dept Ophthalmol & Visual Sci, Halifax, NS, Canada.
[Van Geest, Robert J.; Oberstein, Sarit L.; Schlingemann, Reinier O.] Univ Amsterdam, Acad Med Ctr, Med Retina Unit, NL-1105 AZ Amsterdam, Netherlands.
[Van Geest, Robert J.; Oberstein, Sarit L.; Schlingemann, Reinier O.] Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, Ocular Angiogenesis Grp, NL-1105 AZ Amsterdam, Netherlands.
RP Kazlauskas, A (reprint author), Harvard Univ, Sch Med, Dept Ophthalmol, Schepens Eye Res Inst,Massachusetts Eye & Ear Inf, 20 Staniford St, Boston, MA 02114 USA.
EM andrius_kazlauskas@meei.harvard.edu
FU Department of Defense [WB1XWH-10-1-0392]; NIH [EY012509]; Canadian
Institutes of Health Research (CIHR); Mukai Fund; CIHR [IAO 77736, MOP
97806]; Massachusetts Eye and Ear Infirmary (Boston)
FX Supported by Department of Defense grant WB1XWH-10-1-0392 and NIH grant
EY012509 (A.K.), a Canadian Institutes of Health Research (CIHR)
fellowship (S.P.), Mukai Fund and Massachusetts Eye and Ear Infirmary
(Boston) gifts (S.M.), and CIHR grants IAO 77736 and MOP 97806 (J.M. and
J.C.).
NR 62
TC 15
Z9 15
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
J9 AM J PATHOL
JI Am. J. Pathol.
PD MAY
PY 2013
VL 182
IS 5
BP 1659
EP 1670
DI 10.1016/j.ajpath.2013.01.052
PG 12
WC Pathology
SC Pathology
GA 138TY
UT WOS:000318534100021
PM 23582767
ER
PT J
AU Meyer, NJ
Feng, R
Li, MY
Zhao, Y
Sheu, CC
Tejera, P
Gallop, R
Bellamy, S
Rushefski, M
Lanken, PN
Aplenc, R
O'Keefe, GE
Wurfel, MM
Christiani, DC
Christie, JD
AF Meyer, Nuala J.
Feng, Rui
Li, Mingyao
Zhao, Yang
Sheu, Chau-Chyun
Tejera, Paula
Gallop, Robert
Bellamy, Scarlett
Rushefski, Melanie
Lanken, Paul N.
Aplenc, Richard
O'Keefe, Grant E.
Wurfel, Mark M.
Christiani, David C.
Christie, Jason D.
TI IL1RN Coding Variant Is Associated with Lower Risk of Acute Respiratory
Distress Syndrome and Increased Plasma IL-1 Receptor Antagonist
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
DE functional genetic polymorphism; acute lung injury; acute respiratory
distress syndrome; IL-1 receptor antagonist; replication
ID ACUTE LUNG INJURY; GENOME-WIDE ASSOCIATION; CHAIN-KINASE GENE; CONSENSUS
CONFERENCE; ALLELE FREQUENCIES; ORGAN FAILURE; SEVERE SEPSIS; GENOTYPE
DATA; INTERLEUKIN-1; POLYMORPHISM
AB Rationale: Acute respiratory distress syndrome (ARDS) behaves as a complex genetic trait, yet knowledge of genetic susceptibility factors remains incomplete.
Objectives: To identify genetic risk variants for ARDS using large scale genotyping.
Methods: A multistage genetic association study was conducted of three critically ill populations phenotyped for ARDS. Stage I, a trauma cohort study (n=224), was genotyped with a 50K gene-centric single-nucleotide polymorphism (SNP) array. We tested SNPs associated with ARDS at P<5 x 10(-4) for replication in stage II, a trauma case-control population (n=778). SNPs replicating their association in stage II (P<0.005) were tested in a stage III nested case-control population of mixed subjects in the intensive care unit (n=2,063). Logistic regression was used to adjust for potential clinical confounders. We performed ELISA to test for an association between ARDS-associated genotype and plasma protein levels.
Measurements and Main Results: A total of 12 SNPs met the stage I threshold for an association with ARDS. rs315952 in the IL1RN gene encoding IL-1 receptor antagonist (IL1RA) replicated its association with reduced ARDS risk in stages II (P<0.004) and III (P<0.02), and was robust to clinical adjustment (combined odds ratio=0.81; P=4.2 X 10(-5)). Plasma IL1RA level was associated with rs315952C in a subset of critically ill subjects. The effect of rs315952 was independent from the tandem repeat variant in IL1RN.
Conclusions: The IL1RN SNP rs315952C is associated with decreased, risk of ARDS in three populations with heterogeneous ARDS risk factors, and with increased plasma IL1RA response. IL1RA may attenuate ARDS risk.
C1 [Meyer, Nuala J.; Lanken, Paul N.; Christie, Jason D.] Univ Penn, Dept Med, Pulm Allergy & Crit Care Div, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Feng, Rui; Li, Mingyao; Gallop, Robert; Bellamy, Scarlett; Aplenc, Richard; Christie, Jason D.] Univ Penn, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Zhao, Yang; Sheu, Chau-Chyun; Tejera, Paula; Christiani, David C.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
[Sheu, Chau-Chyun] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Div Pulm & Crit Care Med, Kaohsiung, Taiwan.
[Rushefski, Melanie; Aplenc, Richard] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Div Oncol, Philadelphia, PA 19104 USA.
[O'Keefe, Grant E.] Univ Washington, Harborview Med Ctr, Dept Surg, Seattle, WA 98104 USA.
[Wurfel, Mark M.] Univ Washington, Harborview Med Ctr, Dept Pulm & Crit Care Med, Seattle, WA 98104 USA.
[Christiani, David C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pulm & Crit Care Unit,Dept Med, Boston, MA USA.
RP Meyer, NJ (reprint author), Univ Penn, Dept Med, Pulm Allergy & Crit Care Div, Perelman Sch Med, 3600 Spruce St,8026 Maloney, Philadelphia, PA 19104 USA.
EM nuala.meyer@uphs.upenn.edu
FU National Institutes of Health (NIH); Hospital of the University of
Pennsylvania [HL060290, HL079063]; Harborview [GM066946]; Massachusetts
General Hospital [HL060710]; NIH [RC2HL101770, HL081619, HL090021,
HL102254]
FX Supported by National Institutes of Health (NIH) grants to fund the
study populations, Hospital of the University of Pennsylvania (HL060290,
HL079063), Harborview (GM066946), and Massachusetts General Hospital
(HL060710). Additional NIH grants RC2HL101770, HL081619, HL090021, and
HL102254 supported the genetic and molecular investigations described
herein.
NR 78
TC 24
Z9 26
U1 1
U2 4
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD MAY 1
PY 2013
VL 187
IS 9
BP 950
EP 959
DI 10.1164/rccm.201208-1501OC
PG 10
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 136SC
UT WOS:000318382700014
PM 23449693
ER
PT J
AU Nowak-Machen, M
Schmelzle, M
Hanidziar, D
Junger, W
Exley, M
Otterbein, L
Wu, Y
Csizmadia, E
Doherty, G
Sitkovsky, M
Robson, SC
AF Nowak-Machen, Martina
Schmelzle, Moritz
Hanidziar, Dusan
Junger, Wolfgang
Exley, Mark
Otterbein, Leo
Wu, Yan
Csizmadia, Eva
Doherty, Glen
Sitkovsky, Michail
Robson, Simon C.
TI Pulmonary Natural Killer T Cells Play an Essential Role in Mediating
Hyperoxic Acute Lung Injury
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE lung injury; immunology; ATP; P2X7; oxygen
ID ISCHEMIA-REPERFUSION INJURY; OXYGEN-TOXICITY; TISSUE-DAMAGE; RECEPTOR;
CD39; PROTECTION; MICE; LETHAL; GENERATION; EXPRESSION
AB Critically ill patients are routinely exposed to high concentrations of supplemental oxygen for prolonged periods of time, which can be life-saving in the short term, but such exposure also causes severe lung injury and increases mortality. To address this therapeutic dilemma, we studied the mechanisms of the tissue-damaging effects of oxygen in mice. We show that pulmonary invariant natural killer T (iNKT) cells are unexpectedly crucial in the development of acute oxygen-induced lung injury. iNKT cells express high concentrations of the ectonucleotidase CD39, which regulates their state of activation. Both iNKT cell-deficient (J alpha 18(-/-)) and CD39-null mice tolerate hyperoxia, compared with wild-type control mice that exhibit severe lung injury. An adoptive transfer of wild-type iNKT cells into J alpha 18(-/-) mice results in hyperoxic lung injury, whereas the transfer of CD39-null iNKT cells does not. Pulmonary iNKT cell activation and proliferation are modulated by ATP-dependent purinergic signaling responses. Hyperoxic lung injury can be induced by selective P2X7-receptor blockade in CD39-null mice. Our data indicate that iNKT cells are involved in the pathogenesis of hyperoxic lung injury, and that tissue protection can be mediated through ATP-induced P2X7 receptor signaling, resulting in iNKT cell death. In conclusion, our data suggest that iNKT cells and purinergic signaling should be evaluated as potential novel therapeutic targets to prevent hyperoxic lung injury.
C1 [Nowak-Machen, Martina] Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA.
[Nowak-Machen, Martina] Harvard Univ, Sch Med, Boston, MA USA.
[Nowak-Machen, Martina; Schmelzle, Moritz; Hanidziar, Dusan; Wu, Yan; Csizmadia, Eva; Robson, Simon C.] Beth Israel Deaconess Med Ctr, Dept Med, Gastroenterol & Transplant Inst, Boston, MA 02215 USA.
[Junger, Wolfgang] Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA.
[Exley, Mark] Harvard Univ, Sch Med, Dept Med, Dana Farber Harvard Canc Ctr, Boston, MA USA.
[Doherty, Glen] Univ Coll Dublin, St Vincents Univ Hosp, Dept Med, Dublin 2, Ireland.
[Sitkovsky, Michail] Northeastern Univ, New England Inflammat & Tissue Protect Inst, Boston, MA 02115 USA.
RP Robson, SC (reprint author), Beth Israel Deaconess Med Ctr, Dept Med, Gastroenterol & Transplant Inst, 330 Brookline Ave,E CLS,Room 0612, Boston, MA 02215 USA.
EM srobson@bidmc.harvard.edu
FU National Institutes of Health [T32 GM007592-32]
FX M.N.-M. was supported by National Institutes of Health grant T32
GM007592-32.
NR 43
TC 11
Z9 13
U1 1
U2 3
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1044-1549
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD MAY
PY 2013
VL 48
IS 5
BP 601
EP 609
DI 10.1165/rcmb.2012-0180OC
PG 9
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA 137YU
UT WOS:000318475300008
PM 23349052
ER
PT J
AU Hoffmire, CA
Piegari, RI
Bossarte, RM
AF Hoffmire, Claire A.
Piegari, Rebecca I.
Bossarte, Robert M.
TI Misclassification of veteran status on Washington state death
certificates for suicides from 1999 to 2008
SO ANNALS OF EPIDEMIOLOGY
LA English
DT Article
DE Death certificates; Population surveillance; Public health surveillance;
Suicide; Veterans
ID REPORTING SYSTEM; MORTALITY; RISK
C1 [Hoffmire, Claire A.; Piegari, Rebecca I.; Bossarte, Robert M.] US Dept Vet Affairs, Canandaigua VA Med Ctr, VISN Ctr Excellence Suicide Prevent 2, Canandaigua, NY 14424 USA.
RP Hoffmire, CA (reprint author), US Dept Vet Affairs, Canandaigua VA Med Ctr, VISN Ctr Excellence Suicide Prevent 2, 400 Ft Hill Ave, Canandaigua, NY 14424 USA.
EM Claire.Hoffmire@va.gov
NR 9
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1047-2797
J9 ANN EPIDEMIOL
JI Ann. Epidemiol.
PD MAY
PY 2013
VL 23
IS 5
BP 298
EP 300
DI 10.1016/j.annepidem.2013.03.007
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 140OL
UT WOS:000318664700012
PM 23621996
ER
PT J
AU Gray, PJ
Efstathiou, JA
Shipley, WU
AF Gray, Phillip J.
Efstathiou, Jason A.
Shipley, William U.
TI The opportunity cost of androgen suppression in locally advanced
prostate cancer
SO ASIAN JOURNAL OF ANDROLOGY
LA English
DT Editorial Material
ID PHASE-III TRIAL; QUALITY-OF-LIFE; DEPRIVATION THERAPY; CARDIOVASCULAR
MORTALITY; RADIATION-THERAPY; RANDOMIZED-TRIAL; RADIOTHERAPY; DURATION
AB The use of androgen suppression therapy (AST) and radiotherapy for locally advanced prostate cancer has become the standard of care worldwide. At the same time, it has become clear that AST carries significant risk for side effects. Recently, Denham and colleagues have reported initial quality of life (QoL) results from the TROG 03.04 RADAR trial. The authors identify clinically meaningful decrements in patient-reported QoL for those treated with 18 months of AST vs. 6 months but only marginal differences at 36 months. Once survival data becomes available, these data will help to frame any benefits seen for longer courses of AST.
C1 [Gray, Phillip J.] Harvard Radiat Oncol Program, Boston, MA 02114 USA.
[Gray, Phillip J.; Efstathiou, Jason A.; Shipley, William U.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
RP Gray, PJ (reprint author), Harvard Radiat Oncol Program, Boston, MA 02114 USA.
EM pjgray@partners.org
NR 14
TC 0
Z9 0
U1 0
U2 0
PU ACTA PHARMACOLOGICA SINICA
PI SHANGHAI
PA 294 TAI-YUAN RD, SHANGHAI, 200031, PEOPLES R CHINA
SN 1008-682X
J9 ASIAN J ANDROL
JI Asian J. Androl.
PD MAY
PY 2013
VL 15
IS 3
SI SI
BP 356
EP 357
DI 10.1038/aja.2012.166
PG 2
WC Andrology; Urology & Nephrology
SC Endocrinology & Metabolism; Urology & Nephrology
GA 140YD
UT WOS:000318691500012
PM 23435474
ER
PT J
AU Luo, NL
Chung, BH
Wang, XD
Klein, RL
Tang, CK
Garvey, WT
Fu, YC
AF Luo, Nanlan
Chung, B. Hong
Wang, Xiangdong
Klein, Richard L.
Tang, Chao-Ke
Garvey, W. Timothy
Fu, Yuchang
TI Enhanced adiponectin actions by overexpression of adiponectin receptor 1
in macrophages
SO ATHEROSCLEROSIS
LA English
DT Article
DE Adiponectin receptor; Macrophage foam cells; Metabolic syndrome
ID MONOCYTE-DERIVED MACROPHAGES; PIMA INDIAN POPULATION;
INSULIN-RESISTANCE; LIPID-ACCUMULATION; ADIPOSE-TISSUE; CIRCULATING
ADIPONECTIN; CARDIOVASCULAR-DISEASE; METABOLIC SYNDROME;
SKELETAL-MUSCLE; PROTEIN ACRP30
AB Objective: Adiponectin is one of several important, metabolically active cytokines secreted from adipose tissue. Epidemiologic studies have associated low circulating levels of this adipokine with multiple metabolic disorders including obesity, insulin resistance, type II diabetes, and cardiovascular disease. To investigate how enhanced adiponectin-mediated changes in metabolism in vivo, we generated transgenic mice which specifically overexpress the gene coding for adiponectin receptor 1 (AdipoR1) in mouse macrophages using the human scavenger receptor A-I gene (SR-AI) enhancer/promoter. We found that macrophage-specific AdipoR1 transgenic mice (AdR1-TG) presented reduced whole body weight, fat accumulation and liver steatosis when these transgenic mice were fed with a high fat diet. Moreover, these macrophage AdR1-TG mice exhibited enhanced whole-body glucose tolerance and insulin sensitivity with reduced proinflammatory cytokines, MCP-1 and TNF-alpha, both in the serum and in the insulin target metabolic tissues. Additional studies demonstrated that these macrophage AdR1-TG animals exhibited reduced macrophage foam cell formation in the arterial wall when these transgenic mice were crossed with a low-density lipoprotein receptor (Ldlr) deficient mouse model.
Conclusions: These results suggest that AdipoR1 overexpressed in macrophages can physiologically modulate metabolic activities in vivo by enhancing adiponectin actions in distal metabolically active tissues. The AdipoR1 modified macrophages provide unique interactions with the residented tissues/cells, suggesting a novel role of macrophage adiponectin receptor in improving metabolic disorders in vivo. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Luo, Nanlan; Chung, B. Hong; Garvey, W. Timothy; Fu, Yuchang] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA.
[Wang, Xiangdong] Shandong Univ, Inst Cell Biol, Jinan 250012, Peoples R China.
[Klein, Richard L.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Tang, Chao-Ke] Univ S China, Inst Cardiovasc Res, Hengyang 421001, Peoples R China.
[Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL 35233 USA.
RP Fu, YC (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, Shelby Bldg 1213,1825 Univ Blvd, Birmingham, AL 35294 USA.
EM yfu@uab.edu
FU American Diabetes Association [1-07-RA-49]; UAB Diabetes Research and
Training Center; NIH [DK-083562]
FX We thank Dr. Chris Glass (University of California at San Diego) for
kindly providing the plasmid vector containing the human scavenger
receptor A-I gene (SR-AI) enhancer/promoter. We are grateful to the UAB
Diabetes Research and Training Center for providing outstanding core
services (NIH P30 DK-56336); especially the helpful technical assistance
on en face artery dissections from Ms. Melissa Sammy and Dr. Scott
Ballinger in the core facility. This work was supported by grants from
American Diabetes Association (1-07-RA-49) and the UAB Diabetes Research
and Training Center to YF, and grant from NIH (DK-083562) to TG.
NR 51
TC 15
Z9 15
U1 2
U2 11
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0021-9150
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2013
VL 228
IS 1
BP 124
EP 135
DI 10.1016/j.atherosclerosis.2013.02.026
PG 12
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 139FJ
UT WOS:000318567000019
PM 23510830
ER
PT J
AU Sher, L
AF Sher, Leo
TI High and low testosterone levels may be associated with suicidal
behavior in young and older men, respectively
SO AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
LA English
DT Letter
C1 [Sher, Leo] James J Peters Vet Adm Med Ctr, New York, NY USA.
[Sher, Leo] Mt Sinai Sch Med, New York, NY USA.
RP Sher, L (reprint author), James J Peters Vet Adm Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA.
EM Leo.Sher@mssm.edu
NR 5
TC 7
Z9 7
U1 0
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0004-8674
J9 AUST NZ J PSYCHIAT
JI Aust. N. Z. J. Psych.
PD MAY
PY 2013
VL 47
IS 5
BP 492
EP 493
DI 10.1177/0004867412463976
PG 2
WC Psychiatry
SC Psychiatry
GA 139GW
UT WOS:000318571000021
PM 23047955
ER
PT J
AU Won, JS
Kim, J
Paintlia, MK
Singh, I
Singh, AK
AF Won, Je-Seong
Kim, Jinsu
Paintlia, Manjeet Kaur
Singh, Inderjit
Singh, Avtar K.
TI Role of endogenous psychosine accumulation in oligodendrocyte
differentiation and survival: Implication for Krabbe disease
SO BRAIN RESEARCH
LA English
DT Article
DE Krabbe disease; Psychosine; Oligodendrocyte; Differentiation;
Peroxisome; Myelin
ID TANDEM MASS-SPECTROMETRY; TWITCHER MOUSE; GALACTOSYLSPHINGOSINE
PSYCHOSINE; PROGENITOR CELLS; GLIAL-CELLS; FATTY-ACIDS; PEROXISOMES;
BRAIN; BIOSYNTHESIS; ACTIVATION
AB Krabbe disease is a lethal, demyelinating condition caused by genetic deficiency of galactocerebrosidase (GALC) and resultant accumulation of its cytotoxic substrate, psychosine (galactosylsphingosine), primarily in oligodendrocytes (OLs). Psychosine is generated by galactosylation of sphingosine by UDP-galactose:ceramide galactosyltransferase (CGT), a galactosylceramide synthesizing enzyme which is primarily expressed in OLs. The expression of CGT and the synthesis of galactosyl-sphingolipids are associated with the terminal differentiation of OL, but little is known about the participation of endogenous psychosine accumulation in OL differentiation under GALC deficient conditions. In this study, we report that accumulation of endogenous psychosine under GALC deficient Krabbe conditions impedes OL differentiation process both by decreasing the expression of myelin lipids and protein and by inducing the cell death. of maturating OLs. The psychosine pathology under GALC deficient conditions involves participation of secretory phospholipase A(2) (sPLA(2)) activation and increase in its metabolites, as evidenced by attenuation of psychosine-induced pathology by treatment with pharmacological inhibitor of sPLA(2) 7,7-dimethyleicosadienoic acid (DEDA). These observations suggest for potential therapeutic efficacy of sPLA(2) inhibitor in Krabbe disease. Published by Elsevier B.V.
C1 [Won, Je-Seong; Singh, Avtar K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA.
[Kim, Jinsu; Paintlia, Manjeet Kaur; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA.
[Singh, Avtar K.] Ralph H Johnson Vet Adm Med Ctr, Pathol & Lab Med Serv, Charleston, SC USA.
RP Singh, AK (reprint author), Ralph H Johnson Univ South Carolina, Dept Pathol & Lab Med, Charleston, SC USA.
EM Avtar.Singh@va.gov
FU National Institutes of Health (NIH) [NS064195]; NIH; Veterans
Administration (VA) [NS022576, NS037766, BX001072]
FX This work was supported by a National Institutes of Health (NIH) Grant
(NS064195) and supported, in part, by grants from NIH and Veterans
Administration (VA) Grant (NS022576, NS037766, and BX001072). We also
acknowledge Ms. Joyce Bryan and Ms. Chara Williams for their help in
procurement of animals and supplies.
NR 31
TC 16
Z9 16
U1 0
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
J9 BRAIN RES
JI Brain Res.
PD MAY 1
PY 2013
VL 1508
BP 44
EP 52
DI 10.1016/j.brainres.2013.02.024
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA 141UE
UT WOS:000318751200005
PM 23438514
ER
PT J
AU Modi, S
Saura, C
Henderson, C
Lin, NU
Mahtani, R
Goddard, J
Rodenas, E
Hudis, C
O'Shaughnessy, J
Baselga, J
AF Modi, Shanu
Saura, Cristina
Henderson, Charles
Lin, Nancy U.
Mahtani, Reshma
Goddard, Jill
Rodenas, Eduardo
Hudis, Clifford
O'Shaughnessy, Joyce
Baselga, Jose
TI A multicenter trial evaluating retaspimycin HCL (IPI-504) plus
trastuzumab in patients with advanced or metastatic HER2-positive breast
cancer
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Phase 2; Retaspimycin plus trastuzumab; HER2+MBC
ID PROTEIN 90 INHIBITOR; TANESPIMYCIN 17-AAG; PHASE-II; PHARMACOKINETICS;
COMBINATION; EFFICACY; SAFETY; KINASE; CELLS; ERBB3
AB Heat shock protein 90 (Hsp90) facilitates maturation and stability of HER2. Combining an Hsp90 inhibitor and trastuzumab has demonstrated anti-tumor effects in patients with HER2+ breast cancer. Adults with measurable, locally advanced or metastatic HER2+ breast cancer and prior trastuzumab treatment were enrolled in a phase 2 trial employing weekly 300 mg/m(2) retaspimycin HCl, a potent Hsp90 inhibitor, with 6 mg/kg trastuzumab every 3 weeks. A Simon's two-stage design determined trial expansion by dose-limiting toxicity (DLT) and response rates. Pharmacokinetics and electrocardiograms were evaluated. Twenty-six patients with median age 52.5 years (range 33-72) enrolled with a median of six prior chemotherapeutic regimens (range 2-20). On study, patients received a median of three treatment cycles (range 1-12). No DLTs were observed. Most adverse events (AEs) were grade 1 or 2; common treatment-related AEs included fatigue (46 %), nausea (31 %), and diarrhea (23 %). One patient had treatment-related serious AEs of grade 1 diarrhea and grade 3 hypokalemia. grade 3 transaminase elevation occurred in one patient (4 %) who also had metastatic liver disease. Sixteen patients (62 %) had stable disease, with a median on-study duration of 2.4 months (range 1.1-8.2). No confirmed responses were observed. Retaspimycin HCl at 300 mg/mA(2) weekly in combination with trastuzumab was well tolerated and without significant toxicities. Modest clinical activity was observed, but did not meet criteria for trial expansion. The safety profile for patients on study raises the possibility of retaspimycin HCl underdosing that limited efficacy. Studies employing higher doses are ongoing.
C1 [Modi, Shanu; Hudis, Clifford; Baselga, Jose] Mem Sloan Kettering Canc Ctr, Weill Cornell Med Coll, New York, NY 10065 USA.
[Saura, Cristina] Vall dHebron Univ Hosp, VHIO, Barcelona, Spain.
[Henderson, Charles] Peachtree Hematol Oncol Consultants PC, Atlanta, GA USA.
[Lin, Nancy U.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Mahtani, Reshma] Univ Miami, Sylvester Comprehens Canc Ctr, Deerfield Beach, FL USA.
[Goddard, Jill; Rodenas, Eduardo] Infin Pharmaceut Inc, Cambridge, MA USA.
[O'Shaughnessy, Joyce] US Oncol, Texas Oncol, Baylor Sammons Canc Ctr, Dallas, TX USA.
RP Modi, S (reprint author), Mem Sloan Kettering Canc Ctr, Weill Cornell Med Coll, 300 East 66th St, New York, NY 10065 USA.
EM modis@mskcc.org
OI Modi, Shanu/0000-0001-6427-7373; Saura, Cristina/0000-0001-8296-5065
FU Infinity Pharmaceuticals, Inc., Cambridge, MA, USA
FX Support for this trial was provided by Infinity Pharmaceuticals, Inc.,
Cambridge, MA, USA.
NR 14
TC 25
Z9 25
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD MAY
PY 2013
VL 139
IS 1
BP 107
EP 113
DI 10.1007/s10549-013-2510-5
PG 7
WC Oncology
SC Oncology
GA 138QX
UT WOS:000318524600011
PM 23580070
ER
PT J
AU Rath, MG
Masciari, S
Gelman, R
Miron, A
Miron, P
Foley, K
Richardson, AL
Krop, IE
Verselis, SJ
Dillon, DA
Garber, JE
AF Rath, Michelle G.
Masciari, Serena
Gelman, Rebecca
Miron, Alexander
Miron, Penelope
Foley, Kathleen
Richardson, Andrea L.
Krop, Ian E.
Verselis, Sigitas J.
Dillon, Deborah A.
Garber, Judy E.
TI Prevalence of germline TP53 mutations in HER2+breast cancer patients
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Li-Fraumeni syndrome; Breast cancer; TP53
ID LI-FRAUMENI-SYNDROME; SENSITIVE GEL-ELECTROPHORESIS; ONSET
BREAST-CANCER; P53 MUTATIONS; FAMILIES; TUMORS; CRITERIA
AB Breast cancer is the most frequent tumor in Li-Fraumeni syndrome (LFS), a rare inherited cancer syndrome associated with germline mutations in the TP53 gene. Recent data show that breast cancer in germline TP53 mutation carriers is commonly HER2+ (63-83 %). We assessed the prevalence of germline TP53 mutations in a cohort of women with HER2+ breast cancer diagnosed age a parts per thousand currency sign50 years. We identified blood specimens from 213 women with primary invasive HER2+ breast cancer age a parts per thousand currency sign50 years from a single center. Exon grouping analysis sequencing and multiplex ligation-dependent probe amplification techniques were used to screen for germline TP53 mutations. Among 213 women with HER2+ breast cancer age a parts per thousand currency sign50 years, 3 (ages at diagnosis 23, 32, 44 years) were found to carry a TP53 mutation (1.4 %, 95 % CI 0.3-4.1 %). ER/PR status was not uniform. Two TP53 carriers met Chompret criteria for LFS; none met classic LFS criteria. Although two-thirds of breast cancers in women with TP53 mutations are HER2+, we observed a low prevalence of germline TP53 mutations among unselected young women with HER2+ breast cancer. Given the potential clinical impact, consideration of germline TP53 testing should be given to young women with HER2+ breast cancer, especially if family cancer history is notable.
C1 [Rath, Michelle G.; Masciari, Serena; Krop, Ian E.; Garber, Judy E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Gelman, Rebecca] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
[Miron, Alexander; Miron, Penelope; Foley, Kathleen] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA.
[Richardson, Andrea L.; Dillon, Deborah A.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Verselis, Sigitas J.] Dana Farber Canc Inst, Mol Diagnost Lab, Boston, MA 02215 USA.
RP Garber, JE (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA.
EM Judy_Garber@dfci.harvard.edu
FU Breast Cancer Research Foundation; Dana-Farber/Harvard Cancer Center
SPORE in Breast Cancer Grant [P50 CA89393]; German Research Foundation
FX Dr. Elgene Lim for helpful comments on the manuscript. The work was
supported by the Breast Cancer Research Foundation and the
Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer Grant (No. P50
CA89393). Michelle Rath received funding from the German Research
Foundation.
NR 28
TC 6
Z9 6
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD MAY
PY 2013
VL 139
IS 1
BP 193
EP 198
DI 10.1007/s10549-012-2375-z
PG 6
WC Oncology
SC Oncology
GA 138QX
UT WOS:000318524600020
PM 23580068
ER
PT J
AU Herrin, MA
Feemster, LC
Crothers, K
Uman, JE
Bryson, CL
Au, DH
AF Herrin, Melissa A.
Feemster, Laura Cecere
Crothers, Kristina
Uman, Jane E.
Bryson, Chris L.
Au, David H.
TI Combination Antihypertensive Therapy Among Patients With COPD
SO CHEST
LA English
DT Article
ID OBSTRUCTIVE PULMONARY-DISEASE; CONGESTIVE-HEART-FAILURE; LIPID-LOWERING
TREATMENT; CALCIUM-CHANNEL BLOCKER; ATTACK TRIAL ALLHAT;
RANDOMIZED-TRIAL; BLOOD-PRESSURE; CARDIOVASCULAR MORBIDITY; PHARMACY
RECORDS; BETA-BLOCKERS
AB Background: COPD and hypertension both increase the risk of congestive heart failure (CHF). Current clinical trials do not inform the selection of combination antihypertensive therapy among patients with COPD. We performed a comparative effectiveness study to investigate whether choice of dual agent antihypertensive therapy is associated with risk of hospitalization for CHF among patients with these two conditions.
Methods: We identified a cohort of 7,104 patients with COPD and hypertension receiving care within Veterans Administration hospitals between January 2001 and December 2006, with follow-up through April 2009. We included only patients prescribed two antitypertensive medications. We used Cox proportional hazard models for statistical analysis.
Results: Compared with beta-blockers plus an angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker, patients prescribed a thiazide diuretic plus a beta-blocker (adjusted hazard ratio [HR], 0.49; 95% CI, 0.32-0.75), a thiazide plus an angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker (adjusted HR, 0.50; 95% CI, 0.35-0.71), and a thiazide plus a calcium channel blocker (adjusted HR, 0.55; 95% CI, 0.35-0.88) had a significantly lower risk of hospitalization for CHF. After stratification by history of CHF, we found that this association was isolated to patients without a history of CHF. Adjustment for patient characteristics and comorbidities had a small effect on risk of hospitalization. Choice of antihypertensive medication combination had no significant association with risk of COPD exacerbation.
Conclusions: Among patients with comorbid hypertension and COPD requiring two antitypertensive agents, combination therapy that includes a thiazide diuretic was associated with a significantly lower risk of hospitalization for CHF among patients without a history of CHF.
C1 [Herrin, Melissa A.; Feemster, Laura Cecere; Uman, Jane E.; Bryson, Chris L.; Au, David H.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA.
[Feemster, Laura Cecere; Crothers, Kristina; Au, David H.] Univ Washington, Sch Med, Div Pulm & Crit Care Med, Seattle, WA USA.
[Bryson, Chris L.] Univ Washington, Sch Med, Dept Med, Div Gen Internal Med, Seattle, WA 98195 USA.
RP Herrin, MA (reprint author), 1100 Olive Way,Ste 1400, Seattle, WA 98101 USA.
EM herrinmelissa@gmail.com
OI Crothers, Kristina/0000-0001-9702-0371
FU Department of Veterans Affairs, Health Services Research and
Development; American Lung Association [CI-51755N]; Veterans Affairs
Health Services Research and Development fellowship [TPM 61-037]; Gilead
FX This material is based on work supported by the Department of Veterans
Affairs, Health Services Research and Development, and American Lung
Association Grant CI-51755N. Dr Feemster is supported by a Veterans
Affairs Health Services Research and Development fellowship (TPM
61-037).; The authors have reported to CHEST the following conflicts of
interest: Drs Bryson and Au are coinvestigators on a grant from Gilead
for work unrelated to this manuscript. Dr Au is a research consultant
for Robert Bosch LLC. Mss Herrin and Uman and Drs Feemster and Crothers
have reported that no potential conflicts of interest exist with any
companies/organizations whose products or services may be discussed in
this article.
NR 33
TC 4
Z9 4
U1 2
U2 3
PU AMER COLL CHEST PHYSICIANS
PI NORTHBROOK
PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA
SN 0012-3692
J9 CHEST
JI Chest
PD MAY
PY 2013
VL 143
IS 5
BP 1312
EP 1320
DI 10.1378/chest.12-1770
PG 9
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 137TS
UT WOS:000318461700022
PM 23287970
ER
PT J
AU Bernstein, AS
Rice, MB
AF Bernstein, Aaron S.
Rice, Mary B.
TI Lungs in a Warming World Climate Change and Respiratory Health
SO CHEST
LA English
DT Article
ID EMERGENCY-DEPARTMENT VISITS; FIRE SMOKE EXPOSURE; AIR-POLLUTION; AMBIENT
OZONE; SOUTHERN CALIFORNIA; HOSPITAL ADMISSIONS; ASTHMA; POLLEN;
ASSOCIATIONS; TEMPERATURE
AB Climate change is a health threat no less consequential than cigarette smoking. Increased concentrations of greenhouse gases, and especially CO2, in the earth's atmosphere have already warmed the planet substantially, causing more severe and prolonged heat waves, temperature variability, air pollution, forest fires, droughts, and floods, all of which put respiratory health at risk. These changes in climate and air quality substantially increase respiratory morbidity and mortality for patients with common chronic lung diseases such as asthma and COPD and other serious lung diseases. Physicians have a vital role in addressing climate change, just as they did with tobacco, by communicating how climate change is a serious, but remediable, hazard to their patients.
C1 [Bernstein, Aaron S.] Harvard Univ, Sch Publ Hlth, Boston Childrens Hosp, Ctr Hlth & Global Environm, Boston, MA 02115 USA.
[Bernstein, Aaron S.] Boston Childrens Hosp, Div Gen Med, Boston, MA 02215 USA.
[Rice, Mary B.] Massachusetts Gen Hosp, Pulm Crit Care Unit, Boston, MA 02114 USA.
RP Bernstein, AS (reprint author), Boston Childrens Hosp, Div Gen Pediat, 300 Longwood Ave,Hunnewell 2, Boston, MA 02215 USA.
EM aaron.bernstein@childrens.harvard.edu
OI Rice, Mary/0000-0003-2538-391X
NR 50
TC 14
Z9 14
U1 2
U2 38
PU AMER COLL CHEST PHYSICIANS
PI NORTHBROOK
PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA
SN 0012-3692
J9 CHEST
JI Chest
PD MAY
PY 2013
VL 143
IS 5
BP 1455
EP 1459
DI 10.1378/chest.12-2384
PG 5
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 137TS
UT WOS:000318461700039
PM 23648909
ER
PT J
AU Goyal, L
Muzumdar, MD
Zhu, AX
AF Goyal, Lipika
Muzumdar, Mandar D.
Zhu, Andrew X.
TI Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma
SO CLINICAL CANCER RESEARCH
LA English
DT Review
ID HEPATOCYTE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; FACTOR
MESSENGER-RNA; C-MET; TRANSGENIC MICE; SCATTER FACTOR; IN-VIVO;
LIVER-REGENERATION; MOLECULAR-CLONING; CELL-LINES
AB Hepatocellular carcinoma (HCC) is a significant cause of cancer-related morbidity and mortality worldwide. Despite improvements in local therapies, including surgical resection, liver transplantation, and transarterial embolization, the prognosis remains poor for the majority of patients who develop recurrence or present with advanced disease. Systemic therapy with the tyrosine kinase inhibitor sorafenib represents a milestone in advanced HCC but provides a limited survival benefit. Ongoing efforts to study hepatocarcinogenesis have identified an important role for c-MET signaling in the promotion of tumor growth, angiogenesis, and metastasis. In this review, we summarize the preclinical data from human tissue, cell lines, and animal models that implicate c-MET in the pathogenesis of HCC. We also evaluate potential biomarkers that may estimate prognosis or predict response to c-MET inhibitors for more rational clinical trial design. Finally, we discuss the latest clinical trials of c-MET inhibitors in advanced HCC. (c) 2013 AACR.
C1 [Goyal, Lipika; Muzumdar, Mandar D.; Zhu, Andrew X.] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
[Goyal, Lipika; Muzumdar, Mandar D.] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Zhu, AX (reprint author), Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St,LH-PB 232, Boston, MA 02114 USA.
EM azhu@partners.org
FU NCI NIH HHS [L30 CA171131]
NR 71
TC 80
Z9 86
U1 3
U2 31
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAY 1
PY 2013
VL 19
IS 9
BP 2310
EP 2318
DI 10.1158/1078-0432.CCR-12-2791
PG 9
WC Oncology
SC Oncology
GA 136KX
UT WOS:000318361900007
PM 23388504
ER
PT J
AU De Rienzo, A
Richards, WG
Yeap, BY
Coleman, MH
Sugarbaker, PE
Chirieac, LR
Wang, YYE
Quackenbush, J
Jensen, RV
Bueno, R
AF De Rienzo, Assunta
Richards, William G.
Yeap, Beow Y.
Coleman, Melissa H.
Sugarbaker, Peter E.
Chirieac, Lucian R.
Wang, Yaoyu E.
Quackenbush, John
Jensen, Roderick V.
Bueno, Raphael
TI Sequential Binary Gene Ratio Tests Define a Novel Molecular Diagnostic
Strategy for Malignant Pleural Mesothelioma
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID EXPRESSION PROFILING DATA; LUNG-CANCER; MICROARRAY; SURVIVAL; BIOLOGY
AB Purpose: To develop a standardized approach for molecular diagnostics, we used the gene expression ratio bioinformatic technique to design a molecular signature to diagnose malignant pleural mesothelioma (MPM) from among other potentially confounding diagnoses and differentiate the epithelioid from the sarcomatoid histologic subtype of MPM. In addition, we searched for pathways relevant in MPM in comparison with other related cancers to identify unique molecular features in MPM.
Experimental Design: We conducted microarray analysis on 113 specimens including MPMs and a spectrum of tumors and benign tissues comprising the differential diagnosis of MPM. We generated a sequential combination of binary gene expression ratio tests able to discriminate MPM from other thoracic malignancies. We compared this method with other bioinformatic tools and validated this signature in an independent set of 170 samples. Functional enrichment analysis was conducted to identify differentially expressed probes.
Results: A sequential combination of gene expression ratio tests was the best molecular approach to distinguish MPM from all the other samples. Bioinformatic and molecular validations showed that the sequential gene ratio tests were able to identify the MPM samples with high sensitivity and specificity. In addition, the gene ratio technique was able to differentiate the epithelioid from the sarcomatoid type of MPM. Novel genes and pathways specifically activated in MPM were identified.
Conclusions: New clinically relevant molecular tests have been generated using a small number of genes to accurately distinguish MPMs from other thoracic samples, supporting our hypothesis that the gene expression ratio approach could be a useful tool in the differential diagnosis of cancers. Clin Cancer Res; 19(9); 2493-502. (C) 2013 AACR.
C1 [De Rienzo, Assunta; Richards, William G.; Coleman, Melissa H.; Sugarbaker, Peter E.; Bueno, Raphael] Brigham & Womens Hosp, Thorac Surg Oncol Lab, Boston, MA 02115 USA.
[De Rienzo, Assunta; Richards, William G.; Coleman, Melissa H.; Sugarbaker, Peter E.; Bueno, Raphael] Brigham & Womens Hosp, Int Mesothelioma Program, Div Thorac Surg, Boston, MA 02115 USA.
[De Rienzo, Assunta; Richards, William G.; Yeap, Beow Y.; Coleman, Melissa H.; Sugarbaker, Peter E.; Chirieac, Lucian R.; Bueno, Raphael] Harvard Univ, Sch Med, Boston, MA USA.
[Yeap, Beow Y.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Chirieac, Lucian R.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Wang, Yaoyu E.] Dana Farber Canc Inst, Ctr Canc Computat Biol, Boston, MA 02115 USA.
[Quackenbush, John] Dana Farber Canc Inst, Ctr Canc Computat Biol, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Quackenbush, John] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Jensen, Roderick V.] Virginia Tech, Dept Biol Sci, Blacksburg, VA USA.
RP Bueno, R (reprint author), Brigham & Womens Hosp, Thorac Surg Oncol Lab, 75 Francis St, Boston, MA 02115 USA.
EM rbueno@partners.org
FU National Cancer Institute [RO1-120528]; International Mesothelioma
Program at BWH; Vancouver Foundation
FX This work was supported by National Cancer Institute (RO1-120528 to R.
Bueno) as well as by grants from the International Mesothelioma Program
at BWH (to R. Bueno) and the Maurice Favell Fund at the Vancouver
Foundation (to R. Bueno).
NR 34
TC 3
Z9 3
U1 0
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAY 1
PY 2013
VL 19
IS 9
BP 2493
EP 2502
DI 10.1158/1078-0432.CCR-12-2117
PG 10
WC Oncology
SC Oncology
GA 136KX
UT WOS:000318361900023
PM 23493352
ER
PT J
AU Roh, JL
Wang, XV
Manola, J
Sidransky, D
Forastiere, AA
Koch, WM
AF Roh, Jong-Lyel
Wang, Xin Victoria
Manola, Judith
Sidransky, David
Forastiere, Arlene A.
Koch, Wayne M.
TI Clinical Correlates of Promoter Hypermethylation of Four Target Genes in
Head and Neck Cancer: A Cooperative Group Correlative Study
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; I LUNG-CANCER; DNA METHYLATION;
HUMAN-PAPILLOMAVIRUS; SALIVARY RINSES; SURVIVAL; P16; MUTATIONS; MARKER;
INACTIVATION
AB Purpose: Promoter hypermethylation is a well-documented mechanism for tumor-specific alteration of suppressor gene activity in human malignancy including head and neck cancer (HNC). The abrogation of specific suppressor gene activity may influence tumor behavior and clinical outcome. In this study we examined methylation of DCC, KIF1A, EDNRB, and p16(INK4a) in a large cohort of HNC patients from Eastern Cooperative Group (ECOG) 4393/Radiation Therapy Oncology Group (RTOG) 9614 to identify clinical correlates of methylation of these genes.
Experimental Design: Methylation was assessed by quantitative methylation-specific PCR in DNA from tumor specimens and was considered as a continuous and a binary variable. Clinical data including demographics, stage, risk factor exposure, treatment, and outcome were collected by ECOG and RTOG. Methylation status was also correlated with mutation of TP53 (previously reported) and human papilloma virus status.
Results: Methylation results were available for 368 cases, 353 of which also have p53 mutation status. At least one methylation event was present in all tumors. In multivariate analysis of the entire cohort, methylation of p16 was associated with decreased survival (HR = 1.008; P = 0.045). However, in tumors with disruptive TP53 mutation (poor prognostic group), the additional presence of methylation of p16 was protective (P = 0.019 considering p16 methylation as a continuous variable).
Conclusion: Methylation of tumor-related genes contributes to the biological behavior of HNC and influences overall survival in conjunction with other known prognostic molecular events. Clin Cancer Res; 19(9); 2528-40. (C) 2013 AACR.
C1 [Roh, Jong-Lyel; Sidransky, David; Koch, Wayne M.] Johns Hopkins Univ, Dept Otolaryngol Head & Neck Surg, Sch Med, Baltimore, MD 21287 USA.
[Forastiere, Arlene A.] Johns Hopkins Univ, Dept Oncol, Sch Med, Baltimore, MD 21287 USA.
[Roh, Jong-Lyel] Univ Ulsan, Coll Med, Dept Otolaryngol, Asan Med Ctr, Seoul, South Korea.
[Wang, Xin Victoria; Manola, Judith] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Wang, Xin Victoria] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
RP Koch, WM (reprint author), Johns Hopkins Univ, Dept Otolaryngol, Sch Med, 601 North Caroline St,JHOC 6221, Baltimore, MD 21287 USA.
EM wkoch@jhmi.edu
FU National Institute of Health; National Institute of Dental and
Craniofacial Research [R01 DE013152-11]
FX This work is supported by grants from National Institute of Health and
the National Institute of Dental and Craniofacial Research (R01
DE013152-11).
NR 39
TC 16
Z9 16
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAY 1
PY 2013
VL 19
IS 9
BP 2528
EP 2540
DI 10.1158/1078-0432.CCR-12-3047
PG 13
WC Oncology
SC Oncology
GA 136KX
UT WOS:000318361900026
PM 23444219
ER
PT J
AU Ohashi, K
Sequist, LV
Arcila, ME
Lovly, CM
Chen, X
Rudin, CM
Moran, T
Camidge, DR
Vnencak-Jones, CL
Berry, L
Pan, YM
Sasaki, H
Engelman, JA
Garon, EB
Dubinett, SM
Franklin, WA
Riely, GJ
Sos, ML
Kris, MG
Dias-Santagata, D
Ladanyi, M
Bunn, PA
Pao, W
AF Ohashi, Kadoaki
Sequist, Lecia V.
Arcila, Maria E.
Lovly, Christine M.
Chen, Xi
Rudin, Charles M.
Moran, Teresa
Camidge, David Ross
Vnencak-Jones, Cindy L.
Berry, Lynne
Pan, Yumei
Sasaki, Hidefumi
Engelman, Jeffrey A.
Garon, Edward B.
Dubinett, Steven M.
Franklin, Wilbur A.
Riely, Gregory J.
Sos, Martin L.
Kris, Mark G.
Dias-Santagata, Dora
Ladanyi, Marc
Bunn, Paul A., Jr.
Pao, William
TI Characteristics of Lung Cancers Harboring NRAS Mutations
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID COPY NUMBER GAINS; WILD-TYPE RAS; N-RAS; K-RAS; CLINICAL-FEATURES;
SOMATIC MUTATIONS; BRAF MUTATIONS; TOBACCO-SMOKE; NEVER SMOKERS; CELL
AB Purpose: We sought to determine the frequency and clinical characteristics of patients with lung cancer harboring NRAS mutations. We used preclinical models to identify targeted therapies likely to be of benefit against NRAS-mutant lung cancer cells.
Experimental Design: We reviewed clinical data from patients whose lung cancers were identified at six institutions or reported in the Catalogue of Somatic Mutations in Cancer (COSMIC) to harbor NRAS mutations. Six NRAS-mutant cell lines were screened for sensitivity against inhibitors of multiple kinases (i.e., EGFR, ALK, MET, IGF-1R, BRAF, PI3K, and MEK).
Results: Among 4,562 patients with lung cancers tested, NRAS mutations were present in 30 (0.7%; 95% confidence interval, 0.45%-0.94%); 28 of these had no other driver mutations. 83% had adenocarcinoma histology with no significant differences in gender. While 95% of patients were former or current smokers, smoking-related G:C>T:A transversions were significantly less frequent in NRAS-mutated lung tumors than KRAS-mutant non-small cell lung cancer [NSCLC; NRAS: 13% (4/30), KRAS: 66% (1772/2733), P < 0.00000001]. Five of 6 NRAS-mutant cell lines were sensitive to the MEK inhibitors, selumetinib and trametinib, but not to other inhibitors tested.
Conclusion: NRAS mutations define a distinct subset of lung cancers (similar to 1%) with potential sensitivity to MEK inhibitors. Although NRAS mutations are more common in current/former smokers, the types of mutations are not those classically associated with smoking. Clin Cancer Res; 19(9); 2584-91. (C) 2013 AACR.
C1 [Ohashi, Kadoaki; Lovly, Christine M.; Pan, Yumei; Pao, William] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA.
[Ohashi, Kadoaki; Lovly, Christine M.; Pan, Yumei; Pao, William] Vanderbilt Univ, Sch Med, Dept Med, Div Hematol Oncol, Nashville, TN 37212 USA.
[Chen, Xi] Vanderbilt Univ, Sch Med, Dept Biostat, Div Canc Biostat, Nashville, TN 37212 USA.
[Berry, Lynne] Vanderbilt Univ, Sch Med, Ctr Quantitat Sci, Nashville, TN 37212 USA.
[Vnencak-Jones, Cindy L.] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA.
[Vnencak-Jones, Cindy L.] Vanderbilt Univ, Med Ctr, Dept Microbiol, Nashville, TN USA.
[Vnencak-Jones, Cindy L.] Vanderbilt Univ, Med Ctr, Dept Immunol, Nashville, TN USA.
[Dias-Santagata, Dora] Dept Pathol, Boston, MA USA.
[Sequist, Lecia V.; Engelman, Jeffrey A.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Sequist, Lecia V.; Engelman, Jeffrey A.] Harvard Univ, Sch Med, Boston, MA USA.
[Arcila, Maria E.; Ladanyi, Marc] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA.
[Riely, Gregory J.; Kris, Mark G.] Mem Sloan Kettering Canc Ctr, Dept Med, Div Solid Tumor Oncol, Thorac Oncol Serv, New York, NY 10021 USA.
[Rudin, Charles M.] Johns Hopkins Univ, Baltimore, MD USA.
[Moran, Teresa] Univ Autonoma Barcelona, Catalan Inst Oncol, E-08193 Barcelona, Spain.
[Moran, Teresa] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain.
[Camidge, David Ross; Franklin, Wilbur A.; Bunn, Paul A., Jr.] Univ Colorado, Ctr Canc, Aurora, CO USA.
[Sasaki, Hidefumi] Nagoya City Univ, Sch Med, Dept Surg 2, Nagoya, Aichi 467, Japan.
[Garon, Edward B.; Dubinett, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Translat Oncol Res Lab, Div Hematol Oncol, Santa Monica, CA USA.
[Sos, Martin L.] Univ Calif San Francisco, Howard Hughes Med Inst, Dept Cellular & Mol Pharmacol, San Francisco, CA USA.
[Sos, Martin L.] Max Planck Gesell, Klaus Joachim Zulch Labs, Max Planck Inst Neurol Res, Cologne, Germany.
[Sos, Martin L.] Fac Med, Cologne, Germany.
[Sos, Martin L.] Univ Cologne, Dept Internal Med 1, D-50931 Cologne, Germany.
[Sos, Martin L.] Univ Cologne, Ctr Integrated Oncol Koln Bonn, D-50931 Cologne, Germany.
RP Pao, W (reprint author), Vanderbilt Ingram Canc Ctr, 2220 Pierce Ave 777 PRB, Nashville, TN 37232 USA.
EM william.pao@vanderbilt.edu
OI Kris, Mark/0000-0002-7317-5341
FU NIH NCI [RC2-CA148394, R01-CA121210, P01-CA129243, U54-CA143798];
Program of Research Excellence in Lung Cancer grant [CA90949]; VICC
Cancer Center Core [P30-CA68485]
FX This work was supported by NIH NCI grants RC2-CA148394, R01-CA121210,
P01-CA129243, and U54-CA143798. W. Pao received additional support from
Vanderbilt's Specialized Program of Research Excellence in Lung Cancer
grant (CA90949) and the VICC Cancer Center Core grant (P30-CA68485).
NR 47
TC 36
Z9 38
U1 1
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAY 1
PY 2013
VL 19
IS 9
BP 2584
EP 2591
DI 10.1158/1078-0432.CCR-12-3173
PG 8
WC Oncology
SC Oncology
GA 136KX
UT WOS:000318361900031
PM 23515407
ER
PT J
AU Rao, MK
Morris, CD
O'Malley, JP
Davis, MM
Mori, M
Anderson, S
AF Rao, Maya K.
Morris, Cynthia D.
O'Malley, Jean P.
Davis, Melinda M.
Mori, Motomi
Anderson, Sharon
TI Documentation and Management of CKD in Rural Primary Care
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID CHRONIC KIDNEY-DISEASE; GLOMERULAR-FILTRATION-RATE; UNITED-STATES;
BLOOD-PRESSURE; RENAL-DISEASE; NEPHROLOGY CARE; ESTIMATED GFR; HEALTH;
MORTALITY; ACCESS
AB Background and objectives Recognition of CKD by primary care practitioners is essential in rural communities where nephrology access is limited. This study determined the prevalence of undocumented CKD in patients cared for in rural primary care practices and evaluated characteristics associated with undocumented CKD as well as CKD management.
Design, setting, participants, & measurements A retrospective cohort study, conducted within the Oregon Rural Practice Based Research Network, consisted of 865 CKD patients with serum creatinine >= 1.5 mg/dl in males and >= 1.3 mg/dl in females and an estimated GFR<60 ml/min per 1.73 m(2). Documentation of a CKD diagnosis and laboratory values were abstracted by chart review.
Results Of CKD patients, 51.9% had no documentation of CKD. Undocumented CKD occurred more frequently in female patients (adjusted odds ratio=2.93, 95% confidence interval=2.04, 4.21). The association of serum creatinine reporting versus automating reporting of estimated GFR on CKD documentation was dependent on patient sex, years of practitioner experience, and practitioner clinical training. Hypertensive patients with documented CKD were more likely to have a BP medication change than patients with undocumented CKD (odds ratio=2.07, 95% confidence interval=1.15, 3.73). Only 2 of 449 patients with undocumented CKD were comanaged with a nephrologist compared with 20% of patients with documented CKD (odds ratio=53.20, 95% confidence interval=14.90, 189.90).
Conclusions Undocumented CKD in a rural primary care setting is frequent, particularly in female patients. Depending on practitioner characteristics, automatic reporting of estimated GFR might improve documentation of CKD in this population.
C1 [Rao, Maya K.; Anderson, Sharon] Oregon Hlth & Sci Univ, Dept Med, Div Nephrol & Hypertens, Portland, OR 97201 USA.
[Morris, Cynthia D.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA.
[O'Malley, Jean P.; Mori, Motomi] Oregon Hlth & Sci Univ, Oregon Clin & Translat Res Inst, Portland, OR 97201 USA.
[Davis, Melinda M.] Oregon Hlth & Sci Univ, Dept Family Med, Portland, OR 97201 USA.
[Davis, Melinda M.] Oregon Hlth & Sci Univ, Oregon Rural Practice Based Res Network, Portland, OR 97201 USA.
[Anderson, Sharon] Portland VA Med Ctr, Dept Med, Portland, OR USA.
RP Rao, MK (reprint author), Columbia Univ, Med Ctr, Div Nephrol, 622 West 168th St,PH 4, New York, NY 10032 USA.
EM mr2971@columbia.edu
FU Medical Research Foundation of Oregon Early Clinical Investigator Grant;
National Kidney Foundation; Oregon Clinical and Translational Research
Institute Grant [1 UL 1 RRO2414001]; National Institutes of Health [T32
DK 067864]
FX This research was supported by a Medical Research Foundation of Oregon
Early Clinical Investigator Grant (to M.K.R), a National Kidney
Foundation Research Fellowship (to M.K.R), Oregon Clinical and
Translational Research Institute Grant 1 UL 1 RRO2414001 (to C.D.M.),
and National Institutes of Health Grant T32 DK 067864 (to S.A.).
NR 36
TC 4
Z9 4
U1 0
U2 1
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD MAY
PY 2013
VL 8
IS 5
BP 739
EP 748
DI 10.2215/CJN.02410312
PG 10
WC Urology & Nephrology
SC Urology & Nephrology
GA 138TB
UT WOS:000318531800008
PM 23371962
ER
PT J
AU Orenes-Pinero, E
Manzano-Fernandez, S
Lopez-Cuenca, A
Marin, F
Valdes, M
Januzzi, JL
AF Orenes-Pinero, Esteban
Manzano-Fernandez, Sergio
Lopez-Cuenca, Angel
Marin, Francisco
Valdes, Mariano
Januzzi, James L.
TI beta-Trace Protein: From GFR Marker to Cardiovascular Risk Predictor
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Review
ID PROSTAGLANDIN-D-SYNTHASE; GLOMERULAR-FILTRATION-RATE; CHRONIC
KIDNEY-DISEASE; FLUID SHEAR-STRESS; VASCULAR ENDOTHELIAL-CELLS;
CYSTATIN-C; SERUM CREATININE; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2);
CORONARY ANGIOPLASTY; URINARY EXCRETIONS
AB beta-trace protein, also known as Lipocalin type prostaglandin D synthase, is a low-molecular mass glycoprotein (between 23,000 and 29,000 Da depending on the degree of glycosylation) that converts prostaglandin H2 into prostaglandin D2. beta-trace protein was initially isolated from cerebrospinal fluid and served as a marker of cerebrospinal fluid leakage; however, its cDNA and gene have been isolated in numerous human body tissues, including central nervous system, retina, melanocytes, heart, and male genital organs. In recent years, beta-trace protein has emerged as a promising novel endogenous marker of GFR, representing a more sensitive marker for mild kidney dysfunction than serum creatinine. In this regard, beta-trace protein has been proposed as an alternative marker to Cystatin C for measuring kidney function. Beyond its role for estimating renal function, beta-trace protein is also emerging as a novel biomarker in cardiovascular risk. It has been associated with several cardiovascular disorders, playing a potential role for prognostic stratification in patients with acutely decompensated heart failure and acute coronary syndromes and being advocated as a novel marker for cardiovascular risk prediction. Clin J Am Soc Nephrol 8: 873-881, 2013. doi: 10.2215/CJN.08870812
C1 [Orenes-Pinero, Esteban; Manzano-Fernandez, Sergio; Lopez-Cuenca, Angel; Marin, Francisco; Valdes, Mariano] Univ Murcia, Dept Cardiol, Hosp Univ Virgen Arrixaca, Murcia, Spain.
[Januzzi, James L.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
RP Januzzi, JL (reprint author), Massachusetts Gen Hosp, Div Cardiol, 55 Fruit St, Boston, MA 02114 USA.
EM JJanuzzi@partners.org
FU Fundacion para la Formacion e Investigacion Sanitarias de la Region de
Murcia, Murcia, Spain; DeSanctis Clinical Scholar Endowment
FX E.O.-P. is supported by a postdoctoral contract from Fundacion para la
Formacion e Investigacion Sanitarias de la Region de Murcia, Murcia,
Spain. J.L.J. is supported by the DeSanctis Clinical Scholar Endowment.
NR 54
TC 17
Z9 19
U1 0
U2 10
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD MAY
PY 2013
VL 8
IS 5
BP 873
EP 881
DI 10.2215/CJN.08870812
PG 9
WC Urology & Nephrology
SC Urology & Nephrology
GA 138TB
UT WOS:000318531800025
PM 23335042
ER
PT J
AU Alexander, BM
Ligon, KL
Wen, PY
AF Alexander, Brian M.
Ligon, Keith L.
Wen, Patrick Y.
TI Enhancing radiation therapy for patients with glioblastoma
SO EXPERT REVIEW OF ANTICANCER THERAPY
LA English
DT Review
DE glioblastoma; radiation therapy; radiosensitizer
ID HUMAN-MALIGNANT GLIOMA; DNA-DAMAGE RESPONSE; HISTONE DEACETYLASE
INHIBITOR; TUMOR-CELL RADIOSENSITIVITY; STRAND BREAK REPAIR; HIGH-GRADE
GLIOMAS; HOMOLOGOUS RECOMBINATION REPAIR; IN-VIVO RADIOSENSITIZATION;
TRANS-SODIUM CROCETINATE; STEM-LIKE CELLS
AB Radiation therapy has been the foundation of therapy following maximal surgical resection in patients with newly diagnosed glioblastoma for decades and the primary therapy for unresected tumors. Using the standard approach with radiation and temozolomide, however, outcomes are poor, and glioblastoma remains an incurable disease with the majority of recurrences and progression within the radiation treatment field. As such, there is much interest in elucidating the mechanisms of resistance to radiation therapy and in developing novel approaches to overcoming this treatment resistance.
C1 [Alexander, Brian M.] Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA 02115 USA.
[Ligon, Keith L.] Dana Farber Brigham & Womens Canc Ctr, Dept Pathol, Boston, MA 02215 USA.
[Wen, Patrick Y.] Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, Boston, MA 02115 USA.
RP Alexander, BM (reprint author), Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, 75 Francis St,ASB1-L2, Boston, MA 02115 USA.
EM bmalexander@lroc.harvard.edu
FU Plexxikon; GlaxoSmithKline; Vertex; Amgen; AstraZeneca; Boehringer
Ingelheim; Esai; Exelixis; Genentech/Roche; Geron; Medimmune; Merck;
Novartis; sanofi-aventis; Vascular Biogenics
FX Research support was provided by Plexxikon, GlaxoSmithKline and Vertex
to KL Ligon. Amgen, AstraZeneca, Boehringer Ingelheim, Esai, Exelixis,
Genentech/Roche, Geron, Medimmune, Merck, Novartis, sanofi-aventis and
Vascular Biogenics provided research support to PY Wen. PY Wen is on the
advisory board for Novartis, Genentech/Roche and is a speaker for Merck,
Genentech/Roche and GlaxoSmithKline. The authors have no other relevant
affiliations or financial involvement with any organization or entity
with a financial interest in or financial conflict with the subject
matter or materials discussed in the manuscript apart from those
disclosed.
NR 148
TC 7
Z9 7
U1 2
U2 16
PU EXPERT REVIEWS
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
ENGLAND
SN 1473-7140
EI 1744-8328
J9 EXPERT REV ANTICANC
JI Expert Rev. Anticancer Ther
PD MAY
PY 2013
VL 13
IS 5
BP 569
EP 581
DI 10.1586/ERA.13.44
PG 13
WC Oncology
SC Oncology
GA 138XM
UT WOS:000318545000013
PM 23617348
ER
PT J
AU Pau, C
Saxena, R
Welt, CK
AF Pau, Cindy
Saxena, Richa
Welt, Corrine Kolka
TI Evaluating reported candidate gene associations with polycystic ovary
syndrome
SO FERTILITY AND STERILITY
LA English
DT Article
DE Candidate genes; genome-wide association
ID IMPAIRED GLUCOSE-TOLERANCE; TYPE-2 DIABETES-MELLITUS;
INSULIN-RESISTANCE; AFFECTED WOMEN; ADMIXTURE MAP; VARIANTS; PREVALENCE;
5-ALPHA-REDUCTASE; POLYMORPHISMS; ADIPONECTIN
AB Objective: To replicate variants in candidate genes associated with polycystic ovary syndrome (PCOS) in a population of European women with PCOS and control subjects.
Design: Case-control association analysis and meta-analysis.
Setting: Major academic hospital.
Patient(s): Women of European ancestry with PCOS (n = 525) and controls (n = 472), aged 18-45 years.
Intervention(s): Variants previously associated with PCOS in candidate gene studies were genotyped (n = 39). Metabolic, reproductive, and anthropomorphic parameters were examined as a function of the candidate variants. All genetic association analyses were adjusted for age, body mass index, and ancestry and were reported after correction for multiple testing.
Main Outcome Measure(s): Association of candidate gene variants with PCOS.
Result(s): Three variants, rs3797179 (SRD5A1), rs12473543 (POMC), and rs1501299 (ADIPOQ), were nominally associated with PCOS. However, they did not remain significant after correction for multiple testing, and none of the variants replicated in a sufficiently powered meta-analysis. Variants in the FBN3 gene (rs17202517 and rs73503752) were associated with smaller waist circumferences, and variant rs727428 in the SHBG gene was associated with lower sex hormone-binding globulin levels.
Conclusion(s): Previously identified variants in candidate genes do not seem to be associated with PCOS risk. (c) 2013 by American Society for Reproductive Medicine.
C1 [Pau, Cindy; Welt, Corrine Kolka] Massachusetts Gen Hosp, Reprod Endocrine Unit, Boston, MA 02114 USA.
[Saxena, Richa] Massachusetts Gen Hosp, Ctr Human Genet Res, Dept Anesthesia, Boston, MA 02114 USA.
RP Pau, C (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, BHX 511,55 Fruit St, Boston, MA 02114 USA.
EM cta@partners.org
OI Welt, Corrine/0000-0002-8219-5504
FU National Institutes of Health [1R01HD065029, ADA 1-10-CT-57, 1 UL1
RR025758, M01-RR-01066]
FX This work was supported by National Institutes of Health grants
1R01HD065029 (to C.K.W.), ADA 1-10-CT-57 (to C.K.W.), 1 UL1 RR025758
(Harvard Clinical and Translational Science Center), and M01-RR-01066
(National Center for Research Resources).
NR 42
TC 10
Z9 10
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD MAY
PY 2013
VL 99
IS 6
BP 1774
EP 1778
DI 10.1016/j.fertnstert.2012.12.033
PG 5
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 139VF
UT WOS:000318612400048
PM 23375202
ER
PT J
AU Hilgendorf, KI
Leshchiner, ES
Nedelcu, S
Maynard, MA
Calo, E
Ianari, A
Walensky, LD
Lees, JA
AF Hilgendorf, Keren I.
Leshchiner, Elizaveta S.
Nedelcu, Simona
Maynard, Mindy A.
Calo, Eliezer
Ianari, Alessandra
Walensky, Loren D.
Lees, Jacqueline A.
TI The retinoblastoma protein induces apoptosis directly at the
mitochondria
SO GENES & DEVELOPMENT
LA English
DT Article
DE MOMP; apoptosis; cancer; pRB; retinoblastoma protein
ID TUMOR-SUPPRESSOR PROTEIN; NF-KAPPA-B; BCL-2 FAMILY; CELL-DEATH; MEMBRANE
PERMEABILIZATION; PROAPOPTOTIC FUNCTION; RB FUNCTIONS; DNA-DAMAGE; BAX;
P53
AB The retinoblastoma protein gene RB-1 is mutated in one-third of human tumors. Its protein product, pRB ( retinoblastoma protein), functions as a transcriptional coregulator in many fundamental cellular processes. Here, we report a nonnuclear role for pRB in apoptosis induction via pRB's direct participation in mitochondrial apoptosis. We uncovered this activity by finding that pRB potentiated TNF alpha-induced apoptosis even when translation was blocked. This proapoptotic function was highly BAX- dependent, suggesting a role in mitochondrial apoptosis, and accordingly, a fraction of endogenous pRB constitutively associated with mitochondria. Remarkably, we found that recombinant pRB was sufficient to trigger the BAX- dependent permeabilization of mitochondria or liposomes in vitro. Moreover, pRB interacted with BAX in vivo and could directly bind and conformationally activate BAX in vitro. Finally, by targeting pRB specifically to mitochondria, we generated a mutant that lacked pRB's classic nuclear roles. This mito-tagged pRB retained the ability to promote apoptosis in response to TNF alpha and also additional apoptotic stimuli. Most importantly, induced expression of mito-tagged pRB in Rb-/-; p53(-/-) tumors was sufficient to block further tumor development. Together, these data establish a nontranscriptional role for pRB in direct activation of BAX and mitochondrial apoptosis in response to diverse stimuli, which is profoundly tumor-suppressive.
C1 [Hilgendorf, Keren I.; Nedelcu, Simona; Maynard, Mindy A.; Calo, Eliezer; Ianari, Alessandra; Lees, Jacqueline A.] MIT, David H Koch Inst Integrat Canc Res MIT, Cambridge, MA 02139 USA.
[Hilgendorf, Keren I.; Nedelcu, Simona; Calo, Eliezer; Lees, Jacqueline A.] MIT, Dept Biol, Cambridge, MA 02139 USA.
[Leshchiner, Elizaveta S.] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.
[Leshchiner, Elizaveta S.; Walensky, Loren D.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA.
[Leshchiner, Elizaveta S.; Walensky, Loren D.] Dana Farber Canc Inst, Program Canc Chem Biol, Boston, MA 02215 USA.
[Leshchiner, Elizaveta S.; Walensky, Loren D.] Childrens Hosp, Div Hematol & Oncol, Boston, MA 02115 USA.
[Leshchiner, Elizaveta S.; Walensky, Loren D.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Ianari, Alessandra] Univ Roma La Sapienza, Dept Mol Med, I-00161 Rome, Italy.
RP Lees, JA (reprint author), MIT, David H Koch Inst Integrat Canc Res MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
EM jalees@mit.edu
FU NCI/NIH; NSF; D.H. Koch Graduate Fellowship
FX We thank E. Knudsen for providing the RAT16 parental and LP-RB-inducible
cell lines, A. Letai for wild-type and
Bax-/-/Bak-/- MEFs, S. Lowe for human Rb shRNA,
and M. Hemann for rodent Rb shRNA. We also thank the members of the Lees
laboratory for input during the study and manuscript preparation. This
work was supported by an NCI/NIH grant to J.A.L., who is a Ludwig
Scholar at MIT. K.I.H. was supported by an NSF predoctoral fellowship
and D.H. Koch Graduate Fellowship.
NR 57
TC 31
Z9 33
U1 2
U2 15
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 0890-9369
J9 GENE DEV
JI Genes Dev.
PD MAY 1
PY 2013
VL 27
IS 9
BP 1003
EP 1015
DI 10.1101/gad.211326.112
PG 13
WC Cell Biology; Developmental Biology; Genetics & Heredity
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA 141BQ
UT WOS:000318700800007
PM 23618872
ER
PT J
AU Friedman, DJ
Upadhyay, GA
Altman, RK
Orencole, M
Barrett, CD
Mela, T
Heist, EK
Singh, JP
AF Friedman, Daniel J.
Upadhyay, Gaurav A.
Altman, Robert K.
Orencole, Mary
Barrett, Conor D.
Mela, Theofanie
Heist, E. Kevin
Singh, Jagmeet P.
TI The anatomic and electrical location of the left ventricular lead
predicts ventricular arrhythmia in cardiac resynchronization therapy
SO HEART RHYTHM
LA English
DT Article
DE Congestive heart failure; Heart failure; Cardiac resynchronization
therapy; Lead; Ventricular tachycardia; Ventricular fibrillation
ID DEFIBRILLATOR IMPLANTATION TRIAL; HEART-FAILURE PATIENTS; BUNDLE-BRANCH
BLOCK; REVERSE; ACTIVATION; RISK; TACHYARRHYTHMIAS; DYSSYNCHRONY;
STIMULATION; MORTALITY
AB BACKGROUND Both anatomic and electrical locations of the left ventricular (LV) lead have been identified as important predictors of clinical outcomes in cardiac resynchronization therapy (CRT). The impact of LV lead location on incident device-treated ventricular arrhythmia (VA), however, is not well understood.
OBJECTIVE To assess the relationship between electrical and anatomic LV lead location and device treated VAs in CRT.
METHODS Sixty-nine patients undergoing CRT implantation for standard indications were evaluated. Anatomic LV lead location was assessed by means of coronary venography and chest radiography and categorized as apical or nonapical. Electrical LV lead location was assessed by LV electrical delay (LVLED) and was calculated as the time between the onset of the native QRS on the surface electrocardiogram and sensed signal on the LV lead during implantation and corrected for native QRS. Incident appropriate device-treated VA was assessed via device interrogation.
RESULTS Apical lead placement was an independent predictor of VAs (hazard ratio 5.29; 95% confidence interval 1.69-16.5; P = .004). Among patients with a nonapical lead, LVLED <50% native QRS was an independent predictor of VAs (hazard ratio 6.90; 95% confidence interval 1.53-31.1; P = .012). Those with a nonapical lead and LVLED >= 50% native QRS were at substantiaily lower risk for first incident and recurrent VAs when compared to all other patients.
CONCLUSIONS The apical lead position is associated with an increased risk of VAs in CRT patients. Among patients with a nonapical lead position, an LVLED of <50% of the native QRS is associated with an increased risk of VAs.
C1 [Friedman, Daniel J.; Upadhyay, Gaurav A.; Altman, Robert K.; Orencole, Mary; Barrett, Conor D.; Mela, Theofanie; Heist, E. Kevin; Singh, Jagmeet P.] Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Boston, MA 02114 USA.
RP Singh, JP (reprint author), Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, 55 Fruit St, Boston, MA 02114 USA.
EM jsingh@partners.org
OI Altman, Robert/0000-0002-1612-3561; Friedman, Daniel
/0000-0001-5791-1954
FU Biotronik; Sorin; St Jude Medical; Boston Scientific; Medtronic; Boston;
Scientific; CardioInsight; Thoratec; Biosense Webster
FX Dr Heist has received honoraria from Biotronik, Boston Scientific,
Sorin, and St Jude Medical; research grants from Biotronik, Sorin, and
St Jude Medical; and consulting fees from Boston Scientific, Sorin, and
St Jude Medical. Dr Me la has received honoraria from Boston Scientific,
Medtronic, and St Jude Medical and consulting fees from St Jude Medical.
Ms Orencole has received honoraria from Boston Scientific. Dr Singh has
received research grants from St Jude Medical, Medtronic, Boston
Scientific, and Biotronik; consulting fees from Boston Scientific,
Biotronik, St Jude Medical, Medtronic, CardioInsight, Thoratec, and
Biosense Webster; and honoraria from Medtronic, Biotronik, Guidant, St
Jude Medical, and Sorin.
NR 35
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1547-5271
J9 HEART RHYTHM
JI Heart Rhythm
PD MAY
PY 2013
VL 10
IS 5
BP 668
EP 675
DI 10.1016/j.hrthm.2012.12.025
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 140QY
UT WOS:000318671200016
PM 23274368
ER
PT J
AU Rogers, DJ
Hartnick, CJ
AF Rogers, Derek J.
Hartnick, Christopher J.
TI Endoscopic CO2 laser laryngofissure in pediatric laryngotracheal
reconstruction
SO INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY
LA English
DT Article
DE Laryngotracheal reconstruction; Laryngofissure; Pediatric airway;
Endoscopic carbon dioxide laser; Anterior commissure; Pediatric voice
ID AIRWAY RECONSTRUCTION; VOICE; OUTCOMES
AB Anterior laryngofissure is often needed to provide excellent visualization of the posterior cricoid lamina during pediatric laryngotracheal reconstruction. Focus has shifted from survival and decannulation outcomes to postoperative voice outcomes as surgical techniques continue to improve. Surgeons must perform the laryngofissure extremely precisely to avoid damage to the true vocal folds and ensure proper reapproximation of the anterior commissure. Endoscopic CO2 laser laryngofissure represents a novel technique to divide the anterior commissure and facilitate its accurate reapproximation. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Rogers, Derek J.; Hartnick, Christopher J.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otol & Laryngol, Boston, MA USA.
RP Hartnick, CJ (reprint author), 243 Charles St, Boston, MA 02114 USA.
EM Christopher_Hartnick@meei.harvard.edu
NR 7
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0165-5876
J9 INT J PEDIATR OTORHI
JI Int. J. Pediatr. Otorhinolaryngol.
PD MAY
PY 2013
VL 77
IS 5
BP 850
EP 853
DI 10.1016/j.ijporl.2013.01.015
PG 4
WC Otorhinolaryngology; Pediatrics
SC Otorhinolaryngology; Pediatrics
GA 136SP
UT WOS:000318384000046
PM 23394794
ER
PT J
AU Frazier, AL
Rosenberg, SM
AF Frazier, A. Lindsay
Rosenberg, Shoshana M.
TI Preadolescent and Adolescent Risk Factors for Benign Breast Disease
SO JOURNAL OF ADOLESCENT HEALTH
LA English
DT Review
ID PROLIFERATIVE EPITHELIAL DISORDERS; CANCER RISK; ALCOHOL-CONSUMPTION;
PREMENOPAUSAL WOMEN; NURSES HEALTH; UNITED-STATES; BODY FATNESS;
YOUNG-WOMEN; EARLY-LIFE; DIET
AB Purpose: It is well established that exposures during childhood and adolescence affect breast cancer risk much later in life. Recently, studies have begun to evaluate whether early life exposures might also impact the risk of developing benign breast disease (BBD). A diagnosis of proliferative BBD independent of other breast cancer risk factors also increases the subsequent risk of breast cancer; therefore, understanding how to decrease the incidence of BBD may have important implications for primary breast cancer prevention.
Methods: We reviewed several studies from prospective cohort studies that have investigated the relationship between risk factors during childhood and adolescence, such as anthropometric and reproductive characteristics as well as diet and other behaviors, and subsequent risk of BBD.
Results: Higher intake of vegetable oils, nuts, vitamin E, and fiber and lower consumption of animal fat, red meat, and alcohol are associated with reduced risk of BBD. Childhood weight and adolescent body mass index are inversely associated with BBD risk, whereas a greater peak height velocity during adolescence is associated with a higher risk of BBD. There was no association between age of menarche and risk of BBD.
Conclusion: Early life exposures and behaviors appear to impact BBD risk. The current body of evidence further supports the importance of a life-course approach to breast cancer prevention. (C) 2013 Society for Adolescent Health and Medicine. All rights reserved.
C1 [Frazier, A. Lindsay] Harvard Univ, Sch Med, Div Pediat Oncol, Dana Farber Canc Inst, Boston, MA 02215 USA.
[Rosenberg, Shoshana M.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA.
RP Frazier, AL (reprint author), Harvard Univ, Sch Med, Div Pediat Oncol, Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM lindsay_frazier@dfci.harvard.edu
FU NIH [R25 CA92203]
FX Shoshana Rosenberg is funded by NIH R25 CA92203.
NR 40
TC 5
Z9 6
U1 2
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1054-139X
J9 J ADOLESCENT HEALTH
JI J. Adolesc. Health
PD MAY
PY 2013
VL 52
IS 5
SU S
BP S36
EP S40
DI 10.1016/j.jadohealth.2013.01.007
PG 5
WC Psychology, Developmental; Public, Environmental & Occupational Health;
Pediatrics
SC Psychology; Public, Environmental & Occupational Health; Pediatrics
GA 140UQ
UT WOS:000318681800006
PM 23601609
ER
PT J
AU Shank, ES
Sheridan, RL
Ryan, CM
Keaney, TJ
Martyn, JAJ
AF Shank, Erik S.
Sheridan, Robert L.
Ryan, Colleen M.
Keaney, Timothy J.
Martyn, J. A. Jeevendra
TI Hemodynamic Responses to Dexmedetomidine in Critically Injured Intubated
Pediatric Burned Patients: A Preliminary Study
SO JOURNAL OF BURN CARE & RESEARCH
LA English
DT Article
ID MECHANICAL VENTILATION; POSTTRAUMATIC-STRESS; INDUCED HYPERALGESIA;
CLINICAL-USES; MAJOR BURNS; CHILDREN; SEDATION; PAIN; HYPERTENSION;
PHARMACOLOGY
AB Because of ineffectiveness and tolerance to benzodiazepines and opioids developing with time, drugs acting via other receptor systems (eg, alpha-2 agonists) have been advocated in burn patients to improve sedation and analgesia. This study in severely burned pediatric subjects examined the hemodynamic consequences of dexmedetomidine (Dex) administration. Eight intubated patients with >= 20 to 79% TBSA burns were studied between 7 and 35 days after injury. After baseline measurements of mean arterial blood pressure and heart rhythm were taken, each patient received a 1.0 mu g/kg bolus of Dex followed by an ascending dose infusion protocol (0.7-2.5 mu g/kg/hr), with each dose administered for 15 minutes. There was significant hypotension (27 +/- 7.5%, average drop in mean arterial pressure [MAP] +/- SD), and a decrease in heart rate (HR; 19% +/- 7, average drop in HR +/- SD). The average HR decreased from 146 beats per minute to 120. No bradycardia (HR < 60) or heart blocks were observed. In three patients, the MAP decreased to < 50 mm Hg with the bolus dose of Dex. Of the remaining five patients, three patients completed the study receiving the highest infusion dose of Dex (2.5 mu g/kg/hr), whereas in 2 patients the infusion part of the study was begun, but the study was stopped due to persistent hypotension (MAP < 50 mm Hg). These observations indicate that a bolus dose of Dex (1.0 mu g/kg for 10 minutes) and high infusion rates may require fluid resuscitation or vasopressor support to maintain normotension in critically injured pediatric burn patients. (J Burn Care Res 2013;34:311-317)
C1 [Shank, Erik S.; Martyn, J. A. Jeevendra] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Shank, Erik S.; Sheridan, Robert L.; Ryan, Colleen M.; Keaney, Timothy J.; Martyn, J. A. Jeevendra] Shriners Hosp Children, Boston, MA USA.
[Shank, Erik S.; Sheridan, Robert L.; Ryan, Colleen M.; Martyn, J. A. Jeevendra] Harvard Univ, Sch Med, Boston, MA USA.
[Sheridan, Robert L.; Ryan, Colleen M.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
RP Shank, ES (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Gray Jackson 409,55 Fruit St, Boston, MA 02114 USA.
FU Shriners Hospitals for Children(R)
FX Supported by the Shriners Hospitals for Children (R).
NR 41
TC 4
Z9 4
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1559-047X
J9 J BURN CARE RES
JI J. Burn Care Res.
PD MAY-JUN
PY 2013
VL 34
IS 3
BP 311
EP 317
DI 10.1097/BCR.0b013e318257d94a
PG 7
WC Emergency Medicine; Dermatology; Surgery
SC Emergency Medicine; Dermatology; Surgery
GA 139XO
UT WOS:000318618600016
PM 22929526
ER
PT J
AU Fuzaylov, G
AF Fuzaylov, Gennadiy
TI Burn Victim: Story of a Survivor
SO JOURNAL OF BURN CARE & RESEARCH
LA English
DT Letter
ID GARLIC BURNS
C1 [Fuzaylov, Gennadiy] Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
RP Fuzaylov, G (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Shriners Hosp Burn Children, Boston, MA 02114 USA.
NR 9
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1559-047X
J9 J BURN CARE RES
JI J. Burn Care Res.
PD MAY-JUN
PY 2013
VL 34
IS 3
BP E213
EP E213
DI 10.1097/BCR.0b013e3182642b5c
PG 1
WC Emergency Medicine; Dermatology; Surgery
SC Emergency Medicine; Dermatology; Surgery
GA 139XO
UT WOS:000318618600012
PM 23128137
ER
PT J
AU Ryan, CM
Schneider, JC
Kazis, LE
Lee, A
Li, NC
Hinson, M
Bauk, H
Peck, M
Meyer, WJ
Palmieri, T
Pidcock, FS
Reilly, D
Tompkins, RG
AF Ryan, Colleen M.
Schneider, Jeffrey C.
Kazis, Lewis E.
Lee, Austin
Li, Nien-chen
Hinson, Michelle
Bauk, Helena
Peck, Michael
Meyer, Walter J., III
Palmieri, Tina
Pidcock, Frank S.
Reilly, Debra
Tompkins, Ronald G.
CA Multi-Ctr Benchmarking Study Grp
TI Benchmarks for Multidimensional Recovery After Burn Injury in Young
Adults: The Development, Validation, and Testing of the American Burn
Association/Shriners Hospitals for Children Young Adult Burn Outcome
Questionnaire
SO JOURNAL OF BURN CARE & RESEARCH
LA English
DT Article
ID QUALITY-OF-LIFE; HEALTH SCALE-BRIEF; FOR-CHILDREN; TERM; SURVIVORS;
CONSTRUCTION; PERCEPTIONS; PREDICTORS; PROGRAM; VERSION
AB Although data exist on burn survival, there are little data on long-term burn recovery. Patient-centered health outcomes are useful in monitoring and predicting recovery and evaluating treatments. An outcome questionnaire for young adult burn survivors was developed and tested. This 5-year (2003-2008) prospective, controlled, multicenter study included burned and nonburned adults ages 19 to 30 years. The Young Adult Burn Outcome Questionnaires were completed at initial contact, 10 days, and 6 and 12 months. Factor analysis established construct validity. Reliability assessments used Cronbach alpha and test-retest. Recovery patterns were investigated using generalized linear models, with generalized estimating equations using mixed models and random effects. Burned (n = 153) and nonburned subjects (n = 112) completed 620 questionnaires (47 items). Time from injury to first questionnaire administration was 157 +/- 36 days (mean +/- SEM). Factor analysis included 15 factors: Physical Function, Fine Motor Function, Pain, Itch, Social Function Limited by Physical Function, Perceived Appearance, Social Function Limited by Appearance, Sexual Function, Emotion, Family Function, Family Concern, Satisfaction With Symptom Relief, Satisfaction With Role, Work Reintegration, and Religion. Cronbach alpha ranged from 0.72 to 0.92, with 11 scales >0.8. Test-retest reliability ranged from 0.29 to 0.94, suggesting changes in underlying health status after burns. Recovery curves in five domains, Itch, Perceived Appearance, Social Function Limited by Appearance, Family Concern, and Satisfaction with Symptom Relief, remained below the reference group at 24 months. The Young Adult Burn Outcome Questionnaire is a reliable and valid instrument for multidimensional functional outcomes assessment. Recovery in some domains was incomplete. (J Burn Care Res 2013;34:e121-e142)
C1 [Ryan, Colleen M.; Lee, Austin; Tompkins, Ronald G.] Massachusetts Gen Hosp, Surg Serv, Boston, MA 02114 USA.
[Ryan, Colleen M.; Schneider, Jeffrey C.; Hinson, Michelle; Bauk, Helena; Meyer, Walter J., III; Palmieri, Tina; Tompkins, Ronald G.] Shriners Hosp Children, Sacramento, CA USA.
[Ryan, Colleen M.; Schneider, Jeffrey C.; Tompkins, Ronald G.] Harvard Univ, Med Sch, Cambridge, MA 02138 USA.
[Schneider, Jeffrey C.] Massachusetts Gen Hosp, Dept Phys Med & Rehabil, Boston, MA 02114 USA.
[Kazis, Lewis E.; Li, Nien-chen] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02215 USA.
[Peck, Michael] Univ Arizona, Coll Med, Dept Surg, Phoenix, AZ USA.
[Meyer, Walter J., III] Univ Texas Med Branch, Dept Psychiat, Galveston, TX 77555 USA.
[Palmieri, Tina] Univ Calif Davis, Dept Surg, Davis, CA 95616 USA.
[Pidcock, Frank S.] Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD 21218 USA.
[Pidcock, Frank S.] Kennedy Krieger Inst, Baltimore, MD USA.
[Reilly, Debra] Univ Nebraska, Div Plast & Reconstruct Surg, Omaha, NE 68182 USA.
RP Ryan, CM (reprint author), Massachusetts Gen Hosp, Bigelow 1302,55 Fruit St, Boston, MA 02114 USA.
OI Kazis, Lewis/0000-0003-1800-5849
FU American Burn Association; Shriners Hospitals for Children; Fraser Fund
at the Massachusetts General Hospital
FX This work was supported in part by the author's institutions, the
American Burn Association, the Shriners Hospitals for Children, and the
Fraser Fund at the Massachusetts General Hospital.
NR 54
TC 15
Z9 16
U1 2
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1559-047X
J9 J BURN CARE RES
JI J. Burn Care Res.
PD MAY-JUN
PY 2013
VL 34
IS 3
BP E121
EP E142
DI 10.1097/BCR.0b013e31827e7ecf
PG 22
WC Emergency Medicine; Dermatology; Surgery
SC Emergency Medicine; Dermatology; Surgery
GA 139XO
UT WOS:000318618600001
PM 23511284
ER
PT J
AU Turcu, AF
Erickson, BJ
Lin, E
Guadalix, S
Schwartz, K
Scheithauer, BW
Atkinson, JLD
Young, WF Jr,
AF Turcu, Adina F.
Erickson, Bradley J.
Lin, Eleanor
Guadalix, Sonsoles
Schwartz, Kara
Scheithauer, Bernd W.
Atkinson, John L. D.
Young, William F., Jr.
TI Pituitary Stalk Lesions: The Mayo Clinic Experience
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID XANTHOMA-DISSEMINATUM; METASTASES; SARCOIDOSIS; INVOLVEMENT; GLAND; MR
AB Context: Pituitary stalk lesions have various etiologies, often not clinically apparent. Pathological samples from these lesions are rarely obtained, because of the critical location and function of the hypophyseal stalk.
Objectives: The purpose of this study was to characterize the etiological spectrum of pituitary stalk lesions seen at Mayo Clinic Rochester over 20 years and to determine whether specific magnetic resonance imaging (MRI) characteristics could provide clinician guidance with regard to the etiology of infundibular lesions.
Design: Aretrospective review of patients with pituitary stalk lesions seen at Mayo Clinic Rochester between 1987 and 2006 was conducted. Demographic, clinical presentation, imaging, laboratory, operative, and pathology data were reviewed and are reported using descriptive statistics.
Results: Of the 152 pituitary stalk lesions included, 49 (32%) were neoplastic, 30 (20%) were inflammatory, 13 (9%) were congenital anomalies, and 60 (39%) were of unclear etiology. Diabetes insipidus was diagnosed in 43 (28%) of the 152 patients, and 49 (32%) patients had at least one anterior pituitary hormone deficit. Secondary hypogonadism was the most common endocrine deficiency. Eleven of 13 congenital lesions were round in appearance and 5 of 7 patients with neurosarcoidosis confirmed by pathology had a uniformly thickened pituitary stalk on MRI. There were no statistically significant correlations between hypopituitarism and the pattern of enhancement or size of the lesion.
Conclusions: Findings on MRI remain key in guiding the diagnosis of pituitary stalk lesions, particularly when used in conjunction with other clinical clues. There are no good imaging predictors for hypopituitarism, making clinical evaluation of all patients with pituitary stalk lesions crucial. (J Clin Endocrinol Metab 98: 1812-1818, 2013)
C1 [Turcu, Adina F.; Young, William F., Jr.] Mayo Clin Rochester, Div Endocrinol, Rochester, MN 55905 USA.
[Erickson, Bradley J.; Schwartz, Kara] Mayo Clin Rochester, Dept Radio, Rochester, MN 55905 USA.
[Scheithauer, Bernd W.] Mayo Clin Rochester, Dept Anat Pathol, Rochester, MN 55905 USA.
[Atkinson, John L. D.] Mayo Clin Rochester, Dept Neurol Surg, Rochester, MN 55905 USA.
[Lin, Eleanor] Massachusetts Gen Hosp, Div Endocrinol, Boston, MA 02114 USA.
[Guadalix, Sonsoles] Univ Hosp 12 Octubre, Madrid 28041, Spain.
RP Young, WF Jr, (reprint author), Mayo Clin Rochester, Div Endocrinol Diabet Metab Nutr & Internal Med, 200 1st St Southwest, Rochester, MN 55905 USA.
EM young.william@mayo.edu
FU Mayo Clinic
FX Funding for this study was provided by the Mayo Clinic.
NR 17
TC 11
Z9 15
U1 0
U2 9
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD MAY
PY 2013
VL 98
IS 5
BP 1812
EP 1818
DI 10.1210/jc.2012-4171
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 140WX
UT WOS:000318688200038
PM 23533231
ER
PT J
AU Faje, AT
Karim, L
Taylor, A
Lee, H
Miller, KK
Mendes, N
Meenaghan, E
Goldstein, MA
Bouxsein, ML
Misra, M
Klibanski, A
AF Faje, Alexander T.
Karim, Lamya
Taylor, Alex
Lee, Hang
Miller, Karen K.
Mendes, Nara
Meenaghan, Erinne
Goldstein, Mark A.
Bouxsein, Mary L.
Misra, Madhusmita
Klibanski, Anne
TI Adolescent Girls With Anorexia Nervosa Have Impaired Cortical and
Trabecular Microarchitecture and Lower Estimated Bone Strength at the
Distal Radius
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID QUANTITATIVE COMPUTED-TOMOGRAPHY; PANEL VOLUME CT; HR-PQCT;
FINITE-ELEMENT; POSTMENOPAUSAL WOMEN; FRACTURES; GROWTH; CHILDREN;
TIBIA; EPIDEMIOLOGY
AB Context: Adolescents with anorexia nervosa (AN) have low areal bone mineral density (aBMD) at both cortical and trabecular sites, and recent data show impaired trabecular microarchitecture independent of aBMD. However, data are lacking regarding both cortical microarchitecture and bone strength assessment by finite element analysis (FEA) in adolescents with AN. Because microarchitectural abnormalities and FEA may predict fracture risk independent of aBMD, these data are important to obtain.
Objective: Our objective was to compare both cortical and trabecular bone microarchitecture and FEA estimates of bone strength in adolescent girls with AN vs normal-weight controls.
Design, Setting, and Subjects: We conducted a cross-sectional study at a clinical research center that included 44 adolescent girls (21 with AN and 23 normal-weight controls) 14 to 22 years old.
Main Outcome Measures: We evaluated 1) aBMD (dual-energy x-ray absorptiometry) at the distal radius, lumbar spine, and hip, 2) cortical and trabecular microarchitecture at the ultradistal radius (high-resolution peripheral quantitative computed tomography), and 3) FEA-derived estimates of failure load at the ultradistal radius.
Results: aBMD was lower in girls with AN vs controls at the lumbar spine and hip but not at the distal radius. Girls with AN had lower total (P < .0001) and trabecular volumetric BMD (P = .02) and higher cortical porosity (P = .03) and trabecular separation (P = .04). Despite comparable total cross-sectional area, trabecular area was higher in girls with AN (P = .04), and cortical area and thickness were lower (P = .002 and .02, respectively). FEA-estimated failure load was lower in girls with AN (P = .004), even after controlling for distal radius aBMD.
Conclusions: Both cortical and trabecular microarchitecture are altered in adolescent girls with AN. FEA-estimated failure load is decreased, indicative of reduced bone strength. The finding of reduced cortical bone area in girls with AN is consistent with impaired cortical bone formation at the endosteum as a mechanism underlying these findings. (J Clin Endocrinol Metab 98: 1923-1929, 2013)
C1 [Faje, Alexander T.; Taylor, Alex; Miller, Karen K.; Mendes, Nara; Meenaghan, Erinne; Bouxsein, Mary L.; Misra, Madhusmita; Klibanski, Anne] Massachusetts Gen Hosp Children, Neuroendocrine Unit, Boston, MA 02114 USA.
[Lee, Hang] Massachusetts Gen Hosp Children, Ctr Biostat, Boston, MA 02114 USA.
[Goldstein, Mark A.] Massachusetts Gen Hosp Children, Div Adolescent & Young Adult Med, Boston, MA 02114 USA.
[Misra, Madhusmita] Massachusetts Gen Hosp Children, Pediat Endocrine Unit, Boston, MA 02114 USA.
[Misra, Madhusmita] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Karim, Lamya; Bouxsein, Mary L.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
RP Klibanski, A (reprint author), Massachusetts Gen Hosp, Neuroendocrine Unit, BUL 457, 55 Fruit St, Boston, MA 02114 USA.
EM aklibanski@partners.org
RI Mendes Estella, Nara/A-1469-2015
FU National Institutes of Health [5 UL1 RR025758, 2 RO1 DK062249]; Scanco
Medical AG; [NIH/NCRR 1 S10 RR023405]
FX This work was supported by National Institutes of Health Grants 5 UL1
RR025758 and 2 RO1 DK062249. We acknowledge funding from an equipment
grant (NIH/NCRR 1 S10 RR023405).; Disclosure Summary: A. T. has received
consultant fees from Scanco Medical AG.
NR 38
TC 26
Z9 26
U1 0
U2 1
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD MAY
PY 2013
VL 98
IS 5
BP 1923
EP 1929
DI 10.1210/jc.2012-4153
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 140WX
UT WOS:000318688200052
PM 23509107
ER
PT J
AU Costa-Barbosa, FA
Balasubramanian, R
Keefe, KW
Shaw, ND
Al-Tassan, N
Plummer, L
Dwyer, AA
Buck, CL
Choi, JH
Seminara, SB
Quinton, R
Monies, D
Meyer, B
Hall, JE
Pitteloud, N
Crowley, WF
AF Costa-Barbosa, Flavia Amanda
Balasubramanian, Ravikumar
Keefe, Kimberly W.
Shaw, Natalie D.
Al-Tassan, Nada
Plummer, Lacey
Dwyer, Andrew A.
Buck, Cassandra L.
Choi, Jin-Ho
Seminara, Stephanie B.
Quinton, Richard
Monies, Dorota
Meyer, Brian
Hall, Janet E.
Pitteloud, Nelly
Crowley, William F., Jr.
TI Prioritizing Genetic Testing in Patients With Kallmann Syndrome Using
Clinical Phenotypes
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID IDIOPATHIC HYPOGONADOTROPIC HYPOGONADISM;
GONADOTROPIN-RELEASING-HORMONE; PROKINETICIN RECEPTOR 2; OF-FUNCTION
MUTATIONS; REPRODUCTIVE PHENOTYPES; CHARGE SYNDROME; 1 FGFR1;
DEFICIENCY; GROWTH; KAL1
AB Context: The complexity of genetic testing in Kallmann syndrome (KS) is growing and costly. Thus, it is important to leverage the clinical evaluations of KS patients to prioritize genetic screening.
Objective: The objective of the study was to determine which reproductive and nonreproductive phenotypes of KS subjects have implications for specific gene mutations.
Subjects: Two hundred nineteen KS patients were studied: 151 with identified rare sequence variants (RSVs) in 8 genes known to cause KS (KAL1, NELF, CHD7, HS6ST1, FGF8/FGFR1, or PROK2/PROKR2) and 68 KS subjects who remain RSV negative for all 8 genes.
Main Outcome Measures: Reproductive and nonreproductive phenotypes within each genetic group were measured.
Results: Male KS subjects with KAL1 RSVs displayed the most severe reproductive phenotype with testicularvolumes(TVs) at presentation of 1.5 +/- 0.1 mL vs 3.7 +/- 0.3 mL, P<.05 vs all non-KAL1 probands. In both sexes, synkinesia was enriched but not unique to patients with KAL1 RSVs compared with KAL1-negative probands (43% vs 12%; P<.05). Similarly, dental agenesis and digital bone abnormalities were enriched in patients with RSVs in the FGF8/FGFR1 signaling pathway compared with all other gene groups combined (39% vs 4% and 23% vs 0%; P<.05, respectively). Hearing loss marked the probands with CHD7 RSVs (40% vs 13% in non-CHD7 probands; P<.05). Renal agenesis and cleft lip/palate did not emerge as statistically significant phenotypic predictors.
Conclusions: Certain clinical features in men and women are highly associated with genetic causes of KS. Synkinesia (KAL1), dentalagenesis(FGF8/FGFR1), digital bony abnormalities(FGF8/FGFR1), and hearing loss (CHD7) can be useful for prioritizing genetic screening.
C1 [Costa-Barbosa, Flavia Amanda; Balasubramanian, Ravikumar; Keefe, Kimberly W.; Shaw, Natalie D.; Plummer, Lacey; Buck, Cassandra L.; Choi, Jin-Ho; Seminara, Stephanie B.; Hall, Janet E.; Crowley, William F., Jr.] Massachusetts Gen Hosp, Harvard Reprod Endocrine Sci Ctr, Boston, MA 02114 USA.
[Costa-Barbosa, Flavia Amanda; Balasubramanian, Ravikumar; Keefe, Kimberly W.; Shaw, Natalie D.; Plummer, Lacey; Buck, Cassandra L.; Choi, Jin-Ho; Seminara, Stephanie B.; Hall, Janet E.; Crowley, William F., Jr.] Massachusetts Gen Hosp, Dept Med, Reprod Endocrine Unit, Boston, MA 02114 USA.
[Al-Tassan, Nada; Monies, Dorota; Meyer, Brian] King Faisal Special Hosp & Res Ctr, Dept Genet, Riyadh 11211, Saudi Arabia.
[Dwyer, Andrew A.; Pitteloud, Nelly] CHU Vaudois, Endocrine Diabet & Metab Serv, CH-1011 Lausanne, Switzerland.
[Quinton, Richard] Royal Victoria Infirm, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
RP Crowley, WF (reprint author), Harvard Univ, Sch Med, Bartlett Hall Extens 511,55 Fruit St, Boston, MA 02114 USA.
EM wcrowley@partners.org
RI Dwyer, Andrew/D-8099-2012; PITTELOUD, Nelly/K-2709-2014;
OI Dwyer, Andrew/0000-0002-7023-6794; Meyer, Brian/0000-0002-0388-9568;
Shaw, Natalie/0000-0002-0847-9170; Hall, Janet/0000-0003-4644-3061
FU Harvard Clinical and Translational Science Center (National Center for
Advancing Translational Sciences, National Institutes of Health)
[8UL1TR000170-05]; Harvard University; National Institutes of Health
[U54 HD028138, R01 HD15788, R01 HD056264, R01 HD42708]
FX We thank all our patients, their families, and the collaborating
physicians from across the world who facilitated our recruitment efforts
and volunteered their time and energy to enable this study. We also
thank Dr Ye-Ming Chan for helpful discussions on this manuscript.
Biostatistical analysis was conducted with support from the Harvard
Clinical and Translational Science Center (National Center for Research
Resources and the National Center for Advancing Translational Sciences,
National Institutes of Health Award 8UL1TR000170-05 and financial
contributions from Harvard University and its affiliated academic health
care centers). The content is solely the responsibility of the authors
and does not necessarily represent the official views of Harvard
Catalyst, Harvard University and its affiliated academic health care
centers, or the National Institutes of Health.; This work was supported
by National Institutes of Health Grants U54 HD028138 and R01 HD15788 (to
W.F.C.), R01 HD056264 (to N.P.), and R01 HD42708 (to J.E.H.).
NR 45
TC 33
Z9 34
U1 0
U2 10
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD MAY
PY 2013
VL 98
IS 5
BP E943
EP E953
DI 10.1210/jc.2012-4116
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 140WX
UT WOS:000318688200020
PM 23533228
ER
PT J
AU Dean, JP
Sprenger, CC
Wan, JX
Haugk, K
Ellis, WJ
Lin, DW
Corman, JM
Dalkin, BL
Mostaghel, E
Nelson, PS
Cohen, P
Montgomery, B
Plymate, SR
AF Dean, James P.
Sprenger, Cynthia C.
Wan, Junxiang
Haugk, Kathleen
Ellis, William J.
Lin, Daniel W.
Corman, John M.
Dalkin, Bruce L.
Mostaghel, Elahe
Nelson, Peter S.
Cohen, Pinchas
Montgomery, Bruce
Plymate, Stephen R.
TI Response of the Insulin-Like Growth Factor (IGF) System to IGF-IR
Inhibition and Androgen Deprivation in a Neoadjuvant Prostate Cancer
Trial: Effects of Obesity and Androgen Deprivation
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID FACTOR RECEPTOR ANTIBODY; RADICAL PROSTATECTOMY; BIOCHEMICAL RECURRENCE;
PHASE-II; GLUCOSE-HOMEOSTASIS; TARGETED THERAPY; HORMONE-THERAPY;
RESISTANCE; DOCETAXEL; EFFICACY
AB Context: Prostate cancer patients at increased risk for relapse after prostatectomy were treated in a neoadjuvant study with androgen deprivation therapy (ADT) in combination with cixutumumab, an inhibitory fully human monoclonal antibody against IGF receptor 1 (IGF-IR).
Objective: A clinical trial with prospective collection of serum and tissue was designed to test the potential clinical efficacy of neoadjuvant IGF-IR blockade combined with ADT in these patients. The effect of body mass index (BMI) on response of IGF-IR/insulin components to IGF-IR blockade was also examined.
Design: Eligibility for the trial required the presence of high-risk prostate adenocarcinoma. Treatment consisted of bicalutamide, goserelin, and cixutumumab for 13 weeks before prostatectomy. Here we report on an analysis of serum samples from 29 enrolled patients. Changes in IGF and glucose homeostasis pathways were compared to control samples from patients in a concurrent clinical trial of neoadjuvant ADT alone.
Results: Significant increases were seen in GH (P = .001), IGF-I (P < .0001), IGF-II (P = .003), IGF binding protein (IGFBP)-3 (P < .0001), C-peptide (P = .0038), and insulin (P = .05) compared to patients treated with ADT alone. IGFBP-1 levels were significantly lower in the cixutumumab plus ADT cohort (P = .001). No significant changes in blood glucose were evident. Patients with BMIs in the normal range had significantly higher GH (P < .05) and IGFBP-1 (P < 0.5) levels compared to overweight and obese patients.
Conclusions: Patients with IGF-IR blockade in combination with ADT demonstrated significant changes in IGF and glucose homeostasis pathway factors compared to patients receiving ADT alone. In the patients receiving combination therapy, patients with normal BMI had serum levels of glucose homeostasis components similar to individuals in the ADT-alone cohort, whereas patients with overweight and obese BMIs had serum levels that differed from the ADT cohort.
C1 [Dean, James P.; Mostaghel, Elahe; Nelson, Peter S.; Montgomery, Bruce] Fred Hutchinson Canc Res Ctr, Human Biol Div, Seattle, WA 98109 USA.
[Dean, James P.; Sprenger, Cynthia C.; Mostaghel, Elahe; Nelson, Peter S.; Montgomery, Bruce; Plymate, Stephen R.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
[Wan, Junxiang; Cohen, Pinchas] Univ Calif Los Angeles, Los Angeles, CA 90095 USA.
[Haugk, Kathleen; Plymate, Stephen R.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Ellis, William J.; Lin, Daniel W.; Corman, John M.; Dalkin, Bruce L.] Univ Washington, Dept Urol, Seattle, WA 98195 USA.
[Corman, John M.] Virginia Mason Med Ctr, Seattle, WA 98101 USA.
RP Plymate, SR (reprint author), Univ Washington, Harborview Med Ctr, 325 9th Ave,Box 359625, Seattle, WA 98104 USA.
EM splymate@u.washington.edu
FU National Cancer Institute Pacific Northwest Prostate Cancer Specialized
Program of Research Excellence (SPORE) [2 P50 CA 097186-06 Project 4];
Department of Veterans Affairs; Department of Defense Prostate Cancer
Research Program [W81XWH-07-1-0159]; University of California Los
Angeles Prostate Cancer SPORE [P50 CA92131]; [PO1 CA85859]
FX This clinical trial was supported by the National Cancer Institute
Pacific Northwest Prostate Cancer Specialized Program of Research
Excellence (SPORE) (2 P50 CA 097186-06 Project 4), PO1 CA85859, and the
Department of Veterans Affairs (to S.R.P.). Laboratory data analyses
were supported by Department of Defense Prostate Cancer Research Program
(W81XWH-07-1-0159; to J.P.D.), PO1 CA85859 and the Department of
Veterans Affairs (to S.R.P.), and the University of California Los
Angeles Prostate Cancer SPORE (P50 CA92131).
NR 46
TC 10
Z9 10
U1 0
U2 1
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD MAY
PY 2013
VL 98
IS 5
BP E820
EP E828
DI 10.1210/jc.2012-3856
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 140WX
UT WOS:000318688200002
PM 23533230
ER
PT J
AU Herrick, BW
Wallaert, JB
Eisner, BH
Pais, VM
AF Herrick, Benjamin W.
Wallaert, Jessica B.
Eisner, Brian H.
Pais, Vernon M., Jr.
TI Insurance Status, Stone Composition, and 24-Hour Urine Composition
SO JOURNAL OF ENDOUROLOGY
LA English
DT Article
ID SOCIOECONOMIC-STATUS; KIDNEY-STONES; CALCIUM-PHOSPHATE; ANIMAL PROTEIN;
RISK; SUPERSATURATION; NEPHROLITHIASIS; OXALATE; HYPERURICOSURIA;
UROLITHIASIS
AB Purpose: We examined the stone composition, 24-hour urinary risk factors, and insurance status in patients evaluated in two regional stone clinics to further investigate the relationship between the socioeconomic status and kidney stone formation.
Materials and Methods: We performed a retrospective review of stone formers who completed a 24-hour urinalysis as part of a metabolic evaluation for nephrolithiasis. Insurance status was determined by billing records and those with state-assisted insurance (SAI) were compared to patients with private insurance (PI). Multivariate analyses were performed adjusting for known risk factors for stones.
Results: Three hundred forty-six patients were included. Patients with SAI (16%) were significantly more likely to be female (55% vs. 38%, p = 0.026) and younger (43.5 vs. 49.2, p = 0.003). Among those with stone composition data (n = 200), SAI patients were as likely to form calcium phosphate (CaPhos) as calcium oxalate (CaOx) stones (46.9% vs. 31.3%, p = 0.44). PI patients were significantly less likely to form CaPhos than CaOx stones (10.1% vs. 77.4%, p < 0.001). On multivariate analysis, among those with calcium stones, the odds of forming CaPhos stones over CaOx stones were ten times higher among SAI patients compared to PI, odds ratio 10.2 (95% CI 3.6, 28.6, p < 0.001). Further, patients with SAI had significantly higher urine sodium, pH, and supersaturation of CaPhos, and a lower supersaturation of uric acid compared to patients with PI.
Conclusions: SAI was associated with a greater likelihood of a CaPhos stone composition and increased urinary risk factors for CaPhos stones. These findings may reflect dietary or other unmeasured differences, and have important implications for resource allocation and counseling, as treatment may differ for these groups.
C1 [Herrick, Benjamin W.; Pais, Vernon M., Jr.] Dartmouth Hitchcock Med Ctr, Dept Surg, Div Urol, Lebanon, NH 03756 USA.
[Wallaert, Jessica B.] Dartmouth Inst, Hanover, NH USA.
[Eisner, Brian H.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Herrick, BW (reprint author), Dartmouth Hitchcock Med Ctr, Dept Surg, Div Urol, Ste 5B,1 Med Ctr Dr, Lebanon, NH 03756 USA.
EM benjamin.w.herrick@hitchcock.org
NR 30
TC 1
Z9 1
U1 1
U2 33
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0892-7790
J9 J ENDOUROL
JI J. Endourol.
PD MAY
PY 2013
VL 27
IS 5
BP 652
EP 656
DI 10.1089/end.2012.0490
PG 5
WC Urology & Nephrology
SC Urology & Nephrology
GA 138ZX
UT WOS:000318552100022
PM 23428069
ER
PT J
AU Gershman, B
Eisner, BH
Sheth, S
Sacco, DE
AF Gershman, Boris
Eisner, Brian H.
Sheth, Sonali
Sacco, Dianne E.
TI Ureteral Stenting and Retrograde Pyelography in the Office: Clinical
Outcomes, Cost Effectiveness, and Time Savings
SO JOURNAL OF ENDOUROLOGY
LA English
DT Article
ID LOCAL-ANESTHESIA; FLEXIBLE CYSTOSCOPY; URETEROSCOPY; REMOVAL; PAINFUL
AB Objectives: To examine the clinical outcomes and cost-effectiveness of endourologic procedures performed in the office using standard fluoroscopy and topical anesthesia.
Methods: We performed a retrospective review of all patients who underwent primary ureteral stent placement, ureteral stent exchange, or ureteral catheterization with retrograde pyeolography or Bacillus Calmette-Guerin (BCG) instillation under fluoroscopic guidance in the office. For an evaluation of potential time savings, we compared this to a cohort of similar procedures performed in the operating room during the same time period.
Results: Procedures were attempted in 65 renal units in 38 patients (13 male, 25 female) with a mean age of 62.2 years (range 29.1-95.4 years). Primary ureteral stent placement was successful in 23/24 (95.8%) renal units. Ureteral stent exchange was successful in 19/22 (86.4%) renal units. Ureteral catheterization with retrograde pyelography or BCG instillation was successful in 19/19 (100%) renal units. The total cost savings for the 38 patients in this study, including excess cost from failure in the office, was approximately $91,496, with an average cost savings of $1,551 per procedure. Office-based procedures were associated with a nearly three-fold reduction in total hospital time as a result of reduced periprocedure waiting times.
Conclusions: Ureteral stent placement, ureteral stent exchange, and ureteral catheterization can be performed safely and effectively in the office in both men and women. This avoids general anesthesia and provides significant savings of time and cost for both patients and the health care system.
C1 [Gershman, Boris; Eisner, Brian H.; Sheth, Sonali; Sacco, Dianne E.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA.
RP Sacco, DE (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Urol, GRB 1102,55 Fruit St, Boston, MA 02114 USA.
EM dsacco@partners.org
NR 17
TC 1
Z9 1
U1 1
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0892-7790
J9 J ENDOUROL
JI J. Endourol.
PD MAY
PY 2013
VL 27
IS 5
BP 662
EP 666
DI 10.1089/end.2012.0644
PG 5
WC Urology & Nephrology
SC Urology & Nephrology
GA 138ZX
UT WOS:000318552100024
PM 23638674
ER
PT J
AU Hageman, MGH
Becker, SJE
Bot, AGJ
Guitton, T
Ring, D
AF Hageman, Michiel G. H.
Becker, Stephanie J. E.
Bot, Arjan G. J.
Guitton, Thierry
Ring, David
CA Sci Variation Grp
TI Variation in Recommendation for Surgical Treatment for Compressive
Neuropathy
SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME
LA English
DT Article
DE Carpal tunnel syndrome; decision making; electrodiagnostic testing;
surgical treatment; peripheral nerve
ID COMPENSATION; SURGERY; INJURY; CLAIMS; WORK; HAND
AB Purpose It is our impression that there is substantial, unexplained variation in hand surgeon recommendations for treatment of peripheral mononeuropathy. We tested the null hypothesis that specific patient and provider factors do not influence recommendations for surgery.
Methods Using a web-based survey, hand surgeons recommended surgical or nonsurgical treatment for patients in 2 different scenarios. Six elements of the first scenario (symptoms, circumstances, mindset, diagnosis, objective testing, and expectations) had 2 possibilities that were each independently and randomly assigned to each rater. For the second scenario, 2 different scenarios were randomly assigned to each rater. Multivariable logistic regression sought factors associated with a recommendation for surgery.
Results A total of 186 surgeons of the Science of Variation Group completed a survey regarding recommendation of surgery for 2 different patients based on clinical scenarios. Recommendations for surgery did not vary significantly according to provider characteristics. For the various elements in scenario 1, recommendation for surgery was more likely for patients who were self-employed and continued to work and who had objective electrodiagnostic abnormalities. For the 2 vignettes used in scenario 2, a recommendation for surgery was associated with abnormal electrophysiology.
Conclusions The findings of this study suggest that at least in a survey setting surgeons prefer to offer peripheral nerve decompression to patients with abnormal electrophysiology, particularly those with effective coping strategies.
C1 [Hageman, Michiel G. H.; Becker, Stephanie J. E.; Bot, Arjan G. J.; Guitton, Thierry; Ring, David; Sci Variation Grp] Massachusetts Gen Hosp, Orthopaed Hand & Upper Extrem Serv, Boston, MA 02114 USA.
RP Ring, D (reprint author), Massachusetts Gen Hosp, Yawkey Ctr, Orthopaed Hand Serv, Suite 2100,55 Fruit St, Boston, MA 02114 USA.
EM dring@partners.org
RI Becker, Stephanie/N-5761-2014; Fernandes, C/F-9839-2012; Calcagni,
Maurizio/C-9769-2012;
OI Fernandes, C/0000-0003-0146-6091; Calcagni,
Maurizio/0000-0003-4372-0561; Kennedy, Stephen/0000-0001-8177-4988;
Guitton, Thierry/0000-0002-2599-1985; Goldfarb,
Charles/0000-0001-9672-8853; Kaplan, F. Thomas D./0000-0002-0348-507X
NR 12
TC 2
Z9 2
U1 1
U2 13
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0363-5023
J9 J HAND SURG-AM
JI J. Hand Surg.-Am. Vol.
PD MAY
PY 2013
VL 38A
IS 5
BP 856
EP 862
DI 10.1016/j.jhsa.2013.02.008
PG 7
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA 139KH
UT WOS:000318581100003
PM 23561726
ER
PT J
AU Neuhaus, V
Ring, DC
AF Neuhaus, Valentin
Ring, David C.
TI Latent Class Analysis
SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME
LA English
DT Editorial Material
ID LOW-BACK-PAIN; MUSCULOSKELETAL PAINS; POPULATION; FRACTURES; PATTERNS;
CLASSIFICATION; VALIDATION; ARTHRITIS; INJURY
C1 [Neuhaus, Valentin; Ring, David C.] Massachusetts Gen Hosp, Hand & Upper Extrem Serv, Dept Orthopaed Surg, Boston, MA 02114 USA.
RP Ring, DC (reprint author), Massachusetts Gen Hosp, Hand & Upper Extrem Serv, Dept Orthopaed Surg, Yawkey Ctr Outpatient Care, 55 Fruit St, Boston, MA 02114 USA.
EM dring@partners.org
OI Neuhaus, Valentin/0000-0003-4012-5628
NR 41
TC 3
Z9 3
U1 1
U2 10
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0363-5023
J9 J HAND SURG-AM
JI J. Hand Surg.-Am. Vol.
PD MAY
PY 2013
VL 38A
IS 5
BP 1018
EP 1020
DI 10.1016/j.jhsa.2013.01.024
PG 3
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA 139KH
UT WOS:000318581100028
PM 23474164
ER
PT J
AU Neuhaus, V
Nagy, L
Jupiter, JB
AF Neuhaus, Valentin
Nagy, Ladislav
Jupiter, Jesse B.
TI Bone Loss in the Hand
SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME
LA English
DT Article
ID PROXIMAL INTERPHALANGEAL JOINT; FRACTURE-DISLOCATIONS; SOFT-TISSUE; FREE
FLAP; RECONSTRUCTION; FINGER; ARTHROPLASTY; GRAFT; DEFECTS;
TRANSPLANTATION
AB Traumatic bone loss in hand surgery is challenging for the patient as well as the doctor. Whereas the patient is threatened with a possible amputation or severe disability, the hand surgeon focuses on reconstruction, restoration of the function, bony union, and appearance of the injured hand. Both are confronted with a long-standing and staged treatment coupled with a high risk of complications. This review encompasses the classifications and treatment options of bone loss in hands. The optimal treatment is still prevention of the trauma itself. (J Hand Surg 2013;38A:1032-1039. Copyright (C) 2013 by the American Society for Surgery of the Hand. All rights reserved.)
C1 Massachusetts Gen Hosp, Hand & Upper Extrem Serv, Boston, MA 02114 USA.
Univ Zurich, Hand Serv, Balgrist Hosp, Zurich, Switzerland.
RP Jupiter, JB (reprint author), Massachusetts Gen Hosp, Dept Orthoped Surg, Hand & Upper Extrem Serv, Yawkey Ctr, Suite 2100,55 Fruit St, Boston, MA 02114 USA.
EM jjupiter1@partners.org
OI Neuhaus, Valentin/0000-0003-4012-5628
NR 36
TC 1
Z9 1
U1 0
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0363-5023
J9 J HAND SURG-AM
JI J. Hand Surg.-Am. Vol.
PD MAY
PY 2013
VL 38A
IS 5
BP 1032
EP 1039
DI 10.1016/j.jhsa.2013.02.026
PG 8
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA 139KH
UT WOS:000318581100030
PM 23618459
ER
PT J
AU Karimi, M
Avci, P
Mobasseri, R
Hamblin, MR
Naderi-Manesh, H
AF Karimi, Mahdi
Avci, Pinar
Mobasseri, Rezvan
Hamblin, Michael R.
Naderi-Manesh, Hossein
TI The novel albumin-chitosan core-shell nanoparticles for gene delivery:
preparation, optimization and cell uptake investigation
SO JOURNAL OF NANOPARTICLE RESEARCH
LA English
DT Article
DE Albumin; Chitosan; Nanoparticle; Gene delivery; Optimization
ID BOX-BEHNKEN DESIGN; IN-VITRO; DRUG-DELIVERY; ELECTROSPUN NANOFIBERS;
DESOLVATION PROCESS; DNA NANOPARTICLES; HSA-NANOPARTICLES; THERAPY;
SYSTEMS; SURFACE
AB Natural polymers and proteins such as chitosan (CS) and albumin (Alb) have recently attracted much attention both in drug delivery and gene delivery. The underlying rationale is their unique properties such as biodegradability, biocompatibility and controlled release. This study aimed to prepare novel albumin-chitosan-DNA (Alb-CS-DNA) core-shell nanoparticles as a plasmid delivery system and find the best conditions for their preparation. Phase separation method and ionic interaction were used for preparation of Alb nanoparticles and Alb-CS-DNA core-shell nanoparticles, respectively. The effects of three important independent variables (1) CS/Alb mass ratio, (2) the ratios of moles of the amine groups of cationic polymers to those of the phosphate groups of DNA (N/P ratio), and (3) Alb concentration, on the nanoparticle size and loading efficiency of the plasmid were investigated and optimized through Box-Behnken design of response surface methodology (RSM). The optimum conditions were found to be CS/Alb mass ratio = 3, N/P ratio = 8.24 and Alb concentration = 0.1 mg/mL. The most critical factors for the size of nanoparticles and loading efficiency were Alb concentration and N/P ratio. The optimized nanoparticles had an average size of 176 +/- 3.4 nm and loading efficiency of 80 +/- 3.9 %. Cytotoxicity experiments demonstrated that the prepared nanoparticles were not toxic. The high cellular uptake of nanoparticles (similar to 85 %) was shown by flow cytometry and fluorescent microscopy.
C1 [Karimi, Mahdi; Mobasseri, Rezvan; Naderi-Manesh, Hossein] Tarbiat Modares Univ, Dept Nanobiotechnol, Fac Biol Sci, Tehran, Iran.
[Karimi, Mahdi; Avci, Pinar; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Karimi, Mahdi; Avci, Pinar; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02114 USA.
[Hamblin, Michael R.] Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02119 USA.
[Naderi-Manesh, Hossein] Tarbiat Modares Univ, Dept Biophys, Fac Biol Sci, Tehran, Iran.
RP Naderi-Manesh, H (reprint author), Tarbiat Modares Univ, Dept Biophys, Fac Biol Sci, Tehran, Iran.
EM naderman@modares.ac.ir
OI Karimi, Mahdi/0000-0002-7977-3940; Hamblin, Michael/0000-0001-6431-4605
FU nano initiative; Tarbiat Modares University; US NIH [R01A1050875]
FX This work was partially supported by nano initiative and Tarbiat Modares
University. MR Hamblin was supported by US NIH grant R01A1050875.
NR 52
TC 15
Z9 15
U1 1
U2 57
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1388-0764
J9 J NANOPART RES
JI J. Nanopart. Res.
PD MAY
PY 2013
VL 15
IS 5
AR 1651
DI 10.1007/s11051-013-1651-0
PG 14
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 139BC
UT WOS:000318555400055
PM 24363607
ER
PT J
AU Catana, C
Guimaraes, AR
Rosen, BR
AF Catana, Ciprian
Guimaraes, Alexander R.
Rosen, Bruce R.
TI PET and MR Imaging: The Odd Couple or a Match Made in Heaven?
SO JOURNAL OF NUCLEAR MEDICINE
LA English
DT Article
DE multimodality imaging; PET/MR imaging; applications; oncology;
neurology; cardiology
ID LYMPH-NODE METASTASES; SUPERPARAMAGNETIC IRON-OXIDE;
POSITRON-EMISSION-TOMOGRAPHY; WHOLE-BODY PET/MRI;
ATTENUATION-CORRECTION; FDG-PET/CT; ALZHEIMERS-DISEASE; PROSTATE-CANCER;
MAGNETIC NANOPARTICLES; PEDIATRIC ONCOLOGY
AB PET and MR imaging are modalities routinely used for clinical and research applications. Integrated scanners capable of acquiring PET and MR imaging data in the same session, sequentially or simultaneously, have recently become available for human use. In this article, we describe some of the technical advances that allowed the development of human PET/MR scanners; briefly discuss methodologic challenges and opportunities provided by this novel technology; and present potential oncologic, cardiac, and neuropsychiatric applications. These examples range from studies that might immediately benefit from PET/MR to more advanced applications on which future development might have an even broader impact.
C1 Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
Harvard Univ, Sch Med, Charlestown, MA USA.
RP Catana, C (reprint author), AA Martinos Ctr, Bldg 149,13th St,Room 2-301, Charlestown, MA 02129 USA.
EM ccatana@nmr.mgh.harvard.edu
FU NCI NIH HHS [R01 CA137254]
NR 75
TC 32
Z9 32
U1 0
U2 23
PU SOC NUCLEAR MEDICINE INC
PI RESTON
PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA
SN 0161-5505
J9 J NUCL MED
JI J. Nucl. Med.
PD MAY 1
PY 2013
VL 54
IS 5
BP 815
EP 824
DI 10.2967/jnumed.112.112771
PG 10
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 137CS
UT WOS:000318413200046
PM 23492887
ER
PT J
AU Burstein, HJ
AF Burstein, Harold J.
TI Off-Label Use of Oncology Drugs: Too Much, Too Little, or Just Right?
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Editorial Material
C1 [Burstein, Harold J.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Burstein, Harold J.] Dana Farber Canc Inst, Boston, MA USA.
[Burstein, Harold J.] Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Burstein, HJ (reprint author), Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
NR 3
TC 2
Z9 2
U1 1
U2 2
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD MAY
PY 2013
VL 11
IS 5
BP 505
EP 506
PG 2
WC Oncology
SC Oncology
GA 141US
UT WOS:000318752600001
PM 23667200
ER
PT J
AU Benson, AB
Bekaii-Saab, T
Chan, E
Chen, YJ
Choti, MA
Cooper, HS
Engstrom, PF
Enzinger, PC
Fakih, MG
Fenton, MJ
Fuchs, CS
Grem, JL
Hunt, S
Kamel, A
Leong, LA
Lin, E
May, KS
Mulcahy, MF
Murphy, K
Rohren, E
Ryan, DP
Saltz, L
Sharma, S
Shibata, D
Skibber, JM
Small, W
Sofocleous, CT
Venook, AP
Willett, CG
Gregory, KM
Freedman-Cass, DA
AF Benson, Al B., III
Bekaii-Saab, Tanios
Chan, Emily
Chen, Yi-Jen
Choti, Michael A.
Cooper, Harry S.
Engstrom, Paul F.
Enzinger, Peter C.
Fakih, Marwan G.
Fenton, Moon J.
Fuchs, Charles S.
Grem, Jean L.
Hunt, Steven
Kamel, Ahmed
Leong, Lucille A.
Lin, Edward
May, Kilian Salerno
Mulcahy, Mary F.
Murphy, Kate
Rohren, Eric
Ryan, David P.
Saltz, Leonard
Sharma, Sunil
Shibata, David
Skibber, John M.
Small, William, Jr.
Sofocleous, Constantinos T.
Venook, Alan P.
Willett, Christopher G.
Gregory, Kristina M.
Freedman-Cass, Deborah A.
TI Localized Colon Cancer, Version 3.2013 Featured Updates to the NCCN
Guidelines
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Article
ID NONPOLYPOSIS COLORECTAL-CANCER; STAGE-II; ADJUVANT CHEMOTHERAPY;
MICROSATELLITE-INSTABILITY; MISMATCH REPAIR; LYNCH-SYNDROME; FOLINIC
ACID; FLUOROURACIL; RECURRENCE; EFFICACY
AB The NCCN Clinical Practice Guidelines in Oncology for Colon Cancer begin with the clinical presentation of the patient to the primary care physician or gastroenterologist and address diagnosis, pathologic staging, surgical management, perioperative treatment, patient surveillance, management of recurrent and metastatic disease, and survivorship. The NCCN Colon Cancer Panel meets annually to review comments from reviewers within their institutions and to reevaluate and update their recommendations. In addition, the panel has interim conferences as new data necessitate. These NCCN Guidelines Insights summarize the NCCN Colon Cancer Panel's discussions regarding the treatment of localized disease for the 2013 update of the guidelines.
C1 [Benson, Al B., III; Mulcahy, Mary F.; Small, William, Jr.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA.
[Bekaii-Saab, Tanios] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA.
[Chan, Emily] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Chen, Yi-Jen; Leong, Lucille A.] City Hope Comprehens Canc Ctr, Duarte, CA USA.
[Choti, Michael A.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA.
[Cooper, Harry S.; Engstrom, Paul F.] Fox Chase Canc Ctr, Philadelphia, PA USA.
[Enzinger, Peter C.; Fuchs, Charles S.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA.
[Fakih, Marwan G.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
[Fenton, Moon J.] Univ Tennessee, St Jude Childrens Res Hosp, Hlth Sci Ctr, Knoxville, TN 37996 USA.
[Grem, Jean L.] Nebraska Med Ctr, UNMC Eppley Canc Ctr, Omaha, NE USA.
[Hunt, Steven] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA.
[Hunt, Steven] Washington Univ, Sch Med, St Louis, MO USA.
[Kamel, Ahmed] Univ Alabama Birmingham Comprehens Canc Ctr, Birmingham, AL USA.
[Lin, Edward] Seattle Canc Care Alliance, Fred Hutchinson Canc Res Ctr, Seattle, WA USA.
[May, Kilian Salerno] Roswell Pk Canc Inst, Buffalo, NY USA.
[Rohren, Eric; Skibber, John M.] Univ Texas MD Anderson Canc Ctr, Houston, TX USA.
[Ryan, David P.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Saltz, Leonard; Sofocleous, Constantinos T.] Mem Sloan Kettering Canc Ctr, New York, NY USA.
[Sharma, Sunil] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
[Shibata, David] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
[Venook, Alan P.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
[Willett, Christopher G.] Duke Canc Inst, Durham, NC USA.
RP Benson, AB (reprint author), Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA.
RI Bekaii-Saab, Tanios/E-2733-2011
NR 47
TC 44
Z9 45
U1 0
U2 7
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD MAY
PY 2013
VL 11
IS 5
BP 519
EP 528
PG 10
WC Oncology
SC Oncology
GA 141US
UT WOS:000318752600004
PM 23667203
ER
PT J
AU Ajani, JA
Bentrem, DJ
Besh, S
D'Amico, TA
Das, P
Denlinger, C
Fakih, MG
Fuchs, CS
Gerdes, H
Glasgow, RE
Hayman, JA
Hofstetter, WL
Ilson, DH
Keswani, RN
Kleinberg, LR
Korn, WM
Lockhart, AC
Meredith, K
Mulcahy, MF
Orringer, MB
Posey, JA
Sasson, AR
Scott, WJ
Strong, VE
Varghese, TK
Warren, G
Washington, MK
Willett, C
Wright, CD
McMillian, NR
Sundar, H
AF Ajani, Jaffer A.
Bentrem, David J.
Besh, Stephen
D'Amico, Thomas A.
Das, Prajnan
Denlinger, Crystal
Fakih, Marwan G.
Fuchs, Charles S.
Gerdes, Hans
Glasgow, Robert E.
Hayman, James A.
Hofstetter, Wayne L.
Ilson, David H.
Keswani, Rajesh N.
Kleinberg, Lawrence R.
Korn, W. Michael
Lockhart, A. Craig
Meredith, Kenneth
Mulcahy, Mary F.
Orringer, Mark B.
Posey, James A.
Sasson, Aaron R.
Scott, Walter J.
Strong, Vivian E.
Varghese, Thomas K., Jr.
Warren, Graham
Washington, Mary Kay
Willett, Christopher
Wright, Cameron D.
McMillian, Nicole R.
Sundar, Hema
TI Gastric Cancer, Version 2.2013 Featured Updates to the NCCN Guidelines
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Article
ID LYMPH-NODE DISSECTION; PHASE-III TRIAL; GASTROESOPHAGEAL JUNCTION
ADENOCARCINOMA; RANDOMIZED CLINICAL-TRIAL; GENE AMPLIFICATION; D2
GASTRECTOMY; PERIOPERATIVE CHEMOTHERAPY; HER2 EXPRESSION; SURGICAL
TRIAL; STAGE-II
AB The NCCN Clinical Practice Guidelines in Oncology for Gastric Cancer provide evidence- and consensus-based recommendations for a multidisciplinary approach for the management of patients with gastric cancer. For patients with resectable locoregional cancer, the guidelines recommend gastrectomy with a D1+ or a modified D2 lymph node dissection (performed by experienced surgeons in high-volume centers). Postoperative chemoradiation is the preferred option after complete gastric resection for patients with T3-T4 tumors and node-positive T1-T2 tumors. Postoperative chemotherapy is included as an option after a modified D2 lymph node dissection for this group of patients. Trastuzumab with chemotherapy is recommended as first-line therapy for patients with HER2-positive advanced or metastatic cancer, confirmed by immunohistochemistry and, if needed, by fluorescence in situ hybridization for IHC 2+.
C1 [Ajani, Jaffer A.; Das, Prajnan; Hofstetter, Wayne L.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Bentrem, David J.; Keswani, Rajesh N.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA.
[Besh, Stephen] Univ Tennessee, Hlth Sci Ctr, St Jude Childrens Res Hosp, Knoxville, TN 37996 USA.
[D'Amico, Thomas A.] Duke Canc Inst, Durham, NC USA.
[Denlinger, Crystal; Scott, Walter J.] Fox Chase Canc Ctr, Philadelphia, PA USA.
[Fakih, Marwan G.] City Hope Comprehens Canc Ctr, Duarte, CA USA.
[Fuchs, Charles S.; Strong, Vivian E.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA.
[Gerdes, Hans; Ilson, David H.] Mem Sloan Kettering Canc Ctr, New York, NY USA.
[Glasgow, Robert E.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
[Hayman, James A.; Kleinberg, Lawrence R.; Orringer, Mark B.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
[Hayman, James A.; Kleinberg, Lawrence R.; Orringer, Mark B.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA.
[Korn, W. Michael] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
[Lockhart, A. Craig] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA.
[Lockhart, A. Craig] Washington Univ, Sch Med, St Louis, MO USA.
[Meredith, Kenneth] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
[Posey, James A.] Univ Alabama Birmingham Comprehens Canc Ctr, Birmingham, AL USA.
[Sasson, Aaron R.; Warren, Graham] Nebraska Med Ctr, UNMC Eppley Canc Ctr, Omaha, NE USA.
[Varghese, Thomas K., Jr.] Seattle Canc Care Alliance, Fred Hutchinson Canc Res Ctr, Seattle, WA USA.
[Warren, Graham] Roswell Pk Canc Inst, Buffalo, NY USA.
[Washington, Mary Kay] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Wright, Cameron D.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Ajani, JA (reprint author), Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 44
TC 147
Z9 169
U1 0
U2 12
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD MAY
PY 2013
VL 11
IS 5
BP 531
EP 546
PG 16
WC Oncology
SC Oncology
GA 141US
UT WOS:000318752600005
PM 23667204
ER
PT J
AU Ettinger, DS
Riely, GJ
Akerley, W
Borghaei, H
Chang, AC
Cheney, RT
Chirieac, LR
D'Amico, TA
Demmy, TL
Govindan, R
Grannis, FW
Grant, SC
Horn, L
Jahan, TM
Komaki, R
Kong, FMS
Kris, MG
Krug, LM
Lackner, RP
Lennes, IT
Loo, BW
Martins, R
Otterson, GA
Patel, JD
Pinder-Schenck, MC
Pisters, KM
Reckamp, K
Rohren, E
Shapiro, TA
Swanson, SJ
Tauer, K
Wood, DE
Yang, SC
Gregory, K
Hughes, M
AF Ettinger, David S.
Riely, Gregory J.
Akerley, Wallace
Borghaei, Hossein
Chang, Andrew C.
Cheney, Richard T.
Chirieac, Lucian R.
D'Amico, Thomas A.
Demmy, Todd L.
Govindan, Ramaswamy
Grannis, Frederic W., Jr.
Grant, Stefan C.
Horn, Leora
Jahan, Thierry M.
Komaki, Ritsuko
(Spring) Kong, Feng-Ming
Kris, Mark G.
Krug, Lee M.
Lackner, Rudy P.
Lennes, Inga T.
Loo, Billy W., Jr.
Martins, Renato
Otterson, Gregory A.
Patel, Jyoti D.
Pinder-Schenck, Mary C.
Pisters, Katherine M.
Reckamp, Karen
Rohren, Eric
Shapiro, Theresa A.
Swanson, Scott J.
Tauer, Kurt
Wood, Douglas E.
Yang, Stephen C.
Gregory, Kristina
Hughes, Miranda
TI Thymomas and Thymic Carcinomas Clinical Practice Guidelines in Oncology
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Article
ID ADJUVANT RADIATION-THERAPY; ENDOCRINE NEOPLASIA TYPE-1; PRIMARY
MEDIASTINAL TUMORS; STAGE IVA THYMOMA; OF-THE-ART; EPITHELIAL TUMORS;
PHASE-II; INVASIVE THYMOMA; POSTOPERATIVE RADIOTHERAPY; SURGICAL
RESECTION
AB Masses in the anterior mediastinum can be neoplasms (eg, thymomas, thymic carcinomas, or lung metastases) or non-neoplastic conditions (eg, intrathoracic goiter). Thymomas are the most common primary tumor in the anterior mediastinum, although they are rare. Thymic carcinomas are very rare. Thymomas and thymic carcinomas originate in the thymus. Although thymomas can spread locally, they are much less invasive than thymic carcinomas. Patients with thymomas have 5-year survival rates of approximately 78%. However, 5-year survival rates for thymic carcinomas are only approximately 40%. These guidelines outline the evaluation, treatment, and management of these mediastinal tumors.
C1 [Ettinger, David S.; Yang, Stephen C.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkin, Baltimore, MD USA.
[Riely, Gregory J.; Kris, Mark G.; Krug, Lee M.] Mem Sloan Kettering Canc Ctr, New York, NY USA.
[Akerley, Wallace] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
[Borghaei, Hossein] Fox Chase Canc Ctr, Philadelphia, PA USA.
[Chang, Andrew C.; (Spring) Kong, Feng-Ming] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
[Cheney, Richard T.; Demmy, Todd L.] Roswell Pk Canc Inst, Buffalo, NY USA.
[Chirieac, Lucian R.; Swanson, Scott J.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA.
[D'Amico, Thomas A.] Duke Canc Inst, Durham, NC USA.
[Govindan, Ramaswamy] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA.
[Govindan, Ramaswamy] Univ Washington, Sch Med, Seattle, WA 98195 USA.
[Grannis, Frederic W., Jr.; Reckamp, Karen] City Hope Comprehens Canc Ctr, Duarte, CA USA.
[Grant, Stefan C.] Univ Alabama, Birmingham Comprehens Canc Ctr, Tuscaloosa, AL 35487 USA.
[Horn, Leora] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Jahan, Thierry M.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
[Komaki, Ritsuko; Pisters, Katherine M.; Rohren, Eric] Univ Texas MD Anderson Canc Ctr, Houston, TX USA.
[Lackner, Rudy P.] UNMC Eppley Canc Ctr, Nebraska Med Ctr, Omaha, NE USA.
[Lennes, Inga T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Loo, Billy W., Jr.] Stanford Canc Inst, Stanford, CA USA.
[Martins, Renato; Wood, Douglas E.] Fred Hutchinson Canc Res Ctr, Seattle, WA USA.
[Martins, Renato; Wood, Douglas E.] Seattle Canc Care Alliance, Seattle, WA USA.
[Otterson, Gregory A.] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA.
[Otterson, Gregory A.] Solove Res Inst, Columbus, OH USA.
[Patel, Jyoti D.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA.
[Pinder-Schenck, Mary C.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
[Wood, Douglas E.] Univ Tennessee, Inst Canc, Knoxville, TN 37996 USA.
RP Ettinger, DS (reprint author), Sidney Kimmel Comprehens Canc Ctr Johns Hopkin, Baltimore, MD USA.
NR 131
TC 10
Z9 11
U1 1
U2 4
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD MAY
PY 2013
VL 11
IS 5
BP 562
EP 576
PG 15
WC Oncology
SC Oncology
GA 141US
UT WOS:000318752600007
PM 23667206
ER
PT J
AU Clark, PE
Spiess, PE
Agarwal, N
Biagioli, MC
Eisenberger, MA
Greenberg, RE
Herr, HW
Inman, BA
Kuban, DA
Kuzel, TM
Lele, SM
Michalski, J
Pagliaro, L
Pal, SK
Patterson, A
Plimack, ER
Pohar, KS
Porter, MP
Richie, JP
Sexton, WJ
Shipley, WU
Small, EJ
Trump, DL
Wile, G
Wilson, TG
Dwyer, M
Ho, M
AF Clark, Peter E.
Spiess, Philippe E.
Agarwal, Neeraj
Biagioli, Matthew C.
Eisenberger, Mario A.
Greenberg, Richard E.
Herr, Harry W.
Inman, Brant A.
Kuban, Deborah A.
Kuzel, Timothy M.
Lele, Subodh M.
Michalski, Jeff
Pagliaro, Lance
Pal, Sumanta K.
Patterson, Anthony
Plimack, Elizabeth R.
Pohar, Kamal S.
Porter, Michael P.
Richie, Jerome P.
Sexton, Wade J.
Shipley, William U.
Small, Eric J.
Trump, Donald L.
Wile, Geoffrey
Wilson, Timothy G.
Dwyer, Mary
Ho, Maria
TI Penile Cancer Clinical Practice Guidelines in Oncology
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; SENTINEL NODE-BIOPSY; IMIQUIMOD 5-PERCENT
CREAM; ENDOSCOPIC INGUINAL LYMPHADENECTOMY; CURRENT TNM CLASSIFICATION;
FINE-NEEDLE-ASPIRATION; ORGAN-SPARING SURGERY; PROGNOSTIC-FACTORS;
IN-SITU; INTERSTITIAL BRACHYTHERAPY
AB Squamous cell carcinoma of the penis represents approximately 0.5% of all cancers among men in the United States and other developed countries. Although rare, it is associated with significant disfigurement, and only half of the patients survive beyond 5 years. Proper evaluation of both the primary lesion and lymph nodes is critical, because nodal involvement is the most important factor of survival. The NCCN Clinical Practice Guidelines in Oncology for Penile Cancer provide recommendations on the diagnosis and management of this devastating disease based on evidence and expert consensus.
C1 [Clark, Peter E.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Agarwal, Neeraj; Wile, Geoffrey] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
[Spiess, Philippe E.; Biagioli, Matthew C.; Sexton, Wade J.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
[Eisenberger, Mario A.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA.
[Greenberg, Richard E.; Plimack, Elizabeth R.] Fox Chase Canc Ctr, Philadelphia, PA USA.
[Herr, Harry W.] Mem Sloan Kettering Canc Ctr, New York, NY USA.
[Inman, Brant A.] Duke Canc Inst, Durham, NC USA.
[Kuban, Deborah A.; Pagliaro, Lance] Univ Texas MD Anderson Canc Ctr, Houston, TX USA.
[Kuzel, Timothy M.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA.
[Lele, Subodh M.] Nebraska Med Ctr, UNMC Eppley Canc Ctr, Omaha, NE USA.
[Michalski, Jeff] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA.
[Michalski, Jeff] Univ Washington, Sch Med, Seattle, WA 98195 USA.
[Pal, Sumanta K.; Wilson, Timothy G.] City Hope Comprehens Canc Ctr, Duarte, CA USA.
[Patterson, Anthony] St Jude Childrens Res Hosp, Memphis, TN USA.
[Patterson, Anthony] Univ Tennessee, Hlth Sci Ctr, Knoxville, TN 37996 USA.
[Pohar, Kamal S.] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA.
[Pohar, Kamal S.] Solove Res Inst, Columbus, OH USA.
[Porter, Michael P.] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA.
[Richie, Jerome P.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA.
[Shipley, William U.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Small, Eric J.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
[Trump, Donald L.] Roswell Pk Canc Inst, Buffalo, NY USA.
RP Clark, PE (reprint author), Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
RI Clark, Peter/E-1423-2011
OI Clark, Peter/0000-0002-8006-7015
FU NCI NIH HHS [P30 CA006973]
NR 106
TC 18
Z9 19
U1 0
U2 2
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD MAY
PY 2013
VL 11
IS 5
BP 594
EP 615
PG 22
WC Oncology
SC Oncology
GA 141US
UT WOS:000318752600010
PM 23667209
ER
PT J
AU Patel, VI
Kang, J
Mukhopadhyay, S
Conrad, MF
Brewster, DC
Kwolek, CJ
Cambria, RP
LaMuraglia, GM
AF Patel, Virendra I.
Kang, Jeanwan
Mukhopadhyay, Shankha
Conrad, Mark F.
Brewster, David C.
Kwolek, Christopher J.
Cambria, Richard P.
LaMuraglia, Glenn M.
TI Severe Contralateral Carotid Stenosis or Occlusion Does Not Impact Risk
of Ipsilateral Stroke Following CEA
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Meeting Abstract
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery (SVS)
CY MAY 30-JUN 01, 2013
CL San Francisco, CA
SP Soc Vasc Surg (SVS)
C1 [Patel, Virendra I.; Kang, Jeanwan; Mukhopadhyay, Shankha; Conrad, Mark F.; Brewster, David C.; Kwolek, Christopher J.; Cambria, Richard P.; LaMuraglia, Glenn M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD MAY
PY 2013
VL 57
IS 5
SU S
BP 6S
EP 7S
PG 4
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 140VV
UT WOS:000318685300008
ER
PT J
AU Raux, M
Patel, VI
Cochennec, F
Mukhopadhyay, S
Desgranges, P
Cambria, RP
Becquemin, JP
LaMuraglia, GM
AF Raux, Maxime
Patel, Virendra I.
Cochennec, Frederic
Mukhopadhyay, Shankha
Desgranges, Pascal
Cambria, Richard P.
Becquemin, Jean-Pierre
LaMuraglia, Glenn M.
TI A Propensity-Matched Comparison of Fenestrated EVAR and Open Surgical
Repair of Complex Abdominal Aortic Aneurysms
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Meeting Abstract
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery (SVS)
CY MAY 30-JUN 01, 2013
CL San Francisco, CA
SP Soc Vasc Surg (SVS)
C1 [Raux, Maxime; Cochennec, Frederic; Desgranges, Pascal; Becquemin, Jean-Pierre] Hop Henri Mondor, F-94010 Creteil, France.
[Patel, Virendra I.; Mukhopadhyay, Shankha; Cambria, Richard P.; LaMuraglia, Glenn M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD MAY
PY 2013
VL 57
IS 5
SU S
BP 20S
EP 21S
PG 4
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 140VV
UT WOS:000318685300036
ER
PT J
AU Lombardi, JV
Cambria, RP
Nienaber, C
Chiesa, R
Teebken, O
Lee, A
Mossop, P
Haulon, S
Zhou, Q
Jia, FY
AF Lombardi, Joseph V.
Cambria, Richard P.
Nienaber, Christoph
Chiesa, Roberto
Teebken, Omkee
Lee, Anthony
Mossop, Peter
Haulon, Stephan
Zhou, Qing
Jia, Feiyi
TI Aortic Remodeling After Endovascular Treatment of Complicated Type B
Aortic Dissection Using a Composite Device Design: A Report from the
STABLE Trial
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Meeting Abstract
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery (SVS)
CY MAY 30-JUN 01, 2013
CL San Francisco, CA
SP Soc Vasc Surg (SVS)
C1 [Lombardi, Joseph V.] Cooper Univ Hosp, Camden, NJ USA.
[Cambria, Richard P.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Nienaber, Christoph] Univ Hosp Rostock, Rostock, Germany.
[Chiesa, Roberto] Hosp San Raffaele, I-20132 Milan, Italy.
[Teebken, Omkee] Hannover Med Sch, Hannover, Germany.
[Lee, Anthony] Christine E Lynn Heart & Vasc Inst, Boca Raton, FL USA.
[Mossop, Peter] St Vincents Hosptal, Melbourne, Vic, Australia.
[Haulon, Stephan] Chru Lille, Hosp Cardiol, Lille, France.
[Zhou, Qing; Jia, Feiyi] Med Institutel, W Lafayette, IN USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD MAY
PY 2013
VL 57
IS 5
SU S
BP 21S
EP 22S
PG 4
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 140VV
UT WOS:000318685300038
ER
PT J
AU Morrison, TM
Meyer, CA
Fillinger, MF
Fairman, RM
Glickman, MH
Cambria, RP
Farber, MA
Naslund, TC
Fail, PS
Elmore, JR
White, RA
Dall'Olmo, CA
Williams, DM
AF Morrison, Tina M.
Meyer, Clark A.
Fillinger, Mark F.
Fairman, Ron M.
Glickman, Marc H.
Cambria, Richard P.
Farber, Mark A.
Naslund, Thomas C.
Fail, Peter S.
Elmore, James R.
White, Rodney A.
Dall'Olmo, Carlo A.
Williams, David M.
TI Eligiblity for Endovascular Repair of Short Neck Abdominal Aortic
Aneurysms
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Meeting Abstract
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery (SVS)
CY MAY 30-JUN 01, 2013
CL San Francisco, CA
SP Soc Vasc Surg (SVS)
C1 [Morrison, Tina M.; Meyer, Clark A.] US FDA, Ctr Devices & Radiol Hlth, Silver Spring, MD USA.
[Fillinger, Mark F.] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA.
[Fairman, Ron M.] Univ Penn, Med Ctr, Philadelphia, PA 19104 USA.
[Glickman, Marc H.] Sentara Norfolk Gen Hosp, Norfolk, VA USA.
[Cambria, Richard P.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Farber, Mark A.] Univ N Carolina, Med Ctr, Chapel Hill, NC USA.
[Naslund, Thomas C.] Vanderbilt Univ Sch Med, Nashville, TN USA.
[Fail, Peter S.] Cardiovasc Inst South, Houma, LA USA.
[Elmore, James R.] Geisinger Med Ctr, Danville, PA 17822 USA.
[White, Rodney A.] Harbor UCLA Med Ctr, Los Angeles, CA USA.
[Dall'Olmo, Carlo A.] Michigan Vasc Ctr, Flint, MI USA.
[Williams, David M.] Univ Michigan, Med Ctr, Ann Arbor, MI USA.
NR 0
TC 1
Z9 1
U1 0
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD MAY
PY 2013
VL 57
IS 5
SU S
BP 24S
EP 24S
PG 1
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 140VV
UT WOS:000318685300042
ER
PT J
AU Conrad, MF
Mukhopadhyay, S
Michalczyk, MJ
Opalacz, A
LaMuraglia, GM
Cambria, RP
AF Conrad, Mark F.
Mukhopadhyay, Shankha
Michalczyk, Michael J.
Opalacz, Arissa
LaMuraglia, Glenn M.
Cambria, Richard P.
TI Natural History of Asymptomatic Severe Carotid Artery Stenosis
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Meeting Abstract
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery (SVS)
CY MAY 30-JUN 01, 2013
CL San Francisco, CA
SP Soc Vasc Surg (SVS)
C1 [Conrad, Mark F.; Mukhopadhyay, Shankha; Michalczyk, Michael J.; Opalacz, Arissa; LaMuraglia, Glenn M.; Cambria, Richard P.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD MAY
PY 2013
VL 57
IS 5
SU S
BP 27S
EP 27S
PG 1
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 140VV
UT WOS:000318685300048
ER
PT J
AU Simons, JP
Baril, D
Goodney, PP
Hevelone, ND
Bertges, DJ
Patel, VI
Robinson, WP
Cronenwett, JL
Messina, LM
Schanzer, A
AF Simons, Jessica P.
Baril, Donald
Goodney, Philip P.
Hevelone, Nathanael D.
Bertges, Daniel J.
Patel, Virendra I.
Robinson, William P.
Cronenwett, Jack L.
Messina, Louis M.
Schanzer, Andres
TI The Effect of Postoperative Myocardial Ischemia on Long-Term Survival
After Vascular Surgery
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Meeting Abstract
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery (SVS)
CY MAY 30-JUN 01, 2013
CL San Francisco, CA
SP Soc Vasc Surg (SVS)
C1 [Simons, Jessica P.; Robinson, William P.; Messina, Louis M.; Schanzer, Andres] Univ Massachusetts, Sch Med, Div Vasc & Endovasc Surg, Worcester, MA USA.
[Goodney, Philip P.; Cronenwett, Jack L.] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA.
[Hevelone, Nathanael D.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Bertges, Daniel J.] Univ Vermont, Coll Med, Burlington, VT USA.
[Patel, Virendra I.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD MAY
PY 2013
VL 57
IS 5
SU S
BP 29S
EP 29S
PG 1
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 140VV
UT WOS:000318685300052
ER
PT J
AU Lo, RC
Fokkema, M
Curran, T
Darling, J
Wyers, M
Hamdan, AD
Chaikof, EL
Schermerhorn, ML
AF Lo, Ruby C.
Fokkema, Margriet
Curran, Thomas
Darling, Jeremy
Wyers, Mark
Hamdan, Allen D.
Chaikof, Elliot L.
Schermerhorn, Marc L.
TI Predictors of Access-Site Related Complications After Lower Extremity
Percutaneous Revascularization
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Meeting Abstract
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery (SVS)
CY MAY 30-JUN 01, 2013
CL San Francisco, CA
SP Soc Vasc Surg (SVS)
C1 [Lo, Ruby C.; Fokkema, Margriet; Curran, Thomas; Darling, Jeremy; Wyers, Mark; Hamdan, Allen D.; Chaikof, Elliot L.; Schermerhorn, Marc L.] BIDMC, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD MAY
PY 2013
VL 57
IS 5
SU S
BP 51S
EP 51S
PG 1
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 140VV
UT WOS:000318685300096
ER
PT J
AU Zhang, J
Curran, T
Fokkema, M
Lo, RC
Wyers, M
Hamdan, A
Chaikof, E
Schermerhorn, ML
AF Zhang, Jennifer
Curran, Thomas
Fokkema, Margriet
Lo, Ruby C.
Wyers, Mark
Hamdan, Alan
Chaikof, Elliot
Schermerhorn, Marc L.
TI Predictors of 30-Day Readmission and Analysis of Complications After
Lower Extremity Bypass Using NSQIP
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Meeting Abstract
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery (SVS)
CY MAY 30-JUN 01, 2013
CL San Francisco, CA
SP Soc Vasc Surg (SVS)
C1 [Zhang, Jennifer; Curran, Thomas; Fokkema, Margriet; Lo, Ruby C.; Wyers, Mark; Hamdan, Alan; Chaikof, Elliot; Schermerhorn, Marc L.] BIDMC, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD MAY
PY 2013
VL 57
IS 5
SU S
BP 60S
EP 60S
PG 1
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 140VV
UT WOS:000318685300113
ER
PT J
AU Lee, A
Peterson, C
Moll, H
Csizmadia, E
Rogers, A
Neidich, A
Chien, V
da Silva, C
Ferran, C
AF Lee, Andy
Peterson, Clayton
Moll, Herwig
Csizmadia, Eva
Rogers, Ashley
Neidich, Alon
Chien, Victor
da Silva, Cleide
Ferran, Christiane
TI Loss of Function Studies Highlight the Vasculoprotective Effect of A20
in Transplant Arteriosclerosis (TA)
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Meeting Abstract
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery (SVS)
CY MAY 30-JUN 01, 2013
CL San Francisco, CA
SP Soc Vasc Surg (SVS)
C1 [Lee, Andy; Peterson, Clayton; Moll, Herwig; Csizmadia, Eva; Rogers, Ashley; Chien, Victor; da Silva, Cleide; Ferran, Christiane] BIDMC, Boston, MA USA.
[Neidich, Alon] Tufts Med Sch, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD MAY
PY 2013
VL 57
IS 5
SU S
BP 77S
EP 78S
PG 4
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 140VV
UT WOS:000318685300148
ER
PT J
AU Chien, V
Kaczmarek, E
Daniel, S
Essayagh, S
Choi, L
Choi, J
Lee, A
da Silva, C
Ferran, C
AF Chien, Victor
Kaczmarek, Elzbieta
Daniel, Soizic
Essayagh, Sanah
Choi, Lynn
Choi, Jean
Lee, Andy
da Silva, Cleide
Ferran, Christiane
TI A20 Increases eNOS Expression and Activity to Sustain Endothelial Cell
Function Under Inflammatory Insults
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Meeting Abstract
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery (SVS)
CY MAY 30-JUN 01, 2013
CL San Francisco, CA
SP Soc Vasc Surg (SVS)
C1 [Chien, Victor; Kaczmarek, Elzbieta; Daniel, Soizic; Essayagh, Sanah; Choi, Lynn; Choi, Jean; Lee, Andy; da Silva, Cleide; Ferran, Christiane] BIDMC, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD MAY
PY 2013
VL 57
IS 5
SU S
BP 79S
EP 79S
PG 1
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 140VV
UT WOS:000318685300151
ER
PT J
AU Patel, VI
Ergul, E
Conrad, MF
Gravereaux, E
Schermerhorn, ML
Schanzer, A
Goodney, PP
Cambria, RP
AF Patel, Virendra I.
Ergul, Emel
Conrad, Mark F.
Gravereaux, Edwin
Schermerhorn, Marc L.
Schanzer, Andres
Goodney, Philip P.
Cambria, Richard P.
TI Aneurysm Sac Enlargement Independently Predicts Late Mortality in
Patients Treated With EVAR
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Meeting Abstract
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery (SVS)
CY MAY 30-JUN 01, 2013
CL San Francisco, CA
SP Soc Vasc Surg (SVS)
C1 [Patel, Virendra I.; Ergul, Emel; Conrad, Mark F.; Cambria, Richard P.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Gravereaux, Edwin; Schermerhorn, Marc L.; Schanzer, Andres; Goodney, Philip P.] Vasc Study Grp New England, Lebanon, NH USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD MAY
PY 2013
VL 57
IS 5
SU S
BP 87S
EP 88S
PG 4
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 140VV
UT WOS:000318685300169
ER
PT J
AU Fokkema, M
Goodney, PP
Nedeau, AE
Baribeau, YR
Patel, VI
Moll, FL
de Borst, GJ
Schermerhorn, ML
AF Fokkema, Margriet
Goodney, Philip P.
Nedeau, April E.
Baribeau, Yvonne R.
Patel, Virendra I.
Moll, Frans L.
de Borst, Gert Jan
Schermerhorn, Marc L.
TI Symptom Status and Degree of Ipsilateral Stenosis Determine Whether
Contralateral Stenosis Increases the Risk for Carotid Revascularization
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Meeting Abstract
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery (SVS)
CY MAY 30-JUN 01, 2013
CL San Francisco, CA
SP Soc Vasc Surg (SVS)
C1 [Fokkema, Margriet; Schermerhorn, Marc L.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Goodney, Philip P.] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA.
[Nedeau, April E.] Cent Maine Med Ctr, Lewiston, ME USA.
[Baribeau, Yvonne R.] New England Heart Inst, Manchester, NH USA.
[Patel, Virendra I.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Moll, Frans L.; de Borst, Gert Jan] Univ Med Ctr Utrecht, Utrecht, Netherlands.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD MAY
PY 2013
VL 57
IS 5
SU S
BP 93S
EP 93S
PG 1
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 140VV
UT WOS:000318685300180
ER
PT J
AU Smith, AD
Schaumeier, MJ
Hawkins, AT
Hevelone, ND
Nguyen, LL
AF Smith, Ann D.
Schaumeier, Maria J.
Hawkins, Alexander T.
Hevelone, Nathanael D.
Nguyen, Louis L.
TI Predictors of Major Amputation With Patent Bypass Grafts
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Meeting Abstract
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery (SVS)
CY MAY 30-JUN 01, 2013
CL San Francisco, CA
SP Soc Vasc Surg (SVS)
C1 [Smith, Ann D.; Nguyen, Louis L.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Schaumeier, Maria J.; Hevelone, Nathanael D.] Ctr Surg & Publ Hlth, Boston, MA USA.
[Hawkins, Alexander T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD MAY
PY 2013
VL 57
IS 5
SU S
BP 98S
EP 99S
PG 4
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 140VV
UT WOS:000318685300192
ER
PT J
AU Mosse, YP
Lim, MS
Voss, SD
Wilner, K
Ruffner, K
Laliberte, J
Rolland, D
Balis, FM
Maris, JM
Weigel, BJ
Ingle, AM
Ahern, C
Adamson, PC
Blaney, SM
AF Mosse, Yael P.
Lim, Megan S.
Voss, Stephan D.
Wilner, Keith
Ruffner, Katherine
Laliberte, Julie
Rolland, Delphine
Balis, Frank M.
Maris, John M.
Weigel, Brenda J.
Ingle, Ashish M.
Ahern, Charlotte
Adamson, Peter C.
Blaney, Susan M.
TI Safety and activity of crizotinib for paediatric patients with
refractory solid tumours or anaplastic large-cell lymphoma: a Children's
Oncology Group phase 1 consortium study
SO LANCET ONCOLOGY
LA English
DT Article
ID ALK GENE REARRANGEMENT; LUNG-CANCER; ACTIVATING MUTATIONS; ONCOGENIC
MUTATIONS; KINASE; NEUROBLASTOMA; IDENTIFICATION; CHEMOTHERAPY; FUSION;
ADOLESCENTS
AB Background Various human cancers have ALK gene translocations, amplifications, or oncogenic mutations, such as anaplastic large-cell lymphoma, inflammatory myofibroblastic tumours, non-small-cell lung cancer (NSCLC), and neuroblastoma. Therefore, ALK inhibition could be a useful therapeutic strategy in children. We aimed to determine the safety, recommended phase 2 dose, and antitumour activity of crizotinib in children with refractory solid tumours and anaplastic large-cell lymphoma.
Methods In this open-label, phase 1 dose-escalation trial, patients older than 12 months and younger than 22 years with measurable or evaluable solid or CNS tumours, or anaplastic large-cell lymphoma, refractory to therapy and for whom there was no known curative treatment were eligible. Crizotinib was given twice daily without interruption. Six dose levels (100, 130, 165, 215, 280, 365 mg/m(2) per dose) were assessed in the dose-finding phase of the study (part A1), which is now completed. The primary endpoint was to estimate the maximum tolerated dose, to define the toxic effects of crizotinib, and to characterise the pharmacokinetics of crizotinib in children with refractory cancer. Additionally, patients with confirmed ALK translocations, mutations, or amplification (part A2 of the study) or neuroblastoma (part A3) could enrol at one dose level lower than was currently given in part A1. We assessed ALK genomic status in tumour tissue and used quantitative RT-PCR to measure NPM-ALK fusion transcript in bone marrow and blood samples of patients with anaplastic large-cell lymphoma. All patients who received at least one dose of crizotinib were evaluable for response; patients completing at least one cycle of therapy or experiencing dose limiting toxicity before that were considered fully evaluable for toxicity. This study is registered with ClinicalTrials. gov, NCT00939770.
Findings 79 patients were enrolled in the study from Oct 2, 2009, to May 31, 2012. The median age was 10.1 years (range 1.1-21.4); 43 patients were included in the dose escalation phase (A1), 25 patients in part A2, and 11 patients in part A3. Crizotinib was well tolerated with a recommended phase 2 dose of 280 mg/m(2) twice daily. Grade 4 adverse events in cycle 1 were neutropenia (two) and liver enzyme elevation (one). Grade 3 adverse events that occurred in more than one patient in cycle 1 were lymphopenia (two), and neutropenia (eight). The mean steady state peak concentration of crizotinib was 630 ng/mL and the time to reach this peak was 4 h (range 1-6). Objective tumour responses were documented in 14 of 79 patients (nine complete responses, five partial responses); and the antitumour activity was enriched in patients with known activating ALK aberrations (eight of nine with anaplastic large-cell lymphoma, one of 11 with neuroblastoma, three of seven with inflammatory myofibroblastic tumour, and one of two with NSCLC).
Interpretation The findings suggest that a targeted inhibitor of ALK has antitumour activity in childhood malignancies harbouring ALK translocations, particularly anaplastic large-cell lymphoma and inflammatory myofibroblastic tumours, and that further investigation in the subset of neuroblastoma harbouring known ALK oncogenic mutations is warranted.
C1 [Mosse, Yael P.; Balis, Frank M.; Maris, John M.; Adamson, Peter C.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA.
[Mosse, Yael P.; Balis, Frank M.; Maris, John M.; Adamson, Peter C.] Childrens Hosp Philadelphia, Ctr Childhood Canc Res, Philadelphia, PA 19104 USA.
[Mosse, Yael P.; Balis, Frank M.; Maris, John M.; Adamson, Peter C.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Lim, Megan S.; Laliberte, Julie; Rolland, Delphine] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.
[Voss, Stephan D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston Childrens Hosp,Dept Radiol, Boston, MA 02115 USA.
[Wilner, Keith; Ruffner, Katherine] Pfizer Oncol, La Jolla, CA USA.
[Weigel, Brenda J.] Univ Minnesota, Ctr Canc, Div Pediat Oncol, Minneapolis, MN USA.
[Ingle, Ashish M.] Childrens Oncol Grp, Operat Ctr, Monrovia, CA USA.
[Ahern, Charlotte; Blaney, Susan M.] Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA.
RP Mosse, YP (reprint author), Childrens Hosp Philadelphia, 3501 Civ Ctr Blvd,CTRB 3056, Philadelphia, PA 19104 USA.
EM mosse@chop.edu
FU Pfizer; National Cancer Institute; COG phase 1 and Pilot Consortium
[U01]
FX Pfizer and National Cancer Institute grant to the Children's Oncology
Group.; Funding for this trial was provided to the COG phase 1 and Pilot
Consortium through a U01 mechanism and by Pfizer. We thank Biljana
Georgievska, COG phase 1 Operations Director and the staff in the COG
Operations office. We thank Per Kogner (Karolinska Institute, Stockholm,
Sweden) for his patient referral
NR 31
TC 174
Z9 180
U1 6
U2 22
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1470-2045
J9 LANCET ONCOL
JI Lancet Oncol.
PD MAY
PY 2013
VL 14
IS 6
BP 472
EP 480
DI 10.1016/S1470-2045(13)70095-0
PG 9
WC Oncology
SC Oncology
GA 140UN
UT WOS:000318681500036
PM 23598171
ER
PT J
AU Motzer, RJ
Escudier, B
Tomczak, P
Hutson, TE
Michaelson, MD
Negrier, S
Oudard, S
Gore, ME
Tarazi, J
Hariharan, S
Chen, C
Rosbrook, B
Kim, S
Rini, BI
AF Motzer, Robert J.
Escudier, Bernard
Tomczak, Piotr
Hutson, Thomas E.
Michaelson, M. Dror
Negrier, Sylvie
Oudard, Stephane
Gore, Martin E.
Tarazi, Jamal
Hariharan, Subramanian
Chen, Connie
Rosbrook, Brad
Kim, Sinil
Rini, Brian I.
TI Axitinib versus sorafenib as second-line treatment for advanced renal
cell carcinoma: overall survival analysis and updated results from a
randomised phase 3 trial
SO LANCET ONCOLOGY
LA English
DT Article
ID PROGRESSION-FREE SURVIVAL; PROGNOSTIC-FACTORS; EFFICACY; EVEROLIMUS;
BIOMARKER
AB Background In a phase 3 trial comparing the efficacy and safety of axitinib versus sorafenib as second-line treatment for metastatic renal cell carcinoma, patients given axitinib had a longer progression-free survival (PFS). Here, we report overall survival and updated efficacy, quality of life, and safety results.
Methods Eligible patients had clear cell metastatic renal cell carcinoma, progressive disease after one approved systemic treatment, and an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1.723 patients were stratified by ECOG PS and previous treatment and randomly allocated (1:1) to receive axitinib (5 mg twice daily; n=361) or sorafenib (400 mg twice daily; n=362). The primary endpoint was PFS assessed by a masked, independent radiology review committee. We assessed patient-reported outcomes using validated questionnaires. Baseline characteristics and development of hypertension on treatment were studied as prognostic factors. Efficacy was assessed in the intention-to-treat population, and safety was assessed in patients who received at least one dose of the study drug. This ongoing trial is registered on ClinicalTrials.gov, number NCT00678392.
Findings Median overall survival was 20.1 months (95% CI 16.7-23.4) with axitinib and 19.2 months (17.5-22.3) with sorafenib (hazard ratio [HR] 0.969, 95% CI 0.800-1.174; one-sided p=0.3744). Median investigator-assessed PFS was 8.3 months (95% CI 6.7-9.2) with axitinib and 5.7 months (4.7-6.5) with sorafenib (HR 0.656, 95% CI 0.552-0.779; one-sided p<0.0001). Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment, but decreased at end-of-treatment. Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients. In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20.7 months (95% CI 18.4-24.6) versus 12.9 months (10.1-20.4) in the axitinib group (p=0.0116), and 20.2 months (17.1-32.0) versus 14.8 months (12.0-17.7) in the sorafenib group (one-sided p=0.0020).
Interpretation Although overall survival, a secondary endpoint for the study, did not differ between the two groups, investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group. These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma.
C1 [Motzer, Robert J.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Escudier, Bernard] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France.
[Tomczak, Piotr] Uniwersytet Med, Klin Onkol, Poznan, Poland.
[Hutson, Thomas E.] Baylor Sammons & Texas Oncol Phys Assoc, Sammons Canc Ctr, Dallas, TX USA.
[Michaelson, M. Dror] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Negrier, Sylvie] Ctr Leon Berard, Serv Oncol Med, F-69373 Lyon, France.
[Oudard, Stephane] Univ Paris 05, Georges Pompidou European Hosp, Paris, France.
[Gore, Martin E.] Royal Marsden Hosp, London SW3 6JJ, England.
[Tarazi, Jamal; Rosbrook, Brad; Kim, Sinil] Pfizer Oncol, San Diego, CA USA.
[Hariharan, Subramanian] Pfizer Inc, New York, NY USA.
[Chen, Connie] Pfizer Inc, Global Outcomes Res, New York, NY USA.
[Rini, Brian I.] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA.
RP Motzer, RJ (reprint author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
EM motzerr@mskcc.org
OI Michaelson, Dror/0000-0001-9249-6338
FU Pfizer Inc.; Pfizer; Bayer; GlaxoSmithKline; Novartis; Genentech; Eisai;
Eisai, Bayer; Abbott; Sanofi-Aventis
FX Pfizer Inc.; RJM has served as a consultant or adviser for Pfizer and
has received research funding from Pfizer, Novartis, and
GlaxoSmithKline. BE has served as a consultant or adviser for Bayer,
Pfizer, and Novartis, and has received honoraria from Bayer, Roche,
Pfizer, Genentech, Novartis, and Aveo. TEH has served as a consultant or
adviser for and received honoraria and research funding from Pfizer,
Bayer, GlaxoSmithKline, and Novartis. MDM has served as a consultant or
adviser for Pfizer, Novartis, Aveo, Genentech, and Abbott and has
received research funding from GlaxoSmithKline, Genentech, Pfizer,
Novartis, Eisai, Bayer, and Abbott. SN has served as a consultant or
adviser for Novartis and Pfizer; has received honoraria from Novartis,
Pfizer, GlaxoSmithKline, and Roche; and has received research funding
from Novartis, Pfizer, and GlaxoSmithKline. SO has served as a
consultant or adviser for Roche, Sanofi-Aventis, Novartis, and Bayer;
has received honoraria from Pfizer, Bayer, Novartis, Keocyt, Amgen,
Roche, and Sanofi-Aventis; and has received research funding from
Sanofi-Aventis and Bayer. MEG has served as a consultant or adviser for
and received honoraria from Pfizer and Bayer. JT, SH, CC, BR, and SK are
employees of and own stock in Pfizer. BIR has served as a consultant or
adviser for and received research funding from Pfizer. PT declares that
he has no conflicts of interest.; See the appendix for a full list of
participating countries and principal investigators. This study was
sponsored by Pfizer Inc. Medical writing support, also funded by Pfizer
Inc, was provided by Joanna Bloom, of UBC Scientific Solutions
(Southport, CT, USA).
NR 10
TC 234
Z9 239
U1 1
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1470-2045
J9 LANCET ONCOL
JI Lancet Oncol.
PD MAY
PY 2013
VL 14
IS 6
BP 552
EP 562
DI 10.1016/S1470-2045(13)70093-7
PG 11
WC Oncology
SC Oncology
GA 140UN
UT WOS:000318681500044
PM 23598172
ER
PT J
AU Carbone, K
AF Carbone, Kathryn
TI Untitled
SO MCN-THE AMERICAN JOURNAL OF MATERNAL-CHILD NURSING
LA English
DT Editorial Material
C1 James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
RP Carbone, K (reprint author), James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
EM Kathryn.Carbone@va.gov
NR 4
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0361-929X
J9 MCN-AM J MATERN-CHIL
JI MCN-Am. J. Matern.-Child Nurs.
PD MAY-JUN
PY 2013
VL 38
IS 3
BP 135
EP 135
PG 1
WC Nursing
SC Nursing
GA 140WA
UT WOS:000318685800003
ER
PT J
AU Chung, HJ
Castro, CM
Im, H
Lee, H
Weissleder, R
AF Chung, Hyun Jung
Castro, Cesar M.
Im, Hyungsoon
Lee, Hakho
Weissleder, Ralph
TI A magneto-DNA nanoparticle system for rapid detection and phenotyping of
bacteria
SO NATURE NANOTECHNOLOGY
LA English
DT Article
ID RESISTANT STAPHYLOCOCCUS-AUREUS; CARE-ASSOCIATED INFECTIONS; PCR ASSAY;
IDENTIFICATION; DIAGNOSIS; CELLS
AB So far, although various diagnostic approaches for pathogen detection have been proposed, most are too expensive, lengthy or limited in specificity for clinical use. Nanoparticle systems with unique material properties, however, circumvent these problems and offer improved accuracy over current methods. Here, we present novel magneto-DNA probes capable of rapid and specific profiling of pathogens directly in clinical samples. A nanoparticle hybridization assay, involving ubiquitous and specific probes that target bacterial 16S rRNAs, was designed to detect amplified target DNAs using a miniaturized NMR device. Ultimately, the magneto-DNA platform will allow both universal and specific detection of various clinically relevant bacterial species, with sensitivity down to single bacteria. Furthermore, the assay is robust and rapid, simultaneously diagnosing a panel of 13 bacterial species in clinical specimens within 2 h. The generic platform described could be used to rapidly identify and phenotype pathogens for a variety of applications.
C1 [Chung, Hyun Jung; Castro, Cesar M.; Im, Hyungsoon; Lee, Hakho; Weissleder, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Weissleder, Ralph] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.
[Castro, Cesar M.; Weissleder, Ralph] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA 02114 USA.
RP Lee, H (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, 185 Cambridge St,CPZN 5206, Boston, MA 02114 USA.
EM hlee@mgh.harvard.edu; rweissleder@mgh.harvard.edu
RI Im, Hyungsoon/A-3178-2009; Chung, Hyun Jung/J-3205-2014
OI Im, Hyungsoon/0000-0002-0626-1346;
FU National Institute of Health [R01EB004626, R01EB010011,
HHSN268201000044C, R01HL113156]
FX The authors thank Y. Fisher-Jeffes for reviewing the manuscript, N.
Sergeyev for synthesis of MNPs, S. Chen and M. Mckee for help with
electron microscopy, C. Min for help with the mu NMR device, and J.
Chung, K. S. Yang, J. Carlson, H. Shao and A. V. Ullal for assistance
and many helpful discussions. The work was funded in part by National
Institute of Health (grants R01EB004626, R01EB010011, HHSN268201000044C
and R01HL113156).
NR 33
TC 118
Z9 119
U1 15
U2 151
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1748-3387
J9 NAT NANOTECHNOL
JI Nat. Nanotechnol.
PD MAY
PY 2013
VL 8
IS 5
BP 369
EP 375
DI 10.1038/NNANO.2013.70
PG 7
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA 140VQ
UT WOS:000318684800020
PM 23644570
ER
PT J
AU Walensky, LD
AF Walensky, Loren D.
TI Direct BAKtivation
SO NATURE STRUCTURAL & MOLECULAR BIOLOGY
LA English
DT Editorial Material
ID BH3 DOMAINS; MITOCHONDRIAL APOPTOSIS; PROAPOPTOTIC BAX; ACTIVATION;
BCL-2; MEMBRANE; PERMEABILIZATION; OLIGOMERIZATION; INHIBITOR; BINDING
C1 [Walensky, Loren D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Childrens Hosp Boston,Dept Pediat Oncol, Boston, MA 02115 USA.
[Walensky, Loren D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Childrens Hosp Boston,Linde Program Canc Chem Bio, Boston, MA 02115 USA.
RP Walensky, LD (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Childrens Hosp Boston,Dept Pediat Oncol, 44 Binney St, Boston, MA 02115 USA.
EM loren_walensky@dfci.harvard.edu
FU NCI NIH HHS [R01 CA050239]; NIGMS NIH HHS [R01 GM090299]
NR 22
TC 3
Z9 3
U1 0
U2 9
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1545-9993
J9 NAT STRUCT MOL BIOL
JI Nat. Struct. Mol. Biol.
PD MAY
PY 2013
VL 20
IS 5
BP 536
EP 538
DI 10.1038/nsmb.2579
PG 3
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 139WZ
UT WOS:000318617000003
PM 23649360
ER
PT J
AU Awad, AJ
Walcott, BP
Stapleton, CJ
Yanamadala, V
Nahed, BV
Coumans, JV
AF Awad, Ahmed J.
Walcott, Brian P.
Stapleton, Christopher J.
Yanamadala, Vijay
Nahed, Brian V.
Coumans, Jean-Valery
TI Dabigatran, intracranial hemorrhage, and the neurosurgeon
SO NEUROSURGICAL FOCUS
LA English
DT Article
DE stroke; fatal outcome; tracheostomy; decompressive craniectomy;
warfarin; Pradaxa; dabigatran etexilate
ID DIRECT THROMBIN INHIBITOR; PROTHROMBIN COMPLEX CONCENTRATE; RE-LY TRIAL;
ATRIAL-FIBRILLATION; COAGULATION ASSAYS; INTRACEREBRAL HEMORRHAGE;
ANTICOAGULANT ACTIVITY; WARFARIN; ETEXILATE; PHARMACOKINETICS
AB Dabigatran etexilate (Pradaxa) is a novel oral anticoagulant that has gained FDA approval for the prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation. In randomized trials, the incidence of hemorrhagic events has been demonstrated to be lower in patients treated with dabigatran compared with the traditional anticoagulant warfarin. However, dabigatran does not have reliable laboratory tests to measure levels of anticoagulation and there is no pharmacological antidote. These drawbacks are challenging in the setting of intracerebral hemorrhage. In this article, the authors provide background information on dabigatran, review the existing anecdotal experiences with treating intracerebral hemorrhage related to dabigatran therapy, present a case study of intracranial hemorrhage in a patient being treated with dabigatran, and suggest clinical management strategies. The development of reversal agents is urgently needed given the growing number of patients treated with this medication.
C1 [Awad, Ahmed J.] An Najah Natl Univ, Fac Med & Hlth Sci, Nablus, West Bank, Israel.
[Walcott, Brian P.; Stapleton, Christopher J.; Yanamadala, Vijay; Nahed, Brian V.; Coumans, Jean-Valery] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
[Walcott, Brian P.; Stapleton, Christopher J.; Yanamadala, Vijay; Nahed, Brian V.; Coumans, Jean-Valery] Harvard Univ, Sch Med, Boston, MA USA.
RP Walcott, BP (reprint author), Massachusetts Gen Hosp, 55 Fruit St,White Bldg Room 502, Boston, MA 02114 USA.
EM walcott.brian@mgh.harvard.edu
NR 39
TC 8
Z9 8
U1 2
U2 6
PU AMER ASSOC NEUROLOGICAL SURGEONS
PI ROLLING MEADOWS
PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
SN 1092-0684
J9 NEUROSURG FOCUS
JI Neurosurg. Focus
PD MAY
PY 2013
VL 34
IS 5
AR E7
DI 10.3171/2013.2.FOCUS1323
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 138DR
UT WOS:000318489300008
PM 23634926
ER
PT J
AU Osaki, TH
Jakobiec, FA
Mendoza, PR
Lee, Y
Fay, AM
AF Osaki, Tammy H.
Jakobiec, Frederick A.
Mendoza, Pia R.
Lee, Yongjae
Fay, Aaron M.
TI Immunohistochemical Investigations of Orbital Infantile Hemangiomas and
Adult Encapsulated Cavernous Venous Lesions (Malformation Versus
Hemangioma)
SO OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY
LA English
DT Article
ID GLUT-1 GLUCOSE-TRANSPORTER; PORT-WINE STAIN; VASCULAR MALFORMATIONS;
CAPILLARY HEMANGIOMA; LYMPHATIC MALFORMATIONS; JUVENILE HEMANGIOMAS;
TUMORS; CLASSIFICATION; ENDOTHELIUM; DIAGNOSIS
AB Purpose: Immunohistochemical studies have begun to advance knowledge regarding the pathogenesis of vascular anomalies in many anatomical regions. However, the immunohistochemical features of most orbital tumors have been overlooked. Therefore, a comparative immunohistochemical study of a series of the 2 most common orbital vascular lesions infantile hemangioma (IH) and encapsulated cavernous venous lesion (ECVL), the latter also termed cavernous hemangioma or venous malformation-was undertaken.
Methods: Twenty surgically excised orbital tumors diagnosed clinically and histopathologically as IHs (10 cases) or "cavernous hemangioma" (10 cases) were evaluated pathologically and immunohistochemically using hematoxylin and eosin, Alcian blue, Masson trichrome, GLUT-1, CD31, CD34, D2-40, smooth muscle actin (SMA), desmin, and Ki-67 probes.
Results: All cases reacted strongly with the traditional blood vessel endothelial markers CD31 and CD34 and were negative for D2-40, a selective marker for lymphatic endothelium. All IH were positive for GLUT-1, and all ECVL were negative for GLUT-1. In IH, SMA (but not desmin) stained a monolayer of pericytes and in ECVL multilaminar smooth muscle vascular mural cells and intravascular (interstitial) stromal cells. Nuclear Ki-67 immunostaining was strongly positive in IH (average of 16.3%) and close to zero in ECVL.
Conclusions: Immunophenotypic results for ECVL and IH demonstrated no overlapping staining patterns. Infantile hemangioma had the classical architecture of capillaries. Because of the constant presence of mural smooth muscle, it was concluded that ECVL is an accurate and descriptive term. However, desmin negativity in ECVL indicates myofibroblastic differentiation rather than full-fledged smooth muscle differentiation. Infantile hemangioma may display ectatic channels as the lesion ages but does not acquire multilaminar smooth muscle walls. Its pericytes lack cytoplasmic filaments and desmin reactivity but are SMA-positive because of the presence of poorly polymerized actin in the cytosol. In IH, Ki-67 positivity was observed in the endothelial cells of the solid and more ectatic regions. In contrast, the virtual absence of Ki-67 positivity in ECVL lends further support for the interpretation that it is more closely related to a malformation than a benign neoplasm.
C1 [Osaki, Tammy H.; Jakobiec, Frederick A.; Mendoza, Pia R.; Fay, Aaron M.] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA.
[Osaki, Tammy H.] Univ Fed Sao Paulo, Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
[Jakobiec, Frederick A.; Mendoza, Pia R.] Massachusetts Eye & Ear Infirm, David G Cogan Lab Ophthalm Pathol, Boston, MA 02114 USA.
[Lee, Yongjae] Univ Ulsan, Sch Med, Dept Ophthalmol, Ulsan 680749, South Korea.
[Fay, Aaron M.] Massachusetts Eye & Ear Infirm, Dept Ophthalm Plast & Reconstruct Surg, Boston, MA 02114 USA.
RP Jakobiec, FA (reprint author), Massachusetts Eye & Ear Infirm, David G Cogan Lab Ophthalm Pathol, Suite 328,243 Charles St, Boston, MA 02114 USA.
EM Fred_Jakobiec@meei.harvard.edu
RI Osaki, Tammy /G-1539-2016; Menezes, Isabel/D-9281-2012
NR 70
TC 8
Z9 9
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0740-9303
J9 OPHTHAL PLAST RECONS
JI Ophthalmic Plast. Reconstr. Surg.
PD MAY-JUN
PY 2013
VL 29
IS 3
BP 183
EP 195
DI 10.1097/IOP.0b013e31828b0f1f
PG 13
WC Ophthalmology; Surgery
SC Ophthalmology; Surgery
GA 142HM
UT WOS:000318788000020
PM 23584448
ER
PT J
AU Borodic, GE
AF Borodic, Gary E.
TI Use of Fillers as Adjunct Therapy for the Treatment of Lower Face
Hemifacial Spasm
SO OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY
LA English
DT Article; Proceedings Paper
CT 42nd Annual Fall Scientific Symposium of the
American-Society-of-Ophthalmic-Plastic-and-Reconstructive-Surgery
(ASOPRS)
CY OCT 21-22, 2011
CL Orlando, FL
SP Amer Soc Ophthalm Plast & Reconstruct Surg (ASOPRS)
AB The treatment of hemifacial spasm with periorbital injections of higher doses of botulinum toxin can create disfiguring and undesirable weakness in the lower face during active facial movements. The use of asymmetric hyaluronidate filler injections to the lower face provides a refinement allowing for a lowered neurotoxin dose. The filler creates a ballasting effect and involuntary facial movement. The conventional filler effect also further reduces asymmetric nasolabial folds and marionette lines. Fifteen of 18 patients with lower facial spasms found the filler toxin combination an improvement over neurotoxin alone.
C1 [Borodic, Gary E.] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Quincy, MA 02169 USA.
RP Borodic, GE (reprint author), Harvard Univ, Sch Med, 1261 Furnace Brook Pkwy,Suite 15, Quincy, MA 02169 USA.
EM borodic@aol.com
NR 4
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0740-9303
J9 OPHTHAL PLAST RECONS
JI Ophthalmic Plast. Reconstr. Surg.
PD MAY-JUN
PY 2013
VL 29
IS 3
BP 225
EP 226
DI 10.1097/IOP.0b013e318289577e
PG 2
WC Ophthalmology; Surgery
SC Ophthalmology; Surgery
GA 142HM
UT WOS:000318788000028
PM 23559346
ER
PT J
AU Yoon, MK
McCulley, TJ
AF Yoon, Michael K.
McCulley, Timothy J.
TI Secondary Tarsoconjunctival Graft: A Modification to the Cutler-Beard
Procedure
SO OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY
LA English
DT Article
ID UPPER EYELID RECONSTRUCTION; ACELLULAR DERMAL MATRIX; FREE TARSAL
GRAFTS; HARD PALATE; SURGERY; SCLERA; FLAP
AB Purpose: The Cutler-Beard procedure is a commonly used technique to reconstruct large upper eyelid defects. Eyelid retraction and entropion are common complications. To prevent these problems, the authors modified the traditional Cutler-Beard procedure with secondary placement of an autologous tarsoconjunctival graft.
Methods: This is a retrospective review of 2 patients with large upper eyelid defects necessitating upper eyelid reconstruction. The initial stage is unaltered. At the time of flap division, a tarsoconjunctival graft from the contralateral upper eyelid is sutured to the posterior surface of the newly constructed upper eyelid. Two patients underwent this procedure, and follow up was 4 and 23 months, respectively. Patients developed no postoperative complications, including entropion or retraction.
Conclusions: This modification to the Cutler-Beard operation is a technically simple procedure that can restore a more anatomically correct eyelid and can prevent subsequent entropion or retraction. This technique is unique, offering 3 major advances: first, placing the graft at the second surgical stage; second, replacing the tarsus and conjunctiva with like tissue; and third, preserving a lip of conjunctiva to cover the edge of the newly reconstructed upper eyelid.
C1 [Yoon, Michael K.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
[Yoon, Michael K.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
[McCulley, Timothy J.] Johns Hopkins Sch Med, Wilmer Eye Inst, Baltimore, MD USA.
[McCulley, Timothy J.] King Khalid Eye Specialist Hosp, Riyadh, Saudi Arabia.
RP McCulley, TJ (reprint author), Johns Hopkins Sch Med, Wilmer Eye Inst, 660 North Wolfe St,Wilmer 110, Baltimore, MD 21287 USA.
EM Tmccull5@jhmi.edu
FU Research to Prevent Blindness Inc., New York, NY, U.S.A.
FX Supported, in part, by an unrestricted grant to the Wilmer
Ophthalmological Institute by Research to Prevent Blindness Inc., New
York, NY, U.S.A.
NR 24
TC 5
Z9 5
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0740-9303
J9 OPHTHAL PLAST RECONS
JI Ophthalmic Plast. Reconstr. Surg.
PD MAY-JUN
PY 2013
VL 29
IS 3
BP 227
EP 230
DI 10.1097/IOP.0b013e3182831c84
PG 4
WC Ophthalmology; Surgery
SC Ophthalmology; Surgery
GA 142HM
UT WOS:000318788000029
PM 23446299
ER
PT J
AU Gologorsky, D
Jakobiec, FA
Freitag, SK
AF Gologorsky, Daniel
Jakobiec, Frederick A.
Freitag, Suzanne K.
TI Transconjunctival Elimination of Keratin From an Intratarsal Meibomian
Cyst
SO OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY
LA English
DT Article
ID TRANS-EPIDERMAL ELIMINATION; STEATOCYSTOMA SIMPLEX; DISORDERS; GLAND
AB An unusual example of an intratarsal meibomian keratinous cyst is described in a 69-year-old man with spontaneous transepithelial (conjunctival) elimination. The lesion created an externally visible lump in the eyelid, which on eversion was found to be accompanied by yellow-whitish protruding material with a surrounding circular mound of reactive tissue. Excision revealed a large mass and smaller fragments of anuclear keratin (trichilemmal-type) embedded and sequestered in fibrous tissue with a granulomatous response. A re-excision was required because of persistent and irritating keratinous material, contrasting with the more indolent course of an uncomplicated epidermoid cyst of the eyelid dermis. This is the first documented instance of spontaneous rupture and extrusion of a meibomian tarsal cyst's keratin contents.
C1 [Gologorsky, Daniel] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hanover, NH 03756 USA.
[Jakobiec, Frederick A.; Freitag, Suzanne K.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Cogan Lab Ophthalm Pathol, Boston, MA 02114 USA.
Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA.
RP Jakobiec, FA (reprint author), Massachusetts Eye & Ear Infirm, Cogan Lab Ophthalm Pathol, 243 Charles St,Suite 328, Boston, MA 02114 USA.
EM Fred_Jakobiec@meei.harvard.edu
NR 14
TC 3
Z9 3
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0740-9303
J9 OPHTHAL PLAST RECONS
JI Ophthalmic Plast. Reconstr. Surg.
PD MAY-JUN
PY 2013
VL 29
IS 3
BP E88
EP E91
DI 10.1097/IOP.0b013e3182771532
PG 5
WC Ophthalmology; Surgery
SC Ophthalmology; Surgery
GA 142HM
UT WOS:000318788000009
PM 23250332
ER
PT J
AU Patel, MM
Jakobiec, FA
Zakka, FR
Du, R
Annino, DJ
Borboli-Gerogiannis, S
Daniels, AB
AF Patel, Mrinali M.
Jakobiec, Frederick A.
Zakka, Fouad R.
Du, Rose
Annino, Donald J.
Borboli-Gerogiannis, Sheila
Daniels, Anthony B.
TI Intraorbital Metastasis From Solitary Fibrous Tumor
SO OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY
LA English
DT Article
ID OF-THE-LITERATURE; EXTRAOCULAR-MUSCLES; ORBIT; SYSTEM
AB Solitary fibrous tumor (SFT) is a rare spindle cell tumor of mesenchymal origin that usually arises from pleura or pericardium but can also arise from many extraserosal sites. Although more than 50 cases of primary SFT of the orbit have been reported, there are no reports to date of a malignant nonophthalmic SFT metastasizing in the orbital soft tissues (although sphenoid wing bony involvement has been reported). The authors report here the first case of a patient with intraorbital metastasis of a CD34-positive malignant SFT. The patient was a 57-year-old man with a history of malignant pleural SFT and a prior kidney metastasis. He presented with the rapid appearance of proptosis and massive conjunctival chemosis preventing eyelid closure, and he was found to have a well-circumscribed metastasis to his lateral rectus muscle. Surgical excision cured his ocular symptoms, although he died 3 months later from brain and widespread metastases.
C1 [Patel, Mrinali M.; Jakobiec, Frederick A.; Zakka, Fouad R.; Borboli-Gerogiannis, Sheila; Daniels, Anthony B.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA.
[Du, Rose] Harvard Univ, Brigham & Womens Hosp, Dept Otorhinolaryngol, Sch Med, Boston, MA 02115 USA.
[Annino, Donald J.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Otorhinolaryngol, Boston, MA 02115 USA.
RP Daniels, AB (reprint author), Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Retina Serv, 243 Charles St, Boston, MA 02114 USA.
EM anthony_daniels@meei.harvard.edu
RI Du, Rose/I-5402-2012
OI Du, Rose/0000-0003-2641-6496
NR 24
TC 2
Z9 2
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0740-9303
J9 OPHTHAL PLAST RECONS
JI Ophthalmic Plast. Reconstr. Surg.
PD MAY-JUN
PY 2013
VL 29
IS 3
BP E76
EP E79
DI 10.1097/IOP.0b013e318272f311
PG 4
WC Ophthalmology; Surgery
SC Ophthalmology; Surgery
GA 142HM
UT WOS:000318788000004
PM 23328780
ER
PT J
AU Kumar, ATN
AF Kumar, Anand T. N.
TI Fluorescence lifetime detection in turbid media using spatial frequency
domain filtering of time domain measurements
SO OPTICS LETTERS
LA English
DT Article
ID TOMOGRAPHY
AB It is demonstrated that high spatial frequency filtering of time domain fluorescence signals can allow efficient detection of intrinsic fluorescence lifetimes from turbid media and the rejection of diffuse excitation leakage. The basis of this approach is the separation of diffuse fluorescence signals into diffuse and fluorescent components with distinct spatiotemporal behavior. (C) 2013 Optical Society of America
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Athinoula A Martinos Ctr Biomed Imaging,Dept Radi, Charlestown, MA 02129 USA.
RP Kumar, ATN (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Athinoula A Martinos Ctr Biomed Imaging,Dept Radi, Charlestown, MA 02129 USA.
EM ankumar@nmr.mgh.harvard.edu
FU National Institutes of Health [R01 EB015325]
FX The author thanks Simon Arridge for useful discussions. This work was
supported by the National Institutes of Health, grant R01 EB015325.
NR 9
TC 3
Z9 3
U1 0
U2 7
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 0146-9592
J9 OPT LETT
JI Opt. Lett.
PD MAY 1
PY 2013
VL 38
IS 9
BP 1440
EP 1442
DI 10.1364/OL.38.001440
PG 3
WC Optics
SC Optics
GA 137HF
UT WOS:000318425600027
PM 23632511
ER
PT J
AU Friedlander, AH
AF Friedlander, Arthur H.
TI Carotid artery calcifications are a risk indicator for both myocardial
infarction and stroke
SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY
LA English
DT Letter
C1 [Friedlander, Arthur H.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA.
[Friedlander, Arthur H.] Ronald Reagan UCLA Med Ctr, Hosp Dent Serv, Los Angeles, CA USA.
[Friedlander, Arthur H.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA.
RP Friedlander, AH (reprint author), VA Greater Angeles Healthcare Syst, Los Angeles, CA USA.
NR 4
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 2212-4403
J9 OR SURG OR MED OR PA
JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol.
PD MAY
PY 2013
VL 115
IS 5
BP 700
EP 700
DI 10.1016/j.oooo.2013.02.003
PG 1
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 139PL
UT WOS:000318595700034
PM 23601227
ER
PT J
AU Losina, E
Daigle, ME
Suter, LG
Hunter, DJ
Solomon, DH
Walensky, RP
Jordan, JM
Burbine, SA
Paltiel, AD
Katz, JN
AF Losina, E.
Daigle, M. E.
Suter, L. G.
Hunter, D. J.
Solomon, D. H.
Walensky, R. P.
Jordan, J. M.
Burbine, S. A.
Paltiel, A. D.
Katz, J. N.
TI Disease-modifying drugs for knee osteoarthritis: can they be
cost-effective?
SO OSTEOARTHRITIS AND CARTILAGE
LA English
DT Article
DE Knee osteoarthritis; Cost-effectiveness; Quality of life;
Disease-modifying osteoarthritis drugs (DMOADs)
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PLACEBO-CONTROLLED TRIAL;
RANDOMIZED CONTROLLED-TRIAL; SURGEON PROCEDURE VOLUME; UNITED-STATES;
RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; HEALTH-STATUS; RISK; ASSOCIATION
AB Objective: Disease-modifying osteoarthritis drugs (DMOADs) are under development. Our goal was to determine efficacy, toxicity, and cost thresholds under which DMOADs would be a cost-effective knee OA treatment.
Design: We used the Osteoarthritis Policy Model, a validated computer simulation of knee OA, to compare guideline-concordant care to strategies that insert DMOADs into the care sequence. The guideline-concordant care sequence included conservative pain management, corticosteroid injections, total knee replacement (TKR), and revision TKR. Base case DMOAD characteristics included: 50% chance of suspending progression in the first year (resumption rate of 10% thereafter) and 30% pain relief among those with suspended progression; 0.5%/year risk of major toxicity; and costs of $1,000/year. In sensitivity analyses, we varied suspended progression (20-100%), pain relief (10-100%), major toxicity (0.1-2%), and cost ($1,000-$7,000). Outcomes included costs, quality-adjusted life expectancy, incremental cost-effectiveness ratios (ICERs), and TKR utilization.
Results: Base case DMOADs added 4.00 quality-adjusted life years (QALYs) and $230,000 per 100 persons, with an ICER of $57,500/QALY. DMOADs reduced need for TKR by 15%. Cost-effectiveness was most sensitive to likelihoods of suspended progression and pain relief. DMOADs costing $3,000/year achieved ICERs below $100,000/QALY if the likelihoods of suspended progression and pain relief were 20% and 70%. At a cost of $5,000, these ICERs were attained if the likelihoods of suspended progression and pain relief were both 60%.
Conclusions: Cost, suspended progression, and pain relief are key drivers of value for DMOADs. Plausible combinations of these factors could reduce need for TKR and satisfy commonly cited cost-effectiveness criteria. (C) 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
C1 [Losina, E.; Daigle, M. E.; Burbine, S. A.; Katz, J. N.] Brigham & Womens Hosp, Orthopaed & Arthrit Ctr Outcomes Res, Dept Orthoped Surg, Boston, MA 02115 USA.
[Losina, E.; Solomon, D. H.; Katz, J. N.] Brigham & Womens Hosp, Sect Clin Sci, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA.
[Losina, E.; Solomon, D. H.; Walensky, R. P.; Katz, J. N.] Harvard Univ, Sch Med, Boston, MA USA.
[Losina, E.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Suter, L. G.; Paltiel, A. D.] Yale Univ, New Haven, CT USA.
[Hunter, D. J.] Univ Sydney, Sydney, NSW 2006, Australia.
[Walensky, R. P.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA.
[Walensky, R. P.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Jordan, J. M.] Univ N Carolina, Thurston Arthrit Res Ctr, Chapel Hill, NC USA.
RP Losina, E (reprint author), Brigham & Womens Hosp, Orthopaed & Arthrit Ctr Outcomes Res, 75 Francis St,OBC 1-4016, Boston, MA 02115 USA.
EM elosina@partners.org; m.e.daigle@gmail.com; lisa.suter@yale.edu;
david.hunter@sydney.edu.au; dsolomon@partners.org;
rwalensky@partners.org; joanne_jordan@med.unc.edu;
sara.burbine@gmail.com; david.paltiel@yale.edu; jnkatz@partners.org
OI Walensky, Rochelle P./0000-0002-8795-379X
FU NIH/NIAMS [R01 AR053112, K24 AR057827]; VA Connecticut Healthcare
System; Centers for Medicare 82 Medicaid Services, an Agency of the U.S.
Department of Health and Human Services
[HHSM-500-2008-0025I/HHSM-500-T0001]
FX Supported by: NIH/NIAMS R01 AR053112, K24 AR057827, VA Connecticut
Healthcare System (Dr. Suter), and Centers for Medicare 82 Medicaid
Services, an Agency of the U.S. Department of Health and Human Services
HHSM-500-2008-0025I/HHSM-500-T0001 (Dr. Suter).
NR 66
TC 18
Z9 19
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1063-4584
J9 OSTEOARTHR CARTILAGE
JI Osteoarthritis Cartilage
PD MAY
PY 2013
VL 21
IS 5
BP 655
EP 667
DI 10.1016/j.joca.2013.01.016
PG 13
WC Orthopedics; Rheumatology
SC Orthopedics; Rheumatology
GA 136UW
UT WOS:000318389900003
PM 23380251
ER
PT J
AU Becker, SJE
Bot, AGJ
Curley, SE
Jupiter, JB
Ring, D
AF Becker, S. J. E.
Bot, A. G. J.
Curley, S. E.
Jupiter, J. B.
Ring, D.
TI A prospective randomized comparison of neoprene vs thermoplast
hand-based thumb spica splinting for trapeziometacarpal arthrosis
SO OSTEOARTHRITIS AND CARTILAGE
LA English
DT Article
DE Trapeziometacarpal arthrosis; Thumb spica splint; Orthotics; Disability;
Pain; Satisfaction
ID 1ST CARPOMETACARPAL JOINT; CONTROLLED-TRIALS; OSTEOARTHRITIS;
VALIDATION; SYMPTOMS; SCALE
AB Objective: In patients with trapeziometacarpal arthrosis, we tested the hypothesis that there is no difference in arm-specific disability 5-15 weeks after prescription of a pre-fabricated neoprene or a custom-made thermoplast hand-based thumb spica splint with the metacarpophalangeal joint included and the first interphalangeal joint free.
Method: One hundred nineteen patients with a diagnosis of trapeziometacarpal arthrosis were prospectively randomized to wear either a neoprene or a thermoplast hand-based thumb spica splint. At enrollment, patients completed a set of validated questionnaires. An average of 9 weeks later, patients returned for a second visit. Bivariable analyses assessed factors associated with disability, pain and satisfaction. Analysis was by intention-to-treat.
Results: Sixty-two patients (32 with a neoprene and 30 with a thermoplast splint) completed the study, 51 patients (43%) did not return for the second visit, and six did not complete the protocol for other reasons. Non-completers were significantly younger than completers (P < 0.00044). On average completers rated the neoprene splint as more comfortable (P = 0.048), but there were no detectable differences in Disabilities of the Arm, Shoulder and Hand (DASH), change in DASH, pain, satisfaction, pinch or grip strength between the two splint types in our sample.
Conclusion: When compared to custom-made thermoplast splints, pre-fabricated neoprene hand-based thumb spica splints are, on average, more comfortable, less expensive, and as effective in treating trapeziometacarpal arthrosis. This trial was registered at Clinicaltrials.gov (NCT00438763). (C) 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
C1 [Becker, S. J. E.; Bot, A. G. J.; Curley, S. E.; Jupiter, J. B.; Ring, D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Orthopaed Hand & Upper Extrem Serv, Boston, MA USA.
RP Becker, SJE (reprint author), Massachusetts Gen Hosp, Orthopaed Hand & Upper Extrem Serv, Yawkey Ctr, Suite 2100,55 Fruit St, Boston, MA 02114 USA.
EM sbecker1@partners.org; abot@partners.org; securley@partners.org;
jjupiter1@partners.org; dring@partners.org
RI Becker, Stephanie/N-5761-2014
FU Anna Foundation|NOREF; Genootschap Noorthey; Stichting Vreedefonds;
Prins Bernhard Cultuurfonds/Banning-de Jong fonds; VSB-fonds
FX SJEB is supported by Dutch research grants from Anna Foundation|NOREF,
Genootschap Noorthey, and Stichting Vreedefonds for scientific
research.; AGJB is supported by Dutch research grants from Anna
Foundation|NOREF, Prins Bernhard Cultuurfonds/Banning-de Jong fonds, and
VSB-fonds for scientific research.
NR 20
TC 11
Z9 11
U1 1
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1063-4584
J9 OSTEOARTHR CARTILAGE
JI Osteoarthritis Cartilage
PD MAY
PY 2013
VL 21
IS 5
BP 668
EP 675
DI 10.1016/j.joca.2013.02.006
PG 8
WC Orthopedics; Rheumatology
SC Orthopedics; Rheumatology
GA 136UW
UT WOS:000318389900004
PM 23458785
ER
PT J
AU Stefanik, JJ
Niu, J
Gross, KD
Roemer, FW
Guermazi, A
Felson, DT
AF Stefanik, J. J.
Niu, J.
Gross, K. D.
Roemer, F. W.
Guermazi, A.
Felson, D. T.
TI Using magnetic resonance imaging to determine the compartmental
prevalence of knee joint structural damage
SO OSTEOARTHRITIS AND CARTILAGE
LA English
DT Article
DE Osteoarthritis; Patellofemoral; Magnetic resonance imaging
ID BONE-MARROW LESIONS; FRAMINGHAM OSTEOARTHRITIS; PATELLOFEMORAL JOINT;
PAIN; MRI; CARTILAGE; ABNORMALITIES; LIMITATIONS
AB Objective: To describe the prevalence of magnetic resonance imaging (MRI) detected structural damage in the patellofemoral joint (PFJ) and tibiofemoral joint (TFJ) in a population-based cohort. A secondary aim was to evaluate the patterns of compartmental involvement in knees with pain, between men and women, and in different age and body mass index (BMI) categories.
Methods: We studied 970 knees, one knee per subject, from the Framingham Osteoarthritis Study, a population-based cohort study of persons 51-92 years old. Cartilage damage and bone marrow lesions (BMLs) were assessed using the Whole Organ Magnetic Resonance Imaging Score (WORMS). The prevalence of isolated PFJ, isolated TFJ, and mixed structural damage was determined using the following definitions: any cartilage damage, full thickness cartilage loss, any BML, and the combination of full thickness cartilage loss with any BML.
Results: The mean age and BMI was 63.4 years and 28.6 m/kg(2), respectively; 57% were female. Isolated PFJ damage occurred in 15-20% of knees and isolated TFJ damage occurred in 8-17% of knees depending on the definition used. The prevalence of isolated PFJ damage was greater than isolated TFJ damage using all definitions except the any BML definition. This pattern was similar between genders and among age and BMI categories. In those with knee pain, isolated PFJ was at least as common as TFJ damage depending on the definition used.
Conclusion: Using MRI to assess knee joint structural damage, isolated PFJ damage was at least as common as, if not more common than, isolated TFJ damage. (C) 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
C1 [Stefanik, J. J.; Niu, J.; Gross, K. D.; Roemer, F. W.; Guermazi, A.; Felson, D. T.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Gross, K. D.] Massachusetts Gen Hosp, Inst Hlth Profess, Boston, MA 02114 USA.
[Roemer, F. W.] Klinikum Augsburg, Augsburg, Germany.
RP Stefanik, JJ (reprint author), Boston Univ, Sch Med, Clin Epidemiol Res & Training Unit, 650 Albany St,Suite 200, Boston, MA 02118 USA.
EM stefanik@bu.edu; niujp@bu.edu; grossd@bu.edu;
frank.roemer@klinikum-augsburg.de; ali.guermazi@bu.edu; dfelson@bu.edu
OI Felson, David/0000-0002-2668-2447; Niu, Jingbo/0000-0002-6170-1965
FU Arthritis Foundation; NIH [T32AR007598, R01AG009300, P60AR020613,
R01AG018393, P60AR047785]; Genzyme; Stryker; Merck Serono; Novartis;
Astra Zeneca; National Institutes of Health
FX Dr Stefanik's work was supported by a Postdoctoral Fellowship from the
Arthritis Foundation and NIH grant T32AR007598. The Framingham
Osteoarthritis Study was supported by NIH grants R01AG009300,
P60AR020613, and R01AG018393. Drs. Stefanik, Niu, Gross, and Felson were
also supported by NIH grant P60AR047785.; Dr Guermazi has received
consultancies, speaking fees, and/or honoraria from Genzyme, Stryker,
Merck Serono, Novartis and Astra Zeneca. He is the President of Boston
Imaging Core Lab (BICL), a company providing image assessment services.
Dr Roemer is Chief Medical Officer and shareholder of BICL and has
received consultancies, speaking fees, and/or honoraria from Merck
Serono and the National Institutes of Health.
NR 21
TC 19
Z9 19
U1 2
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1063-4584
J9 OSTEOARTHR CARTILAGE
JI Osteoarthritis Cartilage
PD MAY
PY 2013
VL 21
IS 5
BP 695
EP 699
DI 10.1016/j.joca.2013.02.003
PG 5
WC Orthopedics; Rheumatology
SC Orthopedics; Rheumatology
GA 136UW
UT WOS:000318389900008
PM 23428598
ER
PT J
AU Lee, JH
Kirkham, JC
McCormack, MC
Nicholls, AM
Randolph, MA
Austen, WG
AF Lee, Jeffrey H.
Kirkham, John C.
McCormack, Michael C.
Nicholls, Alexa M.
Randolph, Mark A.
Austen, William G., Jr.
TI The Effect of Pressure and Shear on Autologous Fat Grafting
SO PLASTIC AND RECONSTRUCTIVE SURGERY
LA English
DT Article
ID CELL-ASSISTED LIPOTRANSFER; VIABILITY; BREAST; TRANSPLANTATION;
SURVIVAL; HARVEST; CORRECT
AB Background: Fat grafting has become routine in plastic surgery because of low donor-site morbidity, a low complication rate, and fast recovery time. The optimal technique, however, has yet to be defined. Two critical variables are pressure and shear, both defined as force divided by area. In this study, the authors examined the effect of pressure and shear on human fat grafts in a nude mouse model.
Methods: For negative pressure, tumescent liposuction was performed on fresh panniculectomy specimens. Suction pressure was either -15 inHg or -25 inHg. Lipoaspirate was centrifuged at 1200 g and injected into the flanks of nude mice. For positive pressure, positive pressure was applied to lipoaspirate up to 6 atm for up to 3 minutes and then injected into nude mice. For shear stress, lipoaspirate was centrifuged at 1200 g for 3 minutes and then injected with a fast flow rate (3 to 5 cc/second) or slow flow rate (0.5 to 1 cc/second). After 4 weeks, the fat grafts were analyzed for weight and histology.
Results: For negative pressure, there were no differences in weight or histology with high versus low suction pressures. For positive pressure, application of positive pressures up to 6 atm for up to 3 minutes did not create a significant difference in graft weight or histology at 4 weeks. For shear stress, in vivo, a slow injection pressure yielded a 38 percent increase in weight (p < 0.001) compared with fast injection. Histology was similarly affected.
Conclusions: Higher aspiration pressures up to -0.83 atm did not affect fat graft viability in vivo. Positive pressure up to 6 atm also did not affect fat graft viability. The degree of shear stress, which is a function of flow rate, did significantly affect fat graft viability. Fat grafts injected slowly with low shear stress significantly outperformed fat injected with high shear stress. These data suggest that shear stress is a more important variable regarding fat graft viability than pressure.
C1 [Lee, Jeffrey H.; Kirkham, John C.; McCormack, Michael C.; Nicholls, Alexa M.; Randolph, Mark A.; Austen, William G., Jr.] Massachusetts Gen Hosp, Div Plast & Reconstruct Surg, Boston, MA 02114 USA.
RP Austen, WG (reprint author), Massachusetts Gen Hosp, Div Plast & Reconstruct Surg, 15 Parkman St,WAC 435, Boston, MA 02114 USA.
EM wausten@partners.org
FU LifeCell Corp.
FX This research was partially funded by a research grant from LifeCell
Corp. All research was conducted independently within facilities at the
Massachusetts General Hospital.
NR 25
TC 39
Z9 39
U1 0
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0032-1052
J9 PLAST RECONSTR SURG
JI Plast. Reconstr. Surg.
PD MAY
PY 2013
VL 131
IS 5
BP 1125
EP 1136
DI 10.1097/PRS.0b013e3182879f4a
PG 12
WC Surgery
SC Surgery
GA 138WG
UT WOS:000318540700062
PM 23385989
ER
PT J
AU Elderon, L
Whooley, MA
AF Elderon, Larkin
Whooley, Mary A.
TI Depression and Cardiovascular Disease
SO PROGRESS IN CARDIOVASCULAR DISEASES
LA English
DT Review
DE Cardiovascular disease; Major depressive disorder; Health-related
behaviors; Diagnosis; Treatment
ID CORONARY-HEART-DISEASE; C-REACTIVE PROTEIN; RANDOMIZED-CONTROLLED-TRIAL;
QUALITY IMPROVEMENT STRATEGIES; SEROTONIN REUPTAKE INHIBITORS;
PLACEBO-CONTROLLED TRIAL; MYOCARDIAL-INFARCTION; PHYSICAL-ACTIVITY;
INFLAMMATORY MARKERS; MAJOR DEPRESSION
C1 [Elderon, Larkin] Univ Calif San Francisco, Sch Med, San Francisco, CA 94121 USA.
[Whooley, Mary A.] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94121 USA.
[Whooley, Mary A.] Univ Calif San Francisco, Sch Med, Dept Epidemiol, San Francisco, CA 94121 USA.
[Whooley, Mary A.] Univ Calif San Francisco, Sch Med, Dept Biostat, San Francisco, CA 94121 USA.
[Whooley, Mary A.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Whooley, MA (reprint author), Univ Calif San Francisco, Dept Vet Affairs Med Ctr, 4150 Clement St,111A1, San Francisco, CA 94121 USA.
EM mary.whooley@ucsf.edu
OI Elderon, Larkin/0000-0002-9620-7756
NR 136
TC 40
Z9 41
U1 4
U2 28
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0033-0620
J9 PROG CARDIOVASC DIS
JI Prog. Cardiovasc. Dis.
PD MAY-JUN
PY 2013
VL 55
IS 6
BP 511
EP 523
DI 10.1016/j.pcad.2013.03.010
PG 13
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 140OO
UT WOS:000318665000002
PM 23621961
ER
PT J
AU Edmondson, D
Cohen, BE
AF Edmondson, Donald
Cohen, Beth E.
TI Posttraumatic Stress Disorder and Cardiovascular Disease
SO PROGRESS IN CARDIOVASCULAR DISEASES
LA English
DT Review
DE Posttraumatic stress disorder; Cardiovascular disease; Myocardial
infarction; Acute coronary syndrome; Stroke; Psychosocial risk factors
ID CORONARY-HEART-DISEASE; RANDOMIZED CONTROLLED-TRIAL; C-REACTIVE PROTEIN;
MYOCARDIAL-INFARCTION PATIENTS; NATIONAL COMORBIDITY SURVEY;
QUALITY-OF-LIFE; BREAST-CANCER; MENTAL-DISORDERS; SLEEP DISTURBANCES;
HEALTH BEHAVIORS
C1 [Edmondson, Donald] Columbia Univ, Med Ctr, Dept Med, Ctr Behav Cardiovasc Hlth, New York, NY 10032 USA.
[Cohen, Beth E.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Cohen, Beth E.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Edmondson, D (reprint author), Columbia Univ, Med Ctr, 622W 168th St,PH9-317, New York, NY 10032 USA.
EM dee2109@columbia.edu
RI Edmondson, Donald/G-7486-2016
FU National Institutes of Health, Bethesda, Maryland, United States
[HL-088117, CA-156709]; Columbia University's CTSA from the National
Institutes of Health, Bethesda, Maryland, United States [UL1RR024156];
National Institutes of Health, Bethesda, MD, USA [K23 HL 094765]
FX This work was supported by grants HL-088117 and CA-156709, and in part
by Columbia University's CTSA grant No.UL1RR024156, from the National
Institutes of Health, Bethesda, Maryland, United States. Dr. Cohen was
supported by grant K23 HL 094765 from the National Institutes of Health,
Bethesda, MD, USA. Its contents are solely the responsibility of the
authors and do not necessarily represent the official view of the
National Center for Research Resources or the National Institutes of
Health.
NR 104
TC 32
Z9 32
U1 9
U2 21
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0033-0620
J9 PROG CARDIOVASC DIS
JI Prog. Cardiovasc. Dis.
PD MAY-JUN
PY 2013
VL 55
IS 6
BP 548
EP 556
DI 10.1016/j.pcad.2013.03.004
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 140OO
UT WOS:000318665000005
PM 23621964
ER
PT J
AU Dong, QX
Wang, DH
Bandyopadhyay, A
Gao, H
Gorena, KM
Hildreth, K
Rebel, VI
Walter, CA
Huang, CJ
Sun, LZ
AF Dong, Qiaoxiang
Wang, Danhan
Bandyopadhyay, Abhik
Gao, Hui
Gorena, Karla M.
Hildreth, Kim
Rebel, Vivienne I.
Walter, Christi A.
Huang, Changjiang
Sun, Lu-Zhe
TI Mammospheres from murine mammary stem cell-enriched basal cells: Clonal
characteristics and repopulating potential
SO STEM CELL RESEARCH
LA English
DT Article
ID NEUROSPHERE ASSAY; NEURAL STEM; GLAND; POPULATION; PROGENITOR
AB Identification of murine mammary stem cells (MaSCs) has been attempted with various in vitro and in vivo assays. While, the in vivo repopulation assay remains as the most definitive assay for MaSC detection, it is expensive, time-consuming, and technically challenging. The in vitro mammosphere assay was considered unreliable because of major concerns about its clonal origin. In the current study, co-culture experiments with mammary cells from fluorescent protein transgenic mice and time-lapse video microscopy revealed that >90% mammospheres formed from sorted basal epithelial-enriched cells were of clonal origin in terms of stem cell. These basal-cell derived mammospheres were further distinguished morphologically in a 3-dimensional extracellular matrix culture and functionally in the in vivo repopulation assay. Transplant of single mammospheres or the resultant 3-dimensional solid structures into gland-free mammary fat pads yielded a 70% success rate of multilineage mammary gland reconstitution. Thus, this in vitro sphere formation and differentiation assay is a reliable alternative to the in vivo repopulation assay for the study of MaSCs. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Dong, Qiaoxiang; Bandyopadhyay, Abhik; Hildreth, Kim; Rebel, Vivienne I.; Walter, Christi A.; Sun, Lu-Zhe] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78299 USA.
[Dong, Qiaoxiang; Wang, Danhan; Gao, Hui; Huang, Changjiang; Sun, Lu-Zhe] Wenzhou Med Coll, Sch Environm Sci & Publ Hlth, Univ Town, Wenzhou, Peoples R China.
[Bandyopadhyay, Abhik; Rebel, Vivienne I.; Walter, Christi A.; Sun, Lu-Zhe] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78299 USA.
[Rebel, Vivienne I.] Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78299 USA.
[Walter, Christi A.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
RP Dong, QX (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78299 USA.
EM dongq2@uthscsa.edu; sunl@uthscsa.edu
RI Huang, Changjiang/F-2644-2010; Dong, Qiaoxiang/F-1918-2010;
OI Dong, Qiaoxiang/0000-0003-4003-7919
FU NIH [R01CA75253, R01ES022057]; Bank of America Shelby Rae Tengg
Foundation; Mary Kay Foundation [082-12]; Cancer Therapy and Research
Center at University of Texas Health Science Center at San Antonio
through the NCI Cancer Center [2P30CA054174-17]
FX This work was supported in part by funding from NIH Grants R01CA75253
and R01ES022057, the Bank of America Shelby Rae Tengg Foundation, the
Mary Kay Foundation (#082-12), and the Cancer Therapy and Research
Center at University of Texas Health Science Center at San Antonio
through the NCI Cancer Center Support Grant 2P30CA054174-17 to the flow
cytometry core facility. We thank Dr. John Stingl for his kind
instruction in establishing the in vitro and in vivo assays in our
laboratory. We also thank Dr. Rong Li for the use of the Nikon
BioStation-IM.
NR 17
TC 10
Z9 11
U1 0
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1873-5061
J9 STEM CELL RES
JI Stem Cell Res.
PD MAY
PY 2013
VL 10
IS 3
BP 396
EP 404
DI 10.1016/j.scr.2013.01.007
PG 9
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA 135ZY
UT WOS:000318330400012
PM 23466563
ER
PT J
AU Surman, CBH
Hammerness, PG
Petty, C
Spencer, T
Doyle, R
Napolean, S
Chu, N
Yorks, D
Biederman, J
AF Surman, Craig B. H.
Hammerness, Paul G.
Petty, Carter
Spencer, Thomas
Doyle, Robert
Napolean, Siena
Chu, Nicole
Yorks, Dayna
Biederman, Joseph
TI A pilot open label prospective study of memantine monotherapy in adults
with ADHD
SO WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE ADHD; adults; memantine; psychopharmacology; cognition
ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY
DISORDER; EXECUTIVE FUNCTION DEFICITS; FOLLOW-UP; DOPAMINE; PREVALENCE;
IMPAIRMENTS; PERFORMANCE; MODULATION; TASK
AB Objectives. Available pharmacotherapies treat some adults with ADHD inadequately. A small literature suggests that glutamate modulation could have effects on ADHD. Methods. Memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist, was titrated to a maximum dose of 10 mg BID in 34 adult subjects aged 18-55 who met DSM-IV criteria for ADHD or ADHD NOS on structured interview. Twenty-eight subjects completed 12 weeks exposure. The Adult ADHD Investigator Symptom Report (AISRS), Clinical Global Impression (CGI), a neuropsychological battery sensitive to domains of executive function, and the CANTAB cognitive battery were administered. Paired t-tests compared treated and baseline scores. Results. At week 12, AISRS data showed reduction in total symptoms (-17.5, P < 0.001), inattentive symptoms (-10.6, P < 0.001), and hyperactive symptoms (-6.9, P < 0.01). A total of 44% of subjects had CGI ratings of much or very much improved. Cognitive performance improved in measures of attention, working memory, and other selected executive domains by weeks 6 and 12 (each P < 0.05); simple reaction time declined by week 12 (P < 0.05). There were no severe adverse events, but mild adverse events were common and six subjects discontinued due to adverse effects. Conclusions. Memantine was largely well-tolerated and associated with improvement in ADHD symptoms and neuropsychological performance. Randomized studies are indicated to confirm whether memantine is a novel therapy for ADHD across the lifespan.
C1 [Surman, Craig B. H.; Hammerness, Paul G.; Petty, Carter; Spencer, Thomas; Doyle, Robert; Napolean, Siena; Chu, Nicole; Yorks, Dayna; Biederman, Joseph] Massachusetts Gen Hosp, Clin & Res Program Pediat Psychopharmacol & Adult, Pediat Psychopharmacol Unit, Yawkey Ctr Outpatient Care, Boston, MA 02114 USA.
[Surman, Craig B. H.; Hammerness, Paul G.; Spencer, Thomas; Doyle, Robert; Biederman, Joseph] Harvard Univ, Sch Med, Boston, MA USA.
RP Surman, CBH (reprint author), Massachusetts Gen Hosp, Clin & Res Program Pediat Psychopharmacol & Adult, Suite 2000 185 Alewife Brook Pkwy, Cambridge, MA 02138 USA.
EM csurman@partners.org
FU Abbott; Alza; Cephalon; Eli Lilly; ElMinda the Hilda and Preston Davis
Foundation; McNeil; Merck; New River; Nordic Naturals National
Institutes of Health; Organon; Pfizer; Shire; Takeda; Forest; Elminda
Ltd; Bristol Myers Squibb; Glaxo-SmithKline; Johnson Johnson; Elminda;
MGH Psychiatry Academy; Department of Psychiatry at MGH; Fundacion Dr.
Manuel Camelo A. C. in Monterrey Mexico; AstraZeneca; Boston University;
Celltech; Eli Lilly and Co.; Esai; Fundacion Areces (Spain); Glaxo;
Gliatech; Hastings Center; Janssen; Medice Pharmaceuticals (Germany);
MMC Pediatric; NARSAD; NIDA; NICHD; NIMH; Novartis; Noven; Neurosearch;
Otsuka; Pharmacia; Phase V Communications; Physicians Academy; Prechter
Foundation; Quantia Communications; Reed Exhibitions; Spanish Child
Psychiatry Association; Stanley Foundation; UCB Pharma Inc.; Veritas;
Wyeth; Pediatric Psychopharmacology Council
FX Dr Surman has received research support from Abbott, Alza, Cephalon, Eli
Lilly, ElMinda the Hilda and Preston Davis Foundation, McNeil, Merck,
New River, Nordic Naturals National Institutes of Health, Organon,
Pfizer, Shire, and Takeda; has been a speaker for Janssen-Ortho, McNeil,
Novartis, Shire, and MGH Academy/Reed Medical Education (which received
funding from multiple pharmaceutical companies); and has been a
consultant/advisor for McNeil, Shire, Somaxon and Takeda.; In the past 2
years, Dr Hammerness has received research funds or participated in CME
activities/professional talks supported by the following pharmaceutical
companies: Abbott, Eli Lilly, Forest, McNeil, Shire. Dr Hammerness has
also received research funds from Elminda Ltd and has participated in
speaker training and served on the advisory board for Shire. In the past
2 years, Dr Hammerness has participated, as an investigator, in research
studies funded by the following pharmaceutical companies: Abbott,
Bristol Myers Squibb, Cephalon, Eli Lilly, Glaxo-SmithKline, Johnson &
Johnson, McNeil, Merck, New River, Organon, Pfizer, Shire, Takeda. Dr
Hammerness has also received honoraria from Reed Medical Education (a
logistics collaborator for the MGH Psychiatry Academy). Commercial
entities supporting the MGH Psychiatry Academy are listed on the
Academy's website, www.mghcme.org.; Dr. Joseph Biederman is currently
receiving research support from the following sources: Elminda, Janssen,
McNeil, and Shire.; In 2011, Dr. Joseph Biederman gave a single unpaid
talk for Juste Pharmaceutical Spain, received honoraria from the MGH
Psychiatry Academy for a tuition-funded CME course, and received an
honorarium for presenting at an international scientific conference on
ADHD. He also received an honorarium from Cambridge University Press for
a chapter publication. Dr. Biederman received depart mental royalties
from a copyrighted rating scale used for ADHD diagnoses, paid by Eli
Lilly, Shire and AstraZeneca; these royalties are paid to the Department
of Psychiatry at MGH.; In 2010, Dr. Joseph Biederman received a
speaker's fee from a single talk given at Fundacion Dr. Manuel Camelo A.
C. in Monterrey Mexico. Dr. Biederman provided single consultations for
Shionogi Pharma Inc. and Cipher Pharmaceuticals Inc.; the honoraria for
these consultations were paid to the Department of Psychiatry at the
MGH. Dr. Biederman received honoraria from the MGH Psychiatry Academy
for a tuition- funded CME course.; In previous years, Dr. Joseph
Biederman received research support, consultation fees, or speaker's
fees for/ from the following additional sources: Abbott, Alza,
AstraZeneca, Boston University, Bristol Myers Squibb, Celltech,
Cephalon, Eli Lilly and Co., Esai, Fundacion Areces (Spain), Forest,
Glaxo, Gliatech, Hastings Center, Janssen, McNeil, Medice
Pharmaceuticals (Germany), Merck, MMC Pediatric, NARSAD, NIDA, New
River, NICHD, NIMH, Novartis, Noven, Neurosearch, Organon, Otsuka,
Pfizer, Pharmacia, Phase V Communications, Physicians Academy, The
Prechter Foundation, Quantia Communications, Reed Exhibitions, Shire,
the Spanish Child Psychiatry Association, The Stanley Foundation, UCB
Pharma Inc., Veritas, and Wyeth.; This work has been funded in part by
the Pediatric Psychopharmacology Council.
NR 40
TC 8
Z9 10
U1 1
U2 6
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1562-2975
J9 WORLD J BIOL PSYCHIA
JI World J. Biol. Psychiatry
PD MAY
PY 2013
VL 14
IS 4
BP 291
EP 298
DI 10.3109/15622975.2011.623716
PG 8
WC Psychiatry
SC Psychiatry
GA 140JR
UT WOS:000318650900006
PM 22436083
ER
PT J
AU Hammerness, P
Zusman, R
Systrom, D
Surman, C
Baggish, A
Schillinger, M
Shelley-Abrahamson, R
Wilens, TE
AF Hammerness, Paul
Zusman, Randall
Systrom, David
Surman, Craig
Baggish, Aaron
Schillinger, Mary
Shelley-Abrahamson, Rachel
Wilens, Timothy E.
TI A cardiopulmonary study of lisdexamfetamine in adults with
attention-deficit/hyperactivity disorder
SO WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Cardiac; cardiopulmonary; lisdexamfetamine; ADHD; stimulant
ID SERIOUS CARDIOVASCULAR EVENTS; HEART-RATE RECOVERY; BLOOD-PRESSURE;
FOLLOW-UP; ADHD; RECOMMENDATIONS; STIMULANTS; PREVALENCE; CHILDREN;
DEATH
AB Objectives. Due to concerns about the safety of stimulants for ADHD, novel assessments of the cardiopulmonary impact of these agents are needed. Methods. An open design of lisdexamfetamine (LDX) in 15 adults with DSM-IV ADHD. Following a psychiatric evaluation and medical history, subjects underwent echocardiography (TTE) and cardiopulmonary exercise testing (CPET). LDX was titrated to 70 mg daily over 6 weeks, followed by monthly visits to 6 months. Change in TTE and CPET measures were examined following up to 6 months of LDX. Results. At endpoint, there were no significant alterations in indices of cardiac systolic performance, or in metabolic and ventilatory variables at maximum exertion (P values > 0.05). We found significant mean changes in resting LV systolic dimension and Doppler diastolic indices. Change in heart rate recovery at 1 min met statistical significance (P = 0.05). Conclusions. We did not detect clinically meaningful changes in cardiac structure and function or in metabolic and ventilatory variables at maximum exertion in ADHD adults receiving open LDX. The clinical significance of changes in resting LV dimension and indices of diastolic function are not in the direction of cardiomyopathy. Future large sample controlled study can examine these findings, as well as stimulants' impact on heart rate recovery.
C1 [Hammerness, Paul; Surman, Craig; Schillinger, Mary; Shelley-Abrahamson, Rachel; Wilens, Timothy E.] Massachusetts Gen Hosp, Clin & Res Program Pediat Psychopharmacol & Adult, Cambridge, MA USA.
[Zusman, Randall; Baggish, Aaron] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA.
[Systrom, David] Massachusetts Gen Hosp, Dept Med, Div Pulm & Crit Care Med, Boston, MA 02114 USA.
RP Hammerness, P (reprint author), 185 Alewife Brook Pkwy,Suite 2000, Cambridge, MA 02138 USA.
EM phammerness@partners.org
OI Systrom, David/0000-0002-9610-6330
FU Shire Pharmaceutical; Cephalon; Forest; GlaxoSmithKline; Johnson
Johnson; McNeil; Novartis; Ortho-McNeil Janssen; Shire; Takeda
Pharmaceuticals; Elminda Ltd.; Abbott; Alza; Eli Lilly; Hilda and
Preston Davis Foundation; Merck; New River; Nordic Naturals; Organon;
Pfizer; Takeda; Lilly; Shire Pharma
FX Source of Funding: Investigator Initiated Study funded by Shire
Pharmaceutical (P. Hammerness, PI). Dr. Hammerness: in the past 12
months, Dr Hammerness has participated in CME activities/writing
supported by Shire Pharmaceuticals. Dr Hammerness has participated, as
an investigator/principal investigator, in research studies funded by
the following companies: Cephalon, Forest, GlaxoSmithKline, Johnson &
Johnson, McNeil, Novartis, Ortho-McNeil Janssen, Shire, Takeda
Pharmaceuticals and Elminda Ltd. Dr Hammerness has also received
honoraria from commercial entities supporting the MGH Psychiatry
Academy, www.mghcme.org. Dr Zusman: no disclosures related to this
project. Dr Systrom: No disclosures related to this project. Dr Surman
has received research support from the following: Abbott, Alza,
Cephalon, Eli Lilly, the Hilda and Preston Davis Foundation, McNeil,
Merck, New River, Nordic Naturals, Organon, Pfizer, Shire, and Takeda;
has been a speaker for Janssen-Ortho, McNeil, Novartis, and Shire; and
has been a consultant/advisor to McNeil, Shire, Somaxon and Takeda. Dr
Baggish, Ms Schillinger and Ms Shelley-Abrahamson: no disclosures
related to this project. Dr Wilens receives or has received grant
support from: Abbott, McNeil, Lilly, Merck, and Shire Pharma. Dr Wilens
has been a speaker for the following companies: Lilly, McNeil, Novartis,
Shire Pharma. Dr Wilens is or has been a consultant for: Abbott,
Astra-Zeneca, Euthymics, McNeil, Lilly, NIH, Novartis, Merck, Shire
Pharma. Dr Wilens has a published book with Guilford Press.
NR 34
TC 5
Z9 5
U1 0
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1562-2975
EI 1814-1412
J9 WORLD J BIOL PSYCHIA
JI World J. Biol. Psychiatry
PD MAY
PY 2013
VL 14
IS 4
BP 299
EP 306
DI 10.3109/15622975.2012.678884
PG 8
WC Psychiatry
SC Psychiatry
GA 140JR
UT WOS:000318650900007
PM 22559155
ER
PT J
AU Coverdale, JH
Balon, R
Beresin, EV
Louie, AK
Tait, GR
Roberts, LW
AF Coverdale, John H.
Balon, Richard
Beresin, Eugene V.
Louie, Alan K.
Tait, Glendon R.
Roberts, Laura W.
TI An Argument for Conducting Methodologically Strong, Randomized,
Controlled Trials in Educational Research
SO ACADEMIC PSYCHIATRY
LA English
DT Editorial Material
ID MEDICAL-EDUCATION; CRITICAL-APPRAISAL; CLINICAL-TRIALS; READERS GUIDE;
DESIGN; QUALITY; COHORT
C1 [Coverdale, John H.] Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Balon, Richard] Univ Psychiat Centrum St Jozef, Detroit, MI USA.
[Beresin, Eugene V.] Harvard Univ, Dept Psychiat, Mass Gen Hosp, Boston, MA 02115 USA.
[Louie, Alan K.; Roberts, Laura W.] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA.
[Tait, Glendon R.] Univ Toronto, Toronto Gen Hosp, Dept Psychiat, Toronto, ON M5G 1L7, Canada.
RP Coverdale, JH (reprint author), Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
EM jhc@bcm.tmc.edu
NR 33
TC 1
Z9 1
U1 1
U2 3
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1042-9670
J9 ACAD PSYCHIATR
JI Acad. Psych.
PD MAY-JUN
PY 2013
VL 37
IS 3
BP 145
EP 149
PG 5
WC Education & Educational Research; Psychiatry
SC Education & Educational Research; Psychiatry
GA 137SY
UT WOS:000318459000001
PM 23632922
ER
PT J
AU Axelrad, JE
Mimiaga, MJ
Grasso, C
Mayer, KH
AF Axelrad, Jordan E.
Mimiaga, Matthew J.
Grasso, Chris
Mayer, Kenneth H.
TI Trends in the Spectrum of Engagement in HIV Care and Subsequent Clinical
Outcomes Among Men Who Have Sex with Men (MSM) at a Boston Community
Health Center
SO AIDS PATIENT CARE AND STDS
LA English
DT Article
ID UNITED-STATES; ANTIRETROVIRAL THERAPY; INFECTED PERSONS; MEDICAL-CARE;
PREVENTION; HIV/AIDS; PREVALENCE; DIAGNOSIS; SETTINGS
AB Despite known benefits, only 19-28% of HIV-infected Americans are virologically suppressed (defined as <= 200 copies/mL). Engagement in HIV care represents a continuum from patients unaware they are infected to virological suppression. The electronic medical record of all newly diagnosed HIV-infected MSM seen at Fenway Health between 2000 and 2010 were reviewed. Patients were "engaged'' if they had one negative HIV test and/or one physical exam within 24 months prior to their HIV diagnosis (n = 291). All others were considered "new'' (n = 463). MSM engaged in care prior to HIV diagnosis were more often identified in acute retroviral syndrome or on routine screening, more rapidly linked to care, and less often diagnosed with a concomitant STI than those who were not engaged in care. Nearly 19% of all patients were diagnosed with AIDS the same time they were diagnosed with HIV. Blacks and those with higher CD4 counts at diagnosis were less likely to be virologically suppressed at 1 year. Between 2000 and 2010, patients retained in care were more likely to initiate ART and be virologically suppressed within 1 year independent of initial HIV viral load and CD4 count. Engagement in care prior to seroconversion influences important HIV outcomes. Programs that care for at risk populations should institute routine opt-out HIV testing and test-and-treat programs to optimize HIV care and prevention.
C1 [Axelrad, Jordan E.; Mimiaga, Matthew J.; Grasso, Chris; Mayer, Kenneth H.] Fenway Hlth, Fenway Inst, Boston, MA USA.
[Axelrad, Jordan E.] Tufts Univ, Sch Med, Dept Publ Hlth & Community Med, Boston, MA 02111 USA.
[Axelrad, Jordan E.] Mt Sinai Hosp, Dept Internal Med, New York, NY 10029 USA.
[Mimiaga, Matthew J.] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Mimiaga, Matthew J.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Mayer, Kenneth H.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Infect Dis, Boston, MA 02215 USA.
RP Axelrad, JE (reprint author), Mt Sinai Hosp, Dept Med, Box 1118 1 Gustave L Levy Pl, New York, NY 10029 USA.
EM Jordan.Axelrad@mountsinai.org
OI Axelrad, Jordan/0000-0003-1951-7790
FU Harvard Center for AIDS Research [NIAID 5P30AI06354-08]
FX Sources of support: Harvard Center for AIDS Research (NIAID
5P30AI06354-08).
NR 32
TC 15
Z9 15
U1 3
U2 7
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1087-2914
J9 AIDS PATIENT CARE ST
JI Aids Patient Care STDS
PD MAY
PY 2013
VL 27
IS 5
BP 287
EP 296
DI 10.1089/apc.2012.0471
PG 10
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 138YA
UT WOS:000318546600005
PM 23651106
ER
PT J
AU Peyko, V
Cohen, V
Jellinek-Cohen, SP
Pearl-Davis, M
AF Peyko, Vincent
Cohen, Victor
Jellinek-Cohen, Samantha P.
Pearl-Davis, Michelle
TI Evaluation and treatment of accidental autoinjection of epinephrine
SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
LA English
DT Article
ID ADRENALINE; INJECTION; ISCHEMIA
AB Purpose. A case of accidental autoinjection. of epinephrine is described.
Summary. A 47-year-old man arrived at the emergency department after accidental injection of epinephrine with an autoinjector into his left thumb. His vital signs were stable at admission. The patient was allergic to nuts and thought he may have eaten something containing a pine nut, The patient reported feeling itching in his throat but had no shortness of breath or swollen tongue. He tried to self-administer an epinephrine injection, but it did not inject. While he was checking the device, it accidently injected into his left thumb pad. A review of systems revealed throat discomfort, a tingling sensation of the tongue, and a left-thumb puncture with pain. Physical examination of the left thumb pad revealed a pale, cool thumb with diminished capillary refill and punctuate black discoloration at the site of injection. Topical nitroglycerin paste was applied but had no effect, so terbutaline was ordered. The terbutaline injection was prepared as a 1:1 preparation of terbutaline sulfate 1 mg/mL and 0.9% sodium chloride injection. The immediate effects were the return of color from pale white to red and observable perfusion to the area within seconds. After 20 minutes, the red color remained, with observable perfusion and warmth, in addition to complete neurosensory function. Sixty minutes after terbutaline administration, the patient was discharged home.
Conclusion. A 47-year-old man who accidentally injected himself in the thumb with an epinephrine autoinjector was successfully treated with subcutaneous terbutaline. The treatment had an immediate effect, including revascularization and resolution of pain.
C1 [Peyko, Vincent] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
[Peyko, Vincent] Maimonides Hosp, Dept Pharmaceut Serv, Brooklyn, NY 11219 USA.
[Cohen, Victor] Long Isl Univ, Arnold & Marie Schwartz Coll Pharm & Hlth Sci, Brooklyn, NY USA.
[Jellinek-Cohen, Samantha P.] St Johns Univ, Coll Pharm & Hlth Sci, Queens, NY 11439 USA.
[Pearl-Davis, Michelle] Maimonides Hosp, Dept Emergency Med, Brooklyn, NY 11219 USA.
RP Jellinek-Cohen, SP (reprint author), St Johns Univ, Coll Pharm & Hlth Sci, 8000 Utopia Pkwy, Queens, NY 11439 USA.
EM jellines@stjohns.edu
NR 15
TC 3
Z9 3
U1 0
U2 3
PU AMER SOC HEALTH-SYSTEM PHARMACISTS
PI BETHESDA
PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA
SN 1079-2082
J9 AM J HEALTH-SYST PH
JI Am. J. Health-Syst. Pharm.
PD MAY 1
PY 2013
VL 70
IS 9
BP 778
EP 781
DI 10.2146/ajhp120316
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 137WQ
UT WOS:000318469300010
PM 23592360
ER
PT J
AU Stroupe, KT
Smith, BM
Hogan, TP
St Andre, JR
Gellad, WF
Weiner, S
Lee, TA
Burk, M
Cunningham, F
Piette, JD
Rogers, TJ
Huo, ZP
Weaver, FM
AF Stroupe, Kevin T.
Smith, Bridget M.
Hogan, Timothy P.
St Andre, Justin R.
Gellad, Walid F.
Weiner, Saul
Lee, Todd A.
Burk, Muriel
Cunningham, Francesca
Piette, John D.
Rogers, Thea J.
Huo, Zhiping
Weaver, Frances M.
TI Medication acquisition across systems of care and patient-provider
communication among older veterans
SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
LA English
DT Article
ID HEALTH-CARE; HEART-FAILURE; ADULTS; DISCREPANCIES; HYPERTENSION;
INFORMATION; OUTCOMES; COSTS
AB Purpose. The results of a survey assessing Medicare Part D enrollment, the use of pharmacotherapies for chronic diseases, and other medication-use issues in a population of elderly military veterans are presented.
Methods. Medicare-eligible (i.e., >= 65 years of age) patients with documented recent service use at a single Veterans Affairs (VA) medical center were targeted for a mail survey. Women were oversampled (20%) to ensure an adequate sample size; the sample was weighted to adjust for this oversampling. Usable survey data were received from 458 survey respondents.
Results. Nearly all respondents (93.2%) reported having one or more chronic conditions; of those, 93.3% reported regular use of multiple drug therapies, and 30.1% reported using medications prescribed by both VA and non-VA providers for the same chronic condition. About half of the survey respondents reported at least one office visit with a non-VA physician during the previous year, and 55.8% reported obtaining medications from non-VA pharmacies. More than half (54.1%) of the respondents reported non-VA medication coverage, with 21.2% indicating they were enrolled in Medicare Part D. Among the respondents who reported obtaining medications from non-VA pharmacies, substantial proportions reported discussing those medications with VA physicians never (38.4%) or infrequently (15.7%).
Conclusion. Although large proportions of Medicare-eligible veterans take multiple medications and use non-VA health care services and pharmacies, many do not discuss medications obtained outside the VA system with VA physicians, suggesting that increased efforts to enhance provider patient communication and medication reconciliation across VA and non-VA systems of care may be warranted.
C1 [Stroupe, Kevin T.; Smith, Bridget M.] Edward Hines Jr VA Vet Affairs Hosp, Ctr Management Complex Chron Care CMC3, Hines, IL USA.
[Hogan, Timothy P.] Edith Nourse Rogers Mem Vet Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA.
[Hogan, Timothy P.] Edith Nourse Rogers Mem Vet Hosp, Natl eHlth QUERI Coordinating Ctr, eHlth Qual Enhancement Res Initiat QUERI, Bedford, MA USA.
[St Andre, Justin R.] Hlth Res & Educ Trust, Chicago, IL USA.
[Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Gellad, Walid F.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Lee, Todd A.] Univ Illinois, Chicago, IL USA.
[Cunningham, Francesca] Edward Hines Jr VA Hosp, VA Pharm Benefit Management Strateg Healthcare Gr, Hines, IL 60141 USA.
[Piette, John D.] Univ Michigan, Ctr Clin Management Res, Ann Arbor, MI 48109 USA.
RP Stroupe, KT (reprint author), Edward Hines Jr VA Hosp, Ctr Management Complex Chron Care, 5000 South 5th Ave 151H, Hines, IL 60141 USA.
EM kevin.stroupe@va.gov
FU Office of Research and Development, Veterans Health Administration,
Department of Veterans Affairs; Center for Management of Complex Chronic
Care, Edward Hines, Jr. VA Hospital; VA Health Services Research and
Development [PPO 09-396]
FX Supported in part by the Office of Research and Development, Veterans
Health Administration, Department of Veterans Affairs; the Center for
Management of Complex Chronic Care, Edward Hines, Jr. VA Hospital; and
VA Health Services Research and Development grant PPO 09-396.
NR 31
TC 6
Z9 6
U1 0
U2 7
PU AMER SOC HEALTH-SYSTEM PHARMACISTS
PI BETHESDA
PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA
SN 1079-2082
J9 AM J HEALTH-SYST PH
JI Am. J. Health-Syst. Pharm.
PD MAY 1
PY 2013
VL 70
IS 9
BP 804
EP 813
DI 10.2146/ajhp120222
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 137WQ
UT WOS:000318469300013
PM 23592363
ER
PT J
AU Glasgow, JM
Yano, EM
Kaboli, PJ
AF Glasgow, Justin M.
Yano, Elizabeth M.
Kaboli, Peter J.
TI Impacts of Organizational Context on Quality Improvement
SO AMERICAN JOURNAL OF MEDICAL QUALITY
LA English
DT Article
DE quality improvement; data mining; organizational characteristics;
Veterans Affairs
ID OF-THE-LITERATURE; PATIENT SAFETY; HEALTH-CARE; MODEL; COLLABORATIVES;
HOSPITALS; SUCCESS
AB Variation in how hospitals perform on similar quality improvement (QI) efforts argues for a need to understand how different organizational characteristics affect QI performance. The objective of this study was to use data-mining methods to evaluate relationships between measures of organizational characteristics and hospital QI performance. Organizational characteristics were extracted from 2 surveys and analyzed in 3 separate decision-tree models.The decision trees did not find any predictive associations in this sample of 100 hospitals participating in a national QI collaborative. Further model review identified that measures of QI Experience were associated with an ability to make improvements, whereas measures of Staffing and Culture were associated with an ability to sustain improvements. A key area for future research is to understand the challenges faced as QI teams transition from improving care to sustaining quality and to ascertain what organizational characteristics can best overcome those challenges.
C1 [Glasgow, Justin M.; Kaboli, Peter J.] Iowa City VA Healthcare Syst, Iowa City, IA 52246 USA.
[Glasgow, Justin M.] Univ Iowa, Inst Clin & Translat Sci, Iowa City, IA USA.
[Yano, Elizabeth M.] VA Greater Los Angeles, Ctr Excellence Study Healthcare Provider Behav, Sepulveda, CA USA.
[Yano, Elizabeth M.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA.
[Kaboli, Peter J.] Univ Iowa, Carver Coll Med, Iowa City, IA USA.
RP Glasgow, JM (reprint author), Iowa City VA Healthcare Syst, 601 Highway 6 West,Mailstop 152, Iowa City, IA 52246 USA.
EM justin.glasgow@va.gov
FU University of Iowa Institute for Clinical and Translational Science
[5TL1 RR024981-03]; Department of Veterans Affairs; Veterans Health
Administration; Health Services Research and Development (HSR&D) Service
through the Comprehensive Access and Delivery Research and Evaluation
(CADRE) Center [HFP 04-149]; Veterans Administration (VA) HSR&D Research
Career Scientist Award [RCS 05-195]; VA HSRD; VA Office of Quality and
Performance
FX The authors disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: The work
reported here was supported by a TL1 award from the University of Iowa
Institute for Clinical and Translational Science (5TL1 RR024981-03) and
the Department of Veterans Affairs, Veterans Health Administration,
Health Services Research and Development (HSR&D) Service through the
Comprehensive Access and Delivery Research and Evaluation (CADRE) Center
(HFP 04-149). Dr Yano's effort was funded by a Veterans Administration
(VA) HSR&D Research Career Scientist Award (RCS 05-195). The VA Clinical
Practice Organizational Survey was cosponsored by VA HSR&D and the VA
Office of Quality and Performance.
NR 29
TC 4
Z9 4
U1 3
U2 14
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1062-8606
J9 AM J MED QUAL
JI Am. J. Med. Qual.
PD MAY-JUN
PY 2013
VL 28
IS 3
BP 196
EP 205
DI 10.1177/1062860612456730
PG 10
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 136QY
UT WOS:000318379700002
PM 22942122
ER
PT J
AU Chen, Q
Borzecki, AM
Cevasco, M
Shin, MH
Shwartz, M
Itani, KMF
Rosen, AK
AF Chen, Qi
Borzecki, Ann M.
Cevasco, Marisa
Shin, Marlena H.
Shwartz, Michael
Itani, Kamal M. F.
Rosen, Amy K.
TI Examining the Relationship Between Processes of Care and Selected AHRQ
Patient Safety Indicators Postoperative Wound Dehiscence and Accidental
Puncture or Laceration Using the VA Electronic Medical Record
SO AMERICAN JOURNAL OF MEDICAL QUALITY
LA English
DT Article
DE AHRQ Patient Safety Indicators; processes of care; postoperative wound
dehiscence; accidental puncture or laceration
ID REFLECT DIFFERENCES; QUALITY INDICATORS; IATROGENIC DISEASE; PLEURAL
PROCEDURES; VETERANS; SURGERY; COMPLICATIONS; TIME; EXPLICIT; EVENTS
AB This study examines whether Agency for Healthcare Research and Quality Patient Safety Indicators (PSIs) Postoperative Wound Dehiscence (PWD) and Accidental Puncture or Laceration (APL) events reflect problems with hospital processes of care (POC).The authors randomly selected 112 PSI-flagged PWD/APL discharges from 2002-2007 VA administrative data, identified true cases using chart review, and matched cases with controls.This yielded a total of 95 case-control pairs per PSI. Patient information and clinical processes on each case-control pair were abstracted from the electronic medical record (EMR).Although PWD cases and controls differed on incision and closure types,APL cases and controls were comparable in examined processes. Further exploration of the process differences between PWD cases and controls indicated that they were primarily caused by patients' underlying surgical problems rather than quality of care shortfalls. Documentation of POC was frequently missing in EMRs. Future studies should combine EMR review with alternative approaches, such as direct observation, to better assess POC.
C1 [Chen, Qi; Cevasco, Marisa; Shin, Marlena H.; Shwartz, Michael; Itani, Kamal M. F.; Rosen, Amy K.] VA Boston Healthcare Syst, Boston, MA 02130 USA.
[Chen, Qi; Borzecki, Ann M.; Shwartz, Michael; Itani, Kamal M. F.; Rosen, Amy K.] Boston Univ, Boston, MA 02215 USA.
[Borzecki, Ann M.] Bedford VAMC, Bedford, MA USA.
[Cevasco, Marisa; Itani, Kamal M. F.] Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Chen, Q (reprint author), VA Boston Healthcare Syst, Ctr Org Leadership & Management Res COLMR, 150 S Huntington Ave, Boston, MA 02130 USA.
EM qc2112@bu.edu
FU Department of Veterans Affairs Health Services Research and Development
Service [SDR 07-002]
FX The authors disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: This study was
supported by the Department of Veterans Affairs Health Services Research
and Development Service (Grant Number SDR 07-002).
NR 40
TC 2
Z9 2
U1 1
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1062-8606
J9 AM J MED QUAL
JI Am. J. Med. Qual.
PD MAY-JUN
PY 2013
VL 28
IS 3
BP 206
EP 213
DI 10.1177/1062860612459070
PG 8
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 136QY
UT WOS:000318379700003
PM 23007377
ER
PT J
AU Hosokawa, S
Koseki, H
Nagashima, M
Maeyama, Y
Yomogida, K
Mehr, C
Rutledge, M
Greenfeld, H
Kaneki, M
Tompkins, RG
Martyn, JAJ
Yasuhara, SE
AF Hosokawa, Sachiko
Koseki, Hiroaki
Nagashima, Michio
Maeyama, Yoshihiro
Yomogida, Kentaro
Mehr, Chelsea
Rutledge, Madeleine
Greenfeld, Hannah
Kaneki, Masao
Tompkins, Ronald G.
Martyn, J. A. Jeevendra
Yasuhara, Shingo E.
TI Title efficacy of phosphodiesterase 5 inhibitor on distant burn-induced
muscle autophagy, microcirculation, and survival rate
SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
LA English
DT Article
DE muscle wasting; burn injury; phosphodiesterase 5 inhibitor; sildenafil;
tadalafil; vardenafil; autophagy; skeletal muscle; in vivo microscopy;
Atg8/LC3; autophagosome turnover and maturation
ID NITRIC-OXIDE; MUSCULAR-DYSTROPHY; OXIDATIVE STRESS; RELAXING FACTOR;
INJURY; SILDENAFIL; APOPTOSIS; PROTEIN; MICROSCOPY; LC3
AB Skeletal muscle wasting is an exacerbating factor in the prognosis of critically ill patients. Using a systemic burn injury model in mice, we have established a role of autophagy in the resulting muscle wasting that is distant from the burn trauma. We provide evidence that burn injury increases the autophagy turnover in the distal skeletal muscle by conventional postmortem tissue analyses and by a novel in vivo microscopic method using an autophagy reporter gene (tandem fluorescent LC3). The effect of tadalafil, a phosphodiesterase 5 inhibitor (PDE5I), on burn-induced skeletal muscle autophagy is documented and extends our published results that PDE5Is attenuates muscle degeneration in a muscular dystrophy model. We also designed a translational experiment to examine the impact of PDE5I on whole body and demonstrated that PDE5I administration lessened muscle atrophy, mitigated microcirculatory disturbance, and improved the survival rate after burn injury.
C1 [Hosokawa, Sachiko; Koseki, Hiroaki; Nagashima, Michio; Maeyama, Yoshihiro; Yomogida, Kentaro; Mehr, Chelsea; Rutledge, Madeleine; Greenfeld, Hannah; Kaneki, Masao; Tompkins, Ronald G.; Martyn, J. A. Jeevendra; Yasuhara, Shingo E.] Massachusetts Gen Hosp, Shriners Hosp Children, Dept Anesthesiol & Crit Care & Pain Med, Boston, MA 02114 USA.
[Hosokawa, Sachiko; Koseki, Hiroaki; Nagashima, Michio; Maeyama, Yoshihiro; Yomogida, Kentaro; Mehr, Chelsea; Rutledge, Madeleine; Greenfeld, Hannah; Kaneki, Masao; Tompkins, Ronald G.; Martyn, J. A. Jeevendra; Yasuhara, Shingo E.] Harvard Univ, Sch Med, Boston, MA USA.
RP Yasuhara, SE (reprint author), Massachusetts Gen Hosp, Shriners Hosp Children, 51 Blossom St, Boston, MA 02114 USA.
EM shingo_yasuhara@yahoo.com
OI Nagashima, Michio/0000-0001-7416-5367
FU Shriners Research grant
FX This work is supported by a Shriners Research grant.
NR 52
TC 13
Z9 13
U1 0
U2 3
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193-1849
J9 AM J PHYSIOL-ENDOC M
JI Am. J. Physiol.-Endocrinol. Metab.
PD MAY
PY 2013
VL 304
IS 9
BP E922
EP E933
DI 10.1152/ajpendo.00078.2013
PG 12
WC Endocrinology & Metabolism; Physiology
SC Endocrinology & Metabolism; Physiology
GA 137ZA
UT WOS:000318476000002
PM 23512808
ER
PT J
AU Steenkamp, MM
Nash, WP
Litz, BT
AF Steenkamp, Maria M.
Nash, William P.
Litz, Brett T.
TI Post-Traumatic Stress Disorder Review of the Comprehensive Soldier
Fitness Program
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Review
ID UK ARMED-FORCES; MENTAL-HEALTH; SYMPTOMS; INTERVENTION; ADOLESCENTS;
AFGHANISTAN; PSYCHOLOGY; SCIENCE; TRAUMA; FUTURE
AB Since the start of the wars in Afghanistan and Iraq, the U.S. military has implemented several population-based initiatives to enhance psychological resilience and prevent psychological morbidity in troops. The largest of these initiatives is the Army's Comprehensive Soldier Fitness (CSF) program, which has been disseminated to more than 1 million soldiers. However, to date, CSF has not been independently and objectively reviewed, and the degree to which it successfully promotes adaptive outcomes and prevents the development of deployment-related mental health disorders such as post-traumatic stress disorder (PTSD) is uncertain. This paper critically evaluates the theoretic foundation for and evidence supporting the use of CSF. (Am J Prev Med 2013;44(5):507-512) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine
C1 [Steenkamp, Maria M.; Litz, Brett T.] Boston Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA 02118 USA.
[Steenkamp, Maria M.; Litz, Brett T.] Boston Univ, Sch Med, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA 02118 USA.
[Litz, Brett T.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA.
[Nash, William P.] Boston VA Res Inst, Boston, MA USA.
RP Steenkamp, MM (reprint author), Boston Vet Affairs Med Ctr, 150 South Huntington Ave 13B-73, Boston, MA 02130 USA.
EM maria.steenkamp2@va.gov
NR 35
TC 14
Z9 16
U1 2
U2 32
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0749-3797
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD MAY
PY 2013
VL 44
IS 5
BP 507
EP 512
DI 10.1016/j.amepre.2013.01.013
PG 6
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA 128XS
UT WOS:000317803600012
PM 23597815
ER
PT J
AU Greenwood, TA
Swerdlow, NR
Gur, RE
Cadenhead, KS
Calkins, ME
Dobie, DJ
Freedman, R
Green, MF
Gur, RC
Lazzeroni, LC
Nuechterlein, KH
Olincy, A
Radant, AD
Ray, A
Schork, NJ
Seidman, LJ
Siever, LJ
Silverman, JM
Stone, WS
Sugar, CA
Tsuang, DW
Tsuang, MT
Turetsky, BI
Light, GA
Braff, DL
AF Greenwood, Tiffany A.
Swerdlow, Neal R.
Gur, Raquel E.
Cadenhead, Kristin S.
Calkins, Monica E.
Dobie, Dorcas J.
Freedman, Robert
Green, Michael F.
Gur, Ruben C.
Lazzeroni, Laura C.
Nuechterlein, Keith H.
Olincy, Ann
Radant, Allen D.
Ray, Amrita
Schork, Nicholas J.
Seidman, Larry J.
Siever, Larry J.
Silverman, Jeremy M.
Stone, William S.
Sugar, Catherine A.
Tsuang, Debby W.
Tsuang, Ming T.
Turetsky, Bruce I.
Light, Gregory A.
Braff, David L.
TI Genome-Wide Linkage Analyses of 12 Endophenotypes for Schizophrenia From
the Consortium on the Genetics of Schizophrenia
SO AMERICAN JOURNAL OF PSYCHIATRY
LA English
DT Article
ID SUSCEPTIBILITY LOCUS; PREPULSE INHIBITION; CANDIDATE GENES;
WORKING-MEMORY; FOLLOW-UP; ANTISACCADE PERFORMANCE; CHROMOSOME-15 LOCUS;
POTENTIAL LINKAGE; COMPLEX DISEASES; ASSOCIATION
AB Objective: The Consortium on the Genetics of Schizophrenia has undertaken a large multisite study to characterize 12 neurophysiological and neurocognitive endophenotypic measures as a step toward understanding the complex genetic basis of schizophrenia. The authors previously demonstrated the heritability of these endophenotypes; in the present study, genetic linkage was evaluated.
Method: Each family consisted of a proband with schizophrenia, at least one unaffected sibling, and both parents. A total of 1,286 participants from 296 families were genotyped in two phases, and 1,004 individuals were also assessed for the endophenotypes. Linkage analyses of the 6,055 single-nucleotide polymorphisms that were successfully assayed, 5,760 of which were common to both phases, were conducted using both variance components and pedigree-wide regression methods.
Results: Linkage analyses of the 12 endophenotypes collectively identified one region meeting genome-wide significance criteria, with a LOD (log of odds) score of 4.0 on chromosome 3p14 for the antisaccade task, and another region on 1p36 nearly meeting genome-wide significance, with a LOD score of 3.5. for emotion recognition. Chromosomal regions meeting genome-wide suggestive criteria with LOD scores >2.2 were identified for spatial processing (2p25 and 16q23), sensorimotor dexterity (2q24 and 2q32), prepulse inhibition (5p15), the California Verbal. Learning Test (8q24), the degraded-stimulus Continuous Performance Test (10q26), face memory (10q26 and 12p12), and the Letter-Number Span (14q23).
Conclusions: Twelve regions meeting genome-wide significant and suggestive criteria for previously identified heritable, schizophrenia-related endophenotypes were observed, and several genes of potential neurobiological interest were identified. Replication and further genomic Studies are needed to assess the biological significance of these results. (Am J Psychiatry 2013; 170:521-532)
C1 [Greenwood, Tiffany A.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
VA Puget Sound Hlth Care Syst, Seattle, WA USA.
Univ Colorado Denver, Dept Psychiat, Aurora, CO USA.
Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA.
Stanford Univ, Dept Pediat, Stanford, CA 94305 USA.
Scripps Translat Sci Inst, La Jolla, CA USA.
Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
Beth Israel Deaconess Med Ctr, Massachusetts Mental Hlth Ctr, Publ Psychiat Div, Boston, MA 02215 USA.
Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
James J Peters VA Med Ctr, New York, NY USA.
Univ Calif Los Angeles, Dept Biostat, Sch Publ Hlth, Los Angeles, CA 90024 USA.
Univ Calif San Diego, Inst Genom Med, La Jolla, CA 92093 USA.
Harvard Inst Psychiat Epidemiol & Genet, Boston, MA USA.
VA San Diego Healthcare Syst, VISN 22, Mental Illness Res Educ & Clin Ctr, Los Angeles, CA USA.
RP Greenwood, TA (reprint author), Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
EM tgreenwood@ucsd.edu; dbraff@ucsd.edu
RI Greenwood, Tiffany/F-6356-2012; Tsuang, Debby/L-7234-2016;
OI Greenwood, Tiffany/0000-0002-6080-6503; Tsuang,
Debby/0000-0002-4716-1894; Lazzeroni, Laura/0000-0002-1846-6920
FU Brain Plasticity; Genentech; Janssen Scientific Affairs; Lundbeck
Pharmaceuticals; AstraZeneca; Pfizer; Bristol-Myers Squibb; Hoffman-La
Roche; NIMH [R01-MH-065588, R01-MH-065562, R01-MH-065707, R01-MH-065554,
R01-MH-065578, R01-MH-065558, R01-MH-86135, K01-MH-087889]; NIH
[HNSN268200782096C]
FX Dr. Swerdlow has served as a consultant to Neurocrine. Dr. Green has
served as a consultant to Abbott Laboratories, Amgen, Biogen, Mnemosyne,
Roche, and Shire. Dr. Nuechterlein has received research grant support
from Brain Plasticity, Genentech, and Janssen Scientific Affairs and has
served as a consultant to Genentech and Otsuka. Dr. Olincy has received
research grant support from Lundbeck Pharmaceuticals. Dr. Turetsky has
received research grant support from AstraZeneca and Pfizer and
consulting fees from Bristol-Myers Squibb and Hoffman-La Roche. Dr.
Light has participated in a scientific advisory board meeting for
Astellas. All other authors report no financial relationships with
commercial interests.; Supported by NIMH grants R01-MH-065588,
R01-MH-065562, R01-MH-065707, R01-MH-065554, R01-MH-065578,
R01-MH-065558, R01-MH-86135, and K01-MH-087889. Genotyping services were
provided by the Center for Inherited Disease Research (CIDR). CIDR is
fully funded through a federal contract from NIH to Johns Hopkins
University (contract number HNSN268200782096C).
NR 93
TC 54
Z9 55
U1 3
U2 24
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0002-953X
J9 AM J PSYCHIAT
JI Am. J. Psychiat.
PD MAY
PY 2013
VL 170
IS 5
BP 521
EP 532
DI 10.1176/appi.ajp.2012.12020186
PG 12
WC Psychiatry
SC Psychiatry
GA 135XO
UT WOS:000318324200013
PM 23511790
ER
PT J
AU Nierenberg, AA
AF Nierenberg, Andrew A.
CA Bipolar Trials Network
TI In Whom Does Lithium Work? Response
SO AMERICAN JOURNAL OF PSYCHIATRY
LA English
DT Letter
ID BIPOLAR DISORDER; MAINTENANCE TREATMENT; TRIAL
C1 [Nierenberg, Andrew A.; Bipolar Trials Network] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
RP Nierenberg, AA (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
NR 3
TC 0
Z9 0
U1 0
U2 4
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0002-953X
J9 AM J PSYCHIAT
JI Am. J. Psychiat.
PD MAY
PY 2013
VL 170
IS 5
BP 559
EP 560
DI 10.1176/appi.ajp.2013.13010038r
PG 2
WC Psychiatry
SC Psychiatry
GA 135XO
UT WOS:000318324200020
PM 23632847
ER
PT J
AU Jentes, ES
Han, P
Gershman, MD
Rao, SR
LaRocque, RC
Staples, JE
Ryan, ET
AF Jentes, Emily S.
Han, Pauline
Gershman, Mark D.
Rao, Sowmya R.
LaRocque, Regina C.
Staples, J. Erin
Ryan, Edward T.
CA Global TravEpiNet Consortium
TI Travel Characteristics and Yellow Fever Vaccine Usage Among US Global
TravEpiNet Travelers Visiting Countries with Risk of Yellow Fever Virus
Transmission, 2009-2011
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID INTERNATIONAL-AIRPORT; RELATIVES ABROAD; FRIENDS; RECOMMENDATIONS;
PREVENTION; IMMIGRANTS; KNOWLEDGE; ATTITUDES; DISEASES
AB Yellow fever (YF) vaccine-associated serious adverse events and changing YF epidemiology have challenged healthcare providers to vaccinate only travelers whose risk of YF during travel is greater than their risk of adverse events. We describe the travel characteristics and YF vaccine use among US travelers visiting Global TravEpiNet clinics from January of 2009 to March of 2011. Of 16,660 travelers, 5,588 (34%) had itineraries to areas with risk of YF virus transmission. Of those travelers visiting one country with YF risk (N = 4,517), 71% were vaccinated at the visit, and 20% were presumed to be immune from prior vaccination. However, travelers visiting friends and relatives (odds ratio [OR] = 2.57,95% confidence interval [95% CI] = 1.27-5.22) or going to Nigeria (OR = 3.01,95% CI = 1.37-6.62) were significantly more likely to decline vaccination. To optimize YF vaccine use, clinicians should discuss an individual's risk benefit assessment of vaccination and close knowledge gaps regarding vaccine use among at-risk populations.
C1 [Jentes, Emily S.; Han, Pauline; Gershman, Mark D.] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA.
[Rao, Sowmya R.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA.
[Rao, Sowmya R.] Bedford Vet Adm Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA.
Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Ft Collins, CO USA.
[LaRocque, Regina C.; Ryan, Edward T.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Staples, J. Erin] Ctr Dis Control & Prevent, Arboviral Dis Branch, Div Vector Borne Dis, Ft Collins, CO USA.
RP Jentes, ES (reprint author), Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, 1600 Clifton Rd,MS E-03, Atlanta, GA 30333 USA.
EM ejentes@cdc.gov; hfd7@cdc.gov; dvj8@cdc.gov; sowmya.rao@va.gov;
rclarocque@partners.org; auv1@cdc.gov; etryan@partners.org
FU US Centers for Disease Control and Prevention [U19CI000514, U01CK000175]
FX This work was supported by Grants U19CI000514 and U01CK000175 from the
US Centers for Disease Control and Prevention.
NR 29
TC 2
Z9 2
U1 0
U2 5
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD MAY
PY 2013
VL 88
IS 5
BP 954
EP 961
DI 10.4269/ajtmh.12-0463
PG 8
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 136WR
UT WOS:000318394600025
PM 23458961
ER
PT J
AU Gros, DF
Milanak, ME
Brady, KT
Back, SE
AF Gros, Daniel F.
Milanak, Melissa E.
Brady, Kathleen T.
Back, Sudie E.
TI Frequency and Severity of Comorbid Mood and Anxiety Disorders in
Prescription Opioid Dependence
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Article
ID SUBSTANCE USE DISORDERS; PTSD; ABUSERS; INDEX
AB Background and Objectives: Comorbid substance use disorders and mood and anxiety disorders are associated with more severe psychiatric symptoms, social and occupational impairment, and economic burden. To date, the majority of research has focused on comorbidity in illicit drug users, rather than prescription drug users. To address this gap in the literature, the present cross-sectional study investigated the clinical profiles of individuals with prescription opioid dependence with or without comorbid mood and anxiety disorders.
Methods: Ninety individuals with prescription opioid use were recruited to participate in the study procedures. All participants completed a structured clinical interview and series of self-report measures.
Results and Conclusions: Of the 85 individuals with prescription opioid dependence, 47.1% (n = 40) were diagnosed with a comorbid mood or anxiety disorder. The findings showed that individuals with prescription opioid dependence and comorbid mood and anxiety disorders demonstrated significantly more severe alcohol use, psychiatric symptoms, and sleep impairment than individuals without comorbidity.
Scientific Significance: The findings highlight the frequency and severity of co-occurring mood and anxiety disorders in individuals with prescription opioid dependence and suggest that integrated interventions are needed to address these growing problems.
C1 [Gros, Daniel F.; Brady, Kathleen T.; Back, Sudie E.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA.
[Gros, Daniel F.; Milanak, Melissa E.; Brady, Kathleen T.; Back, Sudie E.] Med Univ S Carolina, Charleston, SC 29425 USA.
RP Gros, DF (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA.
EM grosd@musc.edu
FU NIDA NIH HHS [K23 DA021228, K24 DA00435]
NR 22
TC 8
Z9 8
U1 4
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1055-0496
J9 AM J ADDICTION
JI Am. J. Addict.
PD MAY-JUN
PY 2013
VL 22
IS 3
BP 261
EP 265
DI 10.1111/j.1521-0391.2012.12008.x
PG 5
WC Substance Abuse
SC Substance Abuse
GA 134RO
UT WOS:000318232200013
PM 23617869
ER
PT J
AU Chakravorty, S
Grandner, MA
Kranzler, HR
Mavandadi, S
Kling, MA
Perlis, ML
Oslin, DW
AF Chakravorty, Subhajit
Grandner, Michael A.
Kranzler, Henry R.
Mavandadi, Shahrzad
Kling, Mitchel A.
Perlis, Michael L.
Oslin, David W.
TI Insomnia in Alcohol Dependence: Predictors of Symptoms in a Sample of
Veterans Referred from Primary Care
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Article
ID NATIONAL EPIDEMIOLOGIC SURVEY; DRUG-USE DISORDERS; SLEEP DISTURBANCES;
SUICIDAL IDEATION; UNITED-STATES; DSM-IV; COOCCURRENCE; COMORBIDITY;
POPULATION; PREVALENCE
AB Objective: Patients with alcohol dependence presenting for treatment may have multiple associated co-morbid conditions and limited social supports, which complicate treatment. Each of these factors has been independently associated with complaints of insomnia. In this preliminary study, we investigated the relations between insomnia complaints and socio-demographic factors and psychiatric comorbidity in treatment-seeking patients with alcohol dependence.
Method: We conducted a retrospective chart review on 84 consecutive patients referred to the Behavioral Health Laboratory of the Philadelphia Veterans Affairs Medical Center for evaluation of psychiatric and substance use disorders. Patients met DSM-IV diagnostic criteria for alcohol dependence and completed a series of self-assessments of sleep. Univariate and multivariable analyses were used to examine the relations amongst the variables of interest.
Results: In multivariable models, Sleep Latency was significantly greater in individuals without partners (p = .01), those with psychiatric disorders (p = .03) and smokers (p = .01), with a nonsignificant trend for those with past-year suicidal ideation. No significant predictor of Wake Time After Sleep Onset was seen. Poor Sleep Quality was predicted by younger age (OR = .93 [.88, .98], p = .004) and the presence of a psychiatric disorder (OR = 20.80 [4, 102], p = .0002), with a non-significant trend for suicidal ideation.
Conclusions: Insomnia symptoms in treatment-seeking alcohol dependent patients should prompt consideration of the individuals' psychiatric and psychosocial features.
C1 [Chakravorty, Subhajit; Kranzler, Henry R.; Mavandadi, Shahrzad; Kling, Mitchel A.; Oslin, David W.] Philadelphia Vet Affairs Med Ctr, MIRECC VISN 4, Philadelphia, PA 19104 USA.
[Chakravorty, Subhajit; Grandner, Michael A.; Kranzler, Henry R.; Mavandadi, Shahrzad; Kling, Mitchel A.; Perlis, Michael L.; Oslin, David W.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Chakravorty, S (reprint author), Philadelphia Vet Affairs Med Ctr, MIRECC, 2nd Floor,Postal Code 116,Univ & Woodland Ave, Philadelphia, PA 19104 USA.
EM subhajit.chakravorty@uphs.upenn.edu
OI Kling, Mitchel/0000-0002-2232-1409
FU NHLBI NIH HHS [T32 HL007713, 5T32HL007713, K23 HL110216]; NIEHS NIH HHS
[R21 ES022931]
NR 31
TC 8
Z9 8
U1 3
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1055-0496
J9 AM J ADDICTION
JI Am. J. Addict.
PD MAY-JUN
PY 2013
VL 22
IS 3
BP 266
EP 270
DI 10.1111/j.1521-0391.2012.12009.x
PG 5
WC Substance Abuse
SC Substance Abuse
GA 134RO
UT WOS:000318232200014
PM 23617870
ER
PT J
AU Wilens, TE
AF Wilens, Timothy E.
TI Family History of Substance Use Disorders (SUD) and Offspring SUD:
Results from a Controlled Family Study
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Meeting Abstract
C1 [Wilens, Timothy E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1055-0496
J9 AM J ADDICTION
JI Am. J. Addict.
PD MAY-JUN
PY 2013
VL 22
IS 3
BP 308
EP 308
PG 1
WC Substance Abuse
SC Substance Abuse
GA 134RO
UT WOS:000318232200033
ER
PT J
AU Ward, N
Harvey, M
Czarnecki, K
AF Ward, Nalan
Harvey, Margaret
Czarnecki, Kristen
TI Innovations in Substance Abuse Care Delivery: Does "Orientation Group"
Before Intake Increase Clinician Productivity?
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Meeting Abstract
C1 [Ward, Nalan; Harvey, Margaret; Czarnecki, Kristen] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Ward, Nalan; Harvey, Margaret] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1055-0496
J9 AM J ADDICTION
JI Am. J. Addict.
PD MAY-JUN
PY 2013
VL 22
IS 3
BP 311
EP 311
PG 1
WC Substance Abuse
SC Substance Abuse
GA 134RO
UT WOS:000318232200040
ER
PT J
AU Ross, R
Stoeckel, L
Krashes, M
Connery, H
AF Ross, Rachel
Stoeckel, Luke
Krashes, Michael
Connery, Hilary
TI Drugs at the Dinner Table: Emerging Interface in the Science of
Addiction and Appetitive Behavior
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Meeting Abstract
C1 [Ross, Rachel] MGH McLean Adult Psychiat Residency Training Prog, Mclean, VA USA.
[Stoeckel, Luke] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Ross, Rachel; Krashes, Michael] Beth Israel Deaconess Med Ctr, Boston, MA USA.
[Connery, Hilary] McLean Hosp, Alcohol & Drug Abuse Treatment Program, Mclean, VA USA.
[Ross, Rachel; Stoeckel, Luke; Krashes, Michael; Connery, Hilary] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1055-0496
J9 AM J ADDICTION
JI Am. J. Addict.
PD MAY-JUN
PY 2013
VL 22
IS 3
BP 312
EP 312
PG 1
WC Substance Abuse
SC Substance Abuse
GA 134RO
UT WOS:000318232200044
ER
PT J
AU Wilens, TE
AF Wilens, Timothy E.
TI Substance Use in Young Adults with Bipolar Disorder: 5-Year Findings of
an Ongoing Longitudinal Study
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Meeting Abstract
C1 [Wilens, Timothy E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1055-0496
J9 AM J ADDICTION
JI Am. J. Addict.
PD MAY-JUN
PY 2013
VL 22
IS 3
BP 320
EP 320
PG 1
WC Substance Abuse
SC Substance Abuse
GA 134RO
UT WOS:000318232200067
ER
PT J
AU Ward, N
Margaret, H
AF Ward, Nalan
Margaret, Harvey
TI How to Increase Access to Substance Abuse Treatment: Implementing NIATx
Model
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Meeting Abstract
C1 [Ward, Nalan; Margaret, Harvey] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1055-0496
J9 AM J ADDICTION
JI Am. J. Addict.
PD MAY-JUN
PY 2013
VL 22
IS 3
BP 321
EP 321
PG 1
WC Substance Abuse
SC Substance Abuse
GA 134RO
UT WOS:000318232200069
ER
PT J
AU Iftimia, N
Ferguson, RD
Mujat, M
Patel, AH
Zhang, EZ
Fox, W
Rajadhyaksha, M
AF Iftimia, Nicusor
Ferguson, R. Daniel
Mujat, Mircea
Patel, Ankit H.
Zhang, Ellen Ziyi
Fox, William
Rajadhyaksha, Milind
TI Combined reflectance confocal microscopy/optical coherence tomography
imaging for skin burn assessment
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID LASER-DOPPLER FLOWMETRY; OPTICAL COHERENCE; MULTIPHOTON MICROSCOPY;
WOUND INFECTIONS; DEPTH; DIAGNOSIS; MICROCIRCULATION; MICROANGIOGRAPHY
AB A combined high-resolution reflectance confocal microscopy (RCM)/optical coherence tomography (OCT) instrument for assessing skin burn gravity has been built and tested. This instruments allows for visualizing skin intracellular details with submicron resolution in the RCM mode and morphological and birefringence modifications to depths on the order of 1.2 mm in the OCT mode. Preliminary testing of the dual modality imaging approach has been performed on the skin of volunteers with some burn scars and on normal and thermally-injured Epiderm FTTM skin constructs. The initial results show that these two optical technologies have complementary capabilities that can offer the clinician a set of clinically comprehensive parameters: OCT helps to visualize deeper burn injuries and possibly quantify collagen destruction by measuring skin birefringence, while RCM provides submicron details of the integrity of the epidermal layer and identifies the presence of the superficial blood flow in the upper dermis. Therefore, the combination of these two technologies within the same instrument may provide a more comprehensive set of parameters that may help clinicians to more objectively and nonivasively assess burn injury gravity by determining tissue structural integrity and viability. (C) 2013 Optical Society of America
C1 [Iftimia, Nicusor; Ferguson, R. Daniel; Mujat, Mircea; Patel, Ankit H.] Phys Sci Inc, Andover, MA 01810 USA.
[Zhang, Ellen Ziyi] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Fox, William] Lucid Inc, Rochester, NY 14604 USA.
[Rajadhyaksha, Milind] Mem Sloan Kettering Canc Ctr, Dermatol Serv, New York, NY 10021 USA.
RP Iftimia, N (reprint author), Phys Sci Inc, 20 New England Business Ctr, Andover, MA 01810 USA.
EM iftimia@psicorp.com
FU Department of Defense [W81XWH-11-C-0486]; NCI [1R43CA162561-01A1];
Center for Biomedical OCT Research and Translation [P41EB015903];
National Center for Research Resources; National Institute of Biomedical
Imaging and Bioengineering of the National Institutes of Health
FX The work of the authors was supported by the Department of Defense
through Grant Number W81XWH-11-C-0486 and partially through NCI Grant
Number 1R43CA162561-01A1.; Ellen Ziyi Zhang was supported by the Center
for Biomedical OCT Research and Translation through Grant Number
P41EB015903, awarded by the National Center for Research Resources and
the National Institute of Biomedical Imaging and Bioengineering of the
National Institutes of Health.
NR 45
TC 14
Z9 14
U1 2
U2 30
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD MAY 1
PY 2013
VL 4
IS 5
BP 680
EP 695
DI 10.1364/BOE.4.000680
PG 16
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
Medical Imaging
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
Medical Imaging
GA 137FR
UT WOS:000318421400004
PM 23667785
ER
PT J
AU Pagel, T
Baldessarini, RJ
Franklin, J
Baethge, C
AF Pagel, Tobias
Baldessarini, Ross J.
Franklin, Jeremy
Baethge, Christopher
TI Characteristics of patients diagnosed with schizoaffective disorder
compared with schizophrenia and bipolar disorder
SO BIPOLAR DISORDERS
LA English
DT Review
DE bipolar; meta-analysis; schizoaffective; schizophrenia
ID PSYCHOTIC MOOD DISORDERS; TERM-FOLLOW-UP; PSYCHIATRIC-DISORDERS;
CLINICAL-FEATURES; NEGATIVE SYMPTOMS; THOUGHT-DISORDER; RISK-FACTOR;
PREVALENCE; POPULATION; CLOZAPINE
AB Objectives Information on basic demographic and clinical characteristics of schizoaffective disorder is sparse and subject to sampling bias and low diagnostic reliability. In the present study we aimed to: (i) estimate the demographic and clinical descriptors in schizoaffective disorder patients and (ii) compare the findings with those with schizophrenia and bipolar disorder. Methods To minimize sampling bias and low reliability, we systematically reviewed studies that simultaneously compared schizoaffective, schizophrenia, and bipolar disorder patients. We estimated demographic, clinical, and psychometric characteristics based on weighted pooling, and compared disorders by meta-analysis. We also estimated whether schizoaffective disorder is closer to schizophrenia or to bipolar disorder. Results We identified 50 studies that included 18312 patients. Most characteristics of the 2684 schizoaffective disorder patients fell between those of 4814 diagnosed with bipolar disorder and 10814 with schizophrenia. However, the schizoaffective group had the highest proportion of women (52%), had the youngest age at illness onset (23.3 +/- 3.8years), and had the highest standardized ratings of psychosis and depression. Differences in pooled parameters between schizoaffective versus schizophrenia and versus bipolar disorder subjects were similar. Values for patients with schizoaffective disorders mostly were intermediate between schizophrenia and bipolar disorder. However, the majority of studies showed schizoaffective patients to be more like schizophrenia than bipolar disorder patients in seven out of nine demographic and clinical categories as well as in five out of eight psychometric measures. These results remained similar when we restricted the analyses to studies with psychotic bipolar disorder patients only or to studies using the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IIIR and DSM-IV only. Conclusions The present study provided estimates of important characteristics of schizoaffective disorder as balanced as possible in summarizing the findings from observational studies as unbiased as possible. The results did not support the hypothesis that schizoaffective disorder is primarily an affective disorder. The stronger resemblance of schizoaffective disorder to schizophrenia than to bipolar disorder needs further investigation.
C1 [Pagel, Tobias; Baethge, Christopher] Univ Cologne, Sch Med, Dept Psychiat & Psychotherapy, D-50937 Cologne, Germany.
[Baldessarini, Ross J.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Baldessarini, Ross J.; Baethge, Christopher] Massachusetts Gen Hosp, Int Consortium Psychot & Bipolar Disorders Res, McLean Div, Boston, MA 02114 USA.
[Franklin, Jeremy] Univ Cologne, Sch Med, Inst Med Stat Informat & Epidemiol, D-50937 Cologne, Germany.
RP Baethge, C (reprint author), Univ Cologne, Klin Psychiat & Psychotherapie, Kerpener Str 62, D-50937 Cologne, Germany.
EM cbaethge@uni-koeln.de
FU Bruce J. Anderson Foundation; McLean Private Donors Psychiatric Research
Fund
FX We gratefully acknowledge the assistance of Dr. Elie Cheniaux of the
Institute of Psychiatry, Federal University (Rio de Janeiro, Brazil) in
providing bibliographic references from her review of schizoaffective
disorder. This report is a component of the doctoral dissertation of
Tobias Pagel. The work was supported, in part, by a grant from the Bruce
J. Anderson Foundation and the McLean Private Donors Psychiatric
Research Fund (RJB).
NR 78
TC 20
Z9 20
U1 3
U2 23
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-5647
J9 BIPOLAR DISORD
JI Bipolar Disord.
PD MAY
PY 2013
VL 15
IS 3
BP 229
EP 239
DI 10.1111/bdi.12057
PG 11
WC Clinical Neurology; Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 136OV
UT WOS:000318372100001
PM 23528024
ER
PT J
AU Holloway, CL
DeLaney, TF
Alektiar, KM
Devlin, PM
O'Farrell, DA
Demanes, DJ
AF Holloway, Caroline L.
DeLaney, Thomas F.
Alektiar, Kaled M.
Devlin, Phillip M.
O'Farrell, Desmond A.
Demanes, D. Jeffrey
TI American Brachytherapy Society (ABS) consensus statement for sarcoma
brachytherapy
SO BRACHYTHERAPY
LA English
DT Article
DE Sarcoma; Brachytherapy; Consensus statement
ID SOFT-TISSUE SARCOMA; HIGH-DOSE-RATE; EXTERNAL-BEAM RADIOTHERAPY;
LIMB-SPARING SURGERY; PERIOPERATIVE INTERSTITIAL BRACHYTHERAPY;
INTRAOPERATIVE RADIATION-THERAPY; ADJUVANT RADIATION;
PROGNOSTIC-FACTORS; PULMONARY METASTASECTOMY; RETROPERITONEAL SARCOMA
AB PURPOSE: To present recommendations for the use of brachytherapy (BT) in patients with soft tissue sarcoma (STS).
METHODS: A group of practitioners with expertise and experience in sarcoma BT formulated recommendations for BT in STS based on clinical experience and literature review.
RESULTS: The indications for adjuvant BT are discussed. There is no consensus on the use of BT alone or in combination with external beam radiation therapy (EBRT), but factors that influence the selection of this modality include tumor grade and size, prior surgeries, and tumor recurrence. Low-dose-rate, high-dose-rate, and pulsed-dose-rate radiation are all acceptable BT modalities to use for STS. Recommendations are made for patient selection, techniques, dose rates, and dosages. Outcome data and toxicity data are reviewed.
CONCLUSIONS: BT is a useful component of the treatment of STS. The advantages of BT are the targeted dose distribution, low integral dose, and short treatment times. Ultimately the clinician should select the modality or combination of modalities that are most familiar to the treatment team and suitable to the patient. (C) 2013 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
C1 [Holloway, Caroline L.] BC Canc Agcy, Vancouver Isl Ctr, Dept Radiat Oncol, Victoria, BC V8R 6V5, Canada.
[DeLaney, Thomas F.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA USA.
[Alektiar, Kaled M.] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA.
[Devlin, Phillip M.; O'Farrell, Desmond A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol,Brigham & Womens Canc Ctr, Boston, MA 02115 USA.
Univ Calif Los Angeles, Dept Radiat Oncol, Div Brachytherapy, Los Angeles, CA 90024 USA.
RP Holloway, CL (reprint author), BC Canc Agcy, Vancouver Isl Ctr, Dept Radiat Oncol, 2410 Lee Ave, Victoria, BC V8R 6V5, Canada.
EM cholloway@bccancer.bc.ca
NR 87
TC 15
Z9 15
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1538-4721
J9 BRACHYTHERAPY
JI Brachytherapy
PD MAY-JUN
PY 2013
VL 12
IS 3
BP 179
EP 190
DI 10.1016/j.brachy.2012.12.002
PG 12
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 136BG
UT WOS:000318333800001
PM 23434220
ER
PT J
AU Viswanathan, AN
Szymonifka, J
Tempany-Afdhal, CM
O'Farrell, DA
Cormack, RA
AF Viswanathan, Akila N.
Szymonifka, Jackie
Tempany-Afdhal, Clare M.
O'Farrell, Desmond A.
Cormack, Robert A.
TI A prospective trial of real-time magnetic resonance-guided catheter
placement in interstitial gynecologic brachytherapy
SO BRACHYTHERAPY
LA English
DT Article
DE Interstitial brachytherapy; Gynecologic malignancies; Toxicity
ID CERVIX CANCER BRACHYTHERAPY; DOSE-VOLUME PARAMETERS; INTRACAVITARY
BRACHYTHERAPY; VAGINAL-CANCER; CARCINOMA; OPTIMIZATION; RADIATION;
RECOMMENDATIONS; IMPLANTATION; RECURRENCE
AB PURPOSE: To present outcome and toxicity results of the first real-time intraoperative MRI-guided interstitial approach to gynecologic cancer.
METHODS AND MATERIALS: From February 2004 to December 2006, 25 patients with gynecologic malignancies were enrolled and treated in a prospective clinical trial of real-time MRI-guided interstitial brachytherapy. This was followed by a confirmatory CT imaging scan. Statistical analyses included Kaplan-Meier estimates for overall and relapse-free survival.
RESULTS: MRI visualization of needles during placement permitted accurate placement with no inadvertent insertions. This prevented unnecessary normal-tissue perforation as confirmed by CT simulation. With a mean followup of 3.8 years (range, 2-6.8), 1-, 2-, and 3-year overall survival rates were 80%, 60% and 43%, respectively; corresponding relapse-free survival rates were 79%, 65%, and 59%, respectively. Actuarial acute toxicity rates for any grade were 0% at 0-14 days and 80% (all grade 1) at 14-90 days. Long-term (>180 days) actuarial toxicity rates were 8% gastrointestinal, 4% bladder and 4% vaginal.
CONCLUSIONS: Real-time MRI guidance during insertion of interstitial needles followed by 3D-planning maximized opportunities for tumor targeting and sparing of normal tissues. Although image guidance requires additional anesthesia time, clinical outcomes indicate potential for a successful reduction in toxicity using 3D image-guided in addition to 3D image-planned brachytherapy. (C) 2013 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
C1 [Viswanathan, Akila N.; O'Farrell, Desmond A.; Cormack, Robert A.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
[Szymonifka, Jackie] Massachusetts Gen Hosp, Dept Biostat Sci, Boston, MA 02114 USA.
[Tempany-Afdhal, Clare M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA.
RP Viswanathan, AN (reprint author), Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, 75 Francis St,ASB1-L2, Boston, MA 02115 USA.
EM aviswanathan@lroc.harvard.edu
OI Cormack, Robert/0000-0001-5553-9984
FU Friends of Dana-Farber Cancer Institute
FX Dr. Viswanathan received support from a Friends of Dana-Farber Cancer
Institute Award for this protocol. There are no current external funding
sources for this study.
NR 22
TC 30
Z9 30
U1 2
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1538-4721
J9 BRACHYTHERAPY
JI Brachytherapy
PD MAY-JUN
PY 2013
VL 12
IS 3
BP 240
EP 247
DI 10.1016/j.brachy.2012.08.006
PG 8
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 136BG
UT WOS:000318333800012
PM 23415048
ER
PT J
AU Sampaio, A
Bouix, S
Sousa, N
Vasconcelos, C
Fernandez, M
Shenton, ME
Goncalves, OF
AF Sampaio, Adriana
Bouix, Sylvain
Sousa, Nuno
Vasconcelos, Cristiana
Fernandez, Montse
Shenton, Martha E.
Goncalves, Oscar F.
TI Morphometry of corpus callosum in Williams syndrome: shape as an index
of neural development
SO BRAIN STRUCTURE & FUNCTION
LA English
DT Article
DE Corpus callosum; MRI; Neurodevelopment; Williams syndrome
ID HUMAN CEREBRAL-CORTEX; WHITE-MATTER; BRAIN-DEVELOPMENT; LONGITUDINAL
MRI; ADOLESCENCE; CHILDHOOD; THICKNESS; CHILDREN; ABNORMALITIES;
CONNECTIVITY
AB Brain abnormalities in Williams syndrome (WS) have been consistently reported, despite few studies have devoted attention to connectivity between different brain regions in WS. In this study, we evaluated corpus callosum (CC) morphometry: bending angle, length, thickness and curvature of CC using a new shape analysis method in a group of 17 individuals with WS matched with a typically developing group. We used this multimethod approach because we hypothesized that neurodevelopmental abnormalities might result in both volume changes and structure deformation. Overall, we found reduced absolute CC cross-sectional area and volume in WS (mean CC and subsections). In parallel, we observed group differences regarding CC shape and thickness. Specifically, CC of WS is morphologically different, characterized by a larger bending angle and being more curved in the posterior part. Moreover, although CC in WS is shorter, a larger relative thickness of CC was found in all callosal sections. Finally, groups differed regarding the association between CC measures, age, white matter volume and cognitive performance. In conclusions, abnormal patterns of CC morphology and shape may be implicated in WS cognitive and behavioural phenotype.
C1 [Sampaio, Adriana; Goncalves, Oscar F.] Univ Minho, Sch Psychol, Neuropsychophysiol Lab, CiPsi, Braga, Portugal.
[Bouix, Sylvain; Shenton, Martha E.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Psychiat Neuroimaging Lab,Dept Psychiat, Boston, MA 02215 USA.
[Sousa, Nuno] Univ Minho, Life & Hlth Sci Res Inst, Braga, Portugal.
[Vasconcelos, Cristiana] Hosp Santo Antonio, Dept Neuroradiol, Oporto, Portugal.
[Fernandez, Montse] Univ Santiago de Compostela, Mol Genet Unit, Galician Publ Fdn Genom Med, Santiago De Compostela, Spain.
[Shenton, Martha E.] VA Boston Healthcare Syst, Lab Neurosci, Clin Neurosci Div, Dept Psychiat, Brockton, MA USA.
[Shenton, Martha E.] Harvard Univ, Sch Med, Brockton, MA 02401 USA.
RP Sampaio, A (reprint author), Univ Minho, Sch Psychol, Neuropsychophysiol Lab, CiPsi, Braga, Portugal.
EM adriana.sampaio@psi.uminho.pt; sylvain@bwh.harvard.edu
RI Sousa, Nuno/C-2782-2009; Goncalves, Oscar/G-5278-2010; Sampaio,
Adriana/C-8361-2011;
OI Goncalves, Oscar/0000-0003-2735-9155; Sampaio,
Adriana/0000-0001-7347-1282; Bouix, Sylvain/0000-0003-1326-6054; Sousa,
Nuno/0000-0002-8755-5126
FU Fundacao para a Ciencia e Tecnologia (Portugal) [PIC/IC/83290/2007,
PTDC/PSI-PCL/115316/2009]; National Institutes of Health [K05 MH070047]
FX This research was supported by the grants PIC/IC/83290/2007 and
PTDC/PSI-PCL/115316/2009 from Fundacao para a Ciencia e Tecnologia
(Portugal). This study was also supported, in part, by grants from the
National Institutes of Health (K05 MH070047).
NR 64
TC 3
Z9 3
U1 0
U2 7
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1863-2653
J9 BRAIN STRUCT FUNCT
JI Brain Struct. Funct.
PD MAY
PY 2013
VL 218
IS 3
BP 711
EP 720
DI 10.1007/s00429-012-0423-4
PG 10
WC Anatomy & Morphology; Neurosciences
SC Anatomy & Morphology; Neurosciences & Neurology
GA 135TE
UT WOS:000318310600007
PM 22648762
ER
PT J
AU Lucisano, MP
Nelson, P
Morse, L
Battaglino, R
Watanabe, PCA
da Silva, RAB
da Silva, LAB
AF Lucisano, Marilia Pacifico
Nelson-Filho, Paulo
Morse, Leslie
Battaglino, Ricardo
Aranha Watanabe, Plauto Christopher
Bezerra da Silva, Raquel Assed
Bezerra da Silva, Lea Assed
TI Radiodensitometric and DXA analyses for the measurement of bone mineral
density after systemic alendronate therapy
SO BRAZILIAN ORAL RESEARCH
LA English
DT Article
DE Bone Density; Alendronate; Bone Remodeling
ID X-RAY ABSORPTIOMETRY; QUANTITATIVE COMPUTED-TOMOGRAPHY;
CLINICAL-EFFICACY; IN-VIVO; OSTEOPOROSIS; RATS; MICE; BISPHOSPHONATES;
DEFICIENCY; MECHANISMS
AB Precise techniques for the measurement of maxillary bone mineral density (BMD) are useful for the early diagnosis of systemic diseases. The aim of this study was to compare in vivo the efficacy of dual-energy x-ray absorptiometry (DXA) and radiographic densitometry for the measurement of BMD after systemic administration of sodium alendronate. Wistar rats were randomly allocated to a control group (n = 5), which received distilled water, and a sodium alendronate group (n = 8), which received two doses of chemically pure sodium alendronate (1 mg/kg) per week. After 8 weeks, the animals were euthanized, the tibias were removed, and the BMD of the proximal tibial metaphysis was analyzed radiographically and by DXA. The data were subjected to statistical analysis by the Kruskal-Wallis test at a significance level of 5%. Both of the techniques revealed that the alendronate-treated group had a significantly higher BMD (p < 0.05) than the control group after 8 weeks of treatment. Comparing the groups with and without alendronate therapy revealed increases of 14.9% and 29.6% in BMD, as detected radiographically and by DXA, respectively. In conclusion, both of the methods Were able to detect an increase in BMD of the proximal tibial metaphysis after alendronate therapy.
C1 [Lucisano, Marilia Pacifico; Nelson-Filho, Paulo; Bezerra da Silva, Raquel Assed; Bezerra da Silva, Lea Assed] Univ Sao Paulo, Sch Dent Ribeirao Preto, Dept Pediat Clin Prevent & Community Dent, BR-14049 Ribeirao Preto, SP, Brazil.
[Morse, Leslie] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA.
[Battaglino, Ricardo] Forsyth Inst, Dept Skeletal Biol, Cambridge, MA USA.
[Aranha Watanabe, Plauto Christopher] Univ Sao Paulo, Sch Dent Ribeirao Preto, Dept Morphol Stomatol & Physiol, BR-14049 Ribeirao Preto, SP, Brazil.
RP Nelson, P (reprint author), Univ Sao Paulo, Sch Dent Ribeirao Preto, Dept Pediat Clin Prevent & Community Dent, BR-14049 Ribeirao Preto, SP, Brazil.
EM nelson@forp.usp.br
RI watanabe, plauto/C-6881-2015; battaglino, ricardo/D-2892-2015; Morse,
Leslie/C-9442-2015; Silva, Lea/B-3953-2016; Nelson-Filho,
Paulo/L-1272-2016; Bezerra da Silva, Raquel /M-8655-2016
OI watanabe, plauto/0000-0001-5524-1395; Morse, Leslie/0000-0002-7426-6341;
Silva, Lea/0000-0001-7118-6859; Nelson-Filho, Paulo/0000-0001-8802-6480;
Bezerra da Silva, Raquel /0000-0002-0230-1347
NR 28
TC 1
Z9 1
U1 0
U2 4
PU SOCIEDADE BRASILEIRA DE PESQUISA ODONTOLOGICA
PI SAO PAULO
PA CIDADE UNIV, AV PROF LINEU PRESTES, ARMANDO SALLE OLIVEIRA, AVENIDA
LINEU PRESTES, 2227, CP 8216, SAO PAULO, SP 05508-900, BRAZIL
SN 1806-8324
J9 BRAZ ORAL RES
JI Braz. Oral Res.
PD MAY-JUN
PY 2013
VL 27
IS 3
BP 252
EP 257
PG 6
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 139KX
UT WOS:000318582700010
PM 23739782
ER
PT J
AU Armstrong, WB
Taylor, TH
Kennedy, AR
Melrose, RJ
Messadi, DV
Gu, M
Le, AD
Perloff, M
Civantos, F
Goodwin, WJ
Wirth, LJ
Kerr, AR
Meyskens, FL
AF Armstrong, William B.
Taylor, Thomas H.
Kennedy, Ann R.
Melrose, Raymond J.
Messadi, Diana V.
Gu, Mai
Le, Anh D.
Perloff, Marjorie
Civantos, Francisco
Goodwin, William Jarrard
Wirth, Lori J.
Kerr, Alexander Ross
Meyskens, Frank L., Jr.
TI Bowman Birk Inhibitor Concentrate and Oral Leukoplakia: A Randomized
Phase IIb Trial
SO CANCER PREVENTION RESEARCH
LA English
DT Article
ID PROTEASE ACTIVITY; IN-VITRO; CANCER; C-ERBB-2; CHEMOPREVENTION; SERUM;
SOY; LESIONS; RISK
AB Oral premalignancy serves as an ideal model for study of chemopreventive agents. Although 13-cis-retinoic acid showed reversal of oral premalignancy, toxicity, and reversal of clinical response after cessation of therapy obviated its widespread use. A search for nontoxic agents with cancer preventive activity led us to evaluate Bowman Birk Inhibitor (BBI) formulated as BBI Concentrate (BBIC). We previously reported encouraging results in a phase IIa trial of BBIC in patients with oral leukoplakia with measurable clinical responses and favorable biomarker changes. On the basis of these results, we undertook a randomized, placebo controlled phase IIb trial with patients receiving BBIC or placebo for 6 months, with assessment of clinical response and change in lesion area as primary end point and an intent-to-treat analysis. One hundred and thirty two subjects were randomized; and 89 subjects completed six months on study drug or placebo. Both placebo and BBIC showed a statistically significant decrease in mean lesion area of 17.1% and 20.6%, respectively, and partial or greater clinical responses of 30% and 28% respectively. No significant difference between placebo and study drug arms was observed. Histologic review, review of photographs of lesions, and comparison of serum neu protein and oral mucosal cell protease activity also did not show significant differences between study arms. Probable reasons for these negative results were considered, are discussed, and include a placebo with non-BBIC clinical activity and reduced pharmacokinetic availability of the second batch of BBIC. This experience should be a strong cautionary note to those considering "Green" chemoprevention. (C) 2013 AACR.
C1 [Armstrong, William B.; Taylor, Thomas H.; Meyskens, Frank L., Jr.] UC Irvine, Chao Family Comprehens Canc Ctr, Philadelphia, PA USA.
[Armstrong, William B.] UC Irvine, Dept Otolaryngol Head & Neck Surg, Philadelphia, PA USA.
[Taylor, Thomas H.] Univ Penn, Genet Epidemiol Res Inst, Philadelphia, PA 19104 USA.
[Taylor, Thomas H.] Univ Penn, Dept Epidemiol, Philadelphia, PA 19104 USA.
[Kennedy, Ann R.] Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA.
[Melrose, Raymond J.] Univ So Calif, Dept Pathol, Los Angeles, CA 90089 USA.
[Messadi, Diana V.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA.
[Gu, Mai] Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA USA.
[Le, Anh D.] Univ Penn, Philadelphia, PA 19104 USA.
[Perloff, Marjorie] NCI, Canc Prevent Div, Rockville, MD USA.
[Civantos, Francisco; Goodwin, William Jarrard] Univ Miami, Dept Otolaryngol Head & Neck Surg, Miami, FL USA.
[Wirth, Lori J.] Harvard Univ, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kerr, Alexander Ross] NYU, Coll Dent, New York, NY USA.
RP Meyskens, FL (reprint author), Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Bldg 56,Route 81,101 City Dr Canc Ctr, Orange, CA 92868 USA.
EM flmeyske@uci.edu
FU NIH [U01-CA72294, P30-CA 62203]
FX This work is supported by the NIH (U01-CA72294, P30-CA 62203; to F.L.
Meyskens).
NR 28
TC 17
Z9 18
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1940-6207
J9 CANCER PREV RES
JI Cancer Prev. Res.
PD MAY
PY 2013
VL 6
IS 5
BP 410
EP 418
DI 10.1158/1940-6207.CAPR-13-0004
PG 9
WC Oncology
SC Oncology
GA 137ZE
UT WOS:000318476600007
PM 23639862
ER
PT J
AU Ittmann, M
Huang, J
Radaelli, E
Martin, P
Signoretti, S
Sullivan, R
Simons, BW
Ward, JM
Robinson, BD
Chu, GC
Loda, M
Thomas, G
Borowsky, A
Cardiff, RD
AF Ittmann, Michael
Huang, Jiaoti
Radaelli, Enrico
Martin, Philip
Signoretti, Sabina
Sullivan, Ruth
Simons, Brian W.
Ward, Jerrold M.
Robinson, Brian D.
Chu, Gerald C.
Loda, Massimo
Thomas, George
Borowsky, Alexander
Cardiff, Robert D.
TI Animal Models of Human Prostate Cancer: The Consensus Report of the New
York Meeting of the Mouse Models of Human Cancers Consortium Prostate
Pathology Committee
SO CANCER RESEARCH
LA English
DT Review
ID GENETICALLY-ENGINEERED MICE; TO-MESENCHYMAL TRANSITION; INTRAEPITHELIAL
NEOPLASIA; ANDROGEN RECEPTOR; REACTIVE STROMA; PTEN LOSS; XENOGRAFT
MODELS; IN-VIVO; EXPRESSION; GROWTH
AB Animal models, particularly mouse models, play a central role in the study of the etiology, prevention, and treatment of human prostate cancer. While tissue culture models are extremely useful in understanding the biology of prostate cancer, they cannot recapitulate the complex cellular interactions within the tumor microenvironment that play a key role in cancer initiation and progression. The National Cancer Institute (NCI) Mouse Models of Human Cancers Consortium convened a group of human and veterinary pathologists to review the current animal models of prostate cancer and make recommendations about the pathologic analysis of these models. More than 40 different models with 439 samples were reviewed, including genetically engineered mouse models, xenograft, rat, and canine models. Numerous relevant models have been developed over the past 15 years, and each approach has strengths and weaknesses. Analysis of multiple genetically engineered models has shown that reactive stroma formation is present in all the models developing invasive carcinomas. In addition, numerous models with multiple genetic alterations display aggressive phenotypes characterized by sarcomatoid carcinomas and metastases, which is presumably a histologic manifestation of epithelial-mesenchymal transition. The significant progress in development of improved models of prostate cancer has already accelerated our understanding of the complex biology of prostate cancer and promises to enhance development of new approaches to prevention, detection, and treatment of this common malignancy. (C) 2013 AACR.
C1 [Ittmann, Michael] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA.
[Ittmann, Michael] Michael E DeBakey VA Med Ctr, Houston, TX USA.
[Huang, Jiaoti] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.
[Borowsky, Alexander; Cardiff, Robert D.] Univ Calif Davis, Dept Pathol & Lab Med, Davis, CA 95616 USA.
[Borowsky, Alexander; Cardiff, Robert D.] Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA.
[Martin, Philip] Ctr Adv Preclin Res, Frederick Natl Lab Canc Res, Frederick, MD USA.
[Simons, Brian W.] Johns Hopkins Univ, Sch Med, Dept Mol & Comparat Pathobiol, Baltimore, MD USA.
[Ward, Jerrold M.] NIAID, Virol & Cellular Immunol Sect, Immunogenet Lab, NIH, Bethesda, MD USA.
[Signoretti, Sabina] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
Brigham & Womens Hosp, Dept Med Oncol, Boston, MA 02115 USA.
[Loda, Massimo] Harvard Univ, Sch Med, Dept Pathol, Ctr Mol Oncol Pathol, Boston, MA 02115 USA.
[Loda, Massimo] Harvard Univ, Sch Med, Dept Med Oncol, Ctr Mol Oncol Pathol, Boston, MA 02115 USA.
[Chu, Gerald C.; Loda, Massimo] Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Sullivan, Ruth] Univ Wisconsin, Madison Carbone Canc Ctr, Madison, WI USA.
[Sullivan, Ruth] Res Anim Resources Ctr, Madison, WI USA.
[Sullivan, Ruth] Lab Opt & Computat Instrumentat, Madison, WI USA.
[Robinson, Brian D.] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY USA.
[Thomas, George] Oregon Hlth & Sci Univ, Dept Pathol & Lab Med, Portland, OR 97201 USA.
[Radaelli, Enrico] Univ Milan, Sch Vet Med, Dept Anim Pathol Hyg & Publ Hlth, Milan, Italy.
RP Ittmann, M (reprint author), Baylor Coll Med, Dept Pathol & Immunol, 1 Baylor Plaza, Houston, TX 77030 USA.
EM mittmann@bcm.edu
RI Simons, Brian/G-7352-2015
OI Simons, Brian/0000-0003-0644-211X
FU NCI: U01 Mouse Models of Human Cancers Consortium [U01CA141497, U01
CA141582]; UCLA, Pacific Northwest and DF/HCC SPOREs in Prostate Cancer
[P01 CA89021, RO1 CA131945]; UWCCC Core Grant through the OHSU-Knight
Cancer Institute [P30 CA014520, P30 CA069533 13S5]; Department of
Defense Prostate Cancer Research Program [W81XWH-11-1-0227]; Prostate
Cancer Foundation; [P30CA125123]
FX This study was supported by NCI: U01 Mouse Models of Human Cancers
Consortium (U01CA141497 and U01 CA141582); P30CA125123 (M. Ittmann);
UCLA, Pacific Northwest and DF/HCC SPOREs in Prostate Cancer, P01
CA89021 (M. Loda) and RO1 CA131945 (M. Loda); UWCCC Core Grant P30
CA014520 (R. Sullivan) P30 CA069533 13S5 through the OHSU-Knight Cancer
Institute (G. Thomas); Department of Defense Prostate Cancer Research
Program (W81XWH-11-1-0227; J. Huang); and Prostate Cancer Foundation.
NR 74
TC 64
Z9 68
U1 4
U2 27
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD MAY 1
PY 2013
VL 73
IS 9
BP 2718
EP 2736
DI 10.1158/0008-5472.CAN-12-4213
PG 19
WC Oncology
SC Oncology
GA 136KJ
UT WOS:000318360500002
PM 23610450
ER
PT J
AU Crompton, BD
Carlton, AL
Thorner, AR
Christie, AL
Du, JY
Calicchio, ML
Rivera, MN
Fleming, MD
Kohl, NE
Kung, AL
Stegmaier, K
AF Crompton, Brian D.
Carlton, Anne L.
Thorner, Aaron R.
Christie, Amanda L.
Du, Jinyan
Calicchio, Monica L.
Rivera, Miguel N.
Fleming, Mark D.
Kohl, Nancy E.
Kung, Andrew L.
Stegmaier, Kimberly
TI High-Throughput Tyrosine Kinase Activity Profiling Identifies FAK as a
Candidate Therapeutic Target in Ewing Sarcoma
SO CANCER RESEARCH
LA English
DT Article
ID FOCAL ADHESION KINASE; CELL-MIGRATION; STANDARD CHEMOTHERAPY;
NEUROECTODERMAL TUMOR; GROWTH; RECEPTOR; INHIBITOR; CANCER; FAMILY;
PATHWAY
AB Limited progress has been made in the treatment of advanced-stage pediatric solid tumors despite the accelerated pace of cancer discovery over the last decade. Tyrosine kinase inhibition is one tractable therapeutic modality for treating human malignancy. However, little is known about the kinases critical to the development or maintenance of many pediatric solid tumors such as Ewing sarcoma. Using a fluorescent, bead-based technology to profile activated tyrosine kinases, we identified focal adhesion kinase (FAK, PTK2) as a candidate target in Ewing sarcoma. FAK is a tyrosine kinase critical for cellular adhesion, growth, and survival. As such, it is a compelling target for cancer-based therapy. In this study, we have shown that FAK is highly phosphorylated in primary Ewing sarcoma tumor samples and that downregulation of FAK by short hairpin RNA and treatment with a FAK-selective kinase inhibitor, PF-562271, impaired growth and colony formation in Ewing sarcoma cell lines. Moreover, treatment of Ewing sarcoma cell lines with PF-562271 induced apoptosis and led to downregulation of AKT/mTOR and CAS activity. Finally, we showed that small-molecule inhibition of FAK attenuated Ewing sarcoma tumor growth in vivo. With FAK inhibitors currently in early-phase clinical trials for adult malignancies, these findings may bear immediate relevance to patients with Ewing sarcoma. (C) 2013 AACR.
C1 [Crompton, Brian D.; Carlton, Anne L.; Thorner, Aaron R.; Stegmaier, Kimberly] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA.
[Crompton, Brian D.; Carlton, Anne L.; Thorner, Aaron R.] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
[Fleming, Mark D.] Childrens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Christie, Amanda L.; Kohl, Nancy E.] Dana Farber Canc Inst, Lurie Family Imaging Ctr, Boston, MA 02215 USA.
[Rivera, Miguel N.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Rivera, Miguel N.; Stegmaier, Kimberly] Broad Inst Massachusetts Inst Technol & Harvard U, Cambridge, MA USA.
[Kung, Andrew L.] Columbia Univ, Dept Pediat, Med Ctr, New York, NY 10027 USA.
RP Stegmaier, K (reprint author), Dana Farber Canc Inst, 450 Brookline Ave,D630, Boston, MA 02215 USA.
EM kimberly_stegmaier@dfci.harvard.edu
OI Kung, Andrew/0000-0002-9091-488X; Carlton, Anne/0000-0002-5921-6004
FU Cookies for Kids' Cancer, Golf Fights Cancer, Brian MacIsaac Sarcoma
Foundation; Hyundai Hope on Wheels, Bear Necessities Pediatric Cancer
Foundation, Pedal for Pediatrics; Burroughs Wellcome Fund; Howard Hughes
Medical Institute; Stand-Up-to-Cancer Innovative Research Grant, a
program of the Entertainment Industry Foundation [SU2C-AACR-IRG0509]
FX This work was supported by Cookies for Kids' Cancer, Golf Fights Cancer,
Brian MacIsaac Sarcoma Foundation (K. Stegmaier); Hyundai Hope on
Wheels, Bear Necessities Pediatric Cancer Foundation, Pedal for
Pediatrics (B. D. Crompton); Aid for Cancer Research (A. R. Thorner);
Burroughs Wellcome Fund (M.N. Rivera); and the Howard Hughes Medical
Institute (K. Stegmaier and M.N. Rivera). K. Stegmaier is also supported
by a Stand-Up-to-Cancer Innovative Research Grant, a program of the
Entertainment Industry Foundation (SU2C-AACR-IRG0509).
NR 49
TC 12
Z9 12
U1 0
U2 11
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD MAY 1
PY 2013
VL 73
IS 9
BP 2873
EP 2883
DI 10.1158/0008-5472.CAN-12-1944
PG 11
WC Oncology
SC Oncology
GA 136KJ
UT WOS:000318360500016
PM 23536552
ER
PT J
AU Cuadrado-Tejedor, M
Cabodevilla, JF
Zamarbide, M
Gomez-Isla, T
Franco, R
Perez-Mediavilla, A
AF Cuadrado-Tejedor, Mar
Felipe Cabodevilla, Jesus
Zamarbide, Marta
Gomez-Isla, Teresa
Franco, Rafael
Perez-Mediavilla, Alberto
TI Age-Related Mitochondrial Alterations without Neuronal Loss in the
Hippocampus of a Transgenic Model of Alzheimer's Disease
SO CURRENT ALZHEIMER RESEARCH
LA English
DT Article
DE Alzheimer's disease; early changes; hippocampus; mitochondrial
dysfunction; neuronal loss; neurodegeneration; proteome; transgenic
mouse; Tg2576
ID MOUSE MODEL; AMYLOID DEPOSITION; SYNAPSE LOSS; DEFICITS; PROTEIN; MICE;
STRESS; MEMORY
AB The Tg2576 mouse, which carries the Swedish mutant form of human beta-amyloid precursor protein (hAPP(swe)), develops Alzheimer's Disease (AD)-like phenotype (synaptic pathology, cognitive impairment and beta amyloid -A beta-plaques.) in the absence of significant neuronal loss. We have analyzed the hippocampal proteome of Tg2576, focusing on changes at 7 months of age, when A beta levels begin to increase but cognitive symptoms are still not evident, and at 16 months, when most AD-like features are manifested. Proteins differentially expressed with respect to wild-type animals were grouped according to their biological function and assessed in the context of AD. Metabolic enzymes, propionyl-CoA carboxylase, which has not been previously related to AD, and glutamine synthetase, which is a key enzyme for ammonium removal, were among deregulated proteins. Mitochondria of young animals have to cope with the metabolic stress and elevated ATP demand caused by overexpression of hAPP(swe). Significantly, a large number of mitochondrial proteins (16, 28% of the total) were deregulated in young Tg2576 mice and seven of them were found at normal levels in aged animals. Mitochondrial dysfunction in 7-month-old mice was confirmed by reduction in the inner membrane integrity and increase in the activity of cytochrome c oxidase. The proteome analysis indicates that mitochondrial and overlapping metabolic alterations are adaptive upon aging, and may explain the synaptic pathology and cognitive impairment in the absence of neuronal loss. Animal models such as 7-month-old Tg2576 mice and tools to investigate synaptic alterations before appearance of neuronal death may help in understanding the pathological mechanisms occurring at early stages of AD.
C1 [Cuadrado-Tejedor, Mar; Felipe Cabodevilla, Jesus; Zamarbide, Marta; Franco, Rafael; Perez-Mediavilla, Alberto] Univ Navarra, CIMA, Cellular & Mol Neuropharmacol Lab, E-31008 Pamplona, Spain.
[Perez-Mediavilla, Alberto] Univ Navarra, Dept Biochem & Mol Biol, E-31008 Pamplona, Spain.
[Cuadrado-Tejedor, Mar] Univ Navarra, Dept Anat, E-31008 Pamplona, Spain.
[Gomez-Isla, Teresa] Harvard Univ, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02115 USA.
[Gomez-Isla, Teresa] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Neurol, E-08193 Barcelona, Spain.
RP Perez-Mediavilla, A (reprint author), Univ Navarra, CIMA, Cellular & Mol Neuropharmacol Lab, Avda Pio XII,55, E-31008 Pamplona, Spain.
EM lamediav@unav.es
RI Franco, Rafael/C-3694-2015; Cuadrado-Tejedor, Mar/P-3387-2015;
OI Franco, Rafael/0000-0003-2549-4919; Cuadrado-Tejedor,
Mar/0000-0003-4260-9140
FU European Council DIADEM [QLRT-2000-02362]; Department of Education of
the Government of Navarra, Spain; UTE project FIMA, Spain
FX This study was supported by Grants from the European Council DIADEM
QLRT-2000-02362, Department of Education of the Government of Navarra,
and UTE project FIMA, Spain.
NR 30
TC 14
Z9 14
U1 1
U2 11
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
EMIRATES
SN 1567-2050
J9 CURR ALZHEIMER RES
JI Curr. Alzheimer Res.
PD MAY
PY 2013
VL 10
IS 4
BP 390
EP 405
PG 16
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 136EV
UT WOS:000318345600005
PM 23545067
ER
PT J
AU Markowitz, JT
Alleyn, CA
Phillips, R
Muir, A
Young-Hyman, D
Laffel, LMB
AF Markowitz, Jessica T.
Alleyn, Cielo A.
Phillips, Roxanne
Muir, Andrew
Young-Hyman, Deborah
Laffel, Lori M. B.
TI Disordered Eating Behaviors in Youth with Type 1 Diabetes: Prospective
Pilot Assessment Following Initiation of Insulin Pump Therapy
SO DIABETES TECHNOLOGY & THERAPEUTICS
LA English
DT Article
ID ADOLESCENT FEMALES; MELLITUS; SAFETY; WOMEN; GIRLS
AB Background: There is risk for disordered eating behaviors in type 1 diabetes, especially related to insulin manipulation. Implementation of insulin pump therapy may encourage either normalization of eating behaviors or a greater focus on food intake due to renewed emphasis on carbohydrate counting. There is need for prospective studies to assess disordered eating behaviors upon implementation of pump therapy using diabetes-specific measurement tools.
Subjects and Methods: In a multicenter pilot study, 43 youth with type 1 diabetes, 10-17 years old, were assessed prior to pump initiation and after 1 and 6 months of pump therapy. Youth completed the Diabetes-specific Eating Problems Survey-Revised (DEPS-R), a validated measure of risk for both diabetes-specific and general disordered eating behaviors.
Results: Youth (45% female), 13.3 years old with diabetes for 2.1 years, had a mean hemoglobin A1c of 8.3 +/- 1.3% (68 +/- 14.5 mmol/mol) at baseline. DEPS-R scores decreased over time (P = 0.01). Overall rate of high risk for eating disorders was low. Overweight/obese youth endorsed more disordered eating behaviors than normal-weight participants. DEPS-R scores were correlated with z-score for body mass index at all three time points and with hemoglobin A1c after 1 and 6 months. Hemoglobin A1c did not change significantly over the 6 months and was higher in overweight/obese compared with normal-weight participants.
Conclusions: Initiation of insulin pump therapy was associated with diminished endorsement of disordered eating behaviors in youth with type 1 diabetes. Longer follow-up studies are needed to assess the impact of insulin pump therapy on glycemic control, weight status, and disordered eating behaviors in this vulnerable population.
C1 [Markowitz, Jessica T.; Alleyn, Cielo A.; Phillips, Roxanne; Laffel, Lori M. B.] Joslin Diabet Ctr, Sect Genet & Epidemiol, Pediat Adolescent & Adult Sect, Boston, MA 02215 USA.
[Muir, Andrew] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA.
[Young-Hyman, Deborah] Georgia Hlth Sci Univ, Georgia Prevent Inst, Augusta, GA USA.
RP Laffel, LMB (reprint author), Joslin Diabet Ctr, Sect Genet & Epidemiol, Pediat Adolescent & Adult Sect, 1 Joslin Pl, Boston, MA 02215 USA.
EM lori.laffel@joslin.harvard.edu
FU American Diabetes Association Clinical Research Award [7-08-CR-66];
National Institute of Diabetes and Digestive and Kidney Diseases
[1K23DK092335-01A1]; Eleanor Chesterman Beatson Fund; Katherine Adler
Astrove Youth Education Fund; Maria Griffin Drury Pediatric Fund
FX This work was funded by an American Diabetes Association Clinical
Research Award (number 7-08-CR-66), a K23 award from the National
Institute of Diabetes and Digestive and Kidney Diseases (number
1K23DK092335-01A1), the Eleanor Chesterman Beatson Fund, the Katherine
Adler Astrove Youth Education Fund, and the Maria Griffin Drury
Pediatric Fund.
NR 15
TC 1
Z9 1
U1 2
U2 8
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1520-9156
J9 DIABETES TECHNOL THE
JI Diabetes Technol. Ther.
PD MAY
PY 2013
VL 15
IS 5
BP 428
EP 433
DI 10.1089/dia.2013.0008
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 137ZL
UT WOS:000318477700011
PM 23550556
ER
PT J
AU Harrington, AT
Clarridge, JE
AF Harrington, Amanda T.
Clarridge, Jill E., III
TI Impact of identification of Streptococcus dysgalactiae subspecies
equisimilis from throat cultures in an adult population
SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
LA English
DT Article
DE Pharyngitis; Streptococcus dysgalactiae subspecies equisimilis; Throat
culture
ID BETA-HEMOLYTIC STREPTOCOCCI; GROUP-C STREPTOCOCCI; LANCEFIELD GROUP-C;
ACUTE RHEUMATIC-FEVER; ACUTE PHARYNGITIS; GROUP-A; OUTBREAK;
GLOMERULONEPHRITIS; INFECTION; ANGINOSUS
AB Streptococcus dysgalactiae subspecies equisimilis (SDSE) are isolated from the throat of patients with pharyngitis, although the clinical significance remains debated. We sought to determine the incidence and association with pharyngitis of SDSE in an adult veteran population. Organisms were phenotypically identified to subspecies and Lancefield group, with selective 16S rRNA gene sequencing. From 833 throat cultures, the overall frequency of SDSE was 3.4% (64% group C and 36% group G) as compared to 8.6% for S. pyogenes (GAS). SDSE was described as a large colony in only 29% of the original culture evaluations by bench technologists, and clinical symptoms were similar for GAS and SDSE. Laboratory algorithms that are limited to identification of only GAS or are based on Lancefield group or visual identification of "large-colony type" beta hemolytic Lancefield group C and G streptococci may be missing or misidentifying SDSE along with Anginosus group streptococci. Published by Elsevier Inc.
C1 [Clarridge, Jill E., III] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
Univ Washington, Seattle, WA 98108 USA.
RP Clarridge, JE (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
EM jill.clarridge@va.gov
NR 29
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0732-8893
EI 1879-0070
J9 DIAGN MICR INFEC DIS
JI Diagn. Microbiol. Infect. Dis.
PD MAY
PY 2013
VL 76
IS 1
BP 20
EP 23
DI 10.1016/j.diagmicrobio.2013.02.029
PG 4
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA 135YF
UT WOS:000318325900005
PM 23537788
ER
PT J
AU Camus, M
Jensen, DM
Ohning, GV
Kovacs, TO
Ghassemi, KA
Jutabha, R
Machicado, GA
Dulai, GS
Hines, OJ
AF Camus, M.
Jensen, D. M.
Ohning, G. V.
Kovacs, T. O.
Ghassemi, K. A.
Jutabha, R.
Machicado, G. A.
Dulai, G. S.
Hines, O. J.
TI Severe upper gastrointestinal hemorrhage from linear gastric ulcers in
large hiatal hernias: a large prospective case series of Cameron ulcers
SO ENDOSCOPY
LA English
DT Editorial Material
ID DIAGNOSIS; ANEMIA
AB We report a case series of all consecutive patients hospitalized in our two tertiary referral medical centers over the past 17 years for Cameron ulcers causing severe upper gastrointestinal hemorrhage (GIH) or severe obscure GIH. Cameron ulcers were diagnosed in 25 of the 3960 screened patients with severe upper GIH or severe obscure GIH (0.6%). Of these, 21 patients had a prospective follow-up (median time 20.4 months [interquartile range: 8.5-31.8]). Patients were more often elderly women with chronic anemia, always had large hiatal hernias, and were usually referred for obscure GIH. Twelve of the 21 patients (57%) were referred for surgery while being treated with high-dose proton pump inhibitors (PPIs). The other 9 patients (43 %) continued PPIs without any rebleeding during the follow-up. Cameron ulcers in large hiatal hernias are an uncommon cause of severe upper GIH. The choice of medical vs. surgical therapy should be individualized.
C1 [Camus, M.; Jensen, D. M.; Ohning, G. V.; Kovacs, T. O.; Ghassemi, K. A.; Jutabha, R.; Machicado, G. A.; Dulai, G. S.] Univ Calif Los Angeles, David Geffen Sch Med, CURE Hemostasis Res Grp, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA.
[Jensen, D. M.; Ohning, G. V.; Kovacs, T. O.; Ghassemi, K. A.; Jutabha, R.; Machicado, G. A.; Dulai, G. S.] Univ Calif Los Angeles, Ronald Reagan Med Ctr, Div Digest Dis, Los Angeles, CA USA.
[Camus, M.] Univ Paris 07, Dept Gastroenterol, Lariboisiere Hosp, APHP, F-75221 Paris 05, France.
[Jensen, D. M.; Ohning, G. V.; Kovacs, T. O.; Machicado, G. A.; Dulai, G. S.] Vet Affairs Greater Los Angeles Healthcare, Div Digest Dis, Los Angeles, CA USA.
[Hines, O. J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA.
RP Camus, M (reprint author), Lariboisiere Hosp, APHP, Dept Gastroenterol, 2 Rue Ambroise Pare, F-75010 Paris, France.
EM marine.camus@gmail.com
FU NIDDK NIH HHS [P30 DK041301]
NR 9
TC 2
Z9 3
U1 0
U2 5
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0013-726X
J9 ENDOSCOPY
JI Endoscopy
PD MAY
PY 2013
VL 45
IS 5
BP 397
EP 400
DI 10.1055/s-0032-1326294
PG 4
WC Gastroenterology & Hepatology; Surgery
SC Gastroenterology & Hepatology; Surgery
GA 131VY
UT WOS:000318026600010
PM 23616128
ER
PT J
AU Hasserjian, RP
AF Hasserjian, Robert P.
TI DIAGNOSTIC TESTING FOR BETA GLOBIN DEFECTS. ACUTE MYELOID LEUKEMIA:
ADVANCES IN DIAGNOSIS AND CLASSIFICATION
SO INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
LA English
DT Meeting Abstract
C1 [Hasserjian, Robert P.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Hasserjian, Robert P.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1751-5521
J9 INT J LAB HEMATOL
JI Int. J. Lab. Hematol.
PD MAY
PY 2013
VL 35
SU 1
SI SI
BP 10
EP 10
PG 1
WC Hematology
SC Hematology
GA 135KF
UT WOS:000318286300021
ER
PT J
AU Smock, K
Ledford-Kraemer, M
Meijer, P
Hsu, P
Van Cott, E
AF Smock, Kristi
Ledford-Kraemer, Marlies
Meijer, Piet
Hsu, Peihong
Van Cott, Elizabeth
TI UPDATE ON PROFICIENCY TEST RESULT S FOR HEPARIN-INDUCED
THROMBOCYTOPENIA: A REPORT FROM THE NORTH AMERICAN SPECIALIZED
COAGULATION LABORATORY ASSOCIATION (NASCOLA)
SO INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
LA English
DT Meeting Abstract
C1 [Smock, Kristi] Univ Utah, Dept Pathol, ARUP Labs, Salt Lake City, UT USA.
[Ledford-Kraemer, Marlies] CLOT ED Inc, Islamorada, FL USA.
[Meijer, Piet] ECAT Fdn, Leiden, Netherlands.
[Hsu, Peihong] Hofstra North Shore Long Isl Jewish Sch Med, Dept Lab Med, Lake Success, NY USA.
[Van Cott, Elizabeth] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1751-5521
J9 INT J LAB HEMATOL
JI Int. J. Lab. Hematol.
PD MAY
PY 2013
VL 35
SU 1
SI SI
BP 16
EP 17
PG 2
WC Hematology
SC Hematology
GA 135KF
UT WOS:000318286300032
ER
PT J
AU Van Cott, E
AF Van Cott, Elizabeth
TI COMMON SPECIAL COAGULATION ASSAYS-INSIGHTS FROM QUALITY ASSURANCE
SO INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
LA English
DT Meeting Abstract
C1 [Van Cott, Elizabeth] Massachusetts Gen Hosp, Coagulat Lab, Boston, MA 02114 USA.
[Van Cott, Elizabeth] Massachusetts Gen Hosp, Core Lab, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1751-5521
J9 INT J LAB HEMATOL
JI Int. J. Lab. Hematol.
PD MAY
PY 2013
VL 35
SU 1
SI SI
BP 24
EP 24
PG 1
WC Hematology
SC Hematology
GA 135KF
UT WOS:000318286300044
ER
PT J
AU Hasserjian, RP
AF Hasserjian, Robert P.
TI ACUTE MYELOID LEUKEMIA: ADVANCES IN DIAGNOSIS AND CLASSIFICATION
SO INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
LA English
DT Meeting Abstract
C1 [Hasserjian, Robert P.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Hasserjian, Robert P.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1751-5521
J9 INT J LAB HEMATOL
JI Int. J. Lab. Hematol.
PD MAY
PY 2013
VL 35
SU 1
SI SI
BP 36
EP 36
PG 1
WC Hematology
SC Hematology
GA 135KF
UT WOS:000318286300068
ER
PT J
AU Hsu, PH
Zantek, ND
Meijer, P
Brody, J
Zhang, XM
Smock, KJ
Van Cott, EM
AF Hsu, Peihong
Zantek, Nicole D.
Meijer, Piet
Brody, Judith
Zhang, Xinmin
Smock, Kristi J.
Van Cott, Elizabeth M.
TI FACTOR XIII ASSAYS, A PROBLEM FOR LABORATORY DIAGNOSIS? AN ANALYSIS OF
INTERNATIONAL PROFICIENCY TESTING RESULTS
SO INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
LA English
DT Meeting Abstract
C1 [Hsu, Peihong; Brody, Judith; Zhang, Xinmin] Hofstra North Shore Long Isl Jewish Sch, Dept Pathol Lab Med, Lake Success, NY USA.
[Zantek, Nicole D.] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA.
[Meijer, Piet] ECAT Fdn, NL-2300 AA Leiden, Netherlands.
[Smock, Kristi J.] Univ Utah, Dept Pathol, ARUP Labs, Salt Lake City, UT USA.
[Van Cott, Elizabeth M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1751-5521
J9 INT J LAB HEMATOL
JI Int. J. Lab. Hematol.
PD MAY
PY 2013
VL 35
SU 1
SI SI
BP 68
EP 68
PG 1
WC Hematology
SC Hematology
GA 135KF
UT WOS:000318286300134
ER
PT J
AU Bedair, H
Lawless, B
Malchau, H
AF Bedair, Hany
Lawless, Bryan
Malchau, Henrik
TI Are Implant Designer Series Believable? Comparison of Survivorship
Between Designer Series and National Registries
SO JOURNAL OF ARTHROPLASTY
LA English
DT Article
DE implant; survivorship; registry; revision; failure
ID TOTAL HIP-ARTHROPLASTY; QUALITY-OF-LIFE; UNICOMPARTMENTAL KNEE
ARTHROPLASTY; EARLY FAILURE; FEMORAL COMPONENT; REPLACEMENT
AB Performance of hip and knee implants reported by the designing surgeon(s) is often felt to be more optimistic than those observed in non-designer series. The purpose of this study is to compare the survivorship of hip and knee prostheses in series reported by designers with those in national joint registries. Fifteen different hip and knee implant results published by designers were identified and compared to four national registries. Thirty-two percent of comparisons performed demonstrated greater survivorship in the designer series compared to the registry, while 0% reported lower, and 68% demonstrated no difference. Two implants accounted for the majority (12/16) of the discordances. There was a lower (62%) concordance rate between the registries than between the designer series and registries (68%). (C) 2013 Elsevier Inc. All rights reserved.
C1 [Bedair, Hany; Lawless, Bryan; Malchau, Henrik] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Bedair, H (reprint author), 55 Fruit St,Yawkey Suite 3B, Boston, MA 02114 USA.
OI Malchau, Henrik/0000-0002-4291-2441
NR 22
TC 1
Z9 1
U1 0
U2 0
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 0883-5403
J9 J ARTHROPLASTY
JI J. Arthroplast.
PD MAY
PY 2013
VL 28
IS 5
BP 728
EP 731
DI 10.1016/j.arth.2012.08.027
PG 4
WC Orthopedics
SC Orthopedics
GA 136SI
UT WOS:000318383300004
PM 23414935
ER
PT J
AU Schuman-Olivier, Z
Noordsy, DL
Brunette, MF
AF Schuman-Olivier, Zev
Noordsy, Douglas L.
Brunette, Mary F.
TI Strategies for Reducing Antipsychotic Polypharmacy
SO JOURNAL OF DUAL DIAGNOSIS
LA English
DT Article
DE mindfulness; exercise; polypharmacy; antipsychotic; psychosis;
schizophrenia; addiction; substance abuse; wellness; co-occurring
disorder
ID SUBSTANCE USE DISORDERS; STRESS REDUCTION PROGRAM;
RANDOMIZED-CONTROLLED-TRIALS; MINDFULNESS-BASED THERAPY; COGNITIVE
THERAPY; PHYSICAL-ACTIVITY; BIPOLAR DISORDER; ALCOHOL-USE; MOTIVATIONAL
INTERVENTION; SCHIZOAFFECTIVE DISORDER
AB Antipsychotic polypharmacy (the use of two or more antipsychotics at the same time) is an increasingly common practice even though consensus treatment guidelines do not recommend it. Multiple studies have examined algorithms, decision supports, and educational strategies to change prescriber behaviors. We describe the case study of a young adult with schizoaffective disorder who transferred from residential treatment to an outpatient assertive community treatment for co-occurring disorders, presenting treatment-resistant psychotic and mood disorder symptoms and experiencing intolerable side effects from substantial polypharmacy. This case exemplifies how integrating wellness-oriented strategies, such as mindfulness training and exercise, into treatment and encouraging people to apply these strategies to address persistent symptoms might facilitate reductions in antipsychotic polypharmacy among those with co-occurring disorders. (Journal of Dual Diagnosis, 9: 208-218, 2013)
C1 [Schuman-Olivier, Zev; Brunette, Mary F.] WestBridge Community Serv, Medford, MA 02155 USA.
[Schuman-Olivier, Zev] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Addict Med, Boston, MA USA.
[Noordsy, Douglas L.; Brunette, Mary F.] Geisel Sch Med Dartmouth, Psychiat Res Ctr, Lebanon, NH USA.
RP Schuman-Olivier, Z (reprint author), WestBridge Community Serv, 275 Myst Ave,Suite C, Medford, MA 02155 USA.
EM zschuman@westbridge.org
NR 118
TC 1
Z9 1
U1 3
U2 16
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1550-4263
J9 J DUAL DIAGN
JI J. Dual Diagn.
PD MAY 1
PY 2013
VL 9
IS 2
BP 208
EP 218
DI 10.1080/15504263.2013.778767
PG 11
WC Psychology, Clinical; Substance Abuse; Psychiatry
SC Psychology; Substance Abuse; Psychiatry
GA 136IA
UT WOS:000318354400015
ER
PT J
AU Partin, MR
Powell, AA
Burgess, JF
AF Partin, Melissa R.
Powell, Adam A.
Burgess, James F., Jr.
TI Fecal Occult Blood Test (FOBT) Overuse reply
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Letter
C1 [Partin, Melissa R.; Powell, Adam A.] Minneapolis VA Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN 55417 USA.
[Burgess, James F., Jr.] VA Boston Healthcare Syst, Ctr Org Leadership & Management Res, Boston, MA USA.
RP Partin, MR (reprint author), Minneapolis VA Hlth Care Syst, Ctr Chron Dis Outcomes Res, 1 Vet Dr, Minneapolis, MN 55417 USA.
EM Melissa.partin@va.gov
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD MAY
PY 2013
VL 28
IS 5
BP 611
EP 611
DI 10.1007/s11606-013-2397-1
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 131IG
UT WOS:000317985900006
PM 23475642
ER
PT J
AU Saha, S
Korthuis, PT
Cohn, JA
Sharp, VL
Moore, RD
Beach, MC
AF Saha, Somnath
Korthuis, P. Todd
Cohn, Jonathan A.
Sharp, Victoria L.
Moore, Richard D.
Beach, Mary Catherine
TI Primary Care Provider Cultural Competence and Racial Disparities in HIV
Care and Outcomes
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE culture; ethnic groups; HIV
ID PATIENT-PHYSICIAN RELATIONSHIP; ACTIVE ANTIRETROVIRAL THERAPY;
SELF-REPORTED ADHERENCE; HEALTH-CARE; UNITED-STATES; MEDICATION
ADHERENCE; INFECTED ADULTS; QUALITY; COMMUNICATION; MORTALITY
AB Health professional organizations have advocated for increasing the "cultural competence" (CC) of healthcare providers, to reduce racial and ethnic disparities in patient care. It is unclear whether provider CC is associated with more equitable care.
To evaluate whether provider CC is associated with quality of care and outcomes for patients with HIV/AIDS.
Survey of 45 providers and 437 patients at four urban HIV clinics in the U.S.
Providers' self-rated CC was measured using a novel, 20-item instrument. Outcome measures included patients' receipt of antiretroviral (ARV) therapy, self-efficacy in managing medication regimens, complete 3-day ARV adherence, and viral suppression.
Providers' mean age was 44 years; 56 % were women, and 64 % were white. Patients' mean age was 45; 67 % were men, and 77 % were nonwhite. Minority patients whose providers scored in the middle or highest third on self-rated CC were more likely than those with providers in the lowest third to be on ARVs, have high self-efficacy, and report complete ARV adherence. Racial disparities were observed in receipt of ARVs (adjusted OR, 95 % CI for white vs. nonwhite: 6.21, 1.50-25.7), self-efficacy (3.77, 1.24-11.4), and viral suppression (13.0, 3.43-49.0) among patients of low CC providers, but not among patients of moderate and high CC providers (receipt of ARVs: 0.71, 0.32-1.61; self-efficacy: 1.14, 0.59-2.22; viral suppression: 1.20, 0.60-2.42).
Provider CC was associated with the quality and equity of HIV care. These findings suggest that enhancing provider CC may reduce racial disparities in healthcare quality and outcomes.
C1 [Saha, Somnath] Portland VA Med Ctr, Gen Internal Med Sect, Portland, OR 97239 USA.
[Saha, Somnath; Korthuis, P. Todd] Oregon Hlth & Sci Univ, Div Gen Internal Med & Geriatr, Portland, OR 97201 USA.
[Cohn, Jonathan A.] Wayne State Univ, Sch Med, Dept Med, Div Infect Dis, Detroit, MI 48201 USA.
[Sharp, Victoria L.] St Lukes Roosevelt Hosp, Ctr Comprehens Care, New York, NY USA.
[Moore, Richard D.; Beach, Mary Catherine] Johns Hopkins Univ, Sch Med, Dept Med, Div Gen Internal Med, Baltimore, MD 21205 USA.
RP Saha, S (reprint author), Portland VA Med Ctr, Gen Internal Med Sect, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM sahas@ohsu.edu
FU Health Resources and Services Administration; Agency for Healthcare
Research and Quality [AHRQ 290-01-0012, K08 HS013903-05]; Department of
Veterans Affairs; Generalist Physician Faculty Scholar awards from the
Robert Wood Johnson Foundation; National Institute on Drug Abuse [K23
DA019809]
FX This research was supported by a contract from the Health Resources and
Services Administration and the Agency for Healthcare Research and
Quality (AHRQ 290-01-0012). Representatives of both funding agencies
were involved in the design of the study, but not in its conduct; in
collection, management, analysis, or interpretation of the data; or in
preparation, review, or approval of the manuscript. Drs. Saha, Moore,
and Beach had full access to all of the data in the study and take
responsibility for the integrity of the data and the accuracy of the
data analysis. Dr. Saha was supported by the Department of Veterans
Affairs. Dr. Beach was supported by the Agency for Healthcare Research
and Quality (K08 HS013903-05), and both Drs. Saha and Beach were
supported by Generalist Physician Faculty Scholar awards from the Robert
Wood Johnson Foundation. Dr. Korthuis was supported by the National
Institute on Drug Abuse (K23 DA019809). The views expressed in this
article are those of the authors, and no official endorsement by the
Agency for Healthcare Research and Quality, the Department of Veterans
Affairs, or the U.S. Department of Health and Human Services is intended
or should be inferred.
NR 53
TC 18
Z9 18
U1 1
U2 18
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD MAY
PY 2013
VL 28
IS 5
BP 622
EP 629
DI 10.1007/s11606-012-2298-8
PG 8
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 131IG
UT WOS:000317985900008
PM 23307396
ER
PT J
AU Marshall, R
Beach, MC
Saha, S
Mori, T
Loveless, MO
Hibbard, JH
Cohn, JA
Sharp, VL
Korthuis, PT
AF Marshall, Rebecca
Beach, Mary Catherine
Saha, Somnath
Mori, Tomi
Loveless, Mark O.
Hibbard, Judith H.
Cohn, Jonathan A.
Sharp, Victoria L.
Korthuis, P. Todd
TI Patient Activation and Improved Outcomes in HIV-Infected Patients
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE patient activation; HIV; self-efficacy; medication adherence; patient
outcomes
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY ADHERENCE;
SELF-MANAGEMENT; MEDICATION ADHERENCE; REPORTED ADHERENCE; CHRONIC
DISEASE; UNITED-STATES; MEASURE PAM; VIRAL LOAD; HEALTH
AB The Patient Activation Measure (PAM) assesses several important concepts in chronic care management, including self-efficacy for positive health behaviors. In HIV-infected populations, better self-efficacy for medication management is associated with improved adherence to antiretroviral medications (ARVs), which is critically important for controlling symptoms and slowing disease progression.
To determine 1) characteristics associated with patient activation and 2) associations between patient activation and outcomes in HIV-infected patients.
Cross-sectional survey.
433 patients receiving care in four HIV clinics.
An interviewer conducted face-to-face interviews with patients following their HIV clinic visit. Survey data were supplemented with medical record abstraction to obtain most recent CD4 counts, HIV viral load and antiretroviral medications.
Patient activation was measured using the 13-item PAM (possible range 0-100). Outcomes included CD4 cell count > 200 cells/mL(3), HIV-1 RNA < 400 copies/mL (viral suppression), and patient-reported adherence.
Overall, patient activation was high (mean PAM = 72.3 [SD 16.5, range 34.7-100]). Activation was lower among those without vs. with a high school degree (68.0 vs. 74.0, p < .001), and greater depression (77.6 lowest, 70.2 middle, 68.1 highest tertile, p < .001). There was no association between patient activation and age, race, gender, problematic alcohol use, illicit drug use, or social status. In multivariable models, every 5-point increase in PAM was associated with greater odds of CD4 count > 200 cells/mL(3) (aOR 1.10 [95 % CI 1.01, 1.21]), adherence (aOR 1.18 [95 % CI 1.09, 1.29]) and viral suppression (aOR 1.08 [95 % CI 1.00, 1.17]). The association between PAM and viral suppression was mediated through adherence.
Higher patient activation was associated with more favorable HIV outcomes. Interventions to improve patient activation should be developed and tested for their ability to improve HIV outcomes.
C1 [Marshall, Rebecca] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA.
[Beach, Mary Catherine] Johns Hopkins Univ, Sch Med, Dept Med, Div Gen Internal Med, Baltimore, MD 21205 USA.
[Saha, Somnath] Portland VA Med Ctr, Gen Internal Med Sect, Portland, OR USA.
[Saha, Somnath; Korthuis, P. Todd] Oregon Hlth & Sci Univ, Div Gen Internal Med, Portland, OR 97201 USA.
[Saha, Somnath; Mori, Tomi; Loveless, Mark O.; Hibbard, Judith H.; Korthuis, P. Todd] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA.
[Hibbard, Judith H.] Univ Oregon, Dept Planning Publ Policy & Management, Eugene, OR 97403 USA.
[Cohn, Jonathan A.] Wayne State Univ, Sch Med, Dept Med, Div Infect Dis, Detroit, MI 48201 USA.
[Sharp, Victoria L.] St Lukes Roosevelt Hosp, Ctr Comprehens Care, New York, NY USA.
RP Korthuis, PT (reprint author), Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, 3181 SW Sam Jackson Pk Rd,Mail Code L-475, Portland, OR 97239 USA.
EM korthuis@ohsu.edu
FU Health Resources Service Administration; Agency for Healthcare Research
and Quality [AHRQ 290-01-0012, K08 HS013903-05]; National Institutes of
Health, National Institute on Drug Abuse [K23DA019809]; Robert Wood
Johnson Generalist Physician Faculty Scholars Awards; Department of
Veterans Affairs
FX This research was supported by a contract from the Health Resources
Service Administration and the Agency for Healthcare Research and
Quality (AHRQ 290-01-0012). Dr. Korthuis' time was supported by the
National Institutes of Health, National Institute on Drug Abuse
(K23DA019809). Dr. Beach was supported by the Agency for Healthcare
Research and Quality (K08 HS013903-05), and both Dr. Beach and Dr. Saha
were supported by Robert Wood Johnson Generalist Physician Faculty
Scholars Awards. Dr. Saha is supported by the Department of Veterans
Affairs. The contents of the publication are solely the responsibility
of the authors and do not necessarily represent the views of the funding
agencies or the U.S. government.
NR 41
TC 25
Z9 26
U1 6
U2 20
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD MAY
PY 2013
VL 28
IS 5
BP 668
EP 674
DI 10.1007/s11606-012-2307-y
PG 7
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 131IG
UT WOS:000317985900014
PM 23288378
ER
PT J
AU Bryson, CL
Au, DH
Maciejewski, ML
Piette, JD
Fihn, SD
Jackson, GL
Perkins, M
Wong, ES
Yano, EM
Liu, CF
AF Bryson, Chris L.
Au, David H.
Maciejewski, Matthew L.
Piette, John D.
Fihn, Stephan D.
Jackson, George L.
Perkins, Mark
Wong, Edwin S.
Yano, Elizabeth M.
Liu, Chuan-Fen
TI Wide Clinic-Level Variation in Adherence to Oral Diabetes Medications in
the VA
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE pharmacoepidemiology; health services research; diabetes; veterans;
primary care
ID MYOCARDIAL-INFARCTION; SELF-CARE; MANAGEMENT; IMPROVEMENT
AB While there has been extensive research into patient-specific predictors of medication adherence and patient-specific interventions to improve adherence, there has been little examination of variation in clinic-level medication adherence.
We examined the clinic-level variation of oral hypoglycemic agent (OHA) medication adherence among patients with diabetes treated in the Department of Veterans Affairs (VA) primary care clinics. We hypothesized that there would be systematic variation in clinic-level adherence measures, and that adherence within organizationally-affiliated clinics, such as those sharing local management and support, would be more highly correlated than adherence between unaffiliated clinics.
Retrospective cohort study.
VA hospital and VA community-based primary care clinics in the contiguous 48 states.
444,418 patients with diabetes treated with OHAs and seen in 158 hospital-based clinics and 401 affiliated community primary care clinics during fiscal years 2006 and 2007.
Refill-based medication adherence to OHA.
Adjusting for patient characteristics, the proportion of patients adherent to OHAs ranged from 57 % to 81 % across clinics. Adherence between organizationally affiliated clinics was high (Pearson Correlation = 0.82), and adherence between unaffiliated clinics was low (Pearson Correlation = 0.04).
The proportion of patients adherent to OHAs varied widely across VA primary care clinics. Clinic-level adherence was highly correlated to other clinics in the same organizational unit. Further research should identify which factors common to affiliated clinics influence medication adherence.
C1 [Bryson, Chris L.; Au, David H.; Perkins, Mark; Wong, Edwin S.; Liu, Chuan-Fen] VA Puget Sound Hlth Care Syst, Northwest Ctr Outcomes Res Older Adults, Seattle, WA 98101 USA.
[Bryson, Chris L.; Au, David H.; Fihn, Stephan D.] Univ Washington, Dept Med, Seattle, WA USA.
[Maciejewski, Matthew L.; Jackson, George L.] Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA.
[Maciejewski, Matthew L.; Jackson, George L.] Duke Univ, Med Ctr, Dept Med, Div Gen Internal Med, Durham, NC 27710 USA.
[Piette, John D.] VA Ann Arbor Healthcare Syst, Vet Affairs Ctr Clin Management Res, Ann Arbor, MI USA.
[Piette, John D.] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA.
[Fihn, Stephan D.] Univ Washington, Dept Vet Affairs, Off Analyt & Business Intelligence, Seattle, WA 98195 USA.
[Wong, Edwin S.; Liu, Chuan-Fen] Univ Washington, Sch Publ Hlth & Community Med, Dept Hlth Serv, Seattle, WA 98195 USA.
[Yano, Elizabeth M.] Los Angeles VA, Ctr Study Healthcare Provider Behav, Los Angeles, VA USA.
[Yano, Elizabeth M.] Univ Calif Los Angeles, Dept Hlth Serv, Los Angeles, CA USA.
[Bryson, Chris L.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98101 USA.
RP Bryson, CL (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res Dev, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.
EM Christopher.Bryson@va.gov
FU Department of Veterans Affairs, Health Services Research and Development
[IIR 07-068-2]; VA Career Development Award [03-177]; VA Health Services
Research and Development Postdoctoral Fellowship [TPP 61-024]; Bosch
Inc.; Gilead Sciences; Takeda Pharmaceuticals; Novartis; Surgical Review
Corporation
FX This research was supported by an Investigator Initiated Research Award
(IIR 07-068-2) from the Department of Veterans Affairs, Health Services
Research and Development. Dr. Bryson was supported by VA Career
Development Award 03-177. Dr. Jackson was supported for a portion of
this project by a VA Career Development Award. Dr. Piette is a VA Senior
Research Career Scientist; Dr. Maciejewski and Dr. Yano are VA Research
Career Scientists. Dr. Wong was supported by VA Health Services Research
and Development Postdoctoral Fellowship TPP 61-024. An earlier version
of this manuscript was presented as a poster at the Society of General
Internal Medicine 32nd Annual Meeting in Miami, FL in 2009. Dr. Bryson
takes responsibility for the integrity of the data and the accuracy of
the data analysis. The views expressed in this article are those of the
authors and do not necessarily reflect the position or policy of the
Department of Veterans Affairs.; All authors are federal employees for
the Department of Veterans Affairs. Dr. Au has received consultation
funds from Bosch Inc. and a grant from Gilead Sciences. Dr. Maciejewski
has received consultation funds from Takeda Pharmaceuticals, Novartis
and the Surgical Review Corporation. Dr. Maciejewski also owns stock in
Amgen.
NR 27
TC 5
Z9 5
U1 2
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD MAY
PY 2013
VL 28
IS 5
BP 698
EP 705
DI 10.1007/s11606-012-2331-y
PG 8
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 131IG
UT WOS:000317985900018
PM 23371383
ER
PT J
AU Jubelt, LE
AF Jubelt, Lindsay E.
TI Capsule Commentary on Melzer et.al., Missing Potential Opportunities to
Reduce Repeat COPD Exacerbations
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Editorial Material
C1 [Jubelt, Lindsay E.] Univ Penn, Perelman Sch Med, Robert Wood Johnson Fdn Clin Scholars, Philadelphia, PA 19104 USA.
[Jubelt, Lindsay E.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Jubelt, Lindsay E.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
RP Jubelt, LE (reprint author), Univ Penn, Perelman Sch Med, Robert Wood Johnson Fdn Clin Scholars, Philadelphia, PA 19104 USA.
EM ljubelt@upenn.edu
NR 5
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD MAY
PY 2013
VL 28
IS 5
BP 708
EP 708
DI 10.1007/s11606-012-2299-7
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 131IG
UT WOS:000317985900021
PM 23288376
ER
PT J
AU Bryan, T
Snyder, E
AF Bryan, Teresa
Snyder, Erin
TI The Clinical Breast Exam: A Skill that Should Not Be Abandoned
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE clinical breast exam; women's health; medical education; simulation
ID SIGNIFICANT NUMBER; SCREENING-PROGRAM; NORMAL MAMMOGRAM; WOMEN PRESENT;
CANCER EVEN; PERFORMANCE; SYMPTOMS; PATIENT; TRIAL
AB The clinical breast exam (CBE) is an important tool in the care of women. However, the utility of the screening CBE has been called into question. This article discusses the importance of the CBE as a physical diagnosis tool. Recommendations regarding screening with CBE are reviewed, and evidence surrounding breast cancer screening using CBE is briefly summarized. Clinicians should strive to provide high quality CBEs as part of the general clinical exam for women, particularly those who present with breast complaints, and for patients who choose to have CBE screening. In conclusion, there is a role for the CBE in the care of women, and clinicians should be proficient at performing these exams. Simulation teaching technologies are now available at Department of Veteran Affairs (VA) facilities to enable clinicians to improve their CBE skills.
C1 [Bryan, Teresa; Snyder, Erin] Univ Alabama Birmingham, Med Sch Birmingham, Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA.
RP Bryan, T (reprint author), Univ Alabama Birmingham, Med Sch Birmingham, Birmingham Vet Affairs Med Ctr, FOT 720 1720 2nd Ave South, Birmingham, AL 35294 USA.
EM Teresa.bryan@va.gov
NR 28
TC 8
Z9 8
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD MAY
PY 2013
VL 28
IS 5
BP 719
EP 722
DI 10.1007/s11606-013-2373-9
PG 4
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 131IG
UT WOS:000317985900025
PM 23435772
ER
PT J
AU Huetsch, JC
Uman, JE
Udris, EM
Au, DH
AF Huetsch, John C.
Uman, Jane E.
Udris, Edmunds M.
Au, David H.
TI Predictors of Adherence to Inhaled Medications among Veterans with COPD
(vol 27, pg 1506, 2012)
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Correction
C1 [Huetsch, John C.; Uman, Jane E.; Udris, Edmunds M.; Au, David H.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98108 USA.
[Huetsch, John C.] Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA.
[Au, David H.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA.
RP Huetsch, JC (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98108 USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD MAY
PY 2013
VL 28
IS 5
BP 743
EP 747
DI 10.1007/s11606-013-2377-5
PG 5
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 131IG
UT WOS:000317985900032
ER
PT J
AU Kara, A
McQuillan, P
Dhaliwal, G
AF Kara, Areeba
McQuillan, Patrick
Dhaliwal, Gurpreet
TI A multifaceted case
SO JOURNAL OF HOSPITAL MEDICINE
LA English
DT Article
ID POSTSURGICAL GOUT; HYPERURICEMIA; RISK; PRESENTATIONS; POPULATION;
PREVALENCE; MANAGEMENT; HEALTH; US
C1 [Kara, Areeba; McQuillan, Patrick] Indiana Univ Hlth Phys, Dept Inpatient Med, Indianapolis, IN 46202 USA.
[Dhaliwal, Gurpreet] San Francisco VA Med Ctr, Med Serv, San Francisco, CA USA.
[Dhaliwal, Gurpreet] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
RP Kara, A (reprint author), Indiana Univ Hlth Phys, Dept Inpatient Med, 1633 N Capitol Ave, Indianapolis, IN 46202 USA.
EM akara@iuhealth.org
NR 22
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1553-5592
J9 J HOSP MED
JI J. Hosp. Med.
PD MAY
PY 2013
VL 8
IS 5
BP 267
EP 270
DI 10.1002/jhm.2043
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 139ZS
UT WOS:000318624400007
PM 23606357
ER
PT J
AU Blumenthal, D
Jena, AB
AF Blumenthal, Daniel
Jena, Anupam B.
TI Hospital value-based purchasing
SO JOURNAL OF HOSPITAL MEDICINE
LA English
DT Article
ID QUALITY-OF-CARE; READMISSION RATES; PERFORMANCE; PAY; MORTALITY;
MEDICARE; ASSOCIATION; INTENSITY; IMPACT; INCENTIVES
AB Hospital Value Based Purchasing (VBP) aims to incentivize inpatient providers to delivery high value, as opposed to high volume, health care. The formal mandate of hospitals to provide high value health care through financial incentives marks an important change in Medicare and Medicaid policy. In this opportune review of VBP, we discuss the relevant historical changes in the reimbursement environment of U.S. hospitals that have set the stage for VBP. We describe the structure of the Centers for Medicare and Medicaid Services' VBP program, with a focus on which hospitals are eligible to participate in the program, the specific outcomes measured and incentivized, how rewards and penalties are allocated, and how the program will be funded. In an effort to anticipate some of the issues that lie ahead, we then highlight a number of potential challenges to the success of VBP, and discuss how VBP will impact the delivery and reimbursement of inpatient care services. We conclude by examining how the VBP program is likely to evolve over time. Journal of Hospital Medicine 2013;8:271277. (c) 2013 Society of Hospital Medicine
C1 [Blumenthal, Daniel] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Jena, Anupam B.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
[Jena, Anupam B.] Massachusetts Gen Hosp, Dept Med, Cambridge, MA USA.
[Jena, Anupam B.] Natl Bur Econ Res, Cambridge, MA 02138 USA.
RP Jena, AB (reprint author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.
EM jena@hcp.med.harvard.edu
NR 36
TC 17
Z9 17
U1 3
U2 20
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1553-5592
J9 J HOSP MED
JI J. Hosp. Med.
PD MAY
PY 2013
VL 8
IS 5
BP 271
EP 277
DI 10.1002/jhm.2045
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 139ZS
UT WOS:000318624400008
PM 23589485
ER
PT J
AU Sperduto, PW
Kased, N
Roberge, D
Chao, ST
Shanley, R
Luo, XH
Sneed, PK
Suh, J
Weil, RJ
Jensen, AW
Brown, PD
Shih, HA
Kirkpatrick, J
Gaspar, LE
Fiveash, JB
Chiang, V
Knisely, JPS
Sperduto, CM
Lin, N
Mehta, M
AF Sperduto, Paul W.
Kased, Norbert
Roberge, David
Chao, Samuel T.
Shanley, Ryan
Luo, Xianghua
Sneed, Penny K.
Suh, John
Weil, Robert J.
Jensen, Ashley W.
Brown, Paul D.
Shih, Helen A.
Kirkpatrick, John
Gaspar, Laurie E.
Fiveash, John B.
Chiang, Veronica
Knisely, Jonathan P. S.
Sperduto, Christina Maria
Lin, Nancy
Mehta, Minesh
TI The effect of tumor subtype on the time from primary diagnosis to
development of brain metastases and survival in patients with breast
cancer
SO JOURNAL OF NEURO-ONCOLOGY
LA English
DT Article
DE Breast cancer; Brain metastases; Prognosis; Radiation therapy;
Stereotactic radiosurgery; Estrogen; Progesterone; HER2; Graded
prognostic assessment
ID GRADED PROGNOSTIC ASSESSMENT; RADIATION-THERAPY; RECEPTOR; HER-2
AB Our group has previously published the Diagnosis-Specific Graded Prognostic Assessment (GPA) showing the prognostic factors associated with survival in patients with brain metastases (BM). The purpose of this study is to investigate the relationship of breast cancer subtype to the time interval from primary diagnosis (PD) to development of BM (TPDBM), number of BM at initial BM presentation and survival. We analyzed our previously described multi-institutional retrospective database of 865 breast cancer patients treated for newly-diagnosed BM from 1993 to 2010. Several factors found to be associated with survival were incorporated into the Breast-GPA, including tumor subtype. The GPA database was further analyzed to determine if the subtype correlated with the TPDBM, number of BM, and survival from PD. After exclusions for incomplete data, 383 patients remained eligible for analysis. The subtypes were approximated as follows: Luminal B: triple positive; HER2: HER2 positive/ER/PR negative; Luminal A; ER/PR positive/HER2 negative; Basal: triple negative. Patients with Basal (90), HER2 (119), Luminal B (98) and Luminal A (76) tumor subtypes had a median TPDBM of 27.5, 35.8, 47.4 and 54.4 months (p < 0.01), median survival from PD of 39.6, 66.4, 90.3 and 72.7 months (p < 0.01) and median survival from BM of 7.3, 17.9, 22.9 and 10.0 months (p < 0.01), respectively. Tumor subtype is an important prognostic factor for survival in patients with breast cancer and BM. Although TPDBM is not an independent prognostic factor for survival (and thus not part of the Breast-GPA), the TPDBM does correlate with tumor subtype but does not correlate with the number of BM. Patients with Basal and HER2 tumor subtypes have short TPDBM. Prospective studies are needed to determine if screening brain MRIs are indicated in patients with Basal or HER2 subtypes.
C1 [Sperduto, Paul W.] Univ Minnesota, Minneapolis, MN USA.
[Kased, Norbert; Sneed, Penny K.] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA.
[Roberge, David] Univ Montreal, Notre Dame Hosp, Montreal, PQ H3C 3J7, Canada.
[Chao, Samuel T.; Suh, John] Cleveland Clin, Dept Radiat Oncol, Cleveland, OH 44106 USA.
[Shanley, Ryan; Luo, Xianghua] Univ Minnesota, Mason Canc Ctr, Minneapolis, MN USA.
[Luo, Xianghua] Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA.
[Sneed, Penny K.; Weil, Robert J.] Cleveland Clin, Dept Neurosurg, Cleveland, OH 44106 USA.
[Jensen, Ashley W.] Sanford Roger Maris Canc Ctr, Dept Radiat Oncol, Fargo, ND USA.
[Brown, Paul D.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Shih, Helen A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Kirkpatrick, John] Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC USA.
[Gaspar, Laurie E.] Univ Colorado, Sch Med, Dept Radiat Oncol, Aurora, CO USA.
[Fiveash, John B.] Univ Alabama Birmingham, Med Ctr, Birmingham, AL 35294 USA.
[Chiang, Veronica] Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT USA.
[Chiang, Veronica] Yale Canc Ctr, New Haven, CT USA.
[Knisely, Jonathan P. S.] Hofstra Univ, Sch Med, Dept Radiat Med, Manhasset, NY USA.
[Knisely, Jonathan P. S.] North Shore Long Isl Jewish Hlth Syst, Manhasset, NY USA.
[Sperduto, Christina Maria] Dartmouth Coll, Hanover, NH 03755 USA.
[Lin, Nancy] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Mehta, Minesh] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
RP Sperduto, PW (reprint author), 560 S Maple St,Suite 10, Waconia, MN 55387 USA.
EM psperduto@mropa.com
OI Kirkpatrick, John/0000-0002-4019-0350; mehta, minesh/0000-0002-4812-5713
FU U.S. Department of Defense Breast Cancer Research Program
[W81XWH-062-0033]; NIH [P30- CA77598]
FX Dr. Mehta has served as a consultant to Abbott, Bristol-Meyers-Squibb,
Elekta, Genentech, Merck, Novartis, Novo-cure, Tomotherapy and Viewray;
he serves on the Board of Directors of Pharmacyclics, He holds stock
options in Pharmacyclics and Accuray. Dr. Lin has served as a consultant
to Novartis (<$ 10 K) and GlaxoSmithKline (<$ 10 K). Grant Support This
research was supported in part by Grant W81XWH-062-0033 from the U.S.
Department of Defense Breast Cancer Research Program, to RJW, and by NIH
Grant P30- CA77598 utilizing the services of the Biostatistics Core,
Masonic Cancer Center, University of Minnesota shared resource.
NR 16
TC 28
Z9 29
U1 0
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-594X
J9 J NEURO-ONCOL
JI J. Neuro-Oncol.
PD MAY
PY 2013
VL 112
IS 3
BP 467
EP 472
DI 10.1007/s11060-013-1083-9
PG 6
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 131GR
UT WOS:000317981300018
PM 23462853
ER
PT J
AU Vajro, P
Paolella, G
Fasano, A
AF Vajro, Pietro
Paolella, Giulia
Fasano, Alessio
TI Microbiota and Gut-Liver Axis: Their Influences on Obesity and
Obesity-Related Liver Disease
SO JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
LA English
DT Review
DE gut dysbiosis; gut-liver axis; inflammasome; intestinal permeability;
nonalcoholic fatty liver disease; zonulin
ID INTESTINAL BARRIER FUNCTION; INDUCED HEPATIC STEATOSIS; HIGH-FAT DIET;
NONALCOHOLIC STEATOHEPATITIS; METABOLIC SYNDROME; PEDIATRIC OBESITY;
BODY-WEIGHT; PROBIOTICS; INFLAMMATION; INSULIN
AB A specific bacterial gut microbiota profile with increased extraction of energy has recently been associated with obesity, which has been shown to be a transmissible phenotype by microbiota transplantation. At the same time, there is now increasing evidence that gut microbiota plays a role in the development of hepatic steatosis and its progression to nonalcoholic steatohepatitis. This review summarizes well known and unexpected interacting factors leading to obesity and its related hepatic diseases, including intestinal mucosal permeability and its regulation, gut microbiota and translocation of its biological products, and gut-associated lymphoid tissue. These intestinal factors dictate also the balance between tolerance and immune response, which are critical for most of the complications in near and far organs or systems. We review novel mechanisms involving the development of gut permeability and adipose tissue plasticity, for example, the cross-talk between the gut microbiota, lipopolysaccharide, high-fat diet, and the endocannabinoid system tone, which have not been fully explored. Interactions between gut microbiota and other factors (eg, inflammasome deficiency) also are reviewed as emerging but far from being completely elucidated mechanisms influencing the onset of obesity and nonalcoholic fatty liver disease.
C1 [Vajro, Pietro; Paolella, Giulia] Univ Salerno, Sch Med, I-84081 Baronissi, Sa, Italy.
[Vajro, Pietro; Paolella, Giulia] ELFID, Naples, Italy.
[Fasano, Alessio] Massachusetts Gen Hosp, Mucosal Immunol & Biol Res Ctr, Boston, MA 02114 USA.
RP Vajro, P (reprint author), Univ Salerno, Chair Pediat, Dept Med & Surg, I-84081 Baronissi, Sa, Italy.
EM pvajro@unisa.it
OI VAJRO, PIetro/0000-0002-9418-5880
FU National Institutes of Health grant [DK-48373]; FARB-ex grant
FX This article was partially supported by the National Institutes of
Health grant DK-48373 to A.F. and FARB-ex 60% 2012 grant to P.V.
NR 51
TC 42
Z9 43
U1 3
U2 42
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0277-2116
EI 1536-4801
J9 J PEDIATR GASTR NUTR
JI J. Pediatr. Gastroenterol. Nutr.
PD MAY
PY 2013
VL 56
IS 5
BP 461
EP 468
DI 10.1097/MPG.0b013e318284abb5
PG 8
WC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics
SC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics
GA 131UK
UT WOS:000318021900009
PM 23287807
ER
PT J
AU Sinha, M
Stanley, TL
Webb, J
Scirica, C
Corey, K
Pratt, J
Boepple, PA
Hoppin, A
Misra, M
AF Sinha, Manasi
Stanley, Takara L.
Webb, Jessica
Scirica, Christina
Corey, Kathleen
Pratt, Janey
Boepple, Paul A.
Hoppin, Alison
Misra, Madhusmita
TI Metabolic Effects of Roux-en-Y Gastric Bypass in Obese Adolescents and
Young Adults
SO JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
LA English
DT Article
DE adolescence; glucose; high-sensitivity C-reactive protein; obesity;
roux-en-Y gastric bypass
ID BLOOD-CELL COUNT; WEIGHT-LOSS; BARIATRIC SURGERY; MEDICAL THERAPY
AB Weight loss surgery is an increasingly common treatment option for obese adolescents, but data are limited regarding the metabolic effects of surgical weight loss procedures. We performed a retrospective review of the electronic medical record to determine metabolic outcomes for 24 adolescents and young adults ages 15 to 22 years undergoing Roux-en-Y gastric bypass from 2009 to 2011 as well as 24 age-, sex-, and BMI-matched controls. During a median follow-up of 6 months after Roux-en-Y gastric bypass, fasting glucose, hemoglobin A1c, low-density lipoprotein, triglyceride, and high-sensitivity C-reactive protein decreased significantly. Changes in these measures were not significantly associated with age or extent of weight loss.
C1 [Sinha, Manasi; Stanley, Takara L.; Webb, Jessica; Boepple, Paul A.; Misra, Madhusmita] Massachusetts Gen Hosp, Pediat Endocrine Unit, Boston, MA 02114 USA.
[Scirica, Christina; Corey, Kathleen; Pratt, Janey; Hoppin, Alison] Massachusetts Gen Hosp, Weight Ctr, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Stanley, TL (reprint author), Massachusetts Gen Hosp, LON5-207, Boston, MA 02114 USA.
EM tstanley@partners.org
FU National Institutes of Health [T32HD052961, K23DK089910]; MGH
Multicultural Affairs Office Summer Research Trainee Program; American
Association for the Study of Liver Disease Clinical and Translational
Research Award
FX Funding provided in part by National Institutes of Health T32HD052961 to
M. S. and K23DK089910 to T. L. S., by the MGH Multicultural Affairs
Office Summer Research Trainee Program to J.W., and by the American
Association for the Study of Liver Disease Clinical and Translational
Research Award to K.C.
NR 19
TC 3
Z9 3
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0277-2116
J9 J PEDIATR GASTR NUTR
JI J. Pediatr. Gastroenterol. Nutr.
PD MAY
PY 2013
VL 56
IS 5
BP 528
EP 531
DI 10.1097/MPG.0b013e318283910c
PG 4
WC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics
SC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics
GA 131UK
UT WOS:000318021900020
PM 23274343
ER
PT J
AU Kaplan, JL
Goldstein, AM
Shenoy-Bhangle, A
Badizadegan, K
AF Kaplan, Jess L.
Goldstein, Allan M.
Shenoy-Bhangle, Anuradha
Badizadegan, Kamran
TI Neuromuscular and Vascular Hamartoma of the Small Intestine in a Child
SO JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
LA English
DT Article
ID SMALL-BOWEL; NEUROMESENCHYMAL-HAMARTOMA; DISEASE
C1 [Kaplan, Jess L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Pediat Gastroenterol & Nutr, Boston, MA USA.
[Goldstein, Allan M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat Surg, Boston, MA USA.
[Shenoy-Bhangle, Anuradha] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat Radiol, Boston, MA USA.
[Badizadegan, Kamran] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
RP Kaplan, JL (reprint author), Massachusetts Gen Hosp Children, Div Pediat Gastroenterol & Nutr, 175 Cambridge St,5th Floor, Boston, MA 02114 USA.
EM jlkaplan@partners.org
NR 8
TC 3
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0277-2116
J9 J PEDIATR GASTR NUTR
JI J. Pediatr. Gastroenterol. Nutr.
PD MAY
PY 2013
VL 56
IS 5
BP E33
EP E35
DI 10.1097/MPG.0b013e3182540e7f
PG 3
WC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics
SC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics
GA 131UK
UT WOS:000318021900004
PM 22411271
ER
PT J
AU Davidson, CL
Wingate, LR
AF Davidson, Collin L.
Wingate, LaRicka R.
TI The glass half-full or a hopeful outlook: Which explains more variance
in interpersonal suicide risk in a psychotherapy clinic sample?
SO JOURNAL OF POSITIVE PSYCHOLOGY
LA English
DT Article
DE positive psychology; optimism; hope; suicide; interpersonal
psychological theory
ID COPING SELF-EFFICACY; DISPOSITIONAL OPTIMISM; DEPRESSIVE SYMPTOMS;
SOCIAL SUPPORT; PSYCHOLOGICAL ADJUSTMENT; POSTPARTUM DEPRESSION;
INDIVIDUAL-DIFFERENCES; COLLEGE-STUDENTS; BREAST-CANCER; TRAIT ANXIETY
AB Recent research has suggested that constructs in the field of positive psychology may be important for understanding suicide risk. Specifically, both hope theory and dispositional optimism have been linked to lower levels of suicidal ideation and interpersonal suicide risk. Despite these encouraging findings, no study has investigated the relationships between hope, optimism, and suicide risk in a clinical sample. The current study aimed to address this gap and to determine if hope or optimism was more important for understanding suicide risk as operationalized by the interpersonal-psychological theory and suicidal ideation. Results of hierarchical regression analyses revealed that both hope and optimism predicted lower levels of burdensomeness and thwarted belongingness, but were not significant predictors of suicidal ideation. Further, results revealed that when both hope and optimism were entered into a hierarchical regression in the final step, only optimism remained significant. Theoretical and clinical implications of these findings are discussed.
C1 [Davidson, Collin L.] Denver VA Med Ctr, Denver, CO 80220 USA.
[Wingate, LaRicka R.] Oklahoma State Univ, Stillwater, OK 74078 USA.
RP Davidson, CL (reprint author), Denver VA Med Ctr, AVA VISN 19 MIRECC,1055 Clermont St, Denver, CO 80220 USA.
EM collin.davidson@okstate.edu
NR 63
TC 3
Z9 3
U1 2
U2 13
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1743-9760
J9 J POSIT PSYCHOL
JI J. Posit. Psychol.
PD MAY 1
PY 2013
VL 8
IS 3
BP 263
EP 272
DI 10.1080/17439760.2013.787446
PG 10
WC Psychology, Multidisciplinary
SC Psychology
GA 135MA
UT WOS:000318291000008
ER
PT J
AU Brown, D
Lu, HAJ
AF Brown, Dennis
Lu, Hua A. Jenny
TI Aquaporin-2 Inhibitors: Fishing in the Chemical Pool
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Editorial Material
ID PLASMA-MEMBRANE; IN-VIVO; AQP2; PHOSPHORYLATION; CELLS; RATS
C1 Massachusetts Gen Hosp, Ctr Syst Biol, Program Membrane Biol, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Brown, D (reprint author), Massachusetts Gen Hosp, Simches Res Ctr, 185 Cambridge St,CPZN 8150, Boston, MA 02114 USA.
EM brown.dennis@mgh.harvard.edu
FU NIDDK NIH HHS [DK96586, P30 DK057521, R01 DK096586]
NR 12
TC 0
Z9 0
U1 0
U2 9
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD MAY
PY 2013
VL 24
IS 5
BP 685
EP 686
DI 10.1681/ASN.2013030243
PG 2
WC Urology & Nephrology
SC Urology & Nephrology
GA 134JZ
UT WOS:000318207800001
PM 23599384
ER
PT J
AU Roshanravan, B
Robinson-Cohen, C
Patel, KV
Ayers, E
Littman, AJ
de Boer, IH
Ikizler, TA
Himmelfarb, J
Katzel, LI
Kestenbaum, B
Seliger, S
AF Roshanravan, Baback
Robinson-Cohen, Cassianne
Patel, Kushang V.
Ayers, Ernest
Littman, Alyson J.
de Boer, Ian H.
Ikizler, T. Alp
Himmelfarb, Jonathan
Katzel, Leslie I.
Kestenbaum, Bryan
Seliger, Stephen
TI Association between Physical Performance and All-Cause Mortality in CKD
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID CHRONIC KIDNEY-DISEASE; FUNCTIONING OLDER-ADULTS; CHRONIC-RENAL-FAILURE;
INSULIN-RESISTANCE; BODY-COMPOSITION; CYSTATIN-C; CARDIOVASCULAR HEALTH;
HEMODIALYSIS-PATIENTS; COGNITIVE IMPAIRMENT; ENERGY-METABOLISM
AB In older adults, measurements of physical performance assess physical function and associate with mortality and disability. Muscle wasting and diminished physical performance often accompany CKD, resembling physiologic aging, but whether physical performance associates with clinical outcome in CKD is unknown. We evaluated 385 ambulatory, stroke-free participants with stage 2-4 CKD enrolled in clinic-based cohorts at the University of Washington and University of Maryland and Veterans Affairs Maryland Healthcare systems. We compared handgrip strength, usual gait speed, timed up and go (TUAG), and 6-minute walking distance with normative values and constructed Cox proportional hazards models and receiver operating characteristic curves to test associations with all-cause mortality. Mean age was 61 years and the mean estimated GFR was 41 ml/min per 1.73 m(2). Measures of lower extremity performance were at least 30% lower than predicted, but handgrip strength was relatively preserved. Fifty deaths occurred during the median 3-year follow-up period. After adjustment, each 0.1-m/s decrement in gait speed associated with a 26% higher risk for death, and each 1-second longer TUAG associated with an 8% higher risk for death. On the basis of the receiver operating characteristic analysis, gait speed and TUAG more strongly predicted 3-year mortality than kidney function or commonly measured serum biomarkers. Adding gait speed to a model that included estimated GFR significantly improved the prediction of 3-year mortality. In summary, impaired physical performance of the lower extremities is common in CKD and strongly associates with all-cause mortality. J Am Soc Nephrol 24: 822-830, 2013. doi: 10.1681/ASN.2012070702
C1 [Roshanravan, Baback; Ayers, Ernest; de Boer, Ian H.; Himmelfarb, Jonathan; Kestenbaum, Bryan] Univ Washington, Dept Med, Kidney Res Inst, Div Nephrol, Seattle, WA 98104 USA.
[Robinson-Cohen, Cassianne; Littman, Alyson J.] Univ Washington, Dept Epidemiol, Kidney Res Inst, Seattle, WA 98104 USA.
[Patel, Kushang V.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98104 USA.
[Littman, Alyson J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA.
[Ikizler, T. Alp] Vanderbilt Univ, Med Ctr, Div Nephrol, Nashville, TN USA.
[Katzel, Leslie I.] Univ Maryland, Sch Med, Div Geriatr, Baltimore, MD 21201 USA.
[Seliger, Stephen] Univ Maryland, Sch Med, Div Nephrol, Baltimore, MD 21201 USA.
RP Roshanravan, B (reprint author), Univ Washington, Dept Med, Kidney Res Inst, Div Nephrol, Box 359606,325 9th Ave, Seattle, WA 98104 USA.
EM broshanr@u.washington.edu
OI Robinson-Cohen, Cassianne/0000-0003-4783-7046
FU National Institutes of Health [R01-HL070938, K23-DK063079]; Kidney
Research Institute; National Institute of Diabetes and Digestive and
Kidney Diseases [T32-DK007467-28, F32-K093235]; National Institute on
Aging Claude D. Pepper Older Americans Independence Center
[P30-AG028747]; Department of Veterans Affairs; Baltimore VAMC Geriatric
Research Education and Clinical Center; Northwest Kidney Center
Foundation; VA Rehabilitation Research and Development Career
Development Award [6982]; VA Puget Sound Health Care System, Seattle,
Washington; VA Maryland Healthcare System, Baltimore, Maryland
FX This work was supported by grants from the National Institutes of Health
(R01-HL070938 to J.H. and B.K. and K23-DK063079 to S.S.), the Kidney
Research Institute, the National Institute of Diabetes and Digestive and
Kidney Diseases (T32-DK007467-28 and F32-K093235 to B.R.), the VA
Rehabilitation R&D Merit Review (to S.S. and L.K.), the National
Institute on Aging Claude D. Pepper Older Americans Independence Center
(P30-AG028747), the Department of Veterans Affairs, and the Baltimore
VAMC Geriatric Research Education and Clinical Center, as well as an
unrestricted grant from the Northwest Kidney Center Foundation. A.J.L.
was supported by a VA Rehabilitation Research and Development Career
Development Award (#6982). This study is the result of work supported by
resources from the VA Puget Sound Health Care System, Seattle,
Washington, and the VA Maryland Healthcare System, Baltimore, Maryland.
NR 41
TC 56
Z9 58
U1 2
U2 11
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD MAY
PY 2013
VL 24
IS 5
BP 822
EP 830
DI 10.1681/ASN.2012070702
PG 9
WC Urology & Nephrology
SC Urology & Nephrology
GA 134JZ
UT WOS:000318207800016
PM 23599380
ER
PT J
AU Thames, AD
Hinkin, CH
Byrd, DA
Bilder, RM
Duff, KJ
Mindt, MR
Arentoft, A
Streiff, V
AF Thames, April D.
Hinkin, Charles H.
Byrd, Desiree A.
Bilder, Robert M.
Duff, Kimberley J.
Mindt, Monica Rivera
Arentoft, Alyssa
Streiff, Vanessa
TI Effects of Stereotype Threat, Perceived Discrimination, and Examiner
Race on Neuropsychological Performance: Simple as Black and White?
SO JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY
LA English
DT Article
DE Stereotype threat; Performance anxiety; Neuropsychology; Perceived
discrimination; Examiner-examinee racial discordance; Ethnicity
ID WOMENS MATH PERFORMANCE; PICTURE-VOCABULARY TEST; AFRICAN-AMERICAN;
RACIAL-DISCRIMINATION; TESTS; GAP; INTERVIEWER; PREVALENCE; MECHANISMS;
EDUCATION
AB The purpose of the current study was to examine the predictive roles of stereotype threat and perceived discrimination and the mediating role of examiner-examinee racial discordance on neuropsychological performance in a non-clinical sample of African American and Caucasian individuals. Ninety-two African American (n = 45) and Caucasian (n = 47) adults were randomly assigned to either a stereotype threat or non-threat condition. Within each condition, participants were randomly assigned to either a same race or different race examiner. All participants underwent neuropsychological testing and completed a measure of perceived discrimination. African Americans in the stereotype threat condition performed significantly worse on global NP (Mz = .30, 95% confidence interval [CI] [-0.07, -0.67] than African Americans in the non-threat condition (Mz = 0.09, CI [0.15, 0.33]. African Americans who reported high levels of perceived discrimination performed significantly worse on memory tests when tested by an examiner of a different race, Mz = -1.19, 95% CI [-1.78, -.54], than African Americans who were tested by an examiner of the same race, Mz = 0.24, 95% CI [-0.24, 0.72]. The current study underscores the importance of considering the role of contextual variables in neuropsychological performance, as these variables may obscure the validity of results among certain racial/ethnic groups.
C1 [Thames, April D.; Hinkin, Charles H.; Bilder, Robert M.; Arentoft, Alyssa] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Hinkin, Charles H.; Arentoft, Alyssa; Streiff, Vanessa] Greater Los Angeles VA Healthcare Syst, Dept Psychol, Los Angeles, CA USA.
[Byrd, Desiree A.; Mindt, Monica Rivera] Mt Sinai Sch Med, Dept Neurol & Psychiat, New York, NY USA.
[Duff, Kimberley J.] Cerritos Coll, Dept Psychol, Norwalk, CA USA.
[Mindt, Monica Rivera] Fordham Univ, Dept Psychol, New York, NY 10023 USA.
RP Thames, AD (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, 740 Westwood Plaza C8-746, Los Angeles, CA 90095 USA.
EM athames@mednet.ucla.edu
RI Thames, April/K-1964-2014; Bilder, Robert/A-8894-2008;
OI Thames, April/0000-0001-8414-7189; Bilder, Robert/0000-0001-5085-7852;
Arentoft, Alyssa/0000-0002-4235-4638
FU National Academy of Neuropsychology
FX We acknowledge the following funding source: National Academy of
Neuropsychology (PI: A. Thames). We also thank Ms. Myra Irani, Fredrica
Hendrix, and Natalie Arbid for their assistance with data collection.
The authors report no conflicts of interest.
NR 60
TC 10
Z9 10
U1 5
U2 28
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1355-6177
J9 J INT NEUROPSYCH SOC
JI J. Int. Neuropsychol. Soc.
PD MAY
PY 2013
VL 19
IS 5
BP 583
EP 593
DI 10.1017/S1355617713000076
PG 11
WC Clinical Neurology; Neurosciences; Psychiatry; Psychology
SC Neurosciences & Neurology; Psychiatry; Psychology
GA 136OB
UT WOS:000318370100010
PM 23388089
ER
PT J
AU Ausiello, DA
Al-Awqati, Q
AF Ausiello, Dennis A.
Al-Awqati, Qais
TI Alexander Leaf: in memoriam
SO KIDNEY INTERNATIONAL
LA English
DT Biographical-Item
ID TISSUES
C1 [Ausiello, Dennis A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Al-Awqati, Qais] Columbia Univ, Dept Med, New York, NY USA.
RP Ausiello, DA (reprint author), Massachusetts Gen Hosp, Bulfinch 127,55 Fruit St, Boston, MA 02114 USA.
EM dausiello@partners.org
NR 5
TC 0
Z9 0
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0085-2538
J9 KIDNEY INT
JI Kidney Int.
PD MAY
PY 2013
VL 83
IS 5
BP 771
EP 772
DI 10.1038/ki.2013.87
PG 2
WC Urology & Nephrology
SC Urology & Nephrology
GA 136EI
UT WOS:000318344000001
ER
PT J
AU Zeng, C
Giantsoudi, D
Grassberger, C
Goldberg, S
Niemierko, A
Paganetti, H
Efstathiou, JA
Trofimov, A
AF Zeng, Chuan
Giantsoudi, Drosoula
Grassberger, Clemens
Goldberg, Saveli
Niemierko, Andrzej
Paganetti, Harald
Efstathiou, Jason A.
Trofimov, Alexei
TI Maximizing the biological effect of proton dose delivered with scanned
beams via inhomogeneous daily dose distributions
SO MEDICAL PHYSICS
LA English
DT Article
DE intensity-modulated proton therapy; biological optimization;
fractionation; therapeutic ratio
ID PROSTATE-CANCER; RADIOTHERAPY; THERAPY; HYPOFRACTIONATION; TISSUE; SETUP
AB Purpose: Biological effect of radiation can be enhanced with hypofractionation, localized dose escalation, and, in particle therapy, with optimized distribution of linear energy transfer (LET). The authors describe a method to construct inhomogeneous fractional dose (IFD) distributions, and evaluate the potential gain in the therapeutic effect from their delivery in proton therapy delivered by pencil beam scanning.
Methods: For 13 cases of prostate cancer, the authors considered hypofractionated courses of 60 Gy delivered in 20 fractions. (All doses denoted in Gy include the proton's mean relative biological effectiveness (RBE) of 1.1.) Two types of plans were optimized using two opposed lateral beams to deliver a uniform dose of 3 Gy per fraction to the target by scanning: (1) in conventional full-target plans (FTP), each beam irradiated the entire gland, (2) in split-target plans (STP), beams irradiated only the respective proximal hemispheres (prostate split sagittally). Inverse planning yielded intensity maps, in which discrete position control points of the scanned beam (spots) were assigned optimized intensity values. FTP plans preferentially required a higher intensity of spots in the distal part of the target, while STP, by design, employed proximal spots. To evaluate the utility of IFD delivery, IFD plans were generated by rearranging the spot intensities from FTP or STP intensity maps, separately as well as combined using a variety of mixing weights. IFD courses were designed so that, in alternating fractions, one of the hemispheres of the prostate would receive a dose boost and the other receive a lower dose, while the total physical dose from the IFD course was roughly uniform across the prostate. IFD plans were normalized so that the equivalent uniform dose (EUD) of rectum and bladder did not increase, compared to the baseline FTP plan, which irradiated the prostate uniformly in every fraction. An EUD-based model was then applied to estimate tumor control probability (TCP) and normal tissue complication probability (NTCP). To assess potential local RBE variations, LET distributions were calculated with Monte Carlo, and compared for different plans. The results were assessed in terms of their sensitivity to uncertainties in model parameters and delivery.
Results: IFD courses included equal number of fractions boosting either hemisphere, thus, the combined physical dose was close to uniform throughout the prostate. However, for the entire course, the prostate EUD in IFD was higher than in conventional FTP by up to 14%, corresponding to the estimated increase in TCP to 96% from 88%. The extent of gain depended on the mixing factor, i.e., relative weights used to combine FTP and STP spot weights. Increased weighting of STP typically yielded a higher target EUD, but also led to increased sensitivity of dose to variations in the proton's range. Rectal and bladder EUD were same or lower (per normalization), and the NTCP for both remained below 1%. The LET distributions in IFD also depended strongly on the mixing weights: plans using higher weight of STP spots yielded higher LET, indicating a potentially higher local RBE.
Conclusions: In proton therapy delivered by pencil beam scanning, improved therapeutic outcome can potentially be expected with delivery of IFD distributions, while administering the prescribed quasi-uniform dose to the target over the entire course. The biological effectiveness of IFD may be further enhanced by optimizing the LET distributions. IFD distributions are characterized by a dose gradient located in proximity of the prostate's midplane, thus, the fidelity of delivery would depend crucially on the precision with which the proton range could be controlled. (c) 2013 American Association of Physicists in Medicine.
C1 [Zeng, Chuan] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Zeng, C (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
EM Zeng.Chuan@mgh.harvard.edu
RI Zeng, Chuan/K-5694-2012
OI Zeng, Chuan/0000-0001-7069-2629
FU Federal Share of program income earned by Massachusetts General Hospital
on Proton Therapy Research and Treatment Center [C06 CA059267]
FX This study was supported by the Federal Share of program income earned
by Massachusetts General Hospital on C06 CA059267, Proton Therapy
Research and Treatment Center.
NR 24
TC 7
Z9 7
U1 1
U2 13
PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0094-2405
J9 MED PHYS
JI Med. Phys.
PD MAY
PY 2013
VL 40
IS 5
AR 051708
DI 10.1118/1.4801897
PG 10
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 139AO
UT WOS:000318553900011
PM 23635256
ER
PT J
AU Ravegnini, G
Marino-Enriquez, A
Slater, J
Eilers, G
Wang, YX
Zhu, MJ
Nucci, MR
George, S
Angelini, S
Raut, CP
Fletcher, JA
AF Ravegnini, Gloria
Marino-Enriquez, Adrian
Slater, Jaime
Eilers, Grant
Wang, Yuexiang
Zhu, Meijun
Nucci, Marisa R.
George, Suzanne
Angelini, Sabrina
Raut, Chandrajit P.
Fletcher, Jonathan A.
TI MED12 mutations in leiomyosarcoma and extrauterine leiomyoma
SO MODERN PATHOLOGY
LA English
DT Article
DE fibroid; leiomyoma; leiomyosarcoma; MED12; oncogene; smooth muscle
tumor; uterus
ID OPITZ-KAVEGGIA-SYNDROME; UTERINE LEIOMYOSARCOMAS; FIBROIDS; MEDIATOR;
SARCOMAS; TUMORS; AREAS; CDK8
AB Leiomyoma and leiomyosarcoma share morphological features and smooth muscle differentiation, and both arise most frequently within the uterine corpus of middle-aged women. However, they are considered biologically unrelated tumors due to their disparate clinical, cytogenetic, and molecular features. MED12, the mediator complex subunit 12 gene, has been recently implicated as an oncogene in as many as 70% of sporadic uterine leiomyoma. In the present study, we show MED12 hotspot exon 2 mutations in extrauterine leiomyoma (3 of 19 cases) and in leiomyosarcoma (3 of 13 uterine cases). We also show that MED12 mutations are found in both primary and metastatic leiomyosarcoma. Immunoblotting studies demonstrated MED12 protein expression in 100% of leiomyomas (13) and leiomyosarcomas (20), irrespective of MED12 exon 2 mutation status or histological grade. These findings indicate that MED12 has oncogenic roles in a broad range of smooth muscle neoplasia, including tumors arising in extrauterine locations.
C1 [Ravegnini, Gloria; Marino-Enriquez, Adrian; Slater, Jaime; Eilers, Grant; Wang, Yuexiang; Zhu, Meijun; Nucci, Marisa R.; Fletcher, Jonathan A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Ravegnini, Gloria; Angelini, Sabrina] Univ Bologna, Dept Pharmacol, Bologna, Italy.
[George, Suzanne; Raut, Chandrajit P.] Dana Farber Canc Inst, Ctr Sarcoma & Bone Oncol, Boston, MA 02115 USA.
[Raut, Chandrajit P.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Surg, Boston, MA 02115 USA.
RP Fletcher, JA (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.
EM jfletcher@partners.org
RI RAVEGNINI, GLORIA/K-1330-2016;
OI RAVEGNINI, GLORIA/0000-0002-7774-402X; Angelini,
Sabrina/0000-0002-1609-0421
FU Daniel K. Ludwig Trust for Cancer Research; Sarcoma Alliance for
Research Through Collaboration (SARC) Career Development Award;
Department of Pharmacology, Universita di Bologna; Italian Society of
Pharmacology; Fondazione del Monte di Bologna e Ravenna
FX This study was supported by funding from the Daniel K. Ludwig Trust for
Cancer Research (GR, AM-E, JS, GE, YW, MZ, and JF); a Sarcoma Alliance
for Research Through Collaboration (SARC) Career Development Award
(AM-E); and by the Department of Pharmacology, Universita di Bologna,
Italian Society of Pharmacology, and Fondazione del Monte di Bologna e
Ravenna (all to GR).
NR 29
TC 29
Z9 30
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
J9 MODERN PATHOL
JI Mod. Pathol.
PD MAY
PY 2013
VL 26
IS 5
BP 743
EP 749
DI 10.1038/modpathol.2012.203
PG 7
WC Pathology
SC Pathology
GA 137RX
UT WOS:000318456200014
PM 23222489
ER
PT J
AU Zhu, SM
Nagashima, M
Khan, MAS
Yasuhara, S
Kaneki, M
Martyn, JAJ
AF Zhu, Shimei
Nagashima, Michio
Khan, Mohammed A. S.
Yasuhara, Shingo
Kaneki, Masao
Martyn, J. A. Jeevendra
TI Lack of caspase-3 attenuates immobilization-induced muscle atrophy and
loss of tension generation along with mitigation of apoptosis and
inflammation
SO MUSCLE & NERVE
LA English
DT Article
DE apoptosis; caspase-3; immobilization; inflammation; skeletal muscle
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; HUMAN SKELETAL-MUSCLE;
UBIQUITIN-PROTEASOME; FIBER SIZE; PATHWAYS; DYSFUNCTION; ACTIVATION;
EXPRESSION; PURIFICATION; CONTRIBUTES
AB Introduction: Immobilization by casting induces disuse muscle atrophy (DMA). Methods: Using wild type (WT) and caspase-3 knockout (KO) mice, we evaluated the effect of caspase-3 on muscle mass, apoptosis, and inflammation during DMA. Results: Caspase-3 deficiency significantly attenuated muscle mass decrease [gastrocnemius: 28 +/- 1% in KO vs. 41 +/- 3% in WT; soleus: 47 +/- 2% in KO vs. 56 +/- 2% in WT; (P < 0.05)] and gastrocnemius twitch tension decrease (23 +/- 4% in KO vs. 36 +/- 3% in WT, P < 0.05) at day 14 in immobilized vs. contralateral hindlimb. Lack of caspase-3 decreased immobilization-induced increased apoptotic myonuclei (3.2-fold) and macrophage infiltration (2.2-fold) in soleus muscle and attenuated increased monocyte chemoattractant protein-1 mRNA expression (2-fold in KO vs. 18-fold in WT) in gastrocnemius. Conclusions: Caspase-3 plays a key role in DMA and associated decreased tension, presumably by acting on the apoptosis and inflammation pathways. Muscle Nerve 47: 711721, 2013
C1 [Martyn, J. A. Jeevendra] Shriners Hosp Children, Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA.
Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Martyn, JAJ (reprint author), Shriners Hosp Children, Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Room 206,51 Blossom St, Boston, MA USA.
EM jmartyn@partners.org
OI Nagashima, Michio/0000-0001-7416-5367
FU National Institutes of Health [RO1-055085, P50-25000]; Shriners
Hospitals for Children
FX Supported by grants from the National Institutes of Health (RO1-055085,
P50-25000 project IV) and from Shriners Hospitals for Children to J. A.
Jeevendra Martyn. We thank Dr. Hui Zheng for his advice on statistical
analyses.
NR 45
TC 18
Z9 19
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
J9 MUSCLE NERVE
JI Muscle Nerve
PD MAY
PY 2013
VL 47
IS 5
BP 711
EP 721
DI 10.1002/mus.23642
PG 11
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 134SH
UT WOS:000318234200012
PM 23401051
ER
PT J
AU Cohen-Adad, J
Zhao, W
Keil, B
Ratai, EM
Triantafyllou, C
Lawson, R
Dheel, C
Wald, LL
Rosen, BR
Cudkowicz, M
Atassi, N
AF Cohen-Adad, Julien
Zhao, Wei
Keil, Boris
Ratai, Eva-Maria
Triantafyllou, Christina
Lawson, Robert
Dheel, Christina
Wald, Lawrence L.
Rosen, Bruce R.
Cudkowicz, Merit
Atassi, Nazem
TI 7-T MRI of the spinal cord can detect lateral corticospinal tract
abnormality in amyotrophic lateral sclerosis
SO MUSCLE & NERVE
LA English
DT Article
DE amyotrophic lateral sclerosis; corticospinal; MRI; spinal cord;
ultra-high field
ID MOTOR-NEURON DEGENERATION; ALS; BRAIN; CONTRAST; HYPERINTENSITY; DISEASE
AB Introduction: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder affecting lower and upper motor neurons. Degeneration of the lateral corticospinal tract (CST) is a key finding in ALS cervical spinal cord autopsies. We hypothesized that in vivo ultra-high-field MRI of the cervical spinal cord can detect abnormality in the CST. Methods: A patient with ALS (disease duration 23 months) and a healthy control were scanned at 7-T MRI using a 19-channel coil. Multi-echo T2*-weighted imaging was performed in the spinal cord, covering C2C6. Cross-sectional resolution was 0.37 x 0.37 mm2. Results: We detected clear signal hyperintensity in both segments of the lateral CST in the ALS patient, which was significant when compared with the normal control subject (P < 107). Conclusion: We believe there are potential benefits of 7-T MRI for increased sensitivity and spatial accuracy in characterizing pathology in the spinal cord. Muscle Nerve 47: 760762, 2013
C1 [Cohen-Adad, Julien; Zhao, Wei; Keil, Boris; Ratai, Eva-Maria; Triantafyllou, Christina; Lawson, Robert; Dheel, Christina; Wald, Lawrence L.; Rosen, Bruce R.; Cudkowicz, Merit; Atassi, Nazem] Massachusetts Gen Hosp, Dept Radiol, AA Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Cohen-Adad, Julien; Zhao, Wei; Keil, Boris; Ratai, Eva-Maria; Wald, Lawrence L.; Rosen, Bruce R.; Cudkowicz, Merit; Atassi, Nazem] Harvard Univ, Sch Med, Boston, MA USA.
[Cohen-Adad, Julien] Ecole Polytech, Dept Elect Engn, Montreal, PQ H3C 3A7, Canada.
[Triantafyllou, Christina] MIT, McGovern Inst Brain Res, AA Martinos Imaging Ctr, Cambridge, MA 02139 USA.
[Lawson, Robert; Dheel, Christina; Cudkowicz, Merit; Atassi, Nazem] Massachusetts Gen Hosp, Neurol Clin Trials Unit, Dept Neurol, Charlestown, MA USA.
[Wald, Lawrence L.] MIT, Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
RP Cohen-Adad, J (reprint author), Massachusetts Gen Hosp, Dept Radiol, AA Martinos Ctr Biomed Imaging, Charlestown, MA USA.
EM jcohen@polymtl.ca
RI Keil, Boris/P-1411-2014; Wald, Lawrence/D-4151-2009
FU National Multiple Sclerosis Society [FG 1892A1/1]; National Center for
Research Resources [P41-RR14075]; Harvard NeuroDiscovery Center;
American Academy of Neurology; Muscular Dystrophy Association
FX Supported by the National Multiple Sclerosis Society (FG 1892A1/1), the
National Center for Research Resources (P41-RR14075), a pilot grant from
the Harvard NeuroDiscovery Center, a fellowship grant from the American
Academy of Neurology, and a training grant from the Muscular Dystrophy
Association.
NR 21
TC 9
Z9 9
U1 1
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
J9 MUSCLE NERVE
JI Muscle Nerve
PD MAY
PY 2013
VL 47
IS 5
BP 760
EP 762
DI 10.1002/mus.23720
PG 3
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 134SH
UT WOS:000318234200017
PM 23553571
ER
PT J
AU Healy, BC
Schoenfeld, D
AF Healy, Brian C.
Schoenfeld, David
TI Can the combination of ALSFRS and survival time analysis impact the
outcome in phase III ALS clinical trials?
SO MUSCLE & NERVE
LA English
DT Letter
ID AMYOTROPHIC-LATERAL-SCLEROSIS; PREDICTORS
C1 [Healy, Brian C.; Schoenfeld, David] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
[Healy, Brian C.] Brigham & Womens Hosp, Partners Multiple Sclerosis Ctr, Brookline, MA USA.
[Schoenfeld, David] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
RP Healy, BC (reprint author), Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
NR 7
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
J9 MUSCLE NERVE
JI Muscle Nerve
PD MAY
PY 2013
VL 47
IS 5
BP 779
EP 780
PG 2
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 134SH
UT WOS:000318234200026
PM 23536327
ER
PT J
AU Wright, GD
Hung, DT
Helmann, JD
AF Wright, Gerard D.
Hung, Deborah T.
Helmann, John D.
TI How antibiotics kill bacteria: new models needed?
SO NATURE MEDICINE
LA English
DT Editorial Material
ID CELL-DEATH
C1 [Wright, Gerard D.] McMaster Univ, MG DeGroote Inst Infect Dis Res, Hamilton, ON, Canada.
[Hung, Deborah T.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA USA.
[Hung, Deborah T.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Hung, Deborah T.] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA.
[Hung, Deborah T.] Broad Inst MIT & Harvard, Program Infect Dis, Boston, MA USA.
[Helmann, John D.] Cornell Univ, Dept Microbiol, New York, NY 10021 USA.
RP Wright, GD (reprint author), McMaster Univ, MG DeGroote Inst Infect Dis Res, Hamilton, ON, Canada.
OI Wright, Gerard/0000-0002-9129-7131; Helmann, John/0000-0002-3832-3249
FU NIGMS NIH HHS [R01 GM047446]
NR 7
TC 7
Z9 7
U1 4
U2 49
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
J9 NAT MED
JI Nat. Med.
PD MAY
PY 2013
VL 19
IS 5
BP 544
EP 545
PG 2
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
Medicine
GA 139LA
UT WOS:000318583000025
PM 23652106
ER
PT J
AU Cypess, AM
White, AP
Vemochet, C
Schulz, TJ
Xue, RD
Sass, CA
Huang, TL
Roberts-Toler, C
Weiner, LS
Sze, C
Chacko, AT
Deschamps, LN
Herder, LM
Truchan, N
Glasgow, AL
Holman, AR
Gavrila, A
Hasselgren, PO
Mori, MA
Molla, M
Tseng, YH
AF Cypess, Aaron M.
White, Andrew P.
Vemochet, Cecile
Schulz, Tim J.
Xue, Ruidan
Sass, Christina A.
Huang, Tian Liang
Roberts-Toler, Carla
Weiner, Lauren S.
Sze, Cathy
Chacko, Aron T.
Deschamps, Laura N.
Herder, Lindsay M.
Truchan, Nathan
Glasgow, Allison L.
Holman, Ashley R.
Gavrila, Alina
Hasselgren, Per-Olof
Mori, Marcelo A.
Molla, Michael
Tseng, Yu-Hua
TI Anatomical localization, gene expression profiling and functional
characterization of adult human neck brown fat
SO NATURE MEDICINE
LA English
DT Article
ID ADIPOSE-TISSUE; NONSHIVERING THERMOGENESIS; ADIPOCYTES; COLD; DISTINCT;
IDENTIFICATION; CELL; PROGENITORS; ACTIVATION; SIGNATURES
AB The imbalance between energy intake and expenditure is the underlying cause of the current obesity and diabetes pandemics. Central to these pathologies is the fat depot: white adipose tissue (WAT) stores excess calories, and brown adipose tissue (BAT) consumes fuel for thermogenesis using tissue-specific uncoupling protein 1 (UCP1)(1,2). BAT was once thought to have a functional role in rodents and human infants only, but it has been recently shown that in response to mild cold exposure, adult human BAT consumes more glucose per gram than any other tissue(3). In addition to this nonshivering thermogenesis, human BAT may also combat weight gain by becoming more active in the setting of increased whole-body energy intake(4-7). This phenomenon of BAT-mediated diet-induced thermogenesis has been observed in rodents(8) and suggests that activation of human BAT could be used as a safe treatment for obesity and metabolic dysregulation(9). In this study, we isolated anatomically defined neck fat from adult human volunteers and compared its gene expression, differentiation capacity and basal oxygen consumption to different mouse adipose depots. Although the properties of human neck fat vary substantially between individuals, some human samples share many similarities with classical, also called constitutive, rodent BAT.
C1 [Cypess, Aaron M.; Vemochet, Cecile; Schulz, Tim J.; Xue, Ruidan; Sass, Christina A.; Huang, Tian Liang; Roberts-Toler, Carla; Weiner, Lauren S.; Sze, Cathy; Truchan, Nathan; Holman, Ashley R.; Mori, Marcelo A.; Tseng, Yu-Hua] Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Integrat Physiol & Metab,Res Div, Boston, MA 02115 USA.
[White, Andrew P.; Chacko, Aron T.; Deschamps, Laura N.; Herder, Lindsay M.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Orthopaed Surg, Boston, MA 02215 USA.
[Glasgow, Allison L.] Harvard Univ, Beth Israel Deaconess Med Ctr, Harvard Thorndike Clin Res Ctr, Sch Med, Boston, MA 02215 USA.
[Gavrila, Alina] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Endocrinol, Boston, MA 02215 USA.
[Hasselgren, Per-Olof] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Surg, Boston, MA 02215 USA.
[Molla, Michael] Harvard Univ, Sch Med, Joslin Diabet Ctr, Bioinformat Core,Res Div, Boston, MA 02115 USA.
RP Cypess, AM (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Integrat Physiol & Metab,Res Div, Boston, MA 02115 USA.
EM aaron.cypess@joslin.harvard.edu
RI Schulz, Tim/F-4842-2013
OI Schulz, Tim/0000-0002-8413-3972
FU US National Institutes of Health (NIH) from the National Institute of
Diabetes and Digestive and Kidney Diseases [DK087317, DK081604,
DK046200, DK077097, P30 DK036836, KL2 RR025757]; National Center for
Research Resources, Harvard Catalyst, The Harvard Clinical and
Translational Science Center (NIH) [UL1RR025758, UL1 RR 025758]; Harvard
University; Harvard Stem Cell Institute; Eli Lilly Foundation
FX This work was supported by US National Institutes of Health (NIH) grants
DK087317, DK081604, DK046200, DK077097 and P30 DK036836 from the
National Institute of Diabetes and Digestive and Kidney Diseases KL2
RR025757 and the Clinical Translational Science Award UL1RR025758 to
Harvard University and Beth Israel Deaconess Medical Center from the
National Center for Research Resources, Harvard Catalyst, The Harvard
Clinical and Translational Science Center (NIH award #UL1 RR 025758 and
financial contributions from Harvard University and its affiliated
academic health care centers), as well as the Harvard Stem Cell
Institute and Eli Lilly Foundation. We thank Y.I. Chen and K.K. Kwong
for the magnetic resonance imaging; K. Chaudhary for assistance in
figure design; M. Mittleman, H. Keenan and E. Wilker for biostatistical
advice; J. Skupien for advice on factor analysis; H. Sacks for insights
into the role of brown fat in warming blood; C. Cahill at the Joslin
Diabetes Center Microscopy Core for expertise in histology; M. Rourk and
G. Smyth for assistance in conducting the rodent studies; the teams of
operating room nurses for assistance in tissue collection; and C.R. Kahn
for input in preparing this manuscript. Finally, we are grateful to our
volunteers for their commitment to the studies.
NR 31
TC 218
Z9 220
U1 10
U2 51
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
J9 NAT MED
JI Nat. Med.
PD MAY
PY 2013
VL 19
IS 5
BP 635
EP 639
DI 10.1038/nm.3112
PG 5
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
Medicine
GA 139LA
UT WOS:000318583000038
PM 23603815
ER
PT J
AU Song, JJ
Guyette, JP
Gilpin, SE
Gonzalez, G
Vacanti, JP
Ott, HC
AF Song, Jeremy J.
Guyette, Jacques P.
Gilpin, Sarah E.
Gonzalez, Gabriel
Vacanti, Joseph P.
Ott, Harald C.
TI Regeneration and experimental orthotopic transplantation of a
bioengineered kidney
SO NATURE MEDICINE
LA English
DT Article
ID DECELLULARIZED MATRIX; BASEMENT-MEMBRANE; ARTIFICIAL-KIDNEY; PORCINE
KIDNEYS; RENAL-FUNCTION; CELLS; REPLACEMENT; PODOCYTES; SCAFFOLDS;
ADHESION
AB Approximately 100,000 individuals in the United States currently await kidney transplantation, and 400,000 individuals live with end-stage kidney disease requiring hemodialysis. The creation of a transplantable graft to permanently replace kidney function would address donor organ shortage and the morbidity associated with immunosuppression. Such a bioengineered graft must have the kidney's architecture and function and permit perfusion, filtration, secretion, absorption and drainage of urine. We decellularized rat, porcine and human kidneys by detergent perfusion, yielding acellular scaffolds with vascular, cortical and medullary architecture, a collecting system and ureters. To regenerate functional tissue, we seeded rat kidney scaffolds with epithelial and endothelial cells and perfused these cell-seeded constructs in a whole-organ bioreactor. The resulting grafts produced rudimentary urine in vitro when perfused through their intrinsic vascular bed. When transplanted in an orthotopic position in rat, the grafts were perfused by the recipient's circulation and produced urine through the ureteral conduit in vivo.
C1 [Song, Jeremy J.; Guyette, Jacques P.; Gilpin, Sarah E.; Gonzalez, Gabriel; Vacanti, Joseph P.; Ott, Harald C.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.
[Song, Jeremy J.; Guyette, Jacques P.; Gilpin, Sarah E.; Gonzalez, Gabriel; Vacanti, Joseph P.; Ott, Harald C.] Harvard Univ, Sch Med, Boston, MA USA.
[Vacanti, Joseph P.] Massachusetts Gen Hosp, Dept Surg, Div Pediat Surg, Boston, MA 02114 USA.
[Ott, Harald C.] Massachusetts Gen Hosp, Dept Surg, Div Thorac Surg, Boston, MA 02114 USA.
RP Ott, HC (reprint author), Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.
EM hott@partners.org
FU US National Institutes of Health (NIH) [DP2 OD008749-01]; AOmegaA
Research Fellowship; American Heart Association; NIH [DK43351, DK57521]
FX The present study was supported by the US National Institutes of Health
(NIH) Director's New Innovator Award DP2 OD008749-01 and departmental
funds. J.J.S. was supported by an A Omega A Research Fellowship and an
American Heart Association Predoctoral Fellowship. The Program in
Membrane Biology Microscopy Core is supported by NIH grants DK43351 and
DK57521. We further thank Q.C. Ott for critical review and editing of
the manuscript. We thank C. Hoffman, J. Beagle and M. Duggan for
technical support with urine sample analysis. We thank M. McKee for her
expert support with transmission electron microscopy and A. Tisdale for
her expert support with scanning electron microscopy.
NR 31
TC 215
Z9 228
U1 14
U2 150
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
J9 NAT MED
JI Nat. Med.
PD MAY
PY 2013
VL 19
IS 5
BP 646
EP 651
DI 10.1038/nm.3154
PG 6
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
Medicine
GA 139LA
UT WOS:000318583000040
PM 23584091
ER
PT J
AU EL Andaloussi, S
Maeger, I
Breakefield, XO
Wood, MJA
AF EL Andaloussi, Samir
Maeger, Imre
Breakefield, Xandra O.
Wood, Matthew J. A.
TI Extracellular vesicles: biology and emerging therapeutic opportunities
SO NATURE REVIEWS DRUG DISCOVERY
LA English
DT Article
ID TUMOR-DERIVED MICROVESICLES; MESENCHYMAL STEM-CELL; CALCIUM-DEPENDENT
MANNER; DENDRITIC CELLS; MEMBRANE-VESICLES; PROGENITOR CELLS;
MESSENGER-RNA; MULTIVESICULAR BODIES; HORIZONTAL TRANSFER;
ENDOTHELIAL-CELLS
AB Within the past decade, extracellular vesicles have emerged as important mediators of intercellular communication, being involved in the transmission of biological signals between cells in both prokaryotes and higher eukaryotes to regulate a diverse range of biological processes. In addition, pathophysiological roles for extracellular vesicles are beginning to be recognized in diseases including cancer, infectious diseases and neurodegenerative disorders, highlighting potential novel targets for therapeutic intervention. Moreover, both unmodified and engineered extracellular vesicles are likely to have applications in macro-molecular drug delivery. Here, we review recent progress in understanding extracellular vesicle biology and the role of extracellular vesicles in disease, discuss emerging therapeutic opportunities and consider the associated challenges.
C1 [EL Andaloussi, Samir; Maeger, Imre; Wood, Matthew J. A.] Univ Oxford, Dept Physiol Anat & Genet, Oxford OX1 3QX, England.
[Breakefield, Xandra O.] Massachusetts Gen Hosp, Neurogenet Unit, Charlestown, MA USA.
[EL Andaloussi, Samir] Karolinska Inst, Dept Lab Med, SE-14186 Solna, Sweden.
[Maeger, Imre] Univ Tartu, Inst Technol, EE-50411 Tartu, Estonia.
RP Wood, MJA (reprint author), Univ Oxford, Dept Physiol Anat & Genet, S Parks Rd, Oxford OX1 3QX, England.
EM matthew.wood@dpag.ox.ac.uk
OI Mager, Imre/0000-0003-2242-7227
FU Swedish Society of Medical Research (SSMF); Swedish Medical Research
Council (VR-med unga forskare); Estonian Science Foundation
FX S.E.A. is supported by a postdoctoral research fellowship from the
Swedish Society of Medical Research (SSMF) and the Swedish Medical
Research Council (VR-med unga forskare). I. M. is supported by a
Postdoctoral MOBILITAS Fellowship of the Estonian Science Foundation.
NR 120
TC 249
Z9 251
U1 24
U2 170
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1474-1776
J9 NAT REV DRUG DISCOV
JI Nat. Rev. Drug Discov.
PD MAY
PY 2013
VL 12
IS 5
BP 348
EP 358
DI 10.1038/nrd3978
PG 11
WC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy
SC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy
GA 136GR
UT WOS:000318350900013
PM 23584393
ER
PT J
AU Tepper, PG
Randolph, JF
McConnell, DS
Crawford, SL
El Khoudary, SR
Joffe, H
Gold, EB
Zheng, HY
Bromberger, JT
Sutton-Tyrrell, K
AF Tepper, Ping G.
Randolph, John F., Jr.
McConnell, Daniel S.
Crawford, Sybil L.
El Khoudary, Samar R.
Joffe, Hadine
Gold, Ellen B.
Zheng, Huiyong
Bromberger, Joyce T.
Sutton-Tyrrell, Kim
TI Trajectory Clustering of Estradiol and Follicle-Stimulating Hormone
During the Menopausal Transition Among Women in the Study of Women's
Health Across the Nation (SWAN) EDITORIAL COMMENT
SO OBSTETRICAL & GYNECOLOGICAL SURVEY
LA English
DT Editorial Material
C1 [Tepper, Ping G.; El Khoudary, Samar R.; Sutton-Tyrrell, Kim] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA.
[Bromberger, Joyce T.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol & Psychiat, Pittsburgh, PA USA.
[Randolph, John F., Jr.] Univ Michigan, Sch Publ Hlth, Div Reprod Endocrinol & Infertil, Ann Arbor, MI 48109 USA.
[McConnell, Daniel S.; Zheng, Huiyong] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA.
[Crawford, Sybil L.] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA.
[Joffe, Hadine] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Womens Mental Hlth, Boston, MA USA.
[Gold, Ellen B.] Univ Calif Davis, Sch Med, Dept Publ Hlth Sci, Davis, CA 95616 USA.
RP Tepper, PG (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0029-7828
J9 OBSTET GYNECOL SURV
JI Obstet. Gynecol. Surv.
PD MAY
PY 2013
VL 68
IS 5
BP 361
EP 363
DI 10.1097/01.ogx.0000430387.83358.89
PG 3
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 138BD
UT WOS:000318482300017
ER
PT J
AU Wong, JR
Harris, JK
Rodriguez-Galindo, C
Johnson, KJ
AF Wong, Jeannette R.
Harris, Jenine K.
Rodriguez-Galindo, Carlos
Johnson, Kimberly J.
TI Incidence of Childhood and Adolescent Melanoma in the United States:
1973-2009
SO PEDIATRICS
LA English
DT Article
DE melanoma; childhood; adolescence; incidence; SEER; trends; UV; cancer;
epidemiology
ID CUTANEOUS MALIGNANT-MELANOMA; ULTRAVIOLET-LIGHT EXPOSURE; INDOOR TANNING
FACILITIES; LYMPH-NODE BIOPSY; SKIN-CANCER; XERODERMA-PIGMENTOSUM;
POPULAR ATTITUDES; YOUNG-ADULTS; INVASIVE MELANOMA; MELANOCYTIC NEVI
AB OBJECTIVE: Childhood and adolescent melanoma is rare but has been increasing. To gain insight into possible reasons underlying this observation, we analyzed trends in melanoma incidence diagnosed between the ages of 0 and 19 years among US whites by gender, stage, age at diagnosis, and primary site. We also investigated incidence trends by UV-B exposure levels.
METHODS: By using Surveillance, Epidemiology, and End Results (SEER) program data (1973-2009), we calculated age-adjusted incidence rates (IRs), annual percent changes, and 95% confidence intervals for each category of interest. Incidence trends were also evaluated by using joinpoint and local regression models. SEER registries were categorized with respect to low or high UV-B radiation exposure.
RESULTS: From 1973 through 2009, 1230 children of white race were diagnosed with malignant melanoma. Overall, pediatric melanoma increased by an average of 2% per year (95% confidence interval, 1.4%-2.7%). Girls, 15- to 19-year-olds, and individuals with low UV-B exposure had significantly higher IRs than boys, younger children, and those living in SEER registries categorized as high UV-B. Over the study period, boys experienced increased IRs for melanoma on the face and trunk, and females on the lower limbs and hip. The only decreased incidence trend we observed was among 15- to 19-year-olds in the high UV-B exposure group from 1985 through 2009. Local regression curves indicated similar patterns.
CONCLUSIONS: These results may help elucidate possible risk factors for adolescent melanoma, but additional individual-level studies will be necessary to determine the reasons for increasing incidence trends.
C1 [Wong, Jeannette R.] NCI, Radiat Epidemiol Branch, Div Canc Epidemiol & Genet, Rockville, MD USA.
[Harris, Jenine K.; Johnson, Kimberly J.] Washington Univ, Brown Sch, St Louis, MO USA.
[Johnson, Kimberly J.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA.
[Rodriguez-Galindo, Carlos] Harvard Univ, Dana Farber Canc Inst, Cambridge, MA 02138 USA.
RP Johnson, KJ (reprint author), Washington Univ, 237 Goldfarb Hall,Campus Box 1196,1 Brookings Dr, St Louis, MO 63130 USA.
EM kijohnson@brownschool.wustl.edu
FU National Institutes of Health; National Cancer Institute; National
Institutes of Health (NIH)
FX Supported in part by the intramural research program of the National
Institutes of Health and the National Cancer Institute. Funded by the
National Institutes of Health (NIH).
NR 64
TC 49
Z9 53
U1 0
U2 20
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
J9 PEDIATRICS
JI Pediatrics
PD MAY
PY 2013
VL 131
IS 5
BP 846
EP 854
DI 10.1542/peds.2012-2520
PG 9
WC Pediatrics
SC Pediatrics
GA 135EO
UT WOS:000318270700046
PM 23589817
ER
PT J
AU Rose, O
Blanco, E
Martinez, SM
Sim, EK
Castillo, M
Lozoff, B
Vaucher, YE
Gahagan, S
AF Rose, Olga
Blanco, Estela
Martinez, Suzanna M.
Sim, Eastern Kang
Castillo, Marcela
Lozoff, Betsy
Vaucher, Yvonne E.
Gahagan, Sheila
TI Developmental Scores at 1 Year With Increasing Gestational Age, 37-41
Weeks
SO PEDIATRICS
LA English
DT Article
DE gestational age; term infants; development; cognition; Bayley Scales of
Infant Development
ID LOW-BIRTH-WEIGHT; LATE-PRETERM BIRTH; SOCIOECONOMIC-STATUS;
PREDICTIVE-VALIDITY; INFANT DEVELOPMENT; COGNITIVE FUNCTION;
EARLY-CHILDHOOD; SCHOOL-AGE; NEAR-TERM; OUTCOMES
AB OBJECTIVE: To examine the relationship between gestational age and mental and psychomotor development scores in healthy infants born between 37 and 41 weeks.
METHODS: The cohort included 1562 participants enrolled during infancy in an iron deficiency anemia preventive trial in Santiago, Chile. All participants were healthy, full-term (37-41 weeks) infants who weighed 3 kg or more at birth. Development at 12 months was assessed using the Bayley Scales of Infant Development. Using generalized linear modeling, we analyzed the association between gestational age and 1-year-old developmental status, taking into account potential confounders including birth weight percentile, gender, socioeconomic status, the home environment, iron status, and iron supplementation.
RESULTS: For each additional week of gestation, the Mental Development Index increased by 0.8 points (95% confidence interval = 0.2-1.4), and the Psychomotor Development Index increased by 1.4 points (95% confidence interval = 0.6-2.1) controlling for birth weight percentile, gender, socioeconomic status, and home environment.
CONCLUSIONS: In a large sample of healthy full-term infants, developmental scores obtained using the Bayley Scales of Infant Development at 12 months increased with gestational age (37-41 weeks). There is increasing evidence that birth at 39 to 41 weeks provides developmental advantages compared with birth at 37 to 38 weeks. Because cesarean deliveries and early-term inductions have increased to 40% of all births, consideration of ongoing brain development during the full-term period is an important medical and policy issue.
C1 [Rose, Olga; Sim, Eastern Kang] Harvard Univ, Sch Med, Dept Pediat, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Rose, Olga; Blanco, Estela; Martinez, Suzanna M.; Gahagan, Sheila] Univ Calif San Diego, Div Child Dev & Community Hlth, San Diego, CA 92103 USA.
[Vaucher, Yvonne E.; Gahagan, Sheila] Univ Calif San Diego, Dept Pediat, Div Neonatol, San Diego, CA 92103 USA.
[Castillo, Marcela] Univ Chile, Inst Nutr & Food Technol, Santiago, Chile.
[Lozoff, Betsy] Univ Michigan, Ctr Human Growth & Dev, Ann Arbor, MI 48109 USA.
[Lozoff, Betsy] Univ Michigan, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA.
RP Gahagan, S (reprint author), Univ Calif San Diego, Div Child Dev & Community Hlth, San Diego, CA 92103 USA.
EM sgahagan@ucsd.edu
RI BLANCO, ESTELA/A-2541-2014
OI BLANCO, ESTELA/0000-0002-6232-9210
FU National Heart, Lung, and Blood Institute; National Institute of Child
Health and Human Development [R01HL088530, R01HD33487, R01HD14122];
National Institutes of Health (NIH)
FX Supported by grants from the National Heart, Lung, and Blood Institute
and the National Institute of Child Health and Human Development (grants
R01HL088530, R01HD33487, principal investigator: Gahagan; grants
R01HD14122 and R01HD33487, principal investigator: Lozoff). Funded by
the National Institutes of Health (NIH).
NR 51
TC 15
Z9 16
U1 3
U2 14
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
J9 PEDIATRICS
JI Pediatrics
PD MAY
PY 2013
VL 131
IS 5
BP E1475
EP E1481
DI 10.1542/peds.2012-3215
PG 7
WC Pediatrics
SC Pediatrics
GA 135EO
UT WOS:000318270700012
PM 23589812
ER
PT J
AU Walsh, KE
Roblin, DW
Weingart, SN
Houlahan, KE
Degar, B
Billett, A
Keuker, C
Biggins, C
Li, J
Wasilewski, K
Mazor, KM
AF Walsh, Kathleen E.
Roblin, Douglas W.
Weingart, Saul N.
Houlahan, Kathleen E.
Degar, Barbara
Billett, Amy
Keuker, Christopher
Biggins, Colleen
Li, Justin
Wasilewski, Karen
Mazor, Kathleen M.
TI Medication Errors in the Home: A Multisite Study of Children With Cancer
SO PEDIATRICS
LA English
DT Article
DE antineoplastic agents; medical errors; medication errors; patient
safety; pediatric cancer; quality improvement
ID ADVERSE DRUG EVENTS; RANDOMIZED CONTROLLED-TRIAL; PEDIATRIC INPATIENTS;
ADMINISTRATION ERRORS; HEALTH-LITERACY; CARE; PARENTS
AB OBJECTIVE: As home medication use increases, medications previously managed by nurses are now managed by patients and their families. Our objective was to describe the types of errors occurring in the home medication management of children with cancer.
METHODS: In a prospective observational study at 3 pediatric oncology clinics in the northeastern and southeastern United States, patients undergoing chemotherapy and their parents were recruited from November 2007 through April 2011. We reviewed medical records and checked prescription doses. A trained nurse visited the home, reviewed medication bottles, and observed administration. Two physicians independently made judgments regarding whether an error occurred and its severity. Overall rates of errors were weighted to account for clustering within sites.
RESULTS: We reviewed 963 medications and observed 242 medication administrations in the homes of 92 patients. We found 72 medication errors. Four errors led to significant patient injury. An additional 40 errors had potential for injury: 2 were life-threatening, 13 were serious, and 25 were significant. Error rates varied between study sites (40-121 errors per 100 patients); the weighted overall rate was 70.2 errors per 100 patients (95% confidence interval [CI]: 58.9-81.6). The weighted rate of errors with injury was 3.6 (95% CI: 1.7-5.5) per 100 patients and with potential to injure the patient was 36.3 (95% CI: 29.3-43.3) per 100 patients. Nonchemotherapy medications were more often involved in an error than chemotherapy.
CONCLUSIONS: Medication errors were common in this multisite study of outpatient pediatric cancer care. Rates of preventable medication-related injuries in this outpatient population were comparable or higher than those found in studies of hospitalized patients.
C1 [Walsh, Kathleen E.; Keuker, Christopher] Univ Massachusetts, Sch Med, Dept Pediat, Worcester, MA 01605 USA.
[Mazor, Kathleen M.] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA.
[Walsh, Kathleen E.; Biggins, Colleen; Mazor, Kathleen M.] Meyers Primary Care Inst, Worcester, MA USA.
[Roblin, Douglas W.] Kaiser Permanente, Atlanta, GA USA.
[Weingart, Saul N.; Houlahan, Kathleen E.; Degar, Barbara; Billett, Amy; Li, Justin] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Houlahan, Kathleen E.; Degar, Barbara; Billett, Amy] Childrens Hosp, Boston, MA 02115 USA.
[Wasilewski, Karen] Emory Med Sch, Atlanta, GA USA.
RP Walsh, KE (reprint author), Univ Massachusetts, Sch Med, Dept Pediat, Worcester, MA 01605 USA.
FU Robert Wood Johnson Physician Faculty Scholars award; Charles H. Hood
Foundation; National Cancer Institute [CRN U19 CA 79689]
FX Dr Walsh was supported by a Robert Wood Johnson Physician Faculty
Scholars award. This work was also supported by the Charles H. Hood
Foundation and the National Cancer Institute (CRN U19 CA 79689).
NR 42
TC 19
Z9 20
U1 2
U2 19
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
J9 PEDIATRICS
JI Pediatrics
PD MAY
PY 2013
VL 131
IS 5
BP E1405
EP E1414
DI 10.1542/peds.2012-2434
PG 10
WC Pediatrics
SC Pediatrics
GA 135EO
UT WOS:000318270700003
PM 23629608
ER
PT J
AU Palotie, A
Kallela, M
Anttila, V
AF Palotie, Aarno
Kallela, Mikko
Anttila, Verneri
TI Probing the Brain of Comorbidity
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Editorial Material
ID GENOME-WIDE ASSOCIATION; MIGRAINE
C1 [Palotie, Aarno] Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England.
[Palotie, Aarno; Anttila, Verneri] Univ Helsinki, Inst Mol Med Finland FIMM, FI-00014 Helsinki, Finland.
[Palotie, Aarno; Anttila, Verneri] Broad Inst MIT & Harvard, Program Med & Populat Genet, Cambridge, MA 02142 USA.
[Kallela, Mikko] Univ Helsinki, Cent Hosp, Dept Neurol, Helsinki 00029, Finland.
[Anttila, Verneri] Massachusetts Gen Hosp, Dept Med, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
RP Palotie, A (reprint author), Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Cambridge CB10 1SA, England.
EM ap8@sanger.ac.uk
OI Anttila, Verneri/0000-0002-0073-4675
NR 10
TC 1
Z9 1
U1 0
U2 2
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD MAY 1
PY 2013
VL 5
IS 183
AR 183fs15
DI 10.1126/scitranslmed.3006229
PG 3
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 137FM
UT WOS:000318420900002
PM 23636091
ER
PT J
AU Chen, CC
Walker, WA
AF Chen, Chien-Chang
Walker, W. Allan
TI Probiotics and the mechanism of necrotizing enterocolitis
SO SEMINARS IN PEDIATRIC SURGERY
LA English
DT Article
DE Necrotizing enterocolitis; Probiotics; Intestinal host defense
ID CITROBACTER-RODENTIUM COLITIS; BIRTH-WEIGHT INFANTS;
LACTOBACILLUS-ACIDOPHILUS; BACTERIAL-COLONIZATION; PREMATURE-INFANTS;
PRETERM INFANTS; HUMAN INTESTINE; BREAST-MILK; SUPPLEMENTATION;
INFECTION
AB Necrotizing enterocolitis (NEC) is a severe intestinal inflammatory disorder in newborns. Although the pathogenesis of NEC is not completely understood, we reviewed the literature and our previous studies to explore the mechanism of NEC and to evaluate the role for probiotics in this disease. NEC may be associated with an inappropriate innate immune and excessive inflammatory response of the immature intestine. Probiotics are widely used in promoting human health and adjunctive therapy of human disease. There are growing clinical trials and research studies that support a beneficial role for probiotics for NEC. We have reviewed the literature associated with the use of probiotics in NEC. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Chen, Chien-Chang] Chang Gung Mem Hosp, Dept Pediat, Div Gastroenterol, Tao Yuan, Taiwan.
[Chen, Chien-Chang] Chang Gung Univ, Coll Med, Tao Yuan, Taiwan.
[Walker, W. Allan] Harvard Univ, Sch Med, Div Nutr, Boston, MA USA.
[Walker, W. Allan] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Walker, W. Allan] Massachusetts Gen Hosp, Mucosal Immunol Lab, Charlestown, MA USA.
RP Walker, WA (reprint author), Massachusetts Gen Hosp Children, Mucosal Immunol Lab, 114 16th St, Charlestown, MA 02129 USA.
EM wwalker@partners.org
NR 53
TC 3
Z9 3
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1055-8586
J9 SEMIN PEDIATR SURG
JI Semin. Pediatr. Surg.
PD MAY
PY 2013
VL 22
IS 2
BP 94
EP 100
DI 10.1053/j.sempedsurg.2013.01.0.06
PG 7
WC Pediatrics; Surgery
SC Pediatrics; Surgery
GA 137WG
UT WOS:000318468300006
PM 23611613
ER
PT J
AU Kuna, ST
Reboussin, DM
Borradaile, KE
Sanders, MH
Millman, RP
Zammit, G
Newman, AB
Wadden, TA
Jakicic, JM
Wing, RR
Pi-Sunyer, FX
Foster, GD
AF Kuna, Samuel T.
Reboussin, David M.
Borradaile, Kelley E.
Sanders, Mark H.
Millman, Richard P.
Zammit, Gary
Newman, Anne B.
Wadden, Thomas A.
Jakicic, John M.
Wing, Rena R.
Pi-Sunyer, F. Xavier
Foster, Gary D.
CA Look AHEAD Res Grp
TI Long-Term Effect of Weight Loss on Obstructive Sleep Apnea Severity in
Obese Patients with Type 2 Diabetes
SO SLEEP
LA English
DT Article
DE Apnea-hypopnea index; polysomnogram
ID RANDOMIZED CONTROLLED-TRIAL; LIFE-STYLE INTERVENTION; POSITIVE AIRWAY
PRESSURE; LOW ENERGY DIET; PHYSICAL-ACTIVITY; CARDIOVASCULAR-DISEASE;
HEART HEALTH; RISK-FACTORS; FOLLOW-UP; EXERCISE
AB Study Objectives: To examine whether the initial benefit of weight loss on obstructive sleep apnea (OSA) severity at 1 year is maintained at 4 years.
Design: Randomized controlled trial with follow-up at 1, 2, and 4 years.
Setting: 4 Look AHEAD clinical centers.
Participants: Two hundred sixty-four obese adults with type 2 diabetes and OSA.
Interventions: Intensive lifestyle intervention with a behavioral weight loss program or diabetes support and education.
Measurements: Change in apnea-hypopnea index on polysomnogram.
Results: The intensive lifestyle intervention group's mean weight loss was 10.7 +/- 0.7 (standard error), 7.4 +/- 0.7, and 5.2 +/- 0.7 kg at 1, 2, and 4 years respectively, compared to a less than 1-kg weight loss for the control group at each time (P < 0.001). Apnea-hypopnea index difference between groups was 9.7 +/- 2.0, 8.0 +/- 2.0, and 7.7 +/- 2.3 events/h at 1, 2 and 4 years respectively (P < 0.001). Change in apnea-hypopnea index over time was related to the amount of weight loss (P < 0.0001) and intervention, independent of weight loss (P = 0.001). Remission of OSA at 4 years was 5 times more common with intensive lifestyle intervention (20.7%) than diabetes support and education (3.6%).
Conclusions: Among obese adults with type 2 diabetes and OSA, intensive lifestyle intervention produced greater reductions in weight and apnea-hypopnea index over a 4 year period than did diabetes support and education. Beneficial effects of intensive lifestyle intervention on apnea-hypopnea index at 1 year persisted at 4 years, despite an almost 50% weight regain. Effect of intensive lifestyle intervention on apnea-hypopnea index was largely, but not entirely, due to weight loss.
C1 [Kuna, Samuel T.; Wadden, Thomas A.] Univ Penn, Philadelphia, PA 19104 USA.
[Kuna, Samuel T.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Reboussin, David M.] Wake Forest Univ, Winston Salem, NC 27109 USA.
[Borradaile, Kelley E.; Foster, Gary D.] Temple Univ, Philadelphia, PA 19122 USA.
[Sanders, Mark H.; Newman, Anne B.; Jakicic, John M.] Univ Pittsburgh, Pittsburgh, PA USA.
[Millman, Richard P.; Wing, Rena R.] Brown Univ, Providence, RI 02912 USA.
[Zammit, Gary] Clinilabs, New York, NY USA.
[Pi-Sunyer, F. Xavier] Columbia Univ, New York, NY USA.
RP Kuna, ST (reprint author), Philadelphia VA Med Ctr 111P, 3900 Woodland Ave, Philadelphia, PA 19104 USA.
EM skuna@mail.med.upenn.edu
RI Newman, Anne/C-6408-2013
OI Newman, Anne/0000-0002-0106-1150
FU National Institutes of Health NHLBI [HL070301]; National Institutes of
Health NIDDK [DK60426, DK56992, DK057135]; NIH; CDC; USDA; Robert Wood
Johnson Foundation; Nutrisystem American Beverage Association;
Novo-Nordisk; JennyCraig; Philips Respironics; Abbott; Actelion; Ancile;
Apnex; Arena; Aventis; Cephalon Inc; CHDI; Elan; Epic; Evotec; Forest;
Galderma; Glaxo Smith Kline; H. Lundbeck A/S; King; Merck and Co.;
National Institute of Health (NIH); Neurim; Neurocrine Biosciences;
Neurogen; Organon; Orphan Medical; Otsuka; Pfizer; Predix; Respironics;
Sanofi-Aventis; Sanofi-Synthelabo; Schering-Plough; Sepracor; Shire;
Somaxon; Takeda Pharmaceuticals North America; Targacept; Thymon;
Transcept; UCB Pharma; Vanda; Wyeth-Ayerst Research; NutriSystem
FX This study was supported by the National Institutes of Health NHLBI
grant HL070301 and NIDDK grants DK60426, DK56992, and DK057135; This was
not an industry supported study. Dr. Foster serves on the Scientific
Advisory Board of Con Agra Foods, Nutrisystem, Tate, Lyle and United
Health Group. He has received grants from NIH, CDC, USDA, Robert Wood
Johnson Foundation, Nutrisystem American Beverage Association and
Novo-Nordisk. Dr. Jakicic is a member of Free & Clear Scientific
Advisory Board, has grants or grants pending from BodyMedia, Inc., and
receives payment for lectures by JennyCraig. Dr. Kuna receives grant
support from Philips Respironics. Dr. Sanders is Editor-in-Chief and
Editor for UpToDate (R); Field Editor for Sleep Medicine and Deputy
Editor for the journal SLEEP. He serves as a consultant to Philips
Respironics. Dr. Zammit is a consultant for Actelion, Alexza, Arena,
Aventis, Biovail, Boehringer-Ingelheim, Cephalon, Elan, Eli Lilly,
Evotec, Forest, Glaxo Smith Kline, Jazz Pharmaceuticals, King
Pharmaceuticals, Ligand, McNeil, Merck, Neurocrine Biosciences, Organon,
Pfizer, Renovis, Sanofi-Aventis, Select Comfort, Sepracor, Shire,
Somnus, Takeda Pharmaceuticals, Vela, and Wyeth-Ayerst Research. He also
provides expert testimony for Acorda and has received grants or has
grants pending from Abbott, Actelion, Ancile, Apnex, Arena, Aventis,
Cephalon Inc, CHDI, Elan, Epic, Evotec, Forest, Galderma, Glaxo Smith
Kline, H. Lundbeck A/S, King, Merck and Co., National Institute of
Health (NIH), Neurim, Neurocrine Biosciences, Neurogen, Organon, Orphan
Medical, Otsuka, Pfizer, Predix, Respironics, Sanofi-Aventis,
Sanofi-Synthelabo, Schering-Plough, Sepracor, Shire, Somaxon, Takeda
Pharmaceuticals North America, Targacept, Thymon, Transcept, UCB Pharma,
Predix, Vanda, and Wyeth-Ayerst Research. Dr. Zammit has received
payment for lectures from Neurocrine Biosciences, King Pharmaceuticals,
McNeil, Sanofi-Aventis, Sanofi-Synthelabo, Sepracor, Takeda
Pharmaceuticals, Vela Pharmaceuticals, and Wyeth-Ayerst Research. Dr.
Wadden has received grant support from NutriSystem and serves on the
advisory boards of Novo Nordisk, Orexigen and Vivus. Dr. Millman has
served as a consultant for Johnson and Johnson Business Development. The
other authors have indicated no financial conflicts of interest.
NR 41
TC 51
Z9 54
U1 1
U2 11
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 0161-8105
J9 SLEEP
JI Sleep
PD MAY 1
PY 2013
VL 36
IS 5
BP 641
EP 649
DI 10.5665/sleep.2618
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 137AL
UT WOS:000318406600006
PM 23633746
ER
PT J
AU Zhang, XH
Giovannucci, EL
Wu, KN
Gao, X
Hu, F
Ogino, S
Schernhammer, ES
Fuchs, CS
Redline, S
Willett, WC
Ma, J
AF Zhang, Xuehong
Giovannucci, Edward L.
Wu, Kana
Gao, Xiang
Hu, Frank
Ogino, Shuji
Schernhammer, Eva S.
Fuchs, Charles S.
Redline, Susan
Willett, Walter C.
Ma, Jing
TI Associations of Self-Reported Sleep Duration and Snoring with Colorectal
Cancer Risk in Men and Women
SO SLEEP
LA English
DT Article
DE Sleep duration; snoring; colorectal cancer; incidence; prospective study
ID FOOD FREQUENCY QUESTIONNAIRE; INTERMITTENT HYPOXIA; BREAST-CANCER;
WEIGHT-GAIN; METABOLIC SYNDROME; NURSES HEALTH; COLON-CANCER; MORTALITY;
CORTISOL; COHORT
AB Study Objectives: We assessed the relationship between sleep duration, snoring and colorectal cancer risk.
Design: Prospective cohort studies.
Setting: United States.
Participants: A total of 30,121 men aged 41 to 79 years in the Health Professionals Follow-up Study and 76,368 women aged 40 to 73 years in the Nurses' Health Study.
Interventions: None.
Measurements and Results: We queried information on sleep duration and snoring in 1986/87. Cox proportional hazards regression models were used to estimate multivariable hazard ratios (HRs, 95% CIs). We documented 1,973 incident colorectal cancer cases (709 men and 1,264 women) over a 22-year follow-up period. Compared to sleep an average 7 h, >= 9 h of sleep was significantly associated with a higher risk of colorectal cancer among men (HR = 1.35, 95% CI: 1.00, 1.82), and to a lesser degree, among women (HR = 1.11, 95% CI: 0.85, 1.44). The risk associated with longer sleep was restricted to individuals who regularly snored (men: HR = 1.80, 95% CI: 1.14, 2.84; women: HR = 2.32, 95% CI: 1.24, 4.36) and to overweight individuals (i.e., BMI >= 25 kg/m(2)) (men: HR = 1.52, 95% CI: 1.04, 2.21; women: HR = 1.37, 95% CI: 0.97, 1.94). Short sleep duration (<= 5 h) was not associated with an increased risk of colorectal cancer in the entire sample or in subgroups stratified by snoring or BMI.
Conclusions: Longer sleep duration was associated with an increased risk of developing colorectal cancer among individuals who were overweight or snored regularly. This observation raises the possibility that sleep apnea and its attendant intermittent hypoxemia may contribute to cancer risk.
C1 [Zhang, Xuehong; Giovannucci, Edward L.; Gao, Xiang; Hu, Frank; Schernhammer, Eva S.; Fuchs, Charles S.; Willett, Walter C.; Ma, Jing] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.
[Zhang, Xuehong; Giovannucci, Edward L.; Gao, Xiang; Hu, Frank; Ogino, Shuji; Schernhammer, Eva S.; Fuchs, Charles S.; Willett, Walter C.; Ma, Jing] Harvard Univ, Sch Med, Boston, MA USA.
[Giovannucci, Edward L.; Wu, Kana; Gao, Xiang; Hu, Frank; Willett, Walter C.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Giovannucci, Edward L.; Hu, Frank; Willett, Walter C.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Ogino, Shuji; Fuchs, Charles S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Ogino, Shuji] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Redline, Susan] Brigham & Womens Hosp, Dept Med, Div Sleep Med, Boston, MA 02115 USA.
[Redline, Susan] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
RP Zhang, XH (reprint author), 401 Pk Dr,Suite 301 West, Boston, MA 02115 USA.
EM xuehong.zhang@channing.harvard.edu; jing.ma@channing.harvard.edu
FU NIH [CA87969, 1U54CA155626-01, CA151993, CA55075]
FX The authors thank the participants and staff of the NHS and HPFS for
their valuable contributions as well as the following state cancer
registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL,
IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA,
RI, SC, TN, TX, VA, WA, WY. This study was funded by the NIH grants
CA87969, 1U54CA155626-01, CA151993, and CA55075.
NR 37
TC 28
Z9 29
U1 0
U2 14
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 0161-8105
J9 SLEEP
JI Sleep
PD MAY 1
PY 2013
VL 36
IS 5
BP 681
EP 688
DI 10.5665/sleep.2626
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 137AL
UT WOS:000318406600010
PM 23633750
ER
PT J
AU Ma, ML
Chiu, A
Sahay, G
Doloff, JC
Dholakia, N
Thakrar, R
Cohen, J
Vegas, A
Chen, DL
Bratlie, KM
Dang, T
York, RL
Hollister-Lock, J
Weir, GC
Anderson, DG
AF Ma, Minglin
Chiu, Alan
Sahay, Gaurav
Doloff, Joshua C.
Dholakia, Nimit
Thakrar, Raj
Cohen, Joshua
Vegas, Arturo
Chen, Delai
Bratlie, Kaitlin M.
Dang, Tram
York, Roger L.
Hollister-Lock, Jennifer
Weir, Gordon C.
Anderson, Daniel G.
TI Core-Shell Hydrogel Microcapsules for Improved Islets Encapsulation
SO ADVANCED HEALTHCARE MATERIALS
LA English
DT Article
DE Islets encapsulation; transplantation; core-shell structures;
immuno-protection; microcapsules; hydrogels
ID TYPE-1 DIABETES-MELLITUS; ALGINATE MICROCAPSULES; PANCREATIC-ISLETS;
PORCINE ISLETS; NONIMMUNOSUPPRESSED PATIENTS; GRAFT IMMUNOPROTECTION;
IN-VITRO; CELLS; IMMUNOISOLATION; MICROENCAPSULATION
C1 [Ma, Minglin; Chiu, Alan; Sahay, Gaurav; Doloff, Joshua C.; Dholakia, Nimit; Thakrar, Raj; Vegas, Arturo; Chen, Delai; Dang, Tram; York, Roger L.; Anderson, Daniel G.] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.
[Anderson, Daniel G.] MIT, Dept Chem Engn, Cambridge, MA 02139 USA.
[Anderson, Daniel G.] MIT, Div Hlth Sci Technol, Cambridge, MA 02139 USA.
[Ma, Minglin; Chiu, Alan; Doloff, Joshua C.; Dholakia, Nimit; Thakrar, Raj; Vegas, Arturo; Chen, Delai; Dang, Tram; York, Roger L.; Anderson, Daniel G.] Childrens Hosp, Dept Anesthesiol, Boston, MA 02115 USA.
[Cohen, Joshua; Hollister-Lock, Jennifer; Weir, Gordon C.; Anderson, Daniel G.] Joslin Diabet Ctr, Sect Islet Cell & Regenerat Biol, Div Res, Boston, MA 02215 USA.
[Bratlie, Kaitlin M.] Iowa State Univ, Dept Mat Sci & Engn, Ames, IA 50011 USA.
[Bratlie, Kaitlin M.] Iowa State Univ, Dept Chem & Biol Engn, Ames, IA 50011 USA.
RP Anderson, DG (reprint author), MIT, David H Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
EM dgander@mit.edu
RI York, Roger/C-6547-2008; Dang, Tram/E-7966-2011
OI York, Roger/0000-0002-5105-6800;
FU Juvenile Diabetes Research Foundation [17-2007-1063]; National
Institutes of Health [F32 EB011580-01]
FX This research was supported by the Juvenile Diabetes Research Foundation
under grant 17-2007-1063, and a generous gift from the Tayebati Family
Foundation. K. M. B. is grateful for support from the National
Institutes of Health Postdoctoral Fellowship F32 EB011580-01. We are
grateful to Miri Park, Thema Vietti, Justin Chin, Dr. Christian Kastrup
and Dr. Shan Jiang for help and discussion.
NR 48
TC 31
Z9 31
U1 4
U2 96
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2192-2640
J9 ADV HEALTHC MATER
JI Adv. Healthc. Mater.
PD MAY
PY 2013
VL 2
IS 5
BP 667
EP 672
DI 10.1002/adhm.201200341
PG 6
WC Engineering, Biomedical; Nanoscience & Nanotechnology; Materials
Science, Biomaterials
SC Engineering; Science & Technology - Other Topics; Materials Science
GA 135TU
UT WOS:000318312200004
PM 23208618
ER
PT J
AU Estrella, MM
Abraham, AG
Jing, YZ
Parekh, RS
Tien, PC
Merenstein, D
Pearce, CL
Anastos, K
Cohen, MH
Dehovitz, JA
Gange, SJ
AF Estrella, Michelle M.
Abraham, Alison G.
Jing, Yuezhou
Parekh, Rulan S.
Tien, Phyllis C.
Merenstein, Dan
Pearce, Celeste Leigh
Anastos, Kathryn
Cohen, Mardge H.
Dehovitz, Jack A.
Gange, Stephen J.
TI Antiretroviral-Treated HIV-Infected Women Have Similar Long-Term Kidney
Function Trajectories as HIV-Uninfected Women
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID GLOMERULAR-FILTRATION-RATE; SERUM CREATININE; INTERAGENCY HIV;
RENAL-FUNCTION; TENOFOVIR; THERAPY; NEPHROPATHY; DISEASE; SAFETY; COHORT
AB Natural history studies suggest increased risk for kidney function decline with HIV infection, but few studies have made comparisons with HIV-uninfected women. We examined whether HIV infection treated with highly active antiretroviral therapy (HAART) remains associated with faster kidney function decline in the Women's Interagency HIV Study. HIV-infected women initiating HAART with (n = 105) or without (n = 373) tenofovir (TDF) were matched to HIV-uninfected women on calendar and length of follow-up, age, systolic blood pressure, hepatitis C antibody serostatus, and diabetes history. Linear mixed models were used to evaluate differences in annual estimated glomerular filtration rate (eGFR). Person-visits were 4,741 and 11,512 for the TDF-treated and non-TDF-treated analyses, respectively. Mean baseline eGFRs were higher among women initiated on TDF-containing HAART and lower among those on TDF-sparing HAART compared to their respective HIV-uninfected matches (p < 0.05 for both). HIV-infected women had annual rates of eGFR changes similar to HIV-uninfected matches (p-interaction >0.05 for both). Adjusting for baseline eGFR, mean eGFRs at 1 and 3 years of follow-up among women initiated on TDF-containing HAART were lower than their uninfected matches (-4.98 and -4.26ml/min/1.73 m(2), respectively; p < 0.05 for both). Mean eGFR of women initiated on TDF-sparing HAART was lower versus uninfected matches at 5 years (-2.19ml/min/1.73 m(2), p = 0.03). HAART-treated HIV-infected women had lower mean eGFRs at follow-up but experienced rates of annual eGFR decline similar to HIV-uninfected women. Tenofovir use in HIV-infected women with normal kidney function did not accelerate long-term kidney function decline relative to HIV-uninfected women.
C1 [Estrella, Michelle M.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
[Abraham, Alison G.; Jing, Yuezhou; Parekh, Rulan S.; Gange, Stephen J.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Parekh, Rulan S.] Univ Toronto, Div Nephrol, Toronto, ON, Canada.
[Tien, Phyllis C.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Tien, Phyllis C.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Merenstein, Dan] Georgetown Univ, Med Ctr, Dept Family Med, Washington, DC 20007 USA.
[Pearce, Celeste Leigh] Univ So Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Dept Prevent Med, Los Angeles, CA 90033 USA.
[Anastos, Kathryn] Stroger Hosp, Montefiore Med Ctr, Dept Med, Chicago, IL USA.
[Cohen, Mardge H.] Stroger Hosp, Dept Med, Chicago, IL USA.
[Cohen, Mardge H.] Rush Univ, Med Ctr, Chicago, IL 60612 USA.
[Dehovitz, Jack A.] Suny Downstate Med Ctr, Dept Med, Brooklyn, NY 11203 USA.
RP Estrella, MM (reprint author), Johns Hopkins Univ, Sch Med, Dept Med, Div Nephrol, 1830 East Monument St,Suite 416, Baltimore, MD 21205 USA.
EM mestrel1@jhmi.edu
OI Gange, Stephen/0000-0001-7842-512X
FU National Institute of Allergy and Infectious Diseases [UO1-AI-35004,
UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, UO1-AI-42590];
Eunice Kennedy Shriver National Institute of Child Health and Human
Development [UO1-HD-32632]; National Cancer Institute; National
Institute on Drug Abuse; National Institute on Deafness and Other
Communication Disorders; National Center for Research Resources
(UCSF-CTSI grant) [UL1 RR024131]; NIH-NIDDK grant [K23DK081317]
FX Data in this article were collected by the Women's Interagency HIV Study
(WIHS) Collaborative Study Group with centers (Principal Investigators)
at New York City/Bronx Consortium (Kathryn Anastos); Brooklyn, NY
(Howard Minkoff); Washington, DC, Metropolitan Consortium (Mary Young);
The Connie Wofsy Study Consortium of Northern California (Ruth
Greenblatt); Los Angeles County/Southern California Consortium
(Alexandra Levine); Chicago Consortium (Mardge Cohen); and Data
Coordinating Center (Stephen Gange). The WIHS is funded by the National
Institute of Allergy and Infectious Diseases (UO1-AI-35004,
UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and
UO1-AI-42590) and by the Eunice Kennedy Shriver National Institute of
Child Health and Human Development (UO1-HD-32632). The study is cofunded
by the National Cancer Institute, the National Institute on Drug Abuse,
and the National Institute on Deafness and Other Communication
Disorders. Funding is also provided by the National Center for Research
Resources (UCSF-CTSI grant UL1 RR024131). The contents of this
publication are solely the responsibility of the authors and do not
necessarily represent the official views of the National Institutes of
Health. M.M.E. is supported by NIH-NIDDK grant K23DK081317.
NR 20
TC 0
Z9 0
U1 1
U2 2
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD MAY
PY 2013
VL 29
IS 5
BP 755
EP 760
DI 10.1089/aid.2012.0248
PG 6
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 132NA
UT WOS:000318074200003
PM 23273313
ER
PT J
AU Lahiff, C
Cheifetz, AS
AF Lahiff, C.
Cheifetz, A. S.
TI Commentary: irritable bowel syndrome and the CDAI misleading activity by
straw men; authors' reply
SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS
LA English
DT Editorial Material
ID CROHNS-DISEASE
C1 [Lahiff, C.; Cheifetz, A. S.] Beth Israel Deaconess Med Ctr & Harvard Med Sch, Ctr Inflammatory Bowel Dis, Boston, MA USA.
RP Lahiff, C (reprint author), Beth Israel Deaconess Med Ctr & Harvard Med Sch, Ctr Inflammatory Bowel Dis, Boston, MA USA.
NR 5
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-2813
J9 ALIMENT PHARM THER
JI Aliment. Pharmacol. Ther.
PD MAY
PY 2013
VL 37
IS 10
BP 1021
EP 1022
DI 10.1111/apt.12297
PG 2
WC Gastroenterology & Hepatology; Pharmacology & Pharmacy
SC Gastroenterology & Hepatology; Pharmacology & Pharmacy
GA 131JT
UT WOS:000317989900015
PM 23590539
ER
PT J
AU Lewandrowski, K
Tamerius, J
Menegus, M
Olivo, PD
Lollar, R
Lee-Lewandrowski, E
AF Lewandrowski, Kent
Tamerius, John
Menegus, Marilyn
Olivo, Paul D.
Lollar, Ron
Lee-Lewandrowski, Elizabeth
TI Detection of Influenza A and B Viruses With the Sofia Analyzer A Novel,
Rapid Immunofluorescence-Based In Vitro Diagnostic Device
SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY
LA English
DT Article
DE Influenza virus; Rapid diagnostic test
ID H1N1; METAANALYSIS; PERFORMANCE; INFECTION; TESTS; MANAGEMENT; THAILAND
AB This report describes the clinical evaluation of a novel fluorescent immunoassay (FIA), Sofia Influenza A+B FIA (Quidel, San Diego, CA), for the rapid detection and differentiation of influenza A and B viruses. A total of 2,047 subjects provided nasal swabs and nasopharyngeal swabs or aspirates. The overall sensitivity and specificity for influenza A virus vs virus culture were 94% and 95%, respectively, and for influenza B virus were 89% and 96%, respectively. Fourteen hundred and sixty-one specimens were available for testing with reverse transcriptase polymerase chain reaction (RT-PCR). The sensitivity of the Sofia Influenza A+B FIA for detecting influenza A and B viruses compared with the RT-PCR method was 78% and 86%, respectively. A high percentage of the positive specimens had low cycle threshold values, and almost all of these were positive with the Sofia test. This high level of sensitivity demonstrates that the Sofia influenza A+B FIA could improve the usefulness of rapid influenza virus testing
C1 [Lewandrowski, Kent; Lee-Lewandrowski, Elizabeth] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Tamerius, John; Olivo, Paul D.; Lollar, Ron] Quidel Corp, San Diego, CA USA.
[Menegus, Marilyn] Univ Rochester, Med Ctr, Dept Clin Virol, Rochester, NY 14642 USA.
RP Lewandrowski, K (reprint author), Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
EM Elewandrowski@partners.org
FU Quidel Corp.
FX This study was supported by funding from Quidel Corp.
NR 19
TC 19
Z9 19
U1 0
U2 13
PU AMER SOC CLINICAL PATHOLOGY
PI CHICAGO
PA 2100 W HARRISON ST, CHICAGO, IL 60612 USA
SN 0002-9173
J9 AM J CLIN PATHOL
JI Am. J. Clin. Pathol.
PD MAY
PY 2013
VL 139
IS 5
BP 684
EP 689
DI 10.1309/AJCP7ZTLJCP3LLMA
PG 6
WC Pathology
SC Pathology
GA 131MA
UT WOS:000317996600014
PM 23596120
ER
PT J
AU Le, LP
Garibyan, L
Lara, D
Finberg, KE
Iafrate, AJ
Duncan, LM
Kay, J
Nazarian, RM
AF Le, Long P.
Garibyan, Lilit
Lara, Daniel
Finberg, Karin E.
Iafrate, A. John
Duncan, Lyn M.
Kay, Jonathan
Nazarian, Rosalynn M.
TI Fibrosis-Associated Single-Nucleotide Polymorphisms in TGFB1 and CAV1
Are Not Associated With the Development of Nephrogenic Systemic Fibrosis
SO AMERICAN JOURNAL OF DERMATOPATHOLOGY
LA English
DT Article
DE nephrogenic systemic fibrosis; gadolinium; single-nucleotide
polymorphism; caveolin-1; transforming growth factor-beta 1
ID GROWTH-FACTOR-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1 GENE;
RENAL-DISEASE; GADOLINIUM EXPOSURE; GRAFT FIBROSIS; LIVER FIBROSIS;
HEPATITIS-C; SCLEROSIS; CAVEOLIN-1; PROGRESSION
AB Objective: To test the hypothesis that the subset of patients with impaired renal function who are exposed to gadolinium-containing contrast agents (GCCAs) and develop nephrogenic systemic fibrosis (NSF) have a genetic predisposition for disease.
Methods: We examined whether an intronic single-nucleotide polymorphism (SNP) in caveolin-1 (CAV1 rs4730751) and 2 coding SNPs in transforming growth factor-beta 1 (TGFB1 rs1800471, codon 25; and rs1800470, codon 10) were associated with the NSF phenotype.
Results: Forty-one patients with a history of chronic kidney disease and GCCA administration were studied, including NSF cases (n = 17) and control subjects (n = 24) without clinical or histological evidence of NSF. No significant differences in the genotype frequencies at these SNPs in TGFB1 and CAV1 were found between patients with NSF and subjects without NSF.
Conclusions: We conclude that polymorphisms in the genes encoding TGFB1 and CAV1 previously associated with the development and progression of fibrosis in several organ systems are not associated with development of NSF in this cohort of patients with renal impairment after GCCA exposure.
C1 [Le, Long P.; Lara, Daniel; Iafrate, A. John] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pathol Serv,Diagnost Mol Pathol Lab, Boston, MA 02114 USA.
[Garibyan, Lilit] Harvard Univ, Dept Dermatol, Sch Med, Boston, MA 02114 USA.
[Finberg, Karin E.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.
[Kay, Jonathan] Univ Massachusetts, Sch Med, Dept Med, Div Rheumatol,UMass Mem Med Ctr, Worcester, MA USA.
[Duncan, Lyn M.; Nazarian, Rosalynn M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dermatopathol Unit,Pathol Serv, Boston, MA 02114 USA.
RP Nazarian, RM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dermatopathol Unit,Pathol Serv, 55 Fruit St,Warren 829A, Boston, MA 02114 USA.
EM rmnazarian@partners.org
OI Nazarian, Rosalynn/0000-0003-4003-7193; Kay,
Jonathan/0000-0002-8970-4260
FU Pathology Service at Massachusetts General Hospital
FX Supported by the Austin L. Vickery, Jr. Translational Research Grant
from the Pathology Service at Massachusetts General Hospital.
NR 51
TC 2
Z9 2
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0193-1091
J9 AM J DERMATOPATH
JI Am. J. Dermatopathol.
PD MAY
PY 2013
VL 35
IS 3
BP 351
EP 356
DI 10.1097/DAD.0b013e31826c5508
PG 6
WC Dermatology
SC Dermatology
GA 130LP
UT WOS:000317918800014
PM 23051628
ER
PT J
AU Bartnikas, T
Steinbicker, A
Campagna, D
Blevins, S
Woodward, L
Herrera, C
Bloch, K
Justice, M
Fleming, M
AF Bartnikas, Tom
Steinbicker, Andrea
Campagna, Dean
Blevins, Sherika
Woodward, Lanette
Herrera, Carolina
Bloch, Kenneth
Justice, Monica
Fleming, Mark
TI IDENTIFICATION AND CHARACTERIZATION OF A NOVEL MURINE ALLELE OF TMPRSS6
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Meeting Abstract
C1 [Bartnikas, Tom; Herrera, Carolina] Brown Univ, Providence, RI 02912 USA.
[Steinbicker, Andrea] Univ Munster, Munster, Germany.
[Campagna, Dean; Blevins, Sherika; Fleming, Mark] Boston Childrens Hosp, Boston, MA USA.
[Woodward, Lanette; Justice, Monica] Baylor Coll Med, Houston, TX 77030 USA.
[Bloch, Kenneth] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0361-8609
J9 AM J HEMATOL
JI Am. J. Hematol.
PD MAY
PY 2013
VL 88
IS 5
BP E59
EP E59
PG 1
WC Hematology
SC Hematology
GA 132BT
UT WOS:000318043500093
ER
PT J
AU Duce, J
Lei, P
Tsatsanis, A
Wong, B
Lam, L
Ayton, S
Rogers, J
Finkelstein, D
Bush, A
AF Duce, James
Lei, Peng
Tsatsanis, Andrew
Wong, Bruce
Lam, Linh
Ayton, Scott
Rogers, Jack
Finkelstein, David
Bush, Ashley
TI A NOVEL RELATIONSHIP BETWEEN beta-AMYLOID PROTEIN PRECURSOR AND TAU IN
ALZHEIMER'S DISEASE RELATED IRON DISRUPTION
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Meeting Abstract
C1 [Duce, James; Tsatsanis, Andrew] Univ Leeds, Leeds LS2 9JT, W Yorkshire, England.
[Rogers, Jack] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RI Lei, Peng/F-6326-2010
OI Lei, Peng/0000-0001-5652-1962
NR 0
TC 0
Z9 0
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0361-8609
J9 AM J HEMATOL
JI Am. J. Hematol.
PD MAY
PY 2013
VL 88
IS 5
BP E34
EP E35
PG 2
WC Hematology
SC Hematology
GA 132BT
UT WOS:000318043500051
ER
PT J
AU Metelo, A
Xiang, L
Baker, R
Kamentsky, L
Carpenter, A
Peterson, R
Iliopoulos, O
AF Metelo, Ana
Xiang, Li
Baker, Rania
Kamentsky, Lee
Carpenter, Anne
Peterson, Randall
Iliopoulos, Othon
TI SMALL MOLECULE HIF-2 alpha INHIBITORS SUPPRESS ERYTHROCYTOSIS AND
PATHOLOGIC ANGIOGENESIS OF VHL -/- ZEBRAFISH
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Meeting Abstract
C1 [Metelo, Ana; Xiang, Li; Baker, Rania; Peterson, Randall; Iliopoulos, Othon] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Kamentsky, Lee; Carpenter, Anne] Broad Inst, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0361-8609
J9 AM J HEMATOL
JI Am. J. Hematol.
PD MAY
PY 2013
VL 88
IS 5
BP E25
EP E26
PG 2
WC Hematology
SC Hematology
GA 132BT
UT WOS:000318043500034
ER
PT J
AU Meynard, D
Sun, CC
Chen, WJ
Wu, QF
Chen, SZ
Nelson, CN
Waters, MJ
Babitt, JL
Lin, HY
AF Meynard, Delphine
Sun, Chia Chi
Chen, Wenjie
Wu, Qifang
Chen, Shanzhuo
Nelson, Caroline. N.
Waters, Michael. J.
Babitt, Jodie. L.
Lin, Herbert Y.
TI INFLAMMATION REGULATES TMPRSS6 EXPRESSION VIA STAT5 IN HUMAN CELLS AND
MICE
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Meeting Abstract
C1 [Meynard, Delphine; Sun, Chia Chi; Chen, Wenjie; Wu, Qifang; Chen, Shanzhuo; Babitt, Jodie. L.; Lin, Herbert Y.] Massachusetts Gen Hosp, Program Anemia Signaling Res, Div Nephrol, Program Membrane Biol,Ctr Syst Biol, Boston, MA 02114 USA.
[Meynard, Delphine; Sun, Chia Chi; Chen, Wenjie; Wu, Qifang; Chen, Shanzhuo; Babitt, Jodie. L.; Lin, Herbert Y.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Nelson, Caroline. N.; Waters, Michael. J.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.
[Nelson, Caroline. N.; Waters, Michael. J.] Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia.
RI Nelson, Caroline/H-4213-2013; meynard, delphine/B-4236-2014; waters,
michael/C-9582-2014
NR 0
TC 0
Z9 0
U1 1
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0361-8609
J9 AM J HEMATOL
JI Am. J. Hematol.
PD MAY
PY 2013
VL 88
IS 5
BP E29
EP E30
PG 2
WC Hematology
SC Hematology
GA 132BT
UT WOS:000318043500042
ER
PT J
AU Smith, A
Hahl, P
Davis, T
Thakor, P
Kaja, S
Washburn, C
Rogers, J
AF Smith, Ann
Hahl, Peter
Davis, Taron
Thakor, Preeti
Kaja, Simon
Washburn, Cecilia
Rogers, Jack
TI MODELING HEME, IRON AND COPPER HOMEOSTASIS IN BRAIN INJURY
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Meeting Abstract
C1 [Smith, Ann] UMKC, Kansas City, MO USA.
[Hahl, Peter; Davis, Taron; Thakor, Preeti] Univ Missouri, Sch Biol Sci, Kansas City, MO 64110 USA.
[Kaja, Simon] Univ Missouri, Sch Med, Kansas City, MO 64108 USA.
[Washburn, Cecilia; Rogers, Jack] Massachusetts Gen Hosp, Psychiat Neurosci Dept, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0361-8609
J9 AM J HEMATOL
JI Am. J. Hematol.
PD MAY
PY 2013
VL 88
IS 5
BP E160
EP E160
PG 1
WC Hematology
SC Hematology
GA 132BT
UT WOS:000318043500267
ER
PT J
AU Sun, CC
Chen, WJ
Gutierrez, O
Pietrangelo, A
Babitt, J
Lin, H
AF Sun, Chia Chi
Chen, Wenjie
Gutierrez, Orlando
Pietrangelo, Antonello
Babitt, Jodie
Lin, Herbert
TI A VALIDATED ELISA FOR QUANTITATING HUMAN SERUM HEMOJUVELIN
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Meeting Abstract
C1 [Sun, Chia Chi; Chen, Wenjie; Babitt, Jodie; Lin, Herbert] Harvard Univ, Massachusetts Gen Hosp, Program Anemia Signaling Res, Div Nephrol,Program Membrane Biol,Med Sch, Boston, MA USA.
[Gutierrez, Orlando] Univ Alabama Birmingham, Dept Med, Div Nephrol, Birmingham, AL 35294 USA.
[Pietrangelo, Antonello] Univ Hosp Modena & Reggio Emilia, Mario Coppo Liver Res Ctr, Lab Hereditary & Metab Dis Liver, Modena, Italy.
RI Pietrangelo, Antonello/K-1517-2016
OI Pietrangelo, Antonello/0000-0002-7411-935X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0361-8609
J9 AM J HEMATOL
JI Am. J. Hematol.
PD MAY
PY 2013
VL 88
IS 5
BP E106
EP E107
PG 2
WC Hematology
SC Hematology
GA 132BT
UT WOS:000318043500172
ER
PT J
AU Zumbrennen-Bullough, K
Wu, QF
Chen, WJ
Babitt, J
AF Zumbrennen-Bullough, Kimberly
Wu, Qifang
Chen, Wenjie
Babitt, Jodie
TI MICRORNA-130A DOWNREGULATES HEPCIDIN EXPRESSION DURING IRON DEFICIENCY
BY TARGETING ALK2
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Meeting Abstract
C1 Harvard Univ, Sch Med, Div Nephrol, Program Membrane Biol,Massachusetts Gen Hosp, Cambridge, MA 02138 USA.
Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Syst Biol, Cambridge, MA 02138 USA.
NR 0
TC 0
Z9 0
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0361-8609
J9 AM J HEMATOL
JI Am. J. Hematol.
PD MAY
PY 2013
VL 88
IS 5
BP E9
EP E9
PG 1
WC Hematology
SC Hematology
GA 132BT
UT WOS:000318043500006
ER
PT J
AU Tramontano, AC
Cipriano, LE
Kong, CY
Shepard, JAO
Lanuti, M
Gazelle, GS
McMahon, PM
AF Tramontano, Angela C.
Cipriano, Lauren E.
Kong, Chung Yin
Shepard, Jo-Anne O.
Lanuti, Michael
Gazelle, G. Scott
McMahon, Pamela M.
TI Microsimulation Model Predicts Survival Benefit of Radiofrequency
Ablation and Stereotactic Body Radiotherapy Versus Radiotherapy for
Treating Inoperable Stage I Non-Small Cell Lung Cancer
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Article
DE comparative effectiveness; lung cancer; radiofrequency ablation;
stereotactic body radiotherapy
ID RADIATION-THERAPY; NONSURGICAL CANDIDATES; UNITED-STATES; FOLLOW-UP;
PHASE-II; TUMORS; EFFICACY; HEALTH; MIDTERM
AB OBJECTIVE. A subset of patients with stage IA and IB non-small cell lung cancer (NSCLC) is ineligible for surgical resection and undergoes radiation therapy. Radiofrequency ablation (RFA) and stereotactic body radiotherapy are newer potentially attractive alternative therapies.
MATERIALS AND METHODS. We added RFA and stereotactic body radiotherapy treatment modules to a microsimulation model that simulates lung cancer's natural history, detection, and treatment. Natural history parameters were previously estimated via calibration against tumor registry data and cohort studies; the model was validated with screening study and cohort data. RFA model parameters were calibrated against 2-year survival from the Radiofrequency Ablation of Pulmonary Tumor Response Evaluation (RAPTURE) study, and stereotactic body radiotherapy model parameters were calibrated against 3-year survival from a phase 2 prospective trial. We simulated lifetime histories of identical patients with early-stage NSCLC who were ineligible for resection, who were treated with radiation therapy, RFA, or stereotactic body radiotherapy under a range of scenarios. From 5,000,000 simulated individuals, we selected a cohort of patients with stage I medically inoperable cancer for analysis (n = 2056 per treatment scenario). Main outcomes were life expectancy gains.
RESULTS. RFA or stereotactic body radiotherapy treatment in patients with peripheral stage IA or IB NSCLC who were nonoperative candidates resulted in life expectancy gains of 1.71 and 1.46 life-years, respectively, compared with universal radiation therapy. A strategy where patients with central tumors underwent stereotactic body radiotherapy and those with peripheral tumors underwent RFA resulted in a gain of 2.02 life-years compared with universal radiation therapy. Findings were robust with respect to changes in model parameters.
CONCLUSION. Microsimulation modeling results suggest that RFA and stereotactic body radiotherapy could provide life expectancy gains to patients with stage IA or IB NSCLC who are ineligible for resection.
C1 [Tramontano, Angela C.; Cipriano, Lauren E.; Kong, Chung Yin; Gazelle, G. Scott; McMahon, Pamela M.] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA.
[Kong, Chung Yin; Shepard, Jo-Anne O.; Gazelle, G. Scott; McMahon, Pamela M.] Harvard Univ, Sch Med, Dept Div Radiol, Boston, MA USA.
[Lanuti, Michael] Harvard Univ, Sch Publ Hlth, Dept Div Surg, Boston, MA 02115 USA.
[Gazelle, G. Scott] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA.
RP McMahon, PM (reprint author), Massachusetts Gen Hosp, Inst Technol Assessment, 101 Merrimac St 10th Fl, Boston, MA 02114 USA.
EM pamela@mgh-ita.org
RI Cipriano, Lauren/C-3521-2017
OI Cipriano, Lauren/0000-0001-5568-4516
FU National Cancer Institute [R01 CA97337, K99/R00 CA126147]; American
Cancer Society [2008A060554]
FX This study was funded by the National Cancer Institute (grant R01
CA97337 and support to G. S. Gazelle, and grant K99/R00 CA126147 to P.
M. McMahon) and the American Cancer Society (grant 2008A060554 to G. S.
Gazelle). The National Electrical Manufacturers Association provided G.
S. Gazelle and A. C. Tramontano with funding for an unrelated project.
In March 2010, G. S. Gazelle became a consultant to GE Healthcare on
projects not directly related to lung cancer screening. None of the
other authors has any conflicts of interest.
NR 40
TC 4
Z9 4
U1 0
U2 2
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD MAY
PY 2013
VL 200
IS 5
BP 1020
EP 1027
DI 10.2214/AJR.12.8968
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 133DD
UT WOS:000318116700036
PM 23617484
ER
PT J
AU Kim, KW
Ramaiya, NH
Krajewski, KM
Shinagare, AB
Howard, SA
Jagannathan, JP
Ibrahim, N
AF Kim, Kyung Won
Ramaiya, Nikhil H.
Krajewski, Katherine M.
Shinagare, Atul B.
Howard, Stephanie A.
Jagannathan, Jyothi P.
Ibrahim, Nageatte
TI Ipilimumab-Associated Colitis: CT Findings
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Article
DE colitis; CT; diverticulosis; ipilimumab; segmental colitis
ID INFLAMMATORY-BOWEL-DISEASE; ADVERSE EVENTS; ANTI-CTLA-4 ANTIBODIES;
METASTATIC MELANOMA; CANCER; DIVERTICULOSIS; MANAGEMENT; THERAPY;
PATTERNS; UPDATE
AB OBJECTIVE. The purpose of this article is to describe the CT findings of ipilimumab-associated colitis.
MATERIALS AND METHODS. In this retrospective study, 16 patients diagnosed with ipilimumab-associated colitis and available CT scans obtained at the time of symptoms were found by a search through the electronic medical record database. Two radiologists reviewed the CT images in consensus for the presence of bowel wall thickening, bowel mucosal enhancement, bowel distention, pneumatosis, pericolic fat stranding, and mesenteric vessel engorgement. Medical records were reviewed to note clinical features, management, and outcome.
RESULTS. The common CT findings of ipilimumab-associated colitis were mesenteric vessel engorgement (13/16 [81.3%]) followed by bowel wall thickening (12/16 [75%]) and fluid-filled colonic distention (4/16 [25%]). None of the patients had pneumatosis or halo or target signs. Two distinct CT patterns of ipilimumab-associated colitis were observed: first, the diffuse colitis pattern (n = 12), which is characterized by mesenteric vessel engorgement with mild diffuse bowel wall thickening or fluid-filled distended colon; and, second, the segmental colitis associated with diverticulosis (SCAD) pattern (n = 4), which is characterized by segmental moderate wall thickening and associated pericolic fat stranding in a segment of preexisting diverticulosis. Clinical features and management also differed according to the CT pattern. Patients with the diffuse colitis pattern presented with watery diarrhea and were treated with steroids, whereas the patients with the SCAD pattern presented with mixed watery and bloody diarrhea and cramping pain and were treated with steroids and antibiotics.
CONCLUSION. Two different radiologic and clinical manifestations of ipilimumab-associated colitis were observed: the diffuse colitis pattern and the SCAD pattern.
C1 [Kim, Kyung Won; Ramaiya, Nikhil H.; Krajewski, Katherine M.; Shinagare, Atul B.; Howard, Stephanie A.; Jagannathan, Jyothi P.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Imaging, Boston, MA 02115 USA.
[Kim, Kyung Won] Univ Ulsan, Coll Med, Seoul Asan Med Ctr, Dept Radiol, Seoul, South Korea.
[Kim, Kyung Won] Univ Ulsan, Coll Med, Seoul Asan Med Ctr, Res Inst Radiol, Seoul, South Korea.
[Ibrahim, Nageatte] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Oncol, Boston, MA 02115 USA.
RP Kim, KW (reprint author), Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Imaging, 450 Brookline Ave, Boston, MA 02115 USA.
EM medimash@gmail.com
NR 24
TC 24
Z9 24
U1 1
U2 6
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD MAY
PY 2013
VL 200
IS 5
BP W468
EP W474
DI 10.2214/AJR.12.9751
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 133DD
UT WOS:000318116700008
PM 23718569
ER
PT J
AU Niell, B
Specht, M
Rafferty, E
AF Niell, Bethany
Specht, Michelle
Rafferty, Elizabeth
TI Lobular Neoplasia: What Does It Mean and How Should It Be Treated? Reply
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Letter
ID EXCISIONAL BIOPSY
C1 [Niell, Bethany; Specht, Michelle; Rafferty, Elizabeth] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Avon Comprehens Breast Evaluat Ctr, Boston, MA 02114 USA.
RP Niell, B (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Avon Comprehens Breast Evaluat Ctr, Boston, MA 02114 USA.
NR 3
TC 0
Z9 0
U1 0
U2 0
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD MAY
PY 2013
VL 200
IS 5
BP W539
EP W539
DI 10.2214/AJR.12.10289
PG 1
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 133DD
UT WOS:000318116700021
PM 23617528
ER
PT J
AU Walker, CM
Chung, JH
Abbott, GF
Shepard, JO
AF Walker, Christopher M.
Chung, Jonathan H.
Abbott, Gerald F.
Shepard, JoAnne O.
TI MRI in Lymph Node Staging of Lung Cancer Reply
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Letter
ID QUALITATIVE ASSESSMENT; N-STAGE; PET/CT; EFFICACY
C1 [Walker, Christopher M.; Abbott, Gerald F.; Shepard, JoAnne O.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA.
[Chung, Jonathan H.] Natl Jewish Hlth, Denver, CO USA.
RP Walker, CM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA.
NR 6
TC 0
Z9 0
U1 0
U2 2
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD MAY
PY 2013
VL 200
IS 5
BP W541
EP W541
DI 10.2214/AJR.12.10142
PG 1
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 133DD
UT WOS:000318116700023
PM 23617530
ER
PT J
AU Okumi, M
Scalea, JR
Gillon, BC
Tasaki, M
Villani, V
Cormack, T
Hirakata, A
Shimizu, A
Sachs, DH
Yamada, K
AF Okumi, M.
Scalea, J. R.
Gillon, B. C.
Tasaki, M.
Villani, V.
Cormack, T.
Hirakata, A.
Shimizu, A.
Sachs, D. H.
Yamada, K.
TI The Induction of Tolerance of Renal Allografts by Adoptive Transfer in
Miniature Swine
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE Adoptive transfer; kidney transplantation; MGH miniature swine;
tolerance
ID REGULATORY T-CELLS; TUBULAR EPITHELIAL-CELLS; MAJOR HISTOCOMPATIBILITY
COMPLEX; PERIPHERAL-BLOOD LYMPHOCYTES; TRANSPLANTATION TOLERANCE;
CLASS-I; ANTIGEN PRESENTATION; KIDNEY ALLOGRAFTS; THYMUS; MODEL
AB Our previous in vitro data have demonstrated that regulatory mechanisms are involved in tolerance of class I-mismatched renal allografts in miniature swine treated with 12 days of high dose Cyclsporin A. In this study, we attempted to induce tolerance of class I-mismatched kidneys by adoptive transfer of cells and/or kidneys from long-term tolerant animals. Fifteen SLAdd miniature swine received 1.5 Gy whole body irradiation and class I-mismatched (SLAgg) kidneys from naive pigs with or without cotransplanted kidneys and/or adoptively transferred cells from long-term tolerant (LTT) SLAdd recipients of SLAgg grafts. In addition, three SLAdd miniature swine received class I mismatched kidney with adoptively transferred cells from LTT SLAdd recipients. Naive kidneys transplanted without a LTT kidney were rejected within 9 days. All recipients of naive kidneys along with cells and kidney grafts from LTT animals showed markedly prolonged survival of the naive renal grafts (day 28, >150 and >150 days). These studies suggest that (1) tolerated kidneys have potent regulatory effects and (2) cells from LTT animals infused in conjunction with kidney grafts augment these regulatory effects. To our knowledge, these studies represent the first demonstration of successful adoptive transfer of tolerance in large animals.
C1 [Okumi, M.; Scalea, J. R.; Gillon, B. C.; Tasaki, M.; Villani, V.; Cormack, T.; Hirakata, A.; Shimizu, A.; Sachs, D. H.; Yamada, K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplantat Biol Res Ctr, Boston, MA 02115 USA.
RP Yamada, K (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplantat Biol Res Ctr, Boston, MA 02115 USA.
EM kaz.yamada@tbrc.mgh.harvard.edu
OI Villani, Vincenzo/0000-0002-6078-9766
FU NIH/NIAID [4R37AI031046-21, 1CO6RR20135-01]
FX This work was supported by NIH/NIAID 4R37AI031046-21 and 1CO6RR20135-01.
NR 36
TC 10
Z9 10
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD MAY
PY 2013
VL 13
IS 5
BP 1193
EP 1202
DI 10.1111/ajt.12194
PG 10
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 135GR
UT WOS:000318277100011
PM 23464595
ER
PT J
AU Mengel, M
Chan, S
Climenhaga, J
Kushner, YB
Regele, H
Colvin, RB
Randhawa, P
AF Mengel, M.
Chan, S.
Climenhaga, J.
Kushner, Y. B.
Regele, H.
Colvin, R. B.
Randhawa, P.
TI Banff Initiative for Quality Assurance in Transplantation (BIFQUIT):
Reproducibility of C4d Immunohistochemistry in Kidney Allografts
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE Banff classification; C4d; immunohistochemistry; transplantation
ID ANTIBODY-MEDIATED REJECTION; PERITUBULAR CAPILLARY; IMPROVE
REPRODUCIBILITY; RENAL-ALLOGRAFTS; BIOPSIES; CLASSIFICATION; DEPOSITION;
DIAGNOSIS; PATHOLOGY; ASSOCIATION
AB Detection of C4d is crucial for diagnosing antibody-mediated-rejection. We conducted a multicenter trial to assess the reproducibility for C4d immunohistochemistry on paraffin tissue. Unstained slides from a tissue microarray (TMA) comprising 44 kidney allograft specimens representing a full analytical spectrum for C4d were distributed to 73 institutions. Participants stained TMA slides using local protocols and evaluated their slides following the Banff C4d schema. Local staining details and evaluation scores were collected online. Stained slides were returned for centralized panel re-evaluation. Kappa statistics were used to determine reproducibility. Poor interinstitutional reproducibility was observed (kappa 0.17), which was equally due to limitations in interobserver (kappa 0.44) and interlaboratory reproducibility (kappa 0.46). Depending on the cut-off, reproducibility could be improved by omitting C4d grading and only considering +/- calls. Heat-induced epitope recovery (pH 67, 2030 min, citrate buffer) with polyclonal antibody incubation (<1:80, >40 min) appeared as best practice. The BIFQUIT trial results indicated that C4d staining on paraffin sections varies considerably between laboratories. Refinement of the current Banff C4d scoring schema and harmonization of tissue processing and staining protocols is necessary to achieve acceptable reproducibility.
C1 [Mengel, M.] Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB, Canada.
[Chan, S.; Climenhaga, J.] Univ Alberta, Dept Med, Alberta Transplant Appl Genom Ctr, Div Nephrol & Immunol, Edmonton, AB, Canada.
[Kushner, Y. B.; Colvin, R. B.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Kushner, Y. B.; Colvin, R. B.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Regele, H.] Med Univ Innsbruck, Inst Pathol, A-6020 Innsbruck, Austria.
[Randhawa, P.] Univ Pittsburgh, Dept Pathol, Div Transplantat Pathol, Pittsburgh, PA USA.
RP Mengel, M (reprint author), Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB, Canada.
EM mmengel@ualberta.ca
FU Astellas Canada Inc.
FX We thank Victoria Sheldon and Akshatha Raghuveer for an outstanding
logistical support. This trial was supported by a research grant from
Astellas Canada Inc. to M. M for facilitating Banff Working Group
activities.
NR 29
TC 17
Z9 19
U1 1
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD MAY
PY 2013
VL 13
IS 5
BP 1235
EP 1245
DI 10.1111/ajt.12193
PG 11
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 135GR
UT WOS:000318277100015
PM 23464533
ER
PT J
AU Chen, GD
Ko, DSC
Wang, CX
Qiu, J
Han, M
He, XS
Chen, LZ
AF Chen, G. -D.
Ko, D. Shiu-Chung
Wang, C. -X.
Qiu, J.
Han, M.
He, X. -S.
Chen, L. -Z.
TI Kidney Transplantation From Donors After Cardiac Death: An Initial
Report of 71 Cases From China
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE Cardiac death donors; kidney transplantation; outcome; risk factors
ID DONATION; RECIPIENTS
AB Shortage of deceased donors is a severe problem in recent years in China especially in a culture in which brain death criteria is not widely accepted. Donation after cardiac death (DCD) has been reported to expand the donor pool despite higher rates of primary nonfunction (PNF) and delayed graft function (DGF) after transplantation. We collected 71 DCD kidney transplants performed at our hospital between February, 2007 and June, 2012 with aims to demonstrate the feasibility of DCD donation in China. All patients were followed up, and postoperative complications and graft loss were recorded. The PNF rate was 2.8%, and DGF rate was 28.2%. The 1- and 3-year graft survival was 95.7% and 92.4%. In conclusion, graft survival of DCD kidney transplantation in China is excellent despite of higher rates of PNF and DGF after transplantation.
C1 [Chen, G. -D.; Wang, C. -X.; Qiu, J.; Han, M.; He, X. -S.; Chen, L. -Z.] Sun Yat Sen Univ, Affiliated Hosp 1, Organ Transplant Ctr, Guangzhou 510275, Guangdong, Peoples R China.
[Ko, D. Shiu-Chung] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Urol, Boston, MA 02115 USA.
[Ko, D. Shiu-Chung] Harvard Univ, Sch Med, Dept Surg, Div Transplantat,Massachusetts Gen Hosp, Boston, MA 02115 USA.
RP He, XS (reprint author), Sun Yat Sen Univ, Affiliated Hosp 1, Organ Transplant Ctr, Guangzhou 510275, Guangdong, Peoples R China.
EM gdtrc@163.com; clz@medmail.com.cn
FU 5010 Clinical Research Project of Sun Yat-sen University [2007003];
Ministry of Health [2010159]; Division of Medical Service Management of
Ministry of Health; Special Fund for Science Research by Ministry of
Health [201002004]
FX This study was supported by the 5010 Clinical Research Project of Sun
Yat-sen University (2007003), the Key Clinical Project from the Ministry
of Health (2010159), the Special Fund for Science Research by Ministry
of Health (201002004) and Project by Division of Medical Service
Management of Ministry of Health (2010).
NR 10
TC 13
Z9 22
U1 1
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD MAY
PY 2013
VL 13
IS 5
BP 1323
EP 1326
DI 10.1111/ajt.12190
PG 4
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 135GR
UT WOS:000318277100024
PM 23464380
ER
PT J
AU Graham, LA
Maddox, TM
Itani, KMF
Hawn, MT
AF Graham, Laura A.
Maddox, Thomas M.
Itani, Kamal M. F.
Hawn, Mary T.
TI Coronary Stents and Subsequent Surgery: Reported Provider Attitudes and
Practice Patterns
SO AMERICAN SURGEON
LA English
DT Article; Proceedings Paper
CT 35th Annual Meeting for the Association-of-VA-Surgeons
CY APR 10-12, 2011
CL Irvine, CA
SP Assoc VA Surg, VA Hlth Serv Res & Dev (HSR&D)
ID DRUG-ELUTING STENTS; PERIOPERATIVE CARDIOVASCULAR EVALUATION; NONCARDIAC
SURGERY; BARE-METAL; IMPLEMENTATION; GUIDELINES; INTERVENTION;
THROMBOSIS; FRAMEWORK; OUTCOMES
AB Management of antiplatelet therapy in patients with cardiac stents who need subsequent surgery is complex. Current guidelines recommend delaying elective surgery or, if surgery is emergent, proceeding without aspirin cessation. This study assessed provider knowledge, attitudes, and practices for patients with cardiac stents needing subsequent surgery. A national survey was administered to Veterans Administration surgeons, anesthesiologists, and cardiologists. Questions examined guideline awareness and agreement, perceptions of bleeding risk and stent thrombosis, practice patterns for antiplatelet therapy management, and experience with perioperative stent thrombosis. Chi-square tests and generalized estimating equations were used to examine differences in reported practices. Among 295 respondents, guideline awareness (92%) and agreement (93%) were high but higher among cardiologists and anesthesiologists than surgeons. Guideline agreement and personal experience with stent thrombosis were also associated with reported practice patterns. In adjusted models for early surgeries, cardiologists and anesthesiologists were more likely to report continuation of dual therapy as compared with surgeons regardless of stent type (drug-eluting P = 0.03; bare metal P < 0.01). Despite successful guideline adoption, significant variations in practice patterns by provider type were found. Understanding reasons behind the variation and outcomes of various antiplatelet management strategies are important steps in optimizing care of patients with coronary stents undergoing noncardiac surgery.
C1 [Graham, Laura A.; Hawn, Mary T.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA.
[Maddox, Thomas M.] Univ Colorado Denver, VA Eastern Colorado Hlth Care Syst, Denver, CO USA.
[Itani, Kamal M. F.] Boston Univ, VA Boston Healthcare Syst, Boston, MA 02215 USA.
[Itani, Kamal M. F.] Harvard Univ, Sch Med, Boston, MA USA.
[Hawn, Mary T.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA.
RP Hawn, MT (reprint author), Univ Alabama Birmingham, Dept Surg, Sect Gastrointestinal Surg, 1922 7th Ave South,KB 428, Birmingham, AL 35294 USA.
EM Mary.Hawn@ccc.uab.edu
NR 16
TC 3
Z9 3
U1 0
U2 0
PU SOUTHEASTERN SURGICAL CONGRESS
PI CUMMING
PA 115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA
SN 0003-1348
J9 AM SURGEON
JI Am. Surg.
PD MAY
PY 2013
VL 79
IS 5
BP 514
EP 523
PG 10
WC Surgery
SC Surgery
GA 130VA
UT WOS:000317947000013
PM 23635588
ER
PT J
AU Nagashima, M
Yasuhara, S
Martyn, JAJ
AF Nagashima, Michio
Yasuhara, Shingo
Martyn, J. A. Jeevendra
TI Train-of-Four and Tetanic Fade Are Not Always a Prejunctional Phenomenon
as Evaluated by Toxins Having Highly Specific Pre- and Postjunctional
Actions
SO ANESTHESIA AND ANALGESIA
LA English
DT Article
ID NICOTINIC ACETYLCHOLINE-RECEPTORS; NONDEPOLARIZING MUSCLE-RELAXANTS;
NEUROMUSCULAR-JUNCTION; BOTULINUM-TOXIN; MUSCARINIC AUTORECEPTORS;
TRANSMITTER RELEASE; MOTOR-NERVE; RAT; INHIBITION; EXPRESSION
AB BACKGROUND: Nerve-stimulated fade in muscle is generally accepted as a prejunctional phenomenon mediated by block of prejunctional acetylcholine receptors (AChRs) at the nerve terminal, whereas decrease of twitch tension is considered a postjunctional effect due to block of muscle AChRs. Using ligands with specific pre- or postjunctional effects only, we tested the hypothesis that fade is not necessarily a prejunctional phenomenon.
METHODS: Neuromuscular function in rats was evaluated after IM (2.5 U) or IV (12.0 U) injection of botulinum toxin (Botx), or IV (250 mu g/kg) alpha-bungarotoxin (alpha-BTX) alone. The acute neuromuscular effects of IV 2 mg/kg dihydro-beta-erythroidine (DH beta E), alone and in combination with alpha-BTX, were also tested. Botx decreases vesicular release of ACh, and alpha-BTX binds to postjunctional nicotinic AChRs only, whereas DE beta E binds specifically to prejunctional alpha 3 beta 2 AChRs only. In view of the lack of acute effects of Botx even at 2 hours after IV injection, its neuromuscular effects were also evaluated at 24 hours after IM injection (0.6 U) and compared with IM injection of alpha-BTX (25 mu g/kg) or saline also given 24 hours earlier. The sciatic nerve-tibialis muscle preparation, during train-of-four and tetanic stimulation, was used to test neuromuscular effects in vivo.
RESULTS: IV and IM Botx had no observable neuromuscular effects at 2 hours. IV alpha-BTX caused twitch depression within a few minutes, and significant fade (P = 0.002) at 75% of baseline twitch. tension; these effects persisted until the end of the observation period of 2 hours. IV DH beta E alone caused no significant change in single twitch (P = 0.899) or train-of-four ratio (P = 0.394), but significantly enhanced the fade of IV alpha-BTX (P = 0.001 at 75% of baseline twitch tension). IM Botx or alpha-BTX, at 24 hours after their injection, resulted in a significant decrease of single twitch and tetanic tensions (P < 0.0001), but Botx did not cause fade, whereas alpha-BTX caused significant (P < 0.0001) fade at 24 hours. The tibialis muscle weights and protein expression of alpha 1 subunit of AChR (Western blots) did not differ between Botx, alpha-BTX and saline-injected groups at 24 hours but increased in denervated muscle (positive control).
CONCLUSIONS: Botx-induced decreased ACh release in and of itself does not cause fade but does cause decrease of absolute tensions. Decrease of available (functional) postjunctional AChRs by alpha-BTX did induce fade. The prejunctional fade effects of DH beta E on alpha 3 beta 2 AChRs become manifest only when the margin of safety was decreased by concomitant administration of alpha-BTX. Thus, fade during repetitive stimulation is not always a prejunctional phenomenon and may also reflect the decreased margin of safety of neurotransmission, which can be due to a pure postjunctional AChRs block or to a combination of both pre- and postjunctional AChRs block. Block of prejunctional alpha 3 beta 2 AChRs alone is not necessary and sufficient to cause fade. (Anesth Analg 2013;116:994-1000)
C1 Massachusetts Gen Hosp, Dept Anesthesiol Crit Care & Pain Med, Boston, MA 02114 USA.
Shriners Hosp Children, Boston, MA USA.
Harvard Univ, Sch Med, Dept Anesthesiol, Boston, MA 02114 USA.
RP Martyn, JAJ (reprint author), Harvard Univ, Sch Med, Dept Anesthesia Crit Care & Pain Med, Massachusetts Gen Hosp,Shriners Hosp Children Bos, 51 Blossom St,Room 206, Boston, MA 02114 USA.
EM jmartyn@partners.org
OI Nagashima, Michio/0000-0001-7416-5367
FU National Institutes of Health [RO1 GM 05882, GM P50-2500]; SHC Research
Philanthropy, Tampa, FL
FX This research was supported, in part, by National Institutes of Health
grant number RO1 GM 05882 and GM P50-2500, and by SHC Research
Philanthropy, Tampa, FL (to J.A.J.M.)
NR 27
TC 3
Z9 4
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD MAY
PY 2013
VL 116
IS 5
BP 994
EP 1000
DI 10.1213/ANE.0b013e31828841e3
PG 7
WC Anesthesiology
SC Anesthesiology
GA 134ET
UT WOS:000318193700010
PM 23477960
ER
PT J
AU Coppadoro, A
Berra, L
Bittner, EA
Ecker, JL
Pian-Smith, MCM
AF Coppadoro, Andrea
Berra, Lorenzo
Bittner, Edward A.
Ecker, Jeffrey L.
Pian-Smith, May C. M.
TI Altered Arterial Compliance in Hypertensive Pregnant Women Is Associated
With Preeclampsia
SO ANESTHESIA AND ANALGESIA
LA English
DT Article
ID PULSE-WAVE ANALYSIS; INTRAUTERINE GROWTH RESTRICTION; SERUM URIC-ACID;
GESTATIONAL HYPERTENSION; NITRIC-OXIDE; ENDOTHELIAL DYSFUNCTION; RISK;
ELASTICITY; PRESSURE; HISTORY
AB BACKGROUND: Vascular alterations are present in pregnant women affected by preeclampsia. In this study, we assessed arterial compliance in women affected by hypertensive disorders of pregnancy. We hypothesized that arterial compliance is reduced in women affected by preeclampsia.
METHODS: Forty-three hypertensive pregnant women undergoing evaluation for preeclampsia were studied. Clinical data about each patient and pregnancy were collected. Large (Cl) and small (C2) artery compliance were assessed by radial tonometry, while the patients underwent laboratory tests to diagnose preeclampsia. At the time of delivery, gestational age and newborn data were recorded.
RESULTS: Eighteen women were diagnosed with preeclampsia. C2 levels were lower among preeclamptic versus hypertensive aproteinuric women (mean +/- SD, 4.5 +/- 1.3 vs 5.9 +/- 2.3 mL/mm Hg . 100, P = 0.013, 95% confidence interval [Cl] of difference 0.32-2.55), whereas C1 levels did not differ. In the preeclampsia group, C2 levels correlated with urine total protein concentrations measured the same day (Spearman rho = -0.49, P = 0.047, upper 95% CI -0.01) and with gestational age at first occurrence of hypertension (Spearman rho = 0.59, P = 0.010, lower 95% Cl 0.17). Among singleton gestations, C2 also correlated with newborn birth weight measured at delivery (Spearman rho = 0.43, P = 0.009, lower 95% Cl 0.11). Women who were hypertensive but aproteinuric at the time of compliance assessment, but who subsequently developed preeclampsia (n = 6), had C2 levels similar to those with an early diagnosis of preeclampsia (mean difference 0.37 mL/mm Hg . 100, 95% Cl -2.42 to 1.67) and lower C2 levels than women diagnosed with gestational hypertension (P = 0.019, 95% Cl 0.33-4.42 mL/mm Hg . 100).
CONCLUSIONS: The noninvasive assessment of arterial elasticity may contribute toward characterization of the nature of the pathophysiology in pregnancy-induced hypertensive disorders. The vascular alterations of the small arteries, as assessed by C2, may reflect the "extent of vascular alterations present with preeclampsia. (Anesth Analg 2013;116:1050-56)
C1 [Coppadoro, Andrea; Berra, Lorenzo; Bittner, Edward A.; Pian-Smith, May C. M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Ecker, Jeffrey L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Obstet & Gynecol, Boston, MA 02114 USA.
RP Pian-Smith, MCM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA.
EM mpiansmith@partners.org
FU Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts
General Hospital
FX Supported by the Department of Anesthesia, Critical Care and Pain
Medicine, Massachusetts General Hospital.
NR 32
TC 0
Z9 0
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
EI 1526-7598
J9 ANESTH ANALG
JI Anesth. Analg.
PD MAY
PY 2013
VL 116
IS 5
BP 1050
EP 1056
DI 10.1213/ANE.0b013e318282dc58
PG 7
WC Anesthesiology
SC Anesthesiology
GA 134ET
UT WOS:000318193700017
PM 23337414
ER
PT J
AU Bittner, EA
Martyn, JAJ
Gronert, GA
AF Bittner, Edward A.
Martyn, J. A. Jeevendra
Gronert, Gerald A.
TI The Decision to Use Succinylcholine for Critically III Patients Should
Not Be Based on Duration of Time in the Intensive Care Unit Alone
SO ANESTHESIA AND ANALGESIA
LA English
DT Letter
C1 [Bittner, Edward A.; Martyn, J. A. Jeevendra] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Gronert, Gerald A.] Univ Calif Davis, Depatment Anesthesiol, Davis, CA 95616 USA.
RP Bittner, EA (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
EM ebittner@partners.org
NR 3
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD MAY
PY 2013
VL 116
IS 5
BP 1182
EP 1182
DI 10.1213/ANE.0b013e31828c0046
PG 1
WC Anesthesiology
SC Anesthesiology
GA 134ET
UT WOS:000318193700031
PM 23606469
ER
PT J
AU Thilen, SR
Bryson, CL
Reid, RJ
Wijeysundera, DN
Weaver, EM
Treggiari, MM
AF Thilen, Stephan R.
Bryson, Christopher L.
Reid, Robert J.
Wijeysundera, Duminda N.
Weaver, Edward M.
Treggiari, Miriam M.
TI Patterns of Preoperative Consultation and Surgical Specialty in an
Integrated Healthcare System
SO ANESTHESIOLOGY
LA English
DT Article
ID MAJOR NONCARDIAC SURGERY; MEDICAL CONSULTATION; PERIOPERATIVE MEDICINE;
MANAGED CARE; INTERNISTS; INDEX; WASTE; COST
AB Background: Many patients scheduled for elective surgery are referred for a preoperative medical consultation. Only limited data are available on factors associated with preoperative consultations. The authors hypothesized that surgical specialty contributes to variation in referrals for preoperative consultations.
Methods: This is a cohort study using data from Group Health Cooperative, an integrated healthcare system. The authors included 13,673 patients undergoing a variety of common procedures-primarily low-risk surgeries-representing six surgical specialties, in 2005-2006. The authors identified consultations by family physicians, general internists, pulmonologists, or cardiologists in the 42 days preceding surgery. Multivariable logistic regression was used to estimate the association between surgical specialty and consultation, adjusting for potential confounders including the revised cardiac risk index, age, gender, Deyo comorbidity index, number of prescription medications, and 11 medication classes.
Results: The authors found that 3,063 (22%) of all patients had preoperative consultations, with significant variation by surgical specialty. Patients having ophthalmologic, orthopedic, or urologic surgery were more likely to have consultations compared with those having general surgery-adjusted odds ratios (95% CI) of 3.8 (3.3-4.2), 1.5 (1.3-1.7), and 2.3 (1.8-2.8), respectively. Preoperative consultations were more common in patients with lower revised cardiac risk scores.
Conclusion: There is substantial practice variation among surgical specialties with regard to the use of preoperative consultations in this integrated healthcare system. Given the large number of consultations provided for patients with low cardiac risk and for patients presenting for low-risk surgeries, their indications, the financial burden, and cost-effectiveness of consultations deserve further study.
C1 [Bryson, Christopher L.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA.
[Reid, Robert J.] Grp Hlth Res Inst, Seattle, WA USA.
[Thilen, Stephan R.; Treggiari, Miriam M.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA.
RP Thilen, SR (reprint author), 325 9th Ave,Box 359724, Seattle, WA 98104 USA.
EM sthilen@uw.edu
OI Wijeysundera, Duminda/0000-0002-5897-8605
FU National Institutes of Health, Bethesda, Maryland [T32GM086270]; U.S.
Department of Veterans Affairs, Office of Research and Development,
Health Services Research and Development Center of Excellence; VA Puget
Sound Health Care Systems, Seattle, Washington; Canadian Institutes of
Health Research (Ottawa, Ontario, Canada); Department of Anesthesia at
the University of Toronto, Toronto, Ontario, Canada; Group Health
Research Institute, Seattle, Washington
FX Supported by grant T32GM086270, National Institutes of Health, Bethesda,
Maryland (to Dr. Thilen). This material is based on work supported by
the U.S. Department of Veterans Affairs, Office of Research and
Development, Health Services Research and Development Center of
Excellence; VA Puget Sound Health Care Systems, Seattle, Washington.
Supported by a Clinician Scientist Award from the Canadian Institutes of
Health Research (Ottawa, Ontario, Canada), and a Merit Award from the
Department of Anesthesia at the University of Toronto, Toronto, Ontario,
Canada (to Dr. Wijeysundera). The authors were also supported by Group
Health Research Institute, Seattle, Washington, who waived part of the
indirect costs. Without this support this project may not have been
possible. Meetings at which work has been presented: Preliminary data
were presented at the 5th annual meeting of the Society for
Perioperative Assessment and Quality Improvement, March 3, 2011, Miami
Beach, Florida, and at the annual meeting of the American Society of
Anesthesiologists, October 16, 2011, Chicago, Illinois.
NR 30
TC 9
Z9 10
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-3022
J9 ANESTHESIOLOGY
JI Anesthesiology
PD MAY
PY 2013
VL 118
IS 5
BP 1028
EP 1037
DI 10.1097/ALN.0b013e31828ea68a
PG 10
WC Anesthesiology
SC Anesthesiology
GA 131BA
UT WOS:000317964300008
PM 23503373
ER
PT J
AU Sonpavde, G
Pagliaro, LC
Buonerba, C
Dorff, TB
Lee, RJ
Di Lorenzo, G
AF Sonpavde, G.
Pagliaro, L. C.
Buonerba, C.
Dorff, T. B.
Lee, R. J.
Di Lorenzo, G.
TI Penile cancer: current therapy and future directions
SO ANNALS OF ONCOLOGY
LA English
DT Review
DE biologic agents; chemotherapy; combined modality therapy; molecular
targets; penile cancer; radiotherapy
ID SQUAMOUS-CELL CARCINOMA; LYMPH-NODE INVOLVEMENT; HUMAN-PAPILLOMAVIRUS
DNA; SOUTHWEST-ONCOLOGY-GROUP; PROGNOSTIC-FACTORS; PHASE-II;
UNITED-STATES; INTERSTITIAL BRACHYTHERAPY; BILATERAL LYMPHADENECTOMY;
COMBINATION CHEMOTHERAPY
AB Background: Penile cancer (PC) is a rare cancer in western countries, but is more common in parts of the developing world. Due to its rarity and the consequent lack of randomized trials, current therapy is based on retrospective studies and small prospective trials.
Design: Studies of PC therapy were searched in PubMed and abstracts at major conferences.
Results: PC is generally an aggressive malignancy characterized by early locoregional lymph node (LN) spread and later metastases in distant sites. Given the strong predictive value of LN involvement for overall survival, evaluating regional LNs is critical. Advanced LN involvement is increasingly being treated with multimodality therapy incorporating chemotherapy and/or radiation. A single superior cisplatin-based regimen has not been defined. Further advances may occur with a better collaboration on an international scale and comprehensive understanding of tumor biology. To this end, the preventive role of circumcision and understanding of the oncogenic roles of Human Papilloma Virus-16, and smoking may yield advances. Preliminary data suggest a role for agents targeting epidermal growth factor receptor and angiogenesis.
Conclusion: Advances in therapy for PC will require efficient trial designs, synergistic collaboration, incentives to industry and the efforts of patient advocacy groups and venture philanthropists.
C1 [Sonpavde, G.] UAB Comprehens Canc Ctr, Dept Med, Sect Med Oncol, Birmingham, AL USA.
[Pagliaro, L. C.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA.
[Buonerba, C.; Di Lorenzo, G.] Univ Naples Federico II, Genitourinary Canc Sect, Naples, Italy.
[Buonerba, C.; Di Lorenzo, G.] Univ Naples Federico II, Rare Canc Ctr, Naples, Italy.
[Dorff, T. B.] Univ So Calif, Dept Med, Sect Med Oncol, Los Angeles, CA USA.
[Lee, R. J.] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Div Hematol Oncol,Dept Med,Med Sch, Boston, MA 02114 USA.
RP Di Lorenzo, G (reprint author), Univ Naples Federico II, Genitourinary Canc Sect, Naples, Italy.
EM giuseppedilorenzoncol@hotmail.com
FU Pfizer; BMS; Novartis; Celgene; Sanofi-Aventis
FX GS: Research support and/or advisory board of Pfizer, BMS, Novartis,
Celgene, and Sanofi-Aventis. LCP: Consultant for Janssen and Research
support from Pfizer and Celgene. CB and RJL: these authors have declared
no conflicts of interest. TBD: speaker for Pfizer and Bayer. GDL:
research support from Pfizer and advisory board of Sanofi, Janssen,
Cilag and Novartis.
NR 156
TC 36
Z9 38
U1 1
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD MAY
PY 2013
VL 24
IS 5
BP 1179
EP 1189
DI 10.1093/annonc/mds635
PG 12
WC Oncology
SC Oncology
GA 132YQ
UT WOS:000318105000006
PM 23293117
ER
PT J
AU Oakman, C
Francis, PA
Crown, J
Quinaux, E
Buyse, M
De Azambuja, E
Vila, MM
Andersson, M
Nordenskjold, B
Jakesz, R
Thurlimann, B
Gutierrez, J
Harvey, V
Punzalan, L
Dell'Orto, P
Larsimont, D
Steinberg, I
Gelber, RD
Piccart-Gebhart, M
Viale, G
Di Leo, A
AF Oakman, C.
Francis, P. A.
Crown, J.
Quinaux, E.
Buyse, M.
De Azambuja, E.
Margeli Vila, M.
Andersson, M.
Nordenskjold, B.
Jakesz, R.
Thuerlimann, B.
Gutierrez, J.
Harvey, V.
Punzalan, L.
Dell'Orto, P.
Larsimont, D.
Steinberg, I.
Gelber, R. D.
Piccart-Gebhart, M.
Viale, G.
Di Leo, A.
TI Overall survival benefit for sequential doxorubicin-docetaxel compared
with concurrent doxorubicin and docetaxel in node-positive breast
cancer-8-year results of the Breast International Group 02-98 phase III
trial
SO ANNALS OF ONCOLOGY
LA English
DT Article
DE adjuvant; breast cancer; chemotherapy; docetaxel; doxorubicin;
sequential
ID ADJUVANT CHEMOTHERAPY; RANDOMIZED-TRIAL; PLUS CYCLOPHOSPHAMIDE;
FOLLOW-UP; HIGH-RISK; CANCER; EPIRUBICIN; PACLITAXEL; THERAPY; WOMEN
AB Background: In women with node-positive breast cancer, the Breast International Group (BIG) 02-98 tested the incorporation of docetaxel (Taxotere) into doxorubicin (Adriamycin)-based chemotherapy, and compared sequential and concurrent docetaxel. At 5 years, there was a trend for improved disease-free survival (DFS) with docetaxel. We present results at 8-year median follow-up and exploratory analyses within biologically defined subtypes.
Methods: Patients were randomly assigned to one of four treatments: (i) sequential control: doxorubicin (A) (75 mg/m(2)) x 4 -> classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF); (ii) concurrent control: doxorubicin, cyclophosphamide (AC)(60/600 mg/m(2)) x 4 -> CMF; (iii) sequential docetaxel: A (75 mg/m(2)) x3 -> docetaxel (T) (100 mg/m(2)) x3. CMF and (iv) concurrent docetaxel: AT(50/75 mg/m(2)) x 4 -> CMF. The primary comparison evaluated docetaxel efficacy regardless of the schedule. Exploratory analyses were undertaken within biologically defined subtypes.
Results: Two thousand eight hundred and eighty-seven patients were enrolled. After 93.4 months of median follow-up, there were 916 DFS events. For the primary comparison, there was no significant improvement in DFS from docetaxel [hazard ratio (HR) = 0.91, 95% confidence interval (CI) = 0.80-1.05, P = 0.187]. In secondary comparisons, sequential docetaxel significantly improved DFS compared with sequential control (HR = 0.81, 95% CI = 0.67-0.99, P = 0.036), and significantly improved DFS (HR = 0.84, 95% CI = 0.72-0.99, P = 0.035) and overall survival (OS) (HR = 0.79, 95% CI = 0.65-0.98, P = 0.028) compared with concurrent doxorubicin-docetaxel. Luminal-A disease had the best prognosis. HRs favored addition of sequential docetaxel in all subtypes, except luminal-A; but this observation was not statistically supported because of limited numbers.
Conclusion: With further follow-up, the sequential docetaxel schedule resulted in significantly better OS than concurrent doxorubicin-docetaxel, and continued to show better DFS than sequential doxorubicin-based control.
C1 [Oakman, C.; Di Leo, A.] Hosp Prato, Ist Toscano Tumori, Sandro Pitigliani Med Oncol Unit, I-59100 Prato, Italy.
[Francis, P. A.] Peter MacCallum Canc Ctr, Breast Canc Serv, Melbourne, Vic, Australia.
[Francis, P. A.] Australian & New Zealand Breast Canc Trials Grp, Newcastle, NSW, Australia.
[Francis, P. A.] Int Breast Canc Study Grp, Bern, Switzerland.
[Crown, J.] Irish Clin Oncol Res Grp, Dublin, Ireland.
[Quinaux, E.; Buyse, M.] Int Inst Drug Dev, Louvain, Belgium.
[De Azambuja, E.; Punzalan, L.; Piccart-Gebhart, M.] Univ Libre Brussels, Inst Jules Bordet, Breast European Adjuvant Studies Team, Brussels, Belgium.
[Margeli Vila, M.] Hosp Badalona Germans Trias & Pujol, Med Oncol Unit, Badalona, Spain.
[Andersson, M.] Danish Breast Canc Cooperat Grp, Copenhagen, Denmark.
[Nordenskjold, B.] Univ Sjukhuset, Swedish Breast Canc Grp, Linkoping, Sweden.
[Jakesz, R.] Vienna Med Sch, Austrian Breast & Colorectal Canc Study Grp, Vienna, Austria.
[Thuerlimann, B.] Kantonsspital, Breast Ctr, St Gallen, Switzerland.
[Thuerlimann, B.] Swiss Grp Clin Canc Reserch SAKK, Bern, Switzerland.
[Gutierrez, J.] Clin Las Condes, Grp Oncol Cooperat Chileno Invest, Santiago, Chile.
[Harvey, V.] Auckland City Hosp, Reg Canc & Blood Ctr, Auckland, New Zealand.
[Dell'Orto, P.; Viale, G.] Univ Milan, Sch Med, Milan, Italy.
[Dell'Orto, P.; Viale, G.] European Inst Oncol, Dept Pathol, Milan, Italy.
[Larsimont, D.] Univ Libre Brussels, Inst Jules Bordet, Dept Pathol, Brussels, Belgium.
[Steinberg, I.] Sanofi Oncol, Cambridge, England.
[Gelber, R. D.] IBCSG, Ctr Stat, Boston, MA USA.
[Gelber, R. D.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Piccart-Gebhart, M.] Univ Libre Brussels, Inst Jules Bordet, Brussels, Belgium.
RP Di Leo, A (reprint author), Hosp Prato, Ist Toscano Tumori, Dept Oncol, Sandro Pitigliani Med Oncol Unit, Piazza Osped 2, I-59100 Prato, Italy.
EM adileo@usl4.toscana.it
RI Francis, Prudence/J-4003-2012
FU sanofi-aventis; Associazione Italiana Ricerca Cancro (AIRC), Milan,
Italy; National Health and Medical Research Council [100925, 351164];
Sanofi; Roche; Novartis
FX This work was sponsored and funded by sanofi-aventis. Transtax analyses
were funded by Associazione Italiana Ricerca Cancro (AIRC), Milan,
Italy. Funding was also provided by the National Health and Medical
Research Council [grant numbers 100925, 351164] to the Australian New
Zealand Breast Cancer Trials Group.; Employment is disclosed by IS
[Sanofi pharmaceuticals (AVP global medical leader)]. Stock ownership is
disclosed by IS (Sanofi pharmaceuticals). Consultancy is disclosed by
ADL (Sanofi), BT (Sanofi), JG (Roche, Bristol Myer Squibb) and MP-G
(Sanofi, Amgen, Bayer, Bristol Myer Squibb, Roche, Glaxosmithkline,
Boehringer Inghelneim, PharmaMar). Honoraria is disclosed by ADL
(Sanofi), BT (Sanofi), JC (Sanofi, Roche Genentech), JG (Novartis,
Roche, BMS), PAF (Sanofi), MP-G (Sanofi, Amgen, Bayer, Bristol Myer
Squibb, Roche, Glaxosmithkline, Boehringer, PharmaMar) and VH (Roche,
Sanofi). Research funding is disclosed by BT (Sanofi), JC (Sanofi, Roche
Genentech), MP-G (Sanofi, Amgen, Bayer, Bristol Myer Squibb, Roche,
Glaxosmithkline, Boehringer Inghelneim, PharmaMar) and VH (Roche). Other
remuneration, including travel grants, is dislcosed by BT (Sanofi), JG
(Roche, Novartis) and PAF (Sanofi). All the remaining authors have
declared no conflicts of interest.
NR 33
TC 10
Z9 10
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
J9 ANN ONCOL
JI Ann. Oncol.
PD MAY
PY 2013
VL 24
IS 5
BP 1203
EP 1211
DI 10.1093/annonc/mds627
PG 9
WC Oncology
SC Oncology
GA 132YQ
UT WOS:000318105000008
PM 23293111
ER
PT J
AU Ovrutsky, AR
Chan, ED
Kartalija, M
Bai, XY
Jackson, M
Gibbs, S
Falkinham, JO
Iseman, MD
Reynolds, PR
McDonnell, G
Thomas, V
AF Ovrutsky, Alida R.
Chan, Edward D.
Kartalija, Marinka
Bai, Xiyuan
Jackson, Mary
Gibbs, Sara
Falkinham, Joseph O., III
Iseman, Michael D.
Reynolds, Paul R.
McDonnell, Gerald
Thomas, Vincent
TI Cooccurrence of Free-Living Amoebae and Nontuberculous Mycobacteria in
Hospital Water Networks, and Preferential Growth of Mycobacterium avium
in Acanthamoeba lenticulata
SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY
LA English
DT Article
ID DRINKING-WATER; MOLECULAR-IDENTIFICATION; DISINFECTION TREATMENTS;
DISTRIBUTION-SYSTEMS; RESISTING BACTERIA; INFECTIONS; KERATITIS; HEALTH;
BIODIVERSITY; ENDOSYMBIONT
AB The incidence of lung and other diseases due to nontuberculous mycobacteria (NTM) is increasing. NTM sources include potable water, especially in households where NTM populate pipes, taps, and showerheads. NTM share habitats with free-living amoebae (FLA) and can grow in FLA as parasites or as endosymbionts. FLA containing NTM may form cysts that protect mycobacteria from disinfectants and antibiotics. We first assessed the presence of FLA and NTM in water and biofilm samples collected from a hospital, confirming the high prevalence of NTM and FLA in potable water systems, particularly in biofilms. Acanthamoeba spp. (genotype T4) were mainly recovered (8/17), followed by Hartmannella vermiformis (7/17) as well as one isolate closely related to the genus Flamella and one isolate only distantly related to previously described species. Concerning mycobacteria, Mycobacterium gordonae was the most frequently found isolate (9/17), followed by Mycobacterium peregrinum (4/17), Mycobacterium chelonae (2/17), Mycobacterium mucogenicum (1/17), and Mycobacterium avium (1/17). The propensity of Mycobacterium avium hospital isolate H87 and M. avium collection strain 104 to survive and replicate within various FLA was also evaluated, demonstrating survival of both strains in all amoebal species tested but high replication rates only in Acanthamoeba lenticulata. As A. lenticulata was frequently recovered from environmental samples, including drinking water samples, these results could have important consequences for the ecology of M. avium in drinking water networks and the epidemiology of disease due to this species.
C1 [Ovrutsky, Alida R.; Chan, Edward D.; Kartalija, Marinka; Bai, Xiyuan; Iseman, Michael D.; Reynolds, Paul R.] Natl Jewish Hlth, Denver, CO USA.
[Chan, Edward D.] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Jackson, Mary; Gibbs, Sara] Colorado State Univ, Mycobacteria Res Labs, Ft Collins, CO 80523 USA.
[Ovrutsky, Alida R.; Chan, Edward D.; Bai, Xiyuan; Iseman, Michael D.] Univ Colorado, Div Pulm Sci & Crit Care Med, Denver, CO 80202 USA.
[Kartalija, Marinka; Iseman, Michael D.] Univ Colorado, Div Infect Dis, Denver, CO 80202 USA.
[Falkinham, Joseph O., III] Virginia Polytech Inst & State Univ, Blacksburg, VA 24061 USA.
[McDonnell, Gerald; Thomas, Vincent] STERIS Corp, Paris, France.
RP Thomas, V (reprint author), STERIS Corp, Paris, France.
EM chane@njhealth.org; vincethom2009@yahoo.fr
RI Jackson, Mary/D-5345-2017; Thomas, Vincent/A-8941-2012
OI Thomas, Vincent/0000-0003-4034-9525
FU National Institutes of Health/National Institute of Allergy and
Infectious Diseases [AI089718]
FX This work was supported in part by National Institutes of
Health/National Institute of Allergy and Infectious Diseases grant
AI089718.
NR 46
TC 29
Z9 31
U1 2
U2 33
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0099-2240
EI 1098-5336
J9 APPL ENVIRON MICROB
JI Appl. Environ. Microbiol.
PD MAY
PY 2013
VL 79
IS 10
BP 3185
EP 3192
DI 10.1128/AEM.03823-12
PG 8
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA 132AJ
UT WOS:000318039800006
PM 23475613
ER
PT J
AU Gradl, G
Gradl, G
Wendt, M
Mittlmeier, T
Kundt, G
Jupiter, JB
AF Gradl, Georg
Gradl, Gertraud
Wendt, Martina
Mittlmeier, Thomas
Kundt, Guenther
Jupiter, Jesse B.
TI Non-bridging external fixation employing multiplanar K-wires versus
volar locked plating for dorsally displaced fractures of the distal
radius
SO ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY
LA English
DT Article
DE Distal radius fracture; External fixation; Non-bridging; Functional
outcome; Volar plating
ID INTRAARTICULAR FRACTURES; UNSTABLE FRACTURES; INTERNAL-FIXATION; OPEN
REDUCTION; PART; COMPLICATIONS; WRIST; TRIAL
AB The aim of this study was to compare non-bridging external fixation to palmar angular stable plating with respect to radiological outcome, wrist function, and quality of life.
One hundred and two consecutive patients (mean age: 63 years) were enrolled in the study. Fifty-two patients were randomized for plate osteosynthesis (2.4 mm, Synthes), 50 patients received non-bridging external fixation (AO small fixator). Objective (range of motion, grip strength), patient rated outcomes (quality of life, pain), and radiological outcome were assessed 8 weeks, 6 months, and 1 year after surgery.
Loss of radial length of more than 3 mm was not detected in any group. Volar tilt was better restored by external fixation (7.2A degrees) than by volar plating (0.1A degrees). Wrist function was good in both groups. The external fixator was tolerated very well, and the quality of life assessment revealed comparable results in both groups. Osteoporosis was found in 54 % of patients and had no influence on radiological and functional outcome.
Non-bridging external fixation employing multiplanar K-wires is a suitable treatment option in intra- and extra-articular fractures of the distal radius even in osteoporotic bone.
Prospective randomized trial, Level I.
C1 [Gradl, Georg; Wendt, Martina; Mittlmeier, Thomas] Univ Rostock, Surg Clin, Dept Trauma & Reconstruct Surg, D-18055 Rostock, Germany.
[Gradl, Gertraud; Jupiter, Jesse B.] Massachusetts Gen Hosp, Dept Orthopaed Surg, Hand & Upper Extrem Serv, Boston, MA 02114 USA.
[Gradl, Georg] Univ Aachen, Dept Trauma & Reconstruct Surg, D-52074 Aachen, Germany.
[Kundt, Guenther] Univ Rostock, Dept Med Informat & Biometry, D-18057 Rostock, Germany.
RP Gradl, G (reprint author), Univ Aachen, Dept Trauma & Reconstruct Surg, Pauwelstr 30, D-52074 Aachen, Germany.
EM ggradl@ukaachen.de
FU AO
FX The study was supported by a grant from the AO.
NR 35
TC 15
Z9 15
U1 1
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0936-8051
J9 ARCH ORTHOP TRAUM SU
JI Arch. Orthop. Trauma Surg.
PD MAY
PY 2013
VL 133
IS 5
BP 595
EP 602
DI 10.1007/s00402-013-1698-5
PG 8
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA 131DL
UT WOS:000317972300002
PM 23420065
ER
PT J
AU Bowden, MG
Behrman, AL
Neptune, RR
Gregory, CM
Kautz, SA
AF Bowden, Mark G.
Behrman, Andrea L.
Neptune, Richard R.
Gregory, Chris M.
Kautz, Steven A.
TI Locomotor Rehabilitation of Individuals With Chronic Stroke: Difference
Between Responders and Nonresponders
SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
LA English
DT Article
DE Hemiparesis; Rehabilitation; Stroke; Walking
ID RANDOMIZED CONTROLLED-TRIAL; BODY-WEIGHT SUPPORT; DYNAMIC GAIT INDEX;
TREADMILL; WALKING; POSTSTROKE; RECOVERY; PERFORMANCE; SURVIVORS; SCALE
AB Objectives: To identify the clinical measures associated with improved walking speed after locomotor rehabilitation in individuals poststroke and how those who respond with clinically meaningful changes in walking speed differ from those with smaller speed increases.
Design: A single group pre-post intervention study. Participants were stratified on the basis of a walking speed change of greater than (responders) or less than (nonresponders) .16m/s. Paired sample t tests were run to assess changes in each group, and correlations were run between the change in each variable and change in walking speed.
Setting: Outpatient interdisciplinary rehabilitation research center.
Participants: Hemiparetic subjects (N=27) (17 left hemiparesis; 19 men; age: 58.74 +/- 12.97y; 22.70 +/- 16.38mo poststroke).
Intervention: A 12-week locomotor intervention incorporating training on a treadmill with body weight support and manual trainers accompanied by training overground walking.
Main Outcome Measures: Measures of motor control, balance, functional walking ability, and endurance were collected at pre- and postintervention assessments.
Results: Eighteen responders and 9 nonresponders differed by age (responders=63.6y, nonresponders=49.0y, P=.001) and the lower extremity Fugl-Meyer Assessment score (responders=24.7, nonresponders=19.9, P=.003). Responders demonstrated an average improvement of .27m/s in walking speed as well as significant gains in all variables except daily step activity and paretic step ratio. Conversely, nonresponders demonstrated statistically significant improvements only in walking speed and endurance. However, the walking speed increase of .10m/s was not clinically meaningful. Change in walking speed was negatively correlated with changes in motor control in the nonresponder group, implying that walking speed phis may have been accomplished via compensatory mechanisms.
Conclusions: This study is a step toward discerning the underlying factors contributing to improved walking performance. Archives of Physical Medicine and Rehabilitation 2013;94:856-62 (C) 2013 by the American Congress of Rehabilitation Medicine
C1 [Bowden, Mark G.; Gregory, Chris M.; Kautz, Steven A.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Bowden, Mark G.; Gregory, Chris M.; Kautz, Steven A.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA.
[Bowden, Mark G.; Gregory, Chris M.; Kautz, Steven A.] Med Univ S Carolina, Div Phys Therapy, Charleston, SC 29425 USA.
[Behrman, Andrea L.] Univ Florida, Dept Phys Therapy, Gainesville, FL USA.
[Neptune, Richard R.] Univ Texas Austin, Dept Mech Engn, Austin, TX 78712 USA.
RP Bowden, MG (reprint author), Med Univ S Carolina, Dept Hlth Sci & Res, 77 President St,MSC 700, Charleston, SC 29425 USA.
EM bowdenm@musc.edu
OI Kautz, Steven/0000-0003-3151-8235
FU VA Merit Review [B3983-R]; VA Center of Excellence [F2182C]; VA Career
Development Award [B7177]; National Institutes of Health - National
Center for Medical and Rehabilitation Research (NICHD) [K12 HD055929];
National Institute for Neurological Disorders Stroke
FX Supported by VA Merit Review (grant no. B3983-R); VA Center of
Excellence (grant no. F2182C) (Brain Rehabilitation Research Center); VA
Career Development Award (Phase I): B7177; and K12 HD055929 National
Institutes of Health - National Center for Medical and Rehabilitation
Research (NICHD) and National Institute for Neurological Disorders &
Stroke.
NR 46
TC 26
Z9 27
U1 0
U2 9
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0003-9993
J9 ARCH PHYS MED REHAB
JI Arch. Phys. Med. Rehabil.
PD MAY
PY 2013
VL 94
IS 5
BP 856
EP 862
DI 10.1016/j.apmr.2012.11.032
PG 7
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 134HX
UT WOS:000318202100009
PM 23220082
ER
PT J
AU Ibrahim, SA
Hanusa, BH
Hannon, MJ
Kresevic, D
Long, J
Kwoh, CK
AF Ibrahim, Said A.
Hanusa, Barbara H.
Hannon, Michael J.
Kresevic, Denise
Long, Judith
Kwoh, C. Kent
TI Willingness and Access to Joint Replacement Among African American
Patients With Knee Osteoarthritis: A Randomized, Controlled Intervention
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID TOTAL HIP-ARTHROPLASTY; ETHNIC-DIFFERENCES; RACIAL DISPARITIES; PROBLEM
DRINKERS; UNITED-STATES; ARTHRITIS; PREVALENCE; SURGERY; CARE;
EXPECTATIONS
AB Objective African American patients are significantly less likely to undergo knee replacement for the management of knee osteoarthritis (OA). Racial difference in preference (willingness) has emerged as a key factor. This study was undertaken to examine the efficacy of a patient-centered educational intervention on patient willingness and the likelihood of receiving a referral to an orthopedic clinic. Methods A total of 639 African American patients with moderate-to-severe knee OA from 3 Veterans Affairs primary care clinics were enrolled in a randomized, controlled trial with a 2 x 2 factorial design. Patients were shown a knee OA decision-aid video with or without brief counseling. The main outcome measures were change in patient willingness and receipt of a referral to an orthopedic clinic. Also assessed were whether patients discussed knee pain with their primary care provider or saw an orthopedic surgeon within 12 months of the intervention. Results At baseline, 67% of the participants were definitely/probably willing to consider knee replacement, with no difference among the groups. The intervention increased patient willingness (75%) in all groups at 1 month. For those who received the decision aid intervention alone, the gains were sustained for up to 3 months. By 12 months postintervention, patients who received any intervention were more likely to report engaging their provider in a discussion about knee pain (92% versus 85%), to receive a referral to an orthopedic surgeon (18% versus 13%), and for those with a referral, to attend an orthopedic consult (61% versus 50%). Conclusion An educational intervention significantly increased the willingness of African American patients to consider knee replacement. It also improved the likelihood of patientprovider discussion about knee pain and access to surgical evaluation.
C1 [Ibrahim, Said A.; Long, Judith] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Ibrahim, Said A.; Long, Judith] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Hanusa, Barbara H.; Hannon, Michael J.; Kwoh, C. Kent] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Hannon, Michael J.; Kwoh, C. Kent] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Kresevic, Denise] Univ Hosp Case Med Ctr, Louis Stokes Cleveland VA Med Ctr, Cleveland, OH USA.
[Kresevic, Denise] Case Western Reserve Univ, Cleveland, OH 44106 USA.
RP Ibrahim, SA (reprint author), Univ Penn, Perelman Sch Med, Ctr Hlth Equ Res & Promot, Philadelphia VA Med Ctr Annex, 3900 Woodland Ave, Philadelphia, PA 19104 USA.
EM said.ibrahim2@va.gov
FU Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development, Health Services Research and Development
Service [IIR 05-234-2]; NIH (National Institute of Arthritis and
Musculoskeletal and Skin Diseases) [1K24-AR-055259-01]
FX Supported by the Department of Veterans Affairs, Veterans Health
Administration, Office of Research and Development, Health Services
Research and Development Service (grant IIR 05-234-2 to Dr. Ibrahim).
Dr. Ibrahim's work also was supported by the NIH (National Institute of
Arthritis and Musculoskeletal and Skin Diseases grant
1K24-AR-055259-01).
NR 43
TC 11
Z9 11
U1 1
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD MAY
PY 2013
VL 65
IS 5
BP 1253
EP 1261
DI 10.1002/art.37899
PG 9
WC Rheumatology
SC Rheumatology
GA 133WC
UT WOS:000318170600015
PM 23613362
ER
PT J
AU Riddle, DL
Singh, JA
Harmsen, WS
Schleck, CD
Lewallen, DG
AF Riddle, Daniel L.
Singh, Jasvinder A.
Harmsen, William S.
Schleck, Cathy D.
Lewallen, David G.
TI Clinically Important Body Weight Gain Following Knee Arthroplasty: A
Five-Year Comparative Cohort Study
SO ARTHRITIS CARE & RESEARCH
LA English
DT Article
ID ROCHESTER EPIDEMIOLOGY PROJECT; TOTAL HIP-ARTHROPLASTY; UNITED-STATES;
RISK-FACTORS; OBESITY; ADULTS; POPULATION; OSTEOARTHRITIS; REPLACEMENT;
HEALTH
AB Objective The impact of knee arthroplasty on body weight has not been fully explored. Clinically important weight gain following knee arthroplasty would pose potentially important health risks. Methods We used one of the largest US-based knee arthroplasty registries and a population-based control sample from the same geographic region to determine whether knee arthroplasty increases the risk of clinically important weight gain of 5% of baseline body weight over a 5-year postoperative period. Results Of the persons in the knee arthroplasty sample, 30.0% gained 5% of baseline body weight 5 years following surgery as compared to 19.7% of the control sample. The multivariable-adjusted (age, sex, body mass index, education, comorbidity, and presurgical weight change) odds ratio (OR) was 1.6 (95% confidence interval [95% CI] 1.22.2) in persons with knee arthroplasty as compared to the control sample. Additional arthroplasty procedures during followup further increased the risk for weight gain (OR 2.1, 95% CI 1.43.1) relative to the control sample. Specifically, among patients with knee arthroplasty, younger patients and those who lost greater amounts of weight in the 5-year preoperative period were at greater risk for clinically important weight gain. Conclusion Patients who undergo knee arthroplasty are at an increased risk of clinically important weight gain following surgery. The findings potentially have broad implications to multiple members of the health care team. Future research should develop weight loss/maintenance interventions particularly for younger patients who have lost a substantial amount of weight prior to surgery, as they are most at risk for substantial postsurgical weight gain.
C1 [Riddle, Daniel L.] Virginia Commonwealth Univ, Richmond, VA 23298 USA.
[Singh, Jasvinder A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL USA.
[Harmsen, William S.; Schleck, Cathy D.; Lewallen, David G.] Mayo Clin, Rochester, MN USA.
RP Riddle, DL (reprint author), Virginia Commonwealth Univ, Dept Phys Therapy, POB 980224, Richmond, VA 23298 USA.
EM dlriddle@vcu.edu
OI singh, jasvinder/0000-0003-3485-0006
FU Virginia Commonwealth University Presidential Research Initiative
Program; URL; Savient; Novartis; Takeda; Allergan; Ardea; Osteotech;
Zimmer
FX Supported by a grant from the Virginia Commonwealth University
Presidential Research Initiative Program.; Dr. Riddle has received
honoraria (less than $10,000) for his role as Deputy Editor of Physical
Therapy. Dr. Singh has received consultant fees, speaking fees, and/or
honoraria (less than $10,000 each) from URL, Savient, and Novartis, and
(more than $10,000 each) from Takeda, Allergan, and Ardea, and has
received investigator-initiated grants from Takeda and Savient. Dr.
Lewallen has received consultant fees, speaking fees, and/or honoraria
(less than $10,000 each) from Osteotech and Zimmer, and receives fees
and royalties from Zimmer for hip and knee implants.
NR 49
TC 10
Z9 10
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2151-464X
J9 ARTHRIT CARE RES
JI Arthritis Care Res.
PD MAY
PY 2013
VL 65
IS 5
BP 669
EP 677
DI 10.1002/acr.21880
PG 9
WC Rheumatology
SC Rheumatology
GA 133CJ
UT WOS:000318114700002
PM 23203539
ER
PT J
AU Schmajuk, G
Yazdany, J
AF Schmajuk, Gabriela
Yazdany, Jinoos
TI Underestimation of the Reliability of Codes for Rheumatoid Arthritis
Within Administrative Data: Comment on the Article by Ng et al
SO ARTHRITIS CARE & RESEARCH
LA English
DT Letter
ID VETERANS
C1 [Schmajuk, Gabriela; Yazdany, Jinoos] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Schmajuk, Gabriela] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Schmajuk, G (reprint author), Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 3
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2151-464X
J9 ARTHRIT CARE RES
JI Arthritis Care Res.
PD MAY
PY 2013
VL 65
IS 5
BP 835
EP 836
DI 10.1002/acr.21911
PG 2
WC Rheumatology
SC Rheumatology
GA 133CJ
UT WOS:000318114700028
PM 23212977
ER
PT J
AU Ng, B
Aslam, F
Yu, HJ
AF Ng, Bernard
Aslam, Fawad
Yu, Hong-Jen
TI Underestimation of the Reliability of Codes for Rheumatoid Arthritis
Within Administrative Data: Comment on the Article by Ng et al Reply
SO ARTHRITIS CARE & RESEARCH
LA English
DT Letter
ID DATABASES; DIAGNOSIS; ACCURACY
C1 [Ng, Bernard; Yu, Hong-Jen] Michael E DeBakey VA Med Ctr Hlth Serv, Res & Dev Ctr Excellence, Houston, TX USA.
[Ng, Bernard; Aslam, Fawad] Baylor Coll Med, Houston, TX 77030 USA.
RP Ng, B (reprint author), Michael E DeBakey VA Med Ctr Hlth Serv, Res & Dev Ctr Excellence, Houston, TX USA.
NR 4
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2151-464X
J9 ARTHRIT CARE RES
JI Arthritis Care Res.
PD MAY
PY 2013
VL 65
IS 5
BP 836
EP 838
DI 10.1002/acr.21906
PG 3
WC Rheumatology
SC Rheumatology
GA 133CJ
UT WOS:000318114700029
PM 23212929
ER
PT J
AU Michaelis, LC
Saad, A
Zhong, XB
Le-Rademacher, J
Freytes, CO
Marks, DI
Lazarus, HM
Bird, JM
Holmberg, L
Kamble, RT
Kumar, S
Lill, M
Meehan, KR
Saber, W
Schriber, J
Tay, J
Vogl, DT
Wirk, B
Savani, BN
Gale, RP
Vesole, DH
Schiller, GJ
Abidi, M
Anderson, KC
Nishihori, T
Kalaycio, ME
Vose, JM
Moreb, JS
Drobyski, W
Munker, R
Roy, V
Ghobadi, A
Holland, HK
Nath, R
To, LB
Maiolino, A
Kassim, AA
Giralt, SA
Landau, H
Schouten, HC
Maziarz, RT
Mikhael, J
Kindwall-Keller, T
Stiff, PJ
Gibson, J
Lonial, S
Krishnan, A
Dispenzieri, A
Hari, P
AF Michaelis, Laura C.
Saad, Ayman
Zhong, Xiaobo
Le-Rademacher, Jennifer
Freytes, Cesar O.
Marks, David I.
Lazarus, Hillard M.
Bird, Jennifer M.
Holmberg, Leona
Kamble, Rammurti T.
Kumar, Shaji
Lill, Michael
Meehan, Kenneth R.
Saber, Wael
Schriber, Jeffrey
Tay, Jason
Vogl, Dan T.
Wirk, Baldeep
Savani, Bipin N.
Gale, Robert P.
Vesole, David H.
Schiller, Gary J.
Abidi, Muneer
Anderson, Kenneth C.
Nishihori, Taiga
Kalaycio, Matt E.
Vose, Julie M.
Moreb, Jan S.
Drobyski, William
Munker, Reinhold
Roy, Vivek
Ghobadi, Armin
Holland, H. Kent
Nath, Rajneesh
To, L. Bik
Maiolino, Angelo
Kassim, Adetola A.
Giralt, Sergio A.
Landau, Heather
Schouten, Harry C.
Maziarz, Richard T.
Mikhael, Joseph
Kindwall-Keller, Tamila
Stiff, Patrick J.
Gibson, John
Lonial, Sagar
Krishnan, Amrita
Dispenzieri, Angela
Hari, Parameswaran
CA Ctr Int Blood Marrow Transplant
TI Salvage Second Hematopoietic Cell Transplantation in Myeloma
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Article
DE Second autologous transplantation; Multiple myeloma; Relapsed multiple
myeloma
ID DIAGNOSED MULTIPLE-MYELOMA; HIGH-DOSE THERAPY; ALLOGENEIC
TRANSPLANTATION; AUTOLOGOUS TRANSPLANTATION; MARROW TRANSPLANTATION;
RANDOMIZED TRIAL; SINGLE; BLOOD; CHEMOTHERAPY; SURVIVAL
AB Autologous hematopoietic cell transplantation (AHCT) as initial therapy of patients with multiple myeloma (MM) improves survival. However, data to support this approach for relapsed/progressive disease after initial AHCT (AHCT1) are limited. Using Center for International Blood and Marrow Transplant Research data, we report the outcomes of 187 patients who underwent a second AHCT (AHCT2) for the treatment of relapsed/progressive MM. Planned tandem AHCT was excluded. Median age at AHCT2 was 59 years (range, 28 to 72), and median patient follow-up was 47 months (range, 3 to 97). Nonrelapse mortality after AHCT2 was 2% at 1 year and 4% at 3 years. Median interval from AHCT1 to relapse/progression was 18 months, and median interval between transplantations was 32 months. After AHCT2, the incidence of relapse/progression at 1 and 3 years was 51% and 82%, respectively. At 3 years after AHCT2, progression-free survival was 13%, and overall survival was 46%. In multivariate analyses, those relapsing >= 36 months after AHCT1 had superior progression-free (P = .045) and overall survival (P = .019). Patients who underwent AHCT2 after 2004 had superior survival (P = .026). AHCT2 is safe and feasible for disease progression after AHCT1. In this retrospective study, individuals relapsing >= 36 months from AHCT1 derived greater benefit from AHCT2 compared with those with a shorter disease-free interval. Storage of an adequate graft before AHCT1 will ensure that the option of a second autologous transplantation is retained for patients with relapsed/progressive MM. (C) 2013 American Society for Blood and Marrow Transplantation.
C1 [Michaelis, Laura C.; Stiff, Patrick J.] Loyola Univ, Med Ctr, Maywood, IL 60153 USA.
[Saad, Ayman] Univ Alabama Birmingham, Birmingham, AL USA.
[Zhong, Xiaobo; Le-Rademacher, Jennifer; Saber, Wael; Hari, Parameswaran] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.
[Freytes, Cesar O.] UTHSC Vet Hlth Care Syst, San Antonio, TX USA.
[Marks, David I.; Bird, Jennifer M.] Bristol Childrens Hosp, Bristol, Avon, England.
[Lazarus, Hillard M.] Univ Hosp Cleveland, Case Med Ctr, Cleveland, OH 44106 USA.
[Holmberg, Leona] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Kamble, Rammurti T.] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA.
[Kumar, Shaji; Dispenzieri, Angela] Mayo Clin, Rochester, MN USA.
[Lill, Michael] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
[Meehan, Kenneth R.] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA.
[Schriber, Jeffrey] City Hope Samaritan, Phoenix, AZ USA.
[Tay, Jason] Univ Ottawa, Ottawa, ON, Canada.
[Vogl, Dan T.] Univ Penn, Med Ctr, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
[Wirk, Baldeep; Moreb, Jan S.] Shands Healthcare, Gainesville, FL USA.
[Wirk, Baldeep; Moreb, Jan S.] Univ Florida, Gainesville, FL USA.
[Savani, Bipin N.; Kassim, Adetola A.] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
[Gale, Robert P.] Univ London Imperial Coll Sci Technol & Med, Sect Hematol, London, England.
[Vesole, David H.] Hackensack Univ, Med Ctr, Hackensack, NJ USA.
[Schiller, Gary J.] Univ Calif Los Angeles, Ctr Hlth Sci, Los Angeles, CA 90024 USA.
[Abidi, Muneer] Wayne State Univ, Kamanos Canc Inst, Detroit, MI USA.
[Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Nishihori, Taiga] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
[Kalaycio, Matt E.] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
[Vose, Julie M.] Nebraska Med Ctr, Omaha, NE USA.
[Drobyski, William] Med Coll Wisconsin, Froedtert Mem Lutheran Hosp, Milwaukee, WI 53226 USA.
[Munker, Reinhold] Louisiana State Univ, Hlth Sci Ctr, Shreveport, LA 71105 USA.
[Roy, Vivek] Mayo Clin, Jacksonville, FL 32224 USA.
[Ghobadi, Armin] Washington Univ, St Louis Childrens Hosp, St Louis, MO 63110 USA.
[Holland, H. Kent] Northside Hosp, Blood & Marrow Transplant Program, Atlanta, GA USA.
[Nath, Rajneesh] UMass Mem Med Ctr, Worcester, MA USA.
[To, L. Bik] Royal Adelaide Hosp, Adelaide, SA 5000, Australia.
[Maiolino, Angelo] Hosp Univ Clementino Fraga Filho, Rio De Janeiro, Brazil.
[Giralt, Sergio A.; Landau, Heather] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Schouten, Harry C.] Acad Ziekenhuis Maastricht, Maastricht, Netherlands.
[Maziarz, Richard T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Mikhael, Joseph] Mayo Clin Arizona, Scottsdale, AZ USA.
[Mikhael, Joseph] Phoenix Childrens Hosp, Scottsdale, AZ USA.
[Kindwall-Keller, Tamila] Univ Virginia, Charlottesville, VA USA.
[Gibson, John] Royal Prince Alfred Hosp, Inst Haematol, Camperdown, NSW 2050, Australia.
[Lonial, Sagar] Emory Univ Hosp, Atlanta, GA 30322 USA.
[Krishnan, Amrita] City Hope Natl Med Ctr, Duarte, CA 91010 USA.
RP Hari, P (reprint author), Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, 9200 W Wisconsin Ave,Suite C5500, Milwaukee, WI 53226 USA.
EM phari@mcw.edu
RI Kumar, Shaji/A-9853-2008;
OI Kumar, Shaji/0000-0001-5392-9284; Vogl, Dan/0000-0002-2935-2566; Hari,
Parameswaran/0000-0002-8800-297X; Saad, Ayman /0000-0003-0003-0130;
Dispenzieri, Angela/0000-0001-8780-9512
FU National Cancer Institute (NCI) [U24-CA76518]; National Heart, Lung and
Blood Institute (NHLBI); National Institute of Allergy and Infectious
Diseases (NIAID); NHLBI [5U01HL069294]; NCI; Health Resources and
Services Administration (HRSA/DHHS) [HHSH234200637015C]; Office of Naval
Research [N00014-06-1-0704, N00014-08-1-0058]; Allos, Inc.; Amgen, Inc.;
Angioblast
FX The CIBMTR is supported by Public Health Service Grant/Cooperative
Agreement U24-CA76518 from the National Cancer Institute (NCI), the
National Heart, Lung and Blood Institute (NHLBI), and the National
Institute of Allergy and Infectious Diseases (NIAID); a
Grant/Cooperative Agreement 5U01HL069294 from NHLBI and NCI; a contract
HHSH234200637015C with Health Resources and Services Administration
(HRSA/DHHS); two grants, N00014-06-1-0704 and N00014-08-1-0058, from the
Office of Naval Research; and grants from Allos, Inc.; Amgen, Inc.;
Angioblast; Anonymous donation to the Medical College of Wisconsin;
Ariad; Be the Match Foundation; Blue Cross and Blue Shield Association;
Buchanan Family Foundation; CaridianBCT; Celgene Corporation; CellGenix,
GmbH; Children's Leukemia Research Association; Fresenius-Biotech North
America, Inc.; Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.;
Genzyme Corporation; GlaxoSmithKline; HistoGenetics, Inc.; Kiadis
Pharma; The Leukemia & Lymphoma Society; The Medical College of
Wisconsin; Merck & Co, Inc.; Millennium: The Takeda Oncology Co.;
Milliman USA, Inc.; Miltenyi Biotec, Inc.; National Marrow Donor
Program; Optum Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.;
Otsuka America Pharmaceutical, Inc.; RemedyMD; Sanofi; Seattle Genetics;
Sigma-Tau Pharmaceuticals; Soligenix, Inc.; StemCyte, A Global Cord
Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan
Biovitrum; Tarix Pharmaceuticals; Teva Neuroscience, Inc.; THERAKOS,
Inc.; and Wellpoint, Inc.
NR 31
TC 34
Z9 34
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAY
PY 2013
VL 19
IS 5
BP 760
EP 766
DI 10.1016/j.bbmt.2013.01.004
PG 7
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 133IQ
UT WOS:000318132500013
PM 23298856
ER
PT J
AU Pidala, J
Chai, XY
Kurland, BF
Inamoto, Y
Flowers, MED
Palmer, J
Khera, N
Jagasia, M
Cutler, C
Arora, M
Vogelsang, G
Lee, SJ
AF Pidala, Joseph
Chai, Xiaoyu
Kurland, Brenda F.
Inamoto, Yoshihiro
Flowers, Mary E. D.
Palmer, Jeanne
Khera, Nandita
Jagasia, Madan
Cutler, Corey
Arora, Mukta
Vogelsang, Georgia
Lee, Stephanie J.
TI Analysis of Gastrointestinal and Hepatic Chronic Grant-versus-Host
Disease Manifestations on Major Outcomes: A Chronic Grant-versus-Host
Disease Consortium Study
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Article
DE Chronic GVHD; Gastrointestinal; Hepatic
ID QUALITY-OF-LIFE; BONE-MARROW-TRANSPLANTATION; NIH CONSENSUS CRITERIA;
HEMATOPOIETIC-CELL TRANSPLANTATION; WORKING GROUP-REPORT; DEVELOPMENT
PROJECT; CLINICAL-TRIALS; CHRONIC GVHD; SCALE; VALIDATION
AB Although data support adverse prognosis of overlap subtype of chronic grant-versus-host disease (GVHD), the importance of site of gastrointestinal (GI) and type of hepatic involvement is not known. Using data from the Chronic GVHD Consortium observational cohort study (N = 567, total of 2115 visits), we examined whether the site of GI (esophageal, upper GI, or lower GI) and type of hepatic (bilirubin, alkaline phosphatase, alanine aminotransferase) involvement are associated with overall survival (OS) and nonrelapse mortality (NRM), symptoms, quality of life (QOL) and functional status measures. In multivariate analysis utilizing data from enrollment visits only, lower GI involvement (HR, 1.67; P = .05) and elevated bilirubin (HR, 2.46; P = .001) were associated with OS; both were also associated with NRM. In multivariable analysis using all visits (time-dependent covariates), GI score greater than zero (HR, 1.69; P = .02) and elevated bilirubin (HR, 3.73; P < .001) were associated with OS; results were similar for NRM. Any esophageal involvement and GI score greater than zero were associated with both symptoms and QOL, whereas elevated bilirubin was associated with QOL. We found no consistent evidence that upper GI involvement, alkaline phosphatase, alanine aminotransferase, or NIH liver score add prognostic value for survival, overall symptom burden, or QOL. These data support important differences in patient-reported outcomes according to GI and hepatic involvement among chronic GVHD-affected patients and identify those With elevated bilirubin or higher GI score at any time, or lower GI involvement at cohort enrollment, as patients at greater risk for mortality under current treatment approaches. (C) 2013 American Society for Blood and Marrow Transplantation.
C1 [Pidala, Joseph] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
[Chai, Xiaoyu; Kurland, Brenda F.; Inamoto, Yoshihiro; Flowers, Mary E. D.; Lee, Stephanie J.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Palmer, Jeanne] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Khera, Nandita] Mayo Clin Arizona, Phoenix, AZ USA.
[Jagasia, Madan] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
[Cutler, Corey] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Arora, Mukta] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA.
[Vogelsang, Georgia] Johns Hopkins Univ, Baltimore, MD USA.
RP Pidala, J (reprint author), H Lee Moffitt Canc Ctr & Res Inst, 12902 Magnolia Dr, Tampa, FL 33612 USA.
EM joseph.pidala@moffitt.org
OI Kurland, Brenda/0000-0002-5669-0595
FU NIAID [U54 AI 083028]; [CA 118953]
FX Supported by grant CA 118953 (PI: Stephanie J. Lee) and NIAID U54 AI
083028 (PI: Stephanie J. Lee).
NR 33
TC 14
Z9 14
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAY
PY 2013
VL 19
IS 5
BP 784
EP 791
DI 10.1016/j.bbmt.2013.02.001
PG 8
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 133IQ
UT WOS:000318132500016
PM 23395601
ER
PT J
AU Nikiforow, S
Kim, HT
Bindra, B
McDonough, S
Glotzbecker, B
Armand, P
Koreth, J
Ho, VT
Alyea, EP
Blazar, BR
Ritz, J
Soiffer, RJ
Antin, JH
Cutler, CS
AF Nikiforow, Sarah
Kim, Haesook T.
Bindra, Bhavjot
McDonough, Sean
Glotzbecker, Brett
Armand, Philippe
Koreth, John
Ho, Vincent T.
Alyea, Edwin P., III
Blazar, Bruce R.
Ritz, Jerome
Soiffer, Robert J.
Antin, Joseph H.
Cutler, Corey S.
TI Phase I Study of Alemtuzumab for Therapy of Steroid-Refractory Chronic
Graft-versus-Host Disease
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Article
DE Alemtuzumab; Chronic graft-versus-host disease; Steroid refractory;
Treatment
ID CONSENSUS DEVELOPMENT PROJECT; STEM-CELL TRANSPLANTATION; WORKING
GROUP-REPORT; CLINICAL-TRIALS; INDUCED RESOLUTION; CRITERIA; CD52;
RECONSTITUTION; CAMPATH-1H; RESISTANT
AB Steroid-refractory chronic graft-versus-host disease (cGVHD) carries a poor prognosis with no agreed upon algorithm for treatment. Because both B and T cells contribute to the pathophysiology of cGVHD, we conducted a phase I study in subjects with steroid-refractory cGVHD using the anti-CD52 antibody alemtuzumab to transiently deplete most mononuclear subsets. Three regimens were investigated in a 3+3 dose-escalation design: 3 mg x 6 (dose level 1), 3 mg x I, then 10 mg x 5 (dose level 2) and 3 mg x 1, 10 mg x 1, then 30 mg x 4 (dose level 3) administered over 4 weeks. The maximum tolerated dose of alemtuzumab was dose level 2. Thirteen patients were assessable for toxicities, which were primarily infectious and hematologic. Rates of infectious complications in the first 12 weeks were 0% at dose level 1 (n = 3), 50% at dose level 2 (1 death, n = 6), and 75% at dose level 3 (2 deaths, n = 4). Of 10 patients assessable for response, 7 (70%) responded at 12 weeks, with a 30% complete response rate. Four subjects reduced steroid dose or discontinued an immunosuppressant at 12 weeks. The median decrease in steroid dose at 1 year was 61.6%. Infectious complications occurred predominantly in the first 3 months after therapy, but full B and T cell recovery took well over 12 months. Immunophenotypic profiling revealed early recovery by natural killer cells and relative sparing of CD4+ and CD8+ central memory T cell subsets. Our study indicates that therapy with alemtuzumab for steroid-refractory cGVHD is tolerable with close attention to dosing and may be active in subjects who have failed multiple therapies. The pattern of lymphocyte recovery after alemtuzumab will inform the biology and future therapy of cGVHD. The use of alemtuzumab in the context of therapy for cGVHD deserves study in larger phase II trials. (C) 2013 American Society for Blood and Marrow Transplantation.
C1 [Nikiforow, Sarah; Bindra, Bhavjot; McDonough, Sean; Glotzbecker, Brett; Armand, Philippe; Koreth, John; Ho, Vincent T.; Alyea, Edwin P., III; Ritz, Jerome; Soiffer, Robert J.; Antin, Joseph H.; Cutler, Corey S.] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02215 USA.
[Kim, Haesook T.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
[Blazar, Bruce R.] Univ Minnesota, Dept Pediat, Div Blood & Marrow Transplantat, Minneapolis, MN USA.
RP Nikiforow, S (reprint author), Dana Farber Canc Inst, Div Hematol Malignancies, Smith 353,450 Brookline Ave, Boston, MA 02215 USA.
EM sarah_nikiforow@dfci.harvard.edu
FU Genzyme, Inc.; Gateway for Cancer Research [P-06-005]; National
Institutes of Health [P-01 CA142106]; Stem Cell Cyclists of the Pan Mass
Challenge
FX Supported in part by Genzyme, Inc., the Gateway for Cancer Research
(grant no. P-06-005), and the National Institutes of Health (grant no.
P-01 CA142106). C.C. is supported by the Stem Cell Cyclists of the Pan
Mass Challenge. S.N. is supported by the Friends of Dana-Farber.
NR 32
TC 3
Z9 3
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAY
PY 2013
VL 19
IS 5
BP 804
EP 811
DI 10.1016/j.bbmt.2013.02.009
PG 8
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 133IQ
UT WOS:000318132500019
PM 23416855
ER
PT J
AU Zhan, HC
Cardozo, C
Raza, A
AF Zhan, Huichun
Cardozo, Christopher
Raza, Azra
TI MicroRNAs in myeloproliferative neoplasms
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Review
DE microRNA; myeloproliferative neoplasm; polycythaemia vera; essential
thrombocythaemia; myelofibrosis
ID HEMATOPOIETIC STEM-CELLS; TYROSINE KINASE JAK2; POLYCYTHEMIA-VERA;
ESSENTIAL THROMBOCYTHEMIA; V617F MUTATION; C-MYB; MEGAKARYOCYTIC
DIFFERENTIATION; ERYTHROID-DIFFERENTIATION; MICROPROCESSOR COMPLEX;
NORMAL ERYTHROPOIESIS
AB The chronic myeloproliferative neoplasms (MPN), including polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF), are clonal stem cell disorders characterized by dysregulated haematopoietic stem cell expansion and production of red cells, white cells and platelets alone or in combination. An acquired mutation JAK2V617F can be found in all three disorders and shows many of the phenotypic abnormalities of the diseases in murine models. The disease phenotype is also influenced by other unknown genetic or epigenetic factors. MicroRNAs (miRNA) are 1824 nucleotide single-stranded non-protein-coding RNAs that function primarily as gene repressors by binding to their target messenger RNAs. There is growing evidence that miRNAs regulate haematopoiesis in both haematopoietic stem cells and committed progenitor cells. Here, we review the field of miRNA biology and its regulatory roles in normal haematopoiesis with an emphasis on miRNA deregulations in MPNs. Continued research into how miRNAs impact JAK2V617F clonal expansion, differential haematopoiesis among different MPNs, disease progression and leukaemia transformation will lead to a better understanding of the development of these disorders, their clinical manifestations, and their treatment.
C1 [Zhan, Huichun; Cardozo, Christopher] James J Peters VA Med Ctr, Bronx, NY 10468 USA.
[Zhan, Huichun; Raza, Azra] Columbia Univ, Med Ctr, New York, NY USA.
[Cardozo, Christopher] Mt Sinai Sch Med, New York, NY USA.
RP Zhan, HC (reprint author), James J Peters VA Med Ctr, 3F-12,130 West Kingsbridge Rd, Bronx, NY 10468 USA.
EM Huichun.Zhan@va.gov
FU Veterans Affairs (VA) Career Development Award [10959632]; VA
Rehabilitation Research and Development Service Center [B9212-C]
FX Huichun Zhan is currently supported by Veterans Affairs (VA) Career
Development Award Grant 10959632 and VA Rehabilitation Research and
Development Service Center Grant B9212-C. We are grateful to Dr Jerry L.
Spivak from Johns Hopkins University for his valuable advice and
critical review during the preparation of the manuscript. We thank Dr
Haoyi Zheng from New York University Medical Center for his
indispensable help in editing the manuscript. We thank Dr Naomi Galili
from Columbia University Medical Center for reviewing the manuscript.
NR 136
TC 17
Z9 18
U1 1
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD MAY
PY 2013
VL 161
IS 4
BP 471
EP 483
DI 10.1111/bjh.12276
PG 13
WC Hematology
SC Hematology
GA 133WT
UT WOS:000318172300004
PM 23432162
ER
PT J
AU Zhang, XH
Wu, KN
Cho, EY
Ma, J
Chan, AT
Gao, X
Willett, WC
Fuchs, CS
Giovannucci, EL
AF Zhang, Xuehong
Wu, Kana
Cho, Eunyoung
Ma, Jing
Chan, Andrew T.
Gao, Xiang
Willett, Walter C.
Fuchs, Charles S.
Giovannucci, Edward L.
TI Prospective cohort studies of bowel movement frequency and laxative use
and colorectal cancer incidence in US women and men
SO CANCER CAUSES & CONTROL
LA English
DT Article
DE Bowel movement frequency; Laxative use; Colorectal cancer; Incidence;
Prospective study; Latency
ID UNITED-STATES; COLON-CANCER; RISK-FACTORS; CONSTIPATION; HEALTH;
REPRODUCIBILITY; QUESTIONNAIRE; VALIDITY; POLYPS
AB The associations between bowel movement frequency, laxative use, and colorectal cancer incidence remain uncertain. No published studies have accounted for potential latency between these factors and colorectal cancer onset.
We prospectively examined these associations among 88,173 women in the Nurses' Health Study (NHS, 1982-2010) and 23,722 men in the Health Professionals Follow-up Study (HPFS, 2000-2010). Cox proportional hazards regression models were used to estimate multivariable hazard ratios (HRs, 95 % CIs). We conducted time lagged analyses to evaluate the potential latency in the NHS.
We documented 2,012 incident colorectal cancer cases. The HRs (95 % CIs) for infrequent bowel movement relative to daily were 0.86 (95 % CI 0.71-1.04) in women and 0.81 (95 % CI 0.48-1.37) in men. The HRs for weekly to daily relative to never laxative use were 0.98 (95 % CI 0.81-1.20) in women and 1.41 (95 % CI 0.96-2.06) in men. In women, the HRs for every 3 days or less bowel movement relative to daily were 0.87 (95 % CI 0.59-1.27) for colorectal cancers that developed within 10 years of assessment, 1.03 (95 % CI 0.85-1.26) for 11-18 years after assessment, and 0.73 (95 % CI 0.54-1.01) for 19-28 years after assessment. The corresponding HRs for weekly to daily relative to never laxative use were 0.93 (95 % CI 0.63-1.37), 1.03 (95 % CI 0.74-1.44), and 0.98 (95 % CI 0.71-1.35), respectively.
Bowel movement frequency and laxative use appear not to be associated with colorectal cancer risk in this study.
C1 [Zhang, Xuehong; Cho, Eunyoung; Ma, Jing; Chan, Andrew T.; Gao, Xiang; Willett, Walter C.; Fuchs, Charles S.; Giovannucci, Edward L.] Brigham & Womens Hosp, Channing Div Network Med, Dept Med, Boston, MA 02115 USA.
[Zhang, Xuehong; Cho, Eunyoung; Ma, Jing; Chan, Andrew T.; Gao, Xiang; Willett, Walter C.; Fuchs, Charles S.; Giovannucci, Edward L.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Wu, Kana; Cho, Eunyoung; Gao, Xiang; Willett, Walter C.; Giovannucci, Edward L.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Ma, Jing; Willett, Walter C.; Giovannucci, Edward L.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Chan, Andrew T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
[Fuchs, Charles S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
RP Zhang, XH (reprint author), Brigham & Womens Hosp, Channing Div Network Med, Dept Med, 401 Pk Dr,Suite 301 WEST, Boston, MA 02115 USA.
EM poxue@channing.harvard.edu
FU NIH [CA87969, CA55075, CA137178]
FX We would like to thank the participants and staff of the NHS and HPFS
for their valuable contributions as well as the following state cancer
registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL,
IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA,
RI, SC, TN, TX, VA, WA, WY. The NIH grants CA87969, CA55075, and
CA137178. Dr. Chan is a Damon Runyon Clinical Investigator.
NR 25
TC 5
Z9 5
U1 0
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0957-5243
J9 CANCER CAUSE CONTROL
JI Cancer Causes Control
PD MAY
PY 2013
VL 24
IS 5
BP 1015
EP 1024
DI 10.1007/s10552-013-0176-2
PG 10
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA 131ER
UT WOS:000317975800017
PM 23456271
ER
PT J
AU Elkin, EB
Nobles, JP
Pinheiro, LC
Atoria, CL
Schrag, D
AF Elkin, Elena B.
Nobles, J. Paige
Pinheiro, Laura C.
Atoria, Coral L.
Schrag, Deborah
TI Changes in access to screening mammography, 2008-2011
SO CANCER CAUSES & CONTROL
LA English
DT Article
DE Breast cancer; Screening; Mammography; Access to care
AB Screening mammography is a cornerstone of preventive health care for adult women in the United States. As rates of screening mammography have declined and plateaued in the past decade, access to services remains a concern. In 2011, we repeated a survey of mammography facilities initially surveyed in 2008 in six states. The availability of digital mammography increased and appointment wait times generally improved between the two survey periods, but more facilities required payment upfront. Provisions of the federal healthcare reform law that eliminate cost sharing for selected preventive health services may improve access to screening mammography and prevent further declines in the rate of breast cancer screening.
C1 [Elkin, Elena B.; Nobles, J. Paige; Pinheiro, Laura C.; Atoria, Coral L.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, Hlth Outcomes Res Grp, New York, NY 10021 USA.
[Schrag, Deborah] Dana Farber Canc Inst, Dept Med Oncol, Ctr Outcomes & Policy Res, Boston, MA 02115 USA.
RP Elkin, EB (reprint author), Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, Hlth Outcomes Res Grp, New York, NY 10021 USA.
EM elkine@mskcc.org
FU NCI NIH HHS [K07 CA118189, P30 CA008748]
NR 10
TC 2
Z9 2
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0957-5243
J9 CANCER CAUSE CONTROL
JI Cancer Causes Control
PD MAY
PY 2013
VL 24
IS 5
BP 1057
EP 1059
DI 10.1007/s10552-013-0180-6
PG 3
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA 131ER
UT WOS:000317975800022
PM 23468282
ER
PT J
AU Chan, JA
Mayer, RJ
Jackson, N
Malinowski, P
Regan, E
Kulke, MH
AF Chan, Jennifer A.
Mayer, Robert J.
Jackson, Nadine
Malinowski, Paige
Regan, Eileen
Kulke, Matthew H.
TI Phase I study of sorafenib in combination with everolimus (RAD001) in
patients with advanced neuroendocrine tumors
SO CANCER CHEMOTHERAPY AND PHARMACOLOGY
LA English
DT Article
DE Neuroendocrine; Phase I; Sorafenib; Everolimus
ID ENDOCRINE PANCREATIC TUMORS; RENAL-CELL CARCINOMA; EXPRESSION;
METASTASES; SUNITINIB
AB Sorafenib and everolimus are both active against neuroendocrine tumors (NET). Because of potential synergy between VEGF pathway and mTOR inhibitors, we performed a phase I study to evaluate the safety and feasibility of combining sorafenib and everolimus in patients with advanced NET.
Patients were treated with everolimus 10 mg daily in combination with sorafenib (dose level 1: 200 mg twice daily; dose level 2: 200 mg per morning, 400 mg per evening) using standard phase I dose escalation design. Dose-limiting toxicity (DLT) was defined within the first cycle (28 days) of therapy. Treatment was continued until tumor progression, unacceptable toxicity, or withdrawal of consent. Twelve additional patients were treated at the maximum tolerated dose (MTD) level to further characterize safety and a preliminary assessment of activity.
One patient in Cohort 1 experienced DLT (grade 3 skin rash); the cohort was expanded to 6 patients with no further DLTs. All 3 patients in Cohort 2 experienced DLT, consisting of thrombocytopenia, hand-foot skin reaction, and rash/allergic reaction. Sorafenib 200 mg twice daily in combination with everolimus 10 mg daily was established as the MTD. Independently reviewed best objective responses revealed that 62 % of patients had some degree of tumor shrinkage. By RECIST, we observed partial response in 1 patient, stable disease in 13 patients, and progressive disease in 3 patients.
Sorafenib 200 mg twice daily with everolimus 10 mg daily represents the MTD of this combination in patients with advanced NET. While the combination is active, toxicity concerns may preclude more widespread use.
C1 [Chan, Jennifer A.; Mayer, Robert J.; Jackson, Nadine; Malinowski, Paige; Regan, Eileen; Kulke, Matthew H.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Chan, Jennifer A.; Mayer, Robert J.; Jackson, Nadine; Kulke, Matthew H.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
RP Chan, JA (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA.
EM JANG@PARTNERS.ORG
FU Saul and Gitta Kurlat fund for neuroendocrine tumor research; Novartis;
Bayer; Onyx Pharmaceuticals; Schering-Plough/Merck
FX The authors gratefully acknowledge support from the Saul and Gitta
Kurlat fund for neuroendocrine tumor research. This work was supported
by Novartis, Bayer, and Onyx Pharmaceuticals.; J. Chan: research funding
from Novartis, Schering-Plough/Merck, Bayer, and Onyx Pharmaceuticals.
NR 16
TC 14
Z9 14
U1 1
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0344-5704
J9 CANCER CHEMOTH PHARM
JI Cancer Chemother. Pharmacol.
PD MAY
PY 2013
VL 71
IS 5
BP 1241
EP 1246
DI 10.1007/s00280-013-2118-9
PG 6
WC Oncology; Pharmacology & Pharmacy
SC Oncology; Pharmacology & Pharmacy
GA 135KS
UT WOS:000318287600014
PM 23475104
ER
PT J
AU O'Connor, R
Ooi, MG
Meiller, J
Jakubikova, J
Klippel, S
Delmore, J
Richardson, P
Anderson, K
Clynes, M
Mitsiades, CS
O'Gorman, P
AF O'Connor, Robert
Ooi, Melissa G.
Meiller, Justine
Jakubikova, Jana
Klippel, Steffen
Delmore, Jake
Richardson, Paul
Anderson, Kenneth
Clynes, Martin
Mitsiades, Constantine S.
O'Gorman, Peter
TI The interaction of bortezomib with multidrug transporters: implications
for therapeutic applications in advanced multiple myeloma and other
neoplasias
SO CANCER CHEMOTHERAPY AND PHARMACOLOGY
LA English
DT Article
DE P-glycoprotein; MDR protein; Bortezomib; Elacridar; Co-culture
ID NF-KAPPA-B; PROTEASOME INHIBITOR BORTEZOMIB; P-GLYCOPROTEIN EXPRESSION;
NECROSIS-FACTOR-ALPHA; DRUG-RESISTANCE; IN-VITRO; TUMOR-CELLS;
PHASE-III; LUNG-CARCINOMA; ONCOLOGY-GROUP
AB Bortezomib is an important agent in multiple myeloma treatment, but resistance in cell lines and patients has been described. The main mechanisms of resistance described in cancer fall into one of two categories, pharmacokinetic resistance (PK), e.g. over expression of drug efflux pumps and pharmacodynamic resistance, e.g. apoptosis resistance or altered survival pathways, where the agent reaches an appropriate concentration, but this fails to propagate an appropriate cell death response. Of the known pump mechanisms, P-glycoprotein (P-gp) is the best studied and considered to be the most important in contributing to general PK drug resistance. Resistance to bortezomib is multifactorial and there are conflicting indications that cellular overexpression of P-gp may contribute to resistance agent. Hence, better characterization of the interactions of this drug with classical resistance mechanisms should identify improved treatment applications.
Cell lines with different P-gp expression levels were used to determine the relationship between bortezomib and P-gp. Coculture system with stromal cells was used to determine the effect of the local microenvironment on the bortezomib-elacridar combination. To further assess P-gp function, intracellular accumulation of P-gp probe rhodamine-123 was utilised.
In the present study, we show that bortezomib is a substrate for P-gp, but not for the other drug efflux transporters. Bortezomib activity is affected by P-gp expression and conversely, the expression of P-gp affect bortezomib's ability to act as a P-gp substrate. The local microenvironment did not alter the cellular response to bortezomib. We also demonstrate that bortezomib directly affects the expression and function of P-gp.
Our findings strongly support a role for P-gp in bortezomib resistance and, therefore, suggest that combination of a P-gp inhibitor and bortezomib in P-gp positive myeloma would be a reasonable treatment combination to extend efficacy of this important drug.
C1 [O'Connor, Robert] Dublin City Univ, Sch Nursing & Human Sci, Dublin 9, Ireland.
[O'Connor, Robert; Ooi, Melissa G.; Meiller, Justine; Clynes, Martin; O'Gorman, Peter] Dublin City Univ, Natl Inst Cellular Biotechnol, Dublin 9, Ireland.
[Ooi, Melissa G.; Jakubikova, Jana; Klippel, Steffen; Delmore, Jake; Richardson, Paul; Anderson, Kenneth; Mitsiades, Constantine S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02215 USA.
[O'Gorman, Peter] Mater Misericordiae Univ Hosp, Dept Haematol, Dublin 7, Ireland.
RP Ooi, MG (reprint author), Dublin City Univ, Natl Inst Cellular Biotechnol, Dublin 9, Ireland.
EM mgooi20@gmail.com
OI o'connor, robert/0000-0003-4426-2507
FU Amgen Inc.; AVEO Pharma; Genzyme Corporation; Johnson & Johnson
Pharmaceutical Research & Development, LLC.
FX Dr. Kenneth Anderson disclosed the following relevant financial
relationships: Served as a consultant for Celgene Corporation,
Millennium Pharmaceuticals, Inc., Onyx Pharmaceuticals, Inc., Sanofi and
Gilead. Stock Ownership in Oncopep and Acetylon Pharmaceuticals; Dr.
Paul Richardson disclosed the following relevant financial
relationships: Served as a consultant for Millennium Pharmaceuticals,
Inc., and Johnson & Johnson Pharmaceutical Research & Development, LLC;
Dr. Constantine Mitsiades disclosed the following relevant financial
relationships: Received funding for clinical research from Amgen Inc.,
AVEO Pharma, Genzyme Corporation, Johnson & Johnson Pharmaceutical
Research & Development, LLC. Served as a consultant or received
honoraria from Bristol-Myers Squibb company, Millennium Pharmaceuticals,
Inc., Celgene Corporation, Centocor Research & Development, Inc, Merck &
Co., Inc., Novartis Pharmaceuticals Corporation; Dr. Steffen Klippel
disclosed the following relevant financial relationships: Stock
Ownership in Novartis Pharmaceuticals. The other authors have no
disclosures.
NR 51
TC 19
Z9 21
U1 2
U2 18
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0344-5704
J9 CANCER CHEMOTH PHARM
JI Cancer Chemother. Pharmacol.
PD MAY
PY 2013
VL 71
IS 5
BP 1357
EP 1368
DI 10.1007/s00280-013-2136-7
PG 12
WC Oncology; Pharmacology & Pharmacy
SC Oncology; Pharmacology & Pharmacy
GA 135KS
UT WOS:000318287600026
PM 23589314
ER
PT J
AU Weinberg, I
Giri, J
Calfon, MA
Hawkins, BM
Weinberg, MD
Margey, R
Hannon, K
Schainfeld, RM
Jaff, MR
AF Weinberg, Ido
Giri, Jay
Calfon, Marcella A.
Hawkins, Beau M.
Weinberg, Mitchell D.
Margey, Ronan
Hannon, Kathleen
Schainfeld, Robert M.
Jaff, Michael R.
TI Anatomic correlates of supra-normal ankle brachial indices
SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
LA English
DT Article
DE ankle brachial index; peripheral artery disease; angiography;
incompressible vessels
ID CHRONIC KIDNEY-DISEASE; PERIPHERAL ARTERIAL-DISEASE; DIABETIC-PATIENTS;
SYSTOLIC PRESSURES; LOWER EXTREMITIES; RISK; ASSOCIATION; CALCIFICATION;
PREVALENCE; MANAGEMENT
AB Background Supra-normal ankle brachial index (ABI) (>1.40), poses diagnostic challenges to determine the presence, location, and severity of peripheral artery disease (PAD). The anatomic distribution of PAD in patients with elevated ABI has not been previously described. Methods A retrospective review of all patients referred to the Massachusetts General Hospital vascular diagnostic laboratory from 5 January 2006 to 12 January 2011 who had both a supra-normal ABI and contrast arteriography (CA) within 3 months of each other is reported. Angiographic patterns were described using the Trans Atlantic Inter Society Consensus II (TASC II) classification. Results One-hundred sixteen limbs were analyzed in 92 patients. Mean age was 71.6 years (+/- 11.2); 81.5% (75/92) were male; 85.9% Caucasian (79/92); 67.4% diabetics (62/92); 78.3% hypertensive (72/92); 67.4% hypercholesterolemic (62/92); and 64.1% were current or former tobacco users (59/92). Chronic hemodialysis was present in 18.5% (17/92) and 15.2% (14/92) received chronic corticosteroids. Intermittent claudication was present in 46.7% (43/92) and critical limb ischemia in 52.2% (48/92). Aortoiliac, femoral and infra-popliteal involvement per angiography occurred in 14.9% (15/101), 56.1% (60/107), and 84.0% (84/100), respectively. Multilevel disease was present in 48.8% (42/86) of patients. PAD was absent in 4.7% (4/86) of patients. Toe brachial index <0.7 was found in 92% (92/100) of patients with angiographically confirmed PAD. Conclusion In symptomatic patients referred to a vascular laboratory who were found to have supra-normal ABI, nearly one half exhibited multilevel PAD, and over 80% had infrapopliteal involvement. A supra-normal ABI in such patients mandates evaluation for the presence and extent of PAD. (c) 2013 Wiley Periodicals, Inc.
C1 [Weinberg, Ido; Giri, Jay; Calfon, Marcella A.; Hawkins, Beau M.; Weinberg, Mitchell D.; Margey, Ronan; Hannon, Kathleen; Schainfeld, Robert M.; Jaff, Michael R.] Massachusetts Gen Hosp, Div Cardiovasc Med, Sect Vasc Med, Vasc Ctr, Boston, MA 02114 USA.
RP Jaff, MR (reprint author), 55 Fruit St, Boston, MA 02114 USA.
EM mjaff@partners.org
NR 25
TC 9
Z9 10
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1522-1946
J9 CATHETER CARDIO INTE
JI Catheter. Cardiovasc. Interv.
PD MAY
PY 2013
VL 81
IS 6
BP 1025
EP 1030
DI 10.1002/ccd.24604
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 133SN
UT WOS:000318160200028
PM 22899598
ER
PT J
AU Hawkins, BM
Drachman, DE
AF Hawkins, Beau M.
Drachman, Douglas E.
TI You can get there from here! A novel virtual 4.5F guide facilitates
renal intervention from transradial access
SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
LA English
DT Editorial Material
C1 [Hawkins, Beau M.; Drachman, Douglas E.] Massachusetts Gen Hosp, Div Cardiol, Vasc Med Sect, Boston, MA 02114 USA.
RP Drachman, DE (reprint author), Massachusetts Gen Hosp, Cardiovasc Fellowship Program, 55 Fruit St,Gray Bigelow 800, Boston, MA 02114 USA.
EM ddrachman@partners.org
NR 5
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1522-1946
J9 CATHETER CARDIO INTE
JI Catheter. Cardiovasc. Interv.
PD MAY
PY 2013
VL 81
IS 6
BP 1047
EP 1048
DI 10.1002/ccd.24923
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 133SN
UT WOS:000318160200032
PM 23606498
ER
PT J
AU Alam, MM
Tsai, LL
Rollins, SM
Sheikh, A
Khanam, F
Bufano, MK
Yu, YA
Ying, WF
Kalsy, A
Sultana, T
Abu Sayeed, M
Jahan, N
LaRocque, RC
Harris, JB
Leung, DT
Brooks, WA
Calderwood, SB
Charles, RC
Qadri, F
Ryan, ET
AF Alam, Mohammad Murshid
Tsai, Lillian L.
Rollins, Sean M.
Sheikh, Alaullah
Khanam, Farhana
Bufano, Meagan Kelly
Yu, Yanan
Ying Wu-Freeman
Kalsy, Anuj
Sultana, Tania
Abu Sayeed, M.
Jahan, Nusrat
LaRocque, Regina C.
Harris, Jason B.
Leung, Daniel T.
Brooks, W. Abdullah
Calderwood, Stephen B.
Charles, Richelle C.
Qadri, Firdausi
Ryan, Edward T.
TI Identification of In Vivo-Induced Bacterial Proteins during Human
Infection with Salmonella enterica Serotype Paratyphi A
SO CLINICAL AND VACCINE IMMUNOLOGY
LA English
DT Article
ID ANTIGEN TECHNOLOGY IVIAT; ESCHERICHIA-COLI; SEROVAR TYPHI; FIMBRIAL
OPERONS; GENE-EXPRESSION; REGULATED GENES; YGGG GENE; TYPHIMURIUM;
FEVER; BLOOD
AB Salmonella enterica serotype Paratyphi A is a human-restricted pathogen and the cause of paratyphoid A fever. Using a high-throughput immunoscreening technique, in vivo-induced antigen technology (IVIAT), we identified 20 immunogenic bacterial proteins expressed in humans who were bacteremic with S. Paratyphi A but not those expressed in S. Paratyphi A grown under standard laboratory conditions. The majority of these proteins have known or potential roles in the pathogenesis of S. enterica. These include proteins implicated in cell adhesion, fimbrial structure, adaptation to atypical conditions, oxidoreductase activity, proteolysis, antimicrobial resistance, and ion transport. Of particular interest among these in vivo-expressed proteins were S. Paratyphi A (SPA)2397, SPA2612, and SPA1604. SPA2397 and SPA2612 are prophage related, and SPA1604 is in Salmonella pathogenicity island 11 (SPI-11). Using real-time quantitative PCR (RT-qPCR), we confirmed increased levels of mRNA expressed by genes identified by IVIAT in a comparison of mRNA levels in organisms in the blood of bacteremic patients to those in in vitro cultures. Comparing convalescent-to acute-phase samples, we also detected a significant increase in the reaction of convalescent-phase antibodies with two proteins identified by IVIAT:SPA2397 and SPA0489. SPA2397 is a phage-related lysozyme, Gp19, and SPA0489 encodes a protein containing NlpC/P60 and cysteine, histidine-dependent amidohydrolase/peptidase (CHAP) domains. In a previous study utilizing a different approach, we found that transcripts for 11 and 7 of the genes identified by IVIAT were detectable in organisms in the blood of humans in Bangladesh who were bacteremic with S. Paratyphi A and Salmonella enterica serovar Typhi, respectively. S. Paratyphi A antigens identified by IVIAT warrant further evaluation for their contributions to pathogenesis and might have diagnostic, therapeutic, or preventive relevance.
C1 [Alam, Mohammad Murshid; Sheikh, Alaullah; Khanam, Farhana; Sultana, Tania; Abu Sayeed, M.; Jahan, Nusrat; Leung, Daniel T.; Brooks, W. Abdullah; Qadri, Firdausi] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh.
[Alam, Mohammad Murshid; Tsai, Lillian L.; Rollins, Sean M.; Bufano, Meagan Kelly; Yu, Yanan; Ying Wu-Freeman; Kalsy, Anuj; Sultana, Tania; LaRocque, Regina C.; Harris, Jason B.; Leung, Daniel T.; Calderwood, Stephen B.; Charles, Richelle C.; Ryan, Edward T.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Rollins, Sean M.; LaRocque, Regina C.; Leung, Daniel T.; Charles, Richelle C.; Ryan, Edward T.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Rollins, Sean M.] Fitchburg State Univ, Dept Biol & Chem, Fitchburg, MA USA.
[Harris, Jason B.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Calderwood, Stephen B.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA USA.
[Ryan, Edward T.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
RP Ryan, ET (reprint author), Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
EM etryan@partners.org
OI Rollins, Sean/0000-0002-3724-1989; leung, daniel/0000-0001-8401-0801
FU ICDDR,B; National Institutes of Health; National Institute of Allergy
and Infectious Diseases [R21 AI100023, U01 AI077883, U01 AI058935];
Training Grant in Vaccine Development and Public Health [D43 TW005572];
Career Development Awards [K01 TW07409, K08 AI089721, K08 AI100923];
American Recovery and Reinvestment Act (ARRA) postdoctoral fellowship in
Global Infectious Diseases [TW005572]; Clinical Research Scholars Award
[R24 TW007988]; Fogarty International Center; Physician Scientist Early
Career Award from the Howard Hughes Medical Institute; Massachusetts
General Hospital Physician Scientist Development Award from
Massachusetts General Hospital; Burroughs Wellcome Fund/American Society
of Tropical Medicine and Hygiene Postdoctoral Fellowship in Tropical
Infectious Diseases; Harvard College Program for Research in Science and
Engineering Fellowship; iSURF Award from the Harvard Global Health
Institute
FX This work was supported by the ICDDR,B and by grants from the National
Institutes of Health, including the National Institute of Allergy and
Infectious Diseases (R21 AI100023 and U01 AI077883 to E.T.R. and F.Q.,
U01 AI058935 to S.B.C., E.T.R., and F.Q., Training Grant in Vaccine
Development and Public Health (D43 TW005572 to M.M.A., F.K., A.S., T.S.,
E.T.R., and F.Q.), Career Development Awards (K01 TW07409 to J.B.H., K08
AI089721 to R.C.C., and K08 AI100923 to D.T.L.), an American Recovery
and Reinvestment Act (ARRA) postdoctoral fellowship in Global Infectious
Diseases (TW005572 to D.T.L. and R.C.C.), a Clinical Research Scholars
Award (R24 TW007988 to S.B.C.) from the Fogarty International Center, a
Physician Scientist Early Career Award from the Howard Hughes Medical
Institute (to R.C.L.), a Massachusetts General Hospital Physician
Scientist Development Award from Massachusetts General Hospital (to
R.C.C.), a Burroughs Wellcome Fund/American Society of Tropical Medicine
and Hygiene Postdoctoral Fellowship in Tropical Infectious Diseases (to
D.T.L.), a Harvard College Program for Research in Science and
Engineering Fellowship (to L.L.T.), and an iSURF Award from the Harvard
Global Health Institute (to L.L.T.).
NR 42
TC 6
Z9 6
U1 1
U2 8
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1556-6811
J9 CLIN VACCINE IMMUNOL
JI Clin. Vaccine Immunol.
PD MAY
PY 2013
VL 20
IS 5
BP 712
EP 719
DI 10.1128/CVI.00054-13
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 133OY
UT WOS:000318149500011
PM 23486419
ER
PT J
AU deLemos, AS
Friedman, LS
AF deLemos, Andrew S.
Friedman, Lawrence S.
TI Systemic Causes of Cholestasis
SO CLINICS IN LIVER DISEASE
LA English
DT Article
DE Amyloidosis; Cholestasis of sepsis; Congestive hepatopathy;
Granulomatous hepatitis; Lymphoma; Sarcoidosis; Sickle cell disease;
Total parenteral nutrition
ID SICKLE-CELL-DISEASE; BILE-DUCT SYNDROME; INFLAMMATORY-BOWEL-DISEASE;
TOTAL PARENTERAL-NUTRITION; PYOGENIC LIVER-ABSCESSES; OF-THE-LITERATURE;
SCLEROSING CHOLANGITIS; HEPATOBILIARY TUBERCULOSIS; INTRAHEPATIC
CHOLESTASIS; DIABETIC HEPATOSCLEROSIS
AB Systemic Causes of Cholestasis Andrew S. deLemos and Lawrence S. Friedman Systemic causes of cholestasis constitute a diverse group of diseases across organ systems. The pathophysiology of cholestasis in systemic disease can be a consequence of direct involvement of a disease process within the liver or extrahepatic biliary system or secondary to immunemediated changes in bile flow. Evaluating a patient with cholestasis for a systemic cause requires an understanding of the patient's risk factors, clinical setting (eg, hospitalized or immunosuppressed patient), clinical features, and pattern of laboratory abnormalities.
C1 [deLemos, Andrew S.; Friedman, Lawrence S.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
[deLemos, Andrew S.; Friedman, Lawrence S.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Friedman, Lawrence S.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
[Friedman, Lawrence S.] Newton Wellesley Hosp, Dept Med, Newton, MA 02462 USA.
RP Friedman, LS (reprint author), Newton Wellesley Hosp, Dept Med, 2014 Washington St, Newton, MA 02462 USA.
EM lfriedman@partners.org
FU NIDDK NIH HHS [T32 DK007191]
NR 85
TC 5
Z9 5
U1 2
U2 7
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1089-3261
J9 CLIN LIVER DIS
JI Clin. Liver Dis.
PD MAY
PY 2013
VL 17
IS 2
BP 301
EP +
DI 10.1016/j.cld.2012.11.001
PG 18
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 135AG
UT WOS:000318257800011
PM 23540504
ER
PT J
AU Blais, MA
Malone, JC
AF Blais, Mark A.
Malone, Johanna C.
TI Structure of the DSM-IV Personality disorders as revealed in clinician
ratings
SO COMPREHENSIVE PSYCHIATRY
LA English
DT Article
ID ASSESSMENT PROCEDURE SWAP; ASSESSING AXIS II; MENTAL-DISORDERS; PROPOSED
CHANGES; SAMPLE-SIZE; PART II; DIAGNOSIS; CLASSIFICATION; CRITERIA;
UTILITY
AB The revisions proposed for the DSM-5 would greatly alter how personality pathology is conceptualized, assessed, and diagnosed. One aspect of the proposed changes, elimination of four current personality disorders, has raised considerable controversy. The present study attempts to inform this debate by exploring clinicians' views of the structure of Personality Disorders using the current diagnostic system, the DSM-W. An exploratory factor analysis was conducted on the DSM-IV Personality Disorder criteria using clinician ratings for 280 patients. The factor analysis revealed eight clear and meaningful factors. The eight factors contained all six personality disorders proposed for retention in DSM-5 but also contained clear representations of two disorders (Paranoid and Schizoid) identified for removal from the system. These conditions appear to have clinical utility and their removal may have unintended negative consequences in clinical practice. Dependent and Avoidant criteria also merged to form a new construct with interesting clinical implications. These findings provide new insights into the complex typologies clinicians employ when applying the DSM-IV system to personality disordered patients. Lastly we argue that successful refinement of clinically significant constructs, like diagnostic systems, requires a balanced appraisal of evidence for clinical utility as well as external and internal validity. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Blais, Mark A.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Psychol Assessment Ctr, Boston, MA 02114 USA.
RP Blais, MA (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
EM Mblais@partners.org
NR 44
TC 6
Z9 6
U1 0
U2 10
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0010-440X
J9 COMPR PSYCHIAT
JI Compr. Psychiat.
PD MAY
PY 2013
VL 54
IS 4
BP 326
EP 333
DI 10.1016/j.comppsych.2012.10.014
PG 8
WC Psychiatry
SC Psychiatry
GA 134FU
UT WOS:000318196600003
PM 23219361
ER
PT J
AU Sun, PZ
Wang, Y
Xiao, G
Wu, RH
AF Sun, Phillip Zhe
Wang, Yu
Xiao, Gang
Wu, Renhua
TI Simultaneous experimental determination of labile proton fraction ratio
and exchange rate with irradiation radio frequency power-dependent
quantitative CEST MRI analysis
SO CONTRAST MEDIA & MOLECULAR IMAGING
LA English
DT Article
DE amide proton transfer (APT); chemical exchange saturation transfer
(CEST); pH
ID SATURATION-TRANSFER CEST; ACUTE CEREBRAL-ISCHEMIA; RF IRRADIATION;
CONTRAST AGENTS; PARACEST AGENTS; IN-VIVO; 7 T; PH; RESONANCE; WATER
AB Chemical exchange saturation transfer (CEST) imaging is sensitive to dilute proteins/peptides and microenvironmental properties, and has been increasingly evaluated for molecular imaging and in vivo applications. However, the experimentally measured CEST effect depends on the CEST agent concentration, exchange rate and relaxation time. In addition, there may be non-negligible direct radio-frequency (RF) saturation effects, particularly severe for diamagnetic CEST (DIACEST) agents owing to their relatively small chemical shift difference from that of the bulk water resonance. As such, the commonly used asymmetry analysis only provides CEST-weighted information. Recently, it has been shown with numerical simulation that both labile proton concentration and exchange rate can be determined by evaluating the RF power dependence of DIACEST effect. To validate the simulation results, we prepared and imaged two CEST phantoms: a pH phantom of serially titrated pH at a fixed creatine concentration and a concentration phantom of serially varied creatine concentration titrated to the same pH, and solved the labile proton fraction ratio and exchange rate per-pixel. For the concentration phantom, we showed that the labile proton fraction ratio is proportional to the CEST agent concentration with negligible change in the exchange rate. Additionally, we found the exchange rate of the pH phantom is dominantly base-catalyzed with little difference in the labile proton fraction ratio. In summary, our study demonstrated quantitative DIACEST MRI, which remains promising to augment the conventional CEST-weighted MRI analysis. Copyright (c) 2013 John Wiley & Sons, Ltd.
C1 [Sun, Phillip Zhe; Wang, Yu] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Sun, Phillip Zhe; Wang, Yu] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
[Xiao, Gang] Hanshan Normal Univ, Dept Math & Appl Math, Chaozhou, Guangdong, Peoples R China.
[Xiao, Gang; Wu, Renhua] Shantou Univ, Coll Med, Affiliated Hosp 2, Dept Radiol, Shantou, Guangdong, Peoples R China.
[Xiao, Gang; Wu, Renhua] Prov Key Lab Med Mol Imaging, Shantou, Guangdong, Peoples R China.
RP Sun, PZ (reprint author), Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
EM pzhesun@nmr.mgh.harvard.edu; rhwu@stu.edu.cn
FU AHA/SDG [0835384N]; NIH/NIBIB [1K01EB009771]; NSFC [30930027];
[NIH/NCRR-P41RR14075]
FX This study was supported in part by grants from AHA/SDG 0835384N,
NIH/NIBIB 1K01EB009771, NIH/NCRR-P41RR14075 and NSFC 30930027.
NR 50
TC 11
Z9 11
U1 0
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1555-4309
J9 CONTRAST MEDIA MOL I
JI Contrast Media Mol. Imaging
PD MAY-JUN
PY 2013
VL 8
IS 3
BP 246
EP 251
DI 10.1002/cmmi.1524
PG 6
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 132BC
UT WOS:000318041700005
PM 23606428
ER
PT J
AU Sharon, VR
Armstrong, AW
Jim-On, S
Ibrahimi, OA
Eisen, DB
AF Sharon, Victoria R.
Armstrong, April W.
Jim-On, Shelbi
Ibrahimi, Omar A.
Eisen, Daniel B.
TI Postoperative Preferences in Cutaneous Surgery: A Patient-Centered
Investigation From an Academic Dermatologic Surgery Practice
SO DERMATOLOGIC SURGERY
LA English
DT Article
AB Background Little is known about postoperative preferences regarding dermatologic surgery. Objective To determine patient preferences for postoperative follow-up after dermatologic surgery, desired follow-up interval, reasons for desired follow-up or lack thereof, and factors that may be associated with these preferences. Materials and Methods Patients who underwent Mohs micrographic surgery or excision within 24months of Mohs micrographic surgery or excision were retrospectively surveyed regarding their postoperative follow-up preferences. Procedure, tumor attributes, complications, and medications were recorded. Results Eighty-nine percent of patients considered postoperative follow-up important, with 55% opting for follow-up within 4weeks and an additional 29.1% within 2 to 3months. After multivariate analyses, there were no significantly associated covariates of interest regarding preference for follow-up. Reasons for desiring follow-up included to ensure the wound healed well (50%), to ensure the cancer had not returned (27.9%), and to examine the rest of the skin (18.6%). Conclusion A majority of patients desired postoperative follow-up visits for a variety of reasons. Anticipation of postoperative concerns should be included in dermatologic surgery planning.
C1 [Sharon, Victoria R.; Armstrong, April W.; Jim-On, Shelbi; Eisen, Daniel B.] Univ Calif Davis, Med Ctr, Dept Dermatol, Sacramento, CA 95817 USA.
[Ibrahimi, Omar A.] Connecticut Skin Inst, Stamford, CT USA.
[Ibrahimi, Omar A.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
RP Eisen, DB (reprint author), 3301 C St,Suite 1400, Sacramento, CA 95816 USA.
EM dbeisen@ucdavis.edu
OI Sharon, Victoria/0000-0002-5108-8757; Eisen, Daniel/0000-0001-6741-3182
NR 3
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1076-0512
J9 DERMATOL SURG
JI Dermatol. Surg.
PD MAY
PY 2013
VL 39
IS 5
BP 773
EP 778
DI 10.1111/dsu.12136
PG 6
WC Dermatology; Surgery
SC Dermatology; Surgery
GA 135JL
UT WOS:000318284300014
PM 23432932
ER
PT J
AU Meek, TH
Wisse, BE
Thaler, JP
Guyenet, SJ
Matsen, ME
Fischer, JD
Taborsky, GJ
Schwartz, MW
Morton, GJ
AF Meek, Thomas H.
Wisse, Brent E.
Thaler, Joshua P.
Guyenet, Stephan J.
Matsen, Miles E.
Fischer, Jonathan D.
Taborsky, Gerald J., Jr.
Schwartz, Michael W.
Morton, Gregory J.
TI BDNF Action in the Brain Attenuates Diabetic Hyperglycemia via
Insulin-Independent Inhibition of Hepatic Glucose Production
SO DIABETES
LA English
DT Article
ID NEUROTROPHIC FACTOR; SYNAPTIC PLASTICITY; ENERGY-BALANCE; MESSENGER-RNA;
FOOD-INTAKE; LEPTIN; MICE; RATS; RESISTANCE; OBESITY
AB Recent evidence suggests that central leptin administration fully normalizes hyperglycemia in a rodent model of uncontrolled insulin-deficient diabetes by reducing hepatic glucose production (HGP) and by increasing glucose uptake. The current studies were undertaken to determine whether brain-derived neurotrophic factor (BDNF) action in the brain lowers blood glucose in uncontrolled insulin-deficient diabetes and to investigate the mechanisms mediating this effect. Adult male rats implanted with cannulas to either the lateral cerebral ventricle or the ventromedial hypothalamic nucleus (VMN) received either vehicle or sizeptozotocin to induce uncontrolled insulin-deficient diabetes. Three days later, animals received daily intracerebroventricular or intra-VMN injections of either BDNF or its vehicle. We found that repeated daily intracerebroventricular administration of BDNF attenuated diabetic hyperglycemia independent of changes in food intake. Instead, using tracer dilution techniques during a basal clamp, we found that BDNF lowered blood glucose levels by potently suppressing HGP, without affecting tissue glucose uptake, an effect associated with normalization of both plasma glucagon levels and hepatic expression of gluconeogenic genes. Moreover, BDNF microinjection directly into the VMN also lowered fasting blood glucose levels in uncontrolled insulin-deficient diabetes, but this effect was modest compared with intracerebroventricular administration. We conclude that central nervous system BDNF attenuates diabetic hyperglycemia via an insulin-independent mechanism. This action of BDNF likely involves the VMN and is associated with inhibition of glucagon secretion and a decrease in the rate of HGP. Diabetes 62:1512-1518, 2013
C1 [Meek, Thomas H.; Wisse, Brent E.; Thaler, Joshua P.; Guyenet, Stephan J.; Matsen, Miles E.; Fischer, Jonathan D.; Schwartz, Michael W.; Morton, Gregory J.] Univ Washington, Dept Med, Diabet & Obes Ctr Excellence, Seattle, WA 98195 USA.
[Taborsky, Gerald J., Jr.] Vet Affairs Puget Sound Hlth Care Syst, Vet Affairs Med Ctr, Seattle, WA USA.
RP Morton, GJ (reprint author), Univ Washington, Dept Med, Diabet & Obes Ctr Excellence, Seattle, WA 98195 USA.
EM gjmorton@u.washington.edu
FU National Institutes of Health [DK089053, DK083042, DK050154-13];
Nutrition Obesity Research Center (NORC) [DK035816]; University of
Washington (Seattle, Washington) [T32 DK0007247]; Perkins Coie; American
Heart Association Scientist Development Grant
FX This work was supported by National Institutes of Health grants DK089053
(G.J.M.), DK083042 (M.W.S.), and DK050154-13 (G.J.T.); by the Nutrition
Obesity Research Center (NORC, DK035816) and the Diabetes and Metabolism
Training Grant (T32 DK0007247) at the University of Washington (Seattle,
Washington); by research funding from Perkins Coie; and by an American
Heart Association Scientist Development Grant (G.J.M.). No other
potential conflicts of interest relevant to this article were reported.
NR 25
TC 16
Z9 16
U1 0
U2 9
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
J9 DIABETES
JI Diabetes
PD MAY
PY 2013
VL 62
IS 5
BP 1512
EP 1518
DI 10.2337/db12-0837
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 133HE
UT WOS:000318128700030
PM 23274899
ER
PT J
AU Aguayo-Mazzucato, C
Zavacki, AM
Marinelarena, A
Hollister-Lock, J
El Khattabi, I
Marsili, A
Weir, GC
Sharma, A
Larsen, PR
Bonner-Weir, S
AF Aguayo-Mazzucato, Cristina
Zavacki, Ann Marie
Marinelarena, Alejandra
Hollister-Lock, Jennifer
El Khattabi, Ilham
Marsili, Alessandro
Weir, Gordon C.
Sharma, Arun
Larsen, P. Reed
Bonner-Weir, Susan
TI Thyroid Hormone Promotes Postnatal Rat Pancreatic beta-Cell Development
and Glucose-Responsive Insulin Secretion Through MAFA
SO DIABETES
LA English
DT Article
ID EMBRYONIC STEM-CELLS; RECEPTOR ISOFORM; IN-VIVO; ISLETS; GENE;
DEIODINASE; EXPRESSION; DIGESTION; ALPHA; MOUSE
AB Neonatal beta cells do not secrete glucose-responsive insulin and are considered immature. We previously showed the transcription factor MAFA is key for the functional maturation of beta cells, but the physiological regulators of this process are unknown. Here we show that postnatal rat beta cells express thyroid hormone (TH) receptor isoforms and deiodinases in an age-dependent pattern as glucose responsiveness develops. In vivo neonatal triiodothyronine supplementation and TH inhibition, respectively, accelerated and delayed metabolic development. In vitro exposure of immature islets to triiodothyronine enhanced the expression of Mafa, the secretion of glucose-responsive insulin, and the proportion of responsive cells, all of which are effects that were abolished in the presence of dominant-negative Mafa. Using chromatin immunoprecipitation and electrophoretic mobility shift assay, we show that TH has a direct receptor-ligand interaction with the Mafa promoter and, using a luciferase reporter, that this interaction was functional. Thus, TH can be considered a physiological regulator of functional maturation of beta cells via its induction of Mafa. Diabetes 62:1569-1580, 2013
C1 [Aguayo-Mazzucato, Cristina; Marinelarena, Alejandra; Hollister-Lock, Jennifer; El Khattabi, Ilham; Weir, Gordon C.; Sharma, Arun; Bonner-Weir, Susan] Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Islet Cell & Regenerat Biol, Boston, MA 02115 USA.
[Zavacki, Ann Marie; Marsili, Alessandro; Larsen, P. Reed] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens,Thyroid Sect, Boston, MA USA.
RP Bonner-Weir, S (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Islet Cell & Regenerat Biol, Boston, MA 02115 USA.
EM susan.bonner-weir@joslin.harvard.edu
FU National Institutes of Health [NIH R01 DK 66056, DK 93909, R01 DK 60127,
DK 36256, DK 076117, P30 DK36836]; JDRF [1-2011-591]; Diabetes Research
and Wellness Foundation; Graetz Fund; Sheenan Family Fellowship; Mary
Iaccoca Fellowship; Harvard College Research Program; National Institute
of Diabetes and Digestive and Kidney Diseases
FX This study was supported by grants from the National Institutes of
Health (NIH R01 DK 66056 and DK 93909 [S.B.-W.], R01 DK 60127 [A.S.], DK
36256 [P.R.L.], DK 076117 [A.M.Z.], P30 DK36836 Joslin Diabetes and
Endocrinology Research Center (DERC) Advanced Microscopy Core) and by
JDRF Grant 1-2011-591 (S.B.-W.). This work was also supported by the
Diabetes Research and Wellness Foundation, the Graetz Fund, and an
important group of private donors. C.A.-M. was partially supported by
the Sheenan Family Fellowship and the Mary Iaccoca Fellowship; A.M. was
supported by Harvard College Research Program and the National Institute
of Diabetes and Digestive and Kidney Diseases Short-Term Education
Program for Underrepresented Persons (STEP-UP).
NR 42
TC 38
Z9 40
U1 1
U2 9
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
J9 DIABETES
JI Diabetes
PD MAY
PY 2013
VL 62
IS 5
BP 1569
EP 1580
DI 10.2337/db12-0849
PG 12
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 133HE
UT WOS:000318128700036
PM 23305647
ER
PT J
AU Zraika, S
Koh, DS
Barrow, BM
Lu, B
Kahn, SE
Andrikopoulos, S
AF Zraika, Sakeneh
Koh, Duk-Su
Barrow, Breanne M.
Lu, Bao
Kahn, Steven E.
Andrikopoulos, Sofianos
TI Neprilysin Deficiency Protects Against Fat-Induced Insulin Secretory
Dysfunction by Maintaining Calcium Influx
SO DIABETES
LA English
DT Article
ID PANCREATIC BETA-CELLS; NEUTRAL ENDOPEPTIDASE ACTIVITY; C57BL/6J MICE;
MOUSE MODELS; GLUCOSE; ACIDS; INHIBITION; PALMITATE; PATHWAY; ISLETS
AB Neprilysin contributes to free fatty acid (FFA)-induced cellular dysfunction in nonislet tissues in type 2 diabetes. Here, we show for the first time that with prolonged FFA exposure, islet neprilysin is upregulated and this is associated with reduced insulin pre-mRNA and ATP levels, oxidative/nitrative stress, impaired potassium and calcium channel activities, and decreased glucose-stimulated insulin secretion (GSLS). Genetic ablation of neprilysin specifically protects against FFA-induced impairment of calcium influx and GSIS in vitro and in vivo but does not ameliorate other FFA-induced defects. Importantly, adenoviral overexpression of neprilysin in islets cultured without FFA reproduces the defects in both calcium influx and GSIS, suggesting that upregulation of neprilysin per se mediates insulin secretory dysfunction and that the mechanism for protection conferred by neprilysin deletion involves prevention of reduced calcium influx. Our findings highlight the critical nature of calcium signaling for normal insulin secretion and suggest that interventions to inhibit neprilysin may improve beta-cell function in obese humans with type 2 diabetes. Diabetes 62:1593-1601, 2013
C1 [Zraika, Sakeneh; Barrow, Breanne M.; Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA.
[Zraika, Sakeneh; Barrow, Breanne M.; Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA.
[Koh, Duk-Su] Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA.
[Lu, Bao] Harvard Univ, Sch Med, Dept Pediat, Childrens Hosp, Boston, MA 02115 USA.
[Andrikopoulos, Sofianos] Univ Melbourne, Heidelberg Repatriat Hosp, Dept Med, Heidelberg, Vic, Australia.
RP Zraika, S (reprint author), VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA.
EM zraikas@u.washington.edu
OI Kahn, Steven/0000-0001-7307-9002
FU National Institutes of Health (NIH) [DK-080945]; Department of Veterans
Affairs, VA Puget Sound Health Care System; Diabetes Australia Research
Trust; National Health and Medical Research Council (NHMRC) of
Australia; NIH [DK-017047]; NHMRC of Australia
FX This study was supported by National Institutes of Health (NIH) Grant
DK-080945 (to S.Z.), the Department of Veterans Affairs, VA Puget Sound
Health Care System, the Diabetes Australia Research Trust, and the
National Health and Medical Research Council (NHMRC) of Australia.
Calcium influx and rubidium efflux studies as well as histological
studies were performed at the University of Washington's Diabetes
Research Center Cell Function Analysis Core and Cellular and Molecular
Imaging Core, respectively, both of which are supported by NIH Grant
DK-017047. S.A. was the recipient of a Career Development Award from the
NHMRC of Australia.
NR 48
TC 4
Z9 4
U1 0
U2 2
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
J9 DIABETES
JI Diabetes
PD MAY
PY 2013
VL 62
IS 5
BP 1593
EP 1601
DI 10.2337/db11-1593
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 133HE
UT WOS:000318128700038
PM 23328128
ER
PT J
AU Saxena, R
Saleheen, D
Been, LF
Garavito, ML
Braun, T
Bjonnes, A
Young, R
Ho, WK
Rasheed, A
Frossard, P
Sim, XL
Hassanali, N
Radha, V
Chidambaram, M
Liju, S
Rees, SD
Ng, DPK
Wong, TY
Yamauchi, T
Hara, K
Tanaka, Y
Hirose, H
McCarthy, MI
Morris, AP
Basit, A
Barnett, AH
Katulanda, P
Matthews, D
Mohan, V
Wander, GS
Singh, JR
Mehra, NK
Ralhan, S
Kamboh, MI
Mulvihill, JJ
Maegawa, H
Tobe, K
Maeda, S
Cho, YS
Tai, ES
Kelly, MA
Chambers, JC
Kooner, JS
Kadowaki, T
Deloukas, P
Rader, DJ
Danesh, J
Sanghera, DK
AF Saxena, Richa
Saleheen, Danish
Been, Latonya F.
Garavito, Martha L.
Braun, Timothy
Bjonnes, Andrew
Young, Robin
Ho, Weang Kee
Rasheed, Asif
Frossard, Philippe
Sim, Xueling
Hassanali, Neelam
Radha, Venkatesan
Chidambaram, Manickam
Liju, Samuel
Rees, Simon D.
Ng, Daniel Peng-Keat
Wong, Tien-Yin
Yamauchi, Toshimasa
Hara, Kazuo
Tanaka, Yasushi
Hirose, Hiroshi
McCarthy, Mark I.
Morris, Andrew P.
Basit, Abdul
Barnett, Anthony H.
Katulanda, Prasad
Matthews, David
Mohan, Viswanathan
Wander, Gurpreet S.
Singh, Jai Rup
Mehra, Narinder K.
Ralhan, Sarju
Kamboh, M. Ilyas
Mulvihill, John J.
Maegawa, Hiroshi
Tobe, Kazuyuki
Maeda, Shiro
Cho, Yoon S.
Tai, E. Shyong
Kelly, M. Ann
Chambers, John C.
Kooner, Jaspal S.
Kadowaki, Takashi
Deloukas, Panos
Rader, Daniel J.
Danesh, John
Sanghera, Dharambir K.
CA DIAGRAM
MuTHER
AGEN
TI Genome-Wide Association Study Identifies a Novel Locus Contributing to
Type 2 Diabetes Susceptibility in Sikhs of Punjabi Origin From India
SO DIABETES
LA English
DT Article
ID BODY-MASS INDEX; GAMMA-SARCOGLYCAN; GENOTYPE IMPUTATION;
GENETIC-VARIATION; SOUTH-ASIA; COMPLEX; RISK; POPULATIONS; DISEASES;
IGF2BP2
AB We performed a genome-wide association study (GWAS) and a multistage meta-analysis of type 2 diabetes (T2D) in Punjabi Sikhs from India. Our discovery GWAS in 1,616 individuals (842 case subjects) was followed by in silico replication of the top 513 independent single nucleotide polymorphisms (SNPs) (P < 10(-3)) in Punjabi Sikhs (n = 2,819; 801 case subjects). We further replicated 66 SNPs (P < 10(-4)) through genotyping in a Punjabi Sikh sample (n = 2,894; 1,711 case subjects). On combined meta-analysis in Sikh populations (n = 7,329; 3,354 case subjects), we identified a novel locus in association with T2D at 13q12 represented by a directly genotyped intronic SNP (rs9552911, P = 1.82 x 10(-8)) in the SGCG gene. Next, we undertook in silico replication (stage 2b) of the top 513 signals (P < 10(-3)) in 29,157 non-Sikh South Asians (10,971 case subjects) and de novo genotyping of up to 31 top signals (P < 10(-4)) in 10,817 South Asians (5,157 case subjects) (stage 3b). In combined South Asian meta-analysis, we observed six suggestive associations (P < 10(-5) to < 10(-7)), including SNPs at HMG1L1/CTCFL, PLXNA4, SCAP, and chr5p11. Further evaluation of 31 top SNPs in 33,707 East Asians (16,746 case subjects) (stage 3c) and 47,117 Europeans (8,130 case subjects) (stage 3d), and joint meta-analysis of 128,127 individuals (44,358 case subjects) from 27 multiethnic studies, did not reveal any additional loci nor was there any evidence of replication for the new variant. Our findings provide new evidence on the presence of a population-specific signal in relation to T2D, which may provide additional insights into T2D pathogenesis. Diabetes 62:1746-1755, 2013
C1 [Saxena, Richa; Bjonnes, Andrew] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Human Genet Res, Boston, MA USA.
[Saxena, Richa; Bjonnes, Andrew] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA.
[Saleheen, Danish; Rasheed, Asif; Frossard, Philippe] Ctr Noncommunicable Dis, Karachi, Pakistan.
[Saleheen, Danish; Young, Robin; Ho, Weang Kee; Danesh, John] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England.
[Saleheen, Danish] Univ Penn, Dept Biostat, Philadelphia, PA 19104 USA.
[Saleheen, Danish] Univ Penn, Dept Epidemiol & Med, Philadelphia, PA 19104 USA.
[Been, Latonya F.; Garavito, Martha L.; Braun, Timothy; Mulvihill, John J.; Sanghera, Dharambir K.] Univ Oklahoma, Hlth Sci Ctr, Coll Med, Dept Pediat, Oklahoma City, OK 73190 USA.
[Sim, Xueling] Univ Michigan, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
[Sim, Xueling] Univ Michigan, Dept Stat, Ann Arbor, MI 48109 USA.
[Sim, Xueling] Natl Univ Singapore, Ctr Mol Epidemiol, Singapore 117548, Singapore.
[Hassanali, Neelam; McCarthy, Mark I.; Katulanda, Prasad; Matthews, David] Univ Oxford, Churchill Hosp, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England.
[Radha, Venkatesan; Chidambaram, Manickam; Liju, Samuel; Mohan, Viswanathan] Madras Diabet Res Fdn, Madras, Tamil Nadu, India.
[Rees, Simon D.; Kelly, M. Ann] Univ Birmingham, Coll Med & Dent Sci, Birmingham, W Midlands, England.
[Rees, Simon D.; Barnett, Anthony H.; Kelly, M. Ann] Heart England Natl Hlth Serv Fdn Trust, Ctr Diabet, Birmingham, W Midlands, England.
[Ng, Daniel Peng-Keat; Tai, E. Shyong] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore.
[Wong, Tien-Yin] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
[Wong, Tien-Yin] Natl Univ Singapore, Dept Ophthalmol, Singapore 117548, Singapore.
[Wong, Tien-Yin] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
[Yamauchi, Toshimasa; Hara, Kazuo; Kadowaki, Takashi] Univ Tokyo, Grad Sch Med, Dept Diabet & Metabol Dis, Tokyo, Japan.
[Hara, Kazuo] Univ Tokyo, Century Med & Res Ctr 22, Dept Integrated Mol Sci Metabol Dis, Tokyo, Japan.
[Tanaka, Yasushi] St Marianna Univ, Sch Med, Dept Internal Med, Div Endocrinol & Metab, Kanagawa, Japan.
[Hirose, Hiroshi] Keio Univ, Ctr Hlth, Sch Med, Tokyo, Japan.
[McCarthy, Mark I.; Morris, Andrew P.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
[McCarthy, Mark I.] Churchill Hosp, Oxford Natl Inst Hlth Res, Biomed Res Ctr, Oxford OX3 7LJ, England.
[Basit, Abdul] Baqai Inst Diabetol & Endocrinol, Karachi, Pakistan.
[Katulanda, Prasad] Univ Colombo, Dept Clin Med, Diabet Res Unit, Colombo, Sri Lanka.
[Mohan, Viswanathan] Dr Mohans Diabet Special Ctr, Madras, Tamil Nadu, India.
[Wander, Gurpreet S.; Ralhan, Sarju] Hero Dayanand Med Coll & Heart Inst, Ludhiana, Punjab, India.
[Singh, Jai Rup] Cent Univ Punjab, Bathinda, Punjab, India.
[Mehra, Narinder K.] All India Inst Med Sci & Res, New Delhi, India.
[Kamboh, M. Ilyas] Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA USA.
[Maegawa, Hiroshi] Shiga Univ Med Sci, Dept Med, Shiga, Japan.
[Tobe, Kazuyuki] Toyama Univ, Dept Internal Med 1, Toyama 930, Japan.
[Maeda, Shiro] RIKEN Ctr Genom Med, Lab Endocrinol & Metab, Kanagawa, Japan.
[Cho, Yoon S.] Hallym Univ, Dept Biomed Sci, Chunchon 200702, Gangwon Do, South Korea.
[Tai, E. Shyong] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore 117595, Singapore.
[Tai, E. Shyong] Duke NUS Grad Med Sch Singapore, Singapore, Singapore.
[Chambers, John C.; Kooner, Jaspal S.] Ealing Hosp Natl Hlth Serv Trust, Middlesex, England.
[Chambers, John C.; Kooner, Jaspal S.] Imperial Coll Healthcare Natl Hlth Serv Trust, London, England.
[Chambers, John C.] Univ London Imperial Coll Sci Technol & Med, London, England.
[Kooner, Jaspal S.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Natl Heart & Lung Inst, London, England.
[Deloukas, Panos] Wellcome Trust Sanger Inst, Hinxton, England.
[Rader, Daniel J.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
RP Sanghera, DK (reprint author), Univ Oklahoma, Hlth Sci Ctr, Coll Med, Dept Pediat, Oklahoma City, OK 73190 USA.
EM dharambir-sanghera@ouhsc.edu
RI Deloukas, Panos/B-2922-2013; Altshuler, David/A-4476-2009; Hide, Winston
Hide/C-7217-2009; Zondervan, Krina/M-1143-2013; Boehm,
Bernhard/F-8750-2015; Meitinger, Thomas/O-1318-2015; Rudan,
Igor/I-1467-2012;
OI van Vliet-Ostaptchouk, Jana/0000-0002-7943-3153; Manickam,
Chidambaram/0000-0001-8750-8576; Jorgensen, Torben/0000-0001-9453-2830;
Tai, E Shyong/0000-0003-2929-8966; Hattersley,
Andrew/0000-0001-5620-473X; Deloukas, Panos/0000-0001-9251-070X;
Altshuler, David/0000-0002-7250-4107; Hide, Winston
Hide/0000-0002-8621-3271; Zondervan, Krina/0000-0002-0275-9905; HO,
WEANG KEE/0000-0002-8269-7344; Zeggini, Eleftheria/0000-0003-4238-659X;
Kamboh, M. Ilyas/0000-0002-3453-1438; Rudan, Igor/0000-0001-6993-6884;
CHANG, TIEN-JYUN/0000-0001-9437-5847
FU National Institutes of Health/National Institute of Diabetes and
Digestive and Kidney Diseases [R01-DK-082766]; University of Oklahoma
Health Sciences Center
FX This work was supported by National Institutes of Health/National
Institute of Diabetes and Digestive and Kidney Diseases Grant
R01-DK-082766 and a seed grant from the University of Oklahoma Health
Sciences Center.
NR 55
TC 53
Z9 55
U1 0
U2 27
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
J9 DIABETES
JI Diabetes
PD MAY
PY 2013
VL 62
IS 5
BP 1746
EP 1755
DI 10.2337/db12-1077
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 133HE
UT WOS:000318128700054
PM 23300278
ER
PT J
AU Guo, J
Song, LG
Liu, ML
Segawa, H
Miyamoto, KI
Bringhurst, FR
Kronenberg, HM
Juppner, H
AF Guo, Jun
Song, Lige
Liu, Minlin
Segawa, Hiroko
Miyamoto, Ken-Ichi
Bringhurst, F. Richard
Kronenberg, Henry M.
Jueppner, Harald
TI Activation of a Non-cAMP/PKA Signaling Pathway Downstream of the
PTH/PTHrP Receptor Is Essential for a Sustained Hypophosphatemic
Response to PTH Infusion in Male Mice
SO ENDOCRINOLOGY
LA English
DT Article
ID NA/P-I-COTRANSPORTER; (PTH)/PTH-RELATED PEPTIDE RECEPTOR;
PARATHYROID-HORMONE; PHOSPHOLIPASE-C; PHOSPHATE-TRANSPORT;
DOWN-REGULATION; CHONDROCYTE HYPERTROPHY; VITAMIN-D; NAPI-IIA; OK CELLS
AB PTH increases urinary Pi excretion by reducing expression of two renal cotransporters [NaPi-IIa (Npt2a) and NaPi-IIc (Npt2c)]. In contrast to acute transporter regulation that is cAMP/protein kinase A dependent, long-term effects require phospholipase C (PLC) signaling by the PTH/PTHrP receptor (PPR). To determine whether the latter pathway regulates Pi through Npt2a and/or Npt2c, wild-type mice (Wt) and animals expressing a mutant PPR incapable of PLC activation (DD) were tested in the absence of one (Npt2a(-/-) or Npt2c(-/-)) or both phosphate transporters (2a/2c-dko). PTH infusion for 8 days caused a rapid and persistent decrease in serum Pi in Wt mice, whereas serum Pi in DD mice fell only transiently for the first 2 days. Consistent with these findings, fractional Pi excretion index was increased initially in both animals, but this increase persisted only when the PPR Wt was present. The hypophosphatemic response to PTH infusion was impaired only slightly in PPR Wt/Npt2c(-/-) or DD/Npt2c(-/-) mice. Despite lower baselines, PTH infusion in PPR Wt/Npt2a(-/-) mice decreased serum Pi further, an effect that was attenuated in DD/Npt2a(-/-) mice. Continuous PTH had no effect on serum Pi in 2a/2c-dko mice. PTH administration increased serum 1,25 dihydroxyvitamin D-3 levels in Wt and DD mice and increased levels above the elevated baseline with ablation of either but not of both transporters. Continuous PTH elevated serum fibroblast growth factor 23 and blood Ca2+ equivalently in all groups of mice. Our data indicate that PLC signaling at the PPR contributes to the long-term effect of PTH on Pi homeostasis but not to the regulation of 1,25 dihydroxyvitamin D-3, fibroblast growth factor 23, or blood Ca2+. (Endocrinology 154: 1680-1689, 2013)
C1 [Guo, Jun; Song, Lige; Liu, Minlin; Bringhurst, F. Richard; Kronenberg, Henry M.; Jueppner, Harald] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
[Guo, Jun; Song, Lige; Liu, Minlin; Bringhurst, F. Richard; Kronenberg, Henry M.; Jueppner, Harald] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Segawa, Hiroko; Miyamoto, Ken-Ichi] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Mol Nutr, Tokushima 7708504, Japan.
RP Guo, J (reprint author), Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
EM jguo2@partners.org
FU National Institutes of Health [PO1 DK11794]
FX This work was supported by National Institutes of Health Grant PO1
DK11794.
NR 47
TC 14
Z9 14
U1 1
U2 8
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0013-7227
J9 ENDOCRINOLOGY
JI Endocrinology
PD MAY
PY 2013
VL 154
IS 5
BP 1680
EP 1689
DI 10.1210/en.2012-2240
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 130IV
UT WOS:000317908800003
PM 23515284
ER
PT J
AU Hader, WJ
Tellez-Zenteno, J
Metcalfe, A
Hernandez-Ronquillo, L
Wiebe, S
Kwon, CS
Jette, N
AF Hader, Walter J.
Tellez-Zenteno, Jose
Metcalfe, Amy
Hernandez-Ronquillo, Lisbeth
Wiebe, Samuel
Kwon, Churl-Su
Jette, Nathalie
TI Complications of epilepsy surgery: A systematic review of focal surgical
resections and invasive EEG monitoring
SO EPILEPSIA
LA English
DT Article
DE Surgical risk; Epilepsy; Mortality; Neurologic deficits
ID TEMPORAL-LOBE EPILEPSY; TRIAL
AB Purpose Underutilization of epilepsy surgery remains a major problem and is in part due to physicians' misconceptions about the risks associated with epilepsy surgery. The purpose of this study was to systematically review the literature on complications of focal epilepsy surgery. Methods A literature search was conducted using PubMed and Embase to identify studies examining epilepsy surgery complications. Abstract and full text review, along with data extraction, was done in duplicate. Minor medical and neurologic complications were defined as those that resolved completely within 3months of surgery, whereas major complications persisted beyond that time frame. Descriptive statistics were used to report complication proportions. Key Findings Invasive monitoring: Minor complications were reported in 7.7% of patients, whereas major complications were reported in only 0.6% of patients undergoing invasive monitoring. Resective surgery: Minor and major medical complications were reported in 5.1% and 1.5% of patients respectively, most common being cerebrospinal fluid (CSF) leak. Minor neurologic complications occurred in 10.9% of patients and were twice as frequent in children (11.2% vs. 5.5%). Minor visual field defects were most common (12.9%). Major neurologic complications were noted in 4.7% of patients, with the most common being major visual field defects (2.1% overall). Perioperative mortality was uncommon after epilepsy surgery, occurring in only 0.4% of temporal lobe patients (1.2%extratemporal). Significance The majority of complications after epilepsy surgery are minor or temporary as they tend to resolve completely. Major permanent neurologic complications remain uncommon. Mortality as a result of epilepsy surgery in the modern era is rare.
C1 [Hader, Walter J.; Metcalfe, Amy; Wiebe, Samuel; Jette, Nathalie] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada.
[Tellez-Zenteno, Jose; Hernandez-Ronquillo, Lisbeth] Univ Saskatchewan, Div Neurol, Saskatoon, SK, Canada.
[Metcalfe, Amy; Wiebe, Samuel; Jette, Nathalie] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada.
[Wiebe, Samuel; Jette, Nathalie] Hotchkiss Brain Inst, Calgary, AB, Canada.
[Wiebe, Samuel; Jette, Nathalie] Inst Publ Hlth, Calgary, AB, Canada.
[Kwon, Churl-Su] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
RP Hader, WJ (reprint author), Foothills Med Ctr, Div Neurosurg, Dept Clin Neurosci, 12th Floor,1403 29th St NW, Calgary, AB T2N 2T9, Canada.
EM walter.hader@albertahealthservices.ca
RI Hernandez Ronquillo, Lizbeth/J-4826-2015
OI Hernandez Ronquillo, Lizbeth/0000-0001-7057-9343
FU American Epilepsy Society (AES); Milken Family Foundation; Alberta
Innovates Health Solutions (AI-HS); Alberta Health Services; Canadian
Institutes of Health Research (CIHR); Hotchkiss Brain Institute;
University of Calgary; Canada Research Chair in Neurological Health
Services Research; Royal University Hospital Foundation in Saskatoon
trough the Mudjadik Thyssen Mining Professorship in Neurosciences;
University of Saskatchewan; CIHR in Genetics (Ethics, Law, and Society);
CIHR strategic training grant studentships in Maternal Fetal Newborn
Health and Genetics, Child Development, and Health
FX This study was in part supported by a Clinician Scientist award to N.
Jette from the American Epilepsy Society (AES) and the Milken Family
Foundation and operating grants and or funds from Alberta Innovates
Health Solutions (AI-HS), Alberta Health Services, the Canadian
Institutes of Health Research (CIHR), the Hotchkiss Brain Institute, and
the University of Calgary. N. Jette holds a salary award from AI-HS and
a Canada Research Chair in Neurological Health Services Research. S.
Wiebe holds the Hopewell Professorship of Clinical Neurosciences
Research at the University of Calgary. JF Tellez-Zenteno holds a salary
award from the Royal University Hospital Foundation in Saskatoon trough
the Mudjadik Thyssen Mining Professorship in Neurosciences and also
receives operating funds from the University of Saskatchewan. A.
Metcalfe held a doctoral award from CIHR in Genetics (Ethics, Law, and
Society) and CIHR strategic training grant studentships in Maternal
Fetal Newborn Health and Genetics, Child Development, and Health during
this study.
NR 16
TC 53
Z9 54
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0013-9580
J9 EPILEPSIA
JI Epilepsia
PD MAY
PY 2013
VL 54
IS 5
BP 840
EP 847
DI 10.1111/epi.12161
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA 134UR
UT WOS:000318241000015
PM 23551133
ER
PT J
AU Feldt-Rasmussen, U
Brabant, G
Maiter, D
Jonsson, B
Toogood, A
Koltowska-Haggstrom, M
Rasmussen, AK
Buchfelder, M
Saller, B
Biller, BMK
AF Feldt-Rasmussen, Ulla
Brabant, Georg
Maiter, Dominique
Jonsson, Bjorn
Toogood, Andy
Koltowska-Haggstrom, Maria
Rasmussen, Aase Krogh
Buchfelder, Michael
Saller, Bernhard
Biller, Beverly M. K.
TI Response to GH treatment in adult GH deficiency is predicted by gender,
age, and IGF1 SDS but not by stimulated GH-peak
SO EUROPEAN JOURNAL OF ENDOCRINOLOGY
LA English
DT Article
ID GROWTH-HORMONE DEFICIENCY; HYPOTHALAMIC-PITUITARY DISEASE;
QUALITY-OF-LIFE; REPLACEMENT THERAPY; HYPOPITUITARY ADULTS;
BODY-COMPOSITION; PREMATURE MORTALITY; ENDOCRINE-SOCIETY; DIAGNOSIS;
RESPONSIVENESS
AB Objective: We studied whether the severity of GH deficiency (GHD) defined as i) GH-peak on stimulation tests (insulin tolerance test (ITT), arginine, and glucagon), ii) number of additional pituitary deficits, or iii) baseline IGF1 SDS could impact the response to GH treatment. We further explored whether iv) IGF1 SDS after 24 months of GH replacement or v) Delta IGF1 SDS from baseline to 24 months was related to the phenotypic response to GH treatment.
Design, patients, and measurements: The patient cohort (n=1752; 50% women) was obtained from KIMS (Pfizer International Metabolic Database). The patients were divided into three groups of approximately equal size (tertiles) according to the stimulated GH-peak values and baseline IGF1 SDS and were studied at baseline, 12, and 24 months of GH therapy.
Results: Lower baseline IGF1 SDS predicted better response in weight, BMI, total cholesterol, and triglycerides, while IGF1 SDS after 24 months was associated with reduction in waist/hip ratio, total cholesterol, and improved quality of life (QoL). Age-correlated negatively with the response in body weight, BMI, waist, IGF1 SDS, and total and LDL-cholesterol.
Response in weight and BMI was greater in men than in women, whereas women showed greater improvement in QoL than men. Patients with more severe GHD as assessed by lower GH-peaks and more pituitary hormone deficiencies had a greater increase in IGF1 SDS. The increase in IGF1 SDS was associated with a reduction in waist/hip ratio and an increase in weight, BMI, and triglycerides. There was no correlation with other lipids, blood pressure, or glucose.
Conclusion: Our findings indicate that baseline and 24 months, IGF1 and its degree of increase during GH replacement were more important than stimulated peak GH to predict the phenotypic response. European Journal of Endocrinology 168 733-743
C1 [Feldt-Rasmussen, Ulla; Rasmussen, Aase Krogh] Univ Copenhagen, Natl Univ Hosp, Rigshosp, Dept Med Endocrinol, DK-2100 Copenhagen, Denmark.
[Brabant, Georg] Christ Hosp, Dept Endocrinol, Manchester M20 4BX, Lancs, England.
[Maiter, Dominique] St Luc Univ Hosp, Dept Endocrinol & Nutr, B-1200 Brussels, Belgium.
[Jonsson, Bjorn] Uppsala Univ, Dept Womens & Childrens Hlth, Uppsala, Sweden.
[Toogood, Andy] Univ Hosp Birmingham, NHS Fdn Trust, Dept Endocrinol, Birmingham B15 2TH, W Midlands, England.
[Koltowska-Haggstrom, Maria] Pfizer Inc, Sollentuna, Sweden.
[Buchfelder, Michael] Univ Erlangen Nurnberg, Dept Neurosurg, D-91045 Erlangen, Germany.
[Saller, Bernhard] Pfizer Inc, Tadworth, England.
[Biller, Beverly M. K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neuroendocrine Unit, Boston, MA 02114 USA.
RP Feldt-Rasmussen, U (reprint author), Univ Copenhagen, Natl Univ Hosp, Rigshosp, Dept Med Endocrinol, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
EM ufeldt@rh.dk
FU Pfizer, Inc.; Novo Nordisk; Pfizer; Merck Serono; Arvid Nilsson's Fund
FX G Brabant, B M K Biller, M Buchfelder, U Feldt-Rasmussen, D Maiter, A
Toogood, and B Jonsson received consulting fees from Pfizer, Inc. U
Feldt-Rasmussen received research funding from Novo Nordisk. B M K
Biller received consulting fees from Novo Nordisk and research funding
from Novo Nordisk, Pfizer, and Merck Serono. M Koltowska-Haggstrom is an
employee of Pfizer, Inc. (Sweden), and B Saller is an employee of
Pfizer, Inc. (UK).; Pfizer sponsored the KIMS database. U
Feldt-Rasmussen received a research grant from Arvid Nilsson's Fund.
Salary for her research time is paid by this fund. No authors were paid
for their contributions to this manuscript.
NR 45
TC 4
Z9 4
U1 0
U2 3
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
ENGLAND
SN 0804-4643
EI 1479-683X
J9 EUR J ENDOCRINOL
JI Eur. J. Endocrinol.
PD MAY
PY 2013
VL 168
IS 5
BP 733
EP 743
DI 10.1530/EJE-13-0005
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 131OP
UT WOS:000318003300011
PM 23416951
ER
PT J
AU Sakai, N
Chun, J
Duffield, JS
Wada, T
Luster, AD
Tager, AM
AF Sakai, Norihiko
Chun, Jerold
Duffield, Jeremy S.
Wada, Takashi
Luster, Andrew D.
Tager, Andrew M.
TI LPA(1)-induced cytoskeleton reorganization drives fibrosis through
CTGF-dependent fibroblast proliferation
SO FASEB JOURNAL
LA English
DT Article
DE lysophosphatidic acid; Rho GTPases; myocardin-related transcription
factor-A; myocardin-related transcription factor-B; serum response
factor
ID TISSUE GROWTH-FACTOR; ENCAPSULATING PERITONEAL SCLEROSIS; TGF-BETA
ACTIVATION; PULMONARY-FIBROSIS; MESOTHELIAL CELLS; DIALYSIS PATIENTS;
GENE-EXPRESSION; ACTIN DYNAMICS; LUNG FIBROSIS; C-FOS
AB There has been much recent interest in lysophosphatidic acid (LPA) signaling through one of its receptors, LPA(1), in fibrotic diseases, but the mechanisms by which LPA-LPA(1) signaling promotes pathological fibrosis remain to be fully elucidated. Using a mouse peritoneal fibrosis model, we demonstrate central roles for LPA and LPA(1) in fibroblast proliferation. Genetic deletion or pharmacological antagonism of LPA(1) protected mice from peritoneal fibrosis, blunting the increases in peritoneal collagen by 65.4 and 52.9%, respectively, compared to control animals and demonstrated that peritoneal fibroblast proliferation was highly LPA(1) dependent. Activation of LPA1 on mesothelial cells induced these cells to express connective tissue growth factor (CTGF), driving fibroblast proliferation in a paracrine fashion. Activation of mesothelial cell LPA(1) induced CTGF expression by inducing cytoskeleton reorganization in these cells, causing nuclear translocation of myocardin-related transcription factor (MRTF)-A and MRTF-B. Pharmacological inhibition of MRTF-induced transcription also diminished CTGF expression and fibrosis in the peritoneal fibrosis model, mitigating the increase in peritoneal collagen content by 57.9% compared to controls. LPA(1)-induced cytoskeleton reorganization therefore makes a previously unrecognized but critically important contribution to the profibrotic activities of LPA by driving MRTF-dependent CTGF expression, which, in turn, drives fibroblast proliferation.-Sakai, N., Chun, J., Duffield, J. S., Wada, T., Luster, A. D., Tager, A. M. LPA(1)-induced cytoskeleton reorganization drives fibrosis through CTGF-dependent fibroblast proliferation. FASEB J. 27, 1830-1846 (2013). www.fasebj.org
C1 [Sakai, Norihiko; Luster, Andrew D.; Tager, Andrew M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Immunol & Inflammatory Dis, Boston, MA USA.
[Sakai, Norihiko; Luster, Andrew D.; Tager, Andrew M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Rheumatol Allergy & Immunol, Boston, MA USA.
[Tager, Andrew M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pulm & Crit Care Unit, Boston, MA USA.
[Chun, Jerold] Scripps Res Inst, Dept Mol Biol, Helen L Dorris Inst Neurol & Psychiat Disorders, La Jolla, CA 92037 USA.
[Duffield, Jeremy S.] Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98195 USA.
[Duffield, Jeremy S.] Univ Washington, Ctr Lung Biol, Seattle, WA 98195 USA.
[Duffield, Jeremy S.] Univ Washington, Inst Stem Cell & Regenerat Med, Seattle, WA 98195 USA.
[Wada, Takashi] Kanazawa Univ, Fac Med, Inst Med Pharmaceut & Hlth Sci, Div Nephrol,Dept Lab Med, Kanazawa, Ishikawa, Japan.
RP Tager, AM (reprint author), Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, 149 13th St,Rm 8301, Charlestown, MA 02129 USA.
EM amtager@partners.org
FU U.S. National Institutes of Health (NIH) [R01-HL095732, R01-HL108975];
Scleroderma Research Foundation; Pulmonary Fibrosis Foundation;
Coalition for Pulmonary Fibrosis; Nirenberg Center for Advanced Lung
Disease; Japan Society for the Promotion of Science (JSPS) Excellent
Young Researcher Overseas Visit Program; NIH [R01-MH051699,
R01-DA019674]
FX The authors gratefully acknowledge support from U.S. National Institutes
of Health (NIH) grants R01-HL095732 and R01-HL108975, and Scleroderma
Research Foundation, Pulmonary Fibrosis Foundation, Coalition for
Pulmonary Fibrosis, and Nirenberg Center for Advanced Lung Disease
grants to A.M.T, the Japan Society for the Promotion of Science (JSPS)
Excellent Young Researcher Overseas Visit Program to N.S., and NIH
grants R01-MH051699 and R01-DA019674 to J.C. The authors also thank B.
A. Fontaine for his expert assistance, and Amira Pharmaceuticals (San
Diego, CA, USA) for the kind gift of AM095. The authors declare no
conflicts of interest.
NR 53
TC 38
Z9 39
U1 0
U2 10
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD MAY
PY 2013
VL 27
IS 5
BP 1830
EP 1846
DI 10.1096/fj.12-219378
PG 17
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 134PU
UT WOS:000318226100004
PM 23322166
ER
PT J
AU Nath, AK
Roberts, LD
Liu, Y
Mahon, SB
Kim, S
Ryu, JH
Werdich, A
Januzzi, JL
Boss, GR
Rockwood, GA
MacRae, CA
Brenner, M
Gerszten, RE
Peterson, RT
AF Nath, Anjali K.
Roberts, Lee D.
Liu, Yan
Mahon, Sari B.
Kim, Sonia
Ryu, Justine H.
Werdich, Andreas
Januzzi, James L.
Boss, Gerry R.
Rockwood, Gary A.
MacRae, Calum A.
Brenner, Matthew
Gerszten, Robert E.
Peterson, Randall T.
TI Chemical and metabolomic screens identify novel biomarkers and antidotes
for cyanide exposure
SO FASEB JOURNAL
LA English
DT Article
DE mitochondria; inosine; zebrafish; riboflavin
ID CYTOCHROME-C-OXIDASE; SODIUM-NITROPRUSSIDE; LIPID-PEROXIDATION; SMALL
MOLECULES; DIFFERENT MODES; BILE-ACIDS; INTOXICATION; CELLS; INHIBITION;
ZEBRAFISH
AB Exposure to cyanide causes a spectrum of cardiac, neurological, and metabolic dysfunctions that can be fatal. Improved cyanide antidotes are needed, but the ideal biological pathways to target are not known. To understand better the metabolic effects of cyanide and to discover novel cyanide antidotes, we developed a zebrafish model of cyanide exposure and scaled it for high-throughput chemical screening. In a screen of 3120 small molecules, we discovered 4 novel antidotes that block cyanide toxicity. The most potent antidote was riboflavin. Metabolomic profiling of cyanide-treated zebrafish revealed changes in bile acid and purine metabolism, most notably by an increase in inosine levels. Riboflavin normalizes many of the cyanide-induced neurological and metabolic perturbations in zebrafish. The metabolic effects of cyanide observed in zebrafish were conserved in a rabbit model of cyanide toxicity. Further, humans treated with nitroprusside, a drug that releases nitric oxide and cyanide ions, display increased circulating bile acids and inosine. In summary, riboflavin may be a novel treatment for cyanide toxicity and prophylactic measure during nitroprusside treatment, inosine may serve as a biomarker of cyanide exposure, and metabolites in the bile acid and purine metabolism pathways may shed light on the pathways critical to reversing cyanide toxicity.-Nath, A. K., Roberts, L. D., Liu, Y., Mahon, S. B., Kim, S., Ryu, J. H., Werdich, A., Januzzi, J. L., Boss, G. R., Rockwood, G. A., MacRae, C. A., Brenner, M., Gerszten, R. E., Peterson, R. T. Chemical and metabolomic screens identify novel biomarkers and antidotes for cyanide exposure. FASEB J. 27, 1928-1938 (2013). www.fasebj.org
C1 [Nath, Anjali K.; Roberts, Lee D.; Liu, Yan; Kim, Sonia; Ryu, Justine H.; Januzzi, James L.; Gerszten, Robert E.; Peterson, Randall T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA USA.
[Nath, Anjali K.; Roberts, Lee D.; Liu, Yan; Kim, Sonia; Ryu, Justine H.; Januzzi, James L.; Gerszten, Robert E.; Peterson, Randall T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Cardiol,Dept Med, Charlestown, MA USA.
[Nath, Anjali K.; Roberts, Lee D.; Liu, Yan; Gerszten, Robert E.; Peterson, Randall T.] Broad Inst, Cambridge, MA USA.
[Mahon, Sari B.; Brenner, Matthew] Univ Calif Irvine, Irvine Med Ctr, Orange, CA 92668 USA.
[Werdich, Andreas; MacRae, Calum A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiol,Dept Med, Boston, MA 02115 USA.
[Boss, Gerry R.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
[Rockwood, Gary A.] USA, Analyt Toxicol Div, Med Res Inst Chem Def, Aberdeen Proving Ground, MD USA.
RP Nath, AK (reprint author), Cardiovasc Res Ctr, 149 13th St, Charlestown, MA 02129 USA.
EM anath@cvrc.mgh.harvard.edu; peterson@cvrc.mgh.harvard.edu
OI Roberts, Lee/0000-0002-1455-5248
FU U.S. National Institutes of Health (NIH) grant [T32 HL-007208]; NIH
Countermeasures Against Chemical Threats (Counter ACT) [U54NS063718,
U54NS079201]; CounterACT Program, NIH Office of the Director; National
Institute of Allergy and Infectious Diseases, NIH/U.S. Army Medical
Research and Materiel Command [Y1-OD-9611-01/A120-B.P2009-1]
FX Funding for this project has been provided by U.S. National Institutes
of Health (NIH) grant T32 HL-007208 (A.K.N. and Y.L.) and NIH
Countermeasures Against Chemical Threats (Counter ACT) grants
U54NS063718 and U54NS079201 (S.B.M. and M.B.) and U54NS079201 (R.T.P).
The zebrafish research was supported, in part, by the CounterACT
Program, NIH Office of the Director, and the National Institute of
Allergy and Infectious Diseases, NIH/U.S. Army Medical Research and
Materiel Command interagency agreement no. Y1-OD-9611-01/A120-B.P2009-1
(G.A.R.).
NR 54
TC 12
Z9 13
U1 2
U2 28
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD MAY
PY 2013
VL 27
IS 5
BP 1928
EP 1938
DI 10.1096/fj.12-225037
PG 11
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 134PU
UT WOS:000318226100013
PM 23345455
ER
PT J
AU Montgomery, SB
Goode, DL
Kvikstad, E
Albers, CA
Zhang, ZDD
Mu, XJ
Ananda, G
Howie, B
Karczewski, KJ
Smith, KS
Anaya, V
Richardson, R
Davis, J
MacArthur, DG
Sidow, A
Duret, L
Gerstein, M
Makova, KD
Marchini, J
McVean, G
Lunter, G
AF Montgomery, Stephen B.
Goode, David L.
Kvikstad, Erika
Albers, Cornelis A.
Zhang, Zhengdong D.
Mu, Xinmeng Jasmine
Ananda, Guruprasad
Howie, Bryan
Karczewski, Konrad J.
Smith, Kevin S.
Anaya, Vanessa
Richardson, Rhea
Davis, Joe
MacArthur, Daniel G.
Sidow, Arend
Duret, Laurent
Gerstein, Mark
Makova, Kateryna D.
Marchini, Jonathan
McVean, Gil
Lunter, Gerton
CA 1000 Genomes Project Consortium
TI The origin, evolution, and functional impact of short insertion-deletion
variants identified in 179 human genomes
SO GENOME RESEARCH
LA English
DT Article
ID RECOMBINATION HOT-SPOTS; STRAND BREAK REPAIR; STRUCTURAL VARIATION; DNA;
MICROSATELLITE; GENE; REARRANGEMENTS; INSTABILITY; MECHANISM; POPULATION
AB Short insertions and deletions (indels) are the second most abundant form of human genetic variation, but our understanding of their origins and functional effects lags behind that of other types of variants. Using population-scale sequencing, we have identified a high-quality set of 1.6 million indels from 179 individuals representing three diverse human populations. We show that rates of indel mutagenesis are highly heterogeneous, with 43%-48% of indels occurring in 4.03% of the genome, whereas in the remaining 96% their prevalence is 16 times lower than SNPs. Polymerase slippage can explain upwards of three-fourths of all indels, with the remainder being mostly simple deletions in complex sequence. However, insertions do occur and are significantly associated with pseudo-palindromic sequence features compatible with the fork stalling and template switching (FoSTeS) mechanism more commonly associated with large structural variations. We introduce a quantitative model of polymerase slippage, which enables us to identify indel-hypermutagenic protein-coding genes, some of which are associated with recurrent mutations leading to disease. Accounting for mutational rate heterogeneity due to sequence context, we find that indels across functional sequence are generally subject to stronger purifying selection than SNPs. We find that indel length modulates selection strength, and that indels affecting multiple functionally constrained nucleotides undergo stronger purifying selection. We further find that indels are enriched in associations with gene expression and find evidence for a contribution of nonsense-mediated decay. Finally, we show that indels can be integrated in existing genome-wide association studies (GWAS); although we do not find direct evidence that potentially causal protein-coding indels are enriched with associations to known disease-associated SNPs, our findings suggest that the causal variant underlying some of these associations may be indels.
C1 [Montgomery, Stephen B.] Univ Geneva, Sch Med, Dept Genet Med & Dev, CH-1211 Geneva, Switzerland.
[Montgomery, Stephen B.; Smith, Kevin S.; Anaya, Vanessa; Richardson, Rhea; Sidow, Arend] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA.
[Montgomery, Stephen B.; Goode, David L.; Karczewski, Konrad J.; Davis, Joe; Sidow, Arend] Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA.
[Kvikstad, Erika; Duret, Laurent] Univ Lyon 1, CNRS, INRIA, Lab Biometrie & Biol Evolut,UMR5558, F-69622 Villeurbanne, France.
[Albers, Cornelis A.; MacArthur, Daniel G.] Wellcome Trust Sanger Inst, Cambridge CB10 1HH, England.
[Albers, Cornelis A.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands.
[Zhang, Zhengdong D.] Albert Einstein Coll Med, Dept Genet, Bronx, NY 10461 USA.
[Mu, Xinmeng Jasmine; Gerstein, Mark] Yale Univ, Program Computat Biol & Bioinformat, New Haven, CT 06520 USA.
[Ananda, Guruprasad; Makova, Kateryna D.] Penn State Univ, Dept Biol, University Pk, PA 16802 USA.
[Howie, Bryan] Univ Chicago, Dept Stat, Chicago, IL 60637 USA.
[MacArthur, Daniel G.] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
[Marchini, Jonathan; McVean, Gil] Univ Oxford, Dept Stat, Oxford OX1 3TG, England.
[Kvikstad, Erika; McVean, Gil; Lunter, Gerton] Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
RP Montgomery, SB (reprint author), Univ Geneva, Sch Med, Dept Genet Med & Dev, CH-1211 Geneva, Switzerland.
EM smontgom@stanford.edu; gerton.lunter@well.ox.ac.uk
RI Albers, Kees/A-4170-2015; Lunter, Gerton/H-4939-2016; Mu,
Xinmeng/P-2562-2016;
OI Albers, Kees/0000-0003-4115-3727; Mu, Xinmeng/0000-0002-8079-0828;
Duret, Laurent/0000-0003-2836-3463; McVean, Gil/0000-0002-5012-4162;
Lunter, Gerton/0000-0002-3798-2058; Karczewski,
Konrad/0000-0003-2878-4671; Clarke, Laura/0000-0002-5989-6898
FU NSF [DBI-0965596]; NIH [R01GM087472]; British Heart Foundation
[RG/09/12/28096]; EMBO [ALTF 354-2010]; Wellcome Trust [090532/Z/09/Z];
Edward J. Mallinckrodt Jr. Foundation
FX This research was supported in part by NSF grant DBI-0965596 (to
K.D.M.), NIH grant R01GM087472 (to K.D.M. and Kristin Eckert), British
Heart Foundation grant RG/09/12/28096 (to C.A.A.), EMBO Long Term
Fellowship ALTF 354-2010 (to E.K.), Wellcome Trust core grant
090532/Z/09/Z (G.L. and G.McV.), and the Edward J. Mallinckrodt Jr.
Foundation (S.B.M.). S.B.M. would like to thank Emmanouil T. Dermitzakis
for his support of this work.
NR 48
TC 73
Z9 73
U1 3
U2 29
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1088-9051
J9 GENOME RES
JI Genome Res.
PD MAY
PY 2013
VL 23
IS 5
BP 749
EP 761
DI 10.1101/gr.148718.112
PG 13
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Genetics & Heredity
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Genetics & Heredity
GA 134IA
UT WOS:000318202400001
PM 23478400
ER
PT J
AU Zhou, XB
Qiu, WL
Sathirapongsasuti, JF
Cho, MH
Mancini, JD
Lao, TT
Thibault, DM
Litonjua, AA
Bakke, PS
Gulsvik, A
Lomas, DA
Beaty, TH
Hersh, CP
Anderson, C
Geigenmuller, U
Raby, BA
Rennard, SI
Perrella, MA
Choi, AMK
Quackenbush, J
Silverman, EK
AF Zhou, Xiaobo
Qiu, Weiliang
Sathirapongsasuti, J. Fah
Cho, Michael H.
Mancini, John D.
Lao, Taotao
Thibault, Derek M.
Litonjua, Augusto A.
Bakke, Per S.
Gulsvik, Amund
Lomas, David A.
Beaty, Terri H.
Hersh, Craig P.
Anderson, Christopher
Geigenmuller, Ute
Raby, Benjamin A.
Rennard, Stephen I.
Perrella, Mark A.
Choi, Augustine M. K.
Quackenbush, John
Silverman, Edwin K.
TI Gene expression analysis uncovers novel hedgehog interacting protein
(HHIP) effects in human bronchial epithelial cells
SO GENOMICS
LA English
DT Article
DE Hedgehog interacting protein (HHIP); Gene expression profiling; COPD
(Chronic obstructive pulmonary disease); Extracellular matrix (ECM);
Network modeling
ID OBSTRUCTIVE PULMONARY-DISEASE; GENOME-WIDE ASSOCIATION; SURROGATE
VARIABLE ANALYSIS; CIGARETTE-SMOKE; BINDING PROTEIN; LUNG-CANCER; RECK;
REGULATOR; COPD; IDENTIFICATION
AB Hedgehog interacting protein (HHIP) was implicated in chronic obstructive pulmonary disease (COPD) by genome-wide association studies (GWAS). However, it remains unclear how HHIP contributes to COPD pathogenesis. To identify genes regulated by HHIP, we performed gene expression microarray analysis in a human bronchial epithelial cell line (Beas-2B) stably infected with HHIP shRNAs. HHIP silencing led to differential expression of 296 genes; enrichment for variants nominally associated with COPD was found. Eighteen of the differentially expressed genes were validated by real-time PCR in Beas-2B cells. Seven of 11 validated genes tested in human COPD and control lung tissues demonstrated significant gene expression differences. Functional annotation indicated enrichment for extracellular matrix and cell growth genes. Network modeling demonstrated that the extracellular matrix and cell proliferation genes influenced by HHIP tended to be interconnected. Thus, we identified potential HHIP targets in human bronchial epithelial cells that may contribute to COPD pathogenesis. (c) 2013 Elsevier Inc. All rights reserved.
C1 [Zhou, Xiaobo; Qiu, Weiliang; Cho, Michael H.; Mancini, John D.; Lao, Taotao; Thibault, Derek M.; Litonjua, Augusto A.; Hersh, Craig P.; Anderson, Christopher; Geigenmuller, Ute; Raby, Benjamin A.; Silverman, Edwin K.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.
[Zhou, Xiaobo; Cho, Michael H.; Litonjua, Augusto A.; Hersh, Craig P.; Raby, Benjamin A.; Perrella, Mark A.; Choi, Augustine M. K.; Silverman, Edwin K.] Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA.
[Zhou, Xiaobo; Qiu, Weiliang; Cho, Michael H.; Mancini, John D.; Lao, Taotao; Thibault, Derek M.; Litonjua, Augusto A.; Hersh, Craig P.; Anderson, Christopher; Geigenmuller, Ute; Raby, Benjamin A.; Perrella, Mark A.; Choi, Augustine M. K.; Silverman, Edwin K.] Harvard Univ, Sch Med, Boston, MA USA.
[Sathirapongsasuti, J. Fah; Quackenbush, John] Dana Faber Canc Inst, Dept Biostat & Computat Biol, Boston, MA USA.
[Sathirapongsasuti, J. Fah; Quackenbush, John] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Bakke, Per S.; Gulsvik, Amund] Univ Bergen, Dept Thorac Med, Bergen, Norway.
[Gulsvik, Amund] Univ Bergen, Dept Resp Med, Bergen, Norway.
[Bakke, Per S.; Gulsvik, Amund] Haukeland Hosp, N-5021 Bergen, Norway.
[Lomas, David A.] Univ Cambridge, Dept Med, Cambridge Inst Med Res, Cambridge CB2 2QQ, England.
[Beaty, Terri H.] Johns Hopkins Sch Publ Hlth, Baltimore, MD USA.
[Rennard, Stephen I.] Nebraska Med Ctr, Omaha, NE USA.
[Perrella, Mark A.] Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Zhou, XB (reprint author), Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA.
EM Xiaobo.zhou@channing.harvard.edu; ed.silverman@channing.harvard.edu
OI Qiu, Weiliang/0000-0002-9155-6957; Litonjua, Augusto/0000-0003-0422-5875
FU U.S. National Institutes of Health (NIH) [R01 HL075478, R01 HL084323,
P01 HL083069, P01 HL105339, U01 HL089856, U01 HL089897, P01 H105339];
National Heart, Lung, and Blood Institute [N01HR76101, N01HR76102,
N01HR76103, N01HR76104, N01HR76105, N01HR76106, N01HR76107, N01HR76108,
N01HR76109, N01HR76110, N01HR76111, N01HR76112, N01HR76113, N01HR76114,
N01HR76115, N01HR76116, N01HR76118, N01HR76119]; Centers for Medicare
and Medicaid Services; Agency for Healthcare Research and Quality;
Cooperative Studies Program/ERIC of the US Department of Veterans
Affairs; GlaxoSmithKline; COPD Foundation; National Heart, Lung, and
Blood Institute (NHLBI)
FX This work was supported by the U.S. National Institutes of Health (NIH)
grants R01 HL075478, R01 HL084323, P01 HL083069, P01 HL105339, U01
HL089856 (Silverman), U01 HL089897, and P01 H105339. The National
Emphysema Treatment Trial was supported by the National Heart, Lung, and
Blood Institute, the Centers for Medicare and Medicaid Services and the
Agency for Healthcare Research and Quality. The Normative Aging Study is
supported by the Cooperative Studies Program/ERIC of the US Department
of Veterans Affairs and is a component of the Massachusetts Veterans
Epidemiology Research and Information Center (MAVERIC). The Norway
GenKOLS study (Genetics of Chronic Obstructive Lung Disease, GSK code
RES11080), the ECLIPSE study (clinicaltrials.gov identifier NCT00292552;
GSK code SCO104960) and the ICGN study are funded by GlaxoSmithKline.
The COPDGene project is also supported by the COPD Foundation through
contributions made by an Industry Advisory Board comprised of
AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer and Sunovion. This
study used biological specimens and data provided by the Lung Tissue
Research Consortium (LTRC) supported by the National Heart, Lung, and
Blood Institute (NHLBI).; The National Emphysema Treatment Trial was
supported by the National Heart, Lung, and Blood Institute contracts
N01HR76101, N01HR76102, N01HR76103, N01HR76104, N01HR76105, N01HR76106,
N01HR76107, N01HR76108, N01HR76109, N01HR76110, N01HR76111, N01HR76112,
N01HR76113, N01HR76114, N01HR76115, N01HR76116, N01HR76118 and
N01HR76119.
NR 50
TC 18
Z9 18
U1 2
U2 15
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0888-7543
J9 GENOMICS
JI Genomics
PD MAY
PY 2013
VL 101
IS 5
BP 263
EP 272
DI 10.1016/j.ygeno.2013.02.010
PG 10
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 132HD
UT WOS:000318057600001
PM 23459001
ER
PT J
AU Diver, E
O'Connor, O
Garrett, L
Boruta, D
Goodman, A
Del Carmen, M
Schorge, J
Mueller, P
Growdon, W
AF Diver, Elisabeth
O'Connor, Owen
Garrett, Leslie
Boruta, David
Goodman, Annekathryn
Del Carmen, Marcela
Schorge, John
Mueller, Peter
Growdon, Whitfield
TI Modest benefit of total parenteral nutrition and chemotherapy after
venting gastrostomy tube placement
SO GYNECOLOGIC ONCOLOGY
LA English
DT Article
DE Bowel obstruction; TPN; Chemotherapy
ID MALIGNANT BOWEL OBSTRUCTION; PERITONEAL CANCER INDEX; PERCUTANEOUS
ENDOSCOPIC GASTROSTOMY; ADVANCED OVARIAN-CANCER; GYNECOLOGICAL
MALIGNANCY; INTESTINAL-OBSTRUCTION; EXPERIENCE; CARCINOMA; SURVIVAL;
SURGERY
AB Objective. The aim of the study is to review a single institution's experience with gastrostomy tubes (GTs) performed for malignant bowel obstruction from gynecologic cancers.
Methods. Women with gynecologic cancers who underwent venting GT placement from 2000 to 2008 were identified and clinical data were extracted. Logistic regression and spearman correlational coefficients were used to determine relationships between variables. Survival analysis was performed using the Kaplan-Meier method and a Cox proportional hazard model.
Results. We identified 115 women who underwent GT placement, the majority of whom were diagnosed with ovarian cancer (84%). Median time from cancer diagnosis to GT placement was 2.2 years. Median survival following GT placement was 5.6 weeks. A majority (56%) developed GT complications requiring GT revision. While burden of disease as assessed on CT scan by the validated peritoneal cancer index (PCI) was not associated with survival, low CA-125 within one week of GT placement was associated with improved survival (p<0.01). TPN was administered in 36% of women, was associated with concurrent chemotherapy (p<0.001) and a 5 week survival benefit (p<0.01). Chemotherapy after GT was administered in 40% of women and was associated with a 10 week survival benefit (p<0.001). Age-adjusted multivariate analysis identified chemotherapy as the only independent variable associated with survival.
Conclusions. Women with malignant bowel obstructions from gynecologic cancers requiring palliative GT placement had a guarded prognosis measured in weeks. Gastrostomy tubes near the end of life had a high rate of complications requiring medical intervention. Chemotherapy after GT was associated with TPN administration, and both were associated with a modest extension in survival. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Diver, Elisabeth; Garrett, Leslie; Boruta, David; Goodman, Annekathryn; Del Carmen, Marcela; Schorge, John; Growdon, Whitfield] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept OB GYN,Div Gynecol Oncol, Boston, MA 02114 USA.
[O'Connor, Owen; Mueller, Peter] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol,Div Intervent Radiol, Boston, MA 02114 USA.
[Diver, Elisabeth; O'Connor, Owen; Garrett, Leslie; Boruta, David; Goodman, Annekathryn; Del Carmen, Marcela; Schorge, John; Mueller, Peter; Growdon, Whitfield] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Growdon, W (reprint author), Massachusetts Gen Hosp, Dept Obstet & Gynecol, Div Gynecol Oncol, 55 Fruit St,Yawkey Ctr Outpatient Care 9E, Boston, MA 02114 USA.
EM ediver@partners.org; owen.oconnor7@gmail.com;
lgarret1@bidmc.harvard.edu; dboruta@partners.org; agoodman@partners.org;
mdelcarmen@partners.org; jschorge@partners.org; pmueller@partners.org;
wgrowdon@partners.org
NR 17
TC 7
Z9 7
U1 1
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0090-8258
J9 GYNECOL ONCOL
JI Gynecol. Oncol.
PD MAY
PY 2013
VL 129
IS 2
BP 332
EP 335
DI 10.1016/j.ygyno.2013.02.002
PG 4
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA 132HN
UT WOS:000318058600011
PM 23402902
ER
PT J
AU Gerace, M
Liu, B
Kushak, R
Grabowski, E
AF Gerace, M.
Liu, B.
Kushak, R.
Grabowski, E.
TI Shiga toxin-1 and TNF alpha does not change tissue factor
co-localization with tissue factor pathway inhibitor on human umbilical
vein endothelial cells
SO HAEMOPHILIA
LA English
DT Meeting Abstract
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1351-8216
J9 HAEMOPHILIA
JI Haemophilia
PD MAY
PY 2013
VL 19
IS 3
BP 466
EP 467
PG 2
WC Hematology
SC Hematology
GA 132OM
UT WOS:000318078400068
ER
PT J
AU Gulur, P
Buonanno, FS
AF Gulur, Padma
Buonanno, Ferdinando S.
TI Intracranial Hypotension Caused by Anterior Cervical CSF Alleviated by
an Epidural Blood Patch
SO HEADACHE
LA English
DT Article
DE cerebrospinal fluid; epidural blood patch; headache
ID CEREBROSPINAL-FLUID LEAK
AB We present a case in which a thoracocervical epidural blood patch was used to treat an anteriorly situated cerebrospinal fluid leak following 2 failed blood patches in the lumbar region. The challenge in identifying the source of the leak, deteriorating health of the patient, and risks from the procedure, contributes to the uniqueness of this case.
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Gulur, P (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA.
NR 8
TC 3
Z9 3
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0017-8748
J9 HEADACHE
JI Headache
PD MAY
PY 2013
VL 53
IS 5
BP 838
EP 841
DI 10.1111/head.12051
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA 134VN
UT WOS:000318243800014
PM 23405991
ER
PT J
AU O'Neal, RL
Nam, KT
LaFleur, BJ
Barlow, B
Nozaki, K
Lee, HJ
Kim, WH
Yang, HK
Shi, CJ
Maitra, A
Montgomery, E
Washington, MK
El Rifai, W
Drapkin, RI
Goldenring, JR
AF O'Neal, Ryan L.
Nam, Ki Taek
LaFleur, Bonnie J.
Barlow, Brittney
Nozaki, Koji
Lee, Hyuk-Joon
Kim, Woo Ho
Yang, Han-Kwang
Shi, Chanjuan
Maitra, Anirban
Montgomery, Elizabeth
Washington, M. Kay
El Rifai, Wael
Drapkin, Ronny I.
Goldenring, James R.
TI Human epididymis protein 4 is up-regulated in gastric and pancreatic
adenocarcinomas
SO HUMAN PATHOLOGY
LA English
DT Article
DE WFDC2; HE4; Metaplasia; Adenocarcinoma
ID INTRAEPITHELIAL NEOPLASIA; PROGNOSTIC-SIGNIFICANCE; OVARIAN-CANCER;
CELLS; HE-4; CARCINOMAS; DRIVEN; MODEL
AB Upper gastrointestinal neoplasia in the esophagus, stomach, and pancreas is associated with the formation of preneoplastic metaplasias. We have previously reported the up-regulation of human epididymis protein 4 (HE4) in all metaplasias in the stomach of humans and mice. We have now sought to evaluate the expression of HE4 in metaplasias/preneoplastic precursors and cancers of the human stomach, pancreas, and esophagus. Tissue microarrays for gastric cancers, pancreatic cancers, and esophageal adenocarcinoma were stained with antibodies against HE4. Immunostaining was quantified by digital imaging, and the results were evaluated to assess the expression in metaplasias, the expression in cancer pathological subtypes, and the effects of expression on survival in patients with cancer. In patients with gastric cancer from Korea, HE4 was detected in 74% of intestinal and 90% of diffuse cancers, whereas in a gastric cancer cohort from Johns Hopkins, HE4 was detected in 74% of intestinal-type and 92% of diffuse cancers. Nevertheless, in both cohorts, there was no impact of HE4 expression on overall survival. In the esophagus, we observed the expression of HE4 in scattered endocrine cells within Barrett esophagus samples, but Barrett columnar metaplasias and HE4 were detected in only 2% of esophageal adenocarcinomas. Finally, in the pancreas, HE4 expression was not observed in pancreatic intraepithelial neoplasia lesions, but 46.8% of pancreatic adenocarcinomas expressed HE4. Still, we did not observe any influence of HE4 expression on survival. The results suggest that HE4 is up-regulated during gastric and pancreatic carcinogenesis. (C) 2013 Elsevier Inc. All rights reserved.
C1 [O'Neal, Ryan L.; Nam, Ki Taek; Goldenring, James R.] Vanderbilt Univ, Sch Med, Nashville VA Med Ctr, Nashville, TN 37232 USA.
[O'Neal, Ryan L.; Nam, Ki Taek; Barlow, Brittney; El Rifai, Wael; Goldenring, James R.] Vanderbilt Univ, Sch Med, Dept Surg, Nashville, TN 37232 USA.
[O'Neal, Ryan L.; Nam, Ki Taek; Barlow, Brittney; Goldenring, James R.] Vanderbilt Univ, Sch Med, Epithelia Biol Ctr, Nashville, TN 37232 USA.
[O'Neal, Ryan L.; Nam, Ki Taek; Barlow, Brittney; Goldenring, James R.] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA.
[LaFleur, Bonnie J.] Univ Arizona, Div Epidemiol & Biostat, Tucson, AZ 85724 USA.
[Nozaki, Koji] Univ Tokyo, Dept Gastrointestinal Surg, Tokyo, Japan.
[Lee, Hyuk-Joon; Yang, Han-Kwang] Seoul Natl Univ, Coll Med, Dept Surg, Seoul, South Korea.
[Kim, Woo Ho] Seoul Natl Univ, Coll Med, Dept Pathol, Seoul 151, South Korea.
[Shi, Chanjuan; Maitra, Anirban; Montgomery, Elizabeth] Johns Hopkins Univ, Inst Med, Sol Goldman Pancreat Canc Res Ctr, Dept Pathol, Baltimore, MD 21205 USA.
[Shi, Chanjuan; Washington, M. Kay] Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA.
[El Rifai, Wael] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA.
[Drapkin, Ronny I.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Ctr Mol Oncol Pathol, Boston, MA 02215 USA.
[Goldenring, James R.] Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA.
RP Goldenring, JR (reprint author), Vanderbilt Univ, Sch Med, Epithelia Biol Ctr, 10435-G MRB 4,2213 Garland Ave, Nashville, TN 37232 USA.
EM jim.goldenring@vanderbilt.edu
RI Drapkin, Ronny/E-9944-2016
OI Drapkin, Ronny/0000-0002-6912-6977
FU NIH [RO1 DK071590, U01 CA152990]; ARRA [RO1 DK071590-S1]; Department of
Veterans Affairs
FX These studies were supported by grants from NIH RO1 DK071590 (J.R.G.),
as well as ARRA Supplemental Funding from RO1 DK071590-S1, a Merit
Review Award from the Department of Veterans Affairs, and funding from
NIH U01 CA152990 (R.D.). This work was supported by core resources of
the Vanderbilt Digestive Disease Center (P30 DK058404), the Vanderbilt
SPORE in Gastrointestinal Cancer Tissue Core (P50 CA095103), the
Vanderbilt Epithelial Biology Center, and the Vanderbilt-Ingram Cancer
Center.
NR 21
TC 12
Z9 13
U1 0
U2 9
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0046-8177
J9 HUM PATHOL
JI Hum. Pathol.
PD MAY
PY 2013
VL 44
IS 5
BP 734
EP 742
DI 10.1016/j.humpath.2012.07.017
PG 9
WC Pathology
SC Pathology
GA 134HQ
UT WOS:000318201400007
PM 23084584
ER
PT J
AU Biscuola, M
Van de Vijver, K
Castilla, MA
Romero-Perez, L
Lopez-Garcia, MA
Diaz-Martin, J
Matias-Guiu, X
Oliva, E
Calvo, JP
AF Biscuola, Michele
Van de Vijver, Koen
Angeles Castilla, Maria
Romero-Perez, Laura
Angeles Lopez-Garcia, Maria
Diaz-Martin, Juan
Matias-Guiu, Xavier
Oliva, Esther
Palacios Calvo, Jose
TI Oncogene alterations in endometrial carcinosarcomas
SO HUMAN PATHOLOGY
LA English
DT Article
DE Endometrial carcinosarcomas; Oncogenes; Predictive markers
ID UTERINE SEROUS CARCINOMA; MOLECULAR ALTERATIONS; TISSUE MICROARRAYS;
TARGETED THERAPIES; C-KIT; EXPRESSION; MUTATIONS; EGFR; SARCOMAS; PIK3CA
AB Endometrial carcinosarcomas are aggressive neoplasias composed of high-grade carcinomatous and sarcomatous elements. The pathogenesis and specific genetic alterations underlying these tumors are still not well known. We analyzed alterations in oncogenes involved in the pathogenesis of endometrial carcinomas that might represent predictive markers for specific therapies. Immunohistochemistry for HER2 (tyrosine kinase-type cell surface receptor HER2) and c-KIT (tyrosine-protein kinase Kit) and fluorescence in situ hybridization for EGFR (epidermal growth factor receptor) and ALK (anaplastic lymphoma receptor tyrosine kinase) were carried out for 76 endometrial carcinosarcoma samples on sequential tissue microarray sections. Analysis of 238 mutations across 19 common oncogenes was performed on 34 samples using the Sequenom OncoCarta Panel (Sequenom, Hamburg, Germany). We observed EGFR, HER2, and c-KIT expression in 71%, 1.5%, and 2.7% of tumors, respectively. EGFR amplification was detected in 11 of 76 endometrial carcinosarcomas (14.5%). Four samples showed both amplification and aneuploidy (5.2%). ALK amplification together with chromosome 2 polysomy was found in 1.3% of endometrial carcinosarcomas. In total, 23 mutations in 9 different oncogenes were detected in 15 (44.1%) of 34 endometrial carcinosarcomas. Five endometrial carcinosarcomas (14.7%) had 2 or more mutations. Eleven tumors (32.3%) had mutations affecting the PI3K (phosphoinositide-3-kinase)/AKT (v-akt murine thymoma viral oncogene homolog 1) (6 mutations in PIK3CA (PI3K catalytic alpha polypeptide) and 1 in AKT) and/or RAS/BRAF (serine/threonine-protein kinase B-rat) pathway (3 KRAS [kirsten RAS oncogene homolog], 2 NRAS [neuroblastoma RAS viral oncogene homolog], and 1 BRAF). Mutations in PDGFRA (platelet-derived growth factor receptor, alpha polypeptide) and/or KIT were found in 5 endometrial carcinosarcomas (14.7%). Finally, we found mutations in MET (met proto-oncogene [hepatocyte growth factor receptor]) in 2 tumors (5.9%) and in EGFR in one (2.9%). Our study evidences mutations in oncogenes in endometrial carcinosarcomas that are targets or modulators of response to specific therapies in other human cancers, with PI3IC/AKT being the most frequently altered pathway. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Biscuola, Michele; Angeles Castilla, Maria; Romero-Perez, Laura; Angeles Lopez-Garcia, Maria; Diaz-Martin, Juan; Palacios Calvo, Jose] Univ Seville, Hosp Univ Virgen del Rocio, CSIC, Dept Pathol,Inst Biomed Sevilla IBiS, Seville 41013, Spain.
[Van de Vijver, Koen; Oliva, Esther] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Matias-Guiu, Xavier] Univ Lleida, Dept Pathol & Mol Genet, Hosp Univ Arnau de Vilanova, IRBLLEIDA, Lleida 25198, Spain.
[Palacios Calvo, Jose] Hosp Univ Ramon Y Cajal, Dept Pathol, Madrid 28031, Spain.
RP Calvo, JP (reprint author), Hosp Univ Ramon Y Cajal, Dept Pathol, Madrid 28031, Spain.
EM eoliva@partners.org; jose.palacios@salud.madrid.org
RI Romero-Perez, Laura/C-8314-2015; Castilla, M Angeles/C-9454-2015;
Diaz-Martin, Juan/F-4765-2015; IBIS, SARCOMAS/O-1893-2015; matias-guiu,
xavier/C-3039-2009
OI Romero-Perez, Laura/0000-0003-3196-4382; matias-guiu,
xavier/0000-0002-7201-6605
FU Instituto de Salud Carlos III (ISCIII) [PI07/90324, PI080971]; Junta de
Andalucia (Consejeria de Salud) [PI-0384/2007, PI0581/2009]; Consejeria
de Innovacion (Proyecto de Excelencia) [P07-CVI-03100]; ISCIII-Red de
Biobancos [RD09/0076/00085]; ISCIII [RD06/0020/0013]; Consejeria de
Salud, Junta de Andalucia [PI0581/2009]; PFIS fellowship [F109/00193];
[FISPI10/00922]; [2009SGR794]; [RD06/0020/134]
FX This work was supported by grants from the Instituto de Salud Carlos III
(ISCIII; grant nos. PI07/90324 and PI080971); the Junta de Andalucia
(Consejeria de Salud, grant no. PI-0384/2007, PI0581/2009) and the
Consejeria de Innovacion (Proyecto de Excelencia, grant no.
P07-CVI-03100) to J. P.; grants FISPI10/00922, 2009SGR794, and
RD06/0020/134 to X. M. G.; M. B. is a researcher funded by the
ISCIII-Red de Biobancos RD09/0076/00085. M. A. C. and J. D. are PhD
researchers funded by the ISCIII (grant no. RD06/0020/0013) and the
Consejeria de Salud, Junta de Andalucia (PI0581/2009), respectively. L.
R. P. is a PhD student recipient of a PFIS fellowship (grant no.
F109/00193).
NR 35
TC 3
Z9 4
U1 0
U2 14
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0046-8177
J9 HUM PATHOL
JI Hum. Pathol.
PD MAY
PY 2013
VL 44
IS 5
BP 852
EP 859
DI 10.1016/j.humpath.2012.07.027
PG 8
WC Pathology
SC Pathology
GA 134HQ
UT WOS:000318201400021
PM 23199529
ER
PT J
AU Oliva, E
Pinheiro, NF
Heney, NM
Kaufman, DS
Shipley, WU
Gurski, C
Spicer, B
Paner, GP
Gown, AM
Amin, MB
AF Oliva, Esther
Pinheiro, Nathanael F.
Heney, Niall M.
Kaufman, Donald S.
Shipley, William U.
Gurski, Carol
Spicer, Beverly
Paner, Gladell P.
Gown, Allen M.
Amin, Mahul B.
TI Immunohistochemistry as an adjunct in the differential diagnosis of
radiation-induced atypia versus urothelial carcinoma in situ of the
bladder: a study of 45 cases
SO HUMAN PATHOLOGY
LA English
DT Article
DE Urothelial carcinoma in situ; Radiation changes; CK20; p53; CD44s;
Differential diagnosis
ID URINARY-BLADDER; SELECTIVE BLADDER; NONNEOPLASTIC UROTHELIUM; PROTEIN
EXPRESSION; P53 PROTEIN; CYTOKERATIN-20; CANCER; GRADE; KI-67;
IMMUNOREACTIVITY
AB Muscle invasive urothelial carcinoma has been treated with cystectomy adjuvant therapy. Recently, a bladder-sparing protocol has been offered to selected patients closely followed with surveillance biopsies. In this setting, radiation-induced changes (RAD-Ch) may be very difficult to distinguish from carcinoma in situ, and failing to recognize them may lead to overtreatment. We ascertained the role of immunohistochemistry using cytokeratin (CK) 20, p53, and CD44s in bladder biopsies from 28 patients with a history of bladder radiation and 17 with carcinoma in situ without radiation. Negative or weak multifocal nuclear p53 staining was seen in 24 of 28 RAD-Ch cases, whereas strong and diffuse nuclear p53 staining was found in 8 of 17 carcinoma in situ cases and moderate and focal to multifocal in 3. CK20 showed strong cytoplasmic staining of only umbrella cells in 22 of 28 RAD-Ch cases. In contrast, 11 of 17 carcinomas in situ showed diffuse and strong CK20 positivity and 5 moderate and focal to multifocal positivity. All carcinomas in situ with weak or no p53 showed significant CK20 staining except 1. CD44s displayed diffuse membranous positivity in 7 of 17 RAD-Ch cases and up to mid-third in 8. Only 1 of 17 carcinomas in situ had diffuse membranous CD44s staining. Diffuse and significant CK20 expression was seen in most carcinomas in situ. Strong and diffuse p53 expression was only seen in carcinoma in situ (similar to 50%), whereas diffuse CD44s staining was typically only seen in RAD-Ch. Our data suggest that a CK20(-) p53(-) CD44a panel proves to be very helpful (CK20 more reliable than p53 or CD44s) in the diagnosis of RAD-Ch. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Oliva, Esther; Pinheiro, Nathanael F.; Heney, Niall M.; Kaufman, Donald S.; Shipley, William U.; Gurski, Carol; Spicer, Beverly] Massachusetts Gen Hosp, Boston, MA 02118 USA.
[Paner, Gladell P.; Amin, Mahul B.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
[Gown, Allen M.] PhenoPath Labs, Seattle, WA USA.
RP Oliva, E (reprint author), Massachusetts Gen Hosp, Pathol Dept Warren 2, 55 Fruit St, Boston, MA 02118 USA.
EM eoliva@partners.org
NR 36
TC 3
Z9 3
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0046-8177
J9 HUM PATHOL
JI Hum. Pathol.
PD MAY
PY 2013
VL 44
IS 5
BP 860
EP 866
DI 10.1016/j.humpath.2012.08.011
PG 7
WC Pathology
SC Pathology
GA 134HQ
UT WOS:000318201400022
PM 23199526
ER
PT J
AU Merritt, MA
De Pari, M
Vitonis, AF
Titus, LJ
Cramer, DW
Terry, KL
AF Merritt, M. A.
De Pari, M.
Vitonis, A. F.
Titus, L. J.
Cramer, D. W.
Terry, K. L.
TI Reproductive characteristics in relation to ovarian cancer risk by
histologic pathways
SO HUMAN REPRODUCTION
LA English
DT Article
DE ovarian cancer; histology; reproduction; risk factors; type I; II
ID CLEAR-CELL CARCINOMA; SEROUS CARCINOMA; INCESSANT OVULATION;
FALLOPIAN-TUBE; EPIDEMIOLOGIC EVIDENCE; GENE-MUTATIONS; UNITED-STATES;
MATERNAL RISK; ENDOMETRIOSIS; ARID1A
AB Do reproductive risk factor associations differ across subgroups of invasive epithelial ovarian cancer (EOC) defined by the dualistic model (type I/II) or a histologic pathway-based classification?
Associations with parity, history of endometriosis, tubal ligation and hysterectomy were found to differ in the context of the type I/II and the histologic pathways classification of ovarian cancer.
Shared molecular alterations and candidate precursor lesions suggest that tumor histology and grade may be used to classify ovarian tumors into likely etiologic pathways.
This casecontrol study included 1571 women diagnosed with invasive EOC and 2100 population-based controls that were enrolled from 1992 to 2008. Reproductive risk factors as well as other putative risk factors for ovarian cancer were assessed through in-person interviews.
Eligible cases were diagnosed with incident ovarian cancer, were aged 18 and above and resided in eastern Massachusetts or New Hampshire, USA. Controls were identified through random digit dialing, drivers license and town resident lists and were frequency matched with the cases based on age and study center.
We used polytomous logistic regression to estimate odds ratios (ORs) and 95 confidence intervals (CIs) for type I/II EOC or using a pathway-based grouping of histologic subtypes. In multivariate analyses, we observed that having a history of endometriosis (OR 1.92, 95 CI: 1.362.71) increased the risk for a type I tumor. Factors that were strongly inversely associated with risk for a type I tumor included parity (3 versus 0 children, OR 0.15, 95 CI: 0.110.21), having a previous tubal ligation (OR 0.40, 95 CI: 0.260.60) and more weakly hysterectomy (OR 0.71, 95 CI: 0.451.13). In analyses of histologic pathways, parity (3 versus 0 children, OR 0.13, 95 CI: 0.100.18) and having a previous tubal ligation (OR 0.41, 95 CI: 0.280.60) or hysterectomy (OR 0.54, 95 CI: 0.340.86) were inversely associated with risk of endometrioid/clear cell tumors. Having a history of endometriosis strongly increased the risk for endometrioid/clear cell tumors (OR 2.41, 95 CI: 1.783.26). We did not observe significant differences in the risk associations across these tumor classifications for age at menarche, menstrual cycle length or infertility.
A potential limitation of this study is that dividing the cases into subgroups may limit the power of these analyses, particularly for the less common tumor types. Since cases were enrolled after their diagnosis, it is possible that the most aggressive cases were not included in the study.
This study provides insights about the role of reproductive factors in relation to risk of pathway-based subgroups of ovarian cancer that with further confirmation may assist with the development of improved strategies for the prevention of these different tumor types.
This research is funded by grants from the National Cancer Institute, the Department of Defense Ovarian Cancer Research Program and the Ovarian Cancer Research Fund. The authors have no competing interests to declare.
Not applicable.
C1 [Merritt, M. A.; Cramer, D. W.; Terry, K. L.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Merritt, M. A.; De Pari, M.; Vitonis, A. F.; Cramer, D. W.; Terry, K. L.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Obstet & Gynecol,OB GYN Epidemiol Ctr, Boston, MA 02115 USA.
[Merritt, M. A.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Titus, L. J.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Community & Family Med, Hanover, NH 03756 USA.
RP Merritt, MA (reprint author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
EM merritt@jimmy.harvard.edu
FU National Cancer Institute; NIH [R01CA54419, P50CA105009, R25CA098566];
Department of Defense [W81XWH-10-1-0280]; Ovarian Cancer Research Fund
Liz Tilberis Scholar Award; Department of Defense Ovarian Cancer
Research Program; Ovarian Cancer Research Fund
FX This research was funded by the National Cancer Institute, NIH grants
R01CA54419, P50CA105009 and R25CA098566, the Department of Defense grant
W81XWH-10-1-0280 and the Ovarian Cancer Research Fund Liz Tilberis
Scholar Award.; This research is funded by grants from the National
Cancer Institute, the Department of Defense Ovarian Cancer Research
Program and the Ovarian Cancer Research Fund. The authors have no
competing interests to declare.
NR 59
TC 27
Z9 27
U1 0
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0268-1161
J9 HUM REPROD
JI Hum. Reprod.
PD MAY
PY 2013
VL 28
IS 5
BP 1406
EP 1417
DI 10.1093/humrep/des466
PG 12
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 133AD
UT WOS:000318108900029
PM 23315066
ER
PT J
AU Havulinna, AS
Kettunen, J
Ukkola, O
Osmond, C
Eriksson, JG
Kesaniemi, YA
Jula, A
Peltonen, L
Kontula, K
Salomaa, V
Newton-Cheh, C
AF Havulinna, Aki S.
Kettunen, Johannes
Ukkola, Olavi
Osmond, Clive
Eriksson, Johan G.
Kesaniemi, Y. Antero
Jula, Antti
Peltonen, Leena
Kontula, Kimmo
Salomaa, Veikko
Newton-Cheh, Christopher
TI A Blood Pressure Genetic Risk Score Is a Significant Predictor of
Incident Cardiovascular Events in 32 669 Individuals
SO HYPERTENSION
LA English
DT Article
DE blood pressure; cardiovascular disease; genetic risk score; genetics;
hypertension; prospective cohort study
ID GENOME-WIDE ASSOCIATION; CORONARY-HEART-DISEASE; HOSPITAL DISCHARGE
REGISTER; HYPERTENSION; VARIANTS; STROKE; METAANALYSIS; LOCI
AB Recent genome-wide association studies have identified genetic variants associated with blood pressure (BP). We investigated whether genetic risk scores (GRSs) constructed of these variants would predict incident cardiovascular disease (CVD) events. We genotyped 32 common single nucleotide polymorphisms in several Finnish cohorts, with up to 32 669 individuals after exclusion of prevalent CVD cases. The median follow-up was 9.8 years, during which 2295 incident CVD events occurred. We created GRSs separately for systolic BP and diastolic BP by multiplying the risk allele count of each single nucleotide polymorphism by the effect size estimated in published genome-wide association studies. We performed Cox regression analyses with and without adjustment for clinical factors, including BP at baseline in each cohort. The results were combined by inverse variance-weighted fixed-effects meta-analysis. The GRSs were strongly associated with systolic BP and diastolic BP, and baseline hypertension (all P<10(-62)). Hazard ratios comparing the highest quintiles of systolic BP and diastolic BP GRSs with the lowest quintiles after adjustment for age, age squared, and sex were 1.25 (1.07-1.46; P=0.006) and 1.23 (1.05-1.43; P=0.01), respectively, for incident coronary heart disease; 1.24 (1.01-1.53; P=0.04) and 1.35 (1.09-1.66; P=0.005), respectively, for incident stroke; and 1.23 (1.08-1.40; P=2x10(-6)) and 1.26 (1.11-1.44; P=5x10(-4)), respectively, for composite CVD. In conclusion, BP findings from genome-wide association studies are strongly replicated. GRSs comprising bona fide BP-single nucleotide polymorphisms predicted CVD risk, consistent with a lifelong effect on BP of these variants collectively. (Hypertension. 2013; 61: 987-994.) circle Online Data Supplement
C1 [Havulinna, Aki S.; Kettunen, Johannes; Eriksson, Johan G.; Jula, Antti; Salomaa, Veikko] Natl Inst Hlth & Welf, Dept Chron Dis Prevent, Helsinki, Finland.
[Peltonen, Leena] Wellcome Trust Sanger Inst, Cambridge, England.
[Kettunen, Johannes; Peltonen, Leena] Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki, Finland.
[Eriksson, Johan G.] Univ Helsinki, Cent Hosp, Unit Gen Practice, Helsinki, Finland.
[Eriksson, Johan G.] Univ Helsinki, Dept Gen Practice & Primary Hlth Care, Helsinki, Finland.
[Eriksson, Johan G.] Folkhalsan Res Ctr, Helsinki, Finland.
[Ukkola, Olavi; Kesaniemi, Y. Antero] Univ Oulu, Dept Med, Inst Clin Med, Oulu, Finland.
[Ukkola, Olavi; Kesaniemi, Y. Antero] Oulu Univ Hosp, Clin Res Ctr, Oulu, Finland.
[Osmond, Clive] Univ Southampton, Southampton Gen Hosp, MRC Lifecourse Epidemiol Unit, Southampton, Hants, England.
[Kontula, Kimmo] Univ Helsinki, Dept Med, Helsinki, Finland.
RP Newton-Cheh, C (reprint author), Massachusetts Gen Hosp, Ctr Human Genet Res, Cardiovasc Res Ctr, 185 Cambridge St,CPZN 5-242, Boston, MA 02114 USA.
EM veikko.salomaa@thl.fi; cnewtoncheh@chgr.mgh.harvard.edu
OI Eriksson, Johan/0000-0002-2516-2060
FU National Institute for Health and Welfare; Academy of Finland [129 494,
139 635, 129 255, 126 775, 135 072]; National Institute for Health and
Welfare (THL); Finnish Center for Pensions (ETK); Social Insurance
Institution of Finland (KELA); Local Government Pensions Institution
(KEVA); Finnish Foundation for Cardiovascular Research; Finnish Diabetes
Research Society; Folkhalsan Research Foundation; Novo Nordisk
Foundation; Finska Lakaresallskapet; Signe and Ane Gyllenberg
Foundation; Ahokas Foundation; Juho Vainio Foundation; Sigrid Juselius
Foundation; Burroughs Wellcome Fund; National Institutes of Health
[HL098283]
FX FINRISK was mainly funded by the National Institute for Health and
Welfare. Additional support was obtained from the Academy of Finland
(grant numbers 129 494 and 139 635) to Dr Salomaa. The Health 2000 Study
is funded by the National Institute for Health and Welfare (THL), the
Finnish Center for Pensions (ETK), The Social Insurance Institution of
Finland (KELA), The Local Government Pensions Institution (KEVA), and
other organizations listed on the website of the survey
(http://www.terveys2000.fi). The OPERA study was supported by the
Finnish Foundation for Cardiovascular Research. The Helsinki Birth
Cohort Study has been supported by grants to Dr Eriksson from the
Academy of Finland (Grant numbers 129 255, 126 775, 135 072), the
Finnish Diabetes Research Society, Folkhalsan Research Foundation, Novo
Nordisk Foundation, Finska Lakaresallskapet, Signe and Ane Gyllenberg
Foundation, Ahokas Foundation, and Juho Vainio Foundation. Dr Kontula
was supported by the Sigrid Juselius Foundation and the Finnish
Foundation for Cardiovascular Research. Dr Newton-Cheh and the SNP
genotyping were supported by the Burroughs Wellcome Fund and the
National Institutes of Health (HL098283).
NR 26
TC 24
Z9 25
U1 1
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0194-911X
J9 HYPERTENSION
JI Hypertension
PD MAY
PY 2013
VL 61
IS 5
BP 987
EP +
DI 10.1161/HYPERTENSIONAHA.111.00649
PG 21
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 127SG
UT WOS:000317718200024
PM 23509078
ER
PT J
AU Lieb, W
Jansen, H
Loley, C
Pencina, MJ
Nelson, CP
Newton-Cheh, C
Kathiresan, S
Reilly, MP
Assimes, TL
Boerwinkle, E
Hall, AS
Hengstenberg, C
Laaksonen, R
McPherson, R
Thorsteinsdottir, U
Ziegler, A
Peters, A
Thompson, JR
Konig, IR
Erdmann, J
Samani, NJ
Vasan, RS
Schunkert, H
AF Lieb, Wolfgang
Jansen, Henning
Loley, Christina
Pencina, Michael J.
Nelson, Christopher P.
Newton-Cheh, Christopher
Kathiresan, Sekar
Reilly, Muredach P.
Assimes, Themistocles L.
Boerwinkle, Eric
Hall, Alistair S.
Hengstenberg, Christian
Laaksonen, Reijo
McPherson, Ruth
Thorsteinsdottir, Unnur
Ziegler, Andreas
Peters, Annette
Thompson, John R.
Koenig, Inke R.
Erdmann, Jeanette
Samani, Nilesh J.
Vasan, Ramachandran S.
Schunkert, Heribert
CA CARDIoGRAM
TI Genetic Predisposition to Higher Blood Pressure Increases Coronary
Artery Disease Risk
SO HYPERTENSION
LA English
DT Article
DE blood pressure; coronary artery disease; genetics; polymorphism
ID GENOME-WIDE ASSOCIATION; REGRESSION DILUTION; HEART-DISEASE; FOLLOW-UP;
HYPERTENSION; METAANALYSIS; LOCI; PHENOTYPES; DESIGN; TRIALS
AB Hypertension is a risk factor for coronary artery disease. Recent genome-wide association studies have identified 30 genetic variants associated with higher blood pressure at genome-wide significance (P<5x10(-8)). If elevated blood pressure is a causative factor for coronary artery disease, these variants should also increase coronary artery disease risk. Analyzing genome-wide association data from 22 233 coronary artery disease cases and 64 762 controls, we observed in the Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) consortium that 88% of these blood pressure-associated polymorphisms were likewise positively associated with coronary artery disease, that is, they had an odds ratio >1 for coronary artery disease, a proportion much higher than expected by chance (P=4x10(-5)). The average relative coronary artery disease risk increase per each of the multiple blood pressure-raising alleles observed in the consortium was 3.0% for systolic blood pressure-associated polymorphisms (95% confidence interval, 1.8%-4.3%) and 2.9% for diastolic blood pressure-associated polymorphisms (95% confidence interval, 1.7%-4.1%). In substudies, individuals carrying most systolic blood pressure-and diastolic blood pressure-related risk alleles (top quintile of a genetic risk score distribution) had 70% (95% confidence interval, 50%-94%) and 59% (95% confidence interval, 40%-81%) higher odds of having coronary artery disease, respectively, as compared with individuals in the bottom quintile. In conclusion, most blood pressure-associated polymorphisms also confer an increased risk for coronary artery disease. These findings are consistent with a causal relationship of increasing blood pressure to coronary artery disease. Genetic variants primarily affecting blood pressure contribute to the genetic basis of coronary artery disease. (Hypertension. 2013; 61: 995-1001.) circle Online Data Supplement
C1 [Lieb, Wolfgang] Univ Clin Schleswig Holstein, Inst Epidemiol, Campus Kiel, Germany.
[Jansen, Henning; Hengstenberg, Christian; Schunkert, Heribert] Deutsch Herzzentrum Munich, D-80636 Munich, Germany.
[Jansen, Henning; Hengstenberg, Christian; Schunkert, Heribert] Munich Heart Alliance, DZHK German Ctr Cardiovasc Res, Munich, Germany.
[Loley, Christina; Ziegler, Andreas; Koenig, Inke R.] Med Univ Lubeck, Inst Med Biometrie & Stat, D-23538 Lubeck, Germany.
[Loley, Christina; Erdmann, Jeanette] Med Univ Lubeck, Inst Integrat & Expt Genom, D-23538 Lubeck, Germany.
[Ziegler, Andreas; Erdmann, Jeanette] DZHK German Ctr Cardiovasc Res, Lubeck, Germany.
[Pencina, Michael J.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Vasan, Ramachandran S.] Boston Univ, Sch Med, Prevent Med & Epidemiol Sect, Boston, MA 02118 USA.
[Nelson, Christopher P.; Samani, Nilesh J.] Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England.
[Nelson, Christopher P.; Samani, Nilesh J.] Glenfield Gen Hosp, Leicester Natl Inst Hlth Res, Biomed Res Unit Cardiovasc Dis, Leicester LE3 9QP, Leics, England.
[Newton-Cheh, Christopher; Kathiresan, Sekar] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.
[Newton-Cheh, Christopher; Kathiresan, Sekar] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Newton-Cheh, Christopher; Kathiresan, Sekar] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Newton-Cheh, Christopher; Kathiresan, Sekar] Broad Inst Harvard & Massachusetts Inst Technol M, Program Med & Populat Genet, Cambridge, MA USA.
[Reilly, Muredach P.] Univ Penn, Cardiovasc Inst, Philadelphia, PA 19104 USA.
[Assimes, Themistocles L.] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA.
[Boerwinkle, Eric] Univ Texas Hlth Sci Ctr, Ctr Human Genet, Houston, TX USA.
[Boerwinkle, Eric] Inst Mol Med, Houston, TX USA.
[Hall, Alistair S.] Univ Leeds, Leeds Inst Genet Hlth & Therapeut, Div Epidemiol, Multidisciplinary Cardiovasc Res Ctr, Leeds LS2 9JT, W Yorkshire, England.
[Laaksonen, Reijo] Tampere Univ Hosp, Ctr Sci, Tampere, Finland.
[McPherson, Ruth] Univ Ottawa, Inst Heart, John & Jennifer Ruddy Canadian Cardiovasc Genet C, Ottawa, ON, Canada.
[Thorsteinsdottir, Unnur] DeCODE Genet, Reykjavik, Iceland.
[Thorsteinsdottir, Unnur] Univ Iceland, Fac Med, Reykjavik, Iceland.
[Thompson, John R.] Univ Leicester, Dept Hlth Sci, Leicester, Leics, England.
[Peters, Annette] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Inst Epidemiol 2, Neuherberg, Germany.
[Peters, Annette] Munich Heart Alliance, Munich, Germany.
[Ziegler, Andreas] Zentrum Klin Studien, Lubeck, Germany.
RP Schunkert, H (reprint author), Deutsch Herzzentrum Munich, Lazarettstr 36, D-80636 Munich, Germany.
EM schunkert@dhm.mhn.de
RI Erdmann, Jeanette/P-7513-2014; Altshuler, David/A-4476-2009; Schreiber,
Stefan/B-6748-2008; Laaksonen, Reijo/D-6323-2014; Willenborg,
Christina/D-2668-2012; Boehm, Bernhard/F-8750-2015; Gudnason,
Vilmundur/K-6885-2015; Meitinger, Thomas/O-1318-2015; Peters,
Annette/A-6117-2011; Konig, Inke/A-4544-2009; Lieb, Wolfgang/C-1990-2012
OI Erdmann, Jeanette/0000-0002-4486-6231; Ziegler,
Andreas/0000-0002-8386-5397; Kleber, Marcus/0000-0003-0663-7275;
Altshuler, David/0000-0002-7250-4107; Ramachandran,
Vasan/0000-0001-7357-5970; Schreiber, Stefan/0000-0003-2254-7771;
Willenborg, Christina/0000-0001-5217-6882; Gudnason,
Vilmundur/0000-0001-5696-0084;
FU EU [LSHM-CT-2006-037593]; ENGAGE; BMBF [FKZ: 01GS0831, NO1-HC-25195];
BMBF; DZHK (German Center for Cardiovascular Research); BMBF (German
Ministry of Education and Research)
FX This work was supported by the EU-funded Integrated Projects
Cardiogenics (LSHM-CT-2006-037593) and ENGAGE as well as the BMBF-funded
German National Genome Network (NGFN-Plus) Project Atherogenomics (FKZ:
01GS0831). W. Lieb has in part been supported by the BMBF-funded
(federal ministry for education and research) project GANI_MED. There
was support also by the DZHK (German Center for Cardiovascular Research)
and by the BMBF (German Ministry of Education and Research and by the
Framingham core contract NO1-HC-25195. Information regarding the
CARDIoGRAM members, acknowledgments, funding sources, and disclosures
are detailed in the in the online-only Data Supplement.
NR 29
TC 31
Z9 31
U1 1
U2 18
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0194-911X
J9 HYPERTENSION
JI Hypertension
PD MAY
PY 2013
VL 61
IS 5
BP 995
EP +
DI 10.1161/HYPERTENSIONAHA.111.00275
PG 14
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 127SG
UT WOS:000317718200025
PM 23478099
ER
PT J
AU Raman, SB
Nguyen, MH
Cheng, SJ
Badrane, H
Iczkowski, KA
Wegener, M
Gaffen, SL
Mitchell, AP
Clancy, CJ
AF Raman, Suresh B.
Nguyen, M. Hong
Cheng, Shaoji
Badrane, Hassan
Iczkowski, Kenneth A.
Wegener, Marilyn
Gaffen, Sarah L.
Mitchell, Aaron P.
Clancy, Cornelius J.
TI A Competitive Infection Model of Hematogenously Disseminated Candidiasis
in Mice Redefines the Role of Candida albicans IRS4 in Pathogenesis
SO INFECTION AND IMMUNITY
LA English
DT Article
ID MIXED INFECTIONS; HYPHAL FORMATION; ALBICANS; VIRULENCE; CASPOFUNGIN;
BLOOD; HOMEOSTASIS; EXPRESSION; RESISTANCE; MUTATIONS
AB Candida albicans IRS4 encodes a protein that regulates phosphatidylinositol-(4,5)-bisphosphate, which was shown to contribute to hematogenously disseminated candidiasis (DC) after several days in the standard mouse model. Our objective was to more accurately define the temporal contributions of IRS4 to pathogenesis. During competition assays in vitro, an irs4-null (Delta irs4) mutant exhibited wild-type fitness. In DC experiments, mice were infected intravenously with the Delta irs4 mutant, strain CAI-12 (1 x 10(5) CFU), or a mixture of the strains (0.5 x 10(5) CFU each). In single-strain infections, quantitative PCR revealed reduced Delta irs4 mutant burdens within kidneys at days 1, 4, and 7 but not 6 h. In competitive infections, the Delta irs4 mutant was outcompeted by CAI-12 in each mouse at >= 6 h (competitive indices, P <= 0.0001). At 4 and 7 days, the Delta irs4 mutant burdens during competitive infections were significantly lower than those during single-strain infections (P = 0.01 and P < 0.001, respectively), suggesting increased susceptibility to inflammatory responses. Phagocytic infiltration of kidneys in response to CAI-12 or competitive infections was significantly greater than that in response to Delta irs4 mutant infection at days 1 and 4 (P < 0.001), and the Delta irs4 mutant was more susceptible to phagocytosis and killing by human polymorphonuclear cells (P = 0.01 and P = 0.006, respectively) and mouse macrophages in vitro (P = 0.04 and P = 0.01, respectively). Therefore, IRS4 contributes to tissue invasion at early stages of DC and mediates resistance to phagocytosis as DC progresses. Microarray analysis revealed remarkably similar gene expression by the Delta irs4 mutant and reference strain CAI-12 within blood, suggesting that IRS4 is not significantly involved in the hematogenous stage of disease. A competitive DC model detects attenuated virulence that is not evident with the standard model.
C1 [Raman, Suresh B.; Nguyen, M. Hong; Cheng, Shaoji; Badrane, Hassan; Gaffen, Sarah L.; Clancy, Cornelius J.] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA.
[Wegener, Marilyn; Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Iczkowski, Kenneth A.] Univ Colorado, Dept Pathol, Denver, CO 80202 USA.
[Mitchell, Aaron P.] Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA.
RP Clancy, CJ (reprint author), Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA.
EM cjc76@pitt.edu
OI Mitchell, Aaron/0000-0002-0868-4000
FU NIDCR NIH HHS [R01 DE022550]
NR 31
TC 4
Z9 5
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD MAY
PY 2013
VL 81
IS 5
BP 1430
EP 1438
DI 10.1128/IAI.00743-12
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 126AE
UT WOS:000317582700006
PM 23429534
ER
PT J
AU Han, XZ
Lin, XP
Yu, XQ
Lin, J
Kawai, T
LaRosa, KB
Taubman, MA
AF Han, Xiaozhe
Lin, Xiaoping
Yu, Xiaoqian
Lin, Jiang
Kawai, Toshihisa
LaRosa, Karen B.
Taubman, Martin A.
TI Porphyromonas gingivalis Infection-Associated Periodontal Bone
Resorption Is Dependent on Receptor Activator of NF-kappa B Ligand
SO INFECTION AND IMMUNITY
LA English
DT Article
ID T-CELLS; OSTEOPROTEGERIN LIGAND; IMMUNE-SYSTEM; OSTEOCLAST
DIFFERENTIATION; LYMPHOCYTE DEVELOPMENT; RHEUMATOID-ARTHRITIS;
POSTMENOPAUSAL WOMEN; DISEASE; OSTEOIMMUNOLOGY; INDUCTION
AB Porphyromonas gingivalis is one of the oral microorganisms associated with human chronic periodontitis. The purpose of this study is to determine the role of the receptor activator of nuclear factor-kappa B ligand (RANKL) in P. gingivalis infection-associated periodontal bone resorption. Inbred female Rowett rats were infected orally on four consecutive days (days 0 to 3) with 1 x 10(9) P. gingivalis bacteria (strain ATCC 33277). Separate groups of rats also received an injection of anti-RANKL antibody, osteoprotegerin fusion protein (OPG-Fc), or a control fusion protein (L6-Fc) into gingival papillae in addition to P. gingivalis infection. Robust serum IgG and salivary IgA antibody (P<0.01) and T cell proliferation (P<0.05) responses to P. gingivalis were detected at day 7 and peaked at day 28 in P. gingivalis-infected rats. Both the concentration of soluble RANKL (sRANKL) in rat gingival tissues (P<0.01) and periodontal bone resorption (P<0.05) were significantly elevated at day 28 in the P. gingivalis-infected group compared to levels in the uninfected group. Correspondingly, RANKL-expressing T and B cells in rat gingival tissues were significantly increased at day 28 in the P. gingivalis-infected group compared to the levels in the uninfected group (P<0.01). Injection of anti-RANKL antibody (P<0.05) or OPG-Fc (P<0.01), but not L6-Fc, into rat gingival papillae after P. gingivalis infection resulted in significantly reduced periodontal bone resorption. This study suggests that P. gingivalis infection-associated periodontal bone resorption is RANKL dependent and is accompanied by increased local infiltration of RANKL-expressing T and B cells.
C1 [Han, Xiaozhe; Lin, Xiaoping; Yu, Xiaoqian; Lin, Jiang; Kawai, Toshihisa; LaRosa, Karen B.; Taubman, Martin A.] Forsyth Inst, Dept Immunol & Infect Dis, Cambridge, MA USA.
[Lin, Xiaoping] China Med Univ, Shengjing Hosp, Dept Stomatol, Shenyang, Liaoning Provin, Peoples R China.
[Yu, Xiaoqian] Peking Univ, Dept Periodontol, Sch Stomatol, Beijing 100871, Peoples R China.
[Yu, Xiaoqian] Hosp Stomatol, Beijing, Peoples R China.
[Lin, Jiang] Harbin Med Univ, Coll 4, Dept Stomatol, Harbin, Peoples R China.
RP Han, XZ (reprint author), Forsyth Inst, Dept Immunol & Infect Dis, Cambridge, MA USA.
EM xhan@forsyth.org
FU NIH from the National Institute of Dental and Craniofacial Research
[DE-03420, DE-07327]
FX This work was supported by NIH grants DE-03420 and DE-07327 from the
National Institute of Dental and Craniofacial Research.
NR 35
TC 20
Z9 22
U1 0
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD MAY
PY 2013
VL 81
IS 5
BP 1502
EP 1509
DI 10.1128/IAI.00043-13
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 126AE
UT WOS:000317582700013
PM 23439308
ER
PT J
AU Liu, ZF
Ren, C
Jones, W
Chen, P
Seminara, SB
Chan, YM
Smith, NF
Covey, JM
Wang, J
Chan, KK
AF Liu, Zhongfa
Ren, Chen
Jones, William
Chen, Ping
Seminara, Stephanie B.
Chan, Yee-Ming
Smith, Nicola F.
Covey, Joseph M.
Wang, Jeffrey
Chan, Kenneth K.
TI LC-MS/MS quantification of a neuropeptide fragment kisspeptin-10 (NSC
741805) and characterization of its decomposition product and
pharmacokinetics in rats
SO JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL
AND LIFE SCIENCES
LA English
DT Article
DE Kisspeptin-10; LC-MS/MS; Pharmacokinetics; Metabolites
ID METASTASIS-SUPPRESSOR GENE; PROTEIN-COUPLED RECEPTOR; PITUITARY-GONADAL
AXIS; HORMONE-RELEASE; KISS-1 PEPTIDE; GPR54; ACTIVATION; HUMANS; LIGAND
AB The kisspeptins are critical regulators of mammalian reproduction. Kisspeptin-10 ((45)YNWNSFGLRF-NH254, kisspeptin-112-121 or metastin 45-54, NSC 741805), an active fragment of kisspeptin, has been shown to be a potent stimulator of gonadotropin-releasing hormone and secretion of luteinizing hormone in both rodents and primates. This shorter peptide fragment may have clinical utility potential and it is important to characterize its pharmacokinetic property. Recently, the pharmacokinetics of both kisspeptin-54 and kisspeptin-10 were characterized in humans using a radioimmunoassay (RIA), which measures only the immunoreactive kisspeptin (kisspeptin-IR). In this study, a highly sensitive and specific LC-MS/MS assay was developed to quantify kisspeptin-10 levels in rat plasma. The lower limit of quantitation (LLOQ) was 0.5 ng/mL, the within-day and between-day coefficient of variations (CVs) ranged from 5.2 to 15.4% and 1.3 to 14.2%, and the accuracy values ranged from 98 to 114% and 99 to 105%, respectively. With this method, stability studies demonstrated that kisspeptin-10 degraded rapidly with decomposition half-lives of 6.8 min, 2.9 min and 1.7 min at 4 degrees C, 25 degrees C, and 37 degrees C, respectively. The principal decomposition product was characterized as the N-terminal tyrosine deleted kisspeptin-10 (46)NWDSFGLRF-NH254. Pharmacokinetic study in rats showed that low ng/mL kisspeptin-10 was detected in the first few minutes, and eliminated rapidly and became undetectable 30 min after intravenous (i.v.) bolus administration of 1.0 mg/kg kisspeptin-10. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Liu, Zhongfa; Ren, Chen; Jones, William; Chen, Ping; Chan, Kenneth K.] Ohio State Univ, Coll Pharm, Columbus, OH 43210 USA.
[Seminara, Stephanie B.; Chan, Yee-Ming; Chan, Kenneth K.] Massachusetts Gen Hosp, Harvard Reprod Sci Ctr, Boston, MA 02114 USA.
[Seminara, Stephanie B.; Chan, Yee-Ming; Chan, Kenneth K.] Massachusetts Gen Hosp, Reprod Endocrine Unit, Boston, MA 02114 USA.
[Smith, Nicola F.; Covey, Joseph M.] NCI, Rockville, MD 20852 USA.
[Liu, Zhongfa; Ren, Chen; Jones, William; Chen, Ping; Seminara, Stephanie B.; Chan, Yee-Ming; Smith, Nicola F.; Covey, Joseph M.; Wang, Jeffrey; Chan, Kenneth K.] Ohio State Univ, Coll Med & Publ Hlth, Columbus, OH 43210 USA.
[Wang, Jeffrey] Western Univ Hlth Sci, Coll Pharm, Pomona, CA 91766 USA.
RP Chan, KK (reprint author), Ohio State Univ, Coll Pharm, 500 W 12Th Ave, Columbus, OH 43210 USA.
EM chan.56@osu.edu
RI Liu, Zhongfa/G-8549-2013
FU NIH-RAID program; NICHD; NIDDK under the National Cancer Institute (NCI)
[N01-CM-52205]
FX This research was supported by the NIH-RAID program, NICHD and NIDDK
under the National Cancer Institute (NCI) contract N01-CM-52205.
NR 18
TC 6
Z9 7
U1 0
U2 20
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1570-0232
J9 J CHROMATOGR B
JI J. Chromatogr. B
PD MAY 1
PY 2013
VL 926
BP 1
EP 8
DI 10.1016/j.jchromb.2013.02.027
PG 8
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 131NQ
UT WOS:000318000800001
PM 23524040
ER
PT J
AU Hong, TS
AF Hong, Theodore S.
TI Radiotherapy for Hepatocellular Carcinoma With Tumor Vascular Thrombus:
Ready for Prime Time?
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Editorial Material
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA.
RP Hong, TS (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA.
NR 8
TC 4
Z9 4
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 1
PY 2013
VL 31
IS 13
BP 1619
EP +
DI 10.1200/JCO.2012.48.2703
PG 3
WC Oncology
SC Oncology
GA 133PU
UT WOS:000318152200007
PM 23547073
ER
PT J
AU Bower, JE
Ganz, PA
Irwin, MR
Castellon, S
Arevalo, J
Cole, SW
AF Bower, Julienne E.
Ganz, Patricia A.
Irwin, Michael R.
Castellon, Steven
Arevalo, Jesusa
Cole, Steven W.
TI Cytokine Genetic Variations and Fatigue Among Patients With Breast
Cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID NECROSIS-FACTOR-ALPHA; C-REACTIVE PROTEIN; QUALITY-OF-LIFE; INFLAMMATORY
BIOMARKERS; BEHAVIORAL SYMPTOMS; PERSISTENT FATIGUE; SLEEP DISTURBANCE;
SURVIVORS; POLYMORPHISMS; DEPRESSION
AB Purpose
Fatigue is a common adverse effect of cancer treatment and may persist for years after treatment completion. However, risk factors for post-treatment fatigue have not been determined. On the basis of studies suggesting an inflammatory basis for fatigue, this study tested the hypothesis that expression-regulating polymorphisms in proinflammatory cytokine genes would predict post-treatment fatigue in breast cancer survivors.
Patients and Methods
Women diagnosed with early-stage breast cancer (n = 171) completed questionnaires to assess fatigue and other behavioral symptoms (ie, depressive symptoms, memory complaints, sleep disturbance) and provided blood for genotyping within 3 months after primary treatment. Genomic DNA was extracted from peripheral-blood leukocytes and assayed for single nucleotide polymorphisms (SNPs) in the promoter regions of three cytokine genes: ILB -511 C>T (rs16944), IL6 -174 G > C (rs1800795), and TNF -308 G > A (rs1800629). An additive genetic risk score was computed by summing the number of high-expression alleles (zero, one, or two) across all three polymorphisms.
Results
The genetic risk index was significantly associated with fatigue; as the number of high-expression alleles increased, so did self-reported fatigue severity (P = .002). Analyses of individual SNPs showed that TNF -308 and IL6 - 174 were independently associated with fatigue (P = .032). The genetic risk index was also associated with depressive symptoms (P = .007) and memory complaints (P = .016).
Conclusion
These findings further implicate inflammatory processes as contributors to cancer-related fatigue and suggest a new strategy for identifying and treating patients at risk for this symptom based on genetic variants in proinflammatory cytokine genes. J Clin Oncol 31: 1656-1661. (C) 2013 by American Society of Clinical Oncology
C1 [Bower, Julienne E.; Ganz, Patricia A.; Irwin, Michael R.; Castellon, Steven; Arevalo, Jesusa; Cole, Steven W.] Univ Calif Los Angeles, Los Angeles, CA 90095 USA.
[Castellon, Steven] W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA.
RP Bower, JE (reprint author), Univ Calif Los Angeles, Dept Psychol, 1285 Franz Hall, Los Angeles, CA 90095 USA.
EM jbower@ucla.edu
RI Irwin, Michael/H-4870-2013
OI Irwin, Michael/0000-0002-1502-8431
FU National Institutes of Health [R01-CA109650, R01-CA116778, R01-AG034588,
R01-AG026364, R01-CA160245-01, R01-CA119159, R01-HL095799,
R01-DA032922-01, P30-AG028748]; Cousins Center for
Psychoneuroimmunology; Breast Cancer Research Foundation
FX Supported by National Institutes of Health Grants No. R01-CA109650
(P.A.G.), R01-CA116778 (S.W.C.), R01-AG034588, R01-AG026364,
R01-CA160245-01, R01-CA119159, R01-HL095799, R01-DA032922-01, and
P30-AG028748 (M.I.); the Cousins Center for Psychoneuroimmunology; and
the Breast Cancer Research Foundation.
NR 59
TC 43
Z9 44
U1 1
U2 12
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 1
PY 2013
VL 31
IS 13
BP 1656
EP +
DI 10.1200/JCO.2012.46.2143
PG 7
WC Oncology
SC Oncology
GA 133PU
UT WOS:000318152200013
PM 23530106
ER
PT J
AU Ayas, M
Saber, W
Davies, SM
Harris, RE
Hale, GA
Socie, G
LeRademacher, J
Thakar, M
Deeg, HJJ
Al-Seraihy, A
Battiwalla, M
Camitta, BM
Olsson, R
Bajwa, RS
Bonfim, CM
Pasquini, R
MacMillan, ML
George, B
Copelan, EA
Wirk, B
Al Jefri, A
Fasth, AL
Guinan, EC
Horn, BN
Lewis, VA
Slavin, S
Stepensky, P
Bierings, M
Gale, RP
AF Ayas, Mouhab
Saber, Wael
Davies, Stella M.
Harris, Richard E.
Hale, Gregory A.
Socie, Gerard
LeRademacher, Jennifer
Thakar, Monica
Deeg, H. Joachim J.
Al-Seraihy, Amal
Battiwalla, Minoo
Camitta, Bruce M.
Olsson, Richard
Bajwa, Rajinder S.
Bonfim, Carmem M.
Pasquini, Ricardo
MacMillan, Margaret L.
George, Biju
Copelan, Edward A.
Wirk, Baldeep
Al Jefri, Abdullah
Fasth, Anders L.
Guinan, Eva C.
Horn, Biljana N.
Lewis, Victor A.
Slavin, Shimon
Stepensky, Polina
Bierings, Marc
Gale, Robert Peter
TI Allogeneic Hematopoietic Cell Transplantation for Fanconi Anemia in
Patients With Pretransplantation Cytogenetic Abnormalities,
Myelodysplastic Syndrome, or Acute Leukemia
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID BONE-MARROW-TRANSPLANTATION; LOW-DOSE CYCLOPHOSPHAMIDE; UNRELATED
DONORS; SIBLING DONOR; RISK-FACTOR; FLUDARABINE; REGISTRY; CANCER;
EXPERIENCE; GRAFT
AB Purpose
Allogeneic hematopoietic cell transplantation (HCT) can cure bone marrow failure in patients with Fanconi anemia (FA). Data on outcomes in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome (MDS), or acute leukemia have not been separately analyzed.
Patients and Methods
We analyzed data on 113 patients with FA with cytogenetic abnormalities (n = 54), MDS (n = 45), or acute leukemia (n = 14) who were reported to the Center for International Blood and Marrow Transplant Research from 1985 to 2007.
Results
Neutrophil recovery occurred in 78% and 85% of patients at days 28 and 100, respectively. Day 100 cumulative incidences of acute graft-versus-host disease grades B to D and C to D were 26% (95% CI, 19% to 35%) and 12% (95% CI, 7% to 19%), respectively. Survival probabilities at 1, 3, and 5 years were 64% (95% CI, 55% to 73%), 58% (95% CI, 48% to 67%), and 55% (95% CI, 45% to 64%), respectively. In univariate analysis, younger age was associated with superior 5-year survival (<= v > 14 years: 69% [95% CI, 57% to 80%] v 39% [95% CI, 26% to 53%], respectively; P = .001). In transplantations from HLA-matched related donors (n = 82), younger patients (<= v > 14 years: 78% [95% CI, 64% to 90%] v 34% [95% CI, 20% to 50%], respectively; P < .001) and patients with cytogenetic abnormalities only versus MDS/acute leukemia (67% [95% CI, 52% to 81%] v 43% [95% CI, 27% to 59%], respectively; P = .03) had superior 5-year survival.
Conclusion
Our analysis indicates that long-term survival for patients with FA with cytogenetic abnormalities, MDS, or acute leukemia is achievable. Younger patients and recipients of HLA-matched related donor transplantations who have cytogenetic abnormalities only have the best survival. J Clin Oncol 31: 1669-1676. (C) 2013 by American Society of Clinical Oncology
C1 [Ayas, Mouhab; Al-Seraihy, Amal; Al Jefri, Abdullah] King Faisal Specialist Hosp & Res Ctr, Riyadh 11211, Saudi Arabia.
[Saber, Wael; LeRademacher, Jennifer] Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI USA.
[Thakar, Monica] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Camitta, Bruce M.] Med Coll Wisconsin, Midwest Ctr Canc & Blood Disorders, Milwaukee, WI 53226 USA.
[Camitta, Bruce M.] Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA.
[Davies, Stella M.; Harris, Richard E.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA.
[Bajwa, Rajinder S.] Nationwide Childrens Hosp, Columbus, OH USA.
[Copelan, Edward A.] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
[Hale, Gregory A.] Univ S Florida, All Childrens Hosp, St Petersburg, FL 33701 USA.
[Wirk, Baldeep] Shands Healthcare, Gainesville, FL USA.
[Wirk, Baldeep] Univ Florida, Gainesville, FL USA.
[Deeg, H. Joachim J.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Battiwalla, Minoo] NHLBI, Bethesda, MD 20892 USA.
[MacMillan, Margaret L.] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA.
[Guinan, Eva C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Horn, Biljana N.] Univ Calif San Francisco, Med Ctr, San Francisco, CA USA.
[Socie, Gerard] Hop St Louis, Paris, France.
[Olsson, Richard] Karolinska Univ Hosp, Ctr Allogene Stem Cell Transplantat, Stockholm, Sweden.
[Fasth, Anders L.] Univ Gothenburg, Gothenburg, Sweden.
[Bonfim, Carmem M.; Pasquini, Ricardo] Univ Fed Parana, Hosp Clin, BR-80060000 Curitiba, Parana, Brazil.
[George, Biju] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India.
[Lewis, Victor A.] Alberta Childrens Prov Gen Hosp, Calgary, AB, Canada.
[Slavin, Shimon] Int Ctr Cell Therapy & Canc Immunotherapy, Tel Aviv, Israel.
[Stepensky, Polina] Hadassah Med Ctr, IL-91120 Jerusalem, Israel.
[Bierings, Marc] Wihelmina Childrens Hosp, Utrecht, Netherlands.
[Gale, Robert Peter] Univ London Imperial Coll Sci Technol & Med, London, England.
RP Ayas, M (reprint author), King Faisal Specialist Hosp & Res Ctr, POB 3354,MBC 53, Riyadh 11211, Saudi Arabia.
EM mouhab@kfshrc.edu.sa
RI Bajwa, Rajinder/E-2685-2011;
OI Olsson, Richard/0000-0001-5970-2128; Fasth, Anders/0000-0002-0033-740X
FU NCI NIH HHS [U24-CA76518]; NHLBI NIH HHS [5U01HL069294]; PHS HHS
[HHSH234200637015C, N00014-06-1-0704, N00014-08-1-0058]
NR 55
TC 21
Z9 21
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 1
PY 2013
VL 31
IS 13
BP 1669
EP +
DI 10.1200/JCO.2012.45.9719
PG 10
WC Oncology
SC Oncology
GA 133PU
UT WOS:000318152200015
PM 23547077
ER
PT J
AU Trevino, KM
Fasciano, K
Prigerson, HG
AF Trevino, Kelly M.
Fasciano, Karen
Prigerson, Holly G.
TI Patient-Oncologist Alliance, Psychosocial Well-Being, and Treatment
Adherence Among Young Adults With Advanced Cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; WORKING ALLIANCE; THERAPEUTIC ALLIANCE; BREAST-CANCER;
COMPLICATED GRIEF; SOCIAL SUPPORT; META-ANALYSIS; ADOLESCENT; SCALE;
CARE
AB Purpose
Patients who develop a strong alliance with their health care providers have been shown to have higher levels of psychosocial well-being and rates of treatment adherence. Young adults with cancer have lower levels of psychosocial well-being and treatment adherence relative to patients with cancer in other age groups. This study sought to evaluate the relationships between the patient-oncologist alliance, psychosocial well-being, and treatment adherence in young adults with advanced cancer.
Patients and Methods
Ninety-five young adults (age 20 to 40 years) with advanced cancer were administered measures of alliance, psychosocial well-being, willingness to adhere to treatment, and treatment adherence. Relationships between alliance and psychosocial well-being were examined bivariately. Multiple linear regression models examined the relationship between alliance and adherence, controlling for confounding influences (eg, psychosocial well-being).
Results
Alliance was significantly (P <= .01) and positively associated with greater perceived social support and less severe illness-related grief. After controlling for significant confounding influences (ie, metastases, appraised support, and grief), alliance remained significantly (P <= .01) associated with greater willingness to adhere to treatment and greater adherence to oral medication.
Conclusion
By developing a strong alliance, oncologists may enhance psychosocial well-being and increase treatment adherence in young adult patients with advanced cancer. J Clin Oncol 31:1683-1689. (C) 2013 by American Society of Clinical Oncology
C1 [Trevino, Kelly M.; Fasciano, Karen; Prigerson, Holly G.] Dana Farber Canc Inst, Ctr Psychosocial Epidemiol & Outcomes Res, Boston, MA 01225 USA.
[Trevino, Kelly M.; Fasciano, Karen; Prigerson, Holly G.] Harvard Univ, Sch Med, Boston, MA USA.
[Trevino, Kelly M.; Fasciano, Karen; Prigerson, Holly G.] Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Prigerson, HG (reprint author), Dana Farber Canc Inst, Ctr Psychosocial Epidemiol & Outcomes Res, 1134 Dana Bldg,450 Brookline Ave, Boston, MA 01225 USA.
EM holly_prigerson@dfci.harvard.edu
FU NCI NIH HHS [R01 CA106370]
NR 57
TC 21
Z9 21
U1 5
U2 21
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 1
PY 2013
VL 31
IS 13
BP 1683
EP 1689
DI 10.1200/JCO.2012.46.7993
PG 7
WC Oncology
SC Oncology
GA 133PU
UT WOS:000318152200017
PM 23530105
ER
PT J
AU Neuberg, DS
AF Neuberg, Donna S.
TI No Evidence of Survival Benefit With Addition of Gemtuzumab Ozogamicin
to Standard Medical Research Council Induction Chemotherapy Reply Reply
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Letter
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Neuberg, DS (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 4
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 1
PY 2013
VL 31
IS 13
BP 1701
EP 1701
DI 10.1200/JCO.2013.48.6589
PG 1
WC Oncology
SC Oncology
GA 133PU
UT WOS:000318152200022
ER
PT J
AU Clark, CJ
Morales-Oyarvide, V
Zaydfudim, V
Stauffer, J
Deshpande, V
Smyrk, TC
Chari, ST
Fernandez-del Castillo, C
Farnell, MB
AF Clark, Clancy J.
Morales-Oyarvide, Vicente
Zaydfudim, Victor
Stauffer, John
Deshpande, Vikram
Smyrk, Thomas C.
Chari, Suresh T.
Fernandez-del Castillo, Carlos
Farnell, Michael B.
TI Short-Term and Long-Term Outcomes for Patients with Autoimmune
Pancreatitis After Pancreatectomy: A Multi-institutional Study
SO JOURNAL OF GASTROINTESTINAL SURGERY
LA English
DT Article; Proceedings Paper
CT 53rd Annual Meeting of the Society-for-Surgery-of-the-Alimentary-Tract
(SSAT) / Digestive Disease Week (DDW) / Meeting of the Pancreas-Club
CY MAY 17-22, 2012
CL San Diego, CA
SP Amer Assoc Study Liver Dis (AASLD), Amer Gastroenterol Assoc (AGA), Amer Soc Gastrointestinal Endoscopy (ASGE), Soc Surg Alimentary Tract (SSAT), Pancreas Club, Mayo Clin
DE Autoimmune pancreatitis; IgG4; Surgery; Adult; Pancreatectomy; Chronic
pancreatitis; Survival; Outcomes
ID LYMPHOPLASMACYTIC SCLEROSING PANCREATITIS; INTERNATIONAL STUDY-GROUP;
PANCREATICODUODENECTOMY; DISEASE; PROPOSAL; FISTULA; DEFINITION;
MALIGNANCY; CONSENSUS; SURGERY
AB Autoimmune pancreatitis (AIP) is a rare subtype of chronic pancreatitis that may mimic adenocarcinoma of the pancreas. The aim of this study was to evaluate the short-term and long-term outcomes of pancreatectomy for patients with AIP.
In this multi-institutional study, we identified all patients who underwent pancreatectomy for AIP from 1986 to 2011. AIP was confirmed by pathology review. Clinical presentation, operative details, and postoperative outcomes were analyzed.
Seventy-four patients (median age, 60 years; 69 % male) with AIP underwent pancreatectomy. The main indication for operation was concern for malignancy (n = 59, 80 %). No patients were found to have pancreatic adenocarcinoma on final pathology. Major complications occurred in ten (14 %) patients, with one perioperative death (1 %). Clinically relevant (grade B/C) pancreatic fistulae occurred in two patients. No patients required reoperation for AIP and 11 (17 %) patients developed recurrent AIP.
Although we do not advocate pancreatectomy for AIP, strong suspicion of malignancy may require an operation in selected patients. For patients with AIP, pancreatectomy resulted in few pancreatic fistulae, a low rate of re-intervention, and a 17 % recurrence rate.
C1 [Clark, Clancy J.] Wake Forest Baptist Hlth, Dept Gen Surg, Winston Salem, NC 27157 USA.
[Morales-Oyarvide, Vicente; Fernandez-del Castillo, Carlos] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gastrointestinal Surg, Boston, MA USA.
[Zaydfudim, Victor; Farnell, Michael B.] Mayo Clin, Div Gastroenterol & Gen Surg, Rochester, MN USA.
[Stauffer, John] Mayo Clin, Div Gastroenterol & Gen Surg, Jacksonville, FL 32224 USA.
[Deshpande, Vikram] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Smyrk, Thomas C.] Mayo Clin, Div Anat Pathol, Rochester, MN USA.
[Chari, Suresh T.] Mayo Clin, Div Gastroenterol, Rochester, MN USA.
RP Clark, CJ (reprint author), Wake Forest Baptist Hlth, Dept Gen Surg, Med Ctr Blvd, Winston Salem, NC 27157 USA.
EM cjclark@wakehealth.edu; vmorales2@partners.org;
zayfudim.victor@mayo.edu; stauffer.john@mayo.edu;
vdeshpande@partners.org; smyrk.thomas@mayo.edu; chari.suresh@mayo.edu;
cfernandez@partners.orgA; farnell.michael@mayo.edu
NR 30
TC 5
Z9 5
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1091-255X
J9 J GASTROINTEST SURG
JI J. Gastrointest. Surg.
PD MAY
PY 2013
VL 17
IS 5
BP 899
EP 906
DI 10.1007/s11605-013-2145-1
PG 8
WC Gastroenterology & Hepatology; Surgery
SC Gastroenterology & Hepatology; Surgery
GA 129SJ
UT WOS:000317862200008
PM 23319396
ER
PT J
AU Hegde, JV
Mulkern, RV
Panych, LP
Fennessy, FM
Fedorov, A
Maier, SE
Tempany, CMC
AF Hegde, John V.
Mulkern, Robert V.
Panych, Lawrence P.
Fennessy, Fiona M.
Fedorov, Andriy
Maier, Stephan E.
Tempany, Clare M. C.
TI Multiparametric MRI of prostate cancer: An update on state-of-the-art
techniques and their performance in detecting and localizing prostate
cancer
SO JOURNAL OF MAGNETIC RESONANCE IMAGING
LA English
DT Review
DE prostate cancer; multiparametric MRI; T2-weighted imaging;
diffusion-weighted imaging; dynamic contrast-enhanced imaging; magnetic
resonance spectroscopy
ID APPARENT DIFFUSION-COEFFICIENT; CONTRAST-ENHANCED MRI;
MAGNETIC-RESONANCE-SPECTROSCOPY; LINE-SCAN DIFFUSION; IN-VIVO;
ENDORECTAL-COIL; 3 T; PERIPHERAL ZONE; RADICAL PROSTATECTOMY; SURFACE
COIL
AB Magnetic resonance (MR) examinations of men with prostate cancer are most commonly performed for detecting, characterizing, and staging the extent of disease to best determine diagnostic or treatment strategies, which range from biopsy guidance to active surveillance to radical prostatectomy. Given both the exam's importance to individual treatment plans and the time constraints present for its operation at most institutions, it is essential to perform the study effectively and efficiently. This article reviews the most commonly employed modern techniques for prostate cancer MR examinations, exploring the relevant signal characteristics from the different methods discussed and relating them to intrinsic prostate tissue properties. Also, a review of recent articles using these methods to enhance clinical interpretation and assess clinical performance is provided. J. Magn. Reson. Imaging 2013;37:10351054. (c) 2013 Wiley Periodicals, Inc.
C1 [Hegde, John V.; Mulkern, Robert V.; Panych, Lawrence P.; Fennessy, Fiona M.; Fedorov, Andriy; Maier, Stephan E.; Tempany, Clare M. C.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Hegde, John V.] Harvard Univ, Sch Med, Boston, MA USA.
[Mulkern, Robert V.] Harvard Univ, Childrens Hosp Boston, Sch Med, Dept Radiol, Boston, MA USA.
[Fennessy, Fiona M.] Dana Farber Canc Inst, Dept Imaging, Boston, MA 02115 USA.
RP Tempany, CMC (reprint author), Brigham & Womens Hosp, Dept Radiol, Surg Planning Lab, L1 050,75 Francis St, Boston, MA 02115 USA.
EM ctempany@bwh.harvard.edu
OI Fedorov, Andrey/0000-0003-4806-9413
FU National Institutes of Health (NIH) [R01CA109246, P41EB015898,
P41RR019703, U01CA151261, R01CA111288, P01CA067165, R01CA160902];
Harvard Medical School
FX Contract grant sponsor: National Institutes of Health (NIH); Contract
grant numbers: R01CA109246, P41EB015898, P41RR019703, U01CA151261,
R01CA111288, P01CA067165, and R01CA160902.; We thank Harvard Medical
School for its research fellowship support to one of the authors
(J.V.H.). We also thank Louise Greenberg, Aida Faria, and our
technologists for their dedication to our patients and our clinical
research program.
NR 107
TC 65
Z9 67
U1 2
U2 23
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1053-1807
J9 J MAGN RESON IMAGING
JI J. Magn. Reson. Imaging
PD MAY
PY 2013
VL 37
IS 5
BP 1035
EP 1054
DI 10.1002/jmri.23860
PG 20
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 132DX
UT WOS:000318049200003
PM 23606141
ER
PT J
AU Villano, JL
Wen, PY
Lee, EQ
Nayak, L
Reardon, DA
Rosenfeld, MR
AF Villano, J. Lee
Wen, Patrick Y.
Lee, Eudocia Q.
Nayak, Lakshmi
Reardon, David A.
Rosenfeld, Myrna R.
TI PCV for anaplastic oligodendrogliomas: back to the future or a step
backwards? A point/counterpoint discussion
SO JOURNAL OF NEURO-ONCOLOGY
LA English
DT Editorial Material
ID PHASE-III TRIAL; VINCRISTINE; TUMORS; CHEMOTHERAPY; TEMOZOLOMIDE;
PROCARBAZINE; LOMUSTINE; RADIOTHERAPY; SURVIVAL
C1 [Villano, J. Lee] Univ Kentucky, Dept Internal Med, Lexington, KY USA.
[Villano, J. Lee] Univ Kentucky, Lucille P Markey Canc Ctr, Lexington, KY USA.
[Wen, Patrick Y.; Lee, Eudocia Q.; Nayak, Lakshmi; Reardon, David A.] Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02115 USA.
[Wen, Patrick Y.; Lee, Eudocia Q.; Nayak, Lakshmi] Brigham & Womens Hosp, Dept Neurol, Div Neurooncol, Boston, MA 02115 USA.
[Wen, Patrick Y.; Lee, Eudocia Q.; Nayak, Lakshmi; Reardon, David A.] Harvard Univ, Sch Med, Boston, MA USA.
[Rosenfeld, Myrna R.] Hosp Clin Barcelona, IDIBAPS, Dept Neurol, E-08036 Barcelona, Spain.
RP Rosenfeld, MR (reprint author), Hosp Clin Barcelona, IDIBAPS, Dept Neurol, Villarroel 170, E-08036 Barcelona, Spain.
EM mrrosenf@clinic.ub.es
NR 20
TC 2
Z9 2
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-594X
J9 J NEURO-ONCOL
JI J. Neuro-Oncol.
PD MAY
PY 2013
VL 113
IS 1
BP 143
EP 147
DI 10.1007/s11060-013-1100-z
PG 5
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 135PL
UT WOS:000318300700017
PM 23479035
ER
PT J
AU Yoo, AJ
Leslie-Mazwi, TM
Jovin, TG
AF Yoo, Albert J.
Leslie-Mazwi, Thabele M.
Jovin, Tudor G.
TI Future directions in IAT: better studies, better selection, better
timing and better techniques
SO JOURNAL OF NEUROINTERVENTIONAL SURGERY
LA English
DT Editorial Material
ID ACUTE ISCHEMIC-STROKE; CEREBRAL-ARTERY OCCLUSION; DOOR-TO-BALLOON;
ENDOVASCULAR THERAPY; INFARCT VOLUME; MULTICENTER ANALYSIS; EARLY
RECANALIZATION; NONCONTRAST CT; BLOOD-FLOW; TIME
C1 [Yoo, Albert J.; Leslie-Mazwi, Thabele M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Intervent Neuroradiol Endovasc Neurosurg, Boston, MA 02114 USA.
[Jovin, Tudor G.] Univ Pittsburgh, Med Ctr, Stroke Inst, Pittsburgh, PA USA.
[Jovin, Tudor G.] Univ Pittsburgh, Med Ctr, UPMC Ctr Neuroendovasc Therapy, Pittsburgh, PA USA.
RP Yoo, AJ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Intervent Neuroradiol Endovasc Neurosurg, 55 Fruit St,Gray 241, Boston, MA 02114 USA.
EM ajyoo@partners.org
NR 62
TC 10
Z9 10
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1759-8478
J9 J NEUROINTERV SURG
JI J. NeuroInterventional Surg.
PD MAY
PY 2013
VL 5
SU 1
BP 1
EP 6
DI 10.1136/neurintsurg-2013-010741
PG 6
WC Neuroimaging; Surgery
SC Neurosciences & Neurology; Surgery
GA 134JQ
UT WOS:000318206900001
ER
PT J
AU Gonzalez, RG
Copen, WA
Schaefer, PW
Lev, MH
Pomerantz, SR
Rapalino, O
Chen, JW
Hunter, GJ
Romero, JM
Buchbinder, BR
Larvie, M
Hirsch, JA
Gupta, R
AF Gonzalez, Ramon Gilberto
Copen, William A.
Schaefer, Pamela W.
Lev, Michael H.
Pomerantz, Stuart R.
Rapalino, Otto
Chen, John W.
Hunter, George J.
Romero, Javier M.
Buchbinder, Bradley R.
Larvie, Mykol
Hirsch, Joshua Adam
Gupta, Rajiv
TI The Massachusetts General Hospital acute stroke imaging algorithm: an
experience and evidence based approach
SO JOURNAL OF NEUROINTERVENTIONAL SURGERY
LA English
DT Review
ID ACUTE ISCHEMIC-STROKE; DIFFUSION-WEIGHTED MR; SYMPTOMATIC INTRACEREBRAL
HEMORRHAGE; POSITRON-EMISSION-TOMOGRAPHY; CEREBRAL-ARTERY OCCLUSION;
MAGNETIC-RESONANCE; INTRAARTERIAL THROMBOLYSIS; ENDOVASCULAR THERAPY;
HYPERACUTE STROKE; INFARCT VOLUME
AB The Massachusetts General Hospital Neuroradiology Division employed an experience and evidence based approach to develop a neuroimaging algorithm to best select patients with severe ischemic strokes caused by anterior circulation occlusions (ACOs) for intravenous tissue plasminogen activator and endovascular treatment. Methods found to be of value included the National Institutes of Health Stroke Scale (NIHSS), non-contrast CT, CT angiography (CTA) and diffusion MRI. Perfusion imaging by CT and MRI were found to be unnecessary for safe and effective triage of patients with severe ACOs. An algorithm was adopted that includes: non-contrast CT to identify hemorrhage and large hypodensity followed by CIA to identify the ACO; diffusion MRI to estimate the core infarct; and NIHSS in conjunction with diffusion data to estimate the clinical penumbra.
C1 [Gonzalez, Ramon Gilberto; Copen, William A.; Schaefer, Pamela W.; Lev, Michael H.; Pomerantz, Stuart R.; Rapalino, Otto; Chen, John W.; Hunter, George J.; Romero, Javier M.; Buchbinder, Bradley R.; Larvie, Mykol; Hirsch, Joshua Adam; Gupta, Rajiv] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neuroradiol Div, Boston, MA 02114 USA.
RP Gonzalez, RG (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neuroradiol Div, Boston, MA 02114 USA.
EM rggonzalez@partners.org
FU GE Healthcare
FX JMR is on the imaging committee of the DIAS trial for Lundbeck
Pharmaceuticals. MHL has research support from GE Healthcare and is a
consultant for Millenium Pharmaceuticals.
NR 50
TC 22
Z9 22
U1 0
U2 7
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1759-8478
EI 1759-8486
J9 J NEUROINTERV SURG
JI J. NeuroInterventional Surg.
PD MAY
PY 2013
VL 5
SU 1
BP 7
EP 12
DI 10.1136/neurintsurg-2013-010715
PG 6
WC Neuroimaging; Surgery
SC Neurosciences & Neurology; Surgery
GA 134JQ
UT WOS:000318206900002
PM 23493340
ER
PT J
AU Morais, LT
Leslie-Mazwi, TM
Lev, MH
Albers, GW
Yoo, AJ
AF Morais, Livia T.
Leslie-Mazwi, Thabele M.
Lev, Michael H.
Albers, Gregory W.
Yoo, Albert J.
TI Imaging-based selection for intra-arterial stroke therapies
SO JOURNAL OF NEUROINTERVENTIONAL SURGERY
LA English
DT Editorial Material
ID ACUTE ISCHEMIC-STROKE; CEREBRAL-ARTERY OCCLUSION; FINAL INFARCT VOLUME;
TISSUE-PLASMINOGEN ACTIVATOR; ANGIOGRAPHIC SOURCE IMAGES; MEAN
TRANSIT-TIME; ENDOVASCULAR TREATMENT; CT ANGIOGRAPHY;
COMPUTED-TOMOGRAPHY; MAGNETIC-RESONANCE
C1 [Morais, Livia T.; Lev, Michael H.; Yoo, Albert J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Diagnost Neuroradiol, Boston, MA USA.
[Leslie-Mazwi, Thabele M.; Yoo, Albert J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Intervent Neuroradiol, Boston, MA USA.
[Albers, Gregory W.] Stanford Univ, Dept Neurol, Stanford Stroke Ctr, Stanford, CA 94305 USA.
RP Yoo, AJ (reprint author), Massachusetts Gen Hosp, Div Diagnost & Intervent Neuroradiol, 55 Fruit St,Gray 241, Boston, MA 02114 USA.
EM ajyoo@partners.org
NR 82
TC 5
Z9 5
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1759-8478
J9 J NEUROINTERV SURG
JI J. NeuroInterventional Surg.
PD MAY
PY 2013
VL 5
SU 1
BP 13
EP 20
DI 10.1136/neurintsurg-2013-010733
PG 8
WC Neuroimaging; Surgery
SC Neurosciences & Neurology; Surgery
GA 134JQ
UT WOS:000318206900003
ER
PT J
AU Rost, NS
Smith, EE
Nogueira, RG
Fitzpatrick, KM
Yoo, AJ
Hirsch, JA
Schwamm, LH
AF Rost, Natalia S.
Smith, Eric E.
Nogueira, Raul G.
Fitzpatrick, Kaitlin M.
Yoo, Albert J.
Hirsch, Joshua A.
Schwamm, Lee H.
TI Implementation of a patient selection protocol for intra-arterial
therapy increases treatment rates in patients with acute ischemic stroke
SO JOURNAL OF NEUROINTERVENTIONAL SURGERY
LA English
DT Article
ID MERCI TRIAL; THROMBOLYSIS; CT; PREDICTION; EFFICACY; VOLUMES
AB Background Strategies for patient selection for intraarterial therapy (IAT) in acute ischemic stroke (AIS) are highly variable. The degree of protocol adoption and treatment rates associated with implementation of a service-wide patient selection IAT protocol were assessed.
Methods All patients with AIS prospectively recorded in our stroke database from January 2007 to June 2009 were reviewed. The IAT patient selection protocol was implemented in March 2008. Patients were defined as likely to benefit (LTB) from IAT if they had brain imaging completed within 6 h from last known well time, NIH Stroke Scale score >= 8, infarct volume <= 100 ml and evidence of proximal artery occlusion.
Results Of 1348 subjects identified, 118(8.7%) met the criteria for LTB and 62 (52%) underwent IAT. There was a significant increase in rates of IAT among LTB patients after protocol implementation (61% vs 40%, p<0.02). In LTB patients, factors associated with IAT were stroke duration (OR 0.78, 95% CI 0.6 to 0.9 per hour), arrival within later calendar months during study period (OR 1.1, 95% CI 1.02 to 1.2 per month), intravenous tissue plasminogen activator (OR 0.6, 95% Cl 0.4 to 0.9) and age (OR 0.98, 95% CI 0.95 to 1.02 per year). After multivariable adjustment, only stroke duration (OR 0.65, 95% CI 0.5 to 0.8 per hour) remained an independent predictor of IAT.
Conclusions Most patients with AIS did not meet our criteria for LTB and only 52% of those defined as LTB received IAT. Protocol adoption increased the use of IAT over time; however, further exploration of factors associated with the reasons for non-treatment and the impact of IAT on outcomes is necessary.
C1 [Rost, Natalia S.; Fitzpatrick, Kaitlin M.; Schwamm, Lee H.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Smith, Eric E.] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada.
[Nogueira, Raul G.] Emory Univ, Dept Neurol & Radiol, Atlanta, GA 30322 USA.
[Yoo, Albert J.; Hirsch, Joshua A.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
RP Rost, NS (reprint author), Massachusetts Gen Hosp, Dept Neurol, 175 Cambridge St,Suite 300, Boston, MA 02114 USA.
EM nrost@partners.org
OI Schwamm, Lee/0000-0003-0592-9145; Smith, Eric/0000-0003-3956-1668
FU Penumbra Inc (core imaging laboratory); Intra-tech, a development stage
stroke device company
FX NSR, EES and KMF have nothing to disclose. RGN is a member of the
Physician Advisory Board for Concentric Medical, ev3 Neurovascular,
Coaxia, Rapid Medical, and Neurointervention. He is also the PI for the
TREVO-2 Trial but does not receive any consulting fees. AJY has received
research funding from Penumbra Inc (core imaging laboratory for the
START trial). JAB has received consulting fees from Intra-tech, a
development stage stroke device company. LHS serves as paid stroke
systems consultant to the Massachusetts Department of Public Health and
the Chair of the GWTG National Steering Committee (unpaid).
NR 18
TC 3
Z9 3
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1759-8478
J9 J NEUROINTERV SURG
JI J. NeuroInterventional Surg.
PD MAY
PY 2013
VL 5
SU 1
BP 44
EP 47
DI 10.1136/neurintsurg-2011-010240
PG 4
WC Neuroimaging; Surgery
SC Neurosciences & Neurology; Surgery
GA 134JQ
UT WOS:000318206900008
ER
PT J
AU Mehta, B
Leslie-Mazwi, TM
Chandra, RV
Chaudhry, ZA
Rabinov, JD
Hirsch, JA
Schwamm, LH
Rost, NS
Yoo, AJ
AF Mehta, Brijesh
Leslie-Mazwi, Thabele M.
Chandra, Ronil V.
Chaudhry, Zeshan A.
Rabinov, James D.
Hirsch, Joshua A.
Schwamm, Lee H.
Rost, Natalia S.
Yoo, Albert J.
TI Assessing variability in neurointerventional practice patterns for acute
ischemic stroke
SO JOURNAL OF NEUROINTERVENTIONAL SURGERY
LA English
DT Article
ID ENDOVASCULAR THERAPY; SCALE SCORE; INTRAARTERIAL; TRIAL; RECANALIZATION;
VOLUMES; DISEASE; SAFETY
AB Background Intra-arterial therapy (AT) is increasingly used to treat patients with acute stroke with large vessel occlusions. There are minimal data and guidelines for treatment indications and performance standards. We aimed to gain a better understanding of real-world practice patterns for IAT.
Methods An internet-based survey was launched to address six specific areas of IAT: practice setting, operator background, operational protocols, quality/safety, decision-making and treatment strategies. The survey invitation was distributed to members of multiple neurointerventional societies.
Results Responses from 140 neurointerventionalists worldwide were analyzed. The median annual volume of IAT cases per institution was 40, and the median neurointerventional group size was three staff members. Independent predictors of case volume were presence of comprehensive stroke services and telestroke capability. The median minimum National Institutes of Health Stroke Scale score for treatment consideration was 8, although 60% of respondents reported no minimum score cut-off. There was no strict time window from symptom onset to treatment among 41% of respondents for anterior circulation strokes and among 56% for posterior circulation strokes, instead basing treatment decisions on clinical and imaging findings. Despite the emphasis on imaging-based selection, there was pronounced variability in the criteria used. Only 27% used one imaging approach exclusively. IAT following full- or partial-dose intravenous tissue plasminogen activator was performed by 89%. Mechanical devices were the predominant first-line therapy, but specific device usage depended on practice location. Approximately half preferred conscious sedation during IAT.
Conclusions This survey illustrates significant variation among neurointerventionalists in the real-world use of AT Our findings highlight the need for evidence-based practice guidelines.
C1 [Mehta, Brijesh; Leslie-Mazwi, Thabele M.; Schwamm, Lee H.; Rost, Natalia S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02114 USA.
[Mehta, Brijesh; Leslie-Mazwi, Thabele M.; Chandra, Ronil V.; Chaudhry, Zeshan A.; Rabinov, James D.; Hirsch, Joshua A.; Yoo, Albert J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol,Div Intervent Neuroradiol, Boston, MA 02114 USA.
[Chaudhry, Zeshan A.; Yoo, Albert J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol,Div Diagnost Neuroradiol, Boston, MA 02114 USA.
RP Mehta, B (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, 55 Fruit St,Gray 241, Boston, MA 02114 USA.
EM bmehta@partners.org
OI Schwamm, Lee/0000-0003-0592-9145
FU NINDS [K23NS064052]
FX JAH is on the MERCI Registry Steering Committee but receives no
financial compensation. NSR is supported by the NINDS (K23NS064052).
NR 22
TC 18
Z9 18
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1759-8478
J9 J NEUROINTERV SURG
JI J. NeuroInterventional Surg.
PD MAY
PY 2013
VL 5
SU 1
BP 52
EP 57
DI 10.1136/neurintsurg-2012-010565
PG 6
WC Neuroimaging; Surgery
SC Neurosciences & Neurology; Surgery
GA 134JQ
UT WOS:000318206900010
PM 23235960
ER
PT J
AU Albuquerque, FC
Fiorella, D
Hirsch, JA
Prestigiacomo, C
Tarr, RW
AF Albuquerque, Felipe C.
Fiorella, David
Hirsch, Joshua A.
Prestigiacomo, Charles
Tarr, Robert W.
TI The tribulations of stroke trials
SO JOURNAL OF NEUROINTERVENTIONAL SURGERY
LA English
DT Editorial Material
ID ACUTE ISCHEMIC-STROKE; ENDOVASCULAR TREATMENT; SOURCE IMAGES;
REVASCULARIZATION; OCCLUSIONS; SELECTION; THERAPY; VOLUME; CT
C1 [Albuquerque, Felipe C.] Barrow Neurol Inst, Div Neurol Surg, Phoenix, AZ 85013 USA.
[Fiorella, David] SUNY Stony Brook, Dept Neurosurg, Stony Brook, NY 11794 USA.
[Hirsch, Joshua A.] Massachusetts Gen Hosp, NeuroEndovasc Program, Boston, MA 02114 USA.
[Prestigiacomo, Charles] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurol Surg, Newark, NJ 07103 USA.
[Tarr, Robert W.] Univ Hosp Case Med Ctr, Dept Radiol, Cleveland, OH USA.
RP Albuquerque, FC (reprint author), Barrow Neurol Inst, Div Neurol Surg, 2910 N 3rd Ave, Phoenix, AZ 85013 USA.
EM felipe.albuquerque@bnaneuro.net
NR 17
TC 15
Z9 15
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1759-8478
J9 J NEUROINTERV SURG
JI J. NeuroInterventional Surg.
PD MAY
PY 2013
VL 5
IS 3
BP 181
EP 183
DI 10.1136/neurintsurg-2013-010731
PG 3
WC Neuroimaging; Surgery
SC Neurosciences & Neurology; Surgery
GA 134JP
UT WOS:000318206800001
PM 23572243
ER
PT J
AU Hill, KS
Adams, JM
AF Hill, Karen S.
Adams, Jeffrey M.
TI Emerging Nurse Scientists An Interview With Jeffrey M. Adams, PhD, RN
SO JOURNAL OF NURSING ADMINISTRATION
LA English
DT Editorial Material
C1 [Adams, Jeffrey M.] Massachusetts Gen Hosp, Ctr Innovat Care Delivery, Boston, MA 02114 USA.
[Adams, Jeffrey M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM www.jonaeditor@gmail.com
NR 10
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0002-0443
J9 J NURS ADMIN
JI J. Nurs. Adm.
PD MAY
PY 2013
VL 43
IS 5
BP 247
EP 249
DI 10.1097/NNA.0b013e31828ef2b9
PG 3
WC Nursing
SC Nursing
GA 132MF
UT WOS:000318071800003
ER
PT J
AU Adams, JM
Nikolaev, N
Erickson, JI
Ditomassi, M
Jones, DA
AF Adams, Jeffrey M.
Nikolaev, Nikolay
Erickson, Jeanette Ives
Ditomassi, Marianne
Jones, Dorothy A.
TI Identification of the Psychometric Properties of the Leadership
Influence Over Professional Practice Environments Scale
SO JOURNAL OF NURSING ADMINISTRATION
LA English
DT Article
ID PSYCHOLOGICAL EMPOWERMENT; HOSPITAL CHARACTERISTICS; WORK ENVIRONMENTS;
OUTCOMES; IMPACT; MORTALITY
AB This study uses the qualitatively developed Adams InfluenceModel (c) (AIM) and concepts from the psychometrically validated Revised Professional Practice Environment scale to guide the development of the Leadership Influence Over Professional Practice Environments Scale. Nurse executives and others can use this scale individually or in conjunction with instruments targeting staff or patient perceptions of their influence as part of health services research, leadership development, and professional practice environment enhancement strategy.
C1 [Adams, Jeffrey M.] Massachusetts Gen Hosp, Ctr Innovat Care Delivery, Boston, MA 02114 USA.
[Adams, Jeffrey M.; Erickson, Jeanette Ives; Ditomassi, Marianne] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Nikolaev, Nikolay; Jones, Dorothy A.] Massachusetts Gen Hosp, Yvonne L Munn Ctr Nursing Res, Boston, MA 02114 USA.
[Nikolaev, Nikolay] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA.
[Jones, Dorothy A.] Boston Coll, William F Connell Sch Nursing, Chestnut Hill, MA 02167 USA.
RP Adams, JM (reprint author), Massachusetts Gen Hosp, Ctr Innovat Care Delivery, 275 Cambridge St,POB 4, Boston, MA 02114 USA.
EM JADAMS9@partners.org
FU Yvonne L. Munn Center for Nursing Research; Connell Nursing Research
Scholars grant
FX This research was supported in part by an Yvonne L. Munn Center for
Nursing Research Postdoctoral Fellowship grant and a Connell Nursing
Research Scholars grant.
NR 41
TC 2
Z9 2
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0002-0443
J9 J NURS ADMIN
JI J. Nurs. Adm.
PD MAY
PY 2013
VL 43
IS 5
BP 258
EP 265
DI 10.1097/NNA.0b013e31828eeb55
PG 8
WC Nursing
SC Nursing
GA 132MF
UT WOS:000318071800005
PM 23615367
ER
PT J
AU Pierre, JF
Heneghan, AF
Feliciano, RP
Shanmuganayagam, D
Roenneburg, DA
Krueger, CG
Reed, JD
Kudsk, KA
AF Pierre, Joseph F.
Heneghan, Aaron F.
Feliciano, Rodrigo P.
Shanmuganayagam, Dhanansayan
Roenneburg, Drew A.
Krueger, Christian G.
Reed, Jess D.
Kudsk, Kenneth A.
TI Cranberry Proanthocyanidins Improve the Gut Mucous Layer Morphology and
Function in Mice Receiving Elemental Enteral Nutrition
SO JOURNAL OF PARENTERAL AND ENTERAL NUTRITION
LA English
DT Article
DE enteral nutrition; proanthocyanidins; goblet cells; mucin; cytokines
ID RECURRENT ULCERATIVE-COLITIS; TOTAL PARENTERAL-NUTRITION; MUCOSAL
IMMUNITY; LYMPHOID-TISSUE; HOST-DEFENSE; GRAPE SEEDS; MUC2 MUCIN; RATS;
POLYPHENOLS; PROCYANIDINS
AB Background: Lamina propria Th2 cytokines, interleukin (IL)-4 and IL-13, stimulate goblet cell (GC) proliferation and MUC2 production, which protect the intestinal mucosa. Elemental enteral nutrition (EEN) reduces tissue IL-4 and impairs barrier function. Proanthocyanidins (PACs) stimulate oral mucin levels. We hypothesized that adding PAC to EEN would maintain Th2-without stimulating Th1-cytokines and preserve luminal MUC2 vs EEN alone. Materials and Methods: Seventy mice were randomized to 5 diet groups-standard chow, intragastric EEN, or EEN with lowPAC, midPAC (50 mg), or highPAC (100 mg PAC/kg BW)-for 5 days, starting 2 days after gastric cannulation. Ileal tissue was analyzed for histomorphology and the cytokines IL-4, IL-13, IL-1 beta, IL-6, and TNF-alpha by enzyme-linked immunosorbent assay. MUC2 was measured in intestinal washes. Results: EEN lowered IL-13 (P < .05) compared with standard chow, whereas IL-4 was not significant (P < .07). LowPAC and midPAC increased IL-13 (P < .05), whereas highPAC increased both IL-4 and IL-13 (P < .05) compared with EEN. All EEN diets reduced (P < .05) crypt depth compared with the chow group. Compared with standard chow, GC numbers and luminal MUC2 were reduced with EEN (P < .05). These effects were attenuated (P < .05) with midPAC and highPAC. No changes were observed in tissue Th1 cytokines. Conclusions: Adding PACs to EEN reverses impaired intestinal barrier function following EEN by improving the gut mucous layer and function through increased GC size and number as well as levels of MUC2 and ileal IL-4 and IL-13. (JPEN J Parenter Enteral Nutr. 2013;37:401-409)
C1 [Pierre, Joseph F.; Heneghan, Aaron F.; Roenneburg, Drew A.; Kudsk, Kenneth A.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI 53792 USA.
[Pierre, Joseph F.; Feliciano, Rodrigo P.; Shanmuganayagam, Dhanansayan; Krueger, Christian G.; Reed, Jess D.] Univ Wisconsin, Dept Anim Sci, Madison, WI 53792 USA.
[Feliciano, Rodrigo P.] Univ Wisconsin, Dept Food Sci, Madison, WI 53792 USA.
[Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA.
RP Kudsk, KA (reprint author), Univ Wisconsin, Ctr Clin Sci, G5-341 600 Highland Ave, Madison, WI 53792 USA.
EM kudsk@surgery.wisc.edu
OI Feliciano, Rodrigo/0000-0002-8116-997X
FU Biomedical Laboratory Research & Development Service of the VA Office of
Research and Development [I01BX001672]; National Institutes of Health
(NIH) [R01 GM53439]; Reed Research Group; Fundacao para a Ciencia e a
Tecnologia, Portugal [SFRH/BD/73067/2010]
FX The project described was supported by award number I01BX001672 from the
Biomedical Laboratory Research & Development Service of the VA Office of
Research and Development. The research was also supported by a National
Institutes of Health (NIH) grant (R01 GM53439) and by the Reed Research
Group.; Rodrigo P. Feliciano is recipient of a BD fellowship
(SFRH/BD/73067/2010) from Fundacao para a Ciencia e a Tecnologia,
Portugal. We would like to thank Jennifer J. Meudt and Michael P. Shea
for their technical assistance and Dr Martha Vestling for her assistance
with mass spectrometry.
NR 58
TC 13
Z9 13
U1 3
U2 17
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0148-6071
J9 JPEN-PARENTER ENTER
JI J. Parenter. Enter. Nutr.
PD MAY
PY 2013
VL 37
IS 3
BP 401
EP 409
DI 10.1177/0148607112463076
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 131IW
UT WOS:000317987600015
PM 23064255
ER
PT J
AU Duncan, LE
AF Duncan, Laramie E.
TI Paying Attention to All Results, Positive and Negative
SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
LA English
DT Editorial Material
ID GENOME-WIDE ASSOCIATION; GENE-ENVIRONMENT INTERACTION; HUMAN-BEHAVIOR;
LIFE STRESS; DEPRESSION; METAANALYSIS; 5-HTTLPR; HERITABILITY;
MODERATION; MODEL
C1 [Duncan, Laramie E.] Harvard Univ, Sch Publ Hlth, Massachusetts Gen Hosp, Broad Inst Massachusetts Inst Technol & Halyard M, Cambridge, MA 02138 USA.
RP Duncan, LE (reprint author), Ctr Human Genet Res, Simches Res Bldg,185 Cambridge St, Boston, MA 02144 USA.
EM lduncan@hsph.harvard.edu
FU NICHD NIH HHS [T32HD007289]; NIMH NIH HHS [T32MH017119]
NR 28
TC 7
Z9 7
U1 1
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0890-8567
J9 J AM ACAD CHILD PSY
JI J. Am. Acad. Child Adolesc. Psychiatr.
PD MAY
PY 2013
VL 52
IS 5
BP 462
EP 465
DI 10.1016/j.jaac.2013.02.007
PG 4
WC Psychology, Developmental; Pediatrics; Psychiatry
SC Psychology; Pediatrics; Psychiatry
GA 136WW
UT WOS:000318395100004
PM 23622847
ER
PT J
AU Patel, IJ
Davidson, JC
Nikolic, B
Salazar, GM
Schwartzberg, MS
Walker, TG
Saad, WE
AF Patel, Indravadan J.
Davidson, Jon C.
Nikolic, Boris
Salazar, Gloria M.
Schwartzberg, Marc S.
Walker, T. Gregory
Saad, Wael E.
CA Stand Practice Comm
CIRSE Endorsement
TI Addendum of Newer Anticoagulants to the SIR Consensus Guideline
SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
LA English
DT Editorial Material
ID ASSOCIATION TASK-FORCE; AMERICAN-COLLEGE; UNSTABLE ANGINA; MANAGEMENT;
REVASCULARIZATION; STRATEGIES; INHIBITORS; DISEASE; UPDATE
C1 [Patel, Indravadan J.; Davidson, Jon C.] Univ Hosp Cleveland, Dept Radiol, Cleveland, OH 44106 USA.
[Nikolic, Boris] Stratton Albany Med Ctr, Dept Radiol, Albany, NY USA.
[Salazar, Gloria M.] Harvard Univ, Dept Imaging, Sch Med, Boston, MA USA.
[Walker, T. Gregory] Massachusetts Gen Hosp, Sect Cardiovasc Imaging & Intervent, Boston, MA 02114 USA.
[Schwartzberg, Marc S.] Radiol Associates Cent Florida, Leesburg, FL USA.
Univ Virginia Hlth Syst, Dept Radiol, Charlottesville, VA USA.
RP Davidson, JC (reprint author), Soc Intervent Radiol, 3975 Fair Ridge Dr,Ste 400,North, Fairfax, VA 22033 USA.
EM jon.davidson@uhhospitals.org
NR 13
TC 17
Z9 17
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1051-0443
J9 J VASC INTERV RADIOL
JI J. Vasc. Interv. Radiol.
PD MAY
PY 2013
VL 24
IS 5
BP 641
EP 645
DI 10.1016/j.jvir.2012.12.007
PG 5
WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular
Disease
SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System &
Cardiology
GA 135CL
UT WOS:000318263500004
PM 23622037
ER
PT J
AU Olejnik, J
Alonso, J
Schmidt, KM
Yan, Z
Wang, W
Marzi, A
Ebihara, H
Yang, JH
Patterson, JL
Ryabchikova, E
Muhlberger, E
AF Olejnik, Judith
Alonso, Jesus
Schmidt, Kristina M.
Yan, Zhen
Wang, Wei
Marzi, Andrea
Ebihara, Hideki
Yang, Jinghua
Patterson, Jean L.
Ryabchikova, Elena
Muehlberger, Elke
TI Ebola Virus Does Not Block Apoptotic Signaling Pathways
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID DOUBLE-STRANDED-RNA; DEPENDENT PROTEIN-KINASE; NF-KAPPA-B; CELL-DEATH;
HEMORRHAGIC-FEVER; DENDRITIC CELLS; IN-VITRO; LYMPHOCYTE APOPTOSIS;
CYNOMOLGUS MACAQUES; INFECTED PATIENTS
AB Since viruses rely on functional cellular machinery for efficient propagation, apoptosis is an important mechanism to fight viral infections. In this study, we sought to determine the mechanism of cell death caused by Ebola virus (EBOV) infection by assaying for multiple stages of apoptosis and hallmarks of necrosis. Our data indicate that EBOV does not induce apoptosis in infected cells but rather leads to a nonapoptotic form of cell death. Ultrastructural analysis confirmed necrotic cell death of EBOV-infected cells. To investigate if EBOV blocks the induction of apoptosis, infected cells were treated with different apoptosis-inducing agents. Surprisingly, EBOV-infected cells remained sensitive to apoptosis induced by external stimuli. Neither receptor- nor mitochondrion-mediated apoptosis signaling was inhibited in EBOV infection. Although double-stranded RNA (dsRNA)-induced activation of protein kinase R (PKR) was blocked in EBOV-infected cells, induction of apoptosis mediated by dsRNA was not suppressed. When EBOV-infected cells were treated with dsRNA-dependent caspase recruiter (dsCARE), an antiviral protein that selectively induces apoptosis in cells containing dsRNA, virus titers were strongly reduced. These data show that the inability of EBOV to block apoptotic pathways may open up new strategies toward the development of antiviral therapeutics.
C1 [Olejnik, Judith; Schmidt, Kristina M.; Muehlberger, Elke] Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA.
[Olejnik, Judith; Schmidt, Kristina M.; Muehlberger, Elke] Boston Univ, Natl Emerging Infect Dis Labs, Boston, MA 02118 USA.
[Olejnik, Judith] Univ Marburg, Inst Virol, D-35032 Marburg, Germany.
[Alonso, Jesus; Patterson, Jean L.] Texas Biomed Res Inst, Dept Virol & Immunol, San Antonio, TX USA.
[Yan, Zhen; Wang, Wei] Fourth Mil Med Univ, Sch Pharm, Dept Pharmacogen, State Key Lab Canc Biol, Xian 710032, Peoples R China.
[Marzi, Andrea; Ebihara, Hideki] NIAID, Virol Lab, Div Intramural Res, NIH,Rocky Mt Labs, Hamilton, MT USA.
[Yang, Jinghua] Boston Univ, VA Boston Healthcare Syst, Dept Surg, Boston, MA 02118 USA.
[Ryabchikova, Elena] Russian Acad Sci, Siberian Branch, Inst Chem Biol & Fundamental Med, Novosibirsk, Russia.
RP Muhlberger, E (reprint author), Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA.
EM muehlber@bu.edu
RI Ryabchikova, Elena /G-3089-2013
OI Muhlberger, Elke/0000-0003-3547-9376; Ryabchikova, Elena
/0000-0003-4714-1524
FU NIH [U01-AI082954, CO6 RR12087]; Boston University; German Research
Foundation [SFB 535]; Manchot Foundation; National Natural Science
Foundation of China [NSFC 3092803, NSFC 81071369]; Division of
Intramural Research, National Institute of Allergy and Infectious
Diseases, National Institutes of Health
FX This work was supported by NIH grants U01-AI082954 (to E.M.) and CO6
RR12087 (to J.L.P. and J.A.), start-up funds from Boston University (to
E.M.), and funding from the German Research Foundation (grant SFB 535 to
E.M.) and the Manchot Foundation (to J.O. and E.M). The production of
dsCARE was supported by grants from the National Natural Science
Foundation of China (grants NSFC 3092803 and NSFC 81071369 to J.Y. and
Z.Y.). Funding was also provided by the Division of Intramural Research,
National Institute of Allergy and Infectious Diseases, National
Institutes of Health.
NR 77
TC 10
Z9 10
U1 1
U2 23
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD MAY
PY 2013
VL 87
IS 10
BP 5384
EP 5396
DI 10.1128/JVI.01461-12
PG 13
WC Virology
SC Virology
GA 133QT
UT WOS:000318155000007
PM 23468487
ER
PT J
AU Ackerman, ME
Dugast, AS
McAndrew, EG
Tsoukas, S
Licht, AF
Irvine, DJ
Alter, G
AF Ackerman, Margaret E.
Dugast, Anne-Sophie
McAndrew, Elizabeth G.
Tsoukas, Stephen
Licht, Anna F.
Irvine, Darrell J.
Alter, Galit
TI Enhanced Phagocytic Activity of HIV-Specific Antibodies Correlates with
Natural Production of Immunoglobulins with Skewed Affinity for Fc gamma
R2a and Fc gamma R2b
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS-INFECTION; GAMMA-RIIA GENOTYPE; B-CELL RESPONSES;
FC-RECEPTOR; RHESUS MACAQUES; HIV-1-INFECTED INDIVIDUALS; FCGR2A
POLYMORPHISM; DENDRITIC CELLS; IGG; BINDING
AB While development of an HIV vaccine that can induce neutralizing antibodies remains a priority, decades of research have proven that this is a daunting task. However, accumulating evidence suggests that antibodies with the capacity to harness innate immunity may provide some protection. While significant research has focused on the cytolytic properties of antibodies in acquisition and control, less is known about the role of additional effector functions. In this study, we investigated antibody-dependent phagocytosis of HIV immune complexes, and we observed significant differences in the ability of antibodies from infected subjects to mediate this critical effector function. We observed both quantitative differences in the capacity of antibodies to drive phagocytosis and qualitative differences in their Fc gamma R usage profile. We demonstrate that antibodies from controllers and untreated progressors exhibit increased phagocytic activity, altered Fc domain glycosylation, and skewed interactions with Fc gamma R2a and Fc gamma R2b in both bulk plasma and HIV-specific IgG. While increased phagocytic activity may directly influence immune activation via clearance of inflammatory immune complexes, it is also plausible that Fc receptor usage patterns may regulate the immune response by modulating downstream signals following phagocytosis-driving passive degradation of internalized virus, release of immune modulating cytokines and chemokines, or priming of a more effective adaptive immune response.
C1 [Ackerman, Margaret E.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA.
[Ackerman, Margaret E.; Dugast, Anne-Sophie; McAndrew, Elizabeth G.; Tsoukas, Stephen; Licht, Anna F.; Irvine, Darrell J.; Alter, Galit] MIT, Massachusetts Gen Hosp, Ragon Inst, Charlestown, MA USA.
[Ackerman, Margaret E.; Dugast, Anne-Sophie; McAndrew, Elizabeth G.; Tsoukas, Stephen; Licht, Anna F.; Irvine, Darrell J.; Alter, Galit] Harvard Univ, Charlestown, MA USA.
[Irvine, Darrell J.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA.
[Irvine, Darrell J.] MIT, Dept Mat Sci, Cambridge, MA 02139 USA.
RP Ackerman, ME (reprint author), Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA.
EM margaret.e.ackerman@dartmouth.edu
RI Dugast, AnneSophie/L-9541-2015
FU Collaboration for AIDS Vaccine Discovery: HIV Controllers: Implications
for Vaccine Design [43307]; Susan and Philip T. Ragon Foundation;
Harvard University Center for AIDS Research postdoctoral fellowship
(HUCFAR NIH/NIAID fund) [2P30AI060354-07]
FX These studies were supported by the Collaboration for AIDS Vaccine
Discovery (43307): HIV Controllers: Implications for Vaccine Design and
the Susan and Philip T. Ragon Foundation. M.E.A. was supported by a
Harvard University Center for AIDS Research postdoctoral fellowship
(HUCFAR NIH/NIAID fund 2P30AI060354-07).
NR 60
TC 36
Z9 37
U1 0
U2 8
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD MAY
PY 2013
VL 87
IS 10
BP 5468
EP 5476
DI 10.1128/JVI.03403-12
PG 9
WC Virology
SC Virology
GA 133QT
UT WOS:000318155000014
PM 23468489
ER
PT J
AU Piccinin, AM
Muniz-Terrera, G
Clouston, S
Reynolds, CA
Thorvaldsson, V
Deary, IJ
Deeg, DJH
Johansson, B
Mackinnon, A
Spiro, A
Starr, JM
Skoog, I
Hofer, SM
AF Piccinin, Andrea M.
Muniz-Terrera, Graciela
Clouston, Sean
Reynolds, Chandra A.
Thorvaldsson, Valgeir
Deary, Ian J.
Deeg, Dorly J. H.
Johansson, Boo
Mackinnon, Andrew
Spiro, Avron, III
Starr, John M.
Skoog, Ingmar
Hofer, Scott M.
TI Coordinated Analysis of Age, Sex, and Education Effects on Change in
MMSE Scores
SO JOURNALS OF GERONTOLOGY SERIES B-PSYCHOLOGICAL SCIENCES AND SOCIAL
SCIENCES
LA English
DT Article
DE Cognitive; Coordinated Analysis; Education; Longitudinal; Mental Status
Exam; Meta-analysis; Mixed Model
ID MINI-MENTAL-STATE; 6-YEAR FOLLOW-UP; COGNITIVE DECLINE;
ALZHEIMERS-DISEASE; OLD-AGE; RESERVE HYPOTHESIS; PROCESSING SPEED;
DEMENTIA; PEOPLE; HEALTH
AB We describe and compare the expected performance trajectories of older adults on the Mini-Mental Status Examination (MMSE) across six independent studies from four countries in the context of a collaborative network of longitudinal studies of aging. A coordinated analysis approach is used to compare patterns of change conditional on sample composition differences related to age, sex, and education. Such coordination accelerates evaluation of particular hypotheses. In particular, we focus on the effect of educational attainment on cognitive decline.
Regular and Tobit mixed models were fit to MMSE scores from each study separately. The effects of age, sex, and education were examined based on more than one centering point.
Findings were relatively consistent across studies. On average, MMSE scores were lower for older individuals and declined over time. Education predicted MMSE score, but, with two exceptions, was not associated with decline in MMSE over time.
A straightforward association between educational attainment and rate of cognitive decline was not supported. Thoughtful consideration is needed when synthesizing evidence across studies, as methodologies adopted and sample characteristics, such as educational attainment, invariably differ.
C1 [Piccinin, Andrea M.; Clouston, Sean; Hofer, Scott M.] Univ Victoria, Dept Psychol, Victoria, BC V8W 2Y2, Canada.
[Muniz-Terrera, Graciela] MRC Unit Lifelong Hlth & Ageing, London, England.
[Reynolds, Chandra A.] Univ Calif Riverside, Dept Psychol, Riverside, CA 92521 USA.
[Thorvaldsson, Valgeir; Johansson, Boo] Univ Gothenburg, Dept Psychol, Gothenburg, Sweden.
[Deary, Ian J.] Univ Edinburgh, Dept Psychol, Edinburgh EH8 9YL, Midlothian, Scotland.
[Deeg, Dorly J. H.] VU Univ Med Ctr LASA, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands.
[Mackinnon, Andrew] Univ Melbourne, Ctr Youth Mental Hlth Res, Melbourne, Vic 3010, Australia.
[Spiro, Avron, III] VA Boston Healthcare Syst, Normat Aging Study, Boston, MA USA.
[Starr, John M.] Univ Edinburgh, Alzheimer Scotland Dementia Res Ctr, Edinburgh EH8 9YL, Midlothian, Scotland.
[Skoog, Ingmar] Univ Gothenburg, Gothenburg, Sweden.
RP Piccinin, AM (reprint author), Univ Victoria, Dept Psychol, Victoria, BC V8W 2Y2, Canada.
RI Clouston, Sean/L-4653-2013; Hofer, Scott/D-9090-2014;
OI Clouston, Sean/0000-0002-6124-0329; Hofer, Scott/0000-0001-8923-4337;
Spiro III, Avron/0000-0003-4080-8621; Mackinnon,
Andrew/0000-0003-0831-9801
FU National Institute on Aging at the National Institutes of Health
[AG026453, AG08861]; National Institute on Aging [AG04563, AG10175];
MacArthur Foundation Research Network on Successful Aging; Swedish
Council for Social Research [97:0147:1B]; Swedish Research Council
[2007-2722]; Australian National Health and Medical Research Council;
Swedish Council for Working Life and Social Research; Adlerbertska
Foundation; Hjalmar Svensson Foundation; Knut and Alice Wallenberg
Foundation; Wenner-Gren Foundations; Wilhelm and Martina Lundgrens
Foundation; Swedish Research Council; Swedish Brain Power; Epilife;
Canadian Institutes for Health Research [CUK-103284]; U.S. Department of
Veterans Affairs
FX This work was supported by the National Institute on Aging at the
National Institutes of Health (grant number AG026453) in support of the
Integrative Analysis of Longitudinal Studies of Aging (IALSA) research
network. Swedish Adoption/Twin Study of Aging (SATSA) has been funded by
the National Institute on Aging (AG04563, AG10175), the MacArthur
Foundation Research Network on Successful Aging, the Swedish Council for
Social Research (97:0147:1B), and the Swedish Research Council
(2007-2722). Longitudinal Aging Study Amsterdam (LASA) is largely
supported by the Netherlands Ministry of Health Welfare and Sports.
Healthy Older Person Edinburgh (HOPE) was funded by the Chief Scientist
Office, U.K. Canberra Longitudinal Study (CLS) was funded by the
Australian National Health and Medical Research Council. Origins of
Variance in the Oldest-Old (OCTO-Twin) data collection was funded by the
National Institute on Aging at the National Institutes of Health (grant
number AG08861), the Swedish Council for Working Life and Social
Research, the Adlerbertska Foundation, the Hjalmar Svensson Foundation,
the Knut and Alice Wallenberg Foundation, the Wenner-Gren Foundations,
and the Wilhelm and Martina Lundgrens Foundation. Current work on
Gerontological and Geriatric Population Studies in Gothenburg, Sweden
(H70) and OCTO-Twin was supported by the Swedish Research Council,
Swedish Council for Working Life and Social Research, Swedish Brain
Power, and Epilife. H-70 was funded by the Swedish Research Council.
Support was provided to S. Clouston by the Canadian Institutes for
Health Research (CUK-103284) and to A. Spiro by Merit Review and
Research Career Scientist Awards from the U.S. Department of Veterans
Affairs. This article, however, does not represent the views of the U.S.
Department of Veterans Affairs.
NR 65
TC 21
Z9 24
U1 2
U2 27
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1079-5014
J9 J GERONTOL B-PSYCHOL
JI J. Gerontol. Ser. B-Psychol. Sci. Soc. Sci.
PD MAY
PY 2013
VL 68
IS 3
BP 374
EP 390
DI 10.1093/geronb/gbs077
PG 17
WC Geriatrics & Gerontology; Gerontology; Psychology; Psychology,
Multidisciplinary
SC Geriatrics & Gerontology; Psychology
GA 132PU
UT WOS:000318081800007
PM 23033357
ER
PT J
AU Assis, L
Moretti, AIS
Abrahao, TB
de Souza, HP
Hamblin, MR
Parizotto, NA
AF Assis, Livia
Soares Moretti, Ana Iochabel
Abrahao, Thalita Balsamo
de Souza, Heraldo Possolo
Hamblin, Michael R.
Parizotto, Nivaldo Antonio
TI Low-level laser therapy (808 nm) contributes to muscle regeneration and
prevents fibrosis in rat tibialis anterior muscle after cryolesion
SO LASERS IN MEDICAL SCIENCE
LA English
DT Article
DE LLLT; Muscle cryolesion; Muscle regeneration; MRFs; Growth factors
ID SATELLITE CELL-PROLIFERATION; SKELETAL-MUSCLE; IRRADIATION PROMOTES;
MOLECULAR REGULATION; OXIDATIVE STRESS; GROWTH-FACTOR; IN-VITRO;
ANGIOGENESIS; DIFFERENTIATION; EXPRESSION
AB Muscle regeneration is a complex phenomenon, involving replacement of damaged fibers by new muscle fibers. During this process, there is a tendency to form scar tissue or fibrosis by deposition of collagen that could be detrimental to muscle function. New therapies that could regulate fibrosis and favor muscle regeneration would be important for physical therapy. Low-level laser therapy (LLLT) has been studied for clinical treatment of skeletal muscle injuries and disorders, even though the molecular and cellular mechanisms have not yet been clarified. The aim of this study was to evaluate the effects of LLLT on molecular markers involved in muscle fibrosis and regeneration after cryolesion of the tibialis anterior (TA) muscle in rats. Sixty Wistar rats were randomly divided into three groups: control, injured TA muscle without LLLT, injured TA muscle treated with LLLT. The injured region was irradiated daily for four consecutive days, starting immediately after the lesion using an AlGaAs laser (808 nm, 30 mW, 180 J/cm(2); 3.8 W/cm(2), 1.4 J). The animals were sacrificed on the fourth day after injury. LLLT significantly reduced the lesion percentage area in the injured muscle (p < 0.05), increased mRNA levels of the transcription factors MyoD and myogenin (p < 0.01) and the pro-angiogenic vascular endothelial growth factor (p < 0.01). Moreover, LLLT decreased the expression of the profibrotic transforming growth factor TGF-beta mRNA (p < 0.01) and reduced type I collagen deposition (p < 0.01). These results suggest that LLLT could be an effective therapeutic approach for promoting skeletal muscle regeneration while preventing tissue fibrosis after muscle injury.
C1 [Assis, Livia; Parizotto, Nivaldo Antonio] Univ Fed Sao Carlos, Lab Electrothermophototherapy, Dept Physiotherapy, BR-13560 Sao Carlos, SP, Brazil.
[Soares Moretti, Ana Iochabel; de Souza, Heraldo Possolo] Univ Sao Paulo, Fac Med, Emergency Med Div, Sao Paulo, Brazil.
[Soares Moretti, Ana Iochabel] IAMSPE, Postgrad Hlth Sci Program, Sao Paulo, Brazil.
[Abrahao, Thalita Balsamo] Univ Sao Paulo, Fac Med, Inst Heart, Lab Vasc Biol,Dept Cardiopneumol, Sao Paulo, Brazil.
[Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
RP Moretti, AIS (reprint author), Univ Sao Paulo, Fac Med, Emergency Med Div, Av Dr Arnaldo,455 Sala 3189 01246-903, Sao Paulo, Brazil.
EM aismoretti@yahoo.com.br
RI PARIZOTTO, Nivaldo/D-5347-2014; Assis, Livia/H-8299-2012;
OI PARIZOTTO, Nivaldo/0000-0003-1774-9053; Assis,
Livia/0000-0002-8343-3375; Hamblin, Michael/0000-0001-6431-4605
FU CAPES; CNPQ; FAPESP; NIH [R01AI050875]
FX We acknowledge CAPES, CNPQ and FAPESP for financial support. MR Hamblin
was supported by NIH (grant R01AI050875). Emergency Medicine Division
(LIM 51), Faculdade de Medicina da Universidade de Sao Paulo to provide
technical support in biochemical and molecular biology analyses and
NUPEN (Nucleo de Pesquisa e Ensino em Fototerapia nas Ciencias da Saude)
for supporting and calibrating the laser equipment.
NR 41
TC 25
Z9 28
U1 0
U2 19
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0268-8921
J9 LASER MED SCI
JI Lasers Med. Sci.
PD MAY
PY 2013
VL 28
IS 3
BP 947
EP 955
DI 10.1007/s10103-012-1183-3
PG 9
WC Engineering, Biomedical; Surgery
SC Engineering; Surgery
GA 134BL
UT WOS:000318184600032
PM 22898787
ER
PT J
AU Riedel, CG
Dowen, RH
Lourenco, GF
Kirienko, NV
Heimbucher, T
West, JA
Bowman, SK
Kingston, RE
Dillin, A
Asara, JM
Ruvkun, G
AF Riedel, Christian G.
Dowen, Robert H.
Lourenco, Guinevere F.
Kirienko, Natalia V.
Heimbucher, Thomas
West, Jason A.
Bowman, Sarah K.
Kingston, Robert E.
Dillin, Andrew
Asara, John M.
Ruvkun, Gary
TI DAF-16 employs the chromatin remodeller SWI/SNF to promote stress
resistance and longevity
SO NATURE CELL BIOLOGY
LA English
DT Article
ID NEMATODE CAENORHABDITIS-ELEGANS; C-ELEGANS; LIFE-SPAN; GENE-EXPRESSION;
CELL-DIFFERENTIATION; HUMAN GENOME; CHIP-SEQ; RNA-SEQ; COMPLEX; MUTANTS
AB Organisms are constantly challenged by stresses and privations and require adaptive responses for their survival. The forkhead box O (FOXO) transcription factor DAF-16 (hereafter referred to as DAF-16/FOXO) is a central nexus in these responses, but despite its importance little is known about how it regulates its target genes. Proteomic identification of DAF-16/FOXO-binding partners in Caenorhabditis elegans and their subsequent functional evaluation by RNA interference revealed several candidate DAF-16/FOXO cofactors, most notably the chromatin remodeller SWI/SNF. DAF-16/FOXO and SWI/SNF form a complex and globally co-localize at DAF-16/FOXO target promoters. We show that specifically for gene activation, DAF-16/FOXO depends on SWI/SNF, facilitating SWI/SNF recruitment to target promoters, to activate transcription by presumed remodelling of local chromatin. For the animal, this translates into an essential role for SWI/SNF in DAF-16/FOXO-mediated processes, in particular dauer formation, stress resistance and the promotion of longevity. Thus, we give insight into the mechanisms of DAF-16/FOXO-mediated transcriptional regulation and establish a critical link between ATP-dependent chromatin remodelling and lifespan regulation.
C1 [Riedel, Christian G.; Dowen, Robert H.; Lourenco, Guinevere F.; Kirienko, Natalia V.; West, Jason A.; Bowman, Sarah K.; Kingston, Robert E.; Ruvkun, Gary] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Riedel, Christian G.; Dowen, Robert H.; Lourenco, Guinevere F.; Kirienko, Natalia V.; West, Jason A.; Bowman, Sarah K.; Kingston, Robert E.; Ruvkun, Gary] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA.
[Heimbucher, Thomas; Dillin, Andrew] Salk Inst Biol Studies, Mol & Cell Biol Lab, La Jolla, CA 92037 USA.
[Asara, John M.] Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02115 USA.
[Asara, John M.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
RP Ruvkun, G (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
EM ruvkun@molbio.mgh.harvard.edu
RI West, Jason/I-4445-2014;
OI West, Jason/0000-0002-7252-8651; Riedel, Christian/0000-0002-3689-8022
FU National Institutes of Health [AG014161, AG016636, 5P30CA006516,
2P01CA120964, F32GM093491, F32AI100501-01, GM048405]; Human Frontier
Science Program; European Molecular Biology Organization; American
Cancer Society [122240-PF-12-078-01-RMC]; Tosteson Postdoctoral
Fellowship Award; Damon Runyon Cancer Research Foundation; Glenn
Foundation for Medical Research; Austrian Science Fund (FWF)
FX We thank H. Sawa (National Institute of Genetics, Japan), S. Mitani
(Tokyo Women's Medical University, Japan), M. Hansen (Sanford-Burnham
Medical Research Institute, USA) and the Caenorhabditis Genetics Center
for strains. We thank G. Hayes, U. Kim, M. Borowski, A. Puczinska and D.
Gran for experimental support. We thank I. Cheeseman, K. Bouazoune, M.
Simon, B. Ardehali, W. Mair, T. Montgomery and the Avruch laboratory for
helpful discussions. This work was supported by grants from the National
Institutes of Health to G.R. (AG014161 and AG016636), J.M.A.
(5P30CA006516 and 2P01CA120964), J.A.W. (F32GM093491), N.V.K.
(F32AI100501-01) and R.E.K. (GM048405). C.G.R. was supported by
long-term fellowships from the Human Frontier Science Program and the
European Molecular Biology Organization, R.H.D. by the American Cancer
Society (122240-PF-12-078-01-RMC), N.V.K. by a Tosteson Postdoctoral
Fellowship Award, S.K.B. by the Damon Runyon Cancer Research Foundation,
and T.H. by the Glenn Foundation for Medical Research and the Austrian
Science Fund (FWF).
NR 55
TC 54
Z9 54
U1 2
U2 26
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-7392
EI 1476-4679
J9 NAT CELL BIOL
JI Nat. Cell Biol.
PD MAY
PY 2013
VL 15
IS 5
BP 491
EP +
DI 10.1038/ncb2720
PG 21
WC Cell Biology
SC Cell Biology
GA 135DD
UT WOS:000318265300008
PM 23604319
ER
PT J
AU Nombela-Arrieta, C
Pivarnik, G
Winkel, B
Canty, KJ
Harley, B
Mahoney, JE
Park, SY
Lu, JY
Protopopov, A
Silberstein, LE
AF Nombela-Arrieta, Cesar
Pivarnik, Gregory
Winkel, Beatrice
Canty, Kimberly J.
Harley, Brendan
Mahoney, John E.
Park, Shin-Young
Lu, Jiayun
Protopopov, Alexei
Silberstein, Leslie E.
TI Quantitative imaging of haematopoietic stem and progenitor cell
localization and hypoxic status in the bone marrow microenvironment
SO NATURE CELL BIOLOGY
LA English
DT Article
ID ENDOTHELIAL-CELLS; VASCULAR NICHE; SELF-RENEWAL; OXYGEN;
DIFFERENTIATION; HIF-1-ALPHA; IDENTIFICATION; BALANCE; BIOLOGY; RESIDE
AB The existence of a haematopoietic stem cell niche as a spatially confined regulatory entity relies on the notion that haematopoietic stem and progenitor cells (HSPCs) are strategically positioned in unique bone marrow microenvironments with defined anatomical and functional features. Here, we employ a powerful imaging cytometry platform to perform a comprehensive quantitative analysis of HSPC distribution in bone marrow cavities of femoral bones. We find that HSPCs preferentially localize in endosteal zones, where most closely interact with sinusoidal and non-sinusoidal bone marrow microvessels, which form a distinctive circulatory system. In situ tissue analysis reveals that HSPCs exhibit a hypoxic profile, defined by strong retention of pimonidazole and expression of HIF-1 alpha, regardless of localization throughout the bone marrow, adjacency to vascular structures or cell-cycle status. These studies argue that the characteristic hypoxic state of HSPCs is not solely the result of a minimally oxygenated niche but may be partially regulated by cell-specific mechanisms.
C1 [Nombela-Arrieta, Cesar; Pivarnik, Gregory; Winkel, Beatrice; Canty, Kimberly J.; Park, Shin-Young; Lu, Jiayun; Silberstein, Leslie E.] Childrens Hosp Boston, Dept Lab Med, Div Transfus Med, Boston, MA 02115 USA.
[Harley, Brendan] Univ Illinois, Dept Chem & Biomol Engn, Urbana, IL 61801 USA.
[Mahoney, John E.; Protopopov, Alexei] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA.
RP Nombela-Arrieta, C (reprint author), Childrens Hosp Boston, Dept Lab Med, Div Transfus Med, 300 Longwood Ave, Boston, MA 02115 USA.
EM Cesar.NombelaArrieta@childrens.harvad.edu;
leslie.silberstein@childrens.harvard.edu
OI Nombela-Arrieta, Cesar/0000-0003-0415-259X; Harley,
Brendan/0000-0001-5458-154X
FU Human Frontiers in Science Program long-term fellowship [00194/2008-L];
Harvard Stem Cell Institute; National Heart Lung and Blood Institute,
USA [P01 HL095489, R01 HL093139, HHSN268201000009C]
FX We are grateful to D. Rossi, L. Purton and C. P. Lin for critical
reading of the manuscript and thank the Compucyte Corporation team for
helpful advice. C.N-A. was a recipient of Human Frontiers in Science
Program long-term fellowship 00194/2008-L. This work was financially
supported in part by a seed grant from the Harvard Stem Cell Institute.
L.E.S. is supported by grants P01 HL095489 and R01 HL093139, and
contract HHSN268201000009C from the National Heart Lung and Blood
Institute, USA.
NR 41
TC 150
Z9 150
U1 3
U2 25
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-7392
J9 NAT CELL BIOL
JI Nat. Cell Biol.
PD MAY
PY 2013
VL 15
IS 5
BP 533
EP +
DI 10.1038/ncb2730
PG 20
WC Cell Biology
SC Cell Biology
GA 135DD
UT WOS:000318265300013
PM 23624405
ER
PT J
AU Engelhart, AE
Powner, MW
Szostak, JW
AF Engelhart, Aaron E.
Powner, Matthew W.
Szostak, Jack W.
TI Functional RNAs exhibit tolerance for non-heritable 2 '-5 ' versus 3 '-5
' backbone heterogeneity
SO NATURE CHEMISTRY
LA English
DT Article
ID GLYCEROL NUCLEIC-ACID; HAMMERHEAD RIBOZYME; GENETIC SYSTEM; TEMPLATE;
LIFE; OLIGOMERIZATION; EVOLUTION; ANALOGS; ORIGIN; OLIGORIBONUCLEOTIDES
AB A plausible process for non-enzymatic RNA replication would greatly simplify models of the transition from prebiotic chemistry to simple biology. However, all known conditions for the chemical copying of an RNA template result in the synthesis of a complementary strand that contains a mixture of 2'-5' and 3'-5' linkages, rather than the selective synthesis of only 3'-5' linkages as found in contemporary RNA. Here we show that such backbone heterogeneity is compatible with RNA folding into defined three-dimensional structures that retain molecular recognition and catalytic properties and, therefore, would not prevent the evolution of functional RNAs such as ribozymes. Moreover, the same backbone heterogeneity lowers the melting temperature of RNA duplexes that would otherwise be too stable for thermal strand separation. By allowing copied strands to dissociate, this heterogeneity may have been one of the essential features that allowed RNA to emerge as the first biopolymer.
C1 [Engelhart, Aaron E.] Massachusetts Gen Hosp, Howard Hughes Med Inst, Dept Mol Biol, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA.
RP Engelhart, AE (reprint author), Massachusetts Gen Hosp, Howard Hughes Med Inst, Dept Mol Biol, 185 Cambridge St, Boston, MA 02114 USA.
EM szostak@molbio.mgh.harvard.edu
OI Engelhart, Aaron/0000-0002-1849-7700; Powner,
Matthew/0000-0002-6368-3190
FU NSF [CHE-0809413]; NASA
FX J.W.S. is an Investigator of the Howard Hughes Medical Institute (HHMI).
A. E. E. is supported by an appointment to the NASA Postdoctoral
Program, administered by Oak Ridge Associated Universities through a
contract with NASA. M. W. P. was an HHMI Research Associate. This work
was supported in part through NSF Grant CHE-0809413 to J.W.S. We thank
J. Craig Blain for oligonucleotide mass spectrometry, K. Adamala for
advice with RNA melting experiments and N. Prywes for helpful
discussions and assistance with figure preparation.
NR 44
TC 37
Z9 40
U1 5
U2 59
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1755-4330
EI 1755-4349
J9 NAT CHEM
JI Nat. Chem.
PD MAY
PY 2013
VL 5
IS 5
BP 390
EP 394
DI 10.1038/nchem.1623
PG 5
WC Chemistry, Multidisciplinary
SC Chemistry
GA 131AE
UT WOS:000317961700012
PM 23609089
ER
PT J
AU Dulak, AM
Stojanov, P
Peng, SY
Lawrence, MS
Fox, C
Stewart, C
Bandla, S
Imamura, Y
Schumacher, SE
Shefler, E
McKenna, A
Carter, SL
Cibulskis, K
Sivachenko, A
Saksena, G
Voet, D
Ramos, AH
Auclair, D
Thompson, K
Sougnez, C
Onofrio, RC
Guiducci, C
Beroukhim, R
Zhou, ZR
Lin, L
Lin, J
Reddy, R
Chang, A
Landrenau, R
Pennathur, A
Ogino, S
Luketich, JD
Golub, TR
Gabriel, SB
Lander, ES
Beer, DG
Godfrey, TE
Getz, G
Bass, AJ
AF Dulak, Austin M.
Stojanov, Petar
Peng, Shouyong
Lawrence, Michael S.
Fox, Cameron
Stewart, Chip
Bandla, Santhoshi
Imamura, Yu
Schumacher, Steven E.
Shefler, Erica
McKenna, Aaron
Carter, Scott L.
Cibulskis, Kristian
Sivachenko, Andrey
Saksena, Gordon
Voet, Douglas
Ramos, Alex H.
Auclair, Daniel
Thompson, Kristin
Sougnez, Carrie
Onofrio, Robert C.
Guiducci, Candace
Beroukhim, Rameen
Zhou, Zhongren
Lin, Lin
Lin, Jules
Reddy, Rishindra
Chang, Andrew
Landrenau, Rodney
Pennathur, Arjun
Ogino, Shuji
Luketich, James D.
Golub, Todd R.
Gabriel, Stacey B.
Lander, Eric S.
Beer, David G.
Godfrey, Tony E.
Getz, Gad
Bass, Adam J.
TI Exome and whole-genome sequencing of esophageal adenocarcinoma
identifies recurrent driver events and mutational complexity
SO NATURE GENETICS
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; ERBB2 KINASE DOMAIN; SOMATIC MUTATIONS;
GENE-MUTATIONS; BARRETT-ESOPHAGUS; STRUCTURAL BASIS; PROSTATE-CANCER;
TROYER-SYNDROME; RAC ACTIVATION; LUNG-CANCER
AB The incidence of esophageal adenocarcinoma (EAC) has risen 600% over the last 30 years. With a 5-year survival rate of similar to 15%, the identification of new therapeutic targets for EAC is greatly important. We analyze the mutation spectra from whole-exome sequencing of 149 EAC tumor-normal pairs, 15 of which have also been subjected to whole-genome sequencing. We identify a mutational signature defined by a high prevalence of A>C transversions at AA dinucleotides. Statistical analysis of exome data identified 26 significantly mutated genes. Of these genes, five (TP53, CDKN2A, SMAD4, ARID1A and PIK3CA) have previously been implicated in EAC. The new significantly mutated genes include chromatin-modifying factors and candidate contributors SPG20, TLR4, ELMO1 and DOCK2. Functional analyses of EAC-derived mutations in ELMO1 identifies increased cellular invasion. Therefore, we suggest the potential activation of the RAC1 pathway as a contributor to EAC tumorigenesis.
C1 [Dulak, Austin M.; Stojanov, Petar; Peng, Shouyong; Fox, Cameron; Imamura, Yu; Schumacher, Steven E.; Beroukhim, Rameen; Ogino, Shuji; Golub, Todd R.; Bass, Adam J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Dulak, Austin M.; Stojanov, Petar; Peng, Shouyong; Lawrence, Michael S.; Stewart, Chip; Schumacher, Steven E.; Shefler, Erica; McKenna, Aaron; Carter, Scott L.; Cibulskis, Kristian; Sivachenko, Andrey; Saksena, Gordon; Voet, Douglas; Ramos, Alex H.; Auclair, Daniel; Thompson, Kristin; Sougnez, Carrie; Onofrio, Robert C.; Guiducci, Candace; Beroukhim, Rameen; Golub, Todd R.; Gabriel, Stacey B.; Lander, Eric S.; Getz, Gad; Bass, Adam J.] Broad Inst MIT & Harvard, Canc Program, Cambridge, MA USA.
[Dulak, Austin M.; Stojanov, Petar; Lander, Eric S.] MIT, Dept Biol, Cambridge, MA USA.
[Bandla, Santhoshi; Zhou, Zhongren; Godfrey, Tony E.] Univ Rochester, Dept Surg, Rochester, NY USA.
[Beroukhim, Rameen; Bass, Adam J.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Beroukhim, Rameen; Ogino, Shuji; Golub, Todd R.; Lander, Eric S.; Bass, Adam J.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Lin, Lin; Lin, Jules; Reddy, Rishindra; Chang, Andrew; Beer, David G.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA.
[Landrenau, Rodney; Pennathur, Arjun; Luketich, James D.] Univ Pittsburgh, Med Ctr, Dept Cardiothorac Surg, Pittsburgh, PA USA.
[Ogino, Shuji] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Ogino, Shuji] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Golub, Todd R.] Howard Hughes Med Inst, Chevy Chase, MD USA.
[Getz, Gad] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Getz, Gad] Dept Pathol, Boston, MA USA.
RP Bass, AJ (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
EM gadgetz@broadinstitute.org; adam_bass@dfci.harvard.edu
RI Schumacher, Steven/E-9821-2013; Godfrey, Tony/A-5572-2013;
OI Schumacher, Steven/0000-0002-6819-5647; Godfrey,
Tony/0000-0002-3283-6983; Chang, Andrew/0000-0001-9506-0425
FU US National Human Genome Research Institute (NHGRI) Large-Scale
Sequencing Program [U54 HG003067]; National Cancer Institute [K08
CA134931, R01 CA151993]; DeGregorio Family Foundation; Karin Grunebaum
Cancer Research Foundation; Target Cancer; Connecticut Conquers Cancer;
Dana-Farber/Harvard Cancer Center GI Cancer Specialized Programs of
Research Excellence (US National Institutes of Health (NIH)) [P50
CA127003]; NIH [CA163059, CA46592, CA090665, CA130853]
FX We thank M. Meyerson for helpful discussions and review of the
manuscript and members of the Broad Institute Biological Samples
Platform, Genetic Analysis Platform and Genome Sequencing Platform for
their assistance. We are also grateful for the physicians and hospital
staff whose efforts in collecting these samples are essential to this
research. This work was supported by the US National Human Genome
Research Institute (NHGRI) Large-Scale Sequencing Program (U54 HG003067
to the Broad Institute, E. S. L.), the National Cancer Institute (K08
CA134931 to A.J.B.), the DeGregorio Family Foundation (A.J.B.), the
Karin Grunebaum Cancer Research Foundation (A.J.B.), the Target Cancer
(A.J.B.) and Connecticut Conquers Cancer (A.J.B.). S.O. and Y.I. are
supported by the National Cancer Institute (R01 CA151993 to S.O.) and
the Dana-Farber/Harvard Cancer Center GI Cancer Specialized Programs of
Research Excellence (US National Institutes of Health (NIH) grant P50
CA127003). D. G. B. is supported by NIH grants CA163059 and CA46592.
J.D.L. is supported by NIH grant CA090665. T. E. G. is supported by NIH
grant CA130853.
NR 81
TC 224
Z9 230
U1 7
U2 56
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nature Genet.
PD MAY
PY 2013
VL 45
IS 5
BP 478
EP U37
DI 10.1038/ng.2591
PG 11
WC Genetics & Heredity
SC Genetics & Heredity
GA 133RU
UT WOS:000318158200008
PM 23525077
ER
PT J
AU Berndt, SI
Gustafsson, S
Magi, R
Ganna, A
Wheeler, E
Feitosa, MF
Justice, AE
Monda, KL
Croteau-Chonka, DC
Day, FR
Esko, T
Fall, T
Ferreira, T
Gentilini, D
Jackson, AU
Luan, JA
Randall, JC
Vedantam, S
Willer, CJ
Winkler, TW
Wood, AR
Workalemahu, T
Hu, YJ
Lee, SH
Liang, LM
Lin, DY
Min, JL
Neale, BM
Thorleifsson, G
Yang, J
Albrecht, E
Amin, N
Bragg-Gresham, JL
Cadby, G
den Heijer, M
Eklund, N
Fischer, K
Goel, A
Hottenga, JJ
Huffman, JE
Jarick, I
Johansson, A
Johnson, T
Kanoni, S
Kleber, ME
Konig, IR
Kristiansson, K
Kutalik, Z
Lamina, C
Lecoeur, C
Li, G
Mangino, M
McArdle, WL
Medina-Gomez, C
Muller-Nurasyid, M
Ngwa, JS
Nolte, IM
Lavinia, P
Pechlivanis, S
Perola, M
Peters, MJ
Preuss, M
Rose, LM
Shi, JX
Shungin, D
Smith, AV
Strawbridge, RJ
Surakka, I
Teumer, A
Trip, MD
Tyrer, J
Van Vliet-Ostaptchouk, JV
Vandenput, L
Waite, LL
Zhao, JH
Absher, D
Asselbergs, FW
Atalay, M
Attwood, AP
Balmforth, AJ
Basart, H
Beilby, J
Bonnycastle, LL
Brambilla, P
Bruinenberg, M
Campbell, H
Chasman, DI
Chines, PS
Collins, FS
Connell, JM
Cookson, WO
de Faire, U
de Vegt, F
Dei, M
Dimitriou, M
Edkins, S
Estrada, K
Evans, DM
Farrall, M
Ferrario, MM
Ferrieres, J
Franke, L
Frau, F
Gejman, PV
Grallert, H
Gronberg, H
Gudnason, V
Hall, AS
Hall, P
Hartikainen, AL
Hayward, C
Heard-Costa, NL
Heath, AC
Hebebrand, J
Homuth, G
Hu, FB
Hunt, SE
Hypponen, E
Iribarren, C
Jacobs, KB
Jansson, JO
Jula, A
Kahonen, M
Kathiresan, S
Kee, F
Khaw, KT
Kivimaki, M
Koenig, W
Kraja, AT
Kumari, M
Kuulasmaa, K
Kuusisto, J
Laitinen, JH
Lakka, TA
Langenberg, C
Launer, LJ
Lind, L
Lindstrom, J
Liu, JJ
Liuzzi, A
Lokki, ML
Lorentzon, M
Madden, PA
Magnusson, PK
Manunta, P
Marek, D
Marz, W
Leach, IM
McKnight, B
Medland, SE
Mihailov, E
Milani, L
Montgomery, GW
Mooser, V
Muhleisen, TW
Munroe, PB
Musk, AW
Narisu, N
Navis, G
Nicholson, G
Nohr, EA
Ong, KK
Oostra, BA
Palmer, CNA
Palotie, A
Peden, JF
Pedersen, N
Peters, A
Polasek, O
Pouta, A
Pramstaller, PP
Prokopenko, I
Putter, C
Radhakrishnan, A
Raitakari, O
Rendon, A
Rivadeneira, F
Rudan, I
Saaristo, TE
Sambrook, JG
Sanders, AR
Sanna, S
Saramies, J
Schipf, S
Schreiber, S
Schunkert, H
Shin, SY
Signorini, S
Sinisalo, J
Skrobek, B
Soranzo, N
Stancakova, A
Stark, K
Stephens, JC
Stirrups, K
Stolk, RP
Stumvoll, M
Swift, AJ
Theodoraki, EV
Thorand, B
Tregouet, DA
Tremoli, E
Van der Klauw, MM
van Meurs, JBJ
Vermeulen, SH
Viikari, J
Virtamo, J
Vitart, V
Waeber, G
Wang, ZM
Widen, E
Wild, SH
Willemsen, G
Winkelmann, BR
Witteman, JCM
Wolffenbuttel, BHR
Wong, A
Wright, AF
Zillikens, MC
Amouyel, P
Boehm, BO
Boerwinkle, E
Boomsma, DI
Caulfield, MJ
Chanock, SJ
Cupples, LA
Cusi, D
Dedoussis, GV
Erdmann, J
Eriksson, JG
Franks, PW
Froguel, P
Gieger, C
Gyllensten, U
Hamsten, A
Harris, TB
Hengstenberg, C
Hicks, AA
Hingorani, A
Hinney, A
Hofman, A
Hovingh, KG
Hveem, K
Illig, T
Jarvelin, MR
Jockel, KH
Keinanen-Kiukaanniemi, SM
Kiemeney, LA
Kuh, D
Laakso, M
Lehtimaki, T
Levinson, DF
Martin, NG
Metspalu, A
Morris, AD
Nieminen, MS
Njolstad, I
Ohlsson, C
Oldehinkel, AJ
Ouwehand, WH
Palmer, LJ
Penninx, B
Power, C
Province, MA
Psaty, BM
Qi, L
Rauramaa, R
Ridker, PM
Ripatti, S
Salomaa, V
Samani, NJ
Snieder, H
Sorensen, TIA
Spector, TD
Stefansson, K
Tonjes, A
Tuomilehto, J
Uitterlinden, AG
Uusitupa, M
van der Harst, P
Vollenweider, P
Wallaschofski, H
Wareham, NJ
Watkins, H
Wichmann, HE
Wilson, JF
Abecasis, GR
Assimes, TL
Barroso, I
Boehnke, M
Borecki, IB
Deloukas, P
Fox, CS
Frayling, T
Groop, LC
Haritunian, T
Heid, IM
Hunter, D
Kaplan, RC
Karpe, F
Moffatt, MF
Mohlke, KL
O'Connell, JR
Pawitan, Y
Schadt, EE
Schlessinger, D
Steinthorsdottir, V
Strachan, DP
Thorsteinsdottir, U
van Duijn, CM
Visscher, PM
Di Blasio, AM
Hirschhorn, JN
Lindgren, CM
Morris, AP
Meyre, D
Scherag, A
McCarthy, MI
Speliotes, EK
North, KE
Loos, RJF
Ingelsson, E
AF Berndt, Sonja I.
Gustafsson, Stefan
Maegi, Reedik
Ganna, Andrea
Wheeler, Eleanor
Feitosa, Mary F.
Justice, Anne E.
Monda, Keri L.
Croteau-Chonka, Damien C.
Day, Felix R.
Esko, Tonu
Fall, Tove
Ferreira, Teresa
Gentilini, Davide
Jackson, Anne U.
Luan, Jian'an
Randall, Joshua C.
Vedantam, Sailaja
Willer, Cristen J.
Winkler, Thomas W.
Wood, Andrew R.
Workalemahu, Tsegaselassie
Hu, Yi-Juan
Lee, Sang Hong
Liang, Liming
Lin, Dan-Yu
Min, Josine L.
Neale, Benjamin M.
Thorleifsson, Gudmar
Yang, Jian
Albrecht, Eva
Amin, Najaf
Bragg-Gresham, Jennifer L.
Cadby, Gemma
den Heijer, Martin
Eklund, Niina
Fischer, Krista
Goel, Anuj
Hottenga, Jouke-Jan
Huffman, Jennifer E.
Jarick, Ivonne
Johansson, Asa
Johnson, Toby
Kanoni, Stavroula
Kleber, Marcus E.
Koenig, Inke R.
Kristiansson, Kati
Kutalik, Zoltn
Lamina, Claudia
Lecoeur, Cecile
Li, Guo
Mangino, Massimo
McArdle, Wendy L.
Medina-Gomez, Carolina
Mueller-Nurasyid, Martina
Ngwa, Julius S.
Nolte, Ilja M.
Paternoster, Lavinia
Pechlivanis, Sonali
Perola, Markus
Peters, Marjolein J.
Preuss, Michael
Rose, Lynda M.
Shi, Jianxin
Shungin, Dmitry
Smith, Albert Vernon
Strawbridge, Rona J.
Surakka, Ida
Teumer, Alexander
Trip, Mieke D.
Tyrer, Jonathan
Van Vliet-Ostaptchouk, Jana V.
Vandenput, Liesbeth
Waite, Lindsay L.
Zhao, Jing Hua
Absher, Devin
Asselbergs, Folkert W.
Atalay, Mustafa
Attwood, Antony P.
Balmforth, Anthony J.
Basart, Hanneke
Beilby, John
Bonnycastle, Lori L.
Brambilla, Paolo
Bruinenberg, Marcel
Campbell, Harry
Chasman, Daniel I.
Chines, Peter S.
Collins, Francis S.
Connell, John M.
Cookson, William O.
de Faire, Ulf
de Vegt, Femmie
Dei, Mariano
Dimitriou, Maria
Edkins, Sarah
Estrada, Karol
Evans, David M.
Farrall, Martin
Ferrario, Marco M.
Ferrieres, Jean
Franke, Lude
Frau, Francesca
Gejman, Pablo V.
Grallert, Harald
Groenberg, Henrik
Gudnason, Vilmundur
Hall, Alistair S.
Hall, Per
Hartikainen, Anna-Liisa
Hayward, Caroline
Heard-Costa, Nancy L.
Heath, Andrew C.
Hebebrand, Johannes
Homuth, Georg
Hu, Frank B.
Hunt, Sarah E.
Hyppoenen, Elina
Iribarren, Carlos
Jacobs, Kevin B.
Jansson, John-Olov
Jula, Antti
Kahonen, Mika
Kathiresan, Sekar
Kee, Frank
Khaw, Kay-Tee
Kivimaki, Mika
Koenig, Wolfgang
Kraja, Aldi T.
Kumari, Meena
Kuulasmaa, Kari
Kuusisto, Johanna
Laitinen, Jaana H.
Lakka, Timo A.
Langenberg, Claudia
Launer, Lenore J.
Lind, Lars
Lindstrom, Jaana
Liu, Jianjun
Liuzzi, Antonio
Lokki, Marja-Liisa
Lorentzon, Mattias
Madden, Pamela A.
Magnusson, Patrik K.
Manunta, Paolo
Marek, Diana
Maerz, Winfried
Leach, Irene Mateo
McKnight, Barbara
Medland, Sarah E.
Mihailov, Evelin
Milani, Lili
Montgomery, Grant W.
Mooser, Vincent
Muehleisen, Thomas W.
Munroe, Patricia B.
Musk, Arthur W.
Narisu, Narisu
Navis, Gerjan
Nicholson, George
Nohr, Ellen A.
Ong, Ken K.
Oostra, Ben A.
Palmer, Colin N. A.
Palotie, Aarno
Peden, John F.
Pedersen, Nancy
Peters, Annette
Polasek, Ozren
Pouta, Anneli
Pramstaller, Peter P.
Prokopenko, Inga
Puetter, Carolin
Radhakrishnan, Aparna
Raitakari, Olli
Rendon, Augusto
Rivadeneira, Fernando
Rudan, Igor
Saaristo, Timo E.
Sambrook, Jennifer G.
Sanders, Alan R.
Sanna, Serena
Saramies, Jouko
Schipf, Sabine
Schreiber, Stefan
Schunkert, Heribert
Shin, So-Youn
Signorini, Stefano
Sinisalo, Juha
Skrobek, Boris
Soranzo, Nicole
Stancakova, Alena
Stark, Klaus
Stephens, Jonathan C.
Stirrups, Kathleen
Stolk, Ronald P.
Stumvoll, Michael
Swift, Amy J.
Theodoraki, Eirini V.
Thorand, Barbara
Tregouet, David-Alexandre
Tremoli, Elena
Van der Klauw, Melanie M.
van Meurs, Joyce B. J.
Vermeulen, Sita H.
Viikari, Jorma
Virtamo, Jarmo
Vitart, Veronique
Waeber, Gerard
Wang, Zhaoming
Widen, Elisabeth
Wild, Sarah H.
Willemsen, Gonneke
Winkelmann, Bernhard R.
Witteman, Jacqueline C. M.
Wolffenbuttel, Bruce H. R.
Wong, Andrew
Wright, Alan F.
Zillikens, M. Carola
Amouyel, Philippe
Boehm, Bernhard O.
Boerwinkle, Eric
Boomsma, Dorret I.
Caulfield, Mark J.
Chanock, Stephen J.
Cupples, L. Adrienne
Cusi, Daniele
Dedoussis, George V.
Erdmann, Jeanette
Eriksson, Johan G.
Franks, Paul W.
Froguel, Philippe
Gieger, Christian
Gyllensten, Ulf
Hamsten, Anders
Harris, Tamara B.
Hengstenberg, Christian
Hicks, Andrew A.
Hingorani, Aroon
Hinney, Anke
Hofman, Albert
Hovingh, Kees G.
Hveem, Kristian
Illig, Thomas
Jarvelin, Marjo-Riitta
Joeckel, Karl-Heinz
Keinanen-Kiukaanniemi, Sirkka M.
Kiemeney, Lambertus A.
Kuh, Diana
Laakso, Markku
Lehtimaki, Terho
Levinson, Douglas F.
Martin, Nicholas G.
Metspalu, Andres
Morris, Andrew D.
Nieminen, Markku S.
Njolstad, Inger
Ohlsson, Claes
Oldehinkel, Albertine J.
Ouwehand, Willem H.
Palmer, Lyle J.
Penninx, Brenda
Power, Chris
Province, Michael A.
Psaty, Bruce M.
Qi, Lu
Rauramaa, Rainer
Ridker, Paul M.
Ripatti, Samuli
Salomaa, Veikko
Samani, Nilesh J.
Snieder, Harold
Sorensen, Thorkild I. A.
Spector, Timothy D.
Stefansson, Kari
Tonjes, Anke
Tuomilehto, Jaakko
Uitterlinden, Andre G.
Uusitupa, Matti
van der Harst, Pim
Vollenweider, Peter
Wallaschofski, Henri
Wareham, Nicholas J.
Watkins, Hugh
Wichmann, H-Erich
Wilson, James F.
Abecasis, Goncalo R.
Assimes, Themistocles L.
Barroso, Ines
Boehnke, Michael
Borecki, Ingrid B.
Deloukas, Panos
Fox, Caroline S.
Frayling, Timothy
Groop, Leif C.
Haritunian, Talin
Heid, Iris M.
Hunter, David
Kaplan, Robert C.
Karpe, Fredrik
Moffatt, Miriam F.
Mohlke, Karen L.
O'Connell, Jeffrey R.
Pawitan, Yudi
Schadt, Eric E.
Schlessinger, David
Steinthorsdottir, Valgerdur
Strachan, David P.
Thorsteinsdottir, Unnur
van Duijn, Cornelia M.
Visscher, Peter M.
Di Blasio, Anna Maria
Hirschhorn, Joel N.
Lindgren, Cecilia M.
Morris, Andrew P.
Meyre, David
Scherag, Andr
McCarthy, Mark I.
Speliotes, Elizabeth K.
North, Kari E.
Loos, Ruth J. F.
Ingelsson, Erik
TI Genome-wide meta-analysis identifies 11 new loci for anthropometric
traits and provides insights into genetic architecture
SO NATURE GENETICS
LA English
DT Article
ID BODY-MASS INDEX; EXTREME OBESITY; MISSING HERITABILITY; COMMON VARIANTS;
CONFER RISK; EARLY-ONSET; ASSOCIATION; POPULATION; EXPRESSION; SORTILIN
AB Approaches exploiting trait distribution extremes may be used to identify loci associated with common traits, but it is unknown whether these loci are generalizable to the broader population. In a genome-wide search for loci associated with the upper versus the lower 5th percentiles of body mass index, height and waist-to-hip ratio, as well as clinical classes of obesity, including up to 263,407 individuals of European ancestry, we identified 4 new loci (IGFBP4, H6PD, RSRC1 and PPP2R2A) influencing height detected in the distribution tails and 7 new loci (HNF4G, RPTOR, GNAT2, MRPS33P4, ADCY9, HS6ST3 and ZZZ3) for clinical classes of obesity. Further, we find a large overlap in genetic structure and the distribution of variants between traits based on extremes and the general population and little etiological heterogeneity between obesity subgroups.
C1 [Berndt, Sonja I.; Shi, Jianxin; Jacobs, Kevin B.; Wang, Zhaoming; Chanock, Stephen J.] NCI, US Dept HHS, Div Canc Epidemiol & Genet, US Natl Inst Hlth, Bethesda, MD 20892 USA.
[Gustafsson, Stefan; Ingelsson, Erik] Uppsala Univ, Dept Med Sci, Mol Epidemiol & Sci Life Lab, Uppsala, Sweden.
[Gustafsson, Stefan; Ganna, Andrea; Fall, Tove; Groenberg, Henrik; Hall, Per; Magnusson, Patrik K.; Pedersen, Nancy; Pawitan, Yudi; Ingelsson, Erik] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.
[Maegi, Reedik; Ferreira, Teresa; Randall, Joshua C.; Min, Josine L.; Prokopenko, Inga; Lindgren, Cecilia M.; Morris, Andrew P.; McCarthy, Mark I.; Ingelsson, Erik] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
[Maegi, Reedik; Esko, Tonu; Fischer, Krista; Perola, Markus; Mihailov, Evelin; Milani, Lili; Metspalu, Andres] Univ Tartu, Estonian Genome Ctr, EE-50090 Tartu, Estonia.
[Wheeler, Eleanor; Randall, Joshua C.; Kanoni, Stavroula; Edkins, Sarah; Hunt, Sarah E.; Palotie, Aarno; Radhakrishnan, Aparna; Shin, So-Youn; Soranzo, Nicole; Stirrups, Kathleen; Ouwehand, Willem H.; Ripatti, Samuli; Barroso, Ines; Deloukas, Panos] Wellcome Trust Sanger Inst, Cambridge, England.
[Feitosa, Mary F.; Kraja, Aldi T.; Province, Michael A.; Borecki, Ingrid B.] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA.
[Justice, Anne E.; Monda, Keri L.; North, Kari E.] Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA.
[Monda, Keri L.] Amgen Inc, Ctr Observat Res, Thousand Oaks, CA USA.
[Croteau-Chonka, Damien C.; Mohlke, Karen L.] Univ N Carolina, Dept Genet, Chapel Hill, NC USA.
[Day, Felix R.; Luan, Jian'an; Zhao, Jing Hua; Langenberg, Claudia; Ong, Ken K.; Wareham, Nicholas J.; Loos, Ruth J. F.] Addenbrookes Hosp, MRC, Epidemiol Unit, Inst Metab Sci, Cambridge, England.
[Esko, Tonu; Mihailov, Evelin; Metspalu, Andres] Univ Tartu, Inst Mol & Cell Biol, EE-50090 Tartu, Estonia.
[Gentilini, Davide; Di Blasio, Anna Maria] Ist Auxol Italiano, Dept Mol Biol, Milan, Italy.
[Jackson, Anne U.; Bragg-Gresham, Jennifer L.; Abecasis, Goncalo R.; Boehnke, Michael] Univ Michigan, Dept Biostat, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
[Vedantam, Sailaja; Hirschhorn, Joel N.] Childrens Hosp, Div Genet, Ctr Basic & Translat Obes Res, Boston, MA 02115 USA.
[Vedantam, Sailaja; Hirschhorn, Joel N.] Childrens Hosp, Div Endocrinol, Ctr Basic & Translat Obes Res, Boston, MA 02115 USA.
[Vedantam, Sailaja; Kathiresan, Sekar; Hirschhorn, Joel N.] Broad Inst, Metab Initiat, Cambridge, MA USA.
[Vedantam, Sailaja; Kathiresan, Sekar; Hirschhorn, Joel N.] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
[Vedantam, Sailaja; Hirschhorn, Joel N.] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA.
[Willer, Cristen J.] Univ Michigan, Dept Internal Med Cardiovasc, Ann Arbor, MI 48109 USA.
[Willer, Cristen J.] Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA.
[Willer, Cristen J.; Speliotes, Elizabeth K.] Univ Michigan, Dept Computat Med & Bioinformat, Ann Arbor, MI 48109 USA.
[Winkler, Thomas W.; Heid, Iris M.] Univ Regensburg, Med Ctr, Inst Epidemiol & Prevent Med, D-93053 Regensburg, Germany.
[Wood, Andrew R.; Frayling, Timothy; Ingelsson, Erik] Univ Exeter, Peninsula Coll Med & Dent, Exeter, Devon, England.
[Workalemahu, Tsegaselassie; Hu, Frank B.; Franks, Paul W.; Qi, Lu; Hunter, David] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Workalemahu, Tsegaselassie; Qi, Lu; Hunter, David] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA.
[Workalemahu, Tsegaselassie; Qi, Lu; Hunter, David] Harvard Univ, Sch Med, Boston, MA USA.
[Lee, Sang Hong; Visscher, Peter M.] Emory Univ, Dept Biostat & Bioinformat, Atlanta, GA 30322 USA.
[Liang, Liming] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Liang, Liming] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Lin, Dan-Yu] Univ N Carolina, Dept Biostat, Chapel Hill, NC USA.
[Neale, Benjamin M.] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
[Thorleifsson, Gudmar; Stefansson, Kari; Steinthorsdottir, Valgerdur; Thorsteinsdottir, Unnur] deCODE Genet, Reykjavik, Iceland.
[Yang, Jian; Visscher, Peter M.] Univ Queensland, Princess Alexandra Hosp, Diamantina Inst, Brisbane, Qld, Australia.
[Yang, Jian; Medland, Sarah E.; Montgomery, Grant W.; Martin, Nicholas G.] Queensland Inst Med Res, Brisbane, Qld 4006, Australia.
[Albrecht, Eva; Amin, Najaf; Mueller-Nurasyid, Martina; Gieger, Christian] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Genet Epidemiol, Neuherberg, Germany.
[Medina-Gomez, Carolina; Peters, Marjolein J.; Estrada, Karol; Rivadeneira, Fernando; van Meurs, Joyce B. J.; Witteman, Jacqueline C. M.; Hofman, Albert; Uitterlinden, Andre G.; van Duijn, Cornelia M.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
[Cadby, Gemma; Palmer, Lyle J.] Ontario Inst Canc Res, Toronto, ON, Canada.
[Cadby, Gemma; Palmer, Lyle J.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Prosserman Ctr Hlth Res, Toronto, ON M5G 1X5, Canada.
[Cadby, Gemma] Univ Western Australia, Ctr Genet Epidemiol & Biostat, Crawley, WA, Australia.
[den Heijer, Martin] Vrije Univ Amsterdam, Med Ctr, Dept Internal Med, Amsterdam, Netherlands.
[Eklund, Niina; Kristiansson, Kati; Perola, Markus; Surakka, Ida] Natl Inst Hlth & Welf, Dept Chron Dis Prevent, Unit Publ Hlth Gen, Helsinki, Finland.
[Goel, Anuj; Farrall, Martin; Ripatti, Samuli; Watkins, Hugh] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
[Hottenga, Jouke-Jan; Willemsen, Gonneke; Boomsma, Dorret I.] Vrije Univ Amsterdam, Dept Biol Psychol, Amsterdam, Netherlands.
[Huffman, Jennifer E.; Hayward, Caroline; Vitart, Veronique; Wright, Alan F.] Western Gen Hosp, MRC, Inst Genet & Mol Med, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland.
[Jarick, Ivonne] Univ Marburg, Inst Med Biometry & Epidemiol, Marburg, Germany.
[Johansson, Asa; Gyllensten, Ulf] Uppsala Univ, Dept Immunol Genet & Pathol, Uppsala, Sweden.
[Johansson, Asa] Univ Uppsala Hosp, Uppsala Clin Res Ctr, Uppsala, Sweden.
[Johnson, Toby; Munroe, Patricia B.; Caulfield, Mark J.] Queen Mary Univ London, Barts & London Sch Med & Dent, Genome Ctr, London, England.
[Johnson, Toby; Munroe, Patricia B.; Caulfield, Mark J.] Queen Mary Univ London, Barts & London Sch Med & Dent, William Harvey Res Inst, London, England.
[Kleber, Marcus E.] Ludwigshafen Risk & Cardiovasc Hlth LURIC Study, Freiburg, Germany.
[Koenig, Inke R.; Preuss, Michael] Heidelberg Univ, Med Fac Mannheim, Mannheim Inst Publ Hlth Social & Prevent Med, Mannheim, Germany.
[Koenig, Inke R.; Preuss, Michael] Med Univ Lubeck, Inst Med Biometrie & Stat, Univ Klinikum Schleswig Holstein, D-23538 Lubeck, Germany.
[Kutalik, Zoltn; Marek, Diana] Univ Lausanne, Dept Med Genet, Lausanne, Switzerland.
[Kutalik, Zoltn; Marek, Diana] Swiss Inst Bioinformat, Lausanne, Switzerland.
[Lamina, Claudia] Med Univ Innsbruck, Div Genet Epidemiol Mol & Clin Pharmacol, Dept Med Genet, A-6020 Innsbruck, Austria.
[Lecoeur, Cecile; Skrobek, Boris; Froguel, Philippe; Meyre, David] Univ Lille Nord France, Lille, France.
[Lecoeur, Cecile; Skrobek, Boris; Froguel, Philippe; Meyre, David] Inst Pasteur, CNRS, UMR 8199, Inst Biol Lille, F-59019 Lille, France.
[Li, Guo; Psaty, Bruce M.] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA.
[Mangino, Massimo; Soranzo, Nicole; Spector, Timothy D.] Kings Coll London, Dept Twin Res & Genet Epidemiol, London, England.
[McArdle, Wendy L.] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England.
[Medina-Gomez, Carolina; Peters, Marjolein J.; Estrada, Karol; Rivadeneira, Fernando; van Meurs, Joyce B. J.; Zillikens, M. Carola; Uitterlinden, Andre G.] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.
[Mueller-Nurasyid, Martina] Univ Munich, Dept Med 1, Munich, Germany.
[Mueller-Nurasyid, Martina; Wichmann, H-Erich] Univ Munich, Chair Epidemiol, Inst Med Informat Biometry & Epidemiol, Munich, Germany.
[Mueller-Nurasyid, Martina] Univ Munich, Chair Genet Epidemiol, Inst Med Informat Biometry & Epidemiol, Munich, Germany.
[Ngwa, Julius S.; Cupples, L. Adrienne] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Nolte, Ilja M.; Stolk, Ronald P.; Snieder, Harold] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands.
[Paternoster, Lavinia; Evans, David M.] Univ Bristol, MRC, Ctr Causal Analyses Translat Epidemiol, Sch Social & Community Med, Bristol, Avon, England.
[Pechlivanis, Sonali; Puetter, Carolin; Joeckel, Karl-Heinz; Scherag, Andr] Univ Duisburg Essen, Univ Hosp Essen, Inst Med Informat Biometry & Epidemiol IMIBE, Essen, Germany.
[Perola, Markus; Surakka, Ida; Palotie, Aarno; Widen, Elisabeth; Ripatti, Samuli] Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki, Finland.
[Preuss, Michael; Erdmann, Jeanette] Med Univ Lubeck, Med Klin 2, D-23538 Lubeck, Germany.
[Rose, Lynda M.; Chasman, Daniel I.; Ridker, Paul M.] Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA.
[Shungin, Dmitry; Franks, Paul W.] Lund Univ, Genet & Mol Epidemiol Unit, Dept Clin Sci, Skane Univ Hosp Malmo, Malmo, Sweden.
[Shungin, Dmitry; Franks, Paul W.] Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden.
[Shungin, Dmitry] Umea Univ, Dept Odontol, Umea, Sweden.
[Smith, Albert Vernon; Gudnason, Vilmundur] Iceland Heart Assoc, Kopavogur, Iceland.
[Smith, Albert Vernon; Gudnason, Vilmundur; Stefansson, Kari; Thorsteinsdottir, Unnur] Univ Iceland, Fac Med, Reykjavik, Iceland.
[Strawbridge, Rona J.; Hamsten, Anders] Karolinska Inst, Karolinska Univ Hosp, Dept Med, Atherosclerosis Res Unit, Stockholm, Sweden.
[Teumer, Alexander; Homuth, Georg] Ernst Moritz Arndt Univ Greifswald, Interfac Inst Genet & Funct Genom, Greifswald, Germany.
[Trip, Mieke D.; Basart, Hanneke; Hovingh, Kees G.] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands.
[Trip, Mieke D.] Univ Amsterdam, Acad Med Ctr, Dept Clin & Expt Cardiol, Heart Failure Res Ctr, NL-1105 AZ Amsterdam, Netherlands.
[Tyrer, Jonathan] Univ Cambridge, Dept Oncol, Cambridge, England.
[Van Vliet-Ostaptchouk, Jana V.; Van der Klauw, Melanie M.; Wolffenbuttel, Bruce H. R.] Univ Groningen, Univ Med Ctr Groningen, Dept Endocrinol, Groningen, Netherlands.
[Van Vliet-Ostaptchouk, Jana V.; Bruinenberg, Marcel; Franke, Lude; Stolk, Ronald P.; Van der Klauw, Melanie M.; Wolffenbuttel, Bruce H. R.; Snieder, Harold] Univ Groningen, Univ Med Ctr Groningen, LifeLines Cohort Study, Groningen, Netherlands.
[Vandenput, Liesbeth; Lorentzon, Mattias] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Dept Internal Med, Gothenburg, Sweden.
[Waite, Lindsay L.; Absher, Devin; Ohlsson, Claes] Hudson Alpha Inst Biotechnol, Huntsville, TN USA.
[Asselbergs, Folkert W.] Univ Med Ctr Utrecht, Div Heart & Lungs, Dept Cardiol, Utrecht, Netherlands.
[Atalay, Mustafa; Lakka, Timo A.] Univ Eastern Finland, Inst Biomed Physiol, Kuopio, Finland.
[Attwood, Antony P.; Rendon, Augusto; Ouwehand, Willem H.] Biomed Res Ctr, Natl Inst Hlth Res NIHR, Cambridge, England.
[Balmforth, Anthony J.] Univ Leeds, Div Epidemiol, Multidisciplinary Cardiovasc Res Ctr MCRC, Leeds Inst Genet Hlth & Therapeut LIGHT, Leeds, W Yorkshire, England.
[Beilby, John] Queen Elizabeth II Med Ctr, PathW Lab Western Australia, Dept Mol Genet, Nedlands, WA, Australia.
[Beilby, John] Univ Western Australia, Dept Surg & Pathol, Nedlands, WA 6009, Australia.
[Bonnycastle, Lori L.; Chines, Peter S.; Collins, Francis S.; Narisu, Narisu; Swift, Amy J.] NHGRI, Genome Technol Branch, US Natl Inst Hlth, Bethesda, MD 20892 USA.
[Brambilla, Paolo] Univ Milano Bicocca, Dipartimento Med Sperimentale, Monza, Italy.
[Campbell, Harry; Rudan, Igor; Wild, Sarah H.; Wilson, James F.] Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland.
[Chasman, Daniel I.; Ridker, Paul M.] Harvard Univ, Sch Med, Boston, MA USA.
[Connell, John M.] Univ Glasgow, British Heart Fdn Glasgow Cardiovasc Res Ctr, Glasgow, Lanark, Scotland.
[Connell, John M.] Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland.
[Cookson, William O.; Moffatt, Miriam F.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England.
[de Faire, Ulf] Karolinska Inst, Inst Environm Med, Div Cardiovasc Epidemiol, S-10401 Stockholm, Sweden.
[de Vegt, Femmie; Vermeulen, Sita H.; Kiemeney, Lambertus A.] Radboud Univ Nijmegen, Med Ctr, Dept Epidemiol Biostat & HTA, NL-6525 ED Nijmegen, Netherlands.
[Dei, Mariano; Sanna, Serena] CNR, Ist Ric Genet & Biomed, Monserrato, Italy.
[Dimitriou, Maria; Theodoraki, Eirini V.; Dedoussis, George V.] Harokopio Univ, Dept Dietet Nutr, Athens, Greece.
[Ferrario, Marco M.] Univ Insubria, Epidemiol & Prevent Med Res Ctr, Dept Clin & Expt Med, Varese, Italy.
[Ferrieres, Jean] Toulouse Univ, Sch Med, Rangueil Hosp, Dept Cardiol, Toulouse, France.
[Franke, Lude; van der Harst, Pim] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands.
[Frau, Francesca; Cusi, Daniele] Univ Milan, Dept Hlth Sci, Osped San Paolo, Milan, Italy.
[Gejman, Pablo V.; Sanders, Alan R.] Univ Chicago, Chicago, IL 60637 USA.
[Gejman, Pablo V.; Sanders, Alan R.] Northshore Univ Hlth Syst, Evanston, IL USA.
[Grallert, Harald; Peters, Annette; Illig, Thomas] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Res Unit Mol Epidemiol, Neuherberg, Germany.
[Hall, Alistair S.] Univ Leeds, LIGHT, Multidisciplinary Cardiovasc Res Ctr, Div Cardiovasc & Neuronal Remodelling, Leeds, W Yorkshire, England.
[Hartikainen, Anna-Liisa; Pouta, Anneli] Univ Oulu, Dept Clin Sci Obstet & Gynecol, Oulu, Finland.
[Heard-Costa, Nancy L.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.
[Heath, Andrew C.; Madden, Pamela A.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA.
[Hebebrand, Johannes; Hinney, Anke] Univ Duisburg Essen, Dept Child & Adolescent Psychiat, Essen, Germany.
[Hyppoenen, Elina; Power, Chris] UCL, Inst Child Hlth, MRC, Ctr Paediat Epidemiol & Biostat,Ctr Epidemiol Chi, London, England.
[Iribarren, Carlos] Kaiser Permanente, Northern Calif, Div Res, Oakland, CA USA.
[Jacobs, Kevin B.; Wang, Zhaoming] NCI, SAIC Frederick, Core Genotyping Facil, Frederick, MD 21701 USA.
[Jansson, John-Olov] Univ Gothenburg, Sahlgrenska Acad, Dept Physiol, Inst Neurosci & Physiol,Sahlgrenska Acad, Gothenburg, Sweden.
[Jula, Antti] Natl Inst Hlth & Welf, Populat Studies Unit, Dept Chron Dis Prevent, Turku, Finland.
[Kahonen, Mika] Univ Tampere, Dept Clin Physiol, FIN-33101 Tampere, Finland.
[Kahonen, Mika] Tampere Univ Hosp, Tampere, Finland.
[Kathiresan, Sekar] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.
[Kathiresan, Sekar] Massachusetts Gen Hosp, Cardiol Div, Boston, MA 02114 USA.
[Kathiresan, Sekar] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Kee, Frank] Queens Univ Belfast, UK Clin Res Collaborat UKCRC, Ctr Excellence Publ Hlth Northern Ireland, Belfast, Antrim, North Ireland.
[Khaw, Kay-Tee] Univ Cambridge, Inst Publ Hlth, Dept Publ Hlth & Primary Care, Cambridge, England.
[Kivimaki, Mika; Kumari, Meena; Langenberg, Claudia; Hingorani, Aroon] UCL, Dept Epidemiol & Publ Hlth, London, England.
[Koenig, Wolfgang] Univ Ulm, Med Ctr, Dept Internal Med Cardiol 2, D-89069 Ulm, Germany.
[Kuulasmaa, Kari; Virtamo, Jarmo; Salomaa, Veikko] Natl Inst Hlth & Welf, Dept Chron Dis Prevent, Chron Dis Epidemiol & Prevent Unit, Helsinki, Finland.
[Kuusisto, Johanna; Laakso, Markku] Univ Eastern Finland, Dept Med, Kuopio, Finland.
[Kuusisto, Johanna; Laakso, Markku] Kuopio Univ Hosp, SF-70210 Kuopio, Finland.
[Laitinen, Jaana H.] Finnish Inst Occupat Hlth, Oulu, Finland.
[Lakka, Timo A.; Rauramaa, Rainer] Kuopio Res Inst Exercise Med, Kuopio, Finland.
[Launer, Lenore J.; Harris, Tamara B.] NIA, Lab Epidemiol, US Natl Inst Hlth, Bethesda, MD 20892 USA.
[Lind, Lars] Uppsala Univ, Dept Med Sci, Akademiska Sjukhuset, Uppsala, Sweden.
[Lindstrom, Jaana; Tuomilehto, Jaakko] Natl Inst Hlth & Welf, Diabet Prevent Unit, Helsinki, Finland.
[Liu, Jianjun] Genome Inst Singapore, Singapore, Singapore.
[Liuzzi, Antonio] Ist Auxol Italiano, Dept Internal Med, Verbania, Italy.
[Lokki, Marja-Liisa] Univ Helsinki, Transplantat Lab, Haartman Inst, Helsinki, Finland.
[Manunta, Paolo] Univ Vita Salute San Raffaele, Chair Nephrol San Raffaele Sci Inst, Unite Osped Nephrol & Dialysis, Milan, Italy.
[Maerz, Winfried] Synlab Acad, Mannheim, Germany.
[Leach, Irene Mateo; van der Harst, Pim] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands.
[McKnight, Barbara] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Mooser, Vincent] GlaxoSmithKline, Genet Div, King Of Prussia, PA USA.
[Muehleisen, Thomas W.] Univ Bonn, Inst Human Genet, Bonn, Germany.
[Muehleisen, Thomas W.] Univ Bonn, Dept Genom, Life & Brain Ctr, Bonn, Germany.
[Musk, Arthur W.] Univ Western Australia, Sch Populat Hlth, Nedlands, WA 6009, Australia.
[Musk, Arthur W.] Sir Charles Gairdner Hosp, Dept Resp Med, Nedlands, WA 6009, Australia.
[Musk, Arthur W.] Sir Charles Gairdner Hosp, Busselton Populat Med Res Fdn, Nedlands, WA 6009, Australia.
[Navis, Gerjan] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, Groningen, Netherlands.
[Nicholson, George] MRC, Harwell, Berks, England.
[Nicholson, George] Univ Oxford, Dept Stat, Oxford OX1 3TG, England.
[Nohr, Ellen A.] Aarhus Univ, Dept Publ Hlth, Epidemiol Sect, Aarhus, Denmark.
[Ong, Ken K.; Wong, Andrew; Kuh, Diana] MRC, Unit Lifelong Hlth & Ageing, London, England.
[Oostra, Ben A.] Erasmus MC, Dept Clin Genet, Rotterdam, Netherlands.
[Oostra, Ben A.; van Duijn, Cornelia M.] Leiden Univ, Med Ctr, Ctr Med Syst Biol, Leiden, Netherlands.
[Palmer, Colin N. A.; Morris, Andrew D.] Univ Dundee, Ninewells Hosp & Med Sch, Med Res Inst, Dundee DD1 9SY, Scotland.
[Peden, John F.] Illumina Inc, Cambridge, England.
[Peters, Annette; Thorand, Barbara] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Epidemiol 2, Neuherberg, Germany.
[Peters, Annette] Munich Heart Alliance, Munich, Germany.
[Polasek, Ozren] Univ Split, Fac Med, Split, Croatia.
[Pouta, Anneli; Jarvelin, Marjo-Riitta] Natl Inst Hlth & Welf, Oulu, Finland.
[Pramstaller, Peter P.; Hicks, Andrew A.] European Acad Bozen Bolzano EURAC, Ctr Biomed, Bolzano, Italy.
[Pramstaller, Peter P.] Gen Cent Hosp, Dept Neurol, Bolzano, Italy.
[Pramstaller, Peter P.] Med Univ Lubeck, Dept Neurol, D-23538 Lubeck, Germany.
[Prokopenko, Inga; Karpe, Fredrik; McCarthy, Mark I.] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England.
[Prokopenko, Inga; Karpe, Fredrik; McCarthy, Mark I.] Univ Cambridge, Dept Haematol, Cambridge, England.
[Radhakrishnan, Aparna; Rendon, Augusto; Sambrook, Jennifer G.; Stephens, Jonathan C.; Ouwehand, Willem H.] Cambridge Ctr, Natl Hlth Serv NHS Blood & Transplant, Cambridge, England.
[Raitakari, Olli] Univ Turku, Res Ctr Appl & Prevent Cardiovasc Med, Turku, Finland.
[Raitakari, Olli] Turku Univ Hosp, Dept Clin Physiol & Nucl Med, FIN-20520 Turku, Finland.
[Rendon, Augusto] Inst Publ Hlth, MRC, Biostat Unit, Cambridge, England.
[Saaristo, Timo E.] Finnish Diabet Assoc, Tampere, Finland.
[Saaristo, Timo E.] Pirkanmaa Hosp Dist, Tampere, Finland.
[Saramies, Jouko] South Karelia Cent Hosp, Lappeenranta, Finland.
[Schipf, Sabine] Univ Med Greifswald, Inst Community Med, Greifswald, Germany.
[Schreiber, Stefan] Univ Kiel, Inst Clin Mol Biol, Kiel, Germany.
[Schunkert, Heribert; Erdmann, Jeanette] Deutsch Herzzentrum Munich, Munich, Germany.
[Schunkert, Heribert; Erdmann, Jeanette] DZHK German Ctr Cardiovasc Res, Munich, Germany.
[Signorini, Stefano] Azienda Osped Desio & Vimercate, Milan, Italy.
[Sinisalo, Juha; Nieminen, Markku S.] Univ Helsinki, Cent Hosp, Div Cardiol, Cardiovasc Lab, Helsinki, Finland.
[Stancakova, Alena] Univ Eastern Finland, Kuopio, Finland.
[Stancakova, Alena] Kuopio Univ Hosp, SF-70210 Kuopio, Finland.
[Stark, Klaus; Hengstenberg, Christian] Univ Klinikum Regensburg, Klin & Poliklin Innere Med 2, Regensburg, Germany.
[Stumvoll, Michael; Tonjes, Anke] Univ Leipzig, Dept Med, D-04109 Leipzig, Germany.
[Stumvoll, Michael; Tonjes, Anke] Univ Leipzig, Integrierte Forsch & Behandlungszentren IFB Adipo, D-04109 Leipzig, Germany.
[Tregouet, David-Alexandre] Univ Paris 06, INSERM, UMRS 937, Inst Cardiometab & Nutr ICAN, Paris, France.
[Tremoli, Elena] Univ Milan, Dipartimento Sci Farmacol & Biomol, Ctr Cardiol Monzino, Ist Ricovero & Cura Carattere Sci IRCCS, Milan, Italy.
[Vermeulen, Sita H.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 ED Nijmegen, Netherlands.
[Viikari, Jorma] Univ Turku, Dept Med, Turku, Finland.
[Viikari, Jorma] Turku Univ Hosp, FIN-20520 Turku, Finland.
[Waeber, Gerard; Vollenweider, Peter] CHU Vaudois, Dept Internal Med, Univ Hosp, CH-1011 Lausanne, Switzerland.
[Winkelmann, Bernhard R.] Cardiol Grp, Frankfurt, Germany.
[Amouyel, Philippe] Univ Lille Nord France, INSERM, Inst Pasteur Lille, U744, F-59019 Lille, France.
[Boehm, Bernhard O.] Univ Hosp, Dept Med, Div Endocrinol & Diabet, Ulm, Germany.
[Boerwinkle, Eric] Univ Texas Hlth Sci Ctr, Inst Mol Med, Houston, TX USA.
[Cusi, Daniele] Fdn Filarete, Milan, Italy.
[Eriksson, Johan G.] Univ Helsinki, Dept Gen Practice & Primary Hlth Care, Helsinki, Finland.
[Eriksson, Johan G.] Natl Inst Hlth & Welf, Helsinki, Finland.
[Eriksson, Johan G.] Univ Helsinki, Cent Hosp, Unit Gen Practice, Helsinki, Finland.
[Froguel, Philippe] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Genom Common Dis, London, England.
[Hveem, Kristian] Norwegian Univ Sci & Technol, Helseundersokelsen Nord Trondelag HUNT Res Ctr, Dept Publ Hlth & Gen Practice, Levanger, Norway.
[Illig, Thomas] Hannover Med Sch, Hannover Unified Biobank, Hannover, Germany.
[Jarvelin, Marjo-Riitta] Univ London Imperial Coll Sci Technol & Med, Fac Med, Sch Publ Hlth, Dept Epidemiol & Biostat, London, England.
[Jarvelin, Marjo-Riitta] Univ Oulu, Inst Hlth Sci, Oulu, Finland.
[Jarvelin, Marjo-Riitta; Keinanen-Kiukaanniemi, Sirkka M.] Univ Oulu, Bioctr, Oulu, Finland.
[Keinanen-Kiukaanniemi, Sirkka M.] Oulu Univ Hosp, Unit Gen Practice, Oulu, Finland.
[Kiemeney, Lambertus A.] Radboud Univ Nijmegen, Med Ctr, Dept Urol, NL-6525 ED Nijmegen, Netherlands.
[Kiemeney, Lambertus A.] Comprehens Canc Ctr East, Nijmegen, Netherlands.
[Lehtimaki, Terho] Univ Tampere, Dept Clin Chem, Fimlab Labs, FIN-33101 Tampere, Finland.
[Lehtimaki, Terho] Tampere Univ Hosp, Tampere, Finland.
[Levinson, Douglas F.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
[Njolstad, Inger] Univ Tromso, Fac Hlth Sci, Dept Clin Med, Tromso, Norway.
[Njolstad, Inger] Univ Tromso, Fac Hlth Sci, Dept Community Med, Tromso, Norway.
[Oldehinkel, Albertine J.] Univ Groningen, Univ Med Ctr Groningen, Interdisciplinary Ctr Psychopathol & Emot Regulat, Groningen, Netherlands.
[Penninx, Brenda] Univ Groningen, Univ Med Ctr Groningen, Dept Psychiat, NL-9713 AV Groningen, Netherlands.
[Psaty, Bruce M.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Psaty, Bruce M.] Univ Washington, Dept Med, Seattle, WA USA.
[Psaty, Bruce M.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Psaty, Bruce M.] Grp Hlth Res Inst, Grp Hlth, Seattle, WA USA.
[Rauramaa, Rainer] Kuopio Univ Hosp, Dept Clin Physiol & Nucl Med, SF-70210 Kuopio, Finland.
[Samani, Nilesh J.] Univ Leicester, Dept Cardiovasc Sci, Glenfield Hosp, Leicester, Leics, England.
[Samani, Nilesh J.] Glenfield Hosp, Leicester NIHR Biomed Res Unit Cardiovasc Dis, Leicester, Leics, England.
[Sorensen, Thorkild I. A.] Bispebjerg Hosp, Inst Prevent Med, Copenhagen, Denmark.
[Sorensen, Thorkild I. A.] Univ Copenhagen, Novo Nordisk Fdn Ctr Basic Metab Res, Copenhagen, Denmark.
[Tuomilehto, Jaakko] Danube Univ Krems, Ctr Vasc Prevent, Krems, Austria.
[Tuomilehto, Jaakko] King Abdulaziz Univ, Jeddah 21413, Saudi Arabia.
[Uusitupa, Matti] Univ Eastern Finland, Inst Publ Hlth & Clin Nutr, Kuopio, Finland.
[Uusitupa, Matti; McCarthy, Mark I.] Kuopio Univ Hosp, Res Unit, SF-70210 Kuopio, Finland.
[Wallaschofski, Henri] Univ Med Greifswald, Inst Clin Chem & Lab Med, Greifswald, Germany.
[Wichmann, H-Erich; Heid, Iris M.] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Epidemiol 1, Neuherberg, Germany.
[Assimes, Themistocles L.] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA.
[Barroso, Ines] Univ Cambridge, Addenbrookes Hosp, Metab Res Labs, Inst Metab Sci, Cambridge CB2 2QQ, England.
[Fox, Caroline S.] NHLBI, Div Intramural Res, Framingham Heart Study, Framingham, MA USA.
[Groop, Leif C.] Lund Univ, Dept Clin Sci, Ctr Diabet, Malmo, Sweden.
[Haritunian, Talin] Cedars Sinai Med Ctr, Med Genet Inst, Los Angeles, CA 90048 USA.
[Kaplan, Robert C.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
[Karpe, Fredrik] Churchill Hosp, Oxford NIHR Biomed Res, Oxford OX3 7LJ, England.
[O'Connell, Jeffrey R.] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA.
[Schadt, Eric E.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY USA.
[Schadt, Eric E.] Mt Sinai Sch Med, Inst Genom & Multiscale Biol, New York, NY USA.
[Schlessinger, David] NIA, Genet Lab, Baltimore, MD 21224 USA.
[Strachan, David P.] Univ London, Div Populat Hlth Sci & Educ, London, England.
[Meyre, David] McMaster Univ, Dept Clin Epidemiol & Biostatist, Hamilton, ON, Canada.
[Speliotes, Elizabeth K.] Univ Michigan, Dept Internal Med, Div Gastroenterol, Ann Arbor, MI 48109 USA.
[Loos, Ruth J. F.] Icahn Sch Med Mt Sinai, Charles Bronfman Inst Personalized Med, New York, NY USA.
[Loos, Ruth J. F.] Icahn Sch Med Mt Sinai, Mindich Child Hlth & Dev Inst, New York, NY USA.
[Loos, Ruth J. F.] Icahn Sch Med Mt Sinai, Dept Prevent Med, New York, NY USA.
RP Ingelsson, E (reprint author), Uppsala Univ, Dept Med Sci, Mol Epidemiol & Sci Life Lab, Uppsala, Sweden.
EM erik.ingelsson@medsci.uu.se
RI Erdmann, Jeanette/P-7513-2014; Hinney, Anke/D-6953-2011; Evans,
David/H-6325-2013; Colaus, PsyColaus/K-6607-2013; Lee, Sang
Hong/A-2569-2011; Strawbridge, Rona/H-5422-2012; Deloukas,
Panos/B-2922-2013; van der Klauw, Melanie/A-2138-2014; Hypponen,
Elina/B-2596-2014; Kiemeney, Lambertus/D-3357-2009; Palmer,
Colin/C-7053-2008; Pramstaller, Peter/C-2357-2008; Palmer,
Lyle/K-3196-2014; Fall, Tove/O-7226-2014; Medland, Sarah/C-7630-2013;
Boehm, Bernhard/F-8750-2015; Grallert, Harald/B-3424-2013; Milani,
Lili/C-8759-2011; Gudnason, Vilmundur/K-6885-2015; Ripatti,
Samuli/H-9446-2014; Vegt, F./L-4704-2015; Wilson, James F/A-5704-2009;
Polasek, Ozren/B-6002-2011; Montgomery, Grant/B-7148-2008; Rivadeneira,
Fernando/O-5385-2015; Prokopenko, Inga/H-3241-2014; Johansson,
Asa/G-5270-2011; Thorand, Barbara/B-5349-2014; Peters,
Annette/A-6117-2011; Tregouet, David-Alexandre/E-3961-2016; Vermeulen,
H.H.M./L-4716-2015; Rudan, Igor/I-1467-2012; Smith, Albert/K-5150-2015;
Yang, Jian/A-5852-2010; Study, GoDARTS/K-9448-2016; mangino,
massimo/F-5134-2011; Hayward, Caroline/M-8818-2016; Franke,
Lude/P-7036-2016; Wong, Andrew/M-8899-2016; Konig, Inke/A-4544-2009;
Magnusson, Patrik/C-4458-2017; Feitosa, Mary/K-8044-2012; Hicks,
Andrew/E-9518-2017;
OI Wheeler, Eleanor/0000-0002-8616-6444; Sinisalo,
Juha/0000-0002-0169-5137; Kleber, Marcus/0000-0003-0663-7275; Martin,
Nicholas/0000-0003-4069-8020; Ganna, Andrea/0000-0002-8147-240X;
Watkins, Hugh/0000-0002-5287-9016; Medina-Gomez,
Carolina/0000-0001-7999-5538; Visscher, Peter/0000-0002-2143-8760;
Eriksson, Johan/0000-0002-2516-2060; Evans, David/0000-0003-0663-4621;
Ouwehand, Willem/0000-0002-7744-1790; Scherag,
Andre/0000-0002-9406-4704; Kumari, Meena/0000-0001-9716-1035; Kuulasmaa,
Kari/0000-0003-2165-1411; Wolffenbuttel, Bruce H.R./0000-0001-9262-6921;
Jarvelin, Marjo-Riitta/0000-0002-2149-0630; Vandenput,
Liesbeth/0000-0002-1712-6131; Karpe, Fredrik/0000-0002-2751-1770;
Abecasis, Goncalo/0000-0003-1509-1825; Paternoster,
Lavinia/0000-0003-2514-0889; Manunta, Paolo/0000-0003-3976-9696;
Erdmann, Jeanette/0000-0002-4486-6231; Lakka, Timo/0000-0002-9199-2871;
Ferrario, Marco M/0000-0003-2741-7124; Soranzo,
Nicole/0000-0003-1095-3852; Gieger, Christian/0000-0001-6986-9554;
Franks, Paul/0000-0002-0520-7604; Hinney, Anke/0000-0001-5659-0706; Lee,
Sang Hong/0000-0001-9701-2718; Strawbridge, Rona/0000-0001-8506-3585;
Deloukas, Panos/0000-0001-9251-070X; van der Klauw,
Melanie/0000-0001-7178-009X; Hypponen, Elina/0000-0003-3670-9399;
Kiemeney, Lambertus/0000-0002-2368-1326; Palmer,
Colin/0000-0002-6415-6560; Palmer, Lyle/0000-0002-1628-3055; Medland,
Sarah/0000-0003-1382-380X; Milani, Lili/0000-0002-5323-3102; Gudnason,
Vilmundur/0000-0001-5696-0084; Ripatti, Samuli/0000-0002-0504-1202;
Wilson, James F/0000-0001-5751-9178; Polasek, Ozren/0000-0002-5765-1862;
Montgomery, Grant/0000-0002-4140-8139; Rivadeneira,
Fernando/0000-0001-9435-9441; Prokopenko, Inga/0000-0003-1624-7457;
Johansson, Asa/0000-0002-2915-4498; Thorand,
Barbara/0000-0002-8416-6440; Rudan, Igor/0000-0001-6993-6884; Smith,
Albert/0000-0003-1942-5845; Yang, Jian/0000-0003-2001-2474; mangino,
massimo/0000-0002-2167-7470; Hayward, Caroline/0000-0002-9405-9550;
Franke, Lude/0000-0002-5159-8802; Wong, Andrew/0000-0003-2079-4779;
Feitosa, Mary/0000-0002-0933-2410; Hicks, Andrew/0000-0001-6320-0411;
Radhakrishnan, Aparna/0000-0002-8153-9037; Heard-Costa,
Nancy/0000-0001-9730-0306; Cupples, L. Adrienne/0000-0003-0273-7965;
Shungin, Dmitry/0000-0001-7900-5856; Day, Felix/0000-0003-3789-7651;
Magi, Reedik/0000-0002-2964-6011; Peters, Marjolein/0000-0003-3167-9063;
Esko, Tonu/0000-0003-1982-6569; Kristiansson, Kati/0000-0003-4688-107X;
Willer, Cristen/0000-0001-5645-4966; Rendon,
Augusto/0000-0001-8994-0039; TREMOLI, ELENA/0000-0002-0929-6106; sanna,
serena/0000-0002-3768-1749; Kivimaki, Mika/0000-0002-4699-5627; Johnson,
Toby/0000-0002-5998-3270; van Vliet-Ostaptchouk,
Jana/0000-0002-7943-3153; Hunt, Sarah/0000-0002-8350-1235
FU Aarno Koskelo Foundation; Agency for Science, Technology and Research of
Singapore; Australian National Health and Medical Research Council;
Australian Research Council; BDA Research; BioSHaRE Consortium; British
Heart Foundation; Cedars-Sinai Board of Governors' Chair in Medical
Genetics; Centre for Clinical Research at the University of Leipzig;
Centre of Excellence in Genomics; University of Tartu; Chief Scientist
Office of the Scottish government; City of Kuopio; Social Insurance
Institution of Finland; Department of Educational Assistance; University
and Research of the Autonomous Province of Bolzano; Donald W. Reynolds
Foundation; Dutch Ministry for Health, Welfare and Sports; Dutch
Ministry of Education, Culture and Science; Dutch BBRMI-NL; Dutch Brain
Foundation; Dutch Centre for Medical Systems Biology; Dutch Diabetes
Research Foundation; Dutch Government Economic Structure-Enhancing Fund;
Dutch Inter-University Cardiology Institute; Dutch Kidney Foundation;
Dutch Ministry of Economic Affairs; Dutch Ministry of Justice; Dutch
Research Institute for Diseases in the Elderly; Eleanor Nichols
endowments; Emil Aaltonen Foundation; Erasmus Medical Center; Erasmus
University; Estonian government; European Commission; European Regional
Development Fund; European Research Council; European Science
Foundation; Faculty of Biology and Medicine of Lausanne; Finland's Slot
Machine Association; Finnish Cultural Foundation; Finnish Diabetes
Research Foundation; Finnish Foundation for Cardiovascular Research;
Finnish Funding Agency for Technology and Innovation; Finnish Heart
Association; Finnish Medical Society; Finnish Ministry of Education and
Culture; Finnish Ministry of Health and Social Affairs; Finnish National
Institute for Health and Welfare; Finnish Social Insurance Institution;
Finska Lakaresallskapet; Folkhalsan Research Foundation; Foundation for
Life and Health in Finland; French Ministry of Research; French National
Research Agency; Genetic Association Information Network; German
Diabetes Association; German Federal Ministry of Education and Research;
German Ministry of Cultural Affairs; German National Genome Research
Network; German Research Foundation; GlaxoSmithKline; Goteborg Medical
Society; Greek General Secretary of Research and Technology; Gyllenberg
Foundation; Health Care Centers in Vasa, Narpes and Korsholm; Heinz
Nixdorf Foundation; Helmholtz Zentrum Munchen-German Research Center for
Environmental Health; Icelandic Heart Association; Icelandic Parliament;
Intramural Research Program of the Division of Cancer Epidemiology and
Genetics, the National Cancer Institute, NIH; Italian Ministry of
Education, Universities and Research; Italian Ministry of Health; Juho
Vainio Foundation; Juvenile Diabetes Research Foundation International;
Knut and Alice Wallenberg Foundation; Kuopio, Tampere and Turku
University Hospital Medical Funds; Leducq Foundation; Lundberg
Foundation; March of Dimes; Munich Center of Health Sciences as part of
LMUinnovativ; Municipal Health Care Center and Hospital in Jakobstad;
Municipality of Rotterdam; Narpes Health Care Foundation; National
Alliance for Research on Schizophrenia and Depression Young Investigator
Awards; Netherlands Genomics Initiative; Netherlands Organization for
Health Research and Development; UK NHSBT; US National Institutes of
Health; Nordic Center of Cardiovascular Research; Nordic Center of
Excellence in Disease Genetics; Nordic Centre of Excellence on Systems
Biology in Controlled Dietary Interventions and Cohort Studies; Northern
Netherlands Collaboration of Provinces; Novo Nordisk Foundation;
Ollqvist Foundation; Orion-Farmos Research Foundation; Paavo Nurmi
Foundation; Paivikki and Sakari Sohlberg Foundation; Perklen Foundation;
Petrus and Augusta Hedlunds Foundation; Province of Groningen; Republic
of Croatia Ministry of Science, Education and Sport; Reynold's
Foundation; Royal Society; Samfundet Folkhalsan; Signe and Ane
Gyllenberg Foundation; Sigrid Juselius Foundation; Social Ministry of
the Federal State of Mecklenburg-West Pomerania; Sophia Foundation for
Medical Research; South Tyrolean Sparkasse Foundation; Southern
California Diabetes Endocrinology Research Center; Stockholm County
Council; Strategic Cardiovascular Program of Karolinska Institutet;
Strategic Support for Epidemiological Research at Karolinska Institutet;
Susan G. Komen Breast Cancer Foundation; Swedish Ministry for Higher
Education; Swedish Cancer Society; Swedish Cultural Foundation in
Finland; Swedish Diabetes Association; Swedish Foundation for Strategic
Research; Swedish Heart-Lung Foundation; Swedish Medical Research
Council; Swedish Ministry of Education; Swedish Research Council;
Swedish Royal Academy of Science; Swedish Society for Medical Research;
Swedish Society of Medicine; Swiss National Science Foundation; Tampere
Tuberculosis Foundation; Great Wine Estates of the Margaret River Region
of Western Australia; Paul Michael Donovan Charitable Foundation;
Torsten and Ragnar Soderberg Foundation; Cancer Research UK; UK Diabetes
Association; UK Heart Foundation; UK MRCUK NIHR, Biomedical Research
Centre; UK West Anglia Primary and Community Care; University Medical
Center Groningen; University of Groningen; Vastra Gotaland Foundation;
VU University: the Institute for Health and Care Research and the
Neuroscience Campus Amsterdam; Wellcome Trust; Yrjo Jahnsson Foundation
FX A full list of acknowledgments appears in the Supplementary Note.
Funding was provided by the Aarno Koskelo Foundation; the Academy of
Finland; the Agency for Science, Technology and Research of Singapore;
the Australian National Health and Medical Research Council; the
Australian Research Council; BDA Research; the BioSHaRE Consortium; the
British Heart Foundation; the Cedars-Sinai Board of Governors' Chair in
Medical Genetics; the Centre for Clinical Research at the University of
Leipzig; the Centre of Excellence in Genomics and the University of
Tartu; the Chief Scientist Office of the Scottish government; the City
of Kuopio and the Social Insurance Institution of Finland; the
Department of Educational Assistance, the University and Research of the
Autonomous Province of Bolzano; the Donald W.; Reynolds Foundation; the
Dutch Ministry for Health, Welfare and Sports; the Dutch Ministry of
Education, Culture and Science; Dutch BBRMI-NL; the Dutch Brain
Foundation; the Dutch Centre for Medical Systems Biology; the Dutch
Diabetes Research Foundation; the Dutch Government Economic
Structure-Enhancing Fund; the Dutch Inter-University Cardiology
Institute; the Dutch Kidney Foundation; the Dutch Ministry of Economic
Affairs; the Dutch Ministry of Justice; the Dutch Research Institute for
Diseases in the Elderly; Eleanor Nichols endowments; the Emil Aaltonen
Foundation; Erasmus Medical Center and Erasmus University; the Estonian
government; the European Commission; the European Regional Development
Fund; the European Research Council; the European Science Foundation;
the Faculty of Biology and Medicine of Lausanne; Finland's Slot Machine
Association; the Finnish Cultural Foundation; the Finnish Diabetes
Research Foundation; the Finnish Foundation for Cardiovascular Research;
the Finnish Funding Agency for Technology and Innovation; the Finnish
Heart Association; the Finnish Medical Society; the Finnish Ministry of
Education and Culture; the Finnish Ministry of Health and Social
Affairs; the Finnish National Institute for Health and Welfare; the
Finnish Social Insurance Institution; Finska Lakaresallskapet; the
Folkhalsan Research Foundation; the Foundation for Life and Health in
Finland; the French Ministry of Research; the French National Research
Agency; the Genetic Association Information Network; the German Diabetes
Association; the German Federal Ministry of Education and Research; the
German Ministry of Cultural Affairs; the German National Genome Research
Network; the German Research Foundation; GlaxoSmithKline; the Goteborg
Medical Society; the Greek General Secretary of Research and Technology;
the Gyllenberg Foundation; Health Care Centers in Vasa, Narpes and
Korsholm; the Heinz Nixdorf Foundation; Helmholtz Zentrum Munchen-German
Research Center for Environmental Health; the Icelandic Heart
Association; the Icelandic Parliament; the Intramural Research Program
of the Division of Cancer Epidemiology and Genetics, the National Cancer
Institute, NIH; Italian Ministry of Education, Universities and
Research; Italian Ministry of Health; Juho Vainio Foundation; Juvenile
Diabetes Research Foundation International; the Knut and Alice
Wallenberg Foundation; Kuopio, Tampere and Turku University Hospital
Medical Funds; the Leducq Foundation; the Lundberg Foundation; the March
of Dimes; the Munich Center of Health Sciences as part of LMUinnovativ;
the Municipal Health Care Center and Hospital in Jakobstad; the
Municipality of Rotterdam; the Narpes Health Care Foundation; National
Alliance for Research on Schizophrenia and Depression Young Investigator
Awards; the Netherlands Genomics Initiative; the Netherlands
Organization for Health Research and Development; UK NHSBT; US National
Institutes of Health; the Nordic Center of Cardiovascular Research; the
Nordic Center of Excellence in Disease Genetics; the Nordic Centre of
Excellence on Systems Biology in Controlled Dietary Interventions and
Cohort Studies; the Northern Netherlands Collaboration of Provinces; the
Novo Nordisk Foundation; the Ollqvist Foundation; the Orion-Farmos
Research Foundation; the Paavo Nurmi Foundation; the Paivikki and Sakari
Sohlberg Foundation; the Perklen Foundation; the Petrus and Augusta
Hedlunds Foundation; the Province of Groningen; the Republic of Croatia
Ministry of Science, Education and Sport; the Reynold's Foundation; the
Royal Society; Samfundet Folk; halsan; the Signe and Ane Gyllenberg
Foundation; the Sigrid Juselius Foundation; the Social Ministry of the
Federal State of Mecklenburg-West Pomerania; the Sophia Foundation for
Medical Research; the South Tyrolean Sparkasse Foundation; the Southern
California Diabetes Endocrinology Research Center; the Stockholm County
Council; the Strategic Cardiovascular Program of Karolinska Institutet;
Strategic Support for Epidemiological Research at Karolinska Institutet;
the Susan G. Komen Breast Cancer Foundation; the Swedish Ministry for
Higher Education; the Swedish Cancer Society; the Swedish Cultural
Foundation in Finland; the Swedish Diabetes Association; the Swedish
Foundation for Strategic Research; the Swedish Heart-Lung Foundation;
the Swedish Medical Research Council; the Swedish Ministry of Education;
the Swedish Research Council; the Swedish Royal Academy of Science; the
Swedish Society for Medical Research; the Swedish Society of Medicine;
the Swiss National Science Foundation; the Tampere Tuberculosis
Foundation; The Great Wine Estates of the Margaret River Region of
Western Australia; The Paul Michael Donovan Charitable Foundation; the
Torsten and Ragnar Soderberg Foundation; Cancer Research UK; the UK
Diabetes Association; the UK Heart Foundation; the UK MRC; the UK NIHR,
Biomedical Research Centre; UK West Anglia Primary and Community Care;
the University Medical Center Groningen and the University of Groningen;
the Vastra Gotaland Foundation; VU University: the Institute for Health
and Care Research and the Neuroscience Campus Amsterdam; the Wellcome
Trust; and the Yrjo Jahnsson Foundation.
NR 54
TC 177
Z9 185
U1 5
U2 103
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
J9 NAT GENET
JI Nature Genet.
PD MAY
PY 2013
VL 45
IS 5
BP 501
EP U69
DI 10.1038/ng.2606
PG 14
WC Genetics & Heredity
SC Genetics & Heredity
GA 133RU
UT WOS:000318158200011
PM 23563607
ER
PT J
AU Chen, O
Zhao, J
Chauhan, VP
Cui, J
Wong, C
Harris, DK
Wei, H
Han, HS
Fukumura, D
Jain, RK
Bawendi, MG
AF Chen, Ou
Zhao, Jing
Chauhan, Vikash P.
Cui, Jian
Wong, Cliff
Harris, Daniel K.
Wei, He
Han, Hee-Sun
Fukumura, Dai
Jain, Rakesh K.
Bawendi, Moungi G.
TI Compact high-quality CdSe-CdS core-shell nanocrystals with narrow
emission linewidths and suppressed blinking
SO NATURE MATERIALS
LA English
DT Article
ID LIGHT-EMITTING-DIODES; CADMIUM SELENIDE NANOCRYSTALS; QUANTUM-DOT
BLINKING; SEMICONDUCTOR NANOCRYSTALS; FLUORESCENCE INTERMITTENCY;
IN-VIVO; OPTICAL-PROPERTIES; SINGLE; PHOTOLUMINESCENCE; NANOSTRUCTURES
AB High particle uniformity, high photoluminescence quantum yields, narrow and symmetric emission spectral lineshapes and minimal single-dot emission intermittency (known as blinking) have been recognized as universal requirements for the successful use of colloidal quantum dots in nearly all optical applications. However, synthesizing samples that simultaneously meet all these four criteria has proven challenging. Here, we report the synthesis of such high-quality CdSe-CdS core-shell quantum dots in an optimized process that maintains a slow growth rate of the shell through the use of octanethiol and cadmium oleate as precursors. In contrast with previous observations, single-dot blinking is significantly suppressed with only a relatively thin shell. Furthermore, we demonstrate the elimination of the ensemble luminescence photodarkening that is an intrinsic consequence of quantum dot blinking statistical ageing. Furthermore, the small size and high photoluminescence quantum yields of these novel quantum dots render them superior in vivo imaging agents compared with conventional quantum dots. We anticipate these quantum dots will also result in significant improvement in the performance of quantum dots in other applications such as solid-state lighting and illumination.
C1 [Chen, Ou; Zhao, Jing; Cui, Jian; Wong, Cliff; Harris, Daniel K.; Wei, He; Han, Hee-Sun; Bawendi, Moungi G.] MIT, Dept Chem, Cambridge, MA 02139 USA.
[Chauhan, Vikash P.; Fukumura, Dai; Jain, Rakesh K.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Chauhan, Vikash P.; Fukumura, Dai; Jain, Rakesh K.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Bawendi, MG (reprint author), MIT, Dept Chem, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
EM mgb@mit.edu
RI Chauhan, Vikash/H-8172-2013
OI Chauhan, Vikash/0000-0001-9126-2302
FU NIH [5-U54-CA119349, 5R01CA126642]; ARO through the Institute for
Soldier Nanotechnologies [W911NF-07-D-0004]; NSF [CHE-0714189,
DMR-08-19762, CHE-9808061, DBI-9729592]
FX The work received support from the NIH through grants 5-U54-CA119349
(M.G.B.) and 5R01CA126642 (M.G.B., D.F., R.K.J.), the ARO through the
Institute for Soldier Nanotechnologies (W911NF-07-D-0004), and the NSF
through a Collaborative Research in Chemistry Program (CHE-0714189)
(M.G.B.). This work made use of the MRSEC Shared Experimental Facilities
at MIT, supported by the National Science Foundation under award number
DMR-08-19762 and the MIT DCIF NMR spectrometer funded through National
Science Foundation Grants CHE-9808061 and DBI-9729592.
NR 52
TC 339
Z9 341
U1 42
U2 464
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1476-1122
EI 1476-4660
J9 NAT MATER
JI Nat. Mater.
PD MAY
PY 2013
VL 12
IS 5
BP 445
EP 451
DI 10.1038/NMAT3539
PG 7
WC Chemistry, Physical; Materials Science, Multidisciplinary; Physics,
Applied; Physics, Condensed Matter
SC Chemistry; Materials Science; Physics
GA 130XY
UT WOS:000317954800016
PM 23377294
ER
PT J
AU Lu, BX
Al-Ramahi, I
Valencia, A
Wang, Q
Berenshteyn, F
Yang, HD
Gallego-Flores, T
Ichcho, S
Lacoste, A
Hild, M
DiFiglia, M
Botas, J
Palacino, J
AF Lu, Boxun
Al-Ramahi, Ismael
Valencia, Antonio
Wang, Qiong
Berenshteyn, Frada
Yang, Haidi
Gallego-Flores, Tatiana
Ichcho, Salah
Lacoste, Arnaud
Hild, Marc
DiFiglia, Marian
Botas, Juan
Palacino, James
TI Identification of NUB1 as a suppressor of mutant Huntingtin toxicity via
enhanced protein clearance
SO NATURE NEUROSCIENCE
LA English
DT Article
ID GENE HOMOLOG HDH; IN MOUSE MODEL; PROTEASOMAL DEGRADATION; DISEASE
PROGRESSION; CELLS; NEDD8; NEUROPATHOLOGY; EXPRESSION; MODIFIERS; MOTOR
AB Huntington's disease is caused by expanded CAG repeats in HTT, conferring toxic gain of function on mutant HTT (mHTT) protein. Reducing mHTT amounts is postulated as a strategy for therapeutic intervention. We conducted genome-wide RNA interference screens for genes modifying mHTT abundance and identified 13 hits. We tested 10 in vivo in a Drosophila melanogaster Huntington's disease model, and 6 exhibited activity consistent with the in vitro screening results. Among these, negative regulator of ubiquitin-like protein 1 (NUB1) overexpression lowered mHTT in neuronal models and rescued mHTT-induced death. NUB1 reduces mHTT amounts by enhancing polyubiquitination and proteasomal degradation of mHTT protein. The process requires CUL3 and the ubiquitin-like protein NEDD8 necessary for CUL3 activation. As a potential approach to modulating NUB1 for treatment, interferon-beta lowered mHTT and rescued neuronal toxicity through induction of NUB1. Thus, we have identified genes modifying endogenous mHTT using high-throughput screening and demonstrate NUB1 as an exemplar entry point for therapeutic intervention of Huntington's disease.
C1 [Lu, Boxun] Fudan Univ, Sch Life Sci, Shanghai 200433, Peoples R China.
[Lu, Boxun; Wang, Qiong; Berenshteyn, Frada; Yang, Haidi; Ichcho, Salah; Lacoste, Arnaud; Hild, Marc; Palacino, James] Novartis Inst BioMed Res Inc, Dev & Mol Pathways, Cambridge, MA USA.
[Al-Ramahi, Ismael; Gallego-Flores, Tatiana; Botas, Juan] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
[Al-Ramahi, Ismael; Gallego-Flores, Tatiana; Botas, Juan] Texas Childrens Hosp, Jan & Dan Duncan Neurol Res Inst, Houston, TX 77030 USA.
[Valencia, Antonio; DiFiglia, Marian] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA.
[Valencia, Antonio; DiFiglia, Marian] Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Boston, MA 02114 USA.
RP Palacino, J (reprint author), Novartis Inst BioMed Res Inc, Dev & Mol Pathways, Cambridge, MA USA.
EM luboxun@fudan.edu.cn; james.palacino@novartis.com
RI Al-Ramahi, Ismael/B-4000-2017
OI Al-Ramahi, Ismael/0000-0002-1275-1114
FU John J. Wasmuth postdoctoral fellowship from the Hereditary Disease
Foundation; Hereditary Disease Foundation; US National Institutes of
Health grant [NS074381]
FX The authors wish to thank D. Curtis for discussions and suggestions
during the project, X. Shi for performing the control screening on SMN
level changes, C. Mazur for assistance with cloning and sample
processing, P. Manos and C. Littlefield for assistance with the hESC and
human iPSC experiments, and E. Kim for assistance with the fly
experiments. I.A. was funded by a John J. Wasmuth postdoctoral
fellowship from the Hereditary Disease Foundation. A.V. was funded by
the Hereditary Disease Foundation. M.D. was funded by US National
Institutes of Health grant NS074381.
NR 51
TC 27
Z9 28
U1 1
U2 16
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1097-6256
J9 NAT NEUROSCI
JI Nat. Neurosci.
PD MAY
PY 2013
VL 16
IS 5
BP 562
EP +
DI 10.1038/nn.3367
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA 131WT
UT WOS:000318029300012
PM 23525043
ER
PT J
AU Patel, SR
Sheth, SA
Martinez-Rubio, C
Mian, MK
Asaad, WF
Gerrard, JL
Kwon, CS
Dougherty, DD
Flaherty, AW
Greenberg, BD
Gale, JT
Williams, ZM
Eskandar, EN
AF Patel, Shaun R.
Sheth, Sameer A.
Martinez-Rubio, Clarissa
Mian, Matthew K.
Asaad, Wael F.
Gerrard, Jason L.
Kwon, Churl-Su
Dougherty, Darin D.
Flaherty, Alice W.
Greenberg, Benjamin D.
Gale, John T.
Williams, Ziv M.
Eskandar, Emad N.
TI Studying task-related activity of individual neurons in the human brain
SO NATURE PROTOCOLS
LA English
DT Article
ID SUBTHALAMIC NUCLEUS; PARKINSONS-DISEASE; BEHAVIORAL-CONTROL;
MICROELECTRODE; RESPONSES; STIMULATION; PATHOPHYSIOLOGY; POTENTIALS
AB Single-neuronal studies remain the gold standard for studying brain function. Here we describe a protocol for studying task-related single-neuronal activity in human subjects during neurosurgical procedures involving microelectrode recordings. This protocol has two phases: a preoperative phase and an intraoperative phase. During the preoperative phase, we discuss informed consent, equipment setup and behavioral testing. During the intraoperative phase, we discuss the procedure for microelectrode recordings. Because patients are often awake during these procedures, this protocol can be performed in conjunction with behavioral tasks for studying a variety of cognitive functions. We describe the protocol in detail and provide two examples of expected results. In addition, we discuss the potential difficulties and pitfalls related to intraoperative studies. This protocol takes similar to 1.5 h to complete.
C1 [Patel, Shaun R.; Martinez-Rubio, Clarissa; Mian, Matthew K.; Kwon, Churl-Su; Williams, Ziv M.; Eskandar, Emad N.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
[Patel, Shaun R.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA.
[Sheth, Sameer A.] Columbia Univ, Med Ctr, New York Presbyterian Hosp, Dept Neurosurg, New York, NY USA.
[Asaad, Wael F.] Brown Univ, Alpert Med Sch, Brown Inst Brain Sci, Dept Neurosurg, Providence, RI 02912 USA.
[Gerrard, Jason L.] Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT USA.
[Dougherty, Darin D.; Flaherty, Alice W.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Flaherty, Alice W.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Greenberg, Benjamin D.] Brown Univ, Alpert Med Sch, Brown Inst Brain Sci, Dept Psychiat, Providence, RI 02912 USA.
[Gale, John T.] Cleveland Clin, Dept Neurosci, Cleveland, OH USA.
[Gale, John T.] Cleveland Clin, Ctr Neurol Restorat, Cleveland, OH USA.
RP Patel, SR (reprint author), Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
EM shaun.patel@me.com
RI Asaad, Wael/I-8485-2012
OI Asaad, Wael/0000-0003-4406-9096
FU US National Institutes of Health (NIH) (National Institute on Drug Abuse
(NIDA) [R01DA026297]; National Eye Institute (NEI) [NEI
1R01EY017658-01A1]; National Institute of Mental Health (NIMH)
[MH086400]; Klingenstein Foundation; Howard Hughes Medical Institute;
Dana Foundation; Sackler Programme in Psychobiology; National Institute
of Neurological Disorders and Stroke (NINDS) [R25 NS065743]
FX This work was supported by grants from the US National Institutes of
Health (NIH) (National Institute on Drug Abuse (NIDA) no. R01DA026297).
E.N.E. was supported by National Eye Institute (NEI) grant no. NEI
1R01EY017658-01A1, the National Institute of Mental Health (NIMH) Conte
Award no. MH086400, the Klingenstein Foundation, the Howard Hughes
Medical Institute and the Dana Foundation. S.R.P. was supported by the
Sackler Programme in Psychobiology. S.A.S. was supported by National
Institute of Neurological Disorders and Stroke (NINDS) grant no. R25
NS065743. We thank K. Finnis for providing the 3D reconstructions.
NR 29
TC 2
Z9 2
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1754-2189
J9 NAT PROTOC
JI Nat. Protoc.
PD MAY
PY 2013
VL 8
IS 5
BP 949
EP 957
DI 10.1038/nprot.2013.050
PG 9
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA 133PJ
UT WOS:000318151000010
PM 23598445
ER
PT J
AU Woods, DC
Tilly, JL
AF Woods, Dori C.
Tilly, Jonathan L.
TI Isolation, characterization and propagation of mitotically active germ
cells from adult mouse and human ovaries
SO NATURE PROTOCOLS
LA English
DT Article
ID STEM-CELLS; TRANSCRIPTION FACTOR; IN-VITRO; RETINOIC ACID; PROTEIN;
MICE; DIFFERENTIATION; TRANSPLANTATION; EXPRESSION; OOCYTES
AB Accruing evidence indicates that production of new oocytes (oogenesis) and their enclosure by somatic cells (folliculogenesis) are processes not limited to the perinatal period in mammals. Endpoints ranging from oocyte counts to genetic lineage tracing and transplantation experiments support a paradigm shift in reproductive biology involving active renewal of oocyte-containing follicles during postnatal life. The recent purification of mitotically active oocyte progenitor cells, termed female germline stem cells (fGSCs) or oogonial stem cells (OSCs), from mouse and human ovaries opens up new avenues for research into the biology and clinical utility of these cells. Here we detail methods for the isolation of mouse and human OSCs from adult ovarian tissue, cultivation of the cells after purification, and characterization of the cells before and after ex vivo expansion. The latter methods include analysis of germ cell-specific markers and in vitro oogenesis, as well as the use of intraovarian transplantation to test the oocyte-forming potential of OSCs in vivo.
C1 [Woods, Dori C.; Tilly, Jonathan L.] Harvard Univ, Sch Med, Dept Obstet Gynecol & Reprod Biol, Vincent Ctr Reprod Biol,Massachusetts Gen Hosp, Boston, MA 02115 USA.
RP Tilly, JL (reprint author), Harvard Univ, Sch Med, Dept Obstet Gynecol & Reprod Biol, Vincent Ctr Reprod Biol,Massachusetts Gen Hosp, Boston, MA 02115 USA.
EM jtilly@partners.org
FU Method to Extend Research in Time (MERIT) Award from the National
Institute on Aging (National Institutes of Health (NIH)) [R37-AG012279];
Ruth L. Kirschstein National Research Service Award [NIH F32-AG034809];
Glenn Foundation Award for Research in the Biological Mechanisms of
Aging; Henry and Vivian Rosenberg Philanthropic Fund
FX This work conducted by the authors and discussed herein was supported by
a Method to Extend Research in Time (MERIT) Award from the National
Institute on Aging (National Institutes of Health (NIH) R37-AG012279 to
J.L.T.), a Ruth L. Kirschstein National Research Service Award (NIH
F32-AG034809 to D.C.W.), a Glenn Foundation Award for Research in the
Biological Mechanisms of Aging (J.L.T.) and the Henry and Vivian
Rosenberg Philanthropic Fund (J.L.T.). We thank L. Prickett-Rice and K.
Folz-Donahue of the Harvard Stem Cell Institute for outstanding
technical assistance with flow cytometry, and M. Cooper (Cooper
Graphics) for expert assistance with preparation of Figure 1.
NR 57
TC 41
Z9 44
U1 3
U2 24
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1754-2189
EI 1750-2799
J9 NAT PROTOC
JI Nat. Protoc.
PD MAY
PY 2013
VL 8
IS 5
BP 966
EP 988
DI 10.1038/nprot.2013.047
PG 23
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA 133PJ
UT WOS:000318151000012
PM 23598447
ER
PT J
AU Travis, LB
Wahnefried, WD
Allan, JM
Wood, ME
Ng, AK
AF Travis, Lois B.
Wahnefried, Wendy Demark
Allan, James M.
Wood, Marie E.
Ng, Andrea K.
TI Aetiology, genetics and prevention of secondary neoplasms in adult
cancer survivors
SO NATURE REVIEWS CLINICAL ONCOLOGY
LA English
DT Review
ID ACUTE MYELOID-LEUKEMIA; BONE-MARROW-TRANSPLANTATION; HEMATOPOIETIC-CELL
TRANSPLANTATION; LONG-TERM SURVIVORS; CONTRALATERAL BREAST-CANCER;
NON-HODGKINS-LYMPHOMA; 2ND PRIMARY TUMORS; CHRONIC LYMPHOCYTIC-LEUKEMIA;
WOMENS ENVIRONMENTAL CANCER; SURGICAL ADJUVANT BREAST
AB Second and higher-order malignancies now comprise about 18% of all incident cancers in the USA, superseding first primary cancers of the breast, lung, and prostate. The occurrence of second malignant neoplasms (SMN) is influenced by a myriad of factors, including the late effects of cancer therapy, shared aetiological factors with the primary cancer ( such as tobacco use, excessive alcohol intake, and obesity), genetic predisposition, environmental determinants, host effects, and combinations of factors, including gene-environment interactions. The influence of these factors on SMN in survivors of adult-onset cancer is reviewed here. We also discuss how modifiable behavioural and lifestyle factors may contribute to SMN, and how these factors can be managed. Cancer survivorship provides an opportune time for oncologists and other health-care providers to counsel patients with regard to health promotion, not only to reduce SMN risk, but to minimize co-morbidities. In particular, the importance of smoking cessation, weight control, physical activity, and other factors consonant with adoption of a healthy lifestyle should be consistently emphasized to cancer survivors. Clinicians can also play a critical role by endorsing genetic counselling for selected patients and making referrals to dieticians, exercise trainers, and others to assist with lifestyle change interventions.
C1 [Travis, Lois B.] Univ Rochester, Med Ctr, Dept Radiat Oncol, Rochester, NY 14642 USA.
[Travis, Lois B.] Univ Rochester, Med Ctr, Rubin Ctr Canc Survivorship, Rochester, NY 14642 USA.
[Wahnefried, Wendy Demark] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA.
[Allan, James M.] Newcastle Univ, Newcastle Canc Ctr, Northern Inst Canc Res, Sch Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
[Wood, Marie E.] Univ Vermont, Dept Med, Div Hematol Oncol, Burlington, VT 05405 USA.
[Ng, Andrea K.] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA.
[Ng, Andrea K.] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Travis, LB (reprint author), Univ Rochester, Med Ctr, Dept Radiat Oncol, Rochester, NY 14642 USA.
EM lois_travis@urmc.rochester.edu
RI Allan, James/B-4448-2009
NR 207
TC 45
Z9 46
U1 1
U2 22
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-4774
EI 1759-4782
J9 NAT REV CLIN ONCOL
JI Nat. Rev. Clin. Oncol.
PD MAY
PY 2013
VL 10
IS 5
BP 289
EP 301
DI 10.1038/nrclinonc.2013.41
PG 13
WC Oncology
SC Oncology
GA 133RM
UT WOS:000318157200007
PM 23529000
ER
PT J
AU Cosyns, SMR
Dhaese, I
Thoonen, R
Buys, ES
Vral, A
Brouckaert, P
Lefebvre, RA
AF Cosyns, S. M. R.
Dhaese, I.
Thoonen, R.
Buys, E. S.
Vral, A.
Brouckaert, P.
Lefebvre, R. A.
TI Heme deficiency of soluble guanylate cyclase induces gastroparesis
SO NEUROGASTROENTEROLOGY AND MOTILITY
LA English
DT Article
DE gastrointestinal motility; nitric oxide; soluble guanylate cyclase
ID VASOACTIVE INTESTINAL POLYPEPTIDE; RAT GASTRIC FUNDUS; MOUSE DISTAL
COLON; NITRIC-OXIDE; KNOCKOUT MICE; INHIBITORY NEUROTRANSMISSION;
LONGITUDINAL MUSCLE; MOTILITY; TRANSIT; HYPERTENSION
AB Background Soluble guanylate cyclase (sGC) is the principal target of nitric oxide (NO) to control gastrointestinal motility. The consequence on nitrergic signaling and gut motility of inducing a heme-free status of sGC, as induced by oxidative stress, was investigated. Methods sGC1H105F knock-in (apo-sGC) mice, which express heme-free sGC that has basal activity, but cannot be stimulated by NO, were generated. Key Results Diethylenetriamine NONOate did not increase sGC activity in gastrointestinal tissue of apo-sGC mice. Exogenous NO did not induce relaxation in fundic, jejunal and colonic strips, and pyloric rings of apo-sGC mice. The stomach was enlarged in apo-sGC mice with hypertrophy of the muscularis externa of the fundus and pylorus. In addition, gastric emptying and intestinal transit were delayed and whole-gut transit time was increased in the apo-sGC mice, while distal colonic transit time was maintained. The nitrergic relaxant responses to electrical field stimulation at 14Hz were abolished in fundic and jejunal strips from apo-sGC mice, but in pyloric rings and colonic strips, only the response at 1Hz was abolished, indicating the contribution of other transmitters than NO. Conclusions & Inferences The results indicate that the gastrointestinal consequences of switching from a native sGC to a heme-free sGC, which cannot be stimulated by NO, are most pronounced at the level of the stomach establishing a pivotal role of the activation of sGC by NO in normal gastric functioning. In addition, delayed intestinal transit was observed, indicating that nitrergic activation of sGC also plays a role in the lower gastrointestinal tract.
C1 [Cosyns, S. M. R.; Dhaese, I.; Lefebvre, R. A.] Univ Ghent, Heymans Inst Pharmacol, B-9000 Ghent, Belgium.
[Thoonen, R.; Brouckaert, P.] Univ Ghent, Dept Biomed Mol Biol, B-9000 Ghent, Belgium.
[Thoonen, R.] Mol Cardiol Res Ctr, Tufts Med Ctr, Boston, MA USA.
[Buys, E. S.] Harvard Univ, Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Anesthesia Ctr Crit Care Res,Med Sch, Boston, MA USA.
[Vral, A.] Univ Ghent, Dept Med Basic Sci, B-9000 Ghent, Belgium.
RP Lefebvre, RA (reprint author), Univ Ghent, Heymans Inst Pharmacol, De Pintelaan 185, B-9000 Ghent, Belgium.
EM romain.lefebvre@ugent.be
FU Special Investigation Fund of Ghent University [BOF10/GOA/024]; Fund of
Scientific Research Flanders [G.0021.09N]; COST action (European Network
on Gasotransmitters) [BM1005]
FX This study was financially supported by grant BOF10/GOA/024 from the
Special Investigation Fund of Ghent University, grant G.0021.09N from
the Fund of Scientific Research Flanders, and by COST action BM1005
(European Network on Gasotransmitters).
NR 50
TC 8
Z9 8
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1350-1925
J9 NEUROGASTROENT MOTIL
JI Neurogastroenterol. Motil.
PD MAY
PY 2013
VL 25
IS 5
BP e339
EP e352
DI 10.1111/nmo.12120
PG 14
WC Gastroenterology & Hepatology; Clinical Neurology; Neurosciences
SC Gastroenterology & Hepatology; Neurosciences & Neurology
GA 132DP
UT WOS:000318048400004
PM 23551931
ER
PT J
AU Napadow, V
Sheehan, J
Kim, J
Dassatti, A
Thurler, AH
Surjanhata, B
Vangel, M
Makris, N
Schaechter, JD
Kuo, B
AF Napadow, V.
Sheehan, J.
Kim, J.
Dassatti, A.
Thurler, A. H.
Surjanhata, B.
Vangel, M.
Makris, N.
Schaechter, J. D.
Kuo, B.
TI Brain white matter microstructure is associated with susceptibility to
motion-induced nausea
SO NEUROGASTROENTEROLOGY AND MOTILITY
LA English
DT Article
DE brain imaging; diffusion tensor imaging; nausea; neuroplasticity
AB Nausea is associated with significant morbidity, and there is a wide range in the propensity of individuals to experience nausea. The neural basis of the heterogeneity in nausea susceptibility is poorly understood. Our previous functional magnetic resonance imaging (fMRI) study in healthy adults showed that a visual motion stimulus caused activation in the right MT+/V5 area, and that increased sensation of nausea due to this stimulus was associated with increased activation in the right anterior insula. For the current study, we hypothesized that individual differences in visual motion-induced nausea are due to microstructural differences in the inferior fronto-occipital fasciculus (IFOF), the white matter tract connecting the right visual motion processing area (MT+/V5) and right anterior insula. To test this hypothesis, we acquired diffusion tensor imaging data from 30 healthy adults who were subsequently dichotomized into high and low nausea susceptibility groups based on the Motion Sickness Susceptibility Scale. We quantified diffusion along the IFOF for each subject based on axial diffusivity (AD); radial diffusivity (RD), mean diffusivity (MD) and fractional anisotropy (FA), and evaluated between-group differences in these diffusion metrics. Subjects with high susceptibility to nausea rated significantly (P<0.001) higher nausea intensity to visual motion stimuli and had significantly (P<0.05) lower AD and MD along the right IFOF compared to subjects with low susceptibility to nausea. This result suggests that differences in white matter microstructure within tracts connecting visual motion and nausea-processing brain areas may contribute to nausea susceptibility or may have resulted from an increased history of nausea episodes.
C1 [Napadow, V.; Kim, J.; Vangel, M.; Schaechter, J. D.] Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Boston, MA 02114 USA.
[Sheehan, J.; Dassatti, A.; Thurler, A. H.; Surjanhata, B.; Kuo, B.] Massachusetts Gen Hosp, GI Unit, Boston, MA 02114 USA.
[Makris, N.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
RP Napadow, V (reprint author), Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Dept Radiol, 2301 149 13th St, Charlestown, MA 02129 USA.
EM vitaly@nmr.mgh.harvard.edu
FU National Institutes of Health [K01-AT002166, P01-AT006663, R01-AT004714,
K23-DK069614, R21-DK097499]; National Center for Research Resources
(Harvard Clinical and Translational Science Center) [P41RR14075, CRC 1
UL1 RR025758]; International Foundation of Functional Gastrointestinal
Disorders
FX This work was supported by the National Institutes of Health (grant
numbers K01-AT002166, P01-AT006663, and R01-AT004714 to VN, K23-DK069614
to BK, and R21-DK097499 to both VN and BK); the National Center for
Research Resources (P41RR14075; CRC 1 UL1 RR025758, Harvard Clinical and
Translational Science Center); and the International Foundation of
Functional Gastrointestinal Disorders. The content is solely the
responsibility of the authors and does not necessarily represent the
official views of our sponsors.
NR 8
TC 9
Z9 9
U1 0
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1350-1925
J9 NEUROGASTROENT MOTIL
JI Neurogastroenterol. Motil.
PD MAY
PY 2013
VL 25
IS 5
DI 10.1111/nmo.12084
PG 4
WC Gastroenterology & Hepatology; Clinical Neurology; Neurosciences
SC Gastroenterology & Hepatology; Neurosciences & Neurology
GA 132DP
UT WOS:000318048400017
PM 23360260
ER
PT J
AU Rodriguez, L
Roberts, LD
Larosa, J
Heinz, N
Gerszten, R
Nurko, S
Goldstein, AM
AF Rodriguez, L.
Roberts, L. D.
Larosa, J.
Heinz, N.
Gerszten, R.
Nurko, S.
Goldstein, A. M.
TI Relationship between postprandial metabolomics and colon motility in
children with constipation
SO NEUROGASTROENTEROLOGY AND MOTILITY
LA English
DT Article
DE Children; Colon motility; Constipation; Metabolomic profile
ID FUNCTIONAL GASTROINTESTINAL DISORDERS; ACTIVATION; RESPONSES; HUMANS;
RATS
AB Background The metabolic pathways associated with colonic motility are unknown. To identify potential metabolic targets for treatment of constipation, we examined the metabolic profile before and after a meal challenge in a cohort of children with constipation and determined its relationship with postprandial colon motility patterns. Methods In this prospective study, 187 metabolites were measured by liquid chromatographymass spectrometry at multiple time points before and after a standardized meal in constipated children undergoing a colon manometry. Postprandial metabolite levels were compared with baseline and also correlated with multiple manometric measurements, including the number, frequency, and amplitude of pressure peaks as well as the motility index (MI). Key Results A total of 20 subjects were included (mean age 13.1 +/- 3.4years). No significant metabolite changes were observed at 10min after the meal, whereas 16 amino acid and 22 lipid metabolites had significant (P<0.005) postprandial changes, including decreases in methylhistamine, histamine, and GABA, by 60min. Correlations were observed between normal and abnormal postprandial motility patterns and changes in specific metabolites, including glycerol, carnosine, alanine, asparagine, cytosine, choline, phosphocholine, thyroxine, and triiodothyronine. Interestingly, subjects without the normal postprandial increase in area under the curve (AUC), had markedly increased levels of kynurenic acid and adenosyl-homocysteine. Conclusions & Inferences This is the first study to examine postprandial metabolic changes in children and also to correlate changes in specific metabolites with colonic motility. The results suggest possible metabolic pathways associated with motility and identify potential targets for the treatment of constipation.
C1 [Rodriguez, L.; Roberts, L. D.; Larosa, J.; Heinz, N.; Nurko, S.] Harvard Univ, Sch Med, Ctr Motil & Funct Gastrointestinal Disorders, Div Gastroenterol,Childrens Hosp Boston, Boston, MA USA.
[Roberts, L. D.; Gerszten, R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Div Cardiol, Boston, MA USA.
[Goldstein, A. M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat Surg, Boston, MA USA.
RP Rodriguez, L (reprint author), Childrens Hosp, Ctr Motil & Funct Gastrointestinal Disorders, Div Gastroenterol, 300 Longwood Ave, Boston, MA 02115 USA.
EM leonel.rodriguez@childrens.harvard.edu
OI Roberts, Lee/0000-0002-1455-5248
FU Harvard Clinical and Translational Center Award [UL1 RR025758-01]
FX This study was funded by a Harvard Clinical and Translational Center
Award (UL1 RR025758-01).
NR 29
TC 2
Z9 3
U1 0
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1350-1925
J9 NEUROGASTROENT MOTIL
JI Neurogastroenterol. Motil.
PD MAY
PY 2013
VL 25
IS 5
DI 10.1111/nmo.12086
PG 8
WC Gastroenterology & Hepatology; Clinical Neurology; Neurosciences
SC Gastroenterology & Hepatology; Neurosciences & Neurology
GA 132DP
UT WOS:000318048400014
PM 23421516
ER
PT J
AU Hookway, LA
Fuhr, P
Frazier, M
AF Hookway, Larry Allen
Fuhr, Patti
Frazier, Marcela
TI Use of Ready-Made Spectacles to Meet Visual Needs in a Low-Resource
Adult Population
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE humanitarian eye care; vision correction; presbyopia; refractive error;
readers; functional vision; spectacles; vision; uncorrected refractive
error; visual impairment; blindness
ID WILLINGNESS-TO-PAY; UNCORRECTED PRESBYOPIA; REFRACTIVE ERROR; RURAL
TANZANIA; EYE DISEASE; IMPAIRMENT; CARE; COUNTRIES; BLINDNESS; PACIFIC
AB Purpose. In affluent societies, distance and near vision problems are typically corrected with custom-made eyeglasses. Many persons in less affluent areas do not have the resources for such. The purpose of this study was to assess the use of less expensive ready-made (RM) bifocals and readers to correct distance and near refractive error and presbyopia in an outreach clinic in Nicaragua.
Methods. This is a retrospective review of records of all patients older than 34 years who presented for an eye examination in an outreach clinic in Granada, Nicaragua, in 2010. A visual satisfaction questionnaire had been administered to patients before they were examined and after RM plus sphere bifocals or plus sphere reading spectacles were dispensed. The main outcome measures included pre- and post-distance and near visual acuities, vision satisfaction and difficulty ratings, and perceived cost and willingness to pay for replacement rating.
Results. Ready-made plus sphere spectacles (bifocals or single-vision readers) were dispensed to 95.4% of those examined. The remaining 4.6% required custom prescriptions because of astigmatism, myopia, or anisometropia. The RM bifocals were very well accepted, with high visual satisfaction ratings with the bifocals improving from a presenting value of 11 to 89.4% at distance and from 6.6 to 89.4% at near. Percentage of patients achieving visual acuity of 20/40 or better improved from 60 to 84.5% at distance and from 44 to 97% at near. Percentage achieving functionally good near vision (20/40 or better) improved from 38 to 97% with RM readers. Patients reporting highest satisfaction with near vision improved from 6.3 to 86.6%. Patients indicated that, on average, they would be willing to pay US$ 18.39 to replace the bifocals and US$ 16.67 to replace the readers.
Conclusions. Ready-made bifocals and RM single-vision readers may be an acceptable and affordable alternative for many patients with hyperopia and/or presbyopia where access to custom-made eyeglasses is difficult. (Optom Vis Sci 2013; 90: 494-500)
C1 [Hookway, Larry Allen] NOVA Southeastern Coll Optometry, Ft Lauderdale, FL USA.
[Fuhr, Patti; Frazier, Marcela] Univ Alabama Birmingham, Sch Optometry, Dept Optometry, Birmingham, AL 35294 USA.
[Fuhr, Patti] Birmingham VA Med Ctr, Blind Rehabil Ctr, Birmingham, AL USA.
RP Hookway, LA (reprint author), 320 W Walton St,POB 270, Willard, OH 44890 USA.
EM larryhookway@gmail.com
NR 29
TC 2
Z9 2
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-5488
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD MAY
PY 2013
VL 90
IS 5
BP 494
EP 500
DI 10.1097/OPX.0b013e31828dedf6
PG 7
WC Ophthalmology
SC Ophthalmology
GA 131TW
UT WOS:000318020300015
PM 23584487
ER
PT J
AU Winters-Stone, KM
Dobek, J
Nail, LM
Bennett, JA
Leo, MC
Torgrimson-Ojerio, B
Luoh, SW
Schwartz, A
AF Winters-Stone, K. M.
Dobek, J.
Nail, L. M.
Bennett, J. A.
Leo, M. C.
Torgrimson-Ojerio, B.
Luoh, S. -W.
Schwartz, A.
TI Impact plus resistance training improves bone health and body
composition in prematurely menopausal breast cancer survivors: a
randomized controlled trial
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Chemotherapy; Neoplasm; Obesity; Osteoporosis; Physical activity
ID MINERAL DENSITY; ADJUVANT CHEMOTHERAPY; PREMENOPAUSAL WOMEN; OVARIAN
FAILURE; POSTMENOPAUSAL WOMEN; PHYSICAL-ACTIVITY; FRACTURE RISK;
WEIGHT-GAIN; EXERCISE; ESTROGEN
AB Our randomized controlled trial in prematurely menopausal breast cancer survivors showed that impact + resistance training prevented increases in percentage of body fat compared with controls and also improved BMD at the hip and prevented BMD loss at the spine among exercise-trained women who were menopausal for > 1 year.
Cancer treatment-related menopause worsens bone health and body composition in breast cancer survivors (BCS). We investigated whether impact + resistance training could improve bone mineral density (BMD), reduce bone turnover, build muscle, and decrease fat mass in BCS with premature menopause.
We conducted a randomized controlled trial in 71 BCS (mean age, 46.5 years) within 5 years of treatment-related menopause. Women were randomly assigned to one of two groups: (1) impact + resistance training (prevent osteoporosis with impact + resistance (POWIR)) or (2) exercise placebo (FLEX) 3x/week for 1 year. Outcomes were hip and spine BMD (in grams per square centimeter) and body composition (percent body fat (%BF) and lean and fat mass (in kilograms)) by DXA and bone turnover markers (serum osteocalcin (in nanograms per milliliter) and urinary deoxypryrodinoline (in nanomoles per milliliter).
There were no significant group x time interactions for bone outcomes when using an intent-to-treat approach on the full sample. In analyses restricted to BCS who were menopausal for a parts per thousand yen1 year, POWIR increased BMD at the hip and slowed BMD loss at the spine compared with FLEX (femoral neck-POWIR, 0.004 +/- 0.093 g/cm(2) vs. FLEX, -0.010 +/- 0.089 g/cm(2); p < 0.01; spine-POWIR, -0.003 +/- 0.114 g/cm(2) vs. FLEX, -0.020 +/- 0.110 g/cm(2); p = 0.03). POWIR prevented increases in %BF (POWIR, 0.01 % vs. FLEX, 1.3 %; p < 0.04). Women with attendance to POWIR at a parts per thousand yen64 % had better improvements in %BF than women attending less often (p < 0.03).
Impact + resistance training may effectively combat bone loss and worsening body composition from premature menopause in BCS.
C1 [Winters-Stone, K. M.; Dobek, J.; Nail, L. M.; Bennett, J. A.; Torgrimson-Ojerio, B.] Oregon Hlth & Sci Univ, Sch Nursing, Portland, OR 97239 USA.
[Dobek, J.] Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97239 USA.
[Winters-Stone, K. M.; Nail, L. M.; Bennett, J. A.] Oregon Hlth & Sci Univ, Knight Canc Ctr, Portland, OR 97239 USA.
[Luoh, S. -W.] Portland VA Med Ctr, Portland, OR USA.
[Leo, M. C.] Kaiser Permanente Ctr Hlth Res, Portland, OR USA.
[Schwartz, A.] Idaho State Univ, Pocatello, ID 83209 USA.
[Winters-Stone, K. M.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
RP Winters-Stone, KM (reprint author), Oregon Hlth & Sci Univ, 3455 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM wintersk@ohsu.edu
FU American Cancer Society Research Scholar Grant [RSGPB-06-092-01-CPPB]
FX Funding was provided by an American Cancer Society Research Scholar
Grant (RSGPB-06-092-01-CPPB). We thank the Oregon State Cancer Registry
for their assistance with recruitment; Thera-band, Inc. for providing
elastic exercise bands; and our research assistants, exercise trainers,
and participants.
NR 45
TC 25
Z9 26
U1 2
U2 37
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937-941X
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD MAY
PY 2013
VL 24
IS 5
BP 1637
EP 1646
DI 10.1007/s00198-012-2143-2
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 135HV
UT WOS:000318280100011
PM 22996743
ER
PT J
AU Heist, EK
Perna, F
Chalhoub, F
Danik, S
Barrett, C
Houghtaling, C
Tondo, C
Mahapatra, S
Ruskin, J
Mansour, M
AF Heist, E. Kevin
Perna, Francesco
Chalhoub, Fadi
Danik, Stephan
Barrett, Conor
Houghtaling, Christopher
Tondo, Claudio
Mahapatra, Srijoy
Ruskin, Jeremy
Mansour, Moussa
TI Comparison of Electroanatomical Mapping Systems: Accuracy in Left Atrial
Mapping
SO PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY
LA English
DT Article
DE ablation; atrial fibrillation; electrophysiologyclinical; mapping
ID CATHETER ABLATION; IMAGE INTEGRATION; FIBRILLATION
AB Background Current 3D mapping systems have difficulty rendering complex cardiac structures. Different electroanatomical mapping software has been recently developed which uses a mathematical algorithm to improve interpolation between mapped points and delineation of closely spaced structures. This study tested the feasibility and accuracy of this software in comparison to traditional software. Methods In vivo 3D impedance-based mapping using a multielectrode catheter with a single geometry point cloud was performed in the left atria and pulmonary veins (PV) in 23 patients undergoing catheter ablation for atrial fibrillation. The maps were analyzed with traditional (NavX, St. Jude Medical, Minnetonka, MN, USA), either with or without multichamber mapping versus St. Jude OneModel software and dimensions of cardiac chambers in human studies were compared to preprocedural computed tomographic (CT) or magnetic resonance (MR) scans to determine the relative accuracy of the maps. Results Maps created by the OneModel software provided greater detail of complex cardiac structures compared to traditional software. Comparison of the left atrial/pulmonary vein electroanatomical maps with the CT and MR scans as reference standard demonstrated significantly less error in measurement of all PV ostial long- and short-axis dimensions, inter-PV distance, and ridge width (left PV to left atrial appendage) with the OneModel versus traditional software (P < 0.001 for all dimensions measured). Conclusions The OneModel software produces maps that are more accurate in rendering complex cardiac structures compared to traditional software.
C1 [Mansour, Moussa] Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Mansour, M (reprint author), Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Gray 109,55 Fruit St, Boston, MA 02114 USA.
EM mmansour@partners.org
OI Perna, Francesco/0000-0002-9019-9492
NR 13
TC 0
Z9 0
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0147-8389
EI 1540-8159
J9 PACE
JI PACE-Pacing Clin. Electrophysiol.
PD MAY
PY 2013
VL 36
IS 5
BP 626
EP 631
DI 10.1111/pace.12095
PG 6
WC Cardiac & Cardiovascular Systems; Engineering, Biomedical
SC Cardiovascular System & Cardiology; Engineering
GA 134SD
UT WOS:000318233800022
PM 23437794
ER
PT J
AU Ahluwalia, SC
Levin, JR
Lorenz, KA
Gordon, HS
AF Ahluwalia, Sangeeta C.
Levin, Jennifer R.
Lorenz, Karl A.
Gordon, Howard S.
TI "There's no cure for this condition": How physicians discuss advance
care planning in heart failure
SO PATIENT EDUCATION AND COUNSELING
LA English
DT Article
DE Communication; Qualitative; Advance care planning; Heart failure
ID BREAKING-BAD-NEWS; LIFE-SUSTAINING TREATMENT; COMMUNICATION-SKILLS;
OF-LIFE; SIMULATED INTERVIEWS; MEDICAL-STUDENTS; RANDOMIZED-TRIAL;
CANCER CARE; PREFERENCES; END
AB Objective: To evaluate the extent to which physicians engage in recommended elements of advance care planning (ACP) communication during outpatient clinic visits with heart failure (HF) patients.
Methods: We conducted a qualitative content analysis of 71 audio-recorded and transcribed outpatient visits with 52 patients >= 65 years recently hospitalized for HF and their physicians (n = 44).
Results: We identified 25 instances of ACP-related communication over 15 of the 71 visits: in 17 instances, physicians explained the nature of HF but only once was the life-limiting potential of HF Mentioned. Physicians discussed goals of care in 6 instances but elicited their patients' preferences in only 2 of those instances. Finally, physicians encouraged documentation of preferences in 2 instances.
Conclusions: Despite recommendations for early ACP with HF patients, physicians rarely engaged in fundamental elements of ACP discussions during outpatient visits. We suggest a stepwise approach to supporting the process of ACP communication in practice.
Practice implications: Given the importance of ACP in helping patients plan for their future care, outpatient clinicians should be helped to incorporate these discussions in the routine care of their HF patients. Using a simple heuristic might help physicians engage in fundamental elements of ACP during busy outpatient visits. Published by Elsevier Ireland Ltd.
C1 [Ahluwalia, Sangeeta C.] VA Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Provider Behav, Los Angeles, CA 90064 USA.
[Ahluwalia, Sangeeta C.; Levin, Jennifer R.; Lorenz, Karl A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90064 USA.
[Lorenz, Karl A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Gordon, Howard S.] Jesse Brown Vet Affairs Med Ctr, Chicago, IL USA.
[Gordon, Howard S.] VA Ctr Management Complex Chron Care, Chicago, IL USA.
[Gordon, Howard S.] Univ Illinois, Coll Med, Dept Med, Chicago, IL USA.
RP Ahluwalia, SC (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd 111-G, Los Angeles, CA 90064 USA.
EM sangeeta.ahluwalia@va.gov
RI Gordon, Howard/E-4420-2010
OI Gordon, Howard/0000-0002-6712-5954
FU VA Health Services Research and Development (HSR&D), Department of
Veterans Affairs [ECV-02-254]; Office of Academic Affiliation's VA
Associated Health Postdoctoral Fellowship Program at the VA Greater Los
Angeles HSR&D Center of Excellence
FX Supported in part by grant ECV-02-254 from VA Health Services Research
and Development (HSR&D), Department of Veterans Affairs. Dr. Ahluwalia
is supported by an Office of Academic Affiliation's VA Associated Health
Postdoctoral Fellowship Program at the VA Greater Los Angeles HSR&D
Center of Excellence.
NR 45
TC 9
Z9 9
U1 1
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0738-3991
J9 PATIENT EDUC COUNS
JI Patient Educ. Couns.
PD MAY
PY 2013
VL 91
IS 2
BP 200
EP 205
DI 10.1016/j.pec.2012.12.016
PG 6
WC Public, Environmental & Occupational Health; Social Sciences,
Interdisciplinary
SC Public, Environmental & Occupational Health; Social Sciences - Other
Topics
GA 136AA
UT WOS:000318330600011
PM 23369373
ER
PT J
AU Yang, E
Diers, JR
Huang, YY
Hamblin, MR
Lindsey, JS
Bocian, DF
Holten, D
AF Yang, Eunkyung
Diers, James R.
Huang, Ying-Ying
Hamblin, Michael R.
Lindsey, Jonathan S.
Bocian, David F.
Holten, Dewey
TI Molecular Electronic Tuning of Photosensitizers to Enhance Photodynamic
Therapy: Synthetic Dicyanobacteriochlorins as a Case Study
SO PHOTOCHEMISTRY AND PHOTOBIOLOGY
LA English
DT Article
ID CENTRAL METAL; BACTERIOCHLORINS; OXYGEN; SUBSTITUENTS; PORPHYRINS;
GENERATION; SPECTRA; SENSITIZERS; MELANOMA; EFFICACY
AB Photophysical, photostability, electrochemical and molecular-orbital characteristics are analyzed for a set of stable dicyanobacteriochlorins that are promising photosensitizers for photodynamic therapy (PDT). The bacteriochlorins are the parent compound (BC), dicyano derivative (NC)2BC and corresponding zinc (NC)2BC-Zn and palladium chelate (NC)2BC-Pd. The order of PDT activity against HeLa human cancer cells in vitro is (NC)2BC-Pd>(NC)2BC>(NC)2BC-Zn approximate to BC. The near-infrared absorption feature of each dicyanobacteriochlorin is bathochromically shifted 3550nm (748763nm) from that for BC (713nm). Intersystem crossing to the PDT-active triplet excited state is essentially quantitative for (NC)2BC-Pd. Phosphorescence from (NC)2BC-Pd occurs at 1122nm (1.1eV). This value and the measured ground-state redox potentials fix the triplet excited-state redox properties, which underpin PDT activity via Type-1 (electron transfer) pathways. A perhaps counterintuitive (but readily explicable) result is that of the three dicyanobacteriochlorins, the photosensitizer with the shortest triplet lifetime (7s), (NC)2BC-Pd has the highest activity. Photostabilities of the dicyanobacteriochlorins and other bacteriochlorins studied recently are investigated and discussed in terms of four phenomena: aggregation, reduction, oxidation and chemical reaction. Collectively, the results and analysis provide fundamental insights concerning the molecular design of PDT agents.
C1 [Yang, Eunkyung; Holten, Dewey] Washington Univ, Dept Chem, St Louis, MO 63130 USA.
[Diers, James R.; Bocian, David F.] Univ Calif Riverside, Dept Chem, Riverside, CA 92521 USA.
[Huang, Ying-Ying; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Huang, Ying-Ying; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Huang, Ying-Ying] Guangxi Med Univ, Aesthet & Plast Ctr, Nanning, Peoples R China.
[Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Lindsey, Jonathan S.] N Carolina State Univ, Dept Chem, Raleigh, NC 27695 USA.
RP Lindsey, JS (reprint author), N Carolina State Univ, Dept Chem, Box 8204, Raleigh, NC 27695 USA.
EM jlindsey@ncsu.edu; David.Bocian@ucr.edu; holten@wustl.edu
RI Lindsey, Jonathan/J-7761-2012; Huang, Ying-ying/G-3153-2011;
OI Huang, Ying-ying/0000-0003-3066-6981; Hamblin,
Michael/0000-0001-6431-4605
FU NIH [R01AI050875]; JimmyV NCSU Cancer Therapeutics Training Program;
National Institute of Allergy and Infectious Diseases [R41AI072854];
Division of Chemical Sciences, Geosciences and Biosciences Division,
Office of Basic Energy Sciences of the U.S. Department of Energy
[DE-FG02-05ER15660, DE-FG02-05ER15661]
FX This work was supported by grants from the NIH (R01AI050875 to M. R.
H.), and the JimmyV NCSU Cancer Therapeutics Training Program. Y.-Y.H.
was supported by a grant (R41AI072854) from the National Institute of
Allergy and Infectious Diseases to NIRvana Pharmaceuticals, Inc.
Characterization of the photophysical, redox and molecular-orbital
properties of the bacteriochlorins described herein were initially
motivated by solar energy studies and supported by grants from the
Division of Chemical Sciences, Geosciences and Biosciences Division,
Office of Basic Energy Sciences of the U.S. Department of Energy to
D.F.B. (DE-FG02-05ER15660) and D.H. (DE-FG02-05ER15661).
NR 37
TC 24
Z9 25
U1 3
U2 40
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0031-8655
EI 1751-1097
J9 PHOTOCHEM PHOTOBIOL
JI Photochem. Photobiol.
PD MAY-JUN
PY 2013
VL 89
IS 3
BP 605
EP 618
DI 10.1111/php.12021
PG 14
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 134RU
UT WOS:000318232800010
PM 23163632
ER
PT J
AU Tanaka, M
Mroz, P
Dai, TH
Huang, LY
Morimoto, Y
Kinoshita, M
Yoshihara, Y
Shinomiya, N
Seki, S
Nemoto, K
Hamblin, MR
AF Tanaka, Masamitsu
Mroz, Pawel
Dai, Tianhong
Huang, Liyi
Morimoto, Yuji
Kinoshita, Manabu
Yoshihara, Yasuo
Shinomiya, Nariyoshi
Seki, Shuhji
Nemoto, Koichi
Hamblin, Michael R.
TI Linezolid and Vancomycin Decrease the Therapeutic Effect of Methylene
Blue-Photodynamic therapy in a Mouse Model of MRSA Bacterial Arthritis
SO PHOTOCHEMISTRY AND PHOTOBIOLOGY
LA English
DT Article
ID RESISTANT STAPHYLOCOCCUS-AUREUS; WOUND INFECTIONS; IN-VIVO; MICE;
NEUTROPHILS
AB We previously reported that photodynamic therapy (PDT) using intra-articular methylene blue (MB) could be used to treat arthritis in mice caused by bioluminescent methicillin-resistant Staphylococcus aureus (MRSA) either in a therapeutic or in a preventative mode. PDT accumulated neutrophils into the mouse knee via activation of chemoattractants such as inflammatory cytokines or chemokines. In this study, we asked whether PDT combined with antibiotics used for MRSA could provide added benefit in controlling the infection. We compared MB-PDT alone, systemic administration of either linezolid (LZD) alone or vancomycin (VCM) alone or the combination of PDT with either LZD or VCM. Real-time noninvasive imaging was used to serially follow the progress of the infection. PDT alone was the most effective, whereas LZD alone was ineffective and VCM alone showed some benefit. Surprisingly the addition of LZD or VCM reduced the therapeutic effect of PDT alone (P<0.05). Considering that PDT in this mouse model stimulates neutrophils to be antibacterial rather than actively killing the bacteria, we propose that LZD and VCM might inhibit the activation of inflammatory cytokines without eradicating the bacteria, and thereby reduce the therapeutic effect of PDT.
C1 [Tanaka, Masamitsu; Mroz, Pawel; Dai, Tianhong; Huang, Liyi; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Tanaka, Masamitsu; Mroz, Pawel; Dai, Tianhong; Huang, Liyi; Hamblin, Michael R.] Harvard Univ, Dept Dermatol, Sch Med, Boston, MA 02115 USA.
[Tanaka, Masamitsu; Yoshihara, Yasuo; Nemoto, Koichi] Natl Def Med Coll, Dept Orthoped Surg, Tokorozawa, Saitama 3598513, Japan.
[Tanaka, Masamitsu; Morimoto, Yuji; Shinomiya, Nariyoshi] Natl Def Med Coll, Dept Integrated Physiol & Bionano Med, Tokorozawa, Saitama 3598513, Japan.
[Kinoshita, Manabu; Seki, Shuhji] Natl Def Med Coll, Dept Immunol & Microbiol, Tokorozawa, Saitama 3598513, Japan.
[Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
RP Morimoto, Y (reprint author), Natl Def Med Coll, Dept Integrated Physiol & Bionano Med, Tokorozawa, Saitama 3598513, Japan.
EM moyan@ndmc.ac.jp; ham-blin@helix.mgh.harvard.edu
OI Hamblin, Michael/0000-0001-6431-4605
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
[23659628]; US NIH [R01AI050875]; National Natural Science Foundation of
China [81260239]; Airlift Research Foundation [109421]
FX This work was supported by a Grant-in-Aid for Challenging Exploratory
Research (23659628) from the Ministry of Education, Culture, Sports,
Science and Technology of Japan to Yuji Morimoto. Michael R. Hamblin was
supported by US NIH grant no. R01AI050875, Liyi Huang by National
Natural Science Foundation of China (grant no. 81260239) and Tianhong
Dai by an Airlift Research Foundation Extremity Trauma Research Grant
(grant no. 109421). We would like to thank Hoon Chung MD, PhD (Wellman
Center for Photomedicine, Massachusetts General Hospital) for his
technical support and advice.
NR 23
TC 4
Z9 4
U1 1
U2 16
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0031-8655
J9 PHOTOCHEM PHOTOBIOL
JI Photochem. Photobiol.
PD MAY-JUN
PY 2013
VL 89
IS 3
BP 679
EP 682
DI 10.1111/php.12040
PG 4
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 134RU
UT WOS:000318232800019
PM 23311407
ER
PT J
AU Saladi, SV
Wong, PG
Trivedi, AR
Marathe, HG
Keenen, B
Aras, S
Liew, ZQ
Setaluri, V
de la Serna, IL
AF Saladi, Srinivas V.
Wong, Philip G.
Trivedi, Archit R.
Marathe, Himangi G.
Keenen, Bridget
Aras, Shweta
Liew, Zi-Qi
Setaluri, Vijayasaradhi
de la Serna, Ivana L.
TI BRG1 promotes survival of UV-irradiated melanoma cells by cooperating
with MITF to activate the melanoma inhibitor of apoptosis gene
SO PIGMENT CELL & MELANOMA RESEARCH
LA English
DT Article
DE melanoma; MITF; SWI; SNF enzymes; chromatin remodeling; ultraviolet
radiation; apoptosis; ML-IAP
ID CHROMATIN REMODELING COMPLEXES; TRANSCRIPTION FACTOR;
ULTRAVIOLET-RADIATION; MALIGNANT-MELANOMA; SWI/SNF COMPLEXES; LINEAGE
SURVIVAL; BREAST-CANCER; ML-IAP; PROTEIN; EXPRESSION
AB Microphthalmia-associated transcription factor (MITF) is a survival factor in melanocytes and melanoma cells. MITF regulates expression of antiapoptotic genes and promotes lineage-specific survival in response to ultraviolet (UV) radiation and to chemotherapeutics. SWI/SNF chromatin-remodeling enzymes interact with MITF to regulate MITF target gene expression. We determined that the catalytic subunit, BRG1, of the SWI/SNF complex protects melanoma cells against UV-induced death. BRG1 prevents apoptosis in UV-irradiated melanoma cells by activating expression of the melanoma inhibitor of apoptosis (ML-IAP). Down-regulation of ML-IAP compromises BRG1-mediated survival of melanoma cells in response to UV radiation. BRG1 regulates ML-IAP expression by cooperating with MITF to promote transcriptionally permissive chromatin structure on the ML-IAP promoter. The alternative catalytic subunit, BRM, and the BRG1-associated factor, BAF180, were found to be dispensable for elevated expression of ML-IAP in melanoma cells. Thus, we illuminate a lineage-specific mechanism by which a specific SWI/SNF subunit, BRG1, modulates the cellular response to DNA damage by regulating an antiapoptotic gene and implicate this subunit of the SWI/SNF complex in mediating the prosurvival function of MITF.
C1 [Saladi, Srinivas V.; Wong, Philip G.; Trivedi, Archit R.; Marathe, Himangi G.; Keenen, Bridget; Aras, Shweta; Liew, Zi-Qi; de la Serna, Ivana L.] Univ Toledo, Coll Med, Dept Biochem & Canc Biol, Toledo, OH 43606 USA.
[Setaluri, Vijayasaradhi] Univ Wisconsin, Dept Dermatol, Madison, WI USA.
RP de la Serna, IL (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Canc Ctr, 55 Fruit St, Boston, MA 02114 USA.
EM ivana.delaserna@utoledo.edu
FU National Institute of Health [R01 (ARO59379)]
FX ILD was supported by National Institute of Health R01 (ARO59379).
NR 45
TC 11
Z9 11
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-1471
J9 PIGM CELL MELANOMA R
JI Pigment Cell Melanoma Res.
PD MAY
PY 2013
VL 26
IS 3
BP 377
EP 391
DI 10.1111/pcmr.12088
PG 15
WC Oncology; Cell Biology; Dermatology
SC Oncology; Cell Biology; Dermatology
GA 133CD
UT WOS:000318114100017
PM 23480510
ER
PT J
AU Webber, JT
Askenazi, M
Ficarro, SB
Iglehart, MA
Marto, JA
AF Webber, James T.
Askenazi, Manor
Ficarro, Scott B.
Iglehart, Max A.
Marto, Jarrod A.
TI Library dependent LC-MS/MS acquisition via mzAPI/Live
SO PROTEOMICS
LA English
DT Article
DE LC-MS; Mass informatics; MS; Quantitative proteomics; Technology
ID TRANSFORM MASS-SPECTROMETRY; PEPTIDE; IDENTIFICATION; IONIZATION;
PROTEOMICS
AB The use of MS for characterization of small molecules, nucleotides, and proteins in model organisms as well as primary tissues and clinical samples continues to proliferate at a rapid pace. The complexity and dynamic range of target analytes in biological systems hinders comprehensive analysis and simultaneously drives improvements in instrument hardware and software. As a result, state-of-the-art commercial mass spectrometers are equipped with sophisticated embedded control systems that provide robust acquisition methods accessed through intuitive graphical interfaces. Although optimized for speed, these preconfigured scan functions are otherwise closed to end-user customization beyond simple, analytical-centric parameters supplied by the manufacturer. Here, we present an open-source framework (mzAPI/Live) that enables users to generate arbitrarily complex LC-MSn acquisition methods via simple Python scripting. As a powerful proof-of-concept, we demonstrate real-time assignment of tandem mass spectra through rapid query of NIST peptide libraries. This represents an unprecedented capability to make acquisition decisions based on knowledge of analyte structures determined during the run itself, thus providing a path toward biology-driven MS data acquisition for the broader community.
C1 [Webber, James T.; Askenazi, Manor; Ficarro, Scott B.; Iglehart, Max A.; Marto, Jarrod A.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA.
[Webber, James T.; Askenazi, Manor; Ficarro, Scott B.; Iglehart, Max A.; Marto, Jarrod A.] Dana Farber Canc Inst, Blais Prote Ctr, Boston, MA 02215 USA.
[Askenazi, Manor] Hebrew Univ Jerusalem, Dept Biol Chem, IL-91905 Jerusalem, Israel.
[Askenazi, Manor; Ficarro, Scott B.; Marto, Jarrod A.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
RP Marto, JA (reprint author), Dana Farber Canc Inst, Dept Canc Biol, 450 Brookline Ave,Smith 1158A, Boston, MA 02215 USA.
EM jarrod_marto@dfci.harvard.edu
OI Webber, James/0000-0001-8594-9888
FU NINDS NIH HHS [P01 NS047572, P01NS047572]
NR 23
TC 3
Z9 3
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1615-9853
J9 PROTEOMICS
JI Proteomics
PD MAY
PY 2013
VL 13
IS 9
BP 1412
EP 1416
DI 10.1002/pmic.201200583
PG 5
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 132ED
UT WOS:000318049800004
PM 23457059
ER
PT J
AU Zondervan, RL
Hahn, PF
Sadow, CA
Liu, B
Lee, SI
AF Zondervan, Robert L.
Hahn, Peter F.
Sadow, Cheryl A.
Liu, Bob
Lee, Susanna I.
TI Body CT Scanning in Young Adults: Examination Indications, Patient
Outcomes, and Risk of Radiation-induced Cancer
SO RADIOLOGY
LA English
DT Article
ID ITERATIVE RECONSTRUCTION TECHNIQUE; MINOR HEAD-INJURY;
COMPUTED-TOMOGRAPHY; FEMALE BREAST; RADIOLOGY; RULE; MANAGEMENT;
PROTOCOLS; EXPOSURE; CRITERIA
AB Purpose: To quantify patient outcome and predicted cancer risk from body computed tomography (CT) in young adults and identify common indications for the imaging examination.
Materials and Methods: This retrospective multicenter study was HIPAA compliant and approved by the institutional review boards of three institutions, with waiver of informed consent. The Research Patient Data Registry containing patient medical and billing records of three university-affiliated hospitals in a single metropolitan area was queried for patients 18-35 years old with a social security record who underwent chest or abdominopelvic CT from 2003 to 2007. Patients were analyzed according to body part imaged and scanning frequency. Mortality status and follow-up interval were recorded. The Biologic Effects of Ionizing Radiation VII method was used to calculate expected cancer incidence and death. Examination indication was determined with associated ICD-9 diagnostic code; 95% confidence intervals for percentages were calculated, and the binomial test was used to compare the difference between percentages.
Results: In 21 945 patients, 16 851 chest and 24 112 abdominopelvic CT scans were obtained. During the average 5.5-year (+/- 0.1 [standard deviation]) follow-up, 7.1% (575 of 8057) of chest CT patients and 3.9% (546 of 13 888) of abdominal CT patients had died. In comparison, the predicted risk of dying from CT-induced cancer was 0.1% (five of 8057, P < .01) and 0.1% (eight of 12 472, P < .01), respectively. The most common examination indications were cancer and trauma for chest CT and abdominal pain, trauma, and cancer for abdominopelvic CT. Among patients without a cancer diagnosis in whom only one or two scans were obtained, mortality and predicted risk of radiation-induced cancer death were 3.6% (215 of 5914) and 0.05% (three of 5914, P < .01) for chest CT and 1.9% (219 of 11 291) and 0.1% (six of 11 291, P < .01) for abdominopelvic CT.
Conclusion: Among young adults undergoing body CT, risk of death from underlying morbidity is more than an order of magnitude greater than death from long-term radiation-induced cancer. (C) RSNA, 2013
C1 [Zondervan, Robert L.; Hahn, Peter F.; Liu, Bob; Lee, Susanna I.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Liu, Bob; Lee, Susanna I.] Massachusetts Gen Hosp, Webster Ctr Radiat Res & Educ, Boston, MA 02114 USA.
[Sadow, Cheryl A.] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA.
RP Zondervan, RL (reprint author), Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St, Boston, MA 02114 USA.
EM robert.zondervan@gmail.com
NR 32
TC 26
Z9 30
U1 1
U2 11
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0033-8419
J9 RADIOLOGY
JI Radiology
PD MAY
PY 2013
VL 267
IS 2
BP 460
EP 469
DI 10.1148/radiol.12121324
PG 10
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 132LM
UT WOS:000318069700017
PM 23386731
ER
PT J
AU Cohen, SP
Bicket, MC
Jamison, D
Wilkinson, I
Rathmell, JP
AF Cohen, Steven P.
Bicket, Mark C.
Jamison, David
Wilkinson, Indy
Rathmell, James P.
TI Epidural Steroids A Comprehensive, Evidence-Based Review
SO REGIONAL ANESTHESIA AND PAIN MEDICINE
LA English
DT Review
ID LOW-BACK-PAIN; LUMBAR DISC HERNIATION; RANDOMIZED CONTROLLED-TRIAL;
2000-2010 TASK-FORCE; ACTIVE CONTROL TRIAL; CERVICAL TRANSFORAMINAL
INJECTION; POSTDURAL PUNCTURE HEADACHE; CENTRAL SPINAL STENOSIS; NERVE
ROOT COMPRESSION; CONTRAST FLOW PATTERNS
AB Epidural steroid injections (ESIs) are the most widely utilized pain management procedure in the world, their use supported by more than 45 placebo-controlled studies and dozens of systematic reviews. Despite the extensive literature on the subject, there continues to be considerable controversy surrounding their safety and efficacy. The results of clinical trials and review articles are heavily influenced by specialty, with those done by interventional pain physicians more likely to yield positive findings. Overall, more than half of controlled studies have demonstrated positive findings, suggesting a modest effect size lasting less than 3 months in well-selected individuals. Transforaminal injections are more likely to yield positive results than interlaminar or caudal injections, and subgroup analyses indicate a slightly greater likelihood for a positive response for lumbar herniated disk, compared with spinal stenosis or axial spinal pain. Other factors that may increase the likelihood of a positive outcome in clinical trials include the use of a nonepidural (eg, intramuscular) control group, higher volumes in the treatment group, and the use of depo-steroid. Serious complications are rare following ESIs, provided proper precautions are taken. Although there are no clinical trials comparing different numbers of injections, guidelines suggest that the number of injections should be tailored to individual response, rather than a set series. Most subgroup analyses of controlled studies show no difference in surgical rates between ESI and control patients; however, randomized studies conducted by spine surgeons, in surgically amenable patients with standardized operative criteria, indicate that in some patients the strategic use of ESI may prevent surgery. (Reg Anesth Pain Med 2013; 38: 175-200)
C1 [Cohen, Steven P.; Bicket, Mark C.] Johns Hopkins Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD USA.
[Cohen, Steven P.; Jamison, David] Walter Reed Natl Mil Med Ctr, Dept Anesthesiol, Pain Management Ctr, Bethesda, MD USA.
[Wilkinson, Indy] Womack Army Med Ctr, Dept Anesthesiol, Ft Bragg, NC USA.
[Rathmell, James P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, MGH Pain Ctr, Boston, MA USA.
RP Cohen, SP (reprint author), 550 North Broadway,Suite 301, Baltimore, MD 21029 USA.
EM scohen40@jhmi.edu
FU Center for Rehabilitation Sciences Research, US Army
FX This work was funded in part by the Center for Rehabilitation Sciences
Research, US Army (to S.P.C.).
NR 316
TC 81
Z9 83
U1 7
U2 29
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1098-7339
EI 1532-8651
J9 REGION ANESTH PAIN M
JI Region. Anesth. Pain Med.
PD MAY-JUN
PY 2013
VL 38
IS 3
BP 175
EP 200
DI 10.1097/AAP.0b013e31828ea086
PG 26
WC Anesthesiology
SC Anesthesiology
GA 131BQ
UT WOS:000317966200003
PM 23598728
ER
PT J
AU Bastu, E
Yeh, J
AF Bastu, Ercan
Yeh, John
TI Nature of Light: Spectroscopic Techniques in Obstetrics and Gynecology
Applications
SO REPRODUCTIVE SCIENCES
LA English
DT Review
DE spectroscopy; obstetrics; gynecology; diagnosis; non-invasive
ID NEAR-INFRARED SPECTROSCOPY; MAGNETIC-RESONANCE-SPECTROSCOPY; NONINVASIVE
EMBRYO ASSESSMENT; SERUM PROTEOMIC FEATURES; OVARIAN-CANCER; UTERINE
CERVIX; IN-VIVO; WOMEN; TISSUE; BIOMARKERS
AB In recent years, advances in spectroscopic techniques led to an increase in their medical applications. In medical sciences, emphasis is increasingly placed on instrumental techniques and accurate, quantitative measurements. It is especially apparent in diagnosis, where imaging techniques and laboratory results have became invaluable and compulsory. Breakthroughs in biochemistry made it possible to characterize physiological processes and living organisms at the molecular level. This led to a proliferation of new methods such as DNA tests and the use of biomarkers in daily clinical practice. Characterization of molecular structure and determination of the composition of a mixture are the fields of analytical chemistry and analytical biochemistry.
C1 [Bastu, Ercan] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Obstet & Gynecol, Boston, MA 02215 USA.
[Bastu, Ercan] Istanbul Univ, Sch Med, Dept Obstet & Gynecol, Istanbul, Turkey.
[Yeh, John] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Obstet & Gynecol, Boston, MA USA.
RP Yeh, J (reprint author), Massachusetts Gen Hosp, Dept Obstet & Gynecol, 55 Fruit St, Boston, MA 02114 USA.
EM jyeh@partners.org
NR 42
TC 1
Z9 1
U1 0
U2 7
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1933-7191
J9 REPROD SCI
JI Reprod. Sci.
PD MAY
PY 2013
VL 20
IS 5
BP 500
EP 513
DI 10.1177/1933719112446071
PG 14
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 131KF
UT WOS:000317991200002
PM 22581802
ER
PT J
AU Woods, DC
White, YAR
Niikura, Y
Kiatpongsan, S
Lee, HJ
Tilly, JL
AF Woods, Dori C.
White, Yvonne A. R.
Niikura, Yuichi
Kiatpongsan, Sorapop
Lee, Ho-Joon
Tilly, Jonathan L.
TI Embryonic Stem Cell-Derived Granulosa Cells Participate in Ovarian
Follicle Formation In Vitro and In Vivo
SO REPRODUCTIVE SCIENCES
LA English
DT Article
DE granulosa cells; Foxl2; embryonic stem cell; oocyte; follicle; ovary
ID TRANSCRIPTION FACTOR; GERM-CELLS; MOUSE; OOCYTES; EXPRESSION;
DERIVATION; PROGRESS; DIRECTS; GENES; MICE
AB Differentiating embryonic stem cells (ESCs) can form ovarian follicle-like structures in vitro, consisting of an oocyte-like cell surrounded by somatic cells capable of steroidogenesis. Using a dual-fluorescence reporter system in which mouse ESCs express green fluorescent protein (GFP) under the control of a germ cell-specific Pou5f1 gene promoter and red fluorescent protein (Discosoma sp red [DsRed]) driven by the granulosa cell-specific Forkhead box L2 (Foxl2) gene promoter, we first confirmed in vitro formation of follicle-like structures containing GFP-positive cells surrounded by DsRed-positive cells. Isolated DsRed-positive cells specified from ECSs exhibited a gene expression profile consistent with granulosa cells, as revealed by the detection of messenger RNAs (mRNAs) for Foxl2, follistatin (Fst), anti-Mullerian hormone (Amh), and follicle-stimulating hormone receptor (Fshr) as well as by production of both progesterone and estradiol. In addition, treatment of isolated DsRed-expressing cells with follicle-stimulating hormone (FSH) significantly increased estradiol production over basal levels, confirming the presence of functional FSH receptors in these cells. Last, ESC-derived DsRed-positive cells injected into neonatal mouse ovaries became incorporated within the granulosa cell layer of immature follicles. These studies demonstrate that Foxl2-expressing ovarian somatic cells derived in vitro from differentiating ESCs express granulosa cell markers, actively associate with germ cells in vitro, synthesize steroids, respond to FSH, and participate in folliculogenesis in vivo.
C1 [Woods, Dori C.; White, Yvonne A. R.; Niikura, Yuichi; Kiatpongsan, Sorapop; Lee, Ho-Joon; Tilly, Jonathan L.] Harvard Univ, Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, MGH Vincent Dept Obstet & Gynecol,Med Sch, Boston, MA USA.
[Woods, Dori C.; White, Yvonne A. R.; Niikura, Yuichi; Kiatpongsan, Sorapop; Lee, Ho-Joon; Tilly, Jonathan L.] Harvard Univ, Sch Med, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA.
RP Tilly, JL (reprint author), Massachusetts Gen Hosp, THR 901B,55 Fruit St, Boston, MA 02114 USA.
EM jtilly@partners.org
FU United States Department of Agriculture National Research Initiative
Competitive Grant [2007-35203-18085]; Ruth L. Kirschstein National
Research Service Award [NIH F32-AG034809]; National Institute on Aging
[NIH R37-AG012279]; Glenn Foundation for Research in the Biological
Mechanisms of Aging
FX The author(s) disclosed receipt of the following financial support for
the research, authorship, and/or publication of this article: This work
was supported by a United States Department of Agriculture National
Research Initiative Competitive Grant (2007-35203-18085 to D. C. W.), a
Ruth L. Kirschstein National Research Service Award (NIH F32-AG034809 to
D. C. W.), a Method to Extend Research in Time (MERIT) Award from the
National Institute on Aging (NIH R37-AG012279 to J.L.T.), and a grant
from the Glenn Foundation for Research in the Biological Mechanisms of
Aging (to J.L.T.).
NR 24
TC 9
Z9 10
U1 3
U2 10
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1933-7191
J9 REPROD SCI
JI Reprod. Sci.
PD MAY
PY 2013
VL 20
IS 5
BP 524
EP 535
DI 10.1177/1933719113483017
PG 12
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 131KF
UT WOS:000317991200004
PM 23536570
ER
PT J
AU Ginat, DT
Singh, AD
Moonis, G
AF Ginat, Daniel T.
Singh, Arun D.
Moonis, Gul
TI Untitled Reply
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Letter
C1 [Ginat, Daniel T.; Moonis, Gul] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
[Ginat, Daniel T.; Moonis, Gul] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Singh, Arun D.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
RP Ginat, DT (reprint author), Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
NR 1
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2013
VL 33
IS 5
BP 1090
EP 1090
DI 10.1097/IAE.0b013e318281b992
PG 1
WC Ophthalmology
SC Ophthalmology
GA 131QY
UT WOS:000318011100033
PM 23549093
ER
PT J
AU Singh, JA
Lewallen, DG
AF Singh, Jasvinder A.
Lewallen, David G.
TI Medical and psychological comorbidity predicts poor pain outcomes after
total knee arthroplasty
SO RHEUMATOLOGY
LA English
DT Article
DE pain; function; functional limitation; total knee replacement; primary;
arthroplasty; joint replacement; outcomes; patient-reported outcomes
ID TOTAL HIP-ARTHROPLASTY; UNITED-STATES; REVISION HIP; REPLACEMENT; AGE;
LIMITATION; MORBIDITY; IMPACT; INDEX; TKA
AB Objective. To study comorbidity correlates of moderate to severe pain after total knee arthroplasty (TKA).
Methods. We analysed prospectively collected Total Joint Registry data to examine whether medical (heart disease, peripheral vascular disease, renal disease, chronic obstructive pulmonary disease, diabetes and CTD) and psychological (anxiety and depression) comorbidity is associated with moderate to severe pain after primary or revision TKA. Multivariable-adjusted logistic regression simultaneously adjusted for all comorbidities, age, sex, BMI, underlying diagnosis, American Society of Anesthesiologist (ASA) class, distance from medical centre and implant fixation (only for primary TKA) was used to analyse primary and revision TKA separately.
Results. The primary TKA cohort consisted of 7139 and 4234 TKAs (response rates 65% and 57%) and the revision TKA cohort consisted of 1533 and 881 TKAs at 2 and 5 years (response rates 57% and 48%), respectively. In the primary TKA cohort, anxiety was associated with 1.4 higher odds (95% CI 1.0, 2.0) of moderate to severe index knee pain at 2 years; at 5 years, heart disease (OR 1.7; 95% CI 1.1, 2.6), depression (OR 1.7; 95% CI 1.1, 2.5) and anxiety (OR 1.9; 95% CI 1.2, 3.1) were significantly associated with moderate to severe pain. For revision TKA, CTD (OR 0.5; 95% CI 0.2, 0.9) and depression (OR 1.8; 95% CI 1.1, 3.1) were significantly associated with moderate to severe pain.
Conclusion. This study identified medical and psychological comorbidity risk factors for moderate to severe pain after primary and revision TKA. This information can be used to provide realistic outcome expectations for patients before undergoing primary or revision TKA.
C1 [Singh, Jasvinder A.] Univ Alabama Birmingham, Med Serv, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.] Univ Alabama Birmingham, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham VA Med Ctr, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.; Lewallen, David G.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA.
RP Singh, JA (reprint author), Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.
EM jasvinder.md@gmail.com
OI singh, jasvinder/0000-0003-3485-0006
FU Agency for Health Quality and the Research Center for Education and
Research on Therapeutics (CERTs); Mayo Clinic; National Institutes of
Health (NIH) (Mayo Clinic Center for Clinical and Translational
Research) [1 KL2 RR024151-01]; DePuy; Stryker; Biomet; Zimmer; Takeda;
Savient; URL Pharmaceuticals; Ardea; Allergan; Regeneron; Novartis;
National Institute of Aging; National Cancer Institute; Pipeline
Biomedical
FX The views expressed in this article are those of the authors and do not
necessarily reflect the position or policy of the Department of Veterans
Affairs or the US government. J.A.S. is supported by grants from the
Agency for Health Quality and the Research Center for Education and
Research on Therapeutics (CERTs), the National Institute of Aging and
the National Cancer Institute.; This material is the result of work
supported with research grants from Mayo Clinic Orthopedic Surgery
research funds, National Institutes of Health (NIH) Clinical
Translational Science Award 1 KL2 RR024151-01 (Mayo Clinic Center for
Clinical and Translational Research) and the resources and use of
facilities at the Birmingham VA Medical Center, Birmingham, AL, USA.;
D.G.L. has received royalties from Zimmer, has been a paid consultant
and owns stock in Pipeline Biomedical and his institution has received
research funds from DePuy, Stryker, Biomet and Zimmer. J.A.S. has
received research and travel grants from Takeda and Savient and
consultant fees from URL Pharmaceuticals, Savient, Takeda, Ardea,
Allergan, Regeneron and Novartis.
NR 36
TC 39
Z9 40
U1 2
U2 19
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462-0324
J9 RHEUMATOLOGY
JI RHEUMATOLOGY
PD MAY
PY 2013
VL 52
IS 5
BP 916
EP 923
DI 10.1093/rheumatology/kes402
PG 8
WC Rheumatology
SC Rheumatology
GA 133CG
UT WOS:000318114400025
PM 23325037
ER
PT J
AU Ventura, J
Reise, SP
Keefe, RSE
Hurford, IM
Wood, RC
Bilder, RM
AF Ventura, Joseph
Reise, Steven P.
Keefe, Richard S. E.
Hurford, Irene M.
Wood, Rachel C.
Bilder, Robert M.
TI The Cognitive Assessment Interview (CAI): Reliability and Validity of a
Brief Interview-Based Measure of Cognition
SO SCHIZOPHRENIA BULLETIN
LA English
DT Article
DE schizophrenia; functional outcome; functional capacity; symptoms;
informant ratings; neurocognition
ID PSYCHIATRIC RATING-SCALE; FUNCTIONAL-CAPACITY; QUALITY-ASSURANCE;
SCHIZOPHRENIA; PERFORMANCE; IMPAIRMENT; VALIDATION; PREDICTION;
SYMPTOMS; SELF
AB Objective: To obtain Food and Drug Administration approval for the treatment of cognitive impairments associated with schizophrenia, a drug will need to demonstrate benefits beyond those that may be documented on objective cognitive tests. Interview-based measures of cognition such as the Cognitive Assessment Interview (CAI) are candidate coprimary outcome measures. Methods: Psychiatrically stable schizophrenia outpatients (n = 150) were studied using the CM to obtain information about cognitive functioning from both the patient and an informant. Patients also received objective assessments of neurocognition, functional capacity, functional outcome, and symptoms, at baseline and 1 month later. Results: The CAI had good internal consistency (Cronbach's alpha = .92) and good test-retest reliability (r = .83). The CM was moderately correlated with objective neurocognitive test scores (r's = .39 to -.41) and moderately correlated with social functioning (r = -.38), work functioning (r = -.48), and overall functional outcome (r = -.49). The correlations of CAI scores with external validity indicators did not differ significantly by source of information (patient alone ratings were valid). Overall functional outcome correlated more strongly with patient CM scores (r = -.50) than with objective neurocognitive test scores (r = .29) or functional capacity (r = .29). Conclusions: Field testing of the CM produced reliable ratings of cognitive functioning that were correlated with functional outcome. Patient ratings alone yielded scores with reliability and validity values appropriate for use in clinical trials. The CM appears to provide useful complementary information and possesses practical advantages for rating cognitive functioning including an interview-based method of administration, brief assessment time (15 min for the patient assessment), little or no practice effects, and ease of scoring.
C1 [Ventura, Joseph; Wood, Rachel C.; Bilder, Robert M.] Univ Calif Los Angeles, Dept Psychiat, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA.
[Reise, Steven P.; Bilder, Robert M.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA.
[Keefe, Richard S. E.] Duke Univ, Dept Psychiat & Behav Sci, Durham, NC USA.
[Hurford, Irene M.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Hurford, Irene M.] Philadelphia Vet Affairs Med Ctr, Dept Behav Hlth, Philadelphia, PA USA.
RP Ventura, J (reprint author), Univ Calif Los Angeles, Dept Psychiat, 300 Med Plaza,Room 2243, Los Angeles, CA 90095 USA.
EM jventura@ucla.edu
RI Bilder, Robert/A-8894-2008
OI Bilder, Robert/0000-0001-5085-7852
FU Pfizer, Inc.; National Institute of Mental Health (NIMH) [1R21MH073971,
MH37705, P50 MH066286]; Consortium for Neuropsychiatric Phonemics
[UL1-DE019580, RL1LM009833]
FX This research was supported by an investigator initiated grant from
Pfizer, Inc. and from an National Institute of Mental Health (NIMH)
grant 1R21MH073971 that were awarded to J.V., PhD. This research was
also supported in part by NIMH Grants MH37705 (P.I.: Keith H.
Nuechterlein, PhD), P50 MH066286 (P.I.: Keith H. Nuechterlein, PhD), and
the Consortium for Neuropsychiatric Phonemics UL1-DE019580, RL1LM009833
(PI: R.M.B., PhD).
NR 39
TC 14
Z9 14
U1 1
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAY
PY 2013
VL 39
IS 3
BP 583
EP 591
DI 10.1093/schbul/sbs001
PG 9
WC Psychiatry
SC Psychiatry
GA 133IN
UT WOS:000318132200018
PM 22328641
ER
PT J
AU Harvey, PO
Zaki, J
Lee, J
Ochsner, K
Green, MF
AF Harvey, Philippe-Olivier
Zaki, Jamil
Lee, Junghee
Ochsner, Kevin
Green, Michael F.
TI Neural Substrates of Empathic Accuracy in People With Schizophrenia
SO SCHIZOPHRENIA BULLETIN
LA English
DT Article
DE social cognition; empathic accuracy; emotional expressivity;
schizophrenia; functional imaging
ID SOCIAL COGNITION; MAJOR DEPRESSION; BASES; MIND; ATTRIBUTION;
PERCEPTION; EMOTION; EXPRESSIVITY; CIRCUITRY; FEELINGS
AB Introduction: Empathic deficits in schizophrenia may lead to social dysfunction, but previous studies of schizophrenia have not modeled empathy through paradigms that (1) present participants with naturalistic social stimuli and (2) link brain activity to "accuracy" about inferring other's emotional states. This study addressed this gap by investigating the neural correlates of empathic accuracy (EA) in schizophrenia. Methods: Fifteen schizophrenia patients and 15 controls were scanned while continuously rating the affective state of another person shown in a series of videos (ie, targets). These ratings were compared with targets' own self-rated affect, and EA was defined as the correlation between participants' ratings and targets' self-ratings. Targets' self-reported emotional expressivity also was measured. We searched for brain regions whose activity tracked parametrically with (1) perceivers' EA and (2) targets' expressivity. Results: Patients showed reduced EA compared with controls. The left precuneus, left middle frontal gyms, and bilateral thalamus were significantly more correlated with EA in controls compared with patients. High expressivity in targets was associated with better EA in controls but not in patients. High expressivity was associated with increased brain activity in a large set of regions in controls (eg, fusiform gyrus, medial prefrontal cortex) but not in patients. Discussion: These results use a naturalistic performance measure to confirm that schizophrenic patients demonstrate impaired ability to understand others' internal states. They provide novel evidence about a potential mechanism for this impairment: schizophrenic patients failed to capitalize on targets' emotional expressivity and also demonstrate reduced neural sensitivity to targets' affective cues.
C1 [Harvey, Philippe-Olivier] Douglas Mental Hlth Univ Inst, Montreal, PQ H4H 1R3, Canada.
[Zaki, Jamil] Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA.
[Lee, Junghee; Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA USA.
[Lee, Junghee; Green, Michael F.] Healthcare Ctr Syst, VA Greater Los Angeles, Los Angeles, CA USA.
[Ochsner, Kevin] Columbia Univ, Dept Psychol, New York, NY 10027 USA.
RP Harvey, PO (reprint author), Douglas Mental Hlth Univ Inst, 6875 LaSalle Blvd, Montreal, PQ H4H 1R3, Canada.
EM philippe-olivier.harvey@douglas.mcgill.ca
RI Lee, Junghee/C-5226-2014
OI Lee, Junghee/0000-0001-9567-8700
FU Desert Pacific Mental Illness Research, Education, and Clinical Center;
UCLA Brain Mapping Center; Canadian Institutes of Health Research; Brain
Mapping Medical Research Organization; Brain Mapping Support Foundation;
Pierson-Lovelace Foundation; Ahmanson Foundation; William M. and Linda
R. Dietel Philanthropic Fund at the Northern Piedmont Community
Foundation; Tamkin Foundation; Jennifer Jones-Simon; Capital Group
Companies Charitable Foundation; Robson Family; Northstar Fund;
[MH043292]
FX This work was supported by pilot grants from the Desert Pacific Mental
Illness Research, Education, and Clinical Center and the UCLA Brain
Mapping Center. This work was also supported by grant MH043292 to Dr
M.F.G. Poorang Nori assisted in data collection. Dr P.O.H. is supported
by a postdoctoral fellowship from the Canadian Institutes of Health
Research.; For generous support of the UCLA Brain Mapping Center, we
also thank the Brain Mapping Medical Research Organization, Brain
Mapping Support Foundation, Pierson-Lovelace Foundation, The Ahmanson
Foundation, William M. and Linda R. Dietel Philanthropic Fund at the
Northern Piedmont Community Foundation, Tamkin Foundation, Jennifer
Jones-Simon, Capital Group Companies Charitable Foundation, Robson
Family, and Northstar Fund. Financial Disclosures: The authors have no
financial disclosure to report. The authors have declared that there are
no conflicts of interest in relation to the subject of this study.
NR 56
TC 19
Z9 19
U1 0
U2 14
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAY
PY 2013
VL 39
IS 3
BP 617
EP 628
DI 10.1093/schbul/sbs042
PG 12
WC Psychiatry
SC Psychiatry
GA 133IN
UT WOS:000318132200022
PM 22451493
ER
PT J
AU Lee, J
Kern, RS
Harvey, PO
Horan, WP
Kee, KS
Ochsner, K
Penn, DL
Green, MF
AF Lee, Junghee
Kern, Robert S.
Harvey, Philippe-Olivier
Horan, William P.
Kee, Kimmy S.
Ochsner, Kevin
Penn, David L.
Green, Michael F.
TI An Intact Social Cognitive Process in Schizophrenia: Situational Context
Effects on Perception of Facial Affect
SO SCHIZOPHRENIA BULLETIN
LA English
DT Article
DE schizophrenia; contextual modulation; facial affect processing; social
cognition
ID PREFRONTAL CORTEX; SURPRISED FACES; EMOTION; EXPRESSIONS; TASK;
ORGANIZATION; SPECTRUM; AMYGDALA; FMRI
AB Background: Impaired facial affect recognition is the most consistent social cognitive finding in schizophrenia. Although social situations provide powerful constraints on our perception, little is known about how situational context modulates facial affect recognition in schizophrenia. Methods: Study 1 was a single-site study with 34 schizophrenia patients and 22 healthy controls. Study 2 was a 2-site study with 68 schizophrenia patients and 28 controls. Both studies administered a Situational Context Facial Affect Recognition Task with 2 conditions: a situational context condition and a no-context condition. For the situational context condition, a briefly shown face was preceded by a sentence describing either a fear- or surprise-inducing event. In the no-context condition, a face was presented without a sentence. For both conditions, subjects rated how fearful or surprised the face appeared on a 9-point Likert scale. Results: For the situational context condition of study 1, both patients and controls rated faces as more afraid when they were paired with fear-inducing sentences and as more surprised when they were paired with surprise-inducing sentences. The degree of modulation was comparable across groups. For the no-context condition, patients rated faces comparably to controls. The findings of study 2 replicated those from study 1. Conclusions: Despite previous abnormalities in other types of context paradigms, this study found intact situational context processing in schizophrenia, suggesting that patients benefit from situational context when interpreting ambiguous facial expression. This area of relative social cognitive strength in schizophrenia has implications for social cognitive training programs.
C1 [Lee, Junghee; Kern, Robert S.; Harvey, Philippe-Olivier; Horan, William P.; Kee, Kimmy S.; Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Lee, Junghee; Kern, Robert S.; Harvey, Philippe-Olivier; Horan, William P.; Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Los Angeles, CA USA.
[Harvey, Philippe-Olivier] McGill Univ, Douglas Mental Heath Univ Inst, Montreal, PQ, Canada.
[Kee, Kimmy S.] Calif State Univ, Dept Psychol, Camarillo, CA USA.
[Ochsner, Kevin] Columbia Univ, Dept Psychol, New York, NY 10027 USA.
[Penn, David L.] Univ N Carolina, Dept Psychol, Chapel Hill, NC USA.
RP Lee, J (reprint author), Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, 300 Med Plaza Room 2261, Los Angeles, CA 90095 USA.
EM jungheelee@ucla.edu
RI Lee, Junghee/C-5226-2014
OI Lee, Junghee/0000-0001-9567-8700
FU National Institutes of Mental Health [MH043292, MH087618]
FX National Institutes of Mental Health (MH043292 and MH087618 to PI:
M.F.G., PhD).
NR 36
TC 11
Z9 11
U1 4
U2 13
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAY
PY 2013
VL 39
IS 3
BP 640
EP 647
DI 10.1093/schbul/sbs063
PG 8
WC Psychiatry
SC Psychiatry
GA 133IN
UT WOS:000318132200024
PM 22532704
ER
PT J
AU Mueser, KT
Glynn, SM
Cather, C
Xie, HY
Zarate, R
Smith, LF
Clark, RE
Gottlieb, JD
Wolfe, R
Feldman, J
AF Mueser, Kim T.
Glynn, Shirley M.
Cather, Corrine
Xie, Haiyi
Zarate, Roberto
Smith, Lindy Fox
Clark, Robin E.
Gottlieb, Jennifer D.
Wolfe, Rosemarie
Feldman, James
TI A Randomized Controlled Trial of Family Intervention for Co-occurring
Substance Use and Severe Psychiatric Disorders
SO SCHIZOPHRENIA BULLETIN
LA English
DT Article
DE dual disorders; dual diagnosis; family psychoeducation; family therapy
ID SEVERE MENTAL-ILLNESS; COGNITIVE-BEHAVIORAL THERAPY; DRUG-USE;
MOTIVATIONAL INTERVENTION; INTEGRATED TREATMENT; POWER CALCULATIONS;
ABUSE DISORDERS; CLINICAL-TRIAL; SCHIZOPHRENIA; PEOPLE
AB Substance use disorders have a profound impact on the course of severe mental illnesses and on the family, but little research has evaluated the impact of family intervention for this population. To address this question, a randomized controlled trial was conducted comparing a brief (2-3 mo) Family Education (ED) program with a longer-term (9-18 mo) program that combined education with teaching communication and problem-solving skills, Family Intervention for Dual Disorders (FIDD). A total of 108 clients (77% schizophrenia-spectrum) and a key relative were randomized to either ED or FIDD and assessed at baseline and every 6 months for 3 years. Rates of retention of families in both programs were moderate. Intent-to-treat analyses indicated that clients in both programs improved in psychiatric, substance abuse, and functional outcomes, as did key relatives in knowledge of co-occurring disorders, burden, and mental health functioning. Clients in FIDD had significantly less severe overall psychiatric symptoms and psychotic symptoms and tended to improve more in functioning. Relatives in FIDD improved more in mental health functioning and knowledge of co-occurring disorders. There were no consistent differences between the programs in substance abuse severity or family burden. The findings support the utility of family intervention for co-occurring disorders, and the added benefits of communication and problem-solving training, but also suggest the need to modify these programs to retain more families in treatment in order to provide them with the information and skills they need to overcome the effects of these disorders.
C1 [Mueser, Kim T.; Gottlieb, Jennifer D.] Boston Univ, Ctr Psychiat Rehabil, Boston, MA 02215 USA.
[Mueser, Kim T.; Gottlieb, Jennifer D.] Boston Univ, Dept Occupat Therapy, Boston, MA 02215 USA.
[Glynn, Shirley M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Glynn, Shirley M.; Zarate, Roberto] Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90024 USA.
[Cather, Corrine] Massachusetts Gen Hosp, Schizophrenia Program, Boston, MA 02114 USA.
[Cather, Corrine; Feldman, James] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Xie, Haiyi; Smith, Lindy Fox; Wolfe, Rosemarie] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Psychiat, Hanover, NH 03756 USA.
[Xie, Haiyi; Smith, Lindy Fox; Wolfe, Rosemarie] Dartmouth Psychiat Res Ctr, Concord, NH USA.
[Zarate, Roberto] Pacific Clin, Los Angeles, CA USA.
[Clark, Robin E.] Univ Massachusetts, Sch Med, Ctr Hlth Policy & Res, Shrewsbury, MA USA.
[Feldman, James] Massachusetts Mental Hlth Ctr, Boston, MA 02115 USA.
RP Mueser, KT (reprint author), Boston Univ, Ctr Psychiat Rehabil, 940 Commonwealth Ave, Boston, MA 02215 USA.
EM mueser@bu.edu
FU National Institute of Mental Health; National Institute on Drug Abuse
[MH62629]
FX National Institute of Mental Health; National Institute on Drug Abuse
(MH62629).
NR 73
TC 13
Z9 13
U1 6
U2 25
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAY
PY 2013
VL 39
IS 3
BP 658
EP 672
DI 10.1093/schbul/sbr203
PG 15
WC Psychiatry
SC Psychiatry
GA 133IN
UT WOS:000318132200026
PM 22282453
ER
PT J
AU Walton, E
Turner, J
Gollub, RL
Manoach, DS
Yendiki, A
Ho, BC
Sponheim, SR
Calhoun, VD
Ehrlich, S
AF Walton, Esther
Turner, Jessica
Gollub, Randy L.
Manoach, Dara S.
Yendiki, Anastasia
Ho, Beng-Choon
Sponheim, Scott R.
Calhoun, Vince D.
Ehrlich, Stefan
TI Cumulative Genetic Risk and Prefrontal Activity in Patients With
Schizophrenia
SO SCHIZOPHRENIA BULLETIN
LA English
DT Article
DE schizophrenia; DLPFC; working memory; intermediate phenotype; fMRI;
genetic risk score
ID VAL(108/158) MET GENOTYPE; WORKING-MEMORY TASK; CORTICAL FUNCTION; FMRI
SIGNAL; COMT; CORTEX; ASSOCIATION; ACTIVATION; GENOME; METAANALYSIS
AB The lack of consistency of genetic associations in highly heritable mental illnesses, such as schizophrenia, remains a challenge in molecular psychiatry. Because clinical phenotypes for psychiatric disorders are often ill defined, considerable effort has been made to relate genetic polymorphisms to underlying physiological aspects of schizophrenia (so called intermediate phenotypes), that may be more reliable. Given the polygenic etiology of schizophrenia, the aim of this work was to form a measure of cumulative genetic risk and study its effect on neural activity during working memory (WM) using functional magnetic resonance imaging. Neural activity during the Sternberg Item Recognition Paradigm was measured in 79 schizophrenia patients and 99 healthy controls. Participants were genotyped, and a genetic risk score (GRS), which combined the additive effects of 41 single-nucleotide polymorphism (SNPs) from 34 risk genes for schizophrenia, was calculated. These risk SNPs were chosen according to the continuously updated meta-analysis of genetic studies on schizophrenia available at www.schizophreniaresearchforum.org. We found a positive relationship between GRS and left dorsolateral prefrontal cortex inefficiency during WM processing. GRS was not correlated with age, performance, intelligence, or medication effects and did not differ between acquisition sites, gender, or diagnostic groups. Our study suggests that cumulative genetic risk, combining the impact of many genes with small effects, is associated with a known brain-based intermediate phenotype for schizophrenia. The GRS approach could provide an advantage over studying single genes in studies focusing on the genetic basis of polygenic conditions such as neuropsychiatric disorders.
C1 [Walton, Esther; Gollub, Randy L.; Manoach, Dara S.; Yendiki, Anastasia; Ehrlich, Stefan] Massachusetts Gen Hosp, MGH MIT HMS Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Walton, Esther; Ehrlich, Stefan] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Child & Adolescent Psychiat, D-01307 Dresden, Germany.
[Turner, Jessica; Calhoun, Vince D.] Mind Res Network, Albuquerque, NM USA.
[Gollub, Randy L.; Manoach, Dara S.; Ehrlich, Stefan] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Ho, Beng-Choon] Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA.
[Sponheim, Scott R.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA.
[Sponheim, Scott R.] Univ Minnesota, Ctr Magnet Resonance Res, Minneapolis, MN USA.
[Calhoun, Vince D.] Univ New Mexico, Dept Elect & Comp Engn, Albuquerque, NM 87131 USA.
RP Ehrlich, S (reprint author), Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Child & Adolescent Psychiat, Translat Dev Neurosci Sect, Fetscherstr 74, D-01307 Dresden, Germany.
EM stefan@nmr.mgh.harvard.edu
RI Calhoun, Vince/H-7146-2013; Ho, Beng-Choon/D-6959-2011; Turner,
Jessica/H-7282-2015;
OI Calhoun, Vince/0000-0001-9058-0747; Ho, Beng-Choon/0000-0003-3976-1555;
Turner, Jessica/0000-0003-0076-8434; Ehrlich,
Stefan/0000-0003-2132-4445; Walton, Esther/0000-0002-0935-2200; Gollub,
Randy L./0000-0002-9434-4044
FU National Institutes of Health/National Center for Research Resources
[NIH/NCRR P41RR14075]; Department of Energy [DE-FG02-99ER62764]; Mind
Research Network, Morphometry BIRN [1U24, RR021382A]; Function
Biomedical Informatics Research Network [U24RR021992-01, NIH/NCRR MO1
RR025758-01]; National Institute of Mental Health [1RC1MH089257];
Deutsche Forschungsgemeinschaft; Deutscher Akademischer Auslandsdienst;
Friedrich-Ebert Stiftung
FX National Institutes of Health/National Center for Research Resources
(NIH/NCRR P41RR14075); Department of Energy (DE-FG02-99ER62764); Mind
Research Network, Morphometry BIRN (1U24, RR021382A); Function
Biomedical Informatics Research Network (U24RR021992-01, NIH/NCRR MO1
RR025758-01, National Institute of Mental Health 1RC1MH089257 to
V.D.C.); the Deutsche Forschungsgemeinschaft (Research Fellowship to
S.E.); the Deutscher Akademischer Auslandsdienst; and the
Friedrich-Ebert Stiftung (stipends to E.W.).
NR 43
TC 27
Z9 27
U1 1
U2 21
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD MAY
PY 2013
VL 39
IS 3
BP 703
EP 711
DI 10.1093/schbul/sbr190
PG 9
WC Psychiatry
SC Psychiatry
GA 133IN
UT WOS:000318132200030
PM 22267534
ER
PT J
AU Shinoda, G
De Soysa, TY
Seligson, MT
Yabuuchi, A
Fujiwara, Y
Huang, PY
Hagan, JP
Gregory, RI
Moss, EG
Daley, GQ
AF Shinoda, Gen
De Soysa, T. Yvanka
Seligson, Marc T.
Yabuuchi, Akiko
Fujiwara, Yuko
Huang, Pei Yi
Hagan, John P.
Gregory, Richard I.
Moss, Eric G.
Daley, George Q.
TI Lin28a Regulates Germ Cell Pool Size and Fertility
SO STEM CELLS
LA English
DT Article
DE Germ cells; Lin28a; miR-let7; Fertility
ID GENOME-WIDE ASSOCIATION; MICRORNA; AGE; MENARCHE; LIN-28; ELEGANS;
PUBERTY; MOUSE; RNA
AB Overexpression of LIN28A is associated with human germ cell tumors and promotes primordial germ cell (PGC) development from embryonic stem cells in vitro and in chimeric mice. Knockdown of Lin28a inhibits PGC development in vitro, but how constitutional Lin28a deficiency affects the mammalian reproductive system in vivo remains unknown. Here, we generated Lin28a knockout (KO) mice and found that Lin28a deficiency compromises the size of the germ cell pool in both males and females by affecting PGC proliferation during embryogenesis. Interestingly however, in Lin28a KO males, the germ cell pool partially recovers during postnatal expansion, while fertility remains impaired in both males and females mated to wild-type mice. Embryonic overexpression of let-7, a microRNA negatively regulated by Lin28a, reduces the germ cell pool, corroborating the role of the Lin28a/let-7 axis in regulating the germ lineage. STEM CELLS 2013;31:1001-1009
C1 [Shinoda, Gen; De Soysa, T. Yvanka; Yabuuchi, Akiko; Fujiwara, Yuko; Huang, Pei Yi; Hagan, John P.; Gregory, Richard I.; Daley, George Q.] Boston Childrens Hosp, Stem Cell Transplantat Program, Stem Cell Program, Div Pediat Hematol Oncol, Boston, MA USA.
[Shinoda, Gen; De Soysa, T. Yvanka; Seligson, Marc T.; Yabuuchi, Akiko; Fujiwara, Yuko; Hagan, John P.; Gregory, Richard I.; Daley, George Q.] Harvard Stem Cell Inst, Boston, MA USA.
[Fujiwara, Yuko; Daley, George Q.] Howard Hughes Med Inst, Boston, MA 02115 USA.
[Huang, Pei Yi] Boston Childrens Hosp, Immune Dis Inst, Program Cellular & Mol Med, Boston, MA USA.
[Hagan, John P.; Gregory, Richard I.; Daley, George Q.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Hagan, John P.] Ohio State Univ, Med Ctr, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA.
[Moss, Eric G.] Univ Med & Dent New Jersey, Dept Mol Biol, Newark, NJ 07103 USA.
[Daley, George Q.] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA.
[Daley, George Q.] Manton Ctr Orphan Dis Res, Boston, MA USA.
RP Daley, GQ (reprint author), Childrens Hosp, 1 Blackfan Circle,Karp Bldg,7th Floor, Boston, MA 02115 USA.
EM george.daley@childrens.harvard.edu
OI Hagan, John/0000-0003-0295-4898
FU Alex's Lemonade Stand Foundation; Ellison Medical Foundation; NIDDK
(Hematology Center) for Mouse Embryonic Stem ESCs [P30 DK049216-17];
Gene Targeting Core; Eunice Kennedy Shriver NICHD/NIH (SCCPIR) for The
University of Virginia Center for Research in Reproduction Ligand Assay
and Analysis Core [U54-HD28934]
FX We thank Achia Urbach and Mathew William Lensch for invaluable
discussions and advice, Roderick Bronson and the Harvard Medical School
Rodent Histopathology Core for mouse tissue pathology, and The
University of Virginia Center for Research in Reproduction Ligand Assay
and Analysis Core for hormone measurement. This work was supported by
grants from the Alex's Lemonade Stand Foundation, the Ellison Medical
Foundation, the NIDDK (Hematology Center Grant P30 DK049216-17) for
Mouse Embryonic Stem ESCs and Gene Targeting Core, and the Eunice
Kennedy Shriver NICHD/NIH (SCCPIR) Grant U54-HD28934 for The University
of Virginia Center for Research in Reproduction Ligand Assay and
Analysis Core.
NR 21
TC 16
Z9 16
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1066-5099
J9 STEM CELLS
JI Stem Cells
PD MAY
PY 2013
VL 31
IS 5
BP 1001
EP 1009
DI 10.1002/stem.1343
PG 9
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
Oncology; Cell Biology; Hematology
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 131RV
UT WOS:000318014100016
PM 23378032
ER
PT J
AU Park, HJ
Hong, M
Bronson, RT
Israel, MA
Frankel, WN
Yun, K
AF Park, Hee Jung
Hong, Mingi
Bronson, Roderick T.
Israel, Mark A.
Frankel, Wayne N.
Yun, Kyuson
TI Elevated Id2 Expression Results in Precocious Neural Stem Cell Depletion
and Abnormal Brain Development
SO STEM CELLS
LA English
DT Article
DE Neural stem cells; Id2; Brain tumor; Glioma; Medulloblastoma;
Self-renewal; Apoptosis; Seizure; CyclinG1; Rett syndrome
ID LOOP-HELIX PROTEINS; CENTRAL-NERVOUS-SYSTEM; SELF-RENEWAL;
RETINOBLASTOMA PROTEIN; HUMAN GLIOBLASTOMA; PROGENITOR CELLS; AXONAL
GROWTH; DIFFERENTIATION; PROLIFERATION; NEUROGENESIS
AB Id2 is a helix-loop-helix transcription factor essential for normal development, and its expression is dysregulated in many human neurological conditions. Although it is speculated that elevated Id2 levels contribute to the pathogenesis of these disorders, it is unknown whether dysregulated Id2 expression is sufficient to perturb normal brain development or function. Here, we show that mice with elevated Id2 expression during embryonic stages develop microcephaly, and that females in particular are prone to generalized tonic-clonic seizures. Analyses of Id2 transgenic brains indicate that Id2 activity is highly cell context specific: elevated Id2 expression in naive neural stem cells (NSCs) in early neuroepithelium induces apoptosis and loss of NSCs and intermediate progenitors. Activation of Id2 in maturing neuroepithelium results in less severe phenotypes and is accompanied by elevation of G1 cyclin expression and p53 target gene expression. In contrast, activation of Id2 in committed intermediate progenitors has no significant phenotype. Functional analysis with Id2-overexpressing and Id2-null NSCs shows that Id2 negatively regulates NSC self-renewal in vivo, in contrast to previous cell culture experiments. Deletion of p53 function from Id2-transgenic brains rescues apoptosis and results in increased incidence of brain tumors. Furthermore, Id2 overexpression normalizes the increased self-renewal of p53-null NSCs, suggesting that Id2 activates and modulates the p53 pathway in NSCs. Together, these data suggest that elevated Id2 expression in embryonic brains can cause deregulated NSC self-renewal, differentiation, and survival that manifest in multiple neurological outcomes in mature brains, including microcephaly, seizures, and brain tumors. STEM CELLS 2013;31:1010-1021
C1 [Park, Hee Jung; Hong, Mingi; Frankel, Wayne N.; Yun, Kyuson] Jackson Lab, Bar Harbor, ME 04609 USA.
[Bronson, Roderick T.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Israel, Mark A.] Geisel Sch Med Dartmouth, Norris Cotton Canc Ctr, Lebanon, NH USA.
RP Yun, K (reprint author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.
EM kyuson.yun@jax.org
FU NIH [NS031348]; TJL Cancer Center Support grant [CA034196]
FX We thank Jesse Hammer and Stephen Sampson for assistance with manuscript
preparation; Michaela Petit and Kasima Brown for technical assistance;
Barbara Beyer for EEG electrode implantation and recording, Gene
Expression services, Computational Sciences, and Imaging Services at JAX
for their assistance with the project. We are grateful to Susan Ackerman
and Robert Burgess for their comments on the manuscript. This work was
supported by an NIH grant to W.N.F. (NS031348) and TJL Cancer Center
Support grant CA034196 to K.Y. M. H. is currently affiliated with
Department of Developmental and Regenerative Biology, Icahn School of
Medicine at Mount Sinai, New York, NY.
NR 52
TC 3
Z9 4
U1 1
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1066-5099
J9 STEM CELLS
JI Stem Cells
PD MAY
PY 2013
VL 31
IS 5
BP 1010
EP 1021
DI 10.1002/stem.1351
PG 12
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
Oncology; Cell Biology; Hematology
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 131RV
UT WOS:000318014100017
PM 23390122
ER
PT J
AU Lau, AY
Wong, KSL
Lev, M
Furie, K
Smith, W
Kim, AS
AF Lau, Alexander Y.
Wong, Ka-sing Lawrence
Lev, Michael
Furie, Karen
Smith, Wade
Kim, Anthony S.
TI Burden of Intracranial Steno-Occlusive Lesions on Initial Computed
Tomography Angiography Predicts Poor Outcome in Patients With Acute
Stroke
SO STROKE
LA English
DT Article
DE intracranial stenosis; prognosis; stroke; transient ischemic attack
ID ARTERIAL-STENOSIS; ISCHEMIC-STROKE; ASIAN PATIENTS; RISK-FACTORS;
ATHEROSCLEROSIS; DISEASE; ASPIRIN; RACE
AB Background and Purpose-Computed tomography angiography is an accurate noninvasive method to diagnose intracranial steno-occlusive disease (ICAD) at initial presentation for stroke. We aimed to identify features of computed tomography angiography associated with unfavorable outcome.
Methods-We identified patients with ICAD in the Screening Technology and Outcomes Project in Stroke Study, a prospective imaging-based study of stroke outcomes, in consecutive patients with ischemic stroke or transient ischemic attack (TIA) presenting to 2 academic medical centers. All patients underwent computed tomography angiography, which were graded by 2 neuroradiologists independently. Univariate and multiple logistic regression was used to evaluate predictors of favorable outcome at 6 months, defined as a modified Rankin Scale <= 2.
Results-Among 539 patients that met study entry criteria, ICAD was identified in 212 patients (39%); 116 patients (22%) had concurrent extraintracranial lesions, and 66 patients (12%) had multiple sites of ICAD. Patients with ICAD had more severe stroke (median National Institutes of Health Stroke Scale, 9 versus 3; P<0.001), worse outcomes at 6 months (modified Rankin Scale, 0-2; 57% versus 73%; P<0.001), and higher mortality (18% versus 8%; P=0.001). In the multivariate model, age (odds ratio [OR], 0.75 per decade; 95% confidence interval [CI], 0.65-0.87), female sex (OR, 0.49; 95% CI, 0.32-0.73), multiple sites of ICAD (OR, 0.53; 95% CI, 0.29-0.97), complete occlusion (OR, 0.42; 95% CI, 0.25-0.72), and concurrent extraintracranial lesions (OR, 0.51; 95% CI, 0.31-0.84) negatively predicted favorable outcome.
Conclusions-Findings of multiple sites of ICAD from computed tomography angiography, concurrent extraintracranial lesions, and complete occlusion are independent predictors of unfavorable outcome at 6 months. (Stroke. 2013;44:1310-1316.)
C1 [Lau, Alexander Y.; Smith, Wade; Kim, Anthony S.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
[Lau, Alexander Y.; Wong, Ka-sing Lawrence] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China.
[Lev, Michael] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Furie, Karen] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Furie, Karen] Rhode Isl Hosp, Dept Neurol, Providence, RI USA.
RP Lau, AY (reprint author), Prince Wales Hosp, Shatin, Hong Kong, Peoples R China.
EM alexlau@cuhk.edu.hk
RI Lau, Alexander/N-2485-2015; Wong, Ka Sing Lawrence/N-3434-2015
OI Lau, Alexander/0000-0002-5933-9290; Wong, Ka Sing
Lawrence/0000-0002-2031-9866
FU Department of Health and Human and Human Services, Agency for Healthcare
Research and Quality [RO1-HS011392]; Croucher Foundation; Henry Leung
Fellowship
FX This research was funded by a grant from the Department of Health and
Human and Human Services, Agency for Healthcare Research and Quality,
grant number RO1-HS011392. Dr Lau is a recipient of Croucher Foundation
Fellowship and Henry Leung Fellowship.
NR 26
TC 1
Z9 1
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
J9 STROKE
JI Stroke
PD MAY
PY 2013
VL 44
IS 5
BP 1310
EP 1316
DI 10.1161/STROKEAHA.111.672741
PG 7
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 131WZ
UT WOS:000318030000034
PM 23512979
ER
PT J
AU Messe, SR
Pervez, MA
Smith, EE
Siddique, KA
Hellkamp, AS
Saver, JL
Bhatt, DL
Fonarow, GC
Peterson, ED
Schwamm, LH
AF Messe, Steven R.
Pervez, Muhammad A.
Smith, Eric E.
Siddique, Khawaja A.
Hellkamp, Anne S.
Saver, Jeffrey L.
Bhatt, Deepak L.
Fonarow, Gregg C.
Peterson, Eric D.
Schwamm, Lee H.
TI Lipid Profile, Lipid-lowering Medications, and Intracerebral Hemorrhage
After tPA in Get With The Guidelines-Stroke
SO STROKE
LA English
DT Article
DE hemorrhage; lipid-lowering medication; lipids; stroke; tissue
plasminogen activator
ID ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN ACTIVATOR;
AMERICAN-HEART-ASSOCIATION; PRIOR STATIN USE; INTRAVENOUS THROMBOLYSIS;
INTRACRANIAL HEMORRHAGE; CHOLESTEROL LEVELS; SERUM-CHOLESTEROL; RISK;
TRANSFORMATION
AB Background and Purpose-Symptomatic intracerebral hemorrhage (sICH) after tissue plasminogen activator for acute ischemic stroke is associated with poor outcome. There are conflicting data on sICH risk related to lipid levels and use of lipid-lowering medications. We evaluated whether there are associations between lipid levels, lipid-lowering medications, and sICH in Get With the Guidelines-Stroke.
Methods-We identified acute ischemic stroke patients in the Get With the Guidelines-Stroke data set who were treated with IV tissue plasminogen activator between April 2003 and September 2009 and had complete data on lipid profiles and complications. Potential predictors of sICH were tested in univariate and multivariate analysis.
Results-The analysis included 22 216 IV tissue plasminogen activator-treated acute ischemic stroke patients. Overall, 1104 (4.97%) experienced sICH (National Institute of Neurological Disorders and Stroke definition). In univariate analysis, patients with sICH were more often taking antihypertensive, lipid-lowering, and diabetes mellitus medications. There was no relationship between low density lipoprotein or total cholesterol and sICH in univariate analysis. However, the risk of sICH increased with higher high density lipoprotein, 6.1% in Q4 versus 4.7% in Q1, P=0.0013; and lower triglyceride levels, 5.9% in Q1 versus 4.2% in Q4, P<0.0001. In multivariable models, although the high density lipoprotein and triglyceride levels were modestly associated with sICH, low density lipoprotein and total cholesterol were not. Lipid-lowering medications were not independently associated with sICH.
Conclusions-We found that low density lipoprotein and total cholesterol levels are not associated with risk of sICH after tissue plasminogen activator, although higher high density lipoprotein and lower triglyceride levels were modest risk factors. Lipid-lowering medications are not associated with risk of sICH. (Stroke. 2013;44:1354-1359.)
C1 [Messe, Steven R.] Hosp Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA.
[Pervez, Muhammad A.; Siddique, Khawaja A.; Schwamm, Lee H.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Smith, Eric E.] Univ Calgary, Dept Clin Neurosci, Hotchkiss Brain Inst, Calgary, AB T2N 1N4, Canada.
[Hellkamp, Anne S.; Peterson, Eric D.] Duke Clin Res Ctr, Durham, NC USA.
[Saver, Jeffrey L.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA.
[Saver, Jeffrey L.] Univ Calif Los Angeles, Stroke Ctr, Los Angeles, CA USA.
[Fonarow, Gregg C.] Univ Calif Los Angeles, Div Cardiol, Los Angeles, CA USA.
[Bhatt, Deepak L.] Brigham & Womens Hosp, VA Boston Healthcare Syst, Boston, MA 02115 USA.
[Bhatt, Deepak L.] Harvard Univ, Sch Med, Boston, MA USA.
RP Messe, SR (reprint author), Hosp Univ Penn, 3400 Spruce St,3 W Gates Bldg, Philadelphia, PA 19104 USA.
EM messe@mail.med.upenn.edu
OI Saver, Jeffrey/0000-0001-9141-2251; Schwamm, Lee/0000-0003-0592-9145;
Smith, Eric/0000-0003-3956-1668
FU Janssen Pharmaceutical Companies of Johnson Johnson;
Boeringher-Ingelheim; Merck; Bristol-Myers Squib/Sanofi Pharmaceutical
Partnership; AHA Pharmaceutical Roundtable; National Institutes of
Health; WL Gore; Amarin; AstraZeneca; Bristol-Myers Squibb; Eisai;
Ethicon; Medtronic; Sanofi-Aventis
FX Get With The Guidelines-Stroke (GWTG-Stroke) program is provided by the
American Heart Association/American Stroke Association. The GWTG-Stroke
program is currently supported, in part, by a charitable contribution
from Janssen Pharmaceutical Companies of Johnson & Johnson. GWTG-Stroke
has been funded in the past through support from Boeringher-Ingelheim,
Merck, Bristol-Myers Squib/Sanofi Pharmaceutical Partnership, and the
AHA Pharmaceutical Roundtable. A Young Investigator Database Research
Seed Grant was sponsored by the Council on Clinical Cardiology.; Dr
Messe has served on the speaker's bureau for Boehringer-Ingelheim
(modest, ended 4/2011) and receives research support from the National
Institutes of Health (significant) and WL Gore (modest). Dr Peterson has
served as a consultant for AstraZeneca (modest). Dr Fonarow serves as a
member of the GWTG steering committee, receives research support from
the National Institutes of Health (significant), served as a consultant
to Pfizer (modest); and is an employee of the University of California,
which holds a patent on retriever devices for stroke (significant). Dr
Smith serves as a member of the GWTG Steering Subcommittee. A.S.
Hellkamp is a member of the Duke Clinical Research Institute, which
serves as the AHA GWTG data coordinating Center. Dr Saver serves as an
unpaid volunteer on Get With The Guidelines Committees and is an
employee of the University of California, which receives payments for
his service as a scientific consultant regarding trial design and
conduct to Covidien, CoAxia, Talacris, Brainsgate, and Sygnis, and which
holds a patent on retriever devices for stroke. Dr Bhatt serves on
Advisory Board: Medscape Cardiology; Board of Directors: Boston VA
Research Institute, Society of Chest Pain Centers; Chair: American Heart
Association Get With The Guidelines Science Subcommittee; Honoraria:
American College of Cardiology (Editor, Clinical Trials, Cardiosource),
Duke Clinical Research Institute (clinical trial steering committees),
Slack Publications (Chief Medical Editor, Cardiology Today
Intervention), WebMD (CME steering committees); Other: Senior Associate
Editor, Journal of Invasive Cardiology; Research Grants: Amarin,
AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic,
Sanofi-Aventis, The Medicines Company; Unfunded Research: FlowCo, PLx
Pharma, and Takeda; Research Grants (significant): Amarin, AstraZeneca,
Bristol-Myers Squibb, Eisai, Ethicon, Medtronic, Sanofi-Aventis, and The
Medicines Company. He serves as the chair of the AHA GWTG Science
Subcommittee. Dr Schwamm serves as chair of the AHA/ASA's GWTG Steering
Committee, a consultant to the Research Triangle Institute and to the
Massachusetts Department of Public Health, and serves on the Steering
Committee for Lundbeck's DIAS4 clinical trial. The other authors have no
conflicts to report.
NR 31
TC 3
Z9 4
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
J9 STROKE
JI Stroke
PD MAY
PY 2013
VL 44
IS 5
BP 1354
EP 1359
DI 10.1161/STROKEAHA.111.671966
PG 6
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 131WZ
UT WOS:000318030000041
PM 23493734
ER
PT J
AU Kimberly, WT
Wang, Y
Pham, L
Furie, KL
Gerszten, RE
AF Kimberly, W. Taylor
Wang, Yu
Ly Pham
Furie, Karen L.
Gerszten, Robert E.
TI Metabolite Profiling Identifies a Branched Chain Amino Acid Signature in
Acute Cardioembolic Stroke
SO STROKE
LA English
DT Article
DE cerebrospinal fluid; liquid chromatography; mass spectrometry;
metabolomics; transient ischemic attack stroke
ID TUMOR-NECROSIS-FACTOR; CAUSATIVE CLASSIFICATION; ISCHEMIC-STROKE;
INFARCT VOLUME; METABOLOMICS; BIOMARKERS; RATS; DISEASE; SYSTEM; BLOOD
AB Background and Purpose-There is limited information about changes in metabolism during acute ischemic stroke. The identification of changes in circulating plasma metabolites during cerebral infarction may provide insight into disease pathogenesis and identify novel biomarkers.
Methods-We performed filament occlusion of the middle cerebral artery of Wistar rats and collected plasma and cerebrospinal fluid 2 hours after the onset of ischemia. Plasma samples from control and patients with acute stroke were also analyzed. All samples were examined using liquid chromatography followed by tandem mass spectrometry. Positively charged metabolites, including amino acids, nucleotides, and neurotransmitters, were quantified using electrospray ionization followed by scheduled multiple reaction monitoring.
Results-The concentrations of several metabolites were altered in the setting of cerebral ischemia. We detected a reduction in the branched chain amino acids (valine, leucine, isoleucine) in rat plasma, rat cerebrospinal fluid, and human plasma compared with respective controls (16%, 23%, and 17%, respectively; P<0.01 for each). In patients, lower branched chain amino acids levels also correlated with poor neurological outcome (modified Rankin Scale, 0-2 versus 3-6; P=0.002).
Conclusions-Branched chain amino acids are reduced in ischemic stroke, and the degree of reduction correlates with worse neurological outcome. Whether branched chain amino acids are in a causal pathway or are an epiphenomenon of ischemic stroke remains to be determined. (Stroke. 2013;44:1389-1395.)
C1 [Kimberly, W. Taylor; Ly Pham] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Human Genet Res, Boston, MA USA.
[Kimberly, W. Taylor; Ly Pham] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Neurocrit Care & Emergency Neurol, Boston, MA USA.
[Kimberly, W. Taylor; Wang, Yu] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Martinos Ctr Biomed Imaging, Boston, MA USA.
[Gerszten, Robert E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr, Boston, MA USA.
[Furie, Karen L.] Brown Univ, Dept Neurol, Warren Alpert Med Sch, Providence, RI 02912 USA.
RP Kimberly, WT (reprint author), Lunder 644,55 Fruit St, Boston, MA 02114 USA.
EM wtkimberly@partners.org; gerszten.robert@mgh.harvard.edu
FU Clinical Investigator Training Program: Beth Israel Deaconess Medical
Center, Harvard Medical School; Pfizer Inc; Merck and Co; National
Institute of Health (NIH) [K23NS076597, NIH 5P50NS051343-07, NIH
R01HL096738, R01HL098280]
FX This study was supported by the Clinical Investigator Training Program:
Beth Israel Deaconess Medical Center, Harvard Medical School, in
collaboration with Pfizer Inc and Merck and Co (Dr Kimberly), by
National Institute of Health (NIH) K23NS076597 (Dr Kimberly), NIH
5P50NS051343-07 (Dr Furie), and NIH R01HL096738 and R01HL098280 (Dr
Gerstzen).; Dr Kimberly discloses a research grant (National Institute
of Health [NIH]; significant) and Dr Gerszten discloses a research grant
(NIH; significant).
NR 41
TC 13
Z9 13
U1 6
U2 27
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
J9 STROKE
JI Stroke
PD MAY
PY 2013
VL 44
IS 5
BP 1389
EP +
DI 10.1161/STROKEAHA.111.000397
PG 20
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 131WZ
UT WOS:000318030000046
PM 23520238
ER
PT J
AU James, SK
Pieper, KS
Cannon, CP
Storey, RF
Becker, RC
Steg, PG
Wallentin, L
Harrington, RA
AF James, Stefan K.
Pieper, Karen S.
Cannon, Christopher P.
Storey, Robert F.
Becker, Richard C.
Steg, Philippe Gabriel
Wallentin, Lars
Harrington, Robert A.
CA PLATO Study Grp
TI Ticagrelor in Patients With Acute Coronary Syndromes and Stroke
Interpretation of Subgroups in Clinical Trials
SO STROKE
LA English
DT Editorial Material
DE Acute coronary syndromes; clinical trial; platelet inhibition; Stroke
ID OUTCOMES PLATO TRIAL; PLATELET INHIBITION; CLOPIDOGREL; HISTORY
C1 [James, Stefan K.; Wallentin, Lars] Uppsala Univ, Dept Med Sci, SE-75237 Uppsala, Sweden.
[James, Stefan K.; Wallentin, Lars] Uppsala Univ, Uppsala Clin Res Ctr, SE-75237 Uppsala, Sweden.
[Pieper, Karen S.; Becker, Richard C.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA.
[Cannon, Christopher P.] Brigham & Womens Hosp, TIMI Study Grp, Boston, MA 02115 USA.
[Storey, Robert F.] Univ Sheffield, Dept Cardiovasc Sci, Sheffield, S Yorkshire, England.
[Steg, Philippe Gabriel] INSERM, U698, Paris, France.
[Steg, Philippe Gabriel] Hop Bichat Claude Bernard, Assistance Publ Hop Paris, F-75877 Paris, France.
[Steg, Philippe Gabriel] Univ Paris Diderot, Sorbonne Paris Cite, Paris, France.
[Harrington, Robert A.] Stanford Univ, Dept Med, Stanford, CA 94305 USA.
RP James, SK (reprint author), Uppsala Univ, Dept Med Sci, Dag Hammarskjolds Vag 14B, SE-75237 Uppsala, Sweden.
EM Stefan.James@ucr.uu.se
NR 7
TC 5
Z9 6
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
J9 STROKE
JI Stroke
PD MAY
PY 2013
VL 44
IS 5
BP 1477
EP 1479
DI 10.1161/STROKEAHA.111.000514
PG 3
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 131WZ
UT WOS:000318030000064
PM 23572474
ER
PT J
AU Shikari, H
Antin, JH
Dana, R
AF Shikari, Hasanain
Antin, Joseph H.
Dana, Reza
TI Ocular Graft-versus-Host Disease: A Review
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE allogeneic bone marrow transplantation; hematopoietic stem cells;
graft-versus-host disease; ocular GVHD; ocular surface disease; dry eye
disease
ID BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; CONSENSUS
DEVELOPMENT PROJECT; WORKING GROUP-REPORT; DRY-EYE DISEASE; REGULATORY
T-CELLS; TOPICAL CYCLOSPORINE 0.05-PERCENT; MINOR HISTOCOMPATIBILITY
ANTIGENS; MATCHED RELATED DONORS; TOTAL-BODY IRRADIATION
AB Graft-versus-host disease (GVHD) is a common cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Systemic findings involving the skin, gastrointestinal tract, and liver often overshadow the other manifestations of GVHD. Ocular surface disease remains the most common cause of long-term morbidity in GVHD. Herein, the etiology, pathophysiology, clinical manifestations, and treatment of acute and chronic systemic GVHD are reviewed, with a focus on ocular GVHD. (Surv Ophthalmol 58:233-251, 2013. (C) 2013 Elsevier Inc. All rights reserved.)
C1 [Shikari, Hasanain; Dana, Reza] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
[Shikari, Hasanain; Dana, Reza] Schepens Eye Res Inst, Boston, MA 02114 USA.
[Shikari, Hasanain; Dana, Reza] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
[Antin, Joseph H.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Antin, Joseph H.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Antin, Joseph H.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
RP Dana, R (reprint author), Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.
EM reza.dana@schepens.harvard.edu
NR 181
TC 29
Z9 29
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6257
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD MAY-JUN
PY 2013
VL 58
IS 3
BP 233
EP 251
DI 10.1016/j.survophthal.2012.08.004
PG 19
WC Ophthalmology
SC Ophthalmology
GA 133JO
UT WOS:000318134900002
PM 23541042
ER
PT J
AU Avila-Tang, E
Elf, JL
Cummings, KM
Fong, GT
Hovell, MF
Klein, JD
McMillen, R
Winickoff, JP
Samet, JM
AF Avila-Tang, Erika
Elf, Jessica L.
Cummings, K. Michael
Fong, Geoffrey T.
Hovell, Melbourne F.
Klein, Jonathan D.
McMillen, Robert
Winickoff, Jonathan P.
Samet, Jonathan M.
TI Assessing secondhand smoke exposure with reported measures
SO TOBACCO CONTROL
LA English
DT Review
ID ENVIRONMENTAL TOBACCO-SMOKE; NUTRITION EXAMINATION SURVEY; ACTIVITY
PATTERN SURVEY; COTININE CONCENTRATIONS; PASSIVE SMOKING; ETS EXPOSURE;
LUNG-CANCER; ASTHMA MANAGEMENT; URINARY COTININE; LATINO CHILDREN
AB Non-smokers are exposed to tobacco smoke from the burning cigarette and the exhaled smoke from smokers. In spite of decades of development of approaches to assess secondhand smoke exposure (SHSe), there are still unresolved methodological issues. This manuscript summarises the scientific evidence on the use of SHSe reported measures and their methods, objectives, strengths and limitations; and discusses best practices for assessing behaviour leading to SHSe for lifetime and immediate or current SHSe. Recommendations for advancing measurement science of SHSe are provided. Behavioural measures of SHSe commonly rely on self-reports from children and adults. Most commonly, the methodology includes self, proxy and interview-based reporting styles using retrospective recall or diary-style reporting formats. The reporting method used will vary based upon the subject of interest, assessment objectives and cultural context. Appropriately implemented, reported measures of SHSe provide an accurate, timely and cost-effective method for assessing exposure time, location and quantity in a wide variety of populations.
C1 [Avila-Tang, Erika] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA.
[Avila-Tang, Erika; Elf, Jessica L.] Johns Hopkins Bloomberg Sch Publ Hlth, Inst Global Tobacco Control, Baltimore, MD 21205 USA.
[Avila-Tang, Erika; Klein, Jonathan D.; McMillen, Robert; Winickoff, Jonathan P.] Amer Acad Pediat, Julius B Richmond Ctr Excellence, Elk Grove Village, IL USA.
[Cummings, K. Michael] Med Univ S Carolina, Charleston, SC 29425 USA.
[Fong, Geoffrey T.] Univ Waterloo, Dept Psychol, Waterloo, ON N2L 3G1, Canada.
[Fong, Geoffrey T.] Ontario Inst Canc Res, Toronto, ON, Canada.
[Hovell, Melbourne F.] San Diego State Univ, Ctr Behav Epidemiol, San Diego, CA 92182 USA.
[McMillen, Robert] Mississippi State Univ, Dept Psychol, Starkville, MS USA.
[Winickoff, Jonathan P.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.
[Samet, Jonathan M.] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA.
RP Avila-Tang, E (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Inst Global Tobacco Control, 2213 McElderry St,4th Floor, Baltimore, MD 21205 USA.
EM etang@jhsph.edu
RI Fong, Geoffrey/H-2810-2014
OI Fong, Geoffrey/0000-0001-9098-6472
FU Flight Attendant Medical Research Institute to the Johns Hopkins Center
of Excellence; University of California, San Francisco Bland Lane Center
of Excellence; American Academy of Pediatrics Julius B Richmond Center
of Excellence
FX This work was supported by grants from the Flight Attendant Medical
Research Institute to the Johns Hopkins Center of Excellence; the
University of California, San Francisco Bland Lane Center of Excellence;
and the American Academy of Pediatrics Julius B Richmond Center of
Excellence. The funding organisation had no role in the preparation of
the manuscripts.
NR 60
TC 23
Z9 24
U1 3
U2 17
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0964-4563
EI 1468-3318
J9 TOB CONTROL
JI Tob. Control
PD MAY
PY 2013
VL 22
IS 3
BP 156
EP 163
DI 10.1136/tobaccocontrol-2011-050296
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 126DC
UT WOS:000317590900005
PM 22949496
ER
PT J
AU Nguyen, KH
Wright, RJ
Sorensen, G
Subramanian, SV
AF Nguyen, K. H.
Wright, R. J.
Sorensen, G.
Subramanian, S. V.
TI Association between local indoor smoking ordinances in Massachusetts and
cigarette smoking during pregnancy: a multilevel analysis
SO TOBACCO CONTROL
LA English
DT Article
ID TOBACCO CONTROL; AIR LAWS; REGULATIONS; BEHAVIORS; WORKPLACE; POLICIES;
LEGISLATION; ATTITUDES; CESSATION; STRENGTH
AB Objective To estimate the association between local clean indoor air ordinances and prenatal maternal smoking across 351 municipalities in Massachusetts before the 2004 statewide ban and to test the effect of time since ordinance adoption on the association.
Methods The authors linked 2002 birth certificate data of women who gave birth in the state and reported a Massachusetts residence (n = 67 584) to a database of indoor smoking ordinances in all municipalities. Multilevel regression models accounting for individual- and municipality-level variables estimate the associations between the presence of local smoking ordinances, strength of the ordinances, time since ordinance adoption and prenatal smoking.
Results Compared with those living in municipalities with no ordinances, women living in municipalities with a smoking ordinance had lower odds of prenatal smoking (OR = 0.72, CI = 0.53 to 0.98). No effect was found for 100% smoke-free ordinances. For the analyses testing the effect of time, pregnant women living in municipalities with ordinances enacted >2 years were less likely to smoke than those in municipalities with more recent (<1 year) ordinances.
Conclusions Preventing smoking among women of reproductive age is a public health priority. This study suggests that indoor smoking ordinances were associated with lower prenatal smoking prevalence and the favourable effect increased over time. Findings highlight the public health benefit of tobacco control policies.
C1 [Nguyen, K. H.] Univ Calif San Francisco, Dept Med, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94111 USA.
[Wright, R. J.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Lab, Boston, MA 02115 USA.
[Wright, R. J.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
[Sorensen, G.; Subramanian, S. V.] Harvard Univ, Sch Publ Hlth, Dept Soc Hlth & Human Dev, Boston, MA 02115 USA.
[Sorensen, G.] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA.
RP Nguyen, KH (reprint author), Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, 1450 3rd St, San Francisco, CA 94111 USA.
EM nguyenk@cc.ucsf.edu
FU National Cancer Institute Diversity Supplement Award [R01CA129096];
National Heart, Lung, and Blood Institute Career Development Award [K25
HL081275]; Robert Wood Johnson Investigator Award in Health Policy
Research; National Cancer Institute [K05 CA108663]
FX KHN received support from the National Cancer Institute Diversity
Supplement Award (R01CA129096). SVS was supported by the National Heart,
Lung, and Blood Institute Career Development Award (K25 HL081275) and
the Robert Wood Johnson Investigator Award in Health Policy Research. GS
was supported by the National Cancer Institute (K05 CA108663).
NR 27
TC 11
Z9 11
U1 0
U2 6
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0964-4563
J9 TOB CONTROL
JI Tob. Control
PD MAY
PY 2013
VL 22
IS 3
BP 184
EP 189
DI 10.1136/tobaccocontrol-2011-050157
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 126DC
UT WOS:000317590900016
PM 22166267
ER
PT J
AU Vagefi, PA
Qian, JJ
Carlson, DM
Aparici, CM
Hirose, R
Vincenti, F
Wojciechowski, D
AF Vagefi, Parsia A.
Qian, Jesse J.
Carlson, David M.
Aparici, Carina Mari
Hirose, Ryutaro
Vincenti, Flavio
Wojciechowski, David
TI Native renal function after combined liver-kidney transplant for type 1
hepatorenal syndrome: initial report on the use of postoperative
Technetium-99 m-mercaptoacetyltriglycine scans
SO TRANSPLANT INTERNATIONAL
LA English
DT Article
DE end-stage liver disease; technetium-99 m-mercaptoacetyltriglycine
renogram; renal replacement therapy
ID MELD ERA; OUTCOMES
AB Type 1 hepatorenal syndrome (HRS) is characterized by rapid deterioration of renal function. We sought to assess native kidney function after combined kidney-liver transplant (CLKTx) performed for type 1 HRS. We performed a retrospective, cross-sectional, single-center study. All patients with Type 1 HRS who received a CLKTx at the University of California, San Francisco from 1997 to 2007 were screened for enrollment. Patients with a baseline estimated glomerular filtration rate (eGFR) 30ml/min/1.73m2 were eligible. Twenty-three patients were identified and consented to receive a Technetium-99 m-mercaptoacetyltriglycine (MAG3) nuclear scan to measure the native kidney contribution to overall renal function. Only 4 of the 23 subjects (17.4%) demonstrated native renal function that consisted of a contribution 50% of total renal function. Several factors and comorbidities such as age, gender, race, duration of HRS, need for and duration of renal replacement therapy, need for pressors, urine sodium, proteinuria, and use of octreotide/midodrine were analyzed and not found to be significant in predicting native renal function. The assessment of post-transplant native renal function following CLKTx may allow for improved accuracy in identifying the patients in need of CLKTx, and thus allow for greater optimization of dual-organ allocation strategies in patients with concomitant liver and renal failure.
C1 [Vagefi, Parsia A.] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Qian, Jesse J.] Kaiser Permanente, Med Grp, Stockton, CA USA.
[Carlson, David M.; Aparici, Carina Mari] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA.
[Hirose, Ryutaro] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA.
[Vincenti, Flavio; Wojciechowski, David] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
RP Wojciechowski, D (reprint author), Univ Calif San Francisco, 400,Parnassus Ave Suite A701, San Francisco, CA 94143 USA.
EM david.wojciechowski@ucsf.edu
FU ASTS-Novartis Fellowship in Transplantation Award; AST/Roche Clinical
Science Fellowship grant
FX This study was funded by an ASTS-Novartis Fellowship in Transplantation
Award (PAV) and AST/Roche Clinical Science Fellowship grant (JJQ).
NR 16
TC 3
Z9 3
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0934-0874
J9 TRANSPL INT
JI Transpl. Int.
PD MAY
PY 2013
VL 26
IS 5
BP 471
EP 476
DI 10.1111/tri.12066
PG 6
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 132DV
UT WOS:000318049000006
PM 23384317
ER
PT J
AU Lee, J
Hwang, YJ
Shin, JY
Lee, WC
Wie, J
Kim, KY
Lee, MY
Hwang, D
Ratan, RR
Pae, AN
Kowall, NW
So, I
Kim, JI
Ryu, H
AF Lee, Junghee
Hwang, Yu Jin
Shin, Jong-Yeon
Lee, Won-Chul
Wie, Jinhong
Kim, Ki Yoon
Lee, Min Young
Hwang, Daehee
Ratan, Rajiv R.
Pae, Ae Nim
Kowall, Neil W.
So, Insuk
Kim, Jong-Il
Ryu, Hoon
TI Epigenetic regulation of cholinergic receptor M1 (CHRM1) by histone
H3K9me3 impairs Ca2+ signaling in Huntington's disease
SO ACTA NEUROPATHOLOGICA
LA English
DT Article
DE H3K9me3; Epigenomes; Huntington's disease; Cholinergic receptor M1;
Heterochromatin
ID STRIATAL CELLS; H3; HETEROCHROMATIN; METHYLATION; EXPRESSION; NEURONS;
ESET; METHYLTRANSFERASE; INTERNEURONS; MODULATION
AB Huntington's disease (HD) is an autosomal dominant neurodegenerative disease caused by an expanded trinucleotide CAG repeat in the gene coding for huntingtin. Deregulation of chromatin remodeling is linked to the pathogenesis of HD but the mechanism remains elusive. To identify what genes are deregulated by trimethylated histone H3K9 (H3K9me3)-dependent heterochromatin, we performed H3K9me3-ChIP genome-wide sequencing combined with RNA sequencing followed by platform integration analysis in stable striatal HD cell lines (STHdhQ7/7 and STHdhQ111/111) cells. We found that genes involving neuronal synaptic transmission including cholinergic receptor M1 (CHRM1), cell motility, and neuronal differentiation pathways are downregulated while their promoter regions are highly occupied with H3K9me3 in HD. Moreover, we found that repression of CHRM1 gene expression by H3K9me3 impairs Ca2+-dependent neuronal signal transduction in stable cell lines expressing mutant HD protein. Thus, our data indicate that the epigenetic modifications, such as aberrant H3K9me3-dependent heterochromatin plasticity, directly contribute to the pathogenesis of HD.
C1 [Lee, Junghee; Kowall, Neil W.; Ryu, Hoon] Vet Affairs Boston Healthcare Syst, Boston, MA 02130 USA.
[Lee, Junghee; Kowall, Neil W.; Ryu, Hoon] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.
[Lee, Junghee; Kowall, Neil W.; Ryu, Hoon] Boston Univ, Sch Med, Alzheimers Dis Ctr, Boston, MA 02118 USA.
[Hwang, Yu Jin; Lee, Won-Chul; Kim, Ki Yoon; Ryu, Hoon] Seoul Natl Univ, Coll Med, WCU Neurocyt Grp, Seoul, South Korea.
[Shin, Jong-Yeon; Lee, Won-Chul; Kim, Jong-Il] Seoul Natl Univ, Coll Med, Genome Med Inst, Seoul, South Korea.
[Wie, Jinhong; So, Insuk] Seoul Natl Univ, Coll Med, Dept Physiol & Biomed Sci, Seoul, South Korea.
[Shin, Jong-Yeon; Kim, Jong-Il] Psoma Therapeut Inc, Seoul, South Korea.
[Lee, Min Young; Hwang, Daehee] POSTECH, Dept Chem Engn, Pohang, South Korea.
[Lee, Min Young; Hwang, Daehee] POSTECH, Sch Interdisciplinary Biosci & Bioengn, Pohang, South Korea.
[Ratan, Rajiv R.] Burke Med Res Inst, White Plains, NY USA.
[Pae, Ae Nim] Korea Inst Sci & Technol KIST, Brain Sci Inst, Ctr Neuromed, Seoul 136791, South Korea.
[Ryu, Hoon] Boston Univ, Sch Med, Dept Neurol, VA Boston Healthcare Syst, Boston, MA 02130 USA.
RP Ryu, H (reprint author), Boston Univ, Sch Med, Dept Neurol, VA Boston Healthcare Syst, Bldg 1A,Rm109,150 South Huntington Ave, Boston, MA 02130 USA.
EM hoonryu@bu.edu
RI KIM, JONG-IL/D-1019-2011; Kowall, Neil/G-6364-2012
OI KIM, JONG-IL/0000-0002-7240-3744; Kowall, Neil/0000-0002-6624-0213
FU WCU [800-20080848]; MEST of Korea [2010-0029-403]; KIST; NIH [NS
067283-01A1]
FX We thank to Dr. Marcy MacDonald for STHdhQ7/7 and STHdhQ111/111 cells
and to Min-Kyung Jung for her technical assistance. This study was
supported by WCU Neurocytomics Program Grant (800-20080848) (H. R.) and
SRC Grant (2010-0029-403) (H. R.) from MEST of Korea, Flagship Grant (H.
R.) from KIST and NIH NS 067283-01A1 (H.R.).
NR 36
TC 19
Z9 19
U1 0
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0001-6322
J9 ACTA NEUROPATHOL
JI Acta Neuropathol.
PD MAY
PY 2013
VL 125
IS 5
BP 727
EP 739
DI 10.1007/s00401-013-1103-z
PG 13
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA 130MY
UT WOS:000317923400009
PM 23455440
ER
PT J
AU Tondo, L
Baldessarini, RJ
Vazquez, G
Lepri, B
Visioli, C
AF Tondo, L.
Baldessarini, R. J.
Vazquez, G.
Lepri, B.
Visioli, C.
TI Clinical responses to antidepressants among 1036 acutely depressed
patients with bipolar or unipolar major affective disorders
SO ACTA PSYCHIATRICA SCANDINAVICA
LA English
DT Article
DE antidepressant response; bipolar disorder; depression; major depressive
disorder; switching
ID ELECTROCONVULSIVE-THERAPY; CYCLE ACCELERATION; CONTROLLED-TRIALS; MANIA;
METAANALYSIS; CONTROVERSY; SYMPTOMS; STATES
AB Tondo L, Baldessarini RJ, Vazquez G, Lepri B, Visioli C. Clinical responses to antidepressants among 1036 acutely depressed patients with bipolar or unipolar major affective disorders.
Objective Whether responses to antidepressants differ in bipolar and unipolar depression remains unresolved. Method We analyzed patient characteristics and outcomes of antidepressant treatment of 1036 depressed patients with bipolar-I or bipolar-II disorder, or unipolar major depression, using bivariate and multivariate methods and survival analysis, testing the hypothesis that responses would be superior in unipolar depression. Results Antidepressants were given to 84.8% (878/1036) of depressed patients: 58.9% of 93 bipolar-I, 80.1% of 117 bipolar-II, and 91.3% of 668 unipolar disorder cases. The 158 not given antidepressants had more manias/year, spent more months in mania and depression, and were far more likely to receive mood stabilizers or antipsychotics long term. Improvement of HDRS21 depression ratings ranked: bipolar-II (69.6%)>bipolar-I (62.9%)>unipolar (57.9%; P<0.0001), independent of initial illness severity. Responder rates (50% improved without switching) ranked: bipolar-II (77.0%)>bipolar-I (71.6%)>unipolar (61.7%; P<0.0001). Remission rates (final HDRS<7) ranked: 54.0%, 50.6%, and 40.8% respectively (P=0.02); 67.5% remitted within 12weeks of treatment. Survival-computed median time to remission (15.0weeks, overall) was shortest for bipolar-II patients (10.7weeks). The 3-month risk of switching into maniahypomania ranked: bipolar-II (15.8%)>bipolar-I (8.60%)>unipolar (0.56%). Multivariate modeling found bipolar diagnosis, shorter latency to remission, more recent trial year, and fewer weeks depressed before treatment to be associated with greater percent improvement of HDRS ratings. Conclusion Selective use of antidepressants with or without mood stabilizers in non-agitated, depressed bipolar disorder patients for short periods was effective with moderate risk of potentially dangerous, manic mood elevation.
C1 [Tondo, L.; Baldessarini, R. J.; Vazquez, G.] Massachusetts Gen Hosp, McLean Div, Mailman Res Ctr, Int Consortium Bipolar Disorder Res, Boston, MA 02114 USA.
[Tondo, L.; Lepri, B.; Visioli, C.] Ctr Lucio Bini Mood Disorders Ctr, Cagliari, Italy.
[Baldessarini, R. J.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Vazquez, G.] Univ Palermo, Dept Neurosci, Buenos Aires, DF, Argentina.
RP Tondo, L (reprint author), McLean Hosp, Mailman Res Ctr 212, 115 Mill St, Belmont, MA 02478 USA.
EM ltondo@mclean.harvard.edu
FU Lucio Bini Private Donors Mood Disorders Research Fund; Bruce J.
Anderson Foundation; McLean Private Donors Psychopharmacology Research
Fund
FX Supported in part by the Lucio Bini Private Donors Mood Disorders
Research Fund (to LT), by a grant from the Bruce J. Anderson Foundation,
and by the McLean Private Donors Psychopharmacology Research Fund (to
RJB).
NR 40
TC 27
Z9 27
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-690X
J9 ACTA PSYCHIAT SCAND
JI Acta Psychiatr. Scand.
PD MAY
PY 2013
VL 127
IS 5
BP 355
EP 364
DI 10.1111/acps.12023
PG 10
WC Psychiatry
SC Psychiatry
GA 127VI
UT WOS:000317726500003
PM 23121222
ER
PT J
AU Ahluwalia, SC
Leos, RL
Goebel, JR
Asch, SM
Lorenz, KA
AF Ahluwalia, Sangeeta C.
Leos, Rosana L.
Goebel, Joy R.
Asch, Steven M.
Lorenz, Karl A.
TI Provider Approaches to Palliative Dyspnea Assessment: Implications for
Informatics-Based Clinical Tools
SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE
LA English
DT Article
DE dyspnea; qualitative research; electronic health records; clinical
informatics; palliative care; user-computer interface
ID PHYSICIAN ORDER ENTRY; QUALITY-OF-LIFE; UNITED-STATES;
RESPIRATORY-DISEASES; CONSENSUS STATEMENT; ANXIETY DISORDERS;
PRIMARY-CARE; LUNG-CANCER; MANAGEMENT; BREATHLESSNESS
AB Aim: To understand provider practices around dyspnea assessment to inform the development of an electronic medical record (EMR)-based dyspnea assessment module in an inpatient palliative care consultation template. Design: Qualitative analysis of palliative care provider interviews. Results: Three themes emerged: (1) integration of patient self-report of breathlessness with a clinical observation of dyspnea; (2) identification of patients for dyspnea assessment based on perceived patient need; and (3) variability in preferences for and use of existing severity scales for dyspnea. Conclusions: The assessment approaches described by providers underscore the challenge of developing an informatics tool that supports the natural clinical experience and facilitates standardized care. The complexity of the dyspnea assessment process and variation in provider practices necessitate a level of flexibility and choice to be built into a computer-based tool.
C1 [Ahluwalia, Sangeeta C.] VA Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Provider Behav, Los Angeles, CA 90064 USA.
[Ahluwalia, Sangeeta C.; Asch, Steven M.; Lorenz, Karl A.] RAND Corp, Santa Monica, CA USA.
[Ahluwalia, Sangeeta C.; Leos, Rosana L.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA.
[Goebel, Joy R.] Calif State Univ Long Beach, Sch Nursing, Long Beach, CA 90840 USA.
[Goebel, Joy R.; Lorenz, Karl A.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Asch, Steven M.] Vet Adm Palo Alto Healthcare Syst, Palo Alto, CA USA.
[Asch, Steven M.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA.
[Lorenz, Karl A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Ahluwalia, SC (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd 111-G, Los Angeles, CA 90064 USA.
EM sangeeta.c.ahluwalia@gmail.com
FU Department of Veterans Affairs Comprehensive End-of-Life Care
Initiative, Office of Patient Care Services; Office of Academic
Affiliation's VA Associated Health Postdoctoral Fellowship Program at
the VA Greater Los Angeles HSR&D Center of Excellence
FX The authors disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: This work was
supported by the Department of Veterans Affairs Comprehensive
End-of-Life Care Initiative, Office of Patient Care Services. Dr
Ahluwalia was supported by an Office of Academic Affiliation's VA
Associated Health Postdoctoral Fellowship Program at the VA Greater Los
Angeles HSR&D Center of Excellence.
NR 64
TC 1
Z9 1
U1 1
U2 7
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1049-9091
J9 AM J HOSP PALLIAT ME
JI Am. J. Hosp. Palliat. Med.
PD MAY
PY 2013
VL 30
IS 3
BP 231
EP 238
DI 10.1177/1049909112448922
PG 8
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 127CW
UT WOS:000317674300002
PM 22669935
ER
PT J
AU Howitt, BE
Herfs, M
Brister, K
Oliva, E
Longtine, J
Hecht, JL
Nucci, MR
AF Howitt, Brooke E.
Herfs, Michael
Brister, Kathriel
Oliva, Esther
Longtine, Janina
Hecht, Jonathan L.
Nucci, Marisa R.
TI Intestinal-type Endocervical Adenocarcinoma In Situ An
Immunophenotypically Distinct Subset of AIS Affecting Older Women
SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY
LA English
DT Article
DE cervical adenocarcinoma in situ; intestinal; HPV; p16
ID DIFFERENT HISTOLOGICAL SUBTYPES; HUMAN-PAPILLOMAVIRUS; CERVICAL
ADENOCARCINOMA; UTERINE CERVIX; GLANDULAR LESIONS; GASTRIC MORPHOLOGY;
EXPRESSION; P16(INK4A); DIAGNOSIS; INSITU
AB Conventional endocervical adenocarcinoma in situ (cAIS) is typically strongly and diffusely positive for p16 with a high Ki67 index consistent with its frequent association with high-risk human papillomavirus (HPV) infection. The intestinal variant (iAIS) is less common, and its relationship to HPV infection has not been thoroughly examined. This study compares the clinicopathologic features, frequency of HPV infection, and expression of CDX2 and surrogate biomarkers of HPV infection (p16, Ki67) in cAIS with those of iAIS. A total of 86 cases with a diagnosis of AIS (49 iAIS, 37 cAIS) were identified from our multi-institutional files. Of these, 13 iAIS and 20 cAIS cases had slides and tissue available for histopathologic review, immunohistochemical analysis, and molecular tests. All 86 cases were used to evaluate clinical parameters; however, HPV DNA analysis and immunohistochemical analysis for p16, MIB-1, CDX2, and p53 were performed only on those cases with available slides or paraffin blocks. The average age at diagnosis was significantly higher in iAIS compared with that in cAIS (44.5 vs. 32.6 y) (P = 0.0001). All 20 cAIS cases showed moderate to strong and diffuse p16 staining; however, only 9/13 iAIS cases showed this degree of p16 staining, whereas 4/13 (31%) iAIS cases showed weak and patchy distribution (P < 0.02). Only 6/9 (67%) iAIS cases were positive for either HPV type 18 (5) or 33 (1), in contrast to 11/11 conventional cAIS (P = 0.04). Similarly, 12/14 cAIS, but only 5/13 iAIS, cases showed a high Ki67 proliferative index. CDX2 was positive in all iAIS cases, whereas p53 was negative. Most iAIS cases are positive for high-risk HPV and show moderate to strong and diffuse p16 staining; however, a subset of iAIS shows variable staining with p16 and Ki67, is not associated with HPV, and occurs in a distinctly older age group suggesting an alternative pathogenesis. Awareness that iAIS can show variable staining for p16 and Ki67 is important when resolving problematic endocervical lesions, particularly in small biopsies with unusual p16 staining patterns.
C1 [Howitt, Brooke E.; Longtine, Janina; Nucci, Marisa R.] Brigham & Womens Hosp, Dept Pathol, Div Womens & Perinatal Pathol, Boston, MA 02115 USA.
[Brister, Kathriel; Hecht, Jonathan L.] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA.
[Oliva, Esther] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Herfs, Michael] Univ Liege, Dept Pathol, Liege, Belgium.
RP Nucci, MR (reprint author), Brigham & Womens Hosp, Dept Pathol, Div Womens & Perinatal Pathol, 75 Francis St, Boston, MA 02115 USA.
EM mnucci@partners.org
NR 30
TC 9
Z9 9
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0147-5185
J9 AM J SURG PATHOL
JI Am. J. Surg. Pathol.
PD MAY
PY 2013
VL 37
IS 5
BP 625
EP 633
DI 10.1097/PAS.0b013e318285be00
PG 9
WC Pathology; Surgery
SC Pathology; Surgery
GA 126ZP
UT WOS:000317663100001
PM 23552379
ER
PT J
AU Lim, D
Alvarez, T
Nucci, MR
Gilks, B
Longacre, T
Soslow, RA
Oliva, E
AF Lim, Diana
Alvarez, Teresa
Nucci, Marisa R.
Gilks, Blake
Longacre, Teri
Soslow, Robert A.
Oliva, Esther
TI Interobserver Variability in the Interpretation of Tumor Cell Necrosis
in Uterine Leiomyosarcoma
SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY
LA English
DT Article
DE uterus; leiomyosarcoma; tumor cell necrosis
ID SMOOTH-MUSCLE TUMORS; MITOTICALLY ACTIVE LEIOMYOMAS; PHOSPHOHISTONE H3
PHH3; SOFT-TISSUE SARCOMAS; PROGNOSTIC-FACTORS; MULTIVARIATE-ANALYSIS;
GRADE LEIOMYOSARCOMA; UTERUS; PATHOLOGY; NEOPLASMS
AB On the basis of the most recent World Health Organization classification, distinction of leiomyosarcoma (LMS) from leiomyoma is based on the presence of the following morphologic criteria: (1) nuclear atypia; (2) mitotic index; and (3) tumor cell necrosis (TCN). Unlike ischemic-type necrosis, which may be seen in benign and malignant smooth muscle tumors (SMTs), TCN is thought to be found only in LMS. The distinction between these 2 types of necrosis can be challenging, especially during the early stages, when necrotic foci are small, or when overlapping features are identified. The aim of this study is to assess the interobserver variability in the interpretation of TCN in uterine LMS. Thirty-four LMS cases were retrieved, and a representative hematoxylin and eosin slide showing 1 area of necrosis was selected from each case. Pathologists from 6 different institutions subspecializing in gynecologic pathology performed a blinded, independent review of the slides. Using the current World Health Organization criteria for assessment of TCN, they had to classify the necrotic foci into: (1) TCN; (2) no TCN; or (3) indeterminate for TCN. Agreement among panelists was categorized as: full-all pathologists in agreement; partial-4 or 5 pathologists in agreement; no agreement-<= 3 pathologists placing the case into the same category. Full agreement regarding the presence or absence of TCN was reached in 12 cases (35%) (7 thought to show TCN); partial agreement in 16 (47%); and no general consensus was obtained in 6 (18%). Overall, the level of agreement was moderate (kappa = 0.436). In 8 of 34 instances (23.5%), >= 1 pathologist made a diagnosis of "TCN" and >= 1 pathologist made the diagnosis of "no TCN" for the same slide. The number of cases diagnosed as "indeterminate for TCN" by each pathologist ranged from 0 to 10 with a mean of 5.8. In 20 cases, at least 1 pathologist diagnosed "indeterminate for TCN" (59%), at least 2 and 3 were undecided in 10 (29%) and 4 (12%) cases, respectively, and 4 pathologists diagnosed "indeterminate for TCN" in 1 instance. When excluding foci of necrosis diagnosed as "indeterminate" by any pathologist, disagreement occurred in 2/14 (14%) cases. From these results we conclude that the level of interobserver agreement among expert gynecologic pathologists in the assessment of TCN in uterine SMTs is only moderate. These results further reiterate the importance of assessing for both nuclear atypia and mitotic activity when differentiating between benign and malignant SMTs and not relying solely on the presence of TCN.
C1 [Lim, Diana] Natl Univ Hlth Syst, Singapore, Singapore.
[Alvarez, Teresa] Hosp Univ Bellvitge, Barcelona, Spain.
[Nucci, Marisa R.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Oliva, Esther] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Longacre, Teri] Stanford Univ, Stanford, CA 94305 USA.
[Soslow, Robert A.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Gilks, Blake] Vancouver Gen Hosp, Vancouver, BC, Canada.
RP Oliva, E (reprint author), Massachusetts Gen Hosp, Dept Pathol, 55 Fruit st, Boston, MA 02114 USA.
EM eoliva@partners.org
OI Soslow, Robert/0000-0002-7269-5898
NR 55
TC 13
Z9 14
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0147-5185
EI 1532-0979
J9 AM J SURG PATHOL
JI Am. J. Surg. Pathol.
PD MAY
PY 2013
VL 37
IS 5
BP 650
EP 658
DI 10.1097/PAS.0b013e3182851162
PG 9
WC Pathology; Surgery
SC Pathology; Surgery
GA 126ZP
UT WOS:000317663100004
PM 23552382
ER
PT J
AU Regue, L
Mou, F
Avruch, J
AF Regue, Laura
Mou, Fan
Avruch, Joseph
TI G protein-coupled receptors engage the mammalian Hippo pathway through
F-actin F-Actin, assembled in response to Galpha(12/13) induced
RhoA-GTP, promotes dephosphorylation and activation of the YAP oncogene
SO BIOESSAYS
LA English
DT Article
DE F-actin; Galpha12; 13; G protein-coupled receptors; hippo; TAZ; YAP
ID SIGNALING PATHWAY; TUMOR-SUPPRESSOR; GROWTH-CONTROL; TISSUE-GROWTH;
CELL-PROLIFERATION; ALPHA-CATENIN; SIZE CONTROL; ORGAN SIZE; METASTASIS;
KINASES
AB The Hippo pathway, a cascade of protein kinases that inhibits the oncogenic transcriptional coactivators YAP and TAZ, was discovered in Drosophila as a major determinant of organ size in development. Known modes of regulation involve surface proteins that mediate cell-cell contact or determine epithelial cell polarity which, in a tissue-specific manner, use intracellular complexes containing FERM domain and actin-binding proteins to modulate the kinase activities or directly sequester YAP. Unexpectedly, recent work demonstrates that GPCRs, especially those signaling through Galpha12/13 such as the protease activated receptor PAR1, cause potent YAP dephosphorylation and activation. This response requires active RhoA GTPase and increased assembly of filamentous (F-)actin. Morever, cell architectures that promote F-actin assembly per se also activate YAP by kinase-dependent and independent mechanisms. These findings unveil the ability of GPCRs to activate the YAP oncogene through a newly recognized signaling function of the actin cytoskeleton, likely to be especially important for normal and cancerous stem cells.
C1 [Regue, Laura; Mou, Fan; Avruch, Joseph] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Regue, Laura; Mou, Fan; Avruch, Joseph] Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA.
[Regue, Laura; Mou, Fan; Avruch, Joseph] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
RP Avruch, J (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
EM avruch@molbio.mgh.harvard.edu
FU NIH [DK17776, CA136567, DK057521]
FX Work cited from the author's lab was supported by NIH grants DK17776,
CA136567, and DK057521.
NR 61
TC 10
Z9 11
U1 2
U2 26
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0265-9247
J9 BIOESSAYS
JI Bioessays
PD MAY
PY 2013
VL 35
IS 5
BP 430
EP 435
DI 10.1002/bies.201200163
PG 6
WC Biochemistry & Molecular Biology; Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics
GA 127BC
UT WOS:000317668100008
PM 23450633
ER
PT J
AU Januzzi, JL
Horne, BD
Moore, SA
Galenko, O
Snow, GL
Brunisholz, KD
Muhlestein, JB
Alharethi, R
Carlquist, JF
Budge, D
Rasmussen, K
Kfoury, AG
AF Januzzi, James L.
Horne, Benjamin D.
Moore, Stephanie A.
Galenko, Oxana
Snow, Gregory L.
Brunisholz, Kimberly D.
Muhlestein, Joseph B.
Alharethi, Rami
Carlquist, John F.
Budge, Deborah
Rasmussen, Kismet
Kfoury, Abdallah G.
TI Interleukin receptor family member ST2 concentrations in patients
following heart transplantation
SO BIOMARKERS
LA English
DT Article
DE Biomarkers; biopsy; heart transplantation; prognosis; rejection
ID CARDIAC ALLOGRAFT-REJECTION; MHC CLASS-II; SOLUBLE ST2;
MYOCARDIAL-INFARCTION; ACUTE DYSPNEA; TOLERANCE; PROTEIN; CELLS; IL-33
AB Objective: To evaluate soluble (s) ST2 as a biomarker of rejection, allograft vasculopathy and mortality after orthotopic heart transplantation (OHT).
Methods: sST2 concentrations were measured in 241 patients following OHT.
Results: Elevated sST2 was associated with cellular rejection (CR) >= 1R, with highest rates of CR in the 4th sST2 quartile (p = 0.003). No significant association between sST2 and antibody-mediated rejection or allograft vasculopathy was found. sST2 >= 30 ng/mL independently predicted death over 7-year follow-up (HR = 2.01; 95% CI 1.15-3.51; p = 0.01).
Conclusion: Concentrations of sST2 are associated with the presence of CR and predict long-term mortality following OHT.
C1 [Januzzi, James L.; Moore, Stephanie A.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Horne, Benjamin D.; Snow, Gregory L.; Brunisholz, Kimberly D.; Muhlestein, Joseph B.; Alharethi, Rami; Budge, Deborah; Rasmussen, Kismet; Kfoury, Abdallah G.] Intermt Med Ctr, Cardiovasc Dept, Salt Lake City, UT USA.
[Galenko, Oxana; Carlquist, John F.] LDS Hosp, Cardiovasc Mol Res Lab, Salt Lake City, UT USA.
RP Januzzi, JL (reprint author), Massachusetts Gen Hosp, 32 Fruit St,Yawkey 5984, Boston, MA 02114 USA.
EM jjanuzzi@partners.org
OI Snow, Gregory/0000-0001-8530-1037
FU Critical Diagnostics
FX Dr Januzzi reports receiving grant support from Critical Diagnostics.
Otherwise, no declarations of interest exist.
NR 21
TC 9
Z9 10
U1 1
U2 4
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1354-750X
J9 BIOMARKERS
JI Biomarkers
PD MAY
PY 2013
VL 18
IS 3
BP 250
EP 256
DI 10.3109/1354750X.2013.773081
PG 7
WC Biotechnology & Applied Microbiology; Toxicology
SC Biotechnology & Applied Microbiology; Toxicology
GA 130NX
UT WOS:000317926200009
PM 23557127
ER
PT J
AU Macaya, DJ
Hayakawa, K
Arai, K
Spector, M
AF Macaya, Daniel J.
Hayakawa, Kazuhide
Arai, Ken
Spector, Myron
TI Astrocyte infiltration into injectable collagen-based hydrogels
containing FGF-2 to treat spinal cord injury
SO BIOMATERIALS
LA English
DT Article
DE Collagen; Fibroblast growth factor; Nerve tissue engineering;
Chemotaxis; In vitro test; Spinal cord injury
ID FIBROBLAST-GROWTH-FACTOR; HEPARAN-SULFATE PROTEOGLYCAN; INTRATHECAL
DELIVERY-SYSTEM; FACTOR BFGF; FUNCTIONAL RECOVERY; GLIAL SCAR;
RAT-BRAIN; REACTIVE ASTROCYTES; WHITE-MATTER; REGENERATION
AB Astrocytes can play dual roles in the response to spinal cord injury (SCI) acting as both an inhibitory barrier and a trophic support for growth axons. Therefore, migration of these cells into the defect as opposed to forming a scar at the periphery, may promote axon regeneration through the lesion. However, infiltration requires the conformal filling of the cyst-like lesion, which often forms after SCI, with a biomaterial scaffold encouraging of astrocyte migration. For this application, we investigated injectable collagen-based hydrogels covalently cross-linked with genipin and incorporating fibroblast growth factor-2 (FGF-2) either freely or encapsulated within lipid microtubules (LMTs). An outgrowth assay was used to evaluate in vitro the number of primary rat astrocytes infiltrating into the collagen gels and the distance to which they infiltrated. The presence of FGF-2 within the encapsulating gel significantly increased the number of astrocytes within the gel, their penetration distance into the gel, and caused them to move out in a chain-like pattern, compared to control gels without FGF-2. Genipin cross-linking of the collagen gel decreased the number of infiltrating astrocytes, compared to the non-cross-linked control gel; however, incorporation of FGF-2-containing LMTs within genipin-cross-linked gels restored the astrocyte infiltration to levels approaching non-cross-linked gels incorporating FGF-2. Overall, injectable collagen-genipin hydrogels containing FGF-2-containing LMTs are a promising candidate for the treatment for SCI through the attraction of astrocytes into the graft. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Macaya, Daniel J.; Spector, Myron] Harvard Univ, Brigham & Womens Hosp, Sch Med, VA Boston Healthcare Syst, Boston, MA 02115 USA.
[Macaya, Daniel J.] Harvard Massachusetts Inst Technol, Cambridge, MA USA.
[Hayakawa, Kazuhide; Arai, Ken] Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA USA.
[Hayakawa, Kazuhide; Arai, Ken] Harvard Univ, Sch Med, Charlestown, MA USA.
[Hayakawa, Kazuhide; Arai, Ken] Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA USA.
RP Spector, M (reprint author), 150 S Huntington Ave,MS151, Boston, MA 02130 USA.
EM mspector@rics.bwh.harvard.edu
FU NSF Fellowship; VA Research Career Scientist Award; U.S. Department of
Veterans Affairs, Veterans Health Administration, Rehabilitation
Research and Development Service
FX D.M. was supported by an NSF Fellowship, and MS by a VA Research Career
Scientist Award. The work was supported in part by the U.S. Department
of Veterans Affairs, Veterans Health Administration, Rehabilitation
Research and Development Service.
NR 58
TC 15
Z9 15
U1 5
U2 57
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD MAY
PY 2013
VL 34
IS 14
BP 3591
EP 3602
DI 10.1016/j.biomaterials.2012.12.050
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 125IT
UT WOS:000317534200006
PM 23414684
ER
PT J
AU Bunnell, CA
Gross, AH
Weingart, SN
Kalfin, MJ
Partridge, A
Lane, S
Burstein, HJ
Fine, B
Hilton, NA
Sullivan, C
Hagemeister, EE
Kelly, AE
Colicchio, L
Szabatura, AH
Winer, EP
Salisbury, M
Mann, S
AF Bunnell, Craig A.
Gross, Anne H.
Weingart, Saul N.
Kalfin, Michael Jason
Partridge, Ann
Lane, Sharon
Burstein, Harold J.
Fine, Barbara
Hilton, Nancy A.
Sullivan, Clare
Hagemeister, Erin E.
Kelly, Anne E.
Colicchio, Lynn
Szabatura, Audrea H.
Winer, Eric P.
Salisbury, Mary
Mann, Susan
TI High performance teamwork training and systems redesign in outpatient
oncology
SO BMJ QUALITY & SAFETY
LA English
DT Article
ID PATIENT SAFETY; COMMUNICATION; CARE; TEAMS
AB Background Oncology care is delivered largely in ambulatory settings by interdisciplinary teams. Treatments are often complex, extended in time, dispersed geographically and vulnerable to teamwork failures. To address this risk, we developed and piloted a team training initiative in the breast cancer programme at a comprehensive cancer centre.
Methods Based on clinic observations, interviews with key staff and analyses of incident reports, we developed interventions to address four high-risk areas: (1) miscommunication of chemotherapy order changes on the day of treatment; (2) missing orders on treatment days without concurrent physician appointments; (3) poor follow-up with team members about active patient issues; and (4) conflict between providers and staff. The project team developed protocols and agreements to address team members' roles, responsibilities and behaviours.
Results Using a train-the-trainer model, 92% of breast cancer staff completed training. The incidence of missing orders for unlinked visits decreased from 30% to 2% (p<0.001). Patient satisfaction scores regarding coordination of care improved from 93 to 97 (p=0.026). Providers, infusion nurses and support staff reported improvement in efficiency (75%, 86%, 90%), quality (82%, 93%, 93%) and safety (92%, 92%, 90%) of care, and more respectful behaviour (92%, 79%, 83%) and improved relationships among team members (91%, 85%, 92%). Although most clinicians reported a decrease in non-communicated changes, there was insufficient statistical power to detect a difference.
Conclusions Team training improved communication, task coordination and perceptions of efficiency, quality, safety and interactions among team members as well as patient perception of care coordination.
C1 [Bunnell, Craig A.; Partridge, Ann; Burstein, Harold J.; Winer, Eric P.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Gross, Anne H.; Kalfin, Michael Jason; Fine, Barbara; Hilton, Nancy A.; Sullivan, Clare; Hagemeister, Erin E.; Kelly, Anne E.; Colicchio, Lynn] Dana Farber Canc Inst, Dept Nursing & Patient Care Serv, Boston, MA 02215 USA.
[Weingart, Saul N.] Dana Farber Canc Inst, Ctr Patient Safety, Div Gen Med & Primary Care, Boston, MA 02215 USA.
[Lane, Sharon] Dana Farber Canc Inst, Ctr Patient Safety, Boston, MA 02215 USA.
[Szabatura, Audrea H.] Dana Farber Canc Inst, Dept Pharm & Clin Support, Boston, MA 02215 USA.
[Salisbury, Mary] Cedar Inst Inc, San Antonio, TX USA.
[Mann, Susan] Beth Israel Deaconess Med Ctr, Dept Obstet & Gynecol, Boston, MA 02215 USA.
RP Bunnell, CA (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,Room D 1614, Boston, MA 02215 USA.
EM craig_bunnell@dfci.harvard.edu
FU Controlled Risk Insurance Company/Risk Management Foundation CRICO/RMF
FX Controlled Risk Insurance Company/Risk Management Foundation CRICO/RMF
provided funding for the physician/nurse consultant team that assisted
us on this project.
NR 23
TC 17
Z9 17
U1 2
U2 19
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-5415
J9 BMJ QUAL SAF
JI BMJ Qual. Saf.
PD MAY
PY 2013
VL 22
IS 5
SI SI
BP 405
EP 413
DI 10.1136/bmjqs-2012-000948
PG 9
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 130LD
UT WOS:000317917400005
PM 23349386
ER
PT J
AU Heras, FL
Martuza, R
Caruso, P
Rincon, S
Stemmer-Rachamimov, A
AF Heras, Facundo Las
Martuza, Robert
Caruso, Paul
Rincon, Sandra
Stemmer-Rachamimov, Anat
TI 24-Year-Old Woman with An Internal Auditory Canal Mass Hybrid peripheral
nerve sheath tumor with schwannoma/perineurioma components
SO BRAIN PATHOLOGY
LA English
DT Editorial Material
ID NEUROFIBROMA; PERINEURIOMA; SCHWANNOMA; CHALLENGE
AB Benign peripheral nerve sheath tumors are divided into schwannomas, neurofibromas and perineuriomas. In recent years, tumors with hybrid features, composed of multiple, discrete areas of different histological types, were described. These tumors may represent a diagnostic challenge. A 24-year-old woman with multiple sclerosis was found to have a 1.3 cm TV 0.7 cm AP T2 intermediate lesion within the left internal auditory canal. Gross examination revealed a tan-white, well circumscribed mass. Histologic examination demonstrated a well demarcated, cellular, solid neoplasm with a biphasic pattern. Most of the tumor was composed of spindle cells arranged in fascicles with focal Verocay body formation and diffuse S100 positivity. A second, minor area showed concentric proliferation of neoplastic spindle cells around one or more axons. Tumor cells in this area were positive for perineurial markers, claudin-1 and Glut-1, and focally immunopositive for CD34. We present here a case of a benign peripheral nerve sheath tumor with histological and immunohistochemical features consistent with a dual pattern of differentiation of schwannoma and perineurioma, in the VIIIth cranial nerve. This is, to our knowledge, the first case of a hybrid perineurioma/schwannoma reported in a cranial nerve.
C1 [Heras, Facundo Las] Univ Chile, Clin Hosp, Dept Anat Pathol, Santiago, Chile.
[Martuza, Robert] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
[Caruso, Paul; Rincon, Sandra] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Stemmer-Rachamimov, Anat] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
RP Heras, FL (reprint author), Univ Chile, Clin Hosp, Dept Anat Pathol, Santiago, Chile.
NR 10
TC 1
Z9 1
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1015-6305
EI 1750-3639
J9 BRAIN PATHOL
JI Brain Pathol.
PD MAY
PY 2013
VL 23
IS 3
BP 361
EP 362
DI 10.1111/bpa.12055
PG 2
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA 129TP
UT WOS:000317865800016
ER
PT J
AU Schapira, L
AF Schapira, Lidia
TI The Essential Elements of a Therapeutic Presence
SO CANCER
LA English
DT Editorial Material
C1 [Schapira, Lidia] Massachusetts Gen Hosp, Gillette Ctr Womens Canc, Boston, MA 02114 USA.
RP Schapira, L (reprint author), Massachusetts Gen Hosp, 55 Fruit St,YA 9, Boston, MA 02114 USA.
EM lschapira@partners.org
NR 3
TC 2
Z9 2
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
J9 CANCER-AM CANCER SOC
JI Cancer
PD MAY 1
PY 2013
VL 119
IS 9
BP 1609
EP 1610
PG 2
WC Oncology
SC Oncology
GA 133CM
UT WOS:000318115000002
PM 23341022
ER
PT J
AU Weber, JS
Dummer, R
de Pril, V
Lebbe, C
Hodi, FS
AF Weber, Jeffrey S.
Dummer, Reinhard
de Pril, Veerle
Lebbe, Celeste
Hodi, F. Stephen
CA MDX010-20 Investigators
TI Patterns of Onset and Resolution of Immune-Related Adverse Events of
Special Interest With Ipilimumab Detailed Safety Analysis From a Phase 3
Trial in Patients With Advanced Melanoma
SO CANCER
LA English
DT Article
DE adverse drug events; immune system phenomenon; ipilimumab; mechanism of
action; metastatic melanoma
ID T-CELLS; METASTATIC MELANOMA; GLUCOCORTICOIDS; ANTI-CTLA-4; MANAGEMENT
AB BACKGROUND: Ipilimumab 3 mg/kg was the first agent to demonstrate improved survival in previously treated patients with metastatic melanoma in a phase 3 trial (MDX010-20). Ipilimumab produced a characteristic spectrum of immune-related adverse events (irAEs) of special interest, consistent with its immune-based mechanism of action. METHODS: In MDX010-20, 676 previously treated patients were randomized 3:1:1 to receive ipilimumab 3 mg/kg plus the glycoprotein 100 melanoma antigen vaccine (gp100), ipilimumab 3 mg/kg + placebo, or gp100 vaccine + placebo. For the current report, the authors conducted a detailed analysis of the time to onset and resolution of irAEs associated with ipilimumab therapy. RESULTS: Grade 2 through 5 irAEs generally developed during the induction phase of treatment (0-12 weeks). Most, including grade 3/4 irAEs, were reversible when managed with treatment guidelines using vigilant monitoring and corticosteroids. The median time to resolution (to grade 1 or 0 or to the grade at baseline) of irAEs that had an onset during the induction phase was approximately 6 weeks for grade 2 through 4 irAEs and 8 weeks for grade 3 and 4 irAEs. Across the entire study duration, most grade 2 through 4 irAEs resolved within 12 weeks. CONCLUSIONS: Most ipilimumab-associated irAEs, including grade 3/4 symptoms, developed within 12 weeks of initial dosing and resolved within 12 weeks of onset. IrAEs were well characterized in their evolution and could be managed using published algorithms. Cancer 2013; 119: 1675-82. (C) 2013 American Cancer Society.
C1 [Weber, Jeffrey S.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Donald A Adam Comprehens Melanoma Res Ctr, Tampa, FL 33612 USA.
[Dummer, Reinhard] Univ Zurich, Dept Dermatol, Zurich, Switzerland.
[de Pril, Veerle] Bristol Myers Squibb Co, Braine Lalleud, Belgium.
[Lebbe, Celeste] Paris Publ Assistance Hosp Syst, Clin Invest Ctr, Paris, France.
[Lebbe, Celeste] Hosp St Louis Fac, Dept Dermatol, Paris, France.
[Hodi, F. Stephen] Dana Farber Canc Inst, Melanoma Ctr, Boston, MA 02115 USA.
RP Weber, JS (reprint author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Donald A Adam Comprehens Melanoma Res Ctr, 12902 Magnolia Dr, Tampa, FL 33612 USA.
EM jeffrey.weber@moffitt.org
FU AstraZeneca; Novartis; Cephalon; Merck; Transgene; Bristol-Myers Squibb
[NCT00094653]; Roche; GlaxoSmithKline; Bayer
FX The MDX010-20 trial (NCT00094653) was sponsored by Bristol-Myers Squibb.
Editorial and writing assistance was provided by StemScientific, which
was funded by Bristol-Myers Squibb.; J.S.W. has received honoraria from
Bristol-Myers Squibb. R.D. has received research funding from and has
served as an advisor for AstraZeneca, Novartis, Cephalon, Merck,
Transgene, Bristol-Myers Squibb, Roche, GlaxoSmithKline, and Bayer, and
he also has served as an advisor for Genta and Spirig Pharma. V.d.P. is
an employee of Bristol-Myers Squibb. C.L. has received honoraria from
Bristol-Myers Squibb. F.S.H. has served as a nonpaid consultant and has
received clinical research support from Bristol-Myers Squibb.
NR 20
TC 92
Z9 95
U1 4
U2 16
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
J9 CANCER-AM CANCER SOC
JI Cancer
PD MAY 1
PY 2013
VL 119
IS 9
BP 1675
EP 1682
DI 10.1002/cncr.27969
PG 8
WC Oncology
SC Oncology
GA 133CM
UT WOS:000318115000011
PM 23400564
ER
PT J
AU Gray, PJ
Paly, JJ
Yeap, BY
Sanda, MG
Sandler, HM
Michalski, JM
Talcott, JA
Coen, JJ
Hamstra, DA
Shipley, WU
Hahn, SM
Zietman, AL
Bekelman, JE
Efstathiou, JA
AF Gray, Phillip J.
Paly, Jonathan J.
Yeap, Beow Y.
Sanda, Martin G.
Sandler, Howard. M.
Michalski, Jeff M.
Talcott, James A.
Coen, John J.
Hamstra, Daniel A.
Shipley, William U.
Hahn, Stephen M.
Zietman, Anthony L.
Bekelman, Justin E.
Efstathiou, Jason A.
TI Patient-Reported Outcomes After 3-Dimensional Conformal,
Intensity-Modulated, or Proton Beam Radiotherapy for Localized Prostate
Cancer
SO CANCER
LA English
DT Article
DE 3-dimensional conformal radiotherapy; intensity-modulated radiotherapy;
patient reported outcomes; prostate cancer; proton therapy; quality of
life
ID QUALITY-OF-LIFE; LATE RECTAL TOXICITY; RADIATION-THERAPY; BOWEL
TOXICITY; TIME-COURSE; 3D-CRT; PREDICTORS; SYMPTOMS; ADENOCARCINOMA;
INCONTINENCE
AB BACKGROUND: Recent studies have suggested differing toxicity patterns for patients with prostate cancer who receive treatment with 3-dimensional conformal radiotherapy (3DCRT), intensity-modulated radiotherapy (IMRT), or proton beam therapy (PBT). METHODS: The authors reviewed patient-reported outcomes data collected prospectively using validated instruments that assessed bowel and urinary quality of life (QOL) for patients with localized prostate cancer who received 3DCRT (n = 123), IMRT (n = 153) or PBT (n = 95). Clinically meaningful differences in mean QOL scores were defined as those exceeding half the standard deviation of the base-line mean value. Changes from baseline were compared within groups at the first post-treatment follow-up (2-3 months from the start of treatment) and at 12 months and 24 months. RESULTS: At the first post-treatment follow-up, patients who received 3DCRT and IMRT, but not those who received PBT, reported a clinically meaningful decrement in bowel QOL. At 12 months and 24 months, all 3 cohorts reported clinically meaningful decrements in bowel QOL. Patients who received IMRT reported clinically meaningful decrements in the domains of urinary irritation/obstruction and incontinence at the first post-treatment follow-up. At 12 months, patients who received PBT, but not those who received IMRT or 3DCRT, reported a clinically meaningful decrement in the urinary irritation/obstruction domain. At 24 months, none of the 3 cohorts reported clinically meaningful changes in urinary QOL. CONCLUSIONS: Patients who received 3DCRT, IMRT, or PBT reported distinct patterns of treatment-related QOL. Although the timing of toxicity varied between the cohorts, patients reported similar modest QOL decrements in the bowel domain and minimal QOL decrements in the urinary domains at 24 months. Prospective randomized trials are needed to further examine these differences. Cancer 2013; 119: 1729-35. (C) 2013 American Cancer Society.
C1 [Gray, Phillip J.] Harvard Radiat Oncol Program, Boston, MA USA.
[Paly, Jonathan J.; Yeap, Beow Y.; Shipley, William U.; Zietman, Anthony L.; Efstathiou, Jason A.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Sanda, Martin G.] Beth Israel Deaconess Med Ctr, Div Urol Surg, Boston, MA 02215 USA.
[Sandler, Howard. M.] Cedars Sinai Med Ctr, Dept Radiat Oncol, Los Angeles, CA 90048 USA.
[Michalski, Jeff M.] Washington Univ, Sch Med, Dept Radiat Oncol, St Louis, MO USA.
[Talcott, James A.] Continuum Canc Care Consortium, New York, NY USA.
[Coen, John J.] Hartford Radiat Oncol Associates, Hartford, CT USA.
[Hamstra, Daniel A.] Univ Michigan, Med Ctr, Dept Radiat Oncol, Ann Arbor, MI 48109 USA.
[Hahn, Stephen M.; Bekelman, Justin E.] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19104 USA.
RP Efstathiou, JA (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 100 Blossom St,Cox 3, Boston, MA 02114 USA.
EM jefstathiou@partners.org
RI Sanda, Martin/B-2023-2015
FU Federal Share of program income earned by Massachusetts General Hospital
on Proton Therapy Research and Treatment Cente [C06 CA059267]; National
Institutes of Health (NIH) [R01CA95662, 1RC1CA146596, K07CA163616];
University of Pennsylvania
FX This work was supported by the Federal Share of program income earned by
Massachusetts General Hospital on C06 CA059267, Proton Therapy Research
and Treatment Center, by National Institutes of Health (NIH) grants
R01CA95662, 1RC1CA146596, and K07CA163616, and by internal funding from
the University of Pennsylvania.
NR 45
TC 36
Z9 36
U1 0
U2 14
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
J9 CANCER-AM CANCER SOC
JI Cancer
PD MAY 1
PY 2013
VL 119
IS 9
BP 1729
EP 1735
DI 10.1002/cncr.27956
PG 7
WC Oncology
SC Oncology
GA 133CM
UT WOS:000318115000018
PM 23436283
ER
PT J
AU Motiwala, SR
Januzzi, JL
AF Motiwala, Shweta R.
Januzzi, James L., Jr.
TI Using Biomarkers to "Guide" Heart Failure Management: Current
Perspectives and Future Directions
SO CARDIOLOGY IN REVIEW
LA English
DT Review
DE heart failure; biomarker; natriuretic peptide; therapeutic target;
outcomes
ID BRAIN-NATRIURETIC PEPTIDE; EMERGENCY-DEPARTMENT PRIDE; CARDIAC
RESYNCHRONIZATION THERAPY; VENTRICULAR SYSTOLIC DYSFUNCTION; PROGNOSTIC
VALUE; CARDIOVASCULAR EVENTS; ATRIAL-FIBRILLATION; LOOP DIURETICS; BNP;
PROBNP
AB Over the last several years, cardiac biomarkers have proven to be increasingly useful for disease screening, diagnosis, and prognostication. The most widely used biomarkers in heart failure (HF) are natriuretic peptides (NPs), which can aid in diagnosing HF, while also identifying those who are at higher risk of adverse outcomes. Multiple clinical trials have investigated the role of NPs as therapeutic targets for HF management, but results have been conflicting. Collectively, however, the data suggest that NP levels may be useful in guiding HF management and improving HF-related morbidity and mortality. In this review, we summarize existing data investigating the use of NPs as targets for outpatient HF therapy, focusing on differences in study designs and lessons learned from the results. Although the results for this approach are promising overall, we propose that additional well-designed prospective randomized controlled trials-specifically incorporating the relevant lessons learned from previous studies-are necessary to pivotally establish the role of NP-guided outpatient HF management.
C1 [Motiwala, Shweta R.; Januzzi, James L., Jr.] Massachusetts Gen Hosp, Div Cardiol, Dept Med, Boston, MA 02114 USA.
RP Januzzi, JL (reprint author), Massachusetts Gen Hosp, Div Cardiol, 32 Fruit St,Yawkey 5984, Boston, MA 02114 USA.
EM JJanuzzi@partners.org
FU Roche Diagnostics; Critical Diagnostics; Siemens; BRAHMS; BG Medicine
FX Dr. Januzzi has received grant support from Roche Diagnostics, Critical
Diagnostics, Siemens, BRAHMS, and BG Medicine. Dr. Motiwala declares no
conflicts of interest.
NR 42
TC 4
Z9 4
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1061-5377
J9 CARDIOL REV
JI Cardiol. Rev.
PD MAY-JUN
PY 2013
VL 21
IS 3
BP 127
EP 134
DI 10.1097/CRD.0b013e3182769073
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 126CT
UT WOS:000317590000003
PM 23032578
ER
PT J
AU Shimada, M
AF Shimada, Masako
TI Overview of Calpain-Mediated Regulation of Bone and Fat Mass in
Osteoblasts
SO CELL BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article
DE Calpain; Osteoblasts; Fat; Glucose metabolism; Cell cycle
ID SYMPATHETIC-NERVOUS-SYSTEM; HORMONE-RELATED PEPTIDE; SMALL-SUBUNIT GENE;
PARATHYROID-HORMONE; LEPTIN REGULATION; CELL-PROLIFERATION; TARGETED
DELETION; ENERGY-METABOLISM; NUCLEAR EXPORT; DIFFERENTIATION
AB The receptor for parathyroid hormone (PTH) and PTH-related peptide (PTH1R) belongs to the class II G protein-coupled receptor superfamily. The calpain small subunit encoded by the gene Capns1 is the second protein and the first enzyme identified by a yeast two-hybrid screen using the intracellular C-terminal tail of the rat PTH1R. The calpain regulatory small subunit forms a heterodimer with the calpain large catalytic subunit and modulates various cellular functions as a cysteine protease. To investigate a physiological role of the calpain small subunit in cells of the osteoblast lineage, we generated osteoblast-specific Capns1 knockout mouse models and characterized their bone phenotype. Molecular mechanisms by which calpain modulates cell proliferation of the osteoblast lineage were further examined in vitro. Moreover, we utilized the mutant mice as a disease model of osteoporosis accompanied with impaired bone resorptive function and suggested a possible clinical translation of our basic research finding.
C1 [Shimada, Masako] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
[Shimada, Masako] Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA.
RP Shimada, M (reprint author), Massachusetts Gen Hosp, Endocrine Unit, Thier 10,50 Blossom St, Boston, MA 02114 USA.
EM shimada@helix.mgh.harvard.edu
FU National Institutes of Health [R01 DK072102, P30 DK057521]; William F.
Milton Fund; MGH
FX This work was partially supported by the National Institutes of Health
grants R01 DK072102 and P30 DK057521, the William F. Milton Fund, and
the MGH interim support fund (to M. S.).
NR 35
TC 0
Z9 0
U1 0
U2 2
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1085-9195
J9 CELL BIOCHEM BIOPHYS
JI Cell Biochem. Biophys.
PD MAY
PY 2013
VL 66
IS 1
BP 23
EP 28
DI 10.1007/s12013-012-9393-7
PG 6
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 129RZ
UT WOS:000317860900004
PM 22821549
ER
PT J
AU Cosentino, C
Mostoslavsky, R
AF Cosentino, Claudia
Mostoslavsky, Raul
TI Metabolism, longevity and epigenetics
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Review
DE Acetylation; HDAC; Sirtuin; Aging; Metabolism; Senescence
ID DNA-DAMAGE RESPONSE; ATP-CITRATE LYASE; HISTONE DEACETYLASE SIRT6;
FATTY-ACID OXIDATION; CALORIE RESTRICTION; CELLULAR SENESCENCE;
LIFE-SPAN; CAENORHABDITIS-ELEGANS; SKELETAL-MUSCLE; HUMAN-CELLS
AB Metabolic homeostasis and interventions that influence nutrient uptake are well-established means to influence lifespan even in higher eukaryotes. Until recently, the molecular mechanisms explaining such an effect remained scantily understood. Sirtuins are a group of protein deacetylases that depend on the metabolic intermediate NAD(+) as a cofactor for their function. For this reason they sense metabolic stress and in turn function at multiple levels to exert proper metabolic adaptation. Among other things, sirtuins can perform as histone deacetylases inducing epigenetic changes to modulate transcription and DNA repair. Recent studies have indicated that beyond sirtuins, the activity of other chromatin modifiers, such as histone acetyl transferases, might also be tightly linked to the availability of their intermediate metabolite acetyl-CoA. We summarize current knowledge of the emerging concepts indicating close crosstalk between the epigenetic machineries able to sense metabolic stress, their adaptive metabolic responses and their potential role in longevity.
C1 [Cosentino, Claudia; Mostoslavsky, Raul] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
RP Mostoslavsky, R (reprint author), Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, 185 Cambridge St, Boston, MA 02114 USA.
EM rmostoslavsky@mgh.harvard.edu
FU NCI NIH HHS [R01 CA175727]; NIDDK NIH HHS [R01 DK088190]; NIGMS NIH HHS
[R01 GM093072]
NR 148
TC 16
Z9 18
U1 4
U2 55
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD MAY
PY 2013
VL 70
IS 9
BP 1525
EP 1541
DI 10.1007/s00018-013-1295-3
PG 17
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 126OE
UT WOS:000317626400004
PM 23467663
ER
PT J
AU Patti, ME
AF Patti, Mary-Elizabeth
TI Intergenerational programming of metabolic disease: evidence from human
populations and experimental animal models
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Review
DE Intergenerational; Metabolic disease; Epigenetics
ID HIGH-FAT DIET; LOW-BIRTH-WEIGHT; TRANSGENERATIONAL EPIGENETIC
INHERITANCE; SLOW GROWTH PERIOD; IN-UTERO EXPOSURE; DNA METHYLATION;
CAENORHABDITIS-ELEGANS; C. ELEGANS; GLUCOSE-INTOLERANCE; GENE-EXPRESSION
AB We are in the midst of unparalleled epidemics of obesity and type 2 diabetes-complex phenotypes originating at the intersection of genetic and environmental risk. As detailed in other chapters, evidence indicates that non-genetic, or environmental, risk may initiate during prenatal and early postnatal life [1]. Striking examples in humans include the association of low birth weight (LBW) and/or accelerated early growth with increased risk of insulin resistance, obesity, type 2 diabetes (T2DM), and cardiovascular disease (CVD), and the close relationship between maternal obesity or diabetes with childhood obesity. In this chapter, we will focus on the intriguing emerging data from both human and animal models that indicate that intrauterine and childhood exposures can also influence risk for diabetes and cardiovascular disease in subsequent generations. Understanding the mechanisms responsible for these effects is critical in order to develop effective metabolic and nutritional interventions to interrupt such vicious intergenerational cycles potentiating risk for metabolic disorders.
C1 Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02115 USA.
RP Patti, ME (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02115 USA.
EM mary.elizabeth.patti@joslin.harvard.edu
FU NIDDK NIH HHS [P30 DK036836]
NR 111
TC 28
Z9 28
U1 4
U2 39
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD MAY
PY 2013
VL 70
IS 9
BP 1597
EP 1608
DI 10.1007/s00018-013-1298-0
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 126OE
UT WOS:000317626400007
PM 23435955
ER
PT J
AU Smith, MJ
Esparza, S
Merker, VL
Muzikansky, A
Bredella, MA
Harris, GJ
Kassarjian, A
Cai, WL
Walker, JA
Mautner, VF
Plotkin, SR
AF Smith, Miriam J.
Esparza, Sonia
Merker, Vanessa L.
Muzikansky, Alona
Bredella, Miriam A.
Harris, Gordon J.
Kassarjian, Ara
Cai, Wenli
Walker, James A.
Mautner, Victor F.
Plotkin, Scott R.
TI Plasma S100 beta is not a useful biomarker for tumor burden in
neurofibromatosis
SO CLINICAL BIOCHEMISTRY
LA English
DT Article
DE S100 beta; Neurofibroma; Schwannoma; Biomarker; Neurofibromatosis
ID BRAIN; TYPE-1; GENE
AB Objectives: Neurofibromatosis 1 (NF1), NF2, and schwannomatosis are characterized by a predisposition to develop multiple neurofibromas and schwannomas. Currently, there is no blood test to estimate tumor burden in patients with these disorders. We explored whether S100 beta would act as a biomarker of tumor burden in NF since S100 beta is a classic immunohistochemical marker of astrocytes, oligodendrocytes and Schwann cells and a small study showed S100 beta concentrations correlate with the volume of vestibular schwannomas.
Design and methods: We calculated whole-body tumor burden in subjects with NF1, NF2, and schwannomatosis using whole-body MRI (WBMRI) and measured the concentration of Sloop in plasma using ELISA. We used chi-square tests and Spearman rank correlations to test the relationship between S100 beta levels and whole-body tumor burden.
Results: 127 consecutive patients were enrolled in the study (69 NF1 patients, 28 NF2 patients, and 30 schwannomatosis patients). The median age was 40 years, 43% were male, and median whole-body tumor volume was 26.9 mL. There was no relationship between the presence of internal tumors and the presence of detectable S100 beta in blood for the overall group or for individual diagnoses (p>0.05 by chi-square for all comparisons). Similarly, there was no correlation between whole-body tumor volume and S100 beta concentration for the overall group or for individual diagnoses (p>0.05 by Spearman for all comparisons).
Conclusions: Plasma S100 beta is not a useful biomarker for tumor burden in the neurofibromatoses. Further work is needed to identify a reliable biomarker of tumor burden in NF patients. (C) 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
C1 [Smith, Miriam J.; Esparza, Sonia; Merker, Vanessa L.; Walker, James A.; Plotkin, Scott R.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Esparza, Sonia; Merker, Vanessa L.; Plotkin, Scott R.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Muzikansky, Alona] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
[Bredella, Miriam A.; Cai, Wenli] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Kassarjian, Ara] Corades SL, Dept Radiol, Majadahonda, Spain.
[Walker, James A.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Mautner, Victor F.] Univ Hamburg Hosp, Dept Neurol, Hamburg, Germany.
RP Plotkin, SR (reprint author), Massachusetts Gen Hosp, Yawkey 9E,55 Fruit St, Boston, MA 02114 USA.
EM splotkin@partners.org
RI Smith, Miriam/J-4001-2015
OI Smith, Miriam/0000-0002-3184-0817
FU DOD [NF050202]; Center for Neurofibromatosis and Allied Disorders
FX Support for this project was provided by DOD NF050202 (SRP) and by the
Center for Neurofibromatosis and Allied Disorders. The funders had no
role in the study design; in the collection, analysis and interpretation
of data; in the writing of the report; or in the decision to submit the
article for publication.
NR 11
TC 2
Z9 2
U1 0
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-9120
J9 CLIN BIOCHEM
JI Clin. Biochem.
PD MAY
PY 2013
VL 46
IS 7-8
BP 698
EP 700
DI 10.1016/j.clinbiochem.2012.12.007
PG 3
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 129XU
UT WOS:000317878100026
PM 23261835
ER
PT J
AU Cuenca, AG
Gentile, LF
Lopez, MC
Ungaro, R
Liu, HZ
Xiao, WZ
Seok, J
Mindrinos, MN
Ang, D
Baslanti, TO
Bihorac, A
Efron, PA
Cuschieri, J
Warren, HS
Tompkins, RG
Maier, RV
Baker, HV
Moldawer, LL
AF Cuenca, Alex G.
Gentile, Lori F.
Lopez, M. Cecilia
Ungaro, Ricardo
Liu, Huazhi
Xiao, Wenzhong
Seok, Junhee
Mindrinos, Michael N.
Ang, Darwin
Baslanti, Tezcan Ozrazgat
Bihorac, Azra
Efron, Philip A.
Cuschieri, Joseph
Warren, H. Shaw
Tompkins, Ronald G.
Maier, Ronald V.
Baker, Henry V.
Moldawer, Lyle L.
CA Inflammation Host Response Injury
TI Development of a Genomic Metric That Can Be Rapidly Used to Predict
Clinical Outcome in Severely Injured Trauma Patients
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE blunt trauma; genomic composite score; microarray; validation
ID CONTROLLED MULTICENTER TRIAL; RECEPTOR FUSION PROTEIN; MULTIPLE ORGAN
FAILURE; GENE-EXPRESSION; SEVERE SEPSIS; HOSPITAL DEATHS; SEPTIC SHOCK;
LOCATION; PATTERN; TIME
AB Objective: Many patients have complicated recoveries following severe trauma due to the development of organ injury. Physiological and anatomical prognosticators have had limited success in predicting clinical trajectories. We report on the development and retrospective validation of a simple genomic composite score that can be rapidly used to predict clinical outcomes.
Design: Retrospective cohort study.
Setting: Multi-institutional level 1 trauma centers.
Patients: Data were collected from 167 severely traumatized (injury severity score >15) adult (18-55 yr) patients.
Methods: Microarray-derived genomic data obtained from 167 severely traumatized patients over 28 days were assessed for differences in messenger RNA abundance among individuals with different clinical trajectories. Once a set of genes was identified based on differences in expression over the entire study period, messenger RNA abundance from these subjects obtained in the first 24 hours was analyzed in a blinded fashion using a rapid multiplex platform, and genomic data reduced to a single metric.
Results: From the existing genomic dataset, we identified 63 genes whose leukocyte expression differed between an uncomplicated and complicated clinical outcome over 28 days. Using a multiplex approach that can quantitate messenger RNA abundance in less than 12 hours, we reassessed total messenger RNA abundance from the first 24 hours after trauma and reduced the genomic data to a single composite score using the difference from reference. This composite score showed good discriminatory capacity to distinguish patients with a complicated outcome (area under a receiver-operator curve, 0.811; p <0.001). This was significantly better than the predictive power of either Acute Physiology and Chronic Health Evaluation II or new injury severity score scoring systems.
Conclusions: A rapid genomic composite score obtained in the first 24 hours after trauma can retrospectively identify trauma patients who are likely to develop complicated clinical trajectories. A novel platform is described in which this genomic score can be obtained within 12 hours of blood collection, making it available for clinical decision making. (Crit Care Med 2013; 41:1175-1185)
C1 [Cuenca, Alex G.; Gentile, Lori F.; Ungaro, Ricardo; Liu, Huazhi; Ang, Darwin; Efron, Philip A.; Baker, Henry V.; Moldawer, Lyle L.] Univ Florida, Coll Med, Dept Surg, Gainesville, FL 32611 USA.
[Lopez, M. Cecilia; Baker, Henry V.] Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL USA.
[Xiao, Wenzhong; Seok, Junhee; Mindrinos, Michael N.] Stanford Genome Technol Ctr, Palo Alto, CA USA.
[Baslanti, Tezcan Ozrazgat; Bihorac, Azra] Univ Florida, Coll Med, Dept Anesthesiol, Gainesville, FL USA.
[Cuschieri, Joseph; Maier, Ronald V.] Univ Washington, Harborview Med Ctr, Dept Surg, Seattle, WA 98104 USA.
[Warren, H. Shaw] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Tompkins, Ronald G.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
RP Moldawer, LL (reprint author), Univ Florida, Coll Med, Dept Surg, Gainesville, FL 32611 USA.
EM moldawer@surgery.ufl.edu
RI Bihorac, Azra/Q-6500-2016;
OI Bihorac, Azra/0000-0002-5745-2863; Baker, Henry/0000-0002-8273-5320;
xiao, wenzhong/0000-0003-4944-6380
FU National Institute of General Medical Sciences [K23 GM-087709-03]; T32
training grant in burns and trauma from the National Institutes of
General Medical Sciences [T32 GM-008721-13]; National Research Service
Award [F32 GM-093665-01]; National Institutes of General Medical
Sciences, U.S. Public Health Service; [U54 GM-062119-10]
FX This work was supported, in part, by a contract (U54 GM-062119-10)
awarded by the National Institute of General Medical Sciences. Drs.
Cuenca and Gentile were supported by a T32 training grant (T32
GM-008721-13) in burns and trauma from the National Institutes of
General Medical Sciences. Dr. Cuenca was also supported by an individual
National Research Service Award (F32 GM-093665-01) awarded by the
National Institutes of General Medical Sciences, U.S. Public Health
Service. Dr. Bihorac was supported by an award (K23 GM-087709-03) from
the National Institute of General Medical Sciences.
NR 29
TC 25
Z9 26
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0090-3493
J9 CRIT CARE MED
JI Crit. Care Med.
PD MAY
PY 2013
VL 41
IS 5
BP 1175
EP 1185
DI 10.1097/CCM.0b013e318277131c
PG 11
WC Critical Care Medicine
SC General & Internal Medicine
GA 126ZB
UT WOS:000317661000020
PM 23388514
ER
PT J
AU Herring, AA
Ginde, AA
Fahimi, J
Alter, HJ
Maselli, JH
Espinola, JA
Sullivan, AF
Camargo, CA
AF Herring, Andrew A.
Ginde, Adit A.
Fahimi, Jahan
Alter, Harrison J.
Maselli, Judith H.
Espinola, Janice A.
Sullivan, Ashley F.
Camargo, Carlos A., Jr.
TI Increasing Critical Care Admissions From U.S. Emergency Departments,
2001-2009
SO CRITICAL CARE MEDICINE
LA English
DT Article; Proceedings Paper
CT Annual Meeting of the Society-for-Academic-Emergency-Medicine (SAEM)
CY JUN 01-06, 2011
CL Boston, MA
SP Soc Acad Emergency Med (SAEM)
DE critical care; crowding; emergency service; health care disparities;
hospital/workforce
ID LENGTH-OF-STAY; UNITED-STATES; PATIENT MORTALITY; SEVERE SEPSIS; ILL
PATIENTS; BED NUMBERS; TRENDS; COSTS; ASSOCIATION; OCCUPANCY
AB Objectives: Little is known about how recent system-wide increases in demand for critical care have affected U.S. emergency departments (EDs). This study describes changes in the amount of critical care provided in U.S. EDs between 2001 and 2009.
Design: Analysis of data from the National Hospital Ambulatory Medical Care Survey for the years 2001-2009.
Setting: National multistage probability sample of U.S. ED data. U.S. ED capacity was estimated using the National Emergency Department Inventory-United States.
Patients: ED patients admitted a critical care unit.
Interventions: None.
Measurements: Annual hours of ED-based critical care and annual number critical care ED visits. Clinical characteristics, demographics, insurance status, setting, geographic region, and ED length of stay for critically ill ED patients.
Main Results: Annual critical care unit admissions from U.S. EDs increased by 79% from 1.2 to 2.2 million. The proportion of all ED visits resulting in critical care unit admission increased from 0.9% to 1.6% (p(trend) < 0.001). Between 2001 and 2009, the median ED length of stay for critically ill patients increased from 185 to 245 minutes (+ 60 min; p(trend) < 0.02). For the aggregated years 2001-2009, ED length of stay for critical care visits was longer among black patients (12.6% longer) and Hispanic patients (14.8% longer) than among white patients, and one third of all critical care ED visits had an ED length of stay greater than 6 hrs. Between 2001 and 2009, total annual hours of critical care at U.S. EDs increased by 217% from 3.2 to 10.1 million (p(trend) < 0.001). The average daily amount of critical care provided in U.S. EDs tripled from 1.8 to 5.6 hours per ED per day.
Conclusions: The amount of critical care provided in U.S. EDs has increased substantially over the past decade, driven by increasing numbers of critical care ED visits and lengthening ED length of stay. Increased critical care burden will further stress an already overcapacity U.S. emergency care system. (Crit Care Med 2013; 41:1197-1204)
C1 [Herring, Andrew A.; Fahimi, Jahan; Alter, Harrison J.] Highland Hosp, Alameda Cty Med Ctr, Dept Emergency Med, Oakland, CA USA.
[Ginde, Adit A.] Univ Colorado, Sch Med, Dept Emergency Med, Aurora, CO USA.
[Maselli, Judith H.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Espinola, Janice A.; Sullivan, Ashley F.; Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA.
RP Herring, AA (reprint author), Highland Hosp, Alameda Cty Med Ctr, Dept Emergency Med, Oakland, CA USA.
EM aherring@acmedctr.org
RI bebarta, vikhyat/K-3476-2015; Siry, Bonnie/D-7189-2017
FU NIA NIH HHS [K23 AG040708]
NR 36
TC 27
Z9 27
U1 1
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0090-3493
J9 CRIT CARE MED
JI Crit. Care Med.
PD MAY
PY 2013
VL 41
IS 5
BP 1197
EP 1204
DI 10.1097/CCM.0b013e31827c086f
PG 8
WC Critical Care Medicine
SC General & Internal Medicine
GA 126ZB
UT WOS:000317661000022
PM 23591207
ER
PT J
AU Schell, JO
O'Hare, AM
AF Schell, Jane O.
O'Hare, Ann M.
TI Illness trajectories and their relevance to the care of adults with
kidney disease
SO CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
LA English
DT Review
DE communication; experience of illness; kidney disease; patient-centered;
trajectory
ID STAGE RENAL-DISEASE; LONG-TERM DIALYSIS; DECISION-MAKING; LAST YEAR;
OF-LIFE; FUNCTIONAL DECLINE; CANCER-PATIENTS; OLDER-ADULTS; END;
OUTCOMES
AB Purpose of review
Existing practice guidelines for chronic kidney disease advocate a stage-based approach to management, in which treatment recommendations are based largely on the severity of kidney disease, and future risk for adverse health outcomes. However, the course of kidney disease can vary widely among patients with similar levels of kidney function, and each patient will experience their illness in unique ways.
Recent findings
We summarize recent studies of patterns of kidney function over time among patients with chronic kidney disease, and discuss these findings in the context of relevant conceptual models of illness and communication. Although knowledge of disease severity can provide useful information on life expectancy and risk for future health events, an understanding of each patient's illness trajectory and their unique experience of illness is essential in supporting patient-centered care for patients with kidney disease. This information can be helpful in setting realistic expectations for the future, in communicating about prognosis and in aligning treatment decisions with each patient's goals and preferences.
Summary
We here explain how an understanding of illness trajectories may be useful in predicting and guiding care and decision-making in patients with kidney disease. We highlight the importance of competing disease trajectories, the heterogeneity in renal function trajectories among patients with kidney disease, and the variability in these trajectories over time in individual patients. We discuss how individual disease trajectories can shape each patient's experience of illness. Finally, we explain how an understanding of an individual patient's illness trajectory and experience of illness may be useful in guiding discussions about prognosis and treatment decisions and in supporting a patient-centered approach to care.
C1 [Schell, Jane O.] Univ Pittsburgh, Sch Med, Sect Palliat Care & Med Eth, UPMC, Pittsburgh, PA USA.
[Schell, Jane O.] Univ Pittsburgh, Sch Med, Renal Electrolyte Div, UPMC, Pittsburgh, PA USA.
[O'Hare, Ann M.] VA Puget Sound Healthcare Syst, Dept Med, Seattle, WA USA.
[O'Hare, Ann M.] Univ Washington, Seattle, WA 98195 USA.
RP Schell, JO (reprint author), UPMC Montefiore, Suite 933W,200 Lothrop St, Pittsburgh, PA 15213 USA.
EM schelljo@upmc.edu
FU National Institute on Aging; Centers for Disease Control; Department of
Veterans Affairs
FX A.M.O. receives research funding from the National Institute on Aging,
the Centers for Disease Control and the Department of Veterans Affairs
and royalties from UpToDate. These funding sources had no role in this
work. J.O.S. has no conflicts of interest to declare.
NR 45
TC 9
Z9 9
U1 3
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1062-4821
J9 CURR OPIN NEPHROL HY
JI Curr. Opin. Nephrol. Hypertens.
PD MAY
PY 2013
VL 22
IS 3
BP 316
EP 324
DI 10.1097/MNH.0b013e32835ffaaf
PG 9
WC Urology & Nephrology; Peripheral Vascular Disease
SC Urology & Nephrology; Cardiovascular System & Cardiology
GA 126YK
UT WOS:000317658800010
PM 23518464
ER
PT J
AU Platt, MY
DeLelys, ME
Preffer, FI
Sohani, AR
AF Platt, Mia Y.
DeLelys, Michelle E.
Preffer, Frederic I.
Sohani, Aliyah R.
TI Flow cytometry is of limited utility in the early identification of
"Double-hit" B-cell lymphomas
SO CYTOMETRY PART B-CLINICAL CYTOMETRY
LA English
DT Article
DE flow cytometry; double-hit lymphoma; MYC; BCL2; BCL6; CD20; CD19
ID EXPRESSION; MYC; IMMUNOPHENOTYPE; FEATURES
AB Background: B-cell lymphomas with concurrent translocations of MYC and BCL2 or BCL6, also known as double-hit lymphomas (DHL), are rare malignancies characterized by aggressive clinical behavior and poor prognosis. Previous reports suggest that decreased CD20 and/or CD19 expression by flow cytometry is relatively common in DHL and may help to identify cases requiring additional cytogenetic analysis. Methods: We conducted a retrospective analysis of 26 cases of DHL, and compared their flow cytometric characteristics to cases of Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). Cases were analyzed by four-color flow cytometry, and bivariate dot-plots were reviewed for light scatter characteristics, CD19, CD20, CD45, and surface light chain. Results: Relatively few DHL cases showed dim expression of CD19 or CD20, and statistically significant differences were found only in the frequency of dim CD19 expression between DHL and BL or DLBCL. Although concomitant dim CD19 and CD20 expression was exclusive to DHL, it was present in only a minority of cases. Conclusions: We conclude that although a subset of DHL expresses aberrant levels of CD19 and/or CD20 by flow cytometry, these findings are of limited utility in identifying cases requiring cytogenetic analysis due to their low frequency. Until more sensitive pathologic parameters can be identified and validated, the decision to perform cytogenetic analysis should rest on a combination of clinical, morphologic, and immunophenotypic features suggestive of high-grade, aggressive disease. (c) 2013 International Clinical Cytometry Society
C1 [Platt, Mia Y.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Platt, MY (reprint author), Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St,GRJ 245, Boston, MA 02114 USA.
EM myplatt@partners.org
NR 14
TC 12
Z9 12
U1 0
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4949
J9 CYTOM PART B-CLIN CY
JI Cytom. Part B-Clin. Cytom.
PD MAY
PY 2013
VL 84B
IS 3
BP 143
EP 148
DI 10.1002/cyto.b.21076
PG 6
WC Medical Laboratory Technology; Pathology
SC Medical Laboratory Technology; Pathology
GA 132BE
UT WOS:000318041900003
PM 23341189
ER
PT J
AU Nevis, K
Obregon, P
Walsh, C
Guner-Ataman, B
Burns, CG
Burns, CE
AF Nevis, Kathleen
Obregon, Pablo
Walsh, Conor
Guner-Ataman, Burcu
Burns, C. Geoffrey
Burns, Caroline E.
TI Tbx1 is Required for Second Heart Field Proliferation in Zebrafish
SO DEVELOPMENTAL DYNAMICS
LA English
DT Article
DE tbx1; zebrafish; heart; second heart field; cardiac
ID SYNDROME CANDIDATE GENE; BRANCHIAL ARCH MUTANTS; CARDIAC OUTFLOW TRACT;
PHARYNGEAL ARCH; CARDIOVASCULAR DEVELOPMENT; CARDIOMYOCYTE
DIFFERENTIATION; DELETION SYNDROME; DISTINCT PHASES; EXPRESSION; GROWTH
AB Background: The mammalian outflow tract (OFT) and primitive right ventricle arise by accretion of newly differentiated cells to the arterial pole of the heart tube from multi-potent progenitor cells of the second heart field (SHF). While mounting evidence suggests that the genetic pathways regulating SHF development are highly conserved in zebrafish, this topic remains an active area of investigation. Results: Here, we extend previous observations demonstrating that zebrafish tbx1 (van gogh, vgo) mutants show ventricular and OFT defects consistent with a conserved role in SHF-mediated cardiogenesis. Surprisingly, we reveal through double in situ analyses that tbx1 transcripts are excluded from cardiac progenitor cells and differentiated cardiomyocytes, suggesting a non-autonomous role in SHF development. Further, we find that the diminutive ventricle in vgo animals results from a 25% decrease in cardiomyocyte number that occurs subsequent to heart tube stages. Lastly, we report that although SHF progenitors are specified in the absence of Tbx1, they fail to be maintained due to compromised SHF progenitor cell proliferation. Conclusions: These studies highlight conservation of Tbx1 function in zebrafish SHF biology. Developmental Dynamics 242:550-559, 2013. (C) 2013 Wiley Periodicals, Inc.
C1 [Nevis, Kathleen; Obregon, Pablo; Walsh, Conor; Guner-Ataman, Burcu; Burns, C. Geoffrey; Burns, Caroline E.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA.
[Nevis, Kathleen; Obregon, Pablo; Walsh, Conor; Guner-Ataman, Burcu; Burns, C. Geoffrey; Burns, Caroline E.] Harvard Univ, Sch Med, Boston, MA USA.
[Burns, C. Geoffrey; Burns, Caroline E.] Harvard Stem Cell Inst, Cambridge, MA USA.
RP Burns, CG (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA.
EM gburns@cvrc.mgh.harvard.edu; cburns6@partners.org
FU National Institutes of Health [5F32HL110627, 5R01HL096816,
5R01HL111179]; American Heart Association [10POST4170037,
10GRNT4270021]; Harvard Stem Cell Institute; March of Dimes Foundation
[1-FY12-467]; National Heart Lung and Blood Institute [5R01HL-096816]
FX Grant sponsor: National Institutes of Health; Grant numbers:
5F32HL110627; 5R01HL096816; 5R01HL111179; Grant sponsor: American Heart
Association; Grant numbers: 10POST4170037, 10GRNT4270021; Grant sponsor:
Harvard Stem Cell Institute; Grant sponsor: March of Dimes Foundation;
Grant number: 1-FY12-467.; We thank L. Zon and I. Scott for providing
zebrafish strains; J Holzschuh for providing a detailed Click-iT EdU
labeling protocol; Fred Keeley for providing Elastin2 anti-serum; and
the Developmental Studies Hybridoma Bank under the auspices of the NICHD
and maintained by the University of Iowa, Department of Biological
Sciences, Iowa City, IA 52242, for providing the MF20 antibody. This
work was supported by awards from the National Institutes of Health to
K.N. (5F32HL110627); the American Heart Association to B. G-A.
(10POST4170037); the American Heart Association (Grant in Aid no.
10GRNT4270021); the Harvard Stem Cell Institute (Seed Grant), and the
National Heart Lung and Blood Institute (5R01HL-096816) to C. G. B; and
the Harvard Stem Cell Institute (Young Investigator Award and
Cardiovascular Program Award), National Heart Lung and Blood Institute
(5R01HL111179), and the March of Dimes Foundation (1-FY12-467) to C. E.
B.
NR 49
TC 10
Z9 10
U1 2
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1058-8388
J9 DEV DYNAM
JI Dev. Dyn.
PD MAY
PY 2013
VL 242
IS 5
BP 550
EP 559
DI 10.1002/dvdy.23928
PG 10
WC Anatomy & Morphology; Developmental Biology
SC Anatomy & Morphology; Developmental Biology
GA 131PG
UT WOS:000318005000012
PM 23335360
ER
PT J
AU Hollebecque, A
Postel-Vinay, S
Verweij, J
Demetri, GD
Flaherty, K
Bedard, P
Soria, JC
AF Hollebecque, Antoine
Postel-Vinay, Sophie
Verweij, Jaap
Demetri, George D.
Flaherty, Keith
Bedard, Philippe
Soria, Jean-Charles
TI Modifying phase I methodology to facilitate enrolment of molecularly
selected patients
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE Drug development; Trial methodology; Clinical trials; Phase I studies
ID ADVERSE DRUG-REACTIONS; CELL LUNG-CANCER; PERSONALIZED MEDICINE;
SURVIVAL; TUMORS; SCALE; VEMURAFENIB; PERFORMANCE; INHIBITION;
CHALLENGES
AB Over the last decade, the focus of anticancer drug development has shifted from empirical cytotoxic chemotherapy to mechanism-defined molecularly targeted agents, for which appropriate patient selection at the earliest possible point in drug development is rational and critical to success. With the recently legislated "breakthrough product" definition in the U. S., it may be possible to plan a single trial for registration purposes to confirm a major clinical effect observed in phase I. However, most phase I trial designs remain excessively conservative and are driven by criteria developed for cytotoxic agents with the goal of identifying a "maximum tolerable dose" with acceptable risks to patients. This focus on empiric "most dose with acceptable risk" may be misguided for mechanism-targeting new agents, and this could lead to unnecessary delays, increased costs and even higher risk of missing important signals of activity and benefit. There is a compelling need to modify phase I trial designs to facilitate enrichment in molecularly selected patients who are the most likely to harbour disease driven by the targeted pathway and to avoid unjustified exclusions based on obsolete criteria so that the right subset of patients can participate. After discussion of the main inconsistencies of current phase I designs, we propose a new strategy to facilitate the inclusion of molecularly selected patients, in order to accelerate and mitigate risks in drug development as well as to increase the chance of benefit among trial participants. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Hollebecque, Antoine; Postel-Vinay, Sophie; Soria, Jean-Charles] Univ Paris 11, SITEP, Inst Gustave Roussy, Villejuif, France.
[Verweij, Jaap] Erasmus Univ, Dept Med Oncol, Med Ctr, Dr Daniel Den Hoed Canc Ctr, NL-3075 EA Rotterdam, Netherlands.
[Demetri, George D.] Dana Farber Canc Inst, Ludwig Ctr Cell Signaling & Clin Discovery, Boston, MA 02215 USA.
[Demetri, George D.] Harvard Univ, Sch Med, Boston, MA 02215 USA.
[Flaherty, Keith] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Bedard, Philippe] Univ Toronto, Dept Med, Princess Margaret Hosp, Univ Hlth Network,Div Med Oncol & Hematol, Toronto, ON, Canada.
RP Soria, JC (reprint author), Inst Gustave Roussy, SITEP, 114 Rue Edouard Vaillant, F-94805 Villejuif, France.
EM soria@igr.fr
RI Hollebecque, Antoine/M-2695-2013
OI Hollebecque, Antoine/0000-0003-2869-7551
NR 27
TC 8
Z9 8
U1 0
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
J9 EUR J CANCER
JI Eur. J. Cancer
PD MAY
PY 2013
VL 49
IS 7
BP 1515
EP 1520
DI 10.1016/j.ejca.2012.12.012
PG 6
WC Oncology
SC Oncology
GA 125TG
UT WOS:000317563600001
PM 23333057
ER
PT J
AU Sharma, S
Zhu, L
Davoodi, M
Harris-White, M
Lee, JM
St John, M
Salgia, R
Dubinett, S
AF Sharma, Sherven
Zhu, Li
Davoodi, Michael
Harris-White, Marni
Lee, Jay M.
St John, Maie
Salgia, Ravi
Dubinett, Steven
TI TLR3 agonists and proinflammatory antitumor activities
SO EXPERT OPINION ON THERAPEUTIC TARGETS
LA English
DT Editorial Material
DE cancer; immune suppression; immune therapy; TLR3 agonists
ID TOLL-LIKE RECEPTOR-3; POLYRIBOINOSINIC-POLYRIBOCYTIDYLIC ACID;
POLYINOSINIC-POLYCYTIDYLIC ACID; CANCER-CELLS; DENDRITIC CELLS; I
INTERFERONS; APOPTOSIS; TRIAL
AB Although tumor growth leads to inflammatory responses, the immune system develops tolerance to cancer. One way to break host tolerance to tumors is to activate key immune effector activities. Toward this end, various adjuvants are under investigation in an effort to harness the immune system to overcome tolerance to tumor-associated self-antigens. There is enthusiasm for the use of specific ligands for toll-like receptor 3 (TLR3) that play a key role in the innate immune system. TLR3 agonists serve as immune adjuvants because they potently induce innate immune responses by activating dendritic cell ( DC) maturation and inflammatory cytokine secretion. These activities facilitate the bridge between the innate and adaptive immune systems promoting the expansion of cytotoxic T lymphocytes (CTL) that destroy cancer cells. TLR3 agonists either alone or in combination with tumor antigens have shown success in terms of enhancing immune responses and eliciting antitumor activity in preclinical models. However, TLR3 agonists can also impact regulatory cells that dampen immune responses. Thus, immune strategies that utilize TLR3 agonists should consider the relative induction of suppressive as well as beneficial antitumor immune activities. Herein, we summarize the TLR3 agonists that will hopefully come to clinical fruition.
C1 [Sharma, Sherven; Zhu, Li; Davoodi, Michael; Lee, Jay M.; St John, Maie; Dubinett, Steven] Univ Calif Los Angeles, Dept Med, Div Pulm & Crit Care Med, Lung Canc Res Program, Los Angeles, CA 90024 USA.
[Sharma, Sherven; Lee, Jay M.; St John, Maie; Dubinett, Steven] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
[Sharma, Sherven; Zhu, Li; Davoodi, Michael; Harris-White, Marni; Dubinett, Steven] Vet Affairs Greater Los Angeles Healthcare Syst, Mol Gene Med Lab, Los Angeles, CA USA.
[Salgia, Ravi] Univ Chicago, Dept Med, Chicago, IL 60637 USA.
RP Sharma, S (reprint author), Univ Calif Los Angeles, Dept Med, Vet Affairs Greater Los Angeles Healthcare Syst, Lung Canc Program,Div Pulm & Crit Care Med,Mol Ge, Los Angeles, CA 90024 USA.
EM ssharma@mednet.ucla.edu
FU NCATS NIH HHS [UL1 TR000124, UL1TR000124]; NCI NIH HHS [R01 CA085686,
P50 CA090388, P50 CA90388, R01 CA126944, R01 CA95686]; NIDCR NIH HHS
[K23 DE021193]
NR 17
TC 6
Z9 6
U1 0
U2 9
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1472-8222
J9 EXPERT OPIN THER TAR
JI Expert Opin. Ther. Targets
PD MAY
PY 2013
VL 17
IS 5
BP 481
EP 483
DI 10.1517/14728222.2013.781585
PG 3
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 130RA
UT WOS:000317935400002
PM 23506058
ER
PT J
AU Wu, MX
Ustyugova, IV
Han, LP
Akilov, OE
AF Wu, Mei X.
Ustyugova, Irina V.
Han, Liping
Akilov, Oleg E.
TI Immediate early response gene X-1, a potential prognostic biomarker in
cancers
SO EXPERT OPINION ON THERAPEUTIC TARGETS
LA English
DT Review
DE apoptosis; biomarkers; cancer prognosis; IF1; immediate early response
gene X-1
ID NF-KAPPA-B; MULTIPLE-MYELOMA CELLS; UP-REGULATION; MYELODYSPLASTIC
SYNDROME; PANCREATIC-CANCER; INDUCED APOPTOSIS; BONE-MARROW; F1FO-ATPASE
INHIBITOR; IEX-1 EXPRESSION; CARCINOMA CELLS
AB Introduction: The immediate early response gene X-1 (IEX-1) plays a pivotal role in the regulation of cell apoptosis, proliferation, differentiation and metabolism. Deregulation of IEX-1 expression has been confirmed in multiple cancers in humans, in association with either poor or better prognosis depending on the type and progression stages of the cancer.
Areas covered: This review summarizes clinical studies of altered IEX-1 expression in ovarian, pancreatic, blood, breast and colorectal cancers, lymphoma and myeloma. The authors also outline the current understandings of the complex functions of IEX-1 gained from studies with animal models and tumor cell lines so as to help us comprehend the significance of the clinical findings.
Expert opinion: IEX-1 holds great promise to be a valuable biomarker, either alone or in combination with other genes, for monitoring progression of some cancers. IEX-1 expression is highly sensitive to environmental cues and distinct between normal and cancer cells. However, use of IEX-1 as a biomarker remains a significant challenge because too little is understood about the mechanism underlying the diverse activities of IEX-1 and a standardized clinical assay for IEX-1 detection and validation of clinical results across different studies are still critically lacking.
C1 [Wu, Mei X.; Ustyugova, Irina V.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Wu, Mei X.; Ustyugova, Irina V.] Harvard Univ, Sch Med, Wellman Ctr Photomed, Dept Dermatol, Boston, MA 02114 USA.
[Han, Liping] Henan Univ, Affiliated Hosp 1, Dept Obstet & Gynaecol, Zhengzhou, Peoples R China.
[Akilov, Oleg E.] Univ Pittsburgh, Med Ctr, Dept Dermatol, Pittsburgh, PA 15213 USA.
[Ustyugova, Irina V.] Sanofi Pasteur Biol Co, Cambridge, MA 02139 USA.
RP Wu, MX (reprint author), Massachusetts Gen Hosp, Edwards 222,50 Blossom St, Boston, MA 02114 USA.
EM mwu2@partners.org
FU National Institutes of Health (NIH) [AI050822, CA158756, AI070785];
Senior Research Award from the Crohn's & Colitis Foundation of America
FX This work is supported in part by National Institutes of Health (NIH)
grants AI050822, CA158756 and AI070785 and a Senior Research Award from
the Crohn's & Colitis Foundation of America (to M.X.W.).
NR 79
TC 9
Z9 9
U1 0
U2 8
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1472-8222
J9 EXPERT OPIN THER TAR
JI Expert Opin. Ther. Targets
PD MAY
PY 2013
VL 17
IS 5
BP 593
EP 606
DI 10.1517/14728222.2013.768234
PG 14
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 130RA
UT WOS:000317935400011
PM 23379921
ER
PT J
AU Kashyap, PC
Marcobal, A
Ursell, LK
Larauche, M
Duboc, H
Earle, KA
Sonnenburg, ED
Ferreyra, JA
Higginbottom, SK
Million, M
Tache, Y
Pasricha, PJ
Knight, R
Farrugia, G
Sonnenburg, JL
AF Kashyap, Purna C.
Marcobal, Angela
Ursell, Luke K.
Larauche, Muriel
Duboc, Henri
Earle, Kristen A.
Sonnenburg, Erica D.
Ferreyra, Jessica A.
Higginbottom, Steven K.
Million, Mulugeta
Tache, Yvette
Pasricha, Pankaj J.
Knight, Rob
Farrugia, Gianrico
Sonnenburg, Justin L.
TI Complex Interactions Among Diet, Gastrointestinal Transit, and Gut
Microbiota in Humanized Mice
SO GASTROENTEROLOGY
LA English
DT Article
DE Dietary Carbohydrates; Microbiome; Metabolomics; Serotonin
ID INTESTINE; HEALTH; INFLAMMATION; DISORDERS; SEROTONIN; BACTERIA;
DISEASE; SYSTEM; TRACT; FIBER
AB BACKGROUND & AIMS: Diet has major effects on the intestinal microbiota, but the exact mechanisms that alter complex microbial communities have been difficult to elucidate. In addition to the direct influence that diet exerts on microbes, changes in microbiota composition and function can alter host functions such as gastrointestinal (GI) transit time, which in turn can further affect the microbiota. METHODS: We investigated the relationships among diet, GI motility, and the intestinal microbiota using mice that are germ-free (GF) or humanized (ex-GF mice colonized with human fecal microbiota). RESULTS: Analysis of gut motility revealed that humanized mice fed a standard polysaccharide-rich diet had faster GI transit and increased colonic contractility compared with GF mice. Humanized mice with faster transit due to administration of polyethylene glycol or a nonfermentable cellulose-based diet had similar changes in gut microbiota composition, indicating that diet can modify GI transit, which then affects the composition of the microbial community. However, altered transit in mice fed a diet of fermentable fructooligosaccharide indicates that diet can change gut microbial function, which can affect GI transit. CONCLUSIONS: Based on studies in humanized mice, diet can affect GI transit through microbiota-dependent or microbiota-independent pathways, depending on the type of dietary change. The effect of the microbiota on transit largely depends on the amount and type (fermentable vs nonfermentable) of polysaccharides present in the diet. These results have implications for disorders that affect GI transit and gut microbial communities, including irritable bowel syndrome and inflammatory bowel disease.
C1 [Kashyap, Purna C.; Marcobal, Angela; Earle, Kristen A.; Sonnenburg, Erica D.; Ferreyra, Jessica A.; Higginbottom, Steven K.; Sonnenburg, Justin L.] Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA.
[Pasricha, Pankaj J.] Stanford Univ, Sch Med, Dept Gastroenterol & Hepatol, Stanford, CA 94305 USA.
[Kashyap, Purna C.; Farrugia, Gianrico] Mayo Clin, Dept Gastroenterol & Hepatol, Rochester, MN USA.
[Ursell, Luke K.; Million, Mulugeta; Knight, Rob] Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA.
[Larauche, Muriel; Duboc, Henri; Tache, Yvette] Univ Calif Los Angeles, Dept Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90024 USA.
[Larauche, Muriel; Duboc, Henri; Tache, Yvette] Univ Calif Los Angeles, Div Digest Dis, Ctr Neurobiol Stress, Los Angeles, CA USA.
[Larauche, Muriel; Duboc, Henri; Tache, Yvette] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Knight, Rob] Univ Colorado, Howard Hughes Med Inst, Boulder, CO 80309 USA.
RP Sonnenburg, JL (reprint author), Stanford Univ, Sch Med, Dept Microbiol & Immunol, 299 Campus Dr,Fairchild Bldg D315, Stanford, CA 94305 USA.
EM jsonnenburg@stanford.edu
RI Knight, Rob/D-1299-2010;
OI Larauche, Muriel/0000-0003-3320-3675
FU National Institutes of Health [R01DK085025]; Digestive Diseases Center
[DK-41301, K01 DK088937]
FX Supported by National Institutes of Health grant R01DK085025 (to
J.L.S.), Digestive Diseases Center grant DK-41301 (Animal Models Core;
to Y.T., M. M.) and K01 DK088937 (M.L.).
NR 32
TC 88
Z9 90
U1 14
U2 124
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD MAY
PY 2013
VL 144
IS 5
BP 967
EP 977
DI 10.1053/j.gastro.2013.01.047
PG 11
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 129BR
UT WOS:000317813900026
PM 23380084
ER
PT J
AU Hoshida, Y
Villanueva, A
Sangiovanni, A
Sole, M
Hur, C
Andersson, KL
Chung, RT
Gould, J
Kojima, K
Gupta, S
Taylor, B
Crenshaw, A
Gabriel, S
Minguez, B
Iavarone, M
Friedman, SL
Colombo, M
Llovet, JM
Golub, TR
AF Hoshida, Yujin
Villanueva, Augusto
Sangiovanni, Angelo
Sole, Manel
Hur, Chin
Andersson, Karin L.
Chung, Raymond T.
Gould, Joshua
Kojima, Kensuke
Gupta, Supriya
Taylor, Bradley
Crenshaw, Andrew
Gabriel, Stacey
Minguez, Beatriz
Iavarone, Massimo
Friedman, Scott L.
Colombo, Massimo
Llovet, Josep M.
Golub, Todd R.
TI Prognostic Gene Expression Signature for Patients With Hepatitis
C-Related Early-Stage Cirrhosis
SO GASTROENTEROLOGY
LA English
DT Article
DE Liver Cancer Prevention; Early Detection; Screening; Whole Genome Gene
Expression Profiling
ID GROWTH-FACTOR GENE; HEPATOCELLULAR-CARCINOMA; UNITED-STATES; FUNCTIONAL
POLYMORPHISM; INCREASED SURVIVAL; FIBROSIS; SURVEILLANCE; RISK;
CHALLENGES; STRATEGIES
AB BACKGROUND & AIMS: Cirrhosis affects 1% to 2% of the world population and is the major risk factor for hepatocellular carcinoma (HCC). Hepatitis C cirrhosis-related HCC is the most rapidly increasing cause of cancer death in the United States. Noninvasive methods have been developed to identify patients with asymptomatic early-stage cirrhosis, increasing the burden of HCC surveillance, but biomarkers are needed to identify patients with cirrhosis who are most in need of surveillance. We investigated whether a liver-derived 186-gene signature previously associated with outcomes of patients with HCC is prognostic for patients with newly diagnosed cirrhosis but without HCC. METHODS: We performed gene expression profile analysis of formalin-fixed needle biopsy specimens from the livers of 216 patients with hepatitis C-related early-stage (Child-Pugh class A) cirrhosis who were prospectively followed up for a median of 10 years at an Italian center. We evaluated whether the 186-gene signature was associated with death, progression of cirrhosis, and development of HCC. RESULTS: Fifty-five (25%), 101 (47%), and 60 (28%) patients were classified as having poor-, intermediate-, and good-prognosis signatures, respectively. In multivariable Cox regression modeling, the poor-prognosis signature was significantly associated with death (P = .004), progression to advanced cirrhosis (P < .001), and development of HCC (P = .009). The 10-year rates of survival were 63%, 74%, and 85% and the annual incidence of HCC was 5.8%, 2.2%, and 1.5% for patients with poor-, intermediate-, and good-prognosis signatures, respectively. CONCLUSIONS: A 186-gene signature used to predict outcomes of patients with HCC is also associated with outcomes of patients with hepatitis C-related early-stage cirrhosis. This signature might be used to identify patients with cirrhosis in most need of surveillance and strategies to prevent the development of HCC.
C1 [Hoshida, Yujin; Kojima, Kensuke; Minguez, Beatriz; Friedman, Scott L.; Llovet, Josep M.] Icahn Sch Med Mt Sinai, Div Liver Dis, Mt Sinai Liver Canc Program, Dept Med,Tisch Canc Inst, New York, NY 10029 USA.
[Villanueva, Augusto; Llovet, Josep M.] Hosp Clin Barcelona, HCC Translat Res Lab, Inst Invest Biomed August Pi I Sunyer, Ctr Invest Red Enfermedades Hepat & Digest, Barcelona, Spain.
[Sole, Manel] Hosp Clin Barcelona, Ctr Invest Red Enfermedades Hepat & Digest, Inst Invest Biomed August Pi I Sunyer, Dept Pathol,Barcelona Clin Liver Canc Grp, Barcelona, Spain.
[Sangiovanni, Angelo; Iavarone, Massimo; Colombo, Massimo] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, M&A Migliavacca Ctr Liver Dis, Milan, Italy.
[Sangiovanni, Angelo; Iavarone, Massimo; Colombo, Massimo] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Gastroenterol 1, Milan, Italy.
[Hur, Chin; Andersson, Karin L.; Chung, Raymond T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Gould, Joshua; Gupta, Supriya; Taylor, Bradley; Crenshaw, Andrew; Gabriel, Stacey; Golub, Todd R.] Broad Inst Massachusetts Inst Technol & Harvard U, Cambridge, MA USA.
[Llovet, Josep M.] Inst Catalana Recerca & Estudis Avancats, Barcelona, Spain.
[Golub, Todd R.] Harvard Univ, Sch Med, Childrens Hosp, Boston, MA USA.
[Golub, Todd R.] Howard Hughes Med Inst, Chevy Chase, MD USA.
RP Hoshida, Y (reprint author), Leon & Norma Hess Ctr Sci & Med, Div Liver Dis, Mt Sinai Liver Canc Program, Icahn Sch Med Mt Sinai,Dept Med,Tisch Canc Inst, 1470 Madison Ave, New York, NY 10029 USA.
EM yujin.hoshida@mssm.edu; josep.llovet@mssm.edu; golub@broadinstitute.org
RI Augusto, Villanueva/F-9378-2012; Minguez, Beatriz/N-4456-2014; Llovet,
Josep M /D-4340-2014;
OI Augusto, Villanueva/0000-0003-3585-3727; Minguez,
Beatriz/0000-0002-7276-9666; Llovet, Josep M /0000-0003-0547-2667; Hur,
Chin/0000-0002-2819-7576
FU National Institutes of Health [DK37340, DK56601, AA017067,
1R01DK076986-01, DK078772, AI069939]; Asociacion Espanola Contra el
Cancer; European Commission-FP7 Framework (HEPTROMIC) [259744]; Spanish
National Health Institute [SAF-2010-16055]; Howard Hughes Medical
Institute; Samuel Waxman Cancer Research Foundation; European
Association for the Study of the Liver (Sheila Sherlock Fellowship)
FX Supported by the National Institutes of Health (DK37340, DK56601, and
AA017067 to S. L. F.; 1R01DK076986-01 to J.M.L.; and DK078772 and
AI069939 to R. T. C.), the Asociacion Espanola Contra el Cancer (to
J.M.L.), the European Commission-FP7 Framework (HEPTROMIC, No. 259744 to
J.M.L. and Y.H.), the Spanish National Health Institute (SAF-2010-16055
to J.M.L.), the Howard Hughes Medical Institute (to T. R. G.), the
Samuel Waxman Cancer Research Foundation (to J.M.L.), and the European
Association for the Study of the Liver (Sheila Sherlock Fellowship to
A.V.).
NR 39
TC 52
Z9 54
U1 1
U2 6
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD MAY
PY 2013
VL 144
IS 5
BP 1024
EP 1030
DI 10.1053/j.gastro.2013.01.021
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 129BR
UT WOS:000317813900031
PM 23333348
ER
PT J
AU Lindgren, AM
Hoyos, T
Talkowski, ME
Hanscom, C
Blumenthal, I
Chiang, C
Ernst, C
Pereira, S
Ordulu, Z
Clericuzio, C
Drautz, JM
Rosenfeld, JA
Shaffer, LG
Velsher, L
Pynn, T
Vermeesch, J
Harris, DJ
Gusella, JF
Liao, EC
Morton, CC
AF Lindgren, Amelia M.
Hoyos, Tatiana
Talkowski, Michael E.
Hanscom, Carrie
Blumenthal, Ian
Chiang, Colby
Ernst, Carl
Pereira, Shahrin
Ordulu, Zehra
Clericuzio, Carol
Drautz, Joanne M.
Rosenfeld, Jill A.
Shaffer, Lisa G.
Velsher, Lea
Pynn, Tania
Vermeesch, Joris
Harris, David J.
Gusella, James F.
Liao, Eric C.
Morton, Cynthia C.
TI Haploinsufficiency of KDM6A is associated with severe psychomotor
retardation, global growth restriction, seizures and cleft palate
SO HUMAN GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; HISTONE LYSINE METHYLATION; KABUKI SYNDROME;
SOTOS-SYNDROME; GENE-EXPRESSION; MENTAL-RETARDATION; BIPOLAR DISORDER;
27 DEMETHYLASE; ACTIVE GENES; MOUSE-BRAIN
AB We describe a female subject (DGAP100) with a 46,X,t(X;5)(p11.3;q35.3)inv(5)(q35.3q35.1)dn, severe psychomotor retardation with hypotonia, global postnatal growth restriction, microcephaly, globally reduced cerebral volume, seizures, facial dysmorphia and cleft palate. Fluorescence in situ hybridization and whole-genome sequencing demonstrated that the X chromosome breakpoint disrupts KDM6A in the second intron. No genes were directly disrupted on chromosome 5. KDM6A is a histone 3 lysine 27 demethylase and a histone 3 lysine 4 methyltransferase. Expression of KDM6A is significantly reduced in DGAP100 lymphoblastoid cells compared to control samples. We identified nine additional cases with neurodevelopmental delay and various other features consistent with the DGAP100 phenotype with copy number variation encompassing KDM6A from microarray databases. We evaluated haploinsufficiency of kdm6a in a zebrafish model. kdm6a is expressed in the pharyngeal arches and ethmoid plate of the developing zebrafish, while a kdm6a morpholino knockdown exhibited craniofacial defects. We conclude KDM6A dosage regulation is associated with severe and diverse structural defects and developmental abnormalities.
C1 [Lindgren, Amelia M.; Pereira, Shahrin; Ordulu, Zehra; Morton, Cynthia C.] Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA.
[Hoyos, Tatiana; Liao, Eric C.] Harvard Univ, Massachusetts Gen Hosp, Dept Plast & Reconstruct Surg, Ctr Regenerat Med,Harvard Stem Cell Inst,Med Sch, Boston, MA 02115 USA.
[Talkowski, Michael E.; Hanscom, Carrie; Blumenthal, Ian; Chiang, Colby; Ernst, Carl; Gusella, James F.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Talkowski, Michael E.; Gusella, James F.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA.
[Talkowski, Michael E.; Gusella, James F.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
[Talkowski, Michael E.; Gusella, James F.; Morton, Cynthia C.] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
[Clericuzio, Carol; Drautz, Joanne M.] Univ New Mexico, Dept Pediat Genet, Albuquerque, NM 87131 USA.
[Rosenfeld, Jill A.; Shaffer, Lisa G.] PerkinElmer Inc, Signature Genom Labs, Spokane, WA USA.
[Velsher, Lea; Pynn, Tania] Northwestern Ontario Reg Genet Program, Thunder Bay, ON, Canada.
[Vermeesch, Joris] Univ Louvain, Gasthuisberg, Netherlands.
[Harris, David J.] Harvard Univ, Sch Med, Boston Childrens Hosp, Div Genet, Boston, MA 02115 USA.
[Gusella, James F.] Autism Consortium Boston, Boston, MA USA.
[Morton, Cynthia C.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Morton, Cynthia C.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Morton, CC (reprint author), Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, New Res Bldg,Room 160D,77 Ave Louis Pasteur, Boston, MA 02115 USA.
EM cmorton@partners.org
OI Chiang, Colby/0000-0002-4113-6065
FU National Institutes of Health [PO1GM061354, HD065286, MH095867];
National Institute of General Medical Sciences, and March of Dimes and
Shriners Hospitals for Children
FX We would like to thank DGAP100 and her family for participating in our
research study and all of the healthcare professionals that contributed
to this effort. We would also like to thank Mary Anne Anderson for her
technical assistance at the Massachusetts General Hospital Genomics Core
Facility in the Center for Human Genetic Research, Tammy Gillis and the
MGH NextGen Sequencing Core, and the Cytogenetics Core of Dana Farber
Harvard Cancer Center (P30 CA006516). This work was supported by
PO1GM061354 (CCM), HD065286 (JFG) and MH095867 (MET) from the National
Institutes of Health and the National Institute of General Medical
Sciences, and March of Dimes and Shriners Hospitals for Children (ECL).
NR 67
TC 16
Z9 16
U1 0
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-6717
J9 HUM GENET
JI Hum. Genet.
PD MAY
PY 2013
VL 132
IS 5
BP 537
EP 552
DI 10.1007/s00439-013-1263-x
PG 16
WC Genetics & Heredity
SC Genetics & Heredity
GA 127IG
UT WOS:000317691100005
PM 23354975
ER
PT J
AU Najavits, LM
Hien, D
AF Najavits, Lisa M.
Hien, Denise
TI Helping Vulnerable Populations: A Comprehensive Review of the Treatment
Outcome Literature on Substance Use Disorder and PTSD
SO JOURNAL OF CLINICAL PSYCHOLOGY
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL;
SEEKING-SAFETY THERAPY; COGNITIVE-BEHAVIORAL TREATMENT; INCARCERATED
WOMEN; EMPOWERMENT-MODEL; EXPOSURE THERAPY; TRAUMA TREATMENT; ABUSE
TREATMENT; DEPENDENCE
AB We review treatment studies for comorbid substance use disorder (SUD) and posttraumatic stress disorder (PTSD). Results show positive outcomes on multiple domains. Most models had more effect on PTSD than SUD, suggesting SUD is harder to treat. Seeking Safety (SS) is the most studied model. It shows positive outcomes, and is the only treatment outperforming a control on both PTSD and SUD. Partial-dose SS had more mixed results than the full dose. This first-generation of PTSD/SUD research addresses complex samples excluded from gold standard PTSD-alone literature. Treatments for PTSD/SUD are generally longer than PTSD-alone treatments and present-focused, emphasizing stabilization and coping. The few models with past-focused (exposure-based) components also incorporated present-focused approaches for these vulnerable clients. We discuss public health perspectives to advance the field.
C1 [Najavits, Lisa M.] Boston Univ, Sch Med, Vet Affairs Boston Healthcare Syst, Boston, MA 02215 USA.
[Hien, Denise] CUNY City Coll, New York, NY USA.
RP Najavits, LM (reprint author), VA Boston Healthcare Syst, 150 South Huntington Ave,116-B, Boston, MA 02130 USA.
EM lisa.najavits@va.gov
NR 36
TC 51
Z9 52
U1 3
U2 34
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9762
J9 J CLIN PSYCHOL
JI J. Clin. Psychol.
PD MAY
PY 2013
VL 69
IS 5
BP 433
EP 479
DI 10.1002/jclp.21980
PG 47
WC Psychology, Clinical
SC Psychology
GA 130GI
UT WOS:000317901100001
PM 23592045
ER
PT J
AU Najavits, LM
AF Najavits, Lisa M.
TI The Case of Jared
SO JOURNAL OF CLINICAL PSYCHOLOGY
LA English
DT Article
C1 [Najavits, Lisa M.] VA Boston Healthcare Syst, Boston Sch Med, Boston, MA 02130 USA.
RP Najavits, LM (reprint author), VA Boston Healthcare Syst, 150 South Huntington Ave,116-B, Boston, MA 02130 USA.
EM lisa.najavits@va.gov
NR 0
TC 0
Z9 0
U1 0
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9762
J9 J CLIN PSYCHOL
JI J. Clin. Psychol.
PD MAY
PY 2013
VL 69
IS 5
BP 480
EP 481
DI 10.1002/jclp.21981
PG 2
WC Psychology, Clinical
SC Psychology
GA 130GI
UT WOS:000317901100002
PM 23580346
ER
PT J
AU Schmitz, M
AF Schmitz, Martha
TI The Case: Treating Jared Through Seeking Safety
SO JOURNAL OF CLINICAL PSYCHOLOGY
LA English
DT Article
C1 Univ Calif San Francisco, Sch Med, San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
RP Schmitz, M (reprint author), Univ Calif San Francisco, Sch Med, San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA.
EM Martha.schmitz@va.gov
NR 4
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9762
J9 J CLIN PSYCHOL
JI J. Clin. Psychol.
PD MAY
PY 2013
VL 69
IS 5
BP 490
EP 493
DI 10.1002/jclp.21985
PG 4
WC Psychology, Clinical
SC Psychology
GA 130GI
UT WOS:000317901100006
PM 23564554
ER
PT J
AU Keane, TM
Najavits, LM
AF Keane, Terence M.
Najavits, Lisa M.
TI Interview: Does Complex Trauma Exist? A "Long View" Based on Science and
Service in the Trauma Field
SO JOURNAL OF CLINICAL PSYCHOLOGY
LA English
DT Article
C1 VA Boston Healthcare Syst, Boston, MA 02130 USA.
Boston Univ, Sch Med, Boston, MA 02215 USA.
RP Keane, TM (reprint author), VA Boston Healthcare Syst, Res Serv 151, 150 South Huntington Ave, Boston, MA 02130 USA.
EM terry.keane@va.gov
NR 0
TC 1
Z9 1
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9762
J9 J CLIN PSYCHOL
JI J. Clin. Psychol.
PD MAY
PY 2013
VL 69
IS 5
BP 510
EP 515
DI 10.1002/jclp.21991
PG 6
WC Psychology, Clinical
SC Psychology
GA 130GI
UT WOS:000317901100009
PM 23564601
ER
PT J
AU van der Kolk, B
Najavits, LM
AF van der Kolk, Bessel
Najavits, Lisa M.
TI Interview: What is PTSD Really? Surprises, Twists of History, and the
Politics of Diagnosis and Treatment
SO JOURNAL OF CLINICAL PSYCHOLOGY
LA English
DT Article
C1 [van der Kolk, Bessel] Justice Resource Inst, Ctr Trauma, Brookline, MA 02446 USA.
[Najavits, Lisa M.] VA Boston Healthcare Syst, Boston, MA USA.
[Najavits, Lisa M.] Boston Univ, Sch Med, Boston, MA 02215 USA.
RP van der Kolk, B (reprint author), Justice Resource Inst, Ctr Trauma, 1269 Beacon St, Brookline, MA 02446 USA.
EM bvanderk@traumacenter.org
NR 0
TC 2
Z9 2
U1 8
U2 31
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9762
J9 J CLIN PSYCHOL
JI J. Clin. Psychol.
PD MAY
PY 2013
VL 69
IS 5
BP 516
EP 522
DI 10.1002/jclp.21992
PG 7
WC Psychology, Clinical
SC Psychology
GA 130GI
UT WOS:000317901100010
PM 23592047
ER
PT J
AU Landes, SJ
Garovoy, ND
Burkman, KM
AF Landes, Sara J.
Garovoy, Natara D.
Burkman, Kristine M.
TI Treating Complex Trauma Among Veterans: Three Stage-Based Treatment
Models
SO JOURNAL OF CLINICAL PSYCHOLOGY
LA English
DT Article
DE complex trauma; Veterans; treatment; dialectical behavior therapy; STAIR
narrative therapy; seeking safety
ID THERAPY; PTSD
AB This article addresses the issue of complex trauma in veterans and treatments for symptom presentations resulting from complex trauma exposure. While various definitions have been proposed for complex trauma, the clinical issues related to it are relevant for veterans as they are at risk for cumulative trauma exposures such as multiple combat deployments and military sexual trauma. Several treatments were either developed to address and/or implemented with complex trauma. This article discusses three of these treatments that share a stage-based approach, focusing on the present (e.g., skills training and psychoeducation), which can then be followed, if needed, with a past-focused (e.g., exposure-based) treatment: Dialectical Behavior Therapy (Linehan, 1993), Seeking Safety (Najavits, 2002), Skills Training in Affective and Interpersonal Regulation (STAIR) Narrative Therapy (Cloitre, Cohen, & Koenen, 2006). This article also discusses what is currently being done to address symptom presentations resulting from complex trauma exposure and challenges and possible solutions to implementing this care.
C1 [Landes, Sara J.] VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, Menlo Pk, CA 94025 USA.
[Garovoy, Natara D.] VA Palo Alto Hlth Care Syst, Womens Prevent Outreach & Educ Ctr, Menlo Pk, CA 94025 USA.
[Burkman, Kristine M.] San Francisco VA Med Ctr, PTSD Res Program, San Francisco, CA USA.
RP Landes, SJ (reprint author), VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, 795 Willow Rd, Menlo Pk, CA 94025 USA.
EM sara.landes@va.gov
OI Landes, Sara/0000-0001-8515-2465
NR 10
TC 2
Z9 2
U1 1
U2 25
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9762
J9 J CLIN PSYCHOL
JI J. Clin. Psychol.
PD MAY
PY 2013
VL 69
IS 5
BP 523
EP 533
DI 10.1002/jclp.21988
PG 11
WC Psychology, Clinical
SC Psychology
GA 130GI
UT WOS:000317901100011
PM 23529776
ER
PT J
AU King, LY
Chung, RT
AF King, Lindsay Y.
Chung, Raymond T.
TI IL28B testing in a rapidly changing world: Still relevant?
SO JOURNAL OF HEPATOLOGY
LA English
DT Editorial Material
ID GENOTYPE 1 INFECTION; CHRONIC HEPATITIS-C; COST-EFFECTIVENESS;
VIRUS-INFECTION; HCV INFECTION; TELAPREVIR; BOCEPREVIR; RIBAVIRIN;
PEGINTERFERON; THERAPY
C1 [King, Lindsay Y.; Chung, Raymond T.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
RP Chung, RT (reprint author), Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
EM rtchung@partners.org
NR 18
TC 4
Z9 4
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD MAY
PY 2013
VL 58
IS 5
BP 847
EP 849
DI 10.1016/j.jhep.2013.02.002
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 130CL
UT WOS:000317890200002
PM 23416431
ER
PT J
AU Chren, MM
Linos, E
Torres, JS
Stuart, SE
Parvataneni, R
Boscardin, WJ
AF Chren, Mary-Margaret
Linos, Eleni
Torres, Jeanette S.
Stuart, Sarah E.
Parvataneni, Rupa
Boscardin, W. John
TI Tumor Recurrence 5 Years after Treatment of Cutaneous Basal Cell
Carcinoma and Squamous Cell Carcinoma
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Article
ID MOHS MICROGRAPHIC SURGERY; NONMELANOMA SKIN-CANCER; SURGICAL EXCISION;
COST-EFFECTIVENESS; PRIVATE-PRACTICE; FACE; VALIDITY
AB For most cutaneous basal cell and squamous cell carcinomas (nonnnelanoma skin cancers (NMSCs)), data are insufficient to permit evidence-based choices among treatments. To compare tumor recurrence after treatments, we conducted a prospective cohort study of consecutive patients with primary NMSCs treated with the most common treatments, in two practices in 1999-2000. Recurrence was determined from medical records by observers blinded to treatment type. Follow-up was available for 1,174 patients with 1,488 tumors (93.8%) at median 7.4 years; of these tumors, 24.3% (N=361) were treated with destruction with electrodessication/curettage, 38.3% (N=571) with excision, and 37.4% (N=556) with histologically guided serial excision (Mohs surgery). The overall 5-year tumor recurrence rate (95% confidence interval) was 3.3% (2.3, 4.4). Unadjusted recurrence rates did not differ after treatments: 4.9% (2.3, 7.4) after destruction, 3.5% (1.8, 5.2) after excision, and 2.1% (0.6, 3.5) after Mohs surgery (P=0.26), and no difference was seen after adjustment for risk factors. In tumors treated only with excision or Mohs surgery, the hazard of recurrence was not significantly different, even after adjustment for propensity for treatment with Mohs surgery. These data indicate that common treatments for NMSCs were at least 95% effective, and further studies are needed to guide therapeutic choices for different clinical subgroups.
C1 [Chren, Mary-Margaret; Linos, Eleni; Stuart, Sarah E.; Parvataneni, Rupa] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA.
[Chren, Mary-Margaret; Torres, Jeanette S.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Boscardin, W. John] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Boscardin, W. John] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
RP Chren, MM (reprint author), Zion Canc Res Bldg,2340 Sutter St,Room N412,Box 0, San Francisco, CA 94143 USA.
EM chrenm@derm.ucsf.edu
RI Linos, Eleni/C-4392-2014;
OI Linos, Eleni/0000-0002-5856-6301; , Eleni/0000-0003-2538-0700
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases,
National Institutes of Health [R01 AR 054983, K02 AR02203, K24
AR052667]; Investigator-Initiated Research Grants [IIRs 97010-2 and
04-043-3]; Health Services Research Enhancement Award Program (REAP) of
the Health Services Research; Development Service of the Department of
Veterans Affairs
FX This work was supported by grants from the National Institute of
Arthritis and Musculoskeletal and Skin Diseases, National Institutes of
Health (R01 AR 054983, K02 AR02203, and K24 AR052667), and by
Investigator-Initiated Research Grants (IIRs 97010-2 and 04-043-3) and
the Health Services Research Enhancement Award Program (REAP) of the
Health Services Research and Development Service of the Department of
Veterans Affairs.
NR 29
TC 50
Z9 51
U1 1
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
IS 5
BP 1188
EP 1196
DI 10.1038/jid.2012.403
PG 9
WC Dermatology
SC Dermatology
GA 127KV
UT WOS:000317698800014
PM 23190903
ER
PT J
AU Ang, C
Anyanwu, C
Werth, V
AF Ang, C.
Anyanwu, C.
Werth, V.
TI Mechanic's hands are predictive of reduced lung diffusion capacity and
interstitial lung disease in patients with dermatomyositis
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Ang, C.; Anyanwu, C.; Werth, V.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Ang, C.; Anyanwu, C.; Werth, V.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA.
[Ang, C.] Changi Gen Hosp, Dept Dermatol, Singapore, Singapore.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 1121
BP S190
EP S190
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698901410
ER
PT J
AU Anyanwu, CO
Propert, KJ
Werth, VP
AF Anyanwu, C. O.
Propert, K. J.
Werth, V. P.
TI Determination of cutaneous dermatomyositis severity using the cutaneous
dermatomyositis disease area and severity index
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Anyanwu, C. O.; Werth, V. P.] Philadelphia Vet Affairs Med Ctr, Dept Dermatol, Philadelphia, PA USA.
[Anyanwu, C. O.; Werth, V. P.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA.
[Propert, K. J.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 216
BP S36
EP S36
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698900216
ER
PT J
AU Chang, YC
Propert, KJ
Werth, VP
AF Chang, Y. C.
Propert, K. J.
Werth, V. P.
TI The limitations in measuring improvement in disease activity in patients
with mild cutaneous lupus erythematosus
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Chang, Y. C.; Werth, V. P.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Chang, Y. C.; Werth, V. P.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Propert, K. J.] Hosp Univ Penn, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 190
BP S32
EP S32
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698900190
ER
PT J
AU Chang, YC
Propert, KJ
Sirignano, S
Chong, B
Werth, VP
AF Chang, Y. C.
Propert, K. J.
Sirignano, S.
Chong, B.
Werth, V. P.
TI Disease flare and progression in cutaneous lupus erythematosus: A
longitudinal study of CLE
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Chang, Y. C.; Werth, V. P.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Chang, Y. C.; Werth, V. P.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Propert, K. J.] Hosp Univ Penn, Philadelphia, PA 19104 USA.
[Sirignano, S.; Chong, B.] UT Southwestern, Dallas, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 189
BP S32
EP S32
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698900189
ER
PT J
AU Devlin, P
Chaney, K
Carter, J
Tawa, M
Fisher, DC
Dorosario, A
Adams, N
Watanabe, R
Clark, R
Kupper, TS
AF Devlin, P.
Chaney, K.
Carter, J.
Tawa, M.
Fisher, D. C.
Dorosario, A.
Adams, N.
Watanabe, R.
Clark, R.
Kupper, T. S.
TI Low-dose local ionizing radiation provides "targeted" therapy and
induces durable remission in early stage mycosis fungoides/CTCL
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Devlin, P.; Chaney, K.; Carter, J.; Tawa, M.; Fisher, D. C.; Dorosario, A.; Adams, N.; Watanabe, R.; Clark, R.; Kupper, T. S.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 1103
BP S187
EP S187
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698901392
ER
PT J
AU Elmariah, SB
Conniff, T
Luo, T
Azimi, E
Reddy, VB
Lerner, EA
Wolpowitz, D
AF Elmariah, S. B.
Conniff, T.
Luo, T.
Azimi, E.
Reddy, V. B.
Lerner, E. A.
Wolpowitz, D.
TI Altered cutaneous neural innervation in pruritic dermatoses
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Elmariah, S. B.; Luo, T.; Azimi, E.; Reddy, V. B.; Lerner, E. A.] Massachusetts Gen Hosp, Charlestown, MA USA.
[Conniff, T.; Wolpowitz, D.] Boston Univ, Sch Med, Boston, MA 02118 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 701
BP S119
EP S119
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698900697
ER
PT J
AU Enamandram, M
Donahue, KR
Duncan, LM
Kimball, AB
AF Enamandram, M.
Donahue, K. R.
Duncan, L. M.
Kimball, A. B.
TI Incidence of nonmelanoma skin cancer in patients presenting for routine
dermatological care
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 548
BP S94
EP S94
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698900545
ER
PT J
AU Freeman, EE
Evans, R
Maurer, T
Muhe, L
Easterbrook, P
AF Freeman, E. E.
Evans, R.
Maurer, T.
Muhe, L.
Easterbrook, P.
TI The need for unified international guidance on HIV dermatology
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Freeman, E. E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Evans, R.; Easterbrook, P.] World Hlth Org, HIV Dept, Geneva, Switzerland.
[Muhe, L.] World Hlth Org, Geneva, Switzerland.
[Maurer, T.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 562
BP S96
EP S96
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698900559
ER
PT J
AU Freeman, EE
Easterbrook, P
Muhe, L
Hay, R
Martin, J
Maurer, T
AF Freeman, E. E.
Easterbrook, P.
Muhe, L.
Hay, R.
Martin, J.
Maurer, T.
TI The role of evidence based dermatology in World Health Organization
guidelines
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Freeman, E. E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Easterbrook, P.] World Hlth Org, HIV Dept, Geneva, Switzerland.
[Muhe, L.] World Hlth Org, Dept Child & Adolescent Hlth & Dev, Geneva, Switzerland.
[Hay, R.] Int Fdn Dermatol, London, England.
[Martin, J.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Maurer, T.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 561
BP S96
EP S96
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698900558
ER
PT J
AU Garibyan, L
Wang, LC
Cotter, SE
Dorosario, A
Devlin, PM
AF Garibyan, L.
Wang, L. C.
Cotter, S. E.
Dorosario, A.
Devlin, P. M.
TI Palliative treatment for in-transit cutaneous metastases of Merkel cell
carcinoma using surface-mold computer-optimized high-dose-rate
brachytherapy
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Garibyan, L.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Dorosario, A.; Devlin, P. M.] Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA USA.
[Garibyan, L.; Wang, L. C.] Brigham & Womens Hosp, Dept Dermatol, Boston, MA 02115 USA.
[Cotter, S. E.] Canc Ctr Santa Barbara, Santa Barbara, CA USA.
[Wang, L. C.] Mercy Med Ctr, Inst Canc Care, Baltimore, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 944
BP S161
EP S161
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698901238
ER
PT J
AU Guenova, E
Watanabe, R
Gehad, A
Teague, JE
Adams, N
Dorosario, AA
Glinert, R
Walsch, D
Tawa, M
Carter, JB
Chaney, KA
Fisher, DC
Cutler, CS
Kupper, TS
Clark, RA
AF Guenova, E.
Watanabe, R.
Gehad, A.
Teague, J. E.
Adams, N.
Dorosario, A. A.
Glinert, R.
Walsch, D.
Tawa, M.
Carter, J. B.
Chaney, K. A.
Fisher, D. C.
Cutler, C. S.
Kupper, T. S.
Clark, R. A.
TI Reversible suppression of normal thymic output in patients with leukemic
cutaneous T cell lymphoma
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Guenova, E.; Watanabe, R.; Gehad, A.; Teague, J. E.; Kupper, T. S.; Clark, R. A.] Harvard Skin Dis Res Ctr, Boston, MA USA.
[Adams, N.; Dorosario, A. A.; Glinert, R.; Walsch, D.; Tawa, M.; Carter, J. B.; Chaney, K. A.; Fisher, D. C.; Cutler, C. S.; Kupper, T. S.; Clark, R. A.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA.
RI Guenova, Emmanuella/A-4656-2015
NR 0
TC 0
Z9 0
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 1064
BP S181
EP S181
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698901357
ER
PT J
AU Huang, V
Dowlatshahi, M
Keskin, DB
Reinhold, B
Mayo, TC
Teague, J
Gehad, A
Reinherz, EL
Shuda, M
DeCaprio, IA
Thakuria, M
Dorosario, AA
Clark, R
AF Huang, V.
Dowlatshahi, M.
Keskin, D. B.
Reinhold, B.
Mayo, T. C.
Teague, J.
Gehad, A.
Reinherz, E. L.
Shuda, M.
DeCaprio, I. A.
Thakuria, M.
Dorosario, A. A.
Clark, R.
TI Defective expression of class I antigen presentation pathway members in
Merkel cell carcinoma may underlie low MHC I expression and contribute
to immune evasion
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Huang, V.; Dowlatshahi, M.; Keskin, D. B.; Reinhold, B.; Teague, J.; Gehad, A.; Reinherz, E. L.; DeCaprio, I. A.; Thakuria, M.; Dorosario, A. A.; Clark, R.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA.
[Mayo, T. C.; Shuda, M.] Univ Pittsburgh, Canc Virol Program, Pittsburgh, PA USA.
RI SHUDA, MASAHIRO/F-5505-2011
OI SHUDA, MASAHIRO/0000-0003-0595-2572
NR 0
TC 0
Z9 0
U1 1
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 259
BP S44
EP S44
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698900259
ER
PT J
AU Jain, R
Abtin, A
Roediger, B
Brzoska, AJ
Mitchell, AJ
Ng, LG
Cavanagh, LL
von Andrian, UH
Firth, N
Weninger, W
AF Jain, R.
Abtin, A.
Roediger, B.
Brzoska, A. J.
Mitchell, A. J.
Ng, L. G.
Cavanagh, L. L.
von Andrian, U. H.
Firth, N.
Weninger, W.
TI Perivascular macrophages are key regulators of neutrophil recruitment
during skin infection and are targeted by a Staphylococcus aureus
virulence factor
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Jain, R.; Abtin, A.; Roediger, B.; Mitchell, A. J.; Cavanagh, L. L.; Weninger, W.] Centenary Inst, Newtown, NSW, Australia.
[Brzoska, A. J.; Firth, N.] Univ Sydney, Sch Biol Sci, Sydney, NSW 2006, Australia.
[Ng, L. G.] Biopolis, Singapore Immunol Network, Singapore, Singapore.
[Cavanagh, L. L.] Sydney Med Sch, Sydney, NSW, Australia.
[von Andrian, U. H.] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA USA.
[Weninger, W.] Sydney Med Sch, Discipline Dermatol, Sydney, NSW, Australia.
NR 0
TC 0
Z9 0
U1 1
U2 5
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 1169
BP S198
EP S198
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698901458
ER
PT J
AU Jalian, H
Tam, J
Garibyan, L
Anderson, R
AF Jalian, H.
Tam, J.
Garibyan, L.
Anderson, R.
TI Selective cryolysis of sebaceous glands
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Jalian, H.; Tam, J.; Garibyan, L.; Anderson, R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Jalian, H.] Univ Calif Los Angeles, Div Dermatol, Los Angeles, CA 90024 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 1078
BP S183
EP S183
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698901370
ER
PT J
AU Katiyar, SK
Prasad, R
AF Katiyar, S. K.
Prasad, R.
TI Prostaglandin E2 promotes UV radiation-induced immune suppression via
DNA hypermethylation
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Katiyar, S. K.; Prasad, R.] Univ Alabama Birmingham, Birmingham, AL USA.
[Katiyar, S. K.] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 1243
BP S211
EP S211
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698901532
ER
PT J
AU Kimball, AB
Krueger, J
Sullivan, T
Arbeit, RD
AF Kimball, A. B.
Krueger, J.
Sullivan, T.
Arbeit, R. D.
TI IMO-3100, an antagonist of Toll-like receptor (TLR) 7 and TLR9,
demonstrates clinical activity in psoriasis patients with 4 weeks of
treatment in a phase 2a trial
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Kimball, A. B.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Krueger, J.] Rockefeller Univ, New York, NY 10021 USA.
[Sullivan, T.; Arbeit, R. D.] Idera Pharmaceut Inc, Cambridge, MA USA.
NR 0
TC 2
Z9 2
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 156
BP S26
EP S26
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698900156
ER
PT J
AU Korgavkar, K
Xiong, M
Marcolivio, K
Lew, R
Firoz, E
Weinstock, M
AF Korgavkar, K.
Xiong, M.
Marcolivio, K.
Lew, R.
Firoz, E.
Weinstock, M.
CA VAKCC Trial Grp
TI Measuring the severity of topical 5-fluorouracil toxicity
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Korgavkar, K.; Xiong, M.; Marcolivio, K.; Weinstock, M.] VA Med Ctr, Dermatoepidemiol Unit, Providence, RI USA.
[Marcolivio, K.; Lew, R.; Weinstock, M.; VAKCC Trial Grp] VA Cooperat Studies Program, Boston, MA USA.
[Korgavkar, K.; Xiong, M.; Firoz, E.; Weinstock, M.] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 521
BP S89
EP S89
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698900518
ER
PT J
AU Lee, N
Kleffel, S
Lezcano, MC
Sobolewski, K
DoRosario, A
Frank, MH
Wang, L
Murphy, GF
Schatton, T
AF Lee, N.
Kleffel, S.
Lezcano, M. C.
Sobolewski, K.
DoRosario, A.
Frank, M. H.
Wang, L.
Murphy, G. F.
Schatton, T.
TI ABCB5 identifies a chemorefractory cell population in Merkel cell
carcinoma
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Lee, N.; Kleffel, S.; Sobolewski, K.; Frank, M. H.; Wang, L.; Schatton, T.] Brigham & Womens Hosp, Dept Dermatol, Boston, MA 02115 USA.
[Lezcano, M. C.; Murphy, G. F.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[DoRosario, A.; Wang, L.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA.
[Frank, M. H.; Schatton, T.] Childrens Hosp, Transplantat Res Ctr, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 358
BP S61
EP S61
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698900356
ER
PT J
AU Lefort, K
Brooks, Y
Ostano, P
Carlo-Andre, M
Calpini, V
Albinger-Hegyi, A
Hoetzenecker, W
Dotto, G
AF Lefort, K.
Brooks, Y.
Ostano, P.
Carlo-Andre, M.
Calpini, V.
Albinger-Hegyi, A.
Hoetzenecker, W.
Dotto, G.
TI A miR-34a-SIRT6 axis in the squamous cell differentiation network
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Lefort, K.; Calpini, V.; Hoetzenecker, W.; Dotto, G.] Univ Lausanne, CH-1066 Epalinges, Switzerland.
[Lefort, K.] CHU Vaudois, Lausanne, Switzerland.
[Brooks, Y.; Dotto, G.] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA USA.
[Ostano, P.] Fdn Edo & Elvo Tempia Valenta, Lab Canc Genom, Biella, Italy.
[Carlo-Andre, M.] INSERM, U876, Bordeaux, France.
[Carlo-Andre, M.] Bordeaux Hosp, Natl Reference Ctr Rare Skin Dis, Bordeaux, France.
[Albinger-Hegyi, A.] HNO Zuerich Fraumunster, Zurich, Switzerland.
NR 0
TC 0
Z9 0
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 442
BP S75
EP S75
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698900439
ER
PT J
AU Reddy, VB
Elmariah, SB
Azimi, E
Luo, T
Lerner, EA
AF Reddy, V. B.
Elmariah, S. B.
Azimi, E.
Luo, T.
Lerner, E. A.
TI Mechanisms of itch: Proteases activate Man-related G-protein coupled
receptors
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Reddy, V. B.; Elmariah, S. B.; Azimi, E.; Luo, T.; Lerner, E. A.] Massachusetts Gen Hosp, Charlestown, MA USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 244
BP S41
EP S41
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698900244
ER
PT J
AU Rubina, S
Camp, WL
Hermann, J
Cantrell, W
Cantor, AB
Athar, M
Elmets, CA
AF Rubina, S.
Camp, W. L.
Hermann, J.
Cantrell, W.
Cantor, A. B.
Athar, M.
Elmets, C. A.
TI Tanning beds use and skin cancer biomarkers - a pilot study
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Rubina, S.; Camp, W. L.; Hermann, J.; Cantrell, W.; Athar, M.; Elmets, C. A.] UAB, Birmingham, AL USA.
[Athar, M.; Elmets, C. A.] UAB, SDRC, Birmingham, AL USA.
[Cantor, A. B.] UAB, Div Prevent Med, Birmingham, AL USA.
[Elmets, C. A.] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 1289
BP S219
EP S219
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698901578
ER
PT J
AU Sadik, CD
Kim, ND
Luster, AD
AF Sadik, C. D.
Kim, N. D.
Luster, A. D.
TI Neutrophils orchestrate their own recruitment in immune complex-induced
inflammation by C5aR and Fc gamma R signaling
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Sadik, C. D.; Kim, N. D.; Luster, A. D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Immunol & Inflammatory Dis, Boston, MA USA.
[Sadik, C. D.] UKSH, Dermatol Allergy & Venereol 2Dept, Lubeck, Germany.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 197
BP S33
EP S33
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698900197
ER
PT J
AU Strazzula, L
Nigwekar, S
Steele, D
Tsiaras, W
Sise, M
Bis, S
Smith, GP
Kroshinsky, D
AF Strazzula, L.
Nigwekar, S.
Steele, D.
Tsiaras, W.
Sise, M.
Bis, S.
Smith, G. P.
Kroshinsky, D.
TI Intralesional sodium thiosulfate for the treatment of cutaneous
calciphylaxis
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Strazzula, L.; Nigwekar, S.; Steele, D.; Tsiaras, W.; Sise, M.; Bis, S.; Smith, G. P.; Kroshinsky, D.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RI sebastianovitsch, stepan/G-8507-2013
NR 0
TC 0
Z9 0
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 1120
BP S190
EP S190
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698901412
ER
PT J
AU Strazzula, L
Pratt, D
Zardas, J
Kroshinsky, D
AF Strazzula, L.
Pratt, D.
Zardas, J.
Kroshinsky, D.
TI Dermatology consultation may decrease telaprevir discontinuation among
patients with severe triple therapy-associated rash
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Strazzula, L.; Pratt, D.; Zardas, J.; Kroshinsky, D.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 1115
BP S189
EP S189
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698901404
ER
PT J
AU Strazzula, L
Garibyan, L
Oaklander, AL
Kroshinsky, D
AF Strazzula, L.
Garibyan, L.
Oaklander, A. L.
Kroshinsky, D.
TI Delusions of parasitosis: A possible neuropathic component
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Strazzula, L.; Garibyan, L.; Oaklander, A. L.; Kroshinsky, D.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 1108
BP S188
EP S188
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698901400
ER
PT J
AU Strazzula, L
Cotliar, J
Fox, LP
Gee, S
Hughey, SL
Shinkai, K
Kroshinsky, D
AF Strazzula, L.
Cotliar, J.
Fox, L. P.
Gee, S.
Hughey, S. L.
Shinkai, K.
Kroshinsky, D.
TI Inpatient pseudocellulitis: Assessing the extent of the problem through
dermatology consultation services
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Strazzula, L.; Kroshinsky, D.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Cotliar, J.] Northwestern Med Ctr, Chicago, IL USA.
[Gee, S.] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA.
[Fox, L. P.; Shinkai, K.] Univ Calif San Francisco, Med Ctr, San Francisco, CA USA.
[Hughey, S. L.] Univ Alabama, Tuscaloosa, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 601
BP S102
EP S102
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698900598
ER
PT J
AU Strazzula, L
Kroshinsky, D
AF Strazzula, L.
Kroshinsky, D.
TI Recurrent cellulitis in outpatient primary care: assessing the nature of
the problem
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Strazzula, L.; Kroshinsky, D.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 603
BP S103
EP S103
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698900600
ER
PT J
AU Sung, SM
Kimball, AB
AF Sung, S. M.
Kimball, A. B.
TI Rising educational debt levels in dermatology trainees and effects on
subsequent training choices: An update
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Sung, S. M.; Kimball, A. B.] Massachusetts Gen Hosp, Clin Unit Res Trials & Outcomes Skin CURTIS, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 1011
BP S172
EP S172
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698901301
ER
PT J
AU Timares, L
Nasti, T
Cochran, B
Jaleel, T
Yusuf, N
Elmets, CA
AF Timares, L.
Nasti, T.
Cochran, B.
Jaleel, T.
Yusuf, N.
Elmets, C. A.
TI A new mouse model for studying the development of melanomas
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Timares, L.; Nasti, T.; Cochran, B.; Jaleel, T.; Yusuf, N.; Elmets, C. A.] Univ Alabama Birmingham, Birmingham, AL USA.
[Timares, L.; Yusuf, N.; Elmets, C. A.] Univ Alabama Birmingham, Skin Dis Res Ctr, Birmingham, AL USA.
[Elmets, C. A.] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 1400
BP S238
EP S238
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698901688
ER
PT J
AU Vaid, M
Katiyar, SK
AF Vaid, M.
Katiyar, S. K.
TI Proanthocyanidins inhibit invasive potential of human melanoma cells by
targeting beta-catenin signaling
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Vaid, M.; Katiyar, S. K.] Univ Alabama Birmingham, Birmingham, AL USA.
[Katiyar, S. K.] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 1323
BP S225
EP S225
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698901613
ER
PT J
AU Velez, NF
Karia, PS
Guo, Y
Vartanov, AR
Davids, MS
Brown, JR
Neel, VA
Schmults, CD
AF Velez, N. F.
Karia, P. S.
Guo, Y.
Vartanov, A. R.
Davids, M. S.
Brown, J. R.
Neel, V. A.
Schmults, C. D.
TI Advanced Rai stage and skin cancer tumor stage predicts outcomes of skin
cancer in patients with chronic lymphocytic leukemia
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Karia, P. S.; Guo, Y.; Schmults, C. D.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
[Vartanov, A. R.; Davids, M. S.; Brown, J. R.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Velez, N. F.; Neel, V. A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 534
BP S91
EP S91
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698900531
ER
PT J
AU Watanabe, R
Guenova, E
Gehad, A
Teague, J
Adams, N
Dorosario, AA
Glinert, R
Tawa, M
Carter, JB
Chaney, KA
Fisher, DC
Kupper, TS
Clark, RA
AF Watanabe, R.
Guenova, E.
Gehad, A.
Teague, J.
Adams, N.
Dorosario, A. A.
Glinert, R.
Tawa, M.
Carter, J. B.
Chaney, K. A.
Fisher, D. C.
Kupper, T. S.
Clark, R. A.
TI Reversible Th22 dysfunction and persistent loss of Th17 responses in
patients with L-CTCL
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Watanabe, R.; Guenova, E.; Gehad, A.; Teague, J.; Adams, N.; Dorosario, A. A.; Glinert, R.; Tawa, M.; Carter, J. B.; Chaney, K. A.; Fisher, D. C.; Kupper, T. S.; Clark, R. A.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA.
RI Guenova, Emmanuella/A-4656-2015
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 258
BP S43
EP S43
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698900258
ER
PT J
AU Wehner, MR
Linos, E
Parvataneni, R
Stuart, SE
Boscardin, WJ
Chren, M
AF Wehner, M. R.
Linos, E.
Parvataneni, R.
Stuart, S. E.
Boscardin, W. J.
Chren, M.
TI Risk of subsequent non-melanoma skin cancers in patients with prior
non-melanoma skin cancer
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Meeting Abstract
CT International Investigative Dermatology Meeting
CY MAY 08-11, 2013
CL Edinburgh, SCOTLAND
SP European Soc Dermatol Res, Japanese Soc Investigat Dermatol, Soc Investigat Dermatol
C1 [Wehner, M. R.; Linos, E.; Parvataneni, R.; Stuart, S. E.; Boscardin, W. J.; Chren, M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Wehner, M. R.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
[Chren, M.] San Francisco VA Med Ctr, San Francisco, CA USA.
RI Linos, Eleni/C-4392-2014
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAY
PY 2013
VL 133
SU 1
MA 547
BP S93
EP S93
PG 1
WC Dermatology
SC Dermatology
GA 127KW
UT WOS:000317698900544
ER
PT J
AU Erakat, MS
Chuang, SK
Shanti, RM
Ziccardi, VB
AF Erakat, Mohammed S.
Chuang, Sung-Kiang
Shanti, Rabie M.
Ziccardi, Vincent B.
TI Interval Between Injury and Lingual Nerve Repair as a Prognostic Factor
for Success Using Type I Collagen Conduit
SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
LA English
DT Article
ID FUNCTIONAL SENSORY RECOVERY
AB Purpose: The purpose of the present study was to investigate the role of a type I collagen nerve conduit in the repair of lingual nerve injuries compared with those lingual nerve repairs performed without a collagen membrane and to identify the prognostic factors for functional sensory recovery (FSR).
Materials and Methods: This was a retrospective cohort study evaluating a sample derived from the population of patients who had undergone lingual nerve microsurgery from March 17, 2000, to February 23, 2010 by the same surgeon (V.B.Z.) with complete records available, including follow-up assessments. The primary outcome variable was the interval to successful FSR according to the British Medical Research Council criteria for FSR. The predictor variables were categorized into demographic, surgical, and clinical sensory testing. Appropriate descriptive statistics and univariate and multivariate Cox proportional hazards survival statistics were computed in analyzing the patient age at lingual nerve injury repair (in years), gender, timing of surgical intervention, mechanism of injury, specific surgical procedures, and application of a type I collagen conduit.
Results: The study cohort included 41 patients with 42 lingual nerve injuries who underwent surgical repair. Their mean age was 28.3 +/- 8.3 years (range 13 to 44), with 88% females (n = 32). In the multivariate model, the injury to surgery interval per 1-month increase (hazard ratio 1.23, 95% confidence interval 1.02 to 1.48, P = .029) and injury to surgery interval of 9 months or longer (hazard ratio 4.67, 95% confidence interval 1.04 to 20.87, P = .04) remained significantly associated statistically with successful FSR.
Conclusions: The results of the present study have demonstrated that the injury to surgery interval is the most significant prognostic factor in the repair of lingual nerve injuries. The use of the collagen membrane demonstrated a greater level of FSR compared with those treated without the use of the membrane. However, the results from the collagen conduit were not statistically significant. (C) 2013 American Association of Oral and Maxillofacial Surgeons J Oral Maxillofac Surg 71:833-838, 2013
C1 [Erakat, Mohammed S.] Warren Oral Surg, Warren, NJ USA.
[Erakat, Mohammed S.; Shanti, Rabie M.; Ziccardi, Vincent B.] Univ Med & Dent New Jersey, Dept Oral & Maxillofacial Surg, Newark, NJ 07103 USA.
[Chuang, Sung-Kiang] Harvard Univ, Sch Dent Med, Dept Oral & Maxillofacial Surg, Boston, MA 02115 USA.
[Chuang, Sung-Kiang] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA.
RP Ziccardi, VB (reprint author), Univ Med & Dent New Jersey, Dept Oral & Maxillofacial Surg, 110 Bergen St,Room B-854, Newark, NJ 07103 USA.
EM ziccarvb@umdnj.edu
NR 11
TC 1
Z9 6
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0278-2391
J9 J ORAL MAXIL SURG
JI J. Oral Maxillofac. Surg.
PD MAY
PY 2013
VL 71
IS 5
BP 833
EP 838
DI 10.1016/j.joms.2011.11.026
PG 6
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 128AL
UT WOS:000317740300009
PM 22365982
ER
PT J
AU Laviv, A
Seldin, EB
Dodson, TB
AF Laviv, Amir
Seldin, Edward B.
Dodson, Thomas B.
TI A Simple Modification to the Nasal Hood to Facilitate Capnographic
Measurements: A Technical Note
SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
LA English
DT Article
C1 [Laviv, Amir; Seldin, Edward B.; Dodson, Thomas B.] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA.
RP Laviv, A (reprint author), 55 Fruit St,Warren 1201, Boston, MA 02114 USA.
EM amirlaviv@gmail.com
NR 1
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0278-2391
J9 J ORAL MAXIL SURG
JI J. Oral Maxillofac. Surg.
PD MAY
PY 2013
VL 71
IS 5
BP 854
EP 855
DI 10.1016/j.joms.2013.01.023
PG 2
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 128AL
UT WOS:000317740300012
PM 23598550
ER
PT J
AU Ananthakrishnan, AN
AF Ananthakrishnan, Ashwin N.
TI Antibiotic exposure is associated with development of inflammatory bowel
disease
SO JOURNAL OF PEDIATRICS
LA English
DT Editorial Material
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Ananthakrishnan, AN (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 3
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-3476
J9 J PEDIATR-US
JI J. Pediatr.
PD MAY
PY 2013
VL 162
IS 5
BP 1077
EP 1077
PG 1
WC Pediatrics
SC Pediatrics
GA 129JW
UT WOS:000317836300046
PM 23617975
ER
PT J
AU Watson, AJ
Redbord, K
Taylor, JS
Shippy, A
Kostecki, J
Swerlick, R
AF Watson, Alice J.
Redbord, Kelley
Taylor, James S.
Shippy, Alison
Kostecki, James
Swerlick, Robert
TI Medical error in dermatology practice: Development of a classification
system to drive priority setting in patient safety efforts
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Article
DE medical error; patient safety; practice improvement; quality of care;
Universal Protocol; wrong-site surgery
ID BIOPSY-SITE PHOTOGRAPHY; PHYSICIAN SURVEY; FOLLOW-UP; CARE; PSORIASIS;
SURGERY; QUALITY; RISK
AB Background: To date, no study to our knowledge has examined the nature and scope of medical error in dermatology practice.
Objective: We sought to collect and categorize physician-reported errors in dermatology practice.
Methods: A survey regarding most recent and most serious errors was developed and distributed to dermatologists attending US meetings. A total of 150 responses were received outlining 152 most recent errors and 130 most serious errors. Survey responses, along with classification systems for other specialties, were used to develop a classification system for medical error in dermatology.
Results: The respondents' demographics reflected the specialty: 63% were male, 60% were older than 50 years, and 60% were in solo or group private practice. Of the most recent errors reported, 85% happened once a year or less, and 86% did not result in harm to patients. The most common categories of both most recent and most serious errors were related to assessment (41% and 31%, respectively) and interventions (44% and 52%, respectively). Assessment errors were primarily related to investigations, and commonly involved the biopsy pathway. Intervention errors in the most recent and most serious errors were split between those related to medication (54% and 27%) and those related to procedures (46% and 73%). Of note, 5 and 21 wrong-site surgeries were reported in the most recent and most serious errors groups, respectively.
Limitations: Our findings are subject to respondent and recall bias and our classification system, although an important first step, is likely incomplete.
Conclusion: Our findings highlight several key areas of patient care in need of safety initiatives, namely the biopsy pathway, medication management, and prevention of wrong-site surgery. (J Am Acad Dermatol 2013;68:729-37.)
C1 [Watson, Alice J.] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA.
[Watson, Alice J.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Redbord, Kelley] George Washington Univ, Washington, DC USA.
[Taylor, James S.] Cleveland Clin, Dept Dermatol, Cleveland, OH 44195 USA.
[Shippy, Alison; Kostecki, James] Amer Acad Dermatol, Washington, DC USA.
[Swerlick, Robert] Emory Med Sch, Atlanta, GA USA.
RP Watson, AJ (reprint author), Massachusetts Gen Hosp, Dept Dermatol, 55 Fruit St, Boston, MA 02114 USA.
EM AJWatson@partners.org
NR 27
TC 11
Z9 11
U1 0
U2 5
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0190-9622
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD MAY
PY 2013
VL 68
IS 5
BP 729
EP 737
DI 10.1016/j.jaad.2012.10.058
PG 9
WC Dermatology
SC Dermatology
GA 129IV
UT WOS:000317833500011
PM 23360864
ER
PT J
AU Kimball, AB
Pariser, D
Yamauchi, PS
Menter, A
Teller, CF
Shi, YF
Yong, M
Creamer, K
Hooper, M
Aras, G
Kricorian, G
Gelfand, JM
AF Kimball, Alexa B.
Pariser, David
Yamauchi, Paul S.
Menter, Alan
Teller, Craig F.
Shi, Yifei
Yong, Mellissa
Creamer, Kara
Hooper, Michele
Aras, Girish
Kricorian, Gregory
Gelfand, Joel M.
TI OBSERVE-5 interim analysis: An observational postmarketing safety
registry of etanercept for the treatment of psoriasis
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Article
DE etanercept; infections; lymphoma; nonmelanoma skin cancer; psoriasis;
registry; safety
ID LONG-TERM SAFETY; TRIAL; EFFICACY; MONOTHERAPY; ARTHRITIS
AB Background: Etanercept is approved for the treatment of chronic moderate to severe plaque psoriasis in adults.
Objective: We sought to evaluate the long-term safety of etanercept in a real-world clinical setting. Assessment of etanercept efficacy was a secondary objective.
Methods: OBSERVE-5 is a 5-year observational safety registry initiated in May 2006 at multiple sites in the United States and Canada. Data collection includes the number of serious adverse events, serious infectious events, and prespecified events of medical interest. Efficacy data include body surface area assessments, physician and patient global assessments of psoriasis, and the Dermatology Life Quality Index. This interim analysis presents data from the first 3 years of the follow-up period.
Results: A total of 2511 patients were enrolled. Of 1890 patients continuing in the registry after 3 years, 113 were inactive for 1 to 2 years, and 115 were inactive for longer than 2 years. The 3-year incidence proportions of serious adverse events and serious infectious events based on Kaplan-Meier methodology were 0.14 and 0.04, respectively. The observed numbers of patients experiencing lymphoma, serious infectious events requiring hospitalization, nonmelanoma skin cancer, and malignancies excluding nonmelanoma skin cancer were not higher than the expected number of cases estimated from a large US administrative health claims database.
Limitations: The registry lacks a control group, and the study is too small to measure the frequency of rare events.
Conclusion: Etanercept demonstrated good tolerability in patients with plaque psoriasis in the clinical setting in this interim analysis. No new or unexpected safety concerns were observed. (J Am Acad Dermatol 2013;68:756-64.)
C1 [Kimball, Alexa B.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Yamauchi, Paul S.] Inst Dermatol, Santa Monica, CA USA.
[Yamauchi, Paul S.] Skin Care Ctr, Santa Monica, CA USA.
[Menter, Alan] Baylor Res Inst, Dallas, TX USA.
[Shi, Yifei; Yong, Mellissa; Creamer, Kara; Hooper, Michele; Aras, Girish; Kricorian, Gregory] Amgen Inc, Thousand Oaks, CA 91320 USA.
RP Kimball, AB (reprint author), Massachusetts Gen Hosp, 50 Staniford St,240, Boston, MA 02114 USA.
EM harvardskinstudies@partners.org
FU Immunex Corp; Amgen Inc; Janssen Pharmaceuticals Inc.
FX Funded by Immunex Corp, a wholly owned subsidiary of Amgen Inc. Dikran
Toroser of Amgen Inc and Karen Zimmermann and Rick Davis of Complete
Healthcare Communications (funded by Amgen Inc) provided medical writing
support.; Dr Kimball is an investigator and consultant for Amgen Inc,
Abbott Laboratories, Idera, Janssen Pharmaceuticals Inc, Merck, Pfizer
Inc, and VBL Therapeutics. She consults with Novartis and has fellowship
funding from Janssen Pharmaceuticals Inc. Dr Pariser is an investigator
and consultant for Abbott Laboratories, Amgen Inc, Astellas, Celgene,
Novartis, and Valeant Pharmaceuticals International. He is an
investigator and serves on an advisory board for Galderma Laboratories
LP, Ortho Dermatologics, Pfizer Inc, and Stiefel. He is an investigator
for Basilea, Dow Pharmaceutical Sciences Inc, Eli Lilly and Co, Graceway
Pharmaceuticals LLC, Intendis Inc, Novo Nordisk, Peplin Inc, and
Photocure ASA. He serves on an advisory board for Genentech Inc,
Janssen-Ortho Inc, and Medicis Pharmaceuticals Corp. He is a consultant
for Mela Sciences and has received honoraria from LEO Pharma US. Dr
Yamauchi serves on advisory boards and is a speaker, consultant, and
investigator for Abbott Laboratories, Amgen Inc, and Centocor. Dr Menter
serves on advisory boards and is a speaker, consultant, and investigator
for Abbott Laboratories, Amgen Inc, Centocor, and Wyeth. He serves on
the advisory board and is a consultant and speaker for Galderma
Laboratories LP. He is a consultant and investigator for Eli Lilly and
Co and Stiefel, and an investigator for Allergan, Celgene, Novartis,
Novo Nordisk, Pfizer Inc, and Syntrix Biosystems. Dr Teller is a speaker
for Amgen Inc, Abbott Laboratories, and Janssen Pharmaceuticals Inc. Mr
Shi, Ms Creamer, and Drs Hooper, Aras, and Kricorian are currently
employed by and have stock ownership in Amgen Inc. Dr Yong was employed
by Amgen Inc at the time the study was conducted and currently has stock
ownership in Amgen Inc. Dr Gelfand served as consultant with Abbott
Laboratories, Amgen Inc, Celgene, Centocor, Novartis, and Pfizer Inc,
receiving honoraria. He had grants or has pending grants from Abbott
Laboratories, Amgen Inc, Genentech Inc, Novartis, and Pfizer Inc. He has
received payment for CME work related to psoriasis. He also received a
donation from Amgen Inc to the University of Pennsylvania to further
develop the Dermatology Clinical Effectiveness Research Network.
NR 18
TC 16
Z9 18
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0190-9622
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD MAY
PY 2013
VL 68
IS 5
BP 756
EP 764
DI 10.1016/j.jaad.2012.10.055
PG 9
WC Dermatology
SC Dermatology
GA 129IV
UT WOS:000317833500014
PM 23357569
ER
PT J
AU Wright, CD
AF Wright, Cameron D.
TI Untitled
SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
LA English
DT Editorial Material
C1 [Wright, Cameron D.] Massachusetts Gen Hosp, Dept Thorac Surg, Boston, MA 02114 USA.
RP Wright, CD (reprint author), Massachusetts Gen Hosp, Blake 1570,55 Fruit St, Boston, MA 02114 USA.
EM wright.cameron@mgh.harvard.edu
NR 1
TC 0
Z9 0
U1 1
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5223
J9 J THORAC CARDIOV SUR
JI J. Thorac. Cardiovasc. Surg.
PD MAY
PY 2013
VL 145
IS 5
BP 1325
EP 1325
DI 10.1016/j.jtcvs.2013.01.001
PG 1
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 129LJ
UT WOS:000317840600028
PM 23380511
ER
PT J
AU Ikonomidis, JS
Ivey, CR
Wheeler, JB
Akerman, AW
Rice, A
Patel, RK
Stroud, RE
Shah, AA
Hughes, CG
Ferrari, G
Mukherjee, R
Jones, JA
AF Ikonomidis, John S.
Ivey, Charlotte R.
Wheeler, Jason B.
Akerman, Adam W.
Rice, Allison
Patel, Risha K.
Stroud, Robert E.
Shah, Asad A.
Hughes, Chad G.
Ferrari, Giovanni
Mukherjee, Rupak
Jones, Jeffrey A.
TI Plasma biomarkers for distinguishing etiologic subtypes of thoracic
aortic aneurysm disease
SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
LA English
DT Article
ID MATRIX METALLOPROTEINASES; ENDOGENOUS INHIBITORS; DILATATION; VALVES;
MATRIX-METALLOPROTEINASE-9; NORMALIZATION; EXPRESSION; MICRORNAS; SIZE
AB Background: Thoracic aortic aneurysms (TAAs) develop through an asymptomatic process resulting in gross dilation that progresses to rupture if left undetected and untreated. If detected, patients with TAA are followed over time until the risk of rupture outweighs the risk of surgical repair. Current methodologies for tracking TAA size are limited to expensive computed tomography or magnetic resonance imaging because no acceptable population screening tools are currently available. Previous studies from this laboratory and others have identified differential protein profiles for the matrix metalloproteinases (MMPs) and their endogenous tissue inhibitors (TIMPs), in ascending TAA tissue from patients with bicuspid aortic valves (BAVs), versus patients with idiopathic degenerative disease and a tricuspid aortic valve (TAV). In addition, altered microRNA (miR) expression levels have also been reported in TAAs compared with normal aortic tissue. The objective of our study was to identify circulating factors within plasma that could serve as potential biomarkers for distinguishing etiologic subtypes of aneurysm disease.
Methods: Ascending TAA tissue and plasma specimens were obtained from patients with BAV (n = 21) and TAV (n = 21) at the time of surgical resection. The protein abundance of key MMPs (1, 2, 3, 8, and 9), TIMPs (1, 2, 3, and 4), and miRs (1, 21, 29a, 133a, 143, and 145) was examined using a multianalyte protein profiling system or by quantitative polymerase chain reaction, respectively. Results were compared with normal aortic tissue and plasma obtained from patients without aortic disease (n = 10).
Results: Significant (P <. 05) differences in standardized miR-1 and miR-21 abundance between BAV and TAV aortic tissue samples and different tissue and plasma profiles of analyte differences from normal aorta where observed between the BAV and TAV groups. Linear regression analysis revealed significant linear relationships in plasma and tissue measurements only for MMP-8 and TIMP-1, TIMP-3, and TIMP-4 (P <. 05). Receiver operator curve analysis revealed specific cassettes of analytes predictive of TAA disease. Relative to normal aorta, BAV proteolytic balance was significantly increased for MMP-1, MMP-2, and MMP-7, and for decreased MMP-8 and MMP-9. In contrast, TAV proteolytic balance relative to normal aorta was significantly increased only for MMP-1 and decreased for MMP-8 and MMP-9.
Conclusions: Taken together, these unique data demonstrate differential plasma profiles of MMPs, TIMPs, and miRs in ascending TAA specimens from patients with BAV and TAV. These results suggest that circulating biomarkers may form the foundation for a broader platform of biomarkers capable of detecting the presence of TAA using a simple blood test and may also be useful in personalized strategies to distinguish between etiologic subtypes of TAAs in patients with aneurysm disease. (J Thorac Cardiovasc Surg 2013; 145:1326-33)
C1 [Ikonomidis, John S.; Ivey, Charlotte R.; Wheeler, Jason B.; Akerman, Adam W.; Rice, Allison; Patel, Risha K.; Stroud, Robert E.; Mukherjee, Rupak; Jones, Jeffrey A.] Med Univ S Carolina, Dept Surg, Div Cardiothorac Surg, Charleston, SC 29425 USA.
[Shah, Asad A.; Hughes, Chad G.] Duke Univ, Sch Med, Dept Surg, Div Cardiothorac Surg, Durham, NC USA.
[Ferrari, Giovanni] Univ Penn, Sch Med, Perelman Sch Med, Dept Surg, Philadelphia, PA 19104 USA.
[Jones, Jeffrey A.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC USA.
RP Ikonomidis, JS (reprint author), Med Univ S Carolina, 25 Courtenay Dr,Suite 7030, Charleston, SC 29425 USA.
EM ikonomij@musc.edu
FU National Institutes of Health/National Institute on Aging [AG036954];
National Institutes of Health/National Heart, Lung, and Blood Institute
[HL102121]; Veterans Affairs Merit Award [1 I01 BX000904-01]
FX This study was supported by the following grants: National Institutes of
Health/National Institute on Aging No. AG036954, National Institutes of
Health/National Heart, Lung, and Blood Institute No. HL102121, and
Veterans Affairs Merit Award No. 1 I01 BX000904-01.
NR 20
TC 20
Z9 21
U1 0
U2 10
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5223
J9 J THORAC CARDIOV SUR
JI J. Thorac. Cardiovasc. Surg.
PD MAY
PY 2013
VL 145
IS 5
BP 1326
EP 1333
DI 10.1016/j.jtcvs.2012.12.027
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 129LJ
UT WOS:000317840600029
PM 23312977
ER
PT J
AU Backhus, LM
Hayanga, AJ
Au, D
Zeliadt, SB
AF Backhus, Leah M.
Hayanga, Awori J.
Au, David
Zeliadt, Steven B.
TI The Effect of Provider Density on Lung Cancer Survival Among Blacks and
Whites in the United States
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Article
DE Lung cancer; Racial disparities; Provider density
ID PROSTATE-CANCER; GEOGRAPHIC ACCESS; NORTHERN ENGLAND; HEALTH-CARE;
TRAVEL-TIME; BREAST; DISPARITIES; MORTALITY; SURGERY; RACE
AB Introduction: Lung cancer mortality rates may vary with access to specialty providers and local resources. We sought to examine the effect of access to care, using density of lung cancer care providers, on lung cancer mortality among blacks and whites in the United States.
Methods: We examined U.S. county-level data for age-adjusted lung cancer mortality rates from 2003 to 2007. Our primary independent variable was per capita number of thoracic oncologic providers, adjusting for county-level smoking rates, socioeconomic status, and other geographic factors. Data were obtained from 2009 Area Resource File, National Center for Health Statistics, and the County Health Rankings Project.
Results: Providers of lung cancer care were unevenly distributed among the U.S. counties. For example, 41.4% of the U.S. population reside in counties with less than four thoracic surgeons per 100,000 people, 23.4% in counties with 4 to 15 surgeons per 100,000 people, and 35.3% in counties with more than 15 surgeons per 100,000 people. Geographically, 4.3% of whites compared with 11.2% of blacks lived in high lung cancer mortality zones. Lung cancer mortality did not vary by density of thoracic surgeons or oncology services; however, higher primary care provider density was associated with lung cancer mortality reduction of 4.1 per 100,000 for whites.
Conclusion: Variation in provider density for thoracic oncology in the United States was not associated with a difference in lung cancer mortality. Lower mortality associated with higher primary care provider density suggests that equitable access to primary care may lead to reduced cancer disparities.
C1 [Backhus, Leah M.; Au, David; Zeliadt, Steven B.] VA Puget Sound Healthcare Syst, Seattle, WA USA.
[Backhus, Leah M.; Hayanga, Awori J.] Univ Washington, Div Cardiothorac Surg, Seattle, WA 98195 USA.
[Au, David] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA.
[Au, David; Zeliadt, Steven B.] VA Hlth Serv Res & Dev Serv, Seattle, WA USA.
RP Backhus, LM (reprint author), Univ Washington, Div Cardiothorac Surg, 1959 NE Pacific St,Suite 356310, Seattle, WA 98195 USA.
EM lbackhus@u.washington.edu
OI Backhus, Leah/0000-0002-4553-1003
NR 20
TC 4
Z9 4
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD MAY
PY 2013
VL 8
IS 5
BP 549
EP 553
DI 10.1097/JTO.0b013e318287c24c
PG 5
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA 125ZX
UT WOS:000317582000017
PM 23446202
ER
PT J
AU Conte, MS
Owens, CD
Belkin, M
Creager, MA
Edwards, KL
Gasper, WJ
Kenagy, RD
LeBoeuf, RC
Sobel, M
Clowes, A
AF Conte, Michael S.
Owens, Christopher D.
Belkin, Michael
Creager, Mark A.
Edwards, Karen L.
Gasper, Warren J.
Kenagy, Richard D.
LeBoeuf, Renee C.
Sobel, Michael
Clowes, Alexander
TI A single nucleotide polymorphism in the p27(Kip1) gene is associated
with primary patency of lower extremity vein bypass grafts
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Article; Proceedings Paper
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery (SVS)
CY JUN 16-18, 2011
CL Chicago, IL
SP Soc Vasc Surg (SVS)
ID DEPENDENT KINASE INHIBITORS; SMOOTH-MUSCLE-CELLS; PROMOTER ACTIVITY;
VASCULAR-DISEASE; PREVENT-III; SURGERY; ARTERY; FAILURE; TRIAL;
EDIFOLIGIDE
AB Objective: Factors responsible for the variability in outcomes after lower extremity vein bypass grafting (LEVBG) are poorly understood. Recent evidence has suggested that a single nucleotide polymorphism (SNP) in the promoter region of the p27(Kip1) gene, a cell-cycle regulator, is associated with coronary in-stent restenosis. We hypothesized an association with vein graft patency.
Methods: This was a retrospective genetic association study nested within a prospective cohort of 204 patients from three referral centers undergoing LEVBG for claudication or critical ischemia. The main outcome measure was primary vein graft patency.
Results: All patients were followed up for a minimum of 1 year with duplex graft surveillance (median follow-up, 893 days; interquartile range, 539-1315). Genomic DNA was isolated and SNP analysis for the p27(Kip1)-838C>A variants was performed. Allele frequencies were correlated with graft outcome using survival analysis and Cox proportional hazards modeling. The p27(Kip1)-838C>A allele frequencies observed were CA, 53%; CC, 30%; and AA, 17%, satisfying Hardy-Weinberg equilibrium. Race (P = .025) and history of coronary artery disease (P = .027) were different across the genotypes; all other baseline variables were similar. Primary graft patency was greater among patients with the -838AA genotype (75% AA vs 55% CA/CC at 3 years; P = .029). In a Cox proportional hazards model including age, sex, race, diabetes, critical limb ischemia, redo (vs primary) bypass, vein type, and baseline C-reactive protein level, the p27(Kip1)-838AA genotype was significantly associated with higher graft patency (hazard ratio for failure, 0.4; 95% confidence interval, 0.17-0.93). Genotype was also associated with early (0-1 month) changes in graft lumen diameter by ultrasound imaging.
Conclusions: These data suggest that the p27(Kip1)-838C>A SNP is associated with LEVBG patency and, together with previous reports, underscore a central role for p27(Kip1) in the generic response to vascular injury. (J Vasc Surg 2013;57:1179-85.)
C1 [Conte, Michael S.; Owens, Christopher D.; Gasper, Warren J.] Univ Calif San Francisco, Div Vasc & Endovasc Surg, San Francisco, CA 94143 USA.
[Belkin, Michael] Brigham & Womens Hosp, Div Vasc & Endovasc Surg, Boston, MA 02115 USA.
[Creager, Mark A.; Sobel, Michael] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02115 USA.
[Edwards, Karen L.] Univ Washington, Dept Epidemiol, Inst Publ Hlth Genet, Seattle, WA 98195 USA.
[Kenagy, Richard D.; Clowes, Alexander] Univ Washington, Dept Surg, Seattle, WA 98195 USA.
[LeBoeuf, Renee C.] Univ Washington, Dept Med, Seattle, WA USA.
[Sobel, Michael] Univ Washington, Div Vasc Surg, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
RP Conte, MS (reprint author), Univ Calif San Francisco, Heart & Vasc Ctr, Div Vasc & Endovasc Surg, 400 Parnassus Ave, San Francisco, CA 94143 USA.
EM michael.conte@ucsfmedctr.org
FU CSRD VA [I01 CX000712]; NHLBI NIH HHS [R01 HL098227, HL098227, HL30946,
HL75771, R01 HL030946, R01 HL075771]; NIDDK NIH HHS [P30 DK017047]
NR 32
TC 9
Z9 12
U1 0
U2 5
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD MAY
PY 2013
VL 57
IS 5
BP 1179
EP +
DI 10.1016/j.jvs.2012.11.040
PG 9
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 127RS
UT WOS:000317716700001
PM 23312942
ER
PT J
AU Kougias, P
Orcutt, S
Pak, T
Pisimisis, G
Barshes, NR
Lin, PH
Bechara, CF
AF Kougias, Panos
Orcutt, Sonia
Pak, Taemee
Pisimisis, George
Barshes, Neal R.
Lin, Peter H.
Bechara, Carlos F.
TI Impact of postoperative nadir hemoglobin and blood transfusion on
outcomes after operations for atherosclerotic vascular disease
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Article; Proceedings Paper
CT William J. Von Liebig Forum at the Rapid Session of the Vascular Annual
Meeting of the Society-for-Vascular-Surgery (SVS) /
Peripheral-Vascular-Surgery-Society Session
CY JUN 07-09, 2012
CL National Harbor, MD
SP Soc Vasc Surg (SVS), Peripheral Vasc Surg Soc
ID ACUTE MYOCARDIAL-INFARCTION; CLINICAL-PRACTICE GUIDELINE; ACUTE CORONARY
SYNDROMES; CELL TRANSFUSION; RESTRICTIVE TRANSFUSION; NONCARDIAC
SURGERY; CARDIAC-SURGERY; CRITICAL-CARE; TRIAL; REQUIREMENTS
AB Objective: Controversy surrounds the topic of transfusion policy after noncardiac operations. This study assessed the combined impact of postoperative nadir hemoglobin (nHb) levels and blood transfusion on adverse events after open surgical intervention in patients who undergo operative intervention for atherosclerotic vascular disease. Methods: Consecutive patients who underwent peripheral arterial disease (PAD)-related operations were balanced on baseline characteristics by inverse weighting on propensity score calculated as their probability to have nHb greater than 10 gm/dL on the basis of operation type, demographics, and comorbidities, including the revised cardiac risk index. A multivariate generalized estimating equation analysis was performed to investigate associations between nHb, transfusion, and a composite outcome of perioperative death and myocardial infarction. Logistic and Cox proportional hazards regressions were used to assess the impact of nHb and transfusion on respiratory and wound complications; and a composite end point (CE) of death, myocardial infarction during a 2-year follow-up. Level of statistical significance was set at alpha of 0.0125 to adjust for the increased probability of type I error attributable to multiple comparisons. Results: The analysis cohort included 880 patients (1074 operations). After adjusting for nHb level, the number of units transfused was not associated with the perioperative occurrence of the CE(odds ratio[OR], 1.13; P = .025). Adjusted for the number of units transfused, nHb had no impact on the perioperative CE (OR, 0.62; P = .22). An interaction term between transfusion and nHb level remained nonsignificant (P = .312), indicating that the impact of blood transfusion was the same regardless of the nHb level. Perioperative respiratory complications were more likely in patients receiving transfusions (OR, 1.22; P = .009), and perioperative wound infections were less common in patients with nHb > 10 gm/dL (OR, 0.65; P = .01). During an average follow-up of 24 months, transfused patients were more likely to develop the CE (hazard ratio [HR], 1.15, P = .009), whereas nHb level did not impact the long-term adverse event rate (HR, 0.78; P = .373). The above associations persisted even after adjusting the Cox regression model for the occurrence of perioperative cardiac events. Conclusions: Although nHb less than 10 gm/dL is not associated with death or ACS after PAD-related operations, maintaining nHb greater than 10 gm/dL appears to decrease the risk of wound infection. Blood transfusion is associated with increased risk of perioperative respiratory complications. Until a randomized trial settles this issue definitively, a restrictive transfusion strategy is justified in patients undergoing operations for atherosclerotic vascular disease. (J Vasc Surg 2013;57:1331-7.)
C1 [Kougias, Panos; Pisimisis, George; Barshes, Neal R.; Bechara, Carlos F.] Michael E DeBakey VA Med Ctr, Houston, TX USA.
[Kougias, Panos; Orcutt, Sonia; Pak, Taemee; Pisimisis, George; Barshes, Neal R.; Lin, Peter H.; Bechara, Carlos F.] Baylor Coll Med, Houston, TX 77030 USA.
RP Kougias, P (reprint author), Houston VAMC, Michael E DeBakey Dept Surg, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA.
EM pkougias@bcm.edu
NR 33
TC 3
Z9 3
U1 1
U2 4
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD MAY
PY 2013
VL 57
IS 5
BP 1331
EP 1337
DI 10.1016/j.jvs.2012.10.108
PG 7
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 127RS
UT WOS:000317716700026
PM 23384496
ER
PT J
AU Brown, JR
AF Brown, Jennifer R.
TI Gastric mucosa-associated lymphoid tissue lymphoma resistant to
Helicobacter pylori eradication: what's the best option?
SO LEUKEMIA & LYMPHOMA
LA English
DT Editorial Material
ID MALT LYMPHOMA; T(11/18); THERAPY
C1 [Brown, Jennifer R.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Brown, Jennifer R.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA.
RP Brown, JR (reprint author), Harvard Univ, Sch Med, CLL Ctr, 450 Brookline Ave, Boston, MA 02215 USA.
EM jbrown2@partners.org
NR 11
TC 0
Z9 0
U1 0
U2 3
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1042-8194
J9 LEUKEMIA LYMPHOMA
JI Leuk. Lymphoma
PD MAY
PY 2013
VL 54
IS 5
BP 899
EP 900
DI 10.3109/10428194.2012.746686
PG 2
WC Oncology; Hematology
SC Oncology; Hematology
GA 126ZJ
UT WOS:000317661900001
PM 23127114
ER
PT J
AU Jacobo, SMP
DeAngelis, MM
Kim, IK
Kazlauskas, A
AF Jacobo, Sarah Melissa P.
DeAngelis, Margaret M.
Kim, Ivana K.
Kazlauskas, Andrius
TI Age-Related Macular Degeneration-Associated Silent Polymorphisms in
HtrA1 Impair Its Ability To Antagonize Insulin-Like Growth Factor 1
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; VASCULAR ENDOTHELIAL-CELLS; FACTOR BINDING
PROTEIN-5; SERINE-PROTEASE HTRA1; PULSE PROTEOLYSIS; MESSENGER-RNA;
FACTOR-I; CHOROIDAL NEOVASCULARIZATION; NASCENT POLYPEPTIDE; SECONDARY
STRUCTURE
AB Synonymous single nucleotide polymorphisms (SNPs) within a transcript's coding region produce no change in the amino acid sequence of the protein product and are therefore intuitively assumed to have a neutral effect on protein function. We report that two common variants of high-temperature requirement A1 (HTRA1) that increase the inherited risk of neovascular age-related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of HTRA1 that convert common codons for Ala34 and Gly36 to less frequently used codons. The frequent-to-rare codon conversion reduced the mRNA translation rate and appeared to compromise HtrA1's conformation and function. The protein product generated from the SNP-containing cDNA displayed enhanced susceptibility to proteolysis and a reduced affinity for an anti-HtrA1 antibody. The NvAMD-associated synonymous polymorphisms lie within HtrA1's putative insulin-like growth factor 1 (IGF-1) binding domain. They reduced HtrA1's abilities to associate with IGF-1 and to ameliorate IGF-1-stimulated signaling events and cellular responses. These observations highlight the relevance of synonymous codon usage to protein function and implicate homeostatic protein quality control mechanisms that may go awry in NvAMD.
C1 [Jacobo, Sarah Melissa P.; Kazlauskas, Andrius] Harvard Univ, Sch Med, Dept Ophthalmol, Schepens Eye Res Inst, Boston, MA 02114 USA.
[Jacobo, Sarah Melissa P.; Kazlauskas, Andrius] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
[DeAngelis, Margaret M.] Univ Utah, John A Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT USA.
[Kim, Ivana K.] Harvard Univ, Sch Med, Dept Ophthalmol, Massachusetts Eye & Ear Infirm, Boston, MA USA.
RP Kazlauskas, A (reprint author), Harvard Univ, Sch Med, Dept Ophthalmol, Schepens Eye Res Inst, Boston, MA 02114 USA.
EM andrius_kazlauskas@meei.harvard.edu
RI DeAngelis, e/J-7863-2015;
OI Jacobo, Sarah Melissa/0000-0002-1341-7222
FU AMD Center for Excellence; Thome Memorial Foundation Bank of America;
[EY014458]
FX The AMD Center for Excellence provided support for this project, as did
EY014458 and Thome Memorial Foundation Bank of America grants to M.M.D.
NR 80
TC 8
Z9 8
U1 0
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD MAY
PY 2013
VL 33
IS 10
BP 1976
EP 1990
DI 10.1128/MCB.01283-12
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 130ZN
UT WOS:000317959900009
PM 23478260
ER
PT J
AU Sheth, SA
Eckhardt, CA
Walcott, BP
Eskandar, EN
Simon, MV
AF Sheth, Sameer A.
Eckhardt, Christine A.
Walcott, Brian P.
Eskandar, Emad N.
Simon, Mirela V.
TI Factors Affecting Successful Localization of the Central Sulcus Using
the Somatosensory Evoked Potential Phase Reversal Technique
SO NEUROSURGERY
LA English
DT Article
DE Brain neoplasms; Cerebral cortex; Electrophysiology; Intraoperative;
Monitoring; Neurosurgery; Somatosensory evoked potentials
ID SENSORIMOTOR CORTEX; PRECENTRAL GYRUS; BRAIN PLASTICITY; FUNCTIONAL MRI;
MOTOR CORTEX; SURGERY; TUMORS; SUPPRESSION; RESECTION; EPILEPSY
AB BACKGROUND: Perirolandic surgery is associated with an increased risk of postoperative neurological deficit that can be reduced by accurate recognition of the location of sensorimotor cortex. The median somatosensory evoked potential (MSSEP) phase reversal technique (PRT) reliably identifies the central sulcus (CS) intraoperatively, but does require additional surgical time. Awareness of factors that lengthen the time required for MSSEP PRT has important implications for surgical planning.
OBJECTIVE: To identify factors that affect the time required for CS localization via MSSEP PRT.
METHODS: Multivariate Cox regression analysis, applied in 100 consecutive cases of perirolandic surgery at a single institution from 2005 to 2010, during which CS localization was attempted via a standardized MSSEP PRT.
RESULTS: The CS was reliably identified in 77 cases. The mean time to identification was 5 minutes (SD=5; range, 1-20 minutes). Lesion location either very close to the CS (within the postcentral gyrus) or at an intermediate distance (with edema extending very close to the CS) independently decreased the rate at which the CS was identified by 73% (hazard ratio: 0.27, P<.001) and 55% (hazard ratio: 0.45, P=.007), respectively. Highly destructive pathology reduced this rate by 42% (hazard ratio: 0.58, P=.03), after adjusting for other important factors. Epidural recording, age, and the presence of a burst suppression pattern on the electroencephalogram had no effect.
CONCLUSION: MSSEP PRT is an effective method for CS identification and only marginally lengthens the operative time. However, difficulty in CS localization can be expected in the presence of postcentral gyrus lesions, edema distorting perirolandic anatomy, and with highly destructive pathology.
C1 [Sheth, Sameer A.; Eckhardt, Christine A.; Walcott, Brian P.; Eskandar, Emad N.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
[Simon, Mirela V.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Simon, Mirela V.] Harvard Univ, Sch Med, Boston, MA USA.
RP Sheth, SA (reprint author), Massachusetts Gen Hosp, Dept Neurosurg, 55 Fruit St,White 502, Boston, MA 02114 USA.
EM sheth@post.harvard.edu
NR 31
TC 4
Z9 6
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0148-396X
J9 NEUROSURGERY
JI Neurosurgery
PD MAY
PY 2013
VL 72
IS 5
BP 828
EP 834
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 130KS
UT WOS:000317915100031
PM 23381491
ER
PT J
AU Geiser, DM
Aoki, T
Bacon, CW
Baker, SE
Bhattacharyya, MK
Brandt, ME
Brown, DW
Burgess, LW
Chulze, S
Coleman, JJ
Correll, JC
Covert, SF
Crous, PW
Cuomo, CA
De Hoog, GS
Di Pietro, A
Elmer, WH
Epstein, L
Frandsen, RJN
Freeman, S
Gagkaeva, T
Glenn, AE
Gordon, TR
Gregory, NF
Hammond-Kosack, KE
Hanson, LE
Jimenez-Gasco, MD
Kang, S
Kistler, HC
Kuldau, GA
Leslie, JF
Logrieco, A
Lu, GZ
Lysoe, E
Ma, LJ
McCormick, SP
Migheli, Q
Moretti, A
Munaut, F
O'Donnell, K
Pfenning, L
Ploetz, RC
Proctor, RH
Rehner, SA
Robert, VARG
Rooney, AP
bin Salleh, B
Scandiani, MM
Scauflaire, J
Short, DPG
Steenkamp, E
Suga, H
Summerell, BA
Sutton, DA
Thrane, U
Trail, F
Van Diepeningen, A
VanEtten, HD
Viljoen, A
Waalwijk, C
Ward, TJ
Wingfield, MJ
Xu, JR
Yang, XB
Yli-Mattila, T
Zhang, N
AF Geiser, David M.
Aoki, Takayuki
Bacon, Charles W.
Baker, Scott E.
Bhattacharyya, Madan K.
Brandt, Mary E.
Brown, Daren W.
Burgess, Lester W.
Chulze, Sofia
Coleman, Jeffrey J.
Correll, James C.
Covert, Sarah F.
Crous, Pedro W.
Cuomo, Christina A.
De Hoog, G. Sybren
Di Pietro, Antonio
Elmer, Wade H.
Epstein, Lynn
Frandsen, Rasmus J. N.
Freeman, Stanley
Gagkaeva, Tatiana
Glenn, Anthony E.
Gordon, Thomas R.
Gregory, Nancy F.
Hammond-Kosack, Kim E.
Hanson, Linda E.
Jimenez-Gasco, Maria del Mar
Kang, Seogchan
Kistler, H. Corby
Kuldau, Gretchen A.
Leslie, John F.
Logrieco, Antonio
Lu, Guozhong
Lysoe, Erik
Ma, Li-Jun
McCormick, Susan P.
Migheli, Quirico
Moretti, Antonio
Munaut, Francoise
O'Donnell, Kerry
Pfenning, Ludwig
Ploetz, Randy C.
Proctor, Robert H.
Rehner, Stephen A.
Robert, Vincent A. R. G.
Rooney, Alejandro P.
bin Salleh, Baharuddin
Mercedes Scandiani, Maria
Scauflaire, Jonathan
Short, Dylan P. G.
Steenkamp, Emma
Suga, Haruhisa
Summerell, Brett A.
Sutton, Deanna A.
Thrane, Ulf
Trail, Francis
Van Diepeningen, Anne
VanEtten, Hans D.
Viljoen, Altus
Waalwijk, Cees
Ward, Todd J.
Wingfield, Michael J.
Xu, Jin-Rong
Yang, Xiao-Bing
Yli-Mattila, Tapani
Zhang, Ning
TI One Fungus, One Name: Defining the Genus Fusarium in a Scientifically
Robust Way That Preserves Longstanding Use
SO PHYTOPATHOLOGY
LA English
DT Article
ID SOLANI SPECIES COMPLEX; SUDDEN-DEATH SYNDROME; PHYLOGENY; TUCUMANIAE;
TAXONOMY; REVEALS; GENERA
AB In this letter, we advocate recognizing the genus Fusarium as the sole name for a group that includes virtually all Fusarium species of importance in plant pathology, mycotoxicology, medicine, and basic research. This phylogenetically guided circumscription will free scientists from any obligation to use other genus names, including teleomorphs, for species nested within this clade, and preserve the application of the name Fusarium in the way it has been used for almost a century. Due to recent changes in the International Code of Nomenclature for algae, fungi, and plants, this is an urgent matter that requires community attention. The alternative is to break the longstanding concept of Fusarittm into nine or more genera, and remove important taxa such as those in the E solani species complex from the genus, a move we believe is unnecessary. Here we present taxonomic and nomenclatural proposals that will preserve established research connections and facilitate communication within alid between research communities, and at the same time support strong scientific principles and good taxonomic practice.
C1 [Geiser, David M.; Jimenez-Gasco, Maria del Mar; Kang, Seogchan; Kuldau, Gretchen A.] Penn State Univ, Dept Plant Pathol, University Pk, PA 16802 USA.
[Aoki, Takayuki] Natl Inst Agrobiol Sci, Genet Divers Dept, Tsukuba, Ibaraki 3058602, Japan.
[Bacon, Charles W.; Glenn, Anthony E.] USDA ARS SAA, Athens, GA 30605 USA.
[Baker, Scott E.] Pacific NW Natl Lab, Richland, WA 99352 USA.
[Bhattacharyya, Madan K.; Yang, Xiao-Bing] Iowa State Univ, Dept Plant Pathol & Microbiol, Ames, IA 50011 USA.
[Brandt, Mary E.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.
[Brown, Daren W.; McCormick, Susan P.; O'Donnell, Kerry; Proctor, Robert H.; Rooney, Alejandro P.; Ward, Todd J.] NCAUR ARS USDA, Peoria, IL 61604 USA.
[Burgess, Lester W.] Univ Sydney, Fac Agr, Sydney, NSW 2006, Australia.
[Chulze, Sofia] Univ Nacl Rio Cuarto, Dept Microbiol & Immunol, Cordoba, Argentina.
[Coleman, Jeffrey J.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Correll, James C.] Univ Arkansas, Dept Plant Pathol, Fayetteville, AR 72701 USA.
[Covert, Sarah F.] Univ Georgia, Warnell Sch Forestry & Nat Resources, Athens, GA 30602 USA.
[Crous, Pedro W.; De Hoog, G. Sybren; Robert, Vincent A. R. G.; Van Diepeningen, Anne] CBS KNAW Fungal Biodivers Ctr, Utrecht, Netherlands.
[Cuomo, Christina A.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
[Di Pietro, Antonio] Univ Cordoba, Dept Genet, Cordoba, Spain.
[Elmer, Wade H.] Connecticut Agr Expt Stn, Dept Plant Pathol, New Haven, CT 06504 USA.
[Epstein, Lynn; Gordon, Thomas R.; Short, Dylan P. G.] Univ Calif Davis, Dept Plant Pathol, Davis, CA 95616 USA.
[Frandsen, Rasmus J. N.; Thrane, Ulf] Tech Univ Denmark, Dept Syst Biol, DK-2800 Lyngby, Denmark.
[Freeman, Stanley] Agr Res Org, Volcani Ctr, Dept Plant Pathol & Weed Res, IL-50250 Bet Dagan, Israel.
[Gagkaeva, Tatiana] All Russian Inst Plant Protect, Lab Mycol & Phytopathol, St Petersburg 196608, Russia.
[Gregory, Nancy F.] Univ Delaware, Dept Plant & Soil Sci, Newark, DE 19716 USA.
[Hammond-Kosack, Kim E.] Rothamsted Res, Ctr Sustainable Pest & Dis Management, Harpenden AL5 2JQ, Herts, England.
[Hanson, Linda E.] ARS USDA Sugarbeet & Bean Res Unit, E Lansing, MI 48824 USA.
[Kistler, H. Corby] ARS USDA Cereal Dis Lab, St Paul, MN 55108 USA.
[Leslie, John F.] Kansas State Univ, Dept Plant Pathol, Manhattan, KS 66506 USA.
[Logrieco, Antonio; Moretti, Antonio] CNR, ISPA Inst Sci Food Prod, I-70126 Bari, Italy.
[Lu, Guozhong] Dalian Nationalities Univ, Res Ctr Bioresources & Environm, Liaoning, Peoples R China.
[Lysoe, Erik] Bioforsk Norwegian Inst Agr & Environm Res, Dept Plant Hlth & Plant Protect, N-1432 As, Norway.
[Ma, Li-Jun] Univ Massachusetts, Dept Plant Soil & Insect Sci, Amherst, MA 01003 USA.
[Migheli, Quirico] Univ Sassari, Dipartimento Protez Piante, I-07100 Sassari, Italy.
[Munaut, Francoise; Scauflaire, Jonathan] Catholic Univ Louvain, Earth & Life Inst, B-1348 Louvain, Belgium.
[Pfenning, Ludwig] Univ Fed Lavras, Dept Fitopatol, Lavras, MG, Brazil.
[Ploetz, Randy C.] Univ Florida, Ctr Trop Res & Educ, Dept Plant Pathol, Homestead, FL 33031 USA.
[Rehner, Stephen A.] ARS, Systemat Mycol & Microbiol Lab, USDA, Beltsville, MD 20705 USA.
[bin Salleh, Baharuddin] Univ Sci Malaysia, Sch Biol Sci, George Town, Malaysia.
[Mercedes Scandiani, Maria] Lab Agr Rio Parana, Buenos Aires, DF, Argentina.
[Short, Dylan P. G.] US Agr Res Stn, Salinas, CA 93905 USA.
[Steenkamp, Emma; Wingfield, Michael J.] Univ Pretoria, FABI, Dept Microbiol & Plant Pathol, ZA-0002 Pretoria, South Africa.
[Suga, Haruhisa] Gifu Univ, Gifu, Japan.
[Summerell, Brett A.] Royal Bot Garden Sydney, Sydney, NSW 2000, Australia.
[Sutton, Deanna A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Trail, Francis] Michigan State Univ, Dept Plant Biol, E Lansing, MI 48824 USA.
[VanEtten, Hans D.] Univ Arizona, Div Plant Pathol & Microbiol, Tucson, AZ 85721 USA.
[Viljoen, Altus] Univ Stellenbosch, Dept Plant Pathol, ZA-7602 Matieland, South Africa.
[Waalwijk, Cees] Wageningen Univ & Res, Plant Res Int, NL-6700 Wageningen, Netherlands.
[Xu, Jin-Rong] Purdue Univ, Dept Plant Pathol, W Lafayette, IN 47907 USA.
[Yli-Mattila, Tapani] Univ Turku, Lab Plant Physiol & Mol Biol, Dept Biol, FIN-20014 Turku, Finland.
[Zhang, Ning] Rutgers State Univ, Dept Plant Biol & Pathol, New Brunswick, NJ 08901 USA.
RP Geiser, DM (reprint author), Penn State Univ, Dept Plant Pathol, University Pk, PA 16802 USA.
EM dgeiser@psu.edu
RI Jimenez-Gasco, Maria del Mar/A-9701-2011; Migheli, Quirico/B-7203-2009;
Crous, Pedro/H-1489-2012; Geiser, David/J-9950-2013; Zhang,
Ning/K-3046-2012; Wingfield, Michael/A-9473-2008; Coleman,
Jeffrey/E-2981-2015; Di Pietro, Antonio/K-9220-2014; Thrane,
Ulf/G-2978-2016; Steenkamp, Emma/B-7958-2009;
OI Frandsen, Rasmus John Normand/0000-0002-3799-6062; Moretti,
Antonio/0000-0002-5232-6972; Logrieco, Antonio
Francesco/0000-0002-8606-451X; Kistler, Harold/0000-0001-5312-6297;
Kang, Seogchan/0000-0003-2291-5634; Jimenez-Gasco, Maria del
Mar/0000-0001-7329-0211; Migheli, Quirico/0000-0002-2459-5833; Crous,
Pedro/0000-0001-9085-8825; Zhang, Ning/0000-0003-0755-2505; Di Pietro,
Antonio/0000-0001-5930-5763; Thrane, Ulf/0000-0002-6040-4141; Steenkamp,
Emma/0000-0003-0217-8219; Ma, Li-Jun/0000-0002-2733-3708; Coleman,
Jeffrey/0000-0001-8579-1996
FU U.S. Department of Agriculture (USDA)
FX We thank P. Cantino for his helpful comments on the PhyloCode statement.
We thank all of our colleagues for their helpful input and discussions
on this important issue. The mention of firm names or trade products
does not imply that they are endorsed or recommended by the U.S.
Department of Agriculture (USDA) over other firms or similar products
not mentioned. The USDA is an equal opportunity provider and employer.
Manuscript no. 13-006-J from the Kansas Agricultural Experiment Station,
Manhattan.
NR 46
TC 47
Z9 48
U1 5
U2 114
PU AMER PHYTOPATHOLOGICAL SOC
PI ST PAUL
PA 3340 PILOT KNOB ROAD, ST PAUL, MN 55121 USA
SN 0031-949X
J9 PHYTOPATHOLOGY
JI Phytopathology
PD MAY
PY 2013
VL 103
IS 5
BP 400
EP 408
PG 9
WC Plant Sciences
SC Plant Sciences
GA 129VW
UT WOS:000317873100001
PM 23379853
ER
PT J
AU Fukumoto, T
Kano, A
Ohtani, K
Inoue, M
Yoshihara, A
Izumori, K
Tajima, S
Shigematsu, Y
Tanaka, K
Ohkouchi, T
Ishida, Y
Nishizawa, Y
Tada, Y
Ichimura, K
Gomi, K
Yoo, SD
Sheen, J
Akimitsu, K
AF Fukumoto, Takeshi
Kano, Akihito
Ohtani, Kouhei
Inoue, Megumi
Yoshihara, Akihide
Izumori, Ken
Tajima, Shigeyuki
Shigematsu, Yoshio
Tanaka, Keiji
Ohkouchi, Takeo
Ishida, Yutaka
Nishizawa, Yoko
Tada, Yasuomi
Ichimura, Kazuya
Gomi, Kenji
Yoo, Sang-Dong
Sheen, Jen
Akimitsu, Kazuya
TI Phosphorylation of D-allose by hexokinase involved in regulation of
OsABF1 expression for growth inhibition in Oryza sativa L.
SO PLANTA
LA English
DT Article
DE Abscisic acid; D-Allose; AtABI5; Hexokinase; OsABF1
ID DEFENSE-RELATED GENES; ABSCISIC-ACID; TRANSCRIPTION FACTOR;
SIGNAL-TRANSDUCTION; ABA 8'-HYDROXYLASE; RESPONSE PATHWAYS;
BACTERIAL-BLIGHT; PROTEIN-KINASES; HIGHER-PLANTS; UP-REGULATION
AB We previously reported that a rare sugar d-allose, which is the d-glucose epimer at C3, inhibits the gibberellin-dependent responses such as elongation of the second leaf sheath and induction of alpha-amylase in embryo-less half seeds in rice (Fukumoto et al. 2011). d-Allose suppresses expressions of gibberellin-responsive genes downstream of SLR1 protein in the gibberellin-signaling through hexokinase (HXK)-dependent pathway. In this study, we discovered that d-allose induced expression of ABA-related genes including OsNCED1-3 and OsABA8ox1-3 in rice. Interestingly, d-allose also up-regulated expression of OsABF1, encoding a conserved bZIP transcription factor in ABA signaling, in rice. The d-allose-induced expression of OsABF1 was diminished by a hexokinase inhibitor, d-mannoheptulose (MNH). Consistently, d-allose also inhibited Arabidopsis growth, but failed to trigger growth retardation in the glucose-insensitive2 (gin2) mutant, which is a loss-of-function mutant of the glucose sensor AtHXK1. d-Allose activated AtABI5 expression in transgenic gin2 over-expressing wild-type AtHXK1 but not in gin2 over-expressing the catalytic mutant AtHXK1(S177A), indicating that the d-allose phosphorylation by HXK to d-allose 6-phosphate (A6P) is the first step for the up-regulation of AtABI5 gene expression as well as d-allose-induced growth inhibition. Moreover, overexpression of OsABF1 showed increased sensitivity to d-allose in rice. These findings indicated that the phosphorylation of d-allose at C6 by hexokinase is essential and OsABF1 is involved in the signal transduction for d-allose-induced growth inhibition.
C1 [Fukumoto, Takeshi; Kano, Akihito; Ohtani, Kouhei; Inoue, Megumi; Yoshihara, Akihide; Izumori, Ken; Tajima, Shigeyuki; Tada, Yasuomi; Ichimura, Kazuya; Gomi, Kenji; Akimitsu, Kazuya] Kagawa Univ, Fac Agr, Rare Sugar Res Ctr, Miki, Kagawa 7610795, Japan.
[Fukumoto, Takeshi; Kano, Akihito; Ohtani, Kouhei; Inoue, Megumi; Yoshihara, Akihide; Izumori, Ken; Tajima, Shigeyuki; Tada, Yasuomi; Ichimura, Kazuya; Gomi, Kenji; Akimitsu, Kazuya] Kagawa Univ, Ctr Gene Res, Miki, Kagawa 7610795, Japan.
[Shigematsu, Yoshio; Tanaka, Keiji; Ohkouchi, Takeo] Mitsui Chem Agro Co Ltd, Yasu, Shiga 5202342, Japan.
[Ishida, Yutaka] Shikoku Res Inst Inc, Takamatsu, Kagawa 7610192, Japan.
[Nishizawa, Yoko] Natl Inst Agrobiol Sci, Tsukuba, Ibaragi 3058602, Japan.
[Yoo, Sang-Dong] Sungkyunkwan Univ, Dept Biol Sci, Suwon 440746, South Korea.
[Sheen, Jen] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
RP Akimitsu, K (reprint author), Kagawa Univ, Fac Agr, Rare Sugar Res Ctr, Miki, Kagawa 7610795, Japan.
EM kazuya@ag.kagawa-u.ac.jp
RI Tada, Yasuomi/M-5041-2014;
OI Tada, Yasuomi/0000-0001-9900-069X
FU Programme for Promotion of Basic and Applied Researches for Innovations
in Bio-oriented Industry
FX We thank Rice Genome Resource Center at National Institute of
Agrobiological Sciences (NIAS, Tsukuba, Japan) for providing full-length
cDNA used in this study. This study was supported by the Programme for
Promotion of Basic and Applied Researches for Innovations in
Bio-oriented Industry.
NR 54
TC 9
Z9 9
U1 3
U2 44
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0032-0935
J9 PLANTA
JI Planta
PD MAY
PY 2013
VL 237
IS 5
BP 1379
EP 1391
DI 10.1007/s00425-013-1853-9
PG 13
WC Plant Sciences
SC Plant Sciences
GA 134BZ
UT WOS:000318186000016
PM 23397192
ER
PT J
AU Penney, KL
Li, HJ
Mucci, LA
Loda, M
Sesso, HD
Stampfer, MJ
Ma, J
AF Penney, Kathryn L.
Li, Haojie
Mucci, Lorelei A.
Loda, Massimo
Sesso, Howard D.
Stampfer, Meir J.
Ma, Jing
TI Selenoprotein P genetic variants and mrna expression, circulating
selenium, and prostate cancer risk and survival
SO PROSTATE
LA English
DT Article
DE genetic variation; selenium; prostate cancer
ID POLYMORPHISM; PREVENTION; TRIAL; SUPPLEMENTATION
AB BACKGROUND Low levels of selenium have been associated with increased risk of prostate cancer (PCa). Selenoprotein P is the most abundant selenoprotein in serum and delivers ten selenocysteine residues to tissues. Variation in the selenoprotein P gene (SEPP1) may influence PCa development or modify the effects of selenium. We examined the association of SEPP1 single nucleotide polymorphisms (SNPs) with PCa risk and survival, and tested for interactions. METHODS The Physicians' Health Study (PHS) is a prospective cohort of 22,071 US physicians; we utilized a nested casecontrol study of 1,352 PCa cases and 1,382 controls. We assessed four SNPs capturing common variation within the SEPP1 locus. In a subset of men (n=80), we evaluated SEPP1 mRNA expression in tumors. RESULTS Two SNPs were significantly associated with PCa risk. For rs11959466, each T allele increased risk (odds ratio (OR)=1.31; 95% confidence interval (CI): 1.02,1.69; Ptrend=0.03). For rs13168440, the rare homozygote genotype decreased risk compared to the common homozygote (OR=0.56, 95% CI: 0.33, 0.96). Moreover, there was a significant interaction of rs13168440 with plasma selenium; increasing selenium levels were associated with decreased PCa risk only among men with the minor allele (Pinteraction=0.01). SEPP1 expression was significantly lower in men with lethal PCa than long-term survivors. CONCLUSIONS SEPP1 genetic variation was associated with PCa incidence; replication of these results in an independent dataset is necessary. These findings further support a causal link between selenium and PCa, and suggest that the effect of selenium may differ by genetics. Prostate 73: 700705, 2013. (c) 2012 Wiley Periodicals, Inc.
C1 [Penney, Kathryn L.; Mucci, Lorelei A.; Stampfer, Meir J.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Penney, Kathryn L.; Mucci, Lorelei A.; Stampfer, Meir J.; Ma, Jing] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.
[Penney, Kathryn L.; Mucci, Lorelei A.; Loda, Massimo; Sesso, Howard D.; Stampfer, Meir J.; Ma, Jing] Harvard Univ, Sch Med, Boston, MA USA.
[Li, Haojie] GlaxoSmithKline R&D, Worldwide Epidemiol Oncol, Collegeville, PA USA.
[Loda, Massimo] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Loda, Massimo] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Sesso, Howard D.] Brigham & Womens Hosp, Dept Med, Div Prevent Med & Aging, Boston, MA 02115 USA.
RP Penney, KL (reprint author), Brigham & Womens Hosp, Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA.
EM kpenney@hsph.harvard.edu; jing.ma@channing.harvard.edu
FU Department of Defense [PC073618, PC050569]; National Cancer Institute
[CA42182, CA34944, CA40360, CA141298, CA097193]; National Heart, Lung,
and Blood Institute, Bethesda, Maryland [HL26490, HL34595]; Prostate
Cancer Foundation; National Research Service Award [T32 CA009001]
FX Grant sponsor: Department of Defense; Grant numbers: PC073618, PC050569;
Grant sponsor: National Cancer Institute; Grant numbers: CA42182,
CA34944, CA40360, CA141298, CA097193; Grant sponsor: National Heart,
Lung, and Blood Institute, Bethesda, Maryland; Grant numbers: HL26490,
HL34595; Grant sponsor: Prostate Cancer Foundation; Grant sponsor:
National Research Service Award; Grant number: T32 CA009001.
NR 22
TC 11
Z9 16
U1 0
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-4137
J9 PROSTATE
JI Prostate
PD MAY
PY 2013
VL 73
IS 7
BP 700
EP 705
DI 10.1002/pros.22611
PG 6
WC Endocrinology & Metabolism; Urology & Nephrology
SC Endocrinology & Metabolism; Urology & Nephrology
GA 130PL
UT WOS:000317930600003
PM 23129481
ER
PT J
AU Prencipe, M
Madden, SF
O'Neill, A
O'Hurley, G
Culhane, A
O'Connor, D
Klocker, H
Kay, EW
Gallagher, WM
Watson, WR
AF Prencipe, Maria
Madden, Stephen F.
O'Neill, Amanda
O'Hurley, Gillian
Culhane, Aedin
O'Connor, Darran
Klocker, Helmut
Kay, Elaine W.
Gallagher, William M.
Watson, William R.
TI Identification of transcription factors associated with
castration-resistance: Is the serum responsive factor a potential
therapeutic target?
SO PROSTATE
LA English
DT Article
DE advanced prostate cancer; transcription-factors prediction analysis;
serum response factor (SRF)
ID INDEPENDENT PROSTATE-CANCER; CO-INERTIA ANALYSIS; TUMOR-GROWTH; GENE;
OLIGONUCLEOTIDE; PROLIFERATION; PROGRESSION; MECHANISMS; REGULATOR;
DISCOVERY
AB BACKGROUND Advanced prostate cancer is treated by hormone ablation therapy. However, despite an initial response, the majority of men relapse to develop castration-resistant disease for which there are no effective treatments. We have previously shown that manipulating individual proteins has only minor alterations on the resistant phenotype so we hypothesize that targeting the central transcription factors (TFs) would represent a better therapeutic approach. METHODS We have undertaken a transcriptomic analysis of gene expression differences between the androgen-dependent LNCaP parental cells and its castration-resistant Abl and Hof sublines, revealing 1,660 genes associated with castration-resistance. Using effective bioinformatic techniques, these transcriptomic data were integrated with TF binding sites resulting in a list of TFs associated with the differential gene expression observed. RESULTS Following validation of the gene-chip results, the serum response factor (SRF) was chosen for clinical validation and functional analysis due to its recent association with prostate cancer progression. SRF immunoreactivity in prostate tumor samples was shown for the first time to be associated with castration-resistance. SRF inhibition by siRNA and the small molecule inhibitor CCG-1423 resulted in decreased proliferation. CONCLUSION SRF is a key TF by which resistant cells survive with depleted levels of androgens representing a target for therapeutic manipulation. Prostate 73: 743753, 2013. (c) 2013 Wiley Periodicals, Inc.
C1 [Prencipe, Maria; O'Neill, Amanda; Watson, William R.] Univ Coll Dublin, Conway Inst Biomol & Biomed Res, UCD Sch Med & Med Sci, Dublin 2, Ireland.
[Madden, Stephen F.] Dublin City Univ, Natl Inst Cellular Biotechnol, Dublin 9, Ireland.
[O'Hurley, Gillian; Gallagher, William M.] OncoMark Ltd, NovaUCD, Dublin, Ireland.
[Culhane, Aedin] Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA.
[O'Connor, Darran; Gallagher, William M.] Univ Coll Dublin, Conway Inst Biomol & Biomed Res, UCD Sch Biomol & Biomed Sci, Dublin 2, Ireland.
[Klocker, Helmut] Med Univ Innsbruck, Dept Urol, A-6020 Innsbruck, Austria.
[Kay, Elaine W.] Beaumont Hosp, Dept Pathol, RCSI Educ & Res Ctr, Dublin 9, Ireland.
RP Prencipe, M (reprint author), Univ Coll Dublin, Conway Inst Biomol & Biomed Res, UCD Sch Med & Med Sci, D4, Dublin 2, Ireland.
EM maria.prencipe@ucd.ie
RI Kay, Elaine/D-8539-2013;
OI Gallagher, William/0000-0002-4307-5999
FU Science Foundation Ireland Strategic Research Cluster; Molecular
Therapeutics for Cancer Ireland; FP7 Marie Curie Industry-Academia
Partnership and Pathways Program (FAST-PATH)
FX Grant sponsor: Science Foundation Ireland Strategic Research Cluster;
Grant sponsor: Molecular Therapeutics for Cancer Ireland; Grant sponsor:
FP7 Marie Curie Industry-Academia Partnership and Pathways Program
(FAST-PATH).
NR 43
TC 10
Z9 11
U1 1
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-4137
J9 PROSTATE
JI Prostate
PD MAY
PY 2013
VL 73
IS 7
BP 743
EP 753
DI 10.1002/pros.22618
PG 11
WC Endocrinology & Metabolism; Urology & Nephrology
SC Endocrinology & Metabolism; Urology & Nephrology
GA 130PL
UT WOS:000317930600008
PM 23359479
ER
PT J
AU Theall, KP
Brett, ZH
Shirtcliff, EA
Dunn, EC
Drury, SS
AF Theall, Katherine P.
Brett, Zoe H.
Shirtcliff, Elizabeth A.
Dunn, Erin C.
Drury, Stacy S.
TI Neighborhood disorder and telomeres: Connecting children's exposure to
community level stress and cellular response
SO SOCIAL SCIENCE & MEDICINE
LA English
DT Article
DE Neighborhood; Children; Telomere; Stress; Average telomere length
ID BIOLOGICAL RISK PROFILES; CORONARY HEART-DISEASE; ALLOSTATIC LOAD;
SOCIOECONOMIC-STATUS; EARLY-CHILDHOOD; US ADULTS; RESIDENTIAL
PREFERENCES; CARDIOVASCULAR RISK; PHYSICAL-ACTIVITY; CUMULATIVE RISK
AB Our objective was to explore the utility of salivary telomere length (sTL) as an early indicator of neighborhood-level social environmental risk during child development. We therefore tested the hypothesis that sTL would be associated with markers of social stress exposure in children. Children age 4-14 from 87 neighborhoods were recruited through five urban schools in New Orleans, Louisiana, U.S. Data were collected at the level of the child, family/household, and neighborhood. DNA was obtained from saliva using commercially available kits and sTL was determined for 104 children using quantitative PCR. Analysis was performed on 99 children who had complete data including sTL, social environmental stress, and additional covariates. The mean sTL value was 7.4 T/S (telomere signal/single-copy signal) ratio units (+/- 2.4, range = 2.5-18.0), and 4.7% of the variance in sTL was attributed to differences across neighborhoods. Children living in neighborhoods characterized by high disorder had an sTL value 3.2 units lower than children not living in high disordered environments (p < 0.05) and their odds of having low relative sTL (defined as <1 standard deviation below standardized Z-score mean) values was 3.43 times that of children not living in high disorder environments (adjusted OR = 3.43, 95% CI = 1.22, 9.62). Our findings are consistent with previous studies in adults demonstrating a strong link between psychosocial stress and sTL obtained from peripheral blood, consistent with previous studies in youth demonstrating an association between early life stress and sTL obtained from buccal cell DNA and offer increased support for the hypothesis that sTL represents a non-invasive biological indicator of psychosocial stress exposure (i.e., neighborhood disorder) able to reflect differences in stress exposure levels even in young children. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Theall, Katherine P.] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Global Community Hlth & Behav Sci, New Orleans, LA 70112 USA.
[Brett, Zoe H.; Drury, Stacy S.] Tulane Univ, Sch Med, Dept Psychiat & Behav Sci, New Orleans, LA 70112 USA.
[Shirtcliff, Elizabeth A.] Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA.
[Dunn, Erin C.] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA.
RP Theall, KP (reprint author), Tulane Univ, Sch Publ Hlth & Trop Med, Dept Global Community Hlth & Behav Sci, 1440 Canal St,Suite 2301, New Orleans, LA 70112 USA.
EM ktheall@tulane.edu
FU Centers for Disease Control and Prevention, CDC [1K01SH000002]; National
Institutes of Health, NIH [1R01ES020447-01, R21 MH094688-01,
1R01MH091363, K01-MH077687]; Tulane University (CTREC)
FX This study was supported by grants from the Centers for Disease Control
and Prevention, CDC (1K01SH000002 to K.P.T.), the National Institutes of
Health, NIH (1R01ES020447-01 to K.P.T., R21 MH094688-01 to SSD,
1R01MH091363 (Nelson) for ZB, and K01-MH077687 to E.A.S.), and Tulane
University (CTREC to S.D.). This study was approved by the Tulane and
Louisiana State University Institutional Review Boards. The authors
thank Jeanette Magnus, Richard Scribner, Emily Mabile and Immaculata De
Vivo. There are no conflicts of interest to report. We are indebted to
the parents of the subjects for their cooperation and their permission
for their children to participate in the study.
NR 90
TC 43
Z9 43
U1 5
U2 45
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0277-9536
J9 SOC SCI MED
JI Soc. Sci. Med.
PD MAY
PY 2013
VL 85
BP 50
EP 58
DI 10.1016/j.socscimed.2013.02.030
PG 9
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA 129YQ
UT WOS:000317880300008
PM 23540366
ER
PT J
AU Arikatla, VS
Sankaranarayanan, G
Ahn, W
Chellali, A
De, S
Caroline, GL
Hwabejire, J
DeMoya, M
Schwaitzberg, S
Jones, DB
AF Arikatla, Venkata S.
Sankaranarayanan, Ganesh
Ahn, Woojin
Chellali, Amine
De, Suvranu
Caroline, G. L.
Hwabejire, John
DeMoya, Marc
Schwaitzberg, Steven
Jones, Daniel B.
TI Face and construct validation of a virtual peg transfer simulator
SO SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
LA English
DT Article
DE Virtual reality; Surgical training; Face validity; Construct;
Laparoscopy; Length of trajectory
ID LAPAROSCOPIC SKILLS; SURGICAL SIMULATION; PERFORMANCE; VALIDITY;
SURGERY; SYSTEM; FLS
AB The Fundamentals of Laparoscopic Surgery (FLS) trainer box is now established as a standard for evaluating minimally invasive surgical skills. A particularly simple task in this trainer box is the peg transfer task which is aimed at testing the surgeon's bimanual dexterity, hand-eye coordination, speed, and precision. The Virtual Basic Laparoscopic Skill Trainer (VBLaSTA (c)) is a virtual version of the FLS tasks which allows automatic scoring and real-time, subjective quantification of performance without the need of a human proctor. In this article we report validation studies of the VBLaSTA (c) peg transfer (VBLaST-PTA (c)) simulator.
Thirty-five subjects with medical background were divided into two groups: experts (PGY 4-5, fellows, and practicing surgeons) and novices (PGY 1-3). The subjects were asked to perform the peg transfer task on both the FLS trainer box and the VBLaST-PTA (c) simulator; their performance was evaluated based on established metrics of error and time. A new length of trajectory (LOT) metric has also been introduced for offline analysis. A questionnaire was used to rate the realism of the virtual system on a 5-point Likert scale.
Preliminary face validation of the VBLaST-PTA (c) with 34 subjects rated on a 5-point Likert scale questionnaire revealed high scores for all aspects of simulation, with 3.53 being the lowest mean score across all questions. A two-tailed Mann-Whitney test performed on the total scores showed significant (p = 0.001) difference between the groups. A similar test performed on the task time (p = 0.002) and the LOT (p = 0.004) separately showed statistically significant differences between the experts and the novices (p < 0.05). The experts appear to be traversing shorter overall trajectories in less time than the novices.
VBLaST-PTA (c) showed both face and construct validity and has promise as a substitute for the FLS for training peg transfer skills.
C1 [Arikatla, Venkata S.; Sankaranarayanan, Ganesh; Ahn, Woojin; De, Suvranu] Rensselaer Polytech Inst, Ctr Modeling Simulat & Imaging Med, Troy, NY 12180 USA.
[Chellali, Amine; Schwaitzberg, Steven] Harvard Univ, Sch Med, Dept Surg, Cambridge Hlth Alliance, Boston, MA 02115 USA.
[De, Suvranu] Rensselaer Polytech Inst, Dept Mech Aerosp & Nucl Engn, Troy, NY 12180 USA.
[Caroline, G. L.] Wright State Univ, Dept Biomed Ind & Human Factors Engn, Fairborn, OH USA.
[Hwabejire, John; DeMoya, Marc] Harvard Univ, Massachusetts Gen Hosp, Div Trauma, Boston, MA 02115 USA.
[Jones, Daniel B.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Surg, Boston, MA 02215 USA.
RP Arikatla, VS (reprint author), Rensselaer Polytech Inst, Ctr Modeling Simulat & Imaging Med, Troy, NY 12180 USA.
EM arikav@rpi.edu; des@rpi.edu
FU NIH/NIBIB [5R01EB010037]
FX The authors gratefully acknowledge the support of this study by
NIH/NIBIB (Grant No. 5R01EB010037). They also thank Alex Derevianko of
Massachusetts General Hospital (MGH) for helping conduct the experiments
and Saurabh Dargar of Rensselaer Polytechnic Institute for helping
during the hardware design phase.
NR 24
TC 9
Z9 9
U1 2
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0930-2794
J9 SURG ENDOSC
JI Surg. Endosc.
PD MAY
PY 2013
VL 27
IS 5
BP 1721
EP 1729
DI 10.1007/s00464-012-2664-y
PG 9
WC Surgery
SC Surgery
GA 129PG
UT WOS:000317853100037
PM 23263645
ER
PT J
AU Meireles, OR
Horgan, S
Jacobsen, GR
Katagiri, T
Mathew, A
Sedrak, M
Sandler, BJ
Dotai, T
Savides, TJ
Majid, SF
Nijhawan, S
Talamini, MA
AF Meireles, Ozanan R.
Horgan, Santiago
Jacobsen, Garth R.
Katagiri, Toshio
Mathew, Abraham
Sedrak, Michael
Sandler, Bryan J.
Dotai, Takayuki
Savides, Thomas J.
Majid, Saniea F.
Nijhawan, Sheetal
Talamini, Mark A.
TI Transesophageal endoscopic myotomy (TEEM) for the treatment of
achalasia: the United States human experience
SO SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
LA English
DT Article
DE POEM; TEEM; Myotomy; Achalasia; NOTES; Endoscopic
ID ESOPHAGEAL ACHALASIA; SURGERY
AB From our early experience with NOTES, our group has acquired familiarity with transesophageal submucosal dissection and myotomy in swine model, which allowed us to perfect a model to perform purely endoscopic transesophageal myotomy (TEEM) for the treatment of achalasia and apply it into clinical practice. This study was designed to assess the safety, feasibility, and efficacy of TEEM in a series of patients with achalasia.
Under institutional review board approval, patients were enrolled on our study, where TEEM was offered as an alternative to laparoscopic or robotic Heller myotomy. The inclusion criteria were patients with achalasia confirmed by esophageal manometry, between age 18 and 50 years, and ASA class 2 or lower. The exclusion criteria were pregnancy, prior esophageal surgery, immunosuppression, coagulopathies, and severe medical comorbidities. The procedures were performed under general anesthesia, with the patient in supine position on positive pressure ventilation. With a GIF-180 (Olympus, Tokyo, Japan) positioned at 10 cm above the GEJ, a mucosotomy was performed at the 2 o'clock position, and a submucosal space was developed caudally creating a controlled submucosal tunnel extending 2 cm distal to the GEJ. Upon completion of this tunnel the gastroesophageal lumen was inspected for mucosal integrity. The scope was then reinserted into the submucosal tunnel and using a triangle-tip knife, myotomy was performed starting at 5 cm above the GEJ and ending at 2 cm below the GEJ. During this process the circular muscle layer of the esophagus was carefully divided with preservation of the longitudinal layer. At the end of the procedure, the mucosal incision was closed longitudinally with endoscopic clips and surgical glue.
Five patients underwent TEEM, with no perioperative complication. All patients reported significant improvement of their dysphagia immediately after the procedure. On the first postoperative day, all barium swallows showed disappearance of the classical bird beak taper, rapid emptying of contrast into the stomach, and absence of leaks. All patients were discharged on the second postoperative day on liquid diet. Two patients reported transient heartburn, which were well controlled with medications. The average preoperative GERD-HRQL was 20, which improved to 11.3 at 7 days postoperative and 2 at 30 days postoperative. To date, three patients have already returned for their 6-month follow-up, reporting adequate swallowing and low LES pressures on esophageal manometry (their mean preoperative LES resting pressure was 36.46 mmHg and residual pressure was 43.16 mmHg, whereas the 6-month follow-up mean LES resting pressure was 10.06 mmHg and residual pressure was 0.43 mmHg).
TEEM seems to be safe, feasible, and effective for the treatment of patients with achalasia. Long-term data are still necessary for wide-spread utilization of this novel technique.
C1 [Meireles, Ozanan R.; Horgan, Santiago; Jacobsen, Garth R.; Katagiri, Toshio; Mathew, Abraham; Sedrak, Michael; Sandler, Bryan J.; Dotai, Takayuki; Majid, Saniea F.; Nijhawan, Sheetal; Talamini, Mark A.] Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA.
[Meireles, Ozanan R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA 02114 USA.
[Mathew, Abraham] Penn State Milton S Hershey Med Ctr, Dept Gastroenterol, Hershey, PA USA.
[Savides, Thomas J.] Univ Calif San Diego, Dept Gastroenterol, San Diego, CA 92103 USA.
RP Meireles, OR (reprint author), Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA.
EM omeireles@partners.org
NR 15
TC 7
Z9 7
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0930-2794
J9 SURG ENDOSC
JI Surg. Endosc.
PD MAY
PY 2013
VL 27
IS 5
BP 1803
EP 1809
DI 10.1007/s00464-012-2666-9
PG 7
WC Surgery
SC Surgery
GA 129PG
UT WOS:000317853100049
PM 23525881
ER
PT J
AU Bair, SM
Choueiri, TK
Moslehi, J
AF Bair, Steven M.
Choueiri, Toni K.
Moslehi, Javid
TI Cardiovascular complications associated with novel angiogenesis
inhibitors: Emerging evidence and evolving perspectives
SO TRENDS IN CARDIOVASCULAR MEDICINE
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; ARTERIAL
THROMBOEMBOLIC EVENTS; RANDOMIZED CONTROLLED-TRIALS; NITRIC-OXIDE
SYNTHASE; METASTATIC COLORECTAL-CANCER; TREATMENT-RELATED MORTALITY;
ACTIVATED PROTEIN-KINASE; BLOOD-PRESSURE; FLK-1/KDR ACTIVATION
AB Novel cancer therapies targeting tumor angiogenesis have revolutionized treatment options in a variety of tumors. Specifically, VEGF signaling pathway (VSP) inhibitors have been introduced into clinical practice at a rapid pace over the last decade. It is becoming increasingly clear that VSP inhibitors can cause cardiovascular toxicities including hypertension, thrombosis, and heart failure. This review highlights these toxicities and proposes several strategies in their prevention and treatment. However, we recognize the dearth of data in this area and advocate a multi-disciplinary approach involving cardiologists and oncologists, as well as clinical and translational studies, in understanding and treating VSP-inhibitor associated toxicities. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Bair, Steven M.; Moslehi, Javid] Brigham & Womens Hosp, Dept Med, Div Cardiovasc Med, Boston, MA 02115 USA.
[Bair, Steven M.; Choueiri, Toni K.; Moslehi, Javid] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Med Oncol, Boston, MA 02115 USA.
[Moslehi, Javid] Harvard Univ, Sch Med, Dana Farber Canc Inst, Early Drug Dev Ctr, Boston, MA 02115 USA.
[Moslehi, Javid] Harvard Univ, Sch Med, Dana Farber Canc Inst, Adult Survivorship Clin, Boston, MA 02115 USA.
RP Moslehi, J (reprint author), Brigham & Womens Hosp, Dana Farber Canc Inst, Cardiooncol Program, 75 Francis St, Boston, MA 02115 USA.
EM jmoslehi@partners.org
FU Stanley Sarnoff Fellowship; NIH Career Development Award [K08]; Watkins
Discovery Award Program; Cardiovascular Leadership Council Investigator
Award (both by Brigham and Women's Hospital)
FX We thank Drs. James Michael Kirshenbaum and William George Kaelin, Jr.
for critical review of the manuscript. SMB is supported by the Stanley
Sarnoff Fellowship. JM is supported by an NIH Career Development Award
(K08), Watkins Discovery Award Program, and Cardiovascular Leadership
Council Investigator Award (both by Brigham and Women's Hospital). The
authors thank Dr. William G. Kaelin, Jr. for his continuous mentorship.
NR 65
TC 30
Z9 30
U1 0
U2 3
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 1050-1738
J9 TRENDS CARDIOVAS MED
JI Trends Cardiovasc. Med.
PD MAY
PY 2013
VL 23
IS 4
BP 104
EP 113
DI 10.1016/j.tcm.2012.09.008
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 130BD
UT WOS:000317886800003
PM 23290365
ER
PT J
AU Palevsky, PM
Liu, KD
Brophy, PD
Chawla, LS
Parikh, CR
Thakar, CV
Tolwani, AJ
Waikar, SS
Weisbord, SD
AF Palevsky, Paul M.
Liu, Kathleen D.
Brophy, Patrick D.
Chawla, Lakhmir S.
Parikh, Chirag R.
Thakar, Charuhas V.
Tolwani, Ashita J.
Waikar, Sushrut S.
Weisbord, Steven D.
TI KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for
Acute Kidney Injury
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Editorial Material
ID CONTRAST-INDUCED NEPHROPATHY; ACUTE-RENAL-FAILURE; RANDOMIZED
CONTROLLED-TRIAL; CRITICALLY-ILL PATIENTS; PERCUTANEOUS CORONARY
INTERVENTION; RADIOCONTRAST-INDUCED NEPHROPATHY; INTRAVENOUS
N-ACETYLCYSTEINE; GOAL-DIRECTED THERAPY; ISOTONIC SODIUM-BICARBONATE;
PLACEBO-CONTROLLED TRIAL
AB In response to the recently released 2012 KDIGO (Kidney Disease: Improving Global Outcomes) clinical practice guideline for acute kidney injury (AKI), the National Kidney Foundation organized a group of US experts in adult and pediatric AKI and critical care nephrology to review the recommendations and comment on their relevancy in the context of current US clinical practice and concerns. The first portion of the KDIGO guideline attempts to harmonize earlier consensus definitions and staging criteria for AKI. While the expert panel thought that the KDIGO definition and staging criteria are appropriate for defining the epidemiology of AKI and in the design of clinical trials, the panel concluded that there is insufficient evidence to support their widespread application to clinical care in the United States. The panel generally concurred with the remainder of the KDIGO guidelines that are focused on the prevention and pharmacologic and dialytic management of AKI, although noting the dearth of clinical trial evidence to provide strong evidence-based recommendations and the continued absence of effective therapies beyond hemodynamic optimization and avoidance of nephrotoxins for the prevention and treatment of AKI. Am J Kidney Dis. 61(5): 649-672. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use.
C1 [Palevsky, Paul M.; Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15240 USA.
[Palevsky, Paul M.; Weisbord, Steven D.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15213 USA.
[Liu, Kathleen D.] Univ Calif San Francisco, Dept Med, Div Nephrol, San Francisco, CA USA.
[Brophy, Patrick D.] Univ Iowa, Dept Pediat, Carver Coll Med, Div Nephrol, Iowa City, IA 52242 USA.
[Chawla, Lakhmir S.] George Washington Univ, Dept Anesthesiol & Crit Care Med, Washington, DC USA.
[Chawla, Lakhmir S.] George Washington Univ, Dept Med, Div Renal Dis & Hypertens, Washington, DC USA.
[Parikh, Chirag R.] VA Connecticut Healthcare Syst, Renal Sect, West Haven, CT USA.
[Parikh, Chirag R.] Yale Univ, Sch Med, Dept Med, Nephrol Sect, New Haven, CT 06510 USA.
[Thakar, Charuhas V.] Cincinnati VA Med Ctr, Renal Sect, Cincinnati, OH USA.
[Thakar, Charuhas V.] Univ Cincinnati, Dept Internal Med, Div Nephrol & Hypertens, Cincinnati, OH USA.
[Tolwani, Ashita J.] Univ Alabama Birmingham, Dept Med, Div Nephrol, Birmingham, AL 35294 USA.
[Waikar, Sushrut S.] Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA.
RP Palevsky, PM (reprint author), VA Pittsburgh Healthcare Syst, Rm 7E123 111F-U,Univ Dr, Pittsburgh, PA 15240 USA.
EM palevsky@pitt.edu
OI Palevsky, Paul/0000-0002-7334-5400
NR 164
TC 99
Z9 122
U1 1
U2 22
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD MAY
PY 2013
VL 61
IS 5
BP 649
EP 672
DI 10.1053/j.ajkd.2013.02.349
PG 24
WC Urology & Nephrology
SC Urology & Nephrology
GA 121WV
UT WOS:000317276600003
PM 23499048
ER
PT J
AU Koyner, JL
Garg, AX
Shlipak, MG
Patel, UD
Sint, K
Hong, K
Devarajan, P
Edelstein, CL
Zappitelli, M
Thiessen-Philbrook, H
Parikh, CR
AF Koyner, Jay L.
Garg, Amit X.
Shlipak, Michael G.
Patel, Uptal D.
Sint, Kyaw
Hong, Kwangik
Devarajan, Prasad
Edelstein, Charles L.
Zappitelli, Michael
Thiessen-Philbrook, Heather
Parikh, Chirag R.
CA Translational Res Investigating
TI Urinary Cystatin C and Acute Kidney Injury After Cardiac Surgery
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
DE Acute kidney injury biomarkers; cystatin C; dialysis; perioperative
ID GLOMERULAR-FILTRATION-RATE; INTENSIVE-CARE-UNIT; ACUTE-RENAL-FAILURE;
PREDICTS MORTALITY; POOR OUTCOMES; BIOMARKERS; DURATION; THERAPY;
MARKERS
AB Background: Acute kidney injury (AKI) is common after cardiac surgery and is associated with adverse patient outcomes. Urinary cystatin C (CysC) level is a biomarker of proximal tubule function and may increase earlier in AKI than serum creatinine level.
Study Design: Prospective cohort study.
Settings & Participants: The TRIBE AKI (Translational Research Investigating Biomarker Endpoints in AKI) Consortium prospectively enrolled 1,203 adults and 299 children and adolescents at 8 institutions in 2007-2009.
Index Test: Urinary CysC (in milligrams per liter) within the first 12 hours after surgery.
Outcome: Serum creatinine-based AKI was defined as AKI Network stage 1 (mild AKI) and doubling of serum creatinine from the preoperative value or need for dialysis during hospitalization (severe AKI).
Other Measurements: Analyses were adjusted for characteristics used clinically for AKI risk stratification, including age, sex, race, estimated glomerular filtration rate, diabetes, hypertension, heart failure, nonelective surgery, cardiac catheterization within 72 hours, type of surgery, myocardial infarction, and cardiopulmonary bypass time longer than 120 minutes.
Results: Urinary CysC level measured in the early postoperative period (0-6 and 6-12 hours postoperatively) correlated with both mild and severe AKI in adults and children. However, after analyses were adjusted for other factors, the effect was attenuated for both forms of AKI in both cohorts.
Limitations: Limited numbers of patients with severe AKI and in-hospital dialysis treatment.
Conclusions: Urinary CysC values are not associated significantly with the development of AKI after cardiac surgery in adults and children. Am J Kidney Dis. 61(5): 730-738. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use.
C1 [Koyner, Jay L.] Univ Chicago, Pritzker Sch Med, Dept Med, Nephrol Sect, Chicago, IL 60637 USA.
[Garg, Amit X.; Thiessen-Philbrook, Heather] Univ Western Ontario, Dept Med, Div Nephrol, London, ON, Canada.
[Shlipak, Michael G.] Univ Calif San Francisco, Div Gen Internal Med, San Francisco Vet Adm Med Ctr, San Francisco, CA 94143 USA.
[Patel, Uptal D.] Duke Univ, Sch Med, Durham, NC USA.
[Sint, Kyaw; Hong, Kwangik; Parikh, Chirag R.] Yale Univ, Sch Med, Nephrol Sect, New Haven, CT 06510 USA.
[Sint, Kyaw; Hong, Kwangik; Parikh, Chirag R.] Vet Affairs Med Ctr, Clin Epidemiol Res Ctr, West Haven, CT USA.
[Devarajan, Prasad] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA.
[Edelstein, Charles L.] Univ Colorado, Div Renal Dis, Denver, CO 80202 USA.
[Zappitelli, Michael] McGill Univ, Montreal Childrens Hosp, Ctr Hlth, Dept Pediat,Div Nephrol, Montreal, PQ H3H 1P3, Canada.
RP Parikh, CR (reprint author), Yale Univ, Program Appl Translat Res, 60 Temple St,Ste 6C, New Haven, CT 06510 USA.
EM chirag.parikh@yale.edu
FU American Heart Association Clinical Development Award; National Heart,
Lung and Blood Institute [R01HL-085757]; National Center for Research
Resources [UL1 RR024139]; National Institute of Diabetes and Digestive
and Kidney Diseases [K23DK081616]; National Institutes of Health
[K24DK090203, U01DK082185]
FX The research reported in this article was supported by the American
Heart Association Clinical Development Award and National Heart, Lung
and Blood Institute grant R01HL-085757 (to Dr Parikh). The study was
also supported by Clinical and Translational Science Award grant UL1
RR024139 from the National Center for Research Resources. Dr Koyner was
supported by National Institute of Diabetes and Digestive and Kidney
Diseases grant K23DK081616. Dr Parikh was also supported by National
Institutes of Health grants K24DK090203 and U01DK082185. Urinary CysC
assays were donated by Sekisui Diagnostics LLC. Sekisui Diagnostics LLC
did not participate in the protocol development, analysis, or
interpretation of the results.
NR 32
TC 14
Z9 18
U1 0
U2 12
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD MAY
PY 2013
VL 61
IS 5
BP 730
EP 738
DI 10.1053/j.ajkd.2012.12.006
PG 9
WC Urology & Nephrology
SC Urology & Nephrology
GA 121WV
UT WOS:000317276600014
PM 23332602
ER
PT J
AU Blauwet, C
Sudhakar, S
Doherty, AL
Garshick, E
Zafonte, R
Morse, LR
AF Blauwet, Cheri
Sudhakar, Supreetha
Doherty, Ashley L.
Garshick, Eric
Zafonte, Ross
Morse, Leslie R.
TI Participation in Organized Sports Is Positively Associated with
Employment in Adults with Spinal Cord Injury
SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION
LA English
DT Article
DE Spinal Cord Injury; Employment; Sports; Exercise
ID QUALITY-OF-LIFE; WORK; EARNINGS; PEOPLE; TAIWAN; RETURN; RACE;
INDIVIDUALS; OUTCOMES; TIME
AB Blauwet C, Sudhakar S, Doherty AL, Garshick E, Zafonte R, Morse LR: Participation in organized sports is positively associated with employment in adults with spinal cord injury. Am J Phys Med Rehabil 2013;92:393-401. Objective: The aim of this study was to determine the association between participation in organized sports programs and employment in adults with chronic spinal cord injury.
Design: This is a cross-sectional study of 149 adults with chronic spinal cord injury. Motor level and completeness of injury were confirmed by physical examination. Information related to demographics, employment, level of education, body mass index, duration of injury, participation in individually planned exercise, and participation in organized sports was obtained using a standardized questionnaire. Multivariable logistic regression analyses were used to assess factors associated with employment.
Results: In univariate analyses, employment was associated with younger age (P = 0.001) and a higher level of education (P = 0.01), whereas obesity decreased the likelihood of employment (P = 0.04). Participation in organized sports approached significance (P = 0.06). In the multivariable analysis and after adjusting for age, education, and body mass index, participation in organized sports was significantly associated with employment (odds ratio, 2.4; P = 0.04). Sex, duration of injury, wheelchair use, and participation in individually planned exercise were not significantly associated with employment (P = 0.16-0.94).
Conclusions: In the adults with chronic spinal cord injury, participation in organized sports was positively associated with employment. Further studies are necessary to determine the causative nature of this association and how various factors related to sports participation may contribute.
C1 [Blauwet, Cheri; Zafonte, Ross; Morse, Leslie R.] Harvard Univ, Dept Phys Med & Rehabil, Sch Med, Boston, MA 02114 USA.
[Blauwet, Cheri; Sudhakar, Supreetha; Doherty, Ashley L.; Zafonte, Ross; Morse, Leslie R.] Spaulding Rehabil Hosp, Spaulding Harvard Model Syst, Boston, MA USA.
[Garshick, Eric] VA Boston Healthcare Syst, Pulm & Crit Care Med Sect, Med Serv, Boston, MA USA.
[Garshick, Eric] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Div Network Med,Dept Med, Boston, MA 02114 USA.
RP Morse, LR (reprint author), Harvard Univ, Spaulding Rehabil Hosp, Sch Med, SH SCI Model Syst,Dept Phys Med & Rehabil, 125 Nashua St, Boston, MA 02114 USA.
RI Morse, Leslie/C-9442-2015
OI Morse, Leslie/0000-0002-7426-6341
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases
[1R01AR059270]; Department of Veterans Affairs Office of Research and
Development; Rehabilitation Research and Development Merit Review Grant
[B6618R]; Department of Education, National Institute on Disability and
Rehabilitation Research [H133N110010]
FX Supported by the National Institute of Arthritis and Musculoskeletal and
Skin Diseases grant 1R01AR059270; the Department of Veterans Affairs
Office of Research and Development; Rehabilitation Research and
Development Merit Review Grant B6618R; and the Department of Education,
National Institute on Disability and Rehabilitation Research grant
H133N110010.
NR 31
TC 7
Z9 7
U1 2
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0894-9115
J9 AM J PHYS MED REHAB
JI Am. J. Phys. Med. Rehabil.
PD MAY
PY 2013
VL 92
IS 5
BP 393
EP 401
DI 10.1097/PHM.0b013e3182876a5f
PG 9
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 130LV
UT WOS:000317919600003
PM 23478458
ER
PT J
AU Zamarioli, A
Battaglino, RA
Morse, LR
Sudhakar, S
Maranho, DAC
Okubo, R
Volpon, JB
Shimano, AC
AF Zamarioli, Ariane
Battaglino, Ricardo A.
Morse, Leslie R.
Sudhakar, Supreetha
Maranho, Daniel A. C.
Okubo, Rodrigo
Volpon, Jose B.
Shimano, Antonio C.
TI Standing Frame and Electrical Stimulation Therapies Partially Preserve
Bone Strength in a Rodent Model of Acute Spinal Cord Injury
SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION
LA English
DT Article
DE Bone Fracture; Osteoporosis; Spinal Cord Injury; Rehabilitation Medicine
ID MINERAL DENSITY; CORTICAL BONE; BIOMECHANICAL PROPERTIES; PARAPLEGIC
PATIENTS; MUSCLE ATROPHY; INDIVIDUALS; MASS; RAT; OSTEOPOROSIS;
METABOLISM
AB Zamarioli A, Battaglino RA, Morse LR, Sudhakar S, Maranho DAC, Okubo R, Volpon JB, Shimano AC: Standing frame and electrical stimulation therapies partially preserve bone strength in a rodent model of acute spinal cord injury. Am J Phys Med Rehabil 2013;92:402-410. Objective: The aim of this study was to compare the effect of standing frame and electrical stimulation on bone quality in a rodent transection model of spinal cord injury (SCI).
Design: Seven-week-old male Wistar rats were divided into four groups: sham, n = 10; SCI, n = 7; SCI + standing frame, n = 7; and SCI + electrical stimulation, n = 7. Complete SCI was generated by surgical transection of the cord at the T10 level. Therapies were initiated 3 days after the surgery, 3 days/wk, 20 mins/day, for 30 days. Animals were killed on day 33 postinjury.
Results: No treatment preserved bone mineral density at any skeletal site tested (P = 0.08-0.99). Standing frame therapy preserved maximal load at the lumbar vertebral body (14% vs. 37% reduction, P = 0.01) and prevented SCI-induced loss of stiffness at both the femur (8% vs. 37% reduction, P = 0.03) and the tibia (35% vs. 56% reduction, P < 0.0001). Electrical stimulation therapy reduced SCI-induced loss of stiffness at the tibia only (40% vs. 56% reduction, P = 0.003).
Conclusions: Standing frame and electrical stimulation may have potential as future therapeutic modalities to treat or prevent bone loss after SCI.
C1 [Zamarioli, Ariane; Maranho, Daniel A. C.; Okubo, Rodrigo; Volpon, Jose B.; Shimano, Antonio C.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Biomech Med & Rehabil, Sao Paulo, Brazil.
[Zamarioli, Ariane; Battaglino, Ricardo A.; Morse, Leslie R.] Forsyth Inst, Dept Cytokine Biol, Cambridge, MA USA.
[Battaglino, Ricardo A.] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
[Morse, Leslie R.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA.
[Morse, Leslie R.; Sudhakar, Supreetha] Spaulding Rehabil Hosp, Boston, MA USA.
RP Zamarioli, A (reprint author), Univ Sao Paulo FMRP USP, Fac Med Ribeirao Preto, Lab Bioengn, Dept Biomech Med & Rehabil, Casa 1,3900 Av Bandeirantes, BR-14049900 Ribeirao Preto, SP, Brazil.
RI Zamarioli, Ariane/K-7001-2012; Volpon, Jose /D-3041-2012; Maranho,
Daniel Augusto/C-1337-2013; Morse, Leslie/C-9442-2015; battaglino,
ricardo/D-2892-2015; Shimano, Antonio/E-1455-2014
OI Zamarioli, Ariane/0000-0002-7939-0528; Shimano, Antonio
Carlos/0000-0002-3119-2362; Volpon, Jose /0000-0002-2120-0138; Maranho,
Daniel Augusto/0000-0002-3893-0292; Morse, Leslie/0000-0002-7426-6341;
FU Foundation for Research Support of the State of Sao Paulo (FAPESP),
Brazil
FX Supported by the Foundation for Research Support of the State of Sao
Paulo (FAPESP), Brazil.
NR 54
TC 7
Z9 8
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0894-9115
J9 AM J PHYS MED REHAB
JI Am. J. Phys. Med. Rehabil.
PD MAY
PY 2013
VL 92
IS 5
BP 402
EP 410
DI 10.1097/PHM.0b013e318287697c
PG 9
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 130LV
UT WOS:000317919600004
PM 23478455
ER
PT J
AU Hutter, MM
AF Hutter, Matthew M.
TI Laparoscopic Sleeve Gastrectomy Is Safe and Effective and Should Be a
Covered Benefit
SO ANNALS OF SURGERY
LA English
DT Editorial Material
ID BARIATRIC SURGERY
C1 Massachusetts Gen Hosp, Dept Surg, Codman Ctr Clin Effectiveness Surg, Boston, MA 02114 USA.
RP Hutter, MM (reprint author), Massachusetts Gen Hosp, Dept Surg, Codman Ctr Clin Effectiveness Surg, 15 Parkman St,Wang ACC 335, Boston, MA 02114 USA.
EM mhutter@partners.org
NR 6
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-4932
J9 ANN SURG
JI Ann. Surg.
PD MAY
PY 2013
VL 257
IS 5
BP 798
EP 799
DI 10.1097/SLA.0b013e318290d5e5
PG 2
WC Surgery
SC Surgery
GA 126CQ
UT WOS:000317589500002
PM 23574988
ER
PT J
AU Tilt, AC
Werner, PD
Brown, DF
Alam, HB
Warshaw, AL
Parry, BA
Jazbar, B
Booker, A
Stangenberg, L
Fricchione, GL
Benson, H
Lillemoe, KD
Conrad, C
AF Tilt, Alexandra C.
Werner, Paul D.
Brown, David F.
Alam, Hassan B.
Warshaw, Andrew L.
Parry, Blair A.
Jazbar, Brigita
Booker, Abigail
Stangenberg, Lars
Fricchione, Gregory L.
Benson, Herbert
Lillemoe, Keith D.
Conrad, Claudius
TI Low Degree of Formal Education and Musical Experience Predict Degree of
Music-Induced Stress Reduction in Relatives and Friends of Patients A
Single-Center, Randomized Controlled Trial
SO ANNALS OF SURGERY
LA English
DT Article
DE education; gender; music; music experience; predictabaility of
anxiolysis; relatives of patients
ID PATIENTS ANXIETY; PREOPERATIVE ANXIETY; INTERVENTION; THERAPY
AB Objective: To determine the factors that may predict music-induced relaxation in friends and family of patients in the emergency department.
Background: It remains unclear to date which demographic and experiential factors predict the effectiveness of music-induced relaxation. Furthermore, in-hospital stressors for friends and family of patients rather than patients themselves are underresearched and deserve in-depth investigation to improve this group's experience in health care environments.
Methods: A total of 169 relatives and friends of patients in the emergency department-waiting area completed a series of questionnaires, including the Spielberger State-Trait Anxiety Inventory (STAI), the Music Experience Questionnaire (MEQ), and a demographic survey. They were then randomly assigned to either Case Group (1 hour in the waiting area with classical music in the background) or Control Group (1 hour with no music) before completing a second, identical copy of the STAI to measure change from baseline. Data were analyzed for associations between music intervention, change in STAI scores, MEQ scores, and demographic characteristics.
Results: Participants who underwent the music intervention experienced a 9.8% decrease in overall mean State Anxiety, whereas those in the Control Group experienced no change over time (P = 0.001). Higher education significantly inversely correlated with the effectiveness of music intervention: participants with no formal education beyond high school showed a greater overall mean decrease in State Anxiety than those with a college education or beyond in response to classical music (P = 0.006). Furthermore, MEQ scores indicated that the Social Uplift scale (a measure of one's tendency to be uplifted in a group-oriented manner by music) was highly predictive of the effectiveness of music intervention.
Conclusions: Music is an effective and inexpensive means of reducing anxiety in friends and family of patients, who are underresearched in medicine. Moreover, low educational attainment and tendency to respond positively to music in a group setting can predict the effectiveness of music-induced relaxation.
C1 [Tilt, Alexandra C.; Alam, Hassan B.; Warshaw, Andrew L.; Jazbar, Brigita; Booker, Abigail; Stangenberg, Lars; Lillemoe, Keith D.; Conrad, Claudius] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Brown, David F.; Parry, Blair A.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
[Fricchione, Gregory L.; Benson, Herbert] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Werner, Paul D.] Alliant Int Univ, Calif Sch Profess Psychol, PhD Program Clin Psychol, San Francisco, CA USA.
RP Conrad, C (reprint author), Harvard Univ, Sch Med, 55 Fruit St, Boston, MA 02215 USA.
EM cconrad@partners.org
NR 25
TC 2
Z9 2
U1 2
U2 15
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-4932
J9 ANN SURG
JI Ann. Surg.
PD MAY
PY 2013
VL 257
IS 5
BP 834
EP 838
DI 10.1097/SLA.0b013e31828ee1da
PG 5
WC Surgery
SC Surgery
GA 126CQ
UT WOS:000317589500008
PM 23574990
ER
PT J
AU Gutu, AD
Sgambati, N
Strasbourger, P
Brannon, MK
Jacobs, MA
Haugen, E
Kaul, RK
Johansen, HK
Hoiby, N
Moskowitz, SM
AF Gutu, Alina D.
Sgambati, Nicole
Strasbourger, Pnina
Brannon, Mark K.
Jacobs, Michael A.
Haugen, Eric
Kaul, Rajinder K.
Johansen, Helle Krogh
Hoiby, Niels
Moskowitz, Samuel M.
TI Polymyxin Resistance of Pseudomonas aeruginosa phoQ Mutants Is Dependent
on Additional Two-Component Regulatory Systems
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID CYSTIC-FIBROSIS PATIENTS; CATIONIC ANTIMICROBIAL PEPTIDES; GRAM-NEGATIVE
BACTERIA; ESCHERICHIA-COLI; LIPID-A; PMRA-PMRB; OUTER-MEMBRANE;
ACINETOBACTER-BAUMANNII; PHOSPHATASE-ACTIVITIES; ADAPTIVE RESISTANCE
AB Pseudomonas aeruginosa can develop resistance to polymyxin as a consequence of mutations in the PhoPQ regulatory system, mediated by covalent lipid A modification. Transposon mutagenesis of a polymyxin-resistant phoQ mutant defined 41 novel loci required for resistance, including two regulatory systems, ColRS and CprRS. Deletion of the colRS genes, individually or in tandem, abrogated the polymyxin resistance of a Delta phoQ mutant, as did individual or tandem deletion of cprRS. Individual deletion of colR or colS in a Delta phoQ mutant also suppressed 4-amino-L-arabinose addition to lipid A, consistent with the known role of this modification in polymyxin resistance. Surprisingly, tandem deletion of colRS or cprRS in the Delta phoQ mutant or individual deletion of cprR or cprS failed to suppress 4-amino-L-arabinose addition to lipid A, indicating that this modification alone is not sufficient for PhoPQ-mediated polymyxin resistance in P. aeruginosa. Episomal expression of colRS or cprRS in tandem or of cprR individually complemented the Pm resistance phenotype in the Delta phoQ mutant, while episomal expression of colR, colS, or cprS individually did not. Highly polymyxin-resistant phoQ mutants of P. aeruginosa isolated from polymyxin-treated cystic fibrosis patients harbored mutant alleles of colRS and cprS; when expressed in a Delta phoQ background, these mutant alleles enhanced polymyxin resistance. These results define ColRS and CprRS as two-component systems regulating polymyxin resistance in P. aeruginosa, indicate that addition of 4-amino-L-arabinose to lipid A is not the only PhoPQ-regulated biochemical mechanism required for resistance, and demonstrate that colRS and cprS mutations can contribute to high-level clinical resistance.
C1 [Gutu, Alina D.; Sgambati, Nicole; Moskowitz, Samuel M.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.
[Strasbourger, Pnina; Brannon, Mark K.; Moskowitz, Samuel M.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA.
[Jacobs, Michael A.; Haugen, Eric; Kaul, Rajinder K.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA.
[Johansen, Helle Krogh; Hoiby, Niels] Copenhagen CF Ctr, Dept Clin Microbiol, Copenhagen, Denmark.
[Moskowitz, Samuel M.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
RP Moskowitz, SM (reprint author), Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.
EM smoskowitz@partners.org
OI Haugen, Eric/0000-0001-7444-8981
FU National Heart Lung and Blood Institute [K08HL067903]; National
Institute of Allergy and Infectious Diseases [R01AI067653]; CF
Foundation [MOSKOW01A1]; Novo Nordisk Foundation
FX This work was supported by Public Health Service grants K08HL067903 to
S.M.M. from the National Heart Lung and Blood Institute and R01AI067653
to S.M.M. from the National Institute of Allergy and Infectious
Diseases. This work was also supported by grant MOSKOW01A1 to S.M.M.
from the CF Foundation. H.K.J. was supported by a clinical research
stipend from the Novo Nordisk Foundation.
NR 73
TC 23
Z9 23
U1 1
U2 21
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD MAY
PY 2013
VL 57
IS 5
BP 2204
EP 2215
DI 10.1128/AAC.02353-12
PG 12
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 124ME
UT WOS:000317467600028
PM 23459479
ER
PT J
AU van Gils, JM
Ramkhelawon, B
Fernandes, L
Stewart, MC
Guo, L
Seibert, T
Menezes, GB
Cara, DC
Chow, C
Kinane, TB
Fisher, EA
Balcells, M
Alvarez-Leite, J
Lacy-Hulbert, A
Moore, KJ
AF van Gils, Janine M.
Ramkhelawon, Bhama
Fernandes, Luciana
Stewart, Merran C.
Guo, Liang
Seibert, Tara
Menezes, Gustavo B.
Cara, Denise C.
Chow, Camille
Kinane, T. Bernard
Fisher, Edward A.
Balcells, Mercedes
Alvarez-Leite, Jacqueline
Lacy-Hulbert, Adam
Moore, Kathryn J.
TI Endothelial Expression of Guidance Cues in Vessel Wall Homeostasis
Dysregulation Under Proatherosclerotic Conditions
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Article
DE atherosclerosis; axonal guidance; endothelial-leukocyte interaction;
migration
ID INHIBITS LEUKOCYTE MIGRATION; EPHRINB2 EXPRESSION; CELL-INTERACTIONS;
IN-VIVO; ATHEROSCLEROSIS; ATHEROGENESIS; INFLAMMATION; RETENTION;
RECEPTORS
AB Objective-Emerging evidence suggests that neuronal guidance cues, typically expressed during development, are involved in both physiological and pathological immune responses. We hypothesized that endothelial expression of such guidance cues may regulate leukocyte trafficking into the vascular wall during atherogenesis.
Approach and Results-We demonstrate that members of the netrin, semaphorin, and ephrin family of guidance molecules are differentially regulated under conditions that promote or protect from atherosclerosis. Netrin-1 and semaphorin3A are expressed by coronary artery endothelial cells and potently inhibit chemokine-directed migration of human monocytes. Endothelial expression of these negative guidance cues is downregulated by proatherogenic factors, including oscillatory shear stress and proinflammatory cytokines associated with monocyte entry into the vessel wall. Furthermore, we show using intravital microscopy that inhibition of netrin-1 or semaphorin3A using blocking peptides increases leukocyte adhesion to the endothelium. Unlike netrin-1 and semaphorin3A, the guidance cue ephrinB2 is upregulated under proatherosclerotic flow conditions and functions as a chemoattractant, increasing leukocyte migration in the absence of additional chemokines.
Conclusions-The concurrent regulation of negative and positive guidance cues may facilitate leukocyte infiltration of the endothelium through a balance between chemoattraction and chemorepulsion. These data indicate a previously unappreciated role for axonal guidance cues in maintaining the endothelial barrier and regulating leukocyte trafficking during atherogenesis. (Arterioscler Thromb Vasc Biol. 2013; 33: 911-919.)
C1 [van Gils, Janine M.; Ramkhelawon, Bhama; Stewart, Merran C.; Guo, Liang; Fisher, Edward A.; Moore, Kathryn J.] NYU, Sch Med, Marc & Ruti Bell Vasc Biol & Dis Program, Leon H Charney Div Cardiol,Dept Med, New York, NY 10016 USA.
[Fernandes, Luciana; Menezes, Gustavo B.; Cara, Denise C.; Alvarez-Leite, Jacqueline] Univ Fed Minas Gerais, Dept Biochem & Immunol, Belo Horizonte, MG, Brazil.
[Seibert, Tara] Univ Ottawa, Inst Heart, Ottawa, ON, Canada.
[Chow, Camille; Kinane, T. Bernard; Lacy-Hulbert, Adam] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Program Dev Immunol, Boston, MA USA.
[Balcells, Mercedes] MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Balcells, Mercedes] Ramon Llull Univ, Inst Quim Sarria, IQS Sch Engn, Barcelona, Spain.
RP Moore, KJ (reprint author), NYU, Sch Med, 522 1st Ave,Smilow 705, New York, NY 10016 USA.
EM Kathryn.moore@nyumc.org
OI Balcells, Mercedes/0000-0002-2532-0516; Lacy-Hulbert,
Adam/0000-0003-2162-0156; Moore, kathryn/0000-0003-2505-2547; Guo,
Liang/0000-0003-1633-1544; Fisher, Edward/0000-0001-9802-143X
FU American Heart Association [0655840T, 09POST2080250]; Fondation de la
recherche Medicale; National Institutes of Health [RC1HL100815, R01
HL084312, R01/GM049039]; Canadian Institute of Health Research
(CGS-MSFSS); Conselho Nacional de Desenvolvimento Cientifico e
Tecnologico [01558/2007-6]; Ministerio de Innovacion Plan Nacional
[BFU2009-09804]; Fundacio Empreses IQS; POSIMAT
FX Support for this work came from the American Heart Association
(Grant-in-aid 0655840T to K.J.M.; 09POST2080250 to J.M.V.G.), Fondation
de la recherche Medicale to B.R., National Institutes of Health
(RC1HL100815 to K.J.M.; R01 HL084312 to E. A. F.; R01/GM049039 to M.
B.), Canadian Institute of Health Research (CGS-MSFSS to T. S.),
Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
(01558/2007-6 to L. R. F. and J.I.A.-L.), Ministerio de Innovacion Plan
Nacional BFU2009-09804 (M. B.), Fundacio Empreses IQS (M. B.), and
POSIMAT (M.B.).
NR 29
TC 20
Z9 21
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1079-5642
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD MAY
PY 2013
VL 33
IS 5
BP 911
EP U108
DI 10.1161/ATVBAHA.112.301155
PG 17
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA 124PB
UT WOS:000317476000011
PM 23430612
ER
PT J
AU Li, W
Li, QL
Qin, LF
Ali, R
Qyang, YB
Tassabehji, M
Pober, BR
Sessa, WC
Giordano, FJ
Tellides, G
AF Li, Wei
Li, Qingle
Qin, Lingfeng
Ali, Rahmat
Qyang, Yibing
Tassabehji, May
Pober, Barbara R.
Sessa, William C.
Giordano, Frank J.
Tellides, George
TI Rapamycin Inhibits Smooth Muscle Cell Proliferation and Obstructive
Arteriopathy Attributable to Elastin Deficiency
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Article
DE aorta; elastin; mTOR; smooth muscle cell; Williams syndrome
ID WILLIAMS-BEUREN-SYNDROME; SUPRAVALVULAR AORTIC-STENOSIS;
INTERFERON-GAMMA; SIROLIMUS; MICE; TRANSPLANT; DISEASE; GROWTH; MOUSE;
SUPPRESSION
AB Objective-Patients with elastin deficiency attributable to gene mutation (supravalvular aortic stenosis) or chromosomal microdeletion (Williams syndrome) are characterized by obstructive arteriopathy resulting from excessive smooth muscle cell (SMC) proliferation, mural expansion, and inadequate vessel size. We investigated whether rapamycin, an inhibitor of the cell growth regulator mammalian target of rapamycin (mTOR) and effective against other SMC proliferative disorders, is of therapeutic benefit in experimental models of elastin deficiency.
Approach and Results-As previously reported, Eln(-/-) mice demonstrated SMC hyperplasia and severe stenosis of the aorta, whereas Eln(+/-) mice exhibited a smaller diameter aorta with more numerous but thinner elastic lamellae. Increased mTOR signaling was detected in elastin-deficient aortas of newborn pups that was inhibited by maternal administration of rapamycin. mTOR inhibition reduced SMC proliferation and aortic obstruction in Eln(-/-) pups and prevented medial hyperlamellation in Eln(+/-) weanlings without compromising aortic size. However, rapamycin did not prolong the survival of Eln(-/-) pups, and it retarded the somatic growth of juvenile Eln(+/-) and Eln(+/+) mice. In cell cultures, rapamycin inhibited prolonged mTOR activation and enhanced proliferation of SMC derived from patients with supravalvular aortic stenosis and with Williams syndrome.
Conclusions-mTOR inhibition may represent a pharmacological strategy to treat diffuse arteriopathy resulting from elastin deficiency. (Arterioscler Thromb Vasc Biol. 2013; 33: 1028-1035.)
C1 [Li, Wei; Li, Qingle; Qin, Lingfeng; Ali, Rahmat; Tellides, George] Yale Univ, Sch Med, Dept Surg, Interdept Program Vasc Biol & Therapeut, New Haven, CT 06510 USA.
[Qyang, Yibing; Giordano, Frank J.] Yale Univ, Sch Med, Dept Med, Interdept Program Vasc Biol & Therapeut, New Haven, CT 06510 USA.
[Sessa, William C.] Yale Univ, Sch Med, Dept Pharmacol, Interdept Program Vasc Biol & Therapeut, New Haven, CT 06510 USA.
[Tassabehji, May] Univ Manchester, Dept Med Genet, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England.
[Pober, Barbara R.] Harvard Univ, Sch Med, Dept Pediat, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Tellides, George] Vet Affairs Connecticut Healthcare Syst, West Haven, CT USA.
RP Tellides, G (reprint author), 10 Amistad St 337B, New Haven, CT 06520 USA.
EM george.tellides@yale.edu
FU Kiev Foundation; Williams Syndrome Association; Wellcome Trust
FX This work was supported by the Kiev Foundation and the Williams Syndrome
Association (W.C. Sessa, F.J. Giordano, G. Tellides) and The Wellcome
Trust (M. Tassabehji).
NR 29
TC 9
Z9 10
U1 1
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1079-5642
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD MAY
PY 2013
VL 33
IS 5
BP 1028
EP U400
DI 10.1161/ATVBAHA.112.300407
PG 17
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA 124PB
UT WOS:000317476000025
PM 23493289
ER
PT J
AU Weng, TY
Chiu, WT
Liu, HS
Cheng, HC
Shen, MR
Mount, DB
Chou, CY
AF Weng, Tzu-Yu
Chiu, Wen-Tai
Liu, Hsiao-Sheng
Cheng, Hung-Chi
Shen, Meng-Ru
Mount, David B.
Chou, Cheng-Yang
TI Glycosylation regulates the function and membrane localization of KCC4
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
LA English
DT Article
DE KCC4; N-linked glycosylation; Glycan complexity; Membrane expression;
Tumor formation
ID CELL-SURFACE EXPRESSION; OVARIAN-CANCER CELLS; KCL COTRANSPORT;
N-GLYCOSYLATION; ENDOPLASMIC-RETICULUM; CL-COTRANSPORTER;
CERVICAL-CANCER; INVASION; GLYCANS; PROLIFERATION
AB Glycosylation plays a role in regulating many biological activities, including protein folding and cell surface expression of biomolecules. However, the importance of glycosylation for KCC4 function has not previously been demonstrated. Site-directed mutagenesis was performed on the four putative extracellular N-linked glycosylation sites of KCC4 to determine the role of these sites in KCC4 half-life, cell surface expression, and transporter activity, as well as in KCC4-dependent tumor formation. We showed that triple (N312/331/344/Q) and quadruple (N312/331/344/360/Q) mutations of N-linked glycosylation sites disrupt the N-linked glycosylation of KCC4, resulting in the accumulation of KCC4, predominantly in the endoplasmic reticulum (ER) and not at the cell surface. Further investigation indicated that mutations of the central two (N331/344/Q) N-linked glycosylation sites inhibit the membrane trafficking of KCC4. Our data suggest that the glycan moieties at the N331 and N344 sites were Endo H-resistant, complex-form structures, and that the N312 and N360 sites were Endo H-sensitive, high mannose-containing structures. Under hypotonic stress conditions, the ability to adapt to changes in intracellular chloride ion concentrations and RVD (regulatory volume decrease) activities were less efficient in cells containing the deglycosylated form of KCC4 that were not expressed at the cell surface. Deglycosylated forms of KCC4 also demonstrated decreased tumor formation and lung colonization in mouse xenografts. The difference in glycan complexity may account for the differential impact of each branch on the biological effects of KCC4. We propose that glycosylation is essential for the surface expression, stabilization, and bioactivity of KCC4. (c) 2013 Elsevier B.V. All rights reserved.
C1 [Weng, Tzu-Yu] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 704, Taiwan.
[Chiu, Wen-Tai] Natl Cheng Kung Univ, Coll Engn, Dept Biomed Engn, Tainan 704, Taiwan.
[Liu, Hsiao-Sheng] Natl Cheng Kung Univ, Coll Med, Dept Microbiol & Immunol, Tainan 704, Taiwan.
[Cheng, Hung-Chi] Natl Cheng Kung Univ, Coll Med, Dept Biochem & Mol Biol, Tainan 704, Taiwan.
[Shen, Meng-Ru; Chou, Cheng-Yang] Natl Cheng Kung Univ, Coll Med, Dept Obstet & Gynecol, Tainan 70403, Taiwan.
[Mount, David B.] VA Boston Healthcare Syst, Brigham & Womens Hosp, Div Renal, Boston, MA USA.
RP Chou, CY (reprint author), Natl Cheng Kung Univ & Hosp, Coll Med, Dept Obstet & Gynecol, Tainan 70403, Taiwan.
EM chougyn@mail.ncku.edu.tw
FU Center of Excellence for Cancer Research in Taiwan
[DOH101-TD-C-111-003]; Department of Health, Executive Yuan, Taiwan
FX This research was supported by the established Center of Excellence for
Cancer Research in Taiwan (DOH101-TD-C-111-003), and the Department of
Health, Executive Yuan, Taiwan.
NR 30
TC 9
Z9 10
U1 0
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-4889
J9 BBA-MOL CELL RES
JI Biochim. Biophys. Acta-Mol. Cell Res.
PD MAY
PY 2013
VL 1833
IS 5
BP 1133
EP 1146
DI 10.1016/j.bbamcr.2013.01.018
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 123FT
UT WOS:000317374500018
PM 23376777
ER
PT J
AU McLaughlin, NCR
Didie, ER
Machado, AG
Haber, SN
Eskandar, EN
Greenberg, BD
AF McLaughlin, Nicole C. R.
Didie, Elizabeth R.
Machado, Andre G.
Haber, Suzanne N.
Eskandar, Emad N.
Greenberg, Benjamin D.
TI Improvements in Anorexia Symptoms After Deep Brain Stimulation for
Intractable Obsessive-Compulsive Disorder
SO BIOLOGICAL PSYCHIATRY
LA English
DT Letter
ID EATING-DISORDERS; NERVOSA; INDIVIDUALS; DEPRESSION; ACTIVATION;
LEUKOTOMY; CHOCOLATE
C1 [McLaughlin, Nicole C. R.; Greenberg, Benjamin D.] Butler Hosp, Dept Psychiat & Human Behav, Providence, RI 02906 USA.
[Didie, Elizabeth R.] Brown Univ, Alpert Med Sch, Rhode Isl Hosp, Dept Psychiat & Human Behav, Providence, RI 02912 USA.
[Machado, Andre G.] Cleveland Clin, Neurol Inst, Ctr Neurol Restorat, Cleveland, OH 44106 USA.
[Haber, Suzanne N.] Univ Rochester, Sch Med, Dept Physiol & Pharmacol, Rochester, NY USA.
[Eskandar, Emad N.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
RP McLaughlin, NCR (reprint author), Butler Hosp, Dept Psychiat & Human Behav, Providence, RI 02906 USA.
EM nicole_mclaughlin@brown.edu
RI Machado, Andre/B-7572-2014
OI Machado, Andre/0000-0002-8132-5610
FU NIMH NIH HHS [MH086400, MH73111, P50 MH086400]
NR 23
TC 18
Z9 19
U1 0
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAY 1
PY 2013
VL 73
IS 9
BP E29
EP E31
DI 10.1016/j.biopsych.2012.09.015
PG 3
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 126AO
UT WOS:000317583700004
PM 23128051
ER
PT J
AU Kuter, DJ
Bussel, JB
Newland, A
Baker, RI
Lyons, RM
Wasser, J
Viallard, JF
Macik, G
Rummel, M
Nie, K
Jun, S
AF Kuter, David J.
Bussel, James B.
Newland, Adrian
Baker, Ross I.
Lyons, Roger M.
Wasser, Jeffrey
Viallard, Jean-Francois
Macik, Gail
Rummel, Mathias
Nie, Kun
Jun, Susie
TI Long-term treatment with romiplostim in patients with chronic immune
thrombocytopenia: safety and efficacy
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE thrombopoiesis; thrombopoietic agents; TPO receptor agonists; platelets;
autoimmunity
ID PURPURA ITP; CONTROLLED-TRIAL; DOUBLE-BLIND; IN-VITRO; ELTROMBOPAG;
AUTOANTIBODIES; THROMBOPOIETIN; MANAGEMENT; STANDARD; AMG-531
AB Romiplostim was effective, safe, and well-tolerated over 612months of continuous treatment in Phase 3 trials in patients with immune thrombocytopenia (ITP). This report describes up to 5years of weekly treatment with romiplostim in 292 adult ITP patients in a long-term, single-arm, open-label study. Outcome measures included adverse events (including bleeding, thrombosis, malignancy, and reticulin/fibrosis), platelet response (platelet count >50x109 per litre), and the proportion of patients requiring rescue treatments. Treatmentrelated serious adverse events were infrequent and did not increase with longer treatment. No new classes of adverse events emerged. Thrombotic events occurred in 6 center dot 5% of patients and were not associated with platelet count. Median platelet counts of 50200x109 per litre were maintained with stable doses of romiplostim (mean 58g/kg; generally self-administered at home) throughout the study. A platelet response was achieved at least once by 95% of patients, with a platelet response maintained by all patients on a median 92% of study visits. There was a low rate of bleeding and infrequent need for rescue treatments. In conclusion, this study demonstrated that romiplostim was safe and well-tolerated over 614 patient-years of exposure in ITP patients, and that efficacy was maintained with stable dosing for up to 5years of continuous treatment.
C1 [Kuter, David J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Bussel, James B.] Cornell Univ, Div Hematol, Weill Med Coll, Dept Pediat, New York, NY 10021 USA.
[Bussel, James B.] Cornell Univ, Div Hematol, Weill Med Coll, Dept Med, New York, NY 10021 USA.
[Newland, Adrian] Royal London Hosp, Dept Haematol, London E1 1BB, England.
[Baker, Ross I.] Murdoch Univ, Royal Perth Hosp, Ctr Thrombosis & Haemophilia, Perth, WA, Australia.
[Lyons, Roger M.] Canc Care Ctr South Texas US Oncol, San Antonio, TX USA.
[Wasser, Jeffrey] Univ Connecticut, Sch Med, Dept Med, Div Hematol Oncol, Farmington, CT USA.
[Viallard, Jean-Francois] Univ Bordeaux 2, Hop Haut Leveque, CHU Bordeaux, Pessac, France.
[Macik, Gail] Univ Virginia, Charlottesville, VA USA.
[Rummel, Mathias] Klinikum Justus Liebig Univ, Giessen, Germany.
[Nie, Kun; Jun, Susie] Amgen Inc, Thousand Oaks, CA 91320 USA.
RP Kuter, DJ (reprint author), Massachusetts Gen Hosp, Yawkey 7858,55 Fruit St, Boston, MA 02114 USA.
EM kuter.david@MGH.harvard.edu
FU Amgen Inc.; GlaxoSmithKline; Pfizer; Shionogi; ONO; Eisai Inc.; Cangene;
Genzyme; IgG of America; Immunomedics; Ligand; Sysmex; Eisai;
Octapharma; Roche; Mundipharma
FX DK has consulted for and received research funding from Amgen Inc.,
GlaxoSmithKline, Pfizer, Shionogi, ONO and Eisai Inc. JB has received
research funding from Amgen Inc., Cangene, GlaxoSmithKline, Genzyme, IgG
of America, Immunomedics, Ligand, Eisai Inc., Shionogi and Sysmex; his
family owns stock in Amgen Inc. and GlaxoSmithKline; he has participated
in advisory boards for Amgen Inc., GlaxoSmithKline, Ligand, Shionogi,
and Eisai Inc., and has consulted for Portola. AN has consulted for and
received honoraria from Amgen Inc. and GlaxoSmithKline and has received
research funding from Amgen Inc., Eisai, GlaxoSmithKline, and
Octapharma. RL has consulted for, received research funding from, and
participated in an advisory board for Amgen Inc. JW has consulted for
Amgen Inc. and participated in an Amgen advisory board. JFV has
participated in advisory boards for and spoken at symposia organized by
Amgen Inc. and GlaxoSmithKline. MR has consulted for and received
honoraria from Amgen Inc., GlaxoSmithKline, Roche, and Mundipharma, and
research funding from Roche and Mundipharma. KN is and SJ was an
employee of and stockholder in Amgen Inc.
NR 32
TC 66
Z9 70
U1 1
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
EI 1365-2141
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD MAY
PY 2013
VL 161
IS 3
BP 411
EP 423
DI 10.1111/bjh.12260
PG 13
WC Hematology
SC Hematology
GA 126GV
UT WOS:000317602300015
PM 23432528
ER
PT J
AU Robertson, SM
Amspoker, AB
Cully, JA
Ross, EL
Naik, AD
AF Robertson, S. M.
Amspoker, A. B.
Cully, J. A.
Ross, E. L.
Naik, A. D.
TI Affective symptoms and change in diabetes self-efficacy and glycaemic
control
SO DIABETIC MEDICINE
LA English
DT Article
ID DEPRESSION; STRESS; DISTRESS; ADULTS; TRIAL; CARE
AB Aims To examine the role of baseline depression, anxiety and stress symptoms on post-intervention diabetes self-efficacy and glycaemic control (HbA1c). Methods The current study analysed data from patients (n=85) with treated but uncontrolled Type2 diabetes who participated in a comparative effectiveness study of two diabetes self-management interventions. Hierarchical linear regression was used to examine the relationships between baseline affective symptoms and post-intervention diabetes self-efficacy and the moderating effects of baseline affective symptoms on the relationship between changes in diabetes self-efficacy and post-intervention HbA1c. Results Baseline depression was inversely associated with post-intervention diabetes self-efficacy (P=0.0001) after adjusting for baseline characteristics including diabetes self-efficacy. In contrast, normalmild levels of stress were associated with higher post-intervention diabetes self-efficacy (P=0.04). Anxiety and stress symptoms significantly and independently moderated the relationship between changes in diabetes self-efficacy and post-intervention HbA1c (P=0.02 and P=0.03, respectively). Further evaluation of these interactions demonstrated that changes in diabetes self-efficacy were associated with lower post-intervention HbA1c, but only among those with higher baseline affective symptoms. Conclusions We found a moderating effect across affective symptoms on the relationship between diabetes self-efficacy changes and post-intervention HbA1c in the context of a self-management intervention. Results suggest that patients with poorly controlled diabetes who have higher levels of depression, anxiety and stress symptoms may derive greater benefits from self-management interventions known to improve diabetes self-efficacy.
C1 [Robertson, S. M.; Amspoker, A. B.; Cully, J. A.; Ross, E. L.; Naik, A. D.] Univ Houston, Michael E DeBakey Vet Affairs Med Ctr, Houston Hlth Serv Res &Development Ctr Excellence, Houston, TX 77004 USA.
[Robertson, S. M.; Amspoker, A. B.; Naik, A. D.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
[Amspoker, A. B.; Cully, J. A.; Naik, A. D.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Cully, J. A.; Naik, A. D.] Univ Houston, VA South Cent Mental Illness Res Educ & Clin Ctr, Houston, TX USA.
[Ross, E. L.] Univ Houston, Dept Psychol, Houston, TX USA.
RP Robertson, SM (reprint author), Univ Houston, Michael E DeBakey Vet Affairs Med Ctr, Houston Hlth Serv Res &Development Ctr Excellence, Houston, TX 77004 USA.
EM smr1@bcm.tmc.edu
FU Agency for Healthcare Research and Quality; Centers for Research and
Education on Therapeutics [U18HS016093]; Doris Duke Charitable
Foundation; Veterans Affairs Office of Academic Affiliations; National
Institute of Aging [5K23AG027144]
FX This manuscript is supported with resources and the use of facilities at
the Houston Veterans Affairs Health Services Research and Development
Center of Excellence (HEP90-020) at the Michael E. DeBakey Veterans
Affairs Medical Center, Houston, TX. The parent study from which the
data for the current analysis were derived was funded by the Agency for
Healthcare Research and Quality, Centers for Research and Education on
Therapeutics (U18HS016093) and a Doris Duke Charitable Foundation
Clinical Scientist Development Award (Naik). SMR is a Veterans Affairs
Health Services Research post-doc fellow supported by Veterans Affairs
Office of Academic Affiliations. ADN received support from a National
Institute of Aging Career Development Award (5K23AG027144).
NR 27
TC 7
Z9 7
U1 0
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0742-3071
EI 1464-5491
J9 DIABETIC MED
JI Diabetic Med.
PD MAY
PY 2013
VL 30
IS 5
BP E189
EP E196
DI 10.1111/dme.12146
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 129SQ
UT WOS:000317863000006
PM 23350920
ER
PT J
AU Cheng, G
Torigian, D
Zhuang, HM
Alavi, A
AF Cheng, Gang
Torigian, Drew A.
Zhuang, Hongming
Alavi, Abass
TI When should we recommend use of dual time-point and delayed time-point
imaging techniques in FDG PET?
SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
LA English
DT Review
DE FDG; PET/CT; Dual time-point imaging; Cancer; Diagnosis
ID CELL LUNG-CANCER; POSITRON-EMISSION-TOMOGRAPHY; PHASE F-18-FDG PET;
LYMPH-NODE METASTASES; TUBERCULOSIS-ENDEMIC COUNTRY; SOLITARY PULMONARY
NODULES; BREAST-CANCER; GALLBLADDER CARCINOMA; HEPATIC METASTASES;
GLUCOSE-METABOLISM
AB FDG PET and PET/CT are now widely used in oncological imaging for tumor characterization, staging, restaging, and response evaluation. However, numerous benign etiologies may cause increased FDG uptake indistinguishable from that of malignancy. Multiple studies have shown that dual time-point imaging (DTPI) of FDG PET may be helpful in differentiating malignancy from benign processes. However, exceptions exist, and some studies have demonstrated significant overlap of FDG uptake patterns between benign and malignant lesions on delayed time-point images. In this review, we summarize our experience and opinions on the value of DTPI and delayed time-point imaging in oncology, with a review of the relevant literature. We believe that the major value of DTPI and delayed time-point imaging is the increased sensitivity due to continued clearance of background activity and continued FDG accumulation in malignant lesions, if the same diagnostic criteria (as in the initial standard single time-point imaging) are used. The specificity of DTPI and delayed time-point imaging depends on multiple factors, including the prevalence of malignancies, the patient population, and the cut-off values (either SUV or retention index) used to define a malignancy. Thus, DTPI and delayed time-point imaging would be more useful if performed for evaluation of lesions in regions with significant background activity clearance over time (such as the liver, the spleen, the mediastinum), and if used in the evaluation of the extent of tumor involvement rather than in the characterization of the nature of any specific lesion. Acute infectious and non-infectious inflammatory lesions remain as the major culprit for diminished diagnostic performance of these approaches (especially in tuberculosis-endemic regions). Tumor heterogeneity may also contribute to inconsistent performance of DTPI. The authors believe that selective use of DTPI and delayed time-point imaging will improve diagnostic accuracy and interpretation confidence in FDG PET imaging.
C1 [Cheng, Gang] Philadelphia VA Med Ctr, Dept Radiol, Philadelphia, PA 19104 USA.
[Cheng, Gang; Torigian, Drew A.; Alavi, Abass] Hosp Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA.
[Zhuang, Hongming] Childrens Hosp Philadelphia, Dept Radiol, Philadelphia, PA 19104 USA.
RP Alavi, A (reprint author), Hosp Univ Penn, Dept Radiol, 3400 Spruce St, Philadelphia, PA 19104 USA.
EM abass.alavi@uphs.upenn.edu
NR 93
TC 49
Z9 49
U1 2
U2 20
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1619-7070
EI 1619-7089
J9 EUR J NUCL MED MOL I
JI Eur. J. Nucl. Med. Mol. Imaging
PD MAY
PY 2013
VL 40
IS 5
BP 779
EP 787
DI 10.1007/s00259-013-2343-9
PG 9
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 126NP
UT WOS:000317624700017
PM 23361859
ER
PT J
AU Gray, PJ
Fedewa, SA
Shipley, WU
Efstathiou, JA
Lin, CC
Zietman, AL
Virgo, KS
AF Gray, Phillip J.
Fedewa, Stacey A.
Shipley, William U.
Efstathiou, Jason A.
Lin, Chun Chieh
Zietman, Anthony L.
Virgo, Katherine S.
TI Use of Potentially Curative Therapies for Muscle-invasive Bladder Cancer
in the United States: Results from the National Cancer Data Base
SO EUROPEAN UROLOGY
LA English
DT Article
DE Bladder cancer; Genitourinary cancer; Bladder-sparing therapy; Radical
cystectomy
ID SOUTHWEST-ONCOLOGY-GROUP; RADICAL CYSTECTOMY; TRANSURETHRAL RESECTION;
ORGAN PRESERVATION; CHEMOTHERAPY; RADIOTHERAPY; SURVIVAL; DISPARITIES;
EXPERIENCE; MANAGEMENT
AB Background: Despite its lethal potential, many patients with muscle-invasive bladder cancer (MIBC) do not receive aggressive, potentially curative therapy consistent with established practice standards.
Objective: To characterize the treatments received by patients with MIBC and analyze their use according to sociodemographic, clinical, pathologic, and facility measures.
Design, setting, and participants: Using the National Cancer Data Base, we analyzed 28 691 patients with MIBC (stages II-IV) treated between 2004 and 2008, excluding those with cT4b tumors or distant metastases. Treatments included radical or partial cystectomy with or without chemotherapy (CT), chemoradiotherapy (CRT), radiation therapy (RT), or CT alone and observation following biopsy. Aggressive therapy (AT) was defined as radical or partial cystectomy or definitive RT/CRT (total dose >= 50 Gy).
Outcome measurements and statistical analysis: AT use and correlating variables were assessed by multivariable, generalized estimating equation models adjusted for facility clustering.
Results and limitations: According to the database, 52.5% of patients received AT; 44.9% were treated surgically, 7.6% received definitive CRT or RT, and 25.9% of patients received observation only. AT use decreased with advancing age (odds ratio [ OR]: 0.34 for age 81-90 yr vs <= 50 yr; p < 0.001). AT use was also lower in racial minorities (OR: 0.74 for black race; p < 0.001), the uninsured (OR: 0.73; p < 0.001), Medicaid-insured patients (OR: 0.81; p = 0.01), and at low-volume centers (OR: 0.64 vs high-volume centers; p < 0.001). Use of AT was higher with increasing tumor stage (OR: 2.23 for T3/T4a vs T2; p < 0.001) and nonurothelial histology (OR: 1.25 and 1.43 for squamous and adenocarcinoma, respectively; p < 0.001). Study limitations include retrospective design and lack of information about patient and provider motivations regarding therapy selection.
Conclusions: AT for MIBC appears underused, especially in the elderly and in groups with poor socioeconomic status. These data point to a significant unmet need to inform policy makers, payers, and physicians regarding appropriate therapies for MIBC. (C) 2012 European Association of Urology. Published by Elsevier B. V. All rights reserved. * Corresponding author. Department of Radiation Oncology, Massachusetts General Hospital, 55 Fruit Street, Cox 3, Boston, MA 02114, USA. Tel. +1 617 726 8146; Fax: +1 617 726 3603. E-mail address: wshipley@partners.org (W.U. Shipley).
C1 [Gray, Phillip J.; Shipley, William U.; Efstathiou, Jason A.; Zietman, Anthony L.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Gray, Phillip J.] Harvard Radiat Oncol Program, Boston, MA USA.
[Fedewa, Stacey A.; Lin, Chun Chieh; Virgo, Katherine S.] Amer Canc Soc, Hlth Serv Res Program, Atlanta, GA 30329 USA.
[Virgo, Katherine S.] Emory Univ, Dept Hlth Policy & Management, Atlanta, GA 30322 USA.
RP Shipley, WU (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 55 Fruit St,Cox 3, Boston, MA 02114 USA.
EM wshipley@partners.org
FU American Cancer Society Intramural Research Funding
FX This study was supported in part by American Cancer Society Intramural
Research Funding. The American Cancer Society was involved in data
collection and management.
NR 35
TC 57
Z9 57
U1 0
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0302-2838
J9 EUR UROL
JI Eur. Urol.
PD MAY
PY 2013
VL 63
IS 5
BP 823
EP 829
DI 10.1016/j.eururo.2012.11.015
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA 122SC
UT WOS:000317337400011
PM 23200811
ER
PT J
AU Nguyen, LS
Kim, HG
Rosenfeld, JA
Shen, YP
Gusella, JF
Lacassie, Y
Layman, LC
Shaffer, LG
Gecz, J
AF Nguyen, Lam S.
Kim, Hyung-Goo
Rosenfeld, Jill A.
Shen, Yiping
Gusella, James F.
Lacassie, Yves
Layman, Lawrence C.
Shaffer, Lisa G.
Gecz, Jozef
TI Contribution of copy number variants involving nonsense-mediated mRNA
decay pathway genes to neuro-developmental disorders
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID EXON-JUNCTION COMPLEX; MENTAL-RETARDATION; HUMAN GENOME; MICRODELETION
SYNDROME; QUALITY-CONTROL; EXPRESSION; NMD; SURVEILLANCE; ABUNDANCE;
YEAST
AB The nonsense-mediated mRNA decay (NMD) pathway functions not only to degrade transcripts containing premature termination codons (PTC), but also to regulate the transcriptome. UPF3B and RBM8A, important components of NMD, have been implicated in various forms of intellectual disability (ID) and Thrombocytopenia with Absent Radius (TAR) syndrome, which is also associated with ID. To gauge the contribution of other NMD factors to ID, we performed a comprehensive search for copy number variants (CNVs) of 18 NMD genes among individuals with ID and/or congenital anomalies. We identified 11 cases with heterozygous deletions of the genomic region encompassing UPF2, which encodes for a direct interacting protein of UPF3B. Using RNA-Seq, we showed that the genome-wide consequence of reduced expression of UPF2 is similar to that seen in patients with UPF3B mutations. Out of the 1009 genes found deregulated in patients with UPF2 deletions by at least 2-fold, majority (95) were deregulated similarly in patients with UPF3B mutations. This supports the major role of deletion of UPF2 in ID. Furthermore, we found that four other NMD genes, UPF3A, SMG6, EIF4A3 and RNPS1 are frequently deleted and/or duplicated in the patients. We postulate that dosage imbalances of these NMD genes are likely to be the causes or act as predisposing factors for neuro-developmental disorders. Our findings further emphasize the importance of NMD pathway(s) in learning and memory.
C1 [Nguyen, Lam S.; Gecz, Jozef] Univ Adelaide, Sch Paediat & Reprod Hlth, Adelaide, SA 5006, Australia.
[Kim, Hyung-Goo; Shen, Yiping; Gusella, James F.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Human Genet Res, Boston, MA 02114 USA.
[Kim, Hyung-Goo; Shen, Yiping; Gusella, James F.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA.
[Rosenfeld, Jill A.; Shaffer, Lisa G.] PerkinElmer Inc, Signature Genom Labs, Spokane, WA 99207 USA.
[Lacassie, Yves] Louisiana State Univ, Hlth Sci Ctr, Dept Paediat, Div Genet, New Orleans, LA 70118 USA.
[Lacassie, Yves] Childrens Hosp, New Orleans, LA 70118 USA.
[Kim, Hyung-Goo; Layman, Lawrence C.] Georgia Regents Univ, Dept Obstet & Gynaecol, Augusta, GA 30912 USA.
[Gecz, Jozef] SA Pathol, Dept Genet & Mol Pathol, Adelaide, SA 5006, Australia.
RP Gecz, J (reprint author), Univ Adelaide, Neurogenet Lab, Womens & Childrens Hosp, 72 King William Rd, Adelaide, SA 5006, Australia.
EM jozef.gecz@adelaide.edu.au
OI Gecz, Jozef/0000-0002-7884-6861
FU Wellcome Trust; Australian NHMRC [APP628952]; NH&MRC Principal Research
Fellowship [APP1041920]; MS McLeod Foundation
FX This study makes use of data generated by the DECIPHER Consortium. A
full list of centres who contributed to the generation of the data is
available from http://decipher.sanger.ac. uk and via email from
decipher@sanger.ac.uk. Funding for the project was provided by the
Wellcome Trust.; This work was supported by grants from the Australian
NH&MRC Project Grant APP628952 to J.G. J.G. is supported by NH&MRC
Principal Research Fellowship APP1041920. L.S.N.'s PhD Scholarship is
supported by the MS McLeod Foundation.
NR 71
TC 33
Z9 33
U1 0
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD MAY 1
PY 2013
VL 22
IS 9
BP 1816
EP 1825
DI 10.1093/hmg/ddt035
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 123ZD
UT WOS:000317431100011
PM 23376982
ER
PT J
AU Chu, AY
Workalemahu, T
Paynter, NP
Rose, LM
Giulianini, F
Tanaka, T
Ngwa, JS
Qi, QB
Curhan, GC
Rimm, EB
Hunter, DJ
Pasquale, LR
Ridker, PM
Hu, FB
Chasman, DI
Qi, L
AF Chu, Audrey Y.
Workalemahu, Tsegaselassie
Paynter, Nina P.
Rose, Lynda M.
Giulianini, Franco
Tanaka, Toshiko
Ngwa, Julius S.
Qi, Qibin
Curhan, Gary C.
Rimm, Eric B.
Hunter, David J.
Pasquale, Louis R.
Ridker, Paul M.
Hu, Frank B.
Chasman, Daniel I.
Qi, Lu
CA CHARGE Nutr Working Grp
DietGen Consortium
TI Novel locus including FGF21 is associated with dietary macronutrient
intake
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; FOOD FREQUENCY QUESTIONNAIRE; INSULIN
SENSITIVITY; METABOLIC SYNDROME; OBESITY; RISK; HEALTH; DISEASE; WOMEN;
GENE
AB Dietary intake of macronutrients (carbohydrate, protein, and fat) has been associated with risk of chronic conditions such as obesity and diabetes. Family studies have reported a moderate contribution of genetics to variation in macronutrient intake. In a genome-wide meta-analysis of a population-based discovery cohort (n 33 533), rs838133 in FGF21 (19q13.33), rs197273 near TRAF family member-associated NF-kappa-B activator (TANK) (2p24.2), and rs10163409 in FTO (16q12.2) were among the top associations (P 10(5)) for percentage of total caloric intake from protein and carbohydrate. rs838133 was replicated in silico in an independent sample from the Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE) Nutrition Working Group (n 38 360) and attained genome-wide significance in combined analysis (P-joint 7.9 10(9)). A cytokine involved in cellular metabolism, FGF21 is a potential susceptibility gene for obesity and type 2 diabetes. Our results highlight the potential of genetic variation for determining dietary macronutrient intake.
C1 [Chu, Audrey Y.; Paynter, Nina P.; Rose, Lynda M.; Giulianini, Franco; Ridker, Paul M.; Chasman, Daniel I.] Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA.
[Workalemahu, Tsegaselassie; Qi, Qibin; Curhan, Gary C.; Rimm, Eric B.; Hunter, David J.; Hu, Frank B.; Qi, Lu] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA.
[Workalemahu, Tsegaselassie; Qi, Qibin; Curhan, Gary C.; Rimm, Eric B.; Hunter, David J.; Hu, Frank B.; Qi, Lu] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Pasquale, Louis R.] Brigham & Womens Hosp, Dept Ophthalmol, Boston, MA 02115 USA.
[Ridker, Paul M.] Brigham & Womens Hosp, Div Cardiol, Boston, MA 02115 USA.
[Chasman, Daniel I.] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA.
[Chasman, Daniel I.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Workalemahu, Tsegaselassie; Qi, Qibin; Rimm, Eric B.; Hunter, David J.; Hu, Frank B.; Qi, Lu] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Workalemahu, Tsegaselassie; Qi, Qibin; Rimm, Eric B.; Hunter, David J.; Hu, Frank B.; Qi, Lu] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Tanaka, Toshiko] NIA, Clin Res Branch, Baltimore, MD 21224 USA.
[Ngwa, Julius S.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Pasquale, Louis R.] Harvard Univ, Sch Med, Mass Eye & Ear Infirm, Boston, MA 02115 USA.
RP Qi, L (reprint author), Harvard Univ, Sch Publ Hlth, Dept Nutr & Epidemiol, Bldg 2,Room 323,655 Huntington Ave, Boston, MA 02115 USA.
EM luqi@hsph.harvard.edu
FU National Institutes of Health [DK091718, HL71981, HL073168, CA87969,
CA49449, HL34594, HL088521, U01HG004399, DK080140, DK58845, DK46200,
HL043851, HL080467, CA058988]; Amgen; American Heart Association
Scientist Development Award [0730094N]
FX The HPFS and NHS were supported by grants DK091718, HL71981, HL073168,
CA87969, CA49449, HL34594, HL088521, U01HG004399, DK080140, DK58845 and
DK46200 from the National Institutes of Health. The WGHS is supported by
HL043851, HL080467 and CA058988 from the National Institutes of Health
with collaborative scientific support and funding for genotyping
provided by Amgen. L. Q. is a recipient of the American Heart
Association Scientist Development Award (0730094N).
NR 39
TC 31
Z9 33
U1 1
U2 18
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD MAY 1
PY 2013
VL 22
IS 9
BP 1895
EP 1902
DI 10.1093/hmg/ddt032
PG 8
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 123ZD
UT WOS:000317431100018
PM 23372041
ER
PT J
AU Salgado, CD
Sepkowitz, KA
John, JF
Cantey, JR
Attaway, HH
Freeman, KD
Sharpe, PA
Michels, HT
Schmidt, MG
AF Salgado, Cassandra D.
Sepkowitz, Kent A.
John, Joseph F.
Cantey, J. Robert
Attaway, Hubert H.
Freeman, Katherine D.
Sharpe, Peter A.
Michels, Harold T.
Schmidt, Michael G.
TI Copper Surfaces Reduce the Rate of Healthcare-Acquired Infections in the
Intensive Care Unit
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Article
ID RESISTANT STAPHYLOCOCCUS-AUREUS; NOSOCOMIAL PATHOGENS;
CLOSTRIDIUM-DIFFICILE; MICROBIAL BURDEN; ENVIRONMENT; RISK;
CONTAMINATION; SURVEILLANCE; TRANSMISSION; ENTEROCOCCUS
AB OBJECTIVE. Healthcare-acquired infections (HAIs) cause substantial patient morbidity and mortality. Items in the environment harbor microorganisms that may contribute to HAIs. Reduction in surface bioburden may be an effective strategy to reduce HAIs. The inherent biocidal properties of copper surfaces offer a theoretical advantage to conventional cleaning, as the effect is continuous rather than episodic. We sought to determine whether placement of copper alloy-surfaced objects in an intensive care unit (ICU) reduced the risk of HAI.
DESIGN. Intention-to-treat randomized control trial between July 12, 2010, and June 14, 2011.
SETTING. The ICUs of 3 hospitals.
PATIENTS. Patients presenting for admission to the ICU.
METHODS. Patients were randomly placed in available rooms with or without copper alloy surfaces, and the rates of incident HAI and/or colonization with methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE) in each type of room were compared.
RESULTS. The rate of HAI and/or MRSA or VRE colonization in ICU rooms with copper alloy surfaces was significantly lower than that in standard ICU rooms (0.071 vs 0.123; P = .020). For HAI only, the rate was reduced from 0.081 to 0.034 (P = .013).
CONCLUSIONS. Patients cared for in ICU rooms with copper alloy surfaces had a significantly lower rate of incident HAI and/or colonization with MRSA or VRE than did patients treated in standard rooms. Additional studies are needed to determine the clinical effect of copper alloy surfaces in additional patient populations and settings. Infect Control Hosp Epidemiol 2013;34(5):479-486
C1 [Salgado, Cassandra D.; Cantey, J. Robert] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Sepkowitz, Kent A.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA.
[John, Joseph F.] Ralph H Johnson VA Med Ctr, Dept Med, Charleston, SC USA.
[Attaway, Hubert H.; Schmidt, Michael G.] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA.
[Freeman, Katherine D.] Extrapolate LLC, Delray Beach, FL USA.
[Sharpe, Peter A.] Sharpe & Associates, W Orange, NJ USA.
[Michels, Harold T.] Copper Dev Assoc, New York, NY USA.
RP Salgado, CD (reprint author), Div Infect Dis, 135 Rutledge Ave, Charleston, SC 29425 USA.
EM salgado@musc.edu
OI Schmidt, Michael G/0000-0002-7794-7265
FU US Army Materiel Command, US Department of Defense (DOD)
[W81XWH-07-C-0053]
FX This study was funded by a grant from the US Army Materiel Command, US
Department of Defense (DOD; contract W81XWH-07-C-0053). The funding
source was not involved in the preparation, submission, and review of
the manuscript.
NR 36
TC 87
Z9 90
U1 1
U2 48
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0899-823X
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD MAY
PY 2013
VL 34
IS 5
SI SI
BP 479
EP 486
DI 10.1086/670207
PG 8
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 123XC
UT WOS:000317424200006
PM 23571364
ER
PT J
AU Bernstein, KD
Sethi, R
Trofimov, A
Zeng, C
Fullerton, B
Yeap, BY
Ebb, D
Tarbell, NJ
Yock, TI
MacDonald, SM
AF Bernstein, Karen De Amorim
Sethi, Roshan
Trofimov, Alexei
Zeng, Chuan
Fullerton, Barbara
Yeap, Beow Y.
Ebb, David
Tarbell, Nancy J.
Yock, Torunn I.
MacDonald, Shannon M.
TI Early Clinical Outcomes Using Proton Radiation for Children With Central
Nervous System Atypical Teratoid Rhabdoid Tumors
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article
ID TERATOID/RHABDOID TUMOR; BRAIN-TUMORS; CHEMOTHERAPY; RADIOTHERAPY;
CHILDHOOD; SURVIVAL; THERAPY; PATIENT; MEDULLOBLASTOMA; IRRADIATION
AB Purpose: Atypical teratoid/rhabdoid tumor (AT/RT) is an uncommon and aggressive tumor that often affects infants. Irradiation improves survival but has traditionally been avoided in patients under the age of 3 due to the increasing risk of neurocognitive side effects. We report the first cohort of AT/RT patients treated with proton therapy.
Methods and Materials: All patients with AT/RT treated at Massachusetts General Hospital (MGH) Frances H. Burr Proton Beam Therapy Benter between July 2004 and November 2011 were included in this study. All patients were treated with 3-dimensional conformal proton therapy (3D-CPT).
Results: Ten consecutive patients of a median 2.3 years of age and with a median follow-up of 27.3 months (range, 11.3-99.4 months) were identified. Two patients suffered distant relapse; 1 patient was successfully treated with involved field irradiation and chemotherapy, while the second patient died of disease. At last follow-up, 9 patients were alive without evidence of disease. Proton radiation demonstrated increasing sparing of the cerebrum, temporal lobe, cochlea, and hypothalamus.
Conclusions: Initial clinical outcomes with proton therapy are favorable. The advantages of proton therapy are particularly suited to the treatment of AT/RT, a tumor that often requires irradiation treatment at an age when avoiding irradiation to healthy tissues is most desirable. (C) 2013 Elsevier Inc.
C1 [Bernstein, Karen De Amorim; Sethi, Roshan; Trofimov, Alexei; Zeng, Chuan; Tarbell, Nancy J.; Yock, Torunn I.; MacDonald, Shannon M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA USA.
[Yeap, Beow Y.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA USA.
[Ebb, David] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat Hematol Oncol, Boston, MA USA.
[Fullerton, Barbara] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otol & Laryngol, Boston, MA USA.
RP MacDonald, SM (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Yawkey 112,55 Fruit St, Boston, MA 02114 USA.
EM smacdonald@partners.org
NR 22
TC 5
Z9 6
U1 2
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD MAY 1
PY 2013
VL 86
IS 1
BP 114
EP 120
DI 10.1016/j.ijrobp.2012.12.004
PG 7
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 122VH
UT WOS:000317345700026
ER
PT J
AU Russo, AL
Chen, YH
Martin, NE
Vinjamoori, A
Luthy, SK
Freedman, A
Michaelson, EM
Silver, B
Mauch, PM
Ng, AK
AF Russo, Andrea L.
Chen, Yu-Hui
Martin, Neil E.
Vinjamoori, Anant
Luthy, Sarah K.
Freedman, Arnold
Michaelson, Evan M.
Silver, Barbara
Mauch, Peter M.
Ng, Andrea K.
TI Low-Dose Involved-Field Radiation in the Treatment of Non-Hodgkin
Lymphoma: Predictors of Response and Treatment Failure
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article
ID INDOLENT LYMPHOMAS; LOCAL RADIOTHERAPY
AB Purpose: To investigate clinical and pathologic factors significant in predicting local response and time to further treatment after low-dose involved-field radiation therapy (LD-IFRT) for non-Hodgkin lymphoma (NHL).
Methods and Materials: Records of NHL patients treated at a single institution between April 2004 and September 2011 were retrospectively reviewed. Low-dose involved-field radiation therapy was given as 4 Gy in 2 fractions over 2 consecutive days. Treatment response and disease control were determined by radiographic studies and/or physical examination. A generalized estimating equation model was used to assess the effect of tumor and patient characteristics on disease response. A Cox proportional hazards regression model was used to assess time to further treatment.
Results: We treated a total of 187 sites in 127 patients with LD-IFRT. Histologies included 66% follicular, 9% chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma, 10% marginal zone, 6% mantle cell lymphoma (MCL), and 8% other. Median follow-up time was 23.4 months (range, 0.03-92.2 ;months). The complete response, partial response, and overall response rates were 57%, 25%, and 82%, respectively. A CLL histology was associated with a lower response rate (odds ratio 0.2, 95% confidence interval 0.1-0.5, P=.02). Tumor size, site, age at diagnosis, and prior systemic therapy were not associated with response. The median time to first recurrence was 13.6 months. Those with CLL and age <= 50 years at diagnosis had a shorter time to further treatment for local failures (hazard ratio [HR] 3.63, P=.01 and HR 5.50, P=.02, respectively). Those with CLL and MCL had a shorter time to further treatment for distant failures (HR 11.1 and 16.3, respectively, P<.0001).
Conclusions: High local response rates were achieved with LD-IFRT across most histologies. Chronic lymphocytic leukemia and MCL histologies and age <= 50 years at diagnosis had a shorter time to further treatment after LD-IFRT. (C) 2013 Elsevier Inc.
C1 [Russo, Andrea L.] Harvard Radiat Oncol Program, Boston, MA USA.
[Chen, Yu-Hui] Dana Farber Canc Inst, Biostat Core, Boston, MA 02115 USA.
[Martin, Neil E.; Vinjamoori, Anant; Luthy, Sarah K.; Michaelson, Evan M.; Silver, Barbara; Mauch, Peter M.; Ng, Andrea K.] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA.
[Freedman, Arnold] Brigham & Womens Hosp, Dept Hematol Oncol, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Russo, AL (reprint author), Brigham & Womens Hosp, Dept Radiat Oncol, 75 Francis St,ASB1-L2, Boston, MA 02115 USA.
EM alrusso@partners.org
RI Martin, Neil/E-2193-2014
OI Martin, Neil/0000-0002-8164-8516
NR 20
TC 9
Z9 9
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD MAY 1
PY 2013
VL 86
IS 1
BP 121
EP 127
DI 10.1016/j.ijrobp.2012.12.024
PG 7
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 122VH
UT WOS:000317345700027
PM 23414765
ER
PT J
AU Min, CH
Zhu, XP
Winey, BA
Grogg, K
Testa, M
El Fakhri, G
Bortfeld, TR
Paganetti, H
Shih, HA
AF Min, Chul Hee
Zhu, Xuping
Winey, Brian A.
Grogg, Kira
Testa, Mauro
El Fakhri, Georges
Bortfeld, Thomas R.
Paganetti, Harald
Shih, Helen A.
TI Clinical Application of In-Room Positron Emission Tomography for In Vivo
Treatment Monitoring in Proton Radiation Therapy
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article
ID BEAM THERAPY; PET; RANGE; IMPLEMENTATION; UNCERTAINTIES; VERIFICATION;
IRRADIATION
AB Purpose: The purpose of this study is to evaluate the potential of using in-room positron emission tomography (PET) for treatment verification in proton therapy and for deriving suitable PET scan times.
Methods and Materials: Nine patients undergoing passive scattering proton therapy underwent scanning immediately after treatment with an in-room PET scanner. The scanner was positioned next to the treatment head after treatment. The Monte Carlo (MC) method was used to reproduce PET activities for each patient. To assess the proton beam range uncertainty, we designed a novel concept in which the measured PET activity surface distal to the target at the end of range was compared with MC predictions. The repositioning of patients for the PET scan took, on average, approximately 2 minutes. The PET images were reconstructed considering varying scan times to test the scan time dependency of the method.
Results: The measured PET images show overall good spatial correlations with MC predictions. Some discrepancies could be attributed to uncertainties in the local elemental composition and biological washout. For 8 patients treated with a single field, the average range differences between PET measurements and computed tomography (CT) image-based MC results were <5 mm (<3 mm for 6 of 8 patients) and root-mean-square deviations were 4 to 11 mm with PET-CT image co-registration errors of approximately 2 mm. Our results also show that a short-length PET scan of 5 minutes can yield results similar to those of a 20-minute PET scan.
Conclusions: Our first clinical trials in 9 patients using an in-room PET system demonstrated its potential for in vivo treatment monitoring in proton therapy. For a quantitative range prediction with arbitrary shape of target volume, we suggest using the distal PET activity surface. (C) 2013 Elsevier Inc.
C1 [Min, Chul Hee; Winey, Brian A.; Testa, Mauro; Bortfeld, Thomas R.; Paganetti, Harald; Shih, Helen A.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Min, Chul Hee; Winey, Brian A.; Testa, Mauro; Bortfeld, Thomas R.; Paganetti, Harald; Shih, Helen A.] Harvard Univ, Sch Med, Boston, MA USA.
[Zhu, Xuping; Grogg, Kira; El Fakhri, Georges] Massachusetts Gen Hosp, Ctr Adv Radiol Sci Nucl Med & Mol Imaging, Dept Radiol, Boston, MA 02114 USA.
RP Shih, HA (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 30 Fruit St, Boston, MA 02114 USA.
EM hshih@partners.org
FU National Cancer Institute [P01CA21239, R21CA153455]; National Institute
of Biomedical Imaging and Bioengineering [R21EB12823]
FX This work was supported by grants P01CA21239 "Proton Therapy Research"
and R21CA153455 (Principal Investigator [PI]: G. El Fakhri) from the
National Cancer Institute, and R21EB12823 (PI: G. El Fakhri) from the
National Institute of Biomedical Imaging and Bioengineering.
NR 17
TC 28
Z9 29
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD MAY 1
PY 2013
VL 86
IS 1
BP 183
EP 189
DI 10.1016/j.ijrobp.2012.12.010
PG 7
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 122VH
UT WOS:000317345700036
PM 23391817
ER
PT J
AU Chonde, DB
Abolmaali, N
Arabasz, G
Guimaraes, AR
Catana, C
AF Chonde, Daniel B.
Abolmaali, Nasreddin
Arabasz, Grae
Guimaraes, Alexander R.
Catana, Ciprian
TI Effect of MRI Acoustic Noise on Cerebral Fludeoxyglucose Uptake in
Simultaneous MR-PET Imaging
SO INVESTIGATIVE RADIOLOGY
LA English
DT Article
DE PET; MRI; multimodality imaging; physiological interference; auditory
cortex
ID POSITRON-EMISSION-TOMOGRAPHY; TRANSCRANIAL MAGNETIC STIMULATION;
AUDITORY-CORTEX; ATTENUATION-CORRECTION; INFERIOR COLLICULUS; HUMAN
BRAIN; FMRI; GLUCOSE; CONNECTIVITY; REGISTRATION
AB Integrated scanners capable of simultaneous positron emission tomography (PET) and magnetic resonance imaging (MRI) data acquisition are now available for human use. Although the scanners' manufacturers have made substantial efforts to understand and minimize the mutual electromagnetic interference between the 2 modalities, the potential physiological inference has not been evaluated. In this study, we have studied the influence of the acoustic noise produced by the magnetic resonance (MR) gradients on brain fludeoxyglucose (FDG) uptake in the Siemens MR-BrainPET prototype. Although particular attention was paid to the primary auditory cortex (PAC), a brain-wide analysis was also performed.
Methods: The effects of the MR on the PET count rate and image quantification were first investigated in phantoms. Next, 10 healthy volunteers underwent 2 simultaneous FDG-PET/MR scans in the supine position with the FDG injection occurring inside the MR-BrainPET, alternating between a "quiet" (control) environment in which no MR sequences were run during the FDG uptake phase (the first 40 minutes after radiotracer administration) and a "noisy" (test) environment in which MR sequences were run for the entire time. Cortical and subcortical regions of interest were derived from the high-resolution morphological MR data using FreeSurfer. The changes in the FDG uptake in the FreeSurfer-derived regions of interest between the 2 conditions were analyzed from parametric and static PET images, and on a voxel-by-voxel basis using SPM8 and FreeSurfer.
Results: Only minimal to no electromagnetic interference was observed for most of the MR sequences tested, with a maximum drop in count rate of 1.5% and a maximum change in the measured activity of 1.1% in the corresponding images. The region of interest-based analysis showed statistically significant increases in the right PAC in both the parametric (9.13% [4.73%]) and static (4.18% [2.87%]) images. The SPM8 analysis showed no statistically significant clusters in any images when a P < 0.05 (corrected) was used; however, a P < 0.001 (uncorrected) resolved bilateral statistically significant clusters of increased FDG uptake in the area of the PAC for the parametric image (left, 8.37% [1.55%]; right, 8.20% [1.17%]) but only unilateral increase in the static image (left, 8.68% [3.89%]).
Conclusions: Although the operation of the BrainPET prototype is virtually unaffected by the MR scanner, the acoustic noise produced by the MR gradients causes a focal increase in the FDG uptake in the PAC, which could affect the interpretation of pathological (or brain-activation-related) changes in the FDG uptake in this region if the expected effects are of comparable amplitude.
C1 [Chonde, Daniel B.; Arabasz, Grae; Guimaraes, Alexander R.; Catana, Ciprian] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Chonde, Daniel B.; Arabasz, Grae; Guimaraes, Alexander R.; Catana, Ciprian] Harvard Univ, Sch Med, Charlestown, MA USA.
[Chonde, Daniel B.] Harvard Univ, Program Biophys, Cambridge, MA 02138 USA.
[Abolmaali, Nasreddin] Univ Clin Carl Gustav Carus, OncoRay Natl Ctr Radiat Res Oncol, Dresden, Germany.
RP Chonde, DB (reprint author), Massachusetts Gen Hosp, Charlestown, MA 02129 USA.
EM chonde@nmr.mgh.harvard.edu
FU National Institutes of Health, Bethesda, MD [R01CA137254-01A1,
5T32GM008313, 5T90DA022759-05, T32EB001680]
FX Supported by grants R01CA137254-01A1, 5T32GM008313, 5T90DA022759-05, and
T32EB001680 from the National Institutes of Health, Bethesda, MD.
NR 38
TC 9
Z9 9
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0020-9996
J9 INVEST RADIOL
JI Invest. Radiol.
PD MAY
PY 2013
VL 48
IS 5
BP 302
EP 312
DI 10.1097/RLI.0b013e3182839fbc
PG 11
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 125ZO
UT WOS:000317581100010
PM 23462677
ER
PT J
AU Borus, JS
Blood, E
Volkening, LK
Laffel, L
Shrier, LA
AF Borus, Joshua S.
Blood, Emily
Volkening, Lisa K.
Laffel, Lori
Shrier, Lydia A.
TI Momentary Assessment of Social Context and Glucose Monitoring Adherence
in Adolescents With Type 1 Diabetes
SO JOURNAL OF ADOLESCENT HEALTH
LA English
DT Article
DE Type 1 diabetes; Momentary sampling; Adolescents; Adherence; Social
context
ID GLYCEMIC CONTROL; SELF-CARE; SUPPORT; MELLITUS; MANAGEMENT; SITUATIONS;
FRIENDS; YOUTH
AB Purpose: To investigate the associations between momentary social context and glucose monitoring adherence in adolescents with type 1diabetes (T1D).
Methods: For 14 days, patients (14-18 years old, T1D duration >1 year) of a pediatric diabetes clinic carried handheld computers that prompted them to report their location, companionship, and attitudes toward companions at the times they usually checked their glucose, and again 30 minutes later to report whether they checked their glucose and, if not, why. Associations between social context factors and checking glucose (adherence) were analyzed using logistic generalized estimating equations and adjusted for age, sex, duration of T1D, and pump use.
Results: Thirty-six participants (mean age 16.6 +/- 1.5 years, mean duration of T1D 8.7 +/- 4.4 years) completed 971 context and 1,210 adherence reports, resulting in 805 paired reports. Median signal response rate was 63%. The odds of checking glucose was higher when participants expressed very strong desire to blend in (adjusted odds ratio [AOR] = 2.30, 95% confidence interval 1.07-4.94, p = .03). Strong desire to impress others was associated with decreased likelihood of checking glucose (AOR = .52, 95% confidence interval .28-.97, p = .04.) Location, solitude, type of companion, and attitudes toward companions were not significantly associated with checking glucose.
Conclusions: Desire to blend in may support glucose monitoring adherence and desire to impress others may impede this behavior in adolescents with T1D. Other dimensions of social context were not linked to checking glucose in this study. (C) 2013 Society for Adolescent Health and Medicine. All rights reserved.
C1 [Borus, Joshua S.; Shrier, Lydia A.] Boston Childrens Hosp, Div Adolescent Young Adult Med, Boston, MA 02115 USA.
[Blood, Emily] Boston Childrens Hosp, Clin Res Ctr, Boston, MA 02115 USA.
[Borus, Joshua S.; Blood, Emily; Laffel, Lori; Shrier, Lydia A.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Volkening, Lisa K.; Laffel, Lori] Joslin Diabet Ctr, Genet & Epidemiol Sect, Boston, MA 02215 USA.
[Laffel, Lori] Joslin Diabet Ctr, Pediat Adolescent & Young Adult Sect, Boston, MA 02215 USA.
RP Borus, JS (reprint author), Boston Childrens Hosp, Div Adolescent Young Adult Med, 300 Longwood Ave, Boston, MA 02115 USA.
EM Joshua.borus@childrens.harvard.edu
FU Leadership Education in Adolescent Health (LEAH) from the Maternal and
Child Health Bureau [T71MC00009]; Division of Adolescent/Young Adult
Medicine at Boston Children's Hospital; Katherine Adler Astrove Youth
Education Fund at the Joslin Diabetes Center; Eleanor Chesterman Beatson
Youth Fund; Maria Griffin Drury Pediatric Fund at the Joslin Diabetes
Center
FX This work was supported in part by the Leadership Education in
Adolescent Health (LEAH) training grant no. T71MC00009 from the Maternal
and Child Health Bureau and a Gallagher Award from the Division of
Adolescent/Young Adult Medicine at Boston Children's Hospital. The
Katherine Adler Astrove Youth Education Fund at the Joslin Diabetes
Center, Eleanor Chesterman Beatson Youth Fund, and the Maria Griffin
Drury Pediatric Fund at the Joslin Diabetes Center also provided
support. Portions of this manuscript were presented at the 2012 Annual
Meeting of the Society for Adolescent Health and Medicine.
NR 26
TC 5
Z9 5
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1054-139X
J9 J ADOLESCENT HEALTH
JI J. Adolesc. Health
PD MAY
PY 2013
VL 52
IS 5
BP 578
EP 583
DI 10.1016/j.jadohealth.2012.10.003
PG 6
WC Psychology, Developmental; Public, Environmental & Occupational Health;
Pediatrics
SC Psychology; Public, Environmental & Occupational Health; Pediatrics
GA 126ZD
UT WOS:000317661300013
PM 23298986
ER
PT J
AU Biederman, J
Martelon, M
Faraone, SV
Woodworth, KY
Spencer, TJ
Wozniak, JR
AF Biederman, Joseph
Martelon, MaryKate
Faraone, Stephen V.
Woodworth, K. Yvonne
Spencer, Thomas J.
Wozniak, Janet R.
TI Personal and familial correlates of bipolar (BP)-I disorder in children
with a diagnosis of BP-I disorder with a positive child behavior
checklist (CBCL)-severe dysregulation profile: A controlled study
SO JOURNAL OF AFFECTIVE DISORDERS
LA English
DT Article
DE Mood disorders; Severity of illness index; Screening instrument
ID DEFICIT HYPERACTIVITY DISORDER; ATTENTION-DEFICIT/HYPERACTIVITY
DISORDER; EMOTIONAL SELF-REGULATION; ADHD; CBCL; COMORBIDITY; MANIA;
METAANALYSIS; PREVALENCE; YOUTH
AB Background: Although the DSM-IV provides explicit criteria for the diagnosis of BP-I disorder, this is a complex diagnosis that requires high levels of clinical expertise. Previous work shows children with a unique profile of the CBCL of high scores (2SD) on the attention problems (AP), aggressive behavior (AGG), and anxious-depressed (AD) (A-A-A) subscales are more likely than other children to meet criteria for BP-I disorder in both epidemiological and clinical samples. However, since not all BP-I disorder children have a positive profile questions remain as to its informativeness, particularly in the absence of an expert diagnostician.
Methods: Analyses were conducted comparing personal and familial correlates of BP-I disorder in 140 youth with a structured interview and an expert clinician based DSM-IV diagnosis of BP-I disorder with (N=80) and without (N=60) a positive CBCL- Severe Dysregulation profile, and 129 controls of similar age and sex without ADHD or a mood disorder. Subjects were comprehensively assessed with structured diagnostic interviews and wide range of functional measures. We defined the CBCL-severe dysregulation profile as an aggregate cut-off score of >= 210 on the A-A-A scales.
Results: BP-I probands with and without a positive CBCL-severe dysregulation profile significantly differed from Controls in patterns of psychiatric comorbidity, psychosocial and psychoeducational dysfunction, and cognitive deficits, as well as in their risk for BP-I disorder in first degree relatives.
Limitations: Because the sample was referred and largely Caucasian, findings may not generalize to community samples and other ethnic groups.
Conclusion: A positive CBCL-severe dysregulation profile identifies a severe subgroup of BP-I disorder youth. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Biederman, Joseph; Martelon, MaryKate; Woodworth, K. Yvonne; Spencer, Thomas J.; Wozniak, Janet R.] Massachusetts Gen Hosp, Clin Program Pediat Psychopharmacol & Adult ADHD, Boston, MA 02114 USA.
[Biederman, Joseph; Martelon, MaryKate; Woodworth, K. Yvonne; Spencer, Thomas J.; Wozniak, Janet R.] Massachusetts Gen Hosp, Res Program Pediat Psychopharmacol & Adult ADHD, Boston, MA 02114 USA.
[Biederman, Joseph; Spencer, Thomas J.; Wozniak, Janet R.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY 13210 USA.
[Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Neurosci & Physiol, Syracuse, NY 13210 USA.
RP Biederman, J (reprint author), Massachusetts Gen Hosp, 55 Fruit St,YAW 6A, Boston, MA 02114 USA.
EM jbiederman@partners.org
OI Faraone, Stephen/0000-0002-9217-3982
FU NIH [K08MH001503, R01MH066237, R01MH050657, R01HD036317]; Heinz C.
Prechter Bipolar Research Fund; Susan G. Berk Endowed Fund for Juvenile
Bipolar Disorder
FX This work was supported by NIH grants K08MH001503 and R01MH066237 to Dr
Wozniak and R01MH050657 and R01HD036317 to Dr Biederman. This work was
also supported by a grant from the Heinz C. Prechter Bipolar Research
Fund, the support of members of the MGH Pediatric Psychopharmacology
Council, and the Susan G. Berk Endowed Fund for Juvenile Bipolar
Disorder.
NR 34
TC 12
Z9 12
U1 4
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-0327
J9 J AFFECT DISORDERS
JI J. Affect. Disord.
PD MAY
PY 2013
VL 147
IS 1-3
BP 164
EP 170
DI 10.1016/j.jad.2012.10.028
PG 7
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 115CQ
UT WOS:000316790400024
PM 23164462
ER
PT J
AU Townsend, JD
Sugar, CA
Walshaw, PD
Vasquez, RE
Foland-Ross, LC
Moody, TD
Bookheimer, SY
McGough, JJ
Altshuler, LL
AF Townsend, Jennifer D.
Sugar, Catherine A.
Walshaw, Patricia D.
Vasquez, Roxanne E.
Foland-Ross, Lara C.
Moody, Teena D.
Bookheimer, Susan Y.
McGough, James J.
Altshuler, Lori L.
TI Frontostriatal neuroimaging findings differ in patients with bipolar
disorder who have or do not have ADHD comorbidity
SO JOURNAL OF AFFECTIVE DISORDERS
LA English
DT Article
DE Bipolar disorder; Euthymia; fMRI; ADHD; Response inhibition; Inferior
frontal cortex
ID ATTENTION-DEFICIT/HYPERACTIVITY-DISORDER; DEFICIT HYPERACTIVITY
DISORDER; RESPONSE-INHIBITION; PREFRONTAL CORTEX; COGNITIVE CONTROL;
BRAIN ACTIVATION; CINGULATE CORTEX; DEPRESSION; MANIA; CONNECTIVITY
AB Background: The inferior frontal cortical (IFC)-striatal network plays an integral role in response inhibition and is compromised in patients with Bipolar Disorder (BP) or Attention-Deficit/Hyperactivity Disorder (ADHD). Prior BP functional neuroimaging studies have not accounted for ADHD comorbidity despite its high prevalence.
Methods: The authors conducted an fMRI study using a response inhibition task (Go-NoGo) in 32 euthymic adults with BP, half with comorbid ADHD (BP/ADHD); 16 adults with ADHD alone; and 30 healthy controls. Within- and between-group whole-brain analyses were performed to assess for significant neural function differences.
Results: All groups activated frontal and striatal regions involved in response inhibition. ANOVA results demonstrated significant interaction effects of BP and ADHD in the anterior and posterior cingulate, left superior and middle frontal gyri and left inferior parietal lobule. Follow-up comparisons showed significant differences between BP subjects with and without ADHD. Other regions demonstrated main effects of BP (left inferior frontal gyms, left middle frontal gyms, right superior frontal gyrus and left insula) and ADHD (left inferior frontal gyms, left precentral gyrus and right anterior cingulate).
Limitations: This study, as the first of its kind, requires replication using large sample sizes and controlling for potential effects of medication.
Conclusions: Euthymic bipolar adults with comorbid ADHD have significantly different neural activation patterns from BP patients without this comorbidity. If understanding of the neurobiology of bipolar disorder is to be achieved, it is critical to control for this potential confound, something not done by most prior fMRI studies of adults with BP. Published by Elsevier B.V.
C1 [Townsend, Jennifer D.; Sugar, Catherine A.; Walshaw, Patricia D.; Vasquez, Roxanne E.; Moody, Teena D.; Bookheimer, Susan Y.; McGough, James J.; Altshuler, Lori L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Sugar, Catherine A.; Moody, Teena D.; McGough, James J.] Univ Calif Los Angeles, Jane & Terry Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA.
[Sugar, Catherine A.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90095 USA.
[Foland-Ross, Lara C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Lab Neuroimaging, Los Angeles, CA 90095 USA.
[Altshuler, Lori L.] West Los Angeles Healthcare Ctr, VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA 90073 USA.
RP Altshuler, LL (reprint author), Univ Calif Los Angeles, Mood Disorders Res Program, 300 Med Plaza,Suite 1544,Box 957057, Los Angeles, CA 90095 USA.
EM laltshuler@mednet.ucla.edu
FU Furlotti Family Foundation; National Institutes of Health (NIH):
National Institute of Mental Health [K24 MH001848, R21 MH075944,
5F31MH078556]; National Institutes of Health (NIH): National Center for
Research Resources (NCRR) [RR12169, RR13642, RR00865]; Abbott
Laboratories; Eli Lilly; NeuroSigma Inc.; Supranus; Shionogi
Pharmaceuticals
FX This study was supported by the Furlotti Family Foundation and the
following two components of the National Institutes of Health (NIH): the
National Institute of Mental Health (K24 MH001848 (LA), R21 MH075944
(LA), 5F31MH078556 (LF)) and the National Center for Research Resources
(NCRR) (RR12169, RR13642 and RR00865).; Drs. Bookheimer, Foland-Ross,
Moody and Sugar, Ms. Townsend and Ms. Vasquez report no financial
relationships with commercial interests. Dr. Altshuler has received
research support from Abbott Laboratories; consulting honoraria from Eli
Lilly, Abbott Laboratories, Forest Laboratories and Sepracor; and
speakers bureau honoraria from Forest Laboratories, GlaxoSmith Kline,
Bristol Meyer Squibb/Otsuka America.; Dr. McGough has received
consulting honoraria from Eli Lilly & Co., MedImmune, Shionogi
Pharmaceuticals, Shire, Sunovion, and Targacept, and research support
from Eli Lilly, NeuroSigma Inc., Supranus and Shionogi Pharmaceuticals.
None of the above affiliations should result in a conflict of interest
related to the subject of the manuscript being submitted.
NR 41
TC 5
Z9 6
U1 1
U2 20
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-0327
J9 J AFFECT DISORDERS
JI J. Affect. Disord.
PD MAY
PY 2013
VL 147
IS 1-3
BP 389
EP 396
DI 10.1016/j.jad.2012.08.019
PG 8
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 115CQ
UT WOS:000316790400056
PM 23057969
ER
PT J
AU Bakhru, MR
Sethi, A
Jamidar, PA
Singh, SK
Kwon, RS
Siddiqui, UD
Sawhney, M
Talreja, JP
Kline, P
Malik, U
Gaidhane, M
Sauer, BG
Kahaleh, M
AF Bakhru, Mihir R.
Sethi, Amrita
Jamidar, Priya A.
Singh, Satish K.
Kwon, Richard S.
Siddiqui, Uzma D.
Sawhney, Mandeep
Talreja, Jayant P.
Kline, Pamela
Malik, Umer
Gaidhane, Monica
Sauer, Bryan G.
Kahaleh, Michel
TI Interobserver Agreement for Confocal Imaging of Ampullary Lesions A
Multicenter Single-blinded Study
SO JOURNAL OF CLINICAL GASTROENTEROLOGY
LA English
DT Article
DE probe-based confocal laser endomicroscopy; ampullary lesions;
interobserver agreement; pCLE
ID LASER ENDOMICROSCOPY; ULCERATIVE-COLITIS; TUMORS; DIAGNOSIS; NEOPLASIA;
ACCURACY; BIOPSY
AB Background: Malignant ampullary lesions can be difficult to classify by endoscopy alone. Probe-based confocal laser endomicroscopy (pCLE) permits in vivo assessment of mucosal structures in the gastrointestinal tracts in the real time.
Aim: The objective of this pilot multicenter study was to assess the interobserver agreement and variance in interpretation of pCLE of ampullary lesions.
Methods: Twelve pCLE video clips of ampullary lesions were distributed to 6 gastrointestinal specialists at 5 medical centers, blinded to final pathologic results. Six variables were assessed for interobserver agreement using kappa statistics. Variables included an epithelial outer border with irregular thickness, dark epithelium without discernable individual cells, heterogenously distributed elongated crypts, reduced number of goblet cells, neovascularization, and final diagnosis.
Results: The overall interobserver agreement for all observers was poor to slight for all variables (kappa = 0.02, 0.05, -0.01, 0.04, 0.018) except for the first variable with fair degree of agreement (kappa = 0.27). On the basis of experience, 3 observers were classified as less experienced, whereas 3 were classified as most experienced. Upon stratification, the less experienced observers had poor interobserver agreement for all variables, except 1. The most experienced observers had poor agreement for 2 variables, slight agreement for 3 variables, and fair agreement for the final diagnosis variable.
Conclusions: The overall interpersonal agreement on pCLE for ampullary lesions was poor. The interobserver agreement was not substantially improved for experienced raters. Further standardization of pCLE image criteria is needed for ampullary lesions. Standardized training may improve interrater reliability to an acceptable level.
C1 [Bakhru, Mihir R.; Talreja, Jayant P.; Sauer, Bryan G.] Univ Virginia, Dept Digest Hlth, Charlottesville, VA USA.
[Sethi, Amrita] Columbia Univ, Med Ctr, Dept Gastroenterol, New York, NY USA.
[Kline, Pamela; Malik, Umer; Gaidhane, Monica; Kahaleh, Michel] Weill Cornell Med Coll, Dept Med, Div Gastroenterol & Hepatol, New York, NY USA.
[Jamidar, Priya A.; Siddiqui, Uzma D.] Yale Univ, Dept Gastroenterol, New Haven, CT USA.
[Singh, Satish K.] Boston Univ, Sch Med, Dept Gastroenterol, Boston, MA 02118 USA.
[Sawhney, Mandeep] BIDMC, Dept Gastroenterol, Boston, MA USA.
[Kwon, Richard S.] Univ Michigan, Dept Gastroenterol, Ann Arbor, MI 48109 USA.
RP Kahaleh, M (reprint author), Weill Cornell Med Coll, Pancreas Program, Dept Med, Div Gastroenterol & Hepatol, New York, NY 10021 USA.
EM mkahaleh@gmail.com
RI Gaidhane, Monica/B-9414-2009
OI Gaidhane, Monica/0000-0001-6773-7080
NR 20
TC 7
Z9 8
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0192-0790
J9 J CLIN GASTROENTEROL
JI J. Clin. Gastroenterol.
PD MAY-JUN
PY 2013
VL 47
IS 5
BP 440
EP 442
DI 10.1097/MCG.0b013e3182745f2b
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 124PO
UT WOS:000317477400017
PM 23340063
ER
PT J
AU Amorosa, VK
Aibana, O
Shire, NJ
Dorey-Stein, Z
Ferrara, T
Gilmore, J
Kostman, JR
Lo Re, V
AF Amorosa, Valerianna K.
Aibana, Omowunmi
Shire, Norah J.
Dorey-Stein, Zachariah
Ferrara, Thomas
Gilmore, Joanne
Kostman, Jay R.
Lo Re, Vincent
TI Willingness to Undergo a Repeat Liver Biopsy Among HIV/Hepatitis C
Virus-coinfected and Hepatitis C Virus-monoinfected Patients
SO JOURNAL OF CLINICAL GASTROENTEROLOGY
LA English
DT Article
DE liver biopsy; hepatitis C; HIV/hepatitis C coinfection; HIV; staging of
fibrosis
ID FIBROSIS PROGRESSION
AB Background: Guidelines for chronic hepatitis C virus (HCV) management have recommended that a liver biopsy be repeated at 3-year intervals for HIV/HCV-coinfected patients and 5-year intervals for those with HCV monoinfection to assess fibrosis progression. However, it is unclear if patients are willing to repeat this procedure.
Objective: To determine the prevalence and factors, particularly HIV coinfection, associated with willingness to repeat a liver biopsy.
Methods: A questionnaire was administered to 235 HCV-infected patients (113 with HIV coinfection) between January 2008 and June 2011 who previously underwent liver biopsy. The main outcome was self-reported willingness to repeat the biopsy. The questionnaire collected data on other hypothesized determinants of willingness to repeat the biopsy. These were evaluated by logistic regression.
Results: Among 235 subjects who completed the questionnaire, 32 (14%) reported unwillingness to repeat the biopsy, most commonly because of a perception that it was unimportant for care [13(41%)], concerns regarding pain [12(38%)], and a poor experience with the prior biopsy [7(21%)]. Considering biopsy to be safe [odds ratio (OR), 4.45; 95% CI, 1.50-13.27], important (OR, 4.87; 95% CI, 1.83-12.95), and knowing a person who underwent liver biopsy (OR, 3.45; 95% CI, 1.16-10.23) were associated with willingness to repeat the biopsy. HIV was not associated with willingness to repeat the biopsy (OR, 1.42; 95% CI, 0.67-3.03).
Conclusions: Eighty-six percent of chronic HCV-infected patients were willing to repeat a liver biopsy. HIV was not associated with unwillingness. In patients in whom a repeat liver biopsy is indicated, education on the utility and safety of the biopsy is important to its acceptance.
C1 [Amorosa, Valerianna K.; Lo Re, Vincent] Univ Penn, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
[Amorosa, Valerianna K.; Dorey-Stein, Zachariah; Ferrara, Thomas; Gilmore, Joanne; Kostman, Jay R.; Lo Re, Vincent] Univ Penn, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA.
[Shire, Norah J.; Lo Re, Vincent] Univ Penn, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Aibana, Omowunmi] Harvard Univ, Sch Med, Boston, MA USA.
[Shire, Norah J.] Merck & Co Inc, Whitehouse Stn, NJ 08889 USA.
RP Amorosa, VK (reprint author), Philadelphia VAMC, Infect Dis Sect, Dept Med, Philadelphia, PA 19104 USA.
EM valerianna.amorosa@uphs.upenn.edu
RI Lo Re, Vincent/N-7817-2015
FU National Institutes of Health Research [K01 AI070001]
FX V.L.R. was financially supported by the National Institutes of Health
Research Grant K01 AI070001.
NR 8
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0192-0790
J9 J CLIN GASTROENTEROL
JI J. Clin. Gastroenterol.
PD MAY-JUN
PY 2013
VL 47
IS 5
BP 457
EP 460
DI 10.1097/MCG.0b013e318266fe70
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 124PO
UT WOS:000317477400020
PM 23328300
ER
PT J
AU Pollock, NR
Macovei, L
Kanunfre, K
Dhiman, R
Restrepo, BI
Zarate, I
Pino, PA
Mora-Guzman, F
Fujiwara, RT
Michel, G
Kashino, SS
Campos-Neto, A
AF Pollock, Nira R.
Macovei, Lilia
Kanunfre, Kelly
Dhiman, Rakesh
Restrepo, Blanca I.
Zarate, Izelda
Pino, Paula A.
Mora-Guzman, Francisco
Fujiwara, Ricardo T.
Michel, Gerd
Kashino, Suely S.
Campos-Neto, Antonio
TI Validation of Mycobacterium tuberculosis Rv1681 Protein as a Diagnostic
Marker of Active Pulmonary Tuberculosis
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID SMEAR MICROSCOPY; URINE; IDENTIFICATION; BIOMARKERS; SPECIMENS; NEEDS;
LAM; DNA
AB The development of an accurate antigen detection assay for the diagnosis of active tuberculosis (TB) would represent a major clinical advance. Here, we demonstrate that the Mycobacterium tuberculosis Rv1681 protein is a biomarker for active TB with potential diagnostic utility. We initially identified, by mass spectroscopy, peptides from the Rv1681 protein in urine specimens from 4 patients with untreated active TB. Rabbit IgG anti-recombinant Rv1681 detected Rv1681 protein in lysates and culture filtrates of M. tuberculosis and immunoprecipitated it from pooled urine specimens from two TB patients. An enzyme-linked immunosorbent assay formatted with these antibodies detected Rv1681 protein in unconcentrated urine specimens from 11/25 (44%) TB patients and 1/21 (4.8%) subjects in whom TB was initially clinically suspected but then ruled out by conventional methods. Rv1681 protein was not detected in urine specimens from 10 subjects with Escherichia coli-positive urine cultures, 26 subjects with confirmed non-TB tropical diseases (11 with schistosomiasis, 5 with Chagas' disease, and 10 with cutaneous leishmaniasis), and 14 healthy subjects. These results provide strong validation of Rv1681 protein as a promising biomarker for TB diagnosis.
C1 [Pollock, Nira R.] Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA.
[Macovei, Lilia; Kanunfre, Kelly; Dhiman, Rakesh; Kashino, Suely S.; Campos-Neto, Antonio] Forsyth Inst, Global Infect Dis Res Ctr, Cambridge, MA USA.
[Restrepo, Blanca I.; Zarate, Izelda; Pino, Paula A.] Univ Texas Hlth Sci Ctr Houston, Div Epidemiol, Brownsville, TX USA.
[Mora-Guzman, Francisco] Secretaria Salud Tamaulipas, Matamoros, Mexico.
[Fujiwara, Ricardo T.] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
[Michel, Gerd] Fdn Innovat New Diagnost, Geneva, Switzerland.
RP Pollock, NR (reprint author), Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA.
EM nira.pollock@childrens.harvard.edu; acampos@forsyth.org
RI Fujiwara, Ricardo/J-7579-2012
OI Fujiwara, Ricardo/0000-0002-4713-575X
FU Foundation for Innovative New Diagnostics (FIND); Bill and Melinda Gates
Foundation [OPP1039610]; National Institutes of Health [R01 AI076425,
K23 AI074638]; Harvard Catalyst; Pittsfield Anti-Tuberculosis
Association
FX This work was supported by grants from the Foundation for Innovative New
Diagnostics (FIND) (to A.C.-N.), the Bill and Melinda Gates Foundation
(grant OPP1039610 to A.C.-N. and N.R.P.), the National Institutes of
Health (grant R01 AI076425 to A.C.-N. and grant K23 AI074638 to N.R.P.),
Harvard Catalyst (pilot grant to N.R.P.), and the Pittsfield
Anti-Tuberculosis Association (to N.R.P.).
NR 25
TC 8
Z9 8
U1 0
U2 19
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD MAY
PY 2013
VL 51
IS 5
BP 1367
EP 1373
DI 10.1128/JCM.03192-12
PG 7
WC Microbiology
SC Microbiology
GA 126GT
UT WOS:000317602100004
PM 23390284
ER
PT J
AU Lysaght, S
Ersek, M
AF Lysaght, Susan
Ersek, Mary
TI Settings of Care Within Hospice New Options and Questions About Dying
"At Home"
SO JOURNAL OF HOSPICE & PALLIATIVE NURSING
LA English
DT Article
DE caregiving; hospice; inpatient hospice; place of death
ID FACTORS INFLUENCING DEATH; LIFE CANCER CARE; NO PLACE LIKE; OF-LIFE;
FAMILY CAREGIVERS; HOSPITALIZED-PATIENTS; PEOPLE DIE; END; DETERMINANTS;
PERSPECTIVES
AB Although place of death has been routinely studied in end-of-life care, more analysis on place of death within hospice is needed because of the recent, dramatic rise in the number of hospice patients dying in inpatient settings. Using a case study to illustrate the complexity of determinants of place of death within hospice, this article highlights important known factors and elucidates gaps for further research. Individual- and system-level factors, sociocultural meanings, caregiving, and preferences are shown to have important implications. Additionally, the unique components of home hospice, inpatient hospice, and transitions between these settings may have a fundamental role in the future of quality end-of-life care. Further research on determinants of hospice settings of care is essential to the care of older adults at the end of life.
C1 [Lysaght, Susan; Ersek, Mary] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA.
[Ersek, Mary] Philadelphia Vet Affairs Med Ctr, Natl PROMISE Performance Reporting & Outcomes Mea, Philadelphia, PA USA.
RP Lysaght, S (reprint author), Univ Penn, Sch Nursing, Claire M Fagin Hall,310g,418 Curie Blvd, Philadelphia, PA 19104 USA.
EM slysaght@nursing.upenn.edu
FU John A. Hartford Building Academic Geriatric Nursing Capacity Scholar
Award; Ruth L. Kirschstein Individual NRSA Predoctoral Fellowship
[1F31NR013103]; NINR Individualized Care for At-Risk Older Adults
[T32NR009356]
FX Dr Lysaght was supported by a John A. Hartford Building Academic
Geriatric Nursing Capacity Scholar Award 2010-2012 and a Ruth L.
Kirschstein Individual NRSA Predoctoral Fellowship (1F31NR013103); Dr
Lysaght also received funding through NINR T32NR009356 Individualized
Care for At-Risk Older Adults from 2008 to 2010.
NR 40
TC 5
Z9 5
U1 2
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1522-2179
J9 J HOSP PALLIAT NURS
JI J. Hosp. Palliat. Nurs.
PD MAY
PY 2013
VL 15
IS 3
BP 171
EP 176
DI 10.1097/NJH.0b013e3182765a17
PG 6
WC Nursing
SC Nursing
GA 124QG
UT WOS:000317479700006
PM 23853526
ER
PT J
AU Li, H
Wu, Q
Li, J
Yang, PA
Zhu, ZL
Luo, B
Hsu, HC
Mountz, JD
AF Li, Hao
Wu, Qi
Li, Jun
Yang, PingAr
Zhu, Zilu
Luo, Bao
Hsu, Hui-Chen
Mountz, John D.
TI Cutting Edge: Defective Follicular Exclusion of Apoptotic Antigens Due
to Marginal Zone Macrophage Defects in Autoimmune BXD2 Mice
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; PRECURSOR B-CELLS; INDOLEAMINE
2,3-DIOXYGENASE; PATHOGENIC AUTOANTIBODIES; DENDRITIC CELLS; T-CELLS;
TOLERANCE; INTERLEUKIN-17; RECEPTORS; TRANSPORT
AB Marginal zone macrophages (MZMs) act as a barrier to entry of circulating apoptotic debris into the follicles of secondary lymphoid organs. In autoimmune BXD2 mice, there is a progressive reduction in the function and numbers of MZMs. Absence of MZMs results in retention of apoptotic cell (AC) debris within the marginal zone (MZ) and increased loading of AC Ags on MZ B cells and MZ-precursor (MZ-P) B cells. The MZ-P B cells are capable of translocating the AC Ags to the follicular zone and stimulating T cells. Both MZMs and MZ-P B cells from BXD2 mice express low levels of tolerogenic signals and high levels of inflammatory signals. Thus, the current study suggests a multifaceted mechanism in which MZMs maintain tolerance to apoptotic autoantigens and suppress their translocation to follicles. Lack of clearance of apoptotic debris by MZMs drives follicular Ag-transportation by MZ-P B cells to stimulate an autoimmune response. The Journal of Immunology, 2013, 190:4465-4469.
C1 [Li, Hao; Wu, Qi; Li, Jun; Yang, PingAr; Luo, Bao; Hsu, Hui-Chen; Mountz, John D.] Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.
[Li, Hao; Mountz, John D.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA.
[Zhu, Zilu] Univ Alabama Birmingham, Dept Med, Div Hematol & Oncol, Birmingham, AL 35294 USA.
[Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA.
RP Hsu, HC (reprint author), Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, Room 307,Shelby Bldg,1825 Univ Blvd, Birmingham, AL 35294 USA.
EM rheu078@uab.edu; jdmountz@uab.edu
RI Li, Hao/N-7406-2015;
OI Li, Hao/0000-0002-2171-8826; Zhu, Zilu/0000-0002-1944-0108
FU VA Merit Review Grant [1I01BX000600-01]; National Institutes of
Health/National Institute of Allergy and Infectious Disease [1AI 071110,
ARRA 3RO1AI71110-02S1, 1RO1 AI083705]; American College of Rheumatology
Research and Education Foundation; Arthritis Foundation; Lupus Research
Institute
FX This work was supported by a VA Merit Review Grant (1I01BX000600-01), as
well as grants from the National Institutes of Health/National Institute
of Allergy and Infectious Disease (1AI 071110, ARRA 3RO1AI71110-02S1,
and 1RO1 AI083705), the American College of Rheumatology Research and
Education Foundation, the Arthritis Foundation, and the Lupus Research
Institute. Flow cytometry and confocal imaging were carried out at the
University of Alabama at Birmingham Comprehensive Flow Cytometry Core
(P30 AR048311 and P30 AI027767) and University of Alabama at Birmingham
Analytic Imaging and Immunoreagents Core (P30 AR048311), respectively.
NR 23
TC 9
Z9 9
U1 1
U2 2
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2013
VL 190
IS 9
BP 4465
EP 4469
DI 10.4049/jimmunol.1300041
PG 5
WC Immunology
SC Immunology
GA 130IP
UT WOS:000317907900008
PM 23543760
ER
PT J
AU Ioannou, GN
Haigh, WG
Thorning, D
Savard, C
AF Ioannou, George N.
Haigh, W. Geoffrey
Thorning, David
Savard, Christopher
TI Hepatic cholesterol crystals and crown-like structures distinguish NASH
from simple steatosis
SO JOURNAL OF LIPID RESEARCH
LA English
DT Article
DE Kupffer cells; foam cells; steatohepatitis; nonalcoholic steatohepatitis
ID FATTY LIVER-DISEASE; NONALCOHOLIC STEATOHEPATITIS; DIETARY-CHOLESTEROL;
ADIPOCYTE DEATH; ADIPOSE-TISSUE; UNITED-STATES; MICE; EZETIMIBE; OBESE;
INFLAMMATION
AB We sought to determine whether hepatic cholesterol crystals are present in patients or mice with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NASH), and whether their presence or distribution correlates with the presence of NASH as compared with simple steatosis. We identified, by filipin staining, free cholesterol within hepatocyte lipid droplets in patients with NASH and in C57BL/6J mice that developed NASH following a high-fat high-cholesterol diet. Under polarized light these lipid droplets exhibited strong birefringence suggesting that some of the cholesterol was present in the form of crystals. Activated Kupffer cells aggregated around dead hepatocytes that included strongly birefringent cholesterol crystals, forming "crown-like structures" similar to those recently described in inflamed visceral adipose tissue. These Kupffer cells appeared to process the lipid of dead hepatocytes turning it into activated lipid-laden "foam cells" with numerous small cholesterol-containing droplets. In contrast, hepatocyte lipid droplets in patients and mice with simple steatosis did not exhibit cholesterol crystals and their Kupffer cells did not form crown-like structures or transform into foam cells. Our results suggest that cholesterol crystallization within hepatocyte lipid droplets and aggregation and activation of Kupffer cells in crown-like structures around such droplets represent an important, novel mechanism for progression of simple steatosis to NASH.-Ioannou, G. N., W. G. Haigh, D. Thorning, and C. Savard. Hepatic cholesterol crystals and crown-like structures distinguish NASH from simple steatosis. J. Lipid Res. 2013. 54: 1326-1334.
C1 [Ioannou, George N.; Haigh, W. Geoffrey; Savard, Christopher] Vet Affairs Puget Sound Hlth Care Syst, Res Enhancement Award Program, Seattle, WA USA.
[Thorning, David] Vet Affairs Puget Sound Hlth Care Syst, Dept Pathol, Seattle, WA USA.
[Ioannou, George N.; Haigh, W. Geoffrey; Savard, Christopher] Univ Washington, Dept Med, Div Gastroenterol, Seattle, WA USA.
RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Res Enhancement Award Program, Seattle, WA USA.
EM georgei@medicine.washington.edu
FU Research Enhancement Award Program, Office of Research and Development,
Veterans Affairs Puget Sound Health Care System, Seattle, WA
FX This work was supported by a grant from the Research Enhancement Award
Program (to G.N.I.), Office of Research and Development, Veterans
Affairs Puget Sound Health Care System, Seattle, WA. The authors report
no conflicts of interest.
NR 29
TC 36
Z9 39
U1 1
U2 9
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0022-2275
J9 J LIPID RES
JI J. Lipid Res.
PD MAY
PY 2013
VL 54
IS 5
BP 1326
EP 1334
DI 10.1194/jlr.M034876
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 123MO
UT WOS:000317394300018
PM 23417738
ER
PT J
AU Quiroz, YT
Stern, CE
Reiman, EM
Brickhouse, M
Ruiz, A
Sperling, RA
Lopera, F
Dickerson, BC
AF Quiroz, Yakeel T.
Stern, Chantal E.
Reiman, Eric M.
Brickhouse, Michael
Ruiz, Adriana
Sperling, Reisa A.
Lopera, Francisco
Dickerson, Bradford C.
TI Cortical atrophy in presymptomatic Alzheimer's disease presenilin 1
mutation carriers
SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
LA English
DT Article
ID E280A PS-1 MUTATION; MILD AD DEMENTIA; HIPPOCAMPAL ATROPHY; NORMAL
ADULTS; SERIAL MRI; SIGNATURE; THICKNESS; POPULATION; PREVENTION;
PROPOSAL
AB Background Sporadic late-onset Alzheimer's disease (AD) dementia has been associated with a 'signature' of cortical atrophy in paralimbic and heteromodal association regions measured with MRI.
Objective To investigate whether a similar pattern of cortical atrophy is present in presymptomatic presenilin 1 E280A mutation carriers an average of 6 years before clinical symptom onset.
Methods 40 cognitively normal volunteers from a Colombian population with familial AD were included; 18 were positive for the AD-associated presenilin 1 mutation (carriers, mean age=38) whereas 22 were non-carriers. T1-weighted volumetric MRI images were acquired and cortical thickness was measured. A priori regions of interest from our previous work were used to obtain thickness from AD-signature regions.
Results Compared to non-carriers, presymptomatic presenilin 1 mutation carriers exhibited thinner cortex within the AD-signature summary measure (p<0.008). Analyses of individual regions demonstrated thinner angular gyrus, precuneus and superior parietal lobule in carriers compared to non-carriers, with trend-level effects in the medial temporal lobe.
Conclusion Results demonstrate that cognitively normal individuals genetically determined to develop AD have a thinner cerebral cortex than non-carriers in regions known to be affected by typical late-onset sporadic AD. These findings provide further support for the hypothesis that cortical atrophy is present in preclinical AD more than 5 years prior to symptom onset. Further research is needed to determine whether this method could be used to characterise the age-dependent trajectory of cortical atrophy in presymptomatic stages of AD.
C1 [Quiroz, Yakeel T.; Stern, Chantal E.] Boston Univ, Dept Psychol, Ctr Memory & Brain, Boston, MA 02215 USA.
[Quiroz, Yakeel T.; Ruiz, Adriana; Lopera, Francisco] Univ Antioquia, Grp Neurociencias, Medellin, Colombia.
[Stern, Chantal E.; Sperling, Reisa A.; Dickerson, Bradford C.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA.
[Stern, Chantal E.; Brickhouse, Michael; Sperling, Reisa A.; Dickerson, Bradford C.] Harvard Univ, Sch Med, Boston, MA USA.
[Reiman, Eric M.] Banner Alzheimers Inst, Phoenix, AZ USA.
[Brickhouse, Michael; Dickerson, Bradford C.] Massachusetts Gen Hosp, Dept Neurol, Frontotemporal Dementia Unit, Boston, MA 02114 USA.
[Sperling, Reisa A.] Brigham & Womens Hosp, Dept Neurol, Ctr Alzheimer Res & Treatment, Boston, MA 02115 USA.
[Sperling, Reisa A.; Dickerson, Bradford C.] Massachusetts Gen Hosp, Dept Neurol, Massachusetts Alzheimers Dis Res Ctr, Boston, MA 02114 USA.
RP Dickerson, BC (reprint author), Massachusetts Gen Hosp, Frontotemporal Dementia Unit, 149 13th St,Suite 2691, Charlestown, MA 02129 USA.
EM bradd@nmr.mgh.harvard.edu
FU Boston University Center for Neuroscience; Boston University Alzheimer's
Disease Center pilot award [P30 AG13846]; COLCIENCIAS-Colombia
[1115-343-19127]; National Institute of Neurological Disorders and
Stroke [F31-NS078786-01A1]; National Institute on Aging [R01-AG029411,
P50-AG005134]; Alzheimer's Association [IIRG-09-13356]; Department of
Psychology
FX This study was supported by the Boston University Center for
Neuroscience (to CES), Department of Psychology (to CES and YTQ), a
Boston University Alzheimer's Disease Center pilot award (P30 AG13846 to
CES), and COLCIENCIAS-Colombia (Project: 1115-343-19127 to FL), the
National Institute of Neurological Disorders and Stroke
(F31-NS078786-01A1 to YTQ), the National Institute on Aging
(R01-AG029411 and P50-AG005134 to BCD), and the Alzheimer's Association
(IIRG-09-13356 to BCD).
NR 40
TC 18
Z9 18
U1 0
U2 11
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-3050
J9 J NEUROL NEUROSUR PS
JI J. Neurol. Neurosurg. Psychiatry
PD MAY
PY 2013
VL 84
IS 5
BP 556
EP 561
DI 10.1136/jnnp-2012-303299
PG 6
WC Clinical Neurology; Psychiatry; Surgery
SC Neurosciences & Neurology; Psychiatry; Surgery
GA 123KR
UT WOS:000317388800018
PM 23134660
ER
PT J
AU Maas, MB
Kwolek, CJ
Hirsch, JA
Jaff, MR
Rordorf, GA
AF Maas, Matthew B.
Kwolek, Christopher J.
Hirsch, Joshua A.
Jaff, Michael R.
Rordorf, Guy A.
TI Clinical risk predictors for cerebral hyperperfusion syndrome after
carotid endarterectomy
SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
LA English
DT Article
ID STROKE
AB Background Cerebral hyperperfusion syndrome (CHS) is an important complication of carotid endarterectomy (CEA), yet prior research has been limited to small cohorts and retrospective analyses, or studies using radiographic rather than clinical definitions.
Methods A prospective monitoring system was implemented to monitor CEA outcomes at a major academic medical centre. Independent, trained monitors from the neurology department examined all patients undergoing CEA preoperatively and postoperatively at 24 h and 30 days. Clinical variables were analysed to identify risk factors for CHS, which was defined as cases with postoperative development of a severe headache, new neurological deficits without infarction, seizure or intracerebral haemorrhage.
Results Between 2008 and 2010, 841 CEAs were monitored and CHS occurred in 14 (1.7%) subjects, including seizures in 5 (0.6%) and intracerebral haemorrhage in 4 (0.5%). Univariate analysis identified a history of dyslipidaemia, coronary artery disease, diastolic blood pressure, intraoperative shunt use and non-elective CEA (performed during hospitalisation for a symptomatic ipsilateral stroke, transient ischaemic attack or amaurosis fugax) as potential risks for CHS (all p <= 0.15); other variables-including the degree of ipsilateral and contralateral stenosis, operative time, intraoperative EEG slowing, history of prior CEA or carotid stent and time from prior carotid interventions-were not significant. Logistic regression confirmed the risk association between non-elective CEA and CHS (p=0.046).
Conclusions Independent, prospective monitoring of a large cohort of CEA cases identified a brief time interval between ischaemic symptoms and endarterectomy as the clearest risk factor for CHS.
C1 [Maas, Matthew B.] Northwestern Univ, Dept Neurol, Div Crit Care Neurol, Chicago, IL 60611 USA.
[Maas, Matthew B.; Rordorf, Guy A.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp,Div Vasc & Crit Care Neuro, Boston, MA 02115 USA.
[Kwolek, Christopher J.] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp,Div Vasc & Endovasc Surg, Boston, MA 02115 USA.
[Hirsch, Joshua A.] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp,Div Intervent Neuroradiol, Boston, MA 02115 USA.
[Jaff, Michael R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Div Cardiol,Sect Vasc Med, Boston, MA USA.
RP Maas, MB (reprint author), Northwestern Univ, Dept Neurol, Div Crit Care Neurol, 710 N Lake Shore Dr,11th Floor, Chicago, IL 60611 USA.
EM mbmaas@northwestern.edu
NR 8
TC 10
Z9 10
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-3050
J9 J NEUROL NEUROSUR PS
JI J. Neurol. Neurosurg. Psychiatry
PD MAY
PY 2013
VL 84
IS 5
BP 569
EP 572
DI 10.1136/jnnp-2012-303659
PG 4
WC Clinical Neurology; Psychiatry; Surgery
SC Neurosciences & Neurology; Psychiatry; Surgery
GA 123KR
UT WOS:000317388800020
PM 23243262
ER
PT J
AU Guo, YA
Chekaluk, Y
Zhang, JM
Du, JY
Gray, NS
Wu, CL
Kwiatkowski, DJ
AF Guo, Yanan
Chekaluk, Yvonne
Zhang, Jianming
Du, Jinyan
Gray, Nathanael S.
Wu, Chin-Lee
Kwiatkowski, David J.
TI TSC1 involvement in bladder cancer: diverse effects andtherapeutic
implications
SO JOURNAL OF PATHOLOGY
LA English
DT Article
DE TSC1; TSC2; bladder cancer; kinase inhibitor; Torin1
ID SCLEROSIS GENE TSC1; TYROSINE KINASE; ANTITUMOR-ACTIVITY; MTOR;
MUTATIONS; INHIBITOR; COMPLEX; PHOSPHORYLATION; ACTIVATION; NEOPLASMS
AB TSC1 is often mutated in bladder cancer. However the importance of this event in disease pathogenesis and its implications for therapy are uncertain. We used genomic sequencing to examine the involvement of TSC1 in bladder cancer, and signalling pathway analysis and small-molecule screening to identify targeted therapeutic strategies in TSC1 mutant bladder cancer cell lines. TSC1 loss of heterozygosity was seen in 54% of bladder cancers. Two (4.9%) of these 41 bladder cancers had TSC1 mutations by exon-based sequencing. Analysis of 27 bladder cancer cell lines demonstrated inactivating TSC1 mutations in three: RT-4, HCV29, 971. Interestingly, only RT-4 showed classic feedback inhibition of AKT, and was highly sensitive to treatment with mTOR inhibitors rapamycin and Torin1. 971 cells showed constitutive EGFR activation, and were highly sensitive to combined treatment with the mTOR inhibitor Torin1 and EGFR inhibitors Lapatinib or Afatinib. A BRAF missense mutation G469V was found in HCV29 cells, and AKT activation was dependent on BRAF, but independent of ERK. A kinase inhibitor screen of HCV29 cells showed strong growth inhibition by the Hsp90 inhibitor NVP-AUY922, and we then found synergistic inhibitory effects of NVP-AUY922 combined with either Torin1 or rapamycin on cell survival for both HCV29 and 971 cells. In aggregate, these findings indicate that there are highly variable mutation profiles and signalling pathway activation in TSC1-mutant bladder cancer. Furthermore, combined Hsp90/mTOR inhibition is a promising therapeutic approach for TSC1 mutant bladder cancer. Copyright (c) 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
C1 [Guo, Yanan; Chekaluk, Yvonne; Kwiatkowski, David J.] Brigham & Womens Hosp, Dept Med, Div Translat Med, Boston, MA 02115 USA.
[Guo, Yanan; Chekaluk, Yvonne; Kwiatkowski, David J.] Harvard Univ, Sch Med, Boston, MA USA.
[Zhang, Jianming; Gray, Nathanael S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Du, Jinyan] Broad Inst Harvard Univ & Massachusetts Inst Tech, Cambridge, MA USA.
[Wu, Chin-Lee] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Wu, Chin-Lee] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA.
RP Kwiatkowski, DJ (reprint author), Brigham & Womens Hosp, Dept Med, Div Translat Med, 75 Francis St, Boston, MA 02115 USA.
EM dk@rics.bwh.harvard.edu
FU National Institutes of Health [1P01CA120964]
FX We thank Dr Pasi A Janne and Krishna M Vasudevan (Dana Farber Cancer
Institute, MA, USA) for kindly providing inhibitors used in this study;
Margaret A Knowles (St James's University Hospital, UK) for kindly
providing the HCV29 and 97-1 bladder cancer cell lines; and Laura
McConnail for assistance with the Oncomap screen. This study was
supported by the National Institutes of Health (Grant No. 1P01CA120964).
NR 39
TC 23
Z9 24
U1 0
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3417
J9 J PATHOL
JI J. Pathol.
PD MAY
PY 2013
VL 230
IS 1
BP 17
EP 27
DI 10.1002/path.4176
PG 11
WC Oncology; Pathology
SC Oncology; Pathology
GA 124AE
UT WOS:000317434000004
PM 23401075
ER
PT J
AU Golden-Mason, L
McMahan, RH
Strong, M
Reisdorph, R
Mahaffey, S
Palmer, BE
Cheng, LL
Kulesza, C
Hirashima, M
Niki, T
Rosen, HR
AF Golden-Mason, Lucy
McMahan, Rachel H.
Strong, Michael
Reisdorph, Richard
Mahaffey, Spencer
Palmer, Brent E.
Cheng, Linling
Kulesza, Caroline
Hirashima, Mitsuomi
Niki, Toshiro
Rosen, Hugo R.
TI Galectin-9 Functionally Impairs Natural Killer Cells in Humans and Mice
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID NASOPHARYNGEAL CARCINOMA-CELLS; C VIRUS-INFECTION; NK CELLS; T-CELLS;
ADAPTIVE IMMUNITY; VIRAL-INFECTIONS; LIGAND-BINDING; TIM-3; INNATE;
RECEPTOR
AB Galectin-9 is a pleiotropic immune modulator affecting numerous cell types of innate and adaptive immunity. Patients with chronic infection with either hepatitis C virus (HCV) or HIV have elevated circulating levels. Limited data exist on the regulation of natural killer (NK) cell function through interaction with galectin-9. We found that galectin-9 ligation downregulates multiple immune-activating genes, including eight involved in the NK cell-mediated cytotoxicity pathway, impairs lymphokine-activated killing, and decreases the proportion of gamma interferon (IFN-gamma)-producing NK cells that had been stimulated with interleukin-12 (IL-12)/IL-15. We demonstrate that the transcriptional and functional changes induced by galectin-9 are independent of Tim-3. Consistent with these results for humans, we find that the genetic absence of galectin-9 in mice is associated with greater IFN-gamma production by NK cells and enhanced degranulation. We also show that in the setting of a short-term (4-day) murine cytomegalovirus infection, terminally differentiated NKs accumulate in the livers of galectin-9 knockout mice, and that hepatic NKs spontaneously produce significantly more IFN-gamma in this setting. Taken together, our results indicate that galectin-9 engagement impairs the function of NK cells, including cytotoxicity and cytokine production.
C1 [Golden-Mason, Lucy; McMahan, Rachel H.; Cheng, Linling; Rosen, Hugo R.] UCD, Dept Med, Hepatitis C Ctr, Div Gastroenterol & Hepatol, Aurora, CO USA.
[Golden-Mason, Lucy; Reisdorph, Richard; Mahaffey, Spencer; Rosen, Hugo R.] UCD, Integrated Program Immunol, Denver, CO USA.
[Golden-Mason, Lucy; Reisdorph, Richard; Mahaffey, Spencer; Rosen, Hugo R.] NJH, Denver, CO USA.
[Golden-Mason, Lucy; McMahan, Rachel H.; Rosen, Hugo R.] Denver VA Med Ctr, Denver, CO USA.
[Strong, Michael] NJH, Ctr Genes Environm & Hlth, Denver, CO USA.
[Reisdorph, Richard] NJH, Dept Pediat, Denver, CO USA.
[Palmer, Brent E.] UCD, Div Allergy & Clin Immunol, Aurora, CO USA.
[Kulesza, Caroline] UCD, Dept Microbiol, Aurora, CO USA.
[Hirashima, Mitsuomi; Niki, Toshiro] Kagawa Univ, Fac Med, Dept Immmunol & Immunopathol, Kagawa, Japan.
RP Rosen, HR (reprint author), UCD, Dept Med, Hepatitis C Ctr, Div Gastroenterol & Hepatol, Aurora, CO USA.
EM hugo.rosen@ucdenver.edu
FU VA [R21AIO76161, R21AIO76161-01A2S1]; [U19 AI 1066328]; [K24AI083742]
FX This work was supported by U19 AI 1066328 (H.R.R.), K24AI083742
(H.R.R.), a VA Merit Review grant (H.R.R.), R21AIO76161 (B.E.P.), and
R21AIO76161-01A2S1 (B.E.P.).
NR 50
TC 21
Z9 25
U1 0
U2 13
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD MAY
PY 2013
VL 87
IS 9
BP 4835
EP 4845
DI 10.1128/JVI.01085-12
PG 11
WC Virology
SC Virology
GA 123UK
UT WOS:000317416400006
PM 23408620
ER
PT J
AU Buttenheim, AM
Asch, DA
AF Buttenheim, Alison M.
Asch, David A.
TI Behavioral Economics: The Key to Closing the Gap on Maternal, Newborn
and Child Survival for Millennium Development Goals 4 and 5?
SO MATERNAL AND CHILD HEALTH JOURNAL
LA English
DT Article
DE Behavior change; Behavioral economics; Maternal and child health;
Millennium development goals
ID FINANCIAL INCENTIVES; CONTROLLED-TRIAL; HEALTH BEHAVIOR; VOUCHER SCHEME;
BANGLADESH; DECISIONS; COVERAGE; MODEL
AB Millennium Development Goals (MDGs) 4 and 5 set ambitious targets to reduce maternal, newborn and child mortality by 2015. With 2015 fast approaching, there has been a concerted effort in the global health community to "close the gap" on the MDG targets. Recent consensus initiatives and frameworks have refocused attention on evidence-based, low-cost interventions that can reduce mortality and morbidity, and have argued for additional funding to increase access to and coverage of these life-saving interventions. However, funding alone will not close the gap on MDGs 4 and 5. Even when high-quality, affordable products and services are readily available, uptake is often low. Progress will therefore require not just money, but also advances in health-related behavior change and decision-making. Behavioral economics offers one way to achieve real progress by improving our understanding of how individuals make choices under information and time constraints, and by offering new approaches to make it easier for individuals to do what is in their best interest and harder to do what is not. We introduce five behavioral economic principles and demonstrate how they could boost efforts to improve maternal, newborn, and child health in pursuit of MDGs 4 and 5.
C1 [Buttenheim, Alison M.] Univ Penn, Sch Nursing, Dept Family & Community Hlth, Philadelphia, PA 19104 USA.
[Buttenheim, Alison M.] Univ Penn, LDI Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA.
[Asch, David A.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA.
[Asch, David A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
RP Buttenheim, AM (reprint author), Univ Penn, Sch Nursing, Dept Family & Community Hlth, Fagin 235L,418 Curie Blvd, Philadelphia, PA 19104 USA.
EM abutt@nursing.upenn.edu
OI Asch, David/0000-0002-7970-286X
NR 30
TC 2
Z9 2
U1 0
U2 10
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1092-7875
J9 MATERN CHILD HLTH J
JI Matern. Child Health J.
PD MAY
PY 2013
VL 17
IS 4
BP 581
EP 585
DI 10.1007/s10995-012-1042-7
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 126IS
UT WOS:000317608200002
PM 22618489
ER
PT J
AU Weissman, JS
Vogeli, C
Levy, DE
AF Weissman, Joel S.
Vogeli, Christine
Levy, Douglas E.
TI The Quality of Hospital Care for Medicaid and Private Pay Patients
SO MEDICAL CARE
LA English
DT Article
DE quality of care; medicaid; hospitals; access to care
ID OF-CARE; OUTCOMES; PROGRAM; STATE
AB Context: Understanding Medicaid performance relative to private payers and among other states may lead to better value.
Design, Setting, and Participants: Hospital Quality Alliance data from 2007-2008 were used to create composite "all-or-none" quality scores for nearly 900,000 nonelderly adult patients hospitalized with acute myocardial infarction (AMI), congestive heart failure (CHF), or pneumonia.
Main Outcome Measures: Differences in the quality of care received by Medicaid compared with privately insured patients at the national and state levels.
Results: Nationally, 88% of Medicaid beneficiaries received all appropriate processes of care when hospitalized for AMI, compared with 73% for CHF and 77% for pneumonia. Private patients received higher quality of care than Medicaid patients, but differences were small (1.3 percentage point difference, pneumonia; 2.7, AMI; 2.9, CHF; all P < 0.05). At the state level, the differences averaged <3 percentage points across all conditions, but some states (2-8 states depending on the condition) exhibited significant (P < 0.05) differences of >5 percentage points in favor of private patients. Two states exhibited significantly better quality of care for their Medicaid patients in excess of 5 percentage points. Quality scores for both Medicaid and private patients varied significantly by state but were highly correlated (correlations for AMI = 0.80, CHF = 0.84, pneumonia = 0.80; all P < 0.001).
Conclusions: Small national differences in quality between hospitalized Medicaid and private patients are promising, although merit close monitoring as states are forced to curb Medicaid reimbursements. Although quality for Medicaid patients varied by state, high correlations with private patients suggest that the factors driving quality have more to do with geographic factors in the delivery of hospital services than with state-established Medicaid policies.
C1 [Weissman, Joel S.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg,Ctr Surg & Publ Hlth, Boston, MA 02115 USA.
[Weissman, Joel S.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Weissman, Joel S.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA.
[Vogeli, Christine; Levy, Douglas E.] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA.
[Vogeli, Christine; Levy, Douglas E.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
RP Weissman, JS (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg,Ctr Surg & Publ Hlth, Boston, MA 02115 USA.
EM jweissman@partners.org
FU Kaiser Family Foundation's Commission
FX Supported by the Kaiser Family Foundation's Commission on Medicaid and
the Uninsured.
NR 24
TC 7
Z9 8
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
J9 MED CARE
JI Med. Care
PD MAY
PY 2013
VL 51
IS 5
BP 389
EP 395
DI 10.1097/MLR.0b013e31827fef95
PG 7
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 126WU
UT WOS:000317653900004
PM 23358385
ER
PT J
AU Voils, CI
Maciejewski, ML
Hoyle, RH
Reeve, BB
Gallagher, MP
Bryson, CL
Yancy, WS
AF Voils, Corrine I.
Maciejewski, Matthew L.
Hoyle, Rick H.
Reeve, Bryce B.
Gallagher, Matthew P.
Bryson, Christopher L.
Yancy, William S., Jr.
TI Behavioral Science and Reasons for Nonadherence to Medication Response
SO MEDICAL CARE
LA English
DT Letter
C1 [Voils, Corrine I.; Maciejewski, Matthew L.; Gallagher, Matthew P.; Yancy, William S., Jr.] Duke Univ, Med Ctr, Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC 27706 USA.
[Voils, Corrine I.; Maciejewski, Matthew L.; Yancy, William S., Jr.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27706 USA.
[Hoyle, Rick H.] Duke Univ, Dept Psychol & Neurosci, Durham, NC 27706 USA.
[Reeve, Bryce B.] Univ N Carolina, Dept Hlth Policy & Management, Chapel Hill, NC USA.
[Bryson, Christopher L.] Univ Washington, Vet Affairs Puget Sound, Northwest Ctr Outcomes Res Older Adults, Seattle, WA 98195 USA.
[Bryson, Christopher L.] Univ Washington, Dept Med, Seattle, WA USA.
RP Voils, CI (reprint author), Duke Univ, Med Ctr, Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC 27706 USA.
FU NIA NIH HHS [R21 AG035233]
NR 3
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
J9 MED CARE
JI Med. Care
PD MAY
PY 2013
VL 51
IS 5
BP 468
EP 469
DI 10.1097/MLR.0b013e31828fadbf
PG 3
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 126WU
UT WOS:000317653900016
PM 23552432
ER
PT J
AU Baptista, AP
Olivier, BJ
Goverse, G
Greuter, M
Knippenberg, M
Kusser, K
Domingues, RG
Veiga-Fernandes, H
Luster, AD
Lugering, A
Randall, TD
Cupedo, T
Mebius, RE
AF Baptista, A. P.
Olivier, B. J.
Goverse, G.
Greuter, M.
Knippenberg, M.
Kusser, K.
Domingues, R. G.
Veiga-Fernandes, H.
Luster, A. D.
Lugering, A.
Randall, T. D.
Cupedo, T.
Mebius, R. E.
TI Colonic patch and colonic SILT development are independent and
differentially regulated events
SO MUCOSAL IMMUNOLOGY
LA English
DT Article
ID LYMPHOTOXIN-BETA-RECEPTOR; ISOLATED LYMPHOID FOLLICLES; TISSUE INDUCER
CELLS; INTESTINAL-MUCOSA; DENDRITIC CELLS; PEYERS-PATCHES; DEFICIENT
MICE; B-LYMPHOCYTES; ALPHA-BETA; T-CELLS
AB Intestinal lymphoid tissues have to simultaneously ensure protection against pathogens and tolerance toward commensals. Despite such vital functions, their development in the colon is poorly understood. Here, we show that the two distinct lymphoid tissues of the colon-colonic patches and colonic solitary intestinal lymphoid tissues (SILTs)-can easily be distinguished based on anatomical location, developmental timeframe, and cellular organization. Furthermore, whereas colonic patch development depended on CXCL13-mediated lymphoid tissue inducer (LTi) cell clustering followed by LT alpha-mediated consolidation, early LTi clustering at SILT anlagen did not require CXCL13, CCR6, or CXCR3. Subsequent dendritic cell recruitment to and gp38(+)VCAM-1(+) lymphoid stromal cell differentiation within SILTs required LT alpha; B-cell recruitment and follicular dendritic cell differentiation depended on MyD88-mediated signaling, but not the microflora. In conclusion, our data demonstrate that different mechanisms, mediated mainly by programmed stimuli, induce the formation of distinct colonic lymphoid tissues, therefore suggesting that these tissues may have different functions.
C1 [Baptista, A. P.; Olivier, B. J.; Goverse, G.; Greuter, M.; Knippenberg, M.; Mebius, R. E.] Vrije Univ Amsterdam Med Ctr, Dept Mol Cell Biol & Immunol, Amsterdam, Netherlands.
[Baptista, A. P.] Univ Porto, GABBA PhD Program, P-4100 Oporto, Portugal.
[Kusser, K.; Randall, T. D.] Univ Rochester, Dept Med, Div Rheumatol Allergy & Immunol, Rochester, NY USA.
[Domingues, R. G.; Veiga-Fernandes, H.] Fac Med Lisbon, Inst Mol Med, Lisbon, Portugal.
[Luster, A. D.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis,Div Rheumatol Alle, Charlestown, MA USA.
[Lugering, A.] Univ Munster, Dept Med B, D-48149 Munster, Germany.
[Cupedo, T.] Erasmus Univ, Med Ctr, Dept Hematol, Rotterdam, Netherlands.
RP Mebius, RE (reprint author), Vrije Univ Amsterdam Med Ctr, Dept Mol Cell Biol & Immunol, Amsterdam, Netherlands.
EM r.mebius@vumc.nl
OI Veiga-Fernandes, Henrique/0000-0001-6216-1836
FU Fundacao para a Ciencia e Tecnologia - Portugal [SFRH/BD/33247/2007];
Dutch Digestive Disease Foundation; US National Institutes of Health
[R01CA069212, AI061511, AI072689, HL069409]; Netherlands Organization
for Scientific Research [917.10.377]; VICI [918.56.612]
FX We thank B. Beuger, D. Schut, and E. Keuning for animal care; and D.
Littman, P. Leenen, and S. Nighikawa for antibodies. This work was
supported by grants from Fundacao para a Ciencia e Tecnologia - Portugal
(SFRH/BD/33247/2007 to APB), Dutch Digestive Disease Foundation (to MK),
US National Institutes of Health (R01CA069212 to ADL; and AI061511,
AI072689, and HL069409 to TDR), and Netherlands Organization for
Scientific Research (VIDI grant 917.10.377 to TC; and VICI grant
918.56.612 to REM).
NR 39
TC 16
Z9 16
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1933-0219
J9 MUCOSAL IMMUNOL
JI Mucosal Immunol.
PD MAY
PY 2013
VL 6
IS 3
BP 511
EP 521
DI 10.1038/mi.2012.90
PG 11
WC Immunology
SC Immunology
GA 127TX
UT WOS:000317722800008
PM 22990625
ER
PT J
AU Albacker, LA
Yu, S
Bedoret, D
Lee, WL
Umetsu, SE
Monahan, S
Freeman, GJ
Umetsu, DT
DeKruyff, RH
AF Albacker, L. A.
Yu, S.
Bedoret, D.
Lee, W-L
Umetsu, S. E.
Monahan, S.
Freeman, G. J.
Umetsu, D. T.
DeKruyff, R. H.
TI TIM-4, expressed by medullary macrophages, regulates respiratory
tolerance by mediating phagocytosis of antigen-specific T cells
SO MUCOSAL IMMUNOLOGY
LA English
DT Article
ID AIRWAY HYPERREACTIVITY; DENDRITIC CELLS; ADAPTIVE IMMUNITY; APOPTOTIC
CELLS; PHOSPHATIDYLSERINE; IDENTIFICATION; EXPOSURE; CLEARANCE;
INFLUENZA; RESPONSES
AB Respiratory exposure to antigen induces T cell tolerance via several overlapping mechanisms that limit the immune response. While the mechanisms involved in the development of Treg cells have received much attention, those that result in T cell deletion are largely unknown. Herein, we show that F4/80(+) lymph node medullary macrophages expressing TIM-4, a phosphatidylserine receptor, remove antigen-specific T cells during respiratory tolerance, thereby reducing secondary T cell responses. Blockade of TIM-4 inhibited the phagocytosis of antigen-specific T cells by TIM-4 expressing lymph node medullary macrophages, resulting in an increase in the number of antigen-specific T cells and the abrogation of respiratory tolerance. Moreover, specific depletion of medullary macrophages inhibited the induction of respiratory tolerance, highlighting the key role of TIM-4 and medullary macrophages in tolerance. Therefore, TIM-4-mediated clearance of antigen specific T cells represents an important previously unrecognized mechanism regulating respiratory tolerance.
C1 [Albacker, L. A.; Yu, S.; Bedoret, D.; Lee, W-L; Umetsu, S. E.; Monahan, S.; Umetsu, D. T.; DeKruyff, R. H.] Harvard Univ, Sch Med, Childrens Hosp Boston, Div Immunol, Boston, MA 02115 USA.
[Albacker, L. A.; Yu, S.; Bedoret, D.; Lee, W-L; Umetsu, S. E.; Monahan, S.; Umetsu, D. T.; DeKruyff, R. H.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Freeman, G. J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med,Dept Med Oncol, Boston, MA 02115 USA.
RP DeKruyff, RH (reprint author), Harvard Univ, Sch Med, Childrens Hosp Boston, Div Immunol, Boston, MA 02115 USA.
EM rosemarie.dekruyff@childrens.harvard.edu
FU Program on Immunology, Division of Medical Sciences, Harvard University;
[NIH P01 AI054456]; [NIH RO1 089955]
FX We thank Jessica Walters and the Harvard Digestive Diseases Center
Imaging Core for expert help and Elena Tonti of the von Andrian lab for
training in the removal and orientation of lymph nodes for confocal
microscopy. This work was supported by NIH P01 AI054456 (to D.T.U.,
G.J.F., R.D.K.,), NIH RO1 089955 (to G.F., R.D.K.), and the Program on
Immunology, Division of Medical Sciences, Harvard University (to
L.A.A.).
NR 27
TC 15
Z9 16
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1933-0219
J9 MUCOSAL IMMUNOL
JI Mucosal Immunol.
PD MAY
PY 2013
VL 6
IS 3
BP 580
EP 590
DI 10.1038/mi.2012.100
PG 11
WC Immunology
SC Immunology
GA 127TX
UT WOS:000317722800014
PM 23149665
ER
PT J
AU Chen, BB
Coon, TA
Glasser, JR
McVerry, BJ
Zhao, J
Zhao, YT
Zou, CB
Ellis, B
Sciurba, FC
Zhang, YZ
Mallampalli, RK
AF Chen, Bill B.
Coon, Tiffany A.
Glasser, Jennifer R.
McVerry, Bryan J.
Zhao, Jing
Zhao, Yutong
Zou, Chunbin
Ellis, Bryon
Sciurba, Frank C.
Zhang, Yingze
Mallampalli, Rama K.
TI A combinatorial F box protein directed pathway controls TRAF adaptor
stability to regulate inflammation
SO NATURE IMMUNOLOGY
LA English
DT Article
ID RECEPTOR-ASSOCIATED FACTOR-3; SCF UBIQUITIN LIGASE; FAMILY; DEGRADATION;
ACTIVATION; SEPSIS; IDENTIFICATION; SUBUNIT; FBXL2
AB Uncontrolled activation of tumor necrosis factor receptor-associated factor (TRAF) proteins may result in profound tissue injury by linking surface signals to cytokine release. Here we show that a ubiquitin E3 ligase component, Fbxo3, potently stimulates cytokine secretion from human inflammatory cells by destabilizing a sentinel TRAF inhibitor, Fbxl2. Fbxo3 and TRAF protein in circulation positively correlated with cytokine responses in subjects with sepsis, and we identified a polymorphism in human Fbxo3, with one variant being hypofunctional. A small-molecule inhibitor targeting Fbxo3 was sufficient to lessen severity of cytokine-driven inflammation in several mouse disease models. These studies identified a pathway of innate immunity that may be useful to detect subjects with altered immune responses during critical illness or provide a basis for therapeutic intervention targeting TRAF protein abundance.
C1 [Chen, Bill B.; Coon, Tiffany A.; Glasser, Jennifer R.; McVerry, Bryan J.; Zhao, Jing; Zhao, Yutong; Zou, Chunbin; Ellis, Bryon; Sciurba, Frank C.; Zhang, Yingze; Mallampalli, Rama K.] Univ Pittsburgh, Dept Med, Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15213 USA.
[Mallampalli, Rama K.] Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA USA.
[Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA USA.
RP Mallampalli, RK (reprint author), Univ Pittsburgh, Dept Med, Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15213 USA.
EM chenb@upmc.edu; mallampallirk@upmc.edu
FU US Department of Veterans Affairs, Veterans Health Administration,
Office of Research and Development, Biomedical Laboratory Research and
Development; Merit Review Award from the US Department of Veterans
Affairs; National Institutes [HL096376, HL097376, HL081784, HL068135,
HL098174, HL116472, HL01916, P50HL084948]; American Heart Association
[12SDG9050005, 12SDG12040330, 12GRNT11820019]
FX We thank A. Lagneaux and S. Barge for assistance with studies. This
material is based upon work supported, in part, by the US Department of
Veterans Affairs, Veterans Health Administration, Office of Research and
Development, Biomedical Laboratory Research and Development. This work
was supported by a Merit Review Award from the US Department of Veterans
Affairs and National Institutes of Health R01 grants HL096376, HL097376,
HL081784, HL068135 and HL098174 (to R. K. M.), HL116472 (to B. B. C.),
HL01916 (to Y.Z.) and P50HL084948 (F. C. S.), American Heart Association
awards 12SDG9050005 (to J.Z.) and 12SDG12040330 (to C.Z.), and American
Heart Association Grant-in-Aid 12GRNT11820019 (B.J.M.). The contents
presented do not represent the views of the Department of Veterans
Affairs or the United States Government.
NR 43
TC 46
Z9 48
U1 3
U2 26
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1529-2908
J9 NAT IMMUNOL
JI Nat. Immunol.
PD MAY
PY 2013
VL 14
IS 5
BP 470
EP +
DI 10.1038/ni.2565
PG 11
WC Immunology
SC Immunology
GA 127XL
UT WOS:000317732100012
PM 23542741
ER
PT J
AU Lupfer, C
Thomas, PG
Anand, PK
Vogel, P
Milasta, S
Martinez, J
Huang, GH
Green, M
Kundu, M
Chi, HB
Xavier, RJ
Green, DR
Lamkanfi, M
Dinarello, CA
Doherty, PC
Kanneganti, TD
AF Lupfer, Christopher
Thomas, Paul G.
Anand, Paras K.
Vogel, Peter
Milasta, Sandra
Martinez, Jennifer
Huang, Gonghua
Green, Maggie
Kundu, Mondira
Chi, Hongbo
Xavier, Ramnik J.
Green, Douglas R.
Lamkanfi, Mohamed
Dinarello, Charles A.
Doherty, Peter C.
Kanneganti, Thirumala-Devi
TI Receptor interacting protein kinase 2-mediated mitophagy regulates
inflammasome activation during virus infection
SO NATURE IMMUNOLOGY
LA English
DT Article
ID 1918 INFLUENZA-VIRUS; IFN-GAMMA PRODUCTION; DOUBLE-STRANDED-RNA; CD8(+)
T-CELLS; LISTERIA-MONOCYTOGENES; IL-1-BETA PRODUCTION; IMMUNE-RESPONSE;
DENDRITIC CELLS; AUTOPHAGY; INNATE
AB NOD2 receptor and the cytosolic protein kinase RIPK2 regulate NF-kappa B and MAP kinase signaling during bacterial infections, but the role of this immune axis during viral infections has not been addressed. We demonstrate that Nod2(-/-) and Ripk2(-/-) mice are hypersusceptible to infection with influenza A virus. Ripk2(-/-) cells exhibited defective autophagy of mitochondria (mitophagy), leading to enhanced mitochondrial production of superoxide and accumulation of damaged mitochondria, which resulted in greater activation of the NLRP3 inflammasome and production of IL-18. RIPK2 regulated mitophagy in a kinase-dependent manner by phosphorylating the mitophagy inducer ULK1. Accordingly, Ulk1(-/-) cells exhibited enhanced mitochondrial production of superoxide and activation of caspase-1. These results demonstrate a role for NOD2-RIPK2 signaling in protection against virally triggered immunopathology by negatively regulating activation of the NLRP3 inflammasome and production of IL-18 via ULK1-dependent mitophagy.
C1 [Lupfer, Christopher; Thomas, Paul G.; Anand, Paras K.; Milasta, Sandra; Martinez, Jennifer; Huang, Gonghua; Green, Maggie; Chi, Hongbo; Green, Douglas R.; Doherty, Peter C.; Kanneganti, Thirumala-Devi] St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA.
[Vogel, Peter] St Jude Childrens Res Hosp, Vet Pathol Core, Memphis, TN 38105 USA.
[Kundu, Mondira] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA.
[Xavier, Ramnik J.] Harvard Univ, Sch Med, Gastrointestinal Unit, Boston, MA USA.
[Xavier, Ramnik J.] Harvard Univ, Sch Med, Ctr Study Inflammatory Bowel Dis, Boston, MA USA.
[Xavier, Ramnik J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Computat & Integrat Biol, Boston, MA USA.
[Xavier, Ramnik J.] Broad Inst Massachusetts Inst Technol & Harvard, Cambridge, MA USA.
[Lamkanfi, Mohamed] Univ Ghent, Dept Biochem, B-9000 Ghent, Belgium.
[Lamkanfi, Mohamed] Univ Ghent VIB, Dept Med Prot Res, B-9052 Ghent, Belgium.
[Dinarello, Charles A.] Univ Colorado Denver, Dept Med, Aurora, CO USA.
[Doherty, Peter C.] Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3052, Australia.
RP Kanneganti, TD (reprint author), St Jude Childrens Res Hosp, Dept Immunol, 332 N Lauderdale St, Memphis, TN 38105 USA.
EM thirumala-devi.kanneganti@stjude.org
RI Doherty, Peter Charles/C-4185-2013;
OI Doherty, Peter Charles/0000-0002-5028-3489; Anand,
Paras/0000-0003-2503-3653; Kanneganti,
Thirumala-Devi/0000-0002-6395-6443; Thomas, Paul G./0000-0001-7955-0256
FU EU Framework Program 7 [256432]; European Research Council [281600];
Fund for Scientific Research Flanders [G030212N, 1.2.201.10.N.00,
1.5.122.11.N.00]; US National Institutes of Health [AR056296, AI101935,
CA163507]; American Lebanese Syrian Associated Charities
FX We thank members of the Veterinary Pathology Core lab at St. Jude for
their work in processing of hematoxylin and eosin-stained and
immunohistochemistry slides, members of the Cell and Tissue Imaging Core
facility for their help in preparing and imaging transmission electron
microscopy samples, and A. Coyle, E. Grant, J. Bertin (Millennium
Pharmaceuticals), T. Mak (University of Toronto) and R. Flavell (Yale
University) for providing mutant mice. M. L. is supported by grants from
the EU Framework Program 7 (Marie-Curie grant 256432), European Research
Council (grant 281600) and the Fund for Scientific Research Flanders
(G030212N, 1.2.201.10.N.00 and 1.5.122.11.N.00). This work was supported
by US National Institutes of Health grants (AR056296, AI101935 and
CA163507) and the American Lebanese Syrian Associated Charities to
T.-D.K.
NR 49
TC 96
Z9 100
U1 2
U2 50
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1529-2908
J9 NAT IMMUNOL
JI Nat. Immunol.
PD MAY
PY 2013
VL 14
IS 5
BP 480
EP +
DI 10.1038/ni.2563
PG 11
WC Immunology
SC Immunology
GA 127XL
UT WOS:000317732100013
PM 23525089
ER
PT J
AU Jang, JW
Parambi, RJ
McBride, SM
Goldsmith, TA
Holman, AS
Chan, AW
AF Jang, Joanne W.
Parambi, Ron J.
McBride, Sean M.
Goldsmith, Tessa A.
Holman, Allison S.
Chan, Annie W.
TI Clinical factors predicting for prolonged enteral supplementation in
patients with oropharyngeal cancer treated with chemoradiation
SO ORAL ONCOLOGY
LA English
DT Article
DE Gastrostomy tube; G-tube; Oropharyngeal cancer; Chemoradiation; Squamous
cell cancer of the head and neck; Enteral feeding
ID PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; QUALITY-OF-LIFE;
INTENSITY-MODULATED RADIOTHERAPY; LOCALLY ADVANCED HEAD; LONG-TERM
DYSPHAGIA; BODY-MASS INDEX; NECK-CANCER; DEFINITIVE RADIOTHERAPY;
RADIATION-THERAPY; PHASE-II
AB Objectives: The purpose of this study is to determine the pre-treatment clinical factors associated with prolonged enteral feeding in patients with oropharyngeal cancer treated with chemoradiation.
Materials and methods: One hundred and nine patients with stage III-IVB oropharyngeal carcinoma treated with definitive chemoradiation were analyzed. Feeding tube usage was defined as the duration of active usage for nutritional purposes.
Results: Median follow-up was 4.4 years and median feeding tube usage was 2.5 months. On multivariate analysis, increasing duration of feeding tube usage was associated with narcotic use before treatment (p = 0.04), living alone at the time of treatment (p = 0.04), and larger pre-treatment decrease in body-mass index (p = 0.01). Prolonged feeding tube usage was associated with decreased overall survival (p = 0.06) and disease-free survival (p = 0.02) in univariate analysis.
Conclusions: By identifying patients at risk for prolonged feeding tube usage, aggressive measures can be attempted to prevent feeding tube dependence. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Jang, Joanne W.; Parambi, Ron J.; McBride, Sean M.; Chan, Annie W.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Jang, Joanne W.; McBride, Sean M.] Harvard Univ, Sch Med, Harvard Radiat Oncol Program, Boston, MA USA.
[Goldsmith, Tessa A.; Holman, Allison S.] Massachusetts Gen Hosp, Dept Speech Language & Swallowing Disorders, Boston, MA 02114 USA.
RP Jang, JW (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 55 Fruit St,Lunder LL3, Boston, MA 02114 USA.
EM jwjang@partners.org
NR 32
TC 2
Z9 2
U1 1
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1368-8375
J9 ORAL ONCOL
JI Oral Oncol.
PD MAY
PY 2013
VL 49
IS 5
BP 438
EP 442
DI 10.1016/j.oraloncology.2012.12.003
PG 5
WC Oncology; Dentistry, Oral Surgery & Medicine
SC Oncology; Dentistry, Oral Surgery & Medicine
GA 121SU
UT WOS:000317265300009
PM 23357527
ER
PT J
AU Kunz, PL
Reidy-Lagunes, D
Anthony, LB
Bertino, EM
Brendtro, K
Chan, JA
Chen, H
Jensen, RT
Kim, MK
Klimstra, DS
Kulke, MH
Liu, EH
Metz, DC
Phan, AT
Sippel, RS
Strosberg, JR
Yao, JC
AF Kunz, Pamela L.
Reidy-Lagunes, Diane
Anthony, Lowell B.
Bertino, Erin M.
Brendtro, Kari
Chan, Jennifer A.
Chen, Herbert
Jensen, Robert T.
Kim, Michelle Kang
Klimstra, David S.
Kulke, Matthew H.
Liu, Eric H.
Metz, David C.
Phan, Alexandria T.
Sippel, Rebecca S.
Strosberg, Jonathan R.
Yao, James C.
TI Consensus Guidelines for the Management and Treatment of Neuroendocrine
Tumors
SO PANCREAS
LA English
DT Article
DE neuroendocrine tumors; carcinoid; neuroendocrine/diagnosis;
neuroendocrine/treatment; neuroendocrine/pathology; pheochromocytoma
ID HEPATIC METASTASES; DIAGNOSIS; SURVIVAL; EVEROLIMUS; CARCINOMAS
AB Neuroendocrine tumors are a heterogeneous group of tumors originating in various anatomic locations. The management of this disease poses a significant challenge because of the heterogeneous clinical presentations and varying degrees of aggressiveness. The recent completion of several phase 3 trials, including those evaluating octreotide, sunitinib, and everolimus, demonstrate that rigorous evaluation of novel agents in this disease is possible and can lead to practice-changing outcomes. Nevertheless, there are many aspects to the treatment of neuroendocrine tumors that remain unclear and controversial. The North American Neuroendocrine Tumor Society published a set of consensus guidelines in 2010, which provided an overview for the treatment of patients with these malignancies. Here, we present a set of consensus tables intended to complement these guidelines and serve as a quick, accessible reference for the practicing physician.
C1 [Kunz, Pamela L.] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA.
[Reidy-Lagunes, Diane] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA.
[Anthony, Lowell B.] Univ Kentucky, Med Ctr, Dept Med, Lexington, KY 40536 USA.
[Bertino, Erin M.] Ohio State Med Ctr, Dept Med, Columbus, OH USA.
[Brendtro, Kari] NANETS & NET Patient Advocate, Vancouver, WA USA.
[Chan, Jennifer A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Chen, Herbert; Sippel, Rebecca S.] Univ Wisconsin, Dept Surg, Madison, WI USA.
[Jensen, Robert T.] NIDDK, Digest Dis Branch, Bethesda, MD USA.
[Kim, Michelle Kang] Mt Sinai Sch Med, Dept Med, New York, NY USA.
[Klimstra, David S.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA.
[Kulke, Matthew H.] Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA.
[Liu, Eric H.] Vanderbilt Univ, Dept Surg, Nashville, TN 37240 USA.
[Metz, David C.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
[Phan, Alexandria T.; Yao, James C.] Univ Texas MD Anderson Canc Ctr, Dept Med, Houston, TX 77030 USA.
[Strosberg, Jonathan R.] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Med, Tampa, FL 33682 USA.
RP Kunz, PL (reprint author), Stanford Univ, Sch Med, Dept Med, 875 Blake Wilbur Dr, Stanford, CA 94305 USA.
EM pkunz@stanford.edu
FU Genentech; Merck; Sanofi; Novartis; Onyx/Bayer; Ipsen
FX Pamela L. Kunz receives grant funding from Genentech, Merck, and Sanofi,
is a consultant for OncoMed and Guardant Health, and has stock options
from Guardant Health. Diane Reidy-Lagunes receives grant funding from
Novartis and Merck, is a consultant for Novartis and Pfizer, and
receives honorarium from Novartis. Jennifer A. Chan receives grant
funding from Novartis, Onyx/Bayer, and Merck and has stock options from
Merck. Eric H. Liu is a consultant for Novartis. Lowell B. Anthony
receives grant funding from Novartis. David C. Metz is a consultant for
Novartis and receives grant funding from Ipsen. Alexandria T. Phan is a
consultant for Ipsen. Jonathan R. Strosberg is a consultant for Novartis
and Pfizer, receives grant funding from Genentech and Novartis, and
receives honorarium from Genentech, Pfizer and Sanofi. Matthew H. Kulke
is a consultant for Novartis, Ipsen, Pfizer, and Lexicon and receives
grant funding from Novartis. James C. Yao serves as a consultant for
Novartis, Ipsen, and Pfizer and receives grant funding from Novartis.
The remaining authors declare no conflicts of interest.
NR 22
TC 87
Z9 91
U1 0
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0885-3177
J9 PANCREAS
JI Pancreas
PD MAY
PY 2013
VL 42
IS 4
BP 557
EP 577
DI 10.1097/MPA.0b013e31828e34a4
PG 21
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 126XF
UT WOS:000317655200002
PM 23591432
ER
PT J
AU Park, CH
Lee, IS
Grippo, P
Pandol, SJ
Gukovskaya, AS
Edderkaoui, M
AF Park, Chang-Hwan
Lee, In-Seok
Grippo, Paul
Pandol, Stephen J.
Gukovskaya, Anna S.
Edderkaoui, Mouad
TI Akt Kinase Mediates the Prosurvival Effect of Smoking Compounds in
Pancreatic Ductal Cells
SO PANCREAS
LA English
DT Article
DE pancreatic cancer; smoking; apoptosis; autophagy
ID TOBACCO-SPECIFIC CARCINOGEN; CANCER CELLS; CIGARETTE-SMOKE;
PROTEIN-KINASE; EPITHELIAL-CELLS; NADPH OXIDASE; AUTOPHAGY; GROWTH;
EXPRESSION; RECEPTORS
AB Objectives: Cigarette smoking is a major risk factor for pancreatic cancer (PaCa). However, the mechanisms of smoking-induced PaCa remain unknown. Here we investigated the effect of smoking compounds on cell death pathways in pancreatic ductal cells, precursors of PaCa.
Methods: Human pancreatic ductal cells (HPDE6-c7) were cultured with cigarette smoke extract (CSE) or smoking compound 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Apoptosis and autophagy were assessed by DNA fragmentation and immunofluorescence, respectively.
Results: Exposure to CSE or NNK decreased DNA fragmentation and up-regulated Bcl(XL). Akt kinase was activated by smoking compounds through reactive oxygen species-dependent mechanism. Specifically, Akt activation was prevented by inhibition of nicotinamide adenine dinucleotide oxidase. Molecular or pharmacologic inhibitions of Akt prevented the antiapoptotic effect of smoking compounds. Smoking compounds stimulated rapid (1 hour) and transient activation of 5'-adenosine monophosphate-activated protein kinase and formation of autophagic vacuoles, indicating stimulation of autophagy. Repeated exposure to CSE/NNK (48 hours or longer) abolished the early activation of autophagic markers. Inhibition of Akt prevented the antiautophagic effect of long exposure to smoking compounds, indicating that smoking-induced late activation of Akt prevents autophagy.
Conclusions: Long exposure of pancreatic ductal cells to smoking compounds inhibited apoptosis and autophagy. The results revealed a central role for Akt kinase in mediating key procarcinogenic effects of smoking compounds.
C1 [Park, Chang-Hwan; Lee, In-Seok; Pandol, Stephen J.; Gukovskaya, Anna S.; Edderkaoui, Mouad] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Park, Chang-Hwan; Lee, In-Seok; Pandol, Stephen J.; Gukovskaya, Anna S.; Edderkaoui, Mouad] Univ Calif Los Angeles, Los Angeles, CA USA.
[Park, Chang-Hwan] Chonnam Natl Univ, Sch Med, Div Gastroenterol, Dept Internal Med, Kwangju, South Korea.
[Lee, In-Seok] Catholic Univ Korea, Div Gastroenterol, Dept Internal Med, Seoul, South Korea.
[Grippo, Paul] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL 60611 USA.
RP Edderkaoui, M (reprint author), Bldg 258,Room 340,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM medderkaoui@mednet.ucla.edu
FU National Institute on Alcohol Abuse and Alcoholism [K01 AA019996];
National Center for Complementary and Alternative Medicine; National
Cancer Institute
FX This study was supported by the National Institute on Alcohol Abuse and
Alcoholism (grant K01 AA019996 to M.E.), the National Center for
Complementary and Alternative Medicine (to S.J.P.), and the National
Cancer Institute (to A.S.G.).
NR 37
TC 5
Z9 5
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0885-3177
J9 PANCREAS
JI Pancreas
PD MAY
PY 2013
VL 42
IS 4
BP 655
EP 662
DI 10.1097/MPA.0b013e3182762928
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 126XF
UT WOS:000317655200014
PM 23271397
ER
PT J
AU Carrion, IV
Nedjat-Haiem, FR
Martinez-Tyson, D
Castaneda, H
AF Carrion, Iraida V.
Nedjat-Haiem, Frances R.
Martinez-Tyson, Dinorah
Castaneda, Heide
TI Advance care planning among Colombian, Mexican, and Puerto Rican women
with a cancer diagnosis
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Advance care planning; Latina; Cancer; Health decisions
ID HEALTH; DISPARITIES; LIFE; END; PREFERENCES; DISCUSSIONS; HISPANICS;
ATTITUDES; CULTURE; CUBANS
AB Limited knowledge exists pertaining to advance care planning (ACP) among Colombian, Mexican, and Puerto Rican women with a cancer diagnosis living in Central Florida, in the USA. The purpose of the study is to identify factors that facilitated the completion of ACP and decisions making patterns among the three groups of Latinas.
The research method used was an exploratory qualitative in-depth open-ended semi-structured interview with a grounded theoretical approach and thematic analysis. The interviews were conducted in Spanish with a purposeful sample of 45 Latinas (15 in each group) diagnosed with cancer.
A total of ten women (22 %) in the study documented at least one form of ACP. Thirty-five women identified obstacles to accessing information regarding ACP, relating this to insurance and financial factors. Among the Colombian women, one completed a living will, health care surrogate, and power of attorney (all forms of ACP), and three just a living will. Two Puerto Rican women completed all, two a living will, and one both a living will and an enduring power of attorney. Only one Mexican woman completed a living will.
This study identifies a knowledge gap regarding ACP among Latina women with cancer diagnosis living in Central Florida, in the USA. Differences between the three groups exist as a result of migration/immigration history, family support, education, English language proficiency, income, knowledge gaps, and information ascertained by medical and health professionals. These differences contribute to their readiness, receptiveness, and willingness to engage in documenting a living will, a health care surrogate, and an enduring power of attorney for health decisions.
C1 [Carrion, Iraida V.] Univ S Florida, Sch Social Work, Tampa, FL 33612 USA.
[Nedjat-Haiem, Frances R.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Martinez-Tyson, Dinorah] Univ S Florida, Dept Child & Family, Tampa, FL USA.
[Castaneda, Heide] Univ S Florida, Dept Anthropol, Tampa, FL 33620 USA.
RP Carrion, IV (reprint author), Univ S Florida, Sch Social Work, 13301 Bruce B Downs Blvd MHC 1438, Tampa, FL 33612 USA.
EM icarrion@usf.edu
OI Carrion, Iraida/0000-0003-4076-6644
FU Division of Population Sciences; H. Lee Moffitt Cancer Center and
Research Institute; Division for Equal Health, University of South
Florida in Tampa, FL; National Institute of Health [P20 MDD00375-01]
FX The authors would like to thank Dr. Lee Green and Dr. Richard Roetzheim
for their support and the Latina women who generously participated in
the study. They also thank Ingrid Asmar and Milagros Porter for all
their contributions as research assistants. This study was supported by
the Division of Population Sciences, H. Lee Moffitt Cancer Center and
Research Institute and the Division for Equal Health, University of
South Florida in Tampa, FL, National Institute of Health grant number
P20 MDD00375-01.
NR 39
TC 4
Z9 4
U1 2
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941-4355
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD MAY
PY 2013
VL 21
IS 5
BP 1233
EP 1239
DI 10.1007/s00520-012-1652-z
PG 7
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA 117OK
UT WOS:000316962600005
PM 23192672
ER
PT J
AU Boyce, R
Lenhart, A
Kroeger, A
Velayudhan, R
Roberts, B
Horstick, O
AF Boyce, R.
Lenhart, A.
Kroeger, A.
Velayudhan, R.
Roberts, B.
Horstick, O.
TI Bacillus thuringiensis israelensis (Bti) for the control of dengue
vectors: systematic literature review
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE dengue; vector control; Bacillus thuringiensis israelensis; Aedes
AB Objective To systematically review the literature on the effectiveness of Bacillus thuringiensis israelensis (Bti), when used as a single agent in the field, for the control of dengue vectors. Method Systematic literature search of the published and grey literature was carried out using the following databases: MEDLINE, EMBASE, Global Health, Web of Science, the Cochrane Library, WHOLIS, ELDIS, the New York Academy of Medicine Gray Literature Report, Africa-Wide and Google. All results were screened for duplicates and assessed for eligibility. Relevant data were extracted, and a quality assessment was conducted using the CONSORT 2010 checklist. Results Fourteen studies satisfied the eligibility criteria, incorporating a wide range of interventions and outcome measures. Six studies were classified as effectiveness studies, and the remaining eight examined the efficacy of Bti in more controlled settings. Twelve (all eight efficacy studies and 4 of 6 effectiveness studies) reported reductions in entomological indices with an average duration of control of 24weeks. The two effectiveness studies that did not report significant entomological reductions were both cluster-randomised study designs that utilised basic interventions such as environmental management or general education on environment control practices in their respective control groups. Only one study described a reduction in entomological indices together with epidemiological data, reporting one dengue case in the treated area compared to 15 dengue cases in the untreated area during the observed study period. Conclusion While Bti can be effective in reducing the number of immature Aedes in treated containers in the short term, there is very limited evidence that dengue morbidity can be reduced through the use of Bti alone. There is currently insufficient evidence to recommend the use of Bti as a single agent for the long-term control of dengue vectors and prevention of dengue fever. Further studies examining the role of Bti in combination with other strategies to control dengue vectors are warranted.
C1 [Boyce, R.] Massachusetts Gen Hosp, Dept Internal Med, Boston, MA 02114 USA.
[Lenhart, A.; Kroeger, A.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England.
[Kroeger, A.] World Hlth Org, Special Programme Res & Training Trop Dis, Geneva, Switzerland.
[Velayudhan, R.] World Hlth Org, Dept Control Neglected Trop Dis, Geneva, Switzerland.
[Roberts, B.] London Sch Hyg & Trop Med, London WC1, England.
[Horstick, O.] Inst Publ Hlth, Heidelberg, Germany.
[Horstick, O.] Heidelberg Univ, D-69120 Heidelberg, Germany.
RP Horstick, O (reprint author), Heidelberg Univ, Inst Publ Hlth, INF 324, D-69120 Heidelberg, Germany.
EM Olaf.Horstick@Uni-Heidelberg.de
OI Kroeger, Axel/0000-0001-8438-2904; Boyce, Ross/0000-0002-9489-6324
NR 0
TC 21
Z9 23
U1 3
U2 36
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD MAY
PY 2013
VL 18
IS 5
BP 564
EP 577
DI 10.1111/tmi.12087
PG 14
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 123VZ
UT WOS:000317420800006
PM 23527785
ER
PT J
AU Korman, JB
Fisher, DE
AF Korman, John B.
Fisher, David E.
TI Developing melanoma therapeutics: overview and update
SO WILEY INTERDISCIPLINARY REVIEWS-SYSTEMS BIOLOGY AND MEDICINE
LA English
DT Review
ID KINASE KINASE-1/2 INHIBITOR; BRAF V600E MUTATION; METASTATIC MELANOMA;
CUTANEOUS MELANOMA; RAF INHIBITORS; SOLID TUMORS; CANCER-IMMUNOTHERAPY;
ACQUIRED-RESISTANCE; IMPROVED SURVIVAL; CTLA-4 BLOCKADE
AB Melanoma is a common, often deadly malignancy, historically associated with limited treatment options for advanced disease. In recent years, systems-based research has resulted in significant clinical advancements. Strategic inhibition of mutated oncoproteins and targeting of immune checkpoints have emerged as very promising approaches. Vemurafenib, which received US Food and Drug Administration (FDA) approval in 2011, selectively inhibits BRAFV600E, a hyperactivated mutant signaling kinase in the mitogen-activated protein kinase (MAPK) pathway. Another recently FDA-approved drug, ipilimumab, blocks the cytotoxic T-lymphocyte antigen-4 (CTLA-4) pathway from inhibiting T cell activation. Despite this apparent progress, compelling challenges remain for both researchers and clinicians. Responses to therapy remain unacceptably incomplete and, in most cases, resistance mechanisms quickly develop that lead to relapse and subsequent patient mortality. Combining therapeutic modalities may increase the percentage of responding patients as well as the magnitude and durability of response. Notably, combined therapies involving selective BRAF inhibitors (SBIs) and other inhibitors of MAPK-dependent or MAPK-independent resistance pathways appear particularly promising. Preclinical and clinical studies are needed to comprehensively evaluate the optimal combinations of therapies, to identify melanoma subtypes that will be most responsive, and to determine optimal dosing, timing, and route of delivery. WIREs Syst Biol Med 2013, 5:257271. doi: 10.1002/wsbm.1210 For further resources related to this article, please visit the WIREs website.
C1 [Korman, John B.; Fisher, David E.] Harvard Univ, Sch Med, Dept Dermatol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
RP Fisher, DE (reprint author), Harvard Univ, Sch Med, Dept Dermatol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
EM dfisher3@partners.org
NR 85
TC 8
Z9 8
U1 1
U2 25
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1939-5094
EI 1939-005X
J9 WIRES SYST BIOL MED
JI Wiley Interdiscip. Rev.-Syst. Biol
PD MAY-JUN
PY 2013
VL 5
IS 3
BP 257
EP 271
DI 10.1002/wsbm.1210
PG 15
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 126ID
UT WOS:000317606600001
PM 23408545
ER
PT J
AU Ananthakrishnan, AN
McGinley, EL
AF Ananthakrishnan, A. N.
McGinley, E. L.
TI Weekend hospitalisations and post-operative complications following
urgent surgery for ulcerative colitis and Crohn's disease
SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID INFLAMMATORY-BOWEL-DISEASE; POPULATION-BASED COHORT; SPECIALIST CARE;
MORTALITY; COLECTOMY; IMPACT; OUTCOMES; ADMISSION; VOLUME; RISK
AB Background There is increasing complexity in the management of patients with acute severe exacerbation of inflammatory bowel disease [IBD; Crohn's disease (CD), ulcerative colitis (UC)] with frequent requirement for urgent surgery. Aim To determine whether a weekend effect exists for IBD care in the United States. Methods We used data from the Nationwide Inpatient Sample (NIS) 2007, the largest all-payer hospitalisation database in the United States. Discharges with a diagnosis of CD or UC who underwent urgent intestinal surgery within 2days of hospitalisation were identified using the appropriate ICD-9 codes. The independent effect of admission on a weekend was examined using multivariate logistic regression adjusting for potential confounders. Results Our study included 7,112 urgent intestinal surgeries in IBD patients, 21% of which occurred following weekend admissions. There was no difference in disease severity between weekend and weekday admissions. Post-operative complications were more common following weekend than weekday hospitalisations in UC [odds ratio (OR) 1.71, 95% confidence interval (CI) 1.012.90]. The most common post-operative complication was post-operative infections (Weekend 30% vs. weekday 20%, P=0.04). The most striking difference between weekend and weekday hospitalisations was noted for needing repeat laparotomy (OR 11.5), mechanical wound complications (OR 10.03) and pulmonary complications (OR 2.22). In contrast, occurrence of any post-operative complication in CD was similar between weekday and weekend admissions. Conclusion Patients with UC hospitalised on a weekend undergoing urgent surgery within 2days have an increased risk for post-operative complications, in particular mechanical wound complications, need for repeat laparotomy and post-operative infections.
C1 [Ananthakrishnan, A. N.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
[Ananthakrishnan, A. N.] Harvard Univ, Sch Med, Boston, MA USA.
[McGinley, E. L.] Med Coll Wisconsin, Ctr Patient Care & Outcomes & Res, Milwaukee, WI 53226 USA.
RP Ananthakrishnan, AN (reprint author), Massachusetts Gen Hosp, Crohns & Colitis Ctr, 165 Cambridge St,9th Floor, Boston, MA 02114 USA.
EM aananthakrishnan@partners.org
FU National Institutes of Health [K23 DK097142]
FX Declaration of funding interests: Ananthakrishnan is supported in part
by a grant from the National Institutes of Health (K23 DK097142).
NR 31
TC 10
Z9 10
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-2813
J9 ALIMENT PHARM THER
JI Aliment. Pharmacol. Ther.
PD MAY
PY 2013
VL 37
IS 9
BP 895
EP 904
DI 10.1111/apt.12272
PG 10
WC Gastroenterology & Hepatology; Pharmacology & Pharmacy
SC Gastroenterology & Hepatology; Pharmacology & Pharmacy
GA 118ZH
UT WOS:000317065600005
PM 23451882
ER
PT J
AU Huddle, TS
AF Huddle, Thomas S.
TI Don't Ban the Sunset in Pharmaceutical Advertising If It Doesn't Darken
the Sky
SO AMERICAN JOURNAL OF BIOETHICS
LA English
DT Editorial Material
C1 Univ Alabama, Bimingham Sch Med, Birmingham VA Med Ctr, Tuscaloosa, AL 35487 USA.
RP Huddle, TS (reprint author), Univ Alabama, Bimingham Sch Med, Birmingham VA Med Ctr, 700 19th St S, Tuscaloosa, AL 35487 USA.
EM thuddle@uab.edu
NR 16
TC 1
Z9 1
U1 0
U2 8
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1526-5161
J9 AM J BIOETHICS
JI Am. J. Bioeth.
PD MAY 1
PY 2013
VL 13
IS 5
BP 27
EP 30
DI 10.1080/15265161.2013.776141
PG 4
WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical
SC Social Sciences - Other Topics; Medical Ethics; Social Issues;
Biomedical Social Sciences
GA 120NI
UT WOS:000317176900014
PM 23557043
ER
PT J
AU Rahbari, NN
Weitz, J
AF Rahbari, Nuh N.
Weitz, Juergen
TI Hyaluronic Acid as a Marker of Sinusoidal Obstruction Syndrome after
Oxaliplatin-based Chemotherapy for Colorectal Liver Metastases: Don't
Forget the Tumor
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Editorial Material
ID MULTICENTER RANDOMIZED-TRIAL; 1ST-LINE TREATMENT; PREOPERATIVE
CHEMOTHERAPY; PROGNOSTIC-FACTOR; PHASE-III; CANCER; FLUOROURACIL;
LEUCOVORIN; BEVACIZUMAB; RESECTION
C1 [Rahbari, Nuh N.] Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab Tumor Biol, Boston, MA 02114 USA.
[Rahbari, Nuh N.] Harvard Univ, Sch Med, Boston, MA USA.
[Weitz, Juergen] Univ Hosp Carl Gustav Carus Tech Univ Dresden, Dept Visceral Thorac & Vasc Surg, Dresden, Germany.
RP Rahbari, NN (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab Tumor Biol, Boston, MA 02114 USA.
EM juergen.weitz@uniklinikum-dresden.de
NR 25
TC 1
Z9 1
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD MAY
PY 2013
VL 20
IS 5
BP 1405
EP 1407
DI 10.1245/s10434-013-2916-7
PG 3
WC Oncology; Surgery
SC Oncology; Surgery
GA 122HC
UT WOS:000317308200002
PM 23463087
ER
PT J
AU Baldini, EH
Lapidus, MR
Wang, Q
Manola, J
Orgill, DP
Pomahac, B
Marcus, KJ
Bertagnolli, MM
Devlin, PM
George, S
Abraham, J
Ferrone, ML
Ready, JE
Raut, CP
AF Baldini, Elizabeth H.
Lapidus, Michelle R.
Wang, Qian
Manola, Judith
Orgill, Dennis P.
Pomahac, Bohdan
Marcus, Karen J.
Bertagnolli, Monica M.
Devlin, Phillip M.
George, Suzanne
Abraham, John
Ferrone, Marco L.
Ready, John E.
Raut, Chandrajit P.
TI Predictors for Major Wound Complications Following Preoperative
Radiotherapy and Surgery for Soft-Tissue Sarcoma of the Extremities and
Trunk: Importance of Tumor Proximity to Skin Surface
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Article
ID ADJUVANT RADIATION-THERAPY; POSTOPERATIVE RADIOTHERAPY;
RANDOMIZED-TRIAL; LIMB FUNCTION; PHASE-II; MORBIDITY; RESECTION
AB Preoperative and postoperative RT for the treatment of high-grade soft-tissue sarcoma result in similar local control and overall survival rates, but morbidities differ. Postoperative RT is associated with a higher rate of long-term fibrosis, edema, and joint stiffness. Preoperative RT is associated with higher rates of wound complications. It is important to identify predictors for major wound complications (MWC) and to develop strategies to minimize this outcome. We reviewed our experience to determine predictors for MWC following preoperative radiotherapy (RT) and surgery for soft-tissue sarcoma.
Between January 2006 and May 2011, 103 patients with soft-tissue sarcoma of the extremities and trunk were treated with preoperative RT followed by surgery. MWCs were defined as those requiring operative or prolonged nonoperative management. Fisher's exact test was used to compare rates. Logistic regression was used for multivariable analysis of factors potentially associated with MWCs.
Median tumor size was 8.4 cm (range 2-25). All patients had wide or radical resections. Wound closures were primary in 70 %, a vascularized flap in 27 %, and split-thickness skin graft (STSG) in 3 %. There were 36 MWCs (35 %). Significant predictors for MWCs on univariate analysis included diabetes, tumors > 10 cm, tumors < 3 mm from skin surface, and vascularized flap/STSG closure. The same four variables were significant predictors on multivariable analysis.
MWCs following preoperative RT and surgery were common. Tumor proximity to skin surface < 3 mm is a previously unreported independent predictor, and further strategies to minimize wound complications are needed.
C1 [Baldini, Elizabeth H.; Marcus, Karen J.; Devlin, Phillip M.] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA.
[Lapidus, Michelle R.; Bertagnolli, Monica M.; Raut, Chandrajit P.] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA.
[Orgill, Dennis P.; Pomahac, Bohdan] Brigham & Womens Hosp, Dept Plast Surg, Boston, MA 02115 USA.
[Ferrone, Marco L.; Ready, John E.] Brigham & Womens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA.
[Baldini, Elizabeth H.; Lapidus, Michelle R.; Marcus, Karen J.; Bertagnolli, Monica M.; Devlin, Phillip M.; George, Suzanne; Ferrone, Marco L.; Ready, John E.; Raut, Chandrajit P.] Dana Farber Canc Inst, Ctr Sarcoma & Bone Oncol, Boston, MA 02115 USA.
[Wang, Qian] Beijing Novartis Pharma Co Ltd, Beijing, Peoples R China.
[Manola, Judith] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Abraham, John] Thomas Jefferson Univ, Dept Orthoped Surg, Rothman Inst, Philadelphia, PA 19107 USA.
[George, Suzanne] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
RP Baldini, EH (reprint author), Brigham & Womens Hosp, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA.
EM ebaldini@partners.org
OI Orgill, Dennis/0000-0002-8279-7310
NR 31
TC 26
Z9 29
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD MAY
PY 2013
VL 20
IS 5
BP 1494
EP 1499
DI 10.1245/s10434-012-2797-1
PG 6
WC Oncology; Surgery
SC Oncology; Surgery
GA 122HC
UT WOS:000317308200014
PM 23242820
ER
PT J
AU Gilmore, D
Schulz, M
Liu, R
Zubris, KAV
Padera, RF
Catalano, PJ
Grinstaff, MW
Colson, YL
AF Gilmore, Denis
Schulz, Morgan
Liu, Rong
Zubris, Kimberly Ann V.
Padera, Robert F.
Catalano, Paul J.
Grinstaff, Mark W.
Colson, Yolonda L.
TI Cytoreductive Surgery and Intraoperative Administration of
Paclitaxel-loaded Expansile Nanoparticles Delay Tumor Recurrence in
Ovarian Carcinoma
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Article
ID GYNECOLOGIC-ONCOLOGY-GROUP; STAGE-III OVARIAN; INTRAPERITONEAL
CISPLATIN; CANCER-THERAPY; DRUG-DELIVERY; CHEMOTHERAPY; SURVIVAL; TRIAL;
PH; CARBOPLATIN
AB Locoregional recurrence significantly impacts survival and quality of life in patients with ovarian carcinoma. We hypothesize that local administration of paclitaxel-loaded expansile nanoparticles (pax-eNP) at the time of cytoreductive surgery decreases local tumor recurrence.
In vitro cytotoxicity of pax-eNP was assessed against both the OVCAR-3 human ovarian cancer cell line and tumor cells isolated from a malignant pleural effusion from a patient with multidrug-resistant ovarian cancer. A murine xenogenic model involving surgical cytoreduction of established OVCAR-3 intra-abdominal tumor was used to evaluate in vivo efficacy of intraoperative intraperitoneal (IP) injection of 10 mg/kg of paclitaxel either as pax-eNP or paclitaxel in Cremophor EL/ethanol solution (pax-C/E) versus empty eNP controls. Cytoreductive surgery and intraoperative treatment were performed 4 weeks after established tumor. All animals were sacrificed when empty eNP controls displayed extensive evidence of disease progression.
Labeled-eNP entered tumor cells in vitro within 4 h and specifically accumulated at sites of tumor in vivo. Pax-eNP exhibited dose-dependent cytotoxicity in both OVCAR-3 and patient tumor cells isolated from a malignant pleural effusion and effectively prevented tumor recurrence following debulking (p = 0.003 vs. empty eNP). Furthermore, pax-eNP-treated animals did not develop severe recurrent carcinomatosis compared with 43 % of the pax-C/E-treated cohort, suggesting that single-dose intracavitary pax-eNP is more effective than an equivalent dose of pax-C/E.
Expansile nanoparticles readily enter human ovarian tumor cells and localize to sites of tumor in vivo with pax-eNP cytotoxicity resulting in superior inhibition of locoregional tumor recurrence following cytoreductive surgery.
C1 [Gilmore, Denis; Schulz, Morgan; Liu, Rong; Colson, Yolonda L.] Brigham & Womens Hosp, Dept Surg, Div Thorac Surg, Boston, MA 02115 USA.
[Padera, Robert F.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Catalano, Paul J.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Zubris, Kimberly Ann V.; Grinstaff, Mark W.] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA.
[Zubris, Kimberly Ann V.; Grinstaff, Mark W.] Boston Univ, Dept Chem, Boston, MA 02215 USA.
RP Gilmore, D (reprint author), Brigham & Womens Hosp, Dept Surg, Div Thorac Surg, 75 Francis St, Boston, MA 02115 USA.
EM dgilmor1@bidmc.harvard.edu
OI Grinstaff, Mark/0000-0002-5453-3668
FU Center for Integration of Medicine and Innovative Technology, the
Cross-Disciplinary Training in Nanotechnology for Cancer, NIH [R25
CA153955]; NSF [DMR-1006601]
FX The authors express their appreciation to Brigham and Women's Hospital,
the Dana-Farber Cancer Institute Animal Facility, and Beth Israel
Deaconess Medical Center Confocal Imaging Core who kindly provided their
expertise and guidance. This work was supported by the Center for
Integration of Medicine and Innovative Technology, the
Cross-Disciplinary Training in Nanotechnology for Cancer, NIH R25
CA153955, and the NSF DMR-1006601.
NR 35
TC 8
Z9 9
U1 0
U2 15
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
EI 1534-4681
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD MAY
PY 2013
VL 20
IS 5
BP 1684
EP 1693
DI 10.1245/s10434-012-2696-5
PG 10
WC Oncology; Surgery
SC Oncology; Surgery
GA 122HC
UT WOS:000317308200039
PM 23128939
ER
PT J
AU Liu, SH
Howell, PM
Riker, AI
AF Liu, Suhu
Howell, Paul M.
Riker, Adam I.
TI Up-Regulation of miR-182 Expression after Epigenetic Modulation of Human
Melanoma Cells
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Article
ID MALIGNANT-MELANOMA; DNA METHYLATION; HUMAN CANCER; CPG ISLANDS;
MICRORNA; METASTASIS; IDENTIFICATION; 5-AZACYTIDINE; LINES
AB We sought to investigate the epigenetic regulation of microRNAs (miRNAs) in melanoma.
We treated two highly metastatic human melanoma cell lines, C8161.9 and WM266-4, with the demethylating agents DAC (5-aza-2'-deoxycytidine) and trichostatin A. Locked nucleic acid-based miRNA expression profiling was utilized to examine the differential expression of miRNAs before and after treatment.
We found that miR-182, a miRNA with oncogenic properties, was significantly up-regulated in human melanoma cells after epigenetic modulation. Genome sequence analysis revealed the presence of a prominent CpG island 8-10 kb upstream of mature miR-182. Methylation analysis showed that this genomic region was exclusively methylated in melanoma cells but not in human melanocytes, skin, or peripheral blood mononuclear cells.
These results indicate that an epigenetic mechanism is likely involved in modulating the expression level of miR-182 in melanoma, and increased expression of oncogenic-like miR-182 could be a concern for melanoma patients after epigenetic therapy.
C1 [Liu, Suhu] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Howell, Paul M.] Univ S Alabama, Mitchell Canc Inst, Mobile, AL 36688 USA.
[Riker, Adam I.] Advocate Christ Med Ctr & Canc Inst, Oak Lawn, IL USA.
RP Liu, SH (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA.
EM ariker1234@gmail.com
FU Abraham A. Mitchell Clinical Research Scholar Fund
FX A.I.R. is the recipient of the Abraham A. Mitchell Clinical Research
Scholar Fund, which provided the necessary funding and resources for the
completion of the research described in this article.
NR 32
TC 16
Z9 17
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
EI 1534-4681
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD MAY
PY 2013
VL 20
IS 5
BP 1745
EP 1752
DI 10.1245/s10434-012-2467-3
PG 8
WC Oncology; Surgery
SC Oncology; Surgery
GA 122HC
UT WOS:000317308200047
PM 22752337
ER
PT J
AU Pineles, SL
Rasmusson, AM
Yehuda, R
Lasko, NB
Macklin, ML
Pitman, RK
Orr, SP
AF Pineles, Suzanne L.
Rasmusson, Ann M.
Yehuda, Rachel
Lasko, Natasha B.
Macklin, Michael L.
Pitman, Roger K.
Orr, Scott P.
TI Predicting emotional responses to potentially traumatic events from
pre-exposure waking cortisol levels: a longitudinal study of police and
firefighters
SO ANXIETY STRESS AND COPING
LA English
DT Article
DE cortisol; psychophysiology; trauma; negative affect; neuroticism; stress
ID POSTTRAUMATIC-STRESS-DISORDER; COMORBIDITY SURVEY REPLICATION;
MISSISSIPPI PTSD SCALE; DSM-IV DISORDERS; PSYCHOPHYSIOLOGICAL
ASSESSMENT; SALIVARY CORTISOL; URINARY CORTISOL; CIVILIAN VERSION;
COMBAT VETERANS; FEAR
AB There is a large literature demonstrating that individuals who have experienced traumatic events have alterations in the hypothalamic-pituitary-adrenal (HPA) axis. However, the existing literature does not address the extent to which these alterations represent pre-existing risk factors for developing psychopathology upon exposure to a significant stressor. In the current study, we examined the relationship between waking salivary cortisol level and physiological, personality, and psychological measures in 60 firefighters and police trainees during training, and then again after exposure to a highly stressful, potentially traumatic event (PTE). Waking cortisol was negatively associated with neuroticism, but positively associated with physiological reactivity to loud tones and fear conditioning when assessed during training. Longitudinally, there were significant negative correlations between pre-PTE waking cortisol and post-PTE negative mood and anxiety symptoms, but a positive correlation (trend) between pre-PTE waking cortisol and post-PTE physiological reactivity during recollection of the PTE. Thus, waking cortisol level may serve to predict divergent types of emotional sequelae following PTEs.
C1 [Pineles, Suzanne L.; Rasmusson, Ann M.] VA Boston Healthcare Syst, Womens Hlth Sci Div, Natl Ctr PTSD, Boston, MA USA.
[Pineles, Suzanne L.; Rasmusson, Ann M.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA.
[Yehuda, Rachel] Mt Sinai Sch Med, Dept Psychiat & Neurobiol, Bronx, NY USA.
[Yehuda, Rachel] James J Peters Bronx VA, Dept Psychiat, Bronx, NY USA.
[Lasko, Natasha B.; Pitman, Roger K.; Orr, Scott P.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Lasko, Natasha B.; Pitman, Roger K.; Orr, Scott P.] Harvard Univ, Sch Med, Boston, MA USA.
[Lasko, Natasha B.; Macklin, Michael L.; Orr, Scott P.] Vet Affairs Med Ctr, Res Serv, Manchester, NH USA.
RP Orr, SP (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
EM scott_orr@hms.harvard.edu
FU NIMH NIH HHS [R01-MH60315]
NR 56
TC 8
Z9 10
U1 4
U2 38
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1061-5806
J9 ANXIETY STRESS COPIN
JI Anxiety Stress Coping
PD MAY 1
PY 2013
VL 26
IS 3
BP 241
EP 253
DI 10.1080/10615806.2012.672976
PG 13
WC Neurosciences; Psychiatry; Psychology, Multidisciplinary
SC Neurosciences & Neurology; Psychiatry; Psychology
GA 121XD
UT WOS:000317277600001
PM 22574657
ER
PT J
AU Clancy, CJ
Nguyen, MH
AF Clancy, Cornelius J.
Nguyen, M. Hong
TI Finding the "Missing 50%" of Invasive Candidiasis: How Nonculture
Diagnostics Will Improve Understanding of Disease Spectrum and Transform
Patient Care
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Review
DE invasive candidiasis; candidemia; diagnostic; PCR; beta-D-glucan
ID POLYMERASE-CHAIN-REACTION; D-GLUCAN ASSAY; REAL-TIME PCR; BLOOD
CULTURES; SYSTEMIC CANDIDIASIS; FUNGAL-INFECTIONS; ANTIMANNAN
ANTIBODIES; HEPATIC CANDIDIASIS; ANTIFUNGAL AGENTS; CANCER-PATIENTS
AB Blood cultures are limited for diagnosing invasive candidiasis by poor sensitivity and slow turn-around time. New diagnostics are needed to complement cultures, in particular to identify the "missing 50%" of patients who are blood culture-negative. Mannan/anti-mannan immunoglobulin G, beta-D-glucan (BDG) and polymerase chain reaction (PCR) assays can diagnose candidemia before blood cultures and show promising sensitivity/specificity, but they are not widely investigated in blood culture-negative, deep-seated candidiasis. In a recent study, BDG and PCR were superior to blood cultures in deep-seated candidiasis, suggesting they may identify currently undiagnosed patients and expand our understanding of disease spectrum. Positive predictive values of nonculture tests are limited by the low prevalence of invasive candidiasis, which mandates that results be interpreted judiciously. When used as biomarkers that assess a patient's risk of having invasive candidiasis, tests will facilitate preemptive antifungal strategies. Because negative predictive values are excellent, tests will also be useful for ruling out invasive candidiasis and discontinuing unnecessary antifungal therapy.
C1 [Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Dept Med, Pittsburgh, PA USA.
[Clancy, Cornelius J.; Nguyen, M. Hong] Univ Pittsburgh, Pittsburgh, PA 15261 USA.
RP Clancy, CJ (reprint author), Univ Pittsburgh, Scaife Hall,Ste 869,3550 Terrace St, Pittsburgh, PA 15261 USA.
EM cjc76@pitt.edu
FU ClinicalTrials.gov [NCT01525095]; ViraCor-IBT Laboratories for the
BDG/PCR
FX C. J. C. is a site principal investigator for a multicenter trial of the
T2 Candida Bioassay for candidemia (T2 Biosystems; ClinicalTrials.gov
identifier: NCT01525095). M. H. N. received investigator-initiated
research funding from ViraCor-IBT Laboratories for the BDG/PCR study
cited in this paper [31].
NR 40
TC 88
Z9 91
U1 1
U2 9
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAY 1
PY 2013
VL 56
IS 9
BP 1284
EP 1292
DI 10.1093/cid/cit006
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 123QC
UT WOS:000317404300015
PM 23315320
ER
PT J
AU Dudley, MN
Ambrose, PG
Bhavnani, SM
Craig, WA
Ferraro, MJ
Jones, RN
AF Dudley, Michael N.
Ambrose, Paul G.
Bhavnani, Sujata M.
Craig, William A.
Ferraro, Mary Jane
Jones, Ronald N.
CA Antimicrobial Susceptibility Testi
TI Background and Rationale for Revised Clinical and Laboratory Standards
Institute Interpretive Criteria (Breakpoints) for Enterobacteriaceae and
Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE breakpoints; Enterobacteriaceae; cephalosporins; Pseudomonas; CLSI
ID PHARMACODYNAMICS; INFECTIONS; ORGANISMS; OUTCOMES
AB Widespread resistance in Enterobacteriaceae and Pseudomonas aeruginosa to cephalosporin and monobactam antibiotics due to extended-spectrum beta-lactamases (ESBLs) has resulted in the need for reassessment of the interpretative criteria (breakpoints) established for these agents more than 2 decades ago. Following extensive evaluation, the Clinical and Laboratory Standards Institute recently adopted and published new breakpoints for these agents for use in clinical laboratories and provided updated recommendations for use of the ESBL screening test. This paper summarizes the background and supportive rationale for new interpretative criteria for cephalosporins and aztreonam for testing Enterobacteriaceae.
C1 [Dudley, Michael N.] Rempex Pharmaceut, San Diego, CA 92121 USA.
[Ambrose, Paul G.; Bhavnani, Sujata M.] Inst Clin Pharmacodynam Inc, Latham, NY USA.
[Craig, William A.] Univ Wisconsin, Sch Med, Dept Med, Madison, WI 53706 USA.
[Ferraro, Mary Jane] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Ferraro, Mary Jane] Harvard Univ, Sch Med, Boston, MA USA.
[Jones, Ronald N.] JMI Labs, N Liberty, IA USA.
RP Dudley, MN (reprint author), Rempex Pharmaceut, 11535 Sorrento Valley Rd, San Diego, CA 92121 USA.
EM mdudley@rempexpharma.com
NR 14
TC 56
Z9 57
U1 1
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAY 1
PY 2013
VL 56
IS 9
BP 1301
EP 1309
DI 10.1093/cid/cit017
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 123QC
UT WOS:000317404300018
PM 23334813
ER
PT J
AU Franke, MF
Kaigamba, F
Socci, AR
Hakizamungu, M
Patel, A
Bagiruwigize, E
Niyigena, P
Walker, KDC
Epino, H
Binagwaho, A
Mukherjee, J
Farmer, PE
Rich, ML
AF Franke, Molly F.
Kaigamba, Felix
Socci, Adrienne R.
Hakizamungu, Massudi
Patel, Anita
Bagiruwigize, Emmanuel
Niyigena, Peter
Walker, Kelly D. C.
Epino, Henry
Binagwaho, Agnes
Mukherjee, Joia
Farmer, Paul E.
Rich, Michael L.
TI Improved Retention Associated With Community-Based Accompaniment for
Antiretroviral Therapy Delivery in Rural Rwanda
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE retention; community health workers; nutrition; Africa; HIV
ID SUB-SAHARAN AFRICA; TREATMENT OUTCOMES; TREATMENT PROGRAM; HIV;
ADHERENCE; ADULTS; HAART; RELIABILITY; DEPRESSION; VALIDITY
AB Background. Minimizing death and ensuring high retention and good adherence remain ongoing challenges for human immunodeficiency virus (HIV) treatment programs. We examined whether the addition of community-based accompaniment (characterized by daily home visits from a community health worker, directly observed treatment, nutritional support, transportation stipends, and other support as needed) to the Rwanda national model for antiretroviral therapy (ART) delivery would improve retention in care, viral load suppression, and change in CD4 count, relative to the national model alone.
Methods. We conducted a prospective observational cohort study among 610 HIV-infected adults initiating ART in 1 of 2 programs in rural Rwanda. Psychosocial and clinical characteristics were recorded at ART initiation. Death, treatment retention, and plasma viral load were assessed at 1 year. CD4 count was evaluated at 6-month intervals. Multivariable regression models were used to adjust for baseline differences between the 2 populations.
Results. Eighty-five percent and 79% of participants in the community-based and clinic-based programs, respectively, were retained with viral load suppression at 1 year. After adjusting for CD4 count, depression, physical health quality of life, and food insecurity, community-based accompaniment was protective against death or loss to follow-up during the first year of ART (hazard ratio, 0.17; 95% confidence interval [CI],.09-.35; P <.0001). In a second multivariable analysis, individuals receiving accompaniment were more likely to be retained with a suppressed viral load at 1 year (risk ratio: 1.15; 95% CI, 1.03-1.27; P =.01).
Conclusions. These findings indicate that community-based accompaniment is effective in improving retention, when added to a clinic-based program with fewer patient support mechanisms.
C1 [Franke, Molly F.; Binagwaho, Agnes; Mukherjee, Joia; Farmer, Paul E.] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA 02115 USA.
[Kaigamba, Felix; Bagiruwigize, Emmanuel] Ruhengeri Hosp, Rwanda Minist Hlth, Ruhengeri, Rwanda.
[Franke, Molly F.; Socci, Adrienne R.; Hakizamungu, Massudi; Patel, Anita; Niyigena, Peter; Walker, Kelly D. C.; Epino, Henry; Mukherjee, Joia; Farmer, Paul E.; Rich, Michael L.] Partners Hlth Inshuti Mu Buzima, Rwinkwavu, Rwanda.
[Binagwaho, Agnes] Minist Hlth Rwanda, Kigali, Rwanda.
[Epino, Henry; Mukherjee, Joia; Farmer, Paul E.; Rich, Michael L.] Brigham & Womens Hosp, Div Global Hlth Equ, Boston, MA 02115 USA.
[Epino, Henry] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
RP Franke, MF (reprint author), Harvard Univ, Sch Med, Dept Global Hlth & Social Med, 641 Huntington Ave, Boston, MA 02115 USA.
EM molly_franke@hms.harvard.edu
FU Doris Duke Charitable Foundation
FX This work was supported by the Doris Duke Charitable Foundation.
NR 41
TC 33
Z9 33
U1 0
U2 12
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAY 1
PY 2013
VL 56
IS 9
BP 1319
EP 1326
DI 10.1093/cid/cis1193
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 123QC
UT WOS:000317404300020
PM 23249611
ER
PT J
AU Jena, AB
Karaca-Mandic, P
Weaver, L
Seabury, SA
AF Jena, Anupam B.
Karaca-Mandic, Pinar
Weaver, Lesley
Seabury, Seth A.
TI Predicting New Diagnoses of HIV Infection Using Internet Search Engine
Data
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Letter
C1 [Jena, Anupam B.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
[Jena, Anupam B.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Jena, Anupam B.] Natl Bur Econ Res, Cambridge, MA 02138 USA.
[Karaca-Mandic, Pinar; Weaver, Lesley] Univ Minnesota, Sch Publ Hlth, Div Hlth Policy & Management, Minneapolis, MN USA.
[Seabury, Seth A.] RAND Corp, Santa Monica, CA USA.
RP Jena, AB (reprint author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.
EM jena@hcp.med.harvard.edu
NR 5
TC 7
Z9 7
U1 0
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAY 1
PY 2013
VL 56
IS 9
BP 1352
EP 1353
DI 10.1093/cid/cit022
PG 2
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 123QC
UT WOS:000317404300028
PM 23334812
ER
PT J
AU Dong, Y
Wu, X
Zhang, G
Xu, Z
Zhang, Y
Gautam, V
Kovacs, DM
Wu, A
Yue, Y
Xie, Z
AF Dong, Y.
Wu, X.
Zhang, G.
Xu, Z.
Zhang, Y.
Gautam, V.
Kovacs, D. M.
Wu, A.
Yue, Y.
Xie, Z.
TI Isoflurane Facilitates Synaptic NMDA Receptor Endocytosis in Mice
Primary Neurons
SO CURRENT MOLECULAR MEDICINE
LA English
DT Article
DE Alzheimer's disease; anesthesia; cognition; endocytosis; isoflurane;
NMDA
ID ALZHEIMERS-DISEASE; AMYLOID-BETA; INDUCED APOPTOSIS; ANESTHESIA;
CASPASE-3; ACTIVATION; EXPOSURE; SURGERY; SEVOFLURANE; PRESENILINS
AB Inhalation anesthetic isoflurane has been reported to induce caspase activation and accumulation of beta-amyloid (A beta), however, the down-stream consequences of these effects are largely unknown. Isoflurane has also been shown to impair learning and memory, however, the up-stream mechanisms of these effects remain largely to be determined. Facilitation of synaptic NMDA receptor endocytosis can reduce synaptic function, leading to learning and memory impairment. We therefore set out to determine the effects of isoflurane on synaptic NMDA receptor endocytosis. Primary neurons from wild-type and Alzheimer's disease transgenic mice were treated with 2% isoflurane for six hours. Synaptic surface levels of NMDA receptor 2B (NR2B) and NR2B internalization were determined by surface and cleavable biotinylation assay, western blot analysis and immunofluorescence. Here we show that isoflurane can induce caspase-3 activation, increase levels of beta-site amyloid precursor protein-cleaving enzyme and cause accumulation of A beta in the primary neurons. Isoflurane facilitates synaptic NR2B endocytosis as evidenced by reducing surface NR2B levels, increasing NR2B internalization, and decreasing the ratio of synaptic surface NR2B to synapsin in mice primary neurons. Moreover, caspase activation inhibitor Z-VAD and gamma-secretase inhibitor L-685,458 attenuated the isoflurane-facilitated NR2B endocytosis. These results suggest that isoflurane induces caspase activation and A beta accumulation, leading to facilitation of synaptic NMDA receptor endocytosis, which potentially serve as the upstream mechanism of the isoflurane-induced impairment of learning and memory. These findings will encourage further studies to determine the underlying mechanism by which isoflurane and other anesthetics promote Alzheimer's disease neuropathogenesis and induce cognitive dysfunction.
C1 [Dong, Y.; Xu, Z.; Zhang, Y.; Xie, Z.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Geriatr Anesthesia Res Unit, Charlestown, MA 02129 USA.
[Dong, Y.; Xu, Z.; Zhang, Y.; Gautam, V.; Kovacs, D. M.; Xie, Z.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
[Wu, X.; Zhang, G.] China Med Univ, Fac Forens Med, Dept Forens Pathol, Shenyang 110001, Peoples R China.
[Gautam, V.; Kovacs, D. M.] Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Genet & Aging Res Unit, Neurobiol Dis Lab, Charlestown, MA 02129 USA.
[Wu, A.; Yue, Y.] Capital Med Univ, Beijing Chaoyang Hosp, Dept Anesthesia, Beijing 100020, Peoples R China.
RP Xie, Z (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Geriatr Anesthesia Res Unit, 149 13th St,Room 4310, Charlestown, MA 02129 USA.
EM zxie@partners.org
FU (National Institutes of Health), USA [K08NS048140, R21AG029856,
R21AG038994, R01 GM088801, R01 AG041274]; Jahnigen Career Development
Award (American Geriatrics Society); Investigator Initiated Research
Grant (Alzheimer's Association); Cure Alzheimer's Fund, USA; National
Science Foundation Oversea young scholar collaboration research award,
P.R. China [NSF30928026]
FX This research was supported by K08NS048140, R21AG029856, R21AG038994,
R01 GM088801, R01 AG041274 (National Institutes of Health), USA,
Jahnigen Career Development Award (American Geriatrics Society),
Investigator Initiated Research Grant (Alzheimer's Association), Cure
Alzheimer's Fund (to Z.X.), USA; National Science Foundation Oversea
young scholar collaboration research award NSF30928026, P.R. China (to
Y.Y. and Z.X.). Department of Anesthesia, Critical Care and Pain
Medicine in Massachusetts General Hospital and Harvard Medical School,
Boston, MA, USA generously provided isoflurane for the studies.
NR 43
TC 3
Z9 4
U1 2
U2 21
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
EMIRATES
SN 1566-5240
J9 CURR MOL MED
JI Curr. Mol. Med.
PD MAY
PY 2013
VL 13
IS 4
BP 488
EP 498
PG 11
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 119SH
UT WOS:000317117400003
PM 22950384
ER
PT J
AU Knaub, LA
McCune, S
Chicco, AJ
Miller, M
Moore, RL
Birdsey, N
Lloyd, MI
Villarreal, J
Keller, AC
Watson, PA
Reusch, JEB
AF Knaub, Leslie A.
McCune, Sylvia
Chicco, Adam J.
Miller, Matthew
Moore, Russell L.
Birdsey, Nicholas
Lloyd, Monique I.
Villarreal, Juan
Keller, Amy C.
Watson, Peter A.
Reusch, Jane E. B.
TI Impaired response to exercise intervention in the vasculature in
metabolic syndrome
SO DIABETES & VASCULAR DISEASE RESEARCH
LA English
DT Article
DE Cyclic adenosine monophosphate response element binding protein;
mitochondria; exercise; SHHF; diabetes; vasculature
ID ELEMENT-BINDING PROTEIN; LOW CARDIORESPIRATORY FITNESS; MUSCLE
CELL-PROLIFERATION; ZUCKER OBESE RATS; MITOCHONDRIAL BIOGENESIS;
INSULIN-RESISTANCE; PHYSICAL-ACTIVITY; HEART-FAILURE; NITRIC-OXIDE;
DISEASE RISK
AB Physical activity decreases risk for diabetes and cardiovascular disease morbidity and mortality; however, the specific impact of exercise on the diabetic vasculature is unexamined. We hypothesized that an acute, moderate exercise intervention in diabetic and hypertensive rats would induce mitochondrial biogenesis and mitochondrial antioxidant defence to improve vascular resilience. SHHF/Mcc-fa(cp) lean (hypertensive) and obese (hypertensive, insulin resistant), as well as Sprague Dawley (SD) control rats were run on a treadmill for 8 days. In aortic lysates from SD rats, we observed a significant increase in subunit proteins from oxidative phosphorylation (OxPhos) complexes I-III, with no changes in the lean or obese SHHF rats. Exercise also increased the expression of mitochondrial antioxidant defence uncoupling protein 3 (UCP3) (p < 0.05) in SHHF lean rats, whereas no changes were observed in the SD or SHHF obese rats with exercise. We evaluated upstream signalling pathways for mitochondrial biogenesis, and only peroxisome proliferators-activated receptor gamma coactivator 1 alpha (PGC-1 alpha) significantly decreased in SHHF lean rats (p < 0.05) with exercise. In these experiments, we demonstrate absent mitochondrial induction with exercise exposure in models of chronic vascular disease. These findings suggest that chronic vascular stress results in decreased sensitivity of vasculature to the adaptive mitochondrial responses normally induced by exercise.
C1 [Knaub, Leslie A.; Miller, Matthew; Birdsey, Nicholas; Lloyd, Monique I.; Villarreal, Juan; Keller, Amy C.; Watson, Peter A.; Reusch, Jane E. B.] Univ Colorado Denver, Div Endocrinol Diabet & Metab, Aurora, CO 80045 USA.
[Knaub, Leslie A.; Miller, Matthew; Birdsey, Nicholas; Lloyd, Monique I.; Keller, Amy C.; Watson, Peter A.; Reusch, Jane E. B.] Denver VA Med Ctr, Dept Med, Denver, CO USA.
[McCune, Sylvia; Moore, Russell L.] Univ Colorado, Dept Integrat Physiol, Boulder, CO 80309 USA.
[Chicco, Adam J.] Colorado State Univ, Dept Hlth & Exercise Sci, Ft Collins, CO 80523 USA.
RP Reusch, JEB (reprint author), Univ Colorado Denver, Div Endocrinol Diabet & Metab, Anschutz Med Campus,12801 E 17th Ave,MS8106, Aurora, CO 80045 USA.
EM jane.reusch@ucdenver.edu
FU Department of Veterans Affairs Office of Research and Development;
National Institutes of Health [HL14985, UL1 RR025780]; American Heart
Association [0835545N]
FX This work was supported by the Department of Veterans Affairs Office of
Research and Development (Merit Review JEBR and PAW), National
Institutes of Health (HL14985, UL1 RR025780, JEBR) and American Heart
Association Grant (0835545N, AJC).
NR 65
TC 8
Z9 8
U1 0
U2 10
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1479-1641
J9 DIABETES VASC DIS RE
JI Diabetes Vasc. Dis. Res.
PD MAY
PY 2013
VL 10
IS 3
BP 222
EP 238
DI 10.1177/1479164112459664
PG 17
WC Endocrinology & Metabolism; Peripheral Vascular Disease
SC Endocrinology & Metabolism; Cardiovascular System & Cardiology
GA 122CR
UT WOS:000317293900005
PM 23162060
ER
EF